{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\"APIVrs: 1.01.05\"\\n\"DataVrs: 2023:03:21 23:51:48.013\"\\n\"Expression: solid tumor\"\\n\"NStudiesAvail: 446092\"\\n\"NStudiesFound: 14460\"\\n\"MinRank: 1\"\\n\"MaxRank: 446092\"\\n\"NStudiesUsed: 14460\"\\n\"Field: PrimaryOutcomeMeasure\"\\n\"NUniqueValues: 639518\"\\n\"NUniqueValuesFound: 22497\"\\n\"NStudiesMissingValue: 17400\"\\n\"NStudiesFoundMissingValue: 446\"\\n\\n\"Index\",\"NStudiesWithValue\",\"NStudiesFoundWithValue\",\"FieldValue\"\\n1,1,1,\"\"\"Dynamic\"\" tumor response rate as defined by a 20% modification of tumoral perfusion and cellular density parameters.\"\\n2,1,1,\"\"\"Major\"\" Surgical Morbidity\"\\n3,1,1,\"% of Patients in Whom a Sentinel Lymph Node is Identified\"\\n4,2,2,\"% subjects with adverse events (AEs)\"\\n5,1,1,\"% subjects with changes from baseline in pro-inflammatory cytokines\"\\n6,2,2,\"% subjects with clinically significant change from baseline in clinical laboratory tests\"\\n7,1,1,\"% subjects with dose-limiting toxicities (DLTs)\"\\n8,2,2,\"% subjects with serious adverse events (SAEs)\"\\n9,1,1,\"%AE,ur(0-12) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 12 Hours Post Administration) of BAY1163877\"\\n10,1,1,\"%AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 24 Hours Post Administration) of BAY1163877\"\\n11,1,1,\"%AE,ur(12-24) (Amount of Drug Excreted Via Urine During the Collection Interval 12 - 24 Hours Post Administration) of BAY1163877\"\\n12,1,1,\"%PEAUC\"\\n13,1,1,\"%PECmax\"\\n14,1,1,\"(AI_AUC ) Accumulation Index\"\\n15,1,1,\"(AI_CMAX) Accumulation Index\"\\n16,1,1,\"(AUC(TAU)) Area Under the Concentration-time Curve in One Dosing Interval\"\\n17,1,1,\"(CLT/F) Apparent Total Body Clearance\"\\n18,1,1,\"(Cmax) Maximum Observed Plasma Concentration\"\\n19,1,1,\"(Core Phase)To evaluate the PK of a single intravenous dose (900, 1200 and 1800 mg/m2) of ASA404 in adult cancer patients with impaired hepatic function compared to matching patients with normal hepatic function\"\\n20,1,1,\"(Ctrough) Trough Observed Plasma Concentration\"\\n21,1,1,\"(Escalation stage) Adverse events (AEs)\"\\n22,1,1,\"(Escalation stage) Dose Limiting Toxicities (DLTs)\"\\n23,1,1,\"(Escalation stage) Recommended Phase 2 Dose (RP2D)\"\\n24,1,1,\"(Expansion stage) Overall Response Rate (ORR)\"\\n25,1,1,\"(OS) Overall Survival\"\\n26,1,1,\"(Overall response rate [ORR]) (Phase II)\"\\n27,1,1,\"(Part 1 and 2) Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]\"\\n28,1,1,\"(Part 1) ECG QTc Interval\"\\n29,1,1,\"(Part 1) First-cycle dose-limiting toxicities (DLTs)\"\\n30,1,1,\"(Part A only) Dose Limiting Toxicity of PY314\"\\n31,1,1,\"(percentUR24) Percent Urinary Recovery Over 24 Hours\"\\n32,1,1,\"(Phase 1 )Dose Limiting Toxicity (DLT)\"\\n33,1,1,\"(Phase 1) Determination of Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib\"\\n34,2,2,\"(Phase 1) Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n35,1,1,\"(Phase 1b) Number of Participants with Adverse Events (AEs)investigator assessment\"\\n36,1,1,\"(Phase 1b) Number of Participants with Serious Adverse Events (SAEs)\"\\n37,1,1,\"(Phase 1b) Percentage of Participants with Dose-limiting Toxicity (DLT) During Cycle 1\"\\n38,1,1,\"(Phase 2) Number of Participants with AEs and SAEs\"\\n39,2,2,\"(Phase 2) Overall Response Rate (ORR)\"\\n40,1,1,\"(Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment\"\\n41,1,1,\"(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm\"\\n42,1,1,\"(Phase 3) Progression free survival(PFS) in HER2-negative Metastatic Breast Cancer patients\"\\n43,1,1,\"(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm\"\\n44,1,1,\"(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)\"\\n45,1,1,\"(Phase I) Number of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event (AE), or Discontinuation of Treatment Due to Toxicity [Adverse Events of Concern (AEC)]\"\\n46,1,1,\"(Phase Ib) Dose limiting Toxicity\"\\n47,1,1,\"(Phase Ib) Maximum Tolerated dose\"\\n48,1,1,\"(Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy\"\\n49,2,1,\"(Phase II) Overall Survival\"\\n50,1,1,\"(Phase II) Progression-free survival\"\\n51,1,1,\"(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)\"\\n52,1,1,\"(Safety Lead-in) dose limited toxicity (DLT)\"\\n53,1,1,\"(Safety Lead-in) dose limited toxicity (DLT) of SHR6390+famitinib in the first cycle\"\\n54,1,1,\"(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)\"\\n55,1,1,\"(Safety Lead-in) Number of Participants With Adverse Events (AEs)\"\\n56,1,1,\"(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)\"\\n57,1,1,\"(Safety Lead-in) Recommended Phase II Dose (RP2D)\"\\n58,1,1,\"(Safety Lead-in) Recommended Phase II Dose (RP2D) of SHR6390+famitinib\"\\n59,1,1,\"(T-HALF (Eff, AUC)) Effective Elimination Half-life\"\\n60,1,1,\"(Tmax) Time of Maximum Observed Plasma Concentration\"\\n61,1,1,\"*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic\"\\n62,1,1,\"- DOSE ESCALATION To determine the maximum tolerated dose (MTD) of SAR125844\"\\n63,1,1,\"- EXPANSION Cohort To evaluate the preliminary anti-tumoral effect of SAR125844\"\\n64,1,1,\"- Safety and tolerability endpoints will include evaluation of adverse events and changes in laboratory values and clinical variables from pre-dose values.\"\\n65,1,1,\"- To determine the grade of inhibition of PI3K/mTOR pathways, in pre-surgery setting with BKM120\"\\n66,1,1,\"- To determine the maximum tolerated dose of GSK1120212\"\\n67,1,1,\"- Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by EUS-FNTA.\"\\n68,1,1,\"-Measure plasma concentrations of IPdR, IdUrd, and IdUrd metabolites after a single oral dose of IPdR.-Determine the safety of administering a single oral dose of IPdR.\"\\n69,1,1,\". Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n70,1,1,\"1 Year Progression Free Survival\"\\n71,3,1,\"1 year progression free survival\"\\n72,1,1,\"1 year progression free survival rate of patients with locally advanced pancreatic cancer who are treated with IRE and combination chemotherapy.\"\\n73,1,1,\"1 Year Progression-free Survival Rate\"\\n74,1,1,\"1 year survival rate (Phase II portion)\"\\n75,1,1,\"1) Evaluating the heterogeneity of the PD-L1 tumor expression before and after neoadjuvant therapy using quantitative fluorescence endoscopy using the PD-L1-targeted fluorescent tracer durvalumab-680LT\"\\n76,1,1,\"1- year Progression Free Survival (PFS) Rate\"\\n77,1,1,\"1-month incidence and severity\"\\n78,1,1,\"1-Year Disease-Free Survival Percentage\"\\n79,1,1,\"1-year Distant Progression-free Survival (PFS)\"\\n80,1,1,\"1-year Local Progression-free Survival (PFS)\"\\n81,1,1,\"1-year Locoregional Progression-free Survival (PFS)\"\\n82,1,1,\"1-year New Lesion-Free Survival Rate\"\\n83,1,1,\"1-year Progression Free Survival\"\\n84,1,1,\"1-year Progression Free Survival Rate\"\\n85,1,1,\"1-year Progression-free Survival\"\\n86,1,1,\"1-year progression-free survival (PFS)\"\\n87,1,1,\"1-year progression-free survival (PFS) rate\"\\n88,2,1,\"1-year progression-free survival rate\"\\n89,1,1,\"1-year Progression-Free-Survival (PFS) rate assessed by investigators per RECIST 1.1\"\\n90,1,1,\"1-year rate of progression-free survival\"\\n91,1,1,\"1-year relapse-free survival (RFS) rate.\"\\n92,2,1,\"1-year Survival\"\\n93,4,1,\"1-year Survival Rate\"\\n94,1,1,\"1. Objective Response Rate (ORR) by Week 19\"\\n95,1,1,\"1. Phase 1: Incidence of treatment-related adverse events as assessed by CTCAE v4.0\"\\n96,1,1,\"1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)\"\\n97,1,1,\"1. The dose limiting toxicities with AVN944 in patients with advanced stage solid tumors; 2. Maximum tolerated dose with AVN944 in patients with advanced stage solid tumors\"\\n98,1,1,\"1. The percentage of patients that respond to treatment with the combination of ESK981 monotherapy and nivolumab therapy (Cohort B).\"\\n99,1,1,\"1. To determine the anti-tumor activity of TTX-080 by objective response rate [complete response + partial response) for each tumor arm per RECIST 1.1\"\\n100,1,1,\"1. Tumor response is measured at baseline and evaluated every 3 treatment cycles (9 weeks) by RECIST(CT or MRI measurements), Time to Progression\"\\n101,1,1,\"1. Tumor vessel identification (# tumor vessels visualized per high power field)\"\\n102,1,1,\"1.Dose limited toxicity (DLT)\"\\n103,1,1,\"12 ECG\"\\n104,1,1,\"12 lead ecg\"\\n105,1,1,\"12 Month Landmark Progression Free Survival\"\\n106,1,1,\"12 months Progression-Free Survival\"\\n107,1,1,\"12 Months Progression-Free Survival (PFS) Rate in the Tyrosine Kinase Inhibitor (TKI) Na√Øve Expansion Cohort\"\\n108,1,1,\"12 months Progression-free survival rate(12mPFR)\"\\n109,1,1,\"12 months survival rate\"\\n110,1,1,\"12 Week Progression Free Survival Rate in Refractory Germ Cell Tumors Treated With Sunitinib Malate\"\\n111,1,1,\"12 week Progression Rate in validation cohort\"\\n112,1,1,\"12-lead ECG Assessment\"\\n113,1,1,\"12-Lead electrocardiogram\"\\n114,5,1,\"12-lead electrocardiogram\"\\n115,1,1,\"12-month Progression-free Survival (PFS) rate\"\\n116,1,1,\"12-month radiographic progression-free survival (rPFS) rate\"\\n117,1,1,\"12-week overall response rate (ORR)\"\\n118,1,1,\"12-week Progression Free Rate\"\\n119,1,1,\"12-Week Progression Free Survival\"\\n120,1,1,\"12-Week Progression-Free Survival (PFS)\"\\n121,1,1,\"12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2)\"\\n122,1,1,\"14C-labeled RO5185426 Recovery: Percentage of Dose Excreted in Feces and Urine\"\\n123,1,1,\"16 week progression free survival rate\"\\n124,1,1,\"16 weeks progression-free rate (16W-PFR)\"\\n125,1,1,\"16 Weeks Progression-free Survival\"\\n126,1,1,\"16-week Progression Free Survival\"\\n127,1,1,\"16-week Progression-free Survival (PFS) Rate\"\\n128,2,1,\"16sRNA and metagenomics\"\\n129,1,1,\"18 Month Survival\"\\n130,1,1,\"18 months survival rate\"\\n131,1,1,\"18 Week Progression-free Survival (PFS) Rate\"\\n132,1,1,\"18 Week Progression-free Survival Rate\"\\n133,1,1,\"18 Weeks Progression Free Survival (PFS) Rate\"\\n134,1,1,\"18-Months\\' Overall Survival Percentage (FAS)\"\\n135,1,1,\"18-Months\\' Overall Survival Percentage (PPS)\"\\n136,1,1,\"18F-EF5 uptake (tumor: blood ratio) before and after administration of DCA for a subset of subjects.\"\\n137,1,1,\"18F-EF5 uptake (tumor: blood ratio) before and after carbogen breathing for a subset of subjects.\"\\n138,1,1,\"2 days CTCs viability evaluation after purification by our innovative LUTON microfluidic device\"\\n139,1,1,\"2 Year Disease-free Survival .\"\\n140,1,1,\"2 Year Failure Free Survival\"\\n141,1,1,\"2 Year Local Control Rate\"\\n142,1,1,\"2 year local control rate\"\\n143,2,1,\"2 year overall survival\"\\n144,1,1,\"2 year progression free survival rate\"\\n145,1,1,\"2 year Recurrence-Free Survival Rate\"\\n146,1,1,\"2) Incidence of (severe) adverse events (SAE/AEs) related to administration of durvalumab-680LT assessed by CTCAE\"\\n147,1,1,\"2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer.\"\\n148,2,1,\"2-month Progression-free Survival Rate\"\\n149,1,1,\"2-month Response Rate\"\\n150,1,1,\"2-month Tumor Response\"\\n151,1,1,\"2-y PFS\"\\n152,1,1,\"2-year brain metastasis-free survival estimated with kaplan-Meier method\"\\n153,1,1,\"2-year Disease free survival (DFS) rate\"\\n154,1,1,\"2-year Event-free Survival\"\\n155,1,1,\"2-year local progression-free survival rate\"\\n156,6,1,\"2-year overall survival\"\\n157,1,1,\"2-year Overall Survival (Phase II)\"\\n158,3,1,\"2-year Overall Survival Rate\"\\n159,3,1,\"2-year progression free survival rate\"\\n160,2,1,\"2-year Progression-free Survival\"\\n161,2,1,\"2-year Progression-free Survival (PFS)\"\\n162,2,1,\"2-year Progression-free Survival Rate\"\\n163,1,1,\"2-Year Survival\"\\n164,1,1,\"2. Phase Ib/II: To evaluate clinical activity/efficacy of HS-10370 by assessment of objective response rate\"\\n165,1,1,\"2. Tumor vessel density (# tumor vessels per square cm area observed)\"\\n166,1,1,\"2.Adverse event (AE)\"\\n167,1,1,\"20 patients with Lu-Dotatate MRT response to therapy outcome as Assessed by response evaluation criteria in solid tumours RECIST (version 1.1)\"\\n168,1,1,\"20 Week Progression Free Survival Rate\"\\n169,1,1,\"20S proteasome inhibition\"\\n170,1,1,\"22-30 participants with treatment-related adverse events as assessed based on CTCAE v5.0.\"\\n171,1,1,\"24 Week Progression Free Survival\"\\n172,1,1,\"24-week Clinical Benefit Rate (CBR24w) in Phase II part\"\\n173,1,1,\"24-week progression-free survival (PFS) rate\"\\n174,1,1,\"24-week progression-free survival (PFS) ratev\"\\n175,3,1,\"28-day survival rate\"\\n176,1,1,\"3 Month Complete Response Rate + Partial Response Rate\"\\n177,1,1,\"3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy\"\\n178,1,1,\"3 Month Progression Free Survival (PFS) in the All Eligible Patients by Group/Arm\"\\n179,1,1,\"3-month disease control rate (DCR) will be evaluated using RECIST v 1.1 in cohort B patients.\"\\n180,1,1,\"3-month Progression Free Survival Rate\"\\n181,1,1,\"3-month Progression-free Survival (3-mo PFS) Rate\"\\n182,1,1,\"3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC)\"\\n183,5,1,\"3-year DFS rate\"\\n184,24,1,\"3-year disease free survival rate\"\\n185,1,1,\"3-year iDFS rate\"\\n186,1,1,\"3-year local recurrence-free survival (LRFS)\"\\n187,11,1,\"3-year overall survival\"\\n188,1,1,\"3-Year Overall Survival Rate\"\\n189,1,1,\"3. Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake)\"\\n190,1,1,\"3.Serious adverse event (SAE)\"\\n191,1,1,\"30-day postoperative comorbidity\"\\n192,1,1,\"4 Month Progression-free Survival\"\\n193,1,1,\"4 months progression-free survival\"\\n194,2,2,\"4-month Progression Free Survival (PFS) Rate\"\\n195,1,1,\"4-month Progression-free Survival (PFS) Rate\"\\n196,1,1,\"4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase\"\\n197,2,2,\"4-month Progression-Free Survival Rate\"\\n198,1,1,\"4-month progression-free survival rate (PFS4, in a subgroup (Cohort 1.3) within Substudy 1)\"\\n199,1,1,\"4-month Tumor Response\"\\n200,1,1,\"4. Tumor blood flow (velocity, mm/sec)\"\\n201,1,1,\"4.Maximum tolerated dose (MTD)\"\\n202,1,1,\"4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin\"\\n203,1,1,\"5 year Event Free Survival\"\\n204,3,1,\"5 years disease-free survival\"\\n205,14,1,\"5-year overall survival\"\\n206,1,1,\"5.Recommended phase II dose (RP2D)\"\\n207,1,1,\"6 Month Landmark Progression Free Survival\"\\n208,4,3,\"6 Month Progression Free Survival (PFS)\"\\n209,1,1,\"6 Month Progression Free Survival (PFS) in the Platinum Sensitive Group (Phase II)\"\\n210,1,1,\"6 Month Progression-Free Survival\"\\n211,1,1,\"6 Month Progression-free Survival (PFS)\"\\n212,1,1,\"6 Month Progression-free Survival (PFS6)\"\\n213,1,1,\"6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG) CA125 Criteria)\"\\n214,1,1,\"6 month progression-free-survival-rate (PFS6)\"\\n215,1,1,\"6 months progression free survival rates\"\\n216,1,1,\"6 Week Progression Free Survival\"\\n217,1,1,\"6-12 year old pediatric oncology patients\\' perceptions of their school experiences pre and post cancer diagnosis will be explored;\"\\n218,1,1,\"6-month and 12-month Progression-free Survival (PFS) Rates\"\\n219,1,1,\"6-month disease control rate in the adult cohort\"\\n220,1,1,\"6-month Local Control (i.e., Complete Response, Partial Response, or Stable Disease) at All Treated Sites of Metastatic Disease\"\\n221,1,1,\"6-month objective response rate (ORR) of patients treated with copanlisib and nivolumab\"\\n222,5,1,\"6-month PFS rate\"\\n223,1,1,\"6-month PFS rate (6 month progression-free survival rate)\"\\n224,1,1,\"6-month Progression free survival (PFS)\"\\n225,2,1,\"6-month Progression Free Survival Rate\"\\n226,5,2,\"6-month progression-free survival\"\\n227,2,1,\"6-month progression-free survival (PFS) rate\"\\n228,1,1,\"6-month Progression-free Survival (PFS) rate - Cohort 4\"\\n229,1,1,\"6-Month Progression-Free Survival (PFS6) [Phase II]\"\\n230,1,1,\"6-month Progression-Free Survival Rate\"\\n231,4,2,\"6-month progression-free survival rate\"\\n232,1,1,\"6-Month Progression-free Survival Rate (6m-PFSR)\"\\n233,1,1,\"6-month progression-free survival rate (Group 2)\"\\n234,1,1,\"6-month radiographic progression-free survival\"\\n235,1,1,\"6-month Response Rate (Complete Response, Partial Response, and Stable Disease)\"\\n236,3,1,\"6-month survival rate\"\\n237,1,1,\"6-month survival rate (Group 1)\"\\n238,1,1,\"6-month Tumor Response\"\\n239,1,1,\"6-month-OS rate\"\\n240,1,1,\"6.Objective response rate(ORR)\"\\n241,1,1,\"6m-PFS\"\\n242,1,1,\"8 Week Completion Rate\"\\n243,1,1,\"8-Week Disease Control Rate\"\\n244,1,1,\"8-Week Disease Control Rate (DCR)\"\\n245,1,1,\"8-week Freedom-From-Progression (FFP)\"\\n246,1,1,\"9-month Progression Rate Post-randomization\"\\n247,1,1,\"9-week Progression-free Survival Rate\"\\n248,1,1,\"[18F] FLT uptake as a marker of cellular proliferation\"\\n249,1,1,\"[Part A] Dose Limiting Toxicity (DLT)\"\\n250,1,1,\"[Part A] Dose-limiting toxicity (DLT)\"\\n251,1,1,\"[Part A] Maximum tolerated Dose (MTD)\"\\n252,1,1,\"[Part A] Non-tolerated Dose (NTD)\"\\n253,1,1,\"[Part A] Rate of Dose Limiting Toxicity (DLT)\"\\n254,2,2,\"[Part B] Confirmed objective response rate (ORR)\"\\n255,1,1,\"[Part C -NSCLC Cohort] Objective response rate (ORR)\"\\n256,1,1,\"[Part C] DLT\"\\n257,1,1,\"[Part C] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)\"\\n258,1,1,\"[Parts A and B] Safety Analysis: summarizing adverse events (AEs) and will be based on treatment-emergent AEs (TEAEs)\"\\n259,1,1,\"[Phase 1] Determine the maximum tolerated dose (MTD) of BLU-222\"\\n260,1,1,\"[Phase 1] Determine the recommended Phase 2 dose (RP2D) of BLU-222\"\\n261,1,1,\"[Phase 1] Rate and severity of adverse events\"\\n262,2,1,\"[Phase 2] Overall response rate (ORR)\"\\n263,1,1,\"[Phase 2] Rate and severity of adverse events\"\\n264,1,1,\"[Phase II] Objective Response Rate (ORR)\"\\n265,1,1,\"[Phase III] Progression Free Survival (PFS)\"\\n266,1,1,\"[Stage 1] Maximum applicable dose (MAD) of HS-10352 in combination with fulvestrant\"\\n267,1,1,\"[Stage 1] Maximum tolerated dose (MTD) of HS-10352 in combination with fulvestrant\"\\n268,1,1,\"[Stage 2] Objective response rate (ORR) of HS-10352 in combination with fulvestrant\"\\n269,1,1,\"A Comprehensive Source of Observational Data to assess Stem Cell Transplant\"\\n270,1,1,\"a dose-limiting toxicity (DLT)\"\\n271,1,1,\"A primary endpoint will be to determine any potential dose limiting toxicities, & the Maximal Tolerated Dose of hydralazine & valproic acid regimen.\"\\n272,1,1,\"A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL\"\\n273,1,1,\"A quantitative study on usability\"\\n274,1,1,\"A randomized controlled trial comparing the efficacy of Individual Meaning- Centered Psychotherapy (IMCP), a standardized Individual Supportive Psychotherapy (ISP) and Enhanced Usual Care (EUC)\"\\n275,1,1,\"A recommended Phase II dose (RP2D) as an alternative to establishing the MTD.\"\\n276,1,1,\"AB-106 PK Exposure Parameters\"\\n277,3,1,\"Abdomen\"\\n278,1,1,\"Abemaciclib Maximum Tolerated Dose (MTD) for Diffuse Intrinsic Pontine Glioma (DIPG)\"\\n279,1,1,\"Abemaciclib Maximum Tolerated Dose (MTD) for Recurrent/Refractory Solid Tumors\"\\n280,1,1,\"Ability of CTC levels to predict progression-free survival (PFS) in MBC patients.\"\\n281,1,1,\"Ability to distinguish between receiving placebo or study drug and variables involved (e.g., taste, smell, or decrease in nausea and vomiting)\"\\n282,1,1,\"Ability to interpret medical statistics as measured by a medical data interpretation test\"\\n283,1,1,\"Ability to predict toxicity to chemotherapy, defined as grade 3-4 toxicity, hospitalization, dose delay or reduction, or discontinuation of chemotherapy due to toxicity, as measured by a geriatric assessment tool\"\\n284,1,1,\"Ability to respond to the questions when asked using Google Translate\"\\n285,1,1,\"Ability to safely deliver the combination of mitomycin C and veliparib\"\\n286,1,1,\"Ability to safely deliver veliparib in a continuous dose as monotherapy\"\\n287,1,1,\"Ablation efficacy of EUS-RFA\"\\n288,1,1,\"Abnormal Laboratory Test results\"\\n289,1,1,\"Abnormal T/U waves\"\\n290,1,1,\"Abnormalities in 12-lead ECG parameters (Phase 1)\"\\n291,3,1,\"abscopal effect rate\"\\n292,2,1,\"Abscopal Response Rate\"\\n293,1,1,\"Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA\"\\n294,1,1,\"Absolute Neutrophil Count (ANC) Across All Cycles\"\\n295,1,1,\"Absolute Neutrophil Count (ANC) at EP2006 Initiation\"\\n296,1,1,\"Absolute Oral Bioavailability of [13C]-Labeled Idasanutlin\"\\n297,1,1,\"Absolute Richmond Agitation-Sedation Scale Score at 8 Hour, Points\"\\n298,1,1,\"Absorption\"\\n299,1,1,\"Abstinence for 7 consecutive days and 24 hours at 1, 3, and 6 months\"\\n300,1,1,\"Abuse liability potential of SH bolus versus FH bolus (from the \"\"DRUG LIKING\"\" scale of the DEQ questionnaire)\"\\n301,1,1,\"Accelerometry Test\"\\n302,187,1,\"Acceptability\"\\n303,1,1,\"Acceptability (helpfulness of the intervention)\"\\n304,1,1,\"Acceptability of MyInspiration\"\\n305,29,1,\"Acceptability of the intervention\"\\n306,1,1,\"Acceptability of the PACT application: Acceptability E-Scale [Caregivers]\"\\n307,1,1,\"Acceptability of the PACT application: Acceptability E-Scale [Patients]\"\\n308,1,1,\"Acceptability, effectiveness, and adherence to regimens including polyvinylpyrrolidone-sodium hyaluronate gel\"\\n309,1,1,\"Acceptable signal-to-noise ratio (75 or above)\"\\n310,10,1,\"Acceptance\"\\n311,1,1,\"Access the preliminary antitumor activity of ADG126-pembrolizumab combination regimens\"\\n312,1,1,\"Access toxicity as evidenced by the number and percent of treatment adverse events.\"\\n313,1,1,\"According to response evaluation criteria in solid tumours 1.1ÔºàRECIST1.1Ôºâstandard and iRECIST ÔºàImmune-related response evaluation criteria in solid tumours Ôºâstandard researcher\\'s assessment of progression-free survival (PFS)\"\\n314,9,2,\"Accrual\"\\n315,1,1,\"Accrual for clinical research protocols\"\\n316,1,1,\"Accrual of patients to ComboMATCH treatment trials\"\\n317,1,1,\"Accrual rate (number of patients and caregivers enrolled per month)\"\\n318,1,1,\"Accrual rate in early phase clinical trials\"\\n319,1,1,\"Accrual rate, calculated by total number of patients accrued divided by number of months from the date the study is opened at the fifth site to the evaluation date\"\\n320,1,1,\"Accumulation Half-life of Talazoparib in Combination With Temozolomide.\"\\n321,1,1,\"Accumulation Index (AI) After Multiple Doses of GDC-0449\"\\n322,1,1,\"Accumulation Index of CC-115\"\\n323,1,1,\"Accumulation index of CC-90003\"\\n324,1,1,\"Accumulation Ratio (AR) for AMG 386\"\\n325,1,1,\"Accumulation Ratio (R) of Atezolizumab Based on Concentrations After the First Dose and at Steady State\"\\n326,1,1,\"Accumulation Ratio (R) of Intetumumab - Phase 1 (Part 1)\"\\n327,1,1,\"Accumulation ratio (RAC) after multiple doses\"\\n328,1,1,\"Accumulation ratio (Rac) of Capivasertib\"\\n329,1,1,\"Accumulation Ratio (Rac) of GDC-0575\"\\n330,1,1,\"Accumulation Ratio (Rac) on Cycle 1 Day 28\"\\n331,1,1,\"Accumulation ratio at steady state (Rcmax) of Ipatasertib\"\\n332,1,1,\"Accumulation ratio from first dose to steady-state (PK)\"\\n333,1,1,\"Accumulation Ratio of RO5185426 AUC From 0 to 8 Hours Between Day 21 and Day 1\"\\n334,1,1,\"Accumulation Ratio of Talazoparib in Combination With Temozolomide\"\\n335,1,1,\"Accumulation ratio of trametinib following single and repeat dose(2mg QD)\"\\n336,1,1,\"Accumulation Ratio of Vemurafenib on Day 15\"\\n337,56,2,\"Accuracy\"\\n338,1,1,\"accuracy of 19G Flex Expect needle in the histological diagnosis of pancreatic solid tumors of the head of pancreas\"\\n339,1,1,\"Accuracy of achieving the targeted carboplatin area under the curve (AUC)\"\\n340,1,1,\"accuracy of algorithm\"\\n341,1,1,\"Accuracy of CT\"\\n342,1,1,\"Accuracy of ejection fraction (EF) in the clinic setting, and determine its reproducibility at home.\"\\n343,1,1,\"Accuracy of endoscopists for interpretation of cytologic specimen adequacy and primary diagnosis of malignancy\"\\n344,1,1,\"Accuracy of EUS-guided nCLE in a cohort of cystic pancreatic tumors\"\\n345,1,1,\"accuracy of molecular stool test (Cologuard) and FIT\"\\n346,1,1,\"Accuracy of postoperative ctDNA in monitoring recurrence and metastasis\"\\n347,1,1,\"Accuracy of stylet-free, solid lesion EUS-FNA using the 22 G FNA vs the 25 G FNA needle, in consecutive patients referred to EUS-FNA.\"\\n348,1,1,\"Accuracy of using the model to predict the therapeutic effect of drugs\"\\n349,1,1,\"Accuracy of USPIO MRI on a regional basis\"\\n350,1,1,\"acetylation level of histone H3, open-label period\"\\n351,1,1,\"Achievement of PSA remission assessed using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria\"\\n352,1,1,\"Acquisition of tissue, blood, and other biospecimens for research purposes\"\\n353,1,1,\"Action taken related to larotrectinib treatment\"\\n354,1,1,\"Activated partial thromboplastin time in whole blood sample\"\\n355,15,1,\"Activity\"\\n356,1,1,\"Activity and efficacy of SABR measured by Freedom from local progression assessed by RECIST Criteria\"\\n357,1,1,\"Activity Of Avelumab and Avelumab plus Talazoparib In Patients With Recurrent Or Persistent Endometrial Cancer\"\\n358,1,1,\"Activity of NC-6004 measured by progression-free survival (PFS)\"\\n359,1,1,\"activity of regorafenib screening, in terms of 2-months progression free survival rate\"\\n360,1,1,\"Activity of Vemurafenib in Untreated Brain Metastases\"\\n361,1,1,\"ACTR T cell persistence in subjects previously treated with an ACTR T cell product\"\\n362,31,1,\"Acute kidney injury\"\\n363,1,1,\"acute nausea and vomiting\"\\n364,1,1,\"Acute radiation induced mucositis and dermatitis\"\\n365,1,1,\"Acute respiratory failure rate\"\\n366,5,1,\"Acute toxicities\"\\n367,1,1,\"Acute toxicities data in patients treated with proton therapy\"\\n368,1,1,\"Acute toxicity graded by NCI/DCTDC Common Toxicity Criteria\"\\n369,2,1,\"Acute Toxicity Rate\"\\n370,1,1,\"Acute, subacute toxicities and AEs of neoantigen-expanded autologous immune cell therapy.\"\\n371,1,1,\"Adequacy of peripheral blood mononuclear cell DNA methylation as a surrogate for tumor DNA methylation, measured by effect of dose on reduction in DNA methylation in peripheral blood mononuclear cells\"\\n372,161,3,\"Adherence\"\\n373,1,1,\"Adherence at 70% or more of the completed exercise sessions.\"\\n374,32,1,\"Adherence rate\"\\n375,1,1,\"Adherence rate to the different components of the MyPal services by documentation of user behavior and qualitative analysis\"\\n376,1,1,\"Adherence to guideline-level depression treatment\"\\n377,1,1,\"Adherence to individual items\"\\n378,1,1,\"Adherence to standard of care for hereditary breast and ovarian cancer (HBOC) and Lynch syndromes\"\\n379,1,1,\"Adherence to treatment (participants will be provided a pill diary to record when they take their medication. Study staff will collect the pill diary from participants at their clinic visits).\"\\n380,1,1,\"Adherence: drug accountability\"\\n381,1,1,\"Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups\"\\n382,1,1,\"Administration time of PEG-rhG-CSF in chemotherapy\"\\n383,5,1,\"ADR\"\\n384,1,1,\"Advanced neoplasia and colorectal cancer incidence at 2 years\"\\n385,1,1,\"Advanced neoplasia and colorectal cancer incidence at 3 years\"\\n386,1,1,\"Adverse effects after intravenous infusions\"\\n387,36,3,\"Adverse Event\"\\n388,39,7,\"Adverse event\"\\n389,11,1,\"adverse event\"\\n390,1,1,\"Adverse Event (AE )\"\\n391,9,3,\"Adverse Event (AE)\"\\n392,5,1,\"Adverse event (AE)\"\\n393,1,1,\"Adverse event (AE) safety information for EVT801\"\\n394,1,1,\"Adverse event according to CTCAE version 3 criteria\"\\n395,1,1,\"Adverse event assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 after scheduled TACE-RT for HCC with PVTT\"\\n396,3,1,\"Adverse Event Collection\"\\n397,2,1,\"Adverse Event collection\"\\n398,6,2,\"Adverse event collection\"\\n399,2,1,\"Adverse Event collection and assessment\"\\n400,1,1,\"Adverse Event collection and assessment will be done for all 74 potentially treated subjects.\"\\n401,1,1,\"Adverse event number by treatment group as a measure of safety and tolerability\"\\n402,1,1,\"Adverse event of special interest\"\\n403,1,1,\"Adverse event profile of azacitidine and recombinant interferon alfa-2b in patients with unresectable or metastatic melanoma and renal cell carcinoma\"\\n404,3,1,\"Adverse Event Rates\"\\n405,3,1,\"Adverse Event reporting\"\\n406,4,3,\"Adverse Event(AE)\"\\n407,1,1,\"Adverse event(AE)\"\\n408,1,1,\"Adverse Event(s) and Serious Adverse Event(s)\"\\n409,491,35,\"Adverse Events\"\\n410,504,33,\"Adverse events\"\\n411,57,3,\"adverse events\"\\n412,22,9,\"Adverse Events (AE)\"\\n413,7,2,\"Adverse events (AE)\"\\n414,2,1,\"Adverse events (AE) and serious adverse events (SAE)\"\\n415,1,1,\"Adverse events (AE) of HTMC0435 combined with Temozolomide\"\\n416,1,1,\"Adverse events (AE) rate\"\\n417,1,1,\"Adverse events (AE), serious adverse events (SAEs), suspected unexpected serious adverse reaction (SUSAR), physical examination, etc. (CTCAE 5.0 standard)\"\\n418,95,16,\"Adverse Events (AEs)\"\\n419,53,12,\"Adverse events (AEs)\"\\n420,4,2,\"adverse events (AEs)\"\\n421,1,1,\"Adverse Events (AEs) (Dose escalation part)\"\\n422,1,1,\"Adverse events (AEs) (Phase 1)\"\\n423,1,1,\"adverse events (AEs) adverse events (AEs)\"\\n424,1,1,\"Adverse events (AEs) and changes in laboratory values and vital signs as per protocol.\"\\n425,1,1,\"Adverse events (AEs) and changes in laboratory values and vital signs.\"\\n426,1,1,\"Adverse events (AEs) and changes in laboratory values and vital signs. Pharmacokinetic parameter values for GSK2126458, Change from baseline in protein markers in tumor and/or blood. Blood glucose and insulin levels. Tumor response, RECIST defined\"\\n427,7,1,\"Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n428,7,3,\"Adverse events (AEs) and serious adverse events (SAEs)\"\\n429,1,1,\"Adverse Events (AEs) and Serious Adverse Events (SAEs) measured using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0\"\\n430,1,1,\"Adverse Events (AEs) by incidence and severity\"\\n431,1,1,\"Adverse events (AEs) graded according to CTCAE v4.03.\"\\n432,1,1,\"Adverse events (AEs) of safety run-in part\"\\n433,1,1,\"Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD))\"\\n434,2,1,\"Adverse Events (AEs), and Serious Adverse Events (SAEs)\"\\n435,1,1,\"adverse events (AEs), and serious adverse events (SAEs) overall\"\\n436,1,1,\"Adverse events (AEs), Serious Adverse Events (SAE)Number of patients with AEs and SAEs\"\\n437,1,1,\"Adverse events (AEs), serious adverse events (SAEs)\"\\n438,1,1,\"Adverse events (AEs), serious AEs (SAEs), assessments of clinical laboratory values, and vital sign measurements\"\\n439,1,1,\"Adverse events (Description of event in medical terminology, Intensity, Relationship to drug, Outcome, and/or Follow up )(Part 2)\"\\n440,1,1,\"Adverse Events (Grade 3 or Higher) During First Cycle of Treatment\"\\n441,2,1,\"Adverse Events (Grade 3 or Higher) During Treatment Period\"\\n442,1,1,\"Adverse events (including serious adverse events and adverse events lead to treatment discontinuation) will be described according to severity and to their relationship with the study drug and injection procedure.\"\\n443,2,2,\"Adverse Events (Part 1 and Part 2)\"\\n444,1,1,\"Adverse events (Part 1)\"\\n445,1,1,\"Adverse Events (Parts 1 & 2)\"\\n446,1,1,\"Adverse Events (Parts A & B)\"\\n447,1,1,\"Adverse events (TEAEs) and incidence after initial infusion, treatment-related adverse events and incidence, AESI and incidence of special concern\"\\n448,1,1,\"Adverse Events (Types, Incidence, severity, Relationship to SyB C-0501)\"\\n449,1,1,\"adverse events - type, incidence, severity\"\\n450,1,1,\"Adverse events accessment, changes of physical signs, laboratory examination and 12-lead electrocardiogram.\"\\n451,2,2,\"Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses\"\\n452,1,1,\"Adverse Events according to CTCAE V5.0\"\\n453,1,1,\"Adverse events according to NCI CTCAE version 4.0\"\\n454,1,1,\"Adverse events and dose-limiting toxicities\"\\n455,1,1,\"Adverse Events and Laboratory Parameters\"\\n456,2,1,\"adverse events and other safety assessments\"\\n457,1,1,\"Adverse events and other symptoms as assessed by NCI CTCAE v3.0\"\\n458,1,1,\"Adverse events and safety evaluations\"\\n459,12,4,\"Adverse Events and Serious Adverse Events\"\\n460,1,1,\"Adverse events and Serious Adverse events\"\\n461,9,1,\"Adverse events and serious adverse events\"\\n462,4,1,\"Adverse Events as a Measure of Safety and Tolerability\"\\n463,1,1,\"Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.\"\\n464,1,1,\"Adverse events as a measure of the safety and tolerability profile of pazopanib in combination with GSK1120212 in patients with solid tumors\"\\n465,2,2,\"Adverse events as assessed by (CTCAE) version 4.0\"\\n466,1,1,\"Adverse events as assessed by NCI Common Toxicity Criteria for Adverse Events CTCAE v3.0\"\\n467,1,1,\"Adverse Events as Assessed by NCI CTCAE v 4.0\"\\n468,1,1,\"Adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n469,1,1,\"Adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0\"\\n470,1,1,\"Adverse events assessed according to NCI-CTCAE V5.0\"\\n471,1,1,\"Adverse events associated with technical aspects of the operation\"\\n472,1,1,\"Adverse events attributed to Nivolumab for patients enrolled in this study\"\\n473,1,1,\"Adverse events attributed to the administration of the anti-MUC1 CAR-T cells\"\\n474,1,1,\"Adverse events attributed to the administration of the chimeric antigen receptor T cells\"\\n475,1,1,\"Adverse Events by type, frequency, and severity\"\\n476,1,1,\"Adverse Events Causing Dose Limiting Toxicities\"\\n477,1,1,\"Adverse Events Deemed at Least Possibly Related to Treatment, as Assessed by NCI CTCAE Version 4.0\"\\n478,1,1,\"Adverse events described using the NCI CTCAE criteria\"\\n479,1,1,\"Adverse Events Due to Administration of TAPA-Pulse DC Vaccine\"\\n480,1,1,\"Adverse events evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.\"\\n481,1,1,\"Adverse Events Evaluated by CTCAE 4.0\"\\n482,2,2,\"Adverse events evaluated by NCI CTCAE v5.0\"\\n483,1,1,\"Adverse Events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0\"\\n484,1,1,\"Adverse events graded in accordance with \"\"Common Terminology Criteria for Adverse Events (CTCAE)\"\", NCI version 4.03\"\\n485,1,1,\"Adverse events in part I\"\\n486,1,1,\"Adverse Events Incidence Indicating Safety of Navigational Bronchoscopy-interstitial-Photodynamic Therapy (i-PDT)\"\\n487,1,1,\"Adverse Events Incidence Indicating Safety of Novel Photodynamic Therapy\"\\n488,1,1,\"Adverse events of cavrotolimod alone and in combination with pembrolizumab or cemiplimab\"\\n489,1,1,\"Adverse events of dose escalated alvocidib administered in patients with advanced solid tumors\"\\n490,1,1,\"Adverse events of oral LCL161\"\\n491,1,1,\"Adverse Events of rSIFN-co of recombinant interferon-Œ± administered in solid Tumor\"\\n492,1,1,\"Adverse events of SAIL66[safety and tolerability]\"\\n493,2,1,\"Adverse Events of Special Interest (AESI)\"\\n494,1,1,\"Adverse Events of Special Interest (AESIs) - Cytokine Release Syndrome (CRS)\"\\n495,1,1,\"Adverse Events of Special Interest (AESIs) - Immune Effector cell-associated neurotoxicity syndrome (ICANS)\"\\n496,1,1,\"Adverse Events of the Combination of Glembatumumab Vedotin and CDX-301 (in Cohort 4).\"\\n497,7,3,\"Adverse events profile\"\\n498,1,1,\"Adverse events profile, as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n499,4,1,\"Adverse events rate\"\\n500,2,1,\"Adverse Events Severity and Frequency\"\\n501,1,1,\"Adverse events that are defined as dose limiting toxicities occurring in the first 21 days of treatment in Group 1 and the first 28 days of treatment in Group 2.\"\\n502,2,1,\"Adverse events that are related to treatment\"\\n503,15,1,\"Adverse events that related to treatment\"\\n504,1,1,\"Adverse Events ‚â•Grade 3 during the 28 days (4 weeks) following the single dose of bexmarilimab and surgical adverse events ‚â•Grade 3 during the 14days (2 weeks) following the surgery\"\\n505,1,1,\"Adverse Events(AE)\"\\n506,1,1,\"Adverse events(AE) of SHR-1603\"\\n507,2,1,\"Adverse events(AEs)\"\\n508,1,1,\"Adverse events(AEs), treatment emergent adverse event (TEAEs) ,serious adverse events (SAEs)\"\\n509,1,1,\"Adverse events(Phase 1 dose escalation)\"\\n510,1,1,\"Adverse events, based on the NCI CTC v2.0\"\\n511,1,1,\"Adverse events, clinically significant changes in laboratory results, ECG, and vital signs, to be measured throughout the study.\"\\n512,1,1,\"Adverse events, graded according to NCI CTCAE version 3.0\"\\n513,1,1,\"Adverse events, graded according to the NCI CTC v3.0\"\\n514,1,1,\"Adverse Events, graded by the National Cancer Institute Common Terminology Criteria for Adverse Event\\'s (CTCAE v4.3)\"\\n515,1,1,\"Adverse events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)\"\\n516,2,1,\"Adverse events, laboratory parameters, vital signs\"\\n517,1,1,\"Adverse events, serious adverse events occurrence\"\\n518,2,1,\"Adverse reaction rate\"\\n519,29,8,\"AE\"\\n520,1,1,\"AE and SAE incidence\"\\n521,1,1,\"AE Assessment\"\\n522,1,1,\"Ae feces, 14C: Cumulative Amount of Radioactivity Excreted in Feces for [14C]-TAK-659\"\\n523,1,1,\"AE that leads to the termination or suspension of treatment\"\\n524,1,1,\"Ae total: Total Cumulative Amount of Radioactivity Excreted in Urine and Feces for [14C]-TAK-659\"\\n525,1,1,\"Ae urine,14C: Cumulative Amount of Radioactivity Excreted in Urine for [14C]-TAK-659\"\\n526,1,1,\"Ae urine: Cumulative Amount of TAK-659 Excreted in Urine\"\\n527,1,1,\"Ae(0-tz) of 14C Radioactivity in Urine\"\\n528,1,1,\"Ae(0-tz) of Volasertib and CD 10899 in Urine\"\\n529,1,1,\"AE(Adverse Events)\"\\n530,1,1,\"AE, SAE occurrence and frequency (according to NCI CTCAE 5.0)\"\\n531,1,1,\"Ae,Faeces(0-tz) of 14C Radioactivity\"\\n532,1,1,\"AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8\"\\n533,5,3,\"AE/SAE\"\\n534,1,1,\"Ae: Amount of [^14C]-Alisertib Excreted in Feces\"\\n535,1,1,\"Ae: Amount of [^14C]-Alisertib Excreted in Urine\"\\n536,1,1,\"Ae: Amount of Alisertib Excretion in Urine\"\\n537,18,7,\"AEs\"\\n538,1,1,\"AEs (adverse events)\"\\n539,1,1,\"AEs and changes in laboratory values and vital signs\"\\n540,5,2,\"AEs and SAEs\"\\n541,1,1,\"AEs of special interest (immune-related AEs)\"\\n542,1,1,\"AEs related to study drug\"\\n543,1,1,\"AEs will be recorded and evaluated by CTCAT 5.0.\"\\n544,1,1,\"AEs+SAEs\"\\n545,1,1,\"AEs, laboratory parameters, Cmax, Tmax, AUC, clearance, Vdss elimination half life\"\\n546,2,2,\"AEs, laboratory parameters.\"\\n547,1,1,\"AEs, SAEs and DLT\"\\n548,5,2,\"AEs/SAEs\"\\n549,5,1,\"AESIs\"\\n550,1,1,\"AFP variation rate\"\\n551,1,1,\"After oral administration of [14C] IMP4297 in healthy volunteers, radioactive metabolite spectrogram are obtained to identify the main metabolites and clarify the main biotransformation pathways.\"\\n552,1,1,\"Aggregate specimen length (ASL)\"\\n553,1,1,\"Aggressiveness of care\"\\n554,1,1,\"Agreement rate between urine cell-free DNA and tumor tissue mutation profile\"\\n555,1,1,\"AIM 1 (survival)\"\\n556,1,1,\"AK Lesions Counts/Surface Area\"\\n557,1,1,\"AKT Modulation\"\\n558,1,1,\"Alcohol use intentions and behavior\"\\n559,1,1,\"All cause adverse events\"\\n560,1,1,\"All causes of mortality\"\\n561,1,1,\"All Cohorts: Independent Review Committee (IRC)-assessed objective response rate (ORR) based on confirmed objective response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n562,1,1,\"All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)\"\\n563,1,1,\"All Cohorts: The change from baseline in Fridericia\\'s corrected QT (ŒîQTcF) interval\"\\n564,1,1,\"All Cycle 1 Toxicities >=Grade 3\"\\n565,1,1,\"All health events of interest\"\\n566,1,1,\"All Phase I-II Participants: Overall Response Rate (ORR)\"\\n567,1,1,\"All Phases: Incidence of treatment related adverse events (Safety and tolerability)\"\\n568,1,1,\"All Substudies-Dose Escalation Parts Only: Number of Dose Limiting Toxicities (DLTs)\"\\n569,1,1,\"All Substudies: Incidence of AEs leading to discontinuation of AZD8853\"\\n570,1,1,\"All Substudies: Number of participants with adverse events (AEs)\"\\n571,1,1,\"All Substudies: Number of participants with serious adverse events (SAEs)\"\\n572,1,1,\"All Substudies: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n573,238,2,\"All-cause mortality\"\\n574,1,1,\"ALP laboratory values\"\\n575,1,1,\"ALT concentration in whole blood sample\"\\n576,1,1,\"ALT laboratory values\"\\n577,1,1,\"Alterations in assessment of ECOG\"\\n578,1,1,\"Alterations in clinical laboratory test results\"\\n579,1,1,\"Alterations in ECGs results\"\\n580,1,1,\"Alterations in physical examination findings\"\\n581,1,1,\"Alterations in vital sign measurements\"\\n582,1,1,\"Alternative two-compartment TheraSphere dosimetry methodology\"\\n583,2,1,\"Ambulation time\"\\n584,1,1,\"AMG 228 area under the concentration-time curve (AUC)\"\\n585,1,1,\"AMG 228 half-life (t1/2)\"\\n586,1,1,\"AMG 228 maximum observed concentration (Cmax)\"\\n587,1,1,\"AMG 228 minimum observed concentration (Cmin)\"\\n588,1,1,\"Amivantamab Steady-state Area Under the Curve (AUCss)\"\\n589,1,1,\"Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the urine and faeces from time t1 to time t2\"\\n590,1,1,\"Amount of analyte excreted in urine\"\\n591,1,1,\"Amount of Candida spp in vaginal microbiota\"\\n592,1,1,\"Amount of Estimated Blood Loss (EBL) in ml\"\\n593,1,1,\"Amount of Gardnerella vaginalis in vaginal microbiota\"\\n594,1,1,\"Amount of Lactobacillus in vaginal microbiota\"\\n595,1,1,\"amount of propofol dose used in sedation\"\\n596,1,1,\"Amount of Roniciclib in feces as percentage of the dose of total radioactivity.\"\\n597,1,1,\"Amount of Roniciclib in urine as percentage of the dose of total radioactivity.\"\\n598,1,1,\"Amount of Roniciclib in vomit as percentage of the dose of total radioactivity\"\\n599,1,1,\"Amount of Talazoparib Excreted in Urine During Each Collection Interval (Ae t1-t2)\"\\n600,1,1,\"Amount of tissue micro-fragments\"\\n601,1,1,\"Amount of transdermal water in the skin\"\\n602,1,1,\"Amount, cumulative amount, and cumulative percentage of unchanged adavosertib excreted into urine from time t1 to time t2\"\\n603,1,1,\"Amylase and Lipase (Safety and Tolerability in the Dose Escalation Phase)\"\\n604,1,1,\"An Apparent Volume of Distribution at Steady-state (Vss) of Plasma Concentration of Paclitaxel in Cycle 1 (in the Absence of T-DM1) and Cycle 2 (in the Presence of T-DM1)\"\\n605,1,1,\"An Elimination Half-life (t1/2) of Plasma Concentration of Paclitaxel in Cycle 1 (in the Absence of T-DM1) and Cycle 2 (in the Presence of T-DM1)\"\\n606,1,1,\"analyse a set of 1951 genes for prediction of response measured by time to progression (TTP) ratio (defined as the TTP without drug: TTP on drug) on mTOR inhibition.\"\\n607,1,1,\"Analyse categorical variable outcomes of patient undergoing contrast-enhanced harmonic endoscopic ultrasound imaging using medical record review and chi-square test or Fisher\\'s exact test.\"\\n608,1,1,\"Analyse continuous variable outcomes of patient undergoing contrast-enhanced harmonic endoscopic ultrasound imaging using medical record review and T-tests or Mann-Whitney U test.\"\\n609,1,1,\"Analyse multivariables of patient undergoing contrast-enhanced harmonic endoscopic ultrasound imaging using medical record review and logistic regression or linear regression analyses depending on the outcome.\"\\n610,1,1,\"Analysis of Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration of Pexidartinib and ZAAD-1006a (AUClast) in Part 1\"\\n611,1,1,\"Analysis of Pharmacokinetic Parameter: Area Under the Concentration-Time Curve Up to Infinity of Pexidartinib and ZAAD-1006a (AUCinf) in Part 1\"\\n612,1,1,\"Analysis of Pharmacokinetic Parameter: Maximum Concentration of Pexidartinib and ZAAD-1006a (Cmax) in Part 1\"\\n613,1,1,\"Analysis of Pharmacokinetic Parameter: Time to Reach Maximum Concentration of Pexidartinib and ZAAD-1006a (Tmax) in Part 1\"\\n614,1,1,\"analysis of primary efficacy indicators\"\\n615,1,1,\"Analysis of the adverse events and of the relevant safety laboratory parameters\"\\n616,1,1,\"analyze acute and late toxicities using CTCAE 4.03\"\\n617,1,1,\"analyze quality of life using LASA-3 and FACT-E\"\\n618,1,1,\"and Handgrip Strength\"\\n619,1,1,\"and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle\"\\n620,1,1,\"and to determine the recommended Phase 2 dose of pegaspargase\"\\n621,1,1,\"Androgen Receptor (AR) Activity Level\"\\n622,1,1,\"Androgen Receptor (AR) Messenger RNA (mRNA) Expression\"\\n623,1,1,\"Androgen Receptor (AR) Protein Expression Levels in CTCs\"\\n624,1,1,\"Androgen Receptor Variant 7 (AR-V7) Expression\"\\n625,1,1,\"Angiostatin production\"\\n626,1,1,\"Animal model experiment: to verify the ability of intestinal bacteria to control anti msln car-t targeted killing pancreatic cancer cells.\"\\n627,2,2,\"Anti drug antibodies (ADA)\"\\n628,1,1,\"Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC)\"\\n629,2,2,\"Anti-MAGE-A3 Antibody Concentrations\"\\n630,1,1,\"Anti-MAGE-A3 Antibody Concentrations (CMI)\"\\n631,5,2,\"Anti-tumor activity\"\\n632,1,1,\"Anti-tumor Activity (Phase 2)\"\\n633,1,1,\"Anti-tumor activity assessed by RECIST criteria\"\\n634,1,1,\"Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 2)\"\\n635,1,1,\"Anti-tumor activity by objective response rate (ORR). - (Phase 2 - Expansion)\"\\n636,1,1,\"Anti-tumor activity of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in ER-negative, PgR-negative, HER-2 not-amplified (triple negative) recurrent breast cancer (Part II)\"\\n637,1,1,\"Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator\"\\n638,1,1,\"Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II)\"\\n639,1,1,\"Anti-tumor activity of AVB-S6-500 alone (CBR)\"\\n640,1,1,\"Anti-tumor activity of AVB-S6-500 alone (DOR)\"\\n641,1,1,\"Anti-tumor activity of AVB-S6-500 alone (ORR)\"\\n642,1,1,\"Anti-tumor activity of AVB-S6-500 alone (OS)\"\\n643,1,1,\"Anti-tumor activity of AVB-S6-500 alone (PFS)\"\\n644,1,1,\"Anti-tumor activity of AVB-S6-500 in combination with cabozantinib (ORR)\"\\n645,1,1,\"Anti-tumor activity of AVB-S6-500 in combination with cabozantinib and nivolumab (ORR)\"\\n646,1,1,\"Anti-tumor activity of AVB-S6-500 in combination with Pac\"\\n647,1,1,\"Anti-tumor activity of AVB-S6-500 in combination with PLD\"\\n648,1,1,\"Anti-tumor activity of batiraxcept in combination with PAC measured by progression free survival (PFS) in patients receiving batiraxcept + PAC versus patients receiving Placebo+PAC\"\\n649,1,1,\"Anti-tumor activity of ERY974 in combination with atezolizumab and bevacizumab [Expansion part]\"\\n650,1,1,\"anti-tumor activity of Imatinib mesylate in combination with Gemcitabine\"\\n651,1,1,\"Anti-tumor Activity of ISB 1302 administered Q1W (Part 2)\"\\n652,1,1,\"Anti-tumor activity of pixantrone at the MTD\"\\n653,1,1,\"Anti-tumor activity of PRTH-101 alone and in combination with pembrolizumab\"\\n654,1,1,\"Anti-tumor activity of RAD001 in combination with erlotinib (Phase II)\"\\n655,1,1,\"Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation\"\\n656,1,1,\"Anti-tumor effect of CBL0137 in children with diffuse intrinsic pontine glioma (DIPG) or other H3 K27M-mutant diffuse midline gliomas (Phase II)\"\\n657,1,1,\"Anti-tumor effect of CBL0137 in children with osteosarcomas (Phase II)\"\\n658,1,1,\"anti-tumor effect on PET Scan\"\\n659,1,1,\"Anti-Tumor Efficacy\"\\n660,1,1,\"Anti-tumor efficacy by overall response rate\"\\n661,1,1,\"Anti-tumor efficacy of the combination in terms of response rate\"\\n662,1,1,\"Anti-tumor immune response\"\\n663,1,1,\"Anti-tumour activity\"\\n664,1,1,\"Anti-tumour effect\"\\n665,1,1,\"Anti-tumour efficacy\"\\n666,1,1,\"Anti-tumour efficacy after treatment with 600 mg 2X-121 as single oral agent in a 21-days cycle in mBC patients selected by the 2X-121 DRP\"\\n667,1,1,\"Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations\"\\n668,1,1,\"Antibody response to COVID-19 vaccine after vaccination in cancer patients and health individuals\"\\n669,1,1,\"Antibody-dependent cellular cytotoxicity (ADCC)\"\\n670,1,1,\"Antidrug Antibodies (ADAs)\"\\n671,1,1,\"Antidrug antibody\"\\n672,2,1,\"Antidrug Antibody (ADA)\"\\n673,1,1,\"Antigen specific CD4+ and CD8+ T-cell reactivity to the peptide antigens measured by intracellular cytokine staining\"\\n674,1,1,\"Antigen-Specific Cellular Immune Response\"\\n675,1,1,\"Antigen-specific T-cell response to guanylyl cyclase C (GCC)\"\\n676,1,1,\"Antitumor Activity\"\\n677,12,2,\"Antitumor activity\"\\n678,3,1,\"antitumor activity\"\\n679,1,1,\"Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response\"\\n680,1,1,\"Antitumor Activity as Assessed by Objective Tumor Response According to RECIST Criteria\"\\n681,1,1,\"Antitumor activity as assessed by tumor measurement or evaluation of indicator lesion by computed tomography (CT) or magnetic resonance imaging (MRI)\"\\n682,1,1,\"Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors\"\\n683,1,1,\"Antitumor activity defined as response rate\"\\n684,1,1,\"Antitumor activity endpoints OR, based on RECIST v1.1\"\\n685,1,1,\"Antitumor activity measured by Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)/Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase II)\"\\n686,1,1,\"Antitumor Activity of AG-01 by Overall Response Rate (ORR)\"\\n687,1,1,\"Antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation\"\\n688,1,1,\"antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation\"\\n689,1,1,\"Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease\"\\n690,1,1,\"Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses)\"\\n691,1,1,\"Antitumor activity of the combination in metastatic breast cancer (Expansion phase)\"\\n692,1,1,\"Antitumor Effect - Solid Tumors\"\\n693,1,1,\"Antitumor Effect of Nivolumab as a Single Agent or in Combination With Ipilimumab\"\\n694,1,1,\"Antitumor Objective Response Rate (ORR) (Phase 2)\"\\n695,1,1,\"Antitumoral Response\"\\n696,1,1,\"Antitumour Activity Defined as Progression Free Survival (PFS)\"\\n697,179,1,\"Anxiety\"\\n698,1,1,\"Anxiety as measured by Spielberger State/Trait Anxiety Scale (STAI)\"\\n699,1,1,\"Anxiety symptoms as measured by the Hamilton Anxiety Rating Scale\"\\n700,1,1,\"any injury, harm or medically relevant discomfort occurring for the patients or the staff\"\\n701,1,1,\"Any solid or hematological cancer\"\\n702,1,1,\"Apparent clearance (CL)(mL/min/kg)\"\\n703,1,1,\"Apparent clearance (CL/F) of Ipatasertib and GO37220 after single and multiple doses of Ipatasertib\"\\n704,1,1,\"Apparent Clearance (CL/F) of Lenvatinib From Plasma\"\\n705,1,1,\"Apparent Clearance (CL/F) of Vemurafenib on Day 15\"\\n706,2,1,\"Apparent Clearance Following Oral Administration (CL/F)\"\\n707,1,1,\"Apparent Elimination Half-Life in Plasma (t1/2) of Probe Parent Drugs and Their Metabolites on Day 1\"\\n708,1,1,\"Apparent First-order Terminal Elimination Rate Constant (Kel) in the Fasted and Fed States\"\\n709,1,1,\"Apparent oral clearance (CL/F) after multiple doses\"\\n710,1,1,\"Apparent oral clearance (CL/F) after single dose\"\\n711,1,1,\"Apparent oral clearance (CL/F) for Famitinib after Single dose\"\\n712,1,1,\"Apparent oral clearance (CL/F) for SHR116637 after Single dose\"\\n713,1,1,\"Apparent Oral Clearance (CL/F) of GDC-0575\"\\n714,1,1,\"Apparent Oral Clearance (CL/F) of Unlabeled Idasanutlin\"\\n715,1,1,\"Apparent oral volume (Vz/F) after multiple doses\"\\n716,1,1,\"Apparent oral volume of distribution (Vz/F) after single dose\"\\n717,5,2,\"Apparent plasma clearance (CL/F)\"\\n718,1,1,\"Apparent Plasma Clearance (CL/F) of Probe Parent Drugs on Day 1\"\\n719,2,2,\"Apparent plasma terminal elimination half-life (t1/2)\"\\n720,1,1,\"Apparent Terminal Half-Life (t1/2) of GDC-0575\"\\n721,1,1,\"Apparent terminal half-life (t¬Ω) after single dose\"\\n722,1,1,\"Apparent Terminal Half-life (t¬Ω) of MK-2206 in Participants Receiving Multiple QOD Dosing\"\\n723,1,1,\"Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study\"\\n724,1,1,\"Apparent terminal volume of distribution for niraparib-Stages 1, 2 and 3 PK Phase\"\\n725,1,1,\"Apparent Terminal Volume of Distribution in the Terminal Phase of Lenvatinib (Vz/F)\"\\n726,1,1,\"Apparent Total Body Clearance (CL/F) of AZD2014\"\\n727,1,1,\"Apparent Total Body Clearance (CL/F) of CC-223\"\\n728,1,1,\"Apparent Total Body Clearance (CL/F) of Niraparib and M1 During PK Phase\"\\n729,1,1,\"Apparent total body clearance for niraparib-Stages 1, 2 and 3 PK Phase\"\\n730,1,1,\"Apparent Total Body Clearance of CC-115\"\\n731,4,1,\"Apparent total body clearance of drug from plasma after extravascular administration (CL/F)\"\\n732,1,1,\"Apparent Total Clearance of Azacitidine (CL/F)\"\\n733,1,1,\"Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine\"\\n734,1,1,\"Apparent Total Plasma Clearance (CL/F) of 14C- Radioactivity\"\\n735,1,1,\"Apparent Total Plasma Clearance (CL/F) of Talazoparib\"\\n736,1,1,\"Apparent Total Whole Blood Clearance (CL/F) of 14C- Radioactivity\"\\n737,1,1,\"Apparent t¬Ω after multiple doses\"\\n738,4,1,\"Apparent volume of distribution (Vd)\"\\n739,1,1,\"Apparent Volume of Distribution (Vd/F) of 14C- Radioactivity in Plasma\"\\n740,1,1,\"Apparent Volume of Distribution (Vd/F) of 14C- Radioactivity in Whole Blood\"\\n741,1,1,\"Apparent Volume of Distribution (Vd/F) of Talazoparib\"\\n742,1,1,\"Apparent Volume of Distribution (Vz): After Single Dose\"\\n743,24,1,\"Apparent Volume of Distribution (Vz/F)\"\\n744,17,1,\"Apparent volume of distribution (Vz/F)\"\\n745,1,1,\"Apparent Volume of Distribution (Vz/F) Famitinib after Single dose\"\\n746,1,1,\"Apparent Volume of Distribution (Vz/F) of CC-223\"\\n747,1,1,\"Apparent Volume of Distribution (Vz/F) of Unlabeled Idasanutlin\"\\n748,1,1,\"Apparent Volume of Distribution (Vz/F) SHR116637 after Single dose\"\\n749,1,1,\"Apparent Volume of Distribution at Steady State (Vss/F) for AZD2014 in Plasma\"\\n750,1,1,\"Apparent Volume of Distribution During Terminal Phase (Vz) of EMD 525797 After First Infusion\"\\n751,3,1,\"Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)\"\\n752,1,1,\"Apparent Volume of Distribution of Azacitidine (Vz/F)\"\\n753,1,1,\"Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine\"\\n754,1,1,\"Apparent Volume of Distribution of CC-115\"\\n755,1,1,\"Apparent Volume of Distribution: After Multiple Dose\"\\n756,2,2,\"Appearance of clonality by LAM-PCR\"\\n757,2,2,\"Appearance of replication competent retrovirus by PCR\"\\n758,1,1,\"Appearance of the grade 3 or 4 (Adverse Events graded by NCI CTC version 4.0) clinical or biological toxicity of the combination of digoxin to cisplatin-based chemotherapy during the study\"\\n759,2,1,\"appetite score\"\\n760,1,1,\"Area Under Concentration Versus Time Curve (AUC) Over a Period of 24 Hours (AUC0-24) of Cobimetinib on Day 1, Cycle 1\"\\n761,38,1,\"Area Under Curve (AUC)\"\\n762,1,1,\"Area Under Curve (AUC) of Average Pain From Diary vs. Day (1-5), Calculated by the Trapezoidal Rule.\"\\n763,1,1,\"Area Under Curve (AUC) of carboplatin at the first and last administration day\"\\n764,1,1,\"Area Under Curve (AUC) Time Frame: predose, 0.5, 1, 2, 4, 8, 24 hours post-dose\"\\n765,2,1,\"Area Under Curve From 0 to Infinity (AUC0-infinity)\"\\n766,1,1,\"Area Under Plasma Concentration - Time Curve of Paclitaxel From Time 0 to Infinity (AUC0-inf) in Cycle 1 (in the Absence of T-DM1) and Cycle 2 (in the Presence of T-DM1)\"\\n767,1,1,\"Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1\"\\n768,4,1,\"Area under plasma concentration-time curve from time zero to infinity (AUCinf)\"\\n769,1,1,\"Area under plasma concentration-time curve from zero to infinity (AUC) ratio\"\\n770,1,1,\"Area Under Plasma Concentration-Time Curve of Tilsotolimod From Time 0 to the Time of Last Measurable Concentration (AUCt)\"\\n771,1,1,\"Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt) (Arm 3 Only)\"\\n772,1,1,\"Area Under Serum Concentration-Time Curve of ABBV-368 From Time 0 to the Time of Last Measurable Concentration (AUCt)\"\\n773,1,1,\"Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor\"\\n774,1,1,\"Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436\"\\n775,1,1,\"Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab of Cycle 2\"\\n776,1,1,\"Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m¬≤\"\\n777,1,1,\"Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m¬≤\"\\n778,1,1,\"Area Under the Concentration Time-Curve From 0-24 Hours After a Dose (AUC0-24) for CC-223\"\\n779,1,1,\"Area under the concentration versus time curve (AUC) of LUNA18 [Part A]\"\\n780,1,1,\"Area under the concentration versus time curve from zero to 12 hours (AUC [0-12]) of BAY1217389 in plasma\"\\n781,1,1,\"Area under the concentration versus time curve from zero to 96 hours (AUC [0-96]) of BAY1217389 in plasma\"\\n782,1,1,\"Area under the concentration versus time curve from zero to infinity (AUC) of paclitaxel in plasma\"\\n783,1,1,\"Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP152 (BAY1251152)\"\\n784,1,1,\"Area under the concentration vs. time curve from zero to infinity (AUC) of roniciclib on Cycle 1 Day 1 (without itraconazole)\"\\n785,1,1,\"Area under the concentration vs. time curve from zero to infinity (AUC) of roniciclib on Cycle 1 Day 6 (with itraconazole)\"\\n786,1,1,\"Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose (AUC)\"\\n787,8,1,\"Area under the Concentration-Time Curve (AUC)\"\\n788,1,1,\"Area Under the Concentration-Time Curve (AUC) for RO6958688\"\\n789,1,1,\"Area Under The Concentration-Time Curve (AUC) From 0 to 24 Hours of Golvatinib\"\\n790,1,1,\"Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study\"\\n791,1,1,\"Area Under the Concentration-Time Curve (AUC) of Atezolizumab\"\\n792,1,1,\"Area under the concentration-time curve (AUC) of BAY3375968\"\\n793,1,1,\"Area Under the Concentration-Time Curve (AUC) of GDC-0941\"\\n794,1,1,\"Area under the concentration-time curve (AUC) of PLX2853.\"\\n795,1,1,\"Area under the concentration-time curve (AUC) of PLX51107.\"\\n796,1,1,\"Area under the concentration-time curve (AUC) of PLX73086 [Part 1 of research study]\"\\n797,1,1,\"Area Under the Concentration-Time Curve (AUC) of RO6874281\"\\n798,1,1,\"Area under the concentration-time curve (AUC)(ng¬∑h/mL)\"\\n799,1,1,\"Area Under the Concentration-time Curve During the Dosing Interval (AUC0-tau) for Panitumumab\"\\n800,1,1,\"Area under the concentration-time curve extrapolated to infinity (AUC‚àû)\"\\n801,1,1,\"Area Under the Concentration-Time Curve for CC-115\"\\n802,1,1,\"Area under the concentration-time curve for the elimination phase (AUC)\"\\n803,1,1,\"Area under the concentration-time curve from 0-24 hours (AUC0-24) after single dose\"\\n804,1,1,\"Area Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3\"\\n805,1,1,\"Area under the concentration-time curve from time 0 to 25 hours (AUC(0-25))\"\\n806,1,1,\"Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Entrectinib\"\\n807,1,1,\"Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t)\"\\n808,1,1,\"Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) for AZD2014 in Plasma and Saliva\"\\n809,1,1,\"Area Under the Concentration-time Curve From Time Zero to 24 Hours [AUC(0-24)] After Single and Multiple Dose Administration of BAY1143269\"\\n810,1,1,\"Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Avelumab\"\\n811,1,1,\"Area Under the Concentration-Time Curve From Time Zero to tau (AUC0-tau) of Avelumab\"\\n812,1,1,\"Area Under the Concentration-Time Curve From Time Zero to Time t (AUC0-t) of Avelumab\"\\n813,1,1,\"Area under the concentration-time curve from time zero to time the time of the last measurable concentration (AUC[0-T])\"\\n814,1,1,\"Area under the concentration-time curve from zero (pre-dose) extrapolated to infinite time (AUC 0-infinity) for eribulin mesylate +/- rifampicin\"\\n815,1,1,\"Area under the concentration-time curve from zero (pre-dose) to time of last quantifiable concentration (AUC 0-t) for eribulin mesylate\"\\n816,1,1,\"Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t])\"\\n817,1,1,\"Area under the concentration-time curve in one dosing interval (AUC(TAU)) of Relatlimab\"\\n818,1,1,\"Area under the concentration-time curve of BI 907828 in plasma over the time interval from 0 to 24 hours (AUC 0-24)\"\\n819,1,1,\"Area under the concentration-time curve of DCC-3014\"\\n820,1,1,\"Area Under the Concentration-time Curve of MK-2206 From Time 0 to 48 Hours (AUC0-48hr) in Participants Receiving Multiple QOD Dosing\"\\n821,1,1,\"Area Under the Concentration-Time Curve of Ridaforolimus From Time 0 to 24 Hours (AUC0-24 hr)\"\\n822,1,1,\"Area under the concentration-time curve of selitrectinib in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)\"\\n823,1,1,\"Area under the concentration-time curve of selitrectinib in plasma from time 0 to 24 hours in fed state (AUC(0-24)_fed)\"\\n824,1,1,\"Area under the concentration-time curve of selitrectinib in plasma from time 0 to infinity in fasted state (AUC_fasted)\"\\n825,1,1,\"Area under the concentration-time curve of selitrectinib in plasma from time 0 to infinity in fed state (AUC_fed)\"\\n826,1,1,\"Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)\"\\n827,1,1,\"Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted)\"\\n828,1,1,\"Area Under the Concentration-time Curve Over the Dosing Interval (AUC(0-œÑ)) and AUC From Zero to Infinity (AUC(0-inf)) of Dabrafenib\"\\n829,1,1,\"Area under the concentration-time curve over the dosing interval on multiple dosing (AUC[0-œÑ])\"\\n830,1,1,\"Area under the concentration-time curve time 0 to 8 hours (AUC(0-8))\"\\n831,1,1,\"Area Under the Concentration-Time Curve Zero Time Extrapolated to Infinite Time (AUC0-‚àû)\"\\n832,1,1,\"Area Under the Concentration-Time Curve(ACU 0-22 weeks)\"\\n833,1,1,\"Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin¬Æ\"\\n834,8,1,\"Area Under the Curve\"\\n835,22,2,\"Area under the curve\"\\n836,5,1,\"area under the curve\"\\n837,4,1,\"Area under the Curve (AUC)\"\\n838,37,5,\"Area under the curve (AUC)\"\\n839,1,1,\"Area under the curve (AUC) (0-24) (ng.h/mL) after single dose\"\\n840,1,1,\"Area under the curve (AUC) computed from time zero to the time of the last concentration [AUCall] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n841,1,1,\"Area Under the Curve (AUC) for AZD6244, 100 mg Administered Orally Twice Daily.\"\\n842,1,1,\"Area under the curve (AUC) form time zero to the last measurable concentration AUC (0-t)\"\\n843,2,2,\"Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)\"\\n844,1,1,\"Area under the curve (AUC) from time zero to the last measurable concentration AUC(0-t) of ABBV-085.\"\\n845,1,1,\"Area under the curve (AUC) of absolute neutrophil count (ANC)\"\\n846,1,1,\"Area under the curve (AUC) of capecitabine and metabolites\"\\n847,1,1,\"Area under the curve (AUC) of FORE8394\"\\n848,1,1,\"Area Under the Curve (AUC) of Idasanutlin\"\\n849,1,1,\"Area Under the Curve (AUC) of IMC-A12 Administered at a Dose of 20 mg/kg Every 3 Weeks\"\\n850,1,1,\"Area Under the Curve (AUC) of Pembrolizumab Measured After the First Dose\"\\n851,1,1,\"Area Under the Curve (AUC) of Rociletinib and Rociletinib Metabolites\"\\n852,1,1,\"Area Under the Curve (AUC) on Cycle 1 Day 1 and Cycle 1 Day 9\"\\n853,1,1,\"Area under the curve (AUC) ratios of geometric means of test treatment (savolitnib+rifampicin) relative to reference treatment (savolitinib alone)\"\\n854,1,1,\"Area under the curve (AUC)-BAT8001(antibody-drug conjugate), total antibody and Batansine (a maytansine derivative, which is the 3AA-MDC complex)\"\\n855,1,1,\"Area under the curve (AUCinf)\"\\n856,1,1,\"Area under the curve (AUCtau)\"\\n857,1,1,\"Area under the curve [AUC (0 - 24)] for once daily (QD) dosing of BAY2965501 after single dose in Cycle 1\"\\n858,1,1,\"Area under the curve [AUC (0 - t)] (t=6,12 or 24 dependent on the dosing regimen) of BAY2416964 after single and multiple-dose in Cycle 1\"\\n859,1,1,\"Area under the curve [AUC(0-12)] for 2 times daily (BID) dosing after single dose in Cycle 1 (if applicable))\"\\n860,1,1,\"Area under the curve [AUC(0-12)md] for BID dosing of BAY2965501 after multiple dose (if applicable)\"\\n861,1,1,\"Area under the curve [AUC(0-24)md] for QD dosing of BAY2965501 after multiple dose\"\\n862,2,2,\"Area Under the Curve After the First Test Drug Administration\"\\n863,1,1,\"Area under the curve at steady state: a measure of the exposure to HL-085 or metabolite(s) at steady state.\"\\n864,1,1,\"area under the curve AUClast\"\\n865,1,1,\"Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab at Cycle 1\"\\n866,1,1,\"Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Docetaxel PK Parameters\"\\n867,1,1,\"Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters\"\\n868,1,1,\"Area Under the Curve From Time 24 Hours to 48 Hours (AUC24_48) : Docetaxel PK Parameters\"\\n869,1,1,\"Area Under the Curve From Time Zero to 24 Hour (AUC0-24) for Total and Unbound GDC-0449\"\\n870,1,1,\"Area Under the Curve From Time Zero to 25 Hours Postdose (AUC25) of Docetaxel in Cycle 1\"\\n871,1,1,\"Area Under the Curve From Time Zero to 25 Hours Postdose (AUC25) of Docetaxel in Cycle 4\"\\n872,1,1,\"Area Under the Curve From Time Zero to 6 Hours Post Infusion (AUC0-6hr) of Carboplatin\"\\n873,7,1,\"Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)\"\\n874,1,1,\"Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab\"\\n875,1,1,\"Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of GDC-0575\"\\n876,1,1,\"Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) For Dextrorphan 3 Days Prior to PF-00299804 Dosing\"\\n877,1,1,\"Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) For Dextrorphan on Cycle 2 Day 7\"\\n878,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Dextromethorphan and Dextrorphan 3 Days Prior to PF-00299804 Dosing\"\\n879,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Dextromethorphan and Dextrorphan on Cycle 2 Day 7\"\\n880,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Docetaxel in Cycle 1\"\\n881,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Docetaxel in Cycle 4\"\\n882,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC0-t) of EMD 525797: After Multiple Dose\"\\n883,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC0-t) of EMD 525797: After Single Dose\"\\n884,1,1,\"Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUCÔºâ\"\\n885,1,1,\"Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) for Total and Unbound GDC-0449\"\\n886,1,1,\"Area under the Curve from Time Zero to the Time of the Last Measurable Drug Concentration (AUC0-t)\"\\n887,1,1,\"Area Under the Curve Over Dosing Interval œÑ at Steady State (AUCœÑ,ss) - Dose Finding Part\"\\n888,1,1,\"Area under the curveÔºàAUCÔºâ\"\\n889,1,1,\"Area under the drug concentration curve of selinexor\"\\n890,1,1,\"Area under the drug concentration curve of tegavivint\"\\n891,1,1,\"Area under the drug concentration-time curve from time of dosing extrapolated to infinity (AUC(0-‚àû))\"\\n892,1,1,\"Area under the drug concentration-time curve from time of dosing to time of last observation (AUC(0-t))\"\\n893,1,1,\"Area under the drug concentration-time curve within time span t1 to t2 at steady-state (AUC(t1-t2)-ss)\"\\n894,1,1,\"Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24) of Talazoparib on Day 22\"\\n895,1,1,\"Area Under the MK-2206 Concentration Versus Time Curve From Time Zero to 48 Hours Postdose (AUC 0-48h)\"\\n896,1,1,\"Area under the plasma concentration by time curve (AUC) from time 0 to infinity (AUC0-‚àû)\"\\n897,1,1,\"Area Under the Plasma Concentration Curve (AUC0-24) on Cycle 1 Day 1\"\\n898,1,1,\"Area Under the Plasma Concentration Curve (AUC0-24) on Cycle 1 Day 28\"\\n899,1,1,\"Area under the plasma concentration of BAY1895344 vs. time curve from zero to 12 hours after single-dose (AUC[0-12]) and multiple-dose administrations (AUC[0-12]md) in Cycle 1\"\\n900,1,1,\"area under the plasma concentration time curve (AUC) of AMG 510\"\\n901,1,1,\"Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of [14C]-Pimasertib Following IV Administration on Day 1\"\\n902,1,1,\"Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib Following Oral Administration on Day 1\"\\n903,1,1,\"Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUClast) of 14C-RO5185426 in Both Blood and Plasma\"\\n904,1,1,\"Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time Point (AUC0-t) of [14C]-Pimasertib Following Intravenous (IV) Administration on Day 1\"\\n905,1,1,\"Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time Point (AUC0-t) of Pimasertib Following Oral Administration on Day 1\"\\n906,1,1,\"Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC)\"\\n907,1,1,\"Area Under the Plasma Concentration Time Curve From Zero to the Last Measureable Time Point(AUC 0-t)\"\\n908,1,1,\"Area Under the Plasma Concentration Time-Curve From Time Zero to Extrapolated Infinite Time (AUC [0-inf]) of Unlabeled Idasanutlin\"\\n909,1,1,\"Area Under the Plasma Concentration Time-Curve From Zero to the Last Measured Concentration (AUC[0-last]) of Unlabeled Idasanutlin\"\\n910,67,1,\"Area under the plasma concentration versus time curve (AUC)\"\\n911,1,1,\"Area under the plasma concentration versus time curve (AUC) for Omeprazole\"\\n912,1,1,\"Area under the plasma concentration versus time curve (AUC) for S-Warfarin, Caffeine, Midazolam and Digoxin\"\\n913,1,1,\"Area under the plasma concentration versus time curve (AUC) of CM082\"\\n914,1,1,\"Area under the plasma concentration versus time curve (AUC) of MGCD516\"\\n915,1,1,\"Area Under the Plasma Concentration Versus Time Curve (AUC) of Sorafenib\"\\n916,1,1,\"Area under the plasma concentration versus time curve (AUC) of warfarin or nifedipine\"\\n917,1,1,\"Area under the plasma concentration versus time curve (AUC0-t) for Famitinib after Single dose\"\\n918,1,1,\"Area under the plasma concentration versus time curve (AUC0-t) for SHR116637 after Single dose\"\\n919,1,1,\"Area under the plasma concentration versus time curve (AUC0-t) of Famitinib\"\\n920,1,1,\"Area under the plasma concentration versus time curve (AUC0-‚àû) for Famitinib after Single dose\"\\n921,1,1,\"Area under the plasma concentration versus time curve (AUC0-‚àû) for SHR116637 after Single dose\"\\n922,1,1,\"Area under the plasma concentration versus time curve (AUC0-‚àû) of Famitinib\"\\n923,1,1,\"Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-‚àû )\"\\n924,1,1,\"Area under the plasma concentration versus time curve from time 0 to last time of measurable concentration (AUC0-t)\"\\n925,1,1,\"Area under the plasma concentration versus time curve of Hemay020\"\\n926,1,1,\"Area under the plasma concentration versus time curve(AUC) of CM082 (test product or reference product) under fasted state or after meal\"\\n927,1,1,\"Area under the plasma concentration vs time curve from zero to 12 hours p.a. after first-dose administration (AUC(0-12)) of BAY1163877\"\\n928,1,1,\"Area under the plasma concentration vs time curve from zero to infinity after single (first) dose\"\\n929,2,1,\"Area under the plasma concentration vs. time curve (AUC)\"\\n930,1,1,\"Area Under the Plasma Concentration-Time Curve (AUC from 0 to infinity)\"\\n931,16,1,\"Area under the plasma concentration-time curve (AUC)\"\\n932,1,1,\"Area Under the Plasma Concentration-time Curve (AUC) for AZD2014\"\\n933,1,1,\"Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-‚àû)\"\\n934,1,1,\"Area Under the Plasma Concentration-Time Curve (AUC) of Atezolizumab (PK phase only)\"\\n935,1,1,\"area under the plasma concentration-time curve (AUC) of midazolam\"\\n936,1,1,\"Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1\"\\n937,1,1,\"Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 1 - Dose Escalation: Original Formulation\"\\n938,1,1,\"Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 15 - Dose Escalation: Original Formulation\"\\n939,6,1,\"Area under the plasma concentration-time curve (AUC0-t )\"\\n940,1,1,\"Area under the plasma concentration-time curve (AUC[0-t]) of BAY1082439 after a single dose\"\\n941,1,1,\"Area under the plasma concentration-time curve [AUC0-t, AUC0-inf]\"\\n942,1,1,\"Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1\"\\n943,1,1,\"Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib\"\\n944,1,1,\"Area Under the Plasma Concentration-time Curve From 0 to 12 h After Multiple Dose (AUC(0-12)md) for Refametinib Metabolite M-11\"\\n945,1,1,\"Area Under the Plasma Concentration-time Curve From 0 to 24 h After Multiple Dose (AUC(0-24)md) for Regorafenib\"\\n946,1,1,\"Area Under the Plasma Concentration-time Curve From 0 to 24 h After Multiple Dose (AUC(0-24)md) for Regorafenib Metabolite M-2\"\\n947,1,1,\"Area Under the Plasma Concentration-time Curve From 0 to 24 h After Multiple Dose (AUC(0-24)md) for Regorafenib Metabolite M-5\"\\n948,1,1,\"Area Under the Plasma Concentration-Time Curve From 0 to infinity of Fluzoparib:\"\\n949,1,1,\"Area Under the Plasma Concentration-Time Curve From 0 to t of Fluzoparib:\"\\n950,1,1,\"area under the plasma concentration-time curve from 0 to the last measurable concentration (AUClast)\"\\n951,1,1,\"Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221\"\\n952,1,1,\"Area Under the Plasma Concentration-Time Curve from Hour Zero to Hour 24 AUC[0-24] for ION537\"\\n953,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC 0-infinity) of Niraparib and M1 During PK Phase\"\\n954,1,1,\"Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC[0 to inf]) for niraparib-Stages 1, 2 and 3 PK Phase\"\\n955,1,1,\"Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) For CC-223\"\\n956,1,1,\"Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) After a Single Dose of GDC-0449\"\\n957,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2\"\\n958,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose\"\\n959,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine\"\\n960,1,1,\"Area under the plasma concentration-time curve from time 0 to infinite time (AUC[0-infinity]) of encapsulated doxorubicin\"\\n961,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine\"\\n962,1,1,\"Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for CC-223\"\\n963,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine\"\\n964,1,1,\"Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC[0-t]) for niraparib-Stages 1, 2 and 3 PK Phase\"\\n965,1,1,\"Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Niraparib and Its Major Metabolite (M1) During PK Phase\"\\n966,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero (0) to 24 Hours (AUC24): Docetaxel PK Parameters\"\\n967,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero (0) to 48 Hours (AUC48): Docetaxel PK Parameters\"\\n968,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC [INF])\"\\n969,1,1,\"Area under the plasma concentration-time curve from time zero to 12 hours post-dose (AUC 0-12) of Capivasertib\"\\n970,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC[0-168h]) of Vemurafenib on Day 15\"\\n971,1,1,\"Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for Digoxin\"\\n972,1,1,\"Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for rosuvastatin\"\\n973,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24h]) of Vemurafenib on Day 1\"\\n974,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24h]) of Vemurafenib on Day 15\"\\n975,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours (AUC[0-8h]) of Vemurafenib on Day 1\"\\n976,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours (AUC[0-8h]) of Vemurafenib on Day 15\"\\n977,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours (AUC[0-8h]) of Vemurafenib on Day 9\"\\n978,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours Post Dose AUC(0-8) for Sunitinib and Its Metabolite\"\\n979,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to 8, 12, and 24 Hours (AUC[0-8], AUC[0-12], AUC[0-24]) of Vemurafenib\"\\n980,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of Talazoparib: Alone and in Combination With Rifampin\"\\n981,13,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])\"\\n982,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero to Infinity\"\\n983,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0-inf]) in the Fasted and Fed States\"\\n984,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf))\"\\n985,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of 14C- Radioactivity\"\\n986,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Talazoparib\"\\n987,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of 14C- Radioactivity\"\\n988,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib\"\\n989,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib: Alone and in Combination With Itraconazole\"\\n990,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib: Alone and in Combination With Rifampin\"\\n991,16,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])\"\\n992,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point\"\\n993,1,1,\"Area under the plasma concentration-time curve from time zero to the time \"\"t\"\" (AUC0-t) of the last quantifiable concentration for AZD1775\"\\n994,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Sample With Last Measurable Concentration (AUC[0-last]) in the Fasted and Fed States\"\\n995,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf)\"\\n996,1,1,\"Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-T])\"\\n997,1,1,\"Area Under the Plasma Concentration-Time Curve From Time Zero to Time t (AUC(0-t))\"\\n998,1,1,\"Area under the plasma concentration-time curve from zero to infinity for AZD1775\"\\n999,1,1,\"Area under the plasma concentration-time curve from zero to infinity for osimertinib\"\\n1000,1,1,\"Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)\"\\n1001,1,1,\"Area under the plasma concentration-time curve from zero to time of last quantifiable concentration (AUClast)\"\\n1002,1,1,\"Area Under the Plasma Concentration-time Curve of ABBV-221\"\\n1003,1,1,\"Area Under The Plasma Concentration-Time Curve of RO5212054\"\\n1004,1,1,\"area under the plasma concentration-time curve over the time interval from zero to the last quantifiable drug plasma concentration after dose administration (AUC0-tz)\"\\n1005,1,1,\"Area Under the Plasma Concentration-time Profile From Time Zero (0) to 24 Hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters\"\\n1006,1,1,\"Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinity (AUC0-inf) of Talazoparib: Alone and in Combination With Itraconazole\"\\n1007,1,1,\"Area Under The Plasma Drug Concentration-time Curve After Administration Of Samalizumab\"\\n1008,1,1,\"Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of ABBV-CLS-579\"\\n1009,1,1,\"Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of Metabolite M4\"\\n1010,1,1,\"Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of PD-1 Inhibitor\"\\n1011,1,1,\"Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of VEGFR TKI\"\\n1012,1,1,\"Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last)\"\\n1013,1,1,\"Area under the plasma-concentration-versus time curve from time 0 to infinite time of encapsulated doxorubicin in participants with ovarian cancer\"\\n1014,1,1,\"Area under the plasma-concentration-versus time curve from time 0 to time t of encapsulated doxorubicin in participants with ovarian cancer\"\\n1015,1,1,\"Area Under the receiver operating characteristic curve (ROC)\"\\n1016,1,1,\"Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between immunocompetent and immunocompromised patients.\"\\n1017,1,1,\"Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-514\"\\n1018,1,1,\"Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 1)\"\\n1019,1,1,\"Area under the serum concentration-time curve\"\\n1020,2,2,\"Area under the serum concentration-time curve (AUC)\"\\n1021,1,1,\"Area under the serum concentration-time curve (AUC) of ABBV-368\"\\n1022,1,1,\"Area under the serum concentration-time curve (AUC) of ABBV-428\"\\n1023,1,1,\"Area Under the Serum Concentration-Time Curve (AUC) of RO6895882\"\\n1024,1,1,\"Area under the serum concentration-time curve (AUCt) of ABBV-181\"\\n1025,1,1,\"Area under the serum concentration-time curve (AUCt) of ABBV-927\"\\n1026,1,1,\"Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Infusion\"\\n1027,1,1,\"Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]\"\\n1028,1,1,\"Area Under the Serum Concentration-time Curve of Total Exposure (AUC0-Day 21) of T-DM1 and Total Trastuzumab in Cycle 1 After Q3W Dose Regimen\"\\n1029,1,1,\"Area Under the Serum Concentration-time Curve of Total Exposure (AUClast) of T-DM1 and Total Trastuzumab in Cycle 1 After QW Dose Regimen\"\\n1030,1,1,\"Area under the serum of nanoparticle albumin-bound rapamycin concentration curve\"\\n1031,1,1,\"Area under the serum/plasma concentration time curve (AUC) of ABBV-621\"\\n1032,1,1,\"Area under the serum/plasma concentration time curve (AUC) of Venetoclax\"\\n1033,1,1,\"Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706\"\\n1034,1,1,\"Area under the single-dose plasma concentration-time curve (AUC0-t) of Pemigatinib as monotherapy\"\\n1035,1,1,\"Area Under the Time-concentration Curve From 0 to Infinity Hours (AUC0-‚àû) of Dalotuzumab\"\\n1036,1,1,\"Area Under the Whole Blood Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of 14C- Radioactivity\"\\n1037,1,1,\"Area Under the Whole Blood Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of 14C- Radioactivity\"\\n1038,1,1,\"Arm 1: Number of Participants Who Discontinue Study Treatment Due to an AE\"\\n1039,1,1,\"Arm 1: Number of Participants Who Experience at Least One Adverse Event (AE)\"\\n1040,1,1,\"Arm 1: Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)\"\\n1041,1,1,\"Arm 1: Overall response rate (ORR) by independent radiology review committee (IRC) based on RANO criteria\"\\n1042,1,1,\"Arm 2: Assess the safety and tolerability of DAY101\"\\n1043,1,1,\"Arm 3 (Japan): Number of Participants who Discontinue Study Treatment Due to an AE\"\\n1044,1,1,\"Arm 3 (Japan): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)\"\\n1045,1,1,\"Arm 3 (Japan): Number of Participants with Adverse Events (AEs)\"\\n1046,1,1,\"Arm 3 (Japan): Number of Participants with Injection Site Signs and Symptoms as Assessed by the Subcutaneous Injection Site Signs and Symptoms Questionnaire\"\\n1047,1,1,\"Arm 3: Overall response rate (ORR) by independent radiology review committee (IRC) based on RECIST v1.1 criteria\"\\n1048,1,1,\"Arm 4: Pembrolizumab Area under the Curve (AUC) After MK 3475A Treatment\"\\n1049,1,1,\"Arm 4: Pembrolizumab Maximum Plasma Concentration (Cmax) After MK 3475A Treatment\"\\n1050,1,1,\"Arm 4: Pembrolizumab Trough Concentration (Ctrough) After MK 3475A Treatment\"\\n1051,1,1,\"Arm A\"\\n1052,1,1,\"ARM A: Dose-limiting toxicity (DLT) rate by CTCAE v5.0. Neurotoxicity and cytokine release syndrome (CRS) will be graded according to ASTCT Consensus Grading System.\"\\n1053,1,1,\"Arm A: Maximum tolerated dose of RO5429083\"\\n1054,1,1,\"Arm A: objective response rate on trametinib and dabrafenib\"\\n1055,1,1,\"Arm A: Pharmacokinetics (serum levels of RO5429083)\"\\n1056,1,1,\"Arm A: Safety (Incidence of adverse events related to study drug)\"\\n1057,1,1,\"Arm A: Tumor Growth Control Rate\"\\n1058,1,1,\"Arm B\"\\n1059,1,1,\"ARM B: Dose-limiting toxicity (DLT) rate by CTCAE v5.0. Neurotoxicity and cytokine release syndrome (CRS) will be graded according to ASTCT Consensus Grading System.\"\\n1060,1,1,\"Arm B: objective response rate on trametinib and dabrafenib\"\\n1061,1,1,\"Arm B: Overall Response Rate (ORR): Percentage of Participants with Tumor Response (Partial or Complete) Based on Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) in Cutaneous Melanoma\"\\n1062,1,1,\"Arm B: Tissue distribution of RO5429083 assessed by positron emission tomography (PET)\"\\n1063,1,1,\"Arm C\"\\n1064,1,1,\"Arms 1 and 2: Dose-limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 or Later\"\\n1065,1,1,\"Arms 1 and 2: Number of Participants with Adverse Events (AEs)\"\\n1066,1,1,\"Arms 1 and 2: Number of Study Treatment Discontinuations Due to an Adverse Event (AE)\"\\n1067,1,1,\"Arms 1 and 2: Pembrolizumab Bioavailability (F) After MK-3475A Treatment\"\\n1068,1,1,\"Arms 1, 2, and 3: Pembrolizumab Area under the Curve (AUC) After MK 3475A Treatment\"\\n1069,1,1,\"Arms 1, 2, and 3: Pembrolizumab Maximum Plasma Concentration (Cmax) After MK-3475A Treatment\"\\n1070,1,1,\"Arms 1, 2, and 3: Pembrolizumab Time of Maximum Plasma Concentration (Tmax) After MK-3475A Treatment\"\\n1071,1,1,\"Arms 1, 2, and 3: Pembrolizumab Trough Concentration (Ctrough) After MK-3475A Treatment\"\\n1072,1,1,\"Arms A and C: Overall Response Rate (ORR)\"\\n1073,1,1,\"arterial flow through the tumor\"\\n1074,1,1,\"Assays to determine immunity to the vaccine\\'s antigen\"\\n1075,1,1,\"Assesment of the QoL& irAEs determinants in patients diagnosed with solid or hematologic cancer and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors or CAR-T cells.\"\\n1076,1,1,\"Assess abnormal findings related to TST003\"\\n1077,1,1,\"Assess Adverse events (AEs) of TST003\"\\n1078,1,1,\"Assess age-dependency in pharmacokinetics of doxorubicin in paediatric patients with solid tumours and leukaemia\"\\n1079,1,1,\"Assess amplification/expression of HER2 in archival and tumor tissues.\"\\n1080,1,1,\"Assess clinical activity of TTI-622 maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D) in combination with PLD in the Expansion Phase overall response rate as defined by Response Evaluation Criteria in Solid Tumors (RECIST) .\"\\n1081,1,1,\"Assess clinical activity of TTI-622 MTD or RP2D in combination with PLD in the Expansion Phase; the disease control rate.\"\\n1082,1,1,\"Assess clinical activity of TTI-622 MTD or RP2D in combination with PLD in the Expansion Phase; the immune-related Response Evaluation Criteria in Solid Tumors.\"\\n1083,1,1,\"Assess clinical activity of TTI-622 MTD or RP2D in combination with PLD in the Expansion Phase; the other markers of clinical benefit .\"\\n1084,1,1,\"Assess clinical activity, as measured by disease control rate, of AZD2014 in combination with selumetinib.\"\\n1085,1,1,\"Assess content of consultation by applying a coding scheme to transcripts and design yes/no questions immediately after the first consultation\"\\n1086,1,1,\"Assess decisional conflict by Decisional Conflict Scale immediately after the first consultation and at 3 months after study completion\"\\n1087,1,1,\"Assess DLTs and identify the RP2D of single agent IV T3011\"\\n1088,1,1,\"Assess dose limiting toxicity as defined in the protocol\"\\n1089,1,1,\"Assess efficacy by overall survival\"\\n1090,1,1,\"Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population\"\\n1091,1,1,\"Assess immunogenicity of m-RNA 1273 administered in 2 doses\"\\n1092,1,1,\"Assess maximum tolerated dose as defined in the protocol\"\\n1093,1,1,\"Assess number of adverse events observed during treatment with DF1001 in combination with Nab paclitaxel\"\\n1094,1,1,\"Assess number of adverse events observed during treatment with DF1001 in combination with Nivolumab\"\\n1095,1,1,\"Assess Number of Patients with Confirmed Complete Response (CR) and Partial Response (PR) (MSI/MMR and TNBC Arms Expansion Phase)\"\\n1096,1,1,\"Assess Number of Patients with Confirmed CR and PR (mCRPC Arms Expansion Phase)\"\\n1097,3,3,\"Assess Overall Response Rate\"\\n1098,1,1,\"Assess participants for toxicities related to study treatment\"\\n1099,1,1,\"Assess preliminary efficacy by overall survival\"\\n1100,1,1,\"Assess Safety (Number and distribution and severity adverse events) of subjects\"\\n1101,1,1,\"Assess safety and tolerability of study drug in subjects with advanced solid tumors who have BRAF and/or NRAS mutations\"\\n1102,1,1,\"Assess safety and tolerability of T3011 intravenous administration at MTD or RP2D doses through dose extension study\"\\n1103,1,1,\"Assess safety and tolerability of the IO-108 RP2D as monotherapy or in combination with either pembrolizumab or cemiplimab in patients with solid tumors\"\\n1104,1,1,\"Assess safety changes in electrocardiogram (ECG)\"\\n1105,1,1,\"Assess safety changes of body weight.\"\\n1106,1,1,\"Assess safety of L-NDDP\"\\n1107,1,1,\"Assess the bioavailability (BA) of orally administered CUDC-101\"\\n1108,1,1,\"Assess the biological activity of the study drug in tumors in terms of inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.\"\\n1109,1,1,\"assess the Disease Control Rate of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)\"\\n1110,1,1,\"Assess the dose limiting toxicities (DLTs) and describe the full toxicity profile for each study arm\"\\n1111,1,1,\"Assess the Dose Limiting Toxicities (DLTs) of G1T28/Trilaciclib Administered With Topotecan in Part 1\"\\n1112,1,1,\"Assess the Dose limiting toxicities of TST003\"\\n1113,1,1,\"Assess the dose-limiting toxicity of the single agent NIZ985 and the combination of PDR001\"\\n1114,1,1,\"assess the Duration of Response of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)\"\\n1115,1,1,\"Assess the effect, as measured by response rate of the addition of GRN-1201 to Pembrolizumab\"\\n1116,1,1,\"assess the efficacy of BEZ235 as measured by Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n1117,1,1,\"Assess the efficacy of olaparib in combination with trastuzumab\"\\n1118,1,1,\"Assess the efficacy of P-PSMA-101 (ORR)\"\\n1119,1,1,\"Assess the efficacy of the drug combination abemaciclib and elacestrant.\"\\n1120,1,1,\"Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.\"\\n1121,1,1,\"Assess the exposure of the new formulation of study drug in terms of plasma concentrations.\"\\n1122,1,1,\"Assess the feasibility of DaRT by the safety of DaRT for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva\"\\n1123,1,1,\"Assess the feasibility of manufacturing B7H3 specific CARs from patient-derived lymphocytes\"\\n1124,1,1,\"Assess the feasibility of manufacturing B7H3xCD19 bispecific CARs from patient-derived lymphocytes\"\\n1125,1,1,\"Assess the feasibility of manufacturing CT-0508 by describing the percentage of products passing release criteria.\"\\n1126,1,1,\"assess the optimal fludeoxyglucose F-18 (fluorodeoxyglucose) positron emission tomography (FDG PET) imaging time post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma\"\\n1127,1,1,\"Assess the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies and assess new ABT-263 formulations after once daily dosing (QD) and twice daily dosing (BID).\"\\n1128,1,1,\"Assess the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies.\"\\n1129,1,1,\"Assess the oral bioavailability of veliparib\"\\n1130,1,1,\"assess the Overall Response Rate of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)\"\\n1131,1,1,\"assess the Overall Survival of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)\"\\n1132,1,1,\"Assess the pharmacokinetics (PK) of orally administered CUDC-101\"\\n1133,1,1,\"Assess the preliminary anti-tumor activity of MSC-1 monotherapy\"\\n1134,1,1,\"assess the Progression Free Survival of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)\"\\n1135,1,1,\"Assess the recommended phase II dose (RP2D) of 225Ac-J591 in fractionated dose and multiple dose regimens (phase I)\"\\n1136,1,1,\"assess the safety & tolerability of BEZ235 SDS as single agent and in combination with trastuzumab administered to patients at the MTD level (Safety expansion part)\"\\n1137,1,1,\"Assess the safety and tolerability\"\\n1138,1,1,\"Assess the safety and tolerability of ARQ 092 in subjects with advanced solid tumors and recurrent malignant lymphoma by monitoring frequency and severity of adverse events\"\\n1139,1,1,\"Assess the safety and tolerability of cediranib in combination with oral lomustine and to confirm a dose for further studies with this combination.\"\\n1140,1,1,\"Assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express a bispecific B7H3xCD19 CAR (Arm B)\"\\n1141,1,1,\"Assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express B7H3-specific CAR (Arm A)\"\\n1142,1,1,\"Assess the safety and tolerability of combined therapy in patients with metastatic NSCLC who have progressed on prior PD-1/PD-L1 therapy\"\\n1143,1,1,\"Assess the safety and tolerability of CT-0508 by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors.\"\\n1144,1,1,\"Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only)\"\\n1145,1,1,\"Assess the Safety and Tolerability of Defactinib (VS-6063) in Japanese Subjects With Non-hematologic Malignancies\"\\n1146,1,1,\"Assess the safety and tolerability of EMD 521873\"\\n1147,1,1,\"Assess the safety and tolerability of VS-4718 in subjects with metastatic non-hematologic malignancies\"\\n1148,1,1,\"Assess the safety and tolerability of VS-5584 in subjects with advanced non-hematologic malignancies or lymphoma\"\\n1149,1,1,\"Assess the safety and toxicity profile of each schedule of administration of VS-6766 both as a single agent and in combination with everolimus.\"\\n1150,1,1,\"Assess the safety of Almonertinib: Number of AEs/SAEs\"\\n1151,1,1,\"Assess the safety of EC D-3263 HCl\"\\n1152,1,1,\"Assess the safety of infusion of MILs‚Ñ¢ by Adverse Events per\"\\n1153,1,1,\"Assess the Safety of P-PSMA-101\"\\n1154,1,1,\"Assess the safety profile of ABT-263 in combination with gemcitabine.\"\\n1155,1,1,\"Assess the safety profile of ABT-263 when administered in combination with etoposide/cisplatin in subjects with Cancer.\"\\n1156,1,1,\"Assess the safety profile of navitoclax (ABT-263) when administered in combination with a standard and weekly regimen of docetaxel.\"\\n1157,1,1,\"assess the Time to Response of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)\"\\n1158,1,1,\"Assess Tumor Activity\"\\n1159,1,1,\"Assessing a change in Pain Visual Analog Score (VAS score)\"\\n1160,1,1,\"Assessing Change in Blood markers from Baseline to End of study\"\\n1161,1,1,\"Assessing Change in tumor size from Baseline to End of study\"\\n1162,1,1,\"Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.\"\\n1163,1,1,\"Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors\"\\n1164,1,1,\"Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors\"\\n1165,1,1,\"Assessing safety through toxicities observed using CTCAE version 3.0\"\\n1166,1,1,\"Assessing the safety and tolerability profile of CCT3833. (adverse event)\"\\n1167,1,1,\"Assessment of 12-lead electrocardiogram (ECG) findings in Phase I Dose Escalation phase\"\\n1168,1,1,\"Assessment of a change in the uptake of [18F]- ML-10 by the tumor as observed in comparing the PET scans before and after WBRT.\"\\n1169,1,1,\"Assessment of adverse event (AE) profile\"\\n1170,1,1,\"Assessment of adverse events (based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)general examination\"\\n1171,1,1,\"Assessment of adverse events (based on CTCAE version 3.0), laboratory values, vital sign measurements, cardiac markers, ECG, Echocardiogram\"\\n1172,1,1,\"Assessment of adverse events (based on CTCAE version 3.0), laboratory values, vital sign measurements, general examination, HRCT, SpO2, ECG\"\\n1173,1,1,\"Assessment of adverse events (based on CTCAE version 3.0), laboratory values, vital sign measurements, Karnofsky performance status\"\\n1174,1,1,\"Assessment of adverse events (based on CTCAE version 4.0), eye examination\"\\n1175,1,1,\"Assessment of adverse events (based on CTCAE version 4.0), laboratory values\"\\n1176,1,1,\"Assessment of adverse events (based on CTCAE version 4.0), left ventricular ejection fraction (LVEF)\"\\n1177,1,1,\"Assessment of adverse events (based on CTCAE version 4.0), LVEF\"\\n1178,1,1,\"Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements\"\\n1179,1,1,\"Assessment of adverse events (based on CTCAE version 4.0)general examination\"\\n1180,1,1,\"Assessment of Adverse Events by CTCAE 5.0 of HPN 328\"\\n1181,1,1,\"Assessment of Adverse Events for Dose Limiting Toxicities [Safety and Tolerabillity]\"\\n1182,1,1,\"Assessment of adverse events to evaluate Safety and Tolerability of ATL001\"\\n1183,1,1,\"Assessment of adverse events, clinical laboratory tests (clinical chemistry, haematology, coagulation, urinalysis), glucose management (s-glucose, s-insulin, haemoglobin A1c [HbA1c]), vital signs (pulse rate, blood pressure, weight and body temperature)\"\\n1184,1,1,\"Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort A\"\\n1185,1,1,\"Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort B\"\\n1186,1,1,\"Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort C\"\\n1187,1,1,\"Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D\"\\n1188,1,1,\"Assessment of antitumor activity using RECIST v1.1 (Dose expansion part)\"\\n1189,1,1,\"Assessment of attitudes and beliefs of patients\\' level of distress and incidence of stressors due to the COVID-19 pandemic, measured by survey.\"\\n1190,1,1,\"Assessment of autoimmune adverse events\"\\n1191,1,1,\"assessment of benefits on quality of life after treatment during two months\"\\n1192,1,1,\"Assessment of blood pressure (vital signs) in Phase I Dose Escalation\"\\n1193,1,1,\"Assessment of changes in clinical laboratory tests in Phase I Dose Escalation phase\"\\n1194,1,1,\"Assessment of Clinical Benefit Due to Treatment With Sunitinib\"\\n1195,1,1,\"Assessment of Clinical Symptomatic Response\"\\n1196,1,1,\"Assessment of DCR (disease control rate)\"\\n1197,1,1,\"Assessment of Disease control rate\"\\n1198,1,1,\"Assessment of Disease Control Rate in the Intent to Treat Population- Phase II\"\\n1199,1,1,\"Assessment of dose-limiting toxicities (DLTs).\"\\n1200,1,1,\"Assessment of dose-limiting toxicity\"\\n1201,1,1,\"Assessment of Duration of Response\"\\n1202,1,1,\"Assessment of Echocardiograms (ECHOs) in Phase I Dose Escalation phase\"\\n1203,1,1,\"Assessment of feasibility\"\\n1204,1,1,\"Assessment of hypoxia in head and neck squamous cell cancer using oxygen enhanced Magnetic resonance imaging (using a range of different MR sequences)\"\\n1205,1,1,\"Assessment of iniparib as single agent and in combination with chemotherapeutic agents related dose limiting toxicities (DLTs) observed at first cycle\"\\n1206,1,1,\"Assessment of neurotoxicity via digital capture of neurological assessment (Arm 1)\"\\n1207,1,1,\"Assessment of new malignancies\"\\n1208,2,2,\"Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocol\"\\n1209,1,1,\"Assessment of Objective Response Rate\"\\n1210,1,1,\"Assessment of Objective Response Rate in the Intent to Treat Population - Phase II\"\\n1211,1,1,\"Assessment of OctreoScan diagnostic sensitivity for detecting tumor(s) confirmed as somatostatin receptor positive by biopsy with immunohistochemistry analysis\"\\n1212,1,1,\"Assessment of Oral Bioavailability\"\\n1213,1,1,\"Assessment of ORR (objective response rate)\"\\n1214,1,1,\"Assessment of Overall Response Rate (ORR) following treatment of LEP-ETU at 275 mg/m2 dose\"\\n1215,1,1,\"Assessment of overall response rate using standard imaging and RECIST 1.1 criteria\"\\n1216,1,1,\"Assessment of overall response rate using standard imaging and RECIST v1.1 criteria (Expansion cohort)\"\\n1217,1,1,\"Assessment of patients\\' overall preference and perceptions towards palliative telemedicine vs in person visits during the COVID-19 pandemic.\"\\n1218,1,1,\"Assessment of performance status\"\\n1219,1,1,\"Assessment of PFS (progression free survival)\"\\n1220,1,1,\"Assessment of PK parameter: maximum concentration (Cmax)\"\\n1221,1,1,\"Assessment of PK parameter: time to reach Cmax (Tmax)\"\\n1222,1,1,\"Assessment of PR (vital signs) in Phase I Dose Escalation\"\\n1223,1,1,\"Assessment of preliminary clinical efficacy in Phase II dose expansion\"\\n1224,1,1,\"Assessment of Progression Free Survival\"\\n1225,1,1,\"Assessment of Progression-free Survival (PFS)\"\\n1226,1,1,\"Assessment of respiration rate (vital signs) in Phase I Dose Escalation\"\\n1227,1,1,\"Assessment of response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) in patients with metastatic breast cancer\"\\n1228,2,1,\"Assessment of safety and tolerability\"\\n1229,1,1,\"Assessment of safety and tolerability of BBI608 given in combination with Sorafenib by reporting of adverse events and serious adverse events.\"\\n1230,1,1,\"Assessment of safety and tolerability of CHS-006 administered in combination with toripalimab\"\\n1231,1,1,\"Assessment of serum concentrations of the analyte\"\\n1232,1,1,\"Assessment of serum PSA\"\\n1233,1,1,\"Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with bladder cancer.\"\\n1234,1,1,\"Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with non-small cell lung cancer.\"\\n1235,1,1,\"Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with pancreatic cancer.\"\\n1236,1,1,\"Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with soft-tissue sarcoma.\"\\n1237,1,1,\"Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with triple negative breast cancer.\"\\n1238,1,1,\"Assessment of the antitumor activity of atezolizumab combined with BDB001 and radiotherapy in patients with virus associated tumors.\"\\n1239,1,1,\"Assessment of the concentration of P-selectin in 3 groups in lung cancer patients and compared to the healthy participants.\"\\n1240,1,1,\"Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB\"\\n1241,1,1,\"Assessment of the efficacy of each treatment by evaluation of objective response rate\"\\n1242,1,1,\"Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival (PFS) Using BICR According to RECIST 1.1.\"\\n1243,1,1,\"Assessment of the feasibility by calculating the ratio of normalized fluorescence intensity measured at 620 nm and at 634 nm\"\\n1244,1,1,\"Assessment of the local tumor response of the HF10-injected tumor by a modified target Response Evaluation Criteria In Solid Tumors (RECIST) method\"\\n1245,1,1,\"Assessment of the safety after B7-H3 chimeric antigen receptor T cells infusion (Safety)\"\\n1246,1,1,\"Assessment of the safety after B7-H3-targeted chimeric antigen receptor T cells infusion (Safety)\"\\n1247,1,1,\"Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumab\"\\n1248,2,1,\"Assessment of tolerability\"\\n1249,1,1,\"Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.\"\\n1250,1,1,\"Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.\"\\n1251,1,1,\"Assessment of Treatment Emergent Adverse Events (TEAEs) to evaluate Safety and Tolerability\"\\n1252,1,1,\"Assessment of Treatment Emergent Adverse Events to evaluate Safety and Tolerability: CTCAE\"\\n1253,1,1,\"Assessment of Treatment Related Adverse Events (AEs).\"\\n1254,1,1,\"Assessment on Circulating Levels of VEGF Which Also Contribute to HCC Pathogenesis and on Potential Alterations of These Levels in the Setting of VEGF-inhibition\"\\n1255,1,1,\"Assignment of patients to ComboMATCH treatment trials\"\\n1256,1,1,\"Association between cfMeDIP and Response (defined as either complete response, partial response, or stable disease ‚â• 4 cycles, as per RECIST 1.1. Association between cfMeDIP and Toxicity (defined as ‚â• Grade 2 immune- adverse event (AE) as per CTCAE 5.0).\"\\n1257,1,1,\"Association between germline genetic predictors (single nucleotide variants) of lower testosterone levels and dementia risk\"\\n1258,1,1,\"Association between neoplastic complications and cancers\"\\n1259,1,1,\"Association between self-rated spirituality/religiosity and coping strategies\"\\n1260,1,1,\"Association between skin microbial diversity and immune checkpoint inhibitor (ICI)-induced dermatitis\"\\n1261,1,1,\"Association of Baseline C11-AMT PET SUV Max Value With Objective Response\"\\n1262,1,1,\"Associations between microbial community abundances and clinical outcomes\"\\n1263,1,1,\"AST concentration in whole blood sample\"\\n1264,1,1,\"AST laboratory values\"\\n1265,1,1,\"Asult MTD and DLTs of lexatumumab\"\\n1266,1,1,\"Atelectasis for each patient\"\\n1267,1,1,\"Atezolizumab Serum Concentration at Washout\"\\n1268,1,1,\"Attendance at 70% or more of exercise sessions.\"\\n1269,1,1,\"Attenuation Correction for PET/CT, Assessed Using SUVs (Cohorts I & II)\"\\n1270,1,1,\"Attenuation Correction for PET/MRI, Assessed Using Standard Uptake Values (SUVs) (Cohorts I & II)\"\\n1271,1,1,\"Attributable Length of Stay (ALOS) in 14 Confirmed Catheter Related Infection Cases\"\\n1272,24,1,\"Attrition\"\\n1273,184,6,\"AUC\"\\n1274,1,1,\"AUC (0 to Infinity) of Total Selumetinib\"\\n1275,1,1,\"AUC (0-168)\"\\n1276,1,1,\"AUC (0-21 day) of Patritumab\"\\n1277,1,1,\"AUC (0-inf) after a single dose and AUC (0-24) after single and multiple doses of Ipatasertib\"\\n1278,1,1,\"AUC (0-inf) of Idasanutlin Metabolite\"\\n1279,1,1,\"AUC (0-tau): Area Under the Serum Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for AMG 386 After Week 1 Dose\"\\n1280,1,1,\"AUC (0-tau): Area Under the Serum Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for AMG 386 After Week 4 Dose\"\\n1281,1,1,\"AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n1282,1,1,\"AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n1283,1,1,\"AUC (area under the plasma concentration vs time curve) of BAY43-9006\"\\n1284,2,1,\"AUC (area under the plasma concentration-time curve)\"\\n1285,1,1,\"AUC (PK)\"\\n1286,1,1,\"AUC 0-inf: Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time for Eribulin Mesylate\"\\n1287,16,1,\"AUC 0-t\"\\n1288,1,1,\"AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Eribulin Mesylate\"\\n1289,8,1,\"AUC 0-‚àû\"\\n1290,1,1,\"AUC at Steady State (AUCss) of BEVZ92 and Avastin¬Æ\"\\n1291,1,1,\"AUC computed from time zero to the time of the last positive concentration [AUClast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n1292,1,1,\"AUC Following Single Dose of Drug\"\\n1293,1,1,\"AUC Following Steady State Exposure for 14 Days\"\\n1294,1,1,\"AUC for antibody drug conjugate (ADC), total antibody (TA), derivative 4 of maytansine (DM4), and S methyl derivate of DM4 (DM4-Me) after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1\"\\n1295,1,1,\"AUC From 0 to 168 Hours of RO5185426 Following Day 21 Dose\"\\n1296,1,1,\"AUC From Time 0 to 24 Hours at Steady State(AUC(0-24),ss)\"\\n1297,1,1,\"AUC from time 0 to last data point (AUC(0-tlast))\"\\n1298,1,1,\"AUC from time 0 to the last data point > LLOQ after multiple dosing [AUC(0-tlast)md] of VIP152 (BAY1251152)\"\\n1299,1,1,\"AUC from time 0 to the last data point > Lower limit of quantitation (LLOQ) [AUC(0-tlast)] of VIP152 (BAY1251152)\"\\n1300,1,1,\"AUC from time zero extrapolated to infinity [AUCinf] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n1301,1,1,\"AUC from time zero to the last data point > LLOQ (lower limit of quantification) of BAY1163877 (AUC(0-tlast))\"\\n1302,3,1,\"AUC from time zero to the last quantifiable concentration (AUC0-t)\"\\n1303,1,1,\"AUC of AZ5104 After Single Dosing\"\\n1304,1,1,\"AUC of AZ7550 After Single Dosing\"\\n1305,1,1,\"AUC of AZD9291 After Single Dosing\"\\n1306,1,1,\"AUC of Bapotulimab after first dose administration (Cycle 1) for cohorts receiving doses ‚â• 20 mg\"\\n1307,1,1,\"AUC of BAY1163877\"\\n1308,1,1,\"AUC of Celecoxib on Combination Therapy (Day 14) and AUC of Celecoxib on Celecoxib Monotherapy(Day 7)\"\\n1309,1,1,\"AUC of docetaxel injection\"\\n1310,1,1,\"AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose\"\\n1311,1,1,\"AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose\"\\n1312,1,1,\"AUC of Olaparib\"\\n1313,1,1,\"AUC of Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n1314,1,1,\"AUC of RO5185426 From 0 to 12 Hours on Day 1\"\\n1315,1,1,\"AUC of RO5185426 From 0 to 12 Hours on Day 21\"\\n1316,1,1,\"AUC of RO5185426 From 0 to 8 Hours on Day 21\"\\n1317,1,1,\"AUC of RO5185426 on Day 1 - Dose Escalation: MBP Formulation\"\\n1318,1,1,\"AUC of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC\"\\n1319,1,1,\"AUC of RO5185426 on Day 15 - Dose Escalation: MBP Formulation\"\\n1320,1,1,\"AUC of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC\"\\n1321,1,1,\"AUC of roniciclib in plasma\"\\n1322,1,1,\"AUC of Talazoparib\"\\n1323,1,1,\"AUC of Talazoparib in Combination With Temozolomide\"\\n1324,1,1,\"AUC of Temozolomide in Combination With Talazoparib\"\\n1325,1,1,\"AUC of total radioactivity in whole blood and plasma\"\\n1326,1,1,\"AUC Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth)\"\\n1327,1,1,\"AUC Ratio of Blood:Plasma 14C-labeled RO5185426\"\\n1328,1,1,\"AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n1329,1,1,\"AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n1330,1,1,\"AUC(0-12) after multiple administrations (AUC(0-12)md) of BAY1163877\"\\n1331,1,1,\"AUC(0-12) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-12)norm,md) of BAY1163877\"\\n1332,1,1,\"AUC(0-12) divided by dose (mg) (AUC(0-12)/D) of BAY1163877\"\\n1333,1,1,\"AUC(0-12) divided by dose (mg) after multiple administrations (AUC(0-12)/Dmd) of BAY1163877\"\\n1334,1,1,\"AUC(0-12) divided by dose (mg) per kg body weight (AUC(0-12) norm) of BAY1163877\"\\n1335,1,1,\"AUC(0-12) of BAY2927088 for BID\"\\n1336,1,1,\"AUC(0-12) of N-desmethyl Selumetinib After Single Dose\"\\n1337,1,1,\"AUC(0-12) of N-desmethyl Selumetinib During Oral Twice Daily Dose of Selumetinib\"\\n1338,1,1,\"AUC(0-12) of Selumetinib After Single Dose\"\\n1339,1,1,\"AUC(0-12) of Selumetinib During Oral Twice Daily Dose of Selumetinib\"\\n1340,1,1,\"AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n1341,1,1,\"AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n1342,1,1,\"AUC(0-12)/Dmd (AUC(0-12) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15\"\\n1343,1,1,\"AUC(0-12): AUC from time zero to 12 hours p.a. after first-dose administration\"\\n1344,1,1,\"AUC(0-12)md (AUC(0-12) After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15\"\\n1345,1,1,\"AUC(0-12)md of BAY2927088 for BID\"\\n1346,1,1,\"AUC(0-12)md: AUC(0-12) after multiple dosing\"\\n1347,2,2,\"AUC(0-24)\"\\n1348,1,1,\"AUC(0-24) (AUC from time 0 h to time 24 h post-administration)\"\\n1349,1,1,\"AUC(0-24) of BAY2666605\"\\n1350,1,1,\"AUC(0-24) of BAY2927088 for QD\"\\n1351,1,1,\"AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1\\'-Hydroxymidazolam\"\\n1352,1,1,\"AUC(0-24)md (AUC from time zero to 24 hours after multiple-dose administration) for regorafenib\"\\n1353,1,1,\"AUC(0-24)md based on nominal dosing\"\\n1354,1,1,\"AUC(0-24)md of BAY2666605\"\\n1355,1,1,\"AUC(0-24)md of BAY2927088 for QD\"\\n1356,1,1,\"AUC(0-25) divided by dose (mg) (AUC(0-25)/D)\"\\n1357,1,1,\"AUC(0-25) divided by dose (mg) per kg body weight (AUC(0-25)norm)\"\\n1358,1,1,\"AUC(0-26)md (AUC from time zero to 26 hours after multiple-dose administration) for cetuximab\"\\n1359,1,1,\"AUC(0-504) of BAY1834942 after single dose\"\\n1360,1,1,\"AUC(0-8): Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post-dose for Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion\"\\n1361,1,1,\"AUC(0-inf) of [13C]-Labeled Idasanutlin\"\\n1362,1,1,\"AUC(0-last) and Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Probe Parent Drugs and Their Metabolites on Day 1\"\\n1363,1,1,\"AUC(0-last) and AUC(0-inf) of Probe Parent Drugs and Their Metabolites on Day 20\"\\n1364,1,1,\"AUC(0-last) of [13C]-Labeled Idasanutlin\"\\n1365,1,1,\"AUC(0-last) of Idasanutlin Metabolite\"\\n1366,7,2,\"AUC(0-tlast)\"\\n1367,1,1,\"AUC(0-tlast) (area under the plasma concentration vs time curve from time 0 to the last data point) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n1368,1,1,\"AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point > LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n1369,1,1,\"AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point > LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n1370,1,1,\"AUC(0-tlast) (AUC from time zero to the last data point>LLOQ)\"\\n1371,1,1,\"AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5\"\\n1372,1,1,\"AUC(0-tlast) after multiple administrations divided by dose (mg) (AUC(0-tlast)/Dmd) of BAY1163877\"\\n1373,1,1,\"AUC(0-tlast) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-tlast) norm,md) of BAY1163877\"\\n1374,1,1,\"AUC(0-tlast) divided by dose (mg) (AUC(0-tlast)/D) of BAY1163877\"\\n1375,1,1,\"AUC(0-tlast) divided by dose (mg) per kg body weight (AUC(0-tlast) norm) of BAY1163877\"\\n1376,1,1,\"AUC(0-tlast) for ADC, TA, DM4 and DM4-Me after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1\"\\n1377,1,1,\"AUC(0-tlast) of roniciclib in plasma\"\\n1378,1,1,\"AUC(0-tlast) of total radioactivity in whole blood and plasma\"\\n1379,1,1,\"AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point > LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n1380,1,1,\"AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point > LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n1381,1,1,\"AUC(0-tlast)/D (AUC(0-tlast) divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n1382,1,1,\"AUC(0-tlast)/Dmd (AUC(0-tlast) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15\"\\n1383,1,1,\"AUC(0-tlast)after multiple administrations (AUC(0-tlast)md) of BAY1163877\"\\n1384,1,1,\"AUC(0-tlast)md (AUC(0-tlast) After Multiple Dose Administration) of BAY1163877 on Cycle 1, Day 15\"\\n1385,1,1,\"AUC(0-tlast)norm (AUC(0-tlast) divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n1386,15,1,\"AUC(0-‚àû)\"\\n1387,1,1,\"AUC(Area Under The Plasma Concentration Versus Time Curve)\"\\n1388,1,1,\"AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib\"\\n1389,1,1,\"AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A\"\\n1390,1,1,\"AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin\"\\n1391,1,1,\"AUC(ss) of AZ5104 After Multiple Dosing\"\\n1392,1,1,\"AUC(ss) of AZ7550 After Multiple Dosing\"\\n1393,1,1,\"AUC(ss) of AZD9291 After Multiple Dosing\"\\n1394,1,1,\"AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n1395,1,1,\"AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n1396,1,1,\"AUC/D of BAY1163877\"\\n1397,1,1,\"AUC0-10 (area under the plasma concentration versus time curve from time 0 to 10 hours post dose) of FTD and TPI\"\\n1398,1,1,\"AUC0-168hr in Participants Receiving Multiple QW Dosing\"\\n1399,1,1,\"AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MLN0246\"\\n1400,1,1,\"AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MMAE\"\\n1401,1,1,\"AUC0-24 After Multiple Doses of GDC-0449\"\\n1402,1,1,\"AUC0-24 of Cobimetinib on Day 1, Cycle 1 of Cohort 3\"\\n1403,1,1,\"AUC0-24 of Cobimetinib on Day 14, Cycle 1\"\\n1404,1,1,\"AUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-3\"\\n1405,1,1,\"AUC0-24h (Area under the plasma concentration versus time curve)\"\\n1406,1,1,\"AUC0-4w,1\"\\n1407,1,1,\"AUC0-7day of Mogamulizumab\"\\n1408,50,4,\"AUC0-inf\"\\n1409,2,2,\"AUC0-inf (Area under the curve from time 0 to infinity)\"\\n1410,1,1,\"AUC0-inf of Entrectinib Active Metabolite M5\"\\n1411,1,1,\"AUC0-inf of Volasertib and CD10899 in Plasma\"\\n1412,13,3,\"AUC0-last\"\\n1413,2,2,\"AUC0-last (Area under the curve from time 0 to the last time with quantifiable concentration)\"\\n1414,123,4,\"AUC0-t\"\\n1415,1,1,\"AUC0-t (area under the plasma concentration versus time curve from time 0 to time (t) of the last quantifiable concentration ) of FTD and TPI\"\\n1416,1,1,\"AUC0-t based on encapsulated doxorubicin in patients\"\\n1417,1,1,\"AUC0-t of Olaparib\"\\n1418,1,1,\"AUC0-t Ôºöarea under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration\"\\n1419,1,1,\"AUC0-tz of 14C Radioactivity in Plasma and Whole Blood\"\\n1420,73,2,\"AUC0-‚àû\"\\n1421,1,1,\"AUC0-‚àû based on encapsulated doxorubicin in patients\"\\n1422,1,1,\"AUC0-‚àûÔºöArea Under the Plasma Concentration-time Curve From Time 0 to Infinity\"\\n1423,2,1,\"AUC24\"\\n1424,1,1,\"AUC24 of all talazoparib treatment\"\\n1425,1,1,\"AUCall-to-dose ratio [AUCall/Dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n1426,32,1,\"AUCinf\"\\n1427,1,1,\"AUCinf (area under the plasma concentration versus time curve from time 0 to infinity) of FTD and TPI\"\\n1428,1,1,\"AUCinf of digoxin and rosuvastatin\"\\n1429,1,1,\"AUCinf of midazolam and caffeine\"\\n1430,1,1,\"AUCinf-to-dose ratio [AUCinf/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n1431,87,2,\"AUClast\"\\n1432,1,1,\"AUClast at Single Dose\"\\n1433,1,1,\"AUClast for INC280\"\\n1434,1,1,\"AUClast of digoxin and rosuvastatin\"\\n1435,1,1,\"AUClast of midazolam and caffeine\"\\n1436,1,1,\"AUClast-to-dose ratio [AUClast/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n1437,1,1,\"AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution\"\\n1438,1,1,\"AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve from Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-659\"\\n1439,1,1,\"AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1\"\\n1440,1,1,\"AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15\"\\n1441,1,1,\"AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort\"\\n1442,1,1,\"AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort\"\\n1443,1,1,\"AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort\"\\n1444,1,1,\"AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort\"\\n1445,1,1,\"AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole\"\\n1446,1,1,\"AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib\"\\n1447,1,1,\"AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-659\"\\n1448,1,1,\"AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-659\"\\n1449,1,1,\"AUCnorm of BAY1163877\"\\n1450,1,1,\"AUCt for ABBV-321\"\\n1451,1,1,\"AUCt.ss (AUC for the dosing interval at steady-state)\"\\n1452,1,1,\"AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Ixazomib\"\\n1453,1,1,\"AUCtau for INC280\"\\n1454,1,1,\"AUCœÑ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval (œÑ) for Alisertib\"\\n1455,1,1,\"AUC‚àû for ABBV-321\"\\n1456,1,1,\"AUC‚àû: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution\"\\n1457,1,1,\"AUC‚àû: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib\"\\n1458,1,1,\"AUC‚àû: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A\"\\n1459,1,1,\"AUC‚àû: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1\"\\n1460,1,1,\"AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole\"\\n1461,1,1,\"AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin\"\\n1462,1,1,\"AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-659\"\\n1463,1,1,\"Availability of recommended experimental regimens via clinical trials\"\\n1464,1,1,\"Average 89Zr-trastuzumab SUVmax of lesions identified on baseline FDG-PET/CT\"\\n1465,1,1,\"Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT\"\\n1466,1,1,\"Average change from baseline in gallbladder function (ejection fraction)\"\\n1467,1,1,\"Average change from baseline in gallbladder size (volume by ultrasound)\"\\n1468,1,1,\"Average Change in the Longest Diameter of the Breast MRI Target Lesion\"\\n1469,1,1,\"Average concentration (PK)\"\\n1470,1,1,\"Average concentration of Relatlimab over a dosing interval (Cavg(TAU))\"\\n1471,1,1,\"Average Daily Dose Administered to Subjects in Each Treatment Arm\"\\n1472,1,1,\"Average difference in pre- and post-treatment worst pain score in a 24-hour period at week 8\"\\n1473,1,1,\"average length of hospital stay for febrile neutropenia\"\\n1474,1,1,\"Average Plasma Concentration at Steady State (Css, Avg) After Multiple Doses of GDC-0449\"\\n1475,1,1,\"Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR) for Participants With Response Versus Participants With Progression\"\\n1476,1,1,\"Average Steady State Plasma Concentration (Cavg) of Trametinib When Administered Alone (Monotherapy)\"\\n1477,2,1,\"Average steady-state concentration (Css,av)\"\\n1478,1,1,\"Average Time-matched QT Corrected by the Fridericia Formula (QTcF) Change From Baseline to Day 14\"\\n1479,1,1,\"Average turnaround time of no more than 10 business days for combined EGFR and ALK results reporting in lung cancer\"\\n1480,1,1,\"AZD2014 Concentrations in Plasma Following Administration of [14C]-AZD2014\"\\n1481,1,1,\"AZD2014 Concentrations in Saliva Following Administration of [14C]-AZD2014\"\\n1482,1,1,\"AZD7442 Serum Concentration\"\\n1483,2,1,\"Back/spine\"\\n1484,1,1,\"Barriers to treatment (perceived and real)\"\\n1485,1,1,\"Baseline active tumor volume on [68Ga]FAPI and [18F] FDG PET Scans\"\\n1486,1,1,\"Baseline Enhancing Tumor and Response by RECIST Criteria\"\\n1487,1,1,\"Baseline Gene Expression Levels of the Target Genes (PDGF-R and PDGF), Genes Associated With Induction of Apoptosis (Bcl-2, Bax), and Cell Cycle Regulatory Genes (p53, p21, p27\"\\n1488,1,1,\"Baseline information of children with CNS tumours\"\\n1489,1,1,\"Baseline measurements for DCE-MRI-iAUC60(mMol/sec),Ktrans(min-1),ve,vp,kep(min-1,Enhancing Fraction% DCE-CT-Permeability Surface Product(ml/min/100g),Perfusion(ml/min/100g),Mean Transit Time(sec),Blood Volume (ml/100g),Positive Enhancement Integral(Hus).\"\\n1490,1,1,\"Baseline microbiome alpha diversity in patients prescribed corticosteroids vs those who were not prescribed corticosteroids\"\\n1491,1,1,\"Baseline microbiome alpha diversity in responders versus (vs) non-responders\"\\n1492,1,1,\"Baseline SUVmax on [68Ga]FAPI and [18F] FDG PET Scans\"\\n1493,1,1,\"Baseline total lesion activation on [68Ga]FAPI and [18F] FDG PET Scans\"\\n1494,1,1,\"Baseline Tumor FDG PET SUV Data by Disease Type at Baseline\"\\n1495,1,1,\"Baseline VO2peak in participants with HER2-positive breast cancer\"\\n1496,1,1,\"Basic fruit/vegetable intake\"\\n1497,1,1,\"BDI as a chemosensitivity assay on fresh tumor samples\"\\n1498,2,2,\"BED(Biological effective dose)\"\\n1499,1,1,\"Behavior changes regarding physical activity by self-reported questionnaire\"\\n1500,1,1,\"Behaviors that make a positive impact on decision-making\"\\n1501,1,1,\"Benefit from PMMTB recommended treatment\"\\n1502,1,1,\"Best Biochemical Response (Cancer Antigen [CA-125])\"\\n1503,1,1,\"Best deepness of response\"\\n1504,1,1,\"Best diagnostic performance of computed tomography (CT) reconstruction parameters\"\\n1505,1,1,\"Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype\"\\n1506,1,1,\"Best investigator-assessed response\"\\n1507,6,4,\"Best objective response\"\\n1508,1,1,\"best objective response\"\\n1509,1,1,\"Best Objective Response (BOR) for Dose Escalation Population\"\\n1510,1,1,\"Best objective response (Cohort II)\"\\n1511,1,1,\"Best objective response (complete response or partial response)\"\\n1512,1,1,\"Best Objective Response Based on RECIST Criteria (Evaluable for Response Analysis Set for RECIST Criteria)\"\\n1513,1,1,\"Best Objective Response Evaluated According to the RECIST Criteria by Independent Review\"\\n1514,4,1,\"Best Objective Response Rate\"\\n1515,6,1,\"Best objective response rate\"\\n1516,2,2,\"Best Objective Response Rate (BORR)\"\\n1517,1,1,\"Best objective response rate (ORR)\"\\n1518,1,1,\"Best Observed Radiographic Response Rate (Measured by mRECIST)\"\\n1519,1,1,\"Best Overall Objective Response Rate (ORR) by Modified \"\"Skin\"\" RECIST\"\\n1520,1,1,\"Best Overall Objective Response Rate (ORR) Within 24 Weeks Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n1521,1,1,\"Best Overall PSA Response\"\\n1522,21,12,\"Best Overall Response\"\\n1523,15,6,\"Best overall response\"\\n1524,6,2,\"Best Overall Response (BOR)\"\\n1525,4,1,\"Best overall response (BOR)\"\\n1526,1,1,\"Best overall response (BoR) [Part 3]\"\\n1527,1,1,\"Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria\"\\n1528,1,1,\"Best Overall Response (BOR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) of Bintrafusp Alfa (M7824) & NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy in Participants With Locally Advanced Pancreas Cancer\"\\n1529,1,1,\"Best Overall Response (BOR) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1)\"\\n1530,1,1,\"Best Overall Response (BOR) Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).\"\\n1531,1,1,\"Best Overall Response (BOR) in Participants With Adenocarcinoma Histology\"\\n1532,1,1,\"Best Overall Response (BOR) in Participants With T790M Mutation\"\\n1533,1,1,\"Best Overall Response (BOR) per Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n1534,1,1,\"Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment\"\\n1535,1,1,\"Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments\"\\n1536,1,1,\"Best overall response (complete response [CR] + partial response [PR])\"\\n1537,1,1,\"Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n1538,1,1,\"best overall response (ORR)\"\\n1539,1,1,\"best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Part B)\"\\n1540,1,1,\"Best Overall Response and Objective Response Rate Following Treatment With Tivantinib (ARQ 197) in Participants With Relapsed or Refractory Germ Cell Tumors\"\\n1541,1,1,\"Best Overall Response in Participants After a Dosage of CS-7017 Administered Twice Daily in Combination With Paclitaxel Administered Once Every 3 Weeks to Participants With Advanced Anaplastic Thyroid Cancer (ATC)\"\\n1542,1,1,\"Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer\"\\n1543,1,1,\"Best Overall Response Per Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n1544,9,5,\"Best Overall Response Rate\"\\n1545,1,1,\"Best Overall Response rate\"\\n1546,10,4,\"Best overall response rate\"\\n1547,5,3,\"best overall response rate\"\\n1548,1,1,\"Best Overall Response Rate (BOR)\"\\n1549,1,1,\"best overall response rate (BOR)\"\\n1550,6,2,\"Best Overall Response Rate (BORR)\"\\n1551,2,1,\"Best overall response rate (BORR)\"\\n1552,1,1,\"Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status\"\\n1553,1,1,\"Best Overall Response Rate (BORR) by RECIST v1.1\"\\n1554,1,1,\"Best Overall Response Rate (BORR) Within Brain of Previously Untreated Participants (Assessed by Independent Review Committee [IRC] Using Modified Response Evaluation Criteria in Solid Tumors [RECIST])\"\\n1555,1,1,\"Best Overall Response Rate (ORR) to Alisertib Alone\"\\n1556,1,1,\"Best Overall Response Rate (ORR), Based on Unconfirmed Response Assessment, as Assessed by Central Imaging Review Until 18 Weeks After the Start of Treatment\"\\n1557,1,1,\"Best Overall Response Rate (Phase 2)\"\\n1558,1,1,\"Best Overall Response Rate as Assessed by Response (BORR) Evaluation Criteria in Solid Tumors Version 1.1, With the Modification That Progressive Disease Must be Confirmed on a Subsequent Scan\"\\n1559,1,1,\"Best Overall Response Rate by Investigator\"\\n1560,1,1,\"Best overall response rate by IRC\"\\n1561,1,1,\"Best overall response rate in cohort 2-4\"\\n1562,1,1,\"Best Overall Response Rate in TKI-Naive Participants\"\\n1563,1,1,\"Best overall response rate to talimogene laherparepvec and nivolumab combination therapy (Part II)\"\\n1564,1,1,\"Best overall response rate: proportion of subjects with either complete or partial response according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria at the end of study\"\\n1565,1,1,\"Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)\"\\n1566,1,1,\"Best Overall Responses (BOR) Summary Table as Per Central Review by Group - Phase II\"\\n1567,6,4,\"Best Overall Tumor Response\"\\n1568,1,1,\"Best overall tumor response\"\\n1569,1,1,\"Best Overall Tumor Response (PVNS Cohort) Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Extension\"\\n1570,1,1,\"Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Efficacy Evaluable Population)\"\\n1571,1,1,\"Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Efficacy Evaluable Population)\"\\n1572,1,1,\"Best Percentage Change in Tumour Size\"\\n1573,1,1,\"Best PSA response\"\\n1574,1,1,\"Best radiographic response\"\\n1575,1,1,\"Best Radiological Response in Participants Using the RECIST Criteria\"\\n1576,9,2,\"Best Response\"\\n1577,1,1,\"Best Response (BR)\"\\n1578,1,1,\"Best Response - mITT (Modified Intent-to-treat) Population\"\\n1579,1,1,\"Best Response During Second-Line Treatment\"\\n1580,1,1,\"Best response rate (Phase II)\"\\n1581,1,1,\"Best response to treatment\"\\n1582,1,1,\"Best response, defined to be complete response (CR) or partial response (PR) as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n1583,2,1,\"Best Tumor Response\"\\n1584,1,1,\"Best tumor response\"\\n1585,1,1,\"Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST])\"\\n1586,1,1,\"Best tumor response, defined as the best objective status recorded among patients with measurable disease at baseline using Response Evaluation Criteria in Solid Tumors version 1.1\"\\n1587,1,1,\"Best-Worst Scaling scores showing patient preferences for the attributes of the process of taking panel tests\"\\n1588,1,1,\"Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.\"\\n1589,1,1,\"Better understanding of the epidemiology of CNS metastases from solid tumours\"\\n1590,1,1,\"BF-Mayo Neuro test (Arm 1)\"\\n1591,1,1,\"Bias of the formula for estimated glomerular filtration rate (eGFR) currently in existence in patients with cancer\"\\n1592,1,1,\"Bilirubin, direct and total (mg/dL) laboratory values\"\\n1593,1,1,\"Biochemical recurrence-free survival (bRFS)\"\\n1594,2,1,\"Biochemical Response Rate\"\\n1595,1,1,\"Biochemical Treatment Response\"\\n1596,1,1,\"Biodistribution of 89Zr-M7824 in NSCLC patients\"\\n1597,1,1,\"Biodistribution of [18F]-AlF-RESCA-IL2\"\\n1598,1,1,\"Biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues\"\\n1599,1,1,\"Biologic activity of oblimersen in mononuclear cells and tumor tissues, in terms of B-cell lymphoma 2 (bcl-2) and related protein expression\"\\n1600,1,1,\"Biological activity and therapeutic antitumor activity of everolimus and vatalanib when given at the MTD/RPTD (Cohort II)\"\\n1601,1,1,\"Biological activity of this regimen\"\\n1602,1,1,\"Biological data\"\\n1603,1,1,\"Biological response at week 3\"\\n1604,1,1,\"Biological Response Data Based on Pharmacodynamic Endpoints on Tumour Biopsy Material\"\\n1605,1,1,\"Biologically optimal dose (BOD) defined as the dose level and diet in combination that induces no toxicity requiring dose modification per protocol and achieves a satisfactory pazopanib trough concentration (Cmin greater than 30 ug/mL)\"\\n1606,1,1,\"Biology of Patients Compared with Healthy Controls\"\\n1607,1,1,\"Biomarker (GSK3Œ≤) analysis\"\\n1608,1,1,\"Biomarker analyses to predict treatment response in metastatic cancer\"\\n1609,1,1,\"Biomarker analysis in plasma. Biomarkers in the cellular fraction of blood samples. Gene expression by quantitative PCR. The units are AU (arbitrary units) because what is measured is the relative expression against endogenous controls.\"\\n1610,1,1,\"Biomarker analysis in plasma.Inflammation Markers and Endocrine-Nutritional Markers and Muscle Loss. Units: pg/mL\"\\n1611,1,1,\"Biomarker Cohort: Distribution of Tumor-Infiltrating Lymphocytes (TILs)\"\\n1612,1,1,\"Biomarker Cohort: Number of Tumor-Infiltrating Lymphocytes (TILs)\"\\n1613,1,1,\"Biomarker Cohort: Phenotype of Tumor-Infiltrating Lymphocytes (TILs)\"\\n1614,1,1,\"Biomarker Evaluation\"\\n1615,1,1,\"Biomarker of OPB-111077\"\\n1616,1,1,\"Biomarker response to immune checkpoint inhibitor therapy as measured by Response Evaluation Criteria in Solid Tumors version 1.1 criteria\"\\n1617,1,1,\"Biomarker results turnaround time\"\\n1618,1,1,\"Biomarker signature development\"\\n1619,1,1,\"Biomarkers of ERY974 in combination with atezolizumab and bevacizumab [Biomarker part]\"\\n1620,1,1,\"Biophysical properties of the tumor tissue - measurement of hydraulic conductivity\"\\n1621,1,1,\"Biophysical properties of the tumor tissue - measurement of Young modulus to assess viscoelasticity\"\\n1622,1,1,\"Biopsy sub-study: CD8+ T-cells tumour infiltration assessed in baseline, on-treatment and off-treatment tumour biopsies\"\\n1623,1,1,\"Biosample procurement\"\\n1624,1,1,\"Biospecimen storage\"\\n1625,2,1,\"BIRC-assessed progression-free survival (PFS) as per RECIST v1.1ÔºàStage IIÔºâ\"\\n1626,1,1,\"Blinded independent central review (BICR)-assessed Objective Response Rate (ORR) in participants treated with nivolumab combined with ipilimumab\"\\n1627,4,1,\"Blood biochemistry\"\\n1628,1,1,\"Blood chemistry values\"\\n1629,1,1,\"Blood Concentration of Everolimus at Specified Timepoints\"\\n1630,1,1,\"Blood Counts\"\\n1631,1,1,\"Blood Plasma Volume and Extravascular/Extracellular Volume\"\\n1632,334,3,\"Blood pressure\"\\n1633,7,1,\"Blood Pressure (BP)\"\\n1634,2,1,\"Blood Pressure (mm Hg)\"\\n1635,10,1,\"Blood pressure (mmHg)\"\\n1636,1,1,\"Blood Pressure (Safety and Tolerability in the Dose Escalation Phase)\"\\n1637,1,1,\"Blood pressure by sphygmomanometer\"\\n1638,4,1,\"Blood pressure changes\"\\n1639,1,1,\"Blood pressure changes at baseline, and then weeks 4, 8, and 12 during study treatment\"\\n1640,5,1,\"Blood routine\"\\n1641,1,1,\"Blood sampling to characterize the pharmacokinetics of palifosfamide-tris\"\\n1642,3,1,\"Blood urea nitrogen (BUN)\"\\n1643,1,1,\"Blood, urine and fecal samples will be collected over a period of 336 hours (14 days) to measure 14C, ZK 219477 and its major metabolites following the intravenous administration of 14C-ZK 219477.\"\\n1644,116,1,\"Body composition\"\\n1645,65,1,\"Body Mass Index (BMI)\"\\n1646,48,2,\"Body temperature\"\\n1647,1,1,\"Body Temperature (¬∞C)\"\\n1648,1,1,\"Body temperature by thermometer\"\\n1649,1,1,\"Bone mineral density (BMD) of the distal femur\"\\n1650,1,1,\"Bone PD: Cross-Linked N-telopeptides of Type I collagen (NTx) Levels (Parts A & B)\"\\n1651,1,1,\"Bone specific alkaline phosphatase (BAP) modulation\"\\n1652,1,1,\"Bone Turnover Markers-bone Formation and Bone Resorption\"\\n1653,1,1,\"Boost Dose Toxicity\"\\n1654,1,1,\"Both Dose-Escalation and Dose-Expansion: Number of Participants With Adverse Events (AEs) and Serious AEs\"\\n1655,1,1,\"Bowel emptying patterns\"\\n1656,1,1,\"Breakthrough incidence of Invasive Fungal Infection (IFI), defined according to the revised EORTC/MSG criteria, during prophylaxis use of micafungin\"\\n1657,3,1,\"Breathing\"\\n1658,1,1,\"Build predictive diagnosis database\"\\n1659,1,1,\"Build the next generation biobank of liver-derived organoids\"\\n1660,1,1,\"Bystander and abscopal effects\"\\n1661,1,1,\"C Max of Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n1662,1,1,\"C Max of Talazoparib\"\\n1663,1,1,\"C Max of Talazoparib in Combination With Temozolomide\"\\n1664,1,1,\"C Max of Temozolomide in Combination With Talazoparib\"\\n1665,1,1,\"C(ss, Max) of AZ5104 After Multiple Dosing\"\\n1666,1,1,\"C(ss, Max) of AZ7550 After Multiple Dosing\"\\n1667,1,1,\"C(ss, Max) of AZD9291 After Multiple Dosing\"\\n1668,1,1,\"C48hr of MK-2206 in Participants Receiving Multiple QW Dosing\"\\n1669,1,1,\"CA125 measurements\"\\n1670,1,1,\"Calculate the Cmax and Tmax of participating subjects\"\\n1671,1,1,\"Calculate whole body and organ radiation dosimetry of I-131-CLR1404 to determine the millicurie dose which is expected to deliver 35-40 centigray of radiation to bone marrow\"\\n1672,1,1,\"Calculation of pharmacokinetic parameters of BAY86-9766 and its metabolite (M17).\"\\n1673,1,1,\"Can 18F-FAZA can be used as a prognostic marker in HNSCC?\"\\n1674,10,1,\"Cancer\"\\n1675,1,1,\"Cancer Cachexia\"\\n1676,1,1,\"Cancer cachexia (CC)\"\\n1677,2,1,\"Cancer distress\"\\n1678,1,1,\"Cancer embolism withdraws\"\\n1679,1,1,\"Cancer Treatment Type - Ever Received During Study\"\\n1680,1,1,\"Cancer vs Benign Disease\"\\n1681,1,1,\"Cancer-related mortality after solid organ transplantation\"\\n1682,1,1,\"CANscript decision impact will be captured via a study specific questionnaire\"\\n1683,1,1,\"capability of SCENT B1 to distinguish healthy and tumoral specimens\"\\n1684,1,1,\"Capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1)\"\\n1685,2,2,\"CAR positive T cells in patients\"\\n1686,1,1,\"Cardiac adverse event\"\\n1687,1,1,\"Cardiac assessment\"\\n1688,1,1,\"Cardiac events within 12 months of starting treatment.\"\\n1689,1,1,\"Cardiac functional status and quality of life\"\\n1690,1,1,\"Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin When Delivered Immediately Following Four Cycles of Standard Dose AC.\"\\n1691,1,1,\"Care consumption\"\\n1692,9,1,\"Caregiver burden\"\\n1693,1,1,\"Caregiver burden and caregiver quality of life as measured by the Caregiver Quality of Life-Cancer Index\"\\n1694,1,1,\"Caregiver Burden by Caregiver Reaction Assessment at baseline, 3 months, and 1 year\"\\n1695,1,1,\"Caregiver: Change in Center for Epidemiological Studies Depression Scale (CESD)\"\\n1696,1,1,\"Caries-screening\"\\n1697,1,1,\"Cascade screening rate among Lynch or HBOC positive carriers\"\\n1698,1,1,\"Caspase-8 expression in bone marrow or tumor biopsy samples (Part B)\"\\n1699,1,1,\"Categorization of PD-L1 results (dichotomous, high vs. low) based on pre-treatment tissue samples.\"\\n1700,1,1,\"Category of DLTs\"\\n1701,1,1,\"Causality assessment of TEAEs\"\\n1702,1,1,\"Causality of each adverse event and grading severity according to NCI CTCAE Version 3.0\"\\n1703,1,1,\"Causality of each adverse event to Aurora B/C kinase inhibitor GSK1070916A and grading severity according to NCI CTCAE Version 4.02\"\\n1704,1,1,\"Causality of TEAEs\"\\n1705,2,1,\"Cause specific survival\"\\n1706,2,1,\"Cause-specific survival\"\\n1707,1,1,\"CBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia\"\\n1708,1,1,\"CBR for Hematologic Tumors at Week 16: Multiple Myeloma\"\\n1709,1,1,\"CBR-24week\"\\n1710,1,1,\"CD4+ and CD8+ T cell reactivity to KLH measured by T cell proliferation quantified by tritiated thymidine incorporation\"\\n1711,1,1,\"CD8+ T-cell count.\"\\n1712,1,1,\"Cell killing ability (positive or negative)\"\\n1713,2,1,\"Cell proliferation\"\\n1714,1,1,\"Cell yield\"\\n1715,1,1,\"cell-free DNA or RNA percentages and profiles measured using TapeStation\"\\n1716,1,1,\"Cellularity of Specimens Obtained by Each Individual Technique Based on Cellularity Score\"\\n1717,1,1,\"Central nerve system duration of responseÔºàCNS DORÔºâ\"\\n1718,1,1,\"Central nervous system (CNS) composite endpoint event (CNS-CE event)\"\\n1719,1,1,\"Central nervous system (CNS) objective response rate (ORR)\"\\n1720,1,1,\"Central Nervous System (CNS) Progression-free Survival Rate\"\\n1721,1,1,\"Central Nervous System (CNS) Response Rate by RECIST Criteria\"\\n1722,1,1,\"Central Review-based Progression-Free Survival\"\\n1723,1,1,\"central venous catheter-associated bloodstream infection (CLABSI)\"\\n1724,1,1,\"Centrally Assessed Progression Free Survival\"\\n1725,1,1,\"Ceoi at Multiple Doses\"\\n1726,1,1,\"Cerebrospinal Concentration\"\\n1727,1,1,\"Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells\"\\n1728,1,1,\"Cetuximab Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC œÑ,ss)\"\\n1729,1,1,\"Cetuximab Pharmacokinetics: Confirmatory Serum Concentration\"\\n1730,1,1,\"Cetuximab Pharmacokinetics: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)\"\\n1731,1,1,\"Cetuximab Pharmacokinetics: Measurement of the Time After Administration When the Maximum Plasma Concentration is Reached (Tmax)\"\\n1732,1,1,\"Cetuximab PK: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC œÑ,ss)\"\\n1733,1,1,\"Cetuximab PK: Confirmatory Serum Concentration\"\\n1734,1,1,\"Cetuximab PK: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)\"\\n1735,1,1,\"Cetuximab PK: Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss)\"\\n1736,1,1,\"cfMeDIP-seq-based assays of blood samples collected serially on study. Association between cfMeDIP and Toxicity (defined as ‚â• Grade 2 immune- adverse event (AE) as per CTCAE 5.0)\"\\n1737,1,1,\"Chang of QT interval from Baseline [Safety]\"\\n1738,3,3,\"Change (%) in the sum of diameters of target lesions\"\\n1739,2,2,\"Change and corrected Hemoglobin levels\"\\n1740,1,1,\"Change from baseline by computerized tomography of Chest, abdomen and pelvis\"\\n1741,1,1,\"Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS)\"\\n1742,1,1,\"Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Month 60\"\\n1743,1,1,\"Change From Baseline in Absolute Neutrophil Count (Part A and B)\"\\n1744,1,1,\"Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) Levels-Part 1\"\\n1745,1,1,\"Change From Baseline in Alanine Aminotransferase (Part A and B)\"\\n1746,1,1,\"Change From Baseline in Albumin and Total Protein Levels-Part 1\"\\n1747,1,1,\"Change From Baseline in Amylase and Lipase Levels-Part 1\"\\n1748,1,1,\"Change from Baseline in arterial oxygen saturation\"\\n1749,1,1,\"Change From Baseline in Aspartate Aminotransferase (Part A and B)\"\\n1750,1,1,\"Change From Baseline in Blood Pressure (Part A and B)\"\\n1751,1,1,\"Change From Baseline in Body Temperature (BT)\"\\n1752,3,1,\"Change From Baseline in Body Temperature at the Indicated Time Points\"\\n1753,2,1,\"Change from Baseline in Body Temperature Over Time\"\\n1754,1,1,\"Change from Baseline in body weight\"\\n1755,1,1,\"Change From Baseline in C-Reactive Protein (CRP) Level at Month 60\"\\n1756,1,1,\"Change from baseline in clinical laboratory test results and examination findings[safety and tolerability]\"\\n1757,1,1,\"Change From Baseline in Corrected QT Interval Using Fridericia\\'s Correction (QTcF) at Trastuzumab Steady State\"\\n1758,1,1,\"Change From Baseline in Creatinine (Part A and B)\"\\n1759,1,1,\"Change From Baseline in Creatinine and Bilirubin Levels-Part 1\"\\n1760,2,1,\"Change from Baseline in Diastolic Blood Pressure Over Time\"\\n1761,1,1,\"Change From Baseline in Disease Activity Score Based on 28-joints Count (DAS28) at Month 60\"\\n1762,1,1,\"Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score\"\\n1763,1,1,\"Change from Baseline in ECG Results Over Time: PR Duration\"\\n1764,1,1,\"Change from Baseline in ECG Results Over Time: QRS Duration\"\\n1765,1,1,\"Change from Baseline in ECG Results Over Time: QT Duration\"\\n1766,1,1,\"Change from Baseline in ECG Results Over Time: QTcF Duration\"\\n1767,1,1,\"Change from Baseline in ECG Results Over Time: RR Duration\"\\n1768,1,1,\"Change from Baseline in ECGs\"\\n1769,1,1,\"Change from baseline in ECOG score\"\\n1770,1,1,\"Change from Baseline in Electrocardiogram (ECG) Results Over Time: Heart Rate\"\\n1771,1,1,\"Change from Baseline in electrocardiogram evaluations\"\\n1772,1,1,\"Change from Baseline in Electrocardiogram Procedures\"\\n1773,1,1,\"Change From Baseline in EQ5D-3L Score at Last Follow-up\"\\n1774,1,1,\"Change From Baseline in EQ5D-3L Score at Month 6\"\\n1775,1,1,\"Change From Baseline in EQ5D-3L Score at Month 9\"\\n1776,1,1,\"Change From Baseline in EQ5D-3L Scores at Month 3\"\\n1777,1,1,\"Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Month 60\"\\n1778,1,1,\"Change From Baseline in Erythrocytes Count-Part 1\"\\n1779,1,1,\"Change From Baseline in Euro Quality of Life - 5 Dimensions (EQ-5D) at Month 60\"\\n1780,1,1,\"Change From Baseline in FKSI-15 Score at Last Follow-up\"\\n1781,1,1,\"Change From Baseline in FKSI-15 Score at Month 3\"\\n1782,1,1,\"Change From Baseline in FKSI-15 Score at Month 6\"\\n1783,1,1,\"Change From Baseline in FKSI-15 Score at Month 9\"\\n1784,1,1,\"Change From Baseline in FKSI-DRS Score at Last Follow-up\"\\n1785,1,1,\"Change From Baseline in FKSI-DRS Score at Month 3\"\\n1786,1,1,\"Change From Baseline in FKSI-DRS Score at Month 6\"\\n1787,1,1,\"Change From Baseline in FKSI-DRS Score at Month 9\"\\n1788,1,1,\"Change From Baseline in Free Thyroxine (T4)-Part 1\"\\n1789,1,1,\"Change From Baseline in Free Triiodothyronine (T3)-Part 1\"\\n1790,1,1,\"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Month 60\"\\n1791,12,1,\"Change From Baseline in Heart Rate\"\\n1792,2,1,\"Change from Baseline in Heart Rate (HR)\"\\n1793,1,1,\"Change From Baseline in Heart Rate (Part A and B)\"\\n1794,4,1,\"Change From Baseline in Heart Rate at the Indicated Time Points\"\\n1795,1,1,\"Change From Baseline in Hematocrit (Part A and B)\"\\n1796,1,1,\"Change From Baseline in Hematocrit Level-Part 1\"\\n1797,1,1,\"Change From Baseline in Hemoglobin (Part A and B)\"\\n1798,1,1,\"Change From Baseline in Hemoglobin Level-Part 1\"\\n1799,1,1,\"Change from Baseline in Humoral Immunity\"\\n1800,1,1,\"Change from Baseline in Immune Cell Subsets\"\\n1801,1,1,\"Change From Baseline in Ki-67 Percent Positive Tumor Cells in Biopsied Tumor Tissue at Week 6: Phase 2\"\\n1802,3,1,\"Change from Baseline in laboratory evaluations\"\\n1803,1,1,\"Change from baseline in laboratory parameter values.\"\\n1804,3,1,\"Change From Baseline in Left Ventricular Ejection Fraction (LVEF)\"\\n1805,2,1,\"Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time\"\\n1806,1,1,\"Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study\"\\n1807,1,1,\"Change From Baseline in Maximum Standard Uptake Values (SUVmax)\"\\n1808,1,1,\"Change From Baseline in Mean Duration of the QTc Interval\"\\n1809,1,1,\"Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 1\"\\n1810,1,1,\"Change From Baseline in Oxygen Saturation\"\\n1811,1,1,\"Change From Baseline in Oxygen Saturation (OS)\"\\n1812,1,1,\"Change From Baseline in Oxygen Saturation-Part 1\"\\n1813,1,1,\"Change From Baseline in Pain Visual Analog Scale (VAS) Score at Month 60\"\\n1814,1,1,\"Change From Baseline in Patient\\'s Global Assessment (PtGA) of Disease Activity at Month 60\"\\n1815,1,1,\"Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of Monocyte Activation\"\\n1816,1,1,\"Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of T Cell Activation\"\\n1817,1,1,\"Change From Baseline in Pharmacodynamic Blood Biomarkers- Total Blood Cell Counts\"\\n1818,1,1,\"Change From Baseline in Pharmacodynamic Tissue Biomarkers- Markers Associated With Immune Infiltrate Including CD3, CD4, CD8, Forkhead box P3, CD68, and PD-L1.\"\\n1819,1,1,\"Change From Baseline in Pharmacodynamic Tissue Biomarkers- Protein Expression of VISTA (V-domain Ig suppressor of T cell activation)\"\\n1820,1,1,\"Change From Baseline in Platelets (Part A and B)\"\\n1821,1,1,\"Change From Baseline in Potential of Hydrogen (pH) of Urine-Part 1\"\\n1822,1,1,\"Change From Baseline in Pulse Rate (PR)\"\\n1823,2,1,\"Change from Baseline in Pulse Rate Over Time\"\\n1824,1,1,\"Change From Baseline in Pulse Rate-Part 1\"\\n1825,1,1,\"Change from baseline in QT-interval corrected (QTcF) centrally assessed\"\\n1826,1,1,\"Change From Baseline in QTcF\"\\n1827,2,1,\"Change from baseline in QTcF\"\\n1828,1,1,\"Change from baseline in QTcF interval at each time point on Study Day 9 (average of at least 3 Holter ECG replicates per time point) as compared with time-matched placebo.\"\\n1829,1,1,\"Change from baseline in quality of life (QoL) for Family Caregivers\"\\n1830,1,1,\"Change from baseline in quality of life (QoL) for Patients\"\\n1831,1,1,\"Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)\"\\n1832,1,1,\"Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-Œ≤) to Overall Survival (OS)\"\\n1833,1,1,\"Change from Baseline in Respiration Rate Over Time\"\\n1834,2,2,\"Change From Baseline in Respiratory Rate (RR)\"\\n1835,1,1,\"Change From Baseline in Respiratory Rate-Part 1\"\\n1836,1,1,\"Change from Baseline in serum anti-drug antibody (ADA) titer\"\\n1837,1,1,\"Change From Baseline in Serum Biochemistry (Albumin, Protein, Hemoglobin) During the Treatment Period\"\\n1838,1,1,\"Change From Baseline in Serum Biochemistry (Alkaline Phosphatase [AP], Alanine Aminotransferase [AAT], Lactate Dehydrogenase [LD]) During the Treatment Period\"\\n1839,1,1,\"Change From Baseline in Serum Biochemistry (Bilirubin, Creatinine) During the Treatment Period\"\\n1840,1,1,\"Change From Baseline in Serum Biochemistry (Calcium, Chloride, Magnesium, Potassium, Phosphate, Sodium, Urea) During the Treatment Period\"\\n1841,1,1,\"Change From Baseline in Serum Biochemistry (Erythrocytes) During the Treatment Period\"\\n1842,1,1,\"Change From Baseline in Serum Biochemistry (Platelets, Leukocytes, Lymphocytes, Neutrophils, Monocytes, Eosinophils, Basophils) During the Treatment Period\"\\n1843,2,1,\"Change from Baseline in Serum Cytokines\"\\n1844,1,1,\"Change from baseline in signs and symptoms of neurological disease\"\\n1845,1,1,\"Change From Baseline in Specific Gravity of Urine-Part 1\"\\n1846,1,1,\"Change from baseline in summed peak standardized uptake value lean (SULpeak) after 3 cycles\"\\n1847,1,1,\"Change from baseline in summed SULpeak after 1 cycle\"\\n1848,1,1,\"Change From Baseline in Swollen Joints Count (SJC) at Month 60\"\\n1849,9,2,\"Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)\"\\n1850,1,1,\"Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1\"\\n1851,1,1,\"Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points\"\\n1852,2,1,\"Change from Baseline in Systolic Blood Pressure Over Time\"\\n1853,1,1,\"Change from Baseline in T-Cell Morphology\"\\n1854,2,1,\"Change from Baseline in Targeted Clinical Laboratory Test Results\"\\n1855,1,1,\"Change from baseline in targeted clinical laboratory test results\"\\n1856,1,1,\"Change from Baseline in Targeted Vital Signs\"\\n1857,3,2,\"Change From Baseline in Temperature\"\\n1858,1,1,\"Change From Baseline in Temperature-Part 1\"\\n1859,1,1,\"Change From Baseline in Tender Joints Count (TJC) at Month 60\"\\n1860,1,1,\"Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)\"\\n1861,1,1,\"Change From Baseline in Thyroid Stimulating Hormone (TSH) or Thyrotropin-Part 1\"\\n1862,1,1,\"Change From Baseline in Total Bilirubin (Part A and B)\"\\n1863,1,1,\"Change From Baseline in Tumor Size to the End of Cycle 2\"\\n1864,1,1,\"Change from baseline in tumor tissue oxygen monitoring recordings\"\\n1865,1,1,\"Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels-Part 1\"\\n1866,1,1,\"Change from baseline in vital sign values\"\\n1867,3,1,\"Change from Baseline in vital signs\"\\n1868,1,1,\"Change From Baseline in Vital Signs-Pulse Rate\"\\n1869,1,1,\"Change From Baseline in Vital Signs-Systolic and Diastolic Blood Pressure\"\\n1870,1,1,\"Change from baseline in vital signs[safety and tolerability]\"\\n1871,1,1,\"Change from baseline laboratory assessments and toxicities over time in abnormal Complete Blood Count labs and Complete Metabolic Panel labs assessed by SI laboratory reference ranges\"\\n1872,1,1,\"Change from baseline of left ventricular ejection fraction (LVEF) (Cohorts D and E)\"\\n1873,1,1,\"Change from baseline of quality of life questionnaire\"\\n1874,1,1,\"Change from baseline of the EuroQoL Five Dimensions Questionnaire (EQ-5D).\"\\n1875,1,1,\"Change from baseline of the Karnofsky index\"\\n1876,1,1,\"Change from baseline of the scoring form NCI CTCAE v3 for detecting and quantifying potential adverse events\"\\n1877,1,1,\"Change from baseline Overall QOL of EORTC QLQ - Core 15 at 6 months items\"\\n1878,1,1,\"Change from baseline percentage of CD8+ TIL in patients between the two arms\"\\n1879,1,1,\"Change from Baseline Pharmacodynamic Effects (PD) Following 14 Days of Tomivosertib Monotherapy\"\\n1880,1,1,\"Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation\"\\n1881,1,1,\"Change from baseline to 45 days after End of Treatment (EOT) in laboratory values\"\\n1882,1,1,\"Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants\"\\n1883,1,1,\"Change from baseline to day 11 in mean blood creatinine level.\"\\n1884,1,1,\"Change from baseline to day 11 in mean blood lymphocyte count.\"\\n1885,1,1,\"Change from baseline to day 11 in mean blood urea nitrogen (BUN) level.\"\\n1886,1,1,\"Change from baseline to day 11 in mean serum interleukin-10 (IL-10) levels.\"\\n1887,1,1,\"Change from baseline to day 11 in mean serum interleukin-6 (IL-6).\"\\n1888,1,1,\"Change from baseline to day 11 in mean serum soluble interleukin-2 receptor (sIL-2R) level.\"\\n1889,1,1,\"Change From Baseline to Week 4 in the General Subscale of the MFSI-SF\"\\n1890,1,1,\"Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue\"\\n1891,1,1,\"Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks)\"\\n1892,1,1,\"Change From Start of Run-in Period in Biomarker Expression Levels at Day 0\"\\n1893,1,1,\"Change From the Time-matched Baseline in the Individually Corrected QTc Interval (QTcI)\"\\n1894,1,1,\"Change From Time-Matched Baseline in QT Interval Corrected for Heart Rate (QTc)\"\\n1895,1,1,\"Change in 18F-fluorothymidine (18F-FLT) and 18F-fluorodeoxyglucose (18F-FDG) maximal standardized uptake value (SUV) as response to therapy\"\\n1896,1,1,\"Change in 18F-Fluorothymidine (FLT) Uptake\"\\n1897,1,1,\"Change in 24 Hour Diastolic Blood Pressure (DBP)\"\\n1898,1,1,\"change in 89Zr-bevacizumab uptake\"\\n1899,1,1,\"Change in 89Zr-bevacizumab uptake in tumor lesions between the baseline scan and the scan during treatment\"\\n1900,1,1,\"Change in a lesion\\'s overall mean ADC\"\\n1901,1,1,\"Change in advance care planning\"\\n1902,1,1,\"Change in advance care planning engagement: completion of advance directives, from baseline to 12 weeks post-randomization\"\\n1903,1,1,\"Change in advance care planning engagement: completion of advance directives, from baseline to 24 weeks post-randomization\"\\n1904,1,1,\"Change in advance care planning engagement: completion of advance directives, from baseline to 4 weeks post-randomization\"\\n1905,1,1,\"Change in advance care planning engagement: conversations discussing EoL care, living will, HCP, and DNR orders with doctors, from baseline to 12 weeks post-randomization\"\\n1906,1,1,\"Change in advance care planning engagement: conversations discussing EoL care, living will, HCP, and DNR orders with doctors, from baseline to 24 weeks post-randomization\"\\n1907,1,1,\"Change in advance care planning engagement: conversations discussing EoL care, living will, HCP, and DNR orders with doctors, from baseline to 4 weeks post-randomization\"\\n1908,1,1,\"Change in advance care planning engagement: conversations discussing EoL care, living will, HCP, and DNR orders with family members and loved ones, from baseline to 12 weeks post-randomization\"\\n1909,1,1,\"Change in advance care planning engagement: conversations discussing EoL care, living will, HCP, and DNR orders with family members and loved ones, from baseline to 24 weeks post-randomization\"\\n1910,1,1,\"Change in advance care planning engagement: conversations discussing EoL care, living will, HCP, and DNR orders with family members and loved ones, from baseline to 4 weeks post-randomization\"\\n1911,1,1,\"Change in antitumor activity measured by pathologic response based on tumor regression grading in cohort A patients.\"\\n1912,6,1,\"Change in appetite\"\\n1913,1,1,\"Change in Average Daily Pain Score as Measured Using a Pain Intensity Rating (NRS)\"\\n1914,1,1,\"Change in Average Daily Peripheral Neuropathy Intensity Score From Baseline to Week 6 in Patients Treated With Amitriptyline and Ketamine Hydrochloride vs Placebo\"\\n1915,1,1,\"Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item\"\\n1916,1,1,\"Change in Average Pain Score as Measured Using the European Cooperative Oncology Group (ECOG) Neuropathy Scale (ENS)\"\\n1917,1,1,\"Change in average sP-selectin levels\"\\n1918,1,1,\"Change in Baseline of Fraction of Cytotoxic T-lymphocytes (FCT) for Participants With Response Versus Participants With Progression\"\\n1919,1,1,\"Change in baseline platelet count from the first day of the second cycle of chemotherapy to the lowest count observed (nadir) during the cycle(21 days)\"\\n1920,2,2,\"Change in Bifidobacterium composition of stool\"\\n1921,1,1,\"Change in blood flow (mL/min/100 g) as measured on perfusion CT\"\\n1922,3,1,\"Change in blood pressure (mmHg)\"\\n1923,1,1,\"Change in blood volume (mL/100 g) as measured on perfusion CT\"\\n1924,15,1,\"Change in body mass index (BMI)\"\\n1925,1,1,\"Change in body temperature (Degree Celsius)\"\\n1926,1,1,\"Change in Body weight (kg)\"\\n1927,1,1,\"Change in cachexia staging score from baseline\"\\n1928,2,1,\"Change in cancer related fatigue\"\\n1929,1,1,\"Change in caregiver quality of life, burden and grief over time\"\\n1930,1,1,\"Change in CD8 positron emission tomography (PET) maximum standardized uptake value (SUVmax)\"\\n1931,1,1,\"Change in CD8+ T cells - peripheral blood\"\\n1932,1,1,\"Change in CD8+ T cells in tumor\"\\n1933,1,1,\"Change in chemotherapy-induced peripheral neuropathy (CIPN)\"\\n1934,1,1,\"Change in Circulating Tumor Cell (CTC) Counts in Men With Metastatic Treatment-refractory Castration-resistant Prostate Cancer.\"\\n1935,1,1,\"Change in Circulating Tumor Cells\"\\n1936,1,1,\"Change in Clinical Laboratory Test Results\"\\n1937,1,1,\"Change in Comparison of 89Zr-S095012 tumour uptake (as described using Standardised Uptake Value and concentrations) before and on treatment with different doses of S095012.\"\\n1938,2,2,\"Change in completion of advance directives\"\\n1939,1,1,\"Change in composite response rate of pembrolizumab and ARPI with or without 225Ac-J591\"\\n1940,1,1,\"Change in computed tomography (CT) tumor perfusion parameters (time to peak concentration)\"\\n1941,1,1,\"Change in Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Human epidermal growth factor receptor 2-overexpressing Metastatic Colorectal Cancer\"\\n1942,1,1,\"Change in conformational mutant tumor protein 53 (p53)\"\\n1943,1,1,\"Change in CT tumor perfusion parameter (blood flow)\"\\n1944,1,1,\"Change in CT tumor perfusion parameter (blood volume)\"\\n1945,1,1,\"Change in CT tumor perfusion parameter (Ktrans)\"\\n1946,1,1,\"Change in ctDNA Level Following Chemotherapy\"\\n1947,1,1,\"Change in Cyr61 expression levels (Cohort II)\"\\n1948,4,1,\"Change in daily step count\"\\n1949,1,1,\"Change in daily step count, as measured by Fitbit\"\\n1950,1,1,\"Change in degree of myelosuppression (thrombocytopenia and neutropenia) quantified by both duration of neutropenia and severity of neutropenia\"\\n1951,29,1,\"Change in depression\"\\n1952,1,1,\"change in depression features\"\\n1953,5,1,\"Change in depression severity\"\\n1954,1,1,\"Change in depression, as measured by questionnaire\"\\n1955,1,1,\"Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) survey score\"\\n1956,1,1,\"Change in disease assessments\"\\n1957,1,1,\"Change in disease burden using RECIST 1.1 (solid tumors) or Lugano criteria (NHL).\"\\n1958,1,1,\"Change in disease-related quality of life\"\\n1959,1,1,\"Change in distress score from baseline to 12 months\"\\n1960,1,1,\"Change in distress score from baseline to 3 months\"\\n1961,1,1,\"Change in documentation of advance care planning conversations [Caregivers]\"\\n1962,1,1,\"Change in documentation of advance care planning conversations [Patients]\"\\n1963,1,1,\"Change in Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n1964,1,1,\"Change in Eastern Cooperative Oncology Group performance status (Part B Dose Expansion)\"\\n1965,1,1,\"Change in eGFR from Baseline to On-Treatment, 3-9 weeks after PARPi Initiation (Time Point B)\"\\n1966,1,1,\"Change in Electrocardiogram (ECG)-(R wave)RR interval\"\\n1967,4,2,\"Change in Electrocardiogram (ECG)-QRS duration\"\\n1968,4,2,\"Change in Electrocardiogram (ECG)-QT interval\"\\n1969,3,1,\"Change in Electrocardiogram (ECG)-RR interval\"\\n1970,1,1,\"Change in engagement in advance care planning (end-of-life care discussions)\"\\n1971,1,1,\"Change in EORTC QLQ-C30 Quality of Life score\"\\n1972,1,1,\"Change in EphA2 expression\"\\n1973,1,1,\"Change in fasting glucose and fasting triglycerides\"\\n1974,1,1,\"Change in fatigue, as measured by questionnaire\"\\n1975,1,1,\"Change in FLT Uptake\"\\n1976,1,1,\"Change in FLT Uptake in Responders and Non-responders\"\\n1977,1,1,\"Change in fluorothymidine F-18 (18F-FLT) positron emission tomography (PET)/computed tomography (CT) uptake\"\\n1978,1,1,\"Change in Fluorothymidine F-18 mean standardized uptake value (SUV) as response to therapy.\"\\n1979,1,1,\"Change in formation of atelectasis during high frequency jet ventilation\"\\n1980,1,1,\"Change in Fruit, Vegetable Consumption as Measured by Food Frequency Questionnaire at 3 Months\"\\n1981,1,1,\"Change in full blood Counts (number of cells)\"\\n1982,1,1,\"Change in general activity, as measured by questionnaire\"\\n1983,1,1,\"Change in Gli levels\"\\n1984,1,1,\"Change in global distress score (GDS)\"\\n1985,12,1,\"Change in health-related quality of life\"\\n1986,1,1,\"Change in heart beat (beats/minute)\"\\n1987,1,1,\"Change in heart rate (beats/min)\"\\n1988,1,1,\"Change in hematology/SMA-12 serum biochemistry after [131]I-IAZA injection (first 10 patients)\"\\n1989,1,1,\"Change in immune biomarkers from baseline and after radiation treatments for breast, prostate, and lung cancers.\"\\n1990,1,1,\"Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells from diagnostic biopsy to interval debulking surgery\"\\n1991,1,1,\"Change in intratumoral density of M2 tumor-associated macrophages (CD163+ cells) from diagnostic biopsy to interval debulking surgery\"\\n1992,1,1,\"Change in Ketones from Baseline [Safety]\"\\n1993,1,1,\"Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples\"\\n1994,1,1,\"Change in Ki67 labeling index of > 70%\"\\n1995,1,1,\"Change in ki67 level\"\\n1996,1,1,\"Change in Kinase Expression\"\\n1997,1,1,\"Change in knowledge of advance care planning\"\\n1998,1,1,\"Change in knowledge questionnaire score\"\\n1999,1,1,\"Change in KPI\"\\n2000,1,1,\"Change in LAG3 Expression\"\\n2001,6,1,\"Change in left ventricular ejection fraction (LVEF)\"\\n2002,1,1,\"Change in left-ventricular (LV) function (LV ejection fraction) from baseline to follow-up\"\\n2003,1,1,\"Change in left-ventricular (LV) function (LV fractional shortening) from baseline to follow-up\"\\n2004,1,1,\"Change in left-ventricular (LV) function.(LV ejection fraction) from baseline to end of treatment\"\\n2005,1,1,\"Change in level of engagement in advance care planning [Caregivers]\"\\n2006,1,1,\"Change in level of engagement in advance care planning [Patients]\"\\n2007,1,1,\"Change in level of EORTC QLQ-C15-PAL\"\\n2008,1,1,\"change in level of PD1 and PD1 ligand postoperatively\"\\n2009,1,1,\"Change in levels of p-Histone H3 from baseline (part 1 - dose escalation only)\"\\n2010,1,1,\"Change in maximum standardized uptake value (SUVmax) across three lesions on gallium Ga 68 gozetotide (68Ga-PSMA-11) positron emission tomography (PET) scan (Part B)\"\\n2011,1,1,\"Change in Maximum SUV of Tumors Measured by FDG-PET Post Receipt of 2 Courses of Preoperative Chemotherapy\"\\n2012,1,1,\"Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo\"\\n2013,1,1,\"Change in mean transit time (seconds) as measured on perfusion CT\"\\n2014,1,1,\"Change in microbiome composition from baseline to after Cycle 2 of checkpoint therapy (6-8 weeks) by analyzing longitudinally-collected stool specimens of 800 patients with primary NSCLC, MM, RCC, and TNBC\"\\n2015,1,1,\"Change in minutes of moderate-to-vigorous physical activity (MVPA) per day from Baseline Evaluation\"\\n2016,1,1,\"Change in minutes of weekly exercise, as measured by Fitbit\"\\n2017,1,1,\"Change in modified Borg scale dyspnea intensity before and after the Shuttle Walk Test (SWT)\"\\n2018,12,1,\"Change in muscle mass\"\\n2019,1,1,\"Change in myeloid cells in peripheral blood\"\\n2020,1,1,\"Change in myeloid cells in tumor\"\\n2021,2,1,\"Change in nausea score\"\\n2022,1,1,\"change in neutrophil counts and docetaxel AUC\"\\n2023,1,1,\"Change in Number and Distress Associated with Caregivers and Survivors Symptoms\"\\n2024,1,1,\"Change in Occult blood result from Baseline [Safety]\"\\n2025,1,1,\"Change in overall QOL scores, assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp)\"\\n2026,1,1,\"Change in overall response rate according to RECIST 1.1 criteria\"\\n2027,1,1,\"Change in P-gp level\"\\n2028,1,1,\"Change in Pain Quality Assessment Scale (PQAS) unpleasantness score\"\\n2029,22,1,\"Change in Pain Score\"\\n2030,1,1,\"Change in pain score and treatment success\"\\n2031,1,1,\"Change in pain scores assessed by Brief Pain Inventory (BPI)\"\\n2032,1,1,\"Change in Patient Reported Outcomes Measurement - PROMIS 29\"\\n2033,1,1,\"Change in patient\\'s quality of living over time\"\\n2034,1,1,\"Change in patients\\' engagement in advance care planning, as measured by the Decision Maker subscale of the Advance Care Planning Engagement Survey: Action Measures, from baseline to 12 weeks post-randomization\"\\n2035,1,1,\"Change in patients\\' engagement in advance care planning, as measured by the Decision Maker subscale of the Advance Care Planning Engagement Survey: Action Measures, from baseline to 24 weeks post-randomization\"\\n2036,1,1,\"Change in patients\\' engagement in advance care planning, as measured by the Decision Maker subscale of the Advance Care Planning Engagement Survey: Action Measures, from baseline to 4 weeks post-randomization\"\\n2037,1,1,\"Change in patients\\' engagement in advance care planning, as measured by the Quality of Life subscale of the Advance Care Planning Engagement Survey: Action Measures, from baseline to 12 weeks post-randomization\"\\n2038,1,1,\"Change in patients\\' engagement in advance care planning, as measured by the Quality of Life subscale of the Advance Care Planning Engagement Survey: Action Measures, from baseline to 24 weeks post-randomization\"\\n2039,1,1,\"Change in patients\\' engagement in advance care planning, as measured by the Quality of Life subscale of the Advance Care Planning Engagement Survey: Action Measures, from baseline to 4 weeks post-randomization\"\\n2040,1,1,\"Change in patients\\' quality of life\"\\n2041,1,1,\"Change in PD-L1 Expression Status as Determined by Immunohistochemistry in Pretreatment and Archival Samples\"\\n2042,1,1,\"Change in PD-LI levels\"\\n2043,1,1,\"Change in PD1 expression\"\\n2044,1,1,\"Change in percentage of cancer initiating cells\"\\n2045,1,1,\"Change in Percentage of Fat Consumed\"\\n2046,1,1,\"Change in peripheral blood T cell proliferation (stimulation) and cytokine production in vitro\"\\n2047,1,1,\"Change in permeability (mL/min/100 g) as measured on perfusion CT\"\\n2048,1,1,\"Change in PET/CT scan images\"\\n2049,1,1,\"Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide\"\\n2050,1,1,\"Change in pharmacokinetic behavior of this regimen\"\\n2051,1,1,\"Change in phosphorylation levels of other biomarkers before and after treatment\"\\n2052,1,1,\"Change in phosphorylation levels of v-akt murine thymoma viral oncogene homolog 1 in terms of difference in IHC score\"\\n2053,1,1,\"Change in Physical examination-weight\"\\n2054,1,1,\"Change in Pittsburgh Sleep Quality Index (PSQI) score\"\\n2055,1,1,\"Change in planned management strategy\"\\n2056,1,1,\"Change in Platelet cloaking of Circulating Tumour Cells\"\\n2057,1,1,\"Change in pMEK expression\"\\n2058,2,1,\"Change in postoperative pain scores\"\\n2059,1,1,\"Change in preoperative anxiety scores\"\\n2060,1,1,\"Change in Prostate Apoptosis Response-4 (PAR-4) Levels\"\\n2061,1,1,\"Change in Prostate Cancer Proliferative Index\"\\n2062,1,1,\"Change in psychological distress assessed using Distress Thermometer\"\\n2063,1,1,\"Change in psychological distress, assessed using the Psychological Distress Thermometer\"\\n2064,1,1,\"Change in QOL using Functional Assessment of Cancer Therapy- General (FACT-G) and Functional Assessment of Chronic Illness Therapy- Spirituality (FACT-Sp-12)\"\\n2065,1,1,\"Change in QTcF (QT Corrected According to Fridericia\\'s Formula)\"\\n2066,62,1,\"Change in quality of life\"\\n2067,1,1,\"Change in Quality of life as measured by MD Anderson Dysphagia Inventory (MDADI)\"\\n2068,1,1,\"Change in quality of life as measured by the Sydney Swallow Questionnaire (SSQ).\"\\n2069,1,1,\"Change in quality of life detected though the BN-20 questionnaire\"\\n2070,1,1,\"Change in quality of life detected though the EORTC QLQ-C15-PAL questionnaire\"\\n2071,1,1,\"Change in quality of life for patients, as measured by the FACT-G\"\\n2072,1,1,\"Change in quality of life score, calculated from the PedsQL‚Ñ¢ scale between inclusion and Day 6.\"\\n2073,1,1,\"Change in quality of life, as measured by questionnaire\"\\n2074,1,1,\"Change in radiographic response to treatment for central nervous system (CNS) tumors\"\\n2075,1,1,\"Change in radiographic response to treatment for solid tumors\"\\n2076,1,1,\"Change in radiographically progression-free survival following treatment with Cabozantinib radiographically progression-free after 6 months\"\\n2077,1,1,\"Change in Rate of Drug-Drug Interactions and Drug-Gene Interactions Among Participants\"\\n2078,1,1,\"Change in rates of genomics based clinical research in Ontario\"\\n2079,1,1,\"Change in readiness/motivation to engage in advance care planning\"\\n2080,1,1,\"Change in respiratory frequency (inspiration/minute)\"\\n2081,1,1,\"Change in Response Signature in Transfusion Dependent MDS Patients\"\\n2082,1,1,\"Change in Richmond Agitation-Sedation Scale Score (Baseline to 8 hr), Points\"\\n2083,1,1,\"Change in satisfaction with communication assessed using Satisfaction with Communication Tool\"\\n2084,1,1,\"Change in scores of Canadian Occupational Performance Measure.\"\\n2085,1,1,\"Change in self-efficacy to engage in advance care planning\"\\n2086,1,1,\"Change in self-reported severity of anorexia\"\\n2087,1,1,\"Change in senescence marker P16\"\\n2088,1,1,\"Change in Serum Adiponectin Level\"\\n2089,1,1,\"Change in serum VEGFR2\"\\n2090,1,1,\"Change in Severity of Poor Appetite Following Treatment With Haelan (Fermented Soy Product)\"\\n2091,1,1,\"Change in Standard Glucose Tolerance Test\"\\n2092,1,1,\"Change in standard-uptake-value (SUV-max)\"\\n2093,1,1,\"Change in steady-state (C-trough) enzalutamide caused by relacorilant\"\\n2094,1,1,\"Change in swallow function as measured by the MD Anderson Dysphagia Inventory.\"\\n2095,1,1,\"Change in swallow function as measured by the Sydney Swallow Questionnaire (SSQ).\"\\n2096,1,1,\"Change in symptom intensity and distress using Memorial Symptom Assessment Scale (MSAS)\"\\n2097,1,1,\"Change in Systolic / Diastolic BP (mmHg)\"\\n2098,1,1,\"Change in T-regulatory cells - peripheral blood\"\\n2099,1,1,\"Change in T-regulatory cells in tumor\"\\n2100,1,1,\"Change in the following biomarkers: inflammatory/immune markers uPAR, PAI-1, ULBP2, B7-H1, MIF, TGF-Œ≤; and PSA compared to placebo.\"\\n2101,2,1,\"Change in the gut microbiome\"\\n2102,1,1,\"Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 24 Weeks\"\\n2103,1,1,\"Change in the immune reconstitution of T cell, B cell, and NK cell compartment.\"\\n2104,1,1,\"Change in the intestinal microbiome community\"\\n2105,1,1,\"Change in the number of daily fruit and vegetable servings consumed from baseline to 12 months post intervention\"\\n2106,1,1,\"Change in the number of subjects with dose limiting toxicity (DLT)\"\\n2107,1,1,\"Change in the patient-reported Pediatric Quality of Life Inventory (PedsQL Inventory) from baseline to the last assessment.\"\\n2108,1,1,\"Change in the proportion of active CD8+ T cells infiltrating the tumor\"\\n2109,1,1,\"change in the proportion of patients with a CIPN severity\"\\n2110,1,1,\"Change in the proportion of subjects in assessing safety of 225Ac-J591 in those previously treated with PSMA-TRT.\"\\n2111,1,1,\"Change in the quality of life using the PedsQL Cancer Module¬©\"\\n2112,1,1,\"Change in the score of Cancer-related fatigue during the intervention, after the intervention, and over a 1-year follow-up period compared with baseline\"\\n2113,1,1,\"Change in the Sum of the Longest Diameter (SLD)\"\\n2114,1,1,\"Change in tobacco cessation care delivery of the 5 A\\'s (Ask, Advise, Assess, Assist, and Arrange) and in the percentage of smokers receiving assistance as measured by MediClass classification at 18 months\"\\n2115,1,1,\"Change in treatment regimen due to adverse events\"\\n2116,1,1,\"Change in TSH level after [131]I-IAZA injection\"\\n2117,1,1,\"Change in tumor associated macrophages (TAMS) as assessed by tumor biopsy at 9 weeks.\"\\n2118,1,1,\"Change in tumor burden.\"\\n2119,1,1,\"Change in Tumor Infiltration by Cluster of Differentiation 8 (CD8) Positive Cytotoxic T Lymphocytes\"\\n2120,1,1,\"Change in tumor perfusion as based on Dynamic Contrast Enhanced (DCE)-MRI study\"\\n2121,1,1,\"Change in tumor perfusion based on changes in cellularity as assessed using Diffusion-weighted imaging (DWI)\"\\n2122,1,1,\"Change in tumor poly (ADP-ribose) (PAR) levels from baseline to 3-6 hours after ABT-888 administration\"\\n2123,6,2,\"Change in Tumor Size\"\\n2124,3,1,\"Change in tumor size\"\\n2125,1,1,\"Change in Tumor Size (CTS) From Baseline to the End of Cycle 2\"\\n2126,1,1,\"Change in tumor size in millimetres\"\\n2127,1,1,\"Change in Tumor Uptake\"\\n2128,1,1,\"Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions\"\\n2129,1,1,\"Change in Tumour Size at 8 Weeks Were Analyzed for Comparing Relative Efficacy of AZD8931 Plus Paclitaxel With Paclitaxel Alone\"\\n2130,1,1,\"Change in tumour SUV (Standardized Uptake Value) from baseline to Day 8.\"\\n2131,1,1,\"Change in Urinary leukocyte from Baseline [Safety]\"\\n2132,1,1,\"Change in urinary PGE-M level after paclitaxel treatment\"\\n2133,1,1,\"Change in Urine Bilirubin result from Baseline [Safety]\"\\n2134,1,1,\"Change in Urine erythrocytes from Baseline [Safety]\"\\n2135,1,1,\"Change in Urine Glucose from Baseline [Safety]\"\\n2136,1,1,\"Change in Urine Nitrites from Baseline [Safety]\"\\n2137,1,1,\"Change in Urine protein from Baseline [Safety]\"\\n2138,1,1,\"Change in Urobilinogen from Baseline [Safety]\"\\n2139,1,1,\"Change in use of NGS panel-based testing in Ontario clinical genetic testing laboratories\"\\n2140,1,1,\"Change in vascular endothelial growth factor (VEGF)\"\\n2141,4,1,\"Change in Vital Signs\"\\n2142,1,1,\"Change in vital signs after [131]I-IAZA injection (first 10 patients)\"\\n2143,3,1,\"Change in Vital Signs-blood pressure\"\\n2144,1,1,\"Change in Vital Signs-diastolic blood pressure\"\\n2145,4,2,\"Change in Vital Signs-ear temperature\"\\n2146,2,1,\"Change in Vital Signs-pluse rate\"\\n2147,2,1,\"Change in Vital Signs-pulse rate\"\\n2148,1,1,\"Change in Vital Signs-systolic pressure\"\\n2149,1,1,\"Change in WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared to baseline\"\\n2150,1,1,\"Change in worst pain intensity assessed by the NRS\"\\n2151,1,1,\"Change in yH2AX levels in biopsy specimens\"\\n2152,1,1,\"Change of Alanine aminotransferase (ALT) from Baseline [Safety]\"\\n2153,1,1,\"Change of Albumin (ALB) from Baseline [Safety]\"\\n2154,1,1,\"Change of Alkaline phosphatase (ALP/AKP) from Baseline [Safety]\"\\n2155,1,1,\"Change of Aspartate aminotransferase (AST) from Baseline [Safety]\"\\n2156,1,1,\"Change of Basophil Count from Baseline [Safety]\"\\n2157,1,1,\"Change of Biomarkers of Aging Observed During Study Intervention\"\\n2158,1,1,\"Change of Blood glucose from Baseline [Safety]\"\\n2159,1,1,\"Change of Body Temperature from Baseline [Safety]\"\\n2160,1,1,\"Change of Body Weight from Baseline [Safety]\"\\n2161,1,1,\"Change of Cancer-related Fatigue as Assessed by the Brief Fatigue Inventory (BFI) Total Score at Day 41 (After Exercise Intervention) Minus BFI Total Score at Day 0 (Before Exercise Intervention)\"\\n2162,1,1,\"Change of CD8+ tumor infiltrating lymphocytes\"\\n2163,1,1,\"Change of Coagulation test-Activated partial thromboplastin time (APTT) from Baseline [Safety]\"\\n2164,1,1,\"Change of Coagulation test-Fibrinogen(FIB) from Baseline [Safety]\"\\n2165,1,1,\"Change of Coagulation test-Prothrombin time (PT) from Baseline [Safety]\"\\n2166,1,1,\"Change of Coagulation test-Thrombin time (TT) from Baseline [Safety]\"\\n2167,1,1,\"Change of corrected QT (QTc) interval from Baseline [Safety]\"\\n2168,1,1,\"Change of Creatinine from Baseline [Safety]\"\\n2169,1,1,\"Change of Creatinine Kinase from Baseline [Safety]\"\\n2170,1,1,\"Change of Diastolic pressure from Baseline [Safety]\"\\n2171,1,1,\"Change of Direct bilirubin from Baseline [Safety]\"\\n2172,1,1,\"Change of Eastern Cooperative Oncology Group-Performance Status (ECOG PS) from Baseline [Safety]\"\\n2173,1,1,\"Change of Electronic Frailty Index and Cancer Score/Category\"\\n2174,1,1,\"Change of Eosinophils Count from Baseline [Safety]\"\\n2175,1,1,\"Change of Erythrocyte Count from Baseline [Safety]\"\\n2176,1,1,\"Change of Fridericia\\'s Correction QT (QTcF) interval from Baseline [Safety]\"\\n2177,1,1,\"Change of Glutamyl transpeptidase from Baseline [Safety]\"\\n2178,1,1,\"Change of Heart rate from Baseline [Safety]\"\\n2179,1,1,\"Change of Hematocrit Platelets from Baseline [Safety]\"\\n2180,1,1,\"Change of Hemoglobin from Baseline [Safety]\"\\n2181,1,1,\"Change of Indirect bilirubin from Baseline [Safety]\"\\n2182,1,1,\"Change of Leukocyte Count from Baseline [Safety]\"\\n2183,1,1,\"Change of Lymphocyte Count from Baseline [Safety]\"\\n2184,1,1,\"change of mean Transit Time (mTT) from baseline to 2 months after the first course of treatment\"\\n2185,1,1,\"Change of Monocytes Count from Baseline [Safety]\"\\n2186,1,1,\"Change of mucositis grading\"\\n2187,1,1,\"Change of Neutrophil Count from Baseline [Safety]\"\\n2188,1,1,\"Change of P-R interval from Baseline [Safety]\"\\n2189,1,1,\"Change of Peak Enhancement (PE) from baseline to 2 months after the first course of treatment\"\\n2190,1,1,\"Change of Percentage of Basophil from Baseline [Safety]\"\\n2191,1,1,\"Change of Percentage of Eosinophils from Baseline [Safety]\"\\n2192,1,1,\"Change of Percentage of Lymphocyte from Baseline [Safety]\"\\n2193,1,1,\"Change of Percentage of Monocytes from Baseline [Safety]\"\\n2194,1,1,\"Change of Percentage of Neutrophil from Baseline [Safety]\"\\n2195,1,1,\"Change of Potassium, Sodium, Chloride or Calcium from Baseline [Safety]\"\\n2196,1,1,\"Change of Pulse rate from Baseline [Safety]\"\\n2197,1,1,\"Change of QRS complex from Baseline [Safety]\"\\n2198,1,1,\"Change of R-R interval from Baseline [Safety]\"\\n2199,1,1,\"Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion\"\\n2200,1,1,\"change of Rise Time (RT) from baseline to 2 months after the first course of treatment\"\\n2201,1,1,\"Change of Specific gravity of urine from Baseline [Safety]\"\\n2202,1,1,\"Change of Systolic pressure from Baseline [Safety]\"\\n2203,1,1,\"change of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and EORTC-quality-of-life questionnaire cervical cancer module (EORTC-QLQ-CX24 [Taiwan version]) score at 2 month from C6D22\"\\n2204,1,1,\"change of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and EORTC-quality-of-life questionnaire cervical cancer module (EORTC-QLQ-CX24 [Taiwan version]) score at C4D7 from C2D7\"\\n2205,1,1,\"change of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) and EORTC-quality-of-life questionnaire cervical cancer module (EORTC-QLQ-CX24 [Taiwan version]) score at C6D22 from C4D7\"\\n2206,1,1,\"Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events\"\\n2207,1,1,\"Change of Time To Peak (TTP) from baseline to 2 months after the first course of treatment\"\\n2208,1,1,\"Change of Total bilirubin from Baseline [Safety]\"\\n2209,1,1,\"Change of Total Cholesterol from Baseline [Safety]\"\\n2210,1,1,\"Change of Total Protein (TP) from Baseline [Safety]\"\\n2211,1,1,\"Change of Triglycerides from Baseline [Safety]\"\\n2212,4,1,\"Change of tumor size\"\\n2213,1,1,\"Change of tumor sizes from baseline\"\\n2214,1,1,\"Change of Urea from Baseline [Safety]\"\\n2215,1,1,\"Change of Uric acid from Baseline [Safety]\"\\n2216,1,1,\"Change of Urine pH from Baseline [Safety]\"\\n2217,1,1,\"Change of Wash-in Area Under the Curve (Wi-AUC) from baseline to 2 months after the first course of treatment\"\\n2218,1,1,\"Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment\"\\n2219,1,1,\"Change of Wash-in Rate (WiR) from baseline to 2 months after the first course of treatment\"\\n2220,1,1,\"Change the expression of molecules of putative relevance to the glycine/serine pathway\"\\n2221,1,1,\"Changes from baseline in anti-drug antibody (ADA) responses to 2141-V11 exposure over time\"\\n2222,2,1,\"Changes from baseline in clinical laboratory parameters\"\\n2223,2,1,\"Changes from baseline in ECG results\"\\n2224,1,1,\"Changes From Baseline in Heart Rate During the Treatment Period\"\\n2225,1,1,\"Changes from baseline in immune activity in tumor and peripheral blood\"\\n2226,1,1,\"Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs\"\\n2227,1,1,\"Changes from baseline in laboratory results\"\\n2228,1,1,\"Changes From Baseline in Respiratory Rate During the Treatment Period\"\\n2229,1,1,\"Changes From Baseline in Systolic and Diastolic Blood Pressure During the Treatment Period\"\\n2230,8,2,\"Changes from baseline in vital signs\"\\n2231,1,1,\"Changes From Baseline in Weight During the Treatment Period\"\\n2232,1,1,\"Changes in 64CDP uptake\"\\n2233,1,1,\"Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter\"\\n2234,2,1,\"Changes in anxiety\"\\n2235,1,1,\"Changes in biochemistry as a measure of safety and tolerability for S95005-oxaliplatin\"\\n2236,1,1,\"Changes in biological markers (p21, cleaved PARP, IkB, p65 Rel A, p-AKT, p-ERK and apoptosis) from pre- to post-treatment\"\\n2237,1,1,\"Changes in biomarkers in peripheral blood mononuclear cells and tumor specimens from patients with advanced solid tumors or lymphomas\"\\n2238,1,1,\"Changes in blood glucose (mg/dL) laboratory values compared with baseline\"\\n2239,1,1,\"Changes in BP\"\\n2240,1,1,\"Changes in BUN (mg/dL) laboratory values compared with baseline\"\\n2241,1,1,\"Changes in chloride (mmol/L) laboratory values compared with baseline\"\\n2242,1,1,\"Changes in coagulation as a measure of safety and tolerability for S95005-oxaliplatin\"\\n2243,1,1,\"Changes in Combined Positive Scoring (CPS) in Non-irradiated Sites Assessed by Flow Cytometry\"\\n2244,1,1,\"Changes in corrected QT interval (QTc) duration\"\\n2245,1,1,\"Changes in density (cell counts per mm2) of immune cell (including total T cells, CD8+ T cells, CD56+ cells and Treg cells)\"\\n2246,1,1,\"Changes in Eastern Cooperative Oncology Group (ECOG) performance status from baseline to subsequent scheduled visits\"\\n2247,1,1,\"Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)\"\\n2248,1,1,\"Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin\"\\n2249,1,1,\"Changes in frequency of achieving a decrease in Circulating tumor count (CTC)\"\\n2250,1,1,\"Changes in genomic and immune biomarkers that will be measured in blood and tumor pre-treatment, on-treatment and at progression (progression biopsies only done for those who have complete or partial responses, or stable disease for more than 4 months)\"\\n2251,1,1,\"Changes in genomic and immune biomarkers that will be measured in the baseline biopsy and the first on-treatment biopsy by applying a log-transformation and the t-test.\"\\n2252,1,1,\"Changes in GGT (U/L) laboratory values compared with baseline\"\\n2253,1,1,\"Changes in hematocrit (%) laboratory values compared with baseline\"\\n2254,1,1,\"Changes in hemoglobin (g/dL) laboratory values compared with baseline\"\\n2255,1,1,\"changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy\"\\n2256,1,1,\"Changes in Immune Parameters in the Malignant Ascites of Patients With Advanced Cancer Following Therapy With AZD9150\"\\n2257,1,1,\"Changes in laboratory assessments (hematology and blood biochemistry) (Phase 1)\"\\n2258,1,1,\"Changes in laboratory values compared with baseline results.\"\\n2259,1,1,\"Changes in laboratory values, vital signs, and physical examinations as a measure of safety of dabrafenib +/- trametinib when administered in combination with ipilimumab\"\\n2260,1,1,\"Changes in LDH (U/L) laboratory values comapared with baseline\"\\n2261,1,1,\"Changes in mean corpscular volume (fL) laboratory values compared to baseline\"\\n2262,1,1,\"Changes in MET and Phospho-MET Levels\"\\n2263,1,1,\"Changes in Myeloid-derived Suppressor Cells (MDSC) in Non-irradiated Sites Assessed by Flow Cytometry\"\\n2264,1,1,\"Changes in NICD1 levels\"\\n2265,1,1,\"Changes in overall tumor diameter.\"\\n2266,1,1,\"Changes in patients\\' ctDNA longitudinal samples through treatment, and when available, of primary tumor and metastasis.\"\\n2267,1,1,\"Changes in perceived self-efficacy pre-intervention and post-intervention.\"\\n2268,1,1,\"Changes in Phospho-Chk1 levels in biopsy specimens\"\\n2269,1,1,\"Changes in physical examination and in performance status (ECOG) (Phase 1)\"\\n2270,1,1,\"Changes in plasma encorafenib and LHY746 Cmax and area under the concentration time curve (AUC) in Arm 3.\"\\n2271,1,1,\"Changes in platelet count (thousands/ul) laboratory values compared with baseline\"\\n2272,1,1,\"Changes in potassium (mmol/L) laboratory values compared with baseline\"\\n2273,1,1,\"Changes in potential pharmacodynamic biomarker CD163 in paired tumor tissue in Patients in the Biopsy Cohort Summary of baseline, post baseline and changes from baseline in CD163\"\\n2274,1,1,\"Changes in potential pharmacodynamic biomarker CD8 in paired tumor tissue in Patients in the Biopsy Cohort Summary of baseline, post baseline and changes from baseline in CD8\"\\n2275,1,1,\"Changes in potential pharmacodynamic biomarker MMP9 in paired tumor tissue in Patients in the Biopsy Cohort Summary of baseline, post baseline and changes from baseline in MMP9\"\\n2276,1,1,\"Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer\"\\n2277,1,1,\"Changes in Quality of Life and the changes over time\"\\n2278,1,1,\"Changes in quality of life evaluated by the University of Washington Quality of Life Questionnaire version 4\"\\n2279,1,1,\"Changes in ratios (including T/Treg, CD8+/Treg, CD56+/Treg) based on immunohistochemistry (IHC) and/or immunofluorescence (IF) in the TME between pretreatment and on-treatment (Cycle 2 Day 8) paired tumor biopsies\"\\n2280,1,1,\"Changes in RBC count (millions/uL) laboratory values compared with baseline\"\\n2281,1,1,\"Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and approximately day 12\"\\n2282,1,1,\"changes in residual tumor burden (Solid tumor group)\"\\n2283,2,1,\"Changes in safety laboratory parameters\"\\n2284,1,1,\"Changes in safety parameters, laboratory values, vital signs and physical examinations\"\\n2285,1,1,\"Changes in serum chemokines and circulating immune cells over time\"\\n2286,1,1,\"Changes in serum creatinine (mg/dL) laboratory values compared with baseline\"\\n2287,1,1,\"Changes in sodium (mmol/L) laboratory values compared with baseline\"\\n2288,1,1,\"Changes in standard hematology as a measure of safety and tolerability for S95005-oxaliplatin\"\\n2289,1,1,\"Changes in symptoms, quality of life (QOL), and perceptions about pharmacogenomics (PGx) testing\"\\n2290,1,1,\"Changes in the amount of probe eliminated via urine over an 8-hour period (Ae0-8) in Arm 1\"\\n2291,1,1,\"Changes in the FLT PET/CT vascular parameters for the combination of VEGFR/PDGFR dual kinase inhibitor X-82 and docetaxel\"\\n2292,1,1,\"Changes in the FLT PET/CT vascular parameters for VEGF/PDGF dual kinase inhibitor X-82\"\\n2293,1,1,\"Changes in the Functional Assessment of Cancer Therapy (FACT-G) scores\"\\n2294,1,1,\"Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation.\"\\n2295,1,1,\"Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Anxiety Short Form over time\"\\n2296,1,1,\"Changes in the Patient Reported Outcome Measurement Information System (PROMIS) Depression Short Form over time\"\\n2297,1,1,\"Changes in thymidine kinase, thymidylate synthase, and standardized uptake values\"\\n2298,1,1,\"Changes in Tumor Proportion Scores (TPS) in Non-irradiated Sites Assessed by Flow Cytometry\"\\n2299,1,1,\"Changes in uric acid (mg/dL) laboratory values compared with baseline\"\\n2300,1,1,\"Changes in urinalysis as a measure of safety and tolerability for S95005-oxaliplatin\"\\n2301,1,1,\"Changes in vaginal physical examination\"\\n2302,1,1,\"Changes in vital signs as a measure of safety for S95005-oxaliplatin\"\\n2303,1,1,\"Changes in vital signs, ECGs, and clinical laboratory results\"\\n2304,1,1,\"Changes in vital signs: SBP, DBP, respiratory rate and temperature (Phase 1)\"\\n2305,1,1,\"Changes in vulvar physical examination\"\\n2306,1,1,\"Changes in WBC count (thousands/ul) laboratory values compared with baseline\"\\n2307,1,1,\"Changes induced by antiangiogenic drugs and tyrosine kinase inhibitor in the vascular ultrasound variables\"\\n2308,1,1,\"Changes of Autonomy in daily activities detected through the Barthel Index\"\\n2309,1,1,\"Changes of corrected QT interval (QTc) duration\"\\n2310,2,1,\"Changes of left ventricular ejection fraction (LVEF)\"\\n2311,1,1,\"Changes of the platelet counts after the treatment of Avatrombopag\"\\n2312,1,1,\"Changes of the platelet counts after the treatment of eltrombopag\"\\n2313,1,1,\"Changes of the platelet counts after the treatment of Herombopag at week 12\"\\n2314,1,1,\"Changes of the platelet counts after the treatment of Herombopag at week 24\"\\n2315,1,1,\"Changes of tumor dimension by imaging\"\\n2316,1,1,\"Changes of vital signs in participants compared with baseline results.\"\\n2317,1,1,\"Characteristics of Dose Limiting Toxicities (DLT) during the first cycle of treatment with SXL01.\"\\n2318,1,1,\"Characteristics of dose limiting toxicities (DLTs)\"\\n2319,1,1,\"Characterization of adverse events (AEs) and dose-limiting toxicities (DLT) in study Part A\"\\n2320,1,1,\"Characterization of immune infiltrates\"\\n2321,1,1,\"Characterization of molecular mechanisms\"\\n2322,1,1,\"Characterization of the immune landscapes of CRC and, if possible, PDAC liver MTS by high dimensional flow cytometry\"\\n2323,1,1,\"Characterization of the impact of TTFields on peripheral lymphocytes proliferation ex-vivo - cohort B (PD-1 inhibitors treatment)\"\\n2324,1,1,\"Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions\"\\n2325,1,1,\"Characterize Dose Limiting Toxicities\"\\n2326,1,1,\"Characterize safety and tolerability of MK2206 by monitoring incidence of protocol-defined dose limiting toxicities (DLTs)\"\\n2327,1,1,\"Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met\"\\n2328,1,1,\"Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response.\"\\n2329,1,1,\"Characterize the adverse events associated with CDX-1127 administration\"\\n2330,1,1,\"Characterize the dose limiting toxicities (DLTs) and determine the overall safety and tolerability of MSX-122\"\\n2331,1,1,\"Characterize the frequency of ROS gene fusion, ROS protein overexpression and ROS gene mutations in cell lines and tumors\"\\n2332,1,1,\"Characterize the in vitro response of circulating myeloid cells to angiopoeitins-1 and 2 (ANG1 and 2) in the presence or absence of pharmacologic inhibitors\"\\n2333,1,1,\"Characterize the natural history of adrenocortical cancer (ACC). Data will include clinical presentation, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurrence and overall survival.\"\\n2334,1,1,\"Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation\"\\n2335,1,1,\"Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation.\"\\n2336,1,1,\"characterize the pharmacokinetic profiles of ASA404 and any potential metabolite(s) in plasma and pharmacokinetic profiles of the total radioactivity in blood and plasma after a single intravenous infusion of 3000 mg [14C] ASA404 (60 ¬µCi)\"\\n2337,1,1,\"Characterize the pharmacokinetics (PK) of HPN328\"\\n2338,1,1,\"Characterize the pharmacokinetics (PK) of study drug and capecitabine.\"\\n2339,1,1,\"Characterize the pharmacokinetics (PK) of study drug and docetaxel.\"\\n2340,1,1,\"Characterize the pharmacokinetics (PK) of study drug, gemcitabine and a gemcitabine metabolite.\"\\n2341,1,1,\"Characterize the pharmacokinetics (PK) of the new formulation of study drug (in terms of plasma concentrations) when administered in a fed versus fasted state.\"\\n2342,1,1,\"Characterize the pharmacokinetics (PK) of the study drug and metabolite.\"\\n2343,1,1,\"Characterize the pharmacokinetics (PK) profile of SL-901\"\\n2344,1,1,\"Characterize the pharmacokinetics of ABT-263 when administered in combination with etoposide/cisplatin .\"\\n2345,1,1,\"Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).\"\\n2346,1,1,\"Characterize the pharmacokinetics of rapamycin and irinotecan during the first cycle of treatment.\"\\n2347,1,1,\"Characterize the pharmacokinetics of the study drug.\"\\n2348,1,1,\"Characterize the safety and tolerability of ASP-1929 PIT treatment in combination with anti-PD1 therapy\"\\n2349,1,1,\"Characterize the safety and tolerability of BPI-28592 in subjects with advanced solid tumor malignancies\"\\n2350,1,1,\"Characterize the safety and tolerability of BPI-421286 in subjects with advanced solid tumor malignancies\"\\n2351,1,1,\"Characterize the safety and tolerability of T3011 in combination with pembrolizumab\"\\n2352,1,1,\"Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 alone\"\\n2353,1,1,\"Characterize the safety of GH21 in subjects\"\\n2354,1,1,\"Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.\"\\n2355,1,1,\"Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation\"\\n2356,1,1,\"Characterize the safety of XP-102.\"\\n2357,1,1,\"Characterize the safety profile of study drug in combination with capecitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.\"\\n2358,1,1,\"Characterize the safety profile of study drug in combination with docetaxel in terms of adverse events, clinical laboratory tests and electrocardiograms.\"\\n2359,1,1,\"Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.\"\\n2360,1,1,\"Characterize the safety profile of the new formulation of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.\"\\n2361,1,1,\"Characterize the safety profile of the study drug at 3 dose levels in terms of number of treatment emergent events assessed by CTCAE v5.0., abnormal clinical laboratory and electrocardiograms findings (i.e. QT and QTc intervals).\"\\n2362,5,3,\"Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.\"\\n2363,6,2,\"Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.\"\\n2364,2,1,\"Charlson Comorbidity Index (CCI)\"\\n2365,1,1,\"Charlson Comorbidity Index Score\"\\n2366,1,1,\"chemotherapy feasibility\"\\n2367,1,1,\"Chemotherapy response\"\\n2368,1,1,\"Chemotherapy Toxicity (%FN Risk)\"\\n2369,1,1,\"Chemotherapy-induced peripheral neuropathy (CIPN) symptom severity\"\\n2370,1,1,\"Cheson criteria\"\\n2371,3,1,\"Chest\"\\n2372,1,1,\"Chest pain rate according to CTCAE v4.0\"\\n2373,1,1,\"Child-Behavioral Emotional Functioning: Anxious/Depressed score on CBCL\"\\n2374,2,1,\"Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration\"\\n2375,1,1,\"Chinese Patients\\' Satisfaction Scale (C-PSS)\"\\n2376,1,1,\"Choice of the Next Line of Treatment (LoT) Post-Alectinib\"\\n2377,1,1,\"Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer\"\\n2378,1,1,\"Chronic postsurgical pain\"\\n2379,1,1,\"CIN/FN Episodes: Cycle Level\"\\n2380,1,1,\"Circadian Type Inventory (CTI)\"\\n2381,1,1,\"Circulating levels of myeloid derived suppressor cells\"\\n2382,1,1,\"Circulating NK cells\"\\n2383,1,1,\"circulating tumor cell\"\\n2384,1,1,\"Circulating tumor cell (CTC) isolation and colony counts\"\\n2385,1,1,\"Circulating Tumor Cells (CTC)\"\\n2386,1,1,\"Circulating tumor cells in peripheral blood during head and neck surgery\"\\n2387,1,1,\"Circulating tumor levels correlation to response\"\\n2388,6,1,\"CL\"\\n2389,1,1,\"CL (systemic clearance)\"\\n2390,1,1,\"CL(ss)/F of AZD9291 After Multiple Dosing\"\\n2391,2,1,\"CL/F (Apparent clearance)\"\\n2392,1,1,\"CL/F (oral clearance) of FTD and TPI\"\\n2393,1,1,\"CL/F of [13C]-Labeled Idasanutlin\"\\n2394,1,1,\"CL/F of AZD9291 After Single Dosing\"\\n2395,1,1,\"CL/F of digoxin and rosuvastatin\"\\n2396,1,1,\"CL/F of Idasanutlin Metabolite\"\\n2397,1,1,\"CL/F of midazolam and caffeine\"\\n2398,1,1,\"CL/F of Olaparib\"\\n2399,1,1,\"CL/F of Probe Parent Drugs on Day 20\"\\n2400,1,1,\"CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort\"\\n2401,1,1,\"CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort\"\\n2402,1,1,\"CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort\"\\n2403,1,1,\"CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort\"\\n2404,1,1,\"CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Plasma Concentration for Alisertib Following a Single Dose of [^14C]-Alisertib Oral Solution\"\\n2405,1,1,\"CL/R of Volasertib and CD 10899 in Urine\"\\n2406,1,1,\"CL: Clearance for Eribulin Mesylate\"\\n2407,1,1,\"Classic 3+3 design to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)\"\\n2408,18,1,\"Clearance\"\\n2409,1,1,\"Clearance (CL) for eribulin mesylate\"\\n2410,1,1,\"Clearance (CL) of AMG 386 calculated as dose divided by AUC on week 5.\"\\n2411,1,1,\"Clearance (CL) of Cobimetinib on Day 14 (Steady State), Cycle 1\"\\n2412,1,1,\"Clearance (CL) of RO6895882\"\\n2413,1,1,\"Clearance (CL) of RO6958688\"\\n2414,1,1,\"Clearance (Cl) of Sorafenib\"\\n2415,1,1,\"Clearance [CL] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n2416,1,1,\"Clearance of circulating tumor DNA (cohort D)\"\\n2417,1,1,\"Clearance of Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n2418,1,1,\"Clearance of selinexor\"\\n2419,1,1,\"Clearance of Talazoparib in Combination With Temozolomide\"\\n2420,1,1,\"Clearance of Temozolomide in Combination With Talazoparib\"\\n2421,1,1,\"Clearance rate of circulating tumor deoxyribonucleic acid (ctDNA) with cytoreductive surgery (CRS)\"\\n2422,4,1,\"Clinical Activity\"\\n2423,1,1,\"Clinical activity (Response)(Phase 2)\"\\n2424,1,1,\"Clinical Activity of Avelumab plus Axitinib in Patients with MSS Recurrent or Persistent Endometrial Cancer\"\\n2425,1,1,\"Clinical Activity of combination treatment with ALKS 4230 and pembrolizumab in each Part B tumor type.\"\\n2426,1,1,\"Clinical activity of larotrectinib\"\\n2427,1,1,\"Clinical and biological safety defined by the NCI (Common Toxicity Criteria - Version 4.0, may 2009, http:// ctep.cancer.gov)\"\\n2428,1,1,\"Clinical and laboratory adverse reactions will be closely monitored by periodic physical and laboratory examination.\"\\n2429,1,1,\"Clinical and laboratory values\"\\n2430,1,1,\"Clinical and pathological features of lung metastasis\"\\n2431,1,1,\"Clinical and patient reported outcomes following genetic test results\"\\n2432,4,1,\"Clinical Benefit\"\\n2433,2,1,\"Clinical Benefit (CB)\"\\n2434,1,1,\"Clinical Benefit (CB) Rate (CB = Participants With Objective Tumor Response or Stable Disease > 6 Months)\"\\n2435,1,1,\"Clinical benefit (complete response, partial response and stable disease)\"\\n2436,1,1,\"Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control\"\\n2437,1,1,\"Clinical benefit by Response Evaluation Criteria in Solid Tumors 1.1\"\\n2438,1,1,\"Clinical Benefit Defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Lasting >= 24 Weeks, as Determined by the Investigator According to RECIST v1.1\"\\n2439,1,1,\"Clinical benefit defined as non-progression with no dose-limiting toxicity or other toxicity requiring termination of treatment\"\\n2440,1,1,\"Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer\"\\n2441,1,1,\"Clinical benefit of the combination of intravenous decitabine with oral genistein in phase IIa of the study measure by either volumetric MRI for solid tumor or by bone marrow aspiration or biopsy for leukemia) at the end of cycle 2, 4, 6, 9 and 12.\"\\n2442,32,16,\"Clinical Benefit Rate\"\\n2443,20,4,\"Clinical benefit rate\"\\n2444,23,11,\"Clinical Benefit Rate (CBR)\"\\n2445,15,5,\"Clinical benefit rate (CBR)\"\\n2446,3,1,\"clinical benefit rate (CBR)\"\\n2447,1,1,\"Clinical Benefit Rate (CBR) (CR Rate, PR Rate, and SD)\"\\n2448,1,1,\"Clinical benefit rate (CBR) (Phase I dose expansion)\"\\n2449,1,1,\"Clinical Benefit Rate (CBR) - Cohort 3\"\\n2450,1,1,\"Clinical Benefit Rate (CBR) Associated With BGJ398 Treatment\"\\n2451,1,1,\"Clinical Benefit Rate (CBR) at 24 Weeks of PDR001+LAG525 by Tumor Type in Multiple Solid Tumors and Lymphoma\"\\n2452,1,1,\"Clinical Benefit Rate (CBR) at 6 months\"\\n2453,1,1,\"Clinical Benefit Rate (CBR) Based on Centralized Imaging Review as Per RECIST 1.1\"\\n2454,1,1,\"Clinical Benefit Rate (CBR) by RECIST v1.1 in combination therapy arm\"\\n2455,1,1,\"Clinical Benefit Rate (CBR) for Solid Tumors as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n2456,1,1,\"Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n2457,1,1,\"Clinical Benefit Rate (CBR) in Cohort A\"\\n2458,1,1,\"Clinical benefit rate (CBR) of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring either gBRCAms or gBRCAwt and HRD\"\\n2459,1,1,\"Clinical benefit rate (CBR) of nivolumab with or without ipilimumab\"\\n2460,1,1,\"Clinical Benefit Rate (CBR) of ‚â• 16 Weeks FAS\"\\n2461,1,1,\"Clinical benefit rate (CBR) which is defined as either a partial response (PR) complete response (CR) or stable disease (SD) for ‚â• 12 weeks measured using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\"\\n2462,1,1,\"Clinical Benefit Rate (CBR, %)\"\\n2463,1,1,\"Clinical benefit rate (complete response+ partial response+ stable disease)\"\\n2464,1,1,\"Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease That Lasts More Than 6 Months)\"\\n2465,1,1,\"Clinical Benefit Rate (Complete Response, Partial Response, or Stable Disease)\"\\n2466,1,1,\"Clinical Benefit Rate (CR + PR + SD > 6 Months).\"\\n2467,1,1,\"Clinical benefit rate (percentage of patients with complete response, partial response and stable disease)\"\\n2468,1,1,\"Clinical Benefit Rate (Percentage), Which Includes Confirmed Tumor Response (Complete Response [CR] or Partial Response [PR]) or Stable Disease (SD)\"\\n2469,1,1,\"Clinical benefit rate as defined by survival and/or objective response rate and rate of stable disease lasting more than 6 months with genomics-driven therapy in non-approved indications\"\\n2470,1,1,\"Clinical Benefit Rate as Per Central Review by Group- Phase II\"\\n2471,1,1,\"Clinical Benefit Rate by ESR1 Genotype\"\\n2472,1,1,\"Clinical Benefit Rate for Patients With Advanced Breast Cancer (ABC) (Phase II)\"\\n2473,1,1,\"Clinical Benefit Rate From Cabozantinib (XL184)\"\\n2474,1,1,\"Clinical Benefit Rate of Patients Treated With the Combination of Letrozole and Lapatinib and Then After Progression, Treated With Everolimus, Letrozole and Lapatinib.\"\\n2475,1,1,\"Clinical Benefit Rate of the Combination of Enzalutamide/ Fulvestrant\"\\n2476,1,1,\"Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects\"\\n2477,1,1,\"Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects\"\\n2478,2,1,\"Clinical Benefit Response Rate (CBR)\"\\n2479,1,1,\"Clinical benefit will be assessed\"\\n2480,1,1,\"clinical complete response\"\\n2481,1,1,\"Clinical condition at one-year follow-up\"\\n2482,1,1,\"Clinical condition, defined as diagnosis and stage of disease, treatment, and performance status at baseline\"\\n2483,12,1,\"Clinical efficacy\"\\n2484,1,1,\"Clinical Events Ever During Study (Frequency Threshold: 5%)\"\\n2485,1,1,\"Clinical expansion Part: Objective Response RateÔºàORRÔºâ\"\\n2486,1,1,\"Clinical Impact of Whole Exome Sequencing in Cancer Patients\"\\n2487,1,1,\"Clinical lab testing\"\\n2488,1,1,\"Clinical Laboratory Abnormalities (ANC, Platelets, Hemoglobin, AST/ALT, Bilirubin, Creatinine clearance)(Part 2)\"\\n2489,1,1,\"Clinical Laboratory Safety - Chemistry\"\\n2490,1,1,\"Clinical Laboratory Safety - Coagulation\"\\n2491,1,1,\"Clinical Laboratory Safety - Hematology\"\\n2492,9,2,\"Clinical laboratory tests\"\\n2493,2,1,\"Clinical labs\"\\n2494,1,1,\"Clinical Measure of Lesion Size.\"\\n2495,1,1,\"Clinical measures of interest\"\\n2496,1,1,\"Clinical or Radiographic Progression free survival\"\\n2497,1,1,\"Clinical outcome of SARS-CoV-2 Infection\"\\n2498,1,1,\"Clinical outcome post vaccination\"\\n2499,1,1,\"Clinical performance of 22G and 25G needles\"\\n2500,1,1,\"Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples\"\\n2501,1,1,\"Clinical performance of PIK3CA kit in CTCs, plasma and tumor tissue samples of metastatic breast cancer patients\"\\n2502,1,1,\"Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR))\"\\n2503,1,1,\"Clinical remission/response rate of immune-mediated colitis (IMC)\"\\n2504,39,6,\"Clinical Response\"\\n2505,62,4,\"Clinical response\"\\n2506,1,1,\"Clinical Response (Complete Response + Partial Response)\"\\n2507,1,1,\"Clinical Response as Measured by RECIST\"\\n2508,1,1,\"Clinical response assessed by RECIST\"\\n2509,1,1,\"Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n2510,1,1,\"Clinical Response by RECIST Criteria of Estrogen Receptor Expression\"\\n2511,1,1,\"Clinical Response by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Evaluated Every 8 Weeks\"\\n2512,1,1,\"Clinical Response Outcome\"\\n2513,1,1,\"Clinical Response Per the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n2514,20,3,\"Clinical Response Rate\"\\n2515,25,4,\"Clinical response rate\"\\n2516,1,1,\"Clinical Response Rate (Complete and Partial Response by RECIST and/or CA [Cancer Antigen] 125)\"\\n2517,1,1,\"Clinical Response Rate (CRR)\"\\n2518,1,1,\"Clinical Response Rate (PR+CR)\"\\n2519,1,1,\"Clinical Response Rate Following Induction Chemotherapy\"\\n2520,1,1,\"Clinical response rate of alpha-TEA when combined with trastuzumab\"\\n2521,1,1,\"Clinical Response Rate.\"\\n2522,1,1,\"Clinical Response to Binimetinib Combined With PF-02341066\"\\n2523,1,1,\"Clinical Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide\"\\n2524,1,1,\"Clinical responses associated with oral 5-azacitidine and romidepsin\"\\n2525,1,1,\"Clinical Responses in Patients With Metastatic Ocular Melanoma\"\\n2526,1,1,\"Clinical stage at time of presentation (indicator of early access to system)\"\\n2527,2,2,\"Clinical Tumor Regression\"\\n2528,1,1,\"Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer\"\\n2529,2,2,\"Clinical Tumor Regression.\"\\n2530,1,1,\"Clinical Tumor Response of T-1101 (Tosylate) in Participants with Advanced Cancers Categorization of response based on RECIST 1.1.\"\\n2531,3,1,\"Clinically significant abnormality in physical examinations\"\\n2532,1,1,\"Clinically significant alterations in vital signs, laboratory parameters, physical examination, and electrocardiogram (ECG) results.\"\\n2533,1,1,\"Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)\"\\n2534,1,1,\"Clinically significant changes\"\\n2535,1,1,\"Clinically significant changes from baseline in 12-lead electrocardiogram (ECG)\"\\n2536,1,1,\"Clinically significant changes from baseline in blood biochemistry test\"\\n2537,1,1,\"Clinically significant changes from baseline in coagulation function test\"\\n2538,2,1,\"Clinically significant changes from baseline in physical examination\"\\n2539,1,1,\"Clinically significant changes from baseline in routine blood test\"\\n2540,1,1,\"Clinically significant changes from baseline in routine urine test\"\\n2541,1,1,\"Clinically significant changes from baseline in vital signs examination\"\\n2542,1,1,\"CLr of Idasanutlin Metabolite\"\\n2543,1,1,\"CLR of Olaparib\"\\n2544,1,1,\"CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCœÑ for Alisertib\"\\n2545,1,1,\"CLÔºàClearance RateÔºâ\"\\n2546,646,19,\"Cmax\"\\n2547,2,2,\"Cmax (Maximum concentration)\"\\n2548,1,1,\"Cmax (maximum drug concentration in plasma after single dose administration ) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n2549,1,1,\"Cmax (maximum drug concentration in plasma after single dose administration) of BAY43-9006\"\\n2550,1,1,\"Cmax (maximum drug concentration in plasma)\"\\n2551,1,1,\"Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n2552,1,1,\"Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n2553,4,1,\"Cmax (maximum plasma concentration)\"\\n2554,1,1,\"Cmax (maximum plasma concentration) of FTD and TPI\"\\n2555,1,1,\"Cmax (Peak plasma concentration)\"\\n2556,1,1,\"Cmax (PK)\"\\n2557,1,1,\"Cmax after multiple administrations divided by dose (mg) (Cmax/Dmd) of BAY1163877\"\\n2558,1,1,\"Cmax after multiple administrations divided by dose (mg) per kg body weight (Cmax,norm, md) of BAY1163877\"\\n2559,1,1,\"Cmax After Multiple Doses of GDC-0449\"\\n2560,1,1,\"Cmax at Single Dose\"\\n2561,1,1,\"Cmax at Steady State During a Dosing Interval (Cmax,ss)\"\\n2562,1,1,\"Cmax based on encapsulated doxorubicin in patients\"\\n2563,1,1,\"Cmax divided by dose (mg) (Cmax/D)\"\\n2564,1,1,\"Cmax divided by dose (mg) (Cmax/D) of BAY1163877\"\\n2565,1,1,\"Cmax divided by dose (mg) per kg body weight (Cmax,norm)\"\\n2566,1,1,\"Cmax divided by dose (mg) per kg body weight (Cmax,norm) of BAY1163877\"\\n2567,1,1,\"Cmax During Cycle 1\"\\n2568,1,1,\"Cmax Following Single Dose of Drug\"\\n2569,1,1,\"Cmax Following Steady State Exposure for 14 Days\"\\n2570,1,1,\"Cmax for ADC, TA, DM4 and DM4-Me after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1\"\\n2571,1,1,\"Cmax for INC280\"\\n2572,1,1,\"Cmax for Obinutuzumab\"\\n2573,1,1,\"Cmax for Total [14C] Radioactivity in Whole Blood and Saliva\"\\n2574,1,1,\"Cmax of [13C]-Labeled Idasanutlin\"\\n2575,1,1,\"Cmax of ABBV-321\"\\n2576,1,1,\"Cmax of all talazoparib treatment\"\\n2577,1,1,\"Cmax of AZ5104 After Single Dosing\"\\n2578,1,1,\"Cmax of AZ7550 After Single Dosing\"\\n2579,1,1,\"Cmax of AZD9291 After Single Dosing\"\\n2580,1,1,\"Cmax of Bapotulimab after first dose administration (Cycle 1) for cohorts receiving doses ‚â• 20 mg\"\\n2581,1,1,\"Cmax of BAY1834942 after single dose\"\\n2582,1,1,\"Cmax of BAY2927088\"\\n2583,1,1,\"Cmax of Cobimetinib on Day 1, Cycle 1 in Cohort 3\"\\n2584,1,1,\"Cmax of Cobimetinib on Day 14 (Steady State), Cycle 1\"\\n2585,1,1,\"Cmax of digoxin and rosuvastatin\"\\n2586,1,1,\"Cmax of docetaxel injection\"\\n2587,1,1,\"Cmax of DRP-104\"\\n2588,1,1,\"Cmax of Entrectinib Active Metabolite M5\"\\n2589,1,1,\"Cmax of Fentanyl\"\\n2590,1,1,\"Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose\"\\n2591,1,1,\"Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose\"\\n2592,1,1,\"Cmax of Idasanutlin Metabolite\"\\n2593,1,1,\"Cmax of midazolam and caffeine\"\\n2594,1,1,\"Cmax of MK-2206 in Participants Receiving Multiple QW Dosing\"\\n2595,1,1,\"Cmax of Mogamulizumab\"\\n2596,1,1,\"Cmax of N-desmethyl Selumetinib After Single Dose\"\\n2597,1,1,\"Cmax of N-desmethyl Selumetinib During Oral Twice Daily Dose of Selumetinib\"\\n2598,1,1,\"Cmax of Olaparib\"\\n2599,1,1,\"Cmax of Patritumab\"\\n2600,1,1,\"Cmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3\"\\n2601,1,1,\"Cmax of Probe Parent Drugs and Their Metabolites on Day 1\"\\n2602,1,1,\"Cmax of Probe Parent Drugs and Their Metabolites on Day 20\"\\n2603,1,1,\"Cmax of RO5185426 Following Day 21 Dose\"\\n2604,1,1,\"Cmax of RO5185426 on Day 1 - Dose Escalation: MBP Formulation\"\\n2605,1,1,\"Cmax of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC\"\\n2606,1,1,\"Cmax of RO5185426 on Day 15 - Dose Escalation: MBP Formulation\"\\n2607,1,1,\"Cmax of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC\"\\n2608,1,1,\"Cmax of Selumetinib After Single Dose\"\\n2609,1,1,\"Cmax of Selumetinib During Oral Twice Daily Dose of Selumetinib\"\\n2610,1,1,\"Cmax of total radioactivity in whole blood and plasma\"\\n2611,1,1,\"Cmax of Total Selumetinib\"\\n2612,1,1,\"Cmax of Vemurafenib\"\\n2613,1,1,\"Cmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study\"\\n2614,1,1,\"Cmax of Vemurafenib on Day -1, Cycle 1 of Cohorts 1C and 2A in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study\"\\n2615,1,1,\"Cmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-na√Øve Participants\"\\n2616,1,1,\"Cmax of Vemurafenib on Day 1, Cycle 1 in Cohort 1A in BRAFi-na√Øve Participants\"\\n2617,1,1,\"Cmax of Vemurafenib on Day 14, Cycle 1\"\\n2618,1,1,\"Cmax of Volasertib and CD 10899 in Plasma\"\\n2619,1,1,\"Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth)\"\\n2620,1,1,\"Cmax(Peak Plasma Concentration)\"\\n2621,1,1,\"Cmax,md (Cmax after multiple dose) for regorafenib and cetuximab\"\\n2622,1,1,\"Cmax,md (Cmax After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15\"\\n2623,1,1,\"Cmax,md of BAY2666605\"\\n2624,1,1,\"Cmax,md of BAY2927088\"\\n2625,1,1,\"Cmax,md: Cmax after multiple dosing\"\\n2626,1,1,\"Cmax,norm (Cmax divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n2627,1,1,\"Cmax-to-dose ratio [Cmax/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n2628,1,1,\"Cmax.ss (Cmax at steady-state during a dosage interval)\"\\n2629,1,1,\"Cmax/D (Cmax divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n2630,1,1,\"Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3\"\\n2631,1,1,\"Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1\"\\n2632,1,1,\"Cmax/Dmd (Cmax Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15\"\\n2633,1,1,\"Cmax: Maximum drug concentration in plasma after dose administration\"\\n2634,1,1,\"Cmax: Maximum Observed Concentration for Alisertib\"\\n2635,1,1,\"Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole\"\\n2636,1,1,\"Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin\"\\n2637,1,1,\"Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A\"\\n2638,1,1,\"Cmax: Maximum Observed Plasma and Whole Blood Radioactivity for [14C]-TAK-659\"\\n2639,1,1,\"Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort\"\\n2640,1,1,\"Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort\"\\n2641,1,1,\"Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution\"\\n2642,1,1,\"Cmax: Maximum Observed Plasma Concentration for Eribulin Mesylate\"\\n2643,4,2,\"Cmax: Maximum Observed Plasma Concentration for Ixazomib\"\\n2644,1,1,\"Cmax: Maximum Observed Plasma Concentration for Midazolam and 1\\'-Hydroxymidazolam\"\\n2645,1,1,\"Cmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)\"\\n2646,1,1,\"Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort\"\\n2647,1,1,\"Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort\"\\n2648,1,1,\"Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1\"\\n2649,1,1,\"Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 15\"\\n2650,2,2,\"Cmax: Maximum Observed Plasma Concentration for TAK-659\"\\n2651,1,1,\"Cmax: Maximum Observed Plasma Concentration of Alisertib\"\\n2652,1,1,\"Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion\"\\n2653,1,1,\"Cmax: Maximum Observed Serum Concentration for AMG 386 After Week 1 Dose\"\\n2654,1,1,\"Cmax: Maximum Observed Serum Concentration for AMG 386 After Week 4 Dose\"\\n2655,1,1,\"Cmax: Maximum Observed Serum Concentration for MLN0264\"\\n2656,1,1,\"Cmax: maximum plasma drug concentration for AZD1775\"\\n2657,1,1,\"Cmax: the maximum plasma concentration of HL-085 or metabolite(s);\"\\n2658,1,1,\"Cmaxof roniciclib in plasma\"\\n2659,1,1,\"CmaxÔºöobserved maximum plasma concentration\"\\n2660,1,1,\"Cmin for Obinutuzumab\"\\n2661,1,1,\"Cmin: Minimum Observed Serum Trough Concentration for AMG 386 After Week 1 Dose\"\\n2662,1,1,\"Cmin: Minimum Observed Serum Trough Concentration for AMG 386 After Week 4 Dose\"\\n2663,1,1,\"CNS Overall Response Rate (ORR)\"\\n2664,1,1,\"CNS overall response rate (ORR) (Cohort 1)\"\\n2665,3,1,\"CNS progression free survival\"\\n2666,1,1,\"Co-morbidities by Charlson at baseline\"\\n2667,1,1,\"Co-primary endpoint 1\"\\n2668,1,1,\"Co-primary endpoint 2\"\\n2669,3,1,\"Coagulation function\"\\n2670,1,1,\"Coformulation: Number of participants discontinuing study treatment due to an AE\"\\n2671,1,1,\"Coformulation: Number of participants with ‚â•1 AE\"\\n2672,1,1,\"Coformulation: Number of participants with ‚â•1 DLT\"\\n2673,1,1,\"Cognitive decline - MMSE 30\"\\n2674,1,1,\"Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT\"\\n2675,1,1,\"Cognitive status by Short Orientation Concentration Memory Test at baseline, 3 months, and 1 year\"\\n2676,1,1,\"Cohort 1 - Number of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate)\"\\n2677,1,1,\"Cohort 1 - Progression-free Survival (PFS)\"\\n2678,1,1,\"Cohort 1 and 2: Objective Response Rate\"\\n2679,1,1,\"Cohort 1 and 3: Radiographic Progression Free Survival (rPFS)\"\\n2680,1,1,\"Cohort 1 and Cohort 4: Duration of Confirmed Objective Response, as Determined by the Investigator According to RECIST v1.1\"\\n2681,1,1,\"Cohort 1 and Cohort 4: Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]), as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST), Version (v) 1.1\"\\n2682,1,1,\"Cohort 1, asses efficacy, defined as 16 weeks progression-free survival (PFS) of DS8201a\"\\n2683,1,1,\"Cohort 1, Sequences 1A and 1B: Area under the plasma concentration-time curve from 0 to the last measurable plasma concentration (AUC0-t) for tesetaxel under fed and fasted conditions\"\\n2684,1,1,\"Cohort 1, Sequences 1A and 1B: Maximum observed plasma concentration (Cmax) for tesetaxel under fed and fasted conditions\"\\n2685,1,1,\"Cohort 1: Determine the safety of indocyanine green (all tumor types combined)\"\\n2686,1,1,\"Cohort 1: fraction of [14C]-radioactivity excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point per participant (fefaeces, 0-tz)\"\\n2687,1,1,\"Cohort 1: fraction of [¬π‚Å¥C]-radioactivity excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point per patient (feurine, 0-tz)\"\\n2688,1,1,\"Cohort 1: Identify optimal dosing of indocyanine green before surgery, and camera combination (tumor type-specific)\"\\n2689,1,1,\"Cohort 1: Identify optimal timing of indocyanine green before surgery, and camera combination (tumor type-specific)\"\\n2690,1,1,\"Cohort 1: Recommended Dose (RD) of Lenvatinib\"\\n2691,1,1,\"Cohort 2 (Safety Run-In Cohort 2 and Phase 2 Cohort 2): Confirmed Objective Response Rate (ORR) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n2692,1,1,\"Cohort 2 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n2693,1,1,\"Cohort 2 - Progression-free Survival (PFS)-Overall\"\\n2694,1,1,\"Cohort 2, 3 and 4, asses efficacy defined as ORR-IC (DS-8201a)\"\\n2695,1,1,\"Cohort 2: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity (AUCo-‚àû) for [¬π‚Å¥C]-BI 907828\"\\n2696,1,1,\"Cohort 2: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity (AUCo-‚àû) for BI 907828\"\\n2697,1,1,\"Cohort 2: AUC from 0 to 336 hours (AUC0-336h) for tesetaxel in the presence and absence of itraconazole\"\\n2698,1,1,\"Cohort 2: Cmax for tesetaxel in the presence and absence of itraconazole\"\\n2699,1,1,\"Cohort 2: Confirm the efficacy of indocyanine green used with Near Infrared (NIR) fluorescent imaging as measured by Clinically Significant Event (CSE) rate (tumor type-specific)\"\\n2700,1,1,\"Cohort 2: Determine the sensitivity and specificity of indocyanine green (tumor type-specific)\"\\n2701,1,1,\"Cohort 2: Safety and Tolerability of TKI258\"\\n2702,1,1,\"Cohort 2A: Number of Participants With Best Overall Response (BOR)\"\\n2703,1,1,\"Cohort 2A: Number of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR)\"\\n2704,1,1,\"Cohort 3 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n2705,1,1,\"Cohort 3: Adverse Events\"\\n2706,1,1,\"Cohort 3: AUC0-336h for tesetaxel in the presence and absence of rifampin\"\\n2707,1,1,\"Cohort 3: Cmax for tesetaxel in the presence and absence of rifampin\"\\n2708,1,1,\"Cohort 3A: Recommended Dose (RD) of Lenvatinib When Given in Combination With Etoposide and Ifosfamide\"\\n2709,1,1,\"Cohort 4: Efficacy and Adverse Events\"\\n2710,1,1,\"Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values\"\\n2711,1,1,\"Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity\"\\n2712,1,1,\"Cohort 4: Number of Participants with Adverse Events (AEs)\"\\n2713,1,1,\"Cohort 4: Number of Participants with AEs by Severity\"\\n2714,1,1,\"Cohort 5 asses efficacy,defined as OS of DS-8201a\"\\n2715,1,1,\"Cohort 5: Efficacy and Adverse Events\"\\n2716,1,1,\"Cohort A and B - Progression-free Survival (PFS)\"\\n2717,1,1,\"Cohort A: Objective response rate\"\\n2718,1,1,\"Cohort A: Objective response rate (ORR) by response evaluation ceiteria in solid tumours (RECIST) version 1.1\"\\n2719,1,1,\"Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1\"\\n2720,1,1,\"Cohort A: Signal-to-noise ratio of the target lesion 13C pyruvate metabolism measures will be determined for each patient\"\\n2721,1,1,\"Cohort B-7 (expansion): Objective response rate (ORR) to assess the clinical activity of BT8009 in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma in combination with pembrolizumab using RECIST 1.1.\"\\n2722,1,1,\"Cohort B: Composite response rate by RECIST version 1.1\"\\n2723,1,1,\"Cohort B: Objective Response Rate (ORR)\"\\n2724,1,1,\"Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1\"\\n2725,1,1,\"Cohort B: Target Tumor Metabolism\"\\n2726,1,1,\"Cohort C - Objective Response Rate (ORR)\"\\n2727,1,1,\"Cohort C phase I To determine the maximum tolerated dose (MTD) of PM14 to be used as recommended phase 2 dose (RP2D).\"\\n2728,1,1,\"Cohort C phase II To evaluate the overall response rate (ORR) in irradiated nodules only.\"\\n2729,1,1,\"Cohort C: Pre-IDS ORR\"\\n2730,1,1,\"Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1\"\\n2731,1,1,\"Cohort D phase I To determine the maximum tolerated dose (MTD) of PM14 to be used as recommended phase 2 dose (RP2D).\"\\n2732,1,1,\"Cohort D phase II To evaluate the overall response rate (ORR).\"\\n2733,1,1,\"Cohort D: ORR\"\\n2734,1,1,\"Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1\"\\n2735,1,1,\"Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1\"\\n2736,1,1,\"Cohort Expansion - Assess Objective Response Rate (ORR)\"\\n2737,1,1,\"Cohort Expansion: Objective Response in solid tumors\"\\n2738,1,1,\"Cohort expansionÔºöPreliminary assessment of change in tumor size\"\\n2739,1,1,\"Cohort F: disease control (DC) defined as best overall response of complete response (CR) or partial response (PR) or confirmed stable disease (SD) or Non-CR/ Non-PD where best overall response is defined according to RECIST version 1.1\"\\n2740,1,1,\"Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1\"\\n2741,1,1,\"Cohort G: PFS as Determined by Blinded Independent Central Review (BICR) Based on RECIST v1.1\"\\n2742,1,1,\"Cohort I, II, IV: Progression-Free Survival (PFS), as Assessed by the Investigator Using RECIST V1.1 Criteria\"\\n2743,1,1,\"Cohort I, II, IV: Time to Treatment Failure (TTF), as Assessed by the Investigator Using RECIST V1.1 Criteria\"\\n2744,1,1,\"Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n2745,1,1,\"Cohort II, III: Percentage of Participants With Confirmed Overall Response (OR) (Partial Response [PR] or Complete Response [CR]), as Determined by the Investigator Using RECIST v1.1\"\\n2746,1,1,\"Cohort III, V: Disease-Free Survival (DFS), as Assessed by the Investigator Using RECIST V1.1 Criteria\"\\n2747,1,1,\"Cohort III, V: Event-Free Survival (EFS), as Assessed by the Investigator Using RECIST V1.1 Criteria\"\\n2748,1,1,\"Cohort of Families with IBMFS\"\\n2749,1,1,\"Cohort-Expansion Stage (Cohort H only): Overall Survival (OS)\"\\n2750,1,1,\"Cohort-Expansion Stage (except Cohort H): Progression-Free Survival (PFS)\"\\n2751,4,3,\"Cohort-Expansion Stage: Objective Response Rate (ORR)\"\\n2752,1,1,\"Cohort1: Find out about the routes and rates of excretion of TKI258 and its metabolites\"\\n2753,1,1,\"Cohorts 1 and 2: Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 During Dual-Agent Treatment\"\\n2754,1,1,\"Cohorts 1 and 2: Percentage of Participants With a Confirmed Best Overall Response of CR, PR, or Stable Disease (SD) According to RECIST Version 1.0 During Dual-Agent Treatment\"\\n2755,1,1,\"Cohorts 1, 2, and 3: Objective Response Rate (ORR) Based on Investigator Assessment (INV)\"\\n2756,1,1,\"Cohorts 1a/1b: Evaluate compliance\"\\n2757,1,1,\"Cohorts 1a/1b: Evaluate safety\"\\n2758,1,1,\"Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring AUC.\"\\n2759,1,1,\"Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.\"\\n2760,1,1,\"Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.\"\\n2761,1,1,\"Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.\"\\n2762,1,1,\"Cohorts 2B and 3B: Progression-free Survival (PFS) Rate at Month 4\"\\n2763,1,1,\"Cohorts A, B, and C: Objective Response Rate (ORR)\"\\n2764,1,1,\"Cohorts A, B, C To determine the maximum tolerated dose (MTD) of PM14 to be used as recommended phase 2 dose (RP2D).\"\\n2765,1,1,\"Cohorts A, B,C & D - Maximum Tolerated Dose (MTD)\"\\n2766,1,1,\"Cohorts A, B,C & D - Number of patients with dose limiting toxicities (DLT) in the Maximum Tolerated Dose (MTD) evaluation period\"\\n2767,1,1,\"Cohorts A-1 and A-2 (escalations): Number of participants with dose limiting toxicities on BT8009 alone and in combination with pembrolizumab.\"\\n2768,1,1,\"Cohorts A-1, A-2 and C: Number of participants with treatment emergent adverse events receiving BT8009 alone and in combination with pembrolizumab to assess safety and tolerability\"\\n2769,1,1,\"Cohorts B-1, B-2, and B-3 (expansions): Objective response rate (ORR) to assess the clinical activity of BT8009 as a monotherapy in patients with urothelial cancer using RECIST 1.1.\"\\n2770,1,1,\"Cohorts B-4, B-5, and B-6 (expansions): Objective response rate (ORR) to assess the clinical activity of BT8009 as a monotherapy in patients with selected solid tumor indications associated with Nectin-4 expression using RECIST 1.1.\"\\n2771,1,1,\"Cohorts D and E: Number of Participants with Adverse Events (AE)\"\\n2772,1,1,\"Cohorts D and E: Number of Participants with Laboratory Values Abnormalities\"\\n2773,1,1,\"Cohorts D and E: Number of Participants with Vital Signs Abnormalities\"\\n2774,1,1,\"Cohorts D1 & D2 - Progression-free survival (PFS) rate\"\\n2775,1,1,\"Cohorts E and F To evaluate the progression-free survival rate (PFSR) at 6 months.\"\\n2776,1,1,\"Cohorts E: objective response (OR), defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.\"\\n2777,1,1,\"Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.\"\\n2778,1,1,\"Cohorts Ph1b-D and Ph1b-E: Number of Participants with DLT by Severity\"\\n2779,1,1,\"Cohorts Ph1b-D and Ph1b-E: Number of Participants with Dose-limiting Toxicity (DLT)\"\\n2780,1,1,\"Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion.\"\\n2781,1,1,\"Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images.\"\\n2782,1,1,\"Collect and compare blood, tumor and MPE-derived cell fractions\"\\n2783,1,1,\"Collect blood and/or, where appropriate, urine, hair, stool or saliva samples from patients with solid tumours\"\\n2784,1,1,\"Collect long term ALN-VSP02 safety data\"\\n2785,2,1,\"Collecting, processing and archiving human tissue\"\\n2786,1,1,\"Collection and annotation of biospecimens\"\\n2787,1,1,\"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets\"\\n2788,1,1,\"Collection of Feces and Urine and Measurement of 120mg Fluzoparib Metabolism in Healthy subjects by HPLC\"\\n2789,1,1,\"Collection of the global score of the MAUQ questionnaire (item 1 to 21), filled in by the patients after 6 months of use\"\\n2790,1,1,\"Column biochemical effectiveness\"\\n2791,1,1,\"Column efficiency\"\\n2792,1,1,\"Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib from Time Zero to 168 Hours (AUC [0-168]/dose) of Niraparib and AA After a Single Dose\"\\n2793,1,1,\"Combination 3: Area Under the Plasma Concentration-Time Curve from Time Zero to 168 Hours (AUC [0-168]) of Niraparib and AA After a Single Dose\"\\n2794,1,1,\"Combination 3: Maximum Observed Analyte Plasma Concentration (Cmax) of Niraparib and AA After a Single Dose\"\\n2795,1,1,\"Combination 3: Maximum Observed Analyte Plasma Concentration for Niraparib Normalized by the Dose (Cmax/dose) of Niraparib and AA After a Single Dose\"\\n2796,1,1,\"Combination Dose Expansion: Objective Response Rate (ORR) as defined by RECIST, with ANV419 in combination with pembrolizumab or ipilimumab\"\\n2797,1,1,\"Combination Dose Finding: Incidence, frequency, and severity of Adverse Events with ANV419 in combination with pembrolizumab or ipilimumab\"\\n2798,1,1,\"Combination Dose Finding: Recommended Phase 2 Dose of ANV419 in combination with ipilimumab\"\\n2799,1,1,\"Combination Dose Finding: Recommended Phase 2 Dose of ANV419 in combination with pembrolizumab\"\\n2800,1,1,\"Combination part: The contents of same assessment as Monotherapy.\"\\n2801,1,1,\"Combination therapy (Module 3): Objective response rate (ORR) using each patient\\'s best overall response (BOR) according to RECIST 1.1\"\\n2802,1,1,\"Combination Therapy Period: Arm A and B: Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n2803,1,1,\"Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs)\"\\n2804,1,1,\"Combinatory analysis of genomic, transcriptomic and immunological profile\"\\n2805,1,1,\"Combined Best Overall Response Rate Based on Investigator Assessment\"\\n2806,1,1,\"Combined endpoint - overall survival and weight maintenance\"\\n2807,1,1,\"combined with Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), in patients\"\\n2808,1,1,\"Common Toxicity Criteria for Adverse Events (CTCAE 5.0)\"\\n2809,1,1,\"Comparative Analysis of PET/MRI Images\"\\n2810,1,1,\"Compare AUC of FORE8394 with FORE8394\"\\n2811,1,1,\"Compare Cmax of FORE8394 with FORE8394\"\\n2812,1,1,\"Compare efficacy of 3-component model telemedicine intervention to standard care in terms of depression and pain at baseline and 1, 3, 6, and 12 months\"\\n2813,1,1,\"Compare Efficacy of darbepoetin alfa with Epoetin Alfa as measured by the incidence of red blood cell transfusions.\"\\n2814,1,1,\"Compare FDG PET-based qualitative and quantitative tumor response assessment with standard CT immune RECIST criteria\"\\n2815,1,1,\"Compare longitudinal changes in knowledge scale before and after combination information and communication skills training.\"\\n2816,1,1,\"Compare objective response rate(ORR) between Chemoradiotherapy Based of Cisplatin + Sintilimab Regimen and Chemoradiotherapy Based of Cisplatin Regimen using RECIST 1.1.\"\\n2817,1,1,\"Compare Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at day 127 from baseline\"\\n2818,1,1,\"Compare Overall Survival (OS) between sintilimab +chemotherapy and placebo + chemotherapy.\"\\n2819,1,1,\"Compare Progression Free Survival (PFS) between Chemoradiotherapy Based of Cisplatin + Sintilimab Regimen and Chemoradiotherapy Based of Cisplatin Regimen using RECIST 1.1.\"\\n2820,1,1,\"Compare Progression Free Survival (PFS) between Nimotuzumab + TC Regimen chemotherapy and TC Regimen chemotherapy using RECIST 1.1.\"\\n2821,1,1,\"Compare Progression Free Survival (PFS) Between the Number of Obese and Overweight Participants\"\\n2822,1,1,\"Compare progression free survival between patients on gefitinib or on docetaxel by Progression as per Response Evaluation Criteria In Solid Tumors\"\\n2823,1,1,\"Compare Progression-free Survival in Newly Diagnosed Stage III or IV Clear Cell Ovarian Cancer Patients in Patients in the U.S. and Worldwide (Outside of Japan) Versus Patients in Japan.\"\\n2824,1,1,\"Compare requested pre-intervention measures to received post-intervention measures.\"\\n2825,1,1,\"Compare spatial coordination between the location of CA9 and hypoxia and/or lactate concentration at completion of accrual\"\\n2826,1,1,\"Compare T1/2 of FORE8394 with FORE8394\"\\n2827,1,1,\"Compare the diagnostic yield\"\\n2828,1,1,\"Compare the effect of GSK1120212 on the baseline-adjusted, placebo-corrected, time-matched QTcF(QT interval corrected for heart rate by Fridericia\\'s formula) interval duration in subjects with solid tumor cancers\"\\n2829,1,1,\"Compare the effects of these regimens on increasing hemoglobin levels\"\\n2830,1,1,\"Compare the Growth Modulation Index (GMI) in patients treated with Trabectedin or Gemcitabine in second line\"\\n2831,1,1,\"Compare the metabolic phenotype with the result of histopathological diagnosis and genetic alterations of the specific tumor\"\\n2832,1,1,\"Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo\"\\n2833,1,1,\"Compare the Overall Survival (OS) of Patients Treated With AEZS-108 to the OS of Patients Treated With Doxorubicin.\"\\n2834,1,1,\"Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo\"\\n2835,1,1,\"Compare the proportion of patients for whom a genomically identified recommended therapy could be initiated using the large NGS panel from FoundationOne versus the limited CONTROL panel.\"\\n2836,1,1,\"Compare Tmax of FORE8394 with FORE8394\"\\n2837,1,1,\"comparison between accuracy of CESM and CE-MRI in diagnosing breast cancer.\"\\n2838,1,1,\"Comparison between mean percent change in SUVmax with Prostate-specific antigen (PSA) response group\"\\n2839,1,1,\"Comparison of blood levels of topotecan following oral and IV dosing;\"\\n2840,1,1,\"Comparison of blood levels of topotecan following oral and IV dosing; blood samples will be drawn on Day 1 and Day 8 of Courses 1 and 2.\"\\n2841,1,1,\"Comparison of CT perfusion parameters between the responders and non-responders according to mRECIST assessment for advanced HCC treated by systemic immunotherapy\"\\n2842,1,1,\"Comparison of CT perfusion parameters between the responders and non-responders according to RECIST 1.1 assessment for advanced HCC treated by systemic immunotherapy\"\\n2843,1,1,\"Comparison of Diagnostic Adequacy Scores With SST vs. CST for Cytologic Diagnosis Using a 22G Core Needle.\"\\n2844,1,1,\"Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.\"\\n2845,1,1,\"Comparison of EUS-FNB sensitivity using two types of FNB needles\"\\n2846,1,1,\"Comparison of frequency, phenotype and transcriptional profile of the different immune subsets in the tumor following adoptive cell therapy infusion using spectral flow cytometry and RNA sequencing\"\\n2847,1,1,\"Comparison of MRS findings with the pathology of the specimens\"\\n2848,1,1,\"Comparison of number of patients treated at Vanderbilt Children\\'s Hospital vs Vanderbilt University Hospital\"\\n2849,1,1,\"Comparison of outcomes\"\\n2850,1,1,\"Comparison of patient attitudes regarding clinical trials among cancer patients belonging to different racial/ethnic groups\"\\n2851,1,1,\"Comparison of Percentage of Complete Responders\"\\n2852,1,1,\"Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug\"\\n2853,1,1,\"Comparison of Pre- and Post-treatment Worst Pain in 24 Hours at Week 6 as Measured on the Numeric 0 to 10 Brief Pain Inventory (BPI) Scale\"\\n2854,1,1,\"Comparison of Progression Free Survival (PFS) Between Treatment Groups Using irRECIST and Evaluated by Independent Radiology.\"\\n2855,1,1,\"Comparison of Progression Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole\"\\n2856,1,1,\"Comparison of Progression-free Survival\"\\n2857,1,1,\"Comparison of Quality Scores (PET/CT vs PET/MRI), Comprised of Various Qualities of the Image and Include Contrast, Brightness, Resolution, Etc.\"\\n2858,1,1,\"Comparison of sensitivity, specificity and accuracy of WB-DW-MR scans to 18-F FDG PET scans.\"\\n2859,1,1,\"Comparison of Specificity Rates of Fused FDG-PET/MRI (Cohort III)\"\\n2860,1,1,\"Comparison of the concentration-time profile of Oral Paclitaxel in plasma for 168 hours when taken with or without food.\"\\n2861,1,1,\"Comparison of the incidence of cancer diagnosis\"\\n2862,1,1,\"Comparison of the incidence of engraftment with historical data\"\\n2863,1,1,\"Comparison of the incidence of graft-vs-host disease with historical data\"\\n2864,1,1,\"Comparison of the Percentage of Participants With a Complete Response in Each Treatment Arm\"\\n2865,1,1,\"Comparison of the percentage of treatment patients still alive after 10 years with the percentage of matched historic control patients still alive after 10 years.\"\\n2866,1,1,\"Comparison of the percentage of treatment patients still alive after 2 years with the percentage of matched historic control patients still alive after 2 years.\"\\n2867,1,1,\"Comparison of the percentage of treatment patients still alive after 5 years with the percentage of matched historic control patients still alive after 5 years.\"\\n2868,1,1,\"Comparison of the Progression-free survival (PFS) between the test and the control arms using Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 (Phase 2)\"\\n2869,1,1,\"Comparison of the screening tools (GFI and G8) with a comprehensive geriatric assessment (CGA)\"\\n2870,1,1,\"Comparison of total survival times in days of sarcoma patients treated with AV0113 with total survival times of a cohort of matched historic control patients.\"\\n2871,1,1,\"Comparison of weight gain and rate of weight change\"\\n2872,1,1,\"Complementary Deoxyribonucleic Acid (cDNA) Expression\"\\n2873,1,1,\"Complete and partial control of emesis\"\\n2874,1,1,\"Complete and Partial Response Rate (Phase II)\"\\n2875,1,1,\"Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria\"\\n2876,1,1,\"Complete Clinical Remission\"\\n2877,1,1,\"Complete enucleation of a tumor in the pancreas\"\\n2878,2,1,\"Complete evaluation of untreated lesions with physical examination and appropriate X-rays and/or scans will be performed four to six weeks after the last DC injection.\"\\n2879,1,1,\"Complete gross surgical resection (R0 or R1 resection)\"\\n2880,1,1,\"Complete or partial intracranial response rate in cohort A on the evaluation of each patient\\'s best tumor response by the centralized review committee according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria.\"\\n2881,1,1,\"Complete or Partial Objective Tumor Response\"\\n2882,1,1,\"Complete pathological response (pCR)\"\\n2883,1,1,\"Complete Pathological Response (pCR) Rate\"\\n2884,1,1,\"Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D).\"\\n2885,1,1,\"Complete physical examination including performance status assessed using the Eastern Cooperative Oncology Group (ECOG) Performance Status criteria.\"\\n2886,8,1,\"complete remission\"\\n2887,6,1,\"Complete remission (CR)\"\\n2888,1,1,\"Complete Remission (CR) or Complete Remission With Partial Hematologic Recovery (CRh) Rate (Dose Expansion Phase in Participants With AML)\"\\n2889,1,1,\"Complete resection (R0) rate\"\\n2890,35,3,\"Complete Response\"\\n2891,13,2,\"Complete Response (CR)\"\\n2892,1,1,\"Complete response (CR) during overall phase\"\\n2893,1,1,\"Complete Response (CR) rate (change in target lesion size).\"\\n2894,1,1,\"Complete Response (CR) rate - for AML arm only\"\\n2895,1,1,\"Complete response (CR) rate before or at Month 6\"\\n2896,1,1,\"Complete Response (CR) Rate for UGN-102 Treatment\"\\n2897,1,1,\"Complete response (CR) rate in Cohort C\"\\n2898,1,1,\"Complete Response (CR) Rate in the Brain at 12 Weeks Post-radiation Therapy (RT) Using the RECIST 1.1 Criteria Based on Brain Magnetic Resonance Imaging (MRI)\"\\n2899,1,1,\"Complete response (CR) rate of RAD for the prevention of chemotherapy induced nausea vomiting (CINV) during overall phase (form 1 to 5 days) (overall phase is defined as acute and delayed phase)\"\\n2900,1,1,\"Complete Response (Phase II)\"\\n2901,1,1,\"Complete Response + Partial Response + Stable Disease > 24 Weeks\"\\n2902,1,1,\"Complete response based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n2903,1,1,\"Complete response during the overall phase after the start of the first cisplatin administration\"\\n2904,54,4,\"Complete Response Rate\"\\n2905,1,1,\"Complete response rate (Cohort 1)\"\\n2906,8,1,\"Complete response rate (CRR)\"\\n2907,1,1,\"Complete Response Rate (CRR) as assessed by the Independent Review Committee (IRC)\"\\n2908,1,1,\"complete response rate (CRR) for delayed CINV\"\\n2909,1,1,\"Complete response rate for HIV related malignancies treated with interferon\"\\n2910,1,1,\"Complete Response Rate of the Combination of BMR (Bendamustine + Mitoxantrone + Rituximab)\"\\n2911,1,1,\"Complete Response Rate of the Drug Regimen\"\\n2912,1,1,\"Complete response rate of VEGFR inhibitor-associated hand-foot skin reaction\"\\n2913,1,1,\"Complete Response Rate to 1.3mg/m^2 of Bortezomib With Mitoxantrone and Etoposide in Phase II\"\\n2914,1,1,\"Complete Response Rates for Patients With Metastatic Melanoma\"\\n2915,1,1,\"Completion of all preoperative and operative therapy\"\\n2916,1,1,\"Completion of the Geriatric Assessment (GA)\"\\n2917,30,1,\"Completion rate\"\\n2918,1,1,\"Completion rate of all preoperative and operative therapy\"\\n2919,81,1,\"Compliance\"\\n2920,1,1,\"Compliance with the dietary intervention or standard of care- Baseline veggie meter\"\\n2921,1,1,\"Compliance with the dietary intervention or standard of care- survey\"\\n2922,1,1,\"Complication burden\"\\n2923,1,1,\"Complication rates associated with hyperthermic treatment\"\\n2924,1,1,\"Composite endpoint: Proportion of patients with at least one occurrence of a safety or feasibility event\"\\n2925,1,1,\"Composite of Clinical Outcomes-change over time\"\\n2926,1,1,\"Composite of Number and percent of all treated participants that experience Adverse Events (AEs)\"\\n2927,1,1,\"Composite of Number and percent of all treated participants that experience AEs leading to discontinuation\"\\n2928,1,1,\"Composite of Number and percent of all treated participants that experience serious adverse events (SAEs)\"\\n2929,1,1,\"Composite of Number and percent of all treated subjects that experience AEs leading to death\"\\n2930,1,1,\"Composite of Number and percent of participants with clinical laboratory abnormalities\"\\n2931,1,1,\"Composite of Pharmacokinetics of OSI-906 in plasma: AUC inf, AUC last, C max, t max, t 1/2, CL/F, and Vz/F\"\\n2932,1,1,\"Composite of Pharmacokinetics of OSI-906 in urine: Cumulative amount of drug excreted into urine, feces or bile up to collection time of last measurable concentration (Ae last), Renal Clearance (CL R), and percentage of dose excreted (Ae last%)\"\\n2933,1,1,\"Composite of Pharmacokinetics of TKI258, FMI capsule (supplied in 100 mg strength) and FMI tablet (supplied in 250 mg strength), in patients with advanced solid tumors, excluding breast cancer based on PK parameters AUClast and Cmax\"\\n2934,1,1,\"Composite of Pharmacokinetics: Ceoi or Cmax, Ctrough, Tmax, AUC0-21, t¬Ω, CL, Vss\"\\n2935,1,1,\"Composite of plasma pharmacokinetic parameters of Tivantinib\"\\n2936,1,1,\"Composite of Progression Free Survival [PFS] or Overall Survival [OS]\"\\n2937,1,1,\"Composite of steady state PK parameters of NE and EE\"\\n2938,1,1,\"Composite of steady state PK parameters of NE and EE in combination with trametinib\"\\n2939,1,1,\"Composite of symptomatic arterial thromboembolism (any inpatient diagnosis)\"\\n2940,1,1,\"Composite outcome of all-cause mortality, severe infection, severe diarrhea or fever\"\\n2941,1,1,\"Composite Overall Response Rate (CORR)\"\\n2942,1,1,\"Composite Progression-free Survival (cPFS)\"\\n2943,1,1,\"Composite Prostate Cancer Patient Response Rate (prostate cancer only)\"\\n2944,3,3,\"Composite Response Rate\"\\n2945,1,1,\"Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.\"\\n2946,1,1,\"Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab\"\\n2947,1,1,\"Comprehension of Patient Reported Outcome (PRO) Criteria\"\\n2948,1,1,\"Comprehensive response rate\"\\n2949,1,1,\"Concealment of symptoms\"\\n2950,1,1,\"Concentration of BRAF V600 Mutation as Determined on Plasma cfDNA\"\\n2951,1,1,\"concentration of HSP70 exosomes in the blood and urine\"\\n2952,1,1,\"Concentration of matrix metalloproteinases in the CSF\"\\n2953,1,1,\"Concentration of MK-2206 After 48 Hours (C48hr) in Participants Receiving Multiple QOD Dosing\"\\n2954,1,1,\"Concentration of REGN4018 in serum over time for REGN4018 monotherapy\"\\n2955,1,1,\"Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab\"\\n2956,1,1,\"Concentration of Relatlimab at the end of a dosing interval (Ctau)\"\\n2957,1,1,\"Concentration of total radioactivity in blood and plasma and percentage of radioactive dose in urine and faeces and total balance\"\\n2958,1,1,\"Concentration Slope of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22\"\\n2959,1,1,\"Concentration-time profiles and pharmacokinetic (PK) parameters of total radioactivity in whole blood and plasma; blood over plasma concentration ratios; Concentration-time profile and PK parameters of AVE8062 and RPR258063 in plasma\"\\n2960,1,1,\"Concentrations of Antibodies Against Protein D (Anti-PD)\"\\n2961,1,1,\"Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Parenchymal Brain Metastases\"\\n2962,1,1,\"Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Peripheral Blood (Plasma)\"\\n2963,1,1,\"Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) and Trametinib (Cohort B Only) in CSF Samples.\"\\n2964,1,1,\"concentrations of intratumoral kinase inhibitors upon 2 weeks of treatment\"\\n2965,1,1,\"Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or REGN4018\"\\n2966,1,1,\"Concomitant Antibiotic Prophylaxis\"\\n2967,1,1,\"Concordance among patient, caregiver, and team goals\"\\n2968,1,1,\"Concordance analysis of standardized uptake values (SUVs) between the 2 baseline scans\"\\n2969,1,1,\"Concordance between TBx and LBx at disease progression\"\\n2970,1,1,\"Conditioned nausea and vomiting as measured by Morrow assessment of nausea and emesis (MANE)\"\\n2971,1,1,\"Conduct long term safety evaluations after gene therapy\"\\n2972,1,1,\"Confidence Interval (CI) estimate of patients completing induction chemotherapy cycles\"\\n2973,1,1,\"Confirm the clinical efficacy of ipi/nivo in rare cancer histotypes which have demonstrated to be responsive to the regimen in the CA209-538 study.\"\\n2974,1,1,\"Confirm the recommended Phase 2 dose (RP2D)\"\\n2975,1,1,\"Confirm the recommended phase II dose (RP2D) of durvalumab ¬± tremelimumab in patients receiving standard chemotherapy\"\\n2976,1,1,\"Confirm the recommended phase II dose and schedule of CX5461 in patients with solid tumours\"\\n2977,1,1,\"Confirmation of Tumor Targeting as Measured by the Number of Patients With Assessable Lesions Greater Than or Equal to 2 cm Measured by FDG-PET and SPECT Imaging.\"\\n2978,1,1,\"Confirmed Best Overall Response Rate (BORR)\"\\n2979,2,1,\"Confirmed Objective Response (OR)\"\\n2980,1,1,\"Confirmed Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee\"\\n2981,1,1,\"Confirmed Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by an Independent Review Committee\"\\n2982,1,1,\"Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).\"\\n2983,1,1,\"Confirmed Objective Response Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Investigator.\"\\n2984,1,1,\"Confirmed Objective Response Rate (Breast, Cervical Cohorts)\"\\n2985,1,1,\"Confirmed objective response rate (complete and partial responses) as defined by RECIST\"\\n2986,1,1,\"Confirmed objective response rate (confirmed ORR) [assessed by IRRC]\"\\n2987,1,1,\"Confirmed objective response rate (cORR) per investigator assessment\"\\n2988,1,1,\"Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, and C)\"\\n2989,1,1,\"Confirmed objective response rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 according to investigator assessment\"\\n2990,1,1,\"Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), as Determined by Independent Central Review (ICR)\"\\n2991,8,5,\"Confirmed Objective Response Rate (ORR)\"\\n2992,3,2,\"Confirmed objective response rate (ORR)\"\\n2993,1,1,\"Confirmed objective response rate (ORR) (complete response + partial response)\"\\n2994,1,1,\"Confirmed Objective Response Rate (ORR) as Assessed by Investigator\"\\n2995,1,1,\"Confirmed objective response rate (ORR) as determined by investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\"\\n2996,1,1,\"Confirmed Objective Response Rate (ORR) as Determined by the Investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n2997,1,1,\"Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)\"\\n2998,1,1,\"Confirmed Objective Response Rate (ORR) Assessed By An Independent Review Committee\"\\n2999,1,1,\"Confirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria\"\\n3000,1,1,\"Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR)\"\\n3001,1,1,\"Confirmed objective response rate (ORR) by independent central review (ICR)\"\\n3002,1,1,\"Confirmed objective response rate (ORR) in stage ‚Ö°\"\\n3003,1,1,\"Confirmed Objective Response Rate (ORR) in the Main Cohort of the Refractory Expansion Part\"\\n3004,1,1,\"Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n3005,1,1,\"Confirmed Objective response rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment\"\\n3006,1,1,\"Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only)\"\\n3007,1,1,\"Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC)\"\\n3008,1,1,\"Confirmed objective response rate (ORR)(Part 2)\"\\n3009,1,1,\"Confirmed Objective Response Rate (ORR): Defined as the Proportion of Participants with Complete Response (CR) or Partial Response (PR) on two Consecutive Occasions >/= 4 Weeks Apart, as Determined by Blinded Independent Central Review (BICR)\"\\n3010,1,1,\"Confirmed objective response rate by RECIST 1.1 based on independent central review (ICR).\"\\n3011,1,1,\"Confirmed Objective Response Rate(ORR) assessed by independent central review(ICR).\"\\n3012,1,1,\"Confirmed Objective Tumour Response (According to RECIST Criteria)\"\\n3013,1,1,\"Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n3014,1,1,\"Confirmed ORR (cORR)\"\\n3015,1,1,\"Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments\"\\n3016,1,1,\"Confirmed Overall Response Rate (ORR)\"\\n3017,1,1,\"Confirmed overall response rate (ORR)\"\\n3018,1,1,\"Confirmed Overall Response Rate (ORR) (Complete Response (CR) and Partial Response(PR)) per RECIST V1.1 per investigator assessment\"\\n3019,1,1,\"Confirmed overall response rate (ORR) per RECIST v1.1\"\\n3020,1,1,\"Confirmed overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 assessed by Investigator\"\\n3021,1,1,\"Confirmed Overall Response Rate Per the RECIST 1.1 Criteria\"\\n3022,1,1,\"Confirmed pathologic partial response\"\\n3023,1,1,\"Confirmed Prostate Specific Antigen (PSA) Response\"\\n3024,1,1,\"Confirmed Prostate-Specific Antigen (PSA) Response\"\\n3025,1,1,\"Confirmed Prostate-specific Antigen (PSA) Response Rate\"\\n3026,4,3,\"Confirmed Response Rate\"\\n3027,2,1,\"Confirmed response rate\"\\n3028,1,1,\"Confirmed response rate (Cohort 2)\"\\n3029,1,1,\"Confirmed Response Rate (Complete and Partial)\"\\n3030,1,1,\"Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria\"\\n3031,1,1,\"Confirmed Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II Patients Only)\"\\n3032,1,1,\"Confirmed Response Rate (Partial Response [PR] or Complete Response [CR]) Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 Criteria\"\\n3033,1,1,\"Confirmed response rate as measured by clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phase\"\\n3034,1,1,\"Confirmed response rate as measured by overall response rate (ORR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phase\"\\n3035,1,1,\"Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\"\\n3036,1,1,\"Confirmed Tumor Response\"\\n3037,1,1,\"Confirmed Tumor Response (in the Differentiated Thyroid Cancer Expansion Cohort)\"\\n3038,1,1,\"Confirmed tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n3039,1,1,\"Confirmed Tumor Response Rate\"\\n3040,1,1,\"Confirmed tumor response rate (Phase II)\"\\n3041,1,1,\"Confirmed Tumor Response Rate (Proportion of Participants With Complete Response)\"\\n3042,1,1,\"Confirmed tumor response using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n3043,1,1,\"Confirmed Tumor Responses\"\\n3044,1,1,\"Connor Davidson Resilience Scale Score Change\"\\n3045,16,1,\"Consent rate\"\\n3046,2,1,\"Consent rate for germline testing\"\\n3047,1,1,\"Conspicuity\"\\n3048,1,1,\"Consumer education and training services (CENTS) financial counselors\"\\n3049,1,1,\"Continued Supply Expansion Phase: To compare the safety and tolerability of the tablet and capsule formulation of AZD2281 in all patients: Safety, AEs, Physical Exam, vital signs\"\\n3050,1,1,\"Continued Supply Phase: To enable patients to continue to receive treatment with AZD2281. Safety and tolerability data will be collected to further determine the safety and tolerability of the capsule formulation of AZD2281 in these patients\"\\n3051,1,1,\"Continuous Treatment Period: Changes in QT and QTc intervals\"\\n3052,1,1,\"Contralateral breast cancer\"\\n3053,1,1,\"Contrast-to-noise ratio (CNR)\"\\n3054,1,1,\"Contribution of the caregiver\\'s sense of caregiver burden, as measured by the caregiver version of the CDS at baseline, on increases in patient DHD over time\"\\n3055,1,1,\"Control of nausea and vomiting\"\\n3056,14,1,\"Conversion rate\"\\n3057,1,1,\"Conversion resection rate\"\\n3058,1,1,\"conversion resection rate\"\\n3059,1,1,\"Copies numbers of CAR\"\\n3060,1,1,\"Coping and resilience factors\"\\n3061,1,1,\"Coronavirus disease 2019 (COVID-19) specific psychological stress\"\\n3062,1,1,\"Coronavirus disease-2019 (COVID19)-specific psychological distress\"\\n3063,1,1,\"Correct histological diagnosis of the mass assessed by each needle\"\\n3064,1,1,\"Corrected AUC(0-t) and AUC(0-inf) of GSK1120212B\"\\n3065,1,1,\"Corrected Cmax of GSK1120212B\"\\n3066,1,1,\"Corrected tmax of GSK1120212B\"\\n3067,1,1,\"Correlate change in [18F]F AraG signal following CkIT therapy with change in level of T cell infiltration in tumor biopsies\"\\n3068,1,1,\"Correlate pharmacokinetic parameters of raltegravir and midazolam with irinotecan (CPT-11) and its metabolite SN-38\"\\n3069,1,1,\"Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN.\"\\n3070,1,1,\"Correlation analysis between periodontal status and dental plaque microbiome\"\\n3071,1,1,\"Correlation between carboplatin clearance (CL) and mGFR\"\\n3072,1,1,\"Correlation between change in [18F]FLT PET/CT and progression free and overall survival\"\\n3073,1,1,\"Correlation between clinical parameters and SARS-CoV-2 infection\"\\n3074,1,1,\"Correlation between mammography and breast CT on lesion detection\"\\n3075,1,1,\"Correlation between medication sequence and platelet aggregation\"\\n3076,1,1,\"Correlation between outcome 1 and outcome 2\"\\n3077,1,1,\"Correlation between patient genotype, tumor biomarkers and blood biomarkers with clinical outcome\"\\n3078,1,1,\"Correlation between plasma bacteria composition and prevalence of urological malignancies\"\\n3079,1,1,\"Correlation between pre-treatment computed tomography (CT) tumor perfusion parameters and percentage of patients who achieve curative (R0) surgical resection after neoadjuvant chemotherapy\"\\n3080,1,1,\"Correlation between pre-treatment CT tumor perfusion parameters and tumor response after treatment\"\\n3081,1,1,\"Correlation between stool bacteria composition and prevalence of urological malignancies\"\\n3082,1,1,\"Correlation between study questionnaire answers and patient demographics\"\\n3083,1,1,\"Correlation between study questionnaire answers and the need for additional IV\"\\n3084,1,1,\"Correlation between study questionnaire answers and time required by pharmacokinetic sampling\"\\n3085,1,1,\"Correlation between sub-solid lesions and incidence of acute events\"\\n3086,1,1,\"Correlation between sub-solid lesions and individual risk\"\\n3087,1,1,\"Correlation between the tumor load score and patient response to therapies.\"\\n3088,1,1,\"Correlation between tissue bacteria composition and prevalence of urological malignancies\"\\n3089,1,1,\"Correlation between TMB and the expression level of PD-1/PD-L1\"\\n3090,1,1,\"Correlation between urine bacteria composition and prevalence of urological malignancies\"\\n3091,1,1,\"Correlation of abscopal responses with the radiation dose received\"\\n3092,1,1,\"Correlation of aflibercept level with host antigen presenting cell phenotype at baseline\"\\n3093,1,1,\"Correlation of cerebrospinal fluid levels with plasma levels of different doses of pemetrexed disodium\"\\n3094,1,1,\"Correlation of changes in VEGF levels, serum angiogenesis, and circulating endothelial cells with response and dose levels\"\\n3095,1,1,\"Correlation of clinical response with immunological response\"\\n3096,1,1,\"Correlation of ctDNA clearance with activity of chemotherapy\"\\n3097,1,1,\"Correlation of drug PKs with clinical response and toxicity, particularly the incidence of severe liver toxicity or veno-occlusive disease\"\\n3098,1,1,\"Correlation of EGFR phosphorylation and/or BCRP expression with response to this combination\"\\n3099,1,1,\"Correlation of expression of these polymorphisms with clinical outcomes (toxicity, response, or progression status) in patients treated at the MTD\"\\n3100,1,1,\"Correlation of obesity and IR to other factors associated with the development of the MS that may be altered in the CCS\"\\n3101,1,1,\"Correlation of pre-treatment CT tumor perfusion parameters with overall survival\"\\n3102,1,1,\"Correlation of pre-treatment CT tumor perfusion parameters with progression free survival\"\\n3103,1,1,\"Correlation of promoter methylation with the level of expression of the genes\"\\n3104,1,1,\"Correlation of Relevant Markers of the Pre-identified Gene-expression Signature as Measured by Immunohistochemical Methods and by Quantitative PCR.\"\\n3105,1,1,\"Correlation of response with S6-phosphorylation and AKT-phosphorylation in archived tumor samples\"\\n3106,1,1,\"Correlation of steady-state concentrations of nivolumab correlate with clinical efficacy\"\\n3107,1,1,\"Correlation of steady-state concentrations of pembrolizumab correlate with clinical efficacy and/or toxicity\"\\n3108,1,1,\"Correlation of target tissue inhibition in tumor tissue with PMBCs and normal skin\"\\n3109,1,1,\"Correlation of toxicity profile with pharmacokinetics\"\\n3110,1,1,\"Correlation of Treatment Benefit by group\"\\n3111,1,1,\"Correlation of tumor mutations between tissue biopsy (TBx) and liquid biopsy (LBx) at diagnosis\"\\n3112,1,1,\"Correlation of tumor vascular permeability as measured by dynamic contrast-enhanced MRI with clinical outcome and with tumor angiogenesis as measured by immunohistochemistry (IHC)\"\\n3113,1,1,\"Correlation of ‚Å∏‚ÅπZr-Df-IAB22M2C uptake in biopsied tumors with CD8+ cell measurement by immunohistochemistry (IHC)\"\\n3114,8,1,\"cost-effectiveness\"\\n3115,1,1,\"cost-effectiveness of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model\"\\n3116,1,1,\"Count of Participants That Achieve Pathologic Complete Response (PCR)\"\\n3117,1,1,\"Count of Participants Who Experienced Adverse Events, Evaluated According to the Current Guidelines in National Cancer Institute (NCI) Common Toxicity Criteria Version 4.0\"\\n3118,1,1,\"Count of Participants With a Partial Response (PR) and Complete Response (CR) to Lapatinib Who Have Metastatic Melanoma Harboring ERBB4 Mutations.\"\\n3119,1,1,\"Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine\"\\n3120,1,1,\"Count of Participants With Dose-Limiting Toxicities (DLT)\"\\n3121,1,1,\"Count of Participants With Serious and Non-Serious Adverse Events\"\\n3122,2,1,\"Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)\"\\n3123,1,1,\"Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) Who Were Administered SS1P and Pentostatin or Cyclophosphamide\"\\n3124,1,1,\"Count of Participants With SS1P Antibody Formation\"\\n3125,1,1,\"Count of participants with treatment-emergent adverse events\"\\n3126,1,1,\"Count of Patients for Which T Cells Are Successfully Generated and Infused and Whether Only TN or TCM Could be Generated\"\\n3127,1,1,\"Counts of ‚â• Grade 3 Adverse Events (AE) Graded by CTCAE v4 (Common Terminology Criteria for Adverse Events) That Are Definitely, Probably, or Possibly Related to Treatment (DPPRT)\"\\n3128,1,1,\"COVID-19 experiences and COVID-19 specific distress\"\\n3129,1,1,\"COVID-19 related hospitalizations (Yes/No)\"\\n3130,2,1,\"COVID-19-specific financial and social disruptions\"\\n3131,2,1,\"COVID-19-specific health\"\\n3132,2,1,\"COVID-19-specific health related quality of life (HRQoL)\"\\n3133,2,1,\"COVID-19-specific perceived benefits and social support\"\\n3134,2,1,\"COVID-19-specific psychological distress\"\\n3135,1,1,\"CPG format which is well understood by pediatric oncology healthcare providers (Aim 3)\"\\n3136,2,1,\"CR Rate\"\\n3137,16,1,\"CR rate\"\\n3138,1,1,\"CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.\"\\n3139,1,1,\"Create a data registry of clinical and molecular/genomic data\"\\n3140,1,1,\"Creatinine clearance according to Cockroft-Gault equation\"\\n3141,1,1,\"Creatinine concentration in whole blood sample\"\\n3142,1,1,\"Creatinine Value.\"\\n3143,1,1,\"Creation of a Fanconi Anemia Cell Repository using rare solid tumor samples from patients with Fanconi anemia\"\\n3144,1,1,\"Creation of a Geriatric-Oncology database\"\\n3145,1,1,\"Creation of a registry of older patients within the University of North Carolina\\'s healthcare system\"\\n3146,1,1,\"Creation of data repository for patient characteristics, treatment, and pregnancy outcome data\"\\n3147,1,1,\"CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue\"\\n3148,1,1,\"Cross-Over Pharmacokinetic Phase: To compare plasma concentrations, investigate the plasma and urine pharmacokinetic profiles, and to evaluate the duration of DPD inhibition after the administration of S-1\"\\n3149,1,1,\"Cross-validate the in-house genetic testing platform against the FDA approved Foundation Medicine\"\\n3150,1,1,\"CS-7017-Related Treatment-Emergent Adverse Events Occurring During the Study of Administration of CS-7017 Combined With Erlotinib in Participants With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer Who Failed First-line Therapy\"\\n3151,1,1,\"CSALTS Pain Survey\"\\n3152,1,1,\"CSALTS Sleep Survey\"\\n3153,1,1,\"CT assessment\"\\n3154,1,1,\"CTC, CEC or ctDNA incidence\"\\n3155,1,1,\"CTC-AXL measurement concordance rate\"\\n3156,1,1,\"CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome\"\\n3157,1,1,\"CTCAE version 4.03\"\\n3158,1,1,\"ctDNA Response Rate\"\\n3159,1,1,\"ctDNA response: The proportion of participants with a <50% ratio of mean variant allele frequency (VAF) will be defined as ctDNA responders.\"\\n3160,1,1,\"Ctrough (PK)\"\\n3161,1,1,\"Ctrough Following Steady State Exposure for 14 Days\"\\n3162,1,1,\"Ctrough of Mogamulizumab\"\\n3163,1,1,\"Ctrough of RO5185426 on Day 19\"\\n3164,1,1,\"Ctrough of RO5185426 on Day 21\"\\n3165,1,1,\"cTTP\"\\n3166,1,1,\"Cultivate a repository for assay development\"\\n3167,1,1,\"Cumulative Amount Excreted in Feces of Idasanutlin Metabolite\"\\n3168,1,1,\"Cumulative Amount Excreted in Feces of Unlabeled Idasanutlin\"\\n3169,1,1,\"Cumulative Amount Excreted in Urine of Idasanutlin Metabolite\"\\n3170,1,1,\"Cumulative Amount Excreted in Urine of Unlabeled Idasanutlin\"\\n3171,1,1,\"Cumulative Amount of Radioactivity Excreted in Feces as Percentage of Dosed Radioactivity of [14C]-Labeled Idasanutlin\"\\n3172,1,1,\"Cumulative Amount of Radioactivity Excreted in Feces on Toilet Tissue as Percentage of Dosed Radioactivity of [14C]-Labeled Idasanutlin\"\\n3173,1,1,\"Cumulative Amount of Radioactivity Excreted in Urine as Percentage of Dosed Radioactivity of [14C]-Labeled Idasanutlin\"\\n3174,1,1,\"Cumulative CTCAE grade ‚â• 4 SABR related toxicity (TRAE).\"\\n3175,1,1,\"Cumulative Dose of Panitumumab\"\\n3176,1,1,\"Cumulative double strand deoxyribonucleic acid (dsDNA) damage of normal tissue\"\\n3177,1,1,\"Cumulative elimination of total [14C]-radioactivity (as a fraction of the radioactive dose) in urine and feces (and vomit, if applicable)\"\\n3178,1,1,\"Cumulative excretion of 14C-labeled Anlotinib (radioactivity in feces)\"\\n3179,1,1,\"Cumulative excretion of 14C-labeled Anlotinib (radioactivity in urine)\"\\n3180,1,1,\"Cumulative excretion of 14C-labeled gilteritinib (radioactivity in feces)\"\\n3181,1,1,\"Cumulative excretion of 14C-labeled gilteritinib (radioactivity in urine)\"\\n3182,1,1,\"Cumulative excretion of Anlotinib (in urine)\"\\n3183,1,1,\"Cumulative incidence of symptomatic venous and arterial thromboembolism, in patients with metastatic or locally advanced solid tumors undergoing chemotherapy\"\\n3184,1,1,\"Cumulative maximum tolerated dose (MTD)\"\\n3185,1,1,\"Cumulative maximum tolerated dose (MTD) and recommended phase II dose 225Ac-J591 and 177Lu-PSMA I&T\"\\n3186,1,1,\"Cumulative Percentage of [14C]-AZD2014 Recovered by Day 8\"\\n3187,1,1,\"Cumulative Percentage of Total [14C] Radioactivity Excreted in Stool as a Percentage of the Dose (fe Cum%[f])\"\\n3188,1,1,\"Cumulative Percentage of Total [14C] Radioactivity Excreted in Urine as a Percentage of the Dose (fe Cum%[R])\"\\n3189,1,1,\"Cumulative Recovery of Total Radioactivity in Total Excreta\"\\n3190,1,1,\"Cumulative relative abundance of immunotherapy-responsiveness associated species at day 12 of MET-4\"\\n3191,1,1,\"Cumulative Urinary Excretion of Pamiparib\"\\n3192,1,1,\"Cumulative whole blood:plasma ratio calculated for AUC0-tlast\"\\n3193,1,1,\"Cumulative whole blood:plasma ratio calculated for AUCinf\"\\n3194,1,1,\"Cumulative whole blood:plasma ratio calculated for Cmax\"\\n3195,1,1,\"CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.\"\\n3196,3,1,\"Curative resection rate\"\\n3197,1,1,\"curative resection rate\"\\n3198,1,1,\"cuSCC: Assess the effect of ASP-1929 PIT treatment with anti-PD1 therapy on tumor response\"\\n3199,1,1,\"Cutaneous sensation as measured by Semmes-Weinstein monofilaments\"\\n3200,1,1,\"Cycle 1+2 AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of BAY94-9343 analytes\"\\n3201,1,1,\"Cycle 1+2 AUC(0-tlast) (AUC from time zero to the last data point > LLOQ [lower limit of quantification]) of BAY94-9343 analytes\"\\n3202,1,1,\"Cycle 1+2 Cmax (maximum drug concentration in plasma after the first dose administration) of BAY94-9343 analytes\"\\n3203,1,1,\"Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab\"\\n3204,1,1,\"CYP3A4\"\\n3205,1,1,\"CYP3A5 genotype\"\\n3206,2,1,\"Cytokine Release Syndrome (CRS)\"\\n3207,1,1,\"Cytological diagnostic accuracy of EUS FNA, for \"\"fast\"\" and \"\"slow\"\" passages\"\\n3208,1,1,\"Cytotoxic T-cell Lymphocytes (CTL) Response Rate\"\\n3209,1,1,\"Daily Adherence\"\\n3210,1,1,\"Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1\"\\n3211,1,1,\"Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15\"\\n3212,1,1,\"Dalotuzumab mean serum trough concentration\"\\n3213,1,1,\"Dalotuzumab mean serum trough concentration in combination therapy\"\\n3214,1,1,\"Data Gathering\"\\n3215,1,1,\"Database of somatic mutations and clinical characteristics\"\\n3216,1,1,\"Date and nature of post-diagnosis surgery or biopsy\"\\n3217,1,1,\"Dates of Genomic or Genetic Testing\"\\n3218,1,1,\"Days to ANC Greater Than or Equal to 1,000/uL From the Start of Chemotherapy\"\\n3219,1,1,\"DB Phase: Time to Prostate-Specific Antigen Progression (PSA)\"\\n3220,11,3,\"DCR\"\\n3221,1,1,\"DCR (phase 2)\"\\n3222,246,1,\"Death\"\\n3223,1,1,\"Death during the study\"\\n3224,2,1,\"Death From GVHD\"\\n3225,1,1,\"Death From Regimen Toxicity or Opportunistic Infection\"\\n3226,1,1,\"Death Within 8 Weeks of Infusion\"\\n3227,1,1,\"Decline of prostate specific antigen (PSA) of ‚â•20%\"\\n3228,1,1,\"Decrease in ctDNA Level\"\\n3229,1,1,\"Decrease in Ki-67 mRNA following treatment with entinostat across TNBC breast cancers\"\\n3230,1,1,\"Decrease in regulatory T cells (Treg) or tumor-associated macrophage (TAM) in tumor samples\"\\n3231,1,1,\"Decrease in Tumor Size.\"\\n3232,1,1,\"defection time\"\\n3233,3,3,\"Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD)\"\\n3234,1,1,\"Define a recommended Phase 2 dose (RP2D) of NC410 when combined with standard dose Pembrolizumab\"\\n3235,1,1,\"Define dose limiting adverse events associated with the combination\"\\n3236,1,1,\"Define maximum tolerated dose and identify dose limiting toxicities following IV administration of GPX-150 for Injection once every 3 weeks\"\\n3237,1,1,\"Define outcomes for patients treated at participating institutions\"\\n3238,1,1,\"Define recommended phase 2 dose (RP2D)\"\\n3239,1,1,\"Define RP2D\"\\n3240,1,1,\"Define the Duration of Response (DOR) of ORM-5029 based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [Dose Expansion Only]\"\\n3241,1,1,\"Define the Maximum Tolerated Dose (MTD) and Recommended Phase Two Dose (RPTD) of the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous NSCLC.\"\\n3242,1,1,\"Define the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10 during the dose escalation phase\"\\n3243,1,1,\"Define the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-4during the dose escalation phase\"\\n3244,1,1,\"Define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator NAT2 genotype (NAT2 5, NAT2 6, NAT2 7, or NAT2 14) patients with solid tumors and lymphomas.\"\\n3245,1,1,\"Define the Measurable Disease Response Rate.\"\\n3246,1,1,\"Define the MTD\"\\n3247,1,1,\"Define the MTD of the combination of CC-5013 and paclitaxel in patients with advanced solid tumors\"\\n3248,2,2,\"Define the objective response rate (ORR)\"\\n3249,1,1,\"Define the Objective Response Rate (ORR) of ORM-5029 based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [Dose Expansion Only]\"\\n3250,1,1,\"Define the PSA Response Rate.\"\\n3251,1,1,\"Define the recommended dose level for PT-112(Phase I)\"\\n3252,3,3,\"Define the Recommended Phase 2 Dose\"\\n3253,2,2,\"Define the Recommended Phase 2 Dose (RP2D)\"\\n3254,1,1,\"Define the safety and tolerability of AT13387; establishing the MTD of At13387\"\\n3255,1,1,\"Define the toxicities and characterize pharmacokinetics\"\\n3256,1,1,\"Define the toxicity of 131I-8H9 administered intraperitoneally.\"\\n3257,1,1,\"Define the toxicity spectrum of Marqibo in children with cancer\"\\n3258,1,1,\"Define Toxicities - CTCAE v5.0\"\\n3259,1,1,\"Define toxicities and pharmacokinetics.\"\\n3260,1,1,\"Defining the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of BTX-A51\"\\n3261,2,1,\"Defining the RP2D of ZX-101A\"\\n3262,1,1,\"Definite deterioration of moderate EORTC QLQ-C30 Score\"\\n3263,1,1,\"Definition of radiogenomics signatures that are predictive of patient outcome\"\\n3264,1,1,\"Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS\"\\n3265,1,1,\"Definition of tumor mutational burden, epigenetic and gene expression profile of the CRC and PDAC metastatic liver at bulk and at single cell level\"\\n3266,1,1,\"Degree of cellularity in biopsy sample\"\\n3267,1,1,\"Degree of Demethylation in Patient Tumor Tissue and/or Serum Induced by 5-azacitidine on Specific Tumor Specific Genes (TSGs)\"\\n3268,1,1,\"Degree of interpatient variation of drug PKs\"\\n3269,1,1,\"Degree of vascularization of the skin\"\\n3270,1,1,\"Delayed nausea by Marrow Assessment of Nausea and Emesis at 1, 3, and 6 weeks after study completion\"\\n3271,1,1,\"Demographic and/or physiological factors that are determinants of dactinomycin and VCR disposition\"\\n3272,1,1,\"Demonstrate that VS-6063 (defactinib), will improve PFS at 12 weeks (PFS12) within each cohort.\"\\n3273,1,1,\"Demonstrate the efficacy of intratumoral tilsotolimod in combination with ipilimumab and nivolumab for each cohort\"\\n3274,1,1,\"Deoxyribonucleic acid (DNA) alterations\"\\n3275,207,2,\"Depression\"\\n3276,1,1,\"Depression - Yesavage Test\"\\n3277,1,1,\"Depression as measured by Center for Epidemiology-Depression (CES-D)\"\\n3278,1,1,\"Depression severity as measured by Hamilton Depression rating scale.\"\\n3279,1,1,\"DES and EXP: Safety and Tolerability\"\\n3280,1,1,\"DES: Maximum tolerated dose or recommended Phase 2 dose\"\\n3281,1,1,\"Describe Impact of Information Derived from Exome Sequencing\"\\n3282,1,1,\"Describe physical activity profiles in breast cancer patients over 70 years of age\"\\n3283,1,1,\"Describe sleep profiles in breast cancer patients over 70 years of age\"\\n3284,1,1,\"Describe the clinical activity and safety profile of sorafenib in the treatment of patients with advanced thyroid cancer (metastatic or recurrent) among a selected group of patients refractory to or ineligible to radioactive iodine (RAI) therapy\"\\n3285,1,1,\"Describe the incidence of Dose-intensity limiting toxicities\"\\n3286,1,1,\"Describe the Number and Type of Observed Dose Limiting Toxcities\"\\n3287,1,1,\"Describing toxicities of PAZIT drug combination using NCI CTCAE Version 4.0\"\\n3288,1,1,\"Description of 89Zr-MPDL3280A PK by measuring standardized uptake value (SUV) on the 89Zr-MPDL3280A-PET scans\"\\n3289,1,1,\"Description of biodistribution patterns of [68Ga]Ga-NOTA-SNA002 on PET\"\\n3290,1,1,\"Description of immune effectors in the blood, marrow and tumor diagnosis.\"\\n3291,1,1,\"Description of one or several blood cell types producing soluble PD-L1 in DLBCL, metastatic breast cancer, Hodgkin\\'s lymphoma and non-small cell lung cancer\"\\n3292,3,1,\"Description of patient characteristics at baseline\"\\n3293,1,1,\"Description of patient journey\"\\n3294,1,1,\"Description of PK profile in terms of area under plasma concentration-time curve from zero extrapolated to infinity (AUC)\"\\n3295,1,1,\"Description of PK profile in terms of area under plasma concentration-time curve to time of last measurable concentration (AUC[0-t]) for selumetinib if AUC is not reportable in more than 80% of subjects\"\\n3296,1,1,\"Description of regions of interest (ROI) 89Zr-KN035 by measuring standardized uptake value (SUV) on 89Zr-KN035 PET scans\"\\n3297,1,1,\"Description of standard pain management methods and outcomes in the hospice setting\"\\n3298,1,1,\"Description of the characteristics of patients\"\\n3299,1,1,\"Description of the pharmacokinetic(PK) profile in terms of maximum observed plasma concentration (Cmax)\"\\n3300,1,1,\"Description of Treatment Patterns Used for cHL or sALCL\"\\n3301,1,1,\"Descriptive analysis of possible neurocognitive deficits according to the pathology and treatments received.\"\\n3302,1,1,\"Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Area under curve [AUC]\"\\n3303,1,1,\"Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Area under curve [Cmax]\"\\n3304,1,1,\"Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Clearance (CL)\"\\n3305,1,1,\"Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Ratio of unencapsulated to encapsulated drug over time for Caelyx and TLD-1\"\\n3306,1,1,\"Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Terminal half life [t¬Ω]\"\\n3307,1,1,\"Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: volume of distribution [Vd]\"\\n3308,1,1,\"Det. the max tolerated dose,biologically active doses & recommended phase 2 dose of BMS-599626 when adm. as a daily oral dose to pts with HER2 expressing-metastatic solid tumors who have progressed on or following standard therapy\"\\n3309,1,1,\"Detailed adverse events post NKG2D-based CAR-T therapy.\"\\n3310,1,1,\"Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC.\"\\n3311,1,1,\"Detection (presence/absence) of specific biomarker targets (SRY, HER2, PIK3CA, AR-V7, TMPRSS2-ERG) for pregnant women, breast cancer patients and prostate cancer patients measured using ddPCR\"\\n3312,1,1,\"Detection (quantitative) of [89Zr]-Df-CriPec¬Æ docetaxel in tumour lesions (the short axis diameter of a visually assessable and quantifiable lesion must be ‚â• 2 cm)\"\\n3313,1,1,\"Detection (visual) of [89Zr]-Df-CriPec¬Æ docetaxel in tumour lesions (the short axis diameter of a visually assessable and quantifiable lesion must be ‚â• 2 cm)\"\\n3314,1,1,\"Detection by Polymerase Chain Reaction (PCR) of specific genetic alterations\"\\n3315,1,1,\"Detection of at least one molecular and/ or genetic alteration.\"\\n3316,1,1,\"Detection of cancer or non-cancer using Harbinger Test\"\\n3317,1,1,\"Detection of cancer signal in the cancer cohort\"\\n3318,1,1,\"Detection of signal in the presence of active neoplasm\"\\n3319,1,1,\"Detection of specific genetic alterations of tumoral cells in peripheral samples\"\\n3320,1,1,\"Detection of tissue of origin signal in the cancer cohort\"\\n3321,1,1,\"detection rate of 68Ga-PSMA PET/CT\"\\n3322,1,1,\"Deterioration of Moderate EORTC QLQ-C30 Score\"\\n3323,1,1,\"Deterioration of severe EORTC QLQ-C30\"\\n3324,1,1,\"Deterioration of severe QLQ-C30\"\\n3325,1,1,\"Determination of a RP2D for JTX-8064 monotherapy and in combination with JTX-4014 or pembrolizumab\"\\n3326,1,1,\"Determination of anti-tumor activity of BBP-398\"\\n3327,1,1,\"Determination of appropriate patient populations for future pivotal studies based on overall response rate (ORR) and clinical benefit rate (CBR) as assessed by RECISTv1.1\"\\n3328,1,1,\"Determination of Clinical Benefit (CB), Defined as Sum of Patients Who Present Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ‚â•12 Weeks (CB=CR+PR+SD‚â•12 Weeks) Using Response Evaluation Criteria in Solid Tumors (RECIST Version1.1)\"\\n3329,1,1,\"Determination of DLT and MTD (Part A)\"\\n3330,1,1,\"Determination of Dose Limiting Toxicities (DLT)\"\\n3331,2,2,\"Determination of Dose Limiting Toxicities and Maximum Tolerated Dose\"\\n3332,1,1,\"Determination of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of single and repeated intravenous infusion with Atu027 in subjects with advanced solid tumors\"\\n3333,1,1,\"Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n3334,1,1,\"Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.\"\\n3335,1,1,\"Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside\"\\n3336,1,1,\"Determination of maximal tolerated dose (MTD)\"\\n3337,6,3,\"Determination of Maximum Tolerated Dose (MTD)\"\\n3338,3,1,\"Determination of maximum tolerated dose (MTD)\"\\n3339,3,2,\"determination of maximum tolerated dose (MTD)\"\\n3340,1,1,\"Determination of Maximum Tolerated Dose (MTD) and establish the RP2D of BBP-398.\"\\n3341,1,1,\"Determination of Maximum Tolerated Dose (MTD) and Expansion Dose Level (EDL) [Dose Escalation Only]\"\\n3342,1,1,\"Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-2608 as a single agent\"\\n3343,1,1,\"Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrant\"\\n3344,1,1,\"Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-4008\"\\n3345,1,1,\"determination of maximum tolerated dose (MTD) and recommended Phase 2 dose for patients with UGT1A1*28 genotype (wt/wt and wt/*28)\"\\n3346,1,1,\"Determination of Maximum Tolerated Dose (MTD) during dose escalation\"\\n3347,1,1,\"Determination of Maximum Tolerated Dose (MTD) of BBP-398\"\\n3348,1,1,\"Determination of Maximum Tolerated Dose (MTD) of ET0038\"\\n3349,1,1,\"Determination of Maximum Tolerated Dose (MTD) of ET0111\"\\n3350,1,1,\"Determination of Maximum Tolerated Dose (MTD) of GH21.\"\\n3351,1,1,\"Determination of maximum tolerated dose (MTD) of PG545\"\\n3352,2,2,\"Determination of maximum tolerated dose (MTD) or highest tested dose (HTD).\"\\n3353,1,1,\"Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data\"\\n3354,1,1,\"Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects\"\\n3355,1,1,\"Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab\"\\n3356,1,1,\"Determination of maximum tolerated dose of claudiximab (Phase I: toxicities as assessed by NCI CTCAE version 3.0)\"\\n3357,1,1,\"Determination of maximum-tolerated dose (MTD)\"\\n3358,1,1,\"Determination of MTAP status in tumors\"\\n3359,6,2,\"Determination of MTD\"\\n3360,1,1,\"Determination of MTD and RP2D\"\\n3361,1,1,\"Determination of MTD of ECO-4601\"\\n3362,1,1,\"Determination of MTD of HC-5404-FU\"\\n3363,1,1,\"Determination of MTD of HC-7366\"\\n3364,1,1,\"Determination of MTD/RD\"\\n3365,1,1,\"Determination of MTD; Phase Ib\"\\n3366,1,1,\"Determination of optimal dose of 225Ac-J591 for phase II\"\\n3367,1,1,\"Determination of Phase 2 dose of NM21-1480\"\\n3368,1,1,\"Determination of recommended dose for future studies of ECO-4601\"\\n3369,1,1,\"Determination of recommended Part 2 dose (Part 1)\"\\n3370,2,2,\"Determination of Recommended Phase 2 Dose (RP2D)\"\\n3371,1,1,\"Determination of Recommended Phase 2 Dose (RP2D) of BVD-523 by Dose-limiting Toxicities (DLT).\"\\n3372,1,1,\"Determination of recommended phase 2 dose (RP2D) regimen\"\\n3373,1,1,\"Determination of Recommended Phase 2 Dose (RP2D): safety, preliminary efficacy (based on objective response rate (ORR) defined as the proportion of patients with a complete or partial response) and pharmacokinetics\"\\n3374,1,1,\"Determination of Recommended Phase 2 dose of HC-7366\"\\n3375,1,1,\"Determination of recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2\"\\n3376,1,1,\"Determination of Recommended Phase II dose (RP2D) ÔºàPhase 1bÔºâ\"\\n3377,1,1,\"Determination of Recommended Phase II Dose of MnSOD/Plasmid DNA\"\\n3378,1,1,\"determination of soluble B2M\"\\n3379,1,1,\"determination of soluble PDL1\"\\n3380,1,1,\"Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.\"\\n3381,1,1,\"Determination of the frequency and causality of each adverse event\"\\n3382,1,1,\"Determination of the long-term effect of AV0113 by counting the total survival time in days measured from inclusion time point to death.\"\\n3383,1,1,\"Determination of the maximal dose\"\\n3384,1,1,\"Determination of the maximum dose\"\\n3385,1,1,\"Determination of the Maximum Tolerated Dose\"\\n3386,2,1,\"Determination of the Maximum Tolerated Dose (MTD)\"\\n3387,7,5,\"Determination of the maximum tolerated dose (MTD)\"\\n3388,1,1,\"Determination of the maximum tolerated dose (MTD) and overall safety of SU011248 when administered in combination with paclitaxel/carboplatin in patients with advanced solid tumors (ongoing)\"\\n3389,1,1,\"Determination of the maximum tolerated dose (MTD) by occurrence of dose limiting toxicities (DLT)\"\\n3390,1,1,\"Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.\"\\n3391,1,1,\"Determination of the Maximum Tolerated Dose (MTD) of Single-fraction Stereotactic Body Radiation Therapy (SF-SBRT) in Hepatic Metastases.\"\\n3392,1,1,\"Determination of the maximum tolerated dose (MTD) of VLX600\"\\n3393,1,1,\"Determination of the Maximum Tolerated Dose (MTD) Recommended Phase 2 Dose (RP2D) of BNA035 in patients with advanced solid tumors.\"\\n3394,2,1,\"Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose\"\\n3395,1,1,\"Determination of the maximum tolerated dose based on the incidence of dose limiting toxicities (phase 1b only)\"\\n3396,1,1,\"Determination of the MTD of 2X-121 monotherapy.\"\\n3397,1,1,\"Determination of the MTD of dovitinib given in combination with 2X-121 (MTD).\"\\n3398,1,1,\"Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT)\"\\n3399,1,1,\"Determination of the MTD of VPA in combination with temozolomide and Whole-Brain Radiation\"\\n3400,1,1,\"Determination of the MTD or RP2D of LNS8801 dosed alone and in combination with pembrolizumab\"\\n3401,1,1,\"Determination of the MTD. It will be defined by the occurrence of dose-limiting toxicities (DLT) during the first treatment cycle of each patient\"\\n3402,1,1,\"Determination of the Optimal Long Exposure Dose (OLED)\"\\n3403,1,1,\"Determination of the Optimal Tolerated Regimen (OTR) based on the occurrence of Dose Limiting Toxicities\"\\n3404,1,1,\"Determination of the Pharmacokinetic profile of BAY94-9343 and its metabolites (ADC, Total Antibody, DM4 and DM4-Me)\"\\n3405,1,1,\"Determination of the recommended dose of I-131-CLR1404 in treating subjects with relapsed or refractory advanced solid malignancies\"\\n3406,1,1,\"Determination of the Recommended for Phase 2 Dose (RP2D) (mg)\"\\n3407,1,1,\"Determination of the recommended Phase 2 dose\"\\n3408,1,1,\"Determination of the recommended Phase 2 dose (RP2D)\"\\n3409,4,4,\"Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)\"\\n3410,1,1,\"Determination of the Recommended Phase 2 Dose (RP2D) of DSP-0509 for the Dose Expansion part by assessing dose-limiting toxicities (DLTs)\"\\n3411,1,1,\"Determination of the Recommended Phase 2 Dose (RP2D) to be used in Phase 2a of the study\"\\n3412,1,1,\"Determination of the Recommended Phase 2 Dose by Assessing Dose-limiting Toxicities (DLTs)\"\\n3413,1,1,\"Determination of the Recommended Phase 2 Dose of BBI608 and BBI503 when administered in combination based on DLT criteria, pharmacokinetic/pharmacodynamic observations and tolerability overall\"\\n3414,1,1,\"Determination of the Recommended Phase II Dose (RP2D)\"\\n3415,1,1,\"Determination of the recommended Phase II dose (RPTD) of VLX600\"\\n3416,1,1,\"Determination of the Recommended Phase II Dose for Napabucasin and Amcasertib Arm in Combination With Sorafenib\"\\n3417,1,1,\"Determination of the relative bioavailability of ARQ 197 tablet formulation with capsule C formulation\"\\n3418,1,1,\"Determination of the safety and tolerability of BBI503 administered in combination with selected anti-cancer therapeutics by assessing dose-limiting toxicities (DLTs)\"\\n3419,1,1,\"Determination of the safety and tolerability of BBI608 administered in combination with selected immunotherapeutic agent by assessing dose-limiting toxicities (DLTs)\"\\n3420,1,1,\"Determination of the safety and tolerability of BBI608 and BBI503 when administered in combination by assessing dose-limiting toxicities (DLTs)\"\\n3421,1,1,\"Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)\"\\n3422,1,1,\"Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing duration of study treatment\"\\n3423,1,1,\"Determination of the Safety and Tolerability of INCB001158 as a Single Agent and in Combination With Pembrolizumab: Incidence of Adverse Events\"\\n3424,1,1,\"Determination of the Safety and Tolerability of INCB053914 as Measured by the Number of Participants With Adverse Events\"\\n3425,1,1,\"determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors\"\\n3426,1,1,\"Determination of tolerability and maximum tolerated dose (MTD) of CAL056 mesylate by DLTs using NCI CTCAE version 5.0\"\\n3427,1,1,\"Determination of whether ‚â• 50% of patients utilize nicotine for treating \"\"hunger pain\"\" ‚â• 2 times over a 48-hour period\"\\n3428,1,1,\"Determine alternative dose of interest (ADI) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.\"\\n3429,1,1,\"Determine antitumor activity based on Objective Response Rate (ORR) in Part 2 in patients with NSCLC with targeted mutation\"\\n3430,1,1,\"Determine change in signal after surgery\"\\n3431,1,1,\"Determine confirmed objective response (ORR) with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma\"\\n3432,1,1,\"determine disease response following 2 or 3 CPX-POM treatment cycles by assessing the complete and partial pathologic response rate at the time of radical cystectomy (RC)\"\\n3433,1,1,\"Determine DLTs and RP2Ds in AMXT 1501 in combination with DFMO\"\\n3434,1,1,\"Determine DLTs and RP2Ds in AMXT 1501 in combination with IV DFMO\"\\n3435,1,1,\"Determine Dose Level\"\\n3436,1,1,\"Determine dose limiting toxicities (DLT)\"\\n3437,1,1,\"Determine dose limiting toxicities (DLT) of Marqibo¬Æ administered as a 60 minute intravenous infusion weekly (every 28 days constitute 1 cycle), in children and adolescents with refractory solid tumors and hematologic malignancies.\"\\n3438,1,1,\"Determine Dose limiting toxicities (DLT)and maximum tolerated dose ( MTD) (Part 1 escalation and Part 2 safety run-in)\"\\n3439,1,1,\"Determine dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of iv infusions of AsiDNA.\"\\n3440,1,1,\"Determine dose-limiting toxicities (DLTs) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.\"\\n3441,1,1,\"Determine dose-limiting toxicities and maximum tolerated dose of TKM-080301\"\\n3442,1,1,\"Determine feasibility of using 18F-DCFPyL to detect cancer\"\\n3443,2,2,\"Determine incidence of Treatment Emergent Adverse Events\"\\n3444,1,1,\"Determine incidence of Treatment Emergent Adverse Events (TEAE)\"\\n3445,2,2,\"Determine Maximum Tolerated Dose\"\\n3446,4,2,\"Determine maximum tolerated dose\"\\n3447,5,2,\"Determine maximum tolerated dose (MTD)\"\\n3448,2,2,\"Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)\"\\n3449,1,1,\"Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of NPI-0052\"\\n3450,1,1,\"Determine maximum tolerated dose (MTD) of ABI-011\"\\n3451,1,1,\"Determine Maximum Tolerated Dose (MTD) of BP31510\"\\n3452,1,1,\"Determine maximum tolerated dose (MTD) of C7R-GD2.CART Cells\"\\n3453,1,1,\"Determine maximum tolerated dose (MTD) of copanlisib with fixed dose nivolumab\"\\n3454,1,1,\"Determine Maximum Tolerated Dose (MTD) of FT538\"\\n3455,1,1,\"Determine maximum tolerated dose (MTD) of oral irinotecan\"\\n3456,1,1,\"Determine Maximum Tolerated Dose (MTD) of Topical Compound 31543\"\\n3457,1,1,\"Determine maximum tolerated dose (MTD) of weekly docetaxel in combination with etanercept.\"\\n3458,1,1,\"Determine Maximum Tolerated Dose (MTD) or recommended Phase 2 Dose (RP2D)\"\\n3459,1,1,\"Determine maximum tolerated dose (MTD)for LBH 589 in combination with Sorafenib and establish a recommended phase 2 dose for each drug combination\"\\n3460,1,1,\"Determine maximum tolerated dose and anti-tumor activity of BMS-863233 when administered to subjects with advanced and/or Metastatic solid tumors\"\\n3461,1,1,\"Determine maximum tolerated dose and RP2D administered once daily on Days 1-7\"\\n3462,1,1,\"Determine maximum tolerated dose and RP2D administered po BID on Days 1-7\"\\n3463,1,1,\"Determine Maximum Tolerated Dose based on the occurrence of dose-limiting toxicities.\"\\n3464,1,1,\"Determine Maximum Tolerated Dose of BPU\"\\n3465,1,1,\"Determine maximum tolerated dose of drug combination\"\\n3466,2,2,\"determine maximum tolerated dose of single agent LDE225\"\\n3467,1,1,\"Determine maximum tolerated dose of the drug\"\\n3468,1,1,\"Determine Maximum Tolerated Dose of TRC105 in Combination With Bevacizumab\"\\n3469,1,1,\"Determine maximun tolerated dose (MTD) of FF-10832\"\\n3470,1,1,\"Determine maximun tolerated dose (MTD) of FF-10850\"\\n3471,1,1,\"Determine minimal dose\"\\n3472,1,1,\"Determine MTD (maximum tolerated dose) through assessment of dose-limiting toxicities (DLT)\"\\n3473,2,1,\"Determine MTD/RP2D\"\\n3474,1,1,\"Determine number and types of genomic alterations within tumor types/subtypes\"\\n3475,1,1,\"Determine number of patients experiencing dose limiting toxicities\"\\n3476,1,1,\"Determine Objective Response Rate\"\\n3477,1,1,\"Determine Objective Response Rate (either Complete Response or Partial Response) as determined by RECIST v1.1 guidelines\"\\n3478,1,1,\"Determine of Marqibo¬Æ administered as a 60 minute intravenous infusion weekly (every 28 days constitute 1 cycle), in children and adolescents with refractory solid tumors and hematologic malignancies.\"\\n3479,1,1,\"Determine of the Maximum Tolerated Dose (MTD) of BBI503 monotherapy and in combination with Sorafenib by assessing dose-limiting toxicities (DLTs)\"\\n3480,1,1,\"Determine Overall Response Rate - Phase 2\"\\n3481,1,1,\"Determine Pathologic Complete Response\"\\n3482,1,1,\"Determine patient\\'s safety (# of adverse events/serious adverse events) and tolerability of MM-111 in combination with multiple treatment regimens\"\\n3483,1,1,\"Determine pediatric neoplastic response to proposed chemotherapy. Evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1 expression analysis.\"\\n3484,1,1,\"Determine perioperative PET/CT imaging combined with intraoperative use of handheld gamma probe is feasible during surgical procedure to resect malignancy.\"\\n3485,1,1,\"Determine pharmacodynamic change using FLT-PET/CT scans at baseline, during axitinib exposure and washout\"\\n3486,1,1,\"Determine Pharmacokinetic profile\"\\n3487,1,1,\"Determine preliminary estimates of efficacy, measured by RECIST 1.1 criteria, for ADI-PEG 20 combo with doxorubicin in HER2 negative metastatic breast cancer.\"\\n3488,1,1,\"Determine Progression Free Survival as determined by RECIST v1.1 guidelines\"\\n3489,1,1,\"Determine Progression-free Survival following Treatment (Phase 2)\"\\n3490,1,1,\"Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study\"\\n3491,1,1,\"Determine recommended dose for Phase 2 study of CT-322\"\\n3492,1,1,\"Determine recommended dose of Bendamustine when used in combination with Stereotactic Radiotherapy (STR) for treatment of patients with 1-4 brain metastases.\"\\n3493,2,2,\"Determine Recommended Phase 2 Dose (RP2D)\"\\n3494,1,1,\"Determine recommended Phase 2 Dose (RP2D)\"\\n3495,1,1,\"Determine recommended Phase 2 dose (RP2D) FF-10850\"\\n3496,1,1,\"Determine Recommended Phase 2 Dose following analysis of adverse events, pharmacokinetics and changes in laboratory evaluations.\"\\n3497,1,1,\"Determine recommended Phase 2 Dose Range (RP2DR)\"\\n3498,1,1,\"Determine safety and tolerability of AMXT1501 in combination with DFMO\"\\n3499,1,1,\"Determine safety and tolerability of AMXT1501 in combination with IV DFMO\"\\n3500,1,1,\"Determine safety of (m)-GCN+TTF\"\\n3501,1,1,\"Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL.\"\\n3502,1,1,\"Determine the Combination maximum tolerated dose and dose-limiting toxicities for XL844 alone and in combination with gemcitabine\"\\n3503,1,1,\"Determine the concentration of DXd in brain metastasis tumor tissue after one dose of the HER3-targeted ADC patritumab deruxtecan (HER3-DXd) administered via IV 1-3 days prior to craniotomy.\"\\n3504,1,1,\"Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) or Recommended Phase II Dose (RP2D) in Phase I setting.\"\\n3505,1,1,\"Determine the Dose Limiting Toxicity at 3 weeks (1 cycle), and the Maximum Tolerated Dose at 24 weeks (6 cycles).\"\\n3506,1,1,\"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.\"\\n3507,1,1,\"Determine the dose-limiting toxicity\"\\n3508,1,1,\"Determine the Dose-Limiting Toxicity (DLT) of PR610 for Both a 1-hour and a 24-hour Weekly IV Infusion\"\\n3509,2,2,\"Determine the effect of food on the bioavailability of TKI258\"\\n3510,1,1,\"determine the efficacy of daptomycin to treat gram positive infections\"\\n3511,1,1,\"Determine the feasibility and toxicity of tandem PBSC rescue following high dose chemotherapy as consolidation in pediatric patients with high risk solid tumors.\"\\n3512,1,1,\"Determine the HPV vaccine immunogenicity in females 12-26 years with six special risk groups at one month post the third and final HPV vaccination. Blood analysis taken at one month post third and final HPV vaccine to assess immunogenicity.\"\\n3513,1,1,\"Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)\"\\n3514,1,1,\"Determine the incidence of Treament Emergent Adverse Events (TEAE)\"\\n3515,1,1,\"Determine the maximal tolerated dose of docetaxel in combination with gemcitabine given intravenously every 2 weeks with pegfilgrastim support\"\\n3516,1,1,\"Determine the maximally tolerated doses and dose limiting toxicities of LBH589 in combination with paclitaxel and carboplatin. Preliminary anti-tumor activity will also be assessed.\"\\n3517,1,1,\"Determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594\"\\n3518,1,1,\"Determine the maximum target-inhibiting dose of SU5416 in patients with advanced solid tumors.\"\\n3519,1,1,\"Determine the maximum tolerable dose (MTD) of ABT-263 when administered in combination with etoposide/cisplatin.\"\\n3520,1,1,\"Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) in patients with advanced solid malignancies\"\\n3521,2,1,\"Determine the Maximum Tolerated Dose\"\\n3522,3,2,\"Determine the maximum tolerated dose\"\\n3523,3,2,\"Determine the Maximum Tolerated Dose (MTD)\"\\n3524,5,3,\"Determine the maximum tolerated dose (MTD)\"\\n3525,1,1,\"Determine the maximum tolerated dose (MTD) - Phase 1\"\\n3526,1,1,\"Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009.\"\\n3527,1,1,\"Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of CEP-11981, as defined in the Study Protocol.\"\\n3528,1,1,\"Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)\"\\n3529,1,1,\"Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of oral CUDC-101 in subjects with advanced and refractory solid tumors\"\\n3530,1,1,\"Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinib\"\\n3531,1,1,\"Determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) and schedule of VS-5584 administered to subjects with advanced non-hematologic malignancies or lymphoma\"\\n3532,1,1,\"Determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and schedule of MSX-122\"\\n3533,1,1,\"Determine the maximum tolerated dose (MTD) and toxicities of 4-HPR\"\\n3534,1,1,\"Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1\"\\n3535,1,1,\"Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab).\"\\n3536,1,1,\"Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of oral OSI-906\"\\n3537,1,1,\"Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930\"\\n3538,1,1,\"Determine the maximum tolerated dose (MTD) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.\"\\n3539,1,1,\"Determine the maximum tolerated dose (MTD) for each of 3 intermittent schedules and establish a recommended phase 2 dose of OSI-906\"\\n3540,1,1,\"Determine the maximum tolerated dose (MTD) of ABT-263 in combination with gemcitabine.\"\\n3541,1,1,\"Determine the maximum tolerated dose (MTD) of B7H3-specific CAR (Arm A)\"\\n3542,1,1,\"determine the maximum Tolerated Dose (MTD) of BEZ235 as single agent and in combination with trastuzumab (Dose escalation part)\"\\n3543,1,1,\"Determine the maximum tolerated dose (MTD) of bispecific B7H3xCD19 CAR (Arm B)\"\\n3544,1,1,\"Determine the Maximum Tolerated Dose (MTD) of CPX-POM\"\\n3545,1,1,\"Determine the maximum tolerated dose (MTD) of DSP-0509 by assessing dose-limiting toxicities (DLTs)\"\\n3546,1,1,\"Determine the maximum tolerated dose (MTD) of EZN-2968.\"\\n3547,1,1,\"Determine the maximum tolerated dose (MTD) of irinotecan and rapamycin combination in children with refractory solid tumors.\"\\n3548,1,1,\"Determine the maximum tolerated dose (MTD) of MKC-1 administered orally twice a day (bid) continuously in patients with advanced or refractory solid tumors.\"\\n3549,1,1,\"Determine the maximum tolerated dose (MTD) of navitoclax (ABT-263) with a standard regimen of docetaxel\"\\n3550,1,1,\"Determine the maximum tolerated dose (MTD) of PR104 when administered weekly\"\\n3551,1,1,\"Determine the Maximum Tolerated Dose (MTD) of PR610 for Both a 1-hour and a 24-hour Weekly IV Infusion\"\\n3552,1,1,\"Determine the maximum tolerated dose (MTD) of SNX-5422 when administered twice a week for 28 days.\"\\n3553,1,1,\"Determine the maximum tolerated dose (MTD) or recommended Phase II dose of oral AZD8835 as a single agent and in combination with fulvestrant\"\\n3554,1,1,\"Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles\"\\n3555,1,1,\"Determine the maximum tolerated dose (MTD)/recommended extended dose (RDE) of JS004 injection monotherapy and combination with Toripalimab in patients with advanced solid tumors.\"\\n3556,1,1,\"Determine the maximum tolerated dose and dose limiting toxicity of bevacizumab and sorafenib administered in combination with low dose cyclophosphamide to patients with refractory solid tumors.\"\\n3557,1,1,\"Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan and capecitabine when given in combination with a fixed dose of oxaliplatin in patients with advanced solid tumors.\"\\n3558,1,1,\"Determine the maximum tolerated dose and dose-limiting toxicity of L-NDDP\"\\n3559,1,1,\"Determine the maximum tolerated dose and recommended Phase 2 dose\"\\n3560,1,1,\"Determine the maximum tolerated dose and recommended Phase two dose\"\\n3561,2,2,\"Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities\"\\n3562,1,1,\"Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.\"\\n3563,1,1,\"Determine the maximum tolerated dose of an intravenous safingol in combination with fenretinide\"\\n3564,1,1,\"Determine the maximum tolerated dose of ASN004\"\\n3565,1,1,\"Determine the maximum tolerated dose of BMS-214662 in combination with paclitaxel.\"\\n3566,1,1,\"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin\\'s lymphoma.\"\\n3567,1,1,\"Determine the maximum tolerated dose of docetaxel, cisplatin, and capecitabine in patients with advanced solid tumors.\"\\n3568,1,1,\"Determine the maximum tolerated dose of E7974 in patients with Advanced Solid Tumors.\"\\n3569,2,2,\"Determine the maximum tolerated dose of E7974 in patients with solid malignancies.\"\\n3570,1,1,\"Determine the maximum tolerated dose of EC D-3263 HCl administered orally daily\"\\n3571,1,1,\"Determine the maximum tolerated dose of ONC201\"\\n3572,1,1,\"Determine the maximum tolerated dose of P-PSMA-101\"\\n3573,1,1,\"Determine the Maximum Tolerated Dose of SHR-A1904\"\\n3574,1,1,\"Determine the maximum tolerated dose of ST-067 in phase 1a\"\\n3575,1,1,\"Determine the Maximum Tolerated Doses for the 28-day and 21-day dosing schedules\"\\n3576,1,1,\"Determine the maximum tolerated, biologically active doses and recommended phase 2 dose(s) of BMS-599-626 when administered as a daily uninterrupted oral dose\"\\n3577,1,1,\"Determine the Minimum Effective Dose (MED) Necessary for Durable Local Control, Defined as the Dose Level at Which Local Control (LC) is >= 80% at 1 Year. (Phase II)\"\\n3578,1,1,\"Determine the modulation of HIF-1 alpha mRNA in tumor biopsies pre- and post- administration of EZN-2968.\"\\n3579,1,1,\"Determine the modulation of HIF-1Alpha protein (by ELISA) in solid tumors after treatment with EZN-2208 and bevacizumab.\"\\n3580,4,3,\"Determine the MTD\"\\n3581,1,1,\"Determine the MTD and DLT(s) of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors.\"\\n3582,1,1,\"Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors\"\\n3583,1,1,\"Determine the MTD and pharmacokinetics of hu14.18-IL2 fusion protein\"\\n3584,1,1,\"Determine the MTD and recommended Phase 2 dose (RP2D) of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors.\"\\n3585,1,1,\"Determine the MTD and recommended phase 2 dose of i.v. EZN-2208 administered q3wk.\"\\n3586,1,1,\"Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8\"\\n3587,1,1,\"Determine the MTD and/or RP2D of gamitrinib when administered once weekly.\"\\n3588,1,1,\"Determine the MTD of both navitoclax and docetaxel with a weekly schedule.\"\\n3589,1,1,\"Determine the MTD of DSP-0509 when given in combination pembrolizumab - by assessing DLTs.\"\\n3590,1,1,\"Determine the MTD of ELI-002 and the RP2D\"\\n3591,1,1,\"Determine the MTD of i.v. EZN-2208 administered q3wk and recommended Phase 2 dose of i.v. EZN-2208\"\\n3592,1,1,\"Determine the MTD of i.v. EZN-2208 administered weekly for 3 weeks in a 4-week cycle and recommended Phase 2 dose of i.v. EZN-2208\"\\n3593,1,1,\"Determine the MTD of PX-866\"\\n3594,1,1,\"Determine the number and type of adverse events to characterize the safety of PC14586\"\\n3595,1,1,\"Determine the objective response rate (ORR) at 24 weeks in Black patients with recurrent endometrial cancer treated with lenvatinib 20 mg orally daily in combination with pembrolizumab 200 mg IV every 3 weeks\"\\n3596,1,1,\"Determine the Objective Tumor Response Rate Following Treatment With TKI258\"\\n3597,1,1,\"Determine the optimal individualized dose to give each refractory/relapsed AML subject based on his/her covariates (prior CR duration, prior number of salvage therapies, age).\"\\n3598,1,1,\"Determine the optimal set of scan parameters (e.g., field of view).\"\\n3599,1,1,\"Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer\"\\n3600,1,1,\"Determine the Overall Objective Response\"\\n3601,1,1,\"Determine the Overall Objective Response Rate (CR and PR).\"\\n3602,1,1,\"Determine the overall response rate\"\\n3603,1,1,\"Determine the pharmacokinetic profile of L-NDDP\"\\n3604,1,1,\"Determine the pharmacokinetics and toxicities associated with the administration of recombinant human thrombopoietin (rhTPO)\"\\n3605,1,1,\"Determine the pharmacokinetics of G-202 administered by intravenous infusion daily for 3 consecutive days on a 28-day cycle in patients with advanced solid tumors.\"\\n3606,1,1,\"Determine the PK profile of PX-866.\"\\n3607,1,1,\"Determine the potential effect of the LCP on discharge\"\\n3608,1,1,\"Determine the preliminary activity/efficacy\"\\n3609,1,1,\"Determine the proportion of participants with progression free survival at 6 months\"\\n3610,1,1,\"Determine the rate of dose-limiting toxicities (DLTs)\"\\n3611,1,1,\"Determine the RD of S-1, Leucovorin, and Oxaliplatin in phase I setting\"\\n3612,1,1,\"Determine the recommended dose of BAY 43-9006 (SORAFENIB) in combination with docetaxel in hormone-refractory prostate cancer patients as first line treatment in patients with metastatic hormone refractory prostate cancer.\"\\n3613,1,1,\"Determine the recommended phase 2 dose\"\\n3614,1,1,\"Determine the Recommended Phase 2 dose (RP2D)\"\\n3615,1,1,\"Determine the Recommended Phase 2 Dose (RP2D) and schedule of HST-1011 monotherapy in Part A2.\"\\n3616,1,1,\"Determine the recommended phase 2 dose (RP2D) based on a combination of maximum tolerated dosed (MTD), review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study.\"\\n3617,1,1,\"Determine the recommended phase 2 dose (RP2D) based on Dose limiting toxicities\"\\n3618,1,1,\"Determine the recommended Phase 2 Dose (RP2D) of ABT101 in Part 1\"\\n3619,1,1,\"Determine the recommended Phase 2 dose (RP2D) of GV20-0251 in patients with advanced and/or specific solid tumor malignancies from Cohort Expansion.\"\\n3620,1,1,\"Determine the recommended Phase 2 dose (RP2D) of MHB088C\"\\n3621,1,1,\"Determine the Recommended Phase 2 Dose (RP2D) of Monoclonal Antibody Therapy (Mab) in Combination With Pembrolizumab (Pembro) in Subjects With Advanced Cancer\"\\n3622,1,1,\"Determine the recommended Phase 2 dose (RP2D) of the combination of onapristone and elacestrant (Phase 1).\"\\n3623,1,1,\"Determine the recommended Phase 2 dose (RP2D) of ZX-4081\"\\n3624,1,1,\"Determine the recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with etoposide/cisplatin.\"\\n3625,1,1,\"Determine the recommended Phase 2 dose of 177Lu-FAP-2286 (Phase 1)\"\\n3626,1,1,\"Determine the recommended phase 2 dose of 212-Lead Pentixather\"\\n3627,1,1,\"Determine the recommended Phase 2 dose of the combination of lucitanib and nivolumab (Phase 1b)\"\\n3628,1,1,\"Determine the recommended phase II dose\"\\n3629,2,1,\"Determine the Recommended Phase II Dose (RP2D)\"\\n3630,3,3,\"Determine the recommended Phase II dose (RP2D)\"\\n3631,1,1,\"Determine the recommended phase II dose (RP2D)\"\\n3632,1,1,\"Determine the recommended Phase II dose (RP2D) and preliminarily to develop a suitable dosing regimen\"\\n3633,2,2,\"determine the recommended Phase II dose (RP2D) and preliminarily to develop a suitable dosing regimen\"\\n3634,1,1,\"Determine the recommended Phase II dose; Characterize the dose-limiting toxicities; Determine the pharmacokinetic parameters\"\\n3635,1,1,\"Determine the relative bioavailability of the final market image form of TKI258 (monohydrate capsules) as compared to the clinical service form of TKI258 (anhydrate capsules)\"\\n3636,1,1,\"Determine the relative bioavailability of the final market image form of TKI258 (monohydrate tablets) as compared to the clinical service form of TKI258 (anhydrate capsules)\"\\n3637,1,1,\"Determine the RP2D\"\\n3638,1,1,\"Determine the RPII dose of NC-6004 in combination with gemcitabine\"\\n3639,1,1,\"Determine the safety (effects on the body) and the maximum tolerated dose of JNJ-26483327 in patients with cancer. Determine how JNJ-26483327 taken by patients as an oral capsule is absorbed, broken down and eliminated.\"\\n3640,1,1,\"Determine the safety and efficacy of administration of D-1MT into patients with recurrent or refractory solid tumors. Establish the toxicities of D-1MT and define any dose limiting toxicities if they occur below the maximum doses.\"\\n3641,1,1,\"Determine the safety and maximum tolerated dose of R306465 when given as a daily oral dose during 3 weeks followed by a 1 week recovery period. Study the absorption, break down and elimination of R306465 following oral administration.\"\\n3642,1,1,\"Determine the safety and the maximum tolerated dose of JNJ-26481585. Determine how JNJ-26481585 and its metabolite, JNJ-26395018, are absorbed, broken down and eliminated after oral administration\"\\n3643,1,1,\"Determine the safety and tolerability of ARQ 501 in combination with docetaxel\"\\n3644,1,1,\"Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam\"\\n3645,1,1,\"Determine the safety and tolerability of GL-ONC1, administered intravenously to patients with advanced solid tumors.\"\\n3646,1,1,\"Determine the safety and tolerability of JNJ-38877605 by assessment of the adverse event profile (throughout the study), dose-limiting toxicity (Cycle 1), and the maximum tolerated dose.\"\\n3647,1,1,\"Determine the safety and tolerability of once daily oral doses of AZD2171 when given in combination with one of these anticancer regimens; FOLFOX, Pemetrexed, Irinotecan, Docetaxel\"\\n3648,1,1,\"Determine the safety and tolerability of vaccination comprising the ImMucin vaccine\"\\n3649,1,1,\"Determine the safety and tolerability profile of XmAb20717\"\\n3650,1,1,\"Determine the safety and tolerability, including the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD), of a 2-day pulse of AC480IV both as monotherapy and in combination with docetaxel in patients with advanced solid tumor malignancies.\"\\n3651,1,1,\"Determine the safety and toxicity profile of co-administration of disulfiram and copper gluconate for the treatment of refractory malignancies that have metastasized to the liver\"\\n3652,1,1,\"determine the safety of daptomycin in neutropenic patients\"\\n3653,1,1,\"Determine the safety of JNJ-26854165 and the maximum tolerated dose in patients with advanced stage or refractory solid tumors.\"\\n3654,1,1,\"Determine the safety of the combination of NEO-201 with pembrolizumab the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\"\\n3655,1,1,\"Determine the safety of the drug according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5\"\\n3656,1,1,\"Determine the safety profile (Adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of ABT-348 as monotherapy or in combination\"\\n3657,1,1,\"Determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197\"\\n3658,1,1,\"Determine the safety/toxicity of JX-594 administered by IT injection in this patient population\"\\n3659,1,1,\"Determine the the absolute bioavailability of GSK1120212 following single oral tablet dose co-administered with an IV microdose.\"\\n3660,1,1,\"Determine the toxicity of a reduced intensity conditioning regimen consisting of Fludarabine and Busulfan.\"\\n3661,1,1,\"Determine the toxicity profile of the combination of dasatinib and bevacizumab\"\\n3662,1,1,\"Determine the toxicity profile of the HER2 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.\"\\n3663,1,1,\"Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.\"\\n3664,1,1,\"Determine Toxicity Profile\"\\n3665,1,1,\"Determine whether magnetic resonance image monitoring during radiofrequency interstitial thermal ablation can accurately predict complete destruction of focal tumor along with an adequate margin of normal tissue.\"\\n3666,1,1,\"Determine whether the microbiome composition can predict progression-free survival\"\\n3667,1,1,\"Determine whether the microbiome composition can predict risk for colorectal cancer\"\\n3668,1,1,\"Determine which tumor types are most amenable to detection using peripheral blood ctDNA assay\"\\n3669,1,1,\"Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.\"\\n3670,1,1,\"Determined the maximum tolerated dose (MTD)\"\\n3671,1,1,\"Determined the recommended Phase II dose (RP2D)\"\\n3672,1,1,\"Determining a dose at which no more than one patient out of up to six patients at the same dose level experience a highly probably or probably drug-related dose limiting toxicity (DLT).\"\\n3673,1,1,\"Determining causality of each adverse event Adverse Event to AT13148 and grading severity according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.02.\"\\n3674,1,1,\"Determining the causality and duration of adverse events observed during the study according to NCI CTCAE Version 4.02\"\\n3675,1,1,\"Determining the dose of the test substance in patients between 9 and 21 years of age, at which exposure to the drug will be similar to that recommended for adults.\"\\n3676,1,1,\"Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or pembrolizumab-related or possibly related dose-limiting toxicity (DLT)\"\\n3677,1,1,\"Develop Categories for intervention refinement (Phase 1)\"\\n3678,1,1,\"Develop predictive models of HMA treatment outcomes using SEER-Medicare data\"\\n3679,1,1,\"Develop the structural program\"\\n3680,1,1,\"Development and validation of a laboratory developed test (LDT) using liquid chromatography tandem mass spectrometry to measure pemborlizumab and nivolumab.\"\\n3681,1,1,\"Development and/or optimization of new magnetic resonance (MR) imaging and spectroscopy applications and analysis software\"\\n3682,1,1,\"Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape\"\\n3683,1,1,\"Development of an EORTC questionnaire to assess HRQOL of patients with CML.\"\\n3684,1,1,\"Development of cancer cell lines from tissue archived from patients with Fanconi anemia\"\\n3685,1,1,\"Development of Progression\"\\n3686,1,1,\"Development of the Oncology Opportunity Cost Assessment Tool (OOCAT)\"\\n3687,1,1,\"Development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure as a repository for socio-demographic, environmental, clinical, and family history data\"\\n3688,2,1,\"Device and Procedure related serious adverse event rate\"\\n3689,1,1,\"Diagnosis of benign vs. malignant lesions using DCE-MRI\"\\n3690,1,1,\"Diagnosis of confirmed osteonecrosis of the jaw (ONJ)\"\\n3691,1,1,\"Diagnosis of incident cancers and other chronic diseases\"\\n3692,1,1,\"diagnosis of prostate cancer\"\\n3693,71,5,\"Diagnostic accuracy\"\\n3694,15,1,\"diagnostic accuracy\"\\n3695,1,1,\"Diagnostic accuracy of CEUS FNA endosonography versus standard FNA endosonography in the etiological cyto histological of pancreatic solid tumors using histology core as comparison between the two methods\"\\n3696,1,1,\"Diagnostic accuracy of FAPI-PET/CT in primary tumors\"\\n3697,1,1,\"Diagnostic accuracy of fine needle aspiration Echo Tip¬Æ HD ProCore‚Ñ¢ versus EchoTip¬Æ in the etiological cyto histological in pancreatic solid tumors explored under endoscopy ultrasonography.\"\\n3698,1,1,\"Diagnostic accuracy of multiparametric MR imaging (mpMRI)\"\\n3699,1,1,\"Diagnostic accuracy of needle as assessed by diagnostic yield of needle and final diagnosis method\"\\n3700,1,1,\"Diagnostic Accuracy of the 22G SharkCore‚Ñ¢ and the 22G BNX EUS-FNA needle\"\\n3701,1,1,\"Diagnostic accuracy using pathologic correlation as gold standard measure\"\\n3702,2,1,\"Diagnostic efficacy\"\\n3703,10,3,\"Diagnostic performance\"\\n3704,1,1,\"Diagnostic Performance of Response Rate\"\\n3705,1,1,\"Diagnostic precision of uterine tumours at molecular level\"\\n3706,1,1,\"diagnostic sensitivity of WS technique and SNP technique by EUS-FNB\"\\n3707,1,1,\"diagnostic specificity of WS technique and SNP technique by EUS-FNB\"\\n3708,1,1,\"Diagnostic tissue area\"\\n3709,1,1,\"Diagnostic value of multimodal imaging in primary prostate cancer patients\"\\n3710,16,2,\"Diagnostic Yield\"\\n3711,36,2,\"Diagnostic yield\"\\n3712,1,1,\"Diagnostic Yield on malignancy\"\\n3713,1,1,\"Diagnostic yield: Proportion of patients with adequate tissue for diagnosis obtained by EUS FNA\"\\n3714,1,1,\"Diarrhoea rate of all grades\"\\n3715,1,1,\"Dietary and a physical activity assessments of CCS vs controls\"\\n3716,1,1,\"Dietary assessment by modified Family Habits Questionnaire (FHQ), FVFQ, and Food Frequency Questionnaire (FFQ) at baseline, 4 months, and 7 months\"\\n3717,1,1,\"Dietary assessment by modified Family Habits Questionnaire (FHQ), FVFQ, and Food Frequency Questionnaire (FFQ) at baseline, 4 months, and 8 months\"\\n3718,1,1,\"Difference between initial oncologist treatment proposal and final treatment selected after geriatric assessment\"\\n3719,1,1,\"Difference Between Measures of Weight at Baseline and at Week 24\"\\n3720,1,1,\"Difference between prevalence of positive pathogenic germline mutations\"\\n3721,1,1,\"Difference From Baseline for Bilirubin, Creatinine and Glucose\"\\n3722,1,1,\"Difference From Baseline for Coagulation Parameters\"\\n3723,1,1,\"Difference From Baseline for Electrolytes\"\\n3724,1,1,\"Difference From Baseline for Haematology and Differentials Parameters\"\\n3725,1,1,\"Difference From Baseline for Haemoglobin\"\\n3726,1,1,\"Difference From Baseline for Liver Enzymes\"\\n3727,1,1,\"Difference in Apparent diffusion coefficient value between benign and malignant lesions\"\\n3728,1,1,\"Difference in functional status as measured by Karnofsky performance scores at day 0 of allogeneic bone marrow transplantation and at day 100 post-transplantation\"\\n3729,1,1,\"difference in Hypoxia Inducible Factor-1 gene expression\"\\n3730,1,1,\"Difference in measured versus known quantitative values of the pocket phantom\"\\n3731,1,1,\"Difference in Median Progression Free Survival Time Between Favorable and Unfavorable Biomarker Group\"\\n3732,1,1,\"Difference in prevalence, incidence and persistence of cervical HPV infection in female OTRs compared to immunocompetent controls.\"\\n3733,1,1,\"Difference in quantitative change in tumor size (change in T) in patients with genomic PIK3CA pathway alteration (PIK3CA mutation, amplification, and fluorescence in situ hybridization [FISH] for PTEN loss)\"\\n3734,1,1,\"Difference in reduction in psychological (depression, anxiety, stress) and physical symptoms (fatigue, sleep disturbance) between 3 groups of caregivers: African American, Latinos, and white non-Latinos\"\\n3735,1,1,\"Difference in stool microbiome pattern\"\\n3736,1,1,\"Difference in the percentage of cells which are immune inhibitory (CD11B+, CD163+) macrophages from pre-treatment to first post-treatment biopsy\"\\n3737,1,1,\"Difference in the percentage of patients who report an improvement in their appetite over the intervention period\"\\n3738,1,1,\"Difference in the Seroconversion Rates or Significant Increase by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant)\"\\n3739,1,1,\"Difference of 1 point of concern scores in Measure Yourself Concerns and Well-being (MYCAW) questionnaire from baseline to second evaluation (after completion of all four sessions of therapy)\"\\n3740,1,1,\"Differences across groups related to acceptance of computers (i.e., age, culture, stage of disease, cognitive and physical function, etc.)\"\\n3741,1,1,\"Differences Between Patients and Healthy Controls\"\\n3742,1,1,\"Differences in activation of involved signaling pathways\"\\n3743,1,1,\"Differences in cellular ultra structures\"\\n3744,1,1,\"Differences in Force development and Calcium 2+ sensitivity of single muscle fibers\"\\n3745,1,1,\"Differences in genomic profiles of tumor tissues and ctDNA clearance of third-generation EGFR-TKIs sensitive and primary drug-resistant NSCLC.\"\\n3746,1,1,\"Differences in Myosin isoforms\"\\n3747,1,1,\"Differences in Myosin:Actin ratio\"\\n3748,1,1,\"Differences in outcomes between neuropathic pain patients\"\\n3749,1,1,\"Differences in severe peripheral sensory neurotoxicity rates\"\\n3750,1,1,\"Differences in the detection of total mutational burden between both techniques.\"\\n3751,1,1,\"Differential Gene Expression Between Responsive and Resistant Tumor Treated With Dose-dense Therapy\"\\n3752,1,1,\"Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase)\"\\n3753,1,1,\"Digital-pulse amplitude (DPA) measures\"\\n3754,1,1,\"Dihydrotestosterone (DHT) Concentration in Prostate Tissue\"\\n3755,1,1,\"Direct and Indirect Cost of Rheumatoid Arthritis (RA) Treatment\"\\n3756,1,1,\"Direct Communication About Age-related Concerns: Number of Discussions Related to the Geriatric Assessment That Occur in the Clinic Visit Between the Patient, Oncology Physician, and Caregiver. [Patient-Centered Outcomes Research Institute Specified]\"\\n3757,1,1,\"Direct Comparison of pancreatic mass histologic tissue adequacy using two EUS guided fine needle biopsy needles\"\\n3758,1,1,\"Disappearance of succinate accumulation at M12\"\\n3759,1,1,\"Discontinuation of investigational products due to toxicity\"\\n3760,1,1,\"Discontinuations due to AEs (Part 1 and Part 2)\"\\n3761,1,1,\"Discontinue Study Drug Due to an Adverse Events\"\\n3762,1,1,\"Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC)\"\\n3763,1,1,\"Disease Assessment for Objective Response Rate\"\\n3764,1,1,\"Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease)\"\\n3765,1,1,\"Disease control (ie non progression) at 6 months\"\\n3766,1,1,\"Disease control (stable disease or better) measured by RECIST 1.1\"\\n3767,1,1,\"Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1\"\\n3768,1,1,\"Disease Control at Week 16\"\\n3769,37,14,\"Disease Control Rate\"\\n3770,49,10,\"Disease control rate\"\\n3771,1,1,\"Disease control rate (Applicable for: phase II in cohorts of Colorectal Cancer, Nasopharyngeal Carcinoma and Non-Small Cell Lung Cancer) .\"\\n3772,1,1,\"Disease Control Rate (Cohort I)\"\\n3773,1,1,\"Disease Control Rate (Cohort II)\"\\n3774,1,1,\"Disease Control Rate (DCR )\"\\n3775,57,22,\"Disease Control Rate (DCR)\"\\n3776,2,1,\"Disease Control rate (DCR)\"\\n3777,26,10,\"Disease control rate (DCR)\"\\n3778,2,1,\"disease control rate (DCR)\"\\n3779,1,1,\"Disease control rate (DCR) (in stage ‚Ö°)\"\\n3780,1,1,\"Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1\"\\n3781,2,2,\"Disease control rate (DCR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\"\\n3782,1,1,\"Disease Control Rate (DCR) After 6 Months\"\\n3783,1,1,\"Disease Control Rate (DCR) and Objective Response Rate (ORR) According to the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n3784,1,1,\"Disease Control Rate (DCR) Assessed Locally at Month 9\"\\n3785,1,1,\"Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib\"\\n3786,1,1,\"Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1\"\\n3787,1,1,\"Disease Control Rate (DCR) Based on Investigator Assessments for Participants With at Least 16 Weeks of Treatment\"\\n3788,1,1,\"Disease Control Rate (DCR) by Investigator Assessment\"\\n3789,1,1,\"Disease control rate (DCR) defined as proportion of patients who had complete response, partial response or stable disease by Response Evaluation Criteria in Solid Tumors version 4.1\"\\n3790,1,1,\"Disease control rate (DCR) in stage ‚Ö°\"\\n3791,1,1,\"Disease Control Rate (DCR) in Study Participants\"\\n3792,1,1,\"Disease Control Rate (DCR) in subjects participating in the clinical investigation [ Time Frame: 2.5 years]\"\\n3793,1,1,\"Disease Control Rate (DCR) in Tumor-Specific Cohorts\"\\n3794,1,1,\"Disease control rate (DCR) including complete response + partial response + stable disease\"\\n3795,1,1,\"Disease Control Rate (DCR) of SRA737\"\\n3796,1,1,\"Disease Control Rate (DCR; OR + Stable Disease)\"\\n3797,11,10,\"Disease Control Rate (DCRÔºâ\"\\n3798,1,1,\"Disease Control Rate (Dose Expansion Phase)\"\\n3799,1,1,\"Disease Control Rate (Part A)\"\\n3800,2,1,\"Disease control rate (Phase II)\"\\n3801,1,1,\"Disease Control Rate (Stable Disease or Objective Response)\"\\n3802,1,1,\"Disease Control Rate at 12 Weeks (DCR12)\"\\n3803,1,1,\"Disease control rate at 12 weeks (DCR12)\"\\n3804,1,1,\"Disease Control Rate at 4 Months\"\\n3805,1,1,\"Disease Control Rate at 6 Months Per RECIST v1.1.\"\\n3806,1,1,\"Disease Control Rate at Weeks 17 and 25\"\\n3807,1,1,\"Disease Control Rate using RECIL for lymphoma patients (Part 2)\"\\n3808,1,1,\"Disease Control Rate using RECIST for solid tumor patients (Part 2)\"\\n3809,2,1,\"Disease Control Rate(DCR)\"\\n3810,6,1,\"Disease control rate(DCR)\"\\n3811,1,1,\"Disease Control Rate(DCR) of TY-302 combine with Tamoxifen\"\\n3812,2,1,\"Disease control rate, DCR\"\\n3813,1,1,\"Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months.\"\\n3814,2,2,\"Disease control rate,(DCR)\"\\n3815,1,1,\"Disease control rate; defined as total number of patients whose Best Overall Response(BOR)= Complete Response(CR), Partial Response(PR) or Stable Disease(SD), divided by total number of patients\"\\n3816,3,3,\"Disease Control Rates (DCR)\"\\n3817,2,1,\"Disease Control Success\"\\n3818,1,1,\"Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT\"\\n3819,153,2,\"Disease free survival\"\\n3820,34,1,\"Disease Free Survival (DFS)\"\\n3821,1,1,\"Disease objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\"\\n3822,28,3,\"Disease Progression\"\\n3823,1,1,\"Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)\"\\n3824,1,1,\"Disease progression-free survival(PFS)\"\\n3825,1,1,\"Disease progression-free survival(PFS) evaluated by Independent Review Committee (IRC)\"\\n3826,11,4,\"Disease Response\"\\n3827,11,1,\"Disease response\"\\n3828,1,1,\"Disease Response (Tumor Measurements)Per RECIST Criteria v. 2000\"\\n3829,1,1,\"Disease response according to RECIST criteria\"\\n3830,1,1,\"Disease response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n3831,1,1,\"Disease response after expanded activated NK cell infusion\"\\n3832,1,1,\"Disease response as measured by skin assessment and photography\"\\n3833,1,1,\"Disease response measured with consistent imaging utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1\"\\n3834,1,1,\"Disease Response Rate\"\\n3835,1,1,\"Disease response, according to immune related response criteria (Phase I/II)\"\\n3836,1,1,\"Disease response/composite response\"\\n3837,1,1,\"disease stage\"\\n3838,1,1,\"Disease-Control Rate\"\\n3839,1,1,\"Disease-control Rate\"\\n3840,3,1,\"Disease-control rate\"\\n3841,1,1,\"Disease-control rate (DCR) [Part 3]\"\\n3842,1,1,\"Disease-Free Interval\"\\n3843,1,1,\"Disease-free progression\"\\n3844,42,4,\"Disease-free Survival\"\\n3845,206,7,\"Disease-free survival\"\\n3846,68,4,\"Disease-free survival (DFS)\"\\n3847,1,1,\"Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment\"\\n3848,1,1,\"Disease-free survival at 12 months\"\\n3849,4,1,\"Disease-free survival at 2 years\"\\n3850,2,1,\"disease-free survival at 2-year interval\"\\n3851,2,1,\"disease-free survival at 5-year interval\"\\n3852,7,1,\"Disease-free survival rate\"\\n3853,1,1,\"Disease-free survival rate at 2 years\"\\n3854,1,1,\"Disease-specific Dose-limiting Toxicity and Maximum Tolerated Dose of Flavopiridol Graded According to the CTCAE (Common Toxicity Criteria for Adverse Effects) Version 4.0 (Phase I)\"\\n3855,1,1,\"Disease-specific survival (months)\"\\n3856,1,1,\"disseminated intravascular coagulation\"\\n3857,2,1,\"Distant failure\"\\n3858,1,1,\"Distant Recurrence Free Interval (D-RFi)\"\\n3859,1,1,\"Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by flow cytometry (and/or CyTOF)\"\\n3860,1,1,\"Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by multiplexed immunohistochemistry (mIHC)\"\\n3861,1,1,\"Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by single nuclear RNA-sequencing\"\\n3862,1,1,\"Distress as measured by Impact of Event Scale (IES)\"\\n3863,2,1,\"Distress thermometer\"\\n3864,1,1,\"Distress Thermometer (self-reported distress levels by 11 point scale) Change is being assessed\"\\n3865,3,1,\"Distribution\"\\n3866,1,1,\"Distribution of age\"\\n3867,1,1,\"Distribution of and association patterns between the Child-Pugh score and that of patient\\'s risk of toxicity beyond each dose or cohort, assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0\"\\n3868,1,1,\"Distribution of cancer stage at initial diagnosis and at nivolumab initiation\"\\n3869,1,1,\"Distribution of clinical characteristics in patients with advanced melanoma treated with nivolumab monotherapy\"\\n3870,1,1,\"Distribution of concomitant diseases at nivolumab initiation\"\\n3871,1,1,\"Distribution of current smokers, former smokers, and non-smokers at initial diagnosis\"\\n3872,1,1,\"Distribution of demographic characteristics of patients with advanced melanoma treated with nivolumab monotherapy in the ATU program\"\\n3873,1,1,\"Distribution of different bone marrow failure syndromes\"\\n3874,1,1,\"Distribution of ECOG PS\"\\n3875,1,1,\"Distribution of First Line Treatment Patterns According to Prognostic Group\"\\n3876,1,1,\"Distribution of gender\"\\n3877,1,1,\"Distribution of line of therapy at nivolumab initiation\"\\n3878,1,1,\"Distribution of Lung cancer histology at initial diagnosis\"\\n3879,1,1,\"Distribution of mutations in patients with HCC, intra- and extrahepatic CCA, GBCA, PDAC and gastric cancer\"\\n3880,1,1,\"Distribution of patients working status at nivolumab initiation\"\\n3881,1,1,\"Distribution of Pre-SCT Therapy Regimens\"\\n3882,1,1,\"Distribution of Relapse/Refractory (RR) Treatment Patterns\"\\n3883,1,1,\"Distributions of mutations (including on gene expressions)\"\\n3884,1,1,\"Diversity and Composition of gut microbiota\"\\n3885,1,1,\"Diversity supplement primary outcome: 90-day postoperative cardiovascular complications\"\\n3886,1,1,\"DLCO, FVC, and FEV1 as measured by pulmonary function testing\"\\n3887,75,29,\"DLT\"\\n3888,1,1,\"DLT (dose escalation period)\"\\n3889,1,1,\"DLT (Dose-Limiting Toxicity)\"\\n3890,2,2,\"DLT (for Dose Escalation Phase only)\"\\n3891,3,2,\"DLT and MTD\"\\n3892,1,1,\"DLT as assessed by NCI CTCAE version 3.0\"\\n3893,1,1,\"DLT Assessment\"\\n3894,1,1,\"DLT defined as any grade 3 or greater non-hematologic toxicity attributed to the combination of drugs in this regimen, despite maximal supportive care as assessed by NCI CTCAE v. 3\"\\n3895,1,1,\"DLT defined as grade 3 or worse non-hematologic and sustained (> 5 days) grade 3 hematologic toxicity or grade 4 hematologic toxicity of any duration, and the moderate toxicity is grade 2 toxicity as assessed by CTCAE version 3.0\"\\n3896,1,1,\"DLT defined as hematologic and non-hematologic toxicities toxicities attributable to drug administration occurring during or immediately subsequent to the first course as assessed by CTC version 2.0\"\\n3897,1,1,\"DLT determination\"\\n3898,1,1,\"DLT graded accorded to the National Cancer institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n3899,1,1,\"DLT in Phase I\"\\n3900,1,1,\"DLT incidence\"\\n3901,1,1,\"DLT occurrence and frequency (dose escalation phase)\"\\n3902,1,1,\"DLT Of Botensilimab\"\\n3903,1,1,\"DLT of E7080 Repeatedly Administered Twice a Day\"\\n3904,1,1,\"DLT of first single dose of FS-1502.\"\\n3905,1,1,\"DLT of irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)\"\\n3906,1,1,\"DLT of MBS301\"\\n3907,1,1,\"DLT Part: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n3908,1,1,\"DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n3909,1,1,\"DLT\\'s and MTD Safety and Toxicity profile\"\\n3910,2,2,\"DLT(Dose limit toxity)\"\\n3911,1,1,\"DLT(Dose-Limiting Toxicities)\"\\n3912,1,1,\"DLT(dose-limiting toxicity)\"\\n3913,1,1,\"DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR\"\\n3914,1,1,\"DLT+Expansion Part: Duration of Response (DOR) Based on RECIST 1.1 Assessed by IIR\"\\n3915,1,1,\"DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST and RECIST 1.1 Assessed by Independent Imaging Review (IIR)\"\\n3916,1,1,\"DLT, MTD, Number of participants and severiaty with treatment-related Adverse events (AEs) as assessed by CTCAE v5.0\"\\n3917,11,4,\"DLTs\"\\n3918,1,1,\"DLTs in the first 2 cycles of single drug administration\"\\n3919,1,1,\"DLTs occurring during adjuvant ipilimumab in the dose escalation phase\"\\n3920,1,1,\"DLTs occurring in the feasibility phase\"\\n3921,1,1,\"DLT„ÄÅAE„ÄÅSAE„ÄÅirAE\"\\n3922,1,1,\"DLTÔºàDose limiting toxicityÔºâ\"\\n3923,1,1,\"DNA genomic sequencing\"\\n3924,1,1,\"DNA repository for long-term storage of DNA obtained from patients treated at the Cancer Institute of New Jersey\"\\n3925,1,1,\"DOAC peak concentration\"\\n3926,1,1,\"DOAC trough concentration\"\\n3927,1,1,\"Document progression free survival after treatment with ARQ 501 and gemcitabine\"\\n3928,1,1,\"Documentation of patient preferences regarding clinical trials\"\\n3929,1,1,\"Documentation of patient preferences, understanding, and attitudes regarding clinical trials\"\\n3930,1,1,\"Documentation of patient understanding regarding clinical trials\"\\n3931,1,1,\"Documentation of the Characterization of CTCs from Patients with Solid Tumors\"\\n3932,1,1,\"Documentation of the frequency of specific clinical events in relation to risk factors, diagnosis and treatments provided.\"\\n3933,1,1,\"Documentation of the Quality of CTCs from Patients with Solid Tumors\"\\n3934,1,1,\"Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or pembrolizumab\"\\n3935,1,1,\"Documenting AEs and SAEs and determining causality in relation to BI-1808 and/or pembrolizumab\"\\n3936,1,1,\"Does limiting toxicityÔºàCTC 5.0Ôºâ\"\\n3937,5,1,\"DOR\"\\n3938,1,1,\"DOR(Duration Of Response)\"\\n3939,1,1,\"Dosage (provide right dosage for II phase clinical trial)\"\\n3940,1,1,\"Dosage Limiting Toxicities\"\\n3941,1,1,\"Dosage of PEG-rhG-CSF in chemotherapy\"\\n3942,1,1,\"Dose Assessment\"\\n3943,1,1,\"Dose at which there is no additional differential effect of L-NNA on the tumor vasculature as measured by dynamic contrast-enhanced computed tomography (DCE-CT)\"\\n3944,1,1,\"Dose confirmation\"\\n3945,1,1,\"Dose confirmation (Part B) - Number of patients with DLTs during the on-treatment period\"\\n3946,1,1,\"Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)\"\\n3947,1,1,\"Dose confirmation (Part B) and expansion (Part C) - Objective response\"\\n3948,1,1,\"Dose confirmation stage: Safety and tolerability to determine the subsequent recommended dosing regimen\"\\n3949,1,1,\"Dose De-Escalation Phase: To assess dose limiting toxicities (DLTs) using CTCAE v4.03.\"\\n3950,1,1,\"dose defining\"\\n3951,3,2,\"Dose Determination\"\\n3952,1,1,\"Dose dose modifications due to AEs (Part 1 and Part 2)\"\\n3953,4,2,\"Dose Escalation\"\\n3954,1,1,\"Dose escalation (Part A) - Maximum tolerated dose (MTD) based on number of dose-limiting toxicities (DLTs)\"\\n3955,1,1,\"Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination\"\\n3956,1,1,\"Dose Escalation (Regimens A Through D): Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n3957,1,1,\"Dose Escalation - Determine Maximum Tolerated Dose (MTD)\"\\n3958,1,1,\"Dose Escalation - number of participants with dose limiting toxicities (DLTs) from IMT-009 monotherapy\"\\n3959,1,1,\"Dose escalation : Dose Limiting Toxicity (DLT)\"\\n3960,1,1,\"Dose escalation : Incidence of dose Limiting Toxicity (DLTs)\"\\n3961,1,1,\"Dose Escalation and Dose Expansion Parts: Number of Participants with Clinically Significant Safety Parameters\"\\n3962,1,1,\"Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin : Rate at which the drug is removed from the body (CL)\"\\n3963,1,1,\"Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-t))\"\\n3964,1,1,\"Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Elimination half-life of the drug (T¬Ω)\"\\n3965,1,1,\"Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Maximum concentration (Cmax) after dosing\"\\n3966,1,1,\"Dose Escalation and Dose Expansion Pharmacokinetics of tisotumab vedotin: Time after dosing at which the maximum drug concentration was observed (Tmax)\"\\n3967,2,2,\"Dose Escalation and Dose Expansion phase: Number of participants with adverse events\"\\n3968,1,1,\"Dose Escalation and Dose Expansion: Assess immunogenicity of tisotumab vedotin by measuring and assessing Anti-drug Antibody (ADA)\"\\n3969,1,1,\"Dose Escalation and Dose Expansion: Incidence of Dose Limiting Toxicities (DLTs), AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities [Tolerability]\"\\n3970,1,1,\"Dose Escalation and Dose Expansion: Incidence of drug-related Adverse Events (AEs) and Serious Adverse Events (SAEs) by CTCAE v5.0 [Safety]\"\\n3971,1,1,\"Dose Escalation and Expansion Part: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n3972,1,1,\"Dose escalation and expansion: safety assessment\"\\n3973,1,1,\"Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs)\"\\n3974,1,1,\"Dose Escalation Cohort: AUCt for ABBV-176\"\\n3975,1,1,\"Dose Escalation Cohort: AUC‚àû for ABBV-176\"\\n3976,1,1,\"Dose Escalation Cohort: Cmax of ABBV-176\"\\n3977,1,1,\"Dose Escalation Cohort: Maximum tolerated dose (MTD) of ABBV-176\"\\n3978,1,1,\"Dose Escalation Cohort: Recommended Phase 2 dose (RPTD) for ABBV-176\"\\n3979,1,1,\"Dose Escalation Cohort: t1/2 for ABBV-176\"\\n3980,1,1,\"Dose Escalation Cohort: Terminal phase elimination rate constant (Œ≤) for ABBV-176\"\\n3981,1,1,\"Dose Escalation Cohort: Tmax of ABBV-176\"\\n3982,1,1,\"Dose Escalation Index at Day 15 (+/- 3 Days)\"\\n3983,1,1,\"Dose escalation part and dose expansion part : Incidence of Adverse eventsÔºàAEsÔºâ, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.\"\\n3984,1,1,\"Dose escalation part: Dose-Limiting Toxicity (DLT)\"\\n3985,1,1,\"Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events\"\\n3986,1,1,\"Dose Escalation Part: Maximum Tolerated Dose (MTD)\"\\n3987,1,1,\"Dose escalation part: maximum tolerated dose (MTD)\"\\n3988,1,1,\"Dose Escalation Part: MTD and/or RP2D of Palbociclib and H3B-6545\"\\n3989,1,1,\"Dose Escalation Part: Number of Participants with Dose-Limiting Toxicities (DLT)\"\\n3990,3,2,\"Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)\"\\n3991,1,1,\"Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST])\"\\n3992,1,1,\"Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of Farletuzumab Ecteribulin\"\\n3993,1,1,\"Dose escalation partÔºö Safety and tolerability of SHR-1701 in advanced malignancies.\"\\n3994,2,1,\"Dose Escalation phase Number of participants with dose limiting toxicities (DLTs)\"\\n3995,1,1,\"Dose Escalation Phase of continued supply expansion: To determine safety & tolerability of higher than 200mg bid (to 400mg) of tablet & compare safety & tolerability profile of tablet with 400mg capsule\"\\n3996,1,1,\"Dose Escalation Phase: AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Tme 0 to Infinity\"\\n3997,1,1,\"Dose Escalation Phase: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib\"\\n3998,1,1,\"Dose Escalation Phase: AUC(0-tlast): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Paclitaxel\"\\n3999,1,1,\"Dose Escalation Phase: Cmax: Maximum Observed Plasma Concentration of Alisertib\"\\n4000,1,1,\"Dose Escalation Phase: Cmax: Maximum Observed Plasma Concentration of Paclitaxel\"\\n4001,2,2,\"Dose Escalation Phase: Maximum Tolerated Dose (MTD)\"\\n4002,1,1,\"Dose Escalation Phase: Maximum tolerated dose (MTD) of ABBV-321\"\\n4003,1,1,\"Dose Escalation phase: Number of participants with adverse events (AEs)\"\\n4004,1,1,\"Dose Escalation Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n4005,1,1,\"Dose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)\"\\n4006,1,1,\"Dose Escalation Phase: Number of Participants With Clinically Significant Laboratory Findings\"\\n4007,1,1,\"Dose Escalation Phase: Number of Participants With Clinically Significant Vital Sign Findings\"\\n4008,1,1,\"Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n4009,2,2,\"Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)\"\\n4010,1,1,\"Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)\"\\n4011,1,1,\"Dose Escalation phase: Number of participants with dose-limiting toxicities (DLTs)\"\\n4012,1,1,\"Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1\"\\n4013,1,1,\"Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of PEGPH20 in Combination With Pembrolizumab\"\\n4014,1,1,\"Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for ABBV-321\"\\n4015,1,1,\"Dose Escalation Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Alisertib\"\\n4016,1,1,\"Dose Escalation Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Paclitaxel\"\\n4017,1,1,\"Dose Escalation Phase: T¬Ω: Terminal Phase Elimination Half-Life of Paclitaxel\"\\n4018,2,2,\"DOSE ESCALATION PHASEÔºöIncidence of dose-limiting toxicities (DLTs) at Cycle 0 and Cycle1. Incidence and severity of treatment-emergent adverse events (TEAEs), with severity determined according to National Cancer Institute (NCI) CTCAE v5.0.\"\\n4019,1,1,\"DOSE ESCALATION PRIMARY OUTCOME (Dose Limiting Toxicities (DLTs) at cycle 1)\"\\n4020,1,1,\"Dose Escalation Stage - the dose limiting toxicities (DLTs), using NCI CTCAE v4.0, of oral CB-5083 in subjects with advanced tumors\"\\n4021,1,1,\"Dose Escalation Stage - the pharmacokinetic profile (PK) of oral CB-5083 in subjects with advanced solid tumors; parameters include AUC, Cmax, Tmax and T1/2\"\\n4022,1,1,\"dose escalation study of 06-benzylguanine (BG) and carmustine (BCNU)\"\\n4023,1,1,\"Dose Escalation Study: Maximum-tolerated Dose (MTD) of SC10914\"\\n4024,1,1,\"Dose Escalation Time to Cmax (Tmax) of VEGFR TKI (Combination therapy)\"\\n4025,1,1,\"Dose Escalation To determine the maximum tolerated dose (MTD) of SAR125844\"\\n4026,1,1,\"Dose Escalation to determine the maximum tolerated dose (MTD) of SAR566658\"\\n4027,1,1,\"Dose Escalation- Number of participants with adverse events following administration of IMT-009\"\\n4028,1,1,\"Dose Escalation: Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of ABBV-CLS-484 (Monotherapy)\"\\n4029,1,1,\"Dose Escalation: Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of PD-1 Inhibitor (Combination therapy)\"\\n4030,1,1,\"Dose Escalation: Area Under The Plasma Or Serum Concentration-Time Curve (AUC) Of VEGFR TKI (Combination therapy)\"\\n4031,1,1,\"Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals).\"\\n4032,1,1,\"Dose Escalation: Dose Identification of CART-TnMUC1\"\\n4033,2,2,\"Dose Escalation: Dose intensity by treatment\"\\n4034,1,1,\"Dose escalation: Dose Limiting Toxicities (DLTs)\"\\n4035,1,1,\"Dose Escalation: Dose-limiting Toxicities\"\\n4036,1,1,\"Dose Escalation: Evaluate up to Eighteen Subjects With Tumors Expressing TCRT-ESO-A1 and Having Dose Limiting Toxicity Adverse Events as Assessed by CTCAE-Version 5\"\\n4037,1,1,\"Dose Escalation: Frequency of dose interruptions and reductions, by treatment\"\\n4038,1,1,\"Dose escalation: Frequency of dose interruptions and reductions, by treatment\"\\n4039,1,1,\"Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)\"\\n4040,1,1,\"Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment\"\\n4041,1,1,\"Dose Escalation: Incidence And Severity Of Adverse Events, Including The Incidence Of Dose-limiting Toxicities Within The First Cycle\"\\n4042,1,1,\"Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment\"\\n4043,1,1,\"Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.\"\\n4044,1,1,\"Dose Escalation: Incidence of Adverse Events\"\\n4045,1,1,\"Dose Escalation: Incidence of adverse events (AEs).\"\\n4046,1,1,\"Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities.\"\\n4047,1,1,\"Dose Escalation: Incidence of Dose-limiting Toxicities (DLT), Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)\"\\n4048,1,1,\"Dose Escalation: Incidence of dose-limiting toxicity (DLT)\"\\n4049,1,1,\"Dose Escalation: Incidence of Laboratory abnormalities\"\\n4050,1,1,\"Dose Escalation: Maximum Observed Plasma/Serum Concentration (Cmax) Of ABBV-CLS-484 (Monotherapy)\"\\n4051,1,1,\"Dose Escalation: Maximum Observed Plasma/Serum Concentration (Cmax) Of Programmed Cell Death-1 (PD-1) Inhibitor (Combination therapy)\"\\n4052,1,1,\"Dose Escalation: Maximum Observed Plasma/Serum Concentration (Cmax) Of VEGFRTKI (Combination therapy) Maximum plasma/serum concentration of PD-1 inhibitor\"\\n4053,1,1,\"Dose Escalation: Maximum Tolerated Dose\"\\n4054,1,1,\"Dose Escalation: maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of tisotumab vedotin\"\\n4055,1,1,\"Dose Escalation: Maximum tolerated dose (MTD) of BGB-24714 as monotherapy and in combination with chemotherapy\"\\n4056,1,1,\"Dose Escalation: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of GDC-9545 When Administered as a Single Agent or in Combination with Palbociclib\"\\n4057,1,1,\"Dose Escalation: MTD/Recommended Dose\"\\n4058,1,1,\"Dose Escalation: Number of Participants with a Dose-Limiting Toxicity (DLT)\"\\n4059,1,1,\"Dose Escalation: Number of participants with adverse events (AEs)\"\\n4060,1,1,\"Dose Escalation: Number of Participants with at Least One Adverse Event, Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)\"\\n4061,1,1,\"Dose Escalation: Number of Participants With Dose-Limiting Toxicities (DLT)\"\\n4062,2,1,\"Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle\"\\n4063,1,1,\"Dose Escalation: Number of Participants with Dose-Limiting Toxicities When GDC-9545 is Administered as a Single Agent or in Combination with Palbociclib\"\\n4064,1,1,\"Dose Escalation: Number of patients with dose-limiting toxicities (DLTs)\"\\n4065,1,1,\"Dose Escalation: Objective Response Rate (ORR) Of ABBV-CLS-484 And VEGFR TKI Based On Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Combination therapy)\"\\n4066,1,1,\"Dose escalation: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)\"\\n4067,1,1,\"Dose Escalation: Phase Elimination Rate Half-Life (t1/2) Of ABBV-CLS-484 (Monotherapy)\"\\n4068,1,1,\"Dose Escalation: Phase Elimination Rate Half-Life (t1/2) Of PD-1 Inhibitor (Combination therapy)\"\\n4069,1,1,\"Dose Escalation: Phase Elimination Rate Half-Life (t1/2) Of VEGFR TKI (Combination therapy)\"\\n4070,1,1,\"Dose escalation: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2\"\\n4071,1,1,\"Dose escalation: recommended clinical dose (RCD)\"\\n4072,1,1,\"Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy\"\\n4073,1,1,\"Dose Escalation: Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose of ABBV-CLS-484\"\\n4074,1,1,\"Dose Escalation: Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose of ABBV-CLS-484 and a PD-1 Inhibitor (Combination therapy)\"\\n4075,1,1,\"Dose Escalation: Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose of ABBV-CLS-484 and a VEGFR TKI (Combination therapy)\"\\n4076,1,1,\"Dose Escalation: Recommended Phase 2 dose (RP2D) of BGB-24714 as monotherapy and in combination with chemotherapy\"\\n4077,1,1,\"Dose Escalation: RP2D ABBV-151 + Budigalimab Combination Therapy\"\\n4078,1,1,\"Dose escalation: safety assessment\"\\n4079,1,1,\"Dose Escalation: Time To Cmax (Tmax) Of ABBV-CLS-484 (Monotherapy)\"\\n4080,1,1,\"Dose Escalation: Time To Cmax (Tmax) Of PD-1 Inhibitor (Combination therapy)\"\\n4081,1,1,\"Dose Escalation:Maximum Tolerated Dose (MTD)\"\\n4082,1,1,\"Dose escalationÔºö MTD determination\"\\n4083,1,1,\"Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Number of patients with treatment-related adverse events as assessed by CTCAE to determine the recommended Phase 2 dose (RP2D).\"\\n4084,1,1,\"Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Objective response rate\"\\n4085,4,2,\"Dose Expansion\"\\n4086,1,1,\"Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n4087,1,1,\"Dose expansion : Number of patients with adverse events as a measure of safety and tolerability\"\\n4088,1,1,\"Dose Expansion Part: Disease Control Rate (DCR) for 6 Months\"\\n4089,1,1,\"Dose Expansion Part: Duration of Response\"\\n4090,1,1,\"Dose Expansion Part: Duration of Response (DOR)\"\\n4091,1,1,\"Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events\"\\n4092,1,1,\"Dose Expansion Part: Number of Participants in each Category of Best Overall Response (per Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)\"\\n4093,1,1,\"Dose Expansion Part: Number of Participants with Progression-Free Survival (PFS)\"\\n4094,1,1,\"Dose Expansion Part: Overall Objective Response Rate (per Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)\"\\n4095,1,1,\"Dose Expansion Part: Percentage of Participants With Disease Control\"\\n4096,1,1,\"Dose Expansion Part: Percentage of Participants With Objective Response\"\\n4097,1,1,\"Dose expansion part: recommended phase II dose (RP2D)\"\\n4098,1,1,\"Dose Expansion Part: Time to Progression (TTP)\"\\n4099,1,1,\"Dose Expansion Phase: AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Paclitaxel\"\\n4100,1,1,\"Dose Expansion Phase: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib\"\\n4101,1,1,\"Dose Expansion Phase: AUC(0-tlast): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Paclitaxel\"\\n4102,1,1,\"Dose Expansion Phase: Cmax: Maximum Observed Plasma Concentration of Alisertib\"\\n4103,1,1,\"Dose Expansion Phase: Cmax: Maximum Observed Plasma Concentration of Paclitaxel\"\\n4104,1,1,\"Dose Expansion Phase: Duration of Objective Response\"\\n4105,1,1,\"Dose Expansion phase: Duration of response ( DOR )\"\\n4106,1,1,\"Dose Expansion phase: Duration of Response (DOR)\"\\n4107,1,1,\"Dose Expansion Phase: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n4108,1,1,\"Dose Expansion Phase: Number of Participants With Clinically Significant Laboratory Findings\"\\n4109,1,1,\"Dose Expansion Phase: Number of Participants With Clinically Significant Vital Sign Findings\"\\n4110,1,1,\"Dose Expansion phase: Objective Response Rate (ORR)\"\\n4111,1,1,\"Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n4112,3,3,\"Dose Expansion phase: Overall response rate (ORR)\"\\n4113,1,1,\"Dose Expansion Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Alisertib\"\\n4114,1,1,\"Dose Expansion Phase: Tmax: Time to Reach the Maximum Plasma Concentration of Paclitaxel\"\\n4115,1,1,\"Dose Expansion Phase: To determine overall response rate (ORR) (complete response [CR] + partial response [PR]) per RECIST v1.1\"\\n4116,1,1,\"Dose Expansion Phase: T¬Ω: Terminal Phase Elimination Half-Life of Paclitaxel\"\\n4117,1,1,\"DOSE EXPANSION PHASEÔºöIncidence and severity of TEAEs, with severity determined according to NCI CTCAE v5.0.\"\\n4118,2,2,\"DOSE EXPANSION PHASEÔºöObjective Response Rate (ORR)\"\\n4119,1,1,\"DOSE EXPANSION PHASEÔºöTo evaluate the incidence and severity of TEAEs, with severity determined according to NCI CTCAE v5.0.\"\\n4120,1,1,\"DOSE EXPANSION PRIMARY OUTCOME (treatment-emergent Adverse Events)\"\\n4121,1,1,\"Dose Expansion Stage - safety and tolerability of CB-5083 in subjects with advanced renal-cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET) or solid tumors with RAS-MAPK mutations, if such arms are opened per Sponsor, using NCI CTCAE v4.0\"\\n4122,1,1,\"Dose Expansion Stage - safety and tolerability of oral CB-5083 administered to subjects with RAS mutated metastatic colorectal cancer (mCRC) at the RP2D, using NCI CTCAE v4.0\"\\n4123,1,1,\"Dose expansion stage-efficacy\"\\n4124,1,1,\"Dose expansion stage-safety\"\\n4125,1,1,\"Dose Expansion Study: Recommended Phase II Dose(RP2D) of SC10914\"\\n4126,1,1,\"Dose Expansion: Characterization of clinical benefit rate for TAC-001\"\\n4127,1,1,\"Dose Expansion: Characterization of duration of response for TAC-001\"\\n4128,1,1,\"Dose Expansion: Characterization of ORR for TAC-001\"\\n4129,1,1,\"Dose Expansion: Duration of Stable Disease (SD)\"\\n4130,1,1,\"Dose Expansion: Incidence And Severity Of Adverse Events\"\\n4131,1,1,\"Dose expansion: Number of patients with adverse events as a measure of safety and tolerability\"\\n4132,3,3,\"Dose Expansion: Objective Response Rate (ORR)\"\\n4133,1,1,\"Dose Expansion: Objective response rate (ORR)\"\\n4134,1,1,\"Dose expansion: Objective response rate (ORR)\"\\n4135,1,1,\"Dose Expansion: Objective Response Rate (ORR) Of ABBV-CLS-484 And PD-1 Targeting Agent Based On Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Combination therapy)\"\\n4136,1,1,\"Dose Expansion: Objective Response Rate (ORR) Of ABBV-CLS-484 Based On Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Monotherapy)\"\\n4137,1,1,\"Dose expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\"\\n4138,1,1,\"Dose Expansion: Occurrence of Grade 3 and 4 treatment-related adverse\"\\n4139,1,1,\"Dose Expansion: ORR\"\\n4140,1,1,\"Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BM\"\\n4141,1,1,\"Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment\"\\n4142,1,1,\"Dose Expansion: Percentage of Participants With Confirmed Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment\"\\n4143,1,1,\"Dose Expansion: To assess objective response (OR) of GEN-001 in patients with advanced or metastatic solid tumors, when administered as combined with avelumab.\"\\n4144,1,1,\"Dose Expansion:Overall Response Rate\"\\n4145,1,1,\"Dose exploration only: Number of participants who experience dose limiting toxicities (DLTs)\"\\n4146,1,1,\"Dose Finding\"\\n4147,1,1,\"Dose Finding in part I\"\\n4148,1,1,\"Dose Finding phase: Recommended Phase 2 Dose\"\\n4149,1,1,\"Dose finding stage-MTD or RP2D\"\\n4150,1,1,\"Dose finding stage-safety\"\\n4151,1,1,\"dose for expansion (RDE) of IMM2902\"\\n4152,1,1,\"Dose Intensity\"\\n4153,15,4,\"Dose intensity\"\\n4154,1,1,\"Dose intensity (Phase I)\"\\n4155,1,1,\"Dose intensity in Safety Run-in\"\\n4156,1,1,\"Dose Intensity of Autogene Cevumeran\"\\n4157,1,1,\"Dose Intensity of Each Component of the Treatment Regimen\"\\n4158,1,1,\"Dose intensity of study treatment\"\\n4159,2,1,\"Dose Intensity of Vemurafenib\"\\n4160,1,1,\"Dose Intensity Received by Participants\"\\n4161,2,2,\"Dose intensity.\"\\n4162,3,1,\"Dose interruptions\"\\n4163,1,1,\"Dose interruptions (Phase I)\"\\n4164,1,1,\"Dose interruptions and reductions\"\\n4165,1,1,\"Dose interruptions due to AEs (Part 1 and Part 2)\"\\n4166,1,1,\"Dose interruptions, reductions and dose intensity, by treatment\"\\n4167,1,1,\"Dose interruptions/reductions in Safety Run-in\"\\n4168,1,1,\"Dose level at which AEG35156 is well tolerated based upon development of toxicities during the first cycle of therapy unless delayed or cumulative toxicity is encountered. Assessments done weekly.\"\\n4169,1,1,\"Dose Limint Toxicities (DLT)\"\\n4170,2,2,\"Dose Limit toxicity (DLT)\"\\n4171,1,1,\"Dose limit toxicity (DLT) determination\"\\n4172,1,1,\"Dose limitation toxicities (DLT)\"\\n4173,2,2,\"Dose limited toxicities\"\\n4174,1,1,\"dose limited toxicities\"\\n4175,1,1,\"Dose limited toxicities (Phase I)\"\\n4176,1,1,\"Dose limited toxicities evaluated with NCI-CTC AE v5.0\"\\n4177,3,2,\"Dose Limited Toxicity\"\\n4178,8,6,\"Dose Limited Toxicity (DLT)\"\\n4179,11,3,\"Dose limited toxicity (DLT)\"\\n4180,1,1,\"Dose Limited Toxicity(DLT)\"\\n4181,1,1,\"dose limited toxicity, DLT\"\\n4182,1,1,\"Dose limited toxicityÔºàDLTÔºâ\"\\n4183,17,10,\"Dose Limiting Toxicities\"\\n4184,30,9,\"Dose limiting toxicities\"\\n4185,42,19,\"Dose Limiting Toxicities (DLT)\"\\n4186,13,3,\"Dose limiting toxicities (DLT)\"\\n4187,1,1,\"Dose Limiting Toxicities (DLT) - (safety lead in)\"\\n4188,1,1,\"Dose Limiting Toxicities (DLT) - dose escalation part\"\\n4189,1,1,\"Dose Limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of CEP 18770\"\\n4190,1,1,\"Dose limiting toxicities (DLT) defined as any grade 3 or higher hematological or non-hematological toxicity that is probably or definitely related to treatment according to Common Terminology Criteria for Adverse Events version 4.03 (Phase Ib)\"\\n4191,1,1,\"Dose Limiting Toxicities (DLT) in Safety Part\"\\n4192,1,1,\"Dose limiting toxicities (DLT) in stage ‚Ö†\"\\n4193,1,1,\"Dose limiting toxicities (DLT) in the trial subjects.\"\\n4194,1,1,\"Dose Limiting Toxicities (DLT) of combination therapy (Applicable for: phase Ib stage ).\"\\n4195,1,1,\"Dose limiting toxicities (DLT) of demcizumab given in combination with pembrolizumab\"\\n4196,1,1,\"Dose Limiting Toxicities (DLT) of Kevetrin.\"\\n4197,2,1,\"Dose limiting toxicities (DLT) of PRT1419\"\\n4198,1,1,\"Dose limiting toxicities (DLT) of PRT2527\"\\n4199,1,1,\"Dose Limiting Toxicities (DLT) with a single fixed dose of [177Lu]Ludotadipep during the first cycle (8 [¬±1] weeks) (Phase 1)\"\\n4200,1,1,\"Dose limiting toxicities (DLT) within the first two cycles of treatment\"\\n4201,1,1,\"Dose Limiting Toxicities (DLT)\\'s of the combination of cabazitaxel and cisplatin (part 1)\"\\n4202,1,1,\"Dose limiting toxicities (DLT)(Part 1)\"\\n4203,1,1,\"Dose Limiting Toxicities (DLT), Part A\"\\n4204,21,8,\"Dose Limiting Toxicities (DLTs)\"\\n4205,3,1,\"Dose Limiting toxicities (DLTs)\"\\n4206,19,7,\"Dose limiting toxicities (DLTs)\"\\n4207,4,4,\"Dose limiting toxicities (DLTs) (Phase 1)\"\\n4208,2,1,\"Dose limiting toxicities (DLTs) (Phase ‚Ö†)\"\\n4209,1,1,\"Dose Limiting Toxicities (DLTs) - Phase Ib\"\\n4210,1,1,\"Dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) for determination of RP2D of CyPep-1\"\\n4211,1,1,\"Dose limiting toxicities (DLTs) BJ-001 as a single agent\"\\n4212,1,1,\"Dose limiting toxicities (DLTs) BJ-001 in combination with pembrolizumab inhibitor.\"\\n4213,1,1,\"Dose limiting toxicities (DLTs) of AGEN1884\"\\n4214,1,1,\"Dose Limiting Toxicities (DLTs) of INVAC-1 as single agent in combination with electroporation\"\\n4215,1,1,\"Dose limiting toxicities (DLTs) of OB318\"\\n4216,1,1,\"Dose limiting toxicities (DLTs) of RTX-224\"\\n4217,1,1,\"Dose limiting toxicities (DLTs) of study treatment as determined by incidence and severity of adverse events (AEs)\"\\n4218,1,1,\"Dose limiting toxicities (DLTs) of the combination of LDE225 with paclitaxel in patients with advanced solid tumors\"\\n4219,2,2,\"Dose Limiting Toxicities (DLTs).\"\\n4220,1,1,\"Dose limiting toxicities (grade 3 or higher) defined by Common Toxicity Criteria (CTC) version 4.0\"\\n4221,1,1,\"Dose Limiting Toxicities (Phase 1)\"\\n4222,1,1,\"Dose limiting toxicities (Phase 1)\"\\n4223,1,1,\"Dose Limiting Toxicities according to the NCI-CTCAE V5\"\\n4224,1,1,\"Dose limiting toxicities at 6 weeks post T cell infusion\"\\n4225,1,1,\"Dose Limiting Toxicities at the Indicated Dose Levels, as an Assessment of Dosing Frequency\"\\n4226,1,1,\"Dose limiting toxicities defined as an adverse event which is likely related to the study medication\"\\n4227,1,1,\"Dose Limiting Toxicities During Cycle 1\"\\n4228,1,1,\"Dose Limiting Toxicities During cycle1\"\\n4229,1,1,\"Dose limiting toxicities for CDX-0158\"\\n4230,1,1,\"Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).\"\\n4231,1,1,\"Dose Limiting Toxicities of CC-90003\"\\n4232,1,1,\"Dose limiting toxicities of the combination of methoxyamine and temozolomide\"\\n4233,2,1,\"Dose Limiting Toxicities(DLT)\"\\n4234,1,1,\"Dose limiting toxicities(DLT)\"\\n4235,1,1,\"Dose limiting toxicities(DLTs)\"\\n4236,60,21,\"Dose Limiting Toxicity\"\\n4237,66,20,\"Dose limiting toxicity\"\\n4238,2,1,\"Dose Limiting Toxicity (DLT )\"\\n4239,68,24,\"Dose Limiting Toxicity (DLT)\"\\n4240,1,1,\"Dose limiting Toxicity (DLT)\"\\n4241,85,31,\"Dose limiting toxicity (DLT)\"\\n4242,3,2,\"dose limiting toxicity (DLT)\"\\n4243,1,1,\"Dose Limiting Toxicity (DLT) (Phase 1b)\"\\n4244,1,1,\"Dose Limiting Toxicity (DLT) (Phase I)\"\\n4245,3,1,\"Dose limiting toxicity (DLT) (Phase I)\"\\n4246,1,1,\"Dose Limiting Toxicity (DLT) (Phase Ia)\"\\n4247,1,1,\"Dose Limiting Toxicity (DLT) (Phase Ib)\"\\n4248,2,2,\"Dose Limiting Toxicity (DLT) - Percentage of Participants With DLT Events\"\\n4249,1,1,\"Dose Limiting Toxicity (DLT) - Phase Ia\"\\n4250,1,1,\"Dose Limiting Toxicity (DLT) - Phase l Only\"\\n4251,1,1,\"Dose Limiting Toxicity (DLT) [Phase I Dose Finding]\"\\n4252,7,1,\"Dose Limiting Toxicity (DLT) [Phase I]\"\\n4253,1,1,\"Dose Limiting Toxicity (DLT) according to CTEP Common Terminology Criteria for Adverse Events Version 4.0\"\\n4254,1,1,\"Dose limiting toxicity (DLT) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\"\\n4255,1,1,\"Dose limiting toxicity (DLT) and adverse events (AEs)\"\\n4256,1,1,\"Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)\"\\n4257,1,1,\"Dose limiting toxicity (DLT) and maximum tolerated dose (MTD)\"\\n4258,1,1,\"Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), if reached\"\\n4259,1,1,\"Dose limiting toxicity (DLT) as graded by Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v. 4.03) (Phase I)\"\\n4260,1,1,\"Dose limiting toxicity (DLT) determination\"\\n4261,1,1,\"Dose Limiting Toxicity (DLT) during the first two treatment cycles\"\\n4262,1,1,\"Dose Limiting Toxicity (DLT) Events in Chemotherapy in Combination With Selumetinib\"\\n4263,1,1,\"Dose limiting toxicity (DLT) in monotherapy\"\\n4264,1,1,\"Dose Limiting Toxicity (DLT) Incidence\"\\n4265,1,1,\"Dose limiting toxicity (DLT) incidence (according DLT definition) during the first treatment cycle with pazopanib (28 days)\"\\n4266,1,1,\"Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study\"\\n4267,1,1,\"Dose Limiting Toxicity (DLT) of a single dose of intravenous recombinant human tumor necrosis factor-Œ± plus liposomal doxorubicin\"\\n4268,1,1,\"Dose limiting toxicity (DLT) of CVM-1118 ER Capsule\"\\n4269,1,1,\"Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1\"\\n4270,1,1,\"Dose limiting toxicity (DLT) of guadecitabine (SGI-110) plus cisplatin\"\\n4271,1,1,\"Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors\"\\n4272,1,1,\"Dose limiting toxicity (DLT) of KF-0210 [Tolerability]\"\\n4273,1,1,\"Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)\"\\n4274,2,2,\"Dose limiting toxicity (DLT) of NBM-BMX [Safety and Tolerability]\"\\n4275,1,1,\"Dose limiting toxicity (DLT) of PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007)\"\\n4276,1,1,\"Dose Limiting Toxicity (DLT) of PROMITIL\"\\n4277,1,1,\"Dose limiting toxicity (DLT) of Promitil in combination with external beam radiotherapy (EBR)\"\\n4278,1,1,\"Dose limiting toxicity (DLT) of PRT3645\"\\n4279,1,1,\"Dose limiting toxicity (DLT) of PRT3789\"\\n4280,1,1,\"Dose Limiting Toxicity (DLT) of S95005 when given in combination with oxaliplatin\"\\n4281,1,1,\"Dose limiting toxicity (DLT) of TRX-818\"\\n4282,1,1,\"Dose limiting toxicity (DLT) of TRX-818 in Asians\"\\n4283,1,1,\"Dose Limiting Toxicity (DLT) of TY-302\"\\n4284,1,1,\"Dose Limiting Toxicity (DLT) of TY-302 combine with Tamoxifen\"\\n4285,3,1,\"Dose Limiting Toxicity (DLT) Rate\"\\n4286,1,1,\"Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I)\"\\n4287,1,1,\"Dose limiting toxicity (DLT) to define the maximum tolerated dose (MTD). The DLT is defined as treatment related grade 3 or grade 4 adverse events or abnormal lab test that occurred in the first 28 days after start of study drug.\"\\n4288,1,1,\"dose limiting toxicity (DLT) to define the maximum tolerated dose (MTD). The DLT is defined as treatment related grade 3 or grade 4 adverse events or abnormal lab test that occurred in the first 28 days after start of study drug.\"\\n4289,4,1,\"Dose Limiting Toxicity (DLTs)\"\\n4290,4,2,\"Dose Limiting Toxicity (Phase I)\"\\n4291,1,1,\"Dose Limiting Toxicity - To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients\"\\n4292,2,2,\"Dose Limiting Toxicity [DLT]\"\\n4293,1,1,\"Dose limiting toxicity [DLTs]\"\\n4294,1,1,\"Dose Limiting Toxicity and Maximum Tolerated Dose of ispinesib administered as a 1-hr intravenous infusion on Day 1 of a 28-day cycle in female patients with Stage IIIB or IV breast cancer\"\\n4295,1,1,\"Dose Limiting Toxicity and Maximum Tolerated Dose of ispinesib administered as a 1-hr intravenous infusion on Day 15 of a 28-day cycle in female patients with Stage IIIB or IV breast cancer\"\\n4296,1,1,\"Dose limiting toxicity and maximum tolerated dose of olaparib (Phase I)\"\\n4297,1,1,\"Dose Limiting Toxicity and Recommended Phase 2 dose\"\\n4298,1,1,\"Dose limiting toxicity and the maximum tolerated dose\"\\n4299,1,1,\"Dose Limiting Toxicity Assessment and Maximum Tolerated Dose Determination\"\\n4300,1,1,\"Dose limiting toxicity at Cycle 1\"\\n4301,1,1,\"Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0\"\\n4302,1,1,\"Dose limiting toxicity based on the incidence, intensity, and duration of adverse events that are related to the drug combinations and occur according to according to National Cancer Institute Common Terminology Criteria for Adverse Event version 4.0\"\\n4303,3,2,\"Dose limiting toxicity determination\"\\n4304,1,1,\"Dose limiting toxicity determined by estimation of maximum tolerated dose assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase Ib)\"\\n4305,3,3,\"Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03)\"\\n4306,1,1,\"Dose limiting toxicity for the combination of AZD6738 and gemcitabine.\"\\n4307,1,1,\"Dose Limiting Toxicity graded using the NCI CTCAE v. 4.03\"\\n4308,1,1,\"Dose Limiting Toxicity in cycle 1\"\\n4309,1,1,\"Dose limiting toxicity in cycle 1\"\\n4310,1,1,\"Dose Limiting Toxicity in Run-in Phase\"\\n4311,1,1,\"Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel\"\\n4312,1,1,\"Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study\"\\n4313,1,1,\"Dose limiting toxicity of Doxil in combination with PSC 833\"\\n4314,2,2,\"Dose Limiting Toxicity of ES014\"\\n4315,1,1,\"Dose limiting toxicity of fully human B7H3 CAR-T cells\"\\n4316,1,1,\"Dose Limiting Toxicity of PY159 (Part A only)\"\\n4317,1,1,\"Dose Limiting Toxicity of SRF617\"\\n4318,1,1,\"Dose limiting toxicity of the combination in all cohorts\"\\n4319,2,1,\"Dose Limiting Toxicity Rate\"\\n4320,1,1,\"Dose limiting toxicity rate during cycle 1 of treatment with oral ONC201\"\\n4321,3,1,\"Dose Limiting Toxicity(DLT)\"\\n4322,4,1,\"Dose limiting toxicity(DLT)\"\\n4323,1,1,\"Dose limiting toxicity(DLT) of Mogamulizumab\"\\n4324,1,1,\"Dose Limiting Toxicity, Adverse Event\"\\n4325,1,1,\"Dose limiting Toxicity, DLT\"\\n4326,1,1,\"Dose Limiting Treatment/DLT Evaluable Population\"\\n4327,1,1,\"Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast(dn)) of Docetaxel in Cycle 1\"\\n4328,1,1,\"Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast(dn)) of Docetaxel in Cycle 4\"\\n4329,1,1,\"Dose Normalized AUC, Total Selumetinib\"\\n4330,1,1,\"Dose Normalized AUC, Unbound Selumetinib\"\\n4331,1,1,\"Dose Normalized AUCœÑ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib\"\\n4332,1,1,\"Dose Normalized Cmax, Total Selumetinib\"\\n4333,1,1,\"Dose Normalized Cmax, Unbound Selumetinib\"\\n4334,1,1,\"Dose Normalized Maximum Observed Plasma Concentration (Cmax(dn)) of Docetaxel in Cycle 1\"\\n4335,1,1,\"Dose Normalized Maximum Observed Plasma Concentration (Cmax(dn)) of Docetaxel in Cycle 4\"\\n4336,1,1,\"Dose of AMG 820 where clinically significant or ‚â• Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled is greater than 33%.\"\\n4337,1,1,\"Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose)\"\\n4338,1,1,\"Dose of PS-341 that results in not more than 70% to 80% 20S proteasome inhibition [20S-PI] in combination with a paclitaxel\"\\n4339,1,1,\"dose reduction or discontinuation\"\\n4340,2,1,\"Dose reductions\"\\n4341,1,1,\"Dose reductions (Phase I)\"\\n4342,1,1,\"Dose Resulting in Steady-state Trough\"\\n4343,1,1,\"Dose(s) of ASC 61 to be examined in Part 2 and the recommended Phase 2 dose(s)\"\\n4344,1,1,\"Dose(s) of CTX 471 as a monotherapy and doses of CTX-471 in combination with pembrolizumab to be examined in Part 2 and the recommended Phase 2 dose(s)\"\\n4345,1,1,\"Dose-escalation cohort: DLTs and MTD\"\\n4346,1,1,\"Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n4347,1,1,\"Dose-escalation part and Expansion part: Bone density measurement\"\\n4348,1,1,\"Dose-escalation part and Expansion part: Computed tomography (CT) Imaging assessment\"\\n4349,1,1,\"Dose-escalation part and Expansion part: Ophthalmology\"\\n4350,1,1,\"Dose-escalation part and Expansion part: Safety assessed by Adverse Events (AEs)\"\\n4351,1,1,\"Dose-escalation part and Expansion part:Safety assessed by 12-lead ECGs\"\\n4352,1,1,\"Dose-escalation part and Expansion part:Safety assessed by Body weight\"\\n4353,1,1,\"Dose-escalation part and Expansion part:Safety assessed by Laboratory tests\"\\n4354,1,1,\"Dose-escalation part and Expansion part:Safety assessed by Vital signs\"\\n4355,1,1,\"Dose-escalation Part: Duration of Treatment Emergent Adverse Events (TEAEs) and Related TEAEs\"\\n4356,1,1,\"Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)\"\\n4357,1,1,\"Dose-escalation Part: Number of Subjects With Dose Limiting Toxicities (DLT)\"\\n4358,1,1,\"Dose-escalation Part: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)\"\\n4359,1,1,\"Dose-escalation Part: Number of Subjects With Treatment-Related AEs\"\\n4360,1,1,\"Dose-escalation Part: Number of Treatment Emergent Adverse Events (TEAEs) and Related TEAEs by Severity\"\\n4361,1,1,\"Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine\"\\n4362,1,1,\"Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With Pembrolizumab\"\\n4363,1,1,\"Dose-Escalation Phase: Number of Participants With Dose-Limiting Toxicity (DLT)\"\\n4364,1,1,\"Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368\"\\n4365,1,1,\"Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181\"\\n4366,1,1,\"Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine\"\\n4367,1,1,\"Dose-Escalation Stage: MTD/recommended dose for XB002\"\\n4368,1,1,\"Dose-Escalation Stage: MTD/recommended dose for XL092\"\\n4369,1,1,\"Dose-Escalation Stage: MTD/recommended dose for XL102\"\\n4370,1,1,\"Dose-Escalation Stage: RP2D for TAC-001\"\\n4371,1,1,\"Dose-Escalation: Number of Participants With Dose Limiting Toxicity (DLT)\"\\n4372,1,1,\"Dose-expansion Part: Best Overall Response (BOR) as Assessed by Independent Endpoint Review Committee (IRC)\"\\n4373,1,1,\"Dose-expansion Part: Disease Control Rate According to Response Assessment in Neuro-Oncology (RANO) as Adjudicated by the IRC for Subjects With Glioblastoma\"\\n4374,1,1,\"Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1)\"\\n4375,4,4,\"Dose-Finding\"\\n4376,1,1,\"Dose-Limited Toxicities (DLT)\"\\n4377,1,1,\"Dose-limited toxicities (DLT) of combination therapy with temozolomide, talazoparib and irinotecan\"\\n4378,2,1,\"Dose-limited toxicity (DLT)\"\\n4379,1,1,\"Dose-limited toxicity (DLT) of SHR-1603\"\\n4380,1,1,\"Dose-limiting toxic effects and recommended phase II dose, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n4381,4,1,\"Dose-Limiting Toxicities\"\\n4382,24,11,\"Dose-limiting toxicities\"\\n4383,22,11,\"Dose-limiting toxicities (DLT)\"\\n4384,1,1,\"Dose-limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of Belinostat in Patients With Inoperable HCC (Phase I)\"\\n4385,1,1,\"Dose-limiting toxicities (DLT) and/or subsequent maximum dose\"\\n4386,1,1,\"Dose-limiting toxicities (DLT) of HTMC0435 combined with Temozolomide\"\\n4387,1,1,\"Dose-limiting toxicities (DLT) of talazoparib combined with irinotecan\"\\n4388,1,1,\"Dose-limiting toxicities (DLT), defined as any grade 3 or greater non-hematologic toxicity, assessed using the NCI CTCAE v3.0\"\\n4389,7,5,\"Dose-Limiting Toxicities (DLTs)\"\\n4390,5,2,\"Dose-limiting Toxicities (DLTs)\"\\n4391,20,6,\"Dose-limiting toxicities (DLTs)\"\\n4392,4,2,\"dose-limiting toxicities (DLTs)\"\\n4393,1,1,\"Dose-limiting toxicities (DLTs) and Maximum Tolerated Dose (MTD)\"\\n4394,1,1,\"Dose-limiting toxicities (DLTs) associated with S095033 administration during the first cycle of treatment (Phase 1)\"\\n4395,1,1,\"Dose-limiting toxicities (DLTs) defined based on the rate of drug-related grade 3-5 adverse events assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (CTCAE) (v.) 5.\"\\n4396,1,1,\"Dose-limiting toxicities (DLTs) for olaparib in combination with durvalumab and radiation\"\\n4397,1,1,\"Dose-limiting Toxicities (DLTs) in Phase I Portion\"\\n4398,1,1,\"Dose-limiting toxicities (DLTs) observed in combined administration of EVER4010001 and Pembrolizumab\"\\n4399,1,1,\"Dose-limiting Toxicities (DLTs) of IDE397\"\\n4400,1,1,\"Dose-limiting Toxicities (DLTs) of IDE397 in combination with either docetaxel, paclitaxel, gemcitabine and nab-paclitaxel or pemetrexed\"\\n4401,1,1,\"Dose-limiting toxicities (DLTs) of SAIL66[safety and tolerability]\"\\n4402,1,1,\"Dose-limiting toxicities (DLTs) with IO-202 and IO-202 + pembrolizumab\"\\n4403,1,1,\"Dose-limiting toxicities (Number of participants with a DLT)\"\\n4404,1,1,\"Dose-Limiting Toxicities (Phase 1)\"\\n4405,1,1,\"Dose-Limiting Toxicities (Stage 1)\"\\n4406,1,1,\"Dose-limiting toxicities and maximum tolerated dose\"\\n4407,1,1,\"Dose-limiting toxicities and the recommended dose for phase 2 evaluation of the combination of IPI-926 and cetuximab\"\\n4408,1,1,\"Dose-limiting toxicities as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and maximum-tolerated dose\"\\n4409,1,1,\"Dose-limiting toxicities during dose-escalation phase.\"\\n4410,1,1,\"Dose-limiting toxicities in dose-expansion phase.\"\\n4411,1,1,\"Dose-limiting toxicities of bortezomib graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n4412,1,1,\"Dose-limiting Toxicities of Entinostat When Combined With Aldesleukin Within the Phase I\"\\n4413,1,1,\"Dose-limiting toxicities of veliparib\"\\n4414,1,1,\"Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0\"\\n4415,1,1,\"Dose-limiting toxicities related to the investigational agent\"\\n4416,1,1,\"Dose-limiting Toxicities(DLTs)\"\\n4417,3,2,\"Dose-limiting toxicitiesÔºàDLT)\"\\n4418,3,3,\"Dose-limiting toxicitiesÔºàDLTÔºâ\"\\n4419,9,4,\"Dose-Limiting Toxicity\"\\n4420,14,7,\"Dose-limiting Toxicity\"\\n4421,59,17,\"Dose-limiting toxicity\"\\n4422,5,1,\"dose-limiting toxicity\"\\n4423,1,1,\"Dose-limiting toxicity (Arm A)\"\\n4424,27,11,\"Dose-Limiting Toxicity (DLT)\"\\n4425,14,9,\"Dose-limiting Toxicity (DLT)\"\\n4426,113,26,\"Dose-limiting toxicity (DLT)\"\\n4427,10,6,\"dose-limiting toxicity (DLT)\"\\n4428,2,1,\"Dose-limiting Toxicity (DLT) (Phase I)\"\\n4429,1,1,\"Dose-limiting toxicity (DLT) (Phase I)\"\\n4430,1,1,\"Dose-limiting toxicity (DLT) and incidence, severity, and type of treatment-emergent adverse events (TEAEs),Safety\"\\n4431,1,1,\"Dose-limiting toxicity (DLT) and Maximum tolerated dose (MTD)\"\\n4432,3,2,\"Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD)\"\\n4433,1,1,\"Dose-limiting toxicity (DLT) and RP2D of ADG116 in combination with pembrolizumab.\"\\n4434,1,1,\"Dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (Phase I)\"\\n4435,1,1,\"Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n4436,1,1,\"Dose-limiting toxicity (DLT) defined as an adverse event that is possibly related to the study medication, graded according to the NCI CTCAE version 3.0\"\\n4437,1,1,\"Dose-limiting toxicity (DLT) defined as any related (possibly, probably, or definitely) grade 3 non-hematological toxicity or any attributable grade 4 toxicity graded according to the National Cancer Institute (NCI) CTCAE version 4.0\"\\n4438,1,1,\"Dose-limiting toxicity (DLT) defined as Common Terminology Criteria (CTC) version 2.0 grade 3 or greater non-hematologic toxicity or grade 4 hematologic toxicity with the exception of asymptomatic neutropenia [ANC < 500]\"\\n4439,3,3,\"Dose-limiting toxicity (DLT) defined as grade 3 or higher National Cancer Institute - Common Terminology Criteria (NCI-CTC) toxicities\"\\n4440,1,1,\"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)\"\\n4441,1,1,\"Dose-limiting Toxicity (DLT) Events - Part A\"\\n4442,1,1,\"Dose-limiting toxicity (DLT) graded by National Cancer Institute (NCI) Common Toxicity Criteria\"\\n4443,1,1,\"Dose-Limiting Toxicity (DLT) in Part 1\"\\n4444,1,1,\"Dose-limiting Toxicity (DLT) in Part 1\"\\n4445,1,1,\"Dose-limiting toxicity (DLT) of HRS-1167\"\\n4446,1,1,\"Dose-limiting toxicity (DLT) of pegylated interferon alfa-2b when given with decitabine as assessed by NCI CTCAE version 3.0\"\\n4447,1,1,\"Dose-limiting toxicity (DLT) of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination\"\\n4448,1,1,\"Dose-limiting toxicity (DLT) of sapanisertib in combination with osimertinib in patients with EGFRm NSCLC\"\\n4449,4,2,\"Dose-limiting toxicity (DLT) rate\"\\n4450,1,1,\"Dose-limiting toxicity (DLT) rate scored according to the National Cancer Institute Common Toxicity Criteria version 4\"\\n4451,1,1,\"Dose-limiting toxicity (DLT) will be assessed by CTCAE 5.0.\"\\n4452,1,1,\"Dose-Limiting Toxicity (DLT): Any adverse events meeting the protocol-defined DLT criteria\"\\n4453,1,1,\"Dose-limiting Toxicity (Phase I)\"\\n4454,1,1,\"Dose-limiting toxicity (run-in phase)\"\\n4455,4,1,\"Dose-limiting toxicity and maximum tolerated dose\"\\n4456,1,1,\"Dose-limiting toxicity and maximum tolerated dose (MTD) of vatalanib when administered with pemetrexed disodium as measured by NCI CTCAE v3.0\"\\n4457,1,1,\"Dose-limiting toxicity and maximum tolerated dose as measured by CTC v 3.0\"\\n4458,1,1,\"Dose-Limiting Toxicity and Maximum Tolerated Dose of HS-10342.\"\\n4459,1,1,\"Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities\"\\n4460,1,1,\"Dose-limiting toxicity defined as any grade III or higher toxicity\"\\n4461,1,1,\"Dose-limiting toxicity for The maximum tolerated dose\"\\n4462,1,1,\"Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity\"\\n4463,1,1,\"Dose-limiting toxicity of lenalidomide\"\\n4464,1,1,\"Dose-limiting toxicity of NK012 in patients with UGT1A1*28 (wt/wt and wt/*28) genotype\"\\n4465,1,1,\"Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0\"\\n4466,1,1,\"Dose-limiting toxicity of temsirolimus in combination with intensive re-induction chemotherapy graded according to the NCI CTCAE v4.0\"\\n4467,1,1,\"Dose-limiting toxicity of the combination of bosutinib and pemetrexed\"\\n4468,1,1,\"Dose-limiting toxicity rate\"\\n4469,4,4,\"Dose-limiting toxicity ÔºàDLTÔºâ\"\\n4470,1,1,\"dose-limiting toxicity ÔºàDLTÔºâ„ÄÅadverse eventÔºàAEÔºâ„ÄÅserious adverse eventÔºàSAEÔºâ\"\\n4471,14,10,\"Dose-limiting toxicity(DLT)\"\\n4472,2,2,\"Dose-Limiting Toxicity, DLT\"\\n4473,1,1,\"Dose-limiting toxicity, incidence of treatment-emergent adverse events\"\\n4474,12,4,\"Dose-limiting toxicityÔºàDLTÔºâ\"\\n4475,1,1,\"Dose-limiting toxicityÔºàDLTÔºâby CTCAE5.0\"\\n4476,1,1,\"Dose-limiting toxicityÔºå maximum tolerated dose.\"\\n4477,1,1,\"Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of S,R-TLC388\"\\n4478,1,1,\"Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of S,S-TLC388\"\\n4479,1,1,\"Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of TLC-U1\"\\n4480,1,1,\"Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of TLC-U2\"\\n4481,1,1,\"Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Topotecan\"\\n4482,1,1,\"Dose-normalized area under the plasma concentration-time profile from time zero to extrapolated infinity (AUC0-‚àû) of total Lurbinectedin: Alone and in combination with bosentan\"\\n4483,1,1,\"Dose-Normalized AUC0-6hr (AUC0-6hr/D) of Carboplatin\"\\n4484,1,1,\"Dose-Normalized Cmax (Cmax/D) of Carboplatin\"\\n4485,1,1,\"Dose-normalized maximum observed plasma concentration (Cmax) of total lurbinectedin: Alone and in combination with bosentan.\"\\n4486,1,1,\"Dose-response relationships for normal tissue toxicity after proton therapy\"\\n4487,1,1,\"Dosimetric advantages of whole lung IMRT treatment over standard whole lung irradiation\"\\n4488,1,1,\"Dosimetry estimates of 177Lu-Anti-ED-B mAbs(B5-IgG4)\"\\n4489,1,1,\"Dosimetry estimates of 89Zr-Anti-CLDN18.2 mAbs (NY005).\"\\n4490,1,1,\"dosing frequency of PEG-rhG-CSF in chemotherapy\"\\n4491,1,1,\"Double-blind Part: Overall Survival\"\\n4492,1,1,\"Double-blind, randomized, placebo-controlled part: Overall survival (OS) per investigator assessment using RECIST v1.1\"\\n4493,1,1,\"Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) per investigator assessment using RECIST v1.1\"\\n4494,1,1,\"Down stage rate\"\\n4495,1,1,\"downstaging rate\"\\n4496,2,1,\"Downstaging success rate\"\\n4497,1,1,\"Drop in ejection fraction within 12 months of starting treatment.\"\\n4498,11,1,\"Drop-out rate\"\\n4499,3,1,\"Drug Clearance (CL)\"\\n4500,1,1,\"Drug clearance (CL)\"\\n4501,1,1,\"Drug discontinuation due to toxicity\"\\n4502,1,1,\"Drug interactions\"\\n4503,1,1,\"Drug treatment response\"\\n4504,2,1,\"Drug-related Adverse Events\"\\n4505,1,1,\"Drug-related adverse events\"\\n4506,1,1,\"Drug-related dose-limiting toxicity (DLTs)\"\\n4507,1,1,\"Drug-target Engagement in Circulating Tumor Cells (CTCs): Change From Baseline at Cycle 1 Day 8 in Percent Androgen Receptor Nuclear Localization (%ARNL) by Categories of PSA Decrease From Baseline (‚â•50%, Not ‚â•50%) After Cycle 4\"\\n4508,1,1,\"Drug-target Engagement in CTCs: Change From Baseline at Cycle 1 Day 8 in MTB by Categories of PSA Decrease From Baseline (‚â•30%, Not ‚â•30%) After Cycle 4\"\\n4509,1,1,\"DSN\"\\n4510,1,1,\"DSP107 Serum Concentration\"\\n4511,1,1,\"DTL defined as any grade 3 or greater non-hematological toxicity, and grade 3 or greater skin rash, grade 4 thrombocytopenia and/or neutropenia as assessed by CTCAE version 3.0\"\\n4512,4,4,\"Durable Clinical Benefit (DCB)\"\\n4513,1,1,\"Durable disease control (lack of progression from baseline) of anetumab ravtansine in indications pancreatic and gastric cancer (co-primary endpoint)\"\\n4514,1,1,\"Durable Objective Response Rate - Percentage of Participants With Objective Response\"\\n4515,1,1,\"Durable response rate (DRR) (Cohorts 1 and 2)\"\\n4516,1,1,\"Durable response rate to therapy\"\\n4517,1,1,\"Duration of action of polyvinylpyrrolidone-sodium hyaluronate gel\"\\n4518,1,1,\"Duration of aplasia period\"\\n4519,1,1,\"Duration of Axitinib Treatment\"\\n4520,1,1,\"Duration of Bevacizumab Treatment\"\\n4521,1,1,\"Duration of Clinical Response as Assessed by Investigator According to RECIST v1.1\"\\n4522,1,1,\"Duration of Complete Remission (DOR)\"\\n4523,1,1,\"Duration of Different Types of Chemotherapies Received by Participants During Study\"\\n4524,1,1,\"Duration of Disease (Rheumatoid Arthritis)\"\\n4525,2,1,\"Duration of Disease Control (DDC)\"\\n4526,1,1,\"Duration of Each Therapy\"\\n4527,1,1,\"Duration of Exposure of All Concomitant Chemotherapy\"\\n4528,1,1,\"Duration of grade 3 and 4 thrombocytopenia\"\\n4529,1,1,\"Duration of in vivo persistence of transferred T cells\"\\n4530,1,1,\"Duration of Most Frequently Observed Adverse Events (AEs)\"\\n4531,1,1,\"duration of neutropenia\"\\n4532,1,1,\"Duration of neutropenia (absolute neutrophil count (ANC) < 500/uL)\"\\n4533,1,1,\"Duration of Next LoT\"\\n4534,2,1,\"Duration of Objective Response\"\\n4535,1,1,\"Duration of objective response (CR/PR), defined as time from first objective response to the time to progression or death (Part II).\"\\n4536,1,1,\"Duration of Ovarian Tumor Marker (Cancer Antigen 125 [CA125]) Response\"\\n4537,1,1,\"Duration of overall response or SD\"\\n4538,7,3,\"Duration of Overall Survival (OS)\"\\n4539,1,1,\"Duration of Overall survival (OS) (Arms A and B only)\"\\n4540,1,1,\"Duration of Overall Survival (OS) for the experimental arm vs. the control arm\"\\n4541,1,1,\"Duration of Overall Survival - Percentage of Participants With an Event\"\\n4542,1,1,\"Duration of Overall Survival - Time to Event\"\\n4543,1,1,\"Duration of Overall Survival in All Participants (Data Cutoff 07 September 2010)\"\\n4544,1,1,\"duration of pain\"\\n4545,1,1,\"Duration of Panitumumab Exposure\"\\n4546,1,1,\"Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm\"\\n4547,1,1,\"Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1)\"\\n4548,1,1,\"Duration of Progression-Free Survival (PFS)\"\\n4549,2,1,\"Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1\"\\n4550,1,1,\"Duration of progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR) (Arms A and B only)\"\\n4551,1,1,\"Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)\"\\n4552,1,1,\"Duration of Recurrence-Free Survival\"\\n4553,1,1,\"Duration of Remission (DOR)\"\\n4554,1,1,\"Duration of remission (DOR)\"\\n4555,2,2,\"Duration Of Response\"\\n4556,24,7,\"Duration of Response\"\\n4557,37,6,\"Duration of response\"\\n4558,1,1,\"Duration of response (DCR)\"\\n4559,1,1,\"Duration Of Response (DOR)\"\\n4560,27,15,\"Duration of Response (DOR)\"\\n4561,11,3,\"Duration of Response (DoR)\"\\n4562,12,5,\"Duration of response (DOR)\"\\n4563,5,4,\"Duration of response (DoR)\"\\n4564,2,1,\"duration of response (DOR)\"\\n4565,1,1,\"Duration of Response (DOR) (for Part 1 and Part 2 expansion)\"\\n4566,1,1,\"Duration of response (DOR) (in stage ‚Ö°)\"\\n4567,1,1,\"Duration of response (DoR) (Phase I dose expansion)\"\\n4568,1,1,\"Duration of Response (DOR) - Part 3 and Part 4\"\\n4569,1,1,\"Duration of Response (DoR) [Part 3]\"\\n4570,1,1,\"Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n4571,1,1,\"Duration of Response (DoR) based on central review of tumor measurement\"\\n4572,1,1,\"Duration of Response (DOR) by RECIST v1.1 by Investigator\"\\n4573,1,1,\"Duration of response (DOR) for Participants with Confirmed CR/PR\"\\n4574,1,1,\"Duration of response (DOR) in stage ‚Ö°\"\\n4575,1,1,\"Duration of Response (DOR) in T790M Positive Patients According to RECIST Version 1.1 as Determined by Investigator Assessment\"\\n4576,1,1,\"Duration of Response (DOR) investigation [ Time Frame: 2.5 years]\"\\n4577,1,1,\"Duration of Response (DOR) of TY-302 combine with Tamoxifen\"\\n4578,1,1,\"Duration of Response (DOR) Per Investigator Assessed RECIST v1.1\"\\n4579,1,1,\"Duration of response (DOR) per RECIST 1.1 (Cohorts 1 and 2)\"\\n4580,2,1,\"Duration of Response (DR)\"\\n4581,1,1,\"Duration of Response (DR) for Dose Expansion\"\\n4582,1,1,\"Duration of Response (Efficacy Evaluable Population) - Dose Extension\"\\n4583,1,1,\"Duration of response (expansion cohort)\"\\n4584,1,1,\"Duration of Response (Part B)\"\\n4585,1,1,\"Duration of Response (Phase 2)\"\\n4586,1,1,\"Duration of Response for combination with Binimetinib or in combination with Crizotinib Dose Expansion by Blinded Independent Review Committee\"\\n4587,1,1,\"Duration of Response for Participants With an Objective Response Rate: Part 2 and Part 4\"\\n4588,1,1,\"Duration of Response for Patients in Expansion Cohorts\"\\n4589,1,1,\"Duration of Response in part II\"\\n4590,1,1,\"Duration of response per RECIST v1.1 as per local Investigator\\'s assessment.\"\\n4591,1,1,\"Duration of response rate (DOR) (Expansion Phase only)\"\\n4592,1,1,\"Duration of Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide\"\\n4593,1,1,\"Duration of response, defined as the time from date of first response (CR or PR)\"\\n4594,1,1,\"Duration of SD or Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n4595,1,1,\"Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1\"\\n4596,2,2,\"Duration of Severe (Grade 4) Neutropenia in Cycle 1\"\\n4597,1,1,\"Duration of Severe (Grade 4) Neutropenia in Part 2\"\\n4598,2,1,\"Duration of Severe Neutropenia (DSN)\"\\n4599,1,1,\"Duration of Severe Oral Mucositis (WHO Grade 3 or 4)\"\\n4600,1,1,\"Duration of Solid Tumour in Participants Prior to Enrolment in Study\"\\n4601,1,1,\"Duration of Stable Disease\"\\n4602,3,3,\"Duration of stable disease\"\\n4603,1,1,\"Duration of stable disease (DoSD)\"\\n4604,1,1,\"Duration of Stable Disease in Combination Therapy\"\\n4605,1,1,\"Duration of Stable Disease in Monotherapy\"\\n4606,1,1,\"Duration of stay in day hospital unit\"\\n4607,8,1,\"Duration of Treatment\"\\n4608,1,1,\"Duration of Treatment (DoT)\"\\n4609,1,1,\"Duration of treatment-emergent adverse events (TEAEs)\"\\n4610,1,1,\"Duration of Treatment-related Adverse Events (AEs)\"\\n4611,1,1,\"Duration of Tumor Response Measure\"\\n4612,1,1,\"Duration of Vemurafenib Treatment\"\\n4613,1,1,\"Duration of Vismodegib Treatment\"\\n4614,1,1,\"During dose escalation characterize dose-limiting toxicities (DLTs)\"\\n4615,1,1,\"During dose escalation measure incidence and severity of Treatment Emergent Adverse Events by CTCAE v5.0\"\\n4616,2,2,\"During Dose Escalation: Determine maximum tolerated dose (MTD)\"\\n4617,1,1,\"During Dose Escalation: Incidence of dose-limiting toxicities (DLTs)\"\\n4618,1,1,\"During Dose Escalation: Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events\"\\n4619,1,1,\"During Dose Escalation: Recommended Ph 2 dose of TP-1454\"\\n4620,1,1,\"During Dose Expansion: Determine preliminary antitumor activity of TP-1287 in terms of clinical benefit rate (CBR) at week 16 when administered at the RP2D in patients with sarcoma.\"\\n4621,1,1,\"During Dose Expansion: Determine preliminary antitumor activity of TP-1287 in terms of objective response rate (ORR) when administered at the Recommended Phase 2 Dose (RP2D) in patients with sarcoma\"\\n4622,1,1,\"During Dose Expansion: Determine the preliminary antitumor activity of TP-1454 in combination with ipilimumab and nivolumab\"\\n4623,1,1,\"During Dose Expansion: Recommended Ph 2 dose of TP-1454 in combination with ipilimumab and nivolumab\"\\n4624,1,1,\"During expansion describe the Overall Response Rate for IMGC936 using RECIST v1.1\"\\n4625,1,1,\"Dutch Periodontal Screening Index\"\\n4626,3,1,\"Dyadic coping\"\\n4627,1,1,\"Dynamic SUV change\"\\n4628,1,1,\"Dynamic tumor response rate as defined by a 40% modification of tumoral perfusion and cellular density parameters.\"\\n4629,1,1,\"dynamic Œ±-fetoprotein response (AFP-R)\"\\n4630,7,1,\"dyspnea\"\\n4631,1,1,\"Dyspnea according to CTCAE v4.0\"\\n4632,1,1,\"Dyspnea according to Medical Research Council (MRC) chronic dyspnea scale (5-point)\"\\n4633,1,1,\"Dyspnea as Measured by Oxygen Cost Diagram (OCD)\"\\n4634,1,1,\"E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2\"\\n4635,1,1,\"Early metabolic response\"\\n4636,1,1,\"Early oesophagitis\"\\n4637,1,1,\"Early Progression Rate\"\\n4638,1,1,\"Early Rad51/deoxyribonucleic acid (DNA) damage response (DDR)\"\\n4639,1,1,\"Early signs of clinical activity of the combination of sunitinib malate and dalteparin\"\\n4640,1,1,\"Early therapy response assessment\"\\n4641,1,1,\"Early topoisomerase 1 cleavable complex (Top1cc)/deoxyribonucleic acid (DNA) damage response (DDR)\"\\n4642,1,1,\"Early Tumor Shrinkage (ETS)\"\\n4643,1,1,\"Ears\"\\n4644,1,1,\"EASL criteria for tumor response\"\\n4645,1,1,\"Eastern Cooperative Oncology Group (ECOG) Performance Score\"\\n4646,3,1,\"Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n4647,1,1,\"Eastern Cooperative Oncology Group (ECOG) Performance Status at Each Visit\"\\n4648,1,1,\"Eastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)\"\\n4649,2,1,\"Eastern Cooperative Oncology Group (ECOG) performance status score\"\\n4650,1,1,\"Eastern Cooperative Oncology Group Performance Status (ECOGPS) to measure how participants disease is progressing\"\\n4651,1,1,\"Eastern Cooperative Oncology Group score Assessment\"\\n4652,1,1,\"EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2\"\\n4653,30,2,\"ECG\"\\n4654,1,1,\"ECG Abnormalities (Part 2)\"\\n4655,1,1,\"ECG Evaluation\"\\n4656,1,1,\"ECG interval change\"\\n4657,1,1,\"ECG QTc intervals of patients who receive palifosfamide-tris\"\\n4658,1,1,\"ECG test evaluated by QTc\"\\n4659,1,1,\"ECG values\"\\n4660,1,1,\"Echocardiograms (ECHO)\"\\n4661,1,1,\"echocardiograms changes from baseline\"\\n4662,1,1,\"ECOG assessment\"\\n4663,1,1,\"ECOG Performance Status\"\\n4664,2,1,\"ECOG performance status\"\\n4665,1,1,\"ECOG Performance status (PS)\"\\n4666,1,1,\"ECOG performance status over time\"\\n4667,1,1,\"Effect of aflibercept administration on DC function based on ability to stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic T cell responses (influenza)\"\\n4668,1,1,\"Effect of Anastrozole on Exposure to Olaparib - AUC0-œÑ\"\\n4669,1,1,\"Effect of Anastrozole on Exposure to Olaparib - Cmax ss\"\\n4670,1,1,\"Effect of AZD6094 at single therapeutic dose (600 mg) on ventricular repolarization by analysis of change from baseline-corrected QT\"\\n4671,1,1,\"Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15\"\\n4672,1,1,\"Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15\"\\n4673,1,1,\"Effect of beta-adrenergic blockade on the host immune system\"\\n4674,1,1,\"Effect of beta-adrenergic blockade on the tumor microenvironment\"\\n4675,1,1,\"Effect of capecitabine on the pharmacokinetics of BMS-247550 and to assess the effect of BMS-247550 on the pharmacokinetics of capecitabine\"\\n4676,1,1,\"Effect of Chronic stress on efficacy of immune checkpoint inhibitors\"\\n4677,1,1,\"Effect of DMXAA on coagulation parameters, TNF and other cytokine production, nitric oxide, and serotonin production\"\\n4678,1,1,\"Effect of erlotinib hydrochloride on the disposition of irinotecan hydrochloride\"\\n4679,1,1,\"Effect of erlotinib on EGFR phosphorylation at MTD\"\\n4680,1,1,\"Effect of in vivo aflibercept on the presence of different populations of dendritic cells (DC) and immature cells (ImC)\"\\n4681,1,1,\"Effect of irinotecan hydrochloride on thalidomide pharmacokinetics\"\\n4682,1,1,\"Effect of JI 101 on Pharmacokinetics Area Under Curve (AUC) (0-inf) of RAD001\"\\n4683,1,1,\"Effect of ketoconazole on the pharmacokinetics of ixabepilone\"\\n4684,1,1,\"Effect of Letrozole on Exposure to Olaparib - AUC0-œÑ\"\\n4685,1,1,\"Effect of Letrozole on Exposure to Olaparib - Cmax ss\"\\n4686,1,1,\"Effect of Namzaric¬Æ on cognition among cancer survivors who received brain irradiation\"\\n4687,1,1,\"Effect of Olaparib on Exposure to Anastrozole - AUC0-œÑ\"\\n4688,1,1,\"Effect of Olaparib on Exposure to Anastrozole - Cmax ss\"\\n4689,1,1,\"Effect of Olaparib on Exposure to Letrozole - AUC0-œÑ\"\\n4690,1,1,\"Effect of Olaparib on Exposure to Letrozole - Cmax ss\"\\n4691,1,1,\"Effect of Olaparib on Exposure to Tamoxifen - AUC0-œÑ\"\\n4692,1,1,\"Effect of Olaparib on Exposure to Tamoxifen - Cmax ss\"\\n4693,1,1,\"Effect of RAD001 on Pharmacokinetics AUC(0-inf) of JI-101\"\\n4694,1,1,\"Effect of regorafenib on cardiovascular safety parameters measured by change in QT\\\\QTc on the ECG in patients with advanced solid tumors\"\\n4695,1,1,\"Effect of Tamoxifen on Exposure to Olaparib - AUC0-œÑ\"\\n4696,1,1,\"Effect of Tamoxifen on Exposure to Olaparib - Cmax ss\"\\n4697,1,1,\"Effect of thalidomide on irinotecan hydrochloride pharmacokinetics\"\\n4698,1,1,\"Effect of trilaciclib on Overall Survival (OS) compared with placebo\"\\n4699,1,1,\"Effect of tumor-associated macrophages on treatment efficacy in locally advanced\"\\n4700,1,1,\"Effect on Left Ventricular Ejection Fraction (LVEF)\"\\n4701,1,1,\"Effect on Overall Survival (OS)\"\\n4702,1,1,\"effect on pharmacodynamic biomarkers\"\\n4703,1,1,\"Effecting Change\"\\n4704,1,1,\"Effective half-life of trametinib following single and repeat dose(2mg QD)\"\\n4705,1,1,\"Effectiveness (minimal residual disease)\"\\n4706,1,1,\"Effectiveness and sustainability of heritable cancer syndrome testing in the two novel testing populations\"\\n4707,1,1,\"Effectiveness assessment: Disease control rate\"\\n4708,1,1,\"Effectiveness Diagnosed by Imaging\"\\n4709,1,1,\"Effectiveness of Imetelstat in pediatric dose\"\\n4710,1,1,\"Effectiveness of ST-SBRT\"\\n4711,1,1,\"Effectiveness of TheraSphere¬Æ treatment in participants with liver cancers in a real-life setting\"\\n4712,1,1,\"Effectiveness: Progression-Free Survival\"\\n4713,2,1,\"Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL\"\\n4714,1,1,\"Effects of COVID-19 on cancer therapy and association with clinical outcomes\"\\n4715,1,1,\"Effects of EGFR inhibitors on magnesium homeostasis\"\\n4716,1,1,\"Effects of EGFR inhibitors on the EGFR pathway in the skin prior to and after receiving EGFR inhibitors\"\\n4717,1,1,\"Effects of sorafenib on the disposition of bortezomib\"\\n4718,1,1,\"Effects on Overall Survival\"\\n4719,210,7,\"Efficacy\"\\n4720,27,2,\"efficacy\"\\n4721,1,1,\"Efficacy (as Measured by Objective Response Rate) of Akt Inhibitor MK2206 in Patients With Recurrent High-grade Platinum-resistant Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\"\\n4722,1,1,\"Efficacy (defined as achieving complete remission, partial remission or stable disease)\"\\n4723,1,1,\"Efficacy (in terms of ctDNA clearance) of monalizumab and cetuximab compared to observation (Standard of Care, SOC) in LA-HNSCC patients who have MRD (MRD+) after definitive treatment.\"\\n4724,1,1,\"Efficacy (overall response rate [ORR])\"\\n4725,1,1,\"Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR)\"\\n4726,2,1,\"Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR)\"\\n4727,1,1,\"Efficacy (Phase 2) - Response Evaluation Criteria in Solid Tumors using RECIST v1.1\"\\n4728,1,1,\"Efficacy (recurrence-free survival)\"\\n4729,1,1,\"Efficacy - Overall Survival\"\\n4730,1,1,\"Efficacy - Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n4731,1,1,\"Efficacy - Tumor Response by the European Association for the Study of the Liver (EASL) Criteria\"\\n4732,1,1,\"Efficacy : Proportion of patients for which there was a modification in their care through the nurse device\"\\n4733,1,1,\"Efficacy Analysis\"\\n4734,1,1,\"Efficacy Analysis - Part B\"\\n4735,1,1,\"Efficacy as Assessed by the Overall Clinical Benefit Rate\"\\n4736,1,1,\"Efficacy as measured by Clinical Benefit Rate (percentage of patients with stable disease or better using MRI/CT imaging)\"\\n4737,5,5,\"efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1\"\\n4738,1,1,\"Efficacy as measured by Objective Response Rate\"\\n4739,1,1,\"Efficacy as measured by objective response rate\"\\n4740,1,1,\"Efficacy as Measured by the Objective Response Rate (ORR).\"\\n4741,4,1,\"Efficacy Assessment\"\\n4742,1,1,\"Efficacy assessment in dose-expansion phase\"\\n4743,1,1,\"Efficacy at 3 months\"\\n4744,1,1,\"Efficacy based on overall response rate (ORR)\"\\n4745,4,1,\"Efficacy Endpoint\"\\n4746,6,1,\"Efficacy evaluation\"\\n4747,1,1,\"Efficacy evaluation in solid tumors\"\\n4748,1,1,\"Efficacy Evaluation: Timing\"\\n4749,1,1,\"Efficacy evaluations: Disease status\"\\n4750,1,1,\"Efficacy Expansion Cohort (GC/GEJC, Third Line): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)\"\\n4751,1,1,\"Efficacy Expansion Cohort (HNSCC): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)\"\\n4752,1,1,\"Efficacy Expansion Cohort (Ovarian Cancer): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)\"\\n4753,1,1,\"Efficacy Expansion Cohort(Urothelial Carcinoma): Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), as Adjudicated by Independent Endpoint Review Committee (IERC)\"\\n4754,1,1,\"Efficacy Expansion: Number of participants discontinuing study treatment due to an AE\"\\n4755,1,1,\"Efficacy Expansion: Number of participants with ‚â•1 AE\"\\n4756,1,1,\"Efficacy Expansion: Objective Response Rate (ORR) as assessed by blinded independent central review (BICR) based on adjusted Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\"\\n4757,1,1,\"Efficacy in Patients\"\\n4758,1,1,\"Efficacy in terms of the rate of Progression-Free Survival (PFS)\"\\n4759,1,1,\"Efficacy in terms of Tumor Response Rate according to RECIST 1.1 criteria.\"\\n4760,1,1,\"efficacy include overall response rate, disease free survival and overall survival\"\\n4761,1,1,\"Efficacy Measured by Response Rate in Participants\"\\n4762,1,1,\"Efficacy of adjuvant pembrolizumab in N2 Positive NSCLC\"\\n4763,1,1,\"Efficacy of Atezolizumab in combination with Bevacizumab\"\\n4764,1,1,\"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1\"\\n4765,1,1,\"Efficacy of Belinostat in Terms of Complete or Partial Response; Disappearance of All Target Lesions or at Least a 30% Decrease in the Sum of the Longest Diameter of Target Lesions, Taking as Reference the Baseline Sum LD\"\\n4766,1,1,\"Efficacy of capecitabine + bendamustine combination regimen\"\\n4767,1,1,\"Efficacy of CCT301-59 CAR T cell therapy\"\\n4768,1,1,\"Efficacy of CGTC-102 in patients with solid tumors\"\\n4769,1,1,\"Efficacy of continuously delivered intraventricular methotrexate\"\\n4770,1,1,\"Efficacy of docetaxel and celecoxib by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart\"\\n4771,1,1,\"Efficacy of each modality in locating cancer in each of four regions (primary, hepatic, extra-hepatic abdominal, and extra-abdominal) using lesion analysis\"\\n4772,1,1,\"Efficacy of each modality in locating cancer in each of four regions (primary, hepatic, extra-hepatic abdominal, and extra-abdominal) using region analysis\"\\n4773,1,1,\"efficacy of eltrombopag (50mg once daily)\"\\n4774,1,1,\"Efficacy of ENB003 in combination with pembrolizumab measured by tumor ORR\"\\n4775,1,1,\"Efficacy of entinostat in combination with avelumab at the RP2D versus avelumab plus placebo\"\\n4776,1,1,\"Efficacy of Erlotinib Plus Bevacizumab (Arm A) or Erlotinib Plus Sulindac (Arm B) as Measured by Progression-free Survival.\"\\n4777,1,1,\"Efficacy of F16IL2 in combination with doxorubicin\"\\n4778,1,1,\"Efficacy of HS-10502: Objective response rate (ORR)ÔºàStage 2Ôºâ\"\\n4779,1,1,\"Efficacy of neoadjuvant chemotherapy\"\\n4780,1,1,\"Efficacy of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria.\"\\n4781,1,1,\"Efficacy of Olaparib Alone as Assessed by PFS (Progression-free Survival) Reported as Events Per Month\"\\n4782,1,1,\"Efficacy of Olaparib in Combination With Durvalumab as Assessed by PFS (Progression-free Survival)\"\\n4783,1,1,\"Efficacy of oral etoposide at 50 mg/m2/day given concurrently with radiotherapy\"\\n4784,4,1,\"Efficacy of palliation using the short course scheme compared with the standard scheme\"\\n4785,1,1,\"Efficacy of Panax Ginseng in Reducing Cancer Related Fatigue\"\\n4786,1,1,\"Efficacy of pembrolizumab in combination with eribulin.\"\\n4787,1,1,\"Efficacy of Regenecare¬Æ wound gel, in terms of alleviating pain and itching\"\\n4788,1,1,\"Efficacy of SBRT assessed 6 months after treatment\"\\n4789,1,1,\"Efficacy of SBRT in OP malignancies\"\\n4790,1,1,\"Efficacy of study agents as measured by changes in weight at baseline, and 4 weeks after the beginning of study treatment\"\\n4791,1,1,\"Efficacy of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients\"\\n4792,1,1,\"Efficacy of the combination of Tarceva and Avastin\"\\n4793,1,1,\"Efficacy of the film-forming solution Evonail¬Æ versus placebo on nail damage\"\\n4794,6,1,\"Efficacy of treatment\"\\n4795,1,1,\"efficacy of treatment against Cancer\"\\n4796,1,1,\"Efficacy of Treatment on CIN During Acute Phase of Chemotherapy\"\\n4797,1,1,\"Efficacy outcome evaluation - Disease control rate\"\\n4798,1,1,\"Efficacy outcome evaluation - Objective response rate\"\\n4799,1,1,\"Efficacy outcome evaluation - Overall survival\"\\n4800,1,1,\"Efficacy outcome evaluation - Progression free survival\"\\n4801,1,1,\"Efficacy outcome: Progression free survival\"\\n4802,1,1,\"Efficacy outcome: Response rate\"\\n4803,1,1,\"Efficacy outcomes in patients with metastatic kidney cancer, neuroendocrine carcinoma, non-small cell lung cancer, or melanoma (Cohort II)\"\\n4804,2,2,\"Efficacy Phase: Number of participants who discontinue study treatment due to an AE\"\\n4805,2,2,\"Efficacy Phase: Number of participants who experience one or more AEs\"\\n4806,1,1,\"Efficacy Phase: Number of participants who experience one or more DLTs\"\\n4807,1,1,\"Efficacy Phase: Number of participants who experienced DLTs\"\\n4808,2,2,\"Efficacy Phase: Objective response rate (ORR)\"\\n4809,2,1,\"Efficacy Profile\"\\n4810,1,1,\"Efficacy to reduce fatigue during chemotherapy as assessed by the Brief Fatigue Inventory at course 4\"\\n4811,1,1,\"Efficacy, as determined by objective response measures\"\\n4812,1,1,\"Efficacy: Objective Response Rate (ORR)\"\\n4813,1,1,\"Efficacy: Objective Response Rate - Investigator Assessment (Phase 1b)\"\\n4814,1,1,\"Efficacy: Objective Response Rate, defined as the proportion of patients with a complete or partial response\"\\n4815,1,1,\"Efficacy: Overall survival\"\\n4816,1,1,\"Efficacy: Progression free survival (PFS1) according to modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) of Olaparib maintenance after a platinum based chemotherapy in patients with advanced or metastatic endometrial cancer\"\\n4817,1,1,\"Efficacy: rate of patients who adhere to oral targeted therapy treatment administration.\"\\n4818,1,1,\"Efficacy: Tumor response rate based on Response Evaluation Criteria in Solid Tumour (RECIST) criteria\"\\n4819,1,1,\"EFS - (Event-Free Survival).\"\\n4820,1,1,\"EFS Duration as Per IRC Assessment\"\\n4821,1,1,\"EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib\"\\n4822,1,1,\"EGFR TKI sensitivity biomarkers determination\"\\n4823,1,1,\"Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment\"\\n4824,22,4,\"Electrocardiogram\"\\n4825,1,1,\"Electrocardiogram (ECG) changes [Safety and Tolerability]\"\\n4826,1,1,\"Electrocardiogram measurements\"\\n4827,1,1,\"Electrocardiogram(ECG) abnormality\"\\n4828,1,1,\"Electrocardiogram(ECG) results\"\\n4829,1,1,\"Electrocardiogram: QT Interval (Safety and Tolerability in the Dose Escalation Phase)\"\\n4830,4,1,\"Electrocardiograms (ECGs)\"\\n4831,1,1,\"electrocardiograms (ECGs)\"\\n4832,1,1,\"Elements of mindfulness\"\\n4833,4,1,\"Elimination half life (t1/2)\"\\n4834,1,1,\"Elimination half-life (T1/2) for Famitinib after Single dose\"\\n4835,1,1,\"Elimination Half-Life (t1/2) of RO5185426 Following Day 21 Dose\"\\n4836,1,1,\"Elimination half-life (T1/2)(h)\"\\n4837,1,1,\"Elimination of BMS-582664\"\\n4838,1,1,\"Elimination rate constant (Kel)\"\\n4839,1,1,\"Elucidation of Metabolite Structures and Identification of Major Metabolites in Plasma, Urine, and Faeces\"\\n4840,1,1,\"Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2\"\\n4841,1,1,\"Emergency room visit with a diagnosis of COVID-19 (Yes/No)\"\\n4842,1,1,\"Emotional Distreis. Scale from 1 to 10\"\\n4843,1,1,\"Emotional intimacy\"\\n4844,1,1,\"Employment Hours Worked\"\\n4845,1,1,\"Encorafenib AUC(0-inf)\"\\n4846,1,1,\"Encorafenib AUClast\"\\n4847,1,1,\"Encorafenib Cmax\"\\n4848,1,1,\"Engagement in the core mind-body practices that the patients learned\"\\n4849,1,1,\"Engraftment (neutrophil, platelet, and red blood cells)\"\\n4850,1,1,\"Engraftment Failure\"\\n4851,1,1,\"Engraftment Failure Rate\"\\n4852,1,1,\"Engraftment of ANC and Platelets\"\\n4853,1,1,\"Engraftment rate and transplant related mortality\"\\n4854,1,1,\"Enhancement of the Geriatric-Oncology database by linking it to the Central Medicare Services Database and the Ohio Death Files\"\\n4855,1,1,\"Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC\"\\n4856,1,1,\"Enrollment rates to ComboMATCH treatment trials\"\\n4857,1,1,\"Enzyme-Linked ImmunoSorbent Spot (ELISPOT)\"\\n4858,1,1,\"EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)\"\\n4859,1,1,\"EP2006 Cycles by Treatment Duration\"\\n4860,1,1,\"EP2006 Day of Initiation by Chemotherapy Toxicity: Cycle Level\"\\n4861,1,1,\"EP2006 Day of Initiation by Prophylaxis Type: Cycle Level\"\\n4862,1,1,\"EP2006 Day of Initiation by Tumor Type (Solid Tumor vs. Hematological Tumor): Cycle Level\"\\n4863,1,1,\"EP2006 Day of Initiation Relative to Guidelines by Cancer Type\"\\n4864,1,1,\"EP2006 Day of Initiation: All Cycles\"\\n4865,1,1,\"EP2006 Day of Initiation: Cycle 1\"\\n4866,1,1,\"EP2006 Day of Initiation: Cycle 2\"\\n4867,1,1,\"EP2006 Day of Initiation: Cycle 3\"\\n4868,1,1,\"EP2006 Day of Initiation: Cycle 4\"\\n4869,1,1,\"EP2006 Day of Initiation: Cycle 5\"\\n4870,1,1,\"EP2006 Day of Initiation: Cycle 6\"\\n4871,1,1,\"EP2006 Day of Initiation: Cycle Distribution\"\\n4872,1,1,\"EP2006 Dose (All Cycles)\"\\n4873,1,1,\"EP2006 Dose (Cycle 1)\"\\n4874,1,1,\"EP2006 Dose (Cycle 2)\"\\n4875,1,1,\"EP2006 Dose (Cycle 3)\"\\n4876,1,1,\"EP2006 Dose (Cycle 4)\"\\n4877,1,1,\"EP2006 Dose (Cycle 5)\"\\n4878,1,1,\"EP2006 Dose (Cycle 6)\"\\n4879,1,1,\"EP2006 Dose (Enrollment Cycle)\"\\n4880,1,1,\"EP2006 Dose by Chemotherapy Toxicity: Cycle Level\"\\n4881,1,1,\"EP2006 Dose by Patient Weight: Cycle Level\"\\n4882,1,1,\"EP2006 Dose by Tumor Type: Cycle Level\"\\n4883,1,1,\"EP2006 Duration by Chemotherapy Toxicity: Cycle Level\"\\n4884,1,1,\"EP2006 Duration by Prophylaxis Type: Cycle Level\"\\n4885,1,1,\"EP2006 Duration by Tumor Type: Cycle Level\"\\n4886,1,1,\"EP2006 Treatment Duration in Any Cycle\"\\n4887,1,1,\"EP2006 Treatment Duration in Cycle 1\"\\n4888,1,1,\"EP2006 Treatment Duration in Cycle 2\"\\n4889,1,1,\"EP2006 Treatment Duration in Cycle 3\"\\n4890,1,1,\"EP2006 Treatment Duration in Cycle 4\"\\n4891,1,1,\"EP2006 Treatment Duration in Cycle 5\"\\n4892,1,1,\"EP2006 Treatment Duration in Cycle 6\"\\n4893,1,1,\"Epigenetic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumors\"\\n4894,1,1,\"episodes of retching/vomiting per day during 1 chemotherapy course\"\\n4895,1,1,\"Equivalence between aRECIST and manual RECIST in the evaluation of target lesions at month 12\"\\n4896,1,1,\"Equivalence between aRECIST and manual RECIST in the evaluation of target lesions at month 24\"\\n4897,1,1,\"Equivalence between aRECIST and manual RECIST in the evaluation of target lesions at month 3\"\\n4898,1,1,\"Equivalence between aRECIST and manual RECIST in the evaluation of target lesions at month 6\"\\n4899,1,1,\"Equivalence between aRECIST and manual RECIST in the evaluation of target lesions at time of study enrolment\"\\n4900,1,1,\"Escalation and Expansion: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), including changes in laboratory parameters, vital signs, electrocardiograms (ECGs)\"\\n4901,1,1,\"Escalation: Adverse Events (AEs)\"\\n4902,2,2,\"Escalation: Dose Limiting Toxicities (DLTs)\"\\n4903,1,1,\"Escalation: Incidence of Dose-limiting Toxicities (DLTs) in Cycle 1\"\\n4904,1,1,\"Escalation: Number of participants with clinically significant shifts from baseline in clinical laboratory parameters\"\\n4905,1,1,\"Escalation: Number of patients with Dose Limiting Toxicities (DLTs)\"\\n4906,1,1,\"Escalation: Severity of Dose Limiting Toxicities (DLT)\"\\n4907,1,1,\"Establish a Biorepository of both diseased and normal tissue\"\\n4908,1,1,\"establish a mechanism within the institution to prospectively collect / extract digital remote physiological data among patients with cancer\"\\n4909,1,1,\"Establish a program for the molecular profiling of patients with advanced cancer.\"\\n4910,1,1,\"Establish a safe dose for oral 5-ALA administration.\"\\n4911,1,1,\"Establish feasible dose levels and regimens of AZD2014 and selumetinib when given in combination by close observation of any dose limiting toxicities\"\\n4912,1,1,\"establish Maximum tolerate dose (MTD)\"\\n4913,1,1,\"establish maximum tolerate dose (safety and tolerability)\"\\n4914,2,2,\"Establish Maximum Tolerated Dose\"\\n4915,1,1,\"Establish maximum tolerated dose\"\\n4916,2,1,\"Establish maximum tolerated dose (MTD)\"\\n4917,1,1,\"establish maximum tolerated dose (MTD)\"\\n4918,1,1,\"Establish maximum tolerated dose of carboplatin in combination with 5\\'azacytidine\"\\n4919,1,1,\"Establish maximum tolerated dose of XP-102.\"\\n4920,1,1,\"Establish pharmacokinetic (PK) profile of belinostat from Area under the Curve (AUC) parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4921,1,1,\"Establish pharmacokinetic (PK) profile of belinostat from Fraction Excreted (Fe) Unchanged parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4922,1,1,\"Establish pharmacokinetic (PK) profile of belinostat from Non Renal Clearance (CLnonren) parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4923,1,1,\"Establish pharmacokinetic (PK) profile of belinostat from peak concentration (Cmax) parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4924,1,1,\"Establish pharmacokinetic (PK) profile of belinostat from Total Body Clearance (CLtot) parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4925,1,1,\"Establish pharmacokinetic (PK) profile of belinostat from Volume of Distribution (Vdss) parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4926,1,1,\"Establish pharmacokinetic (PK) profile of belinostat half-life (t1/2) parameters in patients based on renal impairments in cohorts A,B, C, & D\"\\n4927,1,1,\"Establish safety and MTD of Z-endoxifen\"\\n4928,1,1,\"Establish the maximal tolerated dose of cabozantinib in combination with Lu-177 dotatae at a standard dose of 7.4 GBg in four 8-week cycles followed by continuation of cabozantinib.\"\\n4929,1,1,\"Establish the maximum tolerated dose (MTD) (Phase 1)\"\\n4930,1,1,\"Establish the maximum tolerated dose (MTD) and or/ recommended Phase 2 dose (RP2D)\"\\n4931,1,1,\"Establish the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of VS-4718 in subjects with metastatic non-hematologic malignancies\"\\n4932,1,1,\"Establish the maximum tolerated dose (MTD) for the combination of selinexor with Irinotecan.\"\\n4933,1,1,\"Establish the maximum tolerated dose (MTD) of pazopanib with weekly paclitaxel and carboplatin on a 28- day cycle\"\\n4934,1,1,\"Establish the maximum tolerated dose (MTD) of study drug in combination with capecitabine.\"\\n4935,1,1,\"Establish the maximum tolerated dose (MTD) of study drug in combination with docetaxel.\"\\n4936,1,1,\"Establish the maximum tolerated dose (MTD) of study drug in combination with gemcitabine.\"\\n4937,2,1,\"Establish the maximum tolerated dose (MTD) of study drug, with and without G-CSF.\"\\n4938,4,2,\"Establish the maximum tolerated dose (MTD) of study drug.\"\\n4939,1,1,\"Establish the maximum tolerated dose (MTD) of the new formulation of study drug.\"\\n4940,4,2,\"Establish the maximum tolerated dose (MTD) of the study drug.\"\\n4941,1,1,\"Establish the maximum tolerated dose and recommended Phase II dose of two intermittent dosing schedules of AZD2014: 3 days on, 4 days off and 2 days on, 5 days off in combination with weekly paclitaxel in patients with solid tumours.\"\\n4942,1,1,\"Establish the preliminary safety and tolerability profile of oral AZD8835 as a single agent and in combination with fulvestrant\"\\n4943,1,1,\"Establish the recommended dose of G-202 to be used in Phase II studies.\"\\n4944,1,1,\"Establish the Recommended Phase 2 Dose (RP2D) (Phase 1)\"\\n4945,1,1,\"Establish the recommended Phase 2 dose (RP2D) for SL-172154 when administered with MIRV\"\\n4946,1,1,\"Establish the recommended Phase 2 dose (RP2D) for SL-172154 when administered with PLD\"\\n4947,1,1,\"Establish the recommended-for-phase II dose (RP2D) of the combination of ficlatuzumab and cetuximab.\"\\n4948,1,1,\"Establish the safe recommended phase 2 dose\"\\n4949,1,1,\"Establish the safety and tolerability of AZD2281 in combination with cisplatin and gemcitabine in patients with solid tumors. Establish the maximum tolerated dose (MTD) for the combination of AZD2281 with cisplation and gemcitabine.\"\\n4950,1,1,\"Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors\"\\n4951,1,1,\"Establish the safety and tolerability of the combination of ABT-888 with metronomic cyclophosphamide in patients with refractory solid tumors and lymphomas. Establish the MTD of the combination of ABT-888 with metronomic cyclophosphamide.\"\\n4952,1,1,\"Establish the safety, defined by adverse events, of EGFR806-specific CAR T cell infusions (Arm A), and of dual transduced EGFR806xCD19 CAR T cell infusions (Arm B)\"\\n4953,1,1,\"Establish the three-cycle maximum-tolerated dose of 90Y-DOTA-tyr3-Octreotide\"\\n4954,1,1,\"Establish whether CTCs are detectable using novel CMOS technology in patients with metastatic cancer.\"\\n4955,1,1,\"Establishing the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of CCT3833.\"\\n4956,1,1,\"Establishing the Maximum Tolerated Dose (MTD) of AZD0424 alone and in combination\"\\n4957,1,1,\"Establishment of MTD for YQ23 as single agent (Stage 1) and when in combination with Pembrolizumab (Stage 2)\"\\n4958,1,1,\"Estimate and compare the hazard ratios and median survival before and after 1 year from enrollment\"\\n4959,1,1,\"Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as Determined by Overall Response Rate (Complete Response (CR) + Partial Response (PR))\"\\n4960,1,1,\"Estimate of the 6 Month Survival Probability\"\\n4961,1,1,\"Estimate Overall Response Rate\"\\n4962,1,1,\"estimate response rate\"\\n4963,1,1,\"Estimate the dose of intraventricular topotecan that will result in cerebrospinal fluid lactone concentrations exceeding 1 ng/mL for at least 8 hours after an intrathecal injection\"\\n4964,1,1,\"Estimate the maximum tolerated dose (MTD) and dose limiting toxicities (DLT), and describe the full toxicity profile of the two CAR T cell products\"\\n4965,1,1,\"Estimate the maximum tolerated dose (MTD) and the incidence of DLTs in Phase 1 (Completed)\"\\n4966,1,1,\"Estimate the maximum tolerated dose (MTD) of imetelstat given as a 2-hour IV infusion on D1 and D8 every 21 days.\"\\n4967,1,1,\"Estimate the maximum tolerated dose of intraventricular topotecan on this schedule\"\\n4968,1,1,\"estimate the MTD\"\\n4969,1,1,\"Estimate the rates of severe skin toxicities (grade 2) induced by cancer treatments, at 8 months after the start of treatment.\"\\n4970,1,1,\"Estimated Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose AUC(0-24) of Sunitinib and Its Metabolite\"\\n4971,1,1,\"Estimated Kaplan-Meier Progression Free Survival as Assessed by RECIST v1.1\"\\n4972,1,1,\"Estimated Maximum Tolerated Dose of gimatecan\"\\n4973,1,1,\"Estimated Oral Clearance (CL/F) of Sunitinib and Its Metabolite\"\\n4974,1,1,\"Estimated Steady-State Maximum Plasma Concentration (Cmax,ss) of Sunitinib and Its Metabolite\"\\n4975,1,1,\"Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1\"\\n4976,1,1,\"Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2\"\\n4977,1,1,\"Estimates of biochemical changes in the src-FAK and src-PLC- and VEGF signal transduction pathways\"\\n4978,1,1,\"Estimating the feasibility of using Nivolumab as a treatment in bMMRD positive, pediatric patients with refractory or recurrent hypermutated malignancies.\"\\n4979,1,1,\"Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only)\"\\n4980,1,1,\"Estimation of the Proportion of Progression-free Patients at 16 Wks.\"\\n4981,1,1,\"European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores\"\\n4982,1,1,\"European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (QLQ-C30)\"\\n4983,1,1,\"European Organization for Research and Treatment of Cancer quality of life Questionnaire-C30 (QLQ-C30)\"\\n4984,1,1,\"EuroQol-5 Dimension-3 Level (EQ5D-3L) Scores at Baseline\"\\n4985,1,1,\"EUS-biopsied histopathology findings\"\\n4986,1,1,\"EUS-FNB diagnostic accuracy\"\\n4987,1,1,\"EUS-FNB procurement yield of tissue \"\"core\"\" using two different FNB needles.\"\\n4988,1,1,\"Evaluate activity of Glivec in escalating doses 400 up to 800mg/day in patients with a large variety of metastatic solid tumors expressing c-kit or PDGFR.\"\\n4989,1,1,\"Evaluate anti-tumour activity of [225Ac]-FPI-1434 regimen\"\\n4990,1,1,\"Evaluate clinical activity/efficacy of MRTX849\"\\n4991,1,1,\"Evaluate Disease Control Rate\"\\n4992,1,1,\"Evaluate efficacy of MT-6402 in subjects with advanced cancer by objective response rate (ORR) with RECIST 1.1\"\\n4993,1,1,\"Evaluate feasibility of repetitive cycles of this combination .\"\\n4994,1,1,\"Evaluate genomic changes associated with increased risk of skin cancers\"\\n4995,1,1,\"Evaluate how the setting of defaults influences the proportion of Veterans selecting comfort-oriented plans of care in real ADs\"\\n4996,1,1,\"Evaluate incidence of dose-limiting toxicities (DLTs)\"\\n4997,1,1,\"Evaluate incidence of treatment-emergent adverse events (TEAEs)\"\\n4998,1,1,\"Evaluate novel CTC assay method as a predictive tool for prostate, breast and colorectal cancers.\"\\n4999,1,1,\"Evaluate ORR of the combination of HPV vaccine, NHS-IL12, and M7824 in subjects with advanced HPV associated malignancies.\"\\n5000,1,1,\"evaluate overall response rate (ORR)\"\\n5001,1,1,\"Evaluate patients with progression free survival (PFS)\"\\n5002,1,1,\"Evaluate pharmacodynamic measures of the effects of PX-866 on the phosphatidylinositol-3 kinase (PI-3K) pathway and related tumor markers.\"\\n5003,1,1,\"evaluate pharmacokinetics\"\\n5004,2,2,\"Evaluate Pharmacokinetics of the combination regimen\"\\n5005,1,1,\"Evaluate plasma pharmacokinetics and estimate renal elimination of oral administration of XL184\"\\n5006,1,1,\"Evaluate plasma pharmacokinetics and estimate renal elimination of XL844 as a single agent and in combination with gemcitabine\"\\n5007,1,1,\"Evaluate preliminary clinical activity of the combination regimen\"\\n5008,1,1,\"Evaluate Safety and Tolerability\"\\n5009,1,1,\"Evaluate safety and tolerability by measure of incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0\"\\n5010,1,1,\"Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QW\"\\n5011,1,1,\"Evaluate safety and tolerability of SL-172154 when administered with MIRV\"\\n5012,1,1,\"Evaluate safety and tolerability of SL-172154 when administered with PLD\"\\n5013,1,1,\"Evaluate safety and tolerability of treatment with treatment with ACTengine¬Æ IMA203/IMA203CD8 products as monotherapy or in combination with nivolumab\"\\n5014,1,1,\"Evaluate safety based the number of infections\"\\n5015,1,1,\"Evaluate safety of [I-124]-CPD-1028 Injection\"\\n5016,1,1,\"Evaluate safety of intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol¬Æ) for treatment of patients with accessible solid tumors, with or with\"\\n5017,1,1,\"Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)\"\\n5018,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 Pegylated Liposomal Doxorubicin (PLD) in 28-day cycles in escalation phase; type of adverse events\"\\n5019,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; by discontinuations.\"\\n5020,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; by treatment delays.\"\\n5021,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; causal relationship of adverse events.\"\\n5022,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; established MTD\"\\n5023,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; frequency of adverse events.\"\\n5024,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; number of events with changes from baseline in Electrocardiogram (ECG) findings.\"\\n5025,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; number of events with changes from baseline in laboratory assessments.\"\\n5026,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; number of events with changes from baseline in vitals signs.\"\\n5027,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; serious adverse events.\"\\n5028,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; severity of adverse events.\"\\n5029,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; timing of adverse events.\"\\n5030,1,1,\"Evaluate safety profile of TTI-622 when administered in combination with 40 mg/m2 PLD in 28-day cycles in escalation phase; treatment emergent adverse events.\"\\n5031,1,1,\"Evaluate safety, tolerability, and maximum tolerated dose of XL647\"\\n5032,1,1,\"Evaluate serum CLU levels during febrile neutropenia in children followed for cancer\"\\n5033,1,1,\"Evaluate severity of treatment-emergent adverse events (TEAEs)\"\\n5034,1,1,\"Evaluate Skin Temperature Pre and Post Imaging (Pre- and Post- Surgery)\"\\n5035,1,1,\"Evaluate the Adverse Events (AEs), including Serious Adverse Events (SAEs), that occur in patients treated with PRTH-101\"\\n5036,1,1,\"Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment\"\\n5037,1,1,\"Evaluate the appearance of Adverse Events according to NCI-CTCAE v5.0 (National Cancer Institute - Commun Toxicity Criteria For Adverse Events).\"\\n5038,1,1,\"Evaluate the change in response caused by PSP NEURO SERUM on the tactile sensation from baseline to day 28.\"\\n5039,1,1,\"Evaluate the correlation of baseline genomic alterations with clinical outcome.\"\\n5040,1,1,\"evaluate the effect of a high-fat, high-calorie meal on the PK of a single dose of GSK1120212 administered to subjects\"\\n5041,1,1,\"evaluate the effect of administration of fluvoxamine, a CYP1A2 inhibitor, after 2-cycles of ASA404, on the pharmacokinetics of ASA404\"\\n5042,1,1,\"evaluate the effects of ASA404 combined with either paclitaxel + carboplatin or docetaxel on the pharmacokinetics of a cocktail of simvastatin, caffeine, omeprazole, and diclofenac in patients with advanced malignancies.\"\\n5043,1,1,\"evaluate the effects of ASA404 on the pharmacokinetics of a cocktail of simvastatin, caffeine, omeprazole, and diclofenac in patients with advanced malignancies.\"\\n5044,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining 2 year survival\"\\n5045,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining 5 year survival\"\\n5046,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining biologic response\"\\n5047,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course\"\\n5048,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining histologic response\"\\n5049,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining local tumor response\"\\n5050,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining resection rate\"\\n5051,1,1,\"Evaluate the efficacy and clinical utility of TARE-Y90 by examining Transplant rate\"\\n5052,1,1,\"Evaluate the efficacy of elacestrant in combination with onapristone in terms of objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 (Phase 2).\"\\n5053,1,1,\"Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ\"\\n5054,1,1,\"Evaluate the frequency of specific clinical events\"\\n5055,2,2,\"Evaluate the incidence of adverse events (AEs)\"\\n5056,2,2,\"Evaluate the incidence of dose-limiting toxicities (DLTs)\"\\n5057,1,1,\"Evaluate the levels of PI3K/Akt pathway expression per patient\"\\n5058,1,1,\"Evaluate the morbidity and mortality of matched related and unrelated hematopoietic progenitor cell (HPC) transplantation at Children\\'s Memorial Hospital using high dose CD34+ HPCs after a reduced intensity conditioning regimen.\"\\n5059,1,1,\"Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1\"\\n5060,1,1,\"Evaluate the occurrence of DLTs during the first cycle in Part 1\"\\n5061,1,1,\"Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1\"\\n5062,1,1,\"Evaluate the pharmacokinetic (PK) profile of oral TRC102 when administered in combination with TMZ\"\\n5063,1,1,\"Evaluate the pharmacokinetic profile of IV vitamin C at varying doses\"\\n5064,1,1,\"Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules.\"\\n5065,1,1,\"Evaluate the pharmacokinetics of MRTX849\"\\n5066,1,1,\"Evaluate the pharmacokinetics of MRTX849 and TNO155\"\\n5067,1,1,\"Evaluate the pharmacokinetics of XP-102.\"\\n5068,1,1,\"Evaluate the potential for QT/QTc interval prolongation of TH-302 in patients with solid tumors\"\\n5069,1,1,\"Evaluate the preliminary efficacy of P-MUC1C-ALLO1\"\\n5070,1,1,\"Evaluate the proportion of patients who do not undergone active treatment\"\\n5071,1,1,\"Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2\"\\n5072,1,1,\"Evaluate the rate of actionable genomic alternations\"\\n5073,1,1,\"Evaluate the rate of pCR\"\\n5074,1,1,\"Evaluate the relative bioavailability of a PfOS formulation relative to the commercial GSK1120212 tablet formulation in adult subjects with solid tumors\"\\n5075,1,1,\"Evaluate the response rate of S-1, Leucovorin, and Oxaliplatin with recommended dose in phase II\"\\n5076,2,1,\"evaluate the safety\"\\n5077,1,1,\"Evaluate the safety and pharmacokinetics (rate of movement in the body and then the clearance) of CNTO 888 administered as multiple intravenous (IV) infusions in patients with solid tumors throughout the course of the study.\"\\n5078,1,1,\"Evaluate the safety and tolerability of ALRN-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (WT) TP53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - Phase 1\"\\n5079,1,1,\"Evaluate the safety and tolerability of ALRN-6924 in adult patients with advanced solid tumors or lymphomas with wild-type (WT) TP53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - Phase 2\"\\n5080,1,1,\"Evaluate the safety and tolerability of AU-007\"\\n5081,1,1,\"Evaluate the safety and tolerability of C5252\"\\n5082,1,1,\"Evaluate the safety and tolerability of escalating doses of GV20-0251 in refractory advanced malignancy patients as defined in the protocol during dose escalation\"\\n5083,1,1,\"Evaluate the safety and tolerability of escalating doses of IV T3011 in Patients with advanced malignant tumors\"\\n5084,1,1,\"Evaluate the safety and tolerability of escalating doses of single agent IV T3011 Characterize DLTs and identify the MTD and/or the RP2D of single agent IV T3011\"\\n5085,1,1,\"Evaluate the safety and tolerability of escalating doses of single-agent HST-1011 in Part A1 or in combination with cemiplimab in Part B.\"\\n5086,1,1,\"Evaluate the safety and tolerability of GW786034 in patients with relapsed or refractory multiple myeloma (MM).\"\\n5087,1,1,\"Evaluate the safety and tolerability of high dose IV vitamin C as a monotherapy\"\\n5088,1,1,\"Evaluate the safety and tolerability of MSC-1 and determine the recommended dose for MSC-1 monotherapy for further evaluation in the expansion part of the study.\"\\n5089,1,1,\"Evaluate the safety and tolerability of VLI.\"\\n5090,1,1,\"Evaluate the safety and toxicity of zoledronic acid and aldesleukin\"\\n5091,1,1,\"Evaluate the safety of ELI-002\"\\n5092,1,1,\"Evaluate the safety of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD)\"\\n5093,1,1,\"Evaluate the safety profile of PX-866\"\\n5094,1,1,\"Evaluate the safety, tolerability and maximum tolerated dose of 2 different dosing schedules of TLI administered intravenously\"\\n5095,1,1,\"Evaluate the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of AV-412 administered orally 3 times weekly and once weekly in subjects with relapsed or refractory solid tumor malignancies.\"\\n5096,1,1,\"Evaluate the safety/persistence of (including GVHD) of allogeneic EBV specific CTL modified to express artificial T cell receptors targeting CD19 molecule given for persistence or relapse of B-Cell ALL post allogeneic HSCT.\"\\n5097,1,1,\"Evaluate the short term and long term safety (mild/moderate/severe/life-threatening adverse events, premature discontinuations and serious adverse events)\"\\n5098,1,1,\"Evaluate the suitability of the adsorptive patch for collecting VOCs for analysis for early identification of skin cancer.\"\\n5099,1,1,\"Evaluate the suitability of the Solid Phase Microextraction (SPME) for analysis for early identification of skin cancer.\"\\n5100,1,1,\"Evaluate the therapeutic efficacy of active surveillance for small renal masses\"\\n5101,1,1,\"Evaluate the Time to Disease Progression\"\\n5102,1,1,\"Evaluate the tolerability of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD)\"\\n5103,1,1,\"Evaluate therapeutic efficacy assessed by Disease Control (CR, PR, or SD) as defined by the RECIST 1.1 Criteria.\"\\n5104,1,1,\"Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process\"\\n5105,1,1,\"Evaluate treatment response by PERCIST to RECIST 1.1 criteria in early stage of treatment\"\\n5106,1,1,\"Evaluating the safety and tolerability of tadalafil treatment with FLOT chemotherapy by assessing the number of participants with treatment related adverse events usting CTCAE v. 5.0.\"\\n5107,1,1,\"Evaluation of ablation efficacy, ORR (objective response rate)\"\\n5108,1,1,\"Evaluation of adverse events and changes in laboratory values. The potential dose is a dose regimen with no more than 2 out of 6 patients experiencing a dose-limiting toxicity.\"\\n5109,1,1,\"Evaluation of an organized consultation \"\"return home\"\" of patients with a metastatic cancer\"\\n5110,1,1,\"Evaluation of antitumor activity as measured by objective response (CR+PR) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n5111,2,1,\"Evaluation of blood pressure\"\\n5112,1,1,\"Evaluation of blood samples for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly.\"\\n5113,1,1,\"Evaluation of CD8 immune biomarkers assessed in tumor and blood biospecimens\"\\n5114,1,1,\"Evaluation of chemo and radiation toxicities\"\\n5115,1,1,\"Evaluation of Clinical Activity by the Objective Response Rate (ORR; Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n5116,1,1,\"Evaluation of clinical efficacy according RECIST (Part B)\"\\n5117,3,1,\"Evaluation of clinical efficacy: Overall survival.\"\\n5118,1,1,\"Evaluation of Dose-Limiting Toxicity (DLTs) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety events during treatment\"\\n5119,1,1,\"Evaluation of Efficacy of DaRT Treatment in Combination with Pembrolizumab\"\\n5120,1,1,\"Evaluation of efficacy of ipilimumab and nivolumab With or without UV1 vaccine in patients With inoperable malignant pleural mesothelioma progressing after first-line platinum-based chemotherapy.\"\\n5121,1,1,\"Evaluation of efficacy of MPDL3280A after investigational imaging as measured by objective response rate\"\\n5122,1,1,\"Evaluation of endoscopic ultrasound for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly\"\\n5123,1,1,\"Evaluation of Exit Interviews\"\\n5124,1,1,\"Evaluation of Feasibility Outcome To Assess Patient Retention in The Study\"\\n5125,1,1,\"Evaluation of heart rate\"\\n5126,1,1,\"Evaluation of imaging for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly.\"\\n5127,1,1,\"Evaluation of Laboratory Parameters\"\\n5128,1,1,\"Evaluation of Objective Clinical Response (CR/PR/SD)\"\\n5129,1,1,\"Evaluation of Objective Tumour Response\"\\n5130,1,1,\"Evaluation of ORR\"\\n5131,1,1,\"Evaluation of overall response rate of the addition of panitumumab rechallenge to standard third-line therapy\"\\n5132,1,1,\"Evaluation of Overall Survival\"\\n5133,1,1,\"Evaluation of pharmacogenetic, metabolic, and clinical markers that may predict hypertension induced by anti-VEGF therapy (Cohort II)\"\\n5134,1,1,\"Evaluation of Recommended Dose for Expansion (RDE) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety, PK and PD data\"\\n5135,1,1,\"Evaluation of relative bioavailability of RO5045337\"\\n5136,1,1,\"Evaluation of respiration rate\"\\n5137,1,1,\"Evaluation of RP2D\"\\n5138,1,1,\"Evaluation of Safety by assessment of Adverse Events\"\\n5139,1,1,\"Evaluation of Safety by assessment of laboratory data\"\\n5140,1,1,\"Evaluation of Safety by assessment of QTc prolongations\"\\n5141,1,1,\"Evaluation of Safety by assessment of vital signs\"\\n5142,1,1,\"Evaluation of safety include assessment of all SAEs, and all deaths on study or within 35 (¬±5) days of last study treatment\"\\n5143,1,1,\"Evaluation of Safety profile of nal-IRI and TAS-102 - Incidence of Treatment-Emergent Adverse Events\"\\n5144,1,1,\"Evaluation of Safety Related to Electrochemotherapy\"\\n5145,3,1,\"Evaluation of safety: the number of adverse events of vaccination therapy.\"\\n5146,1,1,\"Evaluation of Self-report caregiver reported outcomes at 12 weeks\"\\n5147,1,1,\"Evaluation of Self-Report Caregiver reported outcomes at Baseline\"\\n5148,1,1,\"Evaluation of temperature\"\\n5149,1,1,\"Evaluation of the antitumor activity of Cetuximab treatment in terms of Objective Response Rate (ORR) at the end of treatment\"\\n5150,1,1,\"Evaluation of the efficacy of endocrine therapy + entrectinib in women with ER+/HER2- early breast cancer of the lobular subtype:Residual Cancer Burden (RCB)\"\\n5151,1,1,\"Evaluation of the number of patients who successfully receive NeoTIL-ACT in combination with LDI (feasibility)\"\\n5152,1,1,\"Evaluation of the PK profile of CAL056 mesylate: Apparent terminal elimination half-life (t¬Ω)\"\\n5153,1,1,\"Evaluation of the PK profile of CAL056 mesylate: Area under the concentration-time curve (AUC)\"\\n5154,1,1,\"Evaluation of the PK profile of CAL056 mesylate: Maximum observed concentration (Cmax)\"\\n5155,1,1,\"Evaluation of the PK profile of CAL056 mesylate: Time to reach Cmax (Tmax)\"\\n5156,1,1,\"Evaluation of the quality of life of patients with iron deficiency with or without anemia during treatment for their cancer\"\\n5157,1,1,\"Evaluation of the reactivity if the antibodies against X63 tumor line\"\\n5158,1,1,\"Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)\"\\n5159,1,1,\"Evaluation of the safety (adverse event, clinical laboratory test, 12-lead electrocardiography, chest X-ray, ECOG performance status)\"\\n5160,1,1,\"Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEs\"\\n5161,1,1,\"Evaluation of the safety of Durvalumab plus Tremelimumab in combination with FOLFOX chemotherapy\"\\n5162,1,1,\"Evaluation of the therapeutic response.\"\\n5163,1,1,\"Evaluation of tissue distribution of 177Lu-Anti-ED-B mAbs(B5-IgG4)\"\\n5164,1,1,\"Evaluation of tissue distribution of 89Zr-Anti-CLDN18.2 mAbs(NY005)\"\\n5165,1,1,\"Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)\"\\n5166,1,1,\"Evaluation of Treatment-Related Adverse Events as Assessed by NCI CTCAE v4.0\"\\n5167,2,1,\"Evaluation of tumour response\"\\n5168,1,1,\"Evaluation the the maximum tolerated dose(MTD) by safety data\"\\n5169,50,3,\"Event Free Survival\"\\n5170,45,1,\"Event free survival\"\\n5171,35,2,\"Event Free Survival (EFS)\"\\n5172,6,1,\"event free survival (EFS)\"\\n5173,1,1,\"event free survival(EFS) at 3 year\"\\n5174,1,1,\"Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Morbidly Obese Participants\"\\n5175,1,1,\"Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Obese Participants\"\\n5176,1,1,\"Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Morbidly Obese Participants\"\\n5177,1,1,\"Event Rate Per 100 Participant-Years For First Occurrence of Net Clinical Benefit After Index Date in Obese Participants\"\\n5178,1,1,\"Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Morbidly Obese Participants\"\\n5179,1,1,\"Event Rate Per 100 Participant-Years For First Occurrence of Stroke or Systemic Embolism (SE) Events After Index Date in Obese Participants\"\\n5180,1,1,\"Event-Free (EF) Rate\"\\n5181,1,1,\"Event-free > Survival at 12 Months (Phase 2, DLBCL/Mixed Dose Level 3)\"\\n5182,15,1,\"Event-Free Survival\"\\n5183,37,1,\"Event-free Survival\"\\n5184,125,4,\"Event-free survival\"\\n5185,1,1,\"Event-free survival (Cohort 3)\"\\n5186,18,2,\"Event-Free Survival (EFS)\"\\n5187,28,1,\"Event-free Survival (EFS)\"\\n5188,58,3,\"Event-free survival (EFS)\"\\n5189,1,1,\"Event-Free Survival (EFS) - Percentage of Participants With an Event\"\\n5190,1,1,\"Event-free survival (EFS) at 18 weeks per RECIST (Response Evaluation Criteria in Solid Tumors) Guideline version 1.1.\"\\n5191,1,1,\"Event-free survival (EFS) in patients with high-risk resectable melanoma randomized to neoadjuvant pembrolizumab with patients randomized to adjuvant pembrolizumab\"\\n5192,2,2,\"Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Chemotherapy and Placebo+Chemotherapy Treatment Arms\"\\n5193,1,1,\"Event-free survival of patients with lungcancer\"\\n5194,1,1,\"Evidence and nature of toxicity related to the study treatment assessed using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0\"\\n5195,1,1,\"Evidence of anti tumor activity\"\\n5196,1,1,\"Evidence of response based on \"\"median time to new metastasis\"\"\"\\n5197,1,1,\"Evidence of Response, Based on Median Time to New Metastasis\"\\n5198,1,1,\"Evolution of different biomarkers\"\\n5199,1,1,\"Examination of potential food-effect on pharmacokinetics of RO5045337\"\\n5200,1,1,\"Examine the feasibility of implementing a parenting support intervention in 50 patients with an incurable cancer and their spousal caregivers.\"\\n5201,1,1,\"Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy\"\\n5202,1,1,\"Exatherm-TBH device functionality\"\\n5203,1,1,\"Excretion Balance of Radio-labeled 14C-eribulin: Total Recovery of Radioactive Dose in Urine and Feces.\"\\n5204,1,1,\"Excretion rate of 14C-labeled Anlotinib (radioactivity in feces)\"\\n5205,1,1,\"Excretion rate of 14C-labeled Anlotinib (radioactivity in urine)\"\\n5206,1,1,\"Excretion rate of 14C-labeled gilteritinib (radioactivity in feces)\"\\n5207,1,1,\"Excretion rate of 14C-labeled gilteritinib (radioactivity in urine)\"\\n5208,1,1,\"Excretion rate of 14C-labeled rucaparib(radioactivity in feces)\"\\n5209,1,1,\"Excretion rate of 14C-labeled rucaparib(radioactivity in urine)\"\\n5210,1,1,\"Excretion rate of 14C-labeled rucaparib(radioactivity in vomit, if applicable)\"\\n5211,1,1,\"Excretion ratio and cumulative excretion of radioactivity in urine and feces\"\\n5212,1,1,\"Exercise feasibility: Exercise sessions attendance\"\\n5213,1,1,\"Exercise feasibility: Relative dose-intensity of protein supplement\"\\n5214,1,1,\"EXP: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin)\"\\n5215,1,1,\"Expanded Recommended Phase Two Dose (RPTD) Cohort: Objective Response Rate (ORR)\"\\n5216,1,1,\"Expansion arms: Overall response rate (ORR)\"\\n5217,1,1,\"EXPANSION COHORT A:To evaluate the safety and tolerability of daily oral BKM120 (100 mg) + paclitaxel (200 mg/m2) + carboplatin (AUC 6), both given intravenously (IV) on day 1 of a 21-day cycle, with pegfilgrastim support\"\\n5218,1,1,\"EXPANSION COHORT B: To obtain a preliminary description of efficacy of the regimen established in Group 1 among patients with tumors harboring PTEN mutation or homozygous deletion.\"\\n5219,1,1,\"Expansion Cohorts To evaluate the preliminary anti-tumoral effect of SAR125844\"\\n5220,1,1,\"Expansion part only: Echocardiogram\"\\n5221,1,1,\"Expansion Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n5222,1,1,\"Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases\"\\n5223,1,1,\"Expansion Phase: Best Overall Tumour Response (BOR) by Tumour FMX Uptake Classification at 16 - 24 Hours Post-FMX Dose\"\\n5224,1,1,\"Expansion phase: Duration of response (DOR)\"\\n5225,1,1,\"Expansion Phase: Impact of the Quality of MRI Scan on Tumour Evaluation\"\\n5226,1,1,\"Expansion Portion: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1: Percentage of Participants With Objective Response\"\\n5227,1,1,\"Expansion stage: effectÔºåORR(Objective Response Rate ) by investigator\"\\n5228,1,1,\"Expansion Stage: Objective Response Rate (ORR)\"\\n5229,1,1,\"Expansion Stage: Overall Survival (OS)\"\\n5230,1,1,\"Expansion Stage: Progression-Free Survival (PFS)\"\\n5231,1,1,\"Expansion: Determine the PFS rate in the combination of olaparib plus EP0057 at 16 weeks in SCLC patients.\"\\n5232,1,1,\"Expansion: Disease Control Rate, Assessed According to RECIST v1.1\"\\n5233,1,1,\"Expansion: Duration of Response, Assessed According to RECIST v1.1\"\\n5234,1,1,\"Expansion: Evaluate anti-tumor activity of GEN1047\"\\n5235,1,1,\"Expansion: Objective overall response rate (ORR)\"\\n5236,1,1,\"Expansion: Objective Response Rate, Assessed According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n5237,1,1,\"Expansion: Progression Free Survival, Assessed According to RECIST v1.1\"\\n5238,1,1,\"Expansion: To determine overall response rate of EP0057 plus olaparib in patients with mCRPC\"\\n5239,1,1,\"Expansion: To determine overall response rate of EP0057 plus olaparib in patients with urothelial carcinoma\"\\n5240,1,1,\"Expectations regarding potential benefits and adverse reactions associated with treatment options by Treatment Options Expectations Scale given immediately after the first consultation and at 3 months after study completion\"\\n5241,1,1,\"Experiences during the coronavirus disease 2019 (COVID-19) pandemic\"\\n5242,1,1,\"Exploration of the correlation between the mutational profile and the percentage change in volumetric measurement of the index lesion after the first two cycles of chemotherapy.\"\\n5243,2,2,\"Explore the maximum tolerated dose (MTD)\"\\n5244,1,1,\"Explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies, by assessment of AEs, lab findings, physical examinations, vital signs, cardiac monitoring and ophthalmological examinations\"\\n5245,1,1,\"Exploring the MTD of OrienX010 according to DLT,which defined as the serious degree of adverse events relates to the medicine not less than grade 3 of CTCAE v4.03\"\\n5246,1,1,\"Exposure to a variety of potential sources of GC risk factors\"\\n5247,1,1,\"Exposure to Study Treatment - Dose Intensity\"\\n5248,1,1,\"Exposure to Study Treatment: Duration on Treatment\"\\n5249,1,1,\"Expression of CD40L and cytokines\"\\n5250,1,1,\"Expression of cMET\"\\n5251,1,1,\"Expression of functionally relevant polymorphisms in genes that encode proteins involved in the transport and activation of pemetrexed disodium in patients treated at the MTD\"\\n5252,1,1,\"Expression of Klotho and LRP-6 proteins in gastric adenocarcinoma\"\\n5253,1,1,\"expression of PTPN13 (For Expansion Cohort only)\"\\n5254,1,1,\"Expression status of biomarkers and their dynamic changes during treatment and follow-up\"\\n5255,1,1,\"Extension Cohorts to evaluate the preliminary anti-tumoral effect of SAR566658\"\\n5256,1,1,\"Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (AUC0-inf )\"\\n5257,1,1,\"Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (AUC0-last)\"\\n5258,1,1,\"Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (Cmax)\"\\n5259,1,1,\"Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy\"\\n5260,1,1,\"Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation\"\\n5261,1,1,\"Extent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Median/Min-Max\"\\n5262,1,1,\"Eyes\"\\n5263,1,1,\"Facilitate the development of individualized tumorgraft models for many different types of cancer.\"\\n5264,1,1,\"Facilitation of systematic registration into the Childhood Cancer Research Network\"\\n5265,1,1,\"FACIT-D Trial Outcome Index (TOI)\"\\n5266,1,1,\"Factors contributing to decision-making\"\\n5267,1,1,\"Factors influencing heterogeneity of capacity for biomarker testing, from among modifiable testing practice-related factors, e.g. cost, complexity, technologic complexity, lack of familiarity, physician and patient demand\"\\n5268,4,1,\"Failure Free Survival\"\\n5269,9,3,\"Failure-free survival (FFS)\"\\n5270,1,1,\"failures of the device as well as failure of persons using the device during treatment\"\\n5271,6,1,\"False negative rate\"\\n5272,1,1,\"Familial setting (1)\"\\n5273,1,1,\"Familial setting (2)\"\\n5274,1,1,\"Family Management Measure (FMM).\"\\n5275,1,1,\"Family Reach staff feedback\"\\n5276,121,2,\"Fatigue\"\\n5277,1,1,\"Fatigue as assessed by the brief fatigue index\"\\n5278,1,1,\"Fatigue as measured by brief fatigue inventory (BFI)\"\\n5279,1,1,\"Fatigue as measured by Brief Fatigue Inventory at 2 and 4 weeks after the start of treatment\"\\n5280,1,1,\"Fatigue by brief inventory at 4 and 8 weeks of treatment\"\\n5281,1,1,\"Fatigue incongruence\"\\n5282,8,1,\"Fatigue score\"\\n5283,1,1,\"Fatigue Severity Score 10-12 Weeks After Start of Treatment\"\\n5284,1,1,\"Fatigue Severity Score 3-4 Weeks After Start of Treatment\"\\n5285,1,1,\"Fatigue Severity Score 6-8 Weeks After Start of Treatment\"\\n5286,1,1,\"Fatigue Severity Score at Baseline\"\\n5287,1,1,\"FDG Therapeutic Response\"\\n5288,1,1,\"Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Feces\"\\n5289,1,1,\"Fe: Fraction of Administered Dose of [^14C]-Alisertib Excreted in Urine\"\\n5290,1,1,\"Fe: Fraction of Administered Dose of Alisertib Excreted in Urine\"\\n5291,7,1,\"Feasability\"\\n5292,188,5,\"Feasibility\"\\n5293,17,1,\"feasibility\"\\n5294,1,1,\"Feasibility (intervention completion)\"\\n5295,1,1,\"Feasibility (pertaining to adherence to follow-up assessments)\"\\n5296,1,1,\"Feasibility (pertaining to adherence to intervention)\"\\n5297,1,1,\"Feasibility (pertaining to appropriateness of eligibility criteria)\"\\n5298,1,1,\"Feasibility (pertaining to data linkage)\"\\n5299,3,1,\"Feasibility (pertaining to patient recruitment)\"\\n5300,1,1,\"Feasibility and acceptability of conducting a massage intervention with childhood cancer patients and their primary caregivers\"\\n5301,1,1,\"Feasibility and added value of 68GaNOTA-Anti-HER2 in neoadjuvant setting of breast carcinoma\"\\n5302,1,1,\"Feasibility and safety of temsirolimus and pazopanib when given in combination to patients with advanced solid tumors.\"\\n5303,1,1,\"Feasibility as measured by adherence and assessment completion\"\\n5304,2,1,\"Feasibility as measured by attrition\"\\n5305,6,1,\"Feasibility as measured by study accrual\"\\n5306,1,1,\"Feasibility based on compliance with TTFields therapy\"\\n5307,1,1,\"Feasibility defined as identifying a suitable donor within 4 weeks and meeting minimum T cell doses in the final product\"\\n5308,1,1,\"Feasibility For Participants with Cancer-Related Fatigue (CRF)\"\\n5309,1,1,\"Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure\"\\n5310,1,1,\"Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS)\"\\n5311,1,1,\"Feasibility of a patient to receive at least 3 doses of nivolumab and complete surgery without significant delay attributable to nivolumab therapy\"\\n5312,1,1,\"Feasibility of a screening procedure for major depression\"\\n5313,1,1,\"Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC\"\\n5314,1,1,\"Feasibility of administering genetically engineered glucocorticoid receptor knock out virus specific cytotoxic T-lymphocyte (CTL) lines, as indicated by Overall Survival\"\\n5315,1,1,\"Feasibility of administering Pembrolizumab in combination with Decitabine and hypofractionated index radiation\"\\n5316,1,1,\"Feasibility of anatomical modeling for image guided thoracic surgery\"\\n5317,1,1,\"Feasibility of applying a computer based system for symptom assessment and classification in palliative cancer care\"\\n5318,1,1,\"Feasibility of applying screening tools (Groningen Frailty Indicator [GFI] and G8) in older patients with cancer\"\\n5319,1,1,\"feasibility of automated geriatric co-management program\"\\n5320,1,1,\"Feasibility of case review as assessed by time to issuance of recommendations\"\\n5321,1,1,\"Feasibility of combination retifanlimab and radiation with and without temozolomide as assessed by number of participants who experience adverse events\"\\n5322,1,1,\"Feasibility of Completing All Preoperative Testing and Therapy\"\\n5323,1,1,\"Feasibility of concurrent lithium carbonate and whole-brain radiotherapy as measured by safety and compliance\"\\n5324,1,1,\"Feasibility of conducting a trial of tivozanib in terms of patients completing 2 courses of tivozanib\"\\n5325,1,1,\"Feasibility of DaRT Delivery\"\\n5326,1,1,\"Feasibility of delivering cardiac-sparing IMRT with central quality control in 20 subjects\"\\n5327,1,1,\"Feasibility of evaluating intestinal microbiome composition and autoimmune panels in patients treated with immunooncology combinations through the analysis of stool and blood samples at multiple time-points.\"\\n5328,1,1,\"Feasibility of exome analysis for patient with a malignant solid tumors\"\\n5329,1,1,\"Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg)\"\\n5330,1,1,\"Feasibility of Functional Restoration Program\"\\n5331,1,1,\"Feasibility of haploidentical HSCT\"\\n5332,1,1,\"Feasibility of immunochemotherapy defined as at least 80% of the patients completed all planned courses\"\\n5333,1,1,\"Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose)\"\\n5334,1,1,\"Feasibility of intervention and mode of delivery\"\\n5335,1,1,\"Feasibility of intervention delivery for staff within the rural community\"\\n5336,1,1,\"Feasibility of intratumoral implantation of QuiremSpheres¬Æ by SPECT imaging\"\\n5337,1,1,\"Feasibility of manufacturing NeoTCR-P1\"\\n5338,1,1,\"Feasibility of MMR status analysis on EUS-FNB pancreatic specimens\"\\n5339,1,1,\"Feasibility of MyInspiration:Data Collection\"\\n5340,1,1,\"Feasibility of MyInspiration:Recruitment\"\\n5341,1,1,\"Feasibility of MyInspiration:Usage Patterns\"\\n5342,1,1,\"Feasibility of neoadjuvant administration of MK-3475 and LN-144/Lifileucel in 3 stage IIIB-D melanoma patients (Phase 1)\"\\n5343,1,1,\"Feasibility of NGS on metastatic solid tumor tissue, in terms of number of patients screened, FMI test attempted, FMI test successful, and FMI tests results released to physicians\"\\n5344,1,1,\"Feasibility of NGS result-based non-FDA-approved treatment plan, measured by reasons for ability or inability to receive an anti-cancer agent\"\\n5345,1,1,\"Feasibility of PD-L1 expression analysis on EUS-FNB pancreatic specimens\"\\n5346,1,1,\"Feasibility of performing genomic data-based targeted therapy clinical trials in childhood cancers with poor prognosis, including relapsed or refractory cancers.\"\\n5347,1,1,\"Feasibility of performing single cell gene expression analyses on tracheal aspirates\"\\n5348,1,1,\"Feasibility of pre-planned laser setting in lesion ablation\"\\n5349,1,1,\"Feasibility of providing online, adaptive MRI-guided and gated SBRT as measured by the ability to deliver a full course of MRI-guided SBRT in at least 80% of eligible patients who have completed simulation and planning\"\\n5350,1,1,\"Feasibility of randomization between both treatment arms as assessed by the randomized proportion\"\\n5351,1,1,\"Feasibility of SBRT in OP malignancies\"\\n5352,1,1,\"Feasibility of screening for FA deficiency across different tumor types, defined as adequate number of patients deficient on this pathway\"\\n5353,1,1,\"Feasibility of study as assessed by completion of study accrual within study time frame\"\\n5354,1,1,\"Feasibility of study as assessed by physician responses\"\\n5355,1,1,\"Feasibility of tDCS\"\\n5356,1,1,\"Feasibility of the Administration of Transdermal Testosterone Alternating with Enzalutamide\"\\n5357,1,1,\"Feasibility of the combination therapy in T790M+ lung cancer (dose expansion)\"\\n5358,1,1,\"Feasibility of the drug combination\"\\n5359,1,1,\"Feasibility of the intervention for participants: Acceptability of the Intervention Components\"\\n5360,1,1,\"Feasibility of the intervention for participants: Accessibility of Data Collection Tools\"\\n5361,1,1,\"Feasibility of the intervention for participants: Accrual rate\"\\n5362,1,1,\"Feasibility of the intervention for participants: Adherence for Online Educational Session\"\\n5363,1,1,\"Feasibility of the intervention for participants: Adherence for Text Messages\"\\n5364,1,1,\"Feasibility of the intervention for participants: Adherence for Website\"\\n5365,1,1,\"Feasibility of the intervention for participants: Retention\"\\n5366,1,1,\"Feasibility of the Pro-GRID intervention as assessed by success of intervention delivery for a number of participants\"\\n5367,1,1,\"Feasibility of the scalp cooling device\"\\n5368,1,1,\"Feasibility of the simulation-free hippocampal-avoidance whole brain radiotherapy (HA-WBRT) as measured by the successful completion of the simulation-free HA-WBRT workflow through treatment delivery\"\\n5369,1,1,\"Feasibility of TIL-ACT in combination with LDI - successful infusion: Number of patients receiving a complete TIL-ACT infusion\"\\n5370,1,1,\"Feasibility of TIL-ACT in combination with LDI - successful Rapid Expansion Protocol (REP): Number of patients for whom TIL cultures\"\\n5371,1,1,\"Feasibility of Tranexamic Acid as an Adjunct to Standard Therapy: Number of Participants Eligible and Recruited\"\\n5372,1,1,\"Feasibility of treating patients with stereotactic body radiation therapy (SBRT) and immune checkpoint inhibitor\"\\n5373,2,1,\"Feasibility of Treatment\"\\n5374,4,1,\"Feasibility of treatment\"\\n5375,1,1,\"Feasibility of treatment assessed by successful completion of planned treatment\"\\n5376,1,1,\"Feasibility of using a digital symptom tracking application on HRQoL and cognition in cancer survivors who received brain irradiation\"\\n5377,1,1,\"Feasibility of using facial recognition technology to classify pain\"\\n5378,1,1,\"Feasibility of WES in Cancer patients\"\\n5379,1,1,\"Feasibility questionnaires\"\\n5380,4,1,\"Feasibility rate\"\\n5381,1,1,\"Feasibility testing\"\\n5382,1,1,\"Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor\"\\n5383,1,1,\"Feasibility to Perform Novel Photodynamic Therapy Into Tumor\"\\n5384,1,1,\"Feasibility, as measured by accrual rate\"\\n5385,1,1,\"Feasibility, as measured by the percentage of eligible patients who can be enrolled\"\\n5386,1,1,\"Feasibility, defined as the percentage of patients completing at least 3 doses of drug therapy without dose limiting toxicities (DLTs) and who are able to undergo minimally-invasive surgery as planned\"\\n5387,1,1,\"Feasibility, defined as the true proportion of patients whose CancerCode sequencing results in the identification of at least 1 actionable mutation\"\\n5388,1,1,\"Feasibility, measured as the proportion of patients with at least one actionable alteration\"\\n5389,1,1,\"Feasibility, Safety, Tolerability (patient\\'s complying with the follow-up), and Oncological efficacy\"\\n5390,1,1,\"Feasibility: Accrual rates [Caregivers]\"\\n5391,1,1,\"Feasibility: Accrual rates [Patients]\"\\n5392,1,1,\"Feasibility: Rates of intervention completion [Caregivers]\"\\n5393,1,1,\"Feasibility: Rates of intervention completion [Patients]\"\\n5394,1,1,\"Feasible (if at least 50% of patients enrolled are evaluable in brain by MRI at the 2-month timepoint)\"\\n5395,1,1,\"Fecal Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered\"\\n5396,1,1,\"Fecal Recovery of Total Radioactivity\"\\n5397,1,1,\"Fever and Infections Ever During the Study\"\\n5398,1,1,\"Final diagnosis of benign pancreatic mass\"\\n5399,1,1,\"Final diagnosis of malignant pancreatic mass\"\\n5400,1,1,\"Final Overall Survival (OS) - Initial Treatment Period\"\\n5401,1,1,\"Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population\"\\n5402,1,1,\"Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population\"\\n5403,1,1,\"Financial Burden of Employed Males with Cancer\"\\n5404,1,1,\"Financial distress assessment questionnaire\"\\n5405,1,1,\"Financial status assessment\"\\n5406,1,1,\"Financial toxicity score\"\\n5407,2,2,\"Find Recommended Phase 2 Dose (RP2D) of JAB-3312\"\\n5408,1,1,\"Find Recommended Phase 2 Dose (RP2D) of JAB-8263\"\\n5409,1,1,\"find the highest dose of GW572016 and Topotecan that can be safely given together\"\\n5410,1,1,\"finial clinical stagingÔºàTNMÔºâ\"\\n5411,1,1,\"First co-primary outcome measure is progression-free survival (PFS)\"\\n5412,1,1,\"First course tolerability with rising dose of topotecan to determine the maximum tolerated dose of topotecan when given with pazopanib daily.\"\\n5413,1,1,\"First cycle dose limiting toxicities (DLTs)\"\\n5414,2,2,\"First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD)\"\\n5415,1,1,\"First cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MTD)\"\\n5416,1,1,\"First cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose(MTD)\"\\n5417,1,1,\"First incidence of hand-foot syndrome (HFS) ‚â• grade 2 according to NCI CTCAE vs 3.0\"\\n5418,2,2,\"First-cycle Dose Limiting Toxicities\"\\n5419,1,1,\"First-line Dose Expansion: Incidence of Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)\"\\n5420,1,1,\"FLT Therapeutic Response\"\\n5421,2,2,\"Fluorescence\"\\n5422,1,1,\"Focal lesion of 89Zr-NY001 PET scanning in patients with fibronectin ED-B domain positive solid tumors.\"\\n5423,1,1,\"Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 4 (CD4) T cells at 10 weeks\"\\n5424,1,1,\"Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 8 (CD8) T cells at 10 weeks\"\\n5425,1,1,\"Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 16 weeks\"\\n5426,1,1,\"Fold Change in Serum N-telopeptides From Baseline\"\\n5427,1,1,\"Fold-change increase in CD27/CD28 double positive T cells\"\\n5428,3,1,\"follow up\"\\n5429,2,1,\"Food Effect\"\\n5430,1,1,\"Food Effect Cohort\"\\n5431,1,1,\"Food Effect Stage - the effect of a standard meal on the plasma concentration of oral CB-5083 in subjects with advanced solid tumors\"\\n5432,1,1,\"Food Effect Substudy: AUC 0-inf: Area Under the Concentration-time Curve From Time Zero to Infinity of Cedazuridine in the Fasted and Fed State\"\\n5433,1,1,\"Food Effect Substudy: AUC 0-inf: Area Under the Concentration-time Curve From Time Zero to Infinity of Cedazuridine-epimer in the Fasted and Fed State\"\\n5434,1,1,\"Food Effect Substudy: AUC 0-inf: Area Under the Concentration-time Curve From Time Zero to Infinity of Decitabine in the Fasted and Fed State\"\\n5435,1,1,\"Food Effect Substudy: AUC0-24h: Area Under the Concentration-time Curve From Time Zero to 24 Hours of Cedazuridine in the Fasted and Fed State\"\\n5436,1,1,\"Food Effect Substudy: AUC0-24h: Area Under the Concentration-time Curve From Time Zero to 24 Hours of Cedazuridine-epimer in the Fasted and Fed State\"\\n5437,1,1,\"Food Effect Substudy: AUC0-24h: Area Under the Concentration-time Curve From Time Zero to 24 Hours of Decitabine in the Fasted and Fed State\"\\n5438,1,1,\"Food Effect Substudy: AUC0-8h: Area Under the Concentration-time Curve From Time Zero to 8 Hours of Cedazuridine in the Fasted and Fed State\"\\n5439,1,1,\"Food Effect Substudy: AUC0-8h: Area Under the Concentration-time Curve From Time Zero to 8 Hours of Cedazuridine-epimer in the Fasted and Fed State\"\\n5440,1,1,\"Food Effect Substudy: AUC0-8h: Area Under the Concentration-time Curve From Time Zero to 8 Hours of Decitabine in the Fasted and Fed State\"\\n5441,1,1,\"Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Cedazuridine in the Fasted and Fed State\"\\n5442,1,1,\"Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Cedazuridine-epimer in the Fasted and Fed State\"\\n5443,1,1,\"Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Decitabine in the Fasted and Fed State\"\\n5444,1,1,\"Food Effect Substudy: Cmax: Maximum Observed Plasma Concentration of Cedazuridine in the Fasted and Fed State\"\\n5445,1,1,\"Food Effect Substudy: Cmax: Maximum Observed Plasma Concentration of Cedazuridine-epimer in the Fasted and Fed State\"\\n5446,1,1,\"Food Effect Substudy: Cmax: Maximum Observed Plasma Concentration of Decitabine in the Fasted and Fed State\"\\n5447,1,1,\"Food Effect Substudy: T1/2: Terminal Half Life of Cedazuridine in the Fasted and Fed State\"\\n5448,1,1,\"Food Effect Substudy: T1/2: Terminal Half Life of Cedazuridine-epimer in the Fasted and Fed State\"\\n5449,1,1,\"Food Effect Substudy: T1/2: Terminal Half Life of Decitabine in the Fasted and Fed State\"\\n5450,1,1,\"Food Effect Substudy: Tmax: Time of First Occurrence of Cmax of Cedazuridine in the Fasted and Fed State\"\\n5451,1,1,\"Food Effect Substudy: Tmax: Time of First Occurrence of Cmax of Cedazuridine-epimer in the Fasted and Fed State\"\\n5452,1,1,\"Food Effect Substudy: Tmax: Time of First Occurrence of Cmax of Decitabine in the Fasted and Fed State\"\\n5453,1,1,\"food intake time\"\\n5454,1,1,\"For All Regions Other Than the European Union (EU): Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1\"\\n5455,1,1,\"For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs\"\\n5456,1,1,\"For cohort 2: Efficacy of neratinib in combination with systemic treatment at investigator\\'s choice on previously untreated brain metastasis from HER2 metastatic breast cancer\"\\n5457,1,1,\"For cohort 3: Efficacy of neratinib in combination with systemic treatment at investigator\\'s choice on LM disease from HER2 metastatic breast cancer\"\\n5458,1,1,\"For cohort1: Efficacy of neratinib in combination with systemic treatment at investigator\\'s choice in preventing the next CNS event in HER2 breast cancer with known and treated brain metastasis\"\\n5459,1,1,\"For dose escalation: Incidence of Dose Limiting Toxicities (DLTs) (Combination therapy)\"\\n5460,1,1,\"For dose escalation: Incidence of Dose Limiting Toxicities (DLTs) (Monotherapy)\"\\n5461,1,1,\"For dose escalation: Maximum tolerated dose (MTD) of SAR441000 (Combination therapy)\"\\n5462,1,1,\"For dose escalation: Maximum tolerated dose (MTD) of SAR441000 (Monotherapy)\"\\n5463,1,1,\"For EU Only: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1\"\\n5464,1,1,\"For expansion cohort 1 only: Objective Response Rate (ORR)\"\\n5465,1,1,\"For Expansion Phase, disease control rate (DCR) at Week 8\"\\n5466,1,1,\"For Expansion: Objective Response Rate (ORR)\"\\n5467,1,1,\"For food effect study: To assess PK profiles of DFP-11207 under fed and fasted conditions\"\\n5468,1,1,\"For Part I: DLT\"\\n5469,1,1,\"For Part I: MAD\"\\n5470,1,1,\"For Part I: MTD\"\\n5471,1,1,\"For Phase 1a dose escalation, dose exploration and combination safety lead-in the number of participants with adverse events as assessed by the latest version of CTCAE\"\\n5472,1,1,\"For Phase 1a dose escalation, to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of FPA150\"\\n5473,1,1,\"For Phase 1a Part A, Phase 1b Cohort 1 Safety Run-in, Percentage of Participants who had Dose Limiting Toxicities (DLTs) in Dose Escalation During the First 28 Days of Treatment\"\\n5474,1,1,\"For Phase 1a Part B, Percentage of Participants Experiencing Treatment-Emergent Adverse Events\"\\n5475,1,1,\"For Phase 1a Part B, Percentage of Participants Experiencing Treatment-Emergent Grade 3 or 4 Laboratory Abnormalities\"\\n5476,1,1,\"For Phase 1a Part B, Percentage of Participants with Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG)\"\\n5477,1,1,\"For Phase 1b Cohort 1 Post Safety Run-in, Confirmed Objective Response Rate per RECIST 1.1, as Determined by Investigator\"\\n5478,1,1,\"For Phase 1b Cohort 2, Percentage of Participants Experiencing Treatment-Emergent Adverse Events\"\\n5479,1,1,\"For Phase 1b Cohort 2, Percentage of Participants Experiencing Treatment-Emergent Grade 3 or 4 Laboratory Abnormalities\"\\n5480,1,1,\"For Phase 1b Cohort 2, Percentage of Participants with Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG)\"\\n5481,1,1,\"For Phase 1b, number of participants with adverse events as assessed by the latest version of CTCAE at the maximum tolerated dose (MTD) and/or recommended dose (RD) of FPA150\"\\n5482,1,1,\"For Phase 2 - Best overall response rate of patients to the study treatment as a measure of efficacy of LB-100 study drug\"\\n5483,1,1,\"For Phase Ib - Number of patients with adverse events related to the study treatment as a measure of safety and tolerability of LB-100 study drug\"\\n5484,1,1,\"For the Dose-finding Lead-in Phase, incidence of dose limiting toxicities (DLTs)\"\\n5485,1,1,\"For the leukemia and lymphoma patients, an objective response rate, defined to be the proportion of Complete Responses of less than 0.10\"\\n5486,1,1,\"For the patients with solid tumors, a proportion of patients who do not experience an event, defined to be death, progressive disease, relapse, or second malignancy of less than 0.3\"\\n5487,2,1,\"Forced Expiratory Volume\"\\n5488,12,1,\"Forced Vital Capacity\"\\n5489,1,1,\"Four Cycle Progression-free Survival Rate\"\\n5490,1,1,\"Four Month Progression-free Survival (PFS)\"\\n5491,1,1,\"Four-month Progression-free Survival Rate\"\\n5492,1,1,\"FPT155 + pembrolizumab: Incidence of treatment emergent adverse events\"\\n5493,1,1,\"FPT155 + pembrolizumab: Maximum tolerated dose (MTD) of FPT155\"\\n5494,1,1,\"Fraction of AZD2014 Excreted in Urine as a Percentage of the Dose (fe%[R])\"\\n5495,1,1,\"Fraction of patients experiencing grade III or worse adverse events\"\\n5496,1,1,\"Frailty - Frield frailty Phenotype\"\\n5497,1,1,\"Frailty - G8 Scale\"\\n5498,2,1,\"Frailty assessment\"\\n5499,1,1,\"FRAME-001-specific immune responses in peripheral blood after administration of FRAME-001\"\\n5500,1,1,\"Free glycogen detection in vaginal discharge\"\\n5501,1,1,\"Freedom from first progression at 5 years\"\\n5502,4,1,\"Freedom from progression\"\\n5503,1,1,\"Freedom From Serious Adverse Event (SAE) at 30days\"\\n5504,1,1,\"Freedom From Serious Adverse Events Rate\"\\n5505,1,1,\"Freedom From Study Related SAE at 6 Months\"\\n5506,1,1,\"Freedom From Tumor Progression at 6 Months\"\\n5507,1,1,\"Frequency and characteristics of dose limiting toxicities (DLTs) at each dose level during the first cycle of therapy\"\\n5508,1,1,\"Frequency and characteristics of Dose limiting toxicities at each dose level\"\\n5509,1,1,\"Frequency and extent of psychological distress (Anxiety) (subjective psycho-oncological support needs) in cancer patients and their relatives and the changes over time\"\\n5510,1,1,\"Frequency and extent of psychological distress (Depression) (subjective psycho-oncological support needs) in cancer patients and their relatives and the changes over time\"\\n5511,1,1,\"Frequency and grade of toxicity\"\\n5512,1,1,\"Frequency and kinetics of mixed chimerism as assessed by polymerase chain reaction\"\\n5513,1,1,\"Frequency and nature of AE and SAE by subject\"\\n5514,2,2,\"Frequency and severity of adverse effects as assessed by CTCAE v 4.0\"\\n5515,1,1,\"Frequency and severity of adverse effects as assessed by National Cancer Institute Common Toxicity Criteria (CTC) v2.0\"\\n5516,4,1,\"Frequency and Severity of Adverse Events\"\\n5517,4,4,\"Frequency and Severity of Adverse Events (AE)\"\\n5518,1,1,\"Frequency and Severity of Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 3.0\"\\n5519,1,1,\"Frequency and severity of adverse events as assessed by CTCAE v4\"\\n5520,1,1,\"Frequency and Severity of Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0)\"\\n5521,1,1,\"Frequency and Severity of Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0\"\\n5522,1,1,\"Frequency and severity of adverse events of ES102 in combination with JS001\"\\n5523,1,1,\"Frequency and severity of adverse events of INBRX-109\"\\n5524,1,1,\"Frequency and severity of Adverse Events of IV and IT CF33-hNIS as a monotherapy or in combination with pembrolizumab\"\\n5525,2,1,\"Frequency and severity of AEs and SAEs\"\\n5526,1,1,\"Frequency and severity of AEs and SAEs (Safety)\"\\n5527,1,1,\"Frequency and severity of AEs and/or SAEs\"\\n5528,1,1,\"Frequency and severity of ITIL-168 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest\"\\n5529,1,1,\"Frequency and severity of ITIL-306 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest (AESI)\"\\n5530,2,1,\"Frequency and Severity of Observed Adverse Effects\"\\n5531,1,1,\"Frequency and Severity of Observed Adverse Effects Graded According to NCI CTCAE Version 3.0\"\\n5532,1,1,\"Frequency and Severity of Observed Adverse Events\"\\n5533,1,1,\"Frequency and Severity of Observed Adverse Events, Grade 3 or Higher According to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n5534,1,1,\"Frequency and severity of regimen-related toxicities\"\\n5535,1,1,\"Frequency and Severity of Toxicities\"\\n5536,1,1,\"Frequency and Severity of Toxicity\"\\n5537,1,1,\"Frequency and severity of toxicity incidents assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)\"\\n5538,1,1,\"Frequency and severity of treatment-related adverse events graded per NCI CTCAE version 3.0\"\\n5539,1,1,\"Frequency and types of adverse events and serious adverse events\"\\n5540,1,1,\"Frequency by pathogen type of infectious pathogens\"\\n5541,1,1,\"frequency of \"\"actionable\"\" oncogenic mutations\"\\n5542,1,1,\"Frequency of a cancer causing actionable alteration and individualized treatment recommendation.\"\\n5543,1,1,\"Frequency of acceptance of molecular tumor board recommendations\"\\n5544,1,1,\"Frequency of accidental gas leakage\"\\n5545,1,1,\"Frequency of accidental liquid stool leakage\"\\n5546,1,1,\"Frequency of accidental mucus leakage\"\\n5547,1,1,\"Frequency of acute and chronic graft-versus-host disease\"\\n5548,1,1,\"Frequency of Adverse Event and Severe Adverse Event\"\\n5549,32,1,\"Frequency of Adverse Events\"\\n5550,33,1,\"Frequency of adverse events\"\\n5551,1,1,\"Frequency of adverse events (AEs) (Phase 1b)\"\\n5552,1,1,\"Frequency of adverse events (AEs) and SAE\"\\n5553,2,1,\"Frequency of adverse events (AEs) and SAEs (Phase ‚Ö†)\"\\n5554,1,1,\"Frequency of adverse events (AEs) and serious adverse events (SAEs)\"\\n5555,1,1,\"Frequency of Adverse Events (AEs) leading to dose interruption or treatment discontinuation and death\"\\n5556,1,1,\"Frequency of adverse events attributable to tegavivint\"\\n5557,1,1,\"Frequency of Adverse Events for Entinostat\"\\n5558,1,1,\"Frequency of adverse events of ES101\"\\n5559,1,1,\"Frequency of adverse events of INBRX-105\"\\n5560,1,1,\"Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab\"\\n5561,1,1,\"Frequency of adverse events of selinexor\"\\n5562,1,1,\"Frequency of Adverse Events of Special Interest (AESIs)\"\\n5563,1,1,\"Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with XMT-1660 during the first cycle of treatment (Dose Escalation)\"\\n5564,3,1,\"Frequency of adverse events/serious adverse events\"\\n5565,1,1,\"Frequency of AE and SAEÔºàNCI CTCAE 5.0Ôºâ\"\\n5566,1,1,\"Frequency of AEs leading to discontinuation of study treatment(s)\"\\n5567,3,1,\"Frequency of bowel movements\"\\n5568,1,1,\"Frequency of complications such as rupture, torsion, or malignancy in patients with benign looking conservatively treated masses\"\\n5569,2,1,\"Frequency of consultation\"\\n5570,1,1,\"Frequency of cycle 1 dose limiting toxicities for BAY 1895344 (elimusertib)\"\\n5571,1,1,\"Frequency of cycle 1 dose limiting toxicities of the combination of tiragolumab and atezolizumab in patients < 12 years\"\\n5572,1,1,\"Frequency of cycle 1 dose limiting toxicities of tiragolumab as monotherapy in pediatric patients\"\\n5573,2,1,\"Frequency of DLTs\"\\n5574,7,2,\"Frequency of dose interruptions\"\\n5575,2,1,\"Frequency of dose interruptions and dose reductions\"\\n5576,2,1,\"Frequency of dose interruptions, reductions\"\\n5577,1,1,\"Frequency of Dose limiting Toxicities (DLTs)\"\\n5578,2,1,\"Frequency of dose limiting toxicities (DLTs)\"\\n5579,1,1,\"Frequency of Dose limiting toxicities (DLTs) at each dose level during dose escalation of BAY1895344\"\\n5580,1,1,\"Frequency of dose limiting toxicities as a function of LCL161 during first cycle\"\\n5581,1,1,\"Frequency of dose limiting toxicities of CBL0137 (Phase I)\"\\n5582,1,1,\"Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab\"\\n5583,1,1,\"Frequency of dose limiting toxicities of selinexor\"\\n5584,1,1,\"Frequency of dose limiting toxicities of tegavivint\"\\n5585,1,1,\"Frequency of Dose Limiting Toxicity (DLT)\"\\n5586,1,1,\"Frequency of dose-limiting toxicities (DLT), defined as the maximum dose level of trametinib where at most 1 of 6 patients experience DLT (Cohort A)\"\\n5587,1,1,\"Frequency of Dose-Limiting Toxicities (DLTs)\"\\n5588,1,1,\"Frequency of dose-limiting toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment (Dose Escalation)\"\\n5589,1,1,\"Frequency of dose-limiting toxicities (DLTs) during Phase Ia (Primary safety endpoint during dose-finding phase)\"\\n5590,1,1,\"Frequency of dose-limiting toxicities (DLTs) during Phase Ib (RP2D of IT-DFO in patients with LM from NSCLC)\"\\n5591,1,1,\"Frequency of HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)\"\\n5592,1,1,\"Frequency of laboratory test toxicity grade shifting from baseline\"\\n5593,1,1,\"Frequency of mutations and co-mutations\"\\n5594,1,1,\"Frequency of NTRK fusions in subjects with locally advanced/unresectable or metastatic solid tumors.\"\\n5595,1,1,\"Frequency of Number of Loose/watery Stools\"\\n5596,1,1,\"frequency of objective complete or partial tumor response\"\\n5597,1,1,\"Frequency of Objective Response Defined by RECIST 1.1 Criteria\"\\n5598,1,1,\"Frequency of objective response for the combination of tiragolumab and atezolizumab\"\\n5599,1,1,\"Frequency of objective tumor response as assessed by RECIST 1.1\"\\n5600,1,1,\"Frequency of observed adverse events (AEs)\"\\n5601,1,1,\"Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib ( 1 mg / dose )\"\\n5602,1,1,\"Frequency of Participant Ineligibility Reason\"\\n5603,1,1,\"Frequency of Participant Refusal Reason\"\\n5604,1,1,\"Frequency of Participants Who Experienced Any Grade of Rash As Characterized By The Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0\"\\n5605,1,1,\"Frequency of patients experiencing adverse events of special interest (AESIs)\"\\n5606,1,1,\"Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0\"\\n5607,1,1,\"Frequency of patients experiencing treatment-emergent AEs\"\\n5608,1,1,\"Frequency of patients with expression of analyzed tumor antigen targets\"\\n5609,1,1,\"Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)\"\\n5610,1,1,\"Frequency of patients with protocol-specified HLA subtype\"\\n5611,1,1,\"Frequency of protocol-defined adverse events (AEs)\"\\n5612,1,1,\"Frequency of Response\"\\n5613,4,1,\"Frequency of Serious Adverse Events (SAEs)\"\\n5614,11,1,\"Frequency of serious adverse events (SAEs)\"\\n5615,1,1,\"Frequency of serious adverse events (SAEs) attributable to ICI therapy\"\\n5616,1,1,\"Frequency of serious adverse events (SAEs) related to PTX-35 during the trial\"\\n5617,1,1,\"frequency of stable disease\"\\n5618,1,1,\"Frequency of subjects experiencing treatment-related AEs.\"\\n5619,1,1,\"Frequency of subjects undergoing PGx testing who receive at least one drug/dose selection or modification.\"\\n5620,1,1,\"Frequency of subjects with the expression (gene or protein) of multiple antigens (including, but are not limited to MAGE-A4 , and others) [ Time Frame: 10 years ]\"\\n5621,1,1,\"Frequency of subjects with the expression of multiple tumor associated antigens and/or HPV-16 E6/E7.\"\\n5622,2,1,\"Frequency of TEAEs\"\\n5623,1,1,\"Frequency of TEAEs (Treatment-emergent adverse events)\"\\n5624,1,1,\"Frequency of TEAEs (treatment-emergent adverse events) (Part 1)\"\\n5625,1,1,\"Frequency of TEAEs (treatment-emergent adverse events) (Part 2)\"\\n5626,1,1,\"Frequency of TEAEs, SAEs, and DLTs\"\\n5627,2,1,\"Frequency of Treatment Emergent Adverse Events (TEAEs)\"\\n5628,7,1,\"Frequency of treatment-emergent adverse events (TEAEs)\"\\n5629,1,1,\"Frequency of treatment-emergent adverse events (TEAEs) related to PTX-35 during the trial\"\\n5630,1,1,\"Frequency of treatment-emergent Adverse Events and Dose Limiting Toxicities\"\\n5631,1,1,\"Frequency of Treatment-Emergent Adverse Events(TEAEs)\"\\n5632,1,1,\"Frequency of treatment-related, dose-limiting toxicities (DLT) (Safety Lead-In Cohort)\"\\n5633,1,1,\"Frequency of Tumor Response at 9 Months After Last Treatment\"\\n5634,1,1,\"Frequency, duration and severity of Adverse Events and Serious Adverse Events\"\\n5635,1,1,\"Frequency, duration and severity of drug-related adverse events to assess safety and tolerability\"\\n5636,1,1,\"Frequency, severity, and duration of treatment-emergent AEs (TEAEs)\"\\n5637,1,1,\"Frequency, type, severity and relationship to study drug of adverse events (AEs)\"\\n5638,1,1,\"Frequency, types, severity and relationship to study drug of adverse events (AEs)\"\\n5639,1,1,\"FTD pharmacokinetic parameters AUC0-last and Cmax\"\\n5640,1,1,\"Functional Assessment of Cancer Therapy Kidney Symptom Index - 15 (FKSI-15) Score at Baseline\"\\n5641,1,1,\"Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS) Score at Baseline\"\\n5642,1,1,\"Functional Assessment of Cancer Therapy-General (FACT-G)\"\\n5643,1,1,\"Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)\"\\n5644,1,1,\"Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Subscale Scores\"\\n5645,1,1,\"Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT)\"\\n5646,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Baseline\"\\n5647,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12\"\\n5648,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 18\"\\n5649,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24\"\\n5650,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 30\"\\n5651,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 36\"\\n5652,1,1,\"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 6\"\\n5653,1,1,\"Functional capacity analysis - Barthel Index Analysis -\"\\n5654,1,1,\"Functional decline - Katz (ADL)\"\\n5655,1,1,\"Functional decline - Lawton (IADL)\"\\n5656,1,1,\"Functional drug screen\"\\n5657,1,1,\"Functional execution - Short Physical Performance Battery\"\\n5658,1,1,\"Functional improvement in measurable indexes\"\\n5659,1,1,\"Functional status by Karnofsky and ECOG at baseline, 3 months, and 1 year\"\\n5660,1,1,\"Functional subsets of peripheral CD8 positive T cells\"\\n5661,1,1,\"Fungal species distribution\"\\n5662,1,1,\"Fungitell Assay from BAL in patients with hematologic malignancy or ICU patients/patients after solid organ transplantation and suspected IFI\"\\n5663,1,1,\"Further evaluation of dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of OH2 in patients with solid tumors\"\\n5664,1,1,\"Gait and balance as measured by Tinetti Performance Oriented Assessment of Gait and Balance Instrument\"\\n5665,1,1,\"Gamma camera-based whole-body [99mTc]Tc(CO)3-(HE)3-Ec1 uptake value (%)\"\\n5666,1,1,\"Gamma-H2Ax (Œ≥-H2Ax) Levels in Fresh Tumor\"\\n5667,1,1,\"Gamma-H2Ax (Œ≥-H2Ax) Levels in Skin Tissue\"\\n5668,1,1,\"Gastrointestinal comfort\"\\n5669,1,1,\"GCSF Congruence Score (GCS)\"\\n5670,1,1,\"GCSF Initiation Score (GIS)\"\\n5671,1,1,\"GCSF Persistence Score (GPS)\"\\n5672,1,1,\"Gender-related difference in overall 12-month toxicity\"\\n5673,1,1,\"Gene classifier that will classify lesions as benign or malignant with 95% certainty\"\\n5674,1,1,\"Gene expression in normal tissues\"\\n5675,1,1,\"Gene expression profile using microarray assays\"\\n5676,1,1,\"Gene signature derived hypoxia scores on the same 20 participants.\"\\n5677,1,1,\"Gene transfer expression\"\\n5678,1,1,\"General condition\"\\n5679,1,1,\"General DNA or RNA concentration measured using Qubit\"\\n5680,1,1,\"General quality of life (QOL)\"\\n5681,1,1,\"General satisfaction of MyInspiration\"\\n5682,1,1,\"General user-friendliness of the tool\"\\n5683,1,1,\"Generation of an initial item pool (step 1)\"\\n5684,1,1,\"Genetic Alteration Frequency\"\\n5685,1,1,\"genetic profiles in gastrointestinal stromal tumor (GIST) patients\"\\n5686,1,1,\"Genetic variation in UGT1A1 and BCRP\"\\n5687,1,1,\"Genomic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumors\"\\n5688,1,1,\"Geographical variations in the frequency and morphology of SSNs according to the COVID-19 epidemic\"\\n5689,1,1,\"Geometric Mean Area Under the Curve (AUC) From Time of Dosing to Time of Last Observation (0-T) and Extrapolated to Infinity (INF) Observed Post-Single Dose\"\\n5690,1,1,\"Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by by VZV Interferon-gamma (IFN-g) Enzyme-linked Immunospot (ELISPOT) Assay\"\\n5691,2,1,\"Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA)\"\\n5692,2,1,\"Geometric Mean HI Titer by Visit\"\\n5693,1,1,\"Geometric Mean Maximum Serum Concentration (Cmax) Observed Post-Single Dose\"\\n5694,1,1,\"Geometric Mean Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Observed Sampling Time (AUC[0-last]) of Probe Parent Drugs\"\\n5695,1,1,\"Geometric Mean Ratio of AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Sapanisertib Milled API Capsules Under Fasted and Fed Conditions\"\\n5696,1,1,\"Geometric Mean Ratio of AUC(0-last) and Cmax of Metabolites of Probe Parent Drugs\"\\n5697,1,1,\"Geometric Mean Ratio of AUC(0-last): Area Under the Plasma Concentration Curve From Time Zero to the Time of the Last Quantifiable Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions\"\\n5698,1,1,\"Geometric Mean Ratio of AUC0-6hr/D of Carboplatin\"\\n5699,1,1,\"Geometric Mean Ratio of Cmax/D of Carboplatin\"\\n5700,1,1,\"Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled Active Pharmaceutical Ingredient (API) Capsules Under Fasted and Fed Conditions\"\\n5701,1,1,\"Geometric Mean Ratio of Maximum Plasma Concentration (Cmax) of Probe Parent Drugs\"\\n5702,1,1,\"Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Norethindrone\"\\n5703,1,1,\"Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone\"\\n5704,1,1,\"Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone\"\\n5705,1,1,\"Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Rosiglitazone\"\\n5706,1,1,\"Geometric Mean Titers of Anti-MAGE-A3 Specific CD4+ and CD8+ T-cells Concentrations After Immunization\"\\n5707,1,1,\"Geometric Mean Total Body Clearance of Drug From Serum (CLT) Post-Single Dose\"\\n5708,1,1,\"Geriatric syndromes\"\\n5709,1,1,\"GI associated adverse events\"\\n5710,2,1,\"GI symptoms\"\\n5711,1,1,\"Global health status / Quality of Life\"\\n5712,1,1,\"Global perception of usefulness\"\\n5713,5,1,\"Global survival\"\\n5714,1,1,\"Glucose to Insulin Ratio\"\\n5715,1,1,\"Glycemic control as measured by Glycosylated Hemoglobin Assay\"\\n5716,1,1,\"Glycogen Storage Assessment\"\\n5717,1,1,\"Grad 4 Neutropenia\"\\n5718,1,1,\"Grade 2 or greater toxic effects, based on the NCI CTC v2.0\"\\n5719,1,1,\"Grade 3 and 4 toxicities\"\\n5720,1,1,\"Grade 3 non-hematologic or Grade 4 hematologic toxicity will also define the Maximum Feasible Dose (MFD).\"\\n5721,1,1,\"Grade 3 or greater toxicities assessed using NCI CTC version 2.0\"\\n5722,1,1,\"Grade 3 or higher gastrointestinal toxicity rate\"\\n5723,1,1,\"Grade 3 or higher Treatment Related Adverse Events\"\\n5724,1,1,\"Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0\"\\n5725,1,1,\"Grade 3-4 diarrhea\"\\n5726,1,1,\"Grade 3/4 adverse event rate\"\\n5727,1,1,\"Grade 4 neutropenia for >/= 7 days, febrile neutropenia with Grade 4 neutropenia, Grade 4 thrombocytopenia, Grade 3 or 4 non-hematologic toxicity, hypertension and skin toxicity of Grade 3 or 4 which are not manageable and pharmacokinetics\"\\n5728,1,1,\"grade 4 or non-haematological grade 3 haematological toxicity according to the CTCAE (version 4)\"\\n5729,1,1,\"Grade III or IV GVHD\"\\n5730,1,1,\"Grade of AEs\"\\n5731,1,1,\"Grade of SAEs\"\\n5732,1,1,\"Grade ‚â•3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy\"\\n5733,1,1,\"Graded Standard Local and Systemic Toxicities (using CTCAE graded toxicity scale) months\"\\n5734,1,1,\"Grades 3, 4, and 5, treatment-related adverse events, graded according to the National Cancer Institute (NCI) CTCAE version 3.0\"\\n5735,1,1,\"Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event\"\\n5736,1,1,\"Group 1: Percentage of Participants With Dose Limiting Toxicities (DLT)\"\\n5737,1,1,\"Group A: Evaluate efficacy of zenocutuzumab in combination with afatinib in terms of response.\"\\n5738,1,1,\"Group B: Evaluate efficacy of zenocutuzumab in combination with enzalutamide or abiraterone acetate in terms of Prostate-Specific antigen level ‚â• 50% (PSA50) response.\"\\n5739,1,1,\"Group differences in the outcomes assessed in the protocol relative to prior group assignment in the behavioral clinical trials\"\\n5740,1,1,\"Groups 1 and 2: Dose-Limiting Toxicity of SY-5609\"\\n5741,1,1,\"Groups 1 and 2: Number of Participants With Treatment Emergent Adverse Events\"\\n5742,1,1,\"Groups 1 to 4: Percentage of Participants With Adverse Events (AEs)\"\\n5743,1,1,\"Groups 1 to 4: Percentage of Participants With Change in Vital Signs, Physical Findings, Electrocardiogram (ECG) and Laboratory Parameters\"\\n5744,1,1,\"Groups 3 and 4 (Expansions): Progression Free Survival\"\\n5745,1,1,\"Groups 3 and 4 (Safety Lead-ins): Number of Participants With Dose-Limiting Toxicity\"\\n5746,1,1,\"Groups 3 and 4 (Safety Lead-ins): Number of Participants With TEAEs\"\\n5747,1,1,\"Groups 3 and 4: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\"\\n5748,1,1,\"Gut microbiome associations with cancer diagnoses\"\\n5749,1,1,\"H. pylori prevalence and drug resistance\"\\n5750,1,1,\"Haematology values\"\\n5751,5,1,\"Half life (t1/2)\"\\n5752,1,1,\"Half life (T1/2) of FORE8394\"\\n5753,1,1,\"Half life (t1/2) of PLX2853.\"\\n5754,1,1,\"Half life (t1/2) of PLX51107.\"\\n5755,1,1,\"Half life (t1/2) of PLX73086 [Part 1 of research study]\"\\n5756,1,1,\"Half life of DCC-3014\"\\n5757,1,1,\"Half lifeÔºàT1/2Ôºâof CM082\"\\n5758,13,3,\"Half-life\"\\n5759,5,1,\"Half-life (T1/2)\"\\n5760,13,1,\"Half-life (t1/2)\"\\n5761,2,1,\"Half-life (t1/2) for eribulin mesylate\"\\n5762,1,1,\"Half-life (t1/2) for the Terminal Phase (First Dose) or Dosing Interval (Third Dose) of Panitumumab\"\\n5763,1,1,\"Half-life (t1/2) of RO6895882\"\\n5764,1,1,\"Half-Life (t1/2) of RO6958688\"\\n5765,1,1,\"Half-life Associated With Terminal Slope (lambda_z) of a Semi-logarithmic Concentration-time Curve (t1/2[lambda_z]) for AZD2014 in Plasma\"\\n5766,2,1,\"Half-life associated with terminal slope (Œªz) of a semi-logarithmic concentration-time curve (t¬ΩŒªz)\"\\n5767,1,1,\"Half-life in plasma (t1/2)\"\\n5768,1,1,\"Half-life of 14C-labeled RO5185426 in Both Blood and Plasma\"\\n5769,1,1,\"Half-life of Entinostat\"\\n5770,1,1,\"Half-life of GSK2118436 and metabolites after single 150mg HPMC dose\"\\n5771,1,1,\"Half-life of GSK2118436 and metabolites after single 75mg HPMC dose\"\\n5772,1,1,\"Half-life of Intetumumab - Phase 1 (Part 1)\"\\n5773,1,1,\"Half-life of Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n5774,1,1,\"Half-life of selinexor\"\\n5775,1,1,\"Half-life of Sorafenib\"\\n5776,1,1,\"Half-life of sotrovimab (VIR-7831) post-transplant\"\\n5777,1,1,\"Half-life of Temozolomide in Combination With Talazoparib\"\\n5778,4,2,\"Half-life period(t1/2)\"\\n5779,1,1,\"half-life periodÔºàt1/2Ôºâ\"\\n5780,1,1,\"HD-SCA liquid biopsy biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles\"\\n5781,1,1,\"HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles\"\\n5782,1,1,\"HDL-C in whole blood sample\"\\n5783,3,1,\"Head\"\\n5784,1,1,\"health care use\"\\n5785,1,1,\"Health history taking\"\\n5786,1,1,\"Health problems\"\\n5787,1,1,\"Health related quality of life (HR-QoL) assessed using 3 scales of European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.\"\\n5788,1,1,\"Health utility: is a measure of strength of preference that people have for particular health states. A year in full health is arbitrarily assigned a value of 1: a state that is considered equivalent to death is assigned a value of zero\"\\n5789,1,1,\"Health-related quality of life (composite measure)\"\\n5790,3,1,\"Health-related quality of life (HRQOL)\"\\n5791,1,1,\"Health-related quality of life and coronavirus disease 2019 (COVID-19)-specific domains of interest\"\\n5792,2,1,\"Health-related quality of life of the chronically-ill children/adolescents (Peds-QL 4.0)\"\\n5793,1,1,\"Health-related Quality of Life of the parents (SF-12)\"\\n5794,1,1,\"Healthcare time\"\\n5795,1,1,\"Healthy Eating Index (HEI)-2015 score\"\\n5796,1,1,\"Hearing as measured by the Weber test and the Rinne test at baseline, and then weeks 4, 8, and 12 during study treatment\"\\n5797,1,1,\"Hearing loss as measured by Hearing Loss Inventory, Dizziness Handicap Inventory, and audiogram every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment\"\\n5798,1,1,\"Heart\"\\n5799,210,3,\"Heart rate\"\\n5800,7,1,\"Heart rate (bpm)\"\\n5801,1,1,\"Heart rate in beats per minute in beats per minute of ECG\"\\n5802,1,1,\"HEDIS quality measure of management hypertension\"\\n5803,1,1,\"HEDIS quality measure of management of diabetes\"\\n5804,1,1,\"HEDIS quality measure of management of statin use\"\\n5805,84,1,\"Height\"\\n5806,1,1,\"Height (inches/cm)\"\\n5807,1,1,\"Height of Pediatric and Adolescent Participants\"\\n5808,1,1,\"Hematologic toxicity and non-hematologic toxicity according to NCI-CTCAE version 4.0\"\\n5809,1,1,\"Hematological - Dose Limiting Toxicities\"\\n5810,1,1,\"Hematological biomarker levels\"\\n5811,1,1,\"hematology panels\"\\n5812,2,1,\"Hematopoietic response\"\\n5813,1,1,\"Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response\"\\n5814,9,1,\"Hemodynamics\"\\n5815,1,1,\"Hemoglobin (Safety and Tolerability in the Dose Escalation Phase)\"\\n5816,1,1,\"Hemoglobin concentration in g/dL in whole blood sample\"\\n5817,1,1,\"Hemoglobin Levels at 16 Weeks\"\\n5818,1,1,\"Hepatic metastasis stabilization rate by response criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)\"\\n5819,1,1,\"Hepatic Progression free survival\"\\n5820,1,1,\"Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST)\"\\n5821,1,1,\"Hepatic tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\"\\n5822,1,1,\"hepatitis B virus (HBV) serological status\"\\n5823,1,1,\"Her2/Neu Status\"\\n5824,1,1,\"HER3 receptor occupancy (via quantification of the tumor-localized PET signal produced by 64Cu-DOTA-U3-1287 in the absence and presence of competing unlabeled U3-1287 in subjects with advanced solid tumors (Cohorts 2 through 5))\"\\n5825,1,1,\"Heterogeneity of CA9 expression by immunohistochemistry at completion of accrual\"\\n5826,1,1,\"Heterogeneity of glucose and lactate by bioluminescence imaging at completion of accrual\"\\n5827,1,1,\"Heterogeneity of hypoxia as measured by EF5 binding at completion of accrual\"\\n5828,1,1,\"High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood\"\\n5829,1,1,\"Highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing cohort\"\\n5830,1,1,\"Highest dose tolerated\"\\n5831,1,1,\"Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2\"\\n5832,1,1,\"Histologic diagnostic (tumor)\"\\n5833,1,1,\"Histologic yield\"\\n5834,1,1,\"Histological response after neoadjuvant ADG106 + chemotherapy\"\\n5835,1,1,\"Histological validation of the molecular results obtained in 1. and 2.\"\\n5836,1,1,\"Histopathologic Response\"\\n5837,1,1,\"histopathological and immunomodulatory changes\"\\n5838,2,1,\"Histopathological diagnosis\"\\n5839,1,1,\"Histopathological Endpoints: Immunohistochemical Staining for PSMA\"\\n5840,1,1,\"Histopathological Endpoints: Neovascularization Measured by CD105 and CD31 Markers\"\\n5841,1,1,\"Histopathological Endpoints: Tumor Vascular Density\"\\n5842,1,1,\"HLA-DR expression level of alveolar monocytes at the early phase of infectious Acute Respiratory Distress Syndrome (ARDS)\"\\n5843,1,1,\"HNSCC: Assess the effect of ASP-1929 PIT treatment with anti-PD1 therapy on tumor response\"\\n5844,1,1,\"Home blood pressure measurement\"\\n5845,1,1,\"Hopkins Verbal Learning Test - Revised (HVLT-R)\"\\n5846,1,1,\"Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria.\"\\n5847,1,1,\"Hospital COSTS in 14 Confirmed Catheter Related Infection Cases\"\\n5848,1,1,\"Hospital-based charges/costs\"\\n5849,3,1,\"Hospitalization Days\"\\n5850,1,1,\"Household financial hardship\"\\n5851,1,1,\"HPV-specific immune responses\"\\n5852,3,1,\"human anti-chimeric antibody\"\\n5853,1,1,\"Human biodistribution using blood sampling and PET/CT imaging: reported as relative uptake values per organ at 10, 90 and 150 minutes per individual subject and as a mean over all subjects (Part I).\"\\n5854,1,1,\"Human dosimetry for [F-18]MeFAMP.\"\\n5855,1,1,\"Human dosimetry of 64Cu-DOTA-U3-1287 in subjects with advanced solid tumors (Cohort 1 only)\"\\n5856,1,1,\"Human dosimetry using PET/CT imaging data: radiation dose to individual organs and the equivalent dose for the whole body of each subject and as a mean over all subjects (Part I).\"\\n5857,1,1,\"Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance\"\\n5858,1,1,\"Human-machine collaboration performance\"\\n5859,1,1,\"Humidified phytoncides to simulate the forest greenspace immersion (SFIT)\"\\n5860,1,1,\"Hyperthermia effect and averse event in RT for HCC with PVTT\"\\n5861,1,1,\"ID, whether absolute or functional, shall be defined according to the recommendations contained in NCCN 2012 (NCCN - Practice Guidelines in Oncology - version 2.2012)\"\\n5862,1,1,\"Identification and validation of cancer biomarkers in archival formalin fixed and paraffin embedded tumor samples\"\\n5863,1,1,\"Identification of a maximum tolerated dose and recommended phase 2 dose for OBI-999\"\\n5864,1,1,\"Identification of a maximum tolerated dose of OBI-888\"\\n5865,1,1,\"Identification of Dose-Limiting Toxicity (DLT) and Number of Subjects with DLT in Each Cohort/Level\"\\n5866,1,1,\"Identification of genetic variants and confirmation of the causality of these variants for the patient\\'s pathology whole exome sequencing\"\\n5867,1,1,\"Identification of imaging biomarkers that discriminate EGFR status in patients with NSCLC with a minimum area under the curve of 0.65\"\\n5868,2,1,\"Identification of maximum tolerated dose\"\\n5869,2,1,\"Identification of Maximum Tolerated Dose (MTD)\"\\n5870,1,1,\"Identification of Maximum Tolerated Dose (MTD) & Incidence of Dose-limiting Toxicities (DLTs)\"\\n5871,2,1,\"Identification of metabolites in plasma, urine and fecal samples\"\\n5872,1,1,\"Identification of molecular determinants of drug resistance, tumour progression or treatment toxicity.\"\\n5873,1,1,\"Identification of recommended phase 2 dose of ridaforolimus in combination with bevacizumab\"\\n5874,1,1,\"Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase\"\\n5875,1,1,\"Identification of the longest duration of fasting which is safe\"\\n5876,1,1,\"Identification of the main metabolite and biotransformation pathway of Fluzoparib and investigation of metabolite with proportion >10% in plasma following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.\"\\n5877,1,1,\"Identification of the molecular mechanisms underlying kidney, immune and solid organ transplantation-related diseases.\"\\n5878,1,1,\"Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)\"\\n5879,1,1,\"Identification of the recommended phase II dose (R2PD) regimen for combination osimertinib, necitumumab, trastuzumab (ONT) therapy (Phase Ib)\"\\n5880,1,1,\"Identification of the recommended Phase II dose of temsirolimus to be used in combination with capecitabine in patients with advanced malignancies\"\\n5881,1,1,\"Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy\"\\n5882,1,1,\"Identify a maximum tolerable dose as measured through adverse event reporting, ECGs and laboratory assessments\"\\n5883,1,1,\"Identify a RP2D of DSP-0509 when given in combination with pembrolizumab - by assessing DLTs\"\\n5884,1,1,\"Identify a RP2D of SHR2150 when given in combined regimen\"\\n5885,1,1,\"Identify an appropriate dosing regimen for further investigation of SL-901\"\\n5886,1,1,\"Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A\"\\n5887,1,1,\"Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxel\"\\n5888,1,1,\"Identify and isolate the cancer stem cell populations from primary tumor samples.\"\\n5889,1,1,\"Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis\"\\n5890,1,1,\"Identify biomarkers specific to apatinib or bevacizumab by transcriptome analysis\"\\n5891,1,1,\"Identify cancer patients who meet criteria for genetic counseling and testing\"\\n5892,1,1,\"Identify clinical and morphological predictors of cancer or high grade dysplasia in patients with IPMN. Identify predictors of progression to cancer or high grade dysplasia among patients who are followed in surveillance programs.\"\\n5893,1,1,\"Identify digital profiles (physical activity, sleep) in breast cancer patients over 70 years of age\"\\n5894,1,1,\"Identify DLT, MTD, and RP2D of OP-1250\"\\n5895,1,1,\"Identify DLTs, determine the maximum tolerated dose and select a recommended Phase 2 dose (RP2D) of BI-1808, given via intravenous (IV) infusion, as a single agent (Phase 1, Part A), and in combination with pembrolizumab (Phase 1, Part B)\"\\n5896,1,1,\"Identify dose limiting toxicities in Chinese subjects with select advanced (unresectable, metastatic, or recurrent) solid tumors measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation, and deaths\"\\n5897,1,1,\"Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab.\"\\n5898,1,1,\"Identify Dose Limiting Toxicity (DLT) of BP1001-A\"\\n5899,1,1,\"Identify dose-limiting toxicities (DLT) of FF-10832\"\\n5900,1,1,\"Identify dose-limiting toxicities (DLT) of FF-10850\"\\n5901,1,1,\"Identify Dose-limiting toxicity (DLT)\"\\n5902,1,1,\"Identify exceptional responders with cancer to standard of care chemotherapy\"\\n5903,1,1,\"Identify maximum tolerated dose\"\\n5904,1,1,\"Identify maximum tolerated dose (MTD)\"\\n5905,1,1,\"Identify Maximum Tolerated Dose (MTD) in mg/kg\"\\n5906,1,1,\"Identify maximum tolerated dose (MTD) of BP1001-A\"\\n5907,1,1,\"identify patient-important outcomes related to receiving nutrition services by engaging patients with cancer and clinicians\"\\n5908,1,1,\"Identify predictive models about the risk of febrile neutropenia and neutropenia grade 3/4 in patients with non-hematologic cancer\"\\n5909,1,1,\"Identify recommended dose of DK210 (EGFR)\"\\n5910,1,1,\"Identify recommended phase 2 dose by measuring incidence of dose limiting toxicities at increasing dose levels. Determine the safety and tolerability of VT1021 in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36 high cohort.\"\\n5911,1,1,\"Identify the correct tumor type by Harbinger Test\"\\n5912,1,1,\"Identify the maximum tolerated dose\"\\n5913,1,1,\"Identify the maximum tolerated dose (MTD) and/or the RD of C5252\"\\n5914,1,1,\"Identify the Maximum Tolerated Dose (MTD) or Pharmacologically Active Dose (PAD) within a defined dose range for itacitinib (INCB039110) in the treatment regimens administered\"\\n5915,1,1,\"Identify the MDL (maximum dose level) of single agent ciforadenant\"\\n5916,1,1,\"identify the recommended dose of aerobic training\"\\n5917,1,1,\"identify the recommended doses for the combination of sorafenib and sirolimus for subsequent phase II studies\"\\n5918,1,1,\"Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902\"\\n5919,1,1,\"Identify the recommended Phase 2 dose (RP2D) of GRT-C903 and GRT-R904\"\\n5920,1,1,\"Identify the Recommended Phase 2 Dose from the Escalation Phase\"\\n5921,1,1,\"Identify the recommended Phase 2 dose of AVB-S6-500 in combination with cabozantinib\"\\n5922,1,1,\"Identifying biomarkers predictive of immune-related toxicity associated with immune checkpoint inhibitor therapy.\"\\n5923,1,1,\"Identifying the maximum tolerated dose (MTD) of AZD6738 as a single-agent; and in combination with palliative radiation schedules.\"\\n5924,1,1,\"Identifying the p-HLA epitopes across diverse HLA alleles\"\\n5925,1,1,\"If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.\"\\n5926,3,1,\"IGF-1 Levels\"\\n5927,1,1,\"Illustration of the repartition of COVID+ patient severity (Low/Medium/Severe status) depending on cancer nature, stage and patient age.\"\\n5928,1,1,\"Image Assessment\"\\n5929,1,1,\"Imaging efficacy evaluation\"\\n5930,1,1,\"Imaging tumor response\"\\n5931,1,1,\"IMC-1121B Pharmacokinetics - Area Under the Concentration (AUC) - Cohort 3 During Cycles 3 to 5\"\\n5932,1,1,\"IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohort 3 During Cycles 1 and 2\"\\n5933,1,1,\"IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) - Cohorts 1 and 2 During Cycles 3 to 5\"\\n5934,1,1,\"IMC-1121B Pharmacokinetics: Area Under the Concentration (AUC) Versus Time Curve - Cohorts 1 and 2 During Cycles 1 and 2\"\\n5935,1,1,\"IMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohort 3 During Cycles 3 to 5\"\\n5936,1,1,\"IMC-1121B Pharmacokinetics: Half-Life (t 1/2) - Cohorts 1 and 2 During Cycles 3 to 5\"\\n5937,1,1,\"IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohort 3 During Cycles 1 and 2\"\\n5938,1,1,\"IMC-1121B Pharmacokinetics: Half-Life (t1/2) - Cohorts 1 and 2 During Cycles 1 and 2\"\\n5939,1,1,\"IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 1 and 2\"\\n5940,1,1,\"IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohort 3 During Cycles 3 to 5\"\\n5941,1,1,\"IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 1 and 2\"\\n5942,1,1,\"IMC-1121B Pharmacokinetics: Maximum Serum Concentration (Cmax) - Cohorts 1 and 2 During Cycles 3 to 5\"\\n5943,1,1,\"IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 1 and 2\"\\n5944,1,1,\"IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohort 3 During Cycles 3 to 5\"\\n5945,1,1,\"IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 1 and 2\"\\n5946,1,1,\"IMC-1121B Pharmacokinetics: Steady State Volume of Distribution (Vss) - Cohorts 1 and 2 During Cycles 3 to 5\"\\n5947,1,1,\"Immune Analysis in Tumor Biopsy and Blood (Part 1)\"\\n5948,1,1,\"Immune overall response rate\"\\n5949,1,1,\"Immune reactions to adenovirus and spreading of vector\"\\n5950,2,1,\"Immune reconstitution\"\\n5951,1,1,\"Immune Related Adverse Events (irAEs)\"\\n5952,9,3,\"Immune Response\"\\n5953,28,1,\"Immune response\"\\n5954,1,1,\"Immune Response To Combination IL-2 and Pembrolizumab\"\\n5955,1,1,\"Immune response to SARS-CoV-2 vaccine in cancer patients\"\\n5956,1,1,\"Immune Response to Sipuleucel-T\"\\n5957,1,1,\"Immune response to vaccination against COVID-19 measured as antibody response expressed as geometric mean concentration: arbitrary units (AU)/ml\"\\n5958,1,1,\"Immune response triggered by RFA: Change from rate of tumor infiltrating T lymphocytes on tumoral stroma measured before and after RFA1.\"\\n5959,1,1,\"Immune response triggered by RFA: Change from rate of tumor infiltrating T lymphocytes on tumoral stroma measured before and after RFA2.\"\\n5960,1,1,\"Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune F√∂rster Resonance Energy Transfer (iFRET).\"\\n5961,1,1,\"Immune response, measured by change in blood Th1-associated cytokines production in response to anti-CD3/28 stimulation or >= tumor antigens post-therapy\"\\n5962,1,1,\"Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation\"\\n5963,1,1,\"Immune-associated side effects\"\\n5964,1,1,\"Immune-based mechanism of action\"\\n5965,1,1,\"Immune-related adverse events (irAEs)\"\\n5966,1,1,\"Immune-related Clinical Response, Defined as Proportion of Patients Treated at the Maximum-tolerated Dose (MTD) Who Achieve Either a Complete or Partial Immune-related Response\"\\n5967,1,1,\"immune-related objective response rate\"\\n5968,1,1,\"Immune-related Objective Response Rate in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria (irRC) During Stages 1 and 2\"\\n5969,1,1,\"Immune-Related Overall Response Rate (irORR)\"\\n5970,1,1,\"Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria (irRC) During Stages 1 and 2\"\\n5971,1,1,\"Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive Non-colorectal Adenocarcinoma Participants Using Immune Related Response Criteria (irRC) During Stages 1 and 2\"\\n5972,1,1,\"Immune-related Progression-free Survival (irPFS)\"\\n5973,1,1,\"Immune-related severe (G‚â• 2) adverse events (irAEs)\"\\n5974,1,1,\"Immunogenic effect\"\\n5975,1,1,\"Immunogenicity (Serum anti-HPV 6, 11, 16, and 18 antibody measured using a competitive Luminex immunoassay)\"\\n5976,1,1,\"Immunogenicity - Generation of Cluster of Differentiation-8 (CD8)+ Cluster of Differentiation (CD28)+ memory T-cells\"\\n5977,1,1,\"Immunogenicity Analysis of [68Ga]Ga-NOTA-SNA002\"\\n5978,1,1,\"Immunogenicity of intradermal DC vaccination\"\\n5979,1,1,\"Immunogenicity properties of copper Cu 64 anti-CEA monoclonal antibody M5A\"\\n5980,1,1,\"Immunohistochemistry scores\"\\n5981,1,1,\"Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry\"\\n5982,1,1,\"Immunologic response, measured by the frequency of interferon gamma-releasing T cells specific to CAP-1, an HLA-A2 restricted epitope of CEA, as measured by the ELISPOT assay\"\\n5983,1,1,\"Immunologic: effect on T cell tumor infiltration\"\\n5984,2,1,\"Immunological evaluation will be performed two weeks after the last DC injection.\"\\n5985,1,1,\"Immunophenotypic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumors\"\\n5986,1,1,\"IMP-related dose limiting toxicities (DLT)\"\\n5987,1,1,\"Impact in the quality of life of vulvo-vaginal symptoms.\"\\n5988,1,1,\"Impact of germline genetic testing on both therapeutic management and targeted cancer prevention\"\\n5989,1,1,\"Impact of Patients Access to Their Electronic Medical Records Via the IPC Connect Application on patients anxiety level\"\\n5990,1,1,\"impact of pemetrexed on topotecan pharmacokinetics\"\\n5991,1,1,\"Impact of the coordinated pharmaceutical path on the tolerance of oral therapies against cancer.\"\\n5992,1,1,\"Impact of the use of umbilical cord blood as a source of hematopoietic stem cells\"\\n5993,1,1,\"Impacted (wisdom) teeth\"\\n5994,1,1,\"Impairment of mild EORTC QLQ-C30 score\"\\n5995,1,1,\"Impedance measurements in different frequencies\"\\n5996,1,1,\"Implementation Monitoring\"\\n5997,1,1,\"Implementation of OOCAT\"\\n5998,1,1,\"Improved characterization of different malignant tumor types\"\\n5999,1,1,\"Improvement in clinical benefit response\"\\n6000,1,1,\"Improvement in Nausea Score From Baseline to 2 Hours as Assessed by the Numerical Visual Analogue Scale\"\\n6001,1,1,\"Improvement in preparation for consideration of clinical trials\"\\n6002,1,1,\"Improvement of immune function\"\\n6003,1,1,\"Improvement of neuropathy by WEST assessment at 6, 12, 18, and 24 weeks\"\\n6004,1,1,\"Improvement of sleep, diet and exercise\"\\n6005,1,1,\"Improving Breast Cancer Diagnostic by Novel sonographicTechniques Study\"\\n6006,1,1,\"In adult solid cancer survivors, to determine that the TCC arm will have a larger reduction in psychological stress measured by the Perceived Stress Scale compared to the aerobic exercise and wait-list arms.\"\\n6007,1,1,\"In Part 1 and Part 2, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant\\'s peripheral blood lymphocytes.\"\\n6008,1,1,\"In Part B (Dose Expansion) - disease control rate (DCR).\"\\n6009,1,1,\"In Part B (Dose Expansion) - duration of overall response (DOR).\"\\n6010,1,1,\"In Part B (Dose Expansion) - duration of stable disease.\"\\n6011,1,1,\"In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.\"\\n6012,1,1,\"In part I and part II, Evaluate the safety and tolerability of escalating doses of single dose and multiple dose IT T3011.Characterize DLTs and identify the MTD of IT T3011.\"\\n6013,1,1,\"In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.\"\\n6014,1,1,\"In participants with advanced solid tumors, non Hodgkin\\'s lymphoma or multiple myeloma, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant\\'s peripheral blood lymphocytes.\"\\n6015,1,1,\"In phase Ia: Number of patients with DLT observed in the first cycle (first 21 days) for Schedules A and B, first 28 days for Schedule C), to meet objective of assessing MTD for each schedule in solid tumour patients & in schedule B in the DLBCL cohort\"\\n6016,1,1,\"In phase Ib: Number of patients experiencing DLTs from start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks after Cycle 2 (at the end of each new cycle) in order to determine the recommended phase II dose\"\\n6017,1,1,\"In the dose escalation part, number of participants with dose limiting toxicity (DLT).\"\\n6018,1,1,\"In the dose expansion part, Duration of response (DoR).\"\\n6019,1,1,\"In the dose expansion part,Objective response rate (ORR).\"\\n6020,1,1,\"In vitro experiment: to verify the regulation of intestinal flora on the biological behavior of anti msln car-t in vitro and the role of ACAT-1 in it.\"\\n6021,1,1,\"In vitro peripheral lymphocytes activity characterization under concomitant TTFields therapy - cohort B (under PD-1 inhibitors treatment)\"\\n6022,1,1,\"In vivo experiment: comparison of intestinal microflora and T cell cholesterol metabolism and subtypes between pancreatic cancer patients and healthy people The difference of proportion and the correlation.\"\\n6023,1,1,\"In-field Progression Free Survival\"\\n6024,1,1,\"Incedence of dose limiting toxicity\"\\n6025,2,1,\"Incicende of Adverse Events (AEs)\"\\n6026,1,1,\"Incidence AE and tolerability of PI3-kinase inhibitor BKM120 in combination with docetaxel\"\\n6027,1,1,\"Incidence and characteristics of AE\"\\n6028,1,1,\"Incidence and characteristics of DLTs\"\\n6029,1,1,\"Incidence and degree of Adverse Events and Serious Adverse Events\"\\n6030,2,2,\"Incidence and degree of Adverse Events and Serious Adverse Events [Safety]\"\\n6031,2,2,\"Incidence and grade of adverse events (CTCAE)\"\\n6032,1,1,\"Incidence and grade of adverse events graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03\"\\n6033,3,1,\"Incidence and intensity of adverse events\"\\n6034,1,1,\"Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria (CTC Version 3), that were associated with increasing doses of BIBW 2992\"\\n6035,1,1,\"Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) associated with increasing doses of BIBW 2992\"\\n6036,1,1,\"Incidence and intensity of Adverse Events according to Common Terminology Criteria (CTC version 3)\"\\n6037,1,1,\"Incidence and intensity of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE version 3.0)\"\\n6038,1,1,\"Incidence and intensity of adverse events according to Common Terminology Criteria for Adverse Events (version 3.0) associated with increasing doses of BIBF 1120\"\\n6039,1,1,\"Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 3) associated with increasing doses of BIBW 2992\"\\n6040,1,1,\"Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120\"\\n6041,1,1,\"Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTCAE Version 3.0) associated with increasing doses of BIBF 1120\"\\n6042,1,1,\"Incidence and intensity of Adverse Events according to the Common Terminology Criteria for Adverse Events (version 3.0) associated with increasing doses of BIBF 1120\"\\n6043,1,1,\"Incidence and intensity of Adverse Events according to the Common Terminology Criteria for Adverse Events (Version 3.0) associated with increasing doses of BIBF 1120.\"\\n6044,1,1,\"Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1\"\\n6045,1,1,\"Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2\"\\n6046,1,1,\"Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3\"\\n6047,1,1,\"Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4\"\\n6048,1,1,\"Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5\"\\n6049,1,1,\"Incidence and intensity of AdverseEvents according to Common Terminology Criteria (CTCAE version 3)\"\\n6050,1,1,\"Incidence and magnitude of clinically significant changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\"\\n6051,1,1,\"Incidence and magnitude of clinically significant changes in bilirubin\"\\n6052,1,1,\"Incidence and magnitude of clinically significant changes in red blood cell count, white blood cell count and platelet count\"\\n6053,2,1,\"Incidence and Nature of Adverse Events (AEs)\"\\n6054,2,1,\"Incidence and nature of adverse events (AEs)\"\\n6055,1,1,\"Incidence and Nature of DLTs\"\\n6056,2,1,\"Incidence and nature of DLTs\"\\n6057,1,1,\"Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 in combination with PDR001 only)\"\\n6058,1,1,\"Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 single agent only)\"\\n6059,1,1,\"Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.\"\\n6060,1,1,\"Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278\"\\n6061,4,1,\"Incidence and nature of dose-limiting toxicities\"\\n6062,12,7,\"Incidence and nature of dose-limiting toxicities (DLTs)\"\\n6063,2,2,\"Incidence and nature of dose-limiting toxicities (DLTs) - (Phase 1)\"\\n6064,1,1,\"Incidence and nature of dose-limiting toxicities and adverse events of special interest\"\\n6065,1,1,\"Incidence and nature of Dose-Limiting Toxicity (DLTs)\"\\n6066,2,2,\"Incidence and nature of participants with adverse events (AEs)\"\\n6067,1,1,\"Incidence and severity of adverse event (AE) and serious adverse event (SAE)-Phase1\"\\n6068,10,3,\"Incidence and Severity of Adverse Events\"\\n6069,63,7,\"Incidence and severity of adverse events\"\\n6070,3,1,\"Incidence and Severity of Adverse Events (AEs)\"\\n6071,4,1,\"Incidence and severity of Adverse Events (AEs)\"\\n6072,22,11,\"Incidence and severity of adverse events (AEs)\"\\n6073,1,1,\"Incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0\"\\n6074,4,2,\"Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n6075,10,2,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)\"\\n6076,1,1,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (according to NCI CTCAE 5.0).\"\\n6077,1,1,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Arm A)\"\\n6078,1,1,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03\"\\n6079,1,1,\"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including immune-mediated adverse events (imAEs)\"\\n6080,1,1,\"Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5\"\\n6081,1,1,\"Incidence and severity of Adverse Events (AEs) in Part A\"\\n6082,1,1,\"Incidence and Severity of Adverse Events (AEs) Phase I Part\"\\n6083,4,1,\"Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)\"\\n6084,2,2,\"Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0)\"\\n6085,1,1,\"Incidence and severity of adverse events according to NCI CTCAE\"\\n6086,1,1,\"Incidence and severity of adverse events and lab abnormalities\"\\n6087,5,5,\"Incidence and severity of adverse events and serious adverse events\"\\n6088,1,1,\"Incidence and severity of adverse events as assessed by CTCAE v.5.0\"\\n6089,1,1,\"Incidence and severity of adverse events as assessed by CTCAE v4.0 to determine the tolerability and safety\"\\n6090,2,2,\"Incidence and severity of adverse events as assessed by CTCAE V5.0\"\\n6091,1,1,\"Incidence and severity of adverse events as assessed by CTCAE V5.0.\"\\n6092,1,1,\"Incidence and severity of adverse events from ZN-c5 in combination with abemaciclib\"\\n6093,1,1,\"Incidence and severity of adverse events in stage ‚Ö†\"\\n6094,4,4,\"Incidence and severity of adverse events of special interest (AESIs)\"\\n6095,2,1,\"Incidence and severity of adverse events(AE)\"\\n6096,2,1,\"Incidence and severity of adverse events(AEs)\"\\n6097,1,1,\"Incidence and severity of Adverse Events, according to Common Terminology Criteria (CTC) version 3, with particular scrutiny of events that were considered to be dose-limiting toxicities and those that were serious or significant\"\\n6098,1,1,\"Incidence and severity of AE\"\\n6099,2,2,\"Incidence and Severity of AEs\"\\n6100,10,1,\"Incidence and severity of AEs\"\\n6101,1,1,\"Incidence and severity of AEs (adverse events).\"\\n6102,1,1,\"Incidence and Severity of AEs and Serious Adverse Events (SAEs) in Stage 1\"\\n6103,1,1,\"Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03\"\\n6104,1,1,\"Incidence and severity of AEs in patients receiving EOS100850\"\\n6105,1,1,\"Incidence and severity of AEs in patients receiving inupadenant\"\\n6106,1,1,\"Incidence and severity of AEs, AESIs and SAEs\"\\n6107,1,1,\"Incidence and severity of DLTs reported and their relationship to 2141-V11 administration assessed by NCI CTCAE v4.03\"\\n6108,1,1,\"Incidence and severity of dose-limiting toxicities\"\\n6109,1,1,\"Incidence and severity of dose-limiting toxicities (DLTs) in DLT evaluable subjects during Cycle 1\"\\n6110,1,1,\"Incidence and severity of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), serious TEAEs, and discontinuation due to adverse events (AEs).\"\\n6111,1,1,\"Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensity\"\\n6112,3,3,\"Incidence and severity of grade ‚â•3 laboratory abnormalities\"\\n6113,1,1,\"Incidence and severity of immune-related adverse events (irAEs)\"\\n6114,1,1,\"Incidence and severity of nausea as assessed by the Rhodes Index of Nausea & Vomiting before and after chemotherapy\"\\n6115,1,1,\"Incidence and severity of neutropenia assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.\"\\n6116,1,1,\"Incidence and severity of Participants Who Experience a Serious AE (SAE) as per NCI-CTC AE 5.0ÔºàStage IÔºâ\"\\n6117,1,1,\"Incidence and severity of Participants Who Experience an Adverse Event (AE) as per NCI-CTC AE 5.0ÔºàStage IÔºâ\"\\n6118,1,1,\"Incidence and severity of Participants Who Experience an Immune-related AE (irAE) as per NCI-CTC AE 5.0ÔºàStage IÔºâ\"\\n6119,1,1,\"Incidence and severity of rash development by Skindex questionnaire\"\\n6120,1,1,\"Incidence and severity of SAE\"\\n6121,10,6,\"Incidence and severity of serious adverse events (SAEs)\"\\n6122,1,1,\"Incidence and severity of study treatment-related adverse events measured by the Common Terminology Criteria for Adverse Events (CTCAE) v. 5\"\\n6123,1,1,\"Incidence and severity of TEAEs\"\\n6124,1,1,\"Incidence and severity of TEAEs including TESAEs\"\\n6125,7,3,\"Incidence and severity of treatment emergent adverse events (TEAEs)\"\\n6126,1,1,\"Incidence and severity of treatment emergent Adverse Events and Serious Adverse Events in Safety Run-in\"\\n6127,1,1,\"Incidence and severity of treatment emergent adverse events(TEAEs)\"\\n6128,4,1,\"Incidence and severity of treatment-emergent adverse events\"\\n6129,1,1,\"Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs\"\\n6130,3,1,\"Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)\"\\n6131,22,3,\"Incidence and severity of treatment-emergent adverse events (TEAEs)\"\\n6132,2,2,\"Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment related TEAEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0\"\\n6133,1,1,\"Incidence and severity of treatment-related adverse events and serious adverse events\"\\n6134,1,1,\"Incidence and severity of Treatment-related Adverse Events graded according to CTCAE of intratumoral injection of autologous CD1c (BDCA-1)+ myDC plus avelumab and ipilimumab in combination with iv nivolumab\"\\n6135,1,1,\"Incidence and the grade (severity) of dose-limiting toxicities (DLTs) within 28 days after start of study treatment to identify the MTD and the RP2D\"\\n6136,1,1,\"Incidence changes in clinical laboratory (Part 1A, 1B & 1C only)\"\\n6137,1,1,\"Incidence dose-limiting toxicities\"\\n6138,1,1,\"Incidence of >= grade 2 adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0\"\\n6139,1,1,\"Incidence of >= Grade 3 Mucositis\"\\n6140,1,1,\"Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure\"\\n6141,1,1,\"Incidence of ABN401 adverse events (AEs)\"\\n6142,4,2,\"Incidence of Abnormal Clinical Laboratory Test Results-Biochemistry\"\\n6143,4,2,\"Incidence of Abnormal Clinical Laboratory Test Results-Coagulation test\"\\n6144,4,2,\"Incidence of Abnormal Clinical Laboratory Test Results-hematology\"\\n6145,4,2,\"Incidence of Abnormal Clinical Laboratory Test Results-Urinalysis\"\\n6146,2,1,\"Incidence of abnormal laboratory findings\"\\n6147,8,1,\"Incidence of abnormal laboratory test results\"\\n6148,4,1,\"Incidence of abnormal laboratory tests results\"\\n6149,4,1,\"Incidence of abnormal physical exam findings\"\\n6150,2,2,\"Incidence of abnormalities observed in 12 lead ECG parameters\"\\n6151,1,1,\"Incidence of abnormalities observed in vital signs measurements\"\\n6152,1,1,\"Incidence of abnormalities observed in vital signs measurements and physical examinations\"\\n6153,2,1,\"Incidence of acute graft versus host disease (GVHD)\"\\n6154,1,1,\"Incidence of adverse device events (ADEs) in relation to the medical device\"\\n6155,6,1,\"Incidence of Adverse Drug Reactions (ADRs)\"\\n6156,3,1,\"Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar\"\\n6157,3,1,\"Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0\"\\n6158,1,1,\"Incidence of Adverse Effects as Assessed by CTCAE v 4.0\"\\n6159,1,1,\"Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0\"\\n6160,1,1,\"Incidence of adverse effects graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0\"\\n6161,1,1,\"incidence of adverse enents (AE), serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)\"\\n6162,125,16,\"Incidence of Adverse Events\"\\n6163,6,1,\"Incidence of Adverse events\"\\n6164,511,117,\"Incidence of adverse events\"\\n6165,12,2,\"incidence of adverse events\"\\n6166,8,4,\"Incidence of Adverse Events (AE)\"\\n6167,7,5,\"Incidence of adverse events (AE)\"\\n6168,1,1,\"Incidence of adverse events (AE) (Phase I)\"\\n6169,1,1,\"Incidence of Adverse Events (AE) as characterized by type, frequency, severity (NCI CTCAE Version 5.0), timing, seriousness, and relationship to study therapy\"\\n6170,1,1,\"Incidence of adverse events (AE) in HX301 Monolactate Capsules in patients with advanced solid tumors\"\\n6171,1,1,\"Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation, chemotherapy, or checkpoint blockers in Parts B, C, D\"\\n6172,1,1,\"Incidence of adverse events (AE) of fecal microbiota transplantation (FMT) (Project 3)\"\\n6173,1,1,\"Incidence of adverse events (AE) of HX009 in patients with advanced solid tumors\"\\n6174,1,1,\"Incidence of adverse events (AE)/serious adverse events (SAE)\"\\n6175,74,15,\"Incidence of Adverse Events (AEs)\"\\n6176,4,3,\"Incidence of Adverse events (AEs)\"\\n6177,105,37,\"Incidence of adverse events (AEs)\"\\n6178,1,1,\"Incidence of adverse events (AEs) (Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B)\"\\n6179,1,1,\"Incidence of adverse events (AEs) (Cohorts D and E)\"\\n6180,1,1,\"Incidence of adverse events (AEs) (Phase 1B)\"\\n6181,1,1,\"Incidence of adverse events (AEs) (Phase 2 only)\"\\n6182,1,1,\"Incidence of adverse events (AEs) (Phase I)\"\\n6183,1,1,\"Incidence of adverse events (AEs) (Phase Ib)\"\\n6184,1,1,\"Incidence of adverse events (AEs) and other safety parameters\"\\n6185,15,5,\"Incidence of adverse events (AEs) and serious adverse events (SAEs)\"\\n6186,2,2,\"Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)\"\\n6187,1,1,\"Incidence of adverse events (AEs) and serious adverse events throughout the trial;\"\\n6188,1,1,\"Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)\"\\n6189,1,1,\"Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation study\"\\n6190,1,1,\"Incidence of adverse events (AEs) graded according to NCI CTCAE version 4.0\"\\n6191,1,1,\"Incidence of Adverse Events (AEs) in Part 1\"\\n6192,2,1,\"Incidence of adverse events (AEs) leading to discontinuation\"\\n6193,1,1,\"Incidence of adverse events (AEs) meeting protocol-defined DLT (dose-limiting toxicity) criteria\"\\n6194,1,1,\"Incidence of adverse events (AEs) related to WBHT treatment alone or in combination with SOC chemotherapy according to the NCCN guidelines. nab-paclitaxel or gemcitabine alone\"\\n6195,1,1,\"Incidence of Adverse Events (AEs) SAR442720 and adagrasib\"\\n6196,1,1,\"Incidence of Adverse Events (AEs) SAR442720 and pembrolizumab\"\\n6197,1,1,\"Incidence of Adverse Events (AEs) with DK210 (EGFR)\"\\n6198,1,1,\"Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part A\"\\n6199,1,1,\"Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)\"\\n6200,1,1,\"Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]\"\\n6201,3,2,\"Incidence of adverse events (AEs), serious adverse events (SAEs) including changes in safety laboratory parameters and AEs leading to discontinuation\"\\n6202,1,1,\"Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs)\"\\n6203,1,1,\"Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)\"\\n6204,1,1,\"Incidence of adverse events (AEs), serious AEs\"\\n6205,1,1,\"Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE V4.03)).\"\\n6206,2,2,\"Incidence of adverse events (Dose Escalation and Dose Expansion)\"\\n6207,1,1,\"Incidence of adverse events (Dose escalation phase)\"\\n6208,1,1,\"Incidence of adverse events (dose finding cohort)\"\\n6209,2,1,\"Incidence of adverse events (expansion cohort)\"\\n6210,1,1,\"Incidence of Adverse Events (Grade 2 or Higher), Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0\"\\n6211,1,1,\"Incidence of adverse events (Part 1 and 2)\"\\n6212,1,1,\"Incidence of adverse events (Part 1)\"\\n6213,1,1,\"Incidence of adverse events (Part 2 [Dose Expansion])\"\\n6214,1,1,\"Incidence of adverse events (Parts A-K)\"\\n6215,1,1,\"Incidence of adverse events (Phase I dose expansion)\"\\n6216,1,1,\"Incidence of Adverse Events (Phase I)\"\\n6217,12,4,\"Incidence of adverse events (Phase I)\"\\n6218,1,1,\"Incidence of adverse events (phase I)\"\\n6219,1,1,\"Incidence of adverse events (Phase Ib and II)\"\\n6220,5,1,\"Incidence of adverse events (Phase Ib)\"\\n6221,5,2,\"Incidence of adverse events (Safety and Tolerability)\"\\n6222,1,1,\"Incidence of adverse events (Safety and tolerability) of IMA101 alone or in combination with atezolizumab\"\\n6223,1,1,\"Incidence of adverse events (toxicities) according to NCI CTCAE version 4.0\"\\n6224,1,1,\"Incidence of adverse events - ASTCT\"\\n6225,1,1,\"Incidence of adverse events - CTCAE\"\\n6226,9,2,\"Incidence of Adverse Events [Safety and Tolerability]\"\\n6227,1,1,\"Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6228,4,3,\"Incidence of Adverse events after CD70 CAR-T cells infusion [Safety and Tolerability]\"\\n6229,2,2,\"Incidence of Adverse events after CEA-CAR-T cells infusion [Safety and Tolerability]\"\\n6230,1,1,\"Incidence of adverse events after the treatment of eltrombopag\"\\n6231,1,1,\"Incidence of Adverse Events and Dose Limiting Adverse Events\"\\n6232,1,1,\"Incidence of adverse events and dose limiting toxicities (DLTs)\"\\n6233,1,1,\"Incidence of adverse events and SAEs\"\\n6234,2,1,\"Incidence of adverse events and serious adverse event (defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)) and irAE.\"\\n6235,12,3,\"Incidence of adverse events and serious adverse events\"\\n6236,1,1,\"Incidence of adverse events and server adverse events\"\\n6237,1,1,\"Incidence of adverse events and sevious adverse events\"\\n6238,1,1,\"Incidence of adverse events as a measure of safety\"\\n6239,1,1,\"Incidence of adverse events as assessed by the National Cancer Institute (NCI) CTCAE v 4.0\"\\n6240,1,1,\"Incidence of adverse events as assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5\"\\n6241,1,1,\"Incidence of adverse events as defined as DLTs\"\\n6242,1,1,\"Incidence of Adverse Events as Described and Graded by the National Cancer Institute\\'s Common Terminology Criteria for Adverse Events, Version 4.0\"\\n6243,1,1,\"Incidence of adverse events as graded by NCI CTCAE version 4.0\"\\n6244,1,1,\"Incidence of adverse events as graded by the NCI CTCAE version 4.0\"\\n6245,1,1,\"Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03 criteria (Safety lead-in cohort)\"\\n6246,1,1,\"Incidence of adverse events assessed by NCI CTCAE version 4.03\"\\n6247,1,1,\"Incidence of adverse events assessed by NCI CTCAE version 4.03 (Phase Ib)\"\\n6248,1,1,\"Incidence of adverse events by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03\"\\n6249,4,2,\"Incidence of adverse events by type, frequency, severity, and causality (safety)\"\\n6250,3,1,\"Incidence of adverse events categorized according to physical organ and disease/symptom\"\\n6251,1,1,\"Incidence of adverse events characterized by grade, relationship to study therapy, and prior experience, assessed by NCI CTCAE v4.0\"\\n6252,1,1,\"Incidence of adverse events Common Terminology Criteria for Adverse Events version 4.0\"\\n6253,1,1,\"Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03\"\\n6254,1,1,\"Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0\"\\n6255,1,1,\"Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)\"\\n6256,1,1,\"Incidence of adverse events grade 3 or greater\"\\n6257,1,1,\"Incidence of adverse events grade 3 or higher determined to be possibly, probably or definitely secondary to any of the study treatments\"\\n6258,1,1,\"Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Part I)\"\\n6259,1,1,\"Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Part II)\"\\n6260,1,1,\"Incidence of adverse events graded according to CTCAE version 4 or the Clavien-Dindo classification\"\\n6261,1,1,\"Incidence of adverse events graded according to NCI CTCAE version 4.0 (Part 1)\"\\n6262,1,1,\"Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b)\"\\n6263,1,1,\"Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6264,1,1,\"Incidence of adverse events graded according to the NCI CTCAE version 4.0\"\\n6265,1,1,\"Incidence of adverse events graded according to the NCI CTCAE version 4.03\"\\n6266,1,1,\"Incidence of adverse events graded by NCI CTCAE version 4.0\"\\n6267,1,1,\"Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4.0\"\\n6268,1,1,\"Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03\"\\n6269,1,1,\"Incidence of adverse events in HX009 treatment of patients with relapsed/refractory lymphoma\"\\n6270,1,1,\"Incidence of adverse events in patients given intraperitoneal carboplatin with intravenous paclitaxel at the MTD, assessed by CTCAE v3.0\"\\n6271,1,1,\"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0\"\\n6272,1,1,\"Incidence of adverse events in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumors who are undergoing lymph node mapping\"\\n6273,1,1,\"Incidence of adverse events in Phase 1b as graded by NCI-CTCAE version 5.0\"\\n6274,1,1,\"Incidence of adverse events in Stage I\"\\n6275,1,1,\"Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03\"\\n6276,1,1,\"Incidence of Adverse events meeting protocol defined dose limiting toxicities\"\\n6277,1,1,\"Incidence of adverse events of 4 escalating doses of alpha-tocopheryloxyacetic acid (TEA) therapy when combined with trastuzumab\"\\n6278,1,1,\"Incidence of adverse events of APN401, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6279,1,1,\"Incidence of adverse events of combining daily BKM120 with cisplatin and etoposide as graded by the National Cancer Institute (NC) CTCAE version 4.0\"\\n6280,1,1,\"Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab\"\\n6281,1,1,\"Incidence of adverse events of intratumoral injections of study drugs\"\\n6282,1,1,\"Incidence of adverse events of ipilimumab with anti-GITR agonistic monoclonal antibody BMS-986156 (BMS-986156) and stereotactic body radiation therapy (SBRT) targeting liver lesions\"\\n6283,1,1,\"Incidence of adverse events of ipilimumab with BMS-986156 and SBRT targeting lung lesions\"\\n6284,1,1,\"Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting liver lesions\"\\n6285,1,1,\"Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting lung lesions\"\\n6286,1,1,\"Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0\"\\n6287,1,1,\"Incidence of adverse events of onalespib and CDKI AT7519\"\\n6288,1,1,\"Incidence of adverse events of palliative radio therapy (RT) with lurbinectedin\"\\n6289,1,1,\"Incidence of adverse events of SVN53-67/M57-KLH peptide vaccine in combination with octreotide acetate in patients with neuroendocrine tumors\"\\n6290,1,1,\"Incidence of adverse events of tazemetostat in patients with varying degrees of hepatic dysfunction assessed using Common Terminology Criteria for Adverse Events version 5.0\"\\n6291,1,1,\"Incidence of adverse events of trifluridine/tipiracil hydrochloride combination agent TAS-102 in combination with nanoliposomal irinotecan\"\\n6292,1,1,\"Incidence of Adverse Events of WU-NK-101 in combination with cetuximab as assessed by by CTCAE v5\"\\n6293,1,1,\"Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (Cohorts 1 and 2)\"\\n6294,1,1,\"Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.03\"\\n6295,1,1,\"Incidence of adverse events related to 89Zr-DFO-REGN3767 administration as assessed by CTCAE v5.0\"\\n6296,1,1,\"Incidence of adverse events related to [18F]-AlF-RESCA-IL2 administration as assessed by CTCAE v5.0\"\\n6297,1,1,\"Incidence of adverse events related to the infusion of cells\"\\n6298,1,1,\"Incidence of adverse events that are >= grade 4 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0\"\\n6299,1,1,\"Incidence of Adverse Events to evaluate safety and tolerability of [225Ac]-FPI-2059 and [111In]-FPI-2058\"\\n6300,1,1,\"Incidence of adverse events to measure the safety and tolerability of this treatment combination\"\\n6301,1,1,\"Incidence of adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v4\"\\n6302,1,1,\"Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) alone at each dose level\"\\n6303,1,1,\"Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) when combined with pembrolizumab\"\\n6304,1,1,\"Incidence of adverse events ÔºàSafety and TolerabilityÔºâ\"\\n6305,1,1,\"incidence of adverse events( AE )and Serious adverse events(SAE)\"\\n6306,1,1,\"Incidence of adverse events, as defined by the Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) term and body system, graded according to the National Cancer Institute Common Toxicity Criteria v2.0\"\\n6307,1,1,\"Incidence of adverse events, assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n6308,1,1,\"Incidence of adverse events, assessment of clinical laboratory test findings, physical examination, 12-lead electrocardiogram (ECG), and vital signs measurements\"\\n6309,1,1,\"Incidence of adverse events, defined following the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6310,17,2,\"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0\"\\n6311,1,1,\"Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6312,3,1,\"Incidence of adverse events, graded according to NCI CTC version 2.0\"\\n6313,1,1,\"Incidence of adverse events, graded according to NCI CTCAE version 4.0\"\\n6314,1,1,\"Incidence of adverse events, graded according to the standard Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n6315,8,1,\"Incidence of adverse events.\"\\n6316,1,1,\"Incidence of adverse experiences from oral ONC201 using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n6317,1,1,\"Incidence of Adverse Reactions\"\\n6318,1,1,\"Incidence of adverse reactions to Akt inhibitor MK2206 and lapatinib ditosylate in patients with advanced and unresectable or metastatic HER2+ breast cancer previously treated with trastuzumab as assessed by NCI CTCAE v. 4 (Part II)\"\\n6319,13,3,\"Incidence of AEs\"\\n6320,1,1,\"Incidence of AEs (Adverse Events)\"\\n6321,2,2,\"Incidence of AEs (Part 1)\"\\n6322,1,1,\"Incidence of AEs (Phase II)\"\\n6323,12,1,\"Incidence of AEs and SAEs\"\\n6324,1,1,\"Incidence of AEs and SAEs (Phase 1)\"\\n6325,1,1,\"Incidence of AEs and SAEs related to AZD8701 as monotherapy and in combination with Durvalumab in disease specific expansions treated at the MTD/OBD/MFD\"\\n6326,5,5,\"Incidence of AEs leading to death\"\\n6327,21,15,\"Incidence of AEs leading to discontinuation\"\\n6328,1,1,\"Incidence of AEs leading to discontinuation and deaths\"\\n6329,1,1,\"Incidence of AEs leading to discontinuation in Part 1\"\\n6330,1,1,\"Incidence of AEs leading to dose delays and discontinuation or delay in radical cystectomy (RC)\"\\n6331,1,1,\"Incidence of AEs leading to laboratory abnormalities\"\\n6332,2,1,\"Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria\"\\n6333,1,1,\"Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria\"\\n6334,1,1,\"Incidence of AEs meeting protocol- defined dose-limiting toxicity (DLT) criteria\"\\n6335,1,1,\"Incidence of AEs meeting protocol-defined Dose Limiting Toxicities (DLT) criteria\"\\n6336,1,1,\"Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria\"\\n6337,2,2,\"Incidence of AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria\"\\n6338,2,2,\"Incidence of AEs meeting protocol-defined dose limiting toxicity (DLT) criteria\"\\n6339,4,3,\"Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria\"\\n6340,1,1,\"Incidence of AEs, SAEs and DLTs (safety) parameters.\"\\n6341,1,1,\"Incidence of AEs, SAEs and Dose-limiting Toxicities (DLTs)\"\\n6342,1,1,\"Incidence of AEs, SAEs, and abnormalities in Lab\"\\n6343,1,1,\"Incidence of ALK-positive NSCLC in Spain\"\\n6344,1,1,\"Incidence of all adverse events as assessed by CTCAE v4.0, clinically significant changes in vital signs, ECGs and clinical laboratory tests\"\\n6345,1,1,\"Incidence of all adverse events graded according to NCI CTCAE, v4.0\"\\n6346,1,1,\"Incidence of all adverse events, graded according to the National Cancer Institute Common (NCI) Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n6347,1,1,\"Incidence of all treatment emergent adverse events to inform the safety profile of SL-172154 when administered intratumorally\"\\n6348,2,2,\"incidence of all types/grades of adverse events\"\\n6349,1,1,\"Incidence of alterations in clinical laboratory test results\"\\n6350,1,1,\"Incidence of alterations in electrocardiogram assessment\"\\n6351,1,1,\"Incidence of alterations in vital signs measurements\"\\n6352,1,1,\"Incidence of any other grade 4 or greater toxicity as scored by the NCI Common Toxicity Criteria v2.0\"\\n6353,1,1,\"Incidence of asymptomatic proximal deep vein thrombosis (DVT) of the lower limbs as assessed by bilateral compression ultrasound at baseline and at 3 months\"\\n6354,1,1,\"Incidence of Bacteriemia in a High Dose Busulfan, Melphalan and Thiotepa Chemotherapy Regimen With Autologous Peripheral Blood Stem Cell Rescue in Patients With High Risk and Relapsed or Refractory Pediatric Solid Tumors\"\\n6355,1,1,\"Incidence of baseline laboratory finding, ECG and vital signs changes\"\\n6356,1,1,\"Incidence of cancer among transplanted patients.\"\\n6357,1,1,\"Incidence of cancer treatment adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE)\"\\n6358,1,1,\"Incidence of cART-related ECIs of grade 2 or higher AEs\"\\n6359,1,1,\"Incidence of catheter-associated thrombosis (CAT)\"\\n6360,1,1,\"Incidence of catheter-related infections during the study period (3 months)\"\\n6361,1,1,\"Incidence of changes in clinical laboratory abnormalities\"\\n6362,1,1,\"Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapy\"\\n6363,1,1,\"Incidence of changes in clinical laboratory values (Phase 1 only)\"\\n6364,1,1,\"incidence of chemotherapy interruptions\"\\n6365,1,1,\"Incidence of CIN Grade 4 Episodes by EP2006 Dose: Patient Level\"\\n6366,1,1,\"Incidence of CIN/FN-related Chemotherapy Disturbance by EP2006 Prophylaxis Type: Patient Level\"\\n6367,1,1,\"Incidence of CIN/FN-related Hospitalization Outcomes by EP2006 Practice Patterns (Relative to Guidelines): Patient Level\"\\n6368,1,1,\"Incidence of cisplatin-induced nephrotoxicity\"\\n6369,1,1,\"Incidence of clinical and biological adverse events occurring with ICPi treatment during the study period\"\\n6370,6,1,\"Incidence of clinical laboratory abnormalities\"\\n6371,1,1,\"Incidence of clinical laboratory abnormalities (Part 1)\"\\n6372,3,3,\"Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.\"\\n6373,1,1,\"Incidence of clinically relevant abnormal clinical laboratory parameters\"\\n6374,1,1,\"Incidence of clinically significant abnormal measurements in physical examination, ophthalmological examination, vital signs, electrocardiogram (ECG), pregnancy test, lab tests and ECOG performance status\"\\n6375,1,1,\"Incidence of clinically significant abnormal measurements in physical examination, vital signs, electrocardiogram (ECG), lab tests and ECOG performance status\"\\n6376,1,1,\"Incidence of clinically significant abnormal vital and ECG parameters\"\\n6377,1,1,\"Incidence of clinically significant AEs\"\\n6378,1,1,\"Incidence of Clinically Significant Bacteremia\"\\n6379,8,4,\"Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests\"\\n6380,9,4,\"Incidence of clinically significant changes in clinical laboratory results: Hematology tests\"\\n6381,9,4,\"Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests\"\\n6382,1,1,\"Incidence of clinically significant changes in ECGs\"\\n6383,4,1,\"Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval\"\\n6384,3,1,\"Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval\"\\n6385,4,1,\"Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval\"\\n6386,3,1,\"Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval\"\\n6387,1,1,\"Incidence of clinically significant changes in vital sign - Body Temperature\"\\n6388,1,1,\"Incidence of clinically significant changes in vital sign - Pulse rate\"\\n6389,1,1,\"Incidence of clinically significant changes in vital sign - Systolic and diastolic blood pressure\"\\n6390,1,1,\"Incidence of clinically significant changes in vital signs - Weight\"\\n6391,7,1,\"Incidence of clinically significant changes in vital signs: Blood pressure\"\\n6392,7,1,\"Incidence of clinically significant changes in vital signs: Body temperature\"\\n6393,8,1,\"Incidence of clinically significant changes in vital signs: Heart rate\"\\n6394,1,1,\"Incidence of clinically significant changes in vital signs: Pulse oximetry\"\\n6395,7,1,\"Incidence of clinically significant changes in vital signs: Respiratory rate\"\\n6396,1,1,\"Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results (chemistry, hematology, coagulation, urinalysis), Eastern Cooperative Oncology Group (ECOG) performance status\"\\n6397,1,1,\"Incidence of clinically significant cytomegalovirus (CMV) infection\"\\n6398,1,1,\"Incidence of clinically significant electrocardiogram (ECG) abnormalities as a measure of safety\"\\n6399,1,1,\"Incidence of clinically significant laboratory assessments\"\\n6400,1,1,\"Incidence of clinically significant laboratory values as a measure of safety\"\\n6401,1,1,\"Incidence of complete response (CR), partial response (PR) or stable disease (SD) ‚â•24 weeks (clinical benefit)\"\\n6402,1,1,\"Incidence of composite serious adverse events (Phase I)\"\\n6403,2,1,\"Incidence of Confirmed Herpes-Zoster\"\\n6404,1,1,\"Incidence of conversion of non-inflamed to inflamed melanoma\"\\n6405,9,1,\"Incidence of Death\"\\n6406,11,5,\"Incidence of death\"\\n6407,4,1,\"Incidence of Deaths\"\\n6408,9,7,\"Incidence of deaths\"\\n6409,1,1,\"Incidence of deaths in Part 1\"\\n6410,13,10,\"Incidence of DLT\"\\n6411,1,1,\"Incidence of DLT (Dose limit toxicity) of VIP152 (BAY1251152)\"\\n6412,1,1,\"Incidence of DLT (Dose limit toxicity) of VIP152 (BAY1251152) in combination with Keytruda¬Æ (pembrolizumab)\"\\n6413,1,1,\"Incidence of DLT (Dose limit toxicity) of VIP236\"\\n6414,1,1,\"Incidence of DLT (dose limiting toxicity) of BAY 94-9343\"\\n6415,1,1,\"Incidence of DLT defined as any grade 3 non-hematological toxicity or grade 4 hematological toxicity attributed to selumetinib or cyclosporine graded per National Cancer Institute (NCI) CTCAE version 4.0\"\\n6416,1,1,\"Incidence of DLT events and treatment emergent AEs (TEAEs)\"\\n6417,1,1,\"Incidence of DLT in patients by the end of the first treatment cycle in the co-administration of RAD001 and BEZ235\"\\n6418,1,1,\"incidence of DLT(dose-limiting toxicities)\"\\n6419,9,4,\"Incidence of DLTs\"\\n6420,1,1,\"Incidence of DLTs (Cohorts 1C, 1D, 1E, 1F, and 1G)\"\\n6421,1,1,\"Incidence of DLTs (dose escalation cohorts only), treatment emergent adverse events (TEAEs), and changes in safety parameters\"\\n6422,1,1,\"Incidence of DLTs (dose-limiting toxicity)\"\\n6423,1,1,\"Incidence of DLTs (Phase 1A Part 2)\"\\n6424,1,1,\"Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab\"\\n6425,2,2,\"Incidence of DLTs and treatment-emergent adverse events\"\\n6426,2,2,\"Incidence of DLTs by the NCI CTCAE v4.03\"\\n6427,1,1,\"Incidence of DLTs during Cycle 1 in dose-escalation cohorts\"\\n6428,1,1,\"Incidence of DLTs during Cycle 1 in dose-escalation cohorts during J-arm of the study\"\\n6429,1,1,\"Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A of the study\"\\n6430,1,1,\"Incidence of DLTs during Cycle 1 in dose-escalation cohorts during Part A.1 of the study\"\\n6431,1,1,\"Incidence of DLTs during the first and second cycle of treatment with MBG453 in combination with PDR001 or in combination with decitabine\"\\n6432,1,1,\"Incidence of DLTs during the Safety Run-in\"\\n6433,1,1,\"Incidence of DLTs occurring in the first 4 courses of treatment (feasibility phase)\"\\n6434,1,1,\"Incidence of DLTs with KY1044 in combination with atezolizumab (Phase 1)\"\\n6435,1,1,\"Incidence of dose alterations (Cohort 1D)\"\\n6436,1,1,\"Incidence of dose alterations (Cohorts D and E)\"\\n6437,1,1,\"Incidence of dose dose limiting toxicities (DLTs) by NCI CTCAE, v4.0\"\\n6438,1,1,\"Incidence of dose interruptions\"\\n6439,1,1,\"Incidence of dose interruptions, dose modifications and discontinuations due to AEs\"\\n6440,1,1,\"Incidence of dose interruptions, reductions, and treatment terminations due to AEs/SAEs\"\\n6441,3,2,\"Incidence of dose interruptions.\"\\n6442,1,1,\"Incidence of Dose Limiting Toxcities (DLTs) in escalation and expansion\"\\n6443,10,4,\"Incidence of Dose Limiting Toxicities\"\\n6444,1,1,\"Incidence of Dose Limiting toxicities\"\\n6445,2,2,\"Incidence of Dose limiting toxicities\"\\n6446,20,9,\"Incidence of dose limiting toxicities\"\\n6447,1,1,\"Incidence of dose limiting toxicities (DLT\\'s) (Part 1)\"\\n6448,8,3,\"Incidence of Dose Limiting Toxicities (DLT)\"\\n6449,5,1,\"Incidence of dose limiting toxicities (DLT)\"\\n6450,1,1,\"Incidence of dose limiting toxicities (DLT) (Phase I)\"\\n6451,1,1,\"Incidence of Dose Limiting Toxicities (DLT) associated with increasing doses of BIBF 1120\"\\n6452,1,1,\"Incidence of Dose Limiting Toxicities (DLT) in HX009 in patients with advanced solid tumors\"\\n6453,1,1,\"Incidence of Dose Limiting Toxicities (DLT) in HX301 Monolactate Capsules in patients with advanced solid tumors\"\\n6454,1,1,\"Incidence of Dose Limiting Toxicities (DLT) in the dose escalation part\"\\n6455,1,1,\"Incidence of dose limiting toxicities (DLT) of experimental regimens\"\\n6456,15,10,\"Incidence of Dose Limiting Toxicities (DLTs)\"\\n6457,44,24,\"Incidence of dose limiting toxicities (DLTs)\"\\n6458,1,1,\"incidence of Dose Limiting Toxicities (DLTs)\"\\n6459,1,1,\"Incidence of dose limiting toxicities (DLTs) (Arm A)\"\\n6460,1,1,\"Incidence of dose limiting toxicities (DLTs) (Dose escalation part)\"\\n6461,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) (Part 1A and Part 1C only)\"\\n6462,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) (Part 1A only)\"\\n6463,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Dose Escalation)\"\\n6464,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A only)\"\\n6465,1,1,\"Incidence of dose limiting toxicities (DLTs) (Phase 1)\"\\n6466,1,1,\"Incidence of dose limiting toxicities (DLTs) (Phase 1A Part 1)\"\\n6467,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) - Combination Agents\"\\n6468,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) - Single Agent\"\\n6469,1,1,\"Incidence of dose limiting toxicities (DLTs) and organ exposure to radiation - phase I\"\\n6470,1,1,\"Incidence of dose limiting toxicities (DLTs) by NCI CTCAE v4.0 grade and associated dose of GDC-0349\"\\n6471,2,1,\"Incidence of dose limiting toxicities (DLTs) during cycle 1 (28 days)\"\\n6472,1,1,\"Incidence of dose limiting toxicities (DLTs) during the DLT period\"\\n6473,1,1,\"Incidence of Dose limiting toxicities (DLTs) during the first cycle of treatment with single agent MBG453\"\\n6474,1,1,\"Incidence of dose limiting toxicities (DLTs) experienced during Cycle 1\"\\n6475,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP0739 + Pembrolizumab Safety Lead-in\"\\n6476,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP0739 Single Agent\"\\n6477,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP1002\"\\n6478,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP1570 Single Agent\"\\n6479,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) for ASP2074\"\\n6480,1,1,\"Incidence of dose limiting toxicities (DLTs) in dose escalation study\"\\n6481,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapy\"\\n6482,1,1,\"Incidence of dose limiting toxicities (DLTs) in the DLT evaluation period\"\\n6483,1,1,\"Incidence of dose limiting toxicities (DLTs) in the dose escalation phase\"\\n6484,1,1,\"Incidence of dose limiting toxicities (DLTs) of adverse events\"\\n6485,1,1,\"Incidence of dose limiting toxicities (DLTs) of Apatinib in combination with pembrolizumab\"\\n6486,1,1,\"Incidence of dose limiting toxicities (DLTs) of IP administered AVB-001 to determine the MTD and RP2D in the Dose Escalation Phase (Part 1)\"\\n6487,1,1,\"Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.\"\\n6488,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) that will define the MTD\"\\n6489,1,1,\"Incidence of dose limiting toxicities (DLTs) using the National Cancer Institute (NCI) CTCAE version 4.0\"\\n6490,1,1,\"Incidence of Dose Limiting Toxicities (DLTs) with KY1044 as single agent (Phase 1)\"\\n6491,1,1,\"Incidence of dose limiting toxicities (dose escalation phase)\"\\n6492,1,1,\"Incidence of dose limiting toxicities (dose expansion phase)\"\\n6493,1,1,\"Incidence of dose limiting toxicities (Part 1 [Dose Escalation])\"\\n6494,1,1,\"Incidence of dose limiting toxicities (Phase 1)\"\\n6495,1,1,\"Incidence of Dose limiting toxicities (Phase I)\"\\n6496,1,1,\"Incidence of dose limiting toxicities (Phase II)\"\\n6497,1,1,\"Incidence of dose limiting toxicities according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03\"\\n6498,1,1,\"Incidence of dose limiting toxicities as a determinant of the Recommended Phase 2 Dose (RP2D)\"\\n6499,1,1,\"Incidence of dose limiting toxicities defined as grade 3 or higher toxicity\"\\n6500,1,1,\"Incidence of Dose limiting toxicities during the first cycle of treatment.\"\\n6501,1,1,\"Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only)\"\\n6502,1,1,\"Incidence of dose limiting toxicities to determine the maximum tolerated dose (MTD) and Recommended Phase II dose of SNX281\"\\n6503,9,5,\"Incidence of dose limiting toxicity\"\\n6504,10,3,\"Incidence of Dose Limiting Toxicity (DLT)\"\\n6505,1,1,\"Incidence of Dose limiting toxicity (DLT)\"\\n6506,14,3,\"Incidence of dose limiting toxicity (DLT)\"\\n6507,1,1,\"Incidence of Dose Limiting Toxicity (DLT) and observed adverse events\"\\n6508,1,1,\"Incidence of dose limiting toxicity (DLT) at each dose level\"\\n6509,1,1,\"Incidence of dose limiting toxicity (DLT) Cohort 1\"\\n6510,1,1,\"Incidence of dose limiting toxicity (DLT) Cohort 2\"\\n6511,1,1,\"Incidence of dose limiting toxicity (DLT) graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase Ib)\"\\n6512,1,1,\"Incidence of dose limiting toxicity (DLT) in each dose group\"\\n6513,8,1,\"Incidence of dose limiting toxicity (DLTs)\"\\n6514,1,1,\"incidence of Dose Limiting Toxicity (DLTs) (phase I)\"\\n6515,1,1,\"Incidence of Dose limiting toxiticites (DLTs)\"\\n6516,1,1,\"Incidence of dose modifications (Phase 2 only)\"\\n6517,1,1,\"Incidence of dose reductions\"\\n6518,1,1,\"Incidence of dose reductions of ZW49\"\\n6519,1,1,\"Incidence of dose-limited toxicities (DLTs)\"\\n6520,1,1,\"Incidence of dose-limiting toxicites (DLTs)- Cohort C Part 1\"\\n6521,2,1,\"Incidence of Dose-Limiting Toxicities\"\\n6522,17,12,\"Incidence of dose-limiting toxicities\"\\n6523,1,1,\"incidence of dose-limiting toxicities\"\\n6524,2,2,\"Incidence of Dose-limiting toxicities (DLT)\"\\n6525,4,2,\"Incidence of dose-limiting toxicities (DLT)\"\\n6526,1,1,\"Incidence of dose-limiting toxicities (DLT) as defined in the protocol\"\\n6527,1,1,\"Incidence of dose-limiting toxicities (DLT) in DLT evaluable subjects and the incidence and severity of adverse events.\"\\n6528,5,1,\"Incidence of Dose-Limiting Toxicities (DLTs)\"\\n6529,2,1,\"Incidence of Dose-limiting Toxicities (DLTs)\"\\n6530,1,1,\"Incidence of Dose-limiting toxicities (DLTs)\"\\n6531,33,19,\"Incidence of dose-limiting toxicities (DLTs)\"\\n6532,2,1,\"Incidence of dose-limiting toxicities (DLTs) (Part 1)\"\\n6533,1,1,\"Incidence of dose-limiting toxicities (DLTs) (Phase 2 only)\"\\n6534,1,1,\"Incidence of dose-limiting toxicities (DLTs) and other toxicities\"\\n6535,3,3,\"Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events\"\\n6536,1,1,\"Incidence of dose-limiting toxicities (DLTs) by NCI CTCAE 5.0: Dose Escalation Stage\"\\n6537,1,1,\"Incidence of Dose-limiting Toxicities (DLTs) Defined as the Rate of Drug-related Grade 3-5 Adverse Events Assessed Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (Phase I)\"\\n6538,1,1,\"Incidence of dose-limiting toxicities (DLTs) during dose escalation phase\"\\n6539,1,1,\"Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase\"\\n6540,1,1,\"Incidence of dose-limiting toxicities (DLTs) in Cycle 1\"\\n6541,1,1,\"Incidence of Dose-Limiting Toxicities (DLTs) in patients with advanced solid tumors receiving EOS100850\"\\n6542,1,1,\"Incidence of Dose-Limiting Toxicities (DLTs) in patients with advanced solid tumors receiving inupadenant\"\\n6543,1,1,\"Incidence of Dose-limiting Toxicities (DLTs) in Stage I\"\\n6544,1,1,\"Incidence of dose-limiting toxicities (DLTs) in the dose escalation part\"\\n6545,1,1,\"Incidence of dose-limiting toxicities (DLTs) occurring in the first or second course of treatment (dose-escalation phase)\"\\n6546,1,1,\"Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumab\"\\n6547,2,2,\"Incidence of dose-limiting toxicities (DLTs; Part 1)\"\\n6548,1,1,\"Incidence of dose-limiting toxicities (Part 1)\"\\n6549,4,2,\"Incidence of dose-limiting toxicities (safety)\"\\n6550,3,1,\"Incidence of dose-limiting toxicities within each dose level cohort\"\\n6551,1,1,\"Incidence of dose-limiting toxicities(DLT)\"\\n6552,9,2,\"Incidence of dose-limiting toxicity\"\\n6553,2,1,\"Incidence of Dose-limiting toxicity (DLT)\"\\n6554,14,8,\"Incidence of dose-limiting toxicity (DLT)\"\\n6555,2,2,\"Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period\"\\n6556,1,1,\"Incidence of dose-limiting toxicity (DLT) in each dose group\"\\n6557,1,1,\"Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I)\"\\n6558,1,1,\"Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only\"\\n6559,1,1,\"Incidence of dose-limiting toxicity (DLT).\"\\n6560,1,1,\"Incidence of Dose-limiting toxicity (DLTs)\"\\n6561,3,1,\"Incidence of dose-limiting toxicity (DLTs)\"\\n6562,1,1,\"Incidence of dose-limiting toxicity - Part 1 and Part 2\"\\n6563,1,1,\"Incidence of dose-limiting toxicity and determination of phase II dose\"\\n6564,1,1,\"Incidence of dose-limiting toxicity as assessed by NCI CTCAE v3.0\"\\n6565,1,1,\"Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6566,1,1,\"Incidence of dose-limiting toxicity within 2 days of single administration and 28 days of continuous administration.\"\\n6567,1,1,\"Incidence of dose-limiting toxicity within 28 days of treatment administration for patients with UGT1A1*28 genotype (wt/wt and wt/*28)\"\\n6568,1,1,\"Incidence of dose-limiting toxicity(DLT)\"\\n6569,1,1,\"Incidence of dose-limiting toxicity, determination of maximum tolerated dose (MTD), and recommended Phase 2 dose\"\\n6570,1,1,\"Incidence of drug-related AEs\"\\n6571,1,1,\"Incidence of drug-related AEs in study Part B\"\\n6572,5,2,\"Incidence of drug-related TEAEs\"\\n6573,3,1,\"Incidence of drug-related TESAEs\"\\n6574,1,1,\"Incidence of Durable Stable Disease, Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n6575,1,1,\"Incidence of ECG (PR interval, QRS complex, QT corrected interval prolonged, and QT interval corrected using Fridericia\\'s formula) abnormalities\"\\n6576,1,1,\"Incidence of electrocardiogram (ECG) abnormalities (Cohorts D and E)\"\\n6577,1,1,\"Incidence of electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) abnormalities\"\\n6578,1,1,\"incidence of fatigue or malaise (CTCAE ver. 4, all grades)\"\\n6579,3,1,\"Incidence of febrile neutropenia (FN)\"\\n6580,1,1,\"Incidence of first cycle dose-limiting toxicities (DLTs) of elzovantinib\"\\n6581,1,1,\"Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0046\"\\n6582,1,1,\"Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0131\"\\n6583,1,1,\"Incidence of grade 2-4 diarrhea over the 9-week study period, assessed by CTCAE version 4.0\"\\n6584,1,1,\"incidence of grade 3 hand-foot skin reaction\"\\n6585,1,1,\"Incidence of Grade 3 or 4 drug related adverse events and clinical lab abnormalities defined as Dose Limiting Toxicities (DLTs) using NCI CTCAE v 4.03\"\\n6586,1,1,\"Incidence of grade 3 or higher adverse events using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n6587,1,1,\"Incidence of grade 3 or higher immune-related adverse events (irAEs), graded according to the National Cancer Institute (NCI) CTCAE v4.0\"\\n6588,1,1,\"Incidence of grade 3 or higher treatment-related adverse event (AE) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n6589,1,1,\"Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)\"\\n6590,1,1,\"Incidence of grade 3+ adverse events, as assessed by the NCI CTCAE version 4.0\"\\n6591,1,1,\"Incidence of grade 3+ adverse events, as graded using NCI CTCAE v 4.0\"\\n6592,1,1,\"Incidence of Grade 3-4 Esophagitis\"\\n6593,1,1,\"Incidence of Grade 3-4 Myelosuppression\"\\n6594,1,1,\"Incidence of Grade 3-4 Pneumonitis\"\\n6595,1,1,\"Incidence of grade 3-5 adverse event (AE)\"\\n6596,1,1,\"Incidence of grade 4 or greater mucositis as scored by the National Cancer Institute (NCI) Common Toxicity Criteria v2.0\"\\n6597,1,1,\"Incidence of grade 4 or greater skin toxicity as scored by the NCI Common Toxicity Criteria v2.0\"\\n6598,1,1,\"Incidence of grade >= 3 treatment-emergent adverse events (both immune and non-immune related) (Phase 2)\"\\n6599,1,1,\"Incidence of grade ‚â• 3 Adverse Events (AE)\"\\n6600,4,1,\"Incidence of graft failure\"\\n6601,3,1,\"Incidence of graft-versus-host disease\"\\n6602,1,1,\"Incidence of hematologic (heme) dose-limiting toxicity (Phase I)\"\\n6603,1,1,\"Incidence of hematologic toxicity, including thrombocytopenia, neutropenia, and leukopenia, evaluated via the ordinal CTC\"\\n6604,1,1,\"Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events\"\\n6605,1,1,\"Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events\"\\n6606,1,1,\"Incidence of high-grade immune-mediated adverse events (IMAEs) assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Grade 3 to 4 and Grade 5\"\\n6607,1,1,\"Incidence of hospitalisation due to febrile neutropenia and/or infection\"\\n6608,1,1,\"Incidence of hypercoagulability\"\\n6609,1,1,\"Incidence of Immune Mediated Adverse Events (imAE).\"\\n6610,1,1,\"Incidence of immune related adverse events (irAE)\"\\n6611,1,1,\"Incidence of immune-related adverse events (irAE)\"\\n6612,1,1,\"Incidence of immune-related adverse events (IrAEs)\"\\n6613,1,1,\"Incidence of immune-related adverse events (irAEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE)\"\\n6614,1,1,\"Incidence of immune-related AEs (irAEs), all deaths, and dose-limiting toxicities (DLTs)\"\\n6615,1,1,\"Incidence of immune-related events of clinical interest (ECIs)\"\\n6616,1,1,\"Incidence of IMP treatment discontinuations due to toxicity\"\\n6617,1,1,\"Incidence of Infusion-related adverse events by type, frequency, severity, and causality (safety)\"\\n6618,1,1,\"Incidence of intracranial and extracranial toxicities and dose-limiting toxicities (Phase I)\"\\n6619,1,1,\"Incidence of investigational medicinal product (IMP) dose reductions\"\\n6620,1,1,\"Incidence of irAEs.\"\\n6621,3,1,\"Incidence of lab abnormalities\"\\n6622,2,2,\"Incidence of lab abnormalities (Part 1)\"\\n6623,1,1,\"Incidence of Laboratory Abnormaities\"\\n6624,1,1,\"Incidence of Laboratory abnormalities\"\\n6625,21,4,\"Incidence of laboratory abnormalities\"\\n6626,1,1,\"Incidence of laboratory abnormalities (Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B)\"\\n6627,1,1,\"Incidence of laboratory abnormalities (Cohorts D and E)\"\\n6628,1,1,\"Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])\"\\n6629,1,1,\"Incidence of laboratory abnormalities (Parts A-K)\"\\n6630,1,1,\"Incidence of laboratory abnormalities (Phase 2 only)\"\\n6631,2,1,\"Incidence of laboratory abnormalities (safety)\"\\n6632,1,1,\"Incidence of laboratory abnormalities, based on NCI CTCAE grades of hematology, serum chemistry, and urinalysis test results\"\\n6633,1,1,\"Incidence of late adverse events (Dose Expansion Phase)\"\\n6634,1,1,\"Incidence of Local Recurrence and Pattern of Failure\"\\n6635,1,1,\"Incidence of major transplant related toxicities (Grades IV and IV)\"\\n6636,1,1,\"Incidence of MSI-H across different cancer types in Chinese patients\"\\n6637,1,1,\"Incidence of MTD (Tolerability)\"\\n6638,1,1,\"Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy\"\\n6639,1,1,\"Incidence of neuropsychological and neuroendocrine function in the two arms\"\\n6640,1,1,\"Incidence of neurotoxicity\"\\n6641,1,1,\"Incidence of neurotoxicity (safety)\"\\n6642,1,1,\"Incidence of New Adverse Event (AE) of >= Grade 3 (Phase I)\"\\n6643,1,1,\"Incidence of non-hematologic toxicity, evaluated via the ordinal Common Toxicity Criteria (CTC)\"\\n6644,1,1,\"Incidence of occlusion as defined by the inability to infuse or withdraw 3 cc of saline from the catheter\"\\n6645,1,1,\"Incidence of Outcomes\"\\n6646,1,1,\"Incidence of Outcomes by Chemotherapy Risk: Patient Level\"\\n6647,1,1,\"Incidence of Outcomes by Day of Study Drug Initiation: Cycle Level\"\\n6648,1,1,\"Incidence of Outcomes by Mean GIS: Patient Level\"\\n6649,1,1,\"Incidence of Outcomes by Study Drug Duration: Cycle Level\"\\n6650,1,1,\"Incidence of Outcomes: Cycles Level\"\\n6651,1,1,\"Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels\"\\n6652,1,1,\"Incidence of participants with clinical laboratory abnormalities\"\\n6653,1,1,\"Incidence of participants with clinical laboratory abnormalities in Part 1\"\\n6654,1,1,\"Incidence of Participants with Dose-Limited Toxicities (DLTs)\"\\n6655,1,1,\"Incidence of patients with ototoxicity according to Common Toxicity Criteria, American-Speech-Language-Hearing Association, and Brock\\'s criteria\"\\n6656,1,1,\"Incidence of physical examination findings\"\\n6657,1,1,\"Incidence of post-surgical wound complications\"\\n6658,1,1,\"Incidence of potential-immune related toxicities\"\\n6659,3,1,\"Incidence of Product-Emergent Adverse Events\"\\n6660,1,1,\"Incidence of radiation therapy (RT)-related grade >= 4 toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n6661,1,1,\"Incidence of radiation-related toxicities\"\\n6662,1,1,\"Incidence of Related Adverse Events [Safety and Tolerability]\"\\n6663,1,1,\"Incidence of related clinically significant abnormalities on electrocardiogram (ECG), vital signs, physical examination and laboratory parameters\"\\n6664,1,1,\"Incidence of renal dose-limiting toxicities (DLTs) (Cohorts 1A and 1B)\"\\n6665,7,1,\"Incidence of SAEs\"\\n6666,1,1,\"Incidence of SAEs (Serious Adverse Events)\"\\n6667,1,1,\"Incidence of SAEs.\"\\n6668,4,3,\"Incidence of serious adverse event (SAE)\"\\n6669,20,1,\"Incidence of Serious Adverse Events\"\\n6670,1,1,\"Incidence of Serious Adverse events\"\\n6671,36,1,\"Incidence of serious adverse events\"\\n6672,1,1,\"Incidence of Serious Adverse Events (Phase I)\"\\n6673,1,1,\"Incidence of serious adverse events (randomized and registered patients)\"\\n6674,9,2,\"Incidence of Serious Adverse Events (SAE)\"\\n6675,5,2,\"Incidence of serious adverse events (SAE)\"\\n6676,1,1,\"Incidence of serious adverse events (SAE) and suspected unexpected serious adverse reactions;\"\\n6677,1,1,\"Incidence of serious adverse events (SAE) graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 4.0\"\\n6678,1,1,\"Incidence of serious adverse events (SAE).\"\\n6679,36,8,\"Incidence of Serious Adverse Events (SAEs)\"\\n6680,1,1,\"Incidence of Serious adverse events (SAEs)\"\\n6681,36,10,\"Incidence of serious adverse events (SAEs)\"\\n6682,1,1,\"Incidence of Serious Adverse Events (SAEs) in Part 1\"\\n6683,1,1,\"Incidence of serious adverse events (SAEs), incidence and severity of adverse events (AEs)\"\\n6684,2,1,\"Incidence of serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)\"\\n6685,1,1,\"Incidence of serious adverse events (SAEs), treatment-emergent AEs (TEAEs).\"\\n6686,1,1,\"Incidence of Serious Adverse Events (SAEs).\"\\n6687,3,2,\"Incidence of serious adverse events by type, frequency, severity, and causality (safety)\"\\n6688,1,1,\"Incidence of serious adverse events(SAE)\"\\n6689,1,1,\"Incidence of serious adverse events. (SAE)\"\\n6690,2,1,\"Incidence of serious AEs (SAEs)\"\\n6691,1,1,\"Incidence of Serious and Non-Serious Immune Mediated Adverse Events\"\\n6692,1,1,\"Incidence of Severe Acute Oral Mucositis (Grade of CTC-AE ‚â• 3)\"\\n6693,4,1,\"Incidence of severe adverse events\"\\n6694,1,1,\"Incidence of severe adverse events, defined as any grade 3 or higher adverse event (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03\"\\n6695,1,1,\"Incidence of severe diarrhea toxicity\"\\n6696,1,1,\"Incidence of severe hand-foot syndrome toxicity\"\\n6697,1,1,\"Incidence of severe hematological toxicity\"\\n6698,1,1,\"Incidence of significant laboratory abnormalities, based on hematology, serum chemistry, and urinalysis test results\"\\n6699,1,1,\"Incidence of significant toxicities\"\\n6700,1,1,\"Incidence of SLC01B3 polymorphism (rs11045585)\"\\n6701,1,1,\"Incidence of Specific Adverse Events\"\\n6702,1,1,\"Incidence of Stomatitis\"\\n6703,1,1,\"Incidence of study drug related dose-limiting toxicities (DLTs)\"\\n6704,1,1,\"Incidence of study-drug related Dose Limiting Toxicities (DLTs)\"\\n6705,1,1,\"Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).\"\\n6706,1,1,\"Incidence of subjects with fatal adverse events\"\\n6707,1,1,\"Incidence of subjects with Serious adverse events (SAEs)\"\\n6708,1,1,\"Incidence of subjects with treatment-emergent adverse events greater than or equal to Grade 3\"\\n6709,1,1,\"Incidence of surgical complications (Bladder cohort)\"\\n6710,1,1,\"Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)\"\\n6711,1,1,\"Incidence of symptomatic radionecrosis\"\\n6712,1,1,\"Incidence of symptomatic, proximal and/or distal DVT of the lower limbs as assessed by clinical diagnosis and compression ultrasound within 72 hours of detection of symptoms (during the 3-month observation period)\"\\n6713,3,1,\"Incidence of TEAEs\"\\n6714,1,1,\"Incidence of TEAEs including all AEs,Grade 3-5 AEs, drug-related AEs, and SAEs (Part 1 escalation and Part 2 safety run-in)\"\\n6715,2,2,\"Incidence of TEAEs leading to premature discontinuation\"\\n6716,1,1,\"Incidence of TEAEs ‚â• Grade 3\"\\n6717,1,1,\"Incidence of temporary interruptions or discontinuations\"\\n6718,1,1,\"Incidence of the adverse events from baseline\"\\n6719,1,1,\"Incidence of the development of unpleasant body odors in AYA oncology patients\"\\n6720,1,1,\"Incidence of thrombocytopenia events (platelets <70,000) over the study period of the study groups\"\\n6721,1,1,\"Incidence of Thrombotic events among enrolled cancer patients\"\\n6722,1,1,\"Incidence of toxic death\"\\n6723,4,1,\"Incidence of toxicities\"\\n6724,1,1,\"Incidence of toxicities and adverse events classified according to the Common Terminology Criteria for Adverse Events v4.03\"\\n6725,1,1,\"Incidence of toxicities for the combination of dalteparin and sunitinib malate\"\\n6726,1,1,\"Incidence of toxicities graded according to NCI CTCAE v4.0\"\\n6727,1,1,\"Incidence of Toxicities of Lorvotuzumab Mertansine, Using the NCI Common Terminology Criteria for Adverse Events Version 4.0\"\\n6728,1,1,\"Incidence of toxicities, graded according to Common Terminology Criteria for Adverse Events version 4\"\\n6729,1,1,\"Incidence of toxicities, graded according to NCI CTCAE version 4.0\"\\n6730,16,3,\"Incidence of toxicity\"\\n6731,1,1,\"Incidence of toxicity (dose escalation)\"\\n6732,1,1,\"Incidence of toxicity (Phase I/II)\"\\n6733,1,1,\"Incidence of toxicity as assessed by NCI CTCAE v. 4.0\"\\n6734,1,1,\"Incidence of toxicity as defined using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0\"\\n6735,1,1,\"Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity per Common Terminology Criteria for Adverse Events version 4.0\"\\n6736,1,1,\"Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) V. 4.0\"\\n6737,1,1,\"Incidence of toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (Pharmacodynamic study)\"\\n6738,1,1,\"Incidence of toxicity graded according to NCI CTCAE version 3.0\"\\n6739,1,1,\"Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events\"\\n6740,1,1,\"Incidence of toxicity induced by NK infusion\"\\n6741,1,1,\"Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03\"\\n6742,1,1,\"Incidence of toxicity, graded according to the NCI CTCAE version 5\"\\n6743,1,1,\"Incidence of Treatment (adoptive T cell therapy associated to intravenous injections of Nivolumab) - Emergent Adverse Events\"\\n6744,42,4,\"Incidence of treatment emergent adverse events\"\\n6745,1,1,\"Incidence of Treatment Emergent Adverse Events (AEs) in Part 1 (Dose Escalation)\"\\n6746,4,2,\"Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)\"\\n6747,3,2,\"Incidence of treatment emergent adverse events (safety and tolerability)\"\\n6748,1,1,\"Incidence of Treatment Emergent adverse events (TEAE); % of patients who experience at least 1 Treatment Emergent Adverse Event (TEAE); % of patients who discontinue due to TEAE(s).\"\\n6749,17,2,\"Incidence of Treatment Emergent Adverse Events (TEAEs)\"\\n6750,17,2,\"Incidence of treatment emergent adverse events (TEAEs)\"\\n6751,1,1,\"Incidence of Treatment Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events\"\\n6752,1,1,\"Incidence of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)\"\\n6753,3,2,\"Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0\"\\n6754,1,1,\"Incidence of treatment emergent adverse events in monotherapy and combination therapy\"\\n6755,1,1,\"Incidence of Treatment Emergent Adverse Events in Subjects Treated With Trametinib Monotherapy\"\\n6756,1,1,\"Incidence of treatment emergent serious adverse events (TESAEs)\"\\n6757,9,3,\"Incidence of treatment related adverse events\"\\n6758,6,2,\"Incidence of Treatment Related adverse events (AEs)\"\\n6759,2,2,\"Incidence of treatment related adverse events (AEs)\"\\n6760,1,1,\"Incidence of treatment related adverse events (AEs) (Part 1)\"\\n6761,1,1,\"Incidence of Treatment Related Adverse Events (TRAEs)\"\\n6762,1,1,\"Incidence of treatment related adverse events(TRAE)\"\\n6763,1,1,\"Incidence of treatment related Grade 3 and/or Grade 4 adverse events, defined as dose limiting toxicities, for the doses of PRN1371\"\\n6764,3,1,\"Incidence of Treatment-Emergence Adverse Events (Safety and Tolerability)\"\\n6765,1,1,\"Incidence of Treatment-Emergent abnormal clinical laboratory parameters assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], Version 3.0\"\\n6766,1,1,\"Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs).\"\\n6767,161,17,\"Incidence of Treatment-Emergent Adverse Events\"\\n6768,75,9,\"Incidence of treatment-emergent adverse events\"\\n6769,1,1,\"Incidence of Treatment-Emergent Adverse Events (AE) [Safety and Tolerability]\"\\n6770,1,1,\"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) of YQ23 as single agent (Stage 1) and when in combination with Pembrolizumab (Stage 2)\"\\n6771,1,1,\"Incidence of treatment-emergent adverse events (AEs) and serious AE (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.\"\\n6772,1,1,\"Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs) of IP administered AVB-001 in the Dose Escalation Phase (Part 1)\"\\n6773,1,1,\"Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03\"\\n6774,5,5,\"Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.\"\\n6775,3,2,\"Incidence of Treatment-Emergent Adverse Events (CTCAE)\"\\n6776,1,1,\"Incidence of treatment-emergent adverse events (Phase 1 only)\"\\n6777,34,5,\"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)\"\\n6778,2,1,\"Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)\"\\n6779,10,2,\"Incidence of treatment-emergent adverse events (safety and tolerability)\"\\n6780,1,1,\"Incidence of treatment-emergent adverse events (safety and tolerability) of 68Ga-PSMA-617\"\\n6781,1,1,\"Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of IA therapy in combination with nivolumab: adverse events\"\\n6782,1,1,\"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) on multiple dose\"\\n6783,1,1,\"Incidence of Treatment-Emergent Adverse Events (Safety) of IA therapy with plasma volume escalation (increase from 2X to 3X plasma volume processed): adverse events\"\\n6784,1,1,\"Incidence of treatment-emergent adverse events (safety), graded by CTCAE version 5.0\"\\n6785,1,1,\"Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 in combination with Cetuximab in R/R HNSCC or CRC for Phase 1b Dose Escalation\"\\n6786,1,1,\"Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 monotherapy and in combination with Cetuximab in R/R HNSCC, CRC, cSCC, ASCC, and cervical cancer for Phase 2 Dose Expansion\"\\n6787,1,1,\"Incidence of Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)\"\\n6788,1,1,\"Incidence of Treatment-Emergent Adverse Events (TEAE) assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0\"\\n6789,1,1,\"Incidence Of Treatment-emergent Adverse Events (TEAEs)\"\\n6790,1,1,\"Incidence of Treatment-emergent adverse events (TEAEs)\"\\n6791,74,8,\"Incidence of treatment-emergent adverse events (TEAEs)\"\\n6792,1,1,\"Incidence of treatment-emergent adverse events (TEAEs) and changes in clinical laboratory values (Part 1A & 1B)\"\\n6793,1,1,\"Incidence of treatment-emergent adverse events (TEAEs) through stages 1 and 2 of the study\"\\n6794,1,1,\"Incidence of treatment-emergent adverse events (TEAEs), including Grade ‚â• 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs\"\\n6795,1,1,\"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) of at least Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 severity, and discontinuations due to AEs.\"\\n6796,1,1,\"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) resulting in the permanent discontinuation of study drug, and deaths occurring within the reporting period required for the study\"\\n6797,1,1,\"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108\"\\n6798,1,1,\"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108+pembrolizumab\"\\n6799,1,1,\"Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related AEs, Related SAEs, and AEs Leading to Study Drug Discontinuation in Part 1\"\\n6800,1,1,\"Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest, discontinuations from at home study treatment, and abnormal clinical laboratory tests (hematology, serum chemistry, and urinalysis).\"\\n6801,126,8,\"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]\"\\n6802,1,1,\"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Parts A, B and C)\"\\n6803,1,1,\"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Phase 1 and 2)\"\\n6804,1,1,\"Incidence of Treatment-emergent Adverse Events [Safety and Tolerability] (Phase 1b)\"\\n6805,1,1,\"Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients\"\\n6806,1,1,\"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NKR-2 infusion\"\\n6807,16,3,\"Incidence of Treatment-Emergent Adverse Events [Safety]\"\\n6808,1,1,\"Incidence of treatment-emergent adverse events and changes in clinical laboratory abnormalities (Part 1A, 1B & 1C only)\"\\n6809,1,1,\"Incidence of treatment-emergent adverse events and dose-limiting toxicities (safety and tolerability) and MTD of TAS-117 in Part A\"\\n6810,2,1,\"Incidence of treatment-emergent adverse events and severe adverse events (safety and tolerability)\"\\n6811,3,3,\"Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03\"\\n6812,1,1,\"Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab)\"\\n6813,1,1,\"Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab.\"\\n6814,1,1,\"Incidence of Treatment-Emergent Adverse Events assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], Version 3.0\"\\n6815,2,1,\"Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)\"\\n6816,1,1,\"Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events\"\\n6817,2,2,\"Incidence of treatment-emergent adverse events including dose-limiting toxicities\"\\n6818,1,1,\"Incidence of Treatment-Emergent Adverse Events of ENB003 in combination with pembrolizumab, as assessed by NCI CTCAE Version 5\"\\n6819,1,1,\"Incidence of Treatment-Emergent Adverse Events(Safety)\"\\n6820,1,1,\"Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of ciforadenant as a single agent and in combination with atezolizumab\"\\n6821,2,1,\"Incidence of treatment-emergent adverse events.\"\\n6822,1,1,\"Incidence of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs)\"\\n6823,1,1,\"Incidence of treatment-emergent AEs (TEAEs), SAEs and death(s)\"\\n6824,1,1,\"Incidence of Treatment-Emergent and Non Treatment-Emergent Adverse Events [Safety and Tolerability]\"\\n6825,1,1,\"Incidence of treatment-emergent and serious adverse events in patients treated with IO-108 and IO-108+pembrolizumab\"\\n6826,1,1,\"Incidence of treatment-emergent and serious adverse events in patients treated with IO-202 and IO-202 + pembrolizumab\"\\n6827,6,2,\"Incidence of treatment-emergent serious adverse events (TESAEs)\"\\n6828,5,3,\"Incidence of Treatment-Related Adverse Events\"\\n6829,16,7,\"Incidence of treatment-related adverse events\"\\n6830,1,1,\"Incidence of treatment-related adverse events (AE)\"\\n6831,1,1,\"Incidence of treatment-related adverse events (AEs)\"\\n6832,2,2,\"Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)\"\\n6833,1,1,\"Incidence of Treatment-related adverse events (TRAEs)\"\\n6834,1,1,\"Incidence of treatment-related adverse events (TRAEs) leading to study treatment discontinuation\"\\n6835,4,3,\"Incidence of treatment-related adverse events as assessed by CTCAE v4.0\"\\n6836,1,1,\"Incidence of treatment-related adverse events as assessed using the current NCI-CTCAE.\"\\n6837,1,1,\"Incidence of treatment-related adverse events of infusion of autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells\"\\n6838,1,1,\"Incidence of Treatment-related Adverse EventsÔºåafety and Tolerability\"\\n6839,1,1,\"Incidence of treatment-related grade 3 adverse events\"\\n6840,1,1,\"Incidence of treatment-related grade 3 or higher adverse events (AEs)\"\\n6841,1,1,\"Incidence of treatment-related Grade 3-5 AEs\"\\n6842,1,1,\"Incidence Of Treatment-Related Medical Grade 3 Or Higher Or Psychiatric Grade 4 Or Higher\"\\n6843,1,1,\"Incidence of treatment-related unexpected grade 3 or higher adverse events\"\\n6844,1,1,\"Incidence of use of medications to manage adverse reactions\"\\n6845,1,1,\"Incidence of Vincristine-induced Peripheral Neuropathy\"\\n6846,1,1,\"Incidence of vital sign abnormalities e.g. Systolic and Diastolic BP, Pulse rate.\"\\n6847,1,1,\"Incidence of vital signs abnormalities\"\\n6848,2,1,\"Incidence rate and category of dose limiting toxicities (DLTs)\"\\n6849,1,1,\"Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)\"\\n6850,1,1,\"Incidence rate and density of central venous catheter-related complications (infections, thromboses, extravasation)\"\\n6851,1,1,\"Incidence rate of all treatment-emergent adverse events (TEAEs) from time of ONM-100 administration through Day 28\"\\n6852,1,1,\"Incidence Rate of DLT Within the First Two Cycles of LDE225 (Sonidegib) in Combination With Docetaxel\"\\n6853,1,1,\"Incidence rate of Dose Limiting Toxicities\"\\n6854,2,1,\"Incidence rate of dose limiting toxicities\"\\n6855,1,1,\"Incidence rate of Dose Limiting Toxicities (DLT) during the first cycle of treatment with SXL01.\"\\n6856,1,1,\"Incidence rate of dose limiting toxicities (DLT).\"\\n6857,1,1,\"Incidence rate of dose limiting toxicities (DLTs)\"\\n6858,1,1,\"Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment\"\\n6859,1,1,\"Incidence Rate of Dose Limiting Toxicities (DLTs) Occurring During First Cycle of Treatment\"\\n6860,1,1,\"Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719\"\\n6861,1,1,\"Incidence rate of Dose Limiting Toxicities.\"\\n6862,1,1,\"Incidence rate of Dose Limiting Toxicity (DLT) within the first cycle of nadunolimab in combination with gemcitabine plus carboplatin\"\\n6863,2,1,\"Incidence rate of dose-limiting toxicities and adverse events\"\\n6864,1,1,\"Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent\\'s and uptake rate of cascade testing in families\"\\n6865,1,1,\"Incidence rate of LLL\"\\n6866,1,1,\"Incidence rate of transition from stage 0-1 LLL to stage 2-3 LLL in randomized subgroup\"\\n6867,1,1,\"Incidence rates of adverse events (AEs) after infusion of ET140202 T cells\"\\n6868,1,1,\"Incidence, duration, and severity of Treatment Emergent Adverse Events as assessed by Investigator Evaluation.\"\\n6869,1,1,\"Incidence, nature and severity of adverse events of special interest\"\\n6870,1,1,\"Incidence, nature and severity of bevacizumab related serious adverse events\"\\n6871,10,3,\"Incidence, nature, and severity of adverse events\"\\n6872,1,1,\"Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs)\"\\n6873,1,1,\"Incidence, nature, and severity of adverse events (AEs), with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0\"\\n6874,1,1,\"Incidence, nature, and severity of adverse events and laboratory abnormalities graded per NCI CTCAE v5.0\"\\n6875,1,1,\"Incidence, nature, and severity of adverse events and serious adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0\"\\n6876,1,1,\"Incidence, nature, and severity of adverse events and serious adverse events, graded according to NCI CTCAE, v4.0\"\\n6877,1,1,\"Incidence, nature, and severity of AEs, with severity determined according to NCI CTCAE, v5.0\"\\n6878,1,1,\"Incidence, nature, and severity of all adverse events and serious adverse events\"\\n6879,1,1,\"Incidence, nature, relatedness, and severity of adverse events\"\\n6880,1,1,\"Incidence, severity, and outcome of adverse events (AEs) and serious adverse events (SAEs)\"\\n6881,1,1,\"Incidences and severity of AE\"\\n6882,1,1,\"Incidences of deaths\"\\n6883,1,1,\"Incidences of laboratory abnormalities\"\\n6884,1,1,\"incidences of PORT-A-CATH¬Æ related events (persistent malfunction, thrombosis, infection)\"\\n6885,1,1,\"Incidences of serious adverse events (SAEs)\"\\n6886,1,1,\"Incidendence of Dose Limiting Toxicities (DLTs)\"\\n6887,2,1,\"Incident and severity of adverse events\"\\n6888,1,1,\"Incident of AEs\"\\n6889,1,1,\"Incident of DLTs\"\\n6890,2,2,\"Incident rate of dose limiting toxicities (DLTs)\"\\n6891,1,1,\"Increase in composite knowledge questionnaire score\"\\n6892,1,1,\"Increase in diagnostic yield of pancreatic solid lesions\"\\n6893,1,1,\"Increased length of enrollment time in hospice care\"\\n6894,1,1,\"Increased rate of RO resection\"\\n6895,1,1,\"Independently assessed progression-free survival according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n6896,1,1,\"Individual Quality Scores, Comprised of Various Qualities of the Image and Include Contrast, Brightness, Resolution, Etc.\"\\n6897,1,1,\"Individual Time Course Profile of CD 10899 in Urine: Cumulative Amount of CD 10899 Excreted in Urine\"\\n6898,1,1,\"Individual Time Course Profile of Volasertib in Urine:Cumulative Fraction of Volasertib Excreted in Urine\"\\n6899,1,1,\"Individual Time Course Profiles of 14C-radioactivity in Faeces: Cumulative Fraction of 14C-radioactivity Excreted in Faeces\"\\n6900,1,1,\"Individual Time Course Profiles of 14C-radioactivity in Urine: Cumulative Fraction of 14C-ratioactivity Excreted in Urine\"\\n6901,1,1,\"Individual Time Course Profiles of 14C-radioactivity in Whole Blood and Plasma: Cmax of 14C Labelled Volasertib\"\\n6902,1,1,\"Individual Time Course Profiles of Volasertib and CD 10899 in Plasma: Cmax of Volasertib and CD 10899 (a Metabolite of Volasertib).\"\\n6903,1,1,\"Induction of Immune Response to Mesothelin by Enzyme-linked Immunosorbent Spot (ELISPOT) Assay\"\\n6904,1,1,\"Induction Progression-Free Rate after induction treatment\"\\n6905,1,1,\"Induction Response\"\\n6906,1,1,\"Ineligibility for further cerebral SRS\"\\n6907,2,1,\"infectious complication\"\\n6908,1,1,\"Influence of bevacizumab on platelet aggregation\"\\n6909,1,1,\"Influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs\"\\n6910,1,1,\"Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on event-free survival\"\\n6911,1,1,\"Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on toxicity\"\\n6912,1,1,\"Influence of the COVID-19 pandemic on cancer patient\\'s daily life\"\\n6913,1,1,\"Influence of VEGF on platelet aggregation\"\\n6914,1,1,\"Influence of VEGF or bevacizumab on cyclooxygenesis\"\\n6915,1,1,\"Informed consent collection for possible participation in future non-therapeutic research studies\"\\n6916,1,1,\"Informed consent collection to register with the Childhood Cancer Research Network\"\\n6917,1,1,\"Inhibition of STAT3 phosphorylation in peripheral mononuclear blood cells (PBMCs)pharmacodynamic effect of OPB-51602 in surrogate tissue.\"\\n6918,1,1,\"Inhibition of Yes-associated Protein (YAP1) Expression\"\\n6919,1,1,\"Initial Area Under the DCE-MRI Contrast Agent Concentration Time Curve After 60 Seconds (IAUC60)\"\\n6920,1,1,\"Initial assessment of efficacy in phase 2\"\\n6921,1,1,\"Initial design: Comparison of two dose levels, administered on Days 1 and 15 of each 28-day cycle:\"\\n6922,1,1,\"Initial examination\"\\n6923,1,1,\"Initial objective response per RECIST v1.1\"\\n6924,1,1,\"Initial Overall Survival (OS) for All Participants\"\\n6925,1,1,\"Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration site\"\\n6926,1,1,\"Innocuity of POLYMAX acetabular implant as assessed by data collected on early complications\"\\n6927,1,1,\"Innocuity of POLYMAX acetabular implant as assessed by data collected on late-stage complications\"\\n6928,1,1,\"Insomnia occurrence by Pittsburg Sleep Inventory at 6 weeks\"\\n6929,54,1,\"Insomnia Severity Index (ISI)\"\\n6930,1,1,\"Instrumental Activities of Daily Living - Lawton\\'s Test\"\\n6931,26,1,\"insulin resistance\"\\n6932,1,1,\"Insulin resistance (IR) in CCS vs controls\"\\n6933,1,1,\"Intended and implemented management changes after gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT)\"\\n6934,1,1,\"Intensity of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Part I)\"\\n6935,1,1,\"Intensity of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Part II)\"\\n6936,1,1,\"Intensity of an Treatment Emergent Adverse Event graded using the NCI-CTCAE version 4.03\"\\n6937,1,1,\"Intensity of TEAEs acc. to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.03\"\\n6938,1,1,\"Intensive Care Unit (ICU) admission during COVID-19 related hospitalization (Yes/No)\"\\n6939,1,1,\"Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention\"\\n6940,1,1,\"Inter- and intra-fraction movement of the esophagus as measured by CT scans\"\\n6941,1,1,\"Inter-individual pharmacokinetic variability\"\\n6942,1,1,\"inter-reader discordance rate\"\\n6943,1,1,\"Intercept of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22\"\\n6944,1,1,\"Intercranial clinical benefit\"\\n6945,1,1,\"Interim Overall Survival (OS) - Initial Treatment Period\"\\n6946,1,1,\"International sensitivity index in whole blood sample\"\\n6947,1,1,\"International standardized ratio in whole blood sample\"\\n6948,2,2,\"Intervention adherence rate\"\\n6949,1,1,\"Intracranial (IC) progression-free survival (PFS)\"\\n6950,1,1,\"Intracranial Disease Overall Response Rate by RANO-BM\"\\n6951,1,1,\"Intracranial Disease Overall Response Rate by RECIST 1.1\"\\n6952,2,1,\"Intracranial Objective Response Rate (iORR)\"\\n6953,1,1,\"Intracranial Objective Response Rate (ORR)\"\\n6954,3,2,\"Intracranial progression-free survival\"\\n6955,1,1,\"Intracranial Progression-Free Survival(iPFS)\"\\n6956,1,1,\"Intracranial Response (IR) Rate in Cohort A\"\\n6957,1,1,\"Intrahepatic Disease-free Survival\"\\n6958,1,1,\"Intrahepatic objective response rate (hORRÔºâ\"\\n6959,1,1,\"Intratumor heterogeneity\"\\n6960,1,1,\"Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT\"\\n6961,1,1,\"Intratumoral Concentration\"\\n6962,1,1,\"Introducing more effective graft vs leukemia and graft vs tumor effects with immune donor lymphocytes in patients relapsing following allogeneic bone marrow or blood stem cell transplantation\"\\n6963,1,1,\"Intrusive thoughts, or the tendency to ruminate on or avoid thoughts about stressors\"\\n6964,4,1,\"Invasive Disease-Free Survival (IDFS)\"\\n6965,7,1,\"Invasive disease-free survival (IDFS)\"\\n6966,1,1,\"invasive disease-free survival (IDFS) after breast-conserving surgery\"\\n6967,1,1,\"Inventory of Parent and Peer Attachment (IPPA).\"\\n6968,1,1,\"Investigate the antitumor activity of DS-7300a\"\\n6969,1,1,\"Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.\"\\n6970,1,1,\"Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs)\"\\n6971,1,1,\"Investigative mechanism to allow correlations between genetic polymorphisms and clinical outcomes\"\\n6972,1,1,\"Investigator Assessed Objective Response Rate according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Part 3\"\\n6973,1,1,\"Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population)\"\\n6974,1,1,\"Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population)\"\\n6975,1,1,\"Investigator Defined Dose Limiting Toxicity (DLT) During First Course of Treatment, Treated Set\"\\n6976,1,1,\"Investigator defined dose limiting toxicity (DLT) during first treatment course\"\\n6977,13,1,\"Investigator Global Assessment\"\\n6978,1,1,\"Investigator-assessed confirmed objective response rate (ORR)\"\\n6979,1,1,\"Investigator-Assessed Disease Control Rate (DCR)\"\\n6980,1,1,\"Investigator-assessed Duration of Progression-free Survival\"\\n6981,1,1,\"Investigator-assessed Objective Progression-free Survival (PFS)\"\\n6982,1,1,\"Investigator-Assessed Objective Response Rate (ORR)\"\\n6983,3,2,\"Investigator-assessed objective response rate (ORR)\"\\n6984,1,1,\"Investigator-Assessed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1\"\\n6985,1,1,\"Investigator-assessed objective response rate (ORR) by RECIST 1.1 and immune ORR by iRECIST (for solid tumors) or response by Lugano criteria (for lymphomas)\"\\n6986,1,1,\"Investigator-assessed objective response rate (ORR) per iRECIST (Part 2 only)\"\\n6987,1,1,\"Investigator-assessed objective response rate (ORR) per RECIST 1.1 (Phase 2 only)\"\\n6988,1,1,\"Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapy\"\\n6989,1,1,\"Investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 of IP administered AVB-001 in the Dose Expansion Phase (Part 2)\"\\n6990,1,1,\"Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1\"\\n6991,1,1,\"Investigator-Assessed ORR (Part 2)\"\\n6992,1,1,\"Investigator-assessed Progression Free Survival (PFS)\"\\n6993,1,1,\"Investigator-assessed progression-free survival (IA-PFS)\"\\n6994,1,1,\"Investigator-assessed Progression-Free Survival (PFS)\"\\n6995,1,1,\"Investigator-assessed Progression-free Survival (PFS)\"\\n6996,1,1,\"Investigator-Confirmed PFS According to the Local Standard of Care or per RECIST - Cohort 2\"\\n6997,1,1,\"Investigator-Confirmed Progression-Free Survival (PFS) According to the Local Standard of Care or per Response Evaluation in Solid Tumors (RECIST) - Cohort 1\"\\n6998,1,1,\"Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment\"\\n6999,1,1,\"Invitation to participate in at least one clinical trial currently ongoing\"\\n7000,1,1,\"Iodine Incorporation in Thyroid Cancer Metastases to a Predicted Lesional Absorbed Radiation Dose Equal to or Exceeding 2,000 cGy With the Administration of =< 300 mCi Radioiodine (RAI) (Cohort B)\"\\n7001,1,1,\"IRF-Assessed Progression-Free Survival (PFS)\"\\n7002,1,1,\"irORR\"\\n7003,1,1,\"Is pain score lower after 4 weeks on treatment?\"\\n7004,1,1,\"Item correlation between different assessment platforms\"\\n7005,2,2,\"Ixabepilone Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (R2PD)\"\\n7006,1,1,\"Kaplan Meier Estimate of Percentage of Participants With Disease Progression at 3 Months\"\\n7007,1,1,\"Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator\"\\n7008,1,1,\"Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on an Independent Radiology Assessment According to RECIST 1.1 Criteria\"\\n7009,1,1,\"Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on European Medicines Agency Methodology\"\\n7010,1,1,\"Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on Food and Drug Administration (FDA) Methodology\"\\n7011,1,1,\"Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) Population\"\\n7012,1,1,\"Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population\"\\n7013,3,1,\"Kaplan-Meier Estimate of Progression Free Survival (PFS)\"\\n7014,1,1,\"Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance\"\\n7015,1,1,\"Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Progression-Free Survival at 1 to 3 Years, as Determined by the Investigator Using RECIST v1.1\"\\n7016,2,2,\"Kaplan-Meier Estimates for Progression-free Survival\"\\n7017,1,1,\"Kaplan-Meier Estimates for Time to Treatment Failure (TTF)\"\\n7018,1,1,\"Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.\"\\n7019,1,1,\"Kaplan-Meier Probability of No Disease or Progression at 1 Year\"\\n7020,1,1,\"Karnofsky performance status\"\\n7021,1,1,\"Karnofsky Performance Status (KPS): Baseline\"\\n7022,1,1,\"Key coding categories (Aim 2)\"\\n7023,1,1,\"Kinase activity profiles\"\\n7024,1,1,\"Kinetics of CAR T cells\"\\n7025,1,1,\"Kinetics of TBI-1201 in blood by realtime-PCR and flow cytometry\"\\n7026,1,1,\"Kinetics of TBI-1301 in blood by realtime-PCR\"\\n7027,1,1,\"Kinetics of viral load\"\\n7028,1,1,\"Kinome Signature Predictive of Resistance\"\\n7029,1,1,\"Kinome wide and quantitative (phospho)proteomic profiles\"\\n7030,1,1,\"KN035 safety and tolerability assessed by monitoring AEs per the NCI-CTC-AE Version 4.03, physical examination, electrocardiograms, laboratory measurements and severity of adverse events\"\\n7031,1,1,\"KN044 of abnormalities of physical findings and laboratory tests,\"\\n7032,1,1,\"KN044 of adverse event\"\\n7033,33,1,\"Knowledge\"\\n7034,1,1,\"knowledge GC risk factors and symptoms\"\\n7035,1,1,\"KPS: Week 12 to 16\"\\n7036,1,1,\"KPS: Week 24 to 28\"\\n7037,1,1,\"KPS: Week 4 to 6\"\\n7038,1,1,\"Lab data and vital signs\"\\n7039,1,1,\"Laborarory test abnormality\"\\n7040,1,1,\"Laboratory Abnormalities\"\\n7041,2,1,\"Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])\"\\n7042,1,1,\"laboratory Adverse Events\"\\n7043,2,1,\"Laboratory assessments\"\\n7044,1,1,\"Laboratory correlates\"\\n7045,3,1,\"laboratory evaluations\"\\n7046,1,1,\"Laboratory findings (including: clinical chemistry, hematology, and urinalysis)\"\\n7047,5,2,\"Laboratory parameters\"\\n7048,5,3,\"Laboratory results\"\\n7049,8,1,\"Laboratory Tests\"\\n7050,6,1,\"Laboratory tests\"\\n7051,3,1,\"laboratory tests\"\\n7052,3,1,\"Laboratory Values\"\\n7053,1,1,\"Lambda_z of digoxin and rosuvastatin\"\\n7054,1,1,\"Lambda_z of midazolam and caffeine\"\\n7055,1,1,\"Landmark Overall Survival at 12 Months\"\\n7056,1,1,\"Landmark Overall Survival at 6 Months\"\\n7057,1,1,\"Landmark PFS at 6 months from the date of first dose of study treatment for all patients\"\\n7058,1,1,\"Last positive (quantifiable) concentration [Clast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n7059,1,1,\"Last Quantifiable Concentration (Clast) of Avelumab\"\\n7060,1,1,\"Late Cycle MTD of RO6958688 Without Obinutuzumab Pretreatment for the Step up Dosing Regimen\"\\n7061,1,1,\"Late Rad51/DDR response\"\\n7062,1,1,\"Late toxicities data in patients treated with proton therapy\"\\n7063,1,1,\"Late Toxicities, Graded According to the Radiation Therapy Oncology Group/European Organization for Research, the Treatment of Cancer Late Morbidity Scoring System, and the Common Terminology Criteria for Adverse Events Version 4.0\"\\n7064,1,1,\"Late toxicity graded by NCI/DCTDC Common Toxicity Criteria\"\\n7065,1,1,\"Laxative/stool softener use\"\\n7066,1,1,\"LBH589 Maximum Tolerated Dose (MTD) [Phase I]\"\\n7067,1,1,\"LDL-C in whole blood sample\"\\n7068,1,1,\"Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events\"\\n7069,17,1,\"Lean Body Mass\"\\n7070,23,1,\"Lean body mass\"\\n7071,1,1,\"Lean body mass as measured by the Bioelectrical Impedance Analysis monthly\"\\n7072,1,1,\"Learn the side effects of GW572016 and Topotecan when given together\"\\n7073,1,1,\"Learn whether GW572016 changes how the body handles or processesTopotecan\"\\n7074,1,1,\"Learn whether Topotecan changes how the body handles or processes GW572016\"\\n7075,1,1,\"Left ventricular (LV) thickness-dimension ratio (LVT-D) derived from echocardiogram, reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole\"\\n7076,1,1,\"Left Ventricular Ejection Fraction (LVEF) Over Time\"\\n7077,1,1,\"length of clear fluid toleration\"\\n7078,1,1,\"Length of contact surface between tumor and common carotid artery\"\\n7079,1,1,\"Length of Exposure to NKTR-102\"\\n7080,127,1,\"Length of hospital stay\"\\n7081,1,1,\"Length of Hospitalization Post-operation\"\\n7082,1,1,\"Length of Operative Time\"\\n7083,1,1,\"length of post-operative hospital stay\"\\n7084,1,1,\"Length of Progression-Free Survival\"\\n7085,1,1,\"length of solid food toleration\"\\n7086,1,1,\"Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases\"\\n7087,1,1,\"Length of Subject Survival After Starting Study Treatment\"\\n7088,2,1,\"Length of time receiving study treatment\"\\n7089,1,1,\"Lesion (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET standard uptake values\"\\n7090,1,1,\"Lesion borders (smooth or irregular)\"\\n7091,1,1,\"Lesion Metabolic Avidity\"\\n7092,1,1,\"Lession detection ability\"\\n7093,1,1,\"Level of Biomarkers\"\\n7094,1,1,\"Level of blood C-reactive protein at baseline\"\\n7095,1,1,\"Level of EGFR Expression\"\\n7096,1,1,\"Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors\"\\n7097,1,1,\"Level of treatment engagement (collaboration & coordination of care)\"\\n7098,1,1,\"Levels of LBH589 in the blood\"\\n7099,1,1,\"Levels of LBH589 in the blood on days 1, 5, 8, 9 and 10 of first cycle\"\\n7100,1,1,\"levels of zeta chain -cd247 in cancer patients\"\\n7101,13,1,\"Life quality\"\\n7102,1,1,\"life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model\"\\n7103,1,1,\"Likelihood of Accruing Participants: Feasibility of Enrollment\"\\n7104,3,1,\"Limbs\"\\n7105,1,1,\"Limited Dose Toxicity (LDT)\"\\n7106,1,1,\"Limited Dose Toxicity (LTD)\"\\n7107,1,1,\"Limited G3L Toxicity\"\\n7108,1,1,\"Liquid biopsy analyses\"\\n7109,1,1,\"Liver and overall progression free survival (PFS)\"\\n7110,3,1,\"Liver function tests\"\\n7111,1,1,\"Liver synthetic function\"\\n7112,1,1,\"Lobe/segment to be treated\"\\n7113,20,1,\"Local control\"\\n7114,1,1,\"Local control (Response Evaluation Criteria In Solid Tumors version 1.1)\"\\n7115,1,1,\"Local Control at 2 years\"\\n7116,1,1,\"local control at 2 years\"\\n7117,1,1,\"Local control of the treated lesions using Kaplan-Meyer statistical curves\"\\n7118,10,2,\"Local Control Rate\"\\n7119,2,1,\"Local Control rate\"\\n7120,18,1,\"Local control rate\"\\n7121,5,1,\"local control rate\"\\n7122,1,1,\"local control rate at 3-year\"\\n7123,1,1,\"Local control rate of the treated tumor target per Response Evaluation Criteria in Solid Tumors version 1.1, magnetic resonance imaging (MRI) response or positron emission tomography (PET) response\"\\n7124,1,1,\"Local control rateÔºàLCÔºâ\"\\n7125,1,1,\"Local Disease Control Rates\"\\n7126,3,1,\"Local failure\"\\n7127,2,1,\"Local Failure Rate at 3 Years\"\\n7128,1,1,\"Local intracranial disease progression at 4 months\"\\n7129,1,1,\"local progression - free survival\"\\n7130,3,2,\"Local Progression Free Survival\"\\n7131,5,1,\"Local progression free survival\"\\n7132,2,1,\"Local Progression-free Survival (LPFS)\"\\n7133,9,1,\"Local Recurrence\"\\n7134,2,1,\"Local recurrence-free survival\"\\n7135,4,1,\"Local Tumor Control\"\\n7136,5,3,\"Local tumor control rate\"\\n7137,1,1,\"Local tumor response to therapy\"\\n7138,2,1,\"Loco-regional control\"\\n7139,1,1,\"Loco-regional tumor control after completion of treatment\"\\n7140,1,1,\"Locoregional or disseminated infectious complications:\"\\n7141,1,1,\"long term anti telomerase specific memory responses\"\\n7142,1,1,\"Long-term safety of ACTR T cell product as assessed by adverse events of special interest, regardless of grade or relatedness to the ACTR T cell product\"\\n7143,1,1,\"Long-term safety of ACTR T cell product as assessed by Grade 3 or 4 adverse events related to ACTR T cell product\"\\n7144,1,1,\"Long-term safety of ACTR T cell product as assessed by overall survival\"\\n7145,1,1,\"Long-term safety of ACTR T cell product as assessed by serious adverse events related to ACTR T cell product\"\\n7146,1,1,\"Long-term safety of tazemetostat\"\\n7147,1,1,\"Longitudinal Immunophenotype\"\\n7148,1,1,\"Longitudinal monitoring of HPV+ve tumour burden through analysis of HPV cfDNA by ddPCR to assess treatment success and for early detection of relapse.\"\\n7149,1,1,\"Lower extremity isometric knee extension strength\"\\n7150,1,1,\"Lower extremity muscle strength as measured by Dynamometer\"\\n7151,1,1,\"Lowest on-treatment prostate specific antigen (PSA)\"\\n7152,1,1,\"Lung\"\\n7153,1,1,\"Lung Shunt\"\\n7154,1,1,\"Lung Shunt Fraction (LSF) Ratio\"\\n7155,1,1,\"LY2606368 Radioactivity in Expired Air Over Time Expressed as a Percentage of the Total Radioactive Dose Administered\"\\n7156,1,1,\"Lymph node(N2)downstage rate\"\\n7157,2,1,\"Lymph nodes\"\\n7158,1,1,\"Lymphoid/Plasma Cell Malignancies\"\\n7159,1,1,\"Lytic activation of viral gene expression by NFV\"\\n7160,1,1,\"Magnitude of electroencephalography (EEG) response to verbal stimuli among impending death cancer patients\"\\n7161,1,1,\"Main Extension Study: Safety: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)\"\\n7162,1,1,\"Main Part: Objective Response (OR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 as assessed by Independent Review Committee (IRC)\"\\n7163,1,1,\"Main PK parameters: AUC0-12\"\\n7164,1,1,\"Main PK parameters: AUC0-t\"\\n7165,1,1,\"Main PK parameters: AUC0-‚àû\"\\n7166,1,1,\"Main PK parameters: AUCss\"\\n7167,1,1,\"Main PK parameters: Cavg\"\\n7168,1,1,\"Main PK parameters: CL/F\"\\n7169,1,1,\"Main PK parameters: Cmax\"\\n7170,1,1,\"Main PK parameters: Cmax, ss\"\\n7171,1,1,\"Main PK parameters: Cmin, ss\"\\n7172,1,1,\"Main PK parameters: PTR\"\\n7173,1,1,\"Main PK parameters: Rac for Cmax and AUCtau\"\\n7174,1,1,\"Main PK parameters: t1/2\"\\n7175,1,1,\"Main PK parameters: Tmax\"\\n7176,1,1,\"Main PK parameters: Tmax, ss\"\\n7177,1,1,\"Main PK parameters: Vz/F\"\\n7178,1,1,\"Main study: Objective response rate (ORR)\"\\n7179,1,1,\"Maintenance a Tissue Resource and Registry/Database\"\\n7180,3,1,\"Major morbidity\"\\n7181,1,1,\"Major objective response rate (complete response and partial response)\"\\n7182,6,3,\"Major Pathologic Response (MPR)\"\\n7183,1,1,\"Major pathologic response (mPR)\"\\n7184,2,1,\"Major Pathologic Response (MPR) Rate\"\\n7185,1,1,\"Major pathologic response rate, defined as less than or equal to 10% viable tumor cells in the resected specimen using the methods described by Pataer\"\\n7186,1,1,\"Major Pathological Response\"\\n7187,3,1,\"Major pathological response\"\\n7188,10,2,\"Major Pathological Response (MPR)\"\\n7189,5,1,\"Major pathological response (MPR) rate\"\\n7190,7,2,\"Major pathological response rate (MPR)\"\\n7191,1,1,\"Malignancy rate in surgical pathology\"\\n7192,1,1,\"malignant cells about 1/10 *6 cells.\"\\n7193,1,1,\"malignant cells about 1/10*6 cells.\"\\n7194,1,1,\"Malnutrition Universal Screening Tool Score at initial screening\"\\n7195,1,1,\"Mass Balance: Amount of Total Radioactivity Recovered Into the Urine and Feces From Time Zero to the Last Sampling Time Point (Ae0-t)\"\\n7196,1,1,\"Maturation patterns diagnosis\"\\n7197,1,1,\"Max tolerated dose (MTD) of ALA and radiation\"\\n7198,1,1,\"Maximal degree of tumor regression (Phase II)\"\\n7199,1,1,\"Maximal Observed Plasma Concentration (Cmax) in the Fasted and Fed States\"\\n7200,1,1,\"Maximal plasma exposure (Cmax) for once daily (QD) dosing of BAY2416964 after single-dose and multiple-dose in Cycle 1.\"\\n7201,1,1,\"Maximal plasma exposure (Cmax) of BAY2666605\"\\n7202,1,1,\"Maximal tolerable dose (MTD) in monotherapy\"\\n7203,1,1,\"Maximal Tolerance Dose\"\\n7204,1,1,\"Maximal Tolerance Dose (MTD) of Dp303c\"\\n7205,1,1,\"Maximal Tolerance Dose (MTD) of RC48-ADC\"\\n7206,1,1,\"maximal tolerance dose (MTD) of RC48-ADC\"\\n7207,8,3,\"Maximal tolerated dose\"\\n7208,8,2,\"Maximal tolerated dose (MTD)\"\\n7209,1,1,\"Maximal tolerated dose (MTD) and dose limiting toxicity (DLT)\"\\n7210,1,1,\"Maximal Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of oral Irinotecan based on incidence of Treatment-Emergent Adverse Events\"\\n7211,1,1,\"Maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D)\"\\n7212,1,1,\"Maximal tolerated dose (MTD) hydroxyurea in combination with dose intense temozolomide\"\\n7213,1,1,\"Maximal tolerated dose (MTD) of 177Lu-girentuximab\"\\n7214,1,1,\"Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066\"\\n7215,1,1,\"Maximal Tolerated Dose (MTD) of Cabozantinib-s-malate\"\\n7216,1,1,\"Maximal Tolerated Dose (MTD) of GBR 1302\"\\n7217,1,1,\"Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066\"\\n7218,1,1,\"Maximal Tolerated Dose (MTD) of PROMITIL\"\\n7219,1,1,\"Maximal tolerated dose (MTD) of SAR260301 in combination with vemurafenib (Study Part B)\"\\n7220,1,1,\"Maximal tolerated dose (MTD) of SAR260301 in monotherapy (Study Part A)\"\\n7221,1,1,\"Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab\"\\n7222,1,1,\"Maximal Tolerated Dose (MTD) of Stereoactive Body Radiation Therapy (SBRT)\"\\n7223,1,1,\"Maximal tolerated dose (MTD), defined as one level below at which 2 of 6 patients experience a dose-limiting toxicity (DLT)\"\\n7224,1,1,\"Maximal tolerated dose of AB-1015\"\\n7225,1,1,\"Maximal tolerated dose of high dose vitamin C in combination with Y90 radioembolization\"\\n7226,1,1,\"Maximal tolerated dose of PRGN-3005\"\\n7227,1,1,\"Maximal Tolerated Dose of RO5212054\"\\n7228,1,1,\"Maximal tolerated dose or maximal administered dose\"\\n7229,5,3,\"Maximally Tolerated Dose\"\\n7230,7,1,\"Maximally tolerated dose (MTD)\"\\n7231,1,1,\"Maximally Tolerated Dose (MTD) (Phase 1b)\"\\n7232,1,1,\"Maximally Tolerated Dose (MTD) (Phase I)\"\\n7233,1,1,\"Maximally tolerated dose (MTD) and dose limiting toxicities (DLTs) of KRN5500, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n7234,1,1,\"Maximally tolerated dose (MTD) and/or optimal biological dose (OBD)\"\\n7235,1,1,\"Maximally tolerated dose (MTD) of ATM plus sirolimus\"\\n7236,1,1,\"Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I)\"\\n7237,1,1,\"Maximally Tolerated Dose (MTD) of PEGPH20 when given to patients with cancer\"\\n7238,1,1,\"Maximally tolerated dose (MTD) of PRT2527\"\\n7239,1,1,\"Maximally tolerated dose (MTD) of study drugs\"\\n7240,1,1,\"Maximally Tolerated Dose (MTD) of Vorinostat in Combination With Infusional 5-FU and Radiation Therapy.\"\\n7241,1,1,\"Maximally tolerated dose (MTD), graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n7242,1,1,\"Maximally tolerated dose (MTD)/Recommended phase 2 dose (RP2D) of PRT3645\"\\n7243,1,1,\"Maximally tolerated dose (MTD-MM) of ASTX727 in combination with paclitaxel and pembrolizumab (MK-3475) (Dose Finding Phase)\"\\n7244,1,1,\"Maximally tolerated dose of a combination of SAHA and gemcitabine determined by dose-limiting toxicity as measured by NCI CTCAE v3.0 continuously\"\\n7245,1,1,\"Maximally tolerated dose of alpelisib in combination with cisplatin, based upon evaluation of dose-limiting toxicities and adverse events\"\\n7246,1,1,\"Maximally tolerated dose of orantinib, graded according to the NCI CTC v2.0\"\\n7247,1,1,\"Maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by intravenous (IV) infusion\"\\n7248,1,1,\"Maximally-tolerated dose of Grape Seed Extract in Patients with Solid Tumors\"\\n7249,1,1,\"Maximjum Tolerated Dose (MTD) of the combination of dasatinib and bevacizumab\"\\n7250,3,1,\"Maximum Administered Dose (MAD)\"\\n7251,1,1,\"Maximum administered dose (MAD) of ADG206\"\\n7252,1,1,\"Maximum Administered Dose of Dasatinib (Phase I)\"\\n7253,1,1,\"Maximum administered dose of study drugs\"\\n7254,1,1,\"Maximum applicable dose (MAD) of HS-10502ÔºàStage 1Ôºâ\"\\n7255,1,1,\"Maximum CCI\"\\n7256,1,1,\"Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy\"\\n7257,1,1,\"Maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy\"\\n7258,1,1,\"Maximum change of absolute neutrophil count (ANC) up to End of Treatment visit\"\\n7259,1,1,\"Maximum change of Hb concentration\"\\n7260,1,1,\"Maximum Common Toxicity Criteria (CTC) score\"\\n7261,1,1,\"Maximum Common Toxicity Criteria score (Maximum CTC score)\"\\n7262,1,1,\"Maximum Concentration (C Max)\"\\n7263,37,2,\"Maximum concentration (Cmax)\"\\n7264,1,1,\"Maximum concentration (Cmax) after single dose\"\\n7265,1,1,\"Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.\"\\n7266,1,1,\"Maximum Concentration (Cmax) of Dabrafenib\"\\n7267,1,1,\"Maximum concentration (Cmax) of FORE8394\"\\n7268,1,1,\"Maximum Concentration (Cmax) of Golvatinib\"\\n7269,1,1,\"Maximum Concentration (Cmax) of IMC-A12 Administered at a Dose of 20 mg/kg Every 3 Weeks\"\\n7270,1,1,\"Maximum Concentration (Cmax) of MK-2206 in Participants Receiving Multiple QOD Dosing\"\\n7271,1,1,\"Maximum Concentration (Cmax) of MPDL3280A\"\\n7272,1,1,\"Maximum Concentration (Cmax) of Olaratumab Following Multiple Doses\"\\n7273,1,1,\"Maximum Concentration (Cmax) of Rociletinib and Its Metabolites\"\\n7274,1,1,\"Maximum concentration (Cmax) of the respective dosing interval of BAY2965501 after single dose\"\\n7275,1,1,\"Maximum concentration (Cmax,md) of the respective dosing interval of BAY2965501 after multiple dose\"\\n7276,1,1,\"Maximum concentration of selitrectinib in plasma in fasted state (Cmax_fasted)\"\\n7277,1,1,\"Maximum concentration of selitrectinib in plasma in fed state (Cmax_fed)\"\\n7278,1,1,\"Maximum concentration of SIM1803-1A in plasma (Cmax)\"\\n7279,1,1,\"Maximum degree of non-hematological toxicity.\"\\n7280,1,1,\"Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008])\"\\n7281,1,1,\"Maximum Dose of Panitumumab\"\\n7282,1,1,\"Maximum dose tolerated of nab-paclitaxel\"\\n7283,1,1,\"Maximum drug concentration (Cmax) and minimal drug concentration (Cmin) of BAY1179470 in plasma after single and multiple dose administration\"\\n7284,1,1,\"Maximum drug concentration (Cmax) in plasma for Digoxin\"\\n7285,1,1,\"Maximum drug concentration (Cmax) in plasma for rosuvastatin\"\\n7286,1,1,\"Maximum drug concentration at steady-state (Cmax-ss)\"\\n7287,1,1,\"Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib\"\\n7288,1,1,\"Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib Metabolite M-11\"\\n7289,1,1,\"Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib\"\\n7290,1,1,\"Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-2\"\\n7291,1,1,\"Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Regorafenib Metabolite M-5\"\\n7292,2,1,\"Maximum drug concentration in plasma after single dose administration (Cmax)\"\\n7293,1,1,\"Maximum drug concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY1179470\"\\n7294,1,1,\"Maximum feasible dose defined as the highest dose studied for which the incidence of DLT is less than 33% or the highest safe dose in our study, limited to a maximum MFD dose of 40 mg/hr\"\\n7295,1,1,\"Maximum Feasible Dose in mg of RAD001 (Everolimus)for Women With Metastatic Breast Cancer\"\\n7296,1,1,\"Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer\"\\n7297,1,1,\"Maximum hemoglobin achieved\"\\n7298,1,1,\"Maximum Measured Concentration of the Analyte in Plasma at Steady State (Cmax,ss) - Dose Finding Part\"\\n7299,1,1,\"Maximum measured concentrations of BI 907828 in plasma (C max)\"\\n7300,1,1,\"maximum measured plasma concentration (Cmax)\"\\n7301,15,1,\"Maximum Observed Concentration (Cmax)\"\\n7302,41,3,\"Maximum observed concentration (Cmax)\"\\n7303,1,1,\"Maximum Observed Concentration (Cmax) of AZD2014 in Plasma and Saliva\"\\n7304,1,1,\"Maximum Observed Concentration (Cmax) of GDC-0941\"\\n7305,1,1,\"Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study\"\\n7306,1,1,\"Maximum Observed Concentration (Cmax) of Panitumumab\"\\n7307,1,1,\"Maximum observed concentration (Cmax) of PLX2853.\"\\n7308,1,1,\"Maximum observed concentration (Cmax) of PLX51107.\"\\n7309,1,1,\"Maximum observed concentration (Cmax) of PLX73086 [Part 1 of research study]\"\\n7310,1,1,\"Maximum observed concentration at steady-state (Css,max)\"\\n7311,1,1,\"Maximum Observed Concentration in Plasma of CC-115\"\\n7312,1,1,\"Maximum observed concentration of DCC-3014\"\\n7313,1,1,\"Maximum Observed Dose-normalized Plasma Concentration (Cmax) of S,R-TLC388\"\\n7314,1,1,\"Maximum Observed Dose-normalized Plasma Concentration (Cmax) of S,S-TLC388\"\\n7315,1,1,\"Maximum Observed Dose-normalized Plasma Concentration (Cmax) of TLC-U1\"\\n7316,1,1,\"Maximum Observed Dose-normalized Plasma Concentration (Cmax) of TLC-U2\"\\n7317,1,1,\"Maximum Observed Dose-normalized Plasma Concentration (Cmax) of Topotecan\"\\n7318,1,1,\"Maximum Observed Drug Concentration (Cmax) in Plasma After Single and Multiple Dose Administration of BAY1143269\"\\n7319,1,1,\"Maximum observed drug concentration (Cmax) of BAY1217389 in plasma\"\\n7320,1,1,\"Maximum observed drug concentration (Cmax) of paclitaxel in plasma\"\\n7321,1,1,\"Maximum observed drug concentration (Cmax) of roniciclib on Cycle 1 Day 1 (without itraconazole)\"\\n7322,1,1,\"Maximum observed drug concentration (Cmax) of roniciclib on Cycle 1 Day 6 (with itraconazole)\"\\n7323,1,1,\"Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval (Cmax,md) of VIP152 (BAY1251152)\"\\n7324,1,1,\"Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP152 (BAY1251152)\"\\n7325,1,1,\"Maximum Observed Drug Concentration in Plasma after multiple administrations (Cmax, md) of BAY1163877\"\\n7326,1,1,\"Maximum observed drug concentration in plasma of BAY1895344 after single-dose (Cmax) and multiple-dose administrations (Cmax,md) in Cycle 1\"\\n7327,209,4,\"Maximum Observed Plasma Concentration (Cmax)\"\\n7328,103,3,\"Maximum observed plasma concentration (Cmax)\"\\n7329,1,1,\"Maximum Observed Plasma Concentration (Cmax) After a Single Dose of GDC-0449\"\\n7330,1,1,\"Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of Pemigatinib as monotherapy\"\\n7331,1,1,\"Maximum Observed Plasma Concentration (Cmax) For Dextromethorphan and Dextrorphan 3 Days Prior to PF-00299804 Dosing\"\\n7332,1,1,\"Maximum Observed Plasma Concentration (Cmax) For Dextromethorphan and Dextrorphan on Cycle 2 Day 7\"\\n7333,1,1,\"Maximum observed plasma concentration (Cmax) for eribulin mesylate +/- rifampicin\"\\n7334,1,1,\"Maximum observed plasma concentration (Cmax) for Famitinib after Single dose\"\\n7335,1,1,\"Maximum Observed Plasma Concentration (Cmax) for ION537\"\\n7336,1,1,\"Maximum observed plasma concentration (Cmax) for niraparib-Stages 1, 2 and 3 PK Phase\"\\n7337,1,1,\"Maximum observed plasma concentration (Cmax) for SHR116637 after Single dose\"\\n7338,1,1,\"Maximum Observed Plasma Concentration (Cmax) GDC-0575\"\\n7339,1,1,\"Maximum Observed Plasma Concentration (Cmax) of 14C- Radioactivity\"\\n7340,1,1,\"Maximum observed plasma concentration (Cmax) of ABBV-075\"\\n7341,1,1,\"Maximum observed plasma concentration (Cmax) of ABBV-085.\"\\n7342,1,1,\"maximum observed plasma concentration (Cmax) of AMG 510.\"\\n7343,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Atezolizumab\"\\n7344,1,1,\"Maximum observed plasma concentration (Cmax) of BAY1082439 after a single dose\"\\n7345,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Carboplatin\"\\n7346,1,1,\"Maximum Observed Plasma Concentration (Cmax) of CC-223\"\\n7347,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1\"\\n7348,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Docetaxel in Cycle 1\"\\n7349,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Docetaxel in Cycle 4\"\\n7350,1,1,\"Maximum observed plasma concentration (Cmax) of encapsulated doxorubicin\"\\n7351,1,1,\"Maximum observed plasma concentration (Cmax) of Famitinib\"\\n7352,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Idasanutlin\"\\n7353,2,2,\"Maximum Observed Plasma Concentration (Cmax) of Relatlimab\"\\n7354,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Sunitinib and Its Metabolite\"\\n7355,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Talazoparib\"\\n7356,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Talazoparib on Day 22\"\\n7357,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Itraconazole\"\\n7358,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Rifampin\"\\n7359,1,1,\"Maximum Observed Plasma Concentration (Cmax) of Unlabeled Idasanutlin\"\\n7360,1,1,\"Maximum observed plasma concentration (Cmax) ratio\"\\n7361,1,1,\"Maximum Observed Plasma Concentration (Cmax): Docetaxel PK Parameters\"\\n7362,1,1,\"Maximum Observed Plasma Concentration (Cmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters\"\\n7363,1,1,\"Maximum Observed Plasma Concentration After Single Dose Administration (Cmax)\"\\n7364,1,1,\"Maximum observed plasma concentration after single dose administration (Cmax) of BAY1163877\"\\n7365,1,1,\"Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib\"\\n7366,1,1,\"Maximum observed plasma concentration of encapsulated doxorubicin in participants with ovarian cancer\"\\n7367,1,1,\"Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1\"\\n7368,1,1,\"Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2\"\\n7369,1,1,\"Maximum observed plasma drug concentrations (Cmax)\"\\n7370,1,1,\"Maximum Observed Plasma/Serum Concentration (Cmax) Of ABBV-CLS-579\"\\n7371,1,1,\"Maximum Observed Plasma/Serum Concentration (Cmax) Of Metabolite M4\"\\n7372,1,1,\"Maximum Observed Plasma/Serum Concentration (Cmax) Of PD-1 Inhibitor\"\\n7373,1,1,\"Maximum Observed Plasma/Serum Concentration (Cmax) Of VEGFR TKI\"\\n7374,12,2,\"Maximum observed serum concentration (Cmax)\"\\n7375,2,1,\"maximum observed serum concentration (Cmax)\"\\n7376,1,1,\"Maximum observed serum concentration (Cmax) of ABBV-181\"\\n7377,1,1,\"Maximum Observed Serum Concentration (Cmax) of ABBV-181 (Arm 3 Only)\"\\n7378,1,1,\"Maximum Observed Serum Concentration (Cmax) of ABBV-368\"\\n7379,1,1,\"Maximum observed serum concentration (Cmax) of ABBV-368\"\\n7380,1,1,\"Maximum observed serum concentration (Cmax) of ABBV-428\"\\n7381,1,1,\"Maximum Observed Serum Concentration (Cmax) of ABBV-514\"\\n7382,1,1,\"Maximum observed serum concentration (Cmax) of ABBV-621\"\\n7383,1,1,\"Maximum observed serum concentration (Cmax) of ABBV-927\"\\n7384,1,1,\"Maximum observed serum concentration (Cmax) of ABT-165\"\\n7385,1,1,\"Maximum Observed Serum Concentration (Cmax) of Avelumab\"\\n7386,1,1,\"Maximum Observed Serum Concentration (Cmax) of EMD 525797:After Multiple Dose\"\\n7387,1,1,\"Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 1)\"\\n7388,1,1,\"Maximum Observed Serum Concentration (Cmax) of RO6874281\"\\n7389,1,1,\"Maximum Observed Serum Concentration (Cmax) of RO6895882\"\\n7390,1,1,\"Maximum Observed Serum Concentration (Cmax) of Trastuzumab\"\\n7391,1,1,\"Maximum observed serum concentration (Cmax) of Venetoclax\"\\n7392,1,1,\"Maximum Observed Serum Concentration (Cmax): After Single Dose\"\\n7393,1,1,\"Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706\"\\n7394,1,1,\"Maximum Observed Whole Blood Concentration (Cmax) of 14C- Radioactivity\"\\n7395,1,1,\"Maximum of the worst pain scores from the initiation of paclitaxel therapy (day 1) until day 7 (first week of therapy)\"\\n7396,1,1,\"Maximum Plasma Concentration (CMax)\"\\n7397,106,4,\"Maximum Plasma Concentration (Cmax)\"\\n7398,87,5,\"Maximum plasma concentration (Cmax)\"\\n7399,1,1,\"Maximum Plasma Concentration (Cmax) of ABBV-221\"\\n7400,1,1,\"Maximum plasma concentration (Cmax) of Capivasertib\"\\n7401,1,1,\"Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 1, Cycle 1\"\\n7402,1,1,\"Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3\"\\n7403,1,1,\"Maximum Plasma Concentration (Cmax) of DM1 in Cycle 1 After Q3W Dose Regimen\"\\n7404,1,1,\"Maximum Plasma Concentration (Cmax) of DM1 in Cycle 1 After QW Dose Regimen\"\\n7405,1,1,\"Maximum Plasma Concentration (Cmax) of Entrectinib\"\\n7406,1,1,\"Maximum Plasma Concentration (Cmax) of Fluzoparib:\"\\n7407,1,1,\"Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor\"\\n7408,1,1,\"Maximum plasma concentration (Cmax) of Ipatasertib\"\\n7409,1,1,\"Maximum plasma concentration (Cmax) of LUNA18 [Part A]\"\\n7410,1,1,\"maximum plasma concentration (Cmax) of midazolam\"\\n7411,1,1,\"Maximum Plasma Concentration (Cmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib\"\\n7412,1,1,\"Maximum Plasma Concentration (Cmax) of RO5185426 on Day 1\"\\n7413,1,1,\"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436\"\\n7414,1,1,\"Maximum Plasma Concentration (Cmax) of Tilsotolimod\"\\n7415,1,1,\"Maximum Plasma Concentration (Cmax) of Total and Unbound GDC-0449\"\\n7416,1,1,\"Maximum Plasma Concentration (Cmax) of Vemurafenib on Day 1\"\\n7417,1,1,\"Maximum Plasma Concentration (Cmax) of Vemurafenib on Day 15\"\\n7418,1,1,\"Maximum Plasma Concentration (Cmax) of Vemurafenib on Day 9\"\\n7419,1,1,\"Maximum Plasma Concentration (Cmax) on Cycle 1 Day 1\"\\n7420,1,1,\"Maximum Plasma Concentration (Cmax) on Cycle 1 Day 28\"\\n7421,1,1,\"Maximum Plasma Concentration [Cmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n7422,1,1,\"Maximum Plasma Concentration After Administration Of Samalizumab\"\\n7423,1,1,\"Maximum plasma concentration for osimertinib\"\\n7424,1,1,\"Maximum Plasma Concentration of 14C-labeled RO5185426 (Cmax) in Both Blood and Plasma\"\\n7425,1,1,\"Maximum Plasma Concentration of Azacitidine (Cmax)\"\\n7426,1,1,\"Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine\"\\n7427,1,1,\"Maximum plasma concentration of KZR-261 (Part 1)\"\\n7428,1,1,\"Maximum Plasma Concentration of MK-2206 (Cmax)\"\\n7429,1,1,\"Maximum Plasma Concentration of Paclitaxel in Cycle 1 (in the Absence T-DM1) and Cycle 2 (in the Presence T-DM1)\"\\n7430,1,1,\"Maximum Plasma Concentration of RO5212054\"\\n7431,1,1,\"Maximum plasma rucaparib concentration (Cmax)\"\\n7432,1,1,\"Maximum recovery of the radioactive dose in plasma, urine and feces\"\\n7433,1,1,\"Maximum Reduction From Baseline in Global Longitudinal Strain (GLS) Values\"\\n7434,1,1,\"Maximum Serum Concentration (Cmax) for RO6958688\"\\n7435,1,1,\"Maximum Serum Concentration (Cmax) of Atezolizumab\"\\n7436,1,1,\"Maximum Serum Concentration (Cmax) of Sorafenib\"\\n7437,1,1,\"Maximum Serum Concentration (Cmax) of T-DM1 and Total Trastuzumab in Cycle 1 After Q3W Dose Regimen\"\\n7438,1,1,\"Maximum Serum Concentration (Cmax) of T-DM1 and Total Trastuzumab in Cycle 1 After QW Dose Regimen\"\\n7439,1,1,\"Maximum serum concentration of selinexor\"\\n7440,2,1,\"Maximum serum drug concentration (Cmax)\"\\n7441,1,1,\"Maximum serum drug concentration (Cmax)-BAT8001(antibody-drug conjugate), total antibody and Batansine (a maytansine derivative, which is the 3AA-MDC complex)\"\\n7442,1,1,\"Maximum serum drug concentrationÔºàCmax)\"\\n7443,1,1,\"Maximum serum drug timeÔºàTmaxÔºâ\"\\n7444,1,1,\"Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT)\"\\n7445,1,1,\"Maximum Therapeutic Dose, as defined by the highest dose identified in which ‚â§1/3 or ‚â§2/6 patients do not experience a dose limiting toxicity\"\\n7446,7,2,\"Maximum tolerable dose\"\\n7447,5,2,\"Maximum Tolerable Dose (MTD)\"\\n7448,8,3,\"Maximum tolerable dose (MTD)\"\\n7449,1,1,\"Maximum tolerable dose (MTD) and recommended dose for phase II determined by dose-limiting toxicities (DLT) graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n7450,1,1,\"Maximum tolerable dose (MTD) and RP2D of HTMC0435 combined with Temozolomide\"\\n7451,1,1,\"Maximum tolerable dose (MTD) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study\"\\n7452,1,1,\"Maximum tolerable dose (MTD) based on the number of subjects experiencing dose limiting toxicities (DLTs)\"\\n7453,1,1,\"Maximum Tolerable Dose (MTD) Belinostat, Part A,\"\\n7454,1,1,\"Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day\"\\n7455,1,1,\"Maximum tolerable dose (MTD) of irinotecan\"\\n7456,1,1,\"Maximum Tolerable Dose (MTD) of Two Combination Therapy of Volasertib and Afatinib.\"\\n7457,1,1,\"Maximum tolerable dose (MTD) or a recommended Phase 2 dose (RP2D) - (Phase 1)\"\\n7458,1,1,\"Maximum tolerable dose (MTD) or a tolerated dose below MTD\"\\n7459,1,1,\"Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)\"\\n7460,1,1,\"Maximum tolerable dose (MTD) or dose to absorb saturation\"\\n7461,1,1,\"Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)\"\\n7462,1,1,\"Maximum tolerable dose (MTDÔºâ\"\\n7463,1,1,\"Maximum Tolerable Dose Based on Dose-limiting Toxicity of Sunitinib in Patients Receiving EIAC (Stratum 2)\"\\n7464,1,1,\"Maximum tolerable dose defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n7465,1,1,\"Maximum tolerable dose of cabozantinib-s-malate in combination with vemurafenib based on the incidence of dose-limiting toxicity (DLT) graded according to the National Cancer Institute CTCAE version 4.0.\"\\n7466,1,1,\"Maximum tolerable dose of Nintedanib\"\\n7467,1,1,\"Maximum Tolerable Dose of Selumetinib (AZD6244) Hyd-Sulfate in Combination With Radiation Therapy (RT) and Capecitabine in Participants With Locally Advanced Adenocarcinoma of the Rectum.\"\\n7468,1,1,\"Maximum tolerable doseÔºàMTDÔºâ\"\\n7469,5,1,\"Maximum tolerance dose\"\\n7470,1,1,\"Maximum tolerance dose (MTD)\"\\n7471,1,1,\"Maximum Tolerance Dose (MTD) for phase‚Ö†\"\\n7472,1,1,\"Maximum tolerance doseÔºàMTDÔºâ\"\\n7473,1,1,\"Maximum tolerate dose (MTD) as defined by dose limiting toxicity (DLT)\"\\n7474,1,1,\"Maximum Tolerate Dose of TJ004309 plus Atezolizumab\"\\n7475,1,1,\"Maximum tolerated and recommended dose (MTD) (RD)\"\\n7476,1,1,\"Maximum Tolerated Atezolizumab Dose\"\\n7477,1,1,\"Maximum Tolerated Cell Dose (MTD)\"\\n7478,1,1,\"Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and Aldesleukin\"\\n7479,1,1,\"Maximum tolerated combination doses (MTD)\"\\n7480,1,1,\"Maximum Tolerated Combination Doses of Cobimetinib and Pictilisib During Dose-Escalation Stages 1, 1A and 1B\"\\n7481,1,1,\"Maximum tolerated daily dose of melatonin.\"\\n7482,2,1,\"maximum tolerated dosage\"\\n7483,1,1,\"maximum tolerated dosage (MTD)\"\\n7484,1,1,\"Maximum Tolerated Dosage (MTD) of Intravenous Topotecan When Given in Combination With Oral Erlotinib\"\\n7485,1,1,\"maximum tolerated dosage (MTD) Phase I\"\\n7486,185,62,\"Maximum Tolerated Dose\"\\n7487,211,71,\"Maximum tolerated dose\"\\n7488,42,14,\"maximum tolerated dose\"\\n7489,1,1,\"maximum tolerated dose (For Dose Escalation Portion of the study)\"\\n7490,1,1,\"Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D)\"\\n7491,346,145,\"Maximum Tolerated Dose (MTD)\"\\n7492,6,3,\"Maximum Tolerated dose (MTD)\"\\n7493,1,1,\"Maximum tolerated Dose (MTD)\"\\n7494,278,118,\"Maximum tolerated dose (MTD)\"\\n7495,31,10,\"maximum tolerated dose (MTD)\"\\n7496,1,1,\"Maximum tolerated dose (MTD) (Cohort I)\"\\n7497,1,1,\"Maximum Tolerated Dose (MTD) (Dose Escalation Phase)\"\\n7498,1,1,\"Maximum tolerated dose (MTD) (Dose Escalation Phase)\"\\n7499,1,1,\"Maximum tolerated dose (MTD) (dose-escalation phase)\"\\n7500,1,1,\"Maximum tolerated dose (MTD) (for Part 1a)\"\\n7501,1,1,\"Maximum tolerated dose (MTD) (if available)\"\\n7502,1,1,\"Maximum tolerated dose (MTD) (Part 1)\"\\n7503,1,1,\"Maximum tolerated dose (MTD) (Part 1a)\"\\n7504,1,1,\"Maximum tolerated dose (MTD) (Phase 1 only)\"\\n7505,1,1,\"Maximum tolerated dose (MTD) (phase 1 only)\"\\n7506,4,1,\"Maximum Tolerated Dose (MTD) (Phase 1)\"\\n7507,1,1,\"Maximum tolerated dose (MTD) (Phase 1)\"\\n7508,1,1,\"Maximum tolerated dose (MTD) (phase 1)\"\\n7509,1,1,\"Maximum tolerated dose (MTD) (Phase I dose escalation)\"\\n7510,1,1,\"Maximum tolerated dose (MTD) (phase I dose escalation)\"\\n7511,5,2,\"Maximum Tolerated Dose (MTD) (Phase I)\"\\n7512,9,2,\"Maximum tolerated dose (MTD) (Phase I)\"\\n7513,2,1,\"Maximum tolerated dose (MTD) (phase I)\"\\n7514,1,1,\"Maximum tolerated dose (MTD) (Phase Ia)\"\\n7515,4,4,\"Maximum tolerated dose (MTD) (Phase Ib)\"\\n7516,1,1,\"maximum tolerated dose (MTD) (Phase l)\"\\n7517,3,1,\"Maximum Tolerated Dose (MTD) - Part 1\"\\n7518,1,1,\"Maximum Tolerated Dose (MTD) - Part 1 (Phase 1b)\"\\n7519,1,1,\"Maximum Tolerated Dose (MTD) - Part A\"\\n7520,1,1,\"Maximum Tolerated Dose (MTD) - Part B\"\\n7521,1,1,\"Maximum Tolerated Dose (MTD) - Phase I\"\\n7522,1,1,\"Maximum Tolerated Dose (MTD) [Phase I Dose Finding]\"\\n7523,2,2,\"Maximum tolerated dose (MTD) and Dose limiting toxicity (DLT)\"\\n7524,1,1,\"Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of Intra-Arterial Hepatic Oxaliplatin\"\\n7525,1,1,\"Maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combination of pembrolizumab with paclitaxel, carboplatin and radiation therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n7526,1,1,\"Maximum tolerated dose (MTD) and Dose-limiting toxicities (DLT) of Combination Treatment with Bevacizumab and Bortezomib\"\\n7527,1,1,\"Maximum Tolerated Dose (MTD) and Dose-limiting Toxicity (DLT)\"\\n7528,1,1,\"Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone in combination with carboplatin (AUC 6)\"\\n7529,1,1,\"Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity(DLT)\"\\n7530,1,1,\"Maximum tolerated dose (MTD) and first cycle dose limiting toxicities (DLTs)\"\\n7531,1,1,\"Maximum tolerated dose (MTD) and incidence of dose limiting toxicity (DLT) within the first cycle at each dose level.\"\\n7532,1,1,\"Maximum Tolerated Dose (MTD) and Maximum Acceptable Dose (MAD) of Dasatinib as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to Dasatinib Treatment\"\\n7533,2,1,\"Maximum Tolerated Dose (MTD) and Recommended Dose (RD)\"\\n7534,1,1,\"Maximum tolerated dose (MTD) and recommended dose (RD) by evaluating the safety and tolerability\"\\n7535,1,1,\"Maximum tolerated dose (MTD) and recommended dose (RD) by evaluating the safety and tolerability on single dose\"\\n7536,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose\"\\n7537,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2) - Part A\"\\n7538,4,3,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)\"\\n7539,1,1,\"Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D)\"\\n7540,1,1,\"Maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D)\"\\n7541,3,2,\"Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)\"\\n7542,1,1,\"Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D) in Patients\"\\n7543,1,1,\"Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of a weekly 4-hour carfilzomib infusion in patients with advanced solid malignancies\"\\n7544,1,1,\"Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ipatasertib in combination with definitive chemo-radiation\"\\n7545,1,1,\"Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JTX-4014\"\\n7546,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of RLY-5836\"\\n7547,1,1,\"Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1\"\\n7548,1,1,\"Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the combination of MM3814 and avelumab in patients with deoxyribonucleic acid (DNA) damage response (DDR) deficient advanced solid tumors\"\\n7549,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302\"\\n7550,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302 combine with Tamoxifen\"\\n7551,1,1,\"Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxel\"\\n7552,1,1,\"Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).\"\\n7553,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPIID) of Cetuximab in Combination With Irinotecan\"\\n7554,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of Carboplatin in Combination With Ixabepilone, 32 mg/m^2\"\\n7555,1,1,\"Maximum tolerated dose (MTD) and recommended phase 2 dose of continuous novobiocin administration\"\\n7556,1,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of MK-2206 Administered Weekly in Combination With Weekly Paclitaxel 80 mg/m^2 and Trastuzumab 2 mg/m^2\"\\n7557,2,1,\"Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D)\"\\n7558,1,1,\"Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of eribulin mesylate for patients who have received a tubulin-inhibitor for the recurrent/advanced disease (Phase I)\"\\n7559,1,1,\"Maximum tolerated dose (MTD) and recommended Phase II dose of ganetespib plus paclitaxel plus trastuzumab and pertuzumab\"\\n7560,1,1,\"Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.\"\\n7561,1,1,\"Maximum Tolerated Dose (MTD) and the phase II recommended dose (RP2D)\"\\n7562,1,1,\"Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Cisplatin in Combination With Ixabepilone, 32 mg/m^2\"\\n7563,1,1,\"Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D)\"\\n7564,1,1,\"Maximum Tolerated Dose (MTD) and/or Dose Limiting Toxicity (DLT)\"\\n7565,1,1,\"Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD)\"\\n7566,1,1,\"Maximum tolerated dose (MTD) and/or recomended dose (RD)\"\\n7567,1,1,\"Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)\"\\n7568,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)\"\\n7569,3,3,\"Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D)\"\\n7570,1,1,\"Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)\"\\n7571,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621\"\\n7572,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397\"\\n7573,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 in combination with either docetaxel, paclitaxel, gemcitabine and nab-paclitaxel or pemetrexed\"\\n7574,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-105\"\\n7575,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-109\"\\n7576,1,1,\"Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of Kanitinib in subjects with advanced solid tumors\"\\n7577,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES101\"\\n7578,1,1,\"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES102\"\\n7579,1,1,\"Maximum tolerated dose (MTD) and/or recommended phase 2 dose of cabozantinib S-malate\"\\n7580,1,1,\"Maximum Tolerated Dose (MTD) and/or recommended phase II dose (RP2D) and schedule of BKM120+GSK1120212\"\\n7581,1,1,\"Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RPTD) of ABBV-011\"\\n7582,1,1,\"Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RPTD) of ABBV-011 in Combination with Budigalimab\"\\n7583,1,1,\"Maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D)\"\\n7584,1,1,\"maximum tolerated dose (MTD) as defined by dose limiting toxicity\"\\n7585,2,1,\"Maximum Tolerated Dose (MTD) as determined by number of participants with dose limiting toxicities (DLT)\"\\n7586,1,1,\"Maximum Tolerated Dose (MTD) as determined by number of participants with of dose limiting toxicities (DLT)\"\\n7587,2,1,\"Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities\"\\n7588,2,1,\"Maximum tolerated dose (MTD) assessed by Common Toxicity Criteria (CTC)\"\\n7589,1,1,\"Maximum Tolerated Dose (MTD) Based on DLT\"\\n7590,1,1,\"Maximum tolerated dose (MTD) based on number of Dose-limiting toxicities (DLTs)\"\\n7591,1,1,\"Maximum tolerated dose (MTD) based on the number of subjects experiencing at least 1 DLT\"\\n7592,1,1,\"Maximum Tolerated Dose (MTD) based upon study drug related dose limiting toxicities (DLTs)\"\\n7593,1,1,\"Maximum tolerated dose (MTD) defined as highest dose of ABC294640 at which 0 or 1 patient of 6 experiences a DLT.\"\\n7594,1,1,\"Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity\"\\n7595,1,1,\"Maximum tolerated dose (MTD) defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients\"\\n7596,1,1,\"Maximum tolerated dose (MTD) defined as the highest dose level tested at which =< 2/6 patients experience dose limiting toxicities (DLT) graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE) version 4.0\"\\n7597,1,1,\"Maximum tolerated dose (MTD) defined as the highest dose with less than 25 percent (%) risk of the true Dose limiting toxicity (DLT) rate being equal or above 33 percent (%) during the MTD evaluation period.\"\\n7598,1,1,\"Maximum tolerated dose (MTD) defined as the highest safely tolerated dose where at most 1 patient experiences a dose-limiting toxicities (DLT) and the next higher dose having at least 2 patients who experience DLT\"\\n7599,1,1,\"Maximum tolerated dose (MTD) defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities DLT graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n7600,4,2,\"Maximum tolerated dose (MTD) determination\"\\n7601,1,1,\"Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events\"\\n7602,3,1,\"Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)\"\\n7603,1,1,\"Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D28) of sirolimus when administered in association with CP, MT and ZA\"\\n7604,1,1,\"Maximum tolerated dose (MTD) evaluated using the NCI CTCAE criteria\"\\n7605,1,1,\"Maximum tolerated dose (MTD) for a single dose of BI 2536 BS\"\\n7606,1,1,\"Maximum Tolerated Dose (MTD) for Both Monotherapy and Combination Therapy\"\\n7607,1,1,\"Maximum Tolerated Dose (MTD) for Combination of Selumetinib and Olaparib in Participants with Advanced or Recurrent Solid Tumors\"\\n7608,1,1,\"Maximum tolerated dose (MTD) for KPT-9274 administered alone and with co-administration of niacin ER (extended release) (vitamin B3/nicotinic acid)\"\\n7609,1,1,\"Maximum tolerated dose (MTD) for KPT-9274 co-administered with nivolumab\"\\n7610,1,1,\"Maximum Tolerated Dose (MTD) for MLN2480\"\\n7611,1,1,\"Maximum Tolerated Dose (MTD) for Regimen A and Regimen B\"\\n7612,1,1,\"Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy\"\\n7613,1,1,\"Maximum Tolerated Dose (MTD) for the combination of Temozolomide and DepoCyt\"\\n7614,1,1,\"Maximum tolerated dose (MTD) in any studied regimen\"\\n7615,2,2,\"Maximum Tolerated Dose (MTD) in Part 1\"\\n7616,1,1,\"Maximum Tolerated Dose (MTD) in Participants With Any Solid Tumor (Phase Ib)\"\\n7617,1,1,\"Maximum tolerated dose (MTD) in Stage I\"\\n7618,1,1,\"Maximum tolerated dose (MTD) in stage ‚Ö†\"\\n7619,1,1,\"maximum tolerated dose (MTD) in subjects with relapsed and relapsed/refractory Multiple Myeloma (MM)\"\\n7620,1,1,\"Maximum tolerated dose (MTD) is defined as the highest dose level at which less than 33% of patients experience study treatment-related dose limiting toxicities (DLT)\"\\n7621,1,1,\"Maximum tolerated dose (MTD) of 5-fluoro-2-deoxycytidine (FdCyd) when given with tetrahydrouridine (THU) determined by dose-limiting toxicities\"\\n7622,1,1,\"Maximum Tolerated Dose (MTD) of 90Y-HAT\"\\n7623,1,1,\"Maximum tolerated dose (MTD) of [225Ac]-FPI-2059\"\\n7624,1,1,\"Maximum Tolerated Dose (MTD) of a single dose of intravenous recombinant human tumor necrosis factor-Œ± plus liposomal doxorubicin\"\\n7625,1,1,\"Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181\"\\n7626,1,1,\"Maximum tolerated dose (MTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab\"\\n7627,1,1,\"Maximum Tolerated Dose (MTD) of Abemaciclib and MK-6482/Arm 2\"\\n7628,1,1,\"Maximum Tolerated Dose (MTD) of Abraxane\"\\n7629,1,1,\"Maximum Tolerated Dose (MTD) of Abraxane given with Carboplatin\"\\n7630,1,1,\"Maximum Tolerated Dose (MTD) of ABT-751 in Combination With Carboplatin\"\\n7631,1,1,\"Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin\"\\n7632,1,1,\"Maximum tolerated dose (MTD) of ADG 206\"\\n7633,1,1,\"Maximum tolerated dose (MTD) of afatinib dimaleate in combination with capecitabine (Phase Ib)\"\\n7634,1,1,\"Maximum Tolerated Dose (MTD) of Afatinib in Combination With Herceptin(R)\"\\n7635,4,1,\"Maximum Tolerated Dose (MTD) of Alisertib\"\\n7636,1,1,\"Maximum Tolerated Dose (MTD) of Alisertib and TAK-228 in Participants with Human Papilloma Virus (HPV) Associated Malignancies\"\\n7637,1,1,\"Maximum tolerated dose (MTD) of alisertib in combination with fulvestrant graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n7638,1,1,\"Maximum Tolerated Dose (MTD) of Allogeneic CD4+ T cell Infusion\"\\n7639,1,1,\"Maximum tolerated dose (MTD) of alpelisib in combination with enzalutamide\"\\n7640,1,1,\"Maximum Tolerated Dose (MTD) of ALT-836 in combination with gemcitabine\"\\n7641,1,1,\"Maximum Tolerated Dose (MTD) of AMG 256\"\\n7642,1,1,\"Maximum tolerated dose (MTD) of ASLAN001 when used in combination with Oxaliplatin and Capecitabine (CAPOX) or Oxaliplatin and 5-FU with leucovorin (mFolfox6)\"\\n7643,1,1,\"Maximum Tolerated Dose (MTD) of Atezolizumab\"\\n7644,1,1,\"Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy\"\\n7645,1,1,\"Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)\"\\n7646,1,1,\"Maximum Tolerated Dose (MTD) of BAL101553\"\\n7647,1,1,\"Maximum tolerated dose (MTD) of Bapotulimab\"\\n7648,1,1,\"Maximum tolerated dose (MTD) of BAY1125976\"\\n7649,1,1,\"Maximum tolerated dose (MTD) of BAY1436032\"\\n7650,1,1,\"Maximum Tolerated Dose (MTD) of BC006\"\\n7651,1,1,\"Maximum Tolerated Dose (MTD) of Belinostat\"\\n7652,1,1,\"Maximum Tolerated Dose (MTD) of Belinostat According to Degree of Liver Dysfunction\"\\n7653,1,1,\"Maximum tolerated dose (MTD) of bevacizumab in combination with sunitinib malate determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)\"\\n7654,1,1,\"Maximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT)\"\\n7655,1,1,\"Maximum Tolerated Dose (MTD) of BGT226 (Phase I dose escalation) Safety and tolerability of BGT226 (all patients) Clinical tumor response in patients with advanced breast cancer (Phase II)\"\\n7656,1,1,\"Maximum tolerated dose (MTD) of BI 2536 in combination with pemetrexed\"\\n7657,1,1,\"Maximum Tolerated Dose (MTD) of BI 765063, Part A\"\\n7658,1,1,\"Maximum Tolerated Dose (MTD) of BI 765063, Part B\"\\n7659,1,1,\"Maximum tolerated dose (MTD) of BI 836845 in Japanese patients with advanced solid tumours (as identified by the number of patients with dose-limiting toxicities(DLTs))\"\\n7660,1,1,\"Maximum tolerated dose (MTD) of BI 905677\"\\n7661,1,1,\"Maximum Tolerated Dose (MTD) of BIBF 1120\"\\n7662,1,1,\"Maximum tolerated dose (MTD) of BIBF 1120 in combination with carboplatin and paclitaxel\"\\n7663,3,3,\"Maximum tolerated dose (MTD) of BIBW 2992\"\\n7664,2,2,\"Maximum tolerated dose (MTD) of bivatuzumab mertansine\"\\n7665,1,1,\"Maximum Tolerated Dose (MTD) of BKM120\"\\n7666,1,1,\"Maximum tolerated dose (MTD) of BMS-214662, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n7667,1,1,\"Maximum tolerated dose (MTD) of bortezomib\"\\n7668,1,1,\"Maximum tolerated dose (MTD) of BOS172738\"\\n7669,1,1,\"Maximum Tolerated Dose (MTD) of BYL719 in Combination With T-DM1.\"\\n7670,1,1,\"Maximum tolerated dose (MTD) of CA-170\"\\n7671,1,1,\"Maximum tolerated dose (MTD) of calcitriol\"\\n7672,2,2,\"Maximum Tolerated Dose (MTD) of Capecitabine\"\\n7673,1,1,\"Maximum Tolerated Dose (MTD) of Carboplatin with Trientine\"\\n7674,1,1,\"Maximum Tolerated Dose (MTD) of CC-90003\"\\n7675,1,1,\"Maximum tolerated dose (MTD) of ceritinib and everolimus, defined as the highest dose level in which 6 patients were treated with at most 1 experiencing a dose limiting toxicity\"\\n7676,2,2,\"Maximum Tolerated Dose (MTD) of Cisplatin\"\\n7677,1,1,\"Maximum Tolerated Dose (MTD) of Cisplatin (Phase I)\"\\n7678,1,1,\"Maximum tolerated dose (MTD) of combination of ALRN-6924 and paclitaxel, defined as the isotonic estimate of the toxicity rate closest to 0.30\"\\n7679,1,1,\"Maximum Tolerated Dose (MTD) of Combination Treatment with Lenvatinib and Capecitabine in Advanced and/or Metastatic Cancer Refractory to Standard Treatment\"\\n7680,1,1,\"Maximum Tolerated Dose (MTD) of Combination Vemurafenib\"\\n7681,1,1,\"Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer\"\\n7682,1,1,\"Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100\"\\n7683,1,1,\"Maximum tolerated dose (MTD) of crizotinib\"\\n7684,1,1,\"Maximum Tolerated Dose (MTD) of Crolibulin (Phase I)\"\\n7685,1,1,\"Maximum Tolerated Dose (MTD) of CS5001 if any (for dose escalation part)\"\\n7686,1,1,\"Maximum tolerated dose (MTD) of CVM-1118 ER Capsule\"\\n7687,1,1,\"Maximum Tolerated Dose (MTD) of CX-4945 when used in combination with gemcitabine plus cisplatin. (Phase 1)\"\\n7688,1,1,\"Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel\"\\n7689,1,1,\"Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I)\"\\n7690,1,1,\"Maximum tolerated dose (MTD) of Dasatinib plus Crizotinib\"\\n7691,1,1,\"Maximum Tolerated Dose (MTD) of Dasatinib, Cetuximab and FOLFOX\"\\n7692,1,1,\"Maximum Tolerated Dose (MTD) of DB-1305\"\\n7693,1,1,\"Maximum Tolerated Dose (MTD) of DCC-2701\"\\n7694,1,1,\"Maximum Tolerated Dose (MTD) of Decoy20\"\\n7695,1,1,\"maximum tolerated dose (MTD) of defactinib in combination with avelumab (Part A)\"\\n7696,1,1,\"Maximum Tolerated Dose (MTD) of DMOT4039A\"\\n7697,1,1,\"Maximum Tolerated Dose (MTD) of Docetaxel\"\\n7698,1,1,\"Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab\"\\n7699,1,1,\"Maximum Tolerated Dose (MTD) of Docetaxel When Given in Combination With Oxaliplatin and Fluorouracil (Phase I)\"\\n7700,1,1,\"Maximum Tolerated Dose (MTD) of Doxorubicin\"\\n7701,1,1,\"Maximum Tolerated Dose (MTD) of Doxorubicin Hydrochloride Plus Pembrolizumab According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) Version 4.0 (Phase I)\"\\n7702,1,1,\"Maximum Tolerated Dose (MTD) of Doxorubicine\"\\n7703,1,1,\"Maximum Tolerated Dose (MTD) of E7046\"\\n7704,1,1,\"Maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF)\"\\n7705,1,1,\"Maximum Tolerated Dose (MTD) of ECI301 Delivered in Combination With 30 Gray (Gy) External Beam Radiation to Participants With Metastatic or Locally Advanced Cancer\"\\n7706,1,1,\"Maximum Tolerated Dose (MTD) of Efavirenz\"\\n7707,1,1,\"Maximum tolerated dose (MTD) of elimusertib (BAY 1895344) in combination with irinotecan, fluorouracil, and leucovorin (FOLFIRI)\"\\n7708,1,1,\"Maximum Tolerated Dose (MTD) of Emactuzumab\"\\n7709,1,1,\"Maximum Tolerated Dose (MTD) of Eribulin Mesylate\"\\n7710,1,1,\"Maximum Tolerated Dose (MTD) of Eribulin Mesylate of E7389 in Combination With Carboplatin in Subjects With Advanced Solid Tumors.\"\\n7711,1,1,\"Maximum Tolerated Dose (MTD) of Eribulin-LF\"\\n7712,1,1,\"Maximum Tolerated Dose (MTD) of Erlotinib\"\\n7713,1,1,\"Maximum Tolerated Dose (MTD) of Erlotinib in Combination with Cetuximab\"\\n7714,1,1,\"Maximum Tolerated Dose (MTD) of Erlotinib with Pralatrexate\"\\n7715,1,1,\"Maximum Tolerated Dose (MTD) of ETC-1922159 when administered with pembrolizumab (Part B Dose Escalation)\"\\n7716,1,1,\"Maximum Tolerated Dose (MTD) of Everolimus\"\\n7717,1,1,\"Maximum tolerated dose (MTD) of fenretinide\"\\n7718,1,1,\"Maximum tolerated dose (MTD) of GD2Bi-aATC\"\\n7719,1,1,\"Maximum Tolerated Dose (MTD) of GDC-0575\"\\n7720,1,1,\"Maximum Tolerated Dose (MTD) of Gemcitabine\"\\n7721,1,1,\"Maximum Tolerated Dose (MTD) of Gemzar + Adriamycin Given with Velcade\"\\n7722,1,1,\"Maximum tolerated dose (MTD) of Genasense administered as a 2-hour IV infusion once a week (Part 1) and twice a week (Part 2) to patients with solid tumors\"\\n7723,1,1,\"Maximum tolerated dose (MTD) of GTI-2040 and gemcitabine hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0\"\\n7724,1,1,\"Maximum Tolerated Dose (MTD) of HA121-28 tablets in Advanced and/or Metastatic Cancer Refractory to Standard Treatment\"\\n7725,1,1,\"Maximum Tolerated Dose (MTD) of HAI Abraxane\"\\n7726,1,1,\"Maximum Tolerated Dose (MTD) of Head and Neck SBRT\"\\n7727,1,1,\"Maximum tolerated dose (MTD) of HIPEC carboplatin\"\\n7728,1,1,\"Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors\"\\n7729,1,1,\"Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2\"\\n7730,1,1,\"Maximum tolerated dose (MTD) of HR19024\"\\n7731,1,1,\"Maximum tolerated dose (MTD) of HRS-1167\"\\n7732,1,1,\"Maximum tolerated dose (MTD) of HS-10502ÔºàStage 1Ôºâ\"\\n7733,1,1,\"Maximum tolerated dose (MTD) of hVEGF26-104/RFASE\"\\n7734,1,1,\"Maximum tolerated dose (MTD) of Hydroxychloroquine (HCQ) in combination with Vorinostat in patients with advanced solid tumors\"\\n7735,1,1,\"Maximum tolerated dose (MTD) of hypofractionated radiosurgery defined as the highest dose level where a grade 3 or greater with an attribution score of ‚â• 3 develops in ‚â§ 2 of 6 patients in a dose group\"\\n7736,1,1,\"Maximum tolerated dose (MTD) of imatinib mesylate given concurrently with trastuzumab (Herceptin¬Æ) as measured by CTC v 3.0 at course 1\"\\n7737,1,1,\"Maximum tolerated dose (MTD) of imatinib mesylate, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n7738,1,1,\"Maximum Tolerated Dose (MTD) of IMC-RON8\"\\n7739,1,1,\"Maximum Tolerated Dose (MTD) of IMCgp100 Administered Weekly (Dose Escalation Part)\"\\n7740,1,1,\"Maximum Tolerated Dose (MTD) of IMGN901\"\\n7741,1,1,\"maximum tolerated dose (MTD) of IMM2902\"\\n7742,1,1,\"Maximum tolerated dose (MTD) of IMX-110 in patients with advanced solid tumors for evaluation in Phase 2a.\"\\n7743,1,1,\"Maximum Tolerated Dose (MTD) of Intraperitoneal (IP) tgDCC-E1A in combination with Intravenous (IV) Paclitaxel\"\\n7744,1,1,\"Maximum tolerated dose (MTD) of intraperitoneal carboplatin with intravenous paclitaxel, determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)\"\\n7745,1,1,\"Maximum Tolerated Dose (MTD) of Intratumoral Injection of Clostridium Novyi-NT with Pembrolizumab\"\\n7746,1,1,\"Maximum Tolerated Dose (MTD) of Ipatasertib\"\\n7747,2,1,\"Maximum Tolerated Dose (MTD) of Ipilimumab\"\\n7748,1,1,\"Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)\"\\n7749,2,1,\"Maximum Tolerated Dose (MTD) of Irinotecan\"\\n7750,1,1,\"Maximum Tolerated Dose (MTD) of ISIS 183750 in Advanced Solid Tumors\"\\n7751,1,1,\"Maximum Tolerated Dose (MTD) of Ixazomib and Erlotinib in Advanced Cancer Participants\"\\n7752,1,1,\"Maximum Tolerated Dose (MTD) of JI-101\"\\n7753,1,1,\"Maximum tolerated dose (MTD) of JS014\"\\n7754,1,1,\"Maximum Tolerated Dose (MTD) of Kevetrin\"\\n7755,1,1,\"Maximum tolerated dose (MTD) of KF-0210 alone [Tolerability]\"\\n7756,1,1,\"Maximum tolerated dose (MTD) of KM602, if any\"\\n7757,1,1,\"Maximum tolerated dose (MTD) of lapatinib in course 1\"\\n7758,1,1,\"Maximum Tolerated Dose (MTD) of LDE225 (Sonidegib) in Combination With Docetaxel\"\\n7759,3,1,\"Maximum Tolerated Dose (MTD) of Lenalidomide\"\\n7760,1,1,\"Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)\"\\n7761,1,1,\"Maximum tolerated dose (MTD) of lenvatinib in combination with everolimus: Phase 1\"\\n7762,1,1,\"Maximum Tolerated Dose (MTD) of Lipotecan\"\\n7763,1,1,\"Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib\"\\n7764,1,1,\"Maximum Tolerated Dose (MTD) of LOC-Paclitaxel\"\\n7765,1,1,\"Maximum tolerated dose (MTD) of low dose metronomic (LDM)Topotecan\"\\n7766,1,1,\"Maximum Tolerated Dose (MTD) of LY2510924\"\\n7767,1,1,\"Maximum Tolerated Dose (MTD) of LY3009120\"\\n7768,1,1,\"Maximum Tolerated Dose (MTD) of LY3022855\"\\n7769,1,1,\"Maximum Tolerated Dose (MTD) of LY3039478\"\\n7770,1,1,\"Maximum Tolerated Dose (MTD) of LY3076226\"\\n7771,1,1,\"Maximum Tolerated Dose (MTD) of MEDI-573\"\\n7772,1,1,\"Maximum Tolerated Dose (MTD) of MEDI0639\"\\n7773,1,1,\"Maximum Tolerated Dose (MTD) of MEDI6469\"\\n7774,1,1,\"Maximum Tolerated Dose (MTD) of MEHD7945A\"\\n7775,1,1,\"Maximum Tolerated Dose (MTD) of MGN1703 with Ipilimumab\"\\n7776,1,1,\"Maximum Tolerated Dose (MTD) of Mithramycin\"\\n7777,1,1,\"Maximum Tolerated Dose (MTD) of MK-2206 Administered Every Other Day (QOD) in Combination With Carboplatin and Paclitaxel\"\\n7778,1,1,\"Maximum Tolerated Dose (MTD) of MK1775 in Combination With 5-FU/CDDP Determined by Number of DLTs Per Dose Level: Locally Advanced or Metastatic Esophageal, Head and Neck, or Gastric Cancer\"\\n7779,1,1,\"Maximum Tolerated Dose (MTD) of MLN0264\"\\n7780,1,1,\"Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.\"\\n7781,1,1,\"Maximum Tolerated Dose (MTD) of Nab-Paclitaxel\"\\n7782,1,1,\"Maximum tolerated dose (MTD) of navitoclax\"\\n7783,2,2,\"Maximum tolerated dose (MTD) of NBM-BMX [Safety and Tolerability]\"\\n7784,1,1,\"Maximum Tolerated Dose (MTD) of NC-4016\"\\n7785,1,1,\"Maximum tolerated dose (MTD) of necitumumab combined with osimertinib\"\\n7786,1,1,\"Maximum Tolerated Dose (MTD) of nelfinavir\"\\n7787,1,1,\"Maximum Tolerated Dose (MTD) of NeoTCR-P1\"\\n7788,1,1,\"Maximum Tolerated Dose (MTD) of Neratinib\"\\n7789,1,1,\"Maximum Tolerated Dose (MTD) of Neratinib in Combination With Temsirolimus\"\\n7790,1,1,\"Maximum tolerated dose (MTD) of neratinib when given in combination with everolimus, palbociclib, or trametinib\"\\n7791,1,1,\"Maximum tolerated dose (MTD) of nintedanib\"\\n7792,1,1,\"Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities\"\\n7793,1,1,\"Maximum Tolerated Dose (MTD) of NM21-1480\"\\n7794,1,1,\"Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.\"\\n7795,1,1,\"Maximum tolerated dose (MTD) of O6-benzylguanine defined as the dose preceding that at which 3 of 6 or 4 of 12 patients experience dose-limiting toxicity\"\\n7796,1,1,\"Maximum tolerated dose (MTD) of OB318\"\\n7797,1,1,\"Maximum tolerated dose (MTD) of ON 01910.Na\"\\n7798,1,1,\"Maximum Tolerated Dose (MTD) of Onartuzumab with Chemoradiation Therapy and Erlotinib\"\\n7799,1,1,\"Maximum Tolerated Dose (MTD) of ONCR-177\"\\n7800,1,1,\"Maximum Tolerated Dose (MTD) of OPB-31121\"\\n7801,1,1,\"Maximum Tolerated Dose (MTD) of Oral BAY1143269 Alone and in Combination With Intravenous Docetaxel\"\\n7802,1,1,\"Maximum Tolerated Dose (MTD) of Oral Ixazomib\"\\n7803,1,1,\"Maximum tolerated dose (MTD) of Oraxol\"\\n7804,1,1,\"Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities\"\\n7805,1,1,\"Maximum tolerated dose (MTD) of osimertinib and minnelide\"\\n7806,1,1,\"Maximum Tolerated Dose (MTD) of Pasireotide in Combination With Docetaxel and Prednisone by the Occurrence of Adverse Events and the Associated Grade Per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0\"\\n7807,1,1,\"Maximum Tolerated Dose (MTD) of Pazopanib and Everolimus\"\\n7808,1,1,\"Maximum tolerated dose (MTD) of pazopanib and GSK1120212 when combined in patients with solid tumors\"\\n7809,1,1,\"Maximum Tolerated Dose (MTD) of Pazopanib in combination chemotherapy\"\\n7810,1,1,\"Maximum Tolerated Dose (MTD) of Pazopanib in Combination with Lapatinib or Trastuzumab\"\\n7811,1,1,\"Maximum Tolerated Dose (MTD) of PBF-1129\"\\n7812,1,1,\"Maximum Tolerated Dose (MTD) of PBF-509 as single agent\"\\n7813,1,1,\"Maximum tolerated dose (MTD) of pembrolizumab in combination with binimetinib using the standard 3+3 design (Phase I)\"\\n7814,1,1,\"Maximum tolerated dose (MTD) of peptide alarm therapy (PAT)\"\\n7815,1,1,\"Maximum Tolerated Dose (MTD) of perifosine + temsirolimus combination in children with cancer.\"\\n7816,1,1,\"Maximum Tolerated Dose (MTD) of perifosine monotherapy in children with cancer\"\\n7817,1,1,\"Maximum Tolerated Dose (MTD) of PF-00477736 When Administered in Combination With Gemcitabine\"\\n7818,1,1,\"Maximum Tolerated Dose (MTD) of Pictilisib\"\\n7819,1,1,\"Maximum Tolerated Dose (MTD) of PLX3397 Given in Combination With Standard Dose Eribulin in Participants With Metastatic Breast Cancer (Phase 1b)\"\\n7820,1,1,\"Maximum tolerated dose (MTD) of PMD-026\"\\n7821,1,1,\"Maximum tolerated dose (MTD) of prexasertib based on incidence of dose limiting toxicity assessed National Cancer Institute (NCI) CTCAE version 4.0\"\\n7822,1,1,\"Maximum Tolerated Dose (MTD) of PRGN-3007 (Group A)\"\\n7823,1,1,\"Maximum Tolerated Dose (MTD) of PRGN-3007 (Group B)\"\\n7824,1,1,\"Maximum tolerated dose (MTD) of PS-341 in combination with Doxil (Phase I)\"\\n7825,1,1,\"Maximum Tolerated Dose (MTD) of PTC299 within the tested dose range.\"\\n7826,1,1,\"Maximum Tolerated Dose (MTD) of PU-H71\"\\n7827,1,1,\"Maximum tolerated dose (MTD) of quinacrine dihydrochloride in combination of erlotinib hydrochloride determined by dose-limiting toxicities\"\\n7828,1,1,\"Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) for 10 Day Dosing\"\\n7829,1,1,\"Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) for 5 Day Dosing\"\\n7830,1,1,\"Maximum tolerated dose (MTD) of regorafenib in combination with cetuximab\"\\n7831,1,1,\"Maximum tolerated dose (MTD) of RO4929097 determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)\"\\n7832,2,2,\"Maximum Tolerated Dose (MTD) of RO6874281\"\\n7833,1,1,\"Maximum tolerated dose (MTD) of RP12146 in patients with locally advanced or metastatic solid tumors\"\\n7834,1,1,\"Maximum tolerated dose (MTD) of RP2\"\\n7835,1,1,\"Maximum Tolerated Dose (MTD) of S95005 when given in combination with oxaliplatin\"\\n7836,1,1,\"Maximum Tolerated Dose (MTD) of Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) in Combination\"\\n7837,1,1,\"Maximum tolerated dose (MTD) of SGI-110 plus cisplatin\"\\n7838,1,1,\"Maximum Tolerated Dose (MTD) of Short Infusion LMB-100 + Nab Paclitaxel\"\\n7839,1,1,\"Maximum tolerated dose (MTD) of SHR-1603\"\\n7840,1,1,\"Maximum Tolerated Dose (MTD) of Simvastatin\"\\n7841,1,1,\"Maximum Tolerated Dose (MTD) of Single Agent Metronomic Oral Topotecan\"\\n7842,1,1,\"Maximum Tolerated Dose (MTD) of SL-172154\"\\n7843,1,1,\"Maximum Tolerated Dose (MTD) of SL-172154 when administered intratumorally\"\\n7844,1,1,\"Maximum Tolerated Dose (MTD) of SL-279252\"\\n7845,1,1,\"Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use\"\\n7846,1,1,\"Maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab (Part A)\"\\n7847,1,1,\"Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin\"\\n7848,1,1,\"Maximum tolerated dose (MTD) of sorafenib tosylate, assessed using the NCI CTCAE v3.0 (Part 2)\"\\n7849,1,1,\"Maximum tolerated dose (MTD) of SSG in combination with IFN alpha2b\"\\n7850,1,1,\"Maximum Tolerated Dose (MTD) of ST1968 given I.V. once every week for 2 consecutive weeks every 3 weeks and MTD of ST1968 given I.V. once every 3 weeks\"\\n7851,1,1,\"Maximum tolerated dose (MTD) of STI-3031 that can be administered through the DoseConnect device\"\\n7852,1,1,\"Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15)\"\\n7853,1,1,\"maximum tolerated dose (MTD) of sunitinib\"\\n7854,1,1,\"Maximum Tolerated Dose (MTD) of Sunitinib and Temsirolimus\"\\n7855,2,2,\"Maximum Tolerated Dose (MTD) of T-1101 (Tosylate) in Participants with Advanced Cancers Refractory to Standard Therapy\"\\n7856,1,1,\"Maximum Tolerated Dose (MTD) of TAK-117\"\\n7857,1,1,\"Maximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b\"\\n7858,1,1,\"Maximum Tolerated Dose (MTD) of TAK-280\"\\n7859,1,1,\"Maximum tolerated dose (MTD) of talazoparib combined with irinotecan\"\\n7860,1,1,\"Maximum tolerated dose (MTD) of temozolomide combined with talazoparib\"\\n7861,1,1,\"Maximum tolerated dose (MTD) of temsirolimus\"\\n7862,1,1,\"Maximum Tolerated Dose (MTD) of Temsirolimus and Metformin\"\\n7863,1,1,\"Maximum Tolerated Dose (MTD) of Temsirolimus in Combination With Neratinib\"\\n7864,1,1,\"Maximum tolerated dose (MTD) of temsirolimus in combination with valproic acid\"\\n7865,1,1,\"Maximum tolerated dose (MTD) of TH1902.\"\\n7866,1,1,\"Maximum Tolerated Dose (MTD) of the combination (PBF-509+PDR001) treatment\"\\n7867,1,1,\"Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept\"\\n7868,1,1,\"Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine\"\\n7869,1,1,\"Maximum tolerated dose (MTD) of TKI258\"\\n7870,1,1,\"Maximum Tolerated Dose (MTD) of TPI 287\"\\n7871,1,1,\"Maximum Tolerated Dose (MTD) of Treatment with Regorafenib and Cetuximab\"\\n7872,1,1,\"Maximum tolerated dose (MTD) of TRX-818\"\\n7873,1,1,\"Maximum tolerated dose (MTD) of TRX-818 in Asians\"\\n7874,1,1,\"Maximum Tolerated Dose (MTD) of Vanucizumab\"\\n7875,1,1,\"Maximum tolerated dose (MTD) of vatalanib and everolimus\"\\n7876,1,1,\"Maximum tolerated dose (MTD) of vemurafenib\"\\n7877,1,1,\"Maximum Tolerated Dose (MTD) of Vemurafenib with Carboplatin and Paclitaxel\"\\n7878,1,1,\"Maximum tolerated dose (MTD) of vinflunine and continuously dosed erlotinib\"\\n7879,1,1,\"Maximum tolerated dose (MTD) of vinflunine and intermittently dosed erlotinib\"\\n7880,1,1,\"Maximum tolerated dose (MTD) of vinflunine and pemetrexed disodium\"\\n7881,2,1,\"Maximum Tolerated Dose (MTD) of Volasertib\"\\n7882,1,1,\"Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib\"\\n7883,1,1,\"Maximum tolerated dose (MTD) of vorinostat as assessed by NCI CTCAE v3.0\"\\n7884,1,1,\"Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma\"\\n7885,1,1,\"Maximum Tolerated Dose (MTD) of VSV-IFNŒ≤-NIS Monotherapy and Combination Therapy\"\\n7886,1,1,\"Maximum Tolerated Dose (MTD) of WT2725 Based on the Evaluation of Dose-limiting Toxicity (DLT)\"\\n7887,1,1,\"Maximum Tolerated Dose (MTD) of ZACTIMA (ZD6474) in combination with Gemcitabine and Capecitabine\"\\n7888,1,1,\"Maximum Tolerated Dose (MTD) of3D011-08\"\\n7889,1,1,\"Maximum tolerated dose (MTD) or a tolerated dose below MTD (if MTD is not reached)\"\\n7890,1,1,\"Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE)\"\\n7891,1,1,\"Maximum Tolerated Dose (MTD) or maximally administered dose (MAD) for ABBV-399\"\\n7892,1,1,\"Maximum tolerated dose (MTD) or Maximum administered dose (MAD)\"\\n7893,1,1,\"Maximum tolerated dose (MTD) or maximum administered dose (MAD)\"\\n7894,2,2,\"Maximum tolerated dose (MTD) or maximum administered dose (MAD) of BAY2416964\"\\n7895,1,1,\"Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib\"\\n7896,1,1,\"Maximum tolerated dose (MTD) or maximum administered dose (MAD) within the DLT observation period\"\\n7897,1,1,\"Maximum tolerated dose (MTD) or maximum administered dose (MAD).\"\\n7898,4,2,\"Maximum tolerated dose (MTD) or maximum administrated dose (MAD)\"\\n7899,1,1,\"Maximum tolerated dose (MTD) or Maximum climbing dose (MAD) of Hemay181\"\\n7900,1,1,\"Maximum Tolerated Dose (MTD) or Maximum Feasible Dose\"\\n7901,1,1,\"Maximum tolerated dose (MTD) or Maximum feasible dose (MFD) and determination of the recommended Phase 2 dose (RP2D) of TBio-6517 alone and in combination with pembrolizumab.\"\\n7902,1,1,\"Maximum Tolerated Dose (MTD) or Optimal Biological Dose (OBD) of RO5479599\"\\n7903,1,1,\"Maximum Tolerated Dose (MTD) or Optimal Biological Effect Dose (OBD) and Phase II study recommended dose (RP2D)\"\\n7904,1,1,\"Maximum tolerated dose (MTD) or recommended clinical dose\"\\n7905,1,1,\"Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat\"\\n7906,1,1,\"Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)\"\\n7907,1,1,\"Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) (Phase I dose escalation)\"\\n7908,1,1,\"Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181\"\\n7909,1,1,\"Maximum tolerated dose (MTD) or recommended phase 2 dose of PI3K inhibitor BKM120\"\\n7910,1,1,\"Maximum Tolerated dose (MTD) or recommended phase Ib dose of low-dose irradiation for radio-immunotherapy combination (RP1bD).\"\\n7911,1,1,\"Maximum tolerated dose (MTD) or relevant biological dose (RBD) in the absence of MTD\"\\n7912,1,1,\"Maximum Tolerated Dose (MTD) PXD101\"\\n7913,1,1,\"Maximum Tolerated Dose (MTD) Recommended Dose (RD)\"\\n7914,1,1,\"Maximum Tolerated Dose (MTD) Recommended for Phase 2 Dose of Aerosol Gemcitabine (GCB)\"\\n7915,1,1,\"Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level\"\\n7916,1,1,\"Maximum tolerated dose (MTD))/recommended phase 2 dose of trigriluzole\"\\n7917,1,1,\"Maximum tolerated dose (MTD), based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0\"\\n7918,1,1,\"Maximum tolerated dose (MTD), based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0\"\\n7919,1,1,\"Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 is Below 20%\"\\n7920,1,1,\"Maximum tolerated dose (MTD), if present.\"\\n7921,1,1,\"Maximum Tolerated Dose (MTD), if reached.\"\\n7922,1,1,\"Maximum tolerated dose (MTD), or the maximum tested dose at which multiple DLTs are not observed, of RGX-104 as a single agent, and separately, in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.\"\\n7923,1,1,\"Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D)\"\\n7924,1,1,\"Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702\"\\n7925,1,1,\"Maximum tolerated dose (MTD),RP2D\"\\n7926,1,1,\"Maximum Tolerated Dose (MTD)- Cohorts A, B, C, and D\"\\n7927,1,1,\"Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789\"\\n7928,1,1,\"Maximum tolerated dose (MTD)/maximum administered dose (MAD) (dose escalation)\"\\n7929,1,1,\"Maximum Tolerated Dose (MTD)/Recommended Dose\"\\n7930,1,1,\"Maximum tolerated dose (MTD)/Recommended dose (RD)\"\\n7931,1,1,\"Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1\"\\n7932,1,1,\"Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of GDC-0927\"\\n7933,1,1,\"Maximum tolerated dose (MTD)/RP2D of LCL161 when administered in combination with once weekly paclitaxel\"\\n7934,1,1,\"Maximum tolerated dose (MTD): Dose Escalation Stage\"\\n7935,1,1,\"Maximum tolerated dose (MTD): Frequency of Dose Limiting Toxicities (DLTs) at each dose level during the DLT observation period for Cycle 1\"\\n7936,1,1,\"Maximum Tolerated Dose (MTD): Part 1\"\\n7937,1,1,\"Maximum Tolerated Dose (MTD): The highest dose that does not cause unacceptable side effects\"\\n7938,1,1,\"Maximum Tolerated Dose (MTD)of CP-751,871 in Combination With Paclitaxel and Carboplatin: Phase 1b\"\\n7939,1,1,\"Maximum tolerated dose (MTD)of oral HMPL-295S1.\"\\n7940,1,1,\"Maximum Tolerated Dose (MTD, if available)\"\\n7941,1,1,\"Maximum tolerated dose (MTD, if possible) and the recommended phase 2 dose (RP2D)\"\\n7942,5,4,\"Maximum Tolerated Dose (MTDÔºâ\"\\n7943,6,5,\"Maximum tolerated dose (MTDÔºâ\"\\n7944,1,1,\"Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs\"\\n7945,1,1,\"Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of Dose Limiting Toxicities (DLTs)\"\\n7946,1,1,\"Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of vital signs and abnormal laboratory parameters\"\\n7947,1,1,\"Maximum Tolerated Dose (Part 1 Only)\"\\n7948,2,2,\"Maximum tolerated dose (Part 1)\"\\n7949,2,1,\"Maximum Tolerated Dose (Phase 1)\"\\n7950,7,1,\"Maximum Tolerated Dose (Phase I)\"\\n7951,9,2,\"Maximum tolerated dose (Phase I)\"\\n7952,1,1,\"Maximum tolerated dose (Stage 1)\"\\n7953,1,1,\"Maximum tolerated dose / Recommended Phase 2 dose; Tolerability\"\\n7954,1,1,\"Maximum tolerated dose and dose limiting toxicity.\"\\n7955,2,2,\"Maximum tolerated dose and dose-limiting toxicities as determined in Part A.\"\\n7956,1,1,\"Maximum tolerated dose and dose-limiting toxicity of ixabepilone\"\\n7957,1,1,\"Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I)\"\\n7958,3,2,\"Maximum Tolerated Dose and Recommended Phase 2 Dose\"\\n7959,1,1,\"Maximum tolerated dose and recommended phase 2 dose (RP2D)\"\\n7960,1,1,\"Maximum tolerated dose and recommended phase 2 dose of talazoparib seven day schedule\"\\n7961,1,1,\"Maximum tolerated dose and recommended phase 2 dose of talazoparib three day schedule\"\\n7962,3,1,\"Maximum tolerated dose and recommended phase II dose\"\\n7963,1,1,\"Maximum tolerated dose and recommended phase II dose of liposomal irinotecan in combination with veliparib\"\\n7964,1,1,\"Maximum tolerated dose and recommended phase II dose of metformin hydrochloride when administered with temsirolimus\"\\n7965,1,1,\"Maximum tolerated dose and recommended Phase II dose of this combination in patients with advanced solid tumours.\"\\n7966,1,1,\"Maximum tolerated dose and recommended phase II dose of vorinostat and decitabine\"\\n7967,1,1,\"Maximum Tolerated Dose and Safety\"\\n7968,1,1,\"Maximum tolerated dose and the recommended phase II doses of mFOLFOX given in combination with alisertib, defined as the dose level at which the probability of dose limiting toxicities is 30%\"\\n7969,1,1,\"Maximum tolerated dose and toxicity as assessed by NCI CTC v2.0 (Phase I) (Phase I closed to accrual as of 4/15/05)\"\\n7970,1,1,\"Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range\"\\n7971,1,1,\"Maximum tolerated dose and/or recommended phase 2 dose of cord blood-derived expanded allogeneic natural killer (NK) cells following chemotherapy\"\\n7972,1,1,\"Maximum tolerated dose and/or Recommended Phase 2 Dose:\"\\n7973,1,1,\"Maximum tolerated dose and/or recommended phase II dose\"\\n7974,1,1,\"Maximum Tolerated Dose and/or the recommended Phase II dose of AG-120 in subjects with advanced solid tumors, including glioma\"\\n7975,1,1,\"Maximum Tolerated Dose and/or the recommended Phase II dose of AG881 in patients with advance solid tumors, including gliomas\"\\n7976,1,1,\"Maximum tolerated dose as assessed by NCI CTCAE v.30\"\\n7977,1,1,\"Maximum tolerated dose as assessed by NCI CTCAE v3.0\"\\n7978,1,1,\"Maximum tolerated dose as measured by frequency of dose limiting toxicities\"\\n7979,1,1,\"Maximum tolerated dose based on dose-limiting toxicity using the Common Toxicity Criteria\"\\n7980,1,1,\"Maximum tolerated dose by assessing dose-limiting toxicities (DLTs)\"\\n7981,1,1,\"Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n7982,1,1,\"Maximum tolerated dose defined as the highest dose tested in which none or only one patient experienced dose limiting toxicities as measured by Common Toxicity Criteria\"\\n7983,1,1,\"Maximum tolerated dose defined as the maximum dose at which fewer than 1/3 patients experience dose-limiting toxicities (DLT) graded according to CTCAE\"\\n7984,1,1,\"Maximum tolerated dose defined based on the dose-limiting toxicities graded according to Common Terminology Criteria for Adverse Events v3.0\"\\n7985,1,1,\"Maximum tolerated dose defined for the combination of trametinib, and Trifluridine and Tipiracil Hydrochloride (TAS?102) as the highest dose level at which 0-1 out of 6 patients experience dose limiting toxicities\"\\n7986,2,1,\"Maximum tolerated dose determined by dose-limiting toxicities\"\\n7987,1,1,\"Maximum tolerated dose determined by dose-limiting toxicities assessed using the NCI Common Toxicity Criteria (CTC) version 2.0\"\\n7988,1,1,\"Maximum tolerated dose determined by dose-limiting toxicities graded according to CTC 2.0 toxicity criteria\"\\n7989,1,1,\"Maximum tolerated dose determined by dose-limiting toxicity\"\\n7990,1,1,\"Maximum tolerated dose determined by dose-limiting toxicity graded according to the NCI CTCAE version 4.0\"\\n7991,1,1,\"Maximum tolerated dose determined by incidence of dose limiting toxicity.\"\\n7992,1,1,\"Maximum Tolerated Dose During Cycle 1 Treatment\"\\n7993,1,1,\"Maximum tolerated dose for phase II (Phase Ib)\"\\n7994,1,1,\"Maximum Tolerated Dose for RO4929097\"\\n7995,1,1,\"Maximum tolerated dose for up to 90 days after completion of study treatment\"\\n7996,2,1,\"Maximum tolerated dose in combination with azacitidine\"\\n7997,1,1,\"Maximum tolerated dose in mg/m2 based on the dose-limiting adverse events that occur\"\\n7998,2,2,\"Maximum Tolerated Dose in Phase I\"\\n7999,1,1,\"Maximum Tolerated Dose in Phase I Portion of Study\"\\n8000,1,1,\"Maximum tolerated dose of 4-HPR/LXS oral powder\"\\n8001,1,1,\"Maximum Tolerated Dose of ABBV-075\"\\n8002,1,1,\"Maximum tolerated dose of ABBV-221\"\\n8003,1,1,\"Maximum tolerated dose of AEG35156 in combination with docetaxel\"\\n8004,1,1,\"Maximum tolerated dose of Akt inhibitor MK-2206\"\\n8005,1,1,\"Maximum tolerated dose of alvespimycin hydrochloride\"\\n8006,1,1,\"Maximum tolerated dose of AMV564 in subjects with advanced solid tumors\"\\n8007,1,1,\"Maximum tolerated dose of anti-SEMA4D monoclonal antibody VX15/2503 determined by dose limiting toxicity assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n8008,1,1,\"Maximum tolerated dose of Aurora kinase inhibitor AT9283 (AT9283)\"\\n8009,1,1,\"Maximum Tolerated Dose of AZD5312 in pts with advanced solid tumours where androgen receptor pathway is a potential factor.\"\\n8010,1,1,\"Maximum tolerated dose of BAY1082439\"\\n8011,1,1,\"Maximum Tolerated Dose of Bevacizumab , Based on Incidence of Dose-limiting Toxicity (DLT) Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)\"\\n8012,1,1,\"Maximum tolerated dose of bevacizumab when used in combination with erlotinib hydrochloride determined by dose-limiting toxicities (Phase I)\"\\n8013,1,1,\"Maximum tolerated dose of BEZ235 given twice daily\"\\n8014,1,1,\"Maximum tolerated dose of BIBF 1120\"\\n8015,1,1,\"Maximum tolerated dose of biweekly alvocidib when given in conjunction with oxaliplatin, 5-fluorouracil, and leucovorin calcium\"\\n8016,1,1,\"maximum tolerated dose of BMS-599626\"\\n8017,1,1,\"Maximum tolerated dose of BMS-754807 administered orally (daily schedule) in combination with cetuximab administered standard doses IV (weekly basis) will be determined by observation of dose limiting toxicities during the first 33 days of administration\"\\n8018,1,1,\"Maximum tolerated dose of bortezomib and gemcitabine\"\\n8019,1,1,\"Maximum tolerated dose of BYL719 in combination with letrozole\"\\n8020,1,1,\"Maximum tolerated dose of CA91hu-1\"\\n8021,1,1,\"Maximum Tolerated Dose of Cabazitaxel With Concurrent Adjuvant Radiation\"\\n8022,1,1,\"maximum tolerated dose of cabozantinib plus 13-cis-retinoic acid\"\\n8023,1,1,\"Maximum tolerated dose of capecitabine\"\\n8024,1,1,\"Maximum Tolerated Dose of Cediranib in Combination With Cisplatin and Pemetrexed (Phase I)\"\\n8025,1,1,\"Maximum tolerated dose of Ceramide NanoLiposome in patients with advanced solid tumors.\"\\n8026,1,1,\"Maximum tolerated dose of cetuximab\"\\n8027,1,1,\"Maximum tolerated dose of chloroquine when combined with Carboplatin/Gemcitabine\"\\n8028,1,1,\"Maximum tolerated dose of combination crizotinib and dasatinib in stratum A patients\"\\n8029,1,1,\"Maximum tolerated dose of combination crizotinib and dasatinib in stratum B patients\"\\n8030,1,1,\"Maximum tolerated dose of combination therapy of dabrafenib and trametinib administered concurrently with intensity-modulated radiation therapy (IMRT)\"\\n8031,1,1,\"Maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity\"\\n8032,1,1,\"Maximum tolerated dose of dexrazoxane hydrochloride and cisplatin\"\\n8033,1,1,\"Maximum Tolerated Dose of DMUC4064A\"\\n8034,1,1,\"Maximum tolerated dose of DMXAA\"\\n8035,1,1,\"Maximum tolerated dose of dovitinib lactate, defined as the highest dose level at which < 33% of patients experience study treatment-related dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0\"\\n8036,1,1,\"Maximum tolerated dose of Doxil in combination with PSC 833\"\\n8037,2,1,\"Maximum tolerated dose of EGFRBi-armed autologous activated T-cells\"\\n8038,1,1,\"Maximum tolerated dose of entinostat and isotretinoin in combination\"\\n8039,1,1,\"Maximum tolerated dose of eribulin mesylate administered with gemcitabine hydrochloride in advanced/metastatic solid tumors\"\\n8040,1,1,\"Maximum tolerated dose of erlotinib hydrochloride defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients\"\\n8041,1,1,\"Maximum Tolerated Dose of ES414\"\\n8042,1,1,\"Maximum tolerated dose of everolimus (Phase I)\"\\n8043,1,1,\"Maximum tolerated dose of everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)\"\\n8044,1,1,\"Maximum tolerated dose of everolimus in combination with sequential fluorouracil (5-FU) and leucovorin calcium, panitumumab, modified 5-FU, leucovorin calcium, and oxaliplatin (mFOLFOX6), and mFOLFOX6 with panitumumab\"\\n8045,1,1,\"Maximum tolerated dose of gemcitabine hydrochloride and capecitabine when combined with imatinib mesylate\"\\n8046,1,1,\"Maximum tolerated dose of high-selenium Brassica juncea, irinotecan hydrochloride and capecitabine\"\\n8047,1,1,\"Maximum tolerated dose of HLX10\"\\n8048,1,1,\"Maximum tolerated dose of HLX20 in solid tumors patients\"\\n8049,1,1,\"maximum tolerated dose of HLX23\"\\n8050,1,1,\"Maximum Tolerated Dose of HS-10381\"\\n8051,1,1,\"Maximum Tolerated Dose of HS-20089\"\\n8052,1,1,\"Maximum Tolerated Dose of HSP990 in patients treated once weekly or twice weekly\"\\n8053,3,2,\"Maximum tolerated dose of hydroxychloroquine\"\\n8054,1,1,\"maximum tolerated dose of hypofractionated RT\"\\n8055,1,1,\"Maximum tolerated dose of imatinib when given together with bevacizumab and metronomic cyclophosphamide\"\\n8056,1,1,\"Maximum Tolerated Dose of IMC-11F8\"\\n8057,1,1,\"Maximum Tolerated Dose of Irinotecan in Advanced Solid Tumors\"\\n8058,1,1,\"Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n8059,1,1,\"Maximum tolerated dose of IT-141 administered once every 2 weeks in patients with refractory solid tumors\"\\n8060,1,1,\"Maximum tolerated dose of lapatinib and everolimus (Part I)\"\\n8061,1,1,\"Maximum tolerated dose of lenalidomide\"\\n8062,1,1,\"Maximum Tolerated Dose of Lenalidomide Administered in Combination With Oral Cyclophosphamide (Phase I)\"\\n8063,1,1,\"Maximum tolerated dose of lenolidomide defined as the maximum dose at which fewer than one-third of patients experience DLT\"\\n8064,1,1,\"Maximum tolerated dose of LTLD\"\\n8065,1,1,\"Maximum tolerated dose of metformin + chloroquine\"\\n8066,1,1,\"Maximum tolerated dose of methoxyamine\"\\n8067,1,1,\"Maximum Tolerated Dose of MK-2206 in Combination With Trastuzumab (Part 1) and With Trastuzumab/Lapatinib (Part 2)\"\\n8068,1,1,\"Maximum Tolerated Dose of Monthly Cytotoxic Intraarterial Hepatic Paclitaxel\"\\n8069,1,1,\"Maximum Tolerated Dose of Nab-paclitaxel When Combined Concurrently With Carboplatin and Radiation (Phase I)\"\\n8070,1,1,\"Maximum tolerated dose of nivolumab\"\\n8071,1,1,\"Maximum tolerated dose of NK012 in patients with UGT1A1*28 (wt/wt and wt/*28) genotype\"\\n8072,1,1,\"Maximum tolerated dose of olaparib and radium Ra 223 dichloride\"\\n8073,1,1,\"Maximum tolerated dose of onalespib and CDKI AT7519\"\\n8074,1,1,\"Maximum tolerated dose of onalespib in combination with dabrafenib and trametinib, defined as the highest dose level at which 0 or 1 of six patients has experienced a dose limiting toxicity\"\\n8075,1,1,\"Maximum Tolerated Dose of ONC201 With Nivolumab for Phase II\"\\n8076,1,1,\"Maximum tolerated dose of oral 3-AP determined by dose-limiting toxicities graded according to the NCI CTCAE version 3.0\"\\n8077,1,1,\"Maximum tolerated dose of PACE as first-line therapy\"\\n8078,1,1,\"Maximum tolerated dose of paclitaxel in combination with bortezomib\"\\n8079,1,1,\"Maximum Tolerated Dose of Paclitaxel When T-DM1 (Q3W or QW) and Paclitaxel (QW) Was Administered With and Without Pertuzumab\"\\n8080,1,1,\"Maximum tolerated dose of Pazopanib when used in combination with Carboplatin\"\\n8081,1,1,\"Maximum tolerated dose of pembrolizumab and non-stereotactic wide-field radiation therapy (Phase I)\"\\n8082,1,1,\"Maximum tolerated dose of pembrolizumab and stereotactic body radiation therapy (Phase I)\"\\n8083,1,1,\"Maximum Tolerated Dose of Plinabulin and Nivolumab (Phase I)\"\\n8084,2,2,\"Maximum tolerated dose of PR-104\"\\n8085,1,1,\"Maximum Tolerated Dose of Preoperative Gemcitabine with External-Beam Radiation Therapy\"\\n8086,1,1,\"Maximum tolerated dose of PRL3-zumab, defined as the highest dose level at which < 33% of 6 patients experience a dose-limiting toxicity graded according to Common Terminology Criteria for Adverse Events version 4 (Phase I)\"\\n8087,1,1,\"Maximum tolerated dose of PXD101 in combination with bortezomib\"\\n8088,1,1,\"Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC).\"\\n8089,1,1,\"Maximum tolerated dose of RAD001, in combination with R1507 (Part 1\"\\n8090,1,1,\"Maximum Tolerated dose of RC108\"\\n8091,1,1,\"Maximum Tolerated dose of RC98\"\\n8092,1,1,\"Maximum tolerated dose of recombinant interferon alfa-2b when administered in combination with 5-azacitidine\"\\n8093,1,1,\"Maximum tolerated dose of riluzole\"\\n8094,1,1,\"Maximum tolerated dose of RNR inhibitor COH29, defined as the dose level with no more than 1 dose limiting toxicity (DLT) in the first 6 patients at a dose level below a dose level with DLT in 2 of 6 patients, graded according to CTCAE version 4.0\"\\n8095,1,1,\"Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0\"\\n8096,1,1,\"Maximum tolerated dose of ropidoxuridine\"\\n8097,1,1,\"Maximum Tolerated Dose of RTA 402\"\\n8098,1,1,\"Maximum Tolerated dose of Ruxolitinib in combination with Trastuzumab (Phase I)\"\\n8099,1,1,\"Maximum tolerated dose of sapanisertib in combination with osimertinib in patients with EGFRmutant (m) non-small cell lung cancer (NSCLC)\"\\n8100,1,1,\"Maximum tolerated dose of SBP-101\"\\n8101,1,1,\"Maximum tolerated dose of selumetinib in combination with cixutumumab defined as the dose produced DLT in =< 1 out of 6 patients\"\\n8102,1,1,\"Maximum tolerated dose of siRNA-transfected peripheral blood mononuclear cells APN401, defined as the dose in which the number of patients with dose limiting toxicity is less than or equal to one out of six\"\\n8103,1,1,\"Maximum Tolerated Dose of SLC-391\"\\n8104,1,1,\"Maximum tolerated dose of sorafenib tosylate\"\\n8105,1,1,\"Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)\"\\n8106,1,1,\"Maximum Tolerated Dose of SRA737\"\\n8107,1,1,\"Maximum tolerated dose of SRA737 administered in combination with gemcitabine\"\\n8108,1,1,\"Maximum tolerated dose of stereotactic body radiotherapy (SBRT)\"\\n8109,1,1,\"Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given as a boost in combination with cisplatin and intensity modulated radiation therapy (IMRT)\"\\n8110,1,1,\"Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given for disease metastatic to the head and neck\"\\n8111,1,1,\"Maximum tolerated dose of stereotactic radiosurgery as assessed by NCI CTCAE v3.0\"\\n8112,1,1,\"Maximum Tolerated Dose of Sunitinib (Phase I)\"\\n8113,1,1,\"Maximum Tolerated Dose of T-DM1 When T-DM1 (Q3W or QW) and Paclitaxel (QW) Was Administered With and Without Pertuzumab\"\\n8114,1,1,\"Maximum tolerated dose of talotrexin\"\\n8115,1,1,\"Maximum tolerated dose of tanespimycin\"\\n8116,1,1,\"Maximum tolerated dose of TAS-114 when used in combination with S-1\"\\n8117,1,1,\"Maximum Tolerated Dose of Temozolomide in Combination with Fixed Doses of Paclitaxel and Carboplatin\"\\n8118,1,1,\"Maximum tolerated dose of temsirolimus in combination with pazopanib\"\\n8119,1,1,\"Maximum tolerated dose of the combination of bosutinib and pemetrexed\"\\n8120,1,1,\"Maximum tolerated dose of the combination of intravenous decitabine with oral genistein for children with refractory or recurrent solid malignancies and leukemia\"\\n8121,1,1,\"Maximum tolerated dose of TNF-bound colloidal gold (CYT-6091)\"\\n8122,1,1,\"Maximum tolerated dose of tomotherapy up to 12 Gy\"\\n8123,1,1,\"Maximum tolerated dose of topotecan hydrochloride and veliparib, determined according to incidence of dose-limiting toxicity, graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)\"\\n8124,1,1,\"Maximum tolerated dose of trametinib\"\\n8125,1,1,\"Maximum Tolerated Dose of TTI-101\"\\n8126,1,1,\"Maximum tolerated dose of UCN-01 when combined with carboplatin determined by dose-limiting toxicities graded according to NCI Common Toxicity Criteria (CTC)\"\\n8127,1,1,\"Maximum tolerated dose of vandetanib and temozolomide\"\\n8128,1,1,\"Maximum Tolerated Dose of VEGF Trap (Phase I)\"\\n8129,1,1,\"Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride\"\\n8130,1,1,\"Maximum Tolerated Dose of Veliparib When Given Concurrently With Standard Carboplatin/Paclitaxel and Radiotherapy, Determined According to Incidence of Dose Limiting Toxicity (DLT) (Phase I)\"\\n8131,1,1,\"Maximum tolerated dose of vemurafenib defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33% as graded by the National Cancer Institute Common Toxicity Criteria version 4.0\"\\n8132,1,1,\"Maximum tolerated dose of vinblastine in combination with sirolimus\"\\n8133,2,1,\"Maximum Tolerated Dose of Volasertib\"\\n8134,2,1,\"Maximum tolerated dose of vorinostat\"\\n8135,1,1,\"Maximum Tolerated Dose of Vorinostat in Combination With Isotretinoin\"\\n8136,1,1,\"Maximum tolerated dose of vorinostat when administered in combination with a fixed dose of weekly flavopiridol\"\\n8137,1,1,\"Maximum tolerated dose of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib phosphate)\"\\n8138,1,1,\"Maximum tolerated dose of XK469 in pediatric patients with advanced neuroblastoma\"\\n8139,1,1,\"Maximum Tolerated dose of ZV0203\"\\n8140,1,1,\"Maximum tolerated dose or maximum administered dose\"\\n8141,1,1,\"Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only)\"\\n8142,1,1,\"Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated\"\\n8143,2,1,\"Maximum tolerated dose or recommended Phase 2 dose\"\\n8144,1,1,\"Maximum tolerated dose or recommended phase 2 dose\"\\n8145,1,1,\"Maximum Tolerated Dose Per Fraction of Radiation\"\\n8146,9,5,\"Maximum Tolerated Dose(MTD)\"\\n8147,1,1,\"Maximum tolerated Dose(MTD)\"\\n8148,11,7,\"Maximum tolerated dose(MTD)\"\\n8149,3,1,\"maximum tolerated dose(MTD)\"\\n8150,1,1,\"Maximum tolerated dose(MTD) / Maximum feasible dose (MFD)\"\\n8151,1,1,\"Maximum Tolerated Dose(MTD) of GDC-0941 and Recommended Phase II Dose of GDC-0941 Given in Combination With Cisplatin. - (Phase Ib)\"\\n8152,1,1,\"Maximum tolerated dose(MTD) of Mogamulizumab\"\\n8153,2,2,\"Maximum tolerated dose(MTD) or recommended phase2 doseÔºàRP2DÔºâ\"\\n8154,1,1,\"Maximum tolerated dose(MTD)(If any)\"\\n8155,1,1,\"Maximum Tolerated Dose(MTD)and Dose Limiting(DLT) -phase I\"\\n8156,1,1,\"Maximum tolerated dose(MTD)of paclitaxel liposome injection\"\\n8157,1,1,\"Maximum Tolerated Dose(s)\"\\n8158,1,1,\"Maximum Tolerated Dose(s) (MTD) Identified at Different Dosing Schedules\"\\n8159,1,1,\"Maximum Tolerated Dose(s) MTD(s) of BLYG8824A\"\\n8160,1,1,\"Maximum tolerated dose, defined as one dose level below the dose that induces DLT in more than 1/6 patients\"\\n8161,1,1,\"Maximum tolerated dose, defined as the dose at which no more than 1/6 patients develops dose-limiting toxicity, graded by NCI CTCAE version 4.0\"\\n8162,1,1,\"Maximum tolerated dose, defined as the dose below the dose where at least 2 dose limiting toxicities (DLTs) are observed, graded using CTCAE v4\"\\n8163,1,1,\"Maximum tolerated dose, defined as the highest dose at which no more than 1/6 patients experiences dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n8164,1,1,\"Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT during the initial 2 courses of therapy, graded according to NCI CTCAE version 3.0\"\\n8165,1,1,\"Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT, graded according to NCI CTCAE version 3.0\"\\n8166,1,1,\"Maximum tolerated dose, determined by the number of patients who experience a dose limiting toxicity\"\\n8167,3,2,\"Maximum tolerated dose, measured by adverse event profile\"\\n8168,6,3,\"Maximum Tolerated Dose, MTD\"\\n8169,1,1,\"Maximum tolerated dose, overall toxicity incidence, and toxicity profiles of AFP464 in the treatment of solid tumors\"\\n8170,1,1,\"Maximum tolerated dose/ recommended phase II dose\"\\n8171,1,1,\"Maximum tolerated dose/recommended phase 2 dose\"\\n8172,1,1,\"Maximum Tolerated Dose/Recommended Phase 2 Dose of gamma delta T cells\"\\n8173,1,1,\"Maximum Tolerated Dose/Recommended Phase 2 Dose of Pamiparib in Combination with 5 Fluorouracil-Hydroxea (FHX) and Tislelizumab\"\\n8174,1,1,\"Maximum tolerated dose/recommended phase II dose of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in combination (dose-escalation)\"\\n8175,1,1,\"Maximum tolerated dose/Recommended Phase ‚Ö° Dose(MTD/RP2D)\"\\n8176,2,2,\"Maximum tolerated dose: Measured by adverse event profile\"\\n8177,1,1,\"Maximum Tolerated Dose: the highest dose at which no more than 1 out of 6 patients experiences Dose Limiting Toxicity (DLT) during Cycle 1.\"\\n8178,3,1,\"Maximum tolerated dosed (MTD)\"\\n8179,1,1,\"Maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine\"\\n8180,1,1,\"Maximum Tolerated Doses (MTD) of MLN9708 and Vorinostat\"\\n8181,1,1,\"Maximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib When Administered in Combination in DES\"\\n8182,1,1,\"Maximum Tolerated Doses (MTDs)\"\\n8183,1,1,\"Maximum Tolerated Doses (MTDs) in Combination of Cobimetinib and Ipatasertib During Dose-Escalation Stage 1\"\\n8184,1,1,\"Maximum tolerated doses and recommended phase 2 dose of peposertib (M3814) in combination with hypofractionated radiation and avelumab (Phase I)\"\\n8185,1,1,\"maximum tolerated doses of drugs in combination\"\\n8186,1,1,\"Maximum tolerated doses of vorinostat (SAHA) and capecitabine\"\\n8187,3,2,\"Maximum Tolerated DoseÔºàMTDÔºâ\"\\n8188,4,3,\"Maximum tolerated doseÔºàMTDÔºâ\"\\n8189,1,1,\"Maximum tolerated infusion time for high-dose methotrexate\"\\n8190,1,1,\"Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I)\"\\n8191,1,1,\"Maximum tolerated or administered dose (MTD, MAD)\"\\n8192,1,1,\"Maximum tolerated total dose of stereotactic body radiation to patients with resectable or borderline resectable pancreas cancer following FOLFIRINOX chemotherapy\"\\n8193,2,1,\"Maximum tolerated volume\"\\n8194,1,1,\"Maximum-tolerated (MTD) dose of veliparib in combination with oxaliplatin and capecitabine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n8195,10,2,\"Maximum-tolerated dose\"\\n8196,3,2,\"Maximum-Tolerated Dose (MTD)\"\\n8197,6,1,\"Maximum-tolerated dose (MTD)\"\\n8198,1,1,\"maximum-tolerated dose (MTD)\"\\n8199,1,1,\"Maximum-tolerated dose (MTD) based on the incidence of DLT\"\\n8200,1,1,\"Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0\"\\n8201,1,1,\"Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Toxicity Criteria (CTC) version 2.0\"\\n8202,1,1,\"Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by NCI CTCAE version 3.0\"\\n8203,1,1,\"Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by the Common Terminology Criteria (CTC) version 2.0\"\\n8204,1,1,\"Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT) as assessed by the NCI Common Toxicity Criteria (CTC) version 2.0\"\\n8205,1,1,\"Maximum-tolerated dose (MTD) defined as the highest dose level where 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0\"\\n8206,1,1,\"Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than or equal to 1 out of 6 patients have DLTs using NCI CTCAE version 4.0\"\\n8207,1,1,\"Maximum-tolerated dose (MTD) defined as the those below that results in dose-limiting toxicity (DLT) in >= 2 of 6 new patients, as assessed by CTCAE version 3.0\"\\n8208,1,1,\"Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib.\"\\n8209,1,1,\"Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib.\"\\n8210,1,1,\"Maximum-tolerated dose (MTD) of combination ALIMTA and Taxotere\"\\n8211,1,1,\"Maximum-tolerated dose (MTD) of copanlisib and olaparib\"\\n8212,1,1,\"Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n8213,1,1,\"Maximum-Tolerated Dose (MTD) of GSK2636771 in Combination with Pembrolizumab in Participants with Metastatic Melanoma and PTEN Loss\"\\n8214,1,1,\"Maximum-tolerated dose (MTD) of pegylated interferon alfa-2b when given with decitabine as assessed by NCI CTCAE version 3.0\"\\n8215,1,1,\"Maximum-tolerated dose (MTD) of PV701 based on the incidence of dose-limiting toxicity (DLT) as assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n8216,1,1,\"Maximum-Tolerated Dose (MTD) of RO6958688\"\\n8217,1,1,\"Maximum-tolerated dose (MTD) of sunitinib malate\"\\n8218,1,1,\"Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)\"\\n8219,2,1,\"Maximum-tolerated dose (MTD) or Recommended Phase 2 dose (RP2D)\"\\n8220,1,1,\"Maximum-tolerated dose (MTD), defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT), graded using the NCI CTCAE v. 4.0\"\\n8221,1,1,\"Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib\"\\n8222,1,1,\"Maximum-tolerated dose and recommended phase II dose based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n8223,1,1,\"Maximum-tolerated dose and/or recommended phase II dose\"\\n8224,1,1,\"Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma\"\\n8225,1,1,\"Maximum-tolerated dose as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n8226,1,1,\"Maximum-tolerated dose based on the incidence of dose-limiting toxicity (DLT) defined as any grade III or IV toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)\"\\n8227,1,1,\"Maximum-tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT according to NCI CTCAE version 3.0\"\\n8228,1,1,\"Maximum-tolerated Dose for Cisplatin, Vinblastine and TMZ\"\\n8229,1,1,\"Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)\"\\n8230,1,1,\"Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting Toxicity (Phase Ia)\"\\n8231,1,1,\"Maximum-tolerated dose of elimusertib (BAY 1895344) and concurrent stereotactic body radiation therapy (Dose Escalation Phase)\"\\n8232,1,1,\"Maximum-tolerated Dose of Erlotinib Hydrochloride (Phase I)\"\\n8233,1,1,\"Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)\"\\n8234,1,1,\"Maximum-tolerated dose of lenalidomide with cetuximab, defined as the highest dose level at which 0 or 1 patients out of 6 experiences a dose limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n8235,1,1,\"Maximum-tolerated dose of obatoclax mesylate in combination with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride, defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity\"\\n8236,1,1,\"Maximum-tolerated dose of pazopanib hydrochloride defined as the maximum dose at which fewer that one-third of patients experience DLT\"\\n8237,1,1,\"Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)\"\\n8238,1,1,\"Maximum-tolerated dose of sorafenib tosylate and riluzole in patients with all types of solid tumors\"\\n8239,1,1,\"Maximum-tolerated Radiation Dose\"\\n8240,1,1,\"Maxinum tolerated dose of M2ES\"\\n8241,1,1,\"MD Anderson Symptom Inventory-Score Scale\"\\n8242,1,1,\"Mean (SD) Area Under Concentration Time Curve From Zero to Infinity (AUC 0-oo) of Eribulin\"\\n8243,1,1,\"Mean (SD) Maximum Observed Concentration (Cmax) of Eribulin\"\\n8244,1,1,\"Mean (SD) Pharmacokinetic (PK) Parameter Area Under Concentration Time Curve From Zero to Infinity (AUC0-oo)\"\\n8245,1,1,\"Mean (SD) Pharmacokinetic (PK) Parameter Maximum Observed Plasma Concentration (Cmax)\"\\n8246,1,1,\"Mean 111^In-CS-1008 Serum Area Under the Curve by Gamma Counting Following the Day 1 Infusion of 111^In-CS-1008\"\\n8247,1,1,\"Mean 111^In-CS-1008 Serum Area Under the Curve by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008\"\\n8248,1,1,\"Mean 111^In-CS-1008 Serum Half-life by Gamma Counting Following the Day 1 Infusion of 111^In-CS-1008\"\\n8249,1,1,\"Mean 111^In-CS-1008 Serum Half-life by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008\"\\n8250,1,1,\"Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 1 Infusion of 111^In-CS-1008\"\\n8251,1,1,\"Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008\"\\n8252,1,1,\"Mean 111^In-CS-1008 Serum Total Clearance by Gamma Counting Following the Day 1 Infusion of 111^In-CS-1008\"\\n8253,1,1,\"Mean 111^In-CS-1008 Serum Total Clearance by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008\"\\n8254,1,1,\"Mean 111^In-CS-1008 Serum Volume of Central Compartment by Gamma Counting Following the Day 1 Infusion of 111^In-CS-1008\"\\n8255,1,1,\"Mean 111^In-CS-1008 Serum Volume of Central Compartment by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008\"\\n8256,1,1,\"Mean Age at the Time of Local or Metastatic Progression\"\\n8257,1,1,\"Mean and median Area under the curve (AUC) of ciforadenant\"\\n8258,1,1,\"Mean and median Maximum concentration (Cmax) of ciforadenant\"\\n8259,1,1,\"Mean and median time to complete the entire geriatric assessment\"\\n8260,1,1,\"Mean Area Under the Serum Concentration Curve Extrapolated to Infinite Time for 111-In-CMD-193\"\\n8261,1,1,\"Mean Arterial Enhancement, Per Lesion, as Determined by Dynamic Gadolinium-enhanced Magnetic Resonance Imaging (MRI), Before and Following Bevacizumab Therapy.\"\\n8262,1,1,\"Mean Body Mass Index (BMI) at the Time of Local or Metastatic Progression\"\\n8263,1,1,\"Mean Body Weight at the Time of Local or Metastatic Progression\"\\n8264,1,1,\"Mean CD4 T Cell Infiltration\"\\n8265,1,1,\"Mean CD8 T Cell Infiltration\"\\n8266,1,1,\"Mean Change From Baseline in Diastolic Blood Pressure\"\\n8267,1,1,\"Mean change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status, weight and survival in patients with pancreatic adenocarcinoma according to tissue microRNA expression\"\\n8268,1,1,\"Mean Change from Baseline in Electrocardiogram (ECG) Parameters\"\\n8269,1,1,\"Mean Change From Baseline in Lean Body Mass\"\\n8270,2,1,\"Mean Change From Baseline in Pulse Rate\"\\n8271,1,1,\"Mean Change From Baseline in Respiratory Rate\"\\n8272,2,1,\"Mean Change From Baseline in Systolic Blood Pressure\"\\n8273,3,1,\"Mean Change From Baseline in Temperature\"\\n8274,1,1,\"Mean Change from Baseline in Vital Signs\"\\n8275,2,1,\"Mean Change From Baseline in Weight\"\\n8276,1,1,\"Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval\"\\n8277,1,1,\"Mean Change in QTc From Time-matched Baseline Assessed Using Fridericia\\'s Correction Formula (QTcF) by Study Day and Time Point\"\\n8278,1,1,\"Mean change in scores on the Test of Variables of Attention (TOVA) over time\"\\n8279,1,1,\"Mean change in the Insomnia Severity Index (ISI) total score\"\\n8280,1,1,\"Mean changes in Adaptive Cognitive Evaluation (ACE)\"\\n8281,1,1,\"Mean contrast-to-noise ratio\"\\n8282,1,1,\"Mean Cumulative Dose of Vemurafenib\"\\n8283,1,1,\"Mean Daily Dose of Axitinib\"\\n8284,1,1,\"Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II\"\\n8285,1,1,\"Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3\"\\n8286,1,1,\"Mean Duration of Each Leuprorelin Cycle\"\\n8287,1,1,\"Mean Duration of Leuprorelin Exposure\"\\n8288,1,1,\"Mean Duration of Treatment\"\\n8289,1,1,\"Mean Effective Half-life of 111-In-CMD-193 Based on Gamma Camera Images\"\\n8290,1,1,\"Mean Elimination Half-life (T-HALF) Post-Single Dose\"\\n8291,1,1,\"Mean fatigue level evaluated by Brief Fatigue Inventory (BFI)\"\\n8292,1,1,\"Mean Fraction of Cytotoxic T-lymphocytes (FCT) for Participants With Response Versus Participants With Progression\"\\n8293,1,1,\"Mean Height at the Time of Local or Metastatic Progression\"\\n8294,1,1,\"Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3\"\\n8295,1,1,\"Mean Interval Between Panitumumab Infusions\"\\n8296,1,1,\"Mean levels of area under the curve (AUC) using the ANOVA model\"\\n8297,1,1,\"Mean maximum standard uptake value (SUVmax)\"\\n8298,1,1,\"Mean Number of Days of Sick Leave\"\\n8299,1,1,\"Mean number of missing items in each subscale and the distribution of missing items\"\\n8300,1,1,\"Mean Number of Painful and Swollen Joints at Visit 1\"\\n8301,1,1,\"Mean Number of RBC Transfusions\"\\n8302,1,1,\"Mean Number of RBC Units\"\\n8303,1,1,\"Mean Objective Response Rate (ORR) by Independent Central Review (ICR) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n8304,1,1,\"Mean percent change from baseline at the time of progression in standardized uptake value (SUV)max-ave on paired 11C-YJH08 PET per-lesion (Cohort B only)\"\\n8305,1,1,\"Mean percent change from baseline at the time of progression in standardized uptake value (SUV)max-ave on paired 11C-YJH08 PET per-patient basis (Cohort B only)\"\\n8306,1,1,\"Mean percent change from baseline in intratumoral HP pyruvate/lactate ratio\"\\n8307,1,1,\"Mean Percent Change From Baseline in Peak Intra-tumoral Hyperpolarized Lactate/Pyruvate Ratio (Part B)\"\\n8308,1,1,\"Mean post-treatment participant satisfaction ratings\"\\n8309,1,1,\"Mean Residence Time (MRT) of AZD2014\"\\n8310,1,1,\"Mean residence time (MRTinf)\"\\n8311,1,1,\"Mean Residence Time Adjusted for Infusion Time (MRT [INF])\"\\n8312,1,1,\"Mean residence time extrapolated to infinity [MRTinf] (Dose Escalation Phase)\"\\n8313,1,1,\"Mean Residence Time of the unchanged drug in the systemic circulation (MRTinf)\"\\n8314,1,1,\"Mean residence time when the drug concentration profile is based on values up to and including the last positive concentration [MRTlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n8315,1,1,\"Mean RO5185426 Accumulation Ratios - Dose Escalation: MBP Formulation\"\\n8316,1,1,\"Mean RO5185426 Accumulation Ratios - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- Positive CRC\"\\n8317,1,1,\"Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks\"\\n8318,1,1,\"Mean Score on Clinical Disease Activity Index at Visit 1\"\\n8319,1,1,\"Mean Score on Disease Activity Score Based on 28-Joints Count at Visit 1\"\\n8320,1,1,\"Mean Score on Simple Disease Activity Index at Visit 1\"\\n8321,1,1,\"Mean Serum Clearance of Dalotuzumab\"\\n8322,1,1,\"Mean Serum Cytokines CXCL10 (IP10)\"\\n8323,1,1,\"Mean Serum Cytokines: CXCL9\"\\n8324,1,1,\"Mean Serum Half-lives of 111-In-CMD-193\"\\n8325,1,1,\"Mean Terminal Half-life (t1/2) of Dalotuzumab\"\\n8326,1,1,\"Mean Time of Onset of Rheumatoid Arthritis\"\\n8327,1,1,\"Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing.\"\\n8328,1,1,\"Mean Total Serum Clearance of 111-In-CMD-193\"\\n8329,1,1,\"Mean Total Vemurafenib Dose Per Day\"\\n8330,1,1,\"Mean Trough Serum Concentration (Ctrough) of Dalotuzumab\"\\n8331,1,1,\"Mean Tumor Uptake of 111^In-CS-1008 Based on Gamma Camera Imaging Following the Day 1 and Day 36 Infusions\"\\n8332,1,1,\"Mean Urine Excretion of MK-1775 24 Hours After the Day 1 Monotherapy Dose\"\\n8333,1,1,\"Mean Volume of Central Compartment of 111-In-CMD-193\"\\n8334,1,1,\"Mean Volume of Distribution (Vz) Post-Single Dose\"\\n8335,1,1,\"Measles virus viremia\"\\n8336,1,1,\"Measurable Decrease in Prostate Vascularity During and/or After Radiation Treatment\"\\n8337,1,1,\"Measure Adverse Events according to CTCAE v4.0\"\\n8338,1,1,\"Measure Adverse Events according to CTCAE v4.0.\"\\n8339,1,1,\"measure CNS overall response rate (ORR) (Cohort 2)\"\\n8340,1,1,\"Measure Complication free Surgery\"\\n8341,1,1,\"Measure ECG\"\\n8342,1,1,\"Measure mean fluorescence intensity of histologically confirmed tumor vs normal tissue in patients undergoing routine surgery [Tumor to Background Ratio (TBR)]\"\\n8343,1,1,\"Measure of drug sensitive PDX to a panel of drugs as a predictor of clinical response in matched host\"\\n8344,1,1,\"Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host\"\\n8345,1,1,\"Measure of Humoral Immune Responses measured by ELISA\"\\n8346,1,1,\"Measure of proportion of patients with disease control - Phase II\"\\n8347,1,1,\"Measure of safety\"\\n8348,1,1,\"Measure of Squamous Cell Skin Carcinoma in Patients\"\\n8349,1,1,\"Measure of Tumor Responses measured by the Response Evaluation Criteria in Solid Tumors (RECIST).\"\\n8350,1,1,\"Measure of Tumor-antigen-specific Immunity in Peripheral Blood Mononuclear Cells (PBMC) by Elispot Assay\"\\n8351,1,1,\"Measure of Tumor-antigen-specific Immunity in Sentinel Immunized Node (SIN) by Elispot Assay\"\\n8352,1,1,\"Measure quantitative change in tumor size to assess the clinical activity of abemaciclib.\"\\n8353,1,1,\"Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations\"\\n8354,1,1,\"Measure the Effect of Pre-operative Simvastatin Versus Placebo on the Mevalonate Pathway Synthesis and Target Activation in Benign and Malignant Prostate Tissue.\"\\n8355,1,1,\"Measure the Progression Free Survival (PFS)- Part 3 ( Phase 3)\"\\n8356,1,1,\"Measure the quality and pathology results of prostate samples taken during Contrast-Enhanced Ultrasound (CEUS) with MRI/ Ultrasound fusion.\"\\n8357,1,1,\"Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors.\"\\n8358,1,1,\"Measurement of CD4/CD8 T lymphocyte subsets.\"\\n8359,2,2,\"Measurement of dose-limiting toxicities (DLTs)\"\\n8360,1,1,\"Measurement of genomic profile\"\\n8361,1,1,\"Measurement of patient samples for nivolumab\"\\n8362,1,1,\"Measurement of patient samples for pembrolizumab\"\\n8363,1,1,\"Measurement of pro-inflammatory and anti-inflammatory cytokines\"\\n8364,1,1,\"Measurement of pro-inflammatory and anti-inflammatory cytokines.\"\\n8365,1,1,\"Measurement of Safety and tolerability indexes (Incidence of TEAEs, SAEs and DLTs as assessed by CTCAE version 5.0 and changes in assessed safety parameters) for PeptiCRAd-1 and CPI combination.\"\\n8366,1,1,\"Measurement of Safety and tolerability indexes (Incidence of TEAEs, SAEs and DLTs as assessed by CTCAE version 5.0 and changes in assessed safety parameters) for PeptiCRAd-1 monotherapy.\"\\n8367,1,1,\"Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA\"\\n8368,1,1,\"Measurement of the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.\"\\n8369,1,1,\"Measurement of the uptake and retention of 3\\'-deoxy-3\\'-[18F] fluorothymidine (FLT) in tumors and normal organs\"\\n8370,1,1,\"Measurement of Tumor Texture by CT Scan\"\\n8371,1,1,\"Measures of Functional Independence as Assessed by the Activities of Daily Living (ADL) Questionnaire\"\\n8372,1,1,\"Measures of Functional Independence as Assessed by the Instrumental Activities of Daily Living (IADL) Questionnaire\"\\n8373,1,1,\"Measuring quality of life according to geriatric questionnaires\"\\n8374,1,1,\"Measuring the Efficacy of ZOSTAVAX in Chemotherapy Patients (Changes in ZOSTAVAX-specific IFN-gamma Spot Forming Units Will be Measured by ELISPOT)\"\\n8375,1,1,\"Measuring the positive and negative predictive value of a circulating tumor DNA blood test in detecting the presence of cancer or pre-cancerous lesions\"\\n8376,1,1,\"Measuring the Safety of ZOSTAVAX Given to Chemotherapy Patients (Vaccine Report Card (VRC) to Document Injection-site Adverse Experiences, Systemic Clinical Adverse Experiences (AEs), Concomitant Medications, and Oral Temperatures\"\\n8377,1,1,\"MED\"\\n8378,1,1,\"Median Absolute prostate specific antigen (PSA) at onset of HR-nmCRPC\"\\n8379,1,1,\"Median Amount of Time Subject Survives Without Disease Progression After Treatment\"\\n8380,1,1,\"Median amount of time subject survives without disease progression following the initiation of treatment\"\\n8381,1,1,\"Median duration of response\"\\n8382,1,1,\"Median duration of response (DOR)\"\\n8383,1,1,\"Median Duration of Response (DOR) Per Investigator\"\\n8384,2,2,\"Median Duration of Response (mDOR)\"\\n8385,1,1,\"Median duration of response (mDOR)\"\\n8386,1,1,\"Median duration of time from start of treatment to time of progression\"\\n8387,1,1,\"Median Number of Leuprorelin Cycles\"\\n8388,1,1,\"Median Number of Passes to Establish Diagnosis\"\\n8389,20,4,\"Median Overall Survival\"\\n8390,10,4,\"Median Overall Survival (OS)\"\\n8391,1,1,\"Median Overall Survival (OS) (Phase II)\"\\n8392,1,1,\"Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer\"\\n8393,1,1,\"Median Overall Survival of Patients With Adenocarcinoma of the Pancreas\"\\n8394,1,1,\"Median Overall Survival Response to Abraxane Plus Ipilimumab Therapy\"\\n8395,1,1,\"Median Overall Survival Time\"\\n8396,1,1,\"Median PFS (median Progression-Free Survival)\"\\n8397,13,10,\"Median Progression Free Survival\"\\n8398,2,1,\"Median progression free survival (mPFS)\"\\n8399,22,12,\"Median Progression Free Survival (PFS)\"\\n8400,1,1,\"Median Progression free survival (PFS)\"\\n8401,3,2,\"Median progression free survival (PFS)\"\\n8402,1,1,\"Median progression free survival (PFS) (dose-expansion)\"\\n8403,2,2,\"Median Progression Free Survival (PFS) (Months)\"\\n8404,2,1,\"Median Progression Free Survival (PFS) in Months\"\\n8405,1,1,\"Median Progression Free Survival (PFS) Time\"\\n8406,6,2,\"Median Progression-Free Survival\"\\n8407,9,3,\"Median Progression-free Survival\"\\n8408,1,1,\"median progression-free survival (mPFS)\"\\n8409,7,2,\"Median Progression-Free Survival (PFS)\"\\n8410,7,2,\"Median Progression-free Survival (PFS)\"\\n8411,1,1,\"Median Progression-Free Survival (PFS) (Phase II)\"\\n8412,1,1,\"Median progression-free survival (PFS) (Phase II)\"\\n8413,1,1,\"Median Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria in Participants With Advanced Transitional Cell Carcinoma (TCC) of the Urothelium\"\\n8414,1,1,\"Median Progression-Free Survival (PFS) in Phase II Participants - Prior Bevacizumab and Bevacizumab Naive\"\\n8415,1,1,\"Median Progression-free Survival (PFS) Time\"\\n8416,1,1,\"Median Progression-free Survival (PFS) Time at 1-year.\"\\n8417,1,1,\"Median Progression-Free Survival (PFS) Time in Subjects Randomised to Lanreotide in the Double-Blind Phase or Open-Label Treatment Phase, Assessed by Central Review\"\\n8418,1,1,\"Median Progression-free Survival (PFS) With 95% Confidence Intervals\"\\n8419,1,1,\"Median Progression-Free Survival (Site Read, Investigator Assessment)\"\\n8420,1,1,\"Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria.\"\\n8421,1,1,\"Median Progression-Free Survival Time in Defined Participant Subgroups as Assessed by Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n8422,1,1,\"Median progression-free survivalÔºàmPFSÔºâ\"\\n8423,1,1,\"Median Radiographic Progression Free Survival (PFS)\"\\n8424,1,1,\"Median sessional tolerance\"\\n8425,5,2,\"Median Survival\"\\n8426,1,1,\"Median SUVmax\"\\n8427,1,1,\"Median Time at Which the Maximum Serum Concentration Occurred (Tmax) Post-Single Dose\"\\n8428,1,1,\"Median time from initial diagnosis to nivolumab initiation\"\\n8429,1,1,\"Median time of overall survival(OS)\"\\n8430,1,1,\"Median Time of Progression-free Survival\"\\n8431,1,1,\"Median Time on Investigational Product\"\\n8432,1,1,\"Median Time on Treatment\"\\n8433,3,2,\"Median Time to Disease Progression\"\\n8434,1,1,\"Median Time to First Dose Reduction\"\\n8435,1,1,\"Median Time to Paracentesis\"\\n8436,5,2,\"Median Time to Progression\"\\n8437,6,3,\"Median Time to Progression (TTP)\"\\n8438,1,1,\"Median Time to Progression (TTP) and Median Time to Neurological Progression (TTNP)\"\\n8439,1,1,\"Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors\"\\n8440,1,1,\"Median Time to Treatment Termination (TTT)\"\\n8441,56,1,\"Medication adherence\"\\n8442,1,1,\"Melanoma Expansion Cohort: Number of patients with treatment-related adverse events as assessed by CTCAE\"\\n8443,1,1,\"Melanoma Expansion Cohort: Objective response rate\"\\n8444,1,1,\"Mental health of the parents (BSI-18)\"\\n8445,1,1,\"Merged risk reduction strategies of bilateral salpingo-oophorectomy (BSO) or bilateral mastectomy and imaging\"\\n8446,1,1,\"Message-specific knowledge/recall accuracy\"\\n8447,1,1,\"metabolic complete response assessed using FDG PET whole body scan at 12 weeks of assessment using PERCIST 1.0\"\\n8448,1,1,\"Metabolic phenotypes\"\\n8449,1,1,\"Metabolic profile of FTD and TPI in plasma, urine, and feces\"\\n8450,1,1,\"Metabolic Response of All Pulmonary Lesions and Thoracic Lymph Nodes\"\\n8451,1,1,\"Metabolic syndrome (MS) in survivors of childhood cancer (CCS) vs controls\"\\n8452,5,1,\"Metabolism\"\\n8453,1,1,\"Metabolism induction measured by a change of 50% or more in the AUC\"\\n8454,1,1,\"Metabolite identification of rucaparib in plasma, urine and feces\"\\n8455,1,1,\"Metabolomics of blood samples\"\\n8456,1,1,\"Metabolomics of exhaled air condensate samples\"\\n8457,1,1,\"Metabolomics of tissue samples\"\\n8458,1,1,\"Metabolomics of urine samples\"\\n8459,1,1,\"Metastasis Free Survival (MFS)\"\\n8460,1,1,\"Metastasis progression-free survival in High-risk CINSARC patients\"\\n8461,1,1,\"Metastatic breast cancer management based on tumor molecular profile\"\\n8462,1,1,\"Metastatic: Investigator-Assessed Objective Response Rate (ORR)\"\\n8463,1,1,\"Metronomic Capecitabine With Oral Digoxin\"\\n8464,1,1,\"Microbiome difference between patients with and without AEs>=grade 3\"\\n8465,1,1,\"Microflora analysis accomplished\"\\n8466,1,1,\"Microparticles level will be assessed by automated and standardised measure of their procoagulant power using Kit STA¬©Procoag-PPL (Diagnostica Stago, Asni√®re, France)\"\\n8467,1,1,\"Midazolam AUCinf\"\\n8468,1,1,\"Midazolam Cmax\"\\n8469,1,1,\"Midazolam Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0-infinity)\"\\n8470,1,1,\"Midazolam Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Time Point With Measurable Concentrations (AUC 0-tlast)\"\\n8471,1,1,\"Midazolam Pharmacokinetics: Maximum Concentration (Cmax)\"\\n8472,1,1,\"Midazolam: Area under the plasma concentration-time curve from time zero to infinity (AUC) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).\"\\n8473,1,1,\"Midazolam: Maximum observed plasma concentration (Cmax) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).\"\\n8474,1,1,\"Mild/moderate/severe decline in EORTC QLQ-C30\"\\n8475,1,1,\"Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate\"\\n8476,1,1,\"Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS)\"\\n8477,1,1,\"Minimum Concentration (Cmin) of MPDL3280A\"\\n8478,1,1,\"Minimum Concentration (Cmin) of Rociletinib and Metabolites\"\\n8479,1,1,\"Minimum dose required for local control as assessed by RECIST one-dimensional criterion and volumetric analysis for 90 days after completion of study treatment\"\\n8480,1,1,\"Minimum Drug Concentration (Cmin) for RO6958688\"\\n8481,1,1,\"Minimum drug concentration at steady state (Cmin-ss)\"\\n8482,1,1,\"Minimum level of ProCalcitonin\"\\n8483,2,1,\"Minimum Number of Vaccine Doses Created Using Participant Tumor Sample\"\\n8484,1,1,\"Minimum Observed (Trough) Plasma Concentration (Cmin) in the Fasted and Fed States\"\\n8485,3,1,\"Minimum observed concentration (Cmin)\"\\n8486,1,1,\"Minimum Observed Concentration (Cmin) of Panitumumab\"\\n8487,1,1,\"Minimum observed concentration at steady-state (Css,min)\"\\n8488,1,1,\"Minimum Observed Plasma Concentration (Cmin) of Atezolizumab\"\\n8489,1,1,\"Minimum Observed Plasma Trough Concentration (Cmin) of GDC-0575\"\\n8490,1,1,\"Minimum Observed Serum Concentration (Cmin) of RO6895882\"\\n8491,1,1,\"Minimum Observed Serum Trough Concentration (Cmin) of Trastuzumab\"\\n8492,1,1,\"Minimum plasma concentration (Cmin) of Ipatasertib after multiple doses of Ipatasertib\"\\n8493,1,1,\"Minimum Plasma Concentration (CTrough)\"\\n8494,1,1,\"Minimum Plasma Concentration of MK-2206 (Ctrough)\"\\n8495,1,1,\"Minimum Serum Concentration (Cmin) of Atezolizumab\"\\n8496,1,1,\"Minimum serum concentration of selinexor\"\\n8497,1,1,\"Minutes spent in discussion\"\\n8498,1,1,\"MK-0646 Maximum Tolerable Dose\"\\n8499,1,1,\"MM-302 drug penetration into the brain\"\\n8500,1,1,\"Mobility status: measured by the change in mobility status between baseline and 5 weeks, as measured by the in-house mobility scale\"\\n8501,1,1,\"Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 1 or 2 irAE.\"\\n8502,1,1,\"Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 3 or 4 irAE.\"\\n8503,1,1,\"Modification(s) in the immune blood markers of treated subjects on treatment.\"\\n8504,1,1,\"Modifications of functional MRI parameters\"\\n8505,1,1,\"Modified design: Define the recommended dose and schedule for PT-112 for pivotal studies\"\\n8506,1,1,\"Modified Response Evaluation Criteria in Solid Tumors (RECIST) progression free survival\"\\n8507,1,1,\"Module 1 - Safety and Tolerability of RXC004 by assessment of whether any Dose Limiting Toxicities (DLT) arise from first dose until the end of 21 days of continuous dosing\"\\n8508,1,1,\"Module 2 - Safety and Tolerability of RXC004 in combination with Nivolumab by assessment of whether any Dose Limiting Toxicities (DLT) arise from first dose until the end of 28 days of continuous dosing\"\\n8509,1,1,\"Module 4 only: Effect of ceralasertib on ECG parameters (HR, PR, QRS and QTcF) by ECG recordings\"\\n8510,1,1,\"Module 4 only: Effect of food on ceralasertib absorption by Intensive PK assessments after a single oral dose of ceralasertib (Part A)\"\\n8511,1,1,\"Module A: Incidence of Dose-limiting Toxicity (DLTs ) during the first 28 days of EP0031 treatment\"\\n8512,1,1,\"Modules B and C: Overall Response Rate (ORR) as measured using RECIST v1.1\"\\n8513,1,1,\"Molecular ctDNA characterization under concomitant TTFields therapy - cohort A (EGFR)\"\\n8514,1,1,\"Molecular effects of notch-signaling inhibition\"\\n8515,1,1,\"molecular profiling of solid tumors\"\\n8516,1,1,\"molecular screening(collected of blood,tumor tissue Malignant ascites, pleural effusions, or pericardial effusions will be analyzed)\"\\n8517,1,1,\"Molecular tumorboard\"\\n8518,1,1,\"Molecular tumorboard utilization\"\\n8519,1,1,\"Monitoring of coagulation function [Safety and Tolerability]\"\\n8520,1,1,\"Monitoring of hematology and blood chemistry [Safety and Tolerability]\"\\n8521,1,1,\"Monitoring of urinalysis [Safety and Tolerability]\"\\n8522,1,1,\"Monitoring of Vital signs [Safety and Tolerability]\"\\n8523,1,1,\"Monotherapy (Modules 1 and 2): Progression free survival (percent) rate at 6 months using Investigator assessment according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1)\"\\n8524,1,1,\"Monotherapy Dose Expansion: Objective Response Rate (ORR) as defined by RECIST v1.1\"\\n8525,1,1,\"Monotherapy part: Assessment of adverse events, laboratory findings, physical examination, vital signs, ECG/UCG, chest X-ray, HRCT, SpO2 and ophthalmological examinations.\"\\n8526,1,1,\"Monotherapy Period: Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC 0-inf) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Function\"\\n8527,1,1,\"Monotherapy Period: Area Under the Concentration-Time Curve from Time Zero to Time of Last Concentration (AUC 0-t) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Function\"\\n8528,1,1,\"Monotherapy Period: Maximum Plasma Concentration (Cmax) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Function\"\\n8529,1,1,\"Monotherapy: Incidence of treatment emergent adverse events\"\\n8530,1,1,\"Monotherapy: Maximum tolerated dose (MTD) of FPT155\"\\n8531,1,1,\"Mood state by Profile of Mood States at baseline, 3 months, and 1 year\"\\n8532,79,2,\"Morbidity\"\\n8533,1,1,\"Morningness-Eveningness Questionnaire (MEQ)\"\\n8534,1,1,\"morphine dosage\"\\n8535,756,5,\"Mortality\"\\n8536,1,1,\"Mortality at 2, 4, and 12 weeks after diagnosis of fungemia\"\\n8537,1,1,\"mortality for SARS-CoV-2 infection\"\\n8538,23,1,\"Mortality Rate\"\\n8539,1,1,\"Most Common Sequences for Lines of Therapy in Participants with mCRPC\"\\n8540,1,1,\"Most efficacious dose\"\\n8541,1,1,\"Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months\"\\n8542,1,1,\"Most Mature Height Standard Deviation Score (SDS)\"\\n8543,1,1,\"Most Successful Dose (MSD)\"\\n8544,1,1,\"MP0250 plasma concentration-time profile\"\\n8545,7,2,\"MPR\"\\n8546,1,1,\"MR/US Motion Management Platform\"\\n8547,1,1,\"MRI derived hypoxia scores on 20 participants\"\\n8548,1,1,\"MRI scan for monitoring of tumor size and CIK cell-homing, Fluorescence-activated cell sorting (FACS) analysis\"\\n8549,1,1,\"MRI vs CT for testicular cancer\"\\n8550,13,1,\"MRT\"\\n8551,3,3,\"MST\"\\n8552,107,47,\"MTD\"\\n8553,1,1,\"MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.\"\\n8554,6,3,\"MTD (Maximum Tolerated Dose)\"\\n8555,1,1,\"MTD (maximum tolerated dose) and RD (recommended dose) of PM060184.\"\\n8556,1,1,\"MTD (maximum tolerated dose) of BIBF 1120 in combination with pemetrexed (500 mg/m2).\"\\n8557,1,1,\"MTD (or recommended phase II dose), defined as one dose level below that which produces two instances of DLT during the first 28-day course and the level at which no more than one of six patients experiences DLT during course 1\"\\n8558,1,1,\"MTD (Part 1 and Part 2)\"\\n8559,1,1,\"MTD (Phase 1b)\"\\n8560,1,1,\"MTD after GX-051 intratumoral injection\"\\n8561,1,1,\"MTD alvocidib when administered in conjunction with irinotecan hydrochloride and cisplatin\"\\n8562,1,1,\"MTD and / or a RP2D of EVT801 when administered daily to subjects with advanced or metastatic solid tumours.\"\\n8563,1,1,\"MTD and associated dose schedule\"\\n8564,1,1,\"MTD and DLTof IL-12 in combination with IL-2\"\\n8565,1,1,\"MTD and recommended Phase 2 dose (RP2D)\"\\n8566,1,1,\"MTD and recommended phase II dose\"\\n8567,3,1,\"MTD and RP2D\"\\n8568,1,1,\"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride alone, defined as the highest dose level at which < 2 of 6 patients experience treatment-related dose limiting toxicity (DLT) (Arms 1 and 1E)\"\\n8569,1,1,\"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and cisplatin, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 3 and 3E)\"\\n8570,1,1,\"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)\"\\n8571,1,1,\"MTD and RP2D of eribulin mesylate for patients who have not received a tubulin-inhibitor for the recurrent/advanced disease (Phase I)\"\\n8572,1,1,\"MTD and RP2D of tivantinib in combination with temsirolimus defined as the highest safely tolerated dose where 0/6 or 1/6 patients experience a dose-limiting toxicity (DLT) and two or more patients have experienced a DLT at the next higher dose level\"\\n8573,1,1,\"MTD and RP2D of Unesbulin in Combination With Dacarbazine\"\\n8574,1,1,\"MTD and the recommended phase II doses of imatinib and PTK/ZK administered daily every 28 days\"\\n8575,1,1,\"MTD and/or recommended phase 2 dose of Akt inhibitor MK2206 determined according to incidence of dose-limiting toxicities (DLTs) graded using CTCAE v4.0 (Part A)\"\\n8576,1,1,\"MTD and/or recommended phase II dose defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0\"\\n8577,1,1,\"MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab\"\\n8578,1,1,\"MTD and/or RP2DP2D\"\\n8579,1,1,\"MTD and/or RPTD of ABBV-155\"\\n8580,2,2,\"MTD as assessed by the number of patients with dose-limiting toxicity (DLT)\"\\n8581,1,1,\"MTD as assessed by the number of patients with dose-limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)\"\\n8582,1,1,\"MTD at which fewer than one third of patients experience dose limiting toxicity as assessed by CTCAE v4.0\"\\n8583,1,1,\"MTD at which fewer than one-third of patients experience dose limiting toxicity as assessed by NCI CTCAE version 4.0\"\\n8584,1,1,\"MTD based on the dose-limiting toxicity based on the National Cancer Institute (NCI) CTCAE v. 4.0\"\\n8585,1,1,\"MTD based on the incidence of DLT as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 3.0\"\\n8586,1,1,\"MTD based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n8587,1,1,\"MTD defined as one dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) assessed using NCI CTCAE v3.0\"\\n8588,1,1,\"MTD defined as that dose level immediately below the dose level at which 2 patients out of 3 to 6 patients experienced dose-limiting toxicity using Common Toxicity Criteria version 2.0\"\\n8589,1,1,\"MTD defined as the dose at which fewer than 20% of patients experience DLT assessed using CTC version 2.0\"\\n8590,1,1,\"MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using Common Toxicity Criteria version 2.0\"\\n8591,1,1,\"MTD defined as the dose level at which less than 2 out of 6 patients experience DLT assessed using NCI CTC version 2.0\"\\n8592,1,1,\"MTD defined as the dose level below the dose level that results in DLT in >= 2 of 6 new patients assessed using NCI CTC version 2.0\"\\n8593,1,1,\"MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) as assessed by the National Cancer (NCI) CTCAE v. 4.0\"\\n8594,1,1,\"MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Cohort I)\"\\n8595,1,1,\"MTD defined as the dose level in which 1 of 6 patients experiences DLT assessed using CTCAE version 4.0\"\\n8596,1,1,\"MTD defined as the dose level one level below the lowest dose where greater than or equal to 2 patients experience a DLT assessed by National Cancer Institute (NCI) CTCAE v. 4.0\"\\n8597,1,1,\"MTD defined as the dose level preceding that at which 2 of 6 patients experience dose-limiting toxicity (DLT) assessed using Common Toxicity Criteria version 2.0\"\\n8598,1,1,\"MTD defined as the dose level that is just below the dose on which at least 2 of 6 patients developed a dose-limiting toxicity (DLT) as assessed by CTC version 2.0\"\\n8599,1,1,\"MTD defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity\"\\n8600,1,1,\"MTD defined as the highest dose level at which =< 1/6 subjects experience a study related dose-limiting toxicity (DLT) as assessed by CTC version 2.0\"\\n8601,1,1,\"MTD defined as the highest dose level in which fewer than 2 patients experience a dose limiting toxicity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n8602,1,1,\"MTD defined as the highest dose tested in which greater than 33% of patients experienced dose limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n8603,1,1,\"MTD defined as the highest IMC-A12 dose tested in which none or only one patient had a dose-limiting toxicity (DLT) attributed to IMC-A12 as assessed by NCI CTCAE version 4.0\"\\n8604,1,1,\"MTD defined as the maximum dose at which =< 1 of 3 to 6 subjects in a dose group experience a drug-related dose-limiting toxicity, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (v)4.0\"\\n8605,1,1,\"MTD defined as the maximum dose at which fewer than one-third of patients experience DLT\"\\n8606,1,1,\"MTD defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n8607,1,1,\"MTD defined as the next lower dose in which 1 or more patients experiences a dose limiting toxicity defined as grade 3 or 4 toxicity graded according to the NCI Common Terminology Criteria for Adverse Events version 4.0\"\\n8608,1,1,\"MTD defined based on the toxicities observed during the first cycle of treatment\"\\n8609,4,3,\"MTD determination\"\\n8610,1,1,\"MTD dose of NC-6300\"\\n8611,1,1,\"MTD for NUC-7738 administered via weekly and fortnightly dosing schedules in patients with advanced solid tumours\"\\n8612,1,1,\"MTD for patients with moderate hepatic impairment\"\\n8613,1,1,\"MTD for single doses of BI 2536 BS on 3 consecutive days\"\\n8614,1,1,\"MTD graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n8615,2,1,\"MTD in Phase I\"\\n8616,1,1,\"MTD of ABT-888 and gemcitabine hydrochloride, determined according to incidence of DLT graded using the NCI CTCAE version 4.0\"\\n8617,1,1,\"MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).\"\\n8618,1,1,\"MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).\"\\n8619,1,1,\"MTD of Afatinib in Combination With Trastuzumab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).\"\\n8620,1,1,\"MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4\"\\n8621,1,1,\"MTD of Akt inhibitor MK-2206 and lapatinib ditosylate, defined as the dose level at which less than one-third of patients experience a DLT as graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.4 (Part I)\"\\n8622,1,1,\"MTD of alvocidib when given every three weeks in conjunction with doxorubicin hydrochloride\"\\n8623,1,1,\"MTD of axitinib based on dose-limiting toxicity (DLT) at which fewer than one-third of patients experience DLT, as assessed by CTCAE version 4.0\"\\n8624,1,1,\"MTD of AZD1775, based on the incidence of dose limiting toxicity (DLT), graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03\"\\n8625,1,1,\"MTD of AZD3965\"\\n8626,1,1,\"MTD of belinostat in combination with isotretinoin determined by dose limiting toxicities graded according to NCI CTCAE 4.0\"\\n8627,1,1,\"MTD of biweekly flavopiridol when given in conjunction with irinotecan hydrochloride, fluorouracil, and leucovorin\"\\n8628,1,1,\"MTD of cafusertib based on the incidence of dose limiting toxicities\"\\n8629,1,1,\"MTD of CBP-1018 in Part A\"\\n8630,1,1,\"MTD of CCI-779 and Bryostatin-1 administered in combination, graded according to NCI Common Toxicity Criteria, Version 3.0\"\\n8631,1,1,\"MTD of Cergutuzumab Amunaleukin\"\\n8632,1,1,\"MTD of cilengitide and paclitaxel, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients as graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0\"\\n8633,1,1,\"MTD of cilengitide defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.\"\\n8634,1,1,\"MTD of cisplatin defined as the highest dose level in which six patients have been evaluated for toxicity with no more than one patient experiencing DLT attributable to the study drugs\"\\n8635,1,1,\"MTD of combination of cixutumumab and temsirolimus defined as the highest dose level at which no more than 1 of 6 evaluable patients has had a dose-limiting toxicity\"\\n8636,1,1,\"MTD of dabrafenib, defined as the highest dose level that is estimated to induce a dose-limiting toxicity rate less than 33.3% by the two-way isotonic regression, graded according to NCI CTCAE v4.0\"\\n8637,1,1,\"MTD of decitabine, based on incidence of DLT graded according to NCI CTCAE version 3.0 (Part A)\"\\n8638,1,1,\"MTD of DHES0815A\"\\n8639,1,1,\"MTD of dinaciclib given in combination with epirubicin hydrochloride, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4\"\\n8640,1,1,\"MTD of dinaciclib in combination with Akt inhibitor MK2206 defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients\"\\n8641,1,1,\"MTD of entolimod\"\\n8642,1,1,\"MTD of eribulin mesylate defined as the highest dose tested in which no more than 1 of first 6 patients evaluated for toxicity experience dose-limiting toxicity (DLT) as assessed by NCI CTC version 2.0\"\\n8643,1,1,\"MTD of Erlotinib\"\\n8644,1,1,\"MTD of erlotinib hydrochloride and irinotecan hydrochloride in patients with advanced solid tumors that overexpress epidermal growth factor receptor\"\\n8645,1,1,\"MTD of ET0038\"\\n8646,1,1,\"MTD of HS-10241 based on the incidence of dose limiting toxicities\"\\n8647,1,1,\"MTD of Hsp90 inhibitor AUY922\"\\n8648,1,1,\"MTD of hydroxychloroquine that can be safely administered to cancer patients in association with radiotherapy\"\\n8649,1,1,\"MTD of icotinib hydrochloride, defined as the highest dose level at which =< 1 of 6 evaluable patients experiences a dose-limiting toxicity, as graded using NCI CTCAE version 4.0\"\\n8650,1,1,\"MTD of IFN-alpha-2b, defined as the dose level one level beneath that dose at which 2 or more of 6 patients showed DLT, graded according to NCI CTCAE version 4.0\"\\n8651,1,1,\"MTD of IL-12, defined as the dose level one level beneath that dose at which 2 or more of 6 patients showed DLT, based on the NCI CTC version 2.0\"\\n8652,1,1,\"MTD of IMCgp100 Administered Daily (Dose Escalation Part)\"\\n8653,1,1,\"MTD of irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)\"\\n8654,1,1,\"MTD of ixabepilone defined as the first dosage tier below the MAD in which =< 1/6 patients experiences a DLT\"\\n8655,1,1,\"MTD of lexatumumab w/interferon gamma 1b\"\\n8656,1,1,\"MTD of MBS301\"\\n8657,1,1,\"MTD of MEK162 - Phase I\"\\n8658,1,1,\"MTD of MK-2206 Administered Every Three Weeks (Q3W) in Combination With Carboplatin and Paclitaxel\"\\n8659,1,1,\"MTD of MK-2206 Administered Once Every Week (QW) in Combination With Erlotinib\"\\n8660,1,1,\"MTD of MK-2206 Administered Q3W in Combination With Docetaxel\"\\n8661,1,1,\"MTD of MK-2206 Administered QOD in Combination With Docetaxel\"\\n8662,1,1,\"MTD of MK-2206 Administered QOD in Combination With Erlotinib\"\\n8663,1,1,\"MTD of Nintedanib\"\\n8664,1,1,\"MTD of NM-3 is the dose at which less than or equal to 1 of 6 patients experiences a DLT\"\\n8665,1,1,\"MTD of oral calcitriol when combined with a standard dose of gemcitabine hydrochloride and cisplatin, determined according to incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0\"\\n8666,1,1,\"MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT\"\\n8667,1,1,\"MTD of paclitaxel, bortezomib, and carboplatin defined as the highest safely-tolerated dose where =< 1 patient experience dose-limiting toxicity (DLT) with the next higher dose having at least 2 patients who experience DLT as assessed by CTC version 2.0\"\\n8668,1,1,\"MTD of pioglitazone and carboplatin\"\\n8669,1,1,\"MTD of RAD001, erlotinib and radiotherapy in the re-irradiation setting\"\\n8670,1,1,\"MTD of reirradiation with the pulsed low dose rate technique\"\\n8671,1,1,\"MTD of ribociclib and gemcitabine hydrochloride, defined as the maximum dose level at which =< 1/6 patients have dose limiting toxicities\"\\n8672,1,1,\"MTD of RO4929097 administered with dexamethasone determined according to DLTs graded using CTCAE v4.0\"\\n8673,1,1,\"MTD of RO4929097 and capecitabine, defined as that dose level at which less than one-third of patients experience a dose-limiting toxicity (DLT) graded according to NCI CTCAE version 4.0 (Part 1)\"\\n8674,2,1,\"MTD of RO6870810\"\\n8675,1,1,\"MTD of RO6958688 With/Without Obinutuzumab Pretreatment\"\\n8676,1,1,\"MTD of Selicrelumab in Combination With Vanucizumab\"\\n8677,1,1,\"MTD of selumetinib combined with cetuximab\"\\n8678,1,1,\"MTD of single dose of FS-1502\"\\n8679,1,1,\"MTD of smac mimetic TL32711\"\\n8680,1,1,\"MTD of sunitinib malate, as assessed by the NCI CTCAE version 4.0 (v4.0)\"\\n8681,1,1,\"MTD of tanespimycin in combination with bortezomib in the treatment of solid tumors\"\\n8682,1,1,\"MTD of tanespimycin, gemcitabine hydrochloride, and cisplatin, determined by incidence of dose-limiting toxicity (DLT) graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n8683,1,1,\"MTD of Temsirolimus\"\\n8684,1,1,\"MTD of temsirolimus defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) as graded by the National Cancer Institute (NCI) CTCAE version 4.0\"\\n8685,1,1,\"MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT\"\\n8686,1,1,\"MTD of the addition of ifosfamide to the combination of oxaliplatin and etoposide assessed by CTCAE version 3.0\"\\n8687,1,1,\"MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin\"\\n8688,1,1,\"MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0\"\\n8689,1,1,\"MTD of the combination of ipilimumab with GM-CSF that results in < 33% DLT\"\\n8690,1,1,\"MTD of the combination of ixabepilone and temsirolimus, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)\"\\n8691,1,1,\"MTD of the combination of MK-2206 and paclitaxel defined as the dose level in which less than or equal to 1 out of 6 patients develop dose limiting toxicity assessed using Common Terminology Criteria for Adverse Events version 4 (Phase I)\"\\n8692,1,1,\"MTD of the combination of oxaliplatin and etoposide assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n8693,1,1,\"MTD of the dose of MPT0B640\"\\n8694,1,1,\"MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0\"\\n8695,1,1,\"MTD of veliparib, defined as the highest dose tested in which fewer than 33% of patients experienced dose-limiting toxicity attributable to the study regimen, when at least 6 patients were treated at that dose and were evaluable for toxicity\"\\n8696,2,1,\"MTD of Volasertib\"\\n8697,1,1,\"MTD of vorinostat based on incidence of DLT\"\\n8698,1,1,\"MTD of vorinostat defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT\"\\n8699,1,1,\"MTD of Vorinostat When Administered in Combination With Paclitaxel and Radiotherapy Therapy as Assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)\"\\n8700,1,1,\"MTD of vorinostat, determined according to incidence of dose-limiting toxicities graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0\"\\n8701,2,2,\"MTD or HTD and RP2D.\"\\n8702,3,2,\"MTD or MAD\"\\n8703,1,1,\"MTD or MBED of 1-Methyl-D-tryptophan\"\\n8704,1,1,\"MTD or recommended phase II dose\"\\n8705,1,1,\"MTD regimen for each combination regimen in each arm of the study as determined by an evaluation of AEs and changes in laboratory values. The MTD = highest dosing regimen that results in dose limiting toxicity in <= 1 of 6 patients.\"\\n8706,3,3,\"MTD(Max tolerance does)\"\\n8707,1,1,\"MTD, Defined as One Dose Level Below the Dose That Induced DLT in at Least One Third of Patients at a Dose Level, Graded According to NCI CTCAE Version 3.0 (Phase I)\"\\n8708,1,1,\"MTD, defined as that dose at which fewer than one-third of patients experience DLT, graded according to the NCI CTC version 2.0\"\\n8709,1,1,\"MTD, defined as the dose level among the 9 levels studied having toxicity rate closest to a target of 33%, graded according to CTC version 2.0\"\\n8710,1,1,\"MTD, defined as the dose level that no more than 2/6 or 1/3 patients experience DLT and at least 2/3 or 3/6 patients treated with next higher dose level will have had DLT\"\\n8711,1,1,\"MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level\"\\n8712,1,1,\"MTD, defined as the highest dose level at which =< 3 out of 7 patients experience a dose-limiting toxicity\"\\n8713,1,1,\"MTD, defined as the highest dose level at which no more than 1/6 patients experience DLT\"\\n8714,1,1,\"MTD, defined as the highest dose level below the maximally administered dose at which no more than 1 out of 6 patients experience DLT graded according to NCI CTCAE version 4.0\"\\n8715,1,1,\"MTD, defined as the highest dose level which results in DLT in fewer than 2/6 patients, graded according to the NCI CTC version 2.0\"\\n8716,1,1,\"MTD, defined as the highest dose level with an observed incidence of DLT in no more than 1 out of 6 patients treated at a particular dose level\"\\n8717,1,1,\"MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0\"\\n8718,1,1,\"MTD, defined as the highest dose tested in which none or only one patient experienced DLT attributable to the study drug(s), when at least 6 patients were treated at that dose and are evaluable for toxicity, graded according to the NCI CTC version 2.0\"\\n8719,1,1,\"MTD, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (DLT) graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n8720,1,1,\"MTD, DLT, recommended phase II dose of chronically dosed single-agent veliparib in patients with either a refractory BRCA 1/2- mutated solid cancer; platinum- refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer\"\\n8721,2,2,\"MTD, Maximum Tolerated Dose\"\\n8722,1,1,\"MTD, safety and toxicity\"\\n8723,2,2,\"MTD/MAD\"\\n8724,1,1,\"MTD/MAD based on number of dose-limiting toxicities (DLTs)\"\\n8725,1,1,\"MTD/Recommended Phase 2 Dose (RP2D) of Autogene Cevumeran\"\\n8726,4,3,\"MTD/RP2D\"\\n8727,1,1,\"MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n8728,1,1,\"MTD/RP2D of TORC1/2 inhibitor MLN0128, determined according to incidence of dose-limiting toxicity, as graded using the National Cancer Institute (NCI) CTCAE version 4.0\"\\n8729,1,1,\"MTD/RP2D, defined as < 1/6 patients at highest dose level below max administered dose or fewer than 33% of patients experiencing dose limiting toxicity (DLT), graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0\"\\n8730,1,1,\"MTD: Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug (i.e. Cycle 1) in each cohort.\"\\n8731,1,1,\"MTD: to determine the maximum tolerated dose of CCT303-406\"\\n8732,1,1,\"MTDs of HM95573 and cobimetinib, or HM95573 and cetuximab\"\\n8733,1,1,\"MTDÔºà Maximum tolerated DoseÔºâ\"\\n8734,1,1,\"MTDÔºâ/ RP2D regimen finding\"\\n8735,1,1,\"Multi-Dose Escalation: Incidence of DLTs.\"\\n8736,1,1,\"Multiple chemokine and cytokine levels in peripheral blood\"\\n8737,1,1,\"Multiple dose AUCtau\"\\n8738,1,1,\"Multiple dose Cmax\"\\n8739,1,1,\"Multiple Dose: Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24) of Talazoparib\"\\n8740,1,1,\"Multiple Dose: Area Under the Curve From Time 0 to 24 Hours for Unbound (AUC0-24u) Talazoparib\"\\n8741,1,1,\"Multiple Dose: Maximum Observed Plasma Concentration (Cmax) of Talazoparib\"\\n8742,1,1,\"Multiple Dose: Maximum Observed Plasma Concentration for Unbound (Cmaxu) Talazoparib\"\\n8743,1,1,\"Multiple regression analysis to determine the most significant risk factors and examine the interactions between these factors.\"\\n8744,1,1,\"Multiple risk factor index\"\\n8745,1,1,\"Multiple-dose PK: Area Under the Curve within a dosing interval of tau (=24 hr) at steady state (AUCss,tau) for Platinum\"\\n8746,1,1,\"Multiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib\"\\n8747,1,1,\"Multiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib\"\\n8748,1,1,\"Multiple-dose PK: Average Serum concentration at steady state (Css,av) for Platinum\"\\n8749,1,1,\"Multiple-dose PK: CL/F for Palbociclib\"\\n8750,1,1,\"Multiple-dose PK: Maximum Observed Serum Concentration at Steady State (Css,max) for Platinum\"\\n8751,1,1,\"Multiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib\"\\n8752,1,1,\"Multiple-dose PK: Minimum Observed Serum Concentration at Steady State (Css,min) for Platinum\"\\n8753,1,1,\"Multiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib\"\\n8754,1,1,\"Multiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib\"\\n8755,1,1,\"Multiple-dose PK: Serum Decay Half-Life (T1/2) for Platinum\"\\n8756,1,1,\"Multiple-dose PK: t1/2 for Palbociclib\"\\n8757,1,1,\"Multiple-dose PK: Time to Reach Maximum Observed Serum Concentration at steady state (Tss,max) for Platinum\"\\n8758,1,1,\"Multiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib\"\\n8759,1,1,\"Multiple-dose PK: Vz/F for Palbociclib\"\\n8760,1,1,\"Multiplex immunohistochemistry assay to gain insight into the composition of immune cell subsets\"\\n8761,1,1,\"Muscle strength (kg) measured in 5-repetition maximum (5RM) leg and bench press and lateral row exercise tests\"\\n8762,1,1,\"Mutation characteristics of malignant solid tumors in Chinese children.\"\\n8763,1,1,\"Mutation mapping using the OncoMap and other genotyping techniques\"\\n8764,1,1,\"Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count\"\\n8765,1,1,\"Nadir Measurement for Hemoglobin (Hgb)\"\\n8766,1,1,\"Nadir Serum Asparaginase Activity Response Rate (Dose Finding Phase)\"\\n8767,1,1,\"National Comprehensive Cancer Network (NCCN) Distress thermometer\"\\n8768,1,1,\"natural history of neuroendocrine neoplasms\"\\n8769,1,1,\"Natural logarithm change from baseline to week 13 in uNTx/uCr\"\\n8770,1,1,\"Nature and Degree of Toxicity\"\\n8771,1,1,\"Nature and frequency of Adverse Events (AE)\"\\n8772,1,1,\"Nature and Frequency of Dose-Limiting Toxicities\"\\n8773,1,1,\"Nature and frequency of Serious Adverse Events (SAE)\"\\n8774,2,2,\"Nature of adverse events\"\\n8775,1,1,\"Nature of adverse events graded according to NCI CTCAE, v4.0\"\\n8776,1,1,\"Nature of dose limiting toxicities\"\\n8777,1,1,\"Nature of dose limiting toxicities (DLTs)\"\\n8778,1,1,\"Nature of dose limiting toxicities (DLTs) by NCI CTCAE, v4.0\"\\n8779,1,1,\"Nature of dose limiting toxicities (DLTs)graded according to NCI CTCAE, v4.0\"\\n8780,3,1,\"Nature of dose-limiting toxicities within each dose level cohort\"\\n8781,1,1,\"Nature, frequency and severity of adverse events (AEs)\"\\n8782,1,1,\"Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher\"\\n8783,1,1,\"Necrosis of tumors\"\\n8784,1,1,\"Negative (standardized qualitative) 12 week post therapy (cisplatin + radiation therapy [RT]) FDG positron emission tomography/computed tomography (PET/CT) associated with OS for patients who have a PET/CT\"\\n8785,1,1,\"Negative (standardized qualitative) 12 week post therapy (cisplatin + RT) FDG PET/CT associated with PFS for patients who have a PET/CT\"\\n8786,1,1,\"Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs)\"\\n8787,1,1,\"Neoadjuvant: Number of Participants With Drug-Related Serious Adverse Events (SAEs)\"\\n8788,1,1,\"Neoadjuvant: Rate of Surgery Delay\"\\n8789,1,1,\"Nephrectomy and radiographic progression-free survival (nrPFS)\"\\n8790,1,1,\"Nerve growth factor levels before and after drug administration\"\\n8791,2,1,\"Nerves\"\\n8792,1,1,\"Neurocognitive changes detected through Hopkins Verbal Learning Test - Revised\"\\n8793,1,1,\"Neurocognitive changes detected through Moca Score\"\\n8794,1,1,\"Neurocognitive function as measured by neurocognitive decline on a battery of tests\"\\n8795,1,1,\"Neurologic progression-free survival rate at 6 months\"\\n8796,1,1,\"Neurologic toxicity due to treatment, graded according to the CTCAE version 4.03\"\\n8797,1,1,\"neurological outcome Frankel scores\"\\n8798,1,1,\"neurological outcome Karnofsky score\"\\n8799,1,1,\"neurological outcome urinary sphincter control\"\\n8800,3,1,\"Neurotoxicity\"\\n8801,1,1,\"Neurotoxicity secondary to cancer therapy as measured by FACT-GOG-NTX scale\"\\n8802,1,1,\"Neutralization of endogenous VEGF in serum\"\\n8803,2,2,\"Neutralizing anti-drug antibodies (NADA)\"\\n8804,1,1,\"Neutralizing Antibodies (nAbs)\"\\n8805,1,1,\"Neutralizing antibodies against SARS-CoV-2\"\\n8806,1,1,\"Neutralizing antibody titers\"\\n8807,1,1,\"Neutralizing Antidrug Antibody (ADA)\"\\n8808,6,1,\"Neutropenia\"\\n8809,1,1,\"Neutrophil count in whole blood sample\"\\n8810,1,1,\"New atelectasis for each segment\"\\n8811,1,1,\"Newly diagnosed COVID-19 related complications (not present at baseline)\"\\n8812,1,1,\"NGS\"\\n8813,1,1,\"Nicotine Abstinence\"\\n8814,1,1,\"NIH Toolbox - Friendship\"\\n8815,1,1,\"Nine-month Progression-free Survival Rate\"\\n8816,1,1,\"Non-decay corrected tissue time-activity curves (TACs) from 68Ga-FF58 PET/CT images\"\\n8817,1,1,\"Non-displaceable binding potential (BPND)\"\\n8818,1,1,\"Non-Hematological - Dose Limiting Toxicities\"\\n8819,1,1,\"non-irradiated lesion control rate(NRCR)\"\\n8820,1,1,\"Non-judgmental physical and emotional sensations associated with eating\"\\n8821,1,1,\"Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin\\'s Lymphoma.\"\\n8822,1,1,\"Non-progression at 6 Months - Osteosarcoma\"\\n8823,1,1,\"Non-progression Rate (NPR) at 18 Weeks\"\\n8824,1,1,\"Non-Progression Rate (NPR) at 8 Weeks\"\\n8825,1,1,\"Non-progression rate as measured by RECIST v2.0 at 6 months\"\\n8826,1,1,\"Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD)\"\\n8827,1,1,\"Non-progression rate defined as the proportion of subjects in the analysis population who have no progression of disease\"\\n8828,1,1,\"Non-progressive Disease (Non-PD) Rate at Week 12 According to Prostate Cancer Working Group 2 (PCWG2) Criteria in GSK2636771 200mg/Enzalutamide 160mg - Overall Arm\"\\n8829,1,1,\"Non-Tolerated Dose\"\\n8830,2,1,\"Non-Tolerated Dose (NTD)\"\\n8831,2,1,\"Non-tolerated Dose (NTD)\"\\n8832,3,1,\"Non-tolerated dose (NTD)\"\\n8833,1,1,\"Non-Tolerated Dose (NTD) - Part A\"\\n8834,1,1,\"Non-Tolerated Dose (NTD) - Part B\"\\n8835,1,1,\"Non-Tolerated Dose (NTD): A dose that causes unacceptable side effects\"\\n8836,1,1,\"Nose\"\\n8837,1,1,\"Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels\"\\n8838,1,1,\"NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1\"\\n8839,1,1,\"NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1\"\\n8840,1,1,\"NSCLC Cohort: Evaluate best overall response rate (ORR) by tumor type according to Immune-Response Criteria (iRECIST) in metastatic or locally advanced, squamous or non-squamous NSCLC.\"\\n8841,1,1,\"Number (%) of patients with clinical benefit in Phase 2a\"\\n8842,1,1,\"Number (percent) of subjects experiencing adverse events (AEs) after treatment with U3-1565\"\\n8843,1,1,\"Number and Frequency of Dose Limiting Toxicities (DLTs) With High-dose Calcitriol in Combination With Temozolomide\"\\n8844,1,1,\"Number and frequency of TRAEs, including UARs, and SAEs (safety parameters) - for all tumor types\"\\n8845,1,1,\"Number and grade of adverse events by participant related to PDM08.\"\\n8846,1,1,\"Number and percentage of participants experiencing adverse events as assessed by CTCAE v5.0 (Part 1 & 2)\"\\n8847,1,1,\"Number and percentage of participants experiencing dose-limiting toxicities as assessed by CTCAE v5.0 (Part 1)\"\\n8848,1,1,\"Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core)\"\\n8849,1,1,\"Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths During the Extension Phase (E1)\"\\n8850,1,1,\"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).\"\\n8851,3,3,\"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)\"\\n8852,1,1,\"Number and proportion of subjects experiencing: at least a Dose-Limiting Toxicity (DLT) in each cohort during the first cycle.\"\\n8853,1,1,\"number and severity of adverse events\"\\n8854,1,1,\"Number and severity of adverse events (AEs) reported according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) V5.0\"\\n8855,1,1,\"Number and severity of all adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0\"\\n8856,1,1,\"Number and severity of toxicity incidents categorized via Common Toxicity Criteria (CTC) standard toxicity grading\"\\n8857,1,1,\"Number and severity of toxicity incidents categorized via CTC standard toxicity grading\"\\n8858,1,1,\"Number and severity of toxicity incidents of alvocidib, 5-fluorouracil, leucovorin calcium with and without irinotecan hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n8859,1,1,\"Number and severity of toxicity incidents, based on the NCI CTCAE v3.0\"\\n8860,4,1,\"Number and severity of treatment emergent adverse events (TEAEs)\"\\n8861,1,1,\"Number and severity of treatment-emergent AEs\"\\n8862,1,1,\"Number and type of adverse events detected in the follow up as a measure of safety and tolerability\"\\n8863,6,1,\"Number and type of reported adverse events\"\\n8864,1,1,\"Number and type of somatic genetic variants and germline genetic variants\"\\n8865,1,1,\"Number CT- Detected Lung Nodules by Participant\"\\n8866,146,10,\"Number of Adverse Events\"\\n8867,130,4,\"Number of adverse events\"\\n8868,8,1,\"number of adverse events\"\\n8869,4,1,\"Number of adverse events (AE)\"\\n8870,1,1,\"Number of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03\"\\n8871,1,1,\"Number of adverse events (AE), serious adverse events (SAE), AEs leading to discontinuation, and deaths\"\\n8872,13,3,\"Number of Adverse Events (AEs)\"\\n8873,1,1,\"Number Of Adverse Events (AEs) By The Dose Of iNKT Cell Therapy\"\\n8874,1,1,\"Number of Adverse Events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03\"\\n8875,1,1,\"Number of Adverse Events (AEs) Per Participant\"\\n8876,1,1,\"Number of adverse events and/or serious adverse events\"\\n8877,1,1,\"Number of Adverse Events as a Measure of safety and tolerability\"\\n8878,2,1,\"Number of adverse events due to administration of TAPA-pulse DC vaccine\"\\n8879,1,1,\"Number of Adverse Events From Escalating Doses of NGR-hTNF in Combination With a Fixed Dose of Doxorubicin\"\\n8880,1,1,\"Number of adverse events grade 3 or 4\"\\n8881,1,1,\"Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug\"\\n8882,1,1,\"Number of Adverse Events related to CSR T cell infusion\"\\n8883,1,1,\"Number of Adverse Events that meets the DLT definition\"\\n8884,1,1,\"Number of adverse events to CA9hi-1 and grading their severity according to the National Cancer Institute\\'s Common Terminology Criteria for adverse Events (NCI CTCAE) Version 4.02.\"\\n8885,1,1,\"Number of Adverse Events With Grades ‚â•1 That Are Possibly, Probably, and/or Definitely Related to Treatment\"\\n8886,1,1,\"Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0\"\\n8887,1,1,\"Number of adverse events, or abnormal parameters as a measure of safety and tolerability\"\\n8888,1,1,\"Number of AEs in the Broad Scope MedDRA Anaphylactic Reaction SMQ\"\\n8889,1,1,\"Number of AEs leading to death\"\\n8890,1,1,\"Number of AEs leading to discontinuation\"\\n8891,1,1,\"Number of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria\"\\n8892,1,1,\"Number of all adverse events, graded according to the NCI CTCAE v4.0\"\\n8893,1,1,\"Number of All Study Participants Who Demonstrate a Tumor Response\"\\n8894,1,1,\"Number of an Treatment Emergent Adverse Event\"\\n8895,1,1,\"Number of assays developed\"\\n8896,1,1,\"Number of biospecimens collected\"\\n8897,1,1,\"Number of bleedings related to anticoagulation\"\\n8898,1,1,\"Number of blood donors with a diagnosis of cancer\"\\n8899,1,1,\"Number of cancers diagnosed\"\\n8900,1,1,\"Number of cancers in people with HIV (PWH) who present for care at domestic AMC sites\"\\n8901,1,1,\"Number of capillaries in vaginal mucosa\"\\n8902,1,1,\"Number of cases of SARS-COV-2 infection and mortality rate directly related to the infection in patients being followed for digestive, thoracic, head and neck, gynecologic, cerebral, urologic or cutaneous cancer\"\\n8903,1,1,\"Number of cases of the Dose-limiting toxicity (DLT)\"\\n8904,1,1,\"Number of cases where clinically actionable outcomes were identified by the use of organoids and drug screening (functional precision oncology).\"\\n8905,1,1,\"Number of chronic drugs consumed by the patient. Polipharmacy\"\\n8906,1,1,\"Number of clinical laboratory test abnormalities\"\\n8907,1,1,\"number of clinically diagnosed lung cancer\"\\n8908,1,1,\"Number of clinically significant Chest radiograph findings(chest x-ray, CXR)\"\\n8909,1,1,\"Number of communication styles employed\"\\n8910,1,1,\"Number of completed SAOC visits\"\\n8911,1,1,\"Number of complications related to Implantable Venous Access Device\"\\n8912,1,1,\"Number of courses of G-CSF required\"\\n8913,1,1,\"Number of CTC/DTC in blood\"\\n8914,1,1,\"Number of CTC/DTC in bone marrow\"\\n8915,1,1,\"Number of CTC/DTC in urine\"\\n8916,1,1,\"Number of Cycles of Each Component of the Treatment Regimen\"\\n8917,1,1,\"Number of Cycles of Toxicity\"\\n8918,1,1,\"Number Of Cycles Received\"\\n8919,1,1,\"Number of cycles received of the combination of entinostat, atezolizumab, carboplatin, and etoposide\"\\n8920,1,1,\"Number of Cycles Subjects Received Treatment in Each Treatment Arm\"\\n8921,1,1,\"Number of Cycles with Tiragolumab\"\\n8922,1,1,\"Number of Days Alive and Outside of the Hospital\"\\n8923,1,1,\"Number of days between receipt of archival tumour tissue and generation of the OncoPanel Report\"\\n8924,1,1,\"Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer\"\\n8925,1,1,\"Number of Days of Post Operative Length of Hospital Stay\"\\n8926,1,1,\"Number of Days Participants Experienced Progression Free Survival (PFS)\"\\n8927,1,1,\"Number of Days Subjects Received Treatment in Each Treatment Arm\"\\n8928,1,1,\"Number of Days Until Engraftment Criteria Were Met\"\\n8929,4,1,\"Number of Days With Solicited General Symptoms\"\\n8930,4,1,\"Number of Days With Solicited Local Symptoms\"\\n8931,14,3,\"Number of Deaths\"\\n8932,19,4,\"Number of deaths\"\\n8933,1,1,\"Number of Deaths Due to Any Cause\"\\n8934,1,1,\"Number of deaths for REGN4018 monotherapy\"\\n8935,1,1,\"Number of deaths for REGN4018 with cemiplimab\"\\n8936,1,1,\"Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint\"\\n8937,1,1,\"Number of Differentially Expressed Genes Associated With Clinical Benefit\"\\n8938,2,1,\"Number of DLT\"\\n8939,1,1,\"Number of DLTs Categorized as Per the Nature\"\\n8940,1,1,\"Number of DLTs During Cycle 1\"\\n8941,1,1,\"Number of Documented Dose Reductions During Chemotherapy\"\\n8942,1,1,\"Number of Donor Derived Cells After G-CSF Therapy\"\\n8943,1,1,\"Number of Dose Delays During Chemotherapy\"\\n8944,1,1,\"Number of Dose Independent Significant Toxicities\"\\n8945,1,1,\"Number of dose limiting adverse events (every 2 week cycle)\"\\n8946,1,1,\"Number of dose limiting adverse events (every 3 week cycle)\"\\n8947,8,1,\"Number of Dose Limiting Toxicities\"\\n8948,1,1,\"Number of dose limiting Toxicities\"\\n8949,3,2,\"Number of dose limiting toxicities (DLTs)\"\\n8950,1,1,\"Number of Dose Limiting Toxicities (DLTs) (Phase 1b)\"\\n8951,1,1,\"Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase\"\\n8952,1,1,\"Number of dose limiting toxicities (DLTs) in Dose Escalation and Trastuzumab or Tamoxifen combination arms\"\\n8953,1,1,\"Number of Dose limiting toxicities (DLTs) occurring in Cycle 1\"\\n8954,1,1,\"Number of Dose Limiting Toxicities (DLTs) Within Each Cohort.\"\\n8955,1,1,\"Number of dose limiting toxicities, as defined per protocol, that occur during the first cycle (21 days) of treatment at each dose level\"\\n8956,1,1,\"Number of Dose Modifications due to Adverse Events [Part 2]\"\\n8957,1,1,\"Number of Dose Reductions\"\\n8958,2,1,\"Number Of Dose-limiting Toxicities\"\\n8959,1,1,\"Number of Dose-limiting toxicities\"\\n8960,1,1,\"Number of dose-limiting toxicities\"\\n8961,5,3,\"Number of Dose-Limiting Toxicities (DLTs)\"\\n8962,1,1,\"Number of Dose-limiting Toxicities (DLTs) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) Administered With 3 Times Per Week Intravenous (IV) Alemtuzumab\"\\n8963,1,1,\"Number of dose-limiting toxicities (DLTs) per NCI CTCAE v5.0 during the trial\"\\n8964,1,1,\"Number of Dose-Limiting Toxicities (Phase 1)\"\\n8965,3,3,\"Number of dose-limiting toxicity (DLT)\"\\n8966,1,1,\"Number of Dose-limiting Toxicity Incidents to Determine the Maximum Tolerated Dose of IL-12, Evaluated Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phase I)\"\\n8967,1,1,\"Number of Early Discontinuations of Chemotherapy\"\\n8968,1,1,\"Number of Emesis Free Participants During the Study Period.\"\\n8969,1,1,\"Number of empathic statements and responses to patients\\' expressions of negative emotion\"\\n8970,1,1,\"Number of Epidermal Growth Factor Receptor (EGFR) Mutation Participants Who Achieved Clinical Benefit\"\\n8971,1,1,\"Number of Evaluable Participants With Complete Response (CR) and Partial Response (PR) at One Year\"\\n8972,1,1,\"Number of Evaluable Participants With Tumor Response\"\\n8973,1,1,\"Number of Evaluable Patients With Dose Limiting Toxicity Events in Phase 1\"\\n8974,1,1,\"Number of evaluable patients with objective response as measured by RECIST version 1.1\"\\n8975,1,1,\"Number of Events of Diarrhea With the Indicated Characteristics\"\\n8976,1,1,\"Number of Events of Hepatotoxicity With the Indicated Characteristics\"\\n8977,1,1,\"Number of Events of Rash With the Indicated Characteristics\"\\n8978,1,1,\"Number of Events of Treatment-Related Toxicity\"\\n8979,1,1,\"Number of Ewing/Peripheral PNET Participants in Phase 2 With Complete Response (CR) or Partial Response (PR)\"\\n8980,1,1,\"Number of Grade 1 and Higher Adverse Events Possibly, Probably, or Definitely Related to Topical MTS-01 and 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT)\"\\n8981,1,1,\"Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant\"\\n8982,1,1,\"Number of Grade 3 or Greater Treatment-Emergent Adverse Events by CTCAE v5.0\"\\n8983,1,1,\"Number of Grade 3, 4 and 5 Adverse Events (AEs) Related to TT-702 (Dose Escalation Phase)\"\\n8984,1,1,\"Number of grade 3, 4 and 5 adverse events related to HMBD-001 (Part A & B)\"\\n8985,1,1,\"Number of Grades 3-5 Treatment-Related Immune-Related Adverse Events (irAE) per NCI CTCAE v 5.0 Criteria\"\\n8986,1,1,\"Number of HIV patient that receive durvalumab at least during 4 months\"\\n8987,1,1,\"Number of Incidences of Toxicity - Grades 2 to 5 Related to Standard of Care Chemotherapy\"\\n8988,1,1,\"Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy\"\\n8989,1,1,\"Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy\"\\n8990,2,1,\"Number of infectious events\"\\n8991,1,1,\"Number of KRAS Mutation Participants Who Achieved Clinical Benefit\"\\n8992,2,1,\"Number of laboratory abnormalities\"\\n8993,1,1,\"Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment\"\\n8994,1,1,\"Number of lesions detected by [68Ga]-FF58\"\\n8995,1,1,\"Number of lesions detected by(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET\"\\n8996,1,1,\"number of lung cancer death\"\\n8997,1,1,\"Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)\"\\n8998,1,1,\"Number of Metabolites Identified Overall and as Major\"\\n8999,1,1,\"Number of Metastatic Participants With Radiographic Response\"\\n9000,1,1,\"number of moths without surgical hernia recurrence\"\\n9001,1,1,\"Number of needle passes needed to obtain a pathologic diagnosis.\"\\n9002,1,1,\"Number of Neoadjuvant Participants With Pathologic Response\"\\n9003,1,1,\"Number of Non-Serious Adverse Events Probably Related to Treatment\"\\n9004,1,1,\"Number of NSCLC Patients With Gene-expression Signature and Tumor Antigens in Distinct Concomitant Tumor Lesions Obtained at the Same Time From the Same Patient.\"\\n9005,1,1,\"Number of observed DLTs in patients given intraperitoneal carboplatin with intravenous paclitaxel and intravenous bevacizumab, graded using CTCAE v3.0\"\\n9006,1,1,\"Number of occurrences and incidence of each adverse event (AE)\"\\n9007,1,1,\"Number of Other Adverse Events (AEs)\"\\n9008,1,1,\"Number of Other Adverse Events (AEs) Related to ZD1839\"\\n9009,1,1,\"Number of Outcomes Defined Following the Consensus Process\"\\n9010,1,1,\"Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer\"\\n9011,1,1,\"Number of parents of children willing to be vaccinated after receiving relevant knowledge propagation\"\\n9012,1,1,\"Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria\"\\n9013,3,1,\"Number of Participant Deaths\"\\n9014,1,1,\"Number of Participant Overall Responses as Measured by RECIST Criteria at 12 Months\"\\n9015,1,1,\"Number of Participant Progressors vs. Non-progressors With Tumor Response\"\\n9016,1,1,\"Number of Participant With AE/SAE/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1\"\\n9017,1,1,\"Number of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n9018,1,1,\"Number of Participant With Dose-limiting Toxicities (DLT) During Combination Treatment Period\"\\n9019,1,1,\"Number of participant with objective response\"\\n9020,1,1,\"Number of Participant With Toxicities\"\\n9021,1,1,\"Number of participant with treatment related toxicities\"\\n9022,1,1,\"Number of participant with treatment related toxicities (Phase Ib)\"\\n9023,1,1,\"Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24\"\\n9024,1,1,\"Number of Participants (Par.) With Complete Response (CR), as Assessed by Independent Radiological Review\"\\n9025,1,1,\"Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)\"\\n9026,1,1,\"Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)\"\\n9027,1,1,\"Number of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 60\"\\n9028,1,1,\"Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 60\"\\n9029,1,1,\"Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 60\"\\n9030,1,1,\"Number of Participants Achieving Best Overall Response\"\\n9031,1,1,\"Number of Participants Achieving Complete Response (CR) or Partial Response (CR) to Protocol Therapy.\"\\n9032,1,1,\"Number of participants achieving pathological complete response (pCR) at surgery following neoadjuvant treatment with epirubicin + cyclophosphamide every three weeks for four cycles followed by paclitaxel + carboplatin every three weeks for four cycles\"\\n9033,1,1,\"Number of Participants Achieving Prostate-specific Antigen (PSA) Response.\"\\n9034,1,1,\"Number of Participants Achieving PSA Response at Week 12\"\\n9035,1,1,\"Number of Participants Achieving Seroprotection After Second Dose of Vaccine\"\\n9036,1,1,\"Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume\"\\n9037,3,1,\"Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)\"\\n9038,1,1,\"Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scores\"\\n9039,3,3,\"Number of participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status\"\\n9040,1,1,\"Number of Participants Based on Tumor Response Criteria With Anti-tumor Effect Induce by Graft-versus-tumor Effect.\"\\n9041,1,1,\"Number of Participants by BRAF Mutation Status\"\\n9042,1,1,\"Number of participants by causality of adverse events (AEs) by dose level\"\\n9043,1,1,\"Number of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study\"\\n9044,1,1,\"Number of participants by frequency of adverse events (AEs) by dose level\"\\n9045,1,1,\"Number of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time\"\\n9046,1,1,\"Number of Participants by Response\"\\n9047,1,1,\"Number of participants by severity of adverse events (AEs) by dose level\"\\n9048,1,1,\"Number of participants by timing of adverse events (AEs) by dose level\"\\n9049,1,1,\"Number of participants by type of adverse events (AEs) by dose level\"\\n9050,1,1,\"Number of Participants Categorized According to Association Between the Practice of Aerobic Physical Exercise and Fatigue at Baseline\"\\n9051,1,1,\"Number of Participants Categorized According to Association Between the Practice of Aerobic Physical Exercise and Fatigue at Week 12\"\\n9052,1,1,\"Number of Participants Categorized According to Association Between the Practice of Aerobic Physical Exercise and Fatigue at Week 24\"\\n9053,1,1,\"Number of Participants Categorized According to Association Between the Practice of Aerobic Physical Exercise and Fatigue at Week 36\"\\n9054,1,1,\"Number of Participants Categorized According to Number of Changes to Dose Per Treatment Cycle During 9 Months of Follow-up\"\\n9055,1,1,\"Number of Participants Categorized According to Number of Interruptions to Dose Occurred in Each Treatment Cycle During 9 Months of Follow-up\"\\n9056,1,1,\"Number of Participants Categorized According to Number of Treatment Cycles Received\"\\n9057,1,1,\"Number of Participants Categorized According to the Napping Habits for All Participants at Baseline\"\\n9058,1,1,\"Number of Participants Categorized According to the Napping Habits for All Participants at Week 12\"\\n9059,1,1,\"Number of Participants Categorized According to the Napping Habits for All Participants at Week 24\"\\n9060,1,1,\"Number of Participants Categorized According to the Napping Habits for All Participants at Week 36\"\\n9061,1,1,\"Number of Participants Classified According to Reasons for First-Line Immune-Oncologic Treatment Discontinuation\"\\n9062,1,1,\"Number of Participants Classified According to Reasons for Second-Line Sunitinib Treatment Discontinuation\"\\n9063,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 1\"\\n9064,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 12\"\\n9065,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 18\"\\n9066,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 24\"\\n9067,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 30\"\\n9068,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 36\"\\n9069,1,1,\"Number of Participants Classified According to Time of Taking Treatment at Week 6\"\\n9070,1,1,\"Number of Participants Classified Based on Different Types of BRAF V600 Mutation Patterns in Tumor Samples\"\\n9071,1,1,\"Number of participants completing exercise sessions as a function of the whole programme.\"\\n9072,1,1,\"Number of participants deemed ineligible or refusing to participate\"\\n9073,1,1,\"Number of Participants Discontinue study due to TEAE\"\\n9074,2,1,\"Number of Participants Discontinuing Due to AEs\"\\n9075,2,1,\"Number of Participants Discontinuing From Study Treatment Due to an AE\"\\n9076,1,1,\"Number of participants discontinuing study drug due to adverse events\"\\n9077,5,4,\"Number of Participants Discontinuing Study Drug Due to AEs\"\\n9078,1,1,\"Number of participants discontinuing study drug due to AEs\"\\n9079,3,1,\"Number of Participants Discontinuing Study Drug Due to an Adverse Event\"\\n9080,9,1,\"Number of Participants Discontinuing Study Drug Due to an AE\"\\n9081,6,3,\"Number of Participants Discontinuing Study Treatment Due to AEs\"\\n9082,2,1,\"Number of Participants Discontinuing Study Treatment due to an Adverse Event\"\\n9083,4,3,\"Number of participants discontinuing study treatment due to an AE\"\\n9084,1,1,\"Number of Participants Discontinuing Treatment Due to AEs\"\\n9085,1,1,\"Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.\"\\n9086,2,2,\"Number of Participants Evaluated for Toxicity\"\\n9087,1,1,\"Number of Participants Experiencing a Dose Limiting Toxicity\"\\n9088,1,1,\"Number of Participants Experiencing a Dose Limiting Toxicity (DLT) (Phase I) and the Recommended Phase IB Dose (RP2D)\"\\n9089,1,1,\"Number of Participants Experiencing a Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0)\"\\n9090,1,1,\"Number of Participants Experiencing a Dose-Limiting Toxicity (DLT)\"\\n9091,2,1,\"Number of Participants Experiencing a Dose-limiting Toxicity (DLT)\"\\n9092,1,1,\"Number of participants experiencing a dose-limiting toxicity (DLT)\"\\n9093,1,1,\"Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in Phase\"\\n9094,1,1,\"Number of Participants Experiencing a Safety Event\"\\n9095,19,3,\"Number of Participants Experiencing Adverse Events\"\\n9096,4,1,\"Number of participants experiencing adverse events\"\\n9097,24,12,\"Number of Participants Experiencing Adverse Events (AEs)\"\\n9098,1,1,\"Number of Participants experiencing Adverse Events (AEs)\"\\n9099,3,1,\"Number of participants experiencing Adverse Events (AEs)\"\\n9100,3,1,\"Number of participants experiencing adverse events (AEs)\"\\n9101,1,1,\"Number of participants experiencing adverse events (AEs) /serious adverse events (SAEs)\"\\n9102,1,1,\"Number of Participants Experiencing Adverse Events (AEs) During Safety Lead-in Phase\"\\n9103,1,1,\"Number of participants experiencing adverse events (AEs) leading to discontinuation\"\\n9104,1,1,\"Number of Participants Experiencing Adverse Events Considered to be at Least Possibly Related to the Study Drug\"\\n9105,20,2,\"Number of Participants Experiencing an Adverse Event (AE)\"\\n9106,3,1,\"Number of participants experiencing an adverse event (AE)\"\\n9107,1,1,\"Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in Phase\"\\n9108,1,1,\"Number of Participants Experiencing at Least One Grade 3 to 5 Adverse Events for Each of the Three Combinations of Agents\"\\n9109,10,4,\"Number of participants experiencing clinical and laboratory adverse events (AEs)\"\\n9110,1,1,\"Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy\"\\n9111,1,1,\"Number of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy\"\\n9112,1,1,\"number of participants experiencing clinical or laboratory adverse events\"\\n9113,1,1,\"Number of Participants Experiencing Clinically Significant Electrocardiograms (ECGs)\"\\n9114,1,1,\"Number of Participants Experiencing Clinically Significant Laboratory Parameters (Clinical Chemistry)\"\\n9115,1,1,\"Number of Participants Experiencing Clinically Significant Laboratory Parameters (Hematology)\"\\n9116,1,1,\"Number of Participants Experiencing Clinically Significant Physical Examination Results (Weight Decrease)\"\\n9117,1,1,\"Number of Participants Experiencing Clinically Significant Vital Signs\"\\n9118,1,1,\"Number Of Participants Experiencing DLT Graded According To CTCAE Version 4.03, Observed In The Cycle 1 In Order To Meet The Objective Of Assessment Of The MTD\"\\n9119,1,1,\"Number of participants experiencing dosage limiting toxicity (DLT) in the first treatment cycle of the combination of ADG106 and PD-1 antibody.\"\\n9120,1,1,\"Number of Participants Experiencing Dose Limiting Toxicities\"\\n9121,1,1,\"number of participants experiencing dose limiting toxicities\"\\n9122,2,1,\"Number of Participants Experiencing Dose Limiting Toxicities (DLTs)\"\\n9123,1,1,\"Number of Participants Experiencing Dose Limiting Toxicities (DLTs) During the Dose Escalation Phase\"\\n9124,1,1,\"Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I\"\\n9125,1,1,\"Number of Participants Experiencing Dose-limiting Toxicities\"\\n9126,3,2,\"Number of participants experiencing dose-limiting toxicities\"\\n9127,1,1,\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)\"\\n9128,8,6,\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)\"\\n9129,2,2,\"Number of Participants Experiencing Dose-limiting Toxicities (DLTs)\"\\n9130,1,1,\"Number of Participants Experiencing dose-limiting toxicities (DLTs)\"\\n9131,2,1,\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0)\"\\n9132,1,1,\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1)\"\\n9133,1,1,\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0) in Participants in escalating part.\"\\n9134,1,1,\"Number of Participants Experiencing Dose-limiting Toxicities (DLTs) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 by the Investigator\"\\n9135,1,1,\"Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level associated with administration of BAY2927088\"\\n9136,1,1,\"Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level in the dose escalation part of the study\"\\n9137,1,1,\"Number of participants experiencing dose-limiting toxicities escalating dose levels\"\\n9138,2,2,\"Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors\"\\n9139,1,1,\"Number of Participants Experiencing Dose-Limiting Toxicities in Dose Optimization Cohort 1a\"\\n9140,1,1,\"Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs)\"\\n9141,1,1,\"Number of participants experiencing dose-limiting toxicity (DLTs) at each dose level in the dose-escalation part of the study\"\\n9142,1,1,\"Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month\"\\n9143,1,1,\"Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug\"\\n9144,1,1,\"Number of participants experiencing serious adverse events\"\\n9145,1,1,\"Number of participants experiencing serious adverse events (SAEs) and/or adverse events (AEs) regardless of causality\"\\n9146,1,1,\"Number of Participants Experiencing Serious Adverse Events and Non-serious Adverse Events\"\\n9147,1,1,\"Number of Participants Experiencing Severe Adverse Events (SAEs)\"\\n9148,1,1,\"Number of participants experiencing Severe Adverse Events (SAEs)\"\\n9149,1,1,\"Number of Participants experiencing Severe Adverse Events (SAEs) as assessed by the investigator.\"\\n9150,2,2,\"Number of Participants Experiencing Severe AEs (SAEs)\"\\n9151,7,4,\"Number of participants experiencing study drug-related toxicities\"\\n9152,1,1,\"Number of participants experiencing toxicities\"\\n9153,1,1,\"Number of Participants Experiencing ‚â•1 Adverse Event\"\\n9154,1,1,\"Number of Participants Experiencing ‚â•1 Dose-Limiting Toxicity (DLT) in Cycle 1\"\\n9155,1,1,\"Number of Participants Experiencing ‚â•Grade 3 Severity in Laboratory Parameters (Clinical Chemistry)\"\\n9156,1,1,\"Number of Participants Experiencing ‚â•Grade 3 Severity in Laboratory Parameters (Hematology)\"\\n9157,1,1,\"Number of Participants Experiencing ‚â•Grade 3 Severity in Physical Examination Results (Skin Pigmentation)\"\\n9158,1,1,\"Number of Participants in Each Clinical Response Category\"\\n9159,1,1,\"Number of Participants in Phase IIa of the Study Who Received 12 or More Paclitaxel Doses in Combination With T-DM1 and/or Pertuzumab\"\\n9160,1,1,\"Number of participants in treatment related adverse events assessed by CTCAE v4.0\"\\n9161,1,1,\"Number of Participants on hypomethylating agents (HMA) and the effectiveness of HMA in the SEER-Medicare MDS population\"\\n9162,1,1,\"Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies\"\\n9163,1,1,\"Number of Participants Reporting Adverse Events (AE)\"\\n9164,1,1,\"Number of Participants Reporting Clinically Significant Change From Baseline in Laboratory Values\"\\n9165,1,1,\"Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs\"\\n9166,1,1,\"Number of Participants Reporting Dose-Limiting Toxicity (DLT)\"\\n9167,10,1,\"Number of Participants Reporting One or More Adverse Drug Reactions\"\\n9168,1,1,\"Number of Participants Reporting One or More Adverse Events (AEs) of Special Interest\"\\n9169,1,1,\"Number of Participants Reporting One or More AEs\"\\n9170,1,1,\"Number of Participants Reporting One or More Non-serious Adverse Events (Non-SAEs)\"\\n9171,7,1,\"Number of Participants Reporting One or More Serious Adverse Drug Reactions\"\\n9172,1,1,\"Number of Participants Reporting one or More Serious Adverse Event (SAEs)\"\\n9173,2,1,\"Number of Participants Reporting One or More Serious Adverse Events (SAEs)\"\\n9174,1,1,\"Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)\"\\n9175,1,1,\"Number of Participants Reporting One or More Treatment Emergent Serious Adverse events (TESAEs)\"\\n9176,1,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (AEs) and Serious Adverse Event (SAEs)\"\\n9177,1,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)\"\\n9178,1,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) or Serious Adverse Events (SAE)\"\\n9179,2,1,\"Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)\"\\n9180,2,2,\"Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity\"\\n9181,1,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs)\"\\n9182,5,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n9183,2,1,\"Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n9184,1,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths\"\\n9185,1,1,\"Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1\"\\n9186,2,1,\"Number of participants reporting serious adverse events (SAEs) and non-SAEs\"\\n9187,3,1,\"Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)\"\\n9188,1,1,\"Number of Participants Reporting Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest\"\\n9189,1,1,\"Number of Participants Requiring Blood Transfusion\"\\n9190,1,1,\"Number of Participants Requiring Lymph Node Dissection\"\\n9191,1,1,\"Number of Participants Retreated with Docetaxel in Participants with mCRPC\"\\n9192,1,1,\"Number of Participants taking 5 mg entinostat weekly in combination with avelumab with Adverse Events as a Measure of Safety and Tolerability\"\\n9193,1,1,\"Number of Participants taking defactinib in combination with avelumab with Adverse Events as a Measure of Safety and Tolerability\"\\n9194,1,1,\"Number of Participants That Achieved a Response (Complete or Partial) After Receiving PR104/Docetaxel Versus Docetaxel Alone\"\\n9195,1,1,\"Number of Participants That Experience a Dose Limiting Toxicity\"\\n9196,1,1,\"Number of Participants That Experience Progression-free Survival.\"\\n9197,2,1,\"Number of Participants That Experienced Adverse Events\"\\n9198,2,2,\"Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period\"\\n9199,1,1,\"Number of Participants That Have a T790M Mutation on Their Progression Biopsy.\"\\n9200,1,1,\"Number of participants that result in sufficient pharmacodynamic criteria\"\\n9201,1,1,\"Number of Participants to receive 6 vaccinations\"\\n9202,1,1,\"Number of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment\"\\n9203,1,1,\"Number of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment\"\\n9204,1,1,\"Number of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment\"\\n9205,1,1,\"Number of Participants Who Achieved a Clinical Response With Mixed Dosing Regimen, 10-12 Weeks After Start of Treatment\"\\n9206,1,1,\"Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 3-4 Weeks After Start of Treatment\"\\n9207,1,1,\"Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 6-8 Weeks After Start of Treatment\"\\n9208,1,1,\"Number of Participants Who Achieved a Confirmed Response\"\\n9209,1,1,\"Number of participants who are able to complete neoadjuvant chemotherapy plus EUS-RFA and later undergo surgical tumor resection\"\\n9210,1,1,\"Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.\"\\n9211,1,1,\"Number of Participants Who Completed the Dyspnea Numeric Rating Scale\"\\n9212,1,1,\"Number of Participants Who Could Tolerate Each Dose Level\"\\n9213,1,1,\"Number of Participants Who Could Undergo Partial Nephrectomy After Pazopanib Therapy\"\\n9214,1,1,\"Number of Participants Who Develop at Least a 4-fold or 2.5- Fold Increase in Anti-Human Epidermal Growth Factor Receptor (HER2)/Neu Antibody Dilution Titers\"\\n9215,1,1,\"Number of Participants Who Died - Carbiralizumab Monotherapy\"\\n9216,1,1,\"Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death\"\\n9217,1,1,\"Number of Participants Who Died Due to Any Cause\"\\n9218,1,1,\"Number of Participants Who Died During the Study\"\\n9219,1,1,\"Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)\"\\n9220,1,1,\"Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)\"\\n9221,1,1,\"Number of Participants Who Died: Part 1\"\\n9222,1,1,\"Number of Participants Who Discontinue Study Drug Due to an Adverse Event (AE)\"\\n9223,5,1,\"Number of Participants Who Discontinue Study Drug Due to an AE\"\\n9224,5,3,\"Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)\"\\n9225,9,6,\"Number of Participants Who Discontinue Study Treatment Due to an AE\"\\n9226,3,1,\"Number of participants who discontinue study treatment due to an AE\"\\n9227,2,2,\"Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in Phase\"\\n9228,1,1,\"Number of Participants Who Discontinued First-Line Sunitinib Treatment\"\\n9229,16,1,\"Number of Participants Who Discontinued Study Drug Due to an Adverse Event\"\\n9230,14,2,\"Number of Participants Who Discontinued Study Drug Due to an AE\"\\n9231,1,1,\"Number of Participants Who Discontinued Study Drug Due to TEAEs\"\\n9232,1,1,\"Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)\"\\n9233,1,1,\"Number of Participants Who Discontinued Study Treatment Due to a Treatment-related Adverse Event (AE)\"\\n9234,4,1,\"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event\"\\n9235,1,1,\"Number of Participants Who Discontinued Study Treatment Due to An Adverse Event (AE)\"\\n9236,7,3,\"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)\"\\n9237,20,9,\"Number of Participants Who Discontinued Study Treatment Due to an AE\"\\n9238,4,2,\"Number of participants who discontinued study treatment due to an AE\"\\n9239,1,1,\"Number of Participants who Discontinued the Treatment\"\\n9240,6,1,\"Number of Participants Who Discontinued Treatment Due to an Adverse Event\"\\n9241,3,3,\"Number of Participants Who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests\"\\n9242,1,1,\"Number of Participants who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests\"\\n9243,1,1,\"Number of Participants who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements\"\\n9244,1,1,\"Number of Participants Who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Results\"\\n9245,1,1,\"Number of Participants Who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECGs) Measurement\"\\n9246,2,2,\"Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurement\"\\n9247,1,1,\"Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurements\"\\n9248,1,1,\"Number of Participants who Experience a Clinically Significant Change from Baseline in Vital Signs\"\\n9249,1,1,\"Number of participants who experience a clinically significant change in clinical laboratory tests\"\\n9250,1,1,\"Number of Participants Who Experience a Clinically Significant Change in Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n9251,1,1,\"Number of participants who experience a clinically significant change in vital signs\"\\n9252,1,1,\"Number of Participants Who Experience a Dose Interruption\"\\n9253,1,1,\"Number of Participants who Experience a Dose Interruption\"\\n9254,1,1,\"Number of Participants Who Experience a Dose Limiting Toxicity (DLT)\"\\n9255,1,1,\"Number of Participants who Experience a Dose Limiting Toxicity (DLT)\"\\n9256,1,1,\"Number of Participants Who Experience a Dose Limiting Toxicity (DLT) During the Dose-Escalation Phase\"\\n9257,1,1,\"Number of Participants Who Experience a Dose Reduction\"\\n9258,1,1,\"Number of Participants who Experience a Dose Reduction\"\\n9259,4,2,\"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)\"\\n9260,1,1,\"Number of Participants who Experience a Dose-Limiting Toxicity (DLT)\"\\n9261,1,1,\"Number of Participants who Experience a Dose-limiting Toxicity (DLT)\"\\n9262,1,1,\"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During Safety Lead-in Phase\"\\n9263,1,1,\"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During the First 28-day Cycle of Combination Treatment In Phase 1\"\\n9264,1,1,\"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Part 1 only)\"\\n9265,1,1,\"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Part 2 only)\"\\n9266,1,1,\"Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE)\"\\n9267,5,1,\"Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)\"\\n9268,1,1,\"Number of Participants Who Experience a Treatment-related AE\"\\n9269,1,1,\"Number of Participants Who Experience Adverse Events (Phase I)\"\\n9270,7,2,\"Number of Participants Who Experience an Adverse Event (AE)\"\\n9271,1,1,\"Number of Participants who Experience an Adverse Event (AE)\"\\n9272,1,1,\"Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n9273,1,1,\"Number of Participants Who Experience At Least One adverse event (AE)\"\\n9274,7,4,\"Number of Participants Who Experience at Least One Adverse Event (AE)\"\\n9275,2,2,\"Number of Participants Who Experience At Least One AE\"\\n9276,1,1,\"Number of Participants Who Experience At Least One Treatment Emergent Adverse Event (TEAE)\"\\n9277,1,1,\"Number of Participants Who Experience At Least One Treatment Emergent Serious Adverse Event (SAE)\"\\n9278,1,1,\"Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Tests\"\\n9279,1,1,\"Number of Participants who Experience Clinically Significant Changes in Vital Signs\"\\n9280,1,1,\"Number of Participants Who Experience Clinically Significant Electrocardiogram (ECG) Results\"\\n9281,1,1,\"Number of Participants who experience Dose Limiting Toxicities\"\\n9282,2,1,\"Number of Participants Who Experience Dose Limiting Toxicities (DLTs)\"\\n9283,2,1,\"Number of Participants who Experience Dose Limiting Toxicities (DLTs)\"\\n9284,1,1,\"Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin\"\\n9285,1,1,\"Number of participants who experience dose limiting toxicity as defined in the protocol.\"\\n9286,1,1,\"Number of participants who experience dose limiting toxicity as defined in the protocol. (Phase 1b)\"\\n9287,1,1,\"Number of Participants Who Experience Dose-Limiting Toxicity (DLT)\"\\n9288,1,1,\"Number of Participants Who Experience One or More Adverse Events (AEs)\"\\n9289,1,1,\"Number of Participants Who Experience One or More Dose- Limiting Toxicities (DLTs)\"\\n9290,1,1,\"Number of Participants who Experience One or More Dose-limiting Toxicities (DLTs)\"\\n9291,1,1,\"Number of Participants who Experience One or More Treatment-emergent Adverse Event (TEAE)\"\\n9292,1,1,\"Number of Participants who Experience One or More Treatment-emergent Adverse Events (TEAEs)\"\\n9293,2,1,\"Number of participants who experience one or more treatment-emergent adverse events (TEAEs)\"\\n9294,2,2,\"Number of Participants who Experience One or More Treatment-related Adverse Events\"\\n9295,1,1,\"Number of participants who experience one or more treatment-related adverse events\"\\n9296,1,1,\"Number of Participants Who Experience ‚â•1 Adverse Event (AE)\"\\n9297,3,2,\"Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)\"\\n9298,3,3,\"Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1\"\\n9299,1,1,\"Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD)\"\\n9300,3,1,\"Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)\"\\n9301,2,1,\"Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)\"\\n9302,1,1,\"Number of participants who experienced a dose-limiting toxicity (DLT)\"\\n9303,1,1,\"Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) by Severity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Criteria\"\\n9304,1,1,\"Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 0 and Cycle 1 Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v 3.0)\"\\n9305,1,1,\"Number of Participants Who Experienced a Dose-Limiting Toxicity With a CTCAE Grade of 3 or Above\"\\n9306,1,1,\"Number of Participants Who Experienced a Serious Adverse Event (SAE)\"\\n9307,2,1,\"Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)\"\\n9308,1,1,\"Number of Participants Who Experienced a Treatment-related Adverse Event (AE) or Laboratory Abnormality by Severity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Criteria\"\\n9309,1,1,\"Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)\"\\n9310,1,1,\"Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0\"\\n9311,1,1,\"Number of participants who experienced AE during cycle1.\"\\n9312,15,2,\"Number of Participants Who Experienced an Adverse Event\"\\n9313,32,11,\"Number of Participants Who Experienced an Adverse Event (AE)\"\\n9314,4,2,\"Number of participants who experienced an adverse event (AE)\"\\n9315,1,1,\"Number of Participants Who Experienced an AE\"\\n9316,1,1,\"Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)\"\\n9317,1,1,\"Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28\"\\n9318,1,1,\"Number of Participants Who Experienced at Least 1 Causally Related AE.\"\\n9319,12,1,\"Number of Participants Who Experienced at Least One Adverse Event\"\\n9320,8,4,\"Number of Participants Who Experienced At Least One Adverse Event (AE)\"\\n9321,11,4,\"Number of Participants Who Experienced at Least One Adverse Event (AE)\"\\n9322,1,1,\"Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)\"\\n9323,1,1,\"Number of Participants Who Experienced at Least One SAE\"\\n9324,1,1,\"Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1\"\\n9325,1,1,\"Number of participants who experienced DLT during cycle1.\"\\n9326,1,1,\"Number of Participants Who Experienced Dose Limited Toxicity in Combination Therapy of Nintedanib and Docetaxel\"\\n9327,3,1,\"Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)\"\\n9328,1,1,\"Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 5.0\"\\n9329,1,1,\"Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03\"\\n9330,1,1,\"Number of Participants Who Experienced Dose Limiting Toxicity (DLT)\"\\n9331,1,1,\"Number of Participants Who Experienced Dose-Limiting Toxicities\"\\n9332,19,7,\"Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)\"\\n9333,3,1,\"Number of Participants Who Experienced Dose-limiting Toxicities (DLTs)\"\\n9334,1,1,\"Number of participants who experienced dose-limiting toxicities (DLTs)\"\\n9335,1,1,\"Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) (Phase Ib)\"\\n9336,3,1,\"Number of Participants Who Experienced One or More Adverse Events\"\\n9337,1,1,\"Number of Participants Who Experienced Selected Adverse Events\"\\n9338,1,1,\"Number of Participants Who Experienced Serious Adverse Events (SAE), Adverse Events (AE) Leading to Discontinuation, or Death\"\\n9339,1,1,\"Number of Participants Who Had a Clinical Response (Complete Response + Partial Response) to Treatment (Objective Tumor Regression)\"\\n9340,1,1,\"Number of Participants Who Had a Prostate-specific Antigen (PSA) Response\"\\n9341,1,1,\"Number of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria\"\\n9342,1,1,\"Number of Participants Who Had Adverse Events That Required Dose Modification of T-DM1 or Paclitaxel\"\\n9343,1,1,\"Number of Participants Who Had Brain Metastases\"\\n9344,1,1,\"Number of Participants Who Had Surgical Complications Post-Resection\"\\n9345,1,1,\"Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013\"\\n9346,1,1,\"Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013\"\\n9347,1,1,\"Number of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression)\"\\n9348,1,1,\"Number of Participants Who Progressed\"\\n9349,1,1,\"Number of Participants Who Received Any Concomitant Medications During the Study\"\\n9350,1,1,\"Number of Participants Who Received Any Concomitant Medications During the Study Period\"\\n9351,1,1,\"Number of Participants Who Received Chemotherapy Prior to Enrolment in Study\"\\n9352,1,1,\"Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery\"\\n9353,1,1,\"Number of Participants Who Required Concomitant Medications\"\\n9354,1,1,\"Number of Participants who Switch the Treatment\"\\n9355,1,1,\"Number of Participants Who Switched to IAD Regimen by Visit\"\\n9356,1,1,\"Number of Participants who Undergo Dose Reductions due to TEAE\"\\n9357,1,1,\"Number of Participants Who Were Progression Free at 2 Months\"\\n9358,1,1,\"Number of Participants Who Withdrew Due to Toxicity and Changes in Safety Assessment\"\\n9359,1,1,\"Number of Participants Whose Best Response is a Complete Response (CR) or Partial Response (PR)\"\\n9360,1,1,\"Number of Participants Whose Response Allowed Them to Proceed to Chemoradiation\"\\n9361,2,1,\"Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs\"\\n9362,1,1,\"Number of Participants With 1 or More Different Treatment Lines Before Axitinib Treatment Initiation: Long Responders Versus Refractory Participants\"\\n9363,1,1,\"Number of Participants With 1 or More Metastatic Locations at Diagnosis of Advance or Metastatic Renal Cell Carcinoma Before First Line Treatment Initiation: Long Responders Versus Refractory Participants\"\\n9364,1,1,\"Number of Participants With 1 or More Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)\"\\n9365,7,2,\"Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEs\"\\n9366,1,1,\"Number of participants with 12-lead electrocardiogram (ECG) abnormalities in Safety Part\"\\n9367,1,1,\"Number of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only)\"\\n9368,1,1,\"Number of Participants With >= Grade 3 Laboratory Results\"\\n9369,1,1,\"Number of Participants With >= Grade 3 TEAEs as Assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03\"\\n9370,1,1,\"Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion\"\\n9371,1,1,\"Number of Participants With a Best Observed Response\"\\n9372,2,2,\"Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee (IRC)\"\\n9373,1,1,\"Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Investigator\"\\n9374,1,1,\"Number of Participants With a Best Response\"\\n9375,1,1,\"Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I\"\\n9376,1,1,\"Number of Participants With a Change From Baseline to the Indicated Worst-case Post-Baseline Bazett\\'s Heart Rate-corrected QT Interval (QTc) Value\"\\n9377,1,1,\"Number of Participants With a Change in elF4e Protein Levels in Matched Pre and Post Tumor Biopsies\"\\n9378,1,1,\"Number of Participants With a Change in Maximum NaF PET/CT Standardized Uptake Values\"\\n9379,1,1,\"Number of Participants With a Change in the Level of a Particular Gene Called elF4E [Eukaryotic Initiation Factors (elF)4e Messenger Ribonucleic Acid (mRNA) Levels] in Matched Pre and Post Tumor Biopsies\"\\n9380,1,1,\"Number of Participants With a Change in Total NaF PET/CT Standardized Uptake Values\"\\n9381,1,1,\"Number of Participants With a Clinical Activity-radiographic Response\"\\n9382,1,1,\"Number of Participants With a Clinical Response (Complete Response (CR) + Partial Response (PR)) Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n9383,1,1,\"Number of Participants With a Clinical Response (Partial Response (PR) + Clinical Response (CR))\"\\n9384,1,1,\"Number of Participants with a Clinically Significant Change from Baseline in Clinical Laboratory Tests\"\\n9385,1,1,\"Number of Participants with a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements\"\\n9386,1,1,\"Number of Participants with a Clinically Significant Change from Baseline in Vital Signs\"\\n9387,1,1,\"Number of Participants With a Complete or Partial Response Rate to the Combination of Voriconazole and Caspofungin at 12 Weeks.\"\\n9388,1,1,\"Number of Participants With a Complete Response (CR) + Partial Response (PR)\"\\n9389,1,1,\"Number of Participants With a Congestive Heart Failure Event\"\\n9390,1,1,\"Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ‚â• 20 Points at Worst Record On-study Compared With Baseline\"\\n9391,6,6,\"Number of Participants With a Dose Limiting Toxicity (DLT)\"\\n9392,3,2,\"Number of Participants with a Dose Limiting Toxicity (DLT)\"\\n9393,11,11,\"Number of participants with a Dose Limiting Toxicity (DLT)\"\\n9394,1,1,\"Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)\"\\n9395,1,1,\"Number of participants with a Dose Limiting Toxicity (DLT) in Phase 1b\"\\n9396,1,1,\"Number of participants with a Dose Limiting Toxicity (DLTs)\"\\n9397,1,1,\"Number of Participants With a Dose- Limiting Toxicity (DLT) in Cycle 1\"\\n9398,1,1,\"Number of Participants With a Dose-Limiting Toxicity (DLT)\"\\n9399,4,3,\"Number of Participants With a Dose-limiting Toxicity (DLT)\"\\n9400,1,1,\"Number of participants with a dose-limiting toxicity (DLT)\"\\n9401,1,1,\"Number of participants with a dose-limiting toxicity (DLT) at each dose level\"\\n9402,2,1,\"Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1\"\\n9403,2,2,\"Number of Participants with a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 5.0\"\\n9404,1,1,\"Number of participants with a Dose-Limiting Toxicity (DLT) in the Safety Lead-in Phase\"\\n9405,1,1,\"Number of Participants with a High Grade (>= Grade 3) Protocol Specified TEAE\"\\n9406,1,1,\"Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0\"\\n9407,1,1,\"Number of Participants With a Partial Response\"\\n9408,2,1,\"Number of Participants With a Pathological Complete Response\"\\n9409,1,1,\"Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay\"\\n9410,1,1,\"Number of Participants With a Prostate-specific Antigen Response\"\\n9411,1,1,\"Number of Participants With a Recurrence in the Unirradiated Neck(s)\"\\n9412,13,4,\"Number of Participants With a Response\"\\n9413,1,1,\"Number of Participants With a Response (Partial Response (PR) + Complete Response (CR)) of AZD2171 in Adult Participants With Alveolar Soft Part Sarcoma (ASPS)\"\\n9414,1,1,\"Number of Participants With a Response to Therapy\"\\n9415,1,1,\"Number of Participants With a Response, Evaluated According to RECIST 1.1\"\\n9416,1,1,\"Number of Participants With a Toxic Event\"\\n9417,1,1,\"Number of Participants With a Treatment-Emergent Adverse Event (TEAE)\"\\n9418,4,1,\"Number of Participants With a Treatment-emergent Adverse Event (TEAE)\"\\n9419,1,1,\"Number of Participants with a Treatment-emergent Adverse Event (TEAE)\"\\n9420,1,1,\"Number of Participants with a Treatment-related Adverse Event\"\\n9421,1,1,\"Number of Participants With a Tumor Response (PR + CR) Per RECIST\"\\n9422,1,1,\"Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)\"\\n9423,1,1,\"Number of Participants with Abnormal 12-lead ECG\"\\n9424,1,1,\"Number of participants with abnormal 12-lead electrocardiogram (ECG) readings (Part B Dose Expansion)\"\\n9425,2,1,\"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs\"\\n9426,1,1,\"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose-escalation Phase\"\\n9427,1,1,\"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in the Dose-escalation, Dose-exploration, and Dose-expansion Phase\"\\n9428,1,1,\"Number of participants with abnormal clinical laboratory test results (Part B Dose Expansion)\"\\n9429,1,1,\"Number of Participants With Abnormal Clinical Laboratory Values Reported as Adverse Events\"\\n9430,1,1,\"Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings\"\\n9431,1,1,\"Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings During Combination Treatment Period\"\\n9432,2,1,\"Number of participants with abnormal ECG\"\\n9433,1,1,\"Number of participants with abnormal ECGs (electrocardiograms)\"\\n9434,1,1,\"Number of Participants With Abnormal Echocardiogram (ECHO) Findings\"\\n9435,1,1,\"Number of participants with abnormal ECOG\"\\n9436,1,1,\"Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Parts 1 and 2\"\\n9437,1,1,\"Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs\"\\n9438,2,1,\"Number of Participants With Abnormal Electrocardiogram (ECG) Reported as TEAEs\"\\n9439,1,1,\"Number of Participants With Abnormal Electrocardiograms (ECGs) and Echocardiograms (ECHOs) Reported as TEAEs\"\\n9440,1,1,\"Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs in Dose-escalation Phase\"\\n9441,1,1,\"Number of Participants With Abnormal Hematology Laboratory Values\"\\n9442,1,1,\"Number of Participants With Abnormal Hepatic Test Values\"\\n9443,1,1,\"Number of participants with abnormal Karnofsky PS\"\\n9444,1,1,\"Number of Participants With Abnormal Laboratory Parameter Values (Chemistry) as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version (v) 4.03\"\\n9445,1,1,\"Number of Participants With Abnormal Laboratory Parameter Values (Hematology) as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version 4.03\"\\n9446,3,2,\"Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs\"\\n9447,1,1,\"Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs in Parts 1 and 2\"\\n9448,1,1,\"Number of participants with abnormal laboratory results\"\\n9449,7,2,\"Number of Participants With Abnormal Laboratory Values\"\\n9450,1,1,\"Number of Participants with Abnormal Laboratory Values\"\\n9451,3,2,\"Number of participants with abnormal laboratory values\"\\n9452,11,3,\"Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment\"\\n9453,1,1,\"Number of participants With Abnormal Laboratory Values and/or Adverse Events to assess Safety and tolerability of AZD6738.\"\\n9454,1,1,\"Number of Participants With Abnormal Laboratory Values Reported as Adverse Events at an Incidence of at Least 5%\"\\n9455,2,2,\"Number of Participants with abnormal laboratory values.\"\\n9456,1,1,\"Number of participants with abnormal ophthalmic evaluation\"\\n9457,3,1,\"Number of participants with abnormal physical examinations\"\\n9458,1,1,\"Number of Participants With Abnormal Serum Chemistry Laboratory Values\"\\n9459,1,1,\"Number of Participants With Abnormal Urinalysis Parameters-Part 1\"\\n9460,1,1,\"Number of participants with abnormal vital sign measurements (Part B Dose Expansion)\"\\n9461,1,1,\"Number of Participants with Abnormal Vital Signs\"\\n9462,12,2,\"Number of participants with abnormal vital signs\"\\n9463,1,1,\"Number of Participants With Abnormal Vital Signs and Physical Examination Reported as TEAEs in Parts 1 and 2\"\\n9464,1,1,\"Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAEs\"\\n9465,1,1,\"Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAES in Dose-escalation Phase\"\\n9466,1,1,\"Number of Participants With Abnormal Vital Signs and/or Physical Examination Reported as TEAEs\"\\n9467,2,1,\"Number of Participants With Abnormal Vital Signs Reported as Adverse Events\"\\n9468,3,2,\"Number of Participants With Abnormal Vital Signs Reported as TEAEs\"\\n9469,1,1,\"Number of Participants With Abnormal Vital Signs Reported as TEAEs in the Dose-escalation, Dose-exploration, and Dose-expansion Phase\"\\n9470,1,1,\"Number of Participants With Abnormalities in Selected Hepatic Clinical Laboratory Tests\"\\n9471,1,1,\"Number of Participants With Abnormalities in Selected Thyroid Clinical Laboratory Tests\"\\n9472,1,1,\"Number of Participants With Abnormalities in Urinalysis\"\\n9473,1,1,\"Number of Participants With Abnormalities of Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 in Laboratory Parameters (Clinical Chemistry and Hematology)\"\\n9474,3,2,\"Number of participants with abnormality in clinical chemistry parameters\"\\n9475,3,2,\"Number of participants with abnormality in ECG parameters\"\\n9476,3,2,\"Number of participants with abnormality in hematology parameters\"\\n9477,3,2,\"Number of participants with abnormality in routine urinalysis parameters\"\\n9478,3,2,\"Number of participants with abnormality in vital signs\"\\n9479,1,1,\"Number of participants with activated partial thromboplastin time (aPTT) value abnormalities and/or AEs\"\\n9480,1,1,\"Number of participants with Acute Adverse Events (AEs)\"\\n9481,1,1,\"Number of Participants with Acute Dose Limiting Toxicity (DLT)\"\\n9482,1,1,\"Number of participants with adverse bone density imaging assessments via DEXA scan (Part B Dose Expansion)\"\\n9483,1,1,\"Number of Participants With Adverse Drug Reaction\"\\n9484,12,1,\"Number of Participants With Adverse Drug Reactions\"\\n9485,2,2,\"Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0\"\\n9486,1,1,\"Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Toxicity Criteria for Adverse Events Version 2.0\"\\n9487,5,1,\"Number of participants with adverse event\"\\n9488,3,1,\"Number of Participants With Adverse Event (AE)\"\\n9489,2,2,\"Number of Participants with Adverse Event (AE)\"\\n9490,1,1,\"Number of Participants With Adverse Event (AE) and Serious Adverse Event (SAE)\"\\n9491,1,1,\"Number of Participants with Adverse Event of Hypertension\"\\n9492,1,1,\"Number of Participants with Adverse Event of Interstitial Lung Disease\"\\n9493,1,1,\"Number of Participants with Adverse Event of Myelosuppression\"\\n9494,1,1,\"Number of Participants with Adverse Event of Posterior Reversible Encephalopathy Syndrome\"\\n9495,1,1,\"Number of Participants with Adverse Event of Secondary Malignant Tumors\"\\n9496,1,1,\"Number of Participants with Adverse Event of Thromboembolism\"\\n9497,278,37,\"Number of Participants With Adverse Events\"\\n9498,106,10,\"Number of Participants with Adverse Events\"\\n9499,38,5,\"Number of participants with Adverse Events\"\\n9500,229,39,\"Number of participants with adverse events\"\\n9501,14,2,\"Number of Participants With Adverse Events (AE)\"\\n9502,6,1,\"Number of Participants with Adverse Events (AE)\"\\n9503,1,1,\"Number of participants with adverse events (AE)\"\\n9504,1,1,\"Number of Participants with Adverse events (AE) and Serious Adverse Events (SAEs)\"\\n9505,1,1,\"Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)\"\\n9506,118,15,\"Number of Participants With Adverse Events (AEs)\"\\n9507,51,11,\"Number of Participants with Adverse Events (AEs)\"\\n9508,1,1,\"Number of Participants with adverse events (AEs)\"\\n9509,37,10,\"Number of participants with Adverse Events (AEs)\"\\n9510,74,28,\"Number of participants with adverse events (AEs)\"\\n9511,1,1,\"Number of participants with adverse events (AEs) (Part B Dose Expansion)\"\\n9512,1,1,\"Number of Participants With Adverse Events (AEs) - Carbiralizumab Monotherapy\"\\n9513,1,1,\"Number of Participants With Adverse Events (AEs) - Parts 1, 2 and 5\"\\n9514,1,1,\"Number of Participants with Adverse Events (AEs) According To NCI CTCAE v5.0\"\\n9515,3,1,\"Number of Participants With Adverse Events (AEs) According to Seriousness\"\\n9516,3,1,\"Number of Participants With Adverse Events (AEs) According to Severity\"\\n9517,87,11,\"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n9518,15,2,\"Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n9519,4,1,\"Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n9520,12,2,\"Number of participants with adverse events (AEs) and serious adverse events (SAEs)\"\\n9521,1,1,\"Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1\"\\n9522,1,1,\"Number of participants with adverse events (AEs) and serious adverse events (SAEs) per NCI-CTCAE version 5.0\"\\n9523,1,1,\"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD\"\\n9524,1,1,\"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Parts 1 and 2\"\\n9525,1,1,\"Number of participants with adverse events (AEs) and serious adverse events (SAEs).\"\\n9526,1,1,\"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1\"\\n9527,1,1,\"Number of Participants With Adverse Events (AEs) and Serious AEs\"\\n9528,3,1,\"Number of Participants with Adverse Events (AEs) and Serious AEs\"\\n9529,1,1,\"Number of Participants with Adverse Events (AEs) and Serious AEs as Defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03\"\\n9530,1,1,\"Number of participants with Adverse Events (AEs) as a measure of safety\"\\n9531,3,1,\"Number of participants with Adverse Events (AEs) as a measure of safety and tolerability\"\\n9532,1,1,\"Number of Participants with Adverse Events (AEs) as assessed by NCI-CTCAE v5.0\"\\n9533,3,1,\"Number of Participants With Adverse Events (AEs) by Relationship\"\\n9534,1,1,\"Number of Participants With Adverse Events (AEs) by Seriousness\"\\n9535,1,1,\"Number of participants with adverse events (AEs) in Phase 1\"\\n9536,1,1,\"Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Parts 1, 2 and 5\"\\n9537,1,1,\"Number of Participants With Adverse Events (AEs) or Deaths\"\\n9538,5,1,\"Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment\"\\n9539,1,1,\"Number of Participants with Adverse Events (AEs), AE of Special Interest (AESIs), and Serious AEs (SAEs)\"\\n9540,1,1,\"Number of participants with Adverse events (AEs), Grade 3 and 4 AEs, Serious Adverse events (SAEs), Discontinuations for AEs\"\\n9541,1,1,\"Number of participants with adverse events (AEs), immune mediated AEs (imAEs) and serious AEs (SAEs)\"\\n9542,1,1,\"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)-Part 1\"\\n9543,1,1,\"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-mediated AEs\"\\n9544,1,1,\"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs\"\\n9545,1,1,\"Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), changes in laboratory values, vital signs and ECG parameters\"\\n9546,1,1,\"Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), changes in laboratory values, vital signs, electrocardiogram (ECG), and tolerability (dose interruptions, reductions, and dose intensity)\"\\n9547,1,1,\"Number of participants with Adverse events (AEs).\"\\n9548,1,1,\"Number of Participants with Adverse Events (Alternate dose cohort)\"\\n9549,1,1,\"Number of participants with adverse events (based on CTCAE version 4.0), laboratory values, vital sign measurements, ECG, Physical Examination\"\\n9550,1,1,\"Number of Participants With Adverse Events (Safety)\"\\n9551,3,1,\"Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0\"\\n9552,12,2,\"Number of Participants With Adverse Events and Serious Adverse Events\"\\n9553,7,4,\"Number of participants with adverse events and serious adverse events\"\\n9554,1,1,\"Number of participants with Adverse Events and Serious Adverse Events (SAEs)\"\\n9555,1,1,\"Number of participants with adverse events and serious adverse events as assessed by CTCAE v5.0\"\\n9556,1,1,\"Number of participants with adverse events and serious adverse events of ES102\"\\n9557,1,1,\"Number of participants with adverse events and serious adverse events.\"\\n9558,2,1,\"Number of participants with adverse events and/or abnormal laboratory values that are related to treatment\"\\n9559,2,1,\"Number of Participants With Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of Dose of PD-1 Knockout T Cells Using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in Patients\"\\n9560,4,1,\"Number of Participants With Adverse Events as a Measure of Safety\"\\n9561,14,1,\"Number of Participants with Adverse Events as a Measure of Safety\"\\n9562,39,5,\"Number of Participants With Adverse Events as a Measure of Safety and Tolerability\"\\n9563,113,15,\"Number of Participants with Adverse Events as a Measure of Safety and Tolerability\"\\n9564,1,1,\"Number of Participants with Adverse events as a measure of safety and tolerability\"\\n9565,8,3,\"Number of participants with Adverse Events as a Measure of Safety and Tolerability\"\\n9566,3,1,\"Number of participants with Adverse Events as a measure of safety and tolerability\"\\n9567,38,6,\"Number of participants with adverse events as a measure of safety and tolerability\"\\n9568,1,1,\"Number of participants with adverse events as a measure of safety and tolerability for S95005-oxaliplatin.\"\\n9569,1,1,\"Number of Participants with Adverse Events as a Measure of Safety and Tolerability of 21-Day cycles of AL3818 measured by incidence and severity of treatment-related adverse events (TRAE) - Part 1 (Phase 1b)\"\\n9570,1,1,\"Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with Pembrolizumab in Advanced Solid Cancers\"\\n9571,1,1,\"Number of participants with adverse events as a measure of safety and tolerability of APS001F treatment plus 5-FC and maltose\"\\n9572,1,1,\"Number of participants with adverse events as a measure of safety and tolerability of BAY1436032\"\\n9573,1,1,\"Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine\"\\n9574,1,1,\"Number of participants with adverse events as a measure of safety and tolerability of iC9.GD2.CAR.IL-15 T cells administered to pediatric subjects with relapsed or refractory neuroblastoma or relapsed/refractory osteosarcoma\"\\n9575,1,1,\"Number of participants with adverse events as a measure of safety and tolerability of NeoTCR-P1 or NeoTCR-P1 in combination with nivolumab\"\\n9576,1,1,\"Number of participants with adverse events as a measure of safety and tolerability of SDX-7320 to find the recommended Phase II dose\"\\n9577,1,1,\"Number of Participants With Adverse Events as a Measure of Safety and Tolerability.\"\\n9578,1,1,\"Number of participants with adverse events as a measure safety and tolarability\"\\n9579,1,1,\"Number of participants with adverse events as a measure safety and tolerability\"\\n9580,1,1,\"Number of participants with adverse events as a measurement of safety and tolerability of the combination of intravenous decitabine with oral genistein in children.\"\\n9581,1,1,\"Number of participants with adverse events as assessed by Common Toxicity Criteria for Adverse Events (CTCAE v5.0)\"\\n9582,4,3,\"Number of participants with adverse events as assessed by CTCAE v5.0\"\\n9583,1,1,\"Number of participants with adverse events as assessed by CTCAE v5.0 ADG126-ADG106 combination regimens\"\\n9584,1,1,\"Number of participants with adverse events as assessed by CTCAE v5.0.\"\\n9585,2,2,\"Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs)\"\\n9586,1,1,\"Number of Participants With Adverse Events at Worst CTC Grade\"\\n9587,1,1,\"Number of participants with adverse events by severity, according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0\"\\n9588,1,1,\"Number of Participants with Adverse Events by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0)\"\\n9589,1,1,\"Number of Participants with Adverse Events by Severity, Classified According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03\"\\n9590,1,1,\"Number of Participants With Adverse Events Causing Dose Reduction of Study Treatment: Part 1\"\\n9591,1,1,\"Number of Participants With Adverse Events Causing Temporary Stop of Study Treatment: Part 1\"\\n9592,1,1,\"Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations\"\\n9593,1,1,\"Number of Participants With Adverse Events Due to MSOT Imaging\"\\n9594,1,1,\"Number of participants with adverse events evaluated with CTCAE, version 4.0\"\\n9595,3,1,\"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0\"\\n9596,1,1,\"Number of participants with adverse events following administration of MTB-9655\"\\n9597,1,1,\"Number of Participants With Adverse Events Grade 3 or Greater as Assessed by CTCAE Version 4.0\"\\n9598,1,1,\"Number of Participants With Adverse Events Grade 3 or Higher\"\\n9599,1,1,\"Number of Participants with Adverse Events Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.0\"\\n9600,1,1,\"Number of participants with adverse events in phase 1a\"\\n9601,1,1,\"Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy\"\\n9602,4,2,\"Number of participants with adverse events leading to permanent discontinuation of study intervention\"\\n9603,2,2,\"Number of Participants with Adverse Events Leading to Permanent Treatment Discontinuation with Cabozantinib Tablets\"\\n9604,1,1,\"Number of Participants with Adverse Events Leading to Pertuzumab Discontinuation or Dose Interruption\"\\n9605,1,1,\"Number of Participants With Adverse Events Leading to Treatment Discontinuation\"\\n9606,1,1,\"Number of Participants With Adverse Events of Clinical Interest\"\\n9607,1,1,\"Number of Participants With Adverse Events of Grades 3 and 4 Severity\"\\n9608,3,1,\"Number of Participants With Adverse Events of Special Interest\"\\n9609,8,1,\"Number of Participants With Adverse Events of Special Interest (AESIs)\"\\n9610,2,1,\"Number of participants with adverse events of special interest (AESIs)\"\\n9611,1,1,\"Number of Participants With Adverse Events Possibly, Probably, or Definitely Related to Study Drug\"\\n9612,1,1,\"Number of participants with adverse events prior to commencing a second cycle of treatment.\"\\n9613,2,2,\"Number of Participants with Adverse Events Related to Hepatic Failure, Hepatic Dysfunction, and Pancreatitis\"\\n9614,1,1,\"Number of Participants With Adverse Events Related to Investigational Product\"\\n9615,1,1,\"Number of participants with adverse events that meet the protocol defined criteria of a Dose Limiting Toxicity while receiving BIO 300 in combination with chemoradiotherapy\"\\n9616,1,1,\"Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)\"\\n9617,9,1,\"Number of Participants With Adverse Events.\"\\n9618,11,3,\"Number of participants with adverse events.\"\\n9619,1,1,\"Number of Participants With Adverse Events/Serious Adverse Events\"\\n9620,2,1,\"Number of participants with adverse events/serious adverse events\"\\n9621,1,1,\"Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)\"\\n9622,1,1,\"Number of Participants with Adverse Reactions (ARs)\"\\n9623,4,1,\"Number of Participants With AEs\"\\n9624,1,1,\"Number of Participants With AEs and Clinical Laboratory Abnormalities (Parts 1B and 2 Only)\"\\n9625,1,1,\"Number of Participants With AEs and SAEs-Part 1 BID\"\\n9626,1,1,\"Number of Participants With AEs and SAEs-Part 2\"\\n9627,10,3,\"Number of Participants with AEs by Severity\"\\n9628,1,1,\"Number of Participants With AEs by Severity Grades-Part 1\"\\n9629,1,1,\"Number of Participants With AEs by Severity Grades-Part 2\"\\n9630,1,1,\"Number of Participants With AEs Leading to Any Dose Reduction or Delays\"\\n9631,1,1,\"Number of Participants With AEs Leading to Discontinuation\"\\n9632,5,2,\"Number of Participants with AEs Leading to Discontinuation\"\\n9633,4,2,\"Number of participants with AEs leading to discontinuation\"\\n9634,1,1,\"Number of Participants With AEs Leading to Discontinuation - Carbiralizumab Monotherapy\"\\n9635,1,1,\"Number of participants with AEs leading to study treatment discontinuation\"\\n9636,1,1,\"Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria\"\\n9637,1,1,\"Number of Participants With AEs Meeting Protocol-defined Dose-Limiting Toxicity (DLT) Criteria - Carbiralizumab Monotherapy\"\\n9638,1,1,\"Number of Participants With AEs, SAEs, AESIs According to Severity - Part 1\"\\n9639,1,1,\"Number of Participants With Age Less Than or Equal to (<=) 65 Years and Greater Than (>) 65 Years at Initiation of Axitinib Treatment: Long Responders Versus Refractory Participants\"\\n9640,1,1,\"Number of Participants With All Cause Adverse Events (AEs), Serious Adverse Events, AEs Leading to Discontinuation and Deaths\"\\n9641,1,1,\"Number of Participants With All-causality TEAEs and SAEs, and Treatment-Related TEAEs and SAEs in Part B\"\\n9642,1,1,\"Number of Participants With All-Causality Treatment Emergent Adverse Events(TEAEs) and Serious Adverse Event(SAEs), Treatment-Related TEAEs and SAEs in Part A\"\\n9643,1,1,\"Number of Participants With All-Causality Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2\"\\n9644,1,1,\"Number of Participants With All-cause Mortality by Any/no Grade 4 CIN and/or FN\"\\n9645,1,1,\"Number of Participants With All-cause Mortality by CIN/FN-related Chemotherapy Disturbance\"\\n9646,1,1,\"Number of Participants With American College of Rheumatology (ACR) Criteria\"\\n9647,1,1,\"Number of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death\"\\n9648,1,1,\"Number of participants with an adverse event as a measure of safety and tolerability\"\\n9649,1,1,\"Number of participants with an antitumor response to KBA1412 monotherapy (Part B) or to KBA1412 in combination with pembrolizumab (Part C)\"\\n9650,1,1,\"Number of Participants With an Event Defining SSE Free Survival - Extended Dose vs. Standard Dose\"\\n9651,1,1,\"Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose\"\\n9652,1,1,\"Number of Participants With an Event Defining SSE Free Survival - Three Dose Groups As Randomized\"\\n9653,1,1,\"Number of Participants With an Immune Response\"\\n9654,1,1,\"Number of Participants With an Objective Clinical Response\"\\n9655,1,1,\"Number of Participants With an Objective Clinical Tumor Regression Response\"\\n9656,1,1,\"Number of Participants With an Objective Clinical Tumor Regression Response According to RECIST Criteria\"\\n9657,4,3,\"Number of Participants With an Objective Response\"\\n9658,1,1,\"Number of Participants With an Objective Response (Complete Response + Partial Response)\"\\n9659,1,1,\"Number of Participants With an Objective Response (Partial Response + Complete Response)\"\\n9660,1,1,\"Number of Participants With an Objective Response Rate: Part 2 and Part 4\"\\n9661,1,1,\"Number of Participants With an Objective Tumor Status of Either a Complete Response(CR) or Partial Response (PR), According to RECIST (Response Evaluation Criteria in Solid Tumors) Criteria\"\\n9662,1,1,\"Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n9663,1,1,\"Number of Participants with Anti-DNIB0600A Antibodies\"\\n9664,1,1,\"Number of Participants With Anti-Ramucirumab Antibodies\"\\n9665,1,1,\"Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability.\"\\n9666,2,2,\"Number of Participants with any (serious and non-serious) Adverse Events.\"\\n9667,6,2,\"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)\"\\n9668,1,1,\"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I\"\\n9669,1,1,\"Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Severity, Per National Cancer Institute (NCI) Common Terminology Criteria in Adverse Events (CTCAE)\"\\n9670,1,1,\"Number of Participants With Any Adverse Event, Adverse Events With Severity, Adverse Events Leading to Discontinuation\"\\n9671,4,1,\"Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n9672,1,1,\"Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Grades 3/4, and Death\"\\n9673,1,1,\"Number of participants with any adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, dose interruptions and reductions\"\\n9674,1,1,\"Number of Participants With any Adverse Events of Special Interest (AESI)\"\\n9675,1,1,\"Number of Participants With Any CIN/FN-related Chemotherapy Disturbance by Prophylaxis Type\"\\n9676,1,1,\"Number of Participants With Any CIN/FN-related Chemotherapy Disturbance by Treatment Decision\"\\n9677,1,1,\"Number of Participants With Any Clinical or Laboratory Adverse Event\"\\n9678,1,1,\"Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value\"\\n9679,1,1,\"Number of participants with any clinically significant clinical laboratory test value\"\\n9680,1,1,\"Number of participants with any clinically significant vital sign value\"\\n9681,1,1,\"Number of participants with any dose-limiting toxicity (DLT)\"\\n9682,1,1,\"Number of Participants With Any Grade Increase in Clinical Chemistry Parameters\"\\n9683,1,1,\"Number of participants with any non-serious TE adverse event (TEAE)\"\\n9684,1,1,\"Number of participants with any non-serious TEAE\"\\n9685,1,1,\"Number of participants with any related TEAE\"\\n9686,1,1,\"Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a\"\\n9687,1,1,\"Number of Participants With Any Serious Adverse Event, Death and Cause of Death\"\\n9688,1,1,\"Number of Participants With any Serious Treatment-emergent Adverse Event (TEAE)\"\\n9689,1,1,\"Number of participants with any TE adverse event (TEAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus\"\\n9690,1,1,\"Number of Participants With any TEAE\"\\n9691,1,1,\"Number of participants with any TEAE leading to study drug discontinuation\"\\n9692,2,2,\"Number of participants with any treatment-emergent (TE) serious adverse event (SAE)\"\\n9693,1,1,\"Number of participants with any treatment-emergent (TE) serious adverse event (SAE) in Phase 1, as a measure of the safety and toxicity of lenvatinib in combination with everolimus\"\\n9694,1,1,\"Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)\"\\n9695,1,1,\"Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) and as Per the Severity\"\\n9696,1,1,\"Number of Participants With at Least 1 Adverse Event (AE) of Grade 3 or 4 Based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03\"\\n9697,1,1,\"Number of Participants With at Least 1 AE of CTCAE >=G3\"\\n9698,1,1,\"Number of Participants With at Least 1 Causally Related AE of CTCAE >=G3\"\\n9699,1,1,\"Number of Participants With at Least 1 Causally Related SAE\"\\n9700,1,1,\"Number of Participants With at Least 1 Dose Modification Due to AE in Part 1\"\\n9701,1,1,\"Number of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics\"\\n9702,1,1,\"Number of Participants With at Least 1 Occurrence of Severe (Grade 4) Neutropenia\"\\n9703,1,1,\"Number of Participants With at Least 1 Point Reduction in Score on 7-category Clinical Status Ordinal Scale\"\\n9704,1,1,\"Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1\"\\n9705,1,1,\"Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1\"\\n9706,1,1,\"Number of Participants With at Least 1 ‚â• Grade 3 TEAE in Part 1\"\\n9707,1,1,\"Number of Participants With at Least 1-Grade Shift From Baseline to Worst Post-baseline in Eastern Co-operative Oncology Group Performance Status (ECOG-PS) Score\"\\n9708,1,1,\"Number of Participants With at Least 2-Grade Shift From Baseline in Laboratory Parameters\"\\n9709,1,1,\"Number of Participants With at Least a 3-point Reduction in Pain Score on the M.D. Anderson Symptom Inventory (MDASI)\"\\n9710,1,1,\"Number of Participants with at Least One Adverse Event, Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)\"\\n9711,1,1,\"Number of Participants With At Least One Adverse Event, with Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)\"\\n9712,1,1,\"Number of Participants With at Least One Adverse Events (AEs)\"\\n9713,1,1,\"Number of Participants With At Least One AE Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version (V) 4.0\"\\n9714,2,1,\"Number of Participants With at Least One Dose Limiting Toxicity (DLT)\"\\n9715,1,1,\"Number of Participants With at Least One Dose Limiting Toxicity Associated With Vorinostat Concurrently Administered With Isotretinoin\"\\n9716,2,2,\"Number of Participants With at Least One Dose Limiting Toxicity in Phase I\"\\n9717,1,1,\"Number of Participants With at Least One Severe or Life-Threatening Adverse Event\"\\n9718,1,1,\"Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Treatment-emergent Serious Adverse Event (TESAE), Graded by Severity\"\\n9719,1,1,\"Number of Participants With Best Confirmed Response\"\\n9720,1,1,\"Number of Participants With Best Confirmed Response in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors\"\\n9721,1,1,\"Number of Participants With Best Objective Response Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal Cancer\"\\n9722,4,1,\"Number of Participants With Best Overall Response\"\\n9723,1,1,\"Number of Participants With Best Overall Response (BOR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n9724,1,1,\"Number of Participants With Best Overall Response (BOR) in Part 1\"\\n9725,1,1,\"Number of Participants With Best Overall Response (BOR) in Part 2\"\\n9726,1,1,\"Number of Participants With Best Overall Response as Assessed With Response Criteria in Solid Tumors (RECIST)\"\\n9727,1,1,\"Number of Participants With Best PSA Response at Day 85 by Category - PSA Evaluable Participants\"\\n9728,3,1,\"Number of Participants With Best Response\"\\n9729,1,1,\"Number of Participants With Best Response As Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n9730,1,1,\"Number of Participants With Best Response Per Response Evaluation Criteria for Solid Tumours Version 1.1. (RECIST v1.1)\"\\n9731,1,1,\"Number of Participants With Best Response to First Line Treatment With Tyrosine Kinase Inhibitor (TKI) Before Axitinib Treatment Initiation: Long Responders Versus Refractory Participants\"\\n9732,1,1,\"Number of Participants With Best Tumor Response as Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n9733,1,1,\"Number of Participants With Best Unconfirmed Response at the Time of the Interim Analysis (Week 8)\"\\n9734,1,1,\"Number of Participants With Biochemistry Parameters Values Falling Within Reference Values at Visit 1\"\\n9735,1,1,\"Number of participants with body weight abnormalities in Safety Part\"\\n9736,1,1,\"Number of Participants With Bone Bio-marker Response\"\\n9737,1,1,\"Number of Participants With Brachyury-Specific T-cell Responses\"\\n9738,1,1,\"Number of Participants with BRAF V600 Mutation as Assessed Using the Idylla^TM Diagnostic Platform\"\\n9739,1,1,\"Number of Participants with BRAF V600 Mutation as Assessed Using the Idylla^TM Diagnostic Platform in Participants With BRAF Wild-Type Based on a Prior Tissue Test Result\"\\n9740,1,1,\"Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator\"\\n9741,1,1,\"Number of Participants With Brain Objective Response According to Response Evaluation Criteria In Solid Tumors (RECIST) Criteria at Cycle 7\"\\n9742,1,1,\"Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region\"\\n9743,1,1,\"Number of Participants With C-reactive Protein and Erythrocyte Sedimentation Rate Falling Within Reference Values at Visit 1\"\\n9744,1,1,\"Number of Participants With Cancer-related Mortality by Any CIN/FN-related Chemotherapy Disturbance\"\\n9745,1,1,\"Number of Participants With Cancer-related Mortality by Any/no Grade 4 CIN or FN\"\\n9746,1,1,\"Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03\"\\n9747,1,1,\"Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ]\"\\n9748,1,1,\"Number of Participants With Cardiac Toxicity\"\\n9749,1,1,\"Number of Participants With Categorical Best Overall Response\"\\n9750,1,1,\"Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse\"\\n9751,1,1,\"Number of Participants With Change From Baseline in Cardiac Function\"\\n9752,1,1,\"Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Parts 1 and 2\"\\n9753,1,1,\"Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Parts 1 and 2\"\\n9754,1,1,\"Number of Participants With Change From Baseline in QT/QTc Interval in Local Electrocardiogram in the Dose-escalation, Dose-exploration, and Dose-expansion Phase\"\\n9755,1,1,\"Number of Participants With Change From Baseline in Urinalysis Data With Respect to Normal Range-Parts 1 and 2\"\\n9756,1,1,\"Number of Participants With Change From Baseline in Vital Signs-Parts 1 and 2\"\\n9757,1,1,\"Number of Participants With Change in Prostate Specific Antigen (PSA) Response Rate\"\\n9758,1,1,\"Number of Participants With Changes in Biomarkers\"\\n9759,1,1,\"Number of Participants With Changes in Blood Pressure From Baseline-Part 2\"\\n9760,1,1,\"Number of participants with changes in clinical laboratory tests\"\\n9761,1,1,\"Number of participants with changes in Clinically Significant Vital Sign from baseline\"\\n9762,1,1,\"Number of participants with changes in ECG\"\\n9763,1,1,\"Number of participants with changes in electrocardiograms (ECGs)\"\\n9764,1,1,\"Number of participants with changes in laboratory values, vital signs, physical exam, and electrocardiogram.\"\\n9765,1,1,\"Number of participants with changes in left ventricular ejection fraction (LVEF) from baseline\"\\n9766,1,1,\"Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study\"\\n9767,1,1,\"Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID\"\\n9768,1,1,\"Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD\"\\n9769,1,1,\"Number of Participants With Changes in Pulse Rate From Baseline-Part 2\"\\n9770,1,1,\"Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study\"\\n9771,1,1,\"Number of Participants With Changes in Temperature From Baseline-Part 1 BID\"\\n9772,1,1,\"Number of Participants With Changes in Temperature From Baseline-Part 1 QD\"\\n9773,1,1,\"Number of Participants With Changes in Temperature From Baseline-Part 2\"\\n9774,1,1,\"Number of participants with changes in the clinical laboratory tests results\"\\n9775,1,1,\"Number of participants with changes in the electrocardiogram (ECG) records\"\\n9776,3,2,\"Number of participants with changes in vital signs\"\\n9777,1,1,\"Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment\"\\n9778,1,1,\"Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment\"\\n9779,1,1,\"Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment\"\\n9780,1,1,\"Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade [Phase 1b]\"\\n9781,1,1,\"Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q2W Regimen\"\\n9782,1,1,\"Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q3W Regimen\"\\n9783,1,1,\"Number of Participants With Chest X-Ray Prior to New Therapy\"\\n9784,1,1,\"Number of participants with clinical adverse events at the recommended dose for expansion\"\\n9785,1,1,\"Number of Participants With Clinical Benefit (CB)\"\\n9786,1,1,\"Number of participants with Clinical Benefit Response (CBR) Using Response Criteria in Solid Tumors (RECIST)\"\\n9787,1,1,\"Number of Participants With Clinical Chemistry Changes From Baseline With Respect to the Normal Range\"\\n9788,1,1,\"Number of Participants With Clinical Disease Activity by Categorization at Visit 1\"\\n9789,8,2,\"Number of Participants with Clinical Laboratory Abnormalities\"\\n9790,1,1,\"Number of Participants with Clinical Laboratory Abnormalities in Blood Chemistry Tests by Highest Grade According to NCI-CTCAE v4.0\"\\n9791,1,1,\"Number of Participants with Clinical Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v4.0\"\\n9792,1,1,\"Number of Participants with Clinical Laboratory Abnormalities in Urinalysis Tests by Highest Grade According to NCI-CTCAE v4.0\"\\n9793,4,2,\"Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs\"\\n9794,1,1,\"Number of Participants With Clinical Laboratory Test Abnormalities - Parts 1, 2 and 5\"\\n9795,8,1,\"Number of Participants With Clinical Response\"\\n9796,1,1,\"Number of Participants With Clinical Response (Partial Response + Complete Response)\"\\n9797,1,1,\"Number of Participants With Clinical Response (Partial Response or Complete Response) According to the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n9798,1,1,\"Number of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose\"\\n9799,1,1,\"Number of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose\"\\n9800,1,1,\"Number of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose\"\\n9801,1,1,\"Number of participants with clinical significant shifts from baseline in clinical laboratory parameters\"\\n9802,1,1,\"Number of Participants With Clinical Tumor Regression.\"\\n9803,1,1,\"Number of Participants With Clinically Important Changes in Hematology and Clinical Chemistry Parameters\"\\n9804,1,1,\"Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)\"\\n9805,1,1,\"Number of participants with clinically meaningful changes in Laboratory test results from baseline\"\\n9806,1,1,\"Number of Participants With Clinically Meaningful Changes in Laboratory Values\"\\n9807,1,1,\"Number of participants with clinically meaningful changes in physical examination findings, vital signs or blood chemistry\"\\n9808,1,1,\"Number of Participants With Clinically Meaningful Changes in Vital Signs\"\\n9809,1,1,\"Number of participants with clinically meaningful changes in Vital signs from baseline\"\\n9810,1,1,\"Number of Participants With Clinically Meaningful Prolongation of the QT Interval Corrected for Heart Rate (QTc) From Time-matched Baseline\"\\n9811,1,1,\"Number of Participants With Clinically Significant Abnormalities for Clinical Chemistry Parameters\"\\n9812,1,1,\"Number of Participants With Clinically Significant Abnormalities for Electrocardiogram (ECG)\"\\n9813,1,1,\"Number of Participants With Clinically Significant Abnormalities for Gastrointestinal Parameters\"\\n9814,1,1,\"Number of Participants With Clinically Significant Abnormalities for Hematology Parameters\"\\n9815,1,1,\"Number of Participants With Clinically Significant Abnormalities for Urinalysis Parameters\"\\n9816,1,1,\"Number of Participants With Clinically Significant Abnormalities for Vital Signs Parameters\"\\n9817,1,1,\"Number of Participants With Clinically Significant Adverse Events (AEs) (Physical Assessments and Clinical Lab Tests)\"\\n9818,2,1,\"Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values\"\\n9819,5,1,\"Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities\"\\n9820,1,1,\"Number of participants with clinically significant change from baseline in laboratory abnormalities (Part 1 and Part 2)\"\\n9821,1,1,\"Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities (Parts 1A, 1B, 2A, 2B)\"\\n9822,1,1,\"Number of participants with clinically significant change from baseline in laboratory abnormalities (phase 1a and phase 1b dose escalation phase)\"\\n9823,1,1,\"Number of participants with clinically significant change from baseline in physical exam abnormalities (phase 1a and phase 1b dose escalation phase)\"\\n9824,1,1,\"Number of participants with clinically significant change from baseline in vital sign abnormalities (Part 1 and Part 2)\"\\n9825,1,1,\"Number of participants with clinically significant change from baseline in vital sign abnormalities (phase 1a and phase 1b dose escalation phase)\"\\n9826,19,2,\"Number of Participants With Clinically Significant Change From Baseline in Vital Signs\"\\n9827,1,1,\"Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests\"\\n9828,2,2,\"Number of participants with clinically significant changes in clinical laboratory tests\"\\n9829,2,2,\"Number of participants with clinically significant changes in electrocardiogram (ECG)\"\\n9830,1,1,\"Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements\"\\n9831,1,1,\"Number of participants with clinically significant changes in laboratory assessment data as assessed by CTCAE v5.0.\"\\n9832,1,1,\"Number of participants with clinically significant changes in laboratory parameters, vital signs, physical examination and organ-specific parameters\"\\n9833,6,1,\"Number of Participants with Clinically Significant Changes in Vital Signs\"\\n9834,13,2,\"Number of participants with clinically significant changes in vital signs\"\\n9835,1,1,\"Number of participants with clinically significant changes in vital signs and clinical laboratory parameters\"\\n9836,1,1,\"Number of participants with clinically significant changes in vital signs for all indications\"\\n9837,1,1,\"Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Events\"\\n9838,1,1,\"Number of Participants With Clinically Significant Clinical Laboratory Tests\"\\n9839,1,1,\"Number of Participants With Clinically Significant Echocardiogram Abnormalities\"\\n9840,9,2,\"Number of Participants With Clinically Significant Effects\"\\n9841,1,1,\"Number of Participants With Clinically Significant Effects (Physical Assessments and Safety Lab Tests)\"\\n9842,5,1,\"Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities\"\\n9843,1,1,\"Number of Participants With Clinically Significant Electrocardiogram (EKG)\"\\n9844,1,1,\"Number of Participants With Clinically Significant Findings for 12-lead Electrocardiogram (ECG)\"\\n9845,8,5,\"Number of participants with clinically significant laboratory abnormalities\"\\n9846,1,1,\"Number of participants with clinically significant laboratory abnormalities at recommended dose for expansion\"\\n9847,1,1,\"Number of participants with clinically significant physical exam abnormalities (Part 1 and Part 2)\"\\n9848,1,1,\"Number of Participants With Clinically Significant Physical Examination Results\"\\n9849,1,1,\"Number of participants with clinically significant shifts from baseline in clinical laboratory parameters\"\\n9850,1,1,\"Number of Participants With Clinically Significant TEAEs Related to Laboratory Abnormalities\"\\n9851,1,1,\"Number of Participants With Clinically Significant Treatment-Emergent Values in Hematology, Serum Chemistry Panel, Vital Signs or Weight\"\\n9852,1,1,\"Number of Participants With Clinically Significant Vital Sign Values\"\\n9853,3,1,\"Number of Participants With Clinically Significant Vital Signs\"\\n9854,1,1,\"Number of Participants With Co-morbidities\"\\n9855,1,1,\"Number of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events\"\\n9856,1,1,\"Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events\"\\n9857,1,1,\"Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen\"\\n9858,1,1,\"Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen\"\\n9859,1,1,\"Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region\"\\n9860,1,1,\"Number of Participants With Comorbidities\"\\n9861,1,1,\"Number of participants with complete blood count (CBC) value abnormalities and/or AEs\"\\n9862,13,1,\"Number of Participants With Complete Response\"\\n9863,11,2,\"Number of Participants With Complete Response (CR)\"\\n9864,1,1,\"Number of Participants With Complete Response (CR) and Partial Response (PR)\"\\n9865,2,1,\"Number of Participants With Complete Response (CR) or Partial Response (PR)\"\\n9866,1,1,\"Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1\"\\n9867,1,1,\"Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts\"\\n9868,1,1,\"Number of Participants With Complications Due To Cold Plasma Application\"\\n9869,1,1,\"Number of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment\"\\n9870,1,1,\"Number of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment\"\\n9871,1,1,\"Number of Participants With Concomitant Symptoms of Various Severity 6-8 Weeks After Start of Treatment\"\\n9872,1,1,\"Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon\\'s Cohort\"\\n9873,1,1,\"Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population\"\\n9874,1,1,\"Number of Participants With Confirmed Objective Response (OR) in PF-06747775 200 mg QD Group\"\\n9875,1,1,\"Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12\"\\n9876,1,1,\"Number of Participants With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR)\"\\n9877,1,1,\"Number of Participants With Congestive Heart Failure\"\\n9878,1,1,\"Number of participants with corrected QT (QTc) interval\"\\n9879,1,1,\"Number of Participants With Cycle 1 DLT\"\\n9880,1,1,\"Number of Participants With Cycle 1 Dose-limiting Toxicities (DLT)\"\\n9881,2,2,\"Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)\"\\n9882,1,1,\"Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1\"\\n9883,1,1,\"Number of participants with death\"\\n9884,1,1,\"Number of Participants With Different Metastatic Sites Locations at Diagnosis of Advance or Metastatic Renal Cell Carcinoma Before Axitinib Treatment Initiation: Long Responders Versus Refractory Participants\"\\n9885,1,1,\"Number of Participants with Different Primary Causes of Death\"\\n9886,1,1,\"Number of Participants With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n9887,1,1,\"Number of Participants With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n9888,1,1,\"Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n9889,1,1,\"Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n9890,1,1,\"Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n9891,1,1,\"Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Before Receiving Treatment at 30000 IU Once Weekly\"\\n9892,1,1,\"Number of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment\"\\n9893,1,1,\"Number of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment\"\\n9894,1,1,\"Number of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment\"\\n9895,1,1,\"Number of Participants With Different Type of Renal Cells Before Axitinib Treatment Initiation: Long Responders Versus Refractory Participants\"\\n9896,1,1,\"Number of Participants With Disease Activity Score by Categorization at Visit 1\"\\n9897,2,1,\"Number of Participants With Disease Progression\"\\n9898,1,1,\"Number of Participants With Disease Progression (PD) or Death\"\\n9899,1,1,\"Number of participants with DLT\"\\n9900,1,1,\"Number of participants with DLT for Dose level 3000 mg\"\\n9901,3,1,\"Number of Participants With DLTs\"\\n9902,3,3,\"Number of Participants with DLTs\"\\n9903,6,4,\"Number of participants with DLTs\"\\n9904,1,1,\"Number of participants with DLTs (dose-limiting toxicities) (Part 1)\"\\n9905,1,1,\"Number of participants with DLTs (dose-limiting toxicities) (Part 2)\"\\n9906,1,1,\"Number of Participants With DLTs - Q2W Regimen\"\\n9907,1,1,\"Number of Participants With DLTs According to Severity-Part 1\"\\n9908,2,2,\"Number of participants with DLTs by dose level\"\\n9909,1,1,\"Number of participants with DLTs for REGN4018 with cemiplimab\"\\n9910,1,1,\"Number of Participants With DLTs in First 2 Cycles of Portion B\"\\n9911,1,1,\"Number of Participants With DLTs in Part B1\"\\n9912,1,1,\"Number of participants with DLTs while receiving dalotuzumab and ridaforolimus combination therapy\"\\n9913,1,1,\"Number of Participants With DLTs-Part 2\"\\n9914,1,1,\"Number of Participants With Dose Delays\"\\n9915,1,1,\"Number of Participants With Dose Delays and Reduction\"\\n9916,1,1,\"Number of Participants With Dose Delays Due to Adverse Events\"\\n9917,1,1,\"Number of Participants With Dose Interruptions\"\\n9918,2,1,\"Number of participants with dose interruptions and dose reductions\"\\n9919,1,1,\"Number of Participants With Dose Interruptions and Reductions (Part A and B)\"\\n9920,2,1,\"Number of Participants with Dose Interruptions due to TEAE\"\\n9921,1,1,\"Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium\"\\n9922,15,9,\"Number of Participants With Dose Limiting Toxicities\"\\n9923,2,1,\"Number of Participants with Dose Limiting Toxicities\"\\n9924,18,15,\"Number of participants with dose limiting toxicities\"\\n9925,10,6,\"Number of Participants With Dose Limiting Toxicities (DLT)\"\\n9926,4,1,\"Number of participants with dose limiting toxicities (DLT)\"\\n9927,1,1,\"Number of Participants with Dose Limiting Toxicities (DLT) (Part 1)\"\\n9928,1,1,\"Number of Participants With Dose Limiting Toxicities (DLT) at Each Dose Level\"\\n9929,1,1,\"Number of participants with dose limiting toxicities (DLT) for all indications\"\\n9930,2,1,\"Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)\"\\n9931,1,1,\"Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1\"\\n9932,1,1,\"Number of Participants With Dose Limiting Toxicities (DLT): Phase 1b\"\\n9933,50,29,\"Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n9934,20,13,\"Number of Participants with Dose Limiting Toxicities (DLTs)\"\\n9935,6,2,\"Number of participants with Dose Limiting Toxicities (DLTs)\"\\n9936,14,12,\"Number of participants with dose limiting toxicities (DLTs)\"\\n9937,1,1,\"Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2)\"\\n9938,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) (Part 1)\"\\n9939,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part)\"\\n9940,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C\"\\n9941,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1\"\\n9942,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen\"\\n9943,1,1,\"Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)\"\\n9944,1,1,\"Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities\"\\n9945,1,1,\"Number of participants with Dose Limiting Toxicities (DLTs) as a measure of safety\"\\n9946,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03\"\\n9947,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle in Phase 1 Dose-escalation Cohorts, Japan LIC and Phase 1b Cohort 3, and First 2 Cycles in Phase 1b Cohort 2A\"\\n9948,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) During the Primary DLT Evaluation Period (Cycle 1) in Phase 1b\"\\n9949,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)\"\\n9950,1,1,\"Number of participants with dose limiting toxicities (DLTs) in Dose escalation\"\\n9951,2,2,\"Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1)\"\\n9952,1,1,\"Number of participants with dose limiting toxicities (DLTs) in Dose escalation (Part 1A and 1B)\"\\n9953,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) in Escalation Phase\"\\n9954,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) in Part A and Part C\"\\n9955,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1\"\\n9956,1,1,\"Number of participants with dose limiting toxicities (DLTs) in Phase 1\"\\n9957,2,2,\"Number of Participants With Dose Limiting Toxicities (DLTs) in Process for the Determination of the Maximum Tolerated Dose (MTD).\"\\n9958,3,2,\"Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)\"\\n9959,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).\"\\n9960,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) in the Pilot Part of the Study\"\\n9961,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM\"\\n9962,1,1,\"Number of participants with Dose Limiting Toxicities (DLTs) of the MEDI9253 during the dose escalation phase\"\\n9963,1,1,\"Number of participants with dose limiting toxicities (DLTs) Phase 1a monotherapy and Phase 1b combination therapy dose escalation\"\\n9964,1,1,\"Number of participants with dose limiting toxicities (DLTs) while receiving dalotuzumab alone\"\\n9965,1,1,\"Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities\"\\n9966,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1\"\\n9967,1,1,\"Number of Participants With Dose Limiting Toxicities (DLTs): Phase I\"\\n9968,1,1,\"Number of participants with dose limiting toxicities (Phase I)\"\\n9969,1,1,\"Number of Participants With Dose Limiting Toxicities at Dose Level\"\\n9970,1,1,\"Number of Participants With Dose Limiting Toxicities at Phase 1\"\\n9971,1,1,\"Number of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1\"\\n9972,1,1,\"Number of Participants With Dose Limiting Toxicities During Cycle 1\"\\n9973,1,1,\"Number of participants with dose limiting toxicities in each of the study dose levels\"\\n9974,1,1,\"Number of participants with dose limiting toxicities in the Dose Escalation Portion\"\\n9975,1,1,\"Number of Participants With Dose Limiting Toxicities of Cediranib Maleate in Combination With Olaparib (Phase I)\"\\n9976,1,1,\"Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I)\"\\n9977,1,1,\"Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib\"\\n9978,1,1,\"Number of Participants With Dose Limiting Toxicities.\"\\n9979,1,1,\"Number of Participants With Dose Limiting Toxicities: Part 1 and Part 3\"\\n9980,4,2,\"Number of Participants With Dose Limiting Toxicity\"\\n9981,2,1,\"Number of Participants with Dose Limiting Toxicity\"\\n9982,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT )\"\\n9983,12,3,\"Number of Participants With Dose Limiting Toxicity (DLT)\"\\n9984,7,3,\"Number of Participants with Dose Limiting Toxicity (DLT)\"\\n9985,4,1,\"Number of participants with dose limiting toxicity (DLT)\"\\n9986,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population\"\\n9987,2,1,\"Number of Participants With Dose Limiting Toxicity (DLT) [Phase I]\"\\n9988,1,1,\"Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)\"\\n9989,1,1,\"Number of participants with Dose Limiting Toxicity (DLT) for Dose level 1200 mg and 2000 mg\"\\n9990,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT) of the Combination of T-DM1 and Paclitaxel When T-DM1 Was Administered on Either an Q3W or QW Schedule for Both With and Without Pertuzumab Treatment\"\\n9991,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT) Phase I Part\"\\n9992,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT) With Panitumumab Plus TAS-102 Combination Therapy\"\\n9993,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle\"\\n9994,1,1,\"Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I)\"\\n9995,1,1,\"Number of Participants With Dose Limiting Toxicity [Phase I]\"\\n9996,1,1,\"Number of Participants With Dose Limiting Toxicity Adverse Events - Dose Finding Part\"\\n9997,1,1,\"Number of Participants With Dose Limiting Toxicity in Phase I\"\\n9998,1,1,\"Number of participants with dose limiting toxicity(DLT) to determine maximum tolerated dose(MTD)\"\\n9999,1,1,\"Number of Participants With Dose Reduction\"\\n10000,1,1,\"Number of Participants With Dose Reductions or Delays-Besylate Sub-study\"\\n10001,1,1,\"Number of Participants With Dose Reductions or Delays-Part 1 BID\"\\n10002,1,1,\"Number of Participants With Dose Reductions or Delays-Part 1 QD\"\\n10003,1,1,\"Number of Participants With Dose Reductions or Delays-Part 2\"\\n10004,1,1,\"Number of Participants with Dose-Limited Toxicities (DLTs)\"\\n10005,2,1,\"Number Of Participants With Dose-limiting Toxicities\"\\n10006,4,2,\"Number of Participants With Dose-Limiting Toxicities\"\\n10007,6,5,\"Number of Participants With Dose-limiting Toxicities\"\\n10008,3,2,\"Number of Participants with Dose-Limiting Toxicities\"\\n10009,1,1,\"Number of participants with Dose-limiting Toxicities\"\\n10010,2,2,\"Number of participants with Dose-limiting toxicities\"\\n10011,4,4,\"Number of participants with dose-limiting toxicities\"\\n10012,6,3,\"Number of Participants With Dose-Limiting Toxicities (DLT)\"\\n10013,6,5,\"Number of Participants With Dose-limiting Toxicities (DLT)\"\\n10014,3,2,\"Number of Participants with Dose-limiting Toxicities (DLT)\"\\n10015,1,1,\"Number of participants with Dose-Limiting Toxicities (DLT)\"\\n10016,5,3,\"Number of participants with dose-limiting toxicities (DLT)\"\\n10017,1,1,\"Number of Participants With Dose-limiting Toxicities (DLT) (Part 1)\"\\n10018,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)\"\\n10019,1,1,\"Number of participants with Dose-limiting toxicities (DLT) (phase 1)\"\\n10020,1,1,\"Number of participants with Dose-limiting toxicities (DLT) [Safety and Tolerability]\"\\n10021,1,1,\"Number of Participants with Dose-limiting Toxicities (DLT) During Reinduction Chemotherapy\"\\n10022,1,1,\"Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding\"\\n10023,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLT) in Cycle 1 of Part A\"\\n10024,1,1,\"Number of Participants With Dose-limiting Toxicities (DLT) in Part 1\"\\n10025,1,1,\"Number of Participants with Dose-Limiting Toxicities (DLT) in Participants Receiving DS-9606a\"\\n10026,1,1,\"Number of Participants With Dose-limiting Toxicities (DLT) in Phase I\"\\n10027,1,1,\"Number of Participants with Dose-Limiting Toxicities (DLT) of AGEN1777 as a Single-Agent and in Combination with a PD-1 inhibitor\"\\n10028,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLT) of HX009\"\\n10029,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLT) of PF-05082566 in Combination With MK-3475\"\\n10030,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E\"\\n10031,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase\"\\n10032,1,1,\"Number of Participants With Dose-limiting Toxicities (DLT): Phase 1b\"\\n10033,14,11,\"Number of Participants With Dose-Limiting Toxicities (DLTs)\"\\n10034,21,12,\"Number of Participants With Dose-limiting Toxicities (DLTs)\"\\n10035,1,1,\"Number of Participants With Dose-limiting toxicities (DLTs)\"\\n10036,6,6,\"Number of Participants with Dose-Limiting Toxicities (DLTs)\"\\n10037,8,4,\"Number of Participants with Dose-limiting Toxicities (DLTs)\"\\n10038,4,3,\"Number of participants with Dose-Limiting Toxicities (DLTs)\"\\n10039,1,1,\"Number of participants with Dose-limiting Toxicities (DLTs)\"\\n10040,10,8,\"Number of participants with dose-limiting toxicities (DLTs)\"\\n10041,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLTs) - Part 1\"\\n10042,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLTs) [Phase 1b]\"\\n10043,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts\"\\n10044,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B\"\\n10045,1,1,\"Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.\"\\n10046,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs) During the DLT Period\"\\n10047,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs) During Treatment Cycle 1\"\\n10048,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Gefitinib\"\\n10049,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Osimertinib\"\\n10050,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs) for Dose-escalation Part\"\\n10051,2,2,\"Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1\"\\n10052,1,1,\"Number of participants with Dose-limiting toxicities (DLTs) in Dose Escalation (Part 1)\"\\n10053,1,1,\"Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A\"\\n10054,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs) in Part 1\"\\n10055,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs)-Part 1\"\\n10056,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs)-Parts 1 and 2\"\\n10057,1,1,\"Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b\"\\n10058,1,1,\"Number of Participants With Dose-Limiting Toxicities (Dose Finding Phase)\"\\n10059,1,1,\"Number of Participants With Dose-Limiting Toxicities (Part A)\"\\n10060,1,1,\"Number of Participants With Dose-Limiting Toxicities at Each Dose Level [level/cohort] and the Total Number of Participants With Dose-limiting Toxicities\"\\n10061,1,1,\"Number of Participants With Dose-Limiting Toxicities Cycle 1\"\\n10062,1,1,\"Number of Participants with Dose-limiting Toxicities Following DS-1103a Combination Therapy (Dose Escalation)\"\\n10063,1,1,\"Number of participants with dose-limiting toxicities in the Dose Escalation Arms.\"\\n10064,1,1,\"Number of Participants With Dose-limiting Toxicities in the Dose-escalation Phase\"\\n10065,1,1,\"Number of participants with dose-limiting toxicities.\"\\n10066,1,1,\"Number of Participants With Dose-limiting Toxicity\"\\n10067,1,1,\"Number of participants with dose-limiting toxicity\"\\n10068,5,3,\"Number of Participants With Dose-Limiting Toxicity (DLT)\"\\n10069,7,3,\"Number of Participants With Dose-limiting Toxicity (DLT)\"\\n10070,3,1,\"Number of Participants with Dose-Limiting Toxicity (DLT)\"\\n10071,5,4,\"Number of participants with dose-limiting toxicity (DLT)\"\\n10072,1,1,\"Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b\"\\n10073,1,1,\"Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol\"\\n10074,1,1,\"Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only\"\\n10075,1,1,\"Number of participants with Dose-limiting toxicity (DLTs) for REGN4018 monotherapy\"\\n10076,1,1,\"Number of Participants With Drug Related Grade 3 and Higher Treatment Emergent Adverse Events (TEAEs): Part 1\"\\n10077,1,1,\"Number of Participants With Drug Related Serious Adverse Events (SAEs): Part 1\"\\n10078,1,1,\"Number of Participants With Drug Related Treatment Emergent Adverse Events (TEAEs): Part 1\"\\n10079,1,1,\"Number of Participants With Drug-Related Adverse Events\"\\n10080,1,1,\"Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher\"\\n10081,1,1,\"Number of participants with DTLs (dose-limiting toxicities)\"\\n10082,1,1,\"Number of Participants With Duration of First Line Treatment With Tyrosine Kinase Inhibitor (TKI) Before Axitinib Treatment Initiation: Long Responders Versus Refractory Participants\"\\n10083,2,1,\"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n10084,1,1,\"Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status\"\\n10085,1,1,\"Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events\"\\n10086,1,1,\"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Initiation of Axitinib Treatment: Long Responders Versus Refractory Participants\"\\n10087,1,1,\"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Before First Line Treatment Initiation: Long Responders Versus Refractory Participants\"\\n10088,1,1,\"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status on Axitinib Discontinuation: Long Responders Versus Refractory Participants\"\\n10089,1,1,\"Number of Participants With Echocardiogram Abnormalities Recorded as Adverse Events (AEs)\"\\n10090,10,1,\"Number of participants with electrocardiogram (ECG) abnormalities\"\\n10091,1,1,\"Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)\"\\n10092,2,2,\"Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)\"\\n10093,2,2,\"Number of participants with electrocardiogram (ECG) abnormalities and/or AEs\"\\n10094,1,1,\"Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as TEAEs\"\\n10095,2,1,\"Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events\"\\n10096,1,1,\"Number of Participants With Electrocardiogram (ECG) Findings\"\\n10097,1,1,\"Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I\"\\n10098,1,1,\"Number of Participants With Electrocardiogram Abnormalities\"\\n10099,1,1,\"Number of Participants With Electrocardiogram Abnormalities Recorded as Adverse Events (AEs)\"\\n10100,1,1,\"Number of participants with electrocardiograms (ECG) abnormalities and or adverse events\"\\n10101,7,1,\"Number of Participants With Engraftment\"\\n10102,1,1,\"Number of Participants With Extra-articular Manifestations at Visit 1\"\\n10103,1,1,\"Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane\"\\n10104,1,1,\"Number of Participants With Family History of Rheumatoid Arthritis\"\\n10105,1,1,\"Number of Participants With Fatigue Event Graded Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0\"\\n10106,1,1,\"Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells\"\\n10107,2,2,\"Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)\"\\n10108,1,1,\"Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) Graded According to Common Terminology Criteria Adverse Events (CTCAE), Version 3\"\\n10109,1,1,\"Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)\"\\n10110,1,1,\"Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs)\"\\n10111,2,2,\"Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)\"\\n10112,2,1,\"Number of Participants with first-cycle dose limiting toxicity\"\\n10113,1,1,\"Number of participants with free thyroxine (free T4) value abnormalities and/or AEs\"\\n10114,1,1,\"Number of Participants with Frequency of Imaging from Time of BCR to nmCRPC and nmCRPC to mCRPC\"\\n10115,1,1,\"Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region\"\\n10116,1,1,\"Number of Participants With Germline Deoxyribonucleic Acid (DNA) Repair Mutation Who Experienced Partial or Complete Response.\"\\n10117,1,1,\"Number of Participants With Grade 1 (Mild) Treatment Emergent Adverse Events (TEAE)\"\\n10118,1,1,\"Number of Participants With Grade 1-5 Adverse Events\"\\n10119,1,1,\"Number of Participants With Grade 2 (Moderate) Treatment Emergent Adverse Events (TEAE)\"\\n10120,1,1,\"Number of Participants With Grade 2 and Above Toxicities Attributed to Ribociclib\"\\n10121,1,1,\"Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs\"\\n10122,1,1,\"Number of Participants With Grade 3 (Sever) Treatment Emergent Adverse Events (TEAE)\"\\n10123,1,1,\"Number of Participants With Grade 3 and 4 Dose Limiting Toxicity (DLT) at 2000mg/m(2) Belinostat\"\\n10124,1,1,\"Number of Participants With Grade 3 and 4 Toxicities\"\\n10125,1,1,\"Number of participants with Grade 3 and Grade 4 possibly-related adverse events (PRAEs)\"\\n10126,1,1,\"Number of participants with Grade 3 and Grade 4 Treatment-related adverse events (TRAEs)\"\\n10127,1,1,\"Number of Participants With Grade 3 Bilirubin\"\\n10128,1,1,\"Number of Participants With Grade 3 or 4 Laboratory Results\"\\n10129,1,1,\"Number of Participants With Grade 3 or 4 Thrombocytopenia Occurring Within 30 Days After Initial Administration of Niraparib\"\\n10130,1,1,\"Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)\"\\n10131,1,1,\"Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)\"\\n10132,1,1,\"Number of Participants With Grade 3 or Greater Toxicities Associated With Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n10133,1,1,\"Number of Participants With Grade 3 or Greater Toxicity Attributable to Radiation Treatment\"\\n10134,1,1,\"Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE)\"\\n10135,2,2,\"Number of Participants with Grade 3 or higher Adverse Events\"\\n10136,4,3,\"Number of Participants With Grade 3 or Higher TEAEs\"\\n10137,1,1,\"Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\"\\n10138,1,1,\"Number of participants with grade 3, grade 4, or grade 5 TEAEs\"\\n10139,1,1,\"Number of Participants With Grade 4 (Life Threatening) Treatment Emergent Adverse Events (TEAE)\"\\n10140,1,1,\"Number of Participants With Grade 5 (Fatal) Treatment Emergent Adverse Events (TEAE)\"\\n10141,1,1,\"Number of participants with Grade >/= 2 oral mucositis/stomatitis in Sub-Study\"\\n10142,1,1,\"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study\"\\n10143,1,1,\"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID\"\\n10144,1,1,\"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD\"\\n10145,1,1,\"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2\"\\n10146,1,1,\"Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Parts 1 and 2\"\\n10147,1,1,\"Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study\"\\n10148,1,1,\"Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID\"\\n10149,1,1,\"Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD\"\\n10150,1,1,\"Number of Participants With Grade Change From Baseline in Hematology Data-Part 2\"\\n10151,1,1,\"Number of Participants With Grade Change From Baseline in Hematology Data-Parts 1 and 2\"\\n10152,1,1,\"Number of Participants With Grade Shift for Urinalysis Parameters\"\\n10153,1,1,\"Number of Participants With Grade ‚â•3 Adverse Events Related to Study Drug at Dose Level 140 mcg/kg and 100 mcg/kg\"\\n10154,1,1,\"Number of Participants With Grade ‚â•3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ‚â•0.5% of Participants by Preferred Term\"\\n10155,1,1,\"Number of Participants With Grade ‚â•3 Treatment-Emergent Adverse Events to Monitor, Occurring in ‚â•0.5% of Participants by Category and Preferred Term\"\\n10156,1,1,\"Number of Participants With Grade ‚â•3 Treatment-Emergent Adverse Events, Occurring in ‚â•1% of Participants by System Organ Class and Preferred Term\"\\n10157,1,1,\"Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs)\"\\n10158,1,1,\"Number of Participants With Grades 3, 4 or 5 Dose-Limiting Toxicity (DLT) Related to Study Drug\"\\n10159,1,1,\"Number of Participants With Greater Than (>) 50 Percent (%) Decrease in Trough Concentration at Steady State (Css, Trough)\"\\n10160,1,1,\"Number of Participants With Hand Foot Syndrome Event Graded Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0\"\\n10161,1,1,\"Number of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events\"\\n10162,1,1,\"Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events\"\\n10163,1,1,\"Number of Participants With Hematology Change From Baseline With Respect to the Normal Range\"\\n10164,1,1,\"Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q2W Regimen\"\\n10165,1,1,\"Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q3W Regimen\"\\n10166,1,1,\"Number of Participants With Hematology Laboratory Abnormalities by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Phase 1b]\"\\n10167,1,1,\"Number of Participants With Hematology Parameters Values Falling Within Reference Values at Visit 1\"\\n10168,1,1,\"Number of Participants With Hematology Results by Maximum Grade Increase Post-Baseline\"\\n10169,1,1,\"Number of Participants With High Grade (Grade 3-4) Immune Mediated Adverse Events (IMAEs)\"\\n10170,1,1,\"Number of Participants With High Grade (Grade 5) Immune Mediated Adverse Events (IMAEs)\"\\n10171,1,1,\"Number of Participants With Highest Level of TEAEs Severity\"\\n10172,1,1,\"Number of Participants With hPV19 Drug-Related Adverse Events or Serious Adverse Events\"\\n10173,1,1,\"Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks\"\\n10174,1,1,\"Number of Participants with Immune-mediated Adverse Events (IMAEs)\"\\n10175,1,1,\"Number of participants with immune-related AEs (irAEs)\"\\n10176,1,1,\"Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline\"\\n10177,1,1,\"Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline\"\\n10178,1,1,\"Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline\"\\n10179,1,1,\"Number of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment\"\\n10180,1,1,\"Number of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n10181,2,1,\"Number of Participants with Incidence of Adverse Events (AEs)\"\\n10182,1,1,\"Number of participants with incidence of adverse events by NCI-CTCAE version 4.03\"\\n10183,1,1,\"Number of participants with incidence of dose limiting toxicities (DLTs)\"\\n10184,1,1,\"Number of participants with incidence of Grade 3 and higher adverse events (AEs)\"\\n10185,1,1,\"Number of participants with incidence of Immune mediated adverse events (imAEs)\"\\n10186,1,1,\"Number of Participants With Incidence of Lymphedema\"\\n10187,1,1,\"Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study\"\\n10188,1,1,\"Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID\"\\n10189,1,1,\"Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD\"\\n10190,1,1,\"Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I\"\\n10191,1,1,\"Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I\"\\n10192,1,1,\"Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12\"\\n10193,1,1,\"Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12\"\\n10194,1,1,\"Number of participants with infusion-related reactions (IRRs)\"\\n10195,1,1,\"Number of Participants With International Metastatic Database Consortium (IMDC) Risk Group at Initiation of Axitinib Treatment: Long Responders Versus Refractory Participants\"\\n10196,1,1,\"Number of Participants With International Metastatic Database Consortium (IMDC) Risk Group on Discontinuation of Axitinib Treatment: Long Responders Versus Refractory Participants\"\\n10197,1,1,\"Number of Participants With Intolerable Toxicities in Phase I of the Study\"\\n10198,1,1,\"Number of Participants With Investigational Medicinal Product (IMP)-Related Predefined Safety Criteria Findings\"\\n10199,1,1,\"Number of Participants With Joint Damage at Visit 1\"\\n10200,22,3,\"Number of Participants With Laboratory Abnormalities\"\\n10201,5,1,\"Number of Participants with Laboratory Abnormalities\"\\n10202,13,8,\"Number of participants with laboratory abnormalities\"\\n10203,1,1,\"Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for REGN4018 monotherapy\"\\n10204,1,1,\"Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab\"\\n10205,1,1,\"Number of Participants With Laboratory Abnormalities (Hematology, Clinical Chemistry) at More Than 1 Clinic Visit\"\\n10206,1,1,\"Number of Participants With Laboratory Abnormalities - Carbiralizumab Monotherapy\"\\n10207,1,1,\"Number of Participants With Laboratory Abnormalities [Part 2 & 3]\"\\n10208,2,1,\"Number of participants with laboratory abnormalities by grade\"\\n10209,1,1,\"Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0\"\\n10210,1,1,\"Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria\"\\n10211,1,1,\"Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0\"\\n10212,1,1,\"Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria\"\\n10213,2,2,\"Number of Participants With Laboratory Abnormalities in Specific Liver Tests\"\\n10214,2,2,\"Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests\"\\n10215,1,1,\"Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs)\"\\n10216,1,1,\"Number of Participants With Laboratory Parameters at Initiation of First Line Treatment: Long Responders Versus Refractory Participants\"\\n10217,1,1,\"Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC)\"\\n10218,1,1,\"Number of Participants With Laboratory Results of Worst CTC Grade\"\\n10219,1,1,\"Number of Participants With Laboratory Test Abnormalities - Part 1 and Part 2\"\\n10220,1,1,\"Number of Participants With Laboratory Test Abnormalities in Part A\"\\n10221,2,1,\"Number of Participants With Laboratory Test Abnormalities in Part B\"\\n10222,1,1,\"Number of participants with laboratory test abnormalities in Safety Part\"\\n10223,1,1,\"Number of Participants With Laboratory Test Abnormalities on multiple dose\"\\n10224,1,1,\"Number of Participants With Laboratory Test Abnormalities on single dose\"\\n10225,1,1,\"Number of Participants With Laboratory Test Toxicity Grade Shifting From Baseline\"\\n10226,1,1,\"Number of participants with laboratory value abnormalities\"\\n10227,2,1,\"Number of participants with laboratory value abnormalities and/or adverse events\"\\n10228,1,1,\"Number of Participants with laboratory value abnormalities and/or adverse events (AEs)\"\\n10229,12,3,\"Number of participants with laboratory value abnormalities and/or adverse events (AEs)\"\\n10230,1,1,\"Number of participants with laboratory value abnormalities and/or adverse events (Initial Treatment)\"\\n10231,1,1,\"Number of participants with laboratory value abnormalities and/or adverse events (Retreatment)\"\\n10232,5,3,\"Number of participants with laboratory value abnormalities and/or adverse events related to treatment\"\\n10233,8,2,\"Number of participants with laboratory value abnormalities and/or AEs\"\\n10234,1,1,\"Number of Participants with Lesions detected by [68Ga]-FF58 per Location\"\\n10235,1,1,\"Number of Participants With Level of Education Completed\"\\n10236,1,1,\"Number of Participants With Local Tumor Response According to mRECIST\"\\n10237,1,1,\"Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT)\"\\n10238,1,1,\"Number of Participants with LY3039478 Dose-Limiting Toxicities (DLTs)\"\\n10239,1,1,\"Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs)\"\\n10240,1,1,\"Number of Participants With LY3435151 Dose-Limiting Toxicities (DLTs)\"\\n10241,1,1,\"Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 10-12 Weeks After Start of Treatment\"\\n10242,1,1,\"Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 3-4 Weeks After Start of Treatment\"\\n10243,1,1,\"Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 6-8 Weeks After Start of Treatment\"\\n10244,1,1,\"Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction Prior to Treatment\"\\n10245,1,1,\"Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region\"\\n10246,1,1,\"Number of Participants With Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD)\"\\n10247,1,1,\"Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID\"\\n10248,1,1,\"Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study\"\\n10249,1,1,\"Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD\"\\n10250,1,1,\"Number of Participants With Maximum Urinalysis Change From Baseline-Part 2\"\\n10251,1,1,\"Number of Participants With Median Progression-Free Survival (PFS)\"\\n10252,1,1,\"Number of Participants With Melanoma and Diffuse Large B Cell Lymphoma in Dose Expansion Cohorts Who Achieved Objective Response per RECIST v1.1 and International Working Group, Respectively\"\\n10253,1,1,\"Number of Participants With Memorial Sloan Kettering Cancer Center (MSKCC) Risk Group at Initiation of Axitinib Treatment: Long Responders Versus Refractory Participants\"\\n10254,1,1,\"Number of Participants With Memorial Sloan Kettering Cancer Center (MSKCC) Risk Group Before First Line Treatment Initiation: Long Responders Versus Refractory Participants\"\\n10255,1,1,\"Number of Participants With Memorial Sloan Kettering Cancer Center (MSKCC) Risk Group on Discontinuation of Axitinib Treatment: Long Responders Versus Refractory Participants\"\\n10256,1,1,\"Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs)\"\\n10257,2,2,\"Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)\"\\n10258,1,1,\"Number of Participants With Nephrectomy Procedure Status Before Axitinib Treatment Initiation: Long Responders Versus Refractory Participants\"\\n10259,1,1,\"Number of Participants with no clear pancreas lesions\"\\n10260,1,1,\"Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.\"\\n10261,1,1,\"Number of Participants With Non Progression at 4 Months\"\\n10262,1,1,\"Number of Participants With Non-SAEs and SAEs During Combination Treatment Period\"\\n10263,1,1,\"Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n10264,1,1,\"Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1\"\\n10265,1,1,\"Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)\"\\n10266,1,1,\"Number of Participants With Non-serious Adverse Events (AEs) in Part I (Reported in ‚â•2 of the Participants Overall).\"\\n10267,1,1,\"Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) During run-in Period\"\\n10268,1,1,\"Number of Participants with Non-Serious Adverse Events of Special Interest (AESIs)\"\\n10269,1,1,\"Number of Participants With Non-Serious Adverse Events Related to Docetaxel\"\\n10270,1,1,\"Number of Participants With Non-Serious Adverse Events Related to Pertuzumab\"\\n10271,1,1,\"Number of Participants With Non-Serious Adverse Events Related to Trastuzumab\"\\n10272,1,1,\"Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study\"\\n10273,1,1,\"Number of Participants With Non-serious AEs and SAEs-Part 2\"\\n10274,1,1,\"Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region\"\\n10275,1,1,\"Number of Participants With Notable Change in QTcF and QTcB From Baseline\"\\n10276,1,1,\"Number of Participants With Notable QTc Interval in Parts 1 and 2\"\\n10277,1,1,\"Number of Participants With Objective Radiographic Response (ORR)\"\\n10278,33,5,\"Number of Participants With Objective Response\"\\n10279,1,1,\"Number of participants with Objective Response\"\\n10280,1,1,\"Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))\"\\n10281,3,2,\"Number of Participants With Objective Response (OR)\"\\n10282,1,1,\"Number of Participants With Objective Response (OR) - Part 2\"\\n10283,1,1,\"Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators\"\\n10284,1,1,\"Number of Participants With Objective Response (phase 2)\"\\n10285,1,1,\"Number of Participants With Objective Response - Maximum Tolerated Dose Expansion (MTD) Cohort\"\\n10286,1,1,\"Number of Participants With Objective Response According to RECIST 1.1 Criteria\"\\n10287,1,1,\"Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST\"\\n10288,1,1,\"Number of Participants With Objective Response Based on Data Review Committee\\'s Assessment\"\\n10289,1,1,\"Number of Participants With Objective Response Per RECIST 1.1 as Assessed by Central Imaging\"\\n10290,1,1,\"Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD)\"\\n10291,1,1,\"Number of Participants With Objective Response Rate\"\\n10292,1,1,\"Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0\"\\n10293,1,1,\"Number of Participants With Objective Response Rate (ORR, Either Partial or Complete Response) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria\"\\n10294,1,1,\"Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review Following DS-1103a Combination Therapy (Dose Expansion)\"\\n10295,1,1,\"Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal Cancer\"\\n10296,1,1,\"Number of Participants With Objective Tumor Response\"\\n10297,1,1,\"Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging)\"\\n10298,2,2,\"Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)\"\\n10299,1,1,\"Number of Participants With One or More Adverse Events (AE)\"\\n10300,1,1,\"Number of participants with one or more drug (or procedure)-related adverse events (AEs) or any serious AEs\"\\n10301,1,1,\"Number of Participants With One or More Drug Related Adverse Events\"\\n10302,1,1,\"Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)\"\\n10303,29,2,\"Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration\"\\n10304,1,1,\"Number of Participants With One or More TEAEs Leading to Dose Modifications and Treatment Discontinuation\"\\n10305,2,2,\"Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations\"\\n10306,1,1,\"Number of Participants With One or More Treatment-emergent Adverse Event (TEAE)\"\\n10307,1,1,\"Number of Participants With or Without Blood Pressure Increase as a Predictor of Progression Free Survival (PFS)\"\\n10308,1,1,\"Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST)\"\\n10309,10,8,\"Number of Participants With Overall Response\"\\n10310,3,1,\"Number of Participants With Overall Response (OR)\"\\n10311,1,1,\"Number of Participants With Overall Response (OR), Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR), Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions\"\\n10312,1,1,\"Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.\"\\n10313,1,1,\"Number of Participants With Overall Response as Determined by iRECIST\"\\n10314,2,1,\"Number of Participants With Overall Response Rate\"\\n10315,3,1,\"Number of Participants With Overall Response Rate (ORR)\"\\n10316,1,1,\"Number of Participants With Overall Survival (10 Years) by Treatment\"\\n10317,1,1,\"Number of Participants With Overall Survival (OS)\"\\n10318,1,1,\"Number of Participants With Overall Survival (OS) at One Year\"\\n10319,1,1,\"Number of Participants With Palmar-Plantar Erythrodysaesthesia (HFS) Event Graded Per CTCAE Version 4.0 at Week 12\"\\n10320,1,1,\"Number of Participants With Palmar-Plantar Erythrodysaesthesia (HFS) Event Graded Per CTCAE Version 4.0 at Week 24\"\\n10321,1,1,\"Number of Participants With Palmar-Plantar Erythrodysaesthesia (HFS) Event Graded Per CTCAE Version 4.0 at Week 36\"\\n10322,1,1,\"Number of Participants With Partial and Complete Response.\"\\n10323,2,1,\"Number of Participants With Partial Response\"\\n10324,5,1,\"Number of Participants With Partial Response (PR)\"\\n10325,1,1,\"Number of Participants With Partial Response (PR) at Interim Analysis\"\\n10326,1,1,\"Number of Participants With Partial Response (PR) of Target Lesions\"\\n10327,2,1,\"Number of Participants With Pathologic Complete Response (pCR)\"\\n10328,1,1,\"Number of Participants With Pathological Response\"\\n10329,1,1,\"Number of Participants With Percentage Change From Baseline in Extracellular Signal-regulated Kinase (ERK) Phosphorylation (p-ERK) H Score From Week 0 to Week 2\"\\n10330,1,1,\"Number of Participants With Percentage Change in p-ERK H Score From Week 8 to Week 10\"\\n10331,1,1,\"Number of Participants With Performance Status Score Based on Eastern Cooperative Oncology Group (ECOG) Factors Considered to Affect the Safety and/or Efficacy of Exemestane\"\\n10332,1,1,\"Number of Participants With Peripheral Neuropathy\"\\n10333,1,1,\"Number of participants with physical exam abnormalities\"\\n10334,1,1,\"Number of Participants with physical exam abnormalities and/or adverse events\"\\n10335,1,1,\"Number of participants with physical exam abnormalities and/or Adverse Events (AEs)\"\\n10336,1,1,\"Number of participants with Physical Exam abnormalities and/or adverse events (Initial Treatment)\"\\n10337,1,1,\"Number of participants with Physical Exam abnormalities and/or adverse events (Retreatment)\"\\n10338,2,2,\"Number of participants with Physical Exam abnormalities and/or adverse events related to treatment\"\\n10339,1,1,\"Number of participants with physical exam abnormalities and/or adverse events related to treatment\"\\n10340,3,2,\"Number of participants with physical exam abnormalities and/or AEs\"\\n10341,1,1,\"Number of participants with physical exams abnormalities and/or AEs\"\\n10342,1,1,\"Number of Participants With Positive Margins\"\\n10343,1,1,\"Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n10344,1,1,\"Number of Participants With Post-surgical Complications\"\\n10345,1,1,\"Number of Participants With Potentially Clinically Important (PCI) Changes in Vital Signs: Part 1\"\\n10346,1,1,\"Number of Participants With Potentially Clinically Important (PCI) Values by National Cancer Institute Common Terminology Criteria (NCI-CTC) Grade for Laboratory Values: Part 1\"\\n10347,1,1,\"Number of Participants With PR or CR at 2 Years\"\\n10348,1,1,\"Number of Participants With Presence/Absence Rheumatoid Factor and Anti-Cyclic Citrullinated Protein Antibodies\"\\n10349,1,1,\"Number of Participants With Previous and Current Disease Modifying Anti-Rheumatic Drugs (DMARDs)\"\\n10350,1,1,\"Number of Participants with Prexasertib Dose-Limiting Toxicities (DLT)\"\\n10351,1,1,\"Number of Participants With Prior Joint Replacement or Surgery\"\\n10352,1,1,\"Number of Participants With Progression at the 3 Month Follow up Visit\"\\n10353,1,1,\"Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator\"\\n10354,1,1,\"Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6\"\\n10355,1,1,\"Number of Participants With Progression Free Survival (PFS=Date of Progression of Disease or Death) at 6 Months Using Bevacizumab, Carboplatin, and Paclitaxel in Patients With Measurable Disease for Advanced/Recurrent Endometrial Cancer\"\\n10356,3,1,\"Number of Participants With Progression Free Survival at 6 Months\"\\n10357,1,1,\"Number of Participants With Progression-free Survival (PFS) at Six Months\"\\n10358,1,1,\"Number of Participants With Progression-free Survival at 12 Months Based Upon Clinical and Radiological Assessments Completed as Part of Routine Care\"\\n10359,1,1,\"Number of Participants With Progression-free Survival at 6 Months\"\\n10360,1,1,\"Number of Participants With Progression-free Survival at Six Months (PFS6) in Cohort A\"\\n10361,1,1,\"Number of Participants With Progression-free Survival Incidence at Week 24\"\\n10362,1,1,\"Number of Participants With Progressive Disease (PD) at Interim Analysis\"\\n10363,1,1,\"Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD\"\\n10364,1,1,\"Number of Participants With Protein Expression of AR\"\\n10365,1,1,\"Number of participants with prothrombin time/international normalized ratio (PT/INR) value abnormalities and/or AEs\"\\n10366,1,1,\"Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only).\"\\n10367,1,1,\"Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC\"\\n10368,1,1,\"Number of Participants With PSA50 Response Rate-Part 1 BID\"\\n10369,1,1,\"Number of Participants With PSA50 Response-Besylate Sub-study\"\\n10370,1,1,\"Number of Participants With PSA50 Response-Part 2\"\\n10371,1,1,\"Number of participants with qualified tumor biopsy specimen at baseline\"\\n10372,1,1,\"Number of Participants With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment\"\\n10373,1,1,\"Number of Participants With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment\"\\n10374,1,1,\"Number of Participants With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment\"\\n10375,1,1,\"Number of Participants With R0 Resection\"\\n10376,1,1,\"Number of Participants With Radiographic Disease Response After Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.\"\\n10377,1,1,\"Number of Participants With Radiographic Objective Response (OR)\"\\n10378,1,1,\"Number of Participants With Radiographic Recurrence at 12 Months\"\\n10379,1,1,\"Number of Participants With Radiographic Response\"\\n10380,1,1,\"Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events\"\\n10381,1,1,\"Number of Participants With Recurrence, Progression or Death\"\\n10382,1,1,\"Number of participants with related adverse events\"\\n10383,1,1,\"Number of Participants With Related Adverse Events as a Measure of Safety and Tolerability\"\\n10384,1,1,\"Number of Participants With Reported Adverse Events by Type\"\\n10385,1,1,\"Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs)\"\\n10386,12,4,\"Number of Participants With Response\"\\n10387,1,1,\"Number of Participants With Response Defined Using Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n10388,1,1,\"Number of Participants With Response From Glutamine Preventing Paclitaxel Induced Myalgias or Arthralgias After 2 Courses of Chemotherapy\"\\n10389,1,1,\"Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0)\"\\n10390,1,1,\"Number of Participants With Response Rate During Induction, Dose Escalation, and Concomitant With Radiation.\"\\n10391,1,1,\"Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1\"\\n10392,3,1,\"Number of Participants With Response to Treatment\"\\n10393,1,1,\"Number of Participants With Response Using RECIST Criteria\"\\n10394,1,1,\"Number of Participants With Ridaforolimus Dose Limiting Toxicities\"\\n10395,7,1,\"Number of Participants With SAEs\"\\n10396,1,1,\"Number of Participants with SAEs\"\\n10397,1,1,\"Number of participants with SAEs for REGN4018 with cemiplimab\"\\n10398,30,3,\"Number of Participants With Serious Adverse Events\"\\n10399,6,2,\"Number of Participants with Serious Adverse Events\"\\n10400,5,1,\"Number of Participants With Serious Adverse Events (SAE)\"\\n10401,1,1,\"Number of participants with serious adverse events (SAE) as assessed by CTCAE v5.0\"\\n10402,55,1,\"Number of Participants With Serious Adverse Events (SAEs)\"\\n10403,37,6,\"Number of Participants with Serious Adverse Events (SAEs)\"\\n10404,11,5,\"Number of participants with Serious Adverse Events (SAEs)\"\\n10405,21,5,\"Number of participants with serious adverse events (SAEs)\"\\n10406,1,1,\"Number of Participants With Serious Adverse Events (SAEs) - Carbiralizumab Monotherapy\"\\n10407,1,1,\"Number of Participants With Serious Adverse Events (SAEs) - Parts 1, 2 and 5\"\\n10408,1,1,\"Number of participants with Serious Adverse Events (SAEs) as a measure of safety\"\\n10409,1,1,\"Number of participants with serious adverse events (SAEs) for REGN4018 monotherapy\"\\n10410,1,1,\"Number of Participants With Serious Adverse Events (SAEs) in Part I\"\\n10411,1,1,\"Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Treatment Discontinuation and Adverse Events of Interest (AEIs)\"\\n10412,1,1,\"Number of Participants With Serious Adverse Events Possibly, Probably, and/or Definitely Related to LMB-100 Treated in the Dose Escalation Group\"\\n10413,1,1,\"Number of Participants With Serious Adverse Events Possibly, Probably, and/or Definitely Related to Subcutaneous (s.c. rhIL-15) by Grade Who Have Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)Cancer\"\\n10414,1,1,\"Number of Participants With Serious Adverse Events Related to Bevacizumab\"\\n10415,1,1,\"Number of Participants With Serious Adverse Events Related to Docetaxel\"\\n10416,1,1,\"Number of Participants With Serious Adverse Events Related to Pertuzumab\"\\n10417,1,1,\"Number of Participants With Serious Adverse Events Related to Trastuzumab\"\\n10418,2,2,\"Number of participants with serious AEs (SAEs)\"\\n10419,1,1,\"Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants\"\\n10420,1,1,\"Number of participants with serious AEs as a measure of safety and tolerability\"\\n10421,5,1,\"Number of Participants With Serious and Non-Serious Adverse Events\"\\n10422,4,2,\"Number of Participants With Serious and Non-serious Adverse Events\"\\n10423,18,3,\"Number of Participants with Serious and Non-Serious Adverse Events\"\\n10424,4,2,\"Number of participants with serious and non-serious adverse events\"\\n10425,1,1,\"Number of Participants With Serious and Non-Serious Adverse Events (Phase I & II)\"\\n10426,1,1,\"Number of Participants with Serious and Non-Serious Adverse Events and Type of Serious and Non-Serious Adverse Events\"\\n10427,2,1,\"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)\"\\n10428,1,1,\"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)\"\\n10429,1,1,\"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE)\"\\n10430,2,1,\"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)\"\\n10431,1,1,\"Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution\"\\n10432,1,1,\"Number of Participants With Serious and Non-serious Adverse Events Regardless of Attribution Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0\"\\n10433,3,2,\"Number of Participants With Serious TEAEs\"\\n10434,1,1,\"Number of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events\"\\n10435,1,1,\"Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events\"\\n10436,1,1,\"Number of participants with serum chemistry value abnormalities and/or AEs\"\\n10437,1,1,\"Number of participants with serum prostate specific antigen (PSA) decline according to PSA Working Group criteria\"\\n10438,1,1,\"Number of Participants With Severe (Grade 3 or 4) Oral Mucositis\"\\n10439,1,1,\"Number of Participants With Severe (Grade 4) Neutropenia (SN)\"\\n10440,1,1,\"Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting Toxicity (DLT) AE and Immune-related AEs (irAEs) in Safety Population\"\\n10441,1,1,\"Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs\"\\n10442,1,1,\"Number of participants with severe adverse events (AEs), serious adverse events (SAEs), treatment-related AEs, deaths, or discontinuation of study intervention due to AEs in healthy subjects\"\\n10443,1,1,\"Number of participants with severe adverse events (AEs), serious adverse events (SAEs), treatment-related AEs, deaths, or discontinuation of study intervention due to AEs in patients with advanced solid tumor\"\\n10444,1,1,\"Number of Participants With Severe AEs and SAEs\"\\n10445,2,1,\"Number of Participants with severe cytokine release syndrome(CRS) as a Measure of Safety and Tolerability.\"\\n10446,1,1,\"Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1\"\\n10447,1,1,\"Number of Participants With Shift >=3 Changed From Baseline in Eastern Cooperative Oncology Group Performance (ECOG) Status\"\\n10448,1,1,\"Number of Participants With Shift From Baseline by Grade for Hematology Parameters\"\\n10449,1,1,\"Number of Participants With Shift From Baseline by High/Low Flag for Hematology Paramaters\"\\n10450,1,1,\"Number of Participants With Shift From Baseline in by High/Low Flag for Serum Chemistry- Ungraded\"\\n10451,1,1,\"Number of Participants With Shift From Baseline in Serum Chemistry- Graded\"\\n10452,1,1,\"Number of Participants With Side Effects After Ad/PNP-F-araAMP Treatment\"\\n10453,1,1,\"Number of Participants With Significant Change From Baseline in Electrocardiogram (ECG)\"\\n10454,1,1,\"Number of participants with significant changes in clinical laboratory tests for all indications\"\\n10455,1,1,\"Number of participants with significant changes in ECG for all indications\"\\n10456,1,1,\"Number of participants with significant changes in physical examinations for all indications\"\\n10457,1,1,\"Number of Participants With Simple Disease Activity Index Score by Categorization at Visit 1\"\\n10458,1,1,\"Number of Participants With Smoking Habits\"\\n10459,1,1,\"Number of Participants With Smoking Habits at Initiation of First Line Treatment: Long Responders Versus Refractory Participants\"\\n10460,1,1,\"Number of Participants With Solid Tumor Response ‚â• 16 Weeks for Based Upon Local Investigator Assessments\"\\n10461,1,1,\"Number of Participants With Stable Disease\"\\n10462,1,1,\"Number of Participants With Stable Disease (SD) at Interim Analysis\"\\n10463,1,1,\"Number of Participants With Study Intervention Discontinuations Due to Adverse Events\"\\n10464,1,1,\"Number of Participants With Sunitinib Dose Modifications Within 12 Weeks of First Dose\"\\n10465,1,1,\"Number of Participants With Systemic Features\"\\n10466,1,1,\"Number of Participants with T1 PDAC\"\\n10467,1,1,\"Number of Participants With Talimogene Laherparepvec Detected in Blood and Urine\"\\n10468,1,1,\"Number of Participants with TEAEs\"\\n10469,1,1,\"Number of participants with TEAEs (including irAEs) for REGN4018 with cemiplimab\"\\n10470,1,1,\"Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or Urinalysis\"\\n10471,1,1,\"Number of Participants With TEAEs Leading to Study Drug Discontinuation\"\\n10472,3,1,\"Number of Participants With TEAEs Related to Clinically Significant Laboratory Evaluation Findings\"\\n10473,3,1,\"Number of Participants With TEAEs Related to Clinically Significant Vital Sign Findings\"\\n10474,1,1,\"Number of Participants With TEAEs Related to Electrocardiogram (ECG)\"\\n10475,1,1,\"Number of Participants With TEAEs Related to Hematology and Serum Chemistry\"\\n10476,1,1,\"Number of Participants with TEAEs Related to Laboratory Parameters\"\\n10477,1,1,\"Number of Participants With TEAEs Related to Physical Examination Findings\"\\n10478,1,1,\"Number of Participants With TEAEs Related to Tropinin I and T\"\\n10479,4,1,\"Number of Participants With TEAEs Related to Vital Signs\"\\n10480,1,1,\"Number of Participants with TEAEs Resulting in Permanent Discontinuation of Durvalumab\"\\n10481,1,1,\"Number of Participants with TEAEs Resulting in Permanent Discontinuation of MEDI5395\"\\n10482,1,1,\"Number of Participants With the Abnormal Urinalysis Findings\"\\n10483,1,1,\"Number of Participants With the DLT (Dose-limiting toxicity)s as a Measure of maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)\"\\n10484,1,1,\"Number of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)\"\\n10485,1,1,\"Number of Participants With the Indicated CNS Responses\"\\n10486,1,1,\"Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value\"\\n10487,1,1,\"Number of Participants With the Indicated Shift From Baseline in Blood Pressure at Any Time Post-Baseline\"\\n10488,1,1,\"Number of Participants With the Indicated Shift in Heart Rate From Baseline at Any Time Post-Baseline\"\\n10489,1,1,\"Number of Participants With the Indicated Tumor Response at 12 Weeks From First Dose\"\\n10490,1,1,\"Number of Participants With the Indicated Worst-case Grade Increase From Baseline for the Indicated Hematology Parameters at Any Time Post-Baseline\"\\n10491,1,1,\"Number of Participants With the Indicated Worst-case Toxicity Grade Increase From Baseline for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline\"\\n10492,1,1,\"Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters\"\\n10493,1,1,\"Number of Participants With the Maximum Toxicity Grade for the Indicated Clinical Hematology Parameters\"\\n10494,1,1,\"Number of participants with thyroid stimulating hormone (TSH) value abnormalities and/or AEs\"\\n10495,1,1,\"Number of Participants With Total Protection in the Acute, Delayed and Overall Periods\"\\n10496,1,1,\"Number of Participants With Toxicities of Crizotinib\"\\n10497,1,1,\"Number of Participants With Toxicity Related to Electrochemotherapy\"\\n10498,1,1,\"Number of participants with treatment delays or discontinuations\"\\n10499,18,1,\"Number of Participants With Treatment Emergent Adverse Events\"\\n10500,2,2,\"Number of participants with treatment emergent adverse events (AEs)\"\\n10501,1,1,\"Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of axitinib\"\\n10502,1,1,\"Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of crizotinib\"\\n10503,7,1,\"Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n10504,1,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAE\\'s).\"\\n10505,5,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAE)\"\\n10506,1,1,\"Number of Participants with Treatment Emergent Adverse Events (TEAE)\"\\n10507,40,3,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs)\"\\n10508,10,2,\"Number of Participants with Treatment Emergent Adverse Events (TEAEs)\"\\n10509,4,1,\"Number of participants with Treatment Emergent Adverse Events (TEAEs)\"\\n10510,7,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n10511,1,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events (SAEs) Related to NOX66.\"\\n10512,2,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)\"\\n10513,1,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) in Part A\"\\n10514,21,7,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)\"\\n10515,1,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Part A and Part B\"\\n10516,1,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Parts 1 and 2\"\\n10517,1,1,\"Number of participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v4.0.\"\\n10518,1,1,\"Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0\"\\n10519,1,1,\"Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.03\"\\n10520,1,1,\"Number of Participants with Treatment Emergent Adverse Events (TEAEs) of ‚â•Grade 3 Diarrhea Occurring During the First 4 Cycles of TAK-788 Dosing\"\\n10521,1,1,\"Number of Participants with Treatment Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, and AEs of Special Interest (AESIs) as per Qualitative Toxicity Scale [National Cancer Institute-Common Terminology Criteria for Adverse Events 5.0]\"\\n10522,5,1,\"Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events\"\\n10523,1,1,\"Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of axitinib\"\\n10524,1,1,\"Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of crizotinib\"\\n10525,16,1,\"Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)\"\\n10526,1,1,\"Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) (Parts 1A, 1B, 2A, 2B)\"\\n10527,6,1,\"Number of Participants With Treatment Related Adverse Events\"\\n10528,1,1,\"Number of participants with treatment related adverse events\"\\n10529,1,1,\"Number of Participants With Treatment Related Adverse Events (TEAE), Adverse Events (AE) or Serious Adverse Events (SAE) for Safety for the Phase 1b Portion of the Study\"\\n10530,1,1,\"Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors\"\\n10531,3,1,\"Number of participants with treatment related adverse events as assessed by CTCAE v4.0\"\\n10532,1,1,\"Number of Participants With Treatment Related Dose Delay or Treatment Discontinuation\"\\n10533,1,1,\"Number of participants with treatment related toxicities and adverse events and change from baseline in vitals signs and laboratory parameters\"\\n10534,1,1,\"Number of Participants With Treatment- emergent Adverse Events (TEAEs)\"\\n10535,1,1,\"Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (irAEs)) for REGN4018 monotherapy\"\\n10536,5,1,\"Number Of Participants With Treatment-emergent Adverse Events\"\\n10537,12,2,\"Number of Participants With Treatment-Emergent Adverse Events\"\\n10538,16,1,\"Number of Participants With Treatment-emergent Adverse Events\"\\n10539,15,3,\"Number of participants with treatment-emergent adverse events\"\\n10540,1,1,\"Number of participants with treatment-emergent adverse events (AEs) (Part 1 and Part 2)\"\\n10541,1,1,\"Number of participants with treatment-emergent adverse events (AEs) (phase 1a and 1b dose escalation phases)\"\\n10542,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (AEs) - Q3W Regimen (All-Causality)\"\\n10543,3,1,\"Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n10544,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (AEs) by Severity [Phase 1b]\"\\n10545,1,1,\"Number of participants with treatment-emergent adverse events (AEs) for all indications\"\\n10546,15,3,\"Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)\"\\n10547,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) [Phase 1b]\"\\n10548,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Phase 1B\"\\n10549,2,1,\"Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)\"\\n10550,2,1,\"Number of Participants with Treatment-emergent Adverse Events (TEAE)\"\\n10551,1,1,\"Number Of Participants With Treatment-emergent Adverse Events (TEAEs)\"\\n10552,64,2,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n10553,41,4,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs)\"\\n10554,9,3,\"Number of Participants with Treatment-emergent Adverse Events (TEAEs)\"\\n10555,13,3,\"Number of participants with treatment-emergent adverse events (TEAEs)\"\\n10556,13,1,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n10557,11,4,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n10558,1,1,\"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)- Parts 1, 2, 3, and 4\"\\n10559,14,3,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)\"\\n10560,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose-escalation Phase\"\\n10561,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in the Dose-escalation, Dose-exploration, and Dose-expansion Phase\"\\n10562,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity: Part 2 Phase 1\"\\n10563,1,1,\"Number of participants with treatment-emergent adverse events (TEAEs) categorized by severity\"\\n10564,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Excluding Deaths Due to Disease Progression\"\\n10565,1,1,\"Number of participants with treatment-emergent adverse events (TEAEs) following oral doses of ZSP1603 and placebo,separately.\"\\n10566,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03\"\\n10567,1,1,\"Number of Participants with Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-9606a\"\\n10568,1,1,\"Number of participants with treatment-emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) and their severity\"\\n10569,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Echocardiogram Evaluations\"\\n10570,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Electrocardiogram (ECG) Evaluations\"\\n10571,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Laboratory Parameters\"\\n10572,1,1,\"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs and Physical Examination\"\\n10573,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations (DCs) Due to Adverse Events (AEs)\"\\n10574,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Dose Interruption, Reduction, or Study Drug Discontinuation (Excluding Grade 5 Disease Progression)\"\\n10575,1,1,\"Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1\"\\n10576,2,2,\"Number of participants with treatment-emergent adverse events (TEAEs; all, related, serious, and of special interest) as assessed by CTCAE version 5.0\"\\n10577,1,1,\"Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] for Dose Optimization Cohort 1a.\"\\n10578,1,1,\"Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events (Part A and B)\"\\n10579,1,1,\"Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE Criteria v5.0\"\\n10580,1,1,\"Number of participants with treatment-emergent Adverse Events as assessed by CTCAE v5.0\"\\n10581,8,4,\"Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0\"\\n10582,1,1,\"Number of participants with treatment-emergent adverse events associated with RGX-104 treatment as a single agent, and separately, in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.\"\\n10583,1,1,\"Number of Participants With Treatment-emergent Adverse Events by Frequency and Grade in Each Cohort of Dose and Dosing Schedule and the Total Number of Participants With the Treatment-emergent Adverse Events\"\\n10584,1,1,\"Number of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ‚â•0.2% of Participants by Preferred Term\"\\n10585,1,1,\"Number of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ‚â•0.5% of Participants by Preferred Term\"\\n10586,1,1,\"Number of Participants With Treatment-emergent Adverse Events Occurring in More Than 1 Participant Following Administration With DS-1205c in Combination With Osimertinib\"\\n10587,1,1,\"Number of Participants With Treatment-emergent Adverse Events Occurring in Participants Following Administration With DS-1205c in Combination With Gefitinib\"\\n10588,1,1,\"Number of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ‚â•10% of Participants by System Organ Class\"\\n10589,1,1,\"Number of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term\"\\n10590,1,1,\"Number of Participants With Treatment-emergent Adverse Events to Evaluate Tolerability of Oxaliplatin With Gemcitabine\"\\n10591,1,1,\"Number of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in ‚â•5% of Participants by Category\"\\n10592,1,1,\"Number of participants with Treatment-emergent Adverse Events(TEAEs)\"\\n10593,1,1,\"Number of Participants With Treatment-emergent Adverse Events, by Severity (Dose Finding and Dose Expansion Phases)\"\\n10594,1,1,\"Number of Participants With Treatment-emergent Adverse Events: All Parts\"\\n10595,1,1,\"Number of Participants With Treatment-Emergent AEs - Q2W Regimen (All-Causality)\"\\n10596,1,1,\"Number of Participants With Treatment-Emergent AEs - Q2W Regimen (Treatment-Related)\"\\n10597,1,1,\"Number of Participants With Treatment-Emergent AEs - Q3W Regimen (Treatment-Related)\"\\n10598,1,1,\"Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q2W Regimen (All-Causality and Treatment-Related)\"\\n10599,1,1,\"Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q3W Regimen (All-Causality and Treatment-Related)\"\\n10600,1,1,\"Number of Participants With Treatment-emergent Infusion-related AEs and TEAEs Related to Enapotamab Vedotin\"\\n10601,3,1,\"Number of Participants With Treatment-emergent Serious Adverse Events\"\\n10602,3,1,\"Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)\"\\n10603,1,1,\"Number of participants with treatment-emergent serious adverse events (TESAEs)\"\\n10604,1,1,\"Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)\"\\n10605,1,1,\"Number of Participants With Treatment-free Remission at 1 Year After Study Completion\"\\n10606,25,5,\"Number of Participants With Treatment-Related Adverse Events\"\\n10607,4,1,\"Number of Participants With Treatment-related Adverse Events\"\\n10608,6,2,\"Number of Participants with Treatment-Related Adverse Events\"\\n10609,4,3,\"Number of Participants with Treatment-related Adverse Events\"\\n10610,30,3,\"Number of participants with treatment-related adverse events\"\\n10611,1,1,\"Number of Participants With Treatment-related Adverse Events (AE)\"\\n10612,1,1,\"Number of participants with treatment-related Adverse Events (AEs)\"\\n10613,1,1,\"Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 2 Phase 1\"\\n10614,1,1,\"Number of participants with treatment-related Adverse Events (AEs) as assessed by CTCAE v4.03 as a measure of safety and tolerability\"\\n10615,1,1,\"Number of participants with Treatment-related Adverse Events (AEs).\"\\n10616,1,1,\"Number of participants with treatment-related adverse events (TEAEs; all, related, serious, and of special interest) as assessed by CTCAE version 5.0\"\\n10617,1,1,\"Number of participants with treatment-related adverse events as assessed by AST-021p\"\\n10618,1,1,\"Number of participants with treatment-related adverse events as assessed by CTCAE\"\\n10619,6,2,\"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0\"\\n10620,14,1,\"Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0\"\\n10621,141,9,\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.0\"\\n10622,1,1,\"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 to determine maximal tolerate dose (MTD) of AZD6738.\"\\n10623,5,2,\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.\"\\n10624,10,2,\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.03\"\\n10625,1,1,\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.3 criteria.\"\\n10626,6,1,\"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0\"\\n10627,37,8,\"Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\"\\n10628,7,2,\"Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.\"\\n10629,5,1,\"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0\"\\n10630,1,1,\"Number of Participants With Treatment-Related Adverse Events as assessed by NCI CTCAE v5.0\"\\n10631,1,1,\"Number of participants with treatment-related adverse events as assesses by CTCAE version 4.03.\"\\n10632,1,1,\"Number of participants with treatment-related adverse events as defined by CTCAE v4.03.\"\\n10633,2,1,\"Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0\"\\n10634,1,1,\"Number of participants with treatment-related adverse events assessed by CTCAE v.5.0\"\\n10635,1,1,\"Number of participants with treatment-related adverse events assessed by CTCAE v4.0.\"\\n10636,1,1,\"Number of participants with treatment-related adverse events assessed by CTCAE v4.03.\"\\n10637,1,1,\"Number of Participants With Treatment-Related Adverse Events at Phase 1\"\\n10638,1,1,\"Number of participants with treatment-related adverse events/dose limiting toxicity as assessed by CTCAE v4.0\"\\n10639,1,1,\"Number of participants with treatment-related AEs for all indications\"\\n10640,1,1,\"Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P\"\\n10641,1,1,\"Number of participants with treatment-related serious adverse events (SAE) as assessed by CTCAE v4.0\"\\n10642,1,1,\"Number of Participants With Treatment-related Treatment-emergent Adverse Events\"\\n10643,1,1,\"Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) - Part 1 and Part 2\"\\n10644,1,1,\"Number of Participants With Tumor Infiltrating Lymphocytes (TIL) Growth\"\\n10645,1,1,\"Number of Participants With Tumor Reponse per PCWG2 and RECIST v1.1 (Parts 2A, 2B)\"\\n10646,1,1,\"Number of Participants With Tumor Response (Stable Disease)\"\\n10647,1,1,\"Number of participants with tumor response assessed by Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)\"\\n10648,1,1,\"Number of participants with tumor response assessed by RECIST v1.1\"\\n10649,1,1,\"Number of participants with tumor response throughout the study using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1\"\\n10650,1,1,\"Number of Participants With Tumor Responses Utilizing RECIST 1.1 at Approximately 16 Weeks\"\\n10651,1,1,\"Number of Participants with UGT1A1 Genotype with Severe Toxicities Induced by CPT-11 with Platinum Analogues\"\\n10652,1,1,\"Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen\"\\n10653,1,1,\"Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen\"\\n10654,1,1,\"Number of Participants With Urinalysis Laboratory Abnormalities by Maximum NCI CTCAE Grade [Phase 1b]\"\\n10655,1,1,\"Number of participants with urinalysis value abnormalities and/or AEs\"\\n10656,1,1,\"Number of participants with vaccination-related adverse events\"\\n10657,1,1,\"Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy\"\\n10658,12,1,\"Number of participants with vital sign abnormalities\"\\n10659,2,1,\"Number of participants with vital sign abnormalities and /or adverse events\"\\n10660,2,1,\"Number of participants with vital sign abnormalities and /or adverse events (AEs)\"\\n10661,1,1,\"Number of Participants with vital sign abnormalities and/or adverse events (AEs)\"\\n10662,9,2,\"Number of participants with vital sign abnormalities and/or adverse events (AEs)\"\\n10663,11,4,\"Number of participants with vital sign abnormalities and/or AEs\"\\n10664,1,1,\"Number of participants with vital sign abnormalities in Safety Part\"\\n10665,1,1,\"Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs)\"\\n10666,2,2,\"Number of Participants with vital sign abnormalities.\"\\n10667,1,1,\"Number of Participants With Vital Sign Related TEAEs by Preferred Term (PT)\"\\n10668,1,1,\"Number of participants with vital signs abnormalities\"\\n10669,1,1,\"Number of participants with vital signs abnormalities and/or adverse events (Initial Treatment)\"\\n10670,1,1,\"Number of participants with vital signs abnormalities and/or adverse events (Retreatment)\"\\n10671,4,3,\"Number of participants with vital signs abnormalities and/or adverse events related to treatment\"\\n10672,1,1,\"Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as TEAEs\"\\n10673,1,1,\"Number of Participants With Vital Signs and Physical Findings Abnormalities Reported as TEAEs\"\\n10674,1,1,\"Number of participants with worsening laboratory values as a measure of safety and tolerability\"\\n10675,1,1,\"Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings\"\\n10676,1,1,\"Number of Participants With Worst Case Post-Baseline Results for Body Temperature During Combination Treatment Period\"\\n10677,1,1,\"Number of Participants With Worst Case Post-Baseline Results for Heart Rate During Combination Treatment Period\"\\n10678,1,1,\"Number of Participants With Worst Case Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Results by Maximum Grade Increase Post-Baseline Relative to Baseline During Combination Treatment Period\"\\n10679,1,1,\"Number of Participants With Worst Grade 2 or Higher Adverse Events Occurring in >5% of Participants at Least Possibly Related to Study Drugs\"\\n10680,1,1,\"Number of Participants With Worst Post-Baseline Grade 3 or Higher Toxicity in Laboratory Values\"\\n10681,1,1,\"Number of Participants With Worst Shift From Baseline Values to Post-baseline Values in Clinical Laboratory Parameters\"\\n10682,1,1,\"Number of Participants With ‚â• 30% Change in PSA\"\\n10683,2,2,\"Number of participants with ‚â•1 adverse event (AE)\"\\n10684,1,1,\"Number of participants with ‚â•1 hepatic AE\"\\n10685,1,1,\"Number of participants with ‚â•1 immune-related AE (irAE)\"\\n10686,1,1,\"Number of participants with ‚â•1 serious adverse event (SAE)\"\\n10687,1,1,\"Number of Participants With ‚â•Grade 3 Toxicities Possibly, Probably, or Definitely Related to Treatment of Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy (SBRT)\"\\n10688,2,1,\"Number of Participants Withdrawn Due to Toxicities\"\\n10689,1,1,\"Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study\"\\n10690,1,1,\"Number of Participants Withdrawn Due to Toxicities-Part 1 BID\"\\n10691,1,1,\"Number of Participants Withdrawn Due to Toxicities-Part 1 QD\"\\n10692,1,1,\"Number of Participants Withdrawn Due to Toxicities-Part 2\"\\n10693,1,1,\"Number of Participants Withdrew Due to AEs\"\\n10694,1,1,\"Number of Participants Without Grade 4 Hematological or Grade 3 to 4 Non-hematological Adverse Events\"\\n10695,1,1,\"Number of Participants, e.g. Responders and Non-responders With a Percent Change in Expression Patterns After Chemotherapy With Changes in Expression Patterns After Chemotherapy in Preclinical Models\"\\n10696,3,1,\"Number of passes\"\\n10697,2,1,\"number of passes\"\\n10698,1,1,\"Number of paticipants with dose-limiting toxicities during the DLT evaluation period\"\\n10699,1,1,\"number of patient correctly sampled\"\\n10700,1,1,\"Number of patients able to adhere to resistant starch (RS) supplement schedule\"\\n10701,1,1,\"Number of patients achieving a complete response (CR) or partial response (PR) to HMBD-001 in the chosen tumour types (Part B)\"\\n10702,1,1,\"Number of patients achieving a reduction in tumour volume (Objective response rate; ORR)\"\\n10703,1,1,\"Number of patients achieving progress-free survival (PFS)\"\\n10704,1,1,\"Number of Patients by Cause of Death\"\\n10705,1,1,\"number of patients called in for PET/MRI who have not realized the PET/MRI\"\\n10706,1,1,\"Number of Patients Correlated With Best Overall Response.\"\\n10707,1,1,\"Number of patients discontinuing study intervention due to an adverse event\"\\n10708,1,1,\"Number of Patients enrolled and received LEE011\"\\n10709,1,1,\"Number of patients enrolled in clinical trials at VICC\"\\n10710,2,2,\"Number of patients excluded due to feasibility issues\"\\n10711,1,1,\"Number of patients excluded due to safety issues\"\\n10712,1,1,\"Number of patients excluded due to treatment related safety issues\"\\n10713,1,1,\"Number of Patients Experiencing a DLT\"\\n10714,1,1,\"Number of Patients Experiencing a Dose-limiting Toxicity (Phase I)\"\\n10715,2,2,\"Number of patients experiencing adverse events (AEs) during the entire treatment period\"\\n10716,1,1,\"Number of patients experiencing clinical or laboratory adverse events as a measure of safety and tolerability\"\\n10717,1,1,\"Number of Patients Experiencing Dose Limiting Toxicities (DLT\\'s)\"\\n10718,1,1,\"Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for study drug in monotherapy\"\\n10719,1,1,\"Number of patients experiencing Dose Limiting Toxicities (DLTs) in the MTD evaluation period\"\\n10720,1,1,\"Number of patients experiencing dose limiting toxicities (DLTs), graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0 (Phase I)\"\\n10721,1,1,\"Number of Patients Experiencing Dose Limiting Toxicity (DLT)\"\\n10722,1,1,\"Number of patients experiencing Dose Limiting Toxicity graded according to CTCAE Version 4.03, observed in the Cycle 1 in order to meet the objective of assessment of the MTD of TAS-116 (Part A)\"\\n10723,1,1,\"Number of patients experiencing Dose Limiting Toxicity graded according to CTCAE Version 4.03, observed in the Cycle 1 in order to meet the objective of assessment of the MTD of TAS0728.\"\\n10724,1,1,\"Number of patients experiencing Progression Free Survival (PFS)\"\\n10725,1,1,\"Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.03 (Common Toxicity Criteria for Adverse Effects)during the study (safety and tolerability).\"\\n10726,2,1,\"Number of patients experiencing tumor size reduction\"\\n10727,1,1,\"Number of patients experiencing unacceptable toxicity associated with humanized anti-GD2 antibody/chemotherapy (course 1) and anti-GD2 antibody/chemotherapy/NK cells (course 2).\"\\n10728,1,1,\"Number of patients exposed to other lung cancer treatments\"\\n10729,1,1,\"Number of patients for which their choice of care and death -if occured- site (at hospital or at home) is respected.\"\\n10730,1,1,\"Number of Patients in Expansion Cohorts with Objective Responses\"\\n10731,1,1,\"Number of patients in the safety lead-in (SLI) phase who completed Cycle 1 or had a DLT and were not replaced.\"\\n10732,1,1,\"Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data\"\\n10733,1,1,\"Number of patients included in a province-wide registry of NGS panel-based testing results\"\\n10734,1,1,\"Number of patients included in province-wide repository of genomically-characterized tumour tissue and blood samples and their utilization rates for future research\"\\n10735,1,1,\"Number of patients presenting at least one targetable genomic alteration\"\\n10736,1,1,\"Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects\"\\n10737,1,1,\"Number of patients reaching pharmacologically active dose measurement of CA9hu-1\"\\n10738,1,1,\"Number of patients reaching the dose levels of 750 mg of CA9hu-1 without any dose limiting toxicities.\"\\n10739,1,1,\"Number of patients received planned treatment and CGA evaluated with improvement of good quality of life (QOL)\"\\n10740,1,1,\"Number of patients receiving therapeutic dose-intensive therapy (doses must be at least equivalent to two-thirds the dose that is usually administered according to AMM recommendations)\"\\n10741,1,1,\"Number of Patients Reported With Antigen Specific Cancer Immunotherapeutics (ASCI)-Related grade3/4 Adverse Events (AEs) According to the Common Terminology Criteria (CTCAE) Version 3.0.\"\\n10742,3,3,\"Number of Patients Reported With Serious Adverse Events (SAEs)\"\\n10743,1,1,\"Number of Patients Reported With Unsolicited Adverse Events (AEs) That Were Causally Related to Treatment Administration by Maximum Grade.\"\\n10744,2,1,\"Number of patients reporting Adverse Events (AEs)\"\\n10745,1,1,\"Number of patients reporting treatment-emergent adverse events (TEAEs) in each of the combinations\"\\n10746,1,1,\"Number of Patients Responding to Treatment, by Best Clinical Response Type\"\\n10747,2,1,\"Number of patients screened\"\\n10748,1,1,\"Number of Patients That Achieved a Complete Response (CR)\"\\n10749,1,1,\"Number of Patients That Achieved a Complete Response or a Partial Response (PR)\"\\n10750,1,1,\"Number of patients that develop study drug related toxicity\"\\n10751,1,1,\"Number of patients that do not have disease progression at 16 weeks from start of treatment\"\\n10752,1,1,\"Number of patients that experience grade 3-4 toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)\"\\n10753,1,1,\"Number of patients tolerating dose levels (maximum tolerated dose; MTD) in each of the combinations\"\\n10754,1,1,\"Number of patients treated by immunotherapy and registered in the database.\"\\n10755,1,1,\"Number of patients undergoing adverse events (AEs) or serious adverse events (SAEs)\"\\n10756,1,1,\"Number of Patients Undergoing Surgical Resection After Receiving at Least 4 of the 6 Courses of Preoperative Chemotherapy\"\\n10757,1,1,\"Number of Patients who Achieved Progression-Free Survival\"\\n10758,1,1,\"Number of patients who are free from analgesics within 3 days of TEMLA\"\\n10759,2,1,\"Number of patients who complete pre-op treatment and proceed to surgery\"\\n10760,1,1,\"Number of patients who consent to each arm.\"\\n10761,1,1,\"Number of patients who consented to biobanking\"\\n10762,1,1,\"Number of Patients Who Developed New Severe Adverse Events\"\\n10763,1,1,\"Number of patients who died for SAE as assessed by CTCAE v4.0\"\\n10764,1,1,\"Number of patients who experience dose limiting toxicities\"\\n10765,1,1,\"Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol\"\\n10766,2,1,\"Number of Patients Who Experience Dose Limiting Toxicities by Dose Level\"\\n10767,1,1,\"Number of Patients Who Experienced at Least 1 AE\"\\n10768,1,1,\"Number of Patients Who Experienced DLTs\"\\n10769,1,1,\"Number of Patients Who Experienced Non-Serious AEs\"\\n10770,1,1,\"Number of Patients Who Experienced Serious AEs\"\\n10771,1,1,\"Number of Patients Who Fail to Receive the First Six Scheduled Vaccinations Because of Toxicity\"\\n10772,1,1,\"Number of Patients Who Had Expansion of Natural Killer Cells\"\\n10773,1,1,\"Number of Patients Who Had Response by RECIST Criteria (Response Evaluation Criteria in Solid Tumors)\"\\n10774,1,1,\"Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks\"\\n10775,1,1,\"Number of patients who have greater than or equal to 1 dose-limiting toxicity, assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)\"\\n10776,1,1,\"number of patients who have skeletal related events (SREs)\"\\n10777,1,1,\"number of patients who performed the PET/MRI\"\\n10778,1,1,\"Number of Patients Who Received 2 Doses of Natural Killer (NK) Cell Infusions\"\\n10779,1,1,\"Number of patients who received plerixafor outside of the label indication in Europe and the reason for administration\"\\n10780,1,1,\"Number of Patients Who Received the Highest Dose Level of NK Cells (1x10^6 NK Cells/kg for Patients With Related Donors and 1 x10^5 NK Cells/kg for Patients With Unrelated Donors) With Sustained Donor Lymphoid Engraftment\"\\n10781,1,1,\"Number of patients who refused\"\\n10782,1,1,\"Number of Patients Who Responded to Study Treatment (Phase II)\"\\n10783,1,1,\"Number of Patients Who Survive for at Least 12 Months\"\\n10784,1,1,\"Number of patients who undergone to withdrawal of doxorubicin\"\\n10785,1,1,\"Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy\"\\n10786,1,1,\"Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors\"\\n10787,1,1,\"Number of Patients With a Cellular Response (Anti-MAGE-A3 Specific CD4+ and CD8+ T-cells Concentrations After Immunization)\"\\n10788,1,1,\"Number of Patients With a Change in Mayo Classification\"\\n10789,1,1,\"Number of Patients With a Complete Response (CR) and Partial Response (PR)\"\\n10790,1,1,\"Number of Patients With a Complete Response (CR) or Partial Response (PR) to Treatment\"\\n10791,1,1,\"Number of Patients With a Complete Response (CR) or Partial Response (PR) to Treatment Using irRC Criteria\"\\n10792,1,1,\"Number of patients with a dose-limiting toxicity (DLT)\"\\n10793,1,1,\"Number of Patients With Abnormal Alanine Aminotransferase (ALT) Values by Maximum Grade\"\\n10794,1,1,\"Number of Patients With Abnormal Alkaline Phosphatase (ALK) Values by Maximum Grade\"\\n10795,1,1,\"Number of Patients With Abnormal Aspartate Aminotransferase (AST) Values by Maximum Grade\"\\n10796,1,1,\"Number of Patients With Abnormal Bilirubine (BIL) Values by Maximum Grade\"\\n10797,1,1,\"Number of Patients With Abnormal Creatinine (CREA) Values by Maximum Grade\"\\n10798,1,1,\"Number of Patients With Abnormal Gamma-glutamyl Transpeptidase (GGT) Values by Maximum Grade\"\\n10799,1,1,\"Number of Patients With Abnormal Hemoglobin (HGB) Values by Maximum Grade\"\\n10800,1,1,\"Number of Patients With Abnormal Hypercalcemia (HCA) Values by Maximum Grade\"\\n10801,1,1,\"Number of Patients With Abnormal Hyperkalemia (HKA) Values by Maximum Grade\"\\n10802,1,1,\"Number of Patients With Abnormal Hypernatremia (HNA) Values by Maximum Grade\"\\n10803,1,1,\"Number of Patients With Abnormal Hypoalbuminemia (hAL) Values by Maximum Grade\"\\n10804,1,1,\"Number of Patients With Abnormal Hypocalcemia (hCA) Values by Maximum Grade\"\\n10805,1,1,\"Number of Patients With Abnormal Hypokalemia (hKA) Values by Maximum Grade\"\\n10806,1,1,\"Number of Patients With Abnormal Hyponatremia (hNA) Values by Maximum Grade\"\\n10807,1,1,\"Number of Patients With Abnormal Leukocytes (LEU) Values by Maximum Grade\"\\n10808,1,1,\"Number of Patients With Abnormal Lymphopenia (LYM) Values by Maximum Grade\"\\n10809,1,1,\"Number of Patients With Abnormal Neutrophils (NEU) Values by Maximum Grade\"\\n10810,1,1,\"Number of Patients With Abnormal Platelets (PLT) Values by Maximum Grade\"\\n10811,1,1,\"Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression\"\\n10812,1,1,\"Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib\"\\n10813,13,2,\"Number of Patients With Adverse Events\"\\n10814,8,2,\"Number of Patients with Adverse Events\"\\n10815,162,10,\"Number of patients with adverse events\"\\n10816,2,1,\"Number of Patients with Adverse Events (AEs)\"\\n10817,1,1,\"Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs).\"\\n10818,1,1,\"Number of patients with adverse events (AEs) as a measure of safety and tolerability\"\\n10819,1,1,\"Number of patients with adverse events (AEs) for NOX66\"\\n10820,1,1,\"Number of patients with adverse events (AEs), serious adverse events (SAEs), and treatment emergent adverse events (TEAEs)\"\\n10821,1,1,\"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) or Adverse Events Leading to Discontinuation.\"\\n10822,1,1,\"Number of patients with adverse events (Phase I dose escalation)\"\\n10823,1,1,\"Number of Patients With Adverse Events - Phase II\"\\n10824,1,1,\"Number of patients with adverse events according to NCI-CTC v3.0 CRITERIA as a measure of safety and tolerability\"\\n10825,3,2,\"Number of patients with Adverse Events and Serious Adverse Events\"\\n10826,3,2,\"Number of patients with adverse events and serious adverse events\"\\n10827,1,1,\"Number of patients with adverse events and serious adverse events of RLY-2608 as a single agent\"\\n10828,1,1,\"Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrant\"\\n10829,1,1,\"Number of patients with adverse events and/or dose-limiting toxicities as a measure of safety and tolerability of OTS167 IV infusion.\"\\n10830,1,1,\"Number of patients with Adverse Events and/or Serious Adverse Events\"\\n10831,6,1,\"Number of Patients With Adverse Events as a Measure of Safety and Tolerability\"\\n10832,10,1,\"Number of patients with adverse events as a measure of safety and tolerability\"\\n10833,1,1,\"Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.\"\\n10834,1,1,\"Number of patients with adverse events as a measure of safety and tolerability of PLX038\"\\n10835,1,1,\"Number of patients with adverse events as a measure of safety and tolerability of repeat doses.\"\\n10836,1,1,\"Number of patients with adverse events during combination therapy\"\\n10837,1,1,\"Number of Patients with Adverse Events in Phase 1 Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy\"\\n10838,1,1,\"Number of patients with adverse events including intraoperative and postoperative complications\"\\n10839,1,1,\"Number of patients with Adverse Events of vobramitamab duocarmazine as assessed by CTCAE v4.03\"\\n10840,1,1,\"Number of Patients With Adverse Events Qualified as Dose Limiting Toxicities (DLTs)\"\\n10841,1,1,\"Number of patients with adverse events with significant over-reporting CAR-T cells and other cellular therapies\"\\n10842,12,6,\"Number of patients with adverse events.\"\\n10843,1,1,\"Number of patients with adverse events.(Part 1a)\"\\n10844,1,1,\"Number of patients with Adverse EventsÔºàAEsÔºâ\"\\n10845,4,1,\"Number of patients with AEs and SAEs\"\\n10846,1,1,\"Number of patients with AEs qualified as dose-limiting toxicities (DLTs)\"\\n10847,1,1,\"Number of patients with AEs, SAEs\"\\n10848,1,1,\"Number of Patients With All-Causality Treatment-Emergent Adverse Events(TEAEs) [Part 2 & 3]\"\\n10849,1,1,\"number of patients with an objective response rate (ORR) of AZD5363\"\\n10850,1,1,\"Number of patients with an overall response of liver metastasis according to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n10851,1,1,\"Number of patients with and severity of adverse events (AEs) and serious adverse events (SAEs)\"\\n10852,1,1,\"Number of Patients With Any Adverse Events (AEs) and With AEs by Maximum Grade\"\\n10853,1,1,\"Number of Patients With Any AE(s) and With AEs by Maximum Grade, Related to Treatment Administration\"\\n10854,1,1,\"Number of Patients With Any Serious Adverse Events (SAEs) and With SAEs by Maximum Grade\"\\n10855,1,1,\"Number of Patients With Any Serious Adverse Events (SAEs) and With SAEs by Maximum Grade, Related to Treatment Administration\"\\n10856,1,1,\"Number of Patients With Best Overall Response to Study Treatment (Phase II)\"\\n10857,1,1,\"Number of Patients With CD4+ and CD8+ T Cell Frequency ‚â• 1.24 Cut-off\"\\n10858,1,1,\"Number of patients with change in brain natriuretic peptide (BNP) levels from baseline\"\\n10859,1,1,\"Number of patients with change in EPIC bowel domain score that was worse than 5 points\"\\n10860,1,1,\"Number of patients with change in EPIC urinary domain score that was worse than 2 points\"\\n10861,1,1,\"Number of patients with change in troponin levels from baseline\"\\n10862,2,1,\"Number of patients with changes in electrocardiogram (ECG) results from baseline\"\\n10863,1,1,\"Number of patients with changes in electrocardiogram results from baseline\"\\n10864,1,1,\"Number of patients with changes in electrocariogram (ECG) from baseline\"\\n10865,5,3,\"Number of patients with changes in laboratory parameters from baseline\"\\n10866,1,1,\"Number of patients with changes in physical exam, vital signs, and serial electrocardiograms.\"\\n10867,3,1,\"Number of patients with changes in vital signs from baseline\"\\n10868,1,1,\"Number of patients with changes in vital signs parameters from baseline\"\\n10869,1,1,\"Number of Patients With CIN/FN Episodes: Patient Level\"\\n10870,1,1,\"Number of Patients With Clinical Anti-tumor Activity Phase II)\"\\n10871,1,1,\"Number of patients with clinically actionable findings\"\\n10872,1,1,\"Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term\"\\n10873,1,1,\"Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term\"\\n10874,1,1,\"Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term\"\\n10875,3,3,\"Number of Patients with Clinically Significant Laboratory Abnormalities\"\\n10876,1,1,\"Number of Patients with Clinically Significant Laboratory Abnormalities:\"\\n10877,1,1,\"Number of patients with clinically significant laboratory changes (CTCAE v5.0)\"\\n10878,1,1,\"Number of Patients With Complete or Partial Response Assessed by RECIST Criteria\"\\n10879,2,1,\"Number of patients with complete response\"\\n10880,1,1,\"Number of patients with complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or inevaluable (IE)\"\\n10881,1,1,\"Number of Patients With Confirmed Responses\"\\n10882,1,1,\"Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).\"\\n10883,1,1,\"Number of patients with corneal adverse events impacting study treatment (Escalation cohort)\"\\n10884,1,1,\"Number of patients with corticosteroids treatment at nivolumab initiation\"\\n10885,1,1,\"Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping\"\\n10886,1,1,\"Number of patients with cycle 1 dose limiting toxicities attributable to nanoparticle albumin-bound rapamycin\"\\n10887,1,1,\"Number of Patients With Cytotoxic T-lymphocyte (CTL) Response to Individual Peptides After Immunization With a Combination of 8 Peptides and CpG 7909 or Montanide ISA51.\"\\n10888,1,1,\"Number of Patients With Decline in Serum CA 15-3 (Carcinoma Antigen 15-3)\"\\n10889,1,1,\"Number of Patients With Decreased Gene Expression of CYP19 in Breast Cancer by Adding COX-2 Inhibitor to Exemestane\"\\n10890,1,1,\"Number of Patients With Delayed-Type Hypersensitivity (DTH) Skin Reactions to NY-ESO-1b Peptide\"\\n10891,1,1,\"Number of patients with detectable EGFR mutations in their CTCs\"\\n10892,1,1,\"Number of patients with different tumor response and short term toxicity will be recorded\"\\n10893,2,2,\"Number of patients with DLT\"\\n10894,1,1,\"Number of patients with DLTs\"\\n10895,1,1,\"Number of patients with DLTs in the MTD evaluation period\"\\n10896,1,1,\"Number of patients with dose interruptions and dose changes\"\\n10897,1,1,\"Number of patients with dose limiting adverse events (Escalation cohort)\"\\n10898,3,2,\"Number of Patients With Dose Limiting Toxicities\"\\n10899,2,2,\"Number of patients with Dose Limiting Toxicities\"\\n10900,6,5,\"Number of patients with dose limiting toxicities\"\\n10901,1,1,\"Number of patients with dose limiting toxicities (DLT)\"\\n10902,4,2,\"Number of Patients With Dose Limiting Toxicities (DLTs)\"\\n10903,1,1,\"Number of patients with Dose Limiting Toxicities (DLTs)\"\\n10904,1,1,\"Number of Patients With Dose Limiting Toxicities (DLTs) and Number of Patients With Adverse Events\"\\n10905,1,1,\"Number of Patients With Dose Limiting Toxicities (DLTs) During 1st Course\"\\n10906,1,1,\"Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period\"\\n10907,1,1,\"Number of patients with Dose limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period.\"\\n10908,1,1,\"Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation period and thereafter\"\\n10909,12,7,\"Number of Patients with Dose Limiting Toxicity\"\\n10910,8,1,\"Number of patients with dose limiting toxicity\"\\n10911,1,1,\"Number of patients with Dose Limiting Toxicity (DLT)\"\\n10912,1,1,\"Number of patients with dose limiting toxicity (DLT) by CTCAE 5.0\"\\n10913,1,1,\"Number of patients with Dose limiting Toxicity (DLT) in the Maximum tolerated dose (MTD) evaluation period\"\\n10914,1,1,\"Number of patients with dose limiting toxicity (DLT) in the MTD evaluation period, Part A\"\\n10915,1,1,\"Number of patients with dose limiting toxicity (DLT) in the MTD evaluation period, Part B\"\\n10916,3,3,\"Number of Patients with Dose-limiting Toxicities\"\\n10917,3,1,\"Number of patients with dose-limiting toxicities\"\\n10918,1,1,\"Number of Patients With Dose-Limiting Toxicities (DLT)\"\\n10919,1,1,\"Number of Patients with Dose-Limiting Toxicities (DLTs)\"\\n10920,1,1,\"Number of patients with dose-limiting toxicities (DLTs)\"\\n10921,1,1,\"Number of patients with dose-limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period in combination therapy (Part B)\"\\n10922,1,1,\"Number of patients with dose-limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period in monotherapy (Part A)\"\\n10923,1,1,\"Number of Patients with Dose-Limiting Toxicities (DLTs) Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0\"\\n10924,1,1,\"Number of Patients With Dose-limiting Toxicities (in Safety lead-in)\"\\n10925,1,1,\"Number of patients with dose-limiting toxicities for each dose level as assessed by CTCAE v 4.0\"\\n10926,1,1,\"Number of Patients With Dose-limiting Toxicities, as Assessed by CTCAE v 4.0\"\\n10927,1,1,\"Number of patients with dose-limiting toxicities, as assessed by CTCAE v 4.0\"\\n10928,1,1,\"Number of patients with Dose-Limiting Toxicities:\"\\n10929,4,1,\"Number of patients with dose-limiting toxicity\"\\n10930,1,1,\"number of patients with dose-limiting toxicity\"\\n10931,1,1,\"number of patients with Dose-Limiting Toxicity (DLTs)\"\\n10932,1,1,\"Number of Patients With Dose-limiting Toxicity (Phase I)\"\\n10933,2,2,\"Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose\"\\n10934,1,1,\"Number of Patients With Dose-limiting Toxicity Incidents Graded According to the NCI CTCAE v4.0 (Phase I)\"\\n10935,1,1,\"Number of patients with dose-limiting toxicity.\"\\n10936,1,1,\"Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs)\"\\n10937,1,1,\"Number of patients with electrocardiographic abnormalities and changes in electrocardiograms readings\"\\n10938,1,1,\"Number of patients with FN (all grades) during study Cycle 1\"\\n10939,1,1,\"number of patients with good quality of the imaging\"\\n10940,1,1,\"Number of Patients With Grade 3 or Higher Adverse Events\"\\n10941,1,1,\"Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0 (Phase II)\"\\n10942,1,1,\"number of patients with grade 3 toxicity\"\\n10943,1,1,\"Number of Patients With Grade 3-4 Febrile Neutropenia During Concurrent Chemoradiotherapy\"\\n10944,1,1,\"Number of Patients With Grade ‚â• 3 Toxicity (Phase I)\"\\n10945,1,1,\"Number of Patients with Grade ‚â•2 Laboratory Parameter AEs Reported\"\\n10946,1,1,\"Number of patients with hematopoietic response at 10 weeks.\"\\n10947,1,1,\"Number of patients with histopathologically confirmed complete remission (pCR) (ypT0N0 R0) after preoperative RCTx related to pretherapeutically determined gene expression signature predicting tumor response to RCTx.\"\\n10948,1,1,\"Number of Patients With Improved Disease Control\"\\n10949,1,1,\"Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product\"\\n10950,1,1,\"Number of Patients With Intracranial Response\"\\n10951,2,2,\"Number of patients with laboratory abnormalities\"\\n10952,1,1,\"Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Escalation Phase)\"\\n10953,1,1,\"Number of patients with laboratory abnormalities and changes in laboratory values\"\\n10954,1,1,\"Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated From Clinical Endoscopy\"\\n10955,1,1,\"Number of Patients With Local Recurrence at the Surgical Site Within 12 Months After Stereotactic Radiosurgery (SRS)\"\\n10956,1,1,\"Number of patients with loss of ATM protein\"\\n10957,2,1,\"Number of patients with meaningful immunological features\"\\n10958,1,1,\"Number of patients with meaningful molecular genetic alterations on circulating tumour DNA (ctDNA)\"\\n10959,1,1,\"Number of patients with meaningful molecular genetic alterations on tumor sample\"\\n10960,1,1,\"Number of Patients With Measurable Soft Tissue Disease Will be Assessed Per Solid Tumor Response Criteria (RECIST).\"\\n10961,1,1,\"Number of Patients With Mixed Response (MR) to GSK2132231A\"\\n10962,1,1,\"Number of patients with mutations at nivolumab initiation\"\\n10963,1,1,\"Number of patients with neurological adverse events with significant over-reporting enzalutamide\"\\n10964,1,1,\"Number of patients with newly diagnosed cancer from 1990 to 2005 and treated at Vanderbilt-Ingram Cancer Center (VICC), in middle Tennessee, and the state of Tennessee\"\\n10965,1,1,\"Number of Patients With NY-ESO-1 Specific Cellular Immunity as Measured by an Increase in NY-ESO-1b Specific CD8+ T-cells Following Treatment.\"\\n10966,1,1,\"Number of Patients With NY-ESO-1 Specific Humoral Immunity as Determined by an Increase in Antibody Titer From Baseline.\"\\n10967,2,2,\"Number of Patients With Objective Tumor Regression\"\\n10968,1,1,\"Number of Patients With Objective Tumor Response (OR) to GSK2132231A Study Treatment\"\\n10969,1,1,\"Number of patients with of treatment-related adverse event data per CTCAE v5.0 criteria and frequency of dose limiting toxicities, to determine safety and tolerability of RP-6306 in combination with FOLFIRI.\"\\n10970,1,1,\"Number of patients with of treatment-related adverse event data per CTCAE v5.0 criteria and frequency of dose limiting toxicities, to determine safety and tolerability of RP-6306 in combination with gemcitabine.\"\\n10971,1,1,\"Number of Patients With Overall Objective Response\"\\n10972,1,1,\"Number of patients with Overall response rate (ORR)(complete response/partial response) and progression free survival (PFS) during the Phase II portion of the study\"\\n10973,1,1,\"Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant Growth in Lesions or Symptoms Related to the Lesions Requiring Surgical Intervention\"\\n10974,1,1,\"Number of patients with partial response\"\\n10975,1,1,\"Number of patients with PD-L1 expression at nivolumab initiation\"\\n10976,1,1,\"Number of Patients With Pulmonary Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Calculated From Chest Computed Tomography (CT) Scans\"\\n10977,6,2,\"Number of Patients With Response\"\\n10978,3,1,\"Number of patients with response\"\\n10979,1,1,\"Number of Patients With Response to Treatment Measured by RECIST Criteria\"\\n10980,2,1,\"Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.\"\\n10981,1,1,\"Number of patients with serious and non-serious adverse events\"\\n10982,1,1,\"Number of patients with stable disease\"\\n10983,1,1,\"Number of Patients With Stable Disease at 4 Months.\"\\n10984,1,1,\"Number of patients with standard safety assessments (adverse events and laboratory tests)\"\\n10985,1,1,\"Number of Patients With Toxicities\"\\n10986,1,1,\"Number of Patients With Toxicity\"\\n10987,1,1,\"Number of Patients With Toxicity of Bevacizumab as Assessed by CTCAE v3.0 in This Cohort of Patients.\"\\n10988,1,1,\"Number of patients with treated brain metastasis at nivolumab initiation\"\\n10989,1,1,\"Number of patients with treatment emergent adverse events in dose escalation phase\"\\n10990,1,1,\"Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety]\"\\n10991,1,1,\"Number of patients with treatment related Adverse Events and Serious Adverse Events as assessed by NCI CTCAEV4.03\"\\n10992,1,1,\"Number of patients with treatment related adverse events and/or clinical laboratory abnormalities\"\\n10993,3,3,\"Number of patients with treatment related AEs\"\\n10994,2,2,\"Number of Patients With Treatment Response for Anti-MAGE-A3 Antibodies\"\\n10995,1,1,\"Number of Patients With Treatment Response for Anti-PD\"\\n10996,2,1,\"Number of Patients With Treatment-Emergent Adverse Events\"\\n10997,5,3,\"Number of Patients With Treatment-emergent Adverse Events\"\\n10998,1,1,\"Number of patients with treatment-emergent adverse events (CTCAE v5.0)\"\\n10999,1,1,\"Number of Patients With Treatment-emergent Adverse Events (TEAE)\"\\n11000,3,2,\"Number of Patients With Treatment-emergent Adverse Events (TEAEs)\"\\n11001,1,1,\"Number of patients with treatment-emergent adverse events assessed by NCI CTCAE v4.03\"\\n11002,1,1,\"Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term\"\\n11003,1,1,\"Number of Patients With Treatment-related Adverse Events\"\\n11004,12,1,\"Number of patients with treatment-related adverse events\"\\n11005,1,1,\"Number of patients with treatment-related adverse events as assessed by CTCAE v.4.0\"\\n11006,1,1,\"Number of Patients With Treatment-related Dose Limiting Toxicities in Later Cycles by Dose Level\"\\n11007,1,1,\"Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level\"\\n11008,1,1,\"Number of patients with treatment-related toxicities by maximum observed grade\"\\n11009,1,1,\"Number of patients with tumor response\"\\n11010,1,1,\"Number of Patients With Unacceptable Dose Limiting Toxicities (DLTs)\"\\n11011,1,1,\"Number of Patients With Undetectable PSA\"\\n11012,1,1,\"Number of patients with untreated brain metastasis at nivolumab initiation\"\\n11013,1,1,\"number of patients with variant allele frequency (VAF)\"\\n11014,1,1,\"Number of patients with vital sign abnormalities and changes in vital signs\"\\n11015,1,1,\"Number of patients\\' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment.\"\\n11016,1,1,\"Number of Patricipants with Adverse Events\"\\n11017,1,1,\"Number of People With Adverse Effects\"\\n11018,2,1,\"Number of peripheral tumor lesions identified in standard PET/CT imaging also identifiable in PEM images.\"\\n11019,1,1,\"Number of Phase 1 Participants With Treatment Emergent Adverse Events and Dose Limiting Toxicities\"\\n11020,1,1,\"Number of Phase 2a Participants With Adverse Events as a Measure of Safety and Tolerability\"\\n11021,4,2,\"Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)\"\\n11022,1,1,\"Number of Phase I Patients Receiving 60mg or 80mg BKM120 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage\"\\n11023,1,1,\"Number of Post-operative Adjuvant Therapy Participants With Breast Cancer Recurrence Status\"\\n11024,1,1,\"Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab\"\\n11025,1,1,\"number of recurrences after primary treatment\"\\n11026,1,1,\"Number of referrals to Senior Adult Oncology Center (SAOC)\"\\n11027,2,1,\"Number of Reported Adverse Events\"\\n11028,1,1,\"Number of Responders (Response Rate)\"\\n11029,1,1,\"Number of Responses to Low Dose Naltrexone for Patients With Advanced Melanoma, Castrate Refractory Prostate Cancer (CRPC) or Renal Cancer Via RECIST\"\\n11030,1,1,\"Number of Rheumatoid Arthritis (RA) Related Visits\"\\n11031,1,1,\"Number of self-reported adverse events by arm\"\\n11032,20,1,\"Number of Serious Adverse Events\"\\n11033,3,1,\"Number of serious adverse events (SAE)\"\\n11034,5,2,\"Number of Serious Adverse Events (SAEs)\"\\n11035,1,1,\"Number of Serious Adverse Events (SAEs) Related to ZD1839\"\\n11036,1,1,\"Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events.\"\\n11037,1,1,\"Number of Serious Treatment-Emergent Adverse Events by CTCAE v5.0\"\\n11038,1,1,\"Number of Seroconverted Patients for Anti-MAGE-A3\"\\n11039,1,1,\"Number of Seroconverted Patients for Melanoma Antigen (Anti-MAGE-A3)\"\\n11040,1,1,\"Number of Skin Cancers within the Treatment Area\"\\n11041,1,1,\"Number of solid cancers\"\\n11042,1,1,\"Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)\"\\n11043,1,1,\"Number of study participants with objective tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)\"\\n11044,1,1,\"Number of study participants with progression free survival as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)\"\\n11045,1,1,\"Number of study patients with adverse events as a measure of safety of haploidentical stem cell transplantation and NK cell infusion\"\\n11046,1,1,\"Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03\"\\n11047,1,1,\"Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0\"\\n11048,2,2,\"Number of subjcects with adverse events and serious adverse events\"\\n11049,1,1,\"Number of Subject With Overall Response\"\\n11050,3,3,\"Number of subjects achieving Dose-limiting toxicity (DLT)\"\\n11051,2,1,\"Number of subjects completing questionnaires\"\\n11052,1,1,\"Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period. ÔºàPhase 1bÔºâ\"\\n11053,1,1,\"Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21\"\\n11054,1,1,\"Number of subjects experienced limiting toxicities in the first 6 weeks.\"\\n11055,2,1,\"Number of subjects experiencing a dose-limiting toxicity\"\\n11056,8,1,\"Number of subjects experiencing adverse events\"\\n11057,1,1,\"Number of subjects experiencing Adverse Events (AEs) by severity and overall tabulations by cohort and overall including treatment emergent and Serious AEs\"\\n11058,1,1,\"Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)\"\\n11059,1,1,\"Number of subjects experiencing AEs that are both serious and drug-related in Part B\"\\n11060,1,1,\"Number of Subjects Experiencing DLTs (Dose Limiting Toxicity).\"\\n11061,1,1,\"Number of subjects experiencing dose limiting toxicities\"\\n11062,2,2,\"Number of Subjects Experiencing Dose Limiting Toxicity (DLT)\"\\n11063,3,2,\"Number of subjects experiencing dose-limiting toxicities (DLTs)\"\\n11064,1,1,\"Number of subjects experiencing dose-limiting toxicities(DLTs)\"\\n11065,2,1,\"Number of Subjects Experiencing Dose-limiting Toxicity\"\\n11066,2,2,\"Number of subjects experiencing dose-limiting toxicity\"\\n11067,1,1,\"Number of subjects experiencing study-related toxicities when taking Veliparib in Combination with Lapatinib\"\\n11068,1,1,\"Number of subjects experiencing treatment-emergent adverse events (TEAE), serious TEAEs, TEAEs leading to discontinuation of RT, and TEAEs leading to death\"\\n11069,2,2,\"Number of subjects occuring treatment related adverse events\"\\n11070,3,3,\"Number of subjects participants with adverse events\"\\n11071,5,1,\"Number of Subjects Reporting Adverse Events\"\\n11072,5,4,\"Number of subjects reporting adverse events\"\\n11073,1,1,\"Number of Subjects Reporting Adverse Events (AEs) and Dose-limiting Toxicities (DLTs)\"\\n11074,1,1,\"Number of subjects reporting infusion related reactions\"\\n11075,7,3,\"Number of subjects reporting serious adverse events\"\\n11076,1,1,\"Number of subjects that develop changes in detectable antidrug antibodies to MEDI9090\"\\n11077,1,1,\"Number of Subjects That Maintained Target Hemoglobin Level (11-12 g/dL) Maintenance Weekly for 12 Weeks\"\\n11078,1,1,\"Number of subjects who discontinue DO-2 treatment due to adverse event\"\\n11079,1,1,\"Number of subjects who experience Dose Limiting Toxicities (DLTs)\"\\n11080,1,1,\"Number of subjects who experience specific treatment-emergent adverse events (TEAEs)\"\\n11081,1,1,\"Number of subjects who experience with clinically significant changes in laboratory values\"\\n11082,1,1,\"Number of subjects who experience with TEAEs, SAEs, irAEs and IRRs\"\\n11083,1,1,\"Number of subjects who experience with treatment-related TEAEs, SAEs, irAEs and IRRs\"\\n11084,1,1,\"Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)\"\\n11085,1,1,\"Number of Subjects Who Experienced Dose Limiting Toxicity (DLT)\"\\n11086,1,1,\"Number of Subjects Who Experienced Dose-limiting Toxicities (DLT)\"\\n11087,1,1,\"Number of Subjects Who Reached Maximum Tolerated Dose (MTD)\"\\n11088,1,1,\"Number of subjects with 1 or more SAEs (serious adverse events)\"\\n11089,1,1,\"Number of subjects with 1 or more SAEs (serious adverse events) (Part 1)\"\\n11090,1,1,\"Number of subjects with 1 or more SAEs (serious adverse events) (Part 2)\"\\n11091,1,1,\"Number of subjects with 1 or more TEAEs leading to dose modifications\"\\n11092,1,1,\"Number of subjects with 1 or more TEAEs leading to dose modifications (Part 1)\"\\n11093,1,1,\"Number of subjects with 1 or more TEAEs leading to dose modifications (Part 2)\"\\n11094,1,1,\"Number of subjects with 1 or more TEAEs leading to treatment discontinuation\"\\n11095,1,1,\"Number of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 1)\"\\n11096,1,1,\"Number of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 2)\"\\n11097,1,1,\"Number of Subjects With a Pre-identified Gene Signature (GS) to the recMAGE-A3 Cancer Immunotherapeutic\"\\n11098,7,1,\"Number of subjects with abnormal electrocardiogram\"\\n11099,1,1,\"Number of subjects with abnormal laboratory examination\"\\n11100,9,1,\"Number of subjects with abnormal physical examination\"\\n11101,10,1,\"Number of subjects with abnormal vital signs\"\\n11102,1,1,\"Number of Subjects with adverse event (AE)\"\\n11103,1,1,\"Number of subjects with adverse event.\"\\n11104,17,1,\"Number of Subjects With Adverse Events\"\\n11105,97,4,\"Number of subjects with adverse events\"\\n11106,3,1,\"Number of subjects with Adverse Events (AEs)\"\\n11107,18,5,\"Number of subjects with adverse events (AEs)\"\\n11108,3,1,\"Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n11109,6,1,\"Number of subjects with adverse events (AEs) and serious adverse events (SAEs)\"\\n11110,1,1,\"Number of Subjects With Adverse Events (AEs) and Serious AEs\"\\n11111,1,1,\"Number of subjects with adverse events (AEs) serious adverse events (SAEs) and dose limiting toxicities (DLTs).\"\\n11112,1,1,\"Number of subjects with Adverse Events (AEs) to assess the safety of dabrafenib +/- trametinib when administered in combination with ipilimumab\"\\n11113,1,1,\"Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs)\"\\n11114,1,1,\"Number of subjects with adverse events (Phase Ia)\"\\n11115,1,1,\"Number of subjects with adverse events and percentage of therapy withdrawals due to treatment emergent adverse events\"\\n11116,6,2,\"Number of subjects with adverse events and serious adverse events\"\\n11117,2,1,\"Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability\"\\n11118,2,2,\"Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.\"\\n11119,2,1,\"Number of Subjects With Adverse Events as a Measure of Safety and Tolerability\"\\n11120,10,2,\"Number of subjects with adverse events as a measure of safety and tolerability\"\\n11121,1,1,\"Number of subjects with Adverse Events as a measure safety\"\\n11122,1,1,\"Number of Subjects With Adverse Events as Assessed by CTCAE 4.03\"\\n11123,1,1,\"Number of subjects with adverse events as assessed by CTCAE4.03\"\\n11124,1,1,\"Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC\"\\n11125,2,1,\"Number of Subjects With Adverse Events.\"\\n11126,1,1,\"Number of subjects with AE, IrAEs, IRRs, SAEs and abnormalities in Lab\"\\n11127,1,1,\"Number of subjects with AEs\"\\n11128,3,3,\"Number of subjects with AEs and SAEs\"\\n11129,1,1,\"Number of Subjects With Antitumor Response as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria 1.1\"\\n11130,15,1,\"Number of Subjects With Any and Grade 3 Solicited Local Symptoms\"\\n11131,2,1,\"Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)\"\\n11132,1,1,\"Number of Subjects With Any Dose Limiting Toxicity (DLT)\"\\n11133,2,2,\"Number of subjects with any dose limiting toxicity (DLT)\"\\n11134,1,1,\"Number of subjects with any serious adverse event (SAE), non-serious adverse event (AE) in Phase I Dose Escalation phase\"\\n11135,19,1,\"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms\"\\n11136,11,1,\"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)\"\\n11137,1,1,\"Number of Subjects With at Least 1 Dose Limiting Toxicity (DLT)\"\\n11138,1,1,\"Number of subjects with at least 1 dose-limiting toxicity (DLT)\"\\n11139,1,1,\"Number of Subjects With Best Overall Tumor Response by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)\"\\n11140,1,1,\"Number of Subjects With Best Tumor Response as Measured by the Response Evaluation Criteria in Solid Tumors (RECIST).\"\\n11141,2,1,\"Number of subjects with changes between baseline and post-baseline safety assessments based on safety laboratory results graded by CTCAE v5.0\"\\n11142,1,1,\"Number of subjects with changes in clinical laboratory tests\"\\n11143,1,1,\"Number of subjects with changes in electrocardiogram (ECG)\"\\n11144,1,1,\"Number of subjects with changes in vital signs\"\\n11145,1,1,\"Number of Subjects With Clinical Benefit Response (CBR) Based on the Extramural Review Committee Assessment in Recommended Dose Group\"\\n11146,1,1,\"Number of subjects with clinically significant changes in laboratory values.\"\\n11147,1,1,\"Number of subjects with clinically significant laboratory test abnormalities (Phase 1b)\"\\n11148,1,1,\"Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)\"\\n11149,1,1,\"Number of Subjects With Disease Progression Using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Phase IB)\"\\n11150,1,1,\"Number of subjects with DLT (Dose limiting Toxicity)\"\\n11151,1,1,\"Number of subjects with DLT (Dose limiting Toxicity): dose escalation part\"\\n11152,1,1,\"Number of subjects with dose limiting toxicities\"\\n11153,3,3,\"Number of Subjects With Dose Limiting Toxicities (DLT)\"\\n11154,1,1,\"Number of subjects with dose limiting toxicities (DLT)\"\\n11155,3,2,\"Number of Subjects With Dose Limiting Toxicities (DLTs)\"\\n11156,1,1,\"Number of subjects with Dose Limiting Toxicities (DLTs)\"\\n11157,3,2,\"Number of subjects with dose limiting toxicities (DLTs)\"\\n11158,1,1,\"Number of subjects with dose limiting toxicities (DLTs) at each dose level during the first cycle\"\\n11159,1,1,\"Number of Subjects With Dose Limiting Toxicities (DLTs) Determined in Part-A\"\\n11160,1,1,\"Number of subjects with Dose Limiting Toxicities (DLTs) of TT-10 during the dose escalation phase\"\\n11161,1,1,\"Number of subjects with Dose Limiting Toxicities (DLTs) of TT-4 during the dose escalation phase\"\\n11162,1,1,\"Number of Subjects With Dose Limiting Toxicity (DLT)\"\\n11163,2,2,\"Number of subjects with dose limiting toxicity (DLT)\"\\n11164,1,1,\"Number of Subjects with Dose-Limiting Toxicities (DLT)\"\\n11165,1,1,\"Number of subjects with dose-limiting toxicities (DLT)\"\\n11166,1,1,\"Number of Subjects With Dose-limiting Toxicities (DLTs)\"\\n11167,1,1,\"Number of Subjects with dose-limiting toxicities (DLTs)\"\\n11168,2,1,\"Number of subjects with dose-limiting toxicities (DLTs)\"\\n11169,1,1,\"Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in dose escalation stage\"\\n11170,1,1,\"Number of Subjects With Dose-Limiting Toxicities - Dose Escalation Part\"\\n11171,1,1,\"Number of Subjects With Dose-limiting Toxicity (DLT) During Cycle 1\"\\n11172,1,1,\"Number of subjects with dose-limiting toxicity (DLT) during the first cycle of ARRx (in combination with enzalutamide)\"\\n11173,1,1,\"Number of Subjects With Expression of Tumor Antigens\"\\n11174,1,1,\"Number of Subjects With Grade 3, 4, or 5 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03\"\\n11175,1,1,\"Number of subjects with grade ‚â• 3 TEAEs\"\\n11176,1,1,\"Number of subjects with grade ‚â•3 TEAEs (Part 1)\"\\n11177,1,1,\"Number of subjects with grade ‚â•3 TEAEs (Part 2)\"\\n11178,1,1,\"Number of Subjects With Greater Than Grade 3 or 4 Toxicity\"\\n11179,1,1,\"Number of Subjects with immune related adverse event (irAE)\"\\n11180,1,1,\"Number of Subjects With Immune-related Partial Response (irPR), Immune-related Complete Response (irCR), Immune-related Stable Disease (irSD), Immune-related Progressive Disease (irPD), and Immune-related Not Evaluable (irNE) as Assessed by irRECIST.\"\\n11181,5,1,\"Number of subjects with laboratory tests findings of potential clinical importance\"\\n11182,1,1,\"Number of Subjects With Major Pathological Response (MPR)\"\\n11183,1,1,\"Number of Subjects With NY-ESO-1-Specific Humoral Immunity as Determined by an Increase in Antibody Titer From Baseline.\"\\n11184,1,1,\"Number of Subjects With Objective Response\"\\n11185,2,2,\"Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11186,1,1,\"Number of Subjects With Overall Confirmed Objective Response (OR)\"\\n11187,1,1,\"Number of Subjects With Overall Survival\"\\n11188,1,1,\"Number of subjects with PDR001 dose interruption and/or reduction\"\\n11189,1,1,\"Number of Subjects With Physical Examination During the Treatment Period\"\\n11190,1,1,\"Number of Subjects with serious adverse event (SAE)\"\\n11191,46,1,\"Number of Subjects With Serious Adverse Events (SAEs)\"\\n11192,1,1,\"Number of subjects with serious adverse events as a measure of safety and tolerability\"\\n11193,1,1,\"Number of Subjects With Signs of Long-Term Radiation Toxicity\"\\n11194,1,1,\"Number of subjects with specific Long Term Follow-Up adverse events (AEs), including serious adverse events (SAEs) associated with administration of autologous T cell receptors that have been genetically modified by lentiviral vectors.\"\\n11195,1,1,\"Number of subjects with specific Manganese-related adverse events\"\\n11196,1,1,\"Number of Subjects with Treatment Emergent Adverse Events (TEAE\\'s).\"\\n11197,1,1,\"Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs\"\\n11198,1,1,\"Number of Subjects With Treatment Emergent Adverse Events Related to CC-486 as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03.\"\\n11199,1,1,\"Number of Subjects With Treatment Emergent Adverse Events Related to Pembrolizumab as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03.\"\\n11200,1,1,\"Number of subjects with treatment limiting toxicities (TLT)\"\\n11201,1,1,\"Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death\"\\n11202,5,2,\"Number of Subjects With Treatment-emergent Adverse Events\"\\n11203,1,1,\"Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Treatment-Emergent Serious Adverse Events (TESAE) With a CTCAE Grade of 3 or 4\"\\n11204,2,1,\"Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)\"\\n11205,8,4,\"Number of Subjects With Treatment-emergent Adverse Events (TEAEs)\"\\n11206,1,1,\"Number of Subjects with treatment-emergent adverse events (TEAEs)\"\\n11207,1,1,\"Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs)\"\\n11208,1,1,\"Number of subjects with treatment-emergent adverse events (TEAEs) and significant abnormalities in safety assessments related to anetumab ravtansine (BAY94-9343) in each of the 4 treatment groups\"\\n11209,1,1,\"Number of subjects with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs), and deaths in cohort for subjects with PAM pathway alterations\"\\n11210,1,1,\"Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version)\"\\n11211,1,1,\"Number of Subjects With Treatment-Related Adverse Events\"\\n11212,1,1,\"Number of subjects with treatment-related Adverse Events (AE)\"\\n11213,8,5,\"Number of Subjects with treatment-related adverse events (AEs)\"\\n11214,1,1,\"Number of subjects with treatment-related adverse events (AEs)\"\\n11215,1,1,\"Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0\"\\n11216,1,1,\"Number of Subjects With Tumor Uptake of 111^In-CS-1008 in Target Lesions Based on Gamma Camera Imaging Following the Day 1 and Day 36 Infusions\"\\n11217,1,1,\"Number of subjects with vital sign abnormalities (Phase 1b)\"\\n11218,1,1,\"Number of Subjects Without Any Adverse Events Grade 3 or Higher\"\\n11219,1,1,\"number of successful implantation of the device in patients\"\\n11220,1,1,\"Number of successful US-guided breast biopsy\"\\n11221,1,1,\"Number of T-ALL/LBL Participants With First-Cycle DLT\"\\n11222,1,1,\"Number of targeted molecular alterations\"\\n11223,1,1,\"Number Of TEAEs By The Dose Of iNKT Cell Therapy\"\\n11224,1,1,\"Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I\"\\n11225,1,1,\"Number of thrombotic events\"\\n11226,1,1,\"Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)\"\\n11227,1,1,\"Number of Total Treatment-Emergent Adverse Events (AEs)\"\\n11228,1,1,\"Number of toxicity incidents as assessed by CTC Version 2.0\"\\n11229,1,1,\"Number of toxicity incidents as assessed by CTC version 2.0\"\\n11230,1,1,\"Number of toxicity incidents defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment\"\\n11231,1,1,\"Number of treatment emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03\"\\n11232,1,1,\"Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) as a measure of safety and tolerability.\"\\n11233,1,1,\"Number of Treatment Related Adverse Events Related to T-Cell Receptor (TCR) Gene-Engineered Cells\"\\n11234,6,1,\"Number of treatment related AEs\"\\n11235,1,1,\"Number of Treatment- Emergent Adverse Events (Part 1)\"\\n11236,1,1,\"Number of Treatment- Emergent, Immune-Related, Adverse Events (Part 1)\"\\n11237,15,5,\"Number of treatment-emergent adverse events\"\\n11238,1,1,\"Number of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as a measure of safety\"\\n11239,1,1,\"Number of Treatment-Emergent Adverse Events (TEAE)\"\\n11240,1,1,\"Number of treatment-emergent adverse events (TEAE)\"\\n11241,10,1,\"Number of treatment-emergent adverse events (TEAEs)\"\\n11242,1,1,\"Number of Treatment-emergent Adverse Events (TEAEs) as a measure of safety and tolerability\"\\n11243,1,1,\"Number of Treatment-Emergent Adverse Events by Grade\"\\n11244,1,1,\"Number of Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment\"\\n11245,1,1,\"Number of Treatment-Emergent Adverse Events Resulting in Interruption, Reduction, or Delay of study treatment\"\\n11246,1,1,\"Number of Treatment-Emergent Adverse Events with an Outcome of Death by CTCAE v5.0\"\\n11247,1,1,\"Number of treatment-emergent adverse events with INCMGA00012 in combination with chemotherapy\"\\n11248,1,1,\"Number of Treatment-emergent Adverse Events, as Assessed by NCI CTCAE v4.03\"\\n11249,1,1,\"Number of Treatment-related adverse events\"\\n11250,1,1,\"Number of Tumor Responders in Progressive Breast Cancer or Recurrent Breast Cancer to Exemestane Treatment\"\\n11251,1,1,\"Number of tumors\"\\n11252,2,1,\"Number of Unplanned Hospitalizations\"\\n11253,1,1,\"Number of unscheduled medical consultations or re-hospitalisations\"\\n11254,1,1,\"Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer\"\\n11255,1,1,\"Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to a Prior Diagnosis of Heart Failure\"\\n11256,1,1,\"Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Chronic Kidney Disease\"\\n11257,1,1,\"Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Coronary Artery Disease\"\\n11258,1,1,\"Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Diabetes\"\\n11259,1,1,\"Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Patient\\'s Age (Categorical)\"\\n11260,1,1,\"Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Sex\"\\n11261,1,1,\"Number or Participants with Dose Limiting Toxicities (DLTs)\"\\n11262,1,1,\"Number Participants With Major Hemorrhage\"\\n11263,2,2,\"Number serious adverse events reported for all participants\"\\n11264,5,4,\"Number, frequency and type of adverse events\"\\n11265,1,1,\"Number, frequency, and severity of adverse events (AEs)\"\\n11266,1,1,\"Number/prevalence of alterations by type (SNVs, CNVs, fusions)\"\\n11267,1,1,\"Number/prevalence of alterations by type using Foundation Medicine testing. Descriptive results will also be presented by tumor type.\"\\n11268,1,1,\"Number/prevalence of level 1, 2, 3 and 4 alterations as per OncoKB using comprehensive panel testing versus \"\"real-word\"\" practice in the three cohorts included.\"\\n11269,1,1,\"Number/prevalence of variants with clinical significance\"\\n11270,1,1,\"Numbers and percentage of patients with adverse events (AEs)\"\\n11271,1,1,\"Numbers of DLT\"\\n11272,1,1,\"Numbers of participants with treatment-related adverse events as assessed by CTCAE v5.0\"\\n11273,1,1,\"Numbers of patients experiencing toxicities/adverse events both during and at follow-up after radiation therapy with any of 11 therapeutic modalities.\"\\n11274,1,1,\"Numbers of Patients With Dose Limiting Toxicities\"\\n11275,1,1,\"Numeric Rating Scale (NRS) for PVNS Symptoms Sum of Scores Through Cycle 2 (Efficacy Evaluable Population) - Dose Extension\"\\n11276,1,1,\"Numver of Patients With Telomerase-positive Archival Tumors Who Demonstrate at Least 50% Reduction\"\\n11277,4,1,\"Nutrition\"\\n11278,47,2,\"Nutritional status\"\\n11279,1,1,\"Nutritional status assessment scales - MNA-SF Test\"\\n11280,1,1,\"NV1020 Pharmacokinetics - Presence of NV1020 in Body Fluids/Skin\"\\n11281,1,1,\"O/S\"\\n11282,2,2,\"OBD\"\\n11283,5,3,\"Object response rate (ORR)\"\\n11284,1,1,\"Objective (Radiographic) Response\"\\n11285,1,1,\"Objective Best Tumor Response\"\\n11286,1,1,\"Objective disease response assessment\"\\n11287,1,1,\"Objective Intracranial Response (OIRR)\"\\n11288,1,1,\"Objective intracranial response rate (OIRR) as measured by the modified immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria\"\\n11289,1,1,\"Objective Overall Response in part II\"\\n11290,4,1,\"Objective Overall Response Rate\"\\n11291,2,1,\"Objective overall response rate\"\\n11292,2,2,\"Objective Overall Response Rate (ORR)\"\\n11293,1,1,\"Objective overall response rate (ORR) as per local investigator\\'s assessment\"\\n11294,1,1,\"Objective Overall Response Rate (Stratum 1)\"\\n11295,1,1,\"Objective Overall Response Rate (Stratum 2)\"\\n11296,1,1,\"Objective Partial/Complete Tumor Response Based on the Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST) Criteria\"\\n11297,1,1,\"objective pill count\"\\n11298,1,1,\"Objective Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria\"\\n11299,1,1,\"Objective PSA Response Rate (Number of Patients With a PSA Response)\"\\n11300,1,1,\"Objective PSA responses according to Bubley criteria\"\\n11301,2,2,\"Objective Radiographic Response Rate (ORR)\"\\n11302,1,1,\"Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab\"\\n11303,1,1,\"Objective Radiologic Response Rate (Complete or Partial Response) Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n11304,3,1,\"objective remission rate\"\\n11305,1,1,\"Objective remission rates(ORR)\"\\n11306,2,1,\"Objective reponse rate\"\\n11307,4,2,\"Objective reponse rate (ORR) by RECIST 1.1\"\\n11308,1,1,\"Objective reponse rate(ORR)\"\\n11309,1,1,\"Objective Responce Rate\"\\n11310,25,11,\"Objective Response\"\\n11311,32,6,\"Objective response\"\\n11312,5,1,\"objective response\"\\n11313,1,1,\"Objective Response (Complete and Partial Response)\"\\n11314,1,1,\"Objective Response (Complete and Partial) Evaluated Using RECIST Criteria\"\\n11315,1,1,\"Objective Response (Complete or Partial Response)\"\\n11316,1,1,\"Objective response (complete or partial response)\"\\n11317,1,1,\"Objective Response (Complete Response (CR) + Partial Response (PR)\"\\n11318,1,1,\"Objective Response (Complete Response (CR) + Partial Response (PR))\"\\n11319,1,1,\"Objective Response (Complete Response (CR) + Partial Response (PR)) of Melanoma Tumors\"\\n11320,1,1,\"Objective Response (Complete Response (CR) or Partial Response (PR) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria) or Disease Stabilization for Greater Than 6 Months\"\\n11321,1,1,\"Objective Response (Complete Response (CR) or Partial Response (PR))\"\\n11322,1,1,\"Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas\"\\n11323,1,1,\"Objective response (complete response + partial response) of the non-irradiated disease sites, according to Out-Field immune related response criteria (Phase II)\"\\n11324,1,1,\"Objective response (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or MIBG scoring criteria\"\\n11325,1,1,\"Objective response (complete response or partial response) assessed by Response Evaluation Criteria in Solid (RECIST) 1.1\"\\n11326,1,1,\"Objective Response (CR and PR)\"\\n11327,1,1,\"Objective Response (CR or PR) as Determined by the RECIST Criteria\"\\n11328,1,1,\"Objective Response (Non-Osteosarcoma Strata)\"\\n11329,1,1,\"Objective Response (OR = CR or PR) as Determined by the RECIST Criteria\"\\n11330,15,11,\"Objective Response (OR)\"\\n11331,5,2,\"Objective response (OR)\"\\n11332,1,1,\"Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel\"\\n11333,1,1,\"Objective Response (OR) as Determined by RECIST 1.0\"\\n11334,1,1,\"Objective response (OR) defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) in combination therapy dose confirmation (Part C)\"\\n11335,1,1,\"Objective response (OR) defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) in combination therapy dose expansion (Part D)\"\\n11336,1,1,\"Objective Response (OR) Rate in Participants With Advanced Triple Receptor-Negative Breast Cancer (mTNBC) Harboring Activating Genomic Alterations in Notch Receptors (NA+)\"\\n11337,1,1,\"Objective Response (OR), Defined as a Complete Response (CR) or Partial Response (PR) on Two Consecutive Occasions >/= 4 Weeks Apart, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n11338,1,1,\"Objective Response (ORR)\"\\n11339,1,1,\"Objective Response (Osteosarcoma Stratum)\"\\n11340,1,1,\"Objective Response (Partial Response [PR] or Complete Response [CR]) (Phase II)\"\\n11341,1,1,\"Objective response (partial response or complete response)\"\\n11342,1,1,\"Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria\"\\n11343,1,1,\"Objective response (Phase Ib)\"\\n11344,1,1,\"Objective response (PR or CR), recorded according to standard solid tumor response criteria\"\\n11345,1,1,\"Objective response (qualitative improvement from baseline) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors\"\\n11346,1,1,\"Objective Response - Number of Participants With Objective Response\"\\n11347,1,1,\"Objective Response [Complete Response (CR) + Partial Response (PR)] Rate at 16 Week Open-Label Period (All Treated Population)\"\\n11348,1,1,\"Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as per Independent Review Committee for Combined Therapy in Participants With MET Amplification Determined Centrally by Fluorescence in situ Hybridization(FISH)\"\\n11349,1,1,\"Objective response as assessed by independent review committee\"\\n11350,1,1,\"Objective Response as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria (Arm 1 and Arm 2)\"\\n11351,1,1,\"Objective Response Assessed by the Independent Review Facility Using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11352,1,1,\"Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11353,1,1,\"Objective Response by RECIST Criteria v 1.1\"\\n11354,1,1,\"Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1)\"\\n11355,1,1,\"Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST1.1)\"\\n11356,1,1,\"Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1\"\\n11357,1,1,\"Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11358,1,1,\"Objective Response in Patients With Metastatic Melanoma\"\\n11359,1,1,\"Objective response of fhB7H3.CAR-T cells\"\\n11360,1,1,\"Objective response of fully human B7H3 CAR-T cells\"\\n11361,1,1,\"Objective response per central review of antitumor activity (using Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (Phase 2)\"\\n11362,1,1,\"Objective Response Per RECIST 1.1 Among Patients With Advanced ULMS Treated With Nivolumab and Ipilimumab (Cohort B)\"\\n11363,1,1,\"Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab (Cohort A)\"\\n11364,1,1,\"Objective response rare (ORR)\"\\n11365,280,93,\"Objective Response Rate\"\\n11366,5,1,\"Objective Response rate\"\\n11367,320,92,\"Objective response rate\"\\n11368,80,9,\"objective response rate\"\\n11369,1,1,\"Objective Response Rate ( ORR )\"\\n11370,1,1,\"Objective response rate ([ORR]: Complete Response (CR) + Partial Response (PR)) based on RECIST Version 1.1\"\\n11371,1,1,\"Objective response rate (according to RECIST criteria)\"\\n11372,1,1,\"Objective Response Rate (as Defined by RECIST v1.1) (Part B)\"\\n11373,2,1,\"Objective Response Rate (Complete and Partial Response)\"\\n11374,1,1,\"Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11375,1,1,\"Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11376,1,1,\"Objective response rate (complete response + partial response) in pediatric patients treated with selpercatinib (LOXO-292)\"\\n11377,1,1,\"Objective response rate (complete response + partial response) in pediatric patients treated with tipifarnib\"\\n11378,1,1,\"Objective Response Rate (Complete Response [CR] + Partial Response [PR])\"\\n11379,1,1,\"Objective response rate (complete response [CR] and partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)\"\\n11380,2,1,\"Objective Response Rate (Complete Response and Partial Response)\"\\n11381,1,1,\"Objective Response Rate (Complete Response and Partial Response) as Measured by RECIST Criteria (Phase II)\"\\n11382,3,3,\"Objective response rate (complete response/partial response)\"\\n11383,1,1,\"Objective response rate (confirmed and unconfirmed, complete and partial response) based on the Response Evaluation Criteria in Solid Tumors (RECIST) in patients treated with bortezomib\"\\n11384,1,1,\"Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses) as Assessed by RECIST Version 1.1 of the Doublet Regimen GSK2141795 + Dabrafenib at the Phase I Determined MTD. (Phase II)\"\\n11385,1,1,\"Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses) as Assessed by RECIST Version 1.1 of the Triplet Regimen GSK2141795 + Dabrafenib + Trametinib at the Phase I Determined MTD. (Phase II)\"\\n11386,2,2,\"Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial)\"\\n11387,1,1,\"Objective Response Rate (CR + PR by RECIST) Paclitaxel, Pemetrexed, and Bevacizumab in Patients With Advanced Non-Small Lung Cancer Who Have Received no Prior Treatment for Metastatic Disease.\"\\n11388,3,2,\"Objective Response Rate (CR + PR)\"\\n11389,2,1,\"Objective response rate (CR + PR)\"\\n11390,1,1,\"Objective response rate (CR + PR) evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)\"\\n11391,1,1,\"Objective response rate (CR and PR according to RECIST) and rate of non-progressive disease at 24 weeks\"\\n11392,1,1,\"Objective Response Rate (CR and PR)\"\\n11393,1,1,\"Objective Response Rate (CR or PR) According to RECIST Criteria\"\\n11394,5,3,\"Objective Response Rate (CR+PR)\"\\n11395,1,1,\"Objective response rate (defined as complete response or partial response) assessed using Response Evaluation Criteria in Solid Tumors 1.1\"\\n11396,1,1,\"Objective Response Rate (dose expansion phase only)\"\\n11397,1,1,\"Objective response rate (Dose expansion)\"\\n11398,1,1,\"Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST)\"\\n11399,1,1,\"Objective Response Rate (OR)\"\\n11400,1,1,\"Objective response rate (ORR )\"\\n11401,1,1,\"Objective response rate (ORR = complete response [CR] + partial response [PR]) in pediatric patients treated with BVD-523FB (ulixertinib)\"\\n11402,1,1,\"Objective response rate (ORR = CR + PR) per blinded independent review committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)\"\\n11403,466,214,\"Objective Response Rate (ORR)\"\\n11404,1,1,\"Objective Response rate (ORR)\"\\n11405,1,1,\"Objective response Rate (ORR)\"\\n11406,349,113,\"Objective response rate (ORR)\"\\n11407,44,9,\"objective response rate (ORR)\"\\n11408,1,1,\"Objective response rate (ORR) (ARID1A cohort)\"\\n11409,1,1,\"Objective response rate (ORR) (Cohort 2)\"\\n11410,1,1,\"Objective response rate (ORR) (Cohort A and B)\"\\n11411,1,1,\"Objective response rate (ORR) (Cohort II)\"\\n11412,1,1,\"Objective Response Rate (ORR) (Dose Expansion Phase in Participants With NSCLC)\"\\n11413,2,2,\"Objective Response Rate (ORR) (Dose Expansion)\"\\n11414,1,1,\"Objective response rate (ORR) (Expansion Phase)\"\\n11415,1,1,\"Objective response rate (ORR) (in stage ‚Ö°)\"\\n11416,1,1,\"Objective Response Rate (ORR) (Investigator)\"\\n11417,1,1,\"Objective response rate (ORR) (Part 1b)\"\\n11418,1,1,\"Objective Response Rate (ORR) (Part 1C)\"\\n11419,1,1,\"Objective Response Rate (ORR) (part 2)\"\\n11420,4,4,\"Objective response rate (ORR) (Part 2)\"\\n11421,1,1,\"Objective Response Rate (ORR) (Part 3)\"\\n11422,1,1,\"Objective Response Rate (ORR) (Part II and III only)\"\\n11423,1,1,\"Objective response rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)\"\\n11424,4,2,\"Objective Response Rate (ORR) (Phase 2)\"\\n11425,2,2,\"Objective response rate (ORR) (Phase 2)\"\\n11426,1,1,\"Objective response rate (ORR) (Phase Ib)\"\\n11427,6,4,\"Objective Response Rate (ORR) (Phase II)\"\\n11428,4,3,\"Objective response rate (ORR) (Phase II)\"\\n11429,1,1,\"objective response rate (ORR) (Phase II)\"\\n11430,1,1,\"Objective response rate (ORR) (unconfirmed)\"\\n11431,1,1,\"Objective Response Rate (ORR) ,Based on RECIST 1.1\"\\n11432,1,1,\"Objective response rate (ORR) - Arm: BNT111 + cemiplimab\"\\n11433,1,1,\"Objective Response Rate (ORR) - Cohorts 1, 2\"\\n11434,1,1,\"Objective Response Rate (ORR) - Part 3 and Part 4\"\\n11435,1,1,\"Objective Response Rate (ORR) - Percentage of Participants With Objective Response\"\\n11436,1,1,\"Objective Response Rate (ORR) - Phase Ib\"\\n11437,1,1,\"Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor\"\\n11438,1,1,\"Objective response rate (ORR) 1 month after the last TACE -mRECIST evaluation\"\\n11439,1,1,\"Objective response rate (ORR) [Efficacy]\"\\n11440,1,1,\"Objective response rate (ORR) [Part 3]\"\\n11441,1,1,\"Objective response rate (ORR) Abemaciclib and MK-6482/Arm 2\"\\n11442,1,1,\"Objective response rate (ORR) Abemaciclib/Arm 1\"\\n11443,1,1,\"Objective Response Rate (ORR) according to iwCLL criteria\"\\n11444,1,1,\"Objective Response Rate (ORR) According to RECIST 1.1\"\\n11445,1,1,\"Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator\"\\n11446,1,1,\"objective response rate (ORR) according to RECIST 1.1 criteria\"\\n11447,1,1,\"Objective Response Rate (ORR) according to RECIST version 1.1\"\\n11448,1,1,\"Objective Response Rate (ORR) According to RECIST Version 1.1 as Determined by Investigator Assessment\"\\n11449,1,1,\"Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)\"\\n11450,1,1,\"Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n11451,1,1,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator\\'s Assessment\"\\n11452,1,1,\"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria\"\\n11453,1,1,\"Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\"\\n11454,2,2,\"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\"\\n11455,1,1,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators.\"\\n11456,1,1,\"Objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST)1.1 by imaging central review (ICR)\"\\n11457,1,1,\"Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)\"\\n11458,3,3,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11459,1,1,\"Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)\"\\n11460,1,1,\"Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) assessed by Blinded Independent Central Review (BICR)\"\\n11461,1,1,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Independent Review Committee (IRC)\"\\n11462,1,1,\"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment\"\\n11463,1,1,\"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST\"\\n11464,1,1,\"Objective response rate (ORR) according to the response evaluation‚Ä¢ Solid tumors with PI3K/mTOR activation ‚Ä¢ Human Papilloma Virus (HPV) positive Head and neck squamous cell carcinoma (HNSCC) containing activating PIK3CA mutations\"\\n11465,1,1,\"Objective Response Rate (ORR) After Initiation of Second Line Sunitinib Therapy\"\\n11466,1,1,\"Objective Response Rate (ORR) and Duration of Response (DoR)\"\\n11467,1,1,\"Objective Response Rate (ORR) and SD that persists for at least 4 months in selected solid tumor cohorts\"\\n11468,1,1,\"Objective Response Rate (ORR) and tumor control rate [Time Frame: From first dose up to 24 months]\"\\n11469,1,1,\"Objective response rate (ORR) as (Phase II)\"\\n11470,1,1,\"Objective response rate (ORR) as Assessed by an Independent Central Review (ICR)\"\\n11471,1,1,\"Objective response rate (ORR) as assessed by BIRC per RECIST 1.1\"\\n11472,2,2,\"Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)\"\\n11473,1,1,\"Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11474,1,1,\"Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC)\"\\n11475,1,1,\"Objective Response Rate (ORR) as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n11476,1,1,\"Objective response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n11477,1,1,\"Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per Independent Central Radiology (ICR) assessment\"\\n11478,1,1,\"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11479,1,1,\"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 in Biomarker Subgroups\"\\n11480,1,1,\"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n11481,1,1,\"Objective response rate (ORR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors RECIST 1.1 (brand name)\"\\n11482,1,1,\"Objective Response rate (ORR) as determined by Response Criteria In Solid Tumors (RECIST)1.1 criteria\"\\n11483,1,1,\"Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n11484,1,1,\"Objective Response Rate (ORR) as determined by the percentage of subjects achieving a partial response (PR) or complete response (CR)\"\\n11485,1,1,\"Objective response rate (ORR) as evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.\"\\n11486,1,1,\"Objective Response Rate (ORR) as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n11487,1,1,\"Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1\"\\n11488,1,1,\"Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\"\\n11489,1,1,\"Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\"\\n11490,1,1,\"Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n11491,1,1,\"Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n11492,1,1,\"Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors version 1.1 on both arms\"\\n11493,1,1,\"Objective Response Rate (ORR) as of Week 24 (ORR24wk)\"\\n11494,1,1,\"Objective response rate (ORR) as per RECIST v1.1\"\\n11495,1,1,\"Objective Response Rate (ORR) as per RECIST V1.1 and according to central review\"\\n11496,2,2,\"Objective Response Rate (ORR) assess by Independent Review Committee (IRC)\"\\n11497,1,1,\"Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) in Participants With Non-squamous NSCLC Who Had Received 2 or More Prior Lines of Therapy in the Dose-expansion Phase\"\\n11498,1,1,\"Objective Response Rate (ORR) assessed by Independent Review Committee (IRC) per RECIST v1.1 for Cohort 1\"\\n11499,1,1,\"Objective response rate (ORR) assessed by Investigator per RECIST v.1.1\"\\n11500,1,1,\"Objective Response Rate (ORR) Assessed by Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n11501,1,1,\"Objective Response Rate (ORR) assessed by site investigator as per RECIST 1.1\"\\n11502,1,1,\"Objective Response Rate (ORR) Assessed By The Investigator\\'s Review Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1\"\\n11503,1,1,\"Objective Response Rate (ORR) assessed per RECIST v1.1\"\\n11504,1,1,\"Objective Response Rate (ORR) at 8 weeks by investigators\"\\n11505,1,1,\"Objective response rate (ORR) at recommended dose\"\\n11506,1,1,\"Objective Response Rate (ORR) At Week 16 per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] only), by Investigator Assessment\"\\n11507,1,1,\"Objective response rate (ORR) at Week 24\"\\n11508,1,1,\"Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2\"\\n11509,1,1,\"Objective Response Rate (ORR) Based on Independent Reviewer Assessment\"\\n11510,1,1,\"Objective Response Rate (ORR) Based on Investigator-assessed Response Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose-expansion Phase\"\\n11511,1,1,\"Objective Response Rate (ORR) Based on RECIST v1.1\"\\n11512,1,1,\"Objective Response Rate (ORR) Based on RECIST Version 1.1 - Part 2\"\\n11513,1,1,\"Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during the dose expansion phase\"\\n11514,1,1,\"Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n11515,1,1,\"Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors 1.1\"\\n11516,1,1,\"Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11517,1,1,\"Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)\"\\n11518,1,1,\"Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)\"\\n11519,1,1,\"Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST Version 1.1) in Part 2\"\\n11520,2,1,\"Objective Response Rate (ORR) by Independent Central Review (ICR)\"\\n11521,1,1,\"Objective response rate (ORR) by independent radiology review committee (IRC)\"\\n11522,2,1,\"Objective Response Rate (ORR) by Investigator\"\\n11523,1,1,\"Objective response rate (ORR) by investigator (Part 1B and Part 2)\"\\n11524,1,1,\"Objective Response Rate (ORR) by Investigator Assessment\"\\n11525,1,1,\"Objective response rate (ORR) by IRC according to RECIST v 1.1\"\\n11526,1,1,\"Objective Response Rate (ORR) by local review in Expansion Part\"\\n11527,14,2,\"Objective response rate (ORR) by RECIST 1.1\"\\n11528,1,1,\"Objective Response Rate (ORR) by RECIST 1.1 of NKTR-255 in combination with Cetuximab in R/R metastatic HNSCC or CRC for Phase 2 Dose Expansion\"\\n11529,1,1,\"Objective Response Rate (ORR) by RECIST v1.1 as Assessed by the Investigator\"\\n11530,1,1,\"Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)\"\\n11531,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central imaging vendor (Cohorts 1 and 2 combined, Cohort 1, Cohort 2 and Cohort 4)\"\\n11532,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator\"\\n11533,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per Blinded Independent Central Review (BICR) in patients whose tumors have low programmed cell death ligand (PD-L1) expression\"\\n11534,1,1,\"Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per investigator assessment\"\\n11535,1,1,\"Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment\"\\n11536,7,7,\"Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n11537,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator Review in Cohort A\"\\n11538,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors and Other Lymphoma Version 1.1 (RECIST 1.1) per Site Assessment (Each Disease Indication Evaluated Separately)\"\\n11539,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11540,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants\"\\n11541,1,1,\"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Strong Programmed Cell Death Ligand 1 (PD-L1) Positive Participants\"\\n11542,1,1,\"Objective Response Rate (ORR) by Week 19\"\\n11543,1,1,\"Objective response rate (ORR) defined as complete response (CR) rate plus partial response (PR) rate using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11544,1,1,\"Objective response rate (ORR) defined as completion response or partial response assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n11545,1,1,\"Objective response rate (ORR) defined as the number of subjects with a best objective response (BOR) of confirmed complete response (CR) or partial response (PR) divided by the number of subjects\"\\n11546,1,1,\"Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n11547,1,1,\"Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer 2009) for REGN4018 monotherapy\"\\n11548,1,1,\"Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)\"\\n11549,1,1,\"Objective Response Rate (ORR) During the Combination Therapy Phase\"\\n11550,1,1,\"Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines\"\\n11551,1,1,\"Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n11552,1,1,\"objective response rate (ORR) evaluated by MRI\"\\n11553,1,1,\"Objective Response Rate (ORR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11554,1,1,\"Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases)\"\\n11555,1,1,\"Objective response rate (ORR) for all other cohorts\"\\n11556,1,1,\"Objective Response Rate (ORR) For All Participants in Cohorts 1 and 3\"\\n11557,1,1,\"Objective Response Rate (ORR) for Cohort 2\"\\n11558,1,1,\"Objective Response Rate (ORR) for Dose Expansion Population\"\\n11559,1,1,\"Objective response rate (ORR) for endometrial cohort\"\\n11560,1,1,\"Objective Response Rate (ORR) for Extension Population\"\\n11561,1,1,\"Objective response rate (ORR) for other solid tumors\"\\n11562,1,1,\"Objective Response Rate (ORR) for Part 2B\"\\n11563,1,1,\"Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation\"\\n11564,1,1,\"Objective Response Rate (ORR) for PI3K GNE-positive Participants Registered to S1400B Treated With GDC-0032.\"\\n11565,1,1,\"Objective Response Rate (ORR) for the Phase II Portion of the Study. CR+PR Per RECIST v1.0 Criteria Using a Single Arm , Two Stage Minimax Design.\"\\n11566,1,1,\"Objective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11567,1,1,\"Objective Response Rate (ORR) in chemotherapy-naive participants with advanced/metastatic MCC, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as Determined by independent Central Radiographic Review (ICR)\"\\n11568,1,1,\"Objective Response Rate (ORR) in Cohort 2\"\\n11569,1,1,\"Objective response rate (ORR) in cohort A\"\\n11570,1,1,\"Objective response rate (ORR) in Cohort A (melanoma)\"\\n11571,1,1,\"Objective response rate (ORR) in Cohort B (CSCC)\"\\n11572,1,1,\"Objective response rate (ORR) in Cohorts A and B\"\\n11573,1,1,\"Objective response rate (ORR) in Dose Expansion (Part 2)\"\\n11574,2,1,\"Objective response rate (ORR) in dose expansion (Phase ‚Ö°a)\"\\n11575,1,1,\"Objective Response Rate (ORR) in each Tumor Type\"\\n11576,1,1,\"Objective Response Rate (ORR) in Part 2\"\\n11577,1,1,\"Objective Response Rate (ORR) in Part B (including all patients with germline PTEN mutations in Part A)\"\\n11578,1,1,\"Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells\"\\n11579,1,1,\"Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions\"\\n11580,1,1,\"Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)\"\\n11581,1,1,\"Objective Response Rate (ORR) in Participants With T790M Mutation\"\\n11582,1,1,\"Objective Response Rate (ORR) in Participants without BM at Baseline (Cohort 1)\"\\n11583,1,1,\"Objective response rate (ORR) in patients following treatment with triplet combination (phase 2)\"\\n11584,1,1,\"Objective Response Rate (ORR) in Patients with MSI (Microsatellite Unstable)-negative Solid Tumor Malignancies with a Mutator Phenotype\"\\n11585,1,1,\"Objective response rate (ORR) in patients within expansion arms.\"\\n11586,2,2,\"Objective Response Rate (ORR) in Phase 2 using RECIST v1.1\"\\n11587,1,1,\"Objective response rate (ORR) in Phase II\"\\n11588,1,1,\"Objective response rate (ORR) in Phase IIa\"\\n11589,1,1,\"Objective response rate (ORR) in preselected patients with BRCAness tumoral genotype\"\\n11590,1,1,\"Objective response rate (ORR) in solid tumorÔºàThe ORR of cohort B, C, and E will be evaluated by Independent Review CommitteeÔºâ.\"\\n11591,1,1,\"Objective Response Rate (ORR) in Stage 1 and 2\"\\n11592,1,1,\"Objective Response Rate (ORR) in stage ‚Ö°\"\\n11593,2,2,\"Objective response rate (ORR) in the Expansion cohorts (Part 2)\"\\n11594,1,1,\"Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set\"\\n11595,1,1,\"Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)\"\\n11596,1,1,\"Objective response rate (ORR) in the SOT or HCT cohort\"\\n11597,1,1,\"Objective Response Rate (ORR) in VHL Disease-Associated RCC Tumors\"\\n11598,1,1,\"Objective Response Rate (ORR) investigation [ Time Frame: 2.5 years]\"\\n11599,1,1,\"Objective Response Rate (ORR) measured as for RECIST 1.1 criteria\"\\n11600,1,1,\"Objective Response Rate (ORR) Of ABBV-CLS-579 And PD-1 Targeting Agent Base On Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, of ABBV-CLS-579 in locally or metastatic HNSCC, NSCLC, MSI-H tumors, and advanced ccRCC\"\\n11601,1,1,\"Objective Response Rate (ORR) Of Balstilimab Monotherapy Per Independent Review Committee (IRC) Assessment Based Upon Response Evaluation Criteria In Solid Tumours (RECIST) 1.1\"\\n11602,1,1,\"Objective response rate (ORR) of children with infantile fibrosarcoma (IFS) treated with neoadjuvant larotrectinib prior to local control\"\\n11603,1,1,\"Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)\"\\n11604,1,1,\"Objective Response Rate (ORR) of GSK2636771 in Combination with Pembrolizumab in Participants with Metastatic Melanoma and PTEN Loss\"\\n11605,1,1,\"Objective Response Rate (ORR) of Patients With Non-small Cell Lung Cancer Treated With Nivolumab and Metformin Combination Using RECIST 1.1\"\\n11606,1,1,\"Objective response rate (ORR) of patients with solid tumors treated with HX009 assessed by the Independent Review Committee (IRC)\"\\n11607,1,1,\"Objective Response Rate (ORR) of Pembrolizumab + Chemotherapy + Epacadostat Versus Pembrolizumab + Chemotherapy + Placebo\"\\n11608,1,1,\"Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus Placebo\"\\n11609,1,1,\"Objective Response Rate (ORR) of PV-10 Treated Lesions\"\\n11610,1,1,\"Objective response rate (ORR) of SCIB1 in patients receiving either nivolumab with ipilimumab or pembrolizumab relative to historical data for the nivolumab with ipilimumab combination or pembrolizumab alone in this patient population (Main Study)\"\\n11611,1,1,\"Objective Response Rate (ORR) of SOM230 Monotherapy in Meningioma\"\\n11612,1,1,\"Objective response rate (ORR) of the combination of ADG106 and PD-1 antibody in advanced solid tumors and relapsed/refractory non-hodgkin lymphoma\"\\n11613,1,1,\"Objective response rate (ORR) of the treatment using DC Vaccination for Glioblastoma with molecular markers for immunotherapy.\"\\n11614,1,1,\"Objective Response Rate (ORR) of unirradiated tumors\"\\n11615,1,1,\"Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1)\"\\n11616,1,1,\"Objective Response Rate (ORR) on RECIST v1.1, of ABBV-CLS-579 administered in combination with VEGFR TKI in advanced ccRCC\"\\n11617,2,1,\"Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)\"\\n11618,1,1,\"Objective Response Rate (ORR) per Blinded Independent Central Review (BICR)\"\\n11619,1,1,\"Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by RECIST 1.1 of NKTR-214 Plus Pembrolizumab for Dose Expansion Cohorts 2 and 3.\"\\n11620,1,1,\"Objective Response Rate (ORR) per disease-specific response criteria as assessed by the Investigator\"\\n11621,1,1,\"Objective response rate (ORR) per imaging assessment\"\\n11622,1,1,\"Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)\"\\n11623,1,1,\"Objective Response Rate (ORR) Per Investigator\"\\n11624,1,1,\"Objective Response Rate (ORR) Per Investigator\\'s Assessment by RECIST 1.1 of NKTR-214 at a Dose of 0.006 mg/kg With Pembrolizumab and Platinum-based Chemotherapy for Dose Expansion Cohorts 4+5.\"\\n11625,1,1,\"Objective Response Rate (ORR) Per Modified RECIST v1.1\"\\n11626,1,1,\"Objective Response Rate (ORR) per mRECIST (modified RECIST)\"\\n11627,1,1,\"Objective response rate (ORR) per RECIST 1.1\"\\n11628,1,1,\"Objective Response Rate (ORR) Per RECIST 1.1 Criteria\"\\n11629,1,1,\"Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D)\"\\n11630,1,1,\"Objective response rate (ORR) per RECIST 1.1 in Substudy 1 (in two subgroups Cohort 1.1 and 1.2) and Substudy 3)\"\\n11631,1,1,\"Objective response rate (ORR) per RECIST 1.1a by central assessment\"\\n11632,1,1,\"Objective response rate (ORR) per RECIST according to investigator assessment in the efficacy-evaluable population (Part L)\"\\n11633,1,1,\"Objective response rate (ORR) per RECIST v1.1\"\\n11634,1,1,\"Objective Response Rate (ORR) per RECISTv1.1\"\\n11635,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)\"\\n11636,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Response Assessment in Neuro-Oncology (RANO) as Assessed by Investigator\"\\n11637,1,1,\"Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Phase 2\"\\n11638,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0\"\\n11639,2,2,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n11640,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants\"\\n11641,4,4,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)\"\\n11642,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11643,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11644,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)\"\\n11645,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n11646,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab Dose D Only\"\\n11647,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n11648,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n11649,2,2,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR)\"\\n11650,2,2,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR).\"\\n11651,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigator\"\\n11652,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Cohort A and Cohort B Participants\"\\n11653,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Central Imaging Vendor (CIV) in All Cohort A Participants\"\\n11654,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants\"\\n11655,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ‚â•1%\"\\n11656,1,1,\"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ‚â•10%\"\\n11657,1,1,\"Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Glioblastoma (GBM) by Investigator Assessment in Initial Cohorts\"\\n11658,1,1,\"Objective response rate (ORR) RECIST v1.1.\"\\n11659,1,1,\"Objective response rate (ORR) using immune RECIST (iRECIST) criteria\"\\n11660,1,1,\"Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.\"\\n11661,1,1,\"Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)\"\\n11662,1,1,\"Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)\"\\n11663,1,1,\"Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n11664,1,1,\"Objective response rate (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11665,1,1,\"Objective response rate (ORR) with CMP-001 in combination with a programmed cell death protein 1 (PD-1)-blocking antibody (cemiplimab-rwlc) in study subjects with metastatic or advanced/unresectable CSCC, MCC, or TNBC\"\\n11666,1,1,\"objective response rate (ORR) ÔºàPhase IIÔºâ\"\\n11667,1,1,\"Objective response rate (ORR)(phase ‚Ö°)\"\\n11668,2,2,\"Objective Response Rate (ORR), as determined by IERC, in the analysis population\"\\n11669,1,1,\"Objective Response Rate (ORR), confirmed by CT or MRI, or confirmed by biopsy\"\\n11670,1,1,\"Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements\"\\n11671,1,1,\"Objective Response Rate (ORR), Defined as the Percentage of Patients Achieving a Confirmed Complete or Partial Response, as Defined by Immune-related Response Criteria (irRC)\"\\n11672,1,1,\"Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib\"\\n11673,1,1,\"Objective Response Rate (ORR), investigator assessment\"\\n11674,1,1,\"Objective Response Rate (ORR), Presented in Numbers of Participants\"\\n11675,3,2,\"Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment\"\\n11676,1,1,\"Objective Response Rate (ORR)- Cohort A, Cohort B, and Cohort C Part 2\"\\n11677,2,1,\"Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)\"\\n11678,2,2,\"Objective Response Rate (ORR): Percentage of Participants who Achieve Confirmed Complete Response (CR) or Partial Response (PR)\"\\n11679,1,1,\"Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR), Partial Response (PR), or Minimal Response (MR): Part C, only\"\\n11680,1,1,\"Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)\"\\n11681,1,1,\"Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib.\"\\n11682,1,1,\"Objective Response Rate (ORR-12W)\"\\n11683,1,1,\"Objective response rate (ORR; complete response + partial response [CR + PR]) (Phase 2)\"\\n11684,1,1,\"Objective response rate (ORR; complete response + partial response) in pediatric patients treated with ivosidenib\"\\n11685,1,1,\"Objective response rate (ORR; efficacy of NeoTIL-ACT in combination with LDI)\"\\n11686,1,1,\"Objective response rate (ORR= complete response [CR]+partial response [PR]) (Expansion Phase only)\"\\n11687,1,1,\"Objective Response Rate (ORR= complete response [CR]+partial response [PR]) per RECIST Version 1,1\"\\n11688,1,1,\"Objective response rate (ORRÔºâ\"\\n11689,1,1,\"Objective Response Rate (Part 2 Only)\"\\n11690,1,1,\"Objective Response Rate (Part I)\"\\n11691,1,1,\"Objective Response Rate (Partial Response (PR) + Complete Response (CR) of Belinostat in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Patients With Advanced Thymic Malignancies\"\\n11692,1,1,\"Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma.\"\\n11693,1,1,\"Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment\"\\n11694,1,1,\"Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment\"\\n11695,3,2,\"Objective Response Rate (Phase 2)\"\\n11696,1,1,\"Objective Response Rate (Phase 2a)\"\\n11697,4,1,\"Objective response rate (Phase II)\"\\n11698,1,1,\"Objective response rate (platinum-resistant cohort)\"\\n11699,1,1,\"Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria\"\\n11700,1,1,\"Objective Response Rate (PR or CR)\"\\n11701,1,1,\"Objective Response Rate (PR or CR) by Response Evaluation Criteria in Solid Tumors (RECIST).\"\\n11702,1,1,\"Objective response rate (Proportion of patients with reduction in tumor burden of a predefined amount)\"\\n11703,1,1,\"Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1)\"\\n11704,1,1,\"Objective Response Rate (RECIST Version 1.1)\"\\n11705,1,1,\"Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set\"\\n11706,1,1,\"Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set\"\\n11707,1,1,\"Objective Response Rate - First Tumor Assessment (Other Cohorts)\"\\n11708,1,1,\"Objective Response Rate - Percentage of Participants With Objective Response\"\\n11709,1,1,\"Objective Response Rate - Percentage of Participants With Objective Response in Dose Expansion\"\\n11710,1,1,\"Objective Response Rate [Expansion]\"\\n11711,1,1,\"Objective response rate a in patients with estimated glomerular filtration rate (EGFR) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 1)\"\\n11712,1,1,\"Objective response rate a in patients with human epidermal growth factor receptor 2 (HER2) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 2)\"\\n11713,1,1,\"Objective Response Rate according to RECIST 1.1 by investigator assessment in disease specific expansions treated at the MTD/OB/MFD\"\\n11714,1,1,\"Objective Response Rate According to RECIST 1.1 Per Investigator Assessment for Alpelisib vs. Placebo - PIK3CA Wild-type Cohort\"\\n11715,1,1,\"Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n11716,1,1,\"Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n11717,1,1,\"Objective Response Rate according to Response Evaluation Criteria in Solid Tumors version 1.1\"\\n11718,1,1,\"Objective Response Rate Among KIT-positive Patients\"\\n11719,1,1,\"Objective Response Rate and Duration\"\\n11720,1,1,\"Objective Response Rate and Progression Free Survival\"\\n11721,1,1,\"Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n11722,1,1,\"Objective response rate as assessed by Response Evaluation Criteria in Solid Tumors\"\\n11723,1,1,\"Objective Response Rate as Assessed by the Investigator according to RECIST v1.1ÔºàPhase IIÔºâ\"\\n11724,1,1,\"Objective response rate as assessed by the investigator using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (brand name)\"\\n11725,1,1,\"Objective response rate as determined by the Invertigator using RECIST V1.1\"\\n11726,1,1,\"Objective Response Rate as Evaluated by Response Evaluation Criteria In Solid Tumors ( RECIST)\"\\n11727,1,1,\"Objective Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n11728,1,1,\"Objective response rate as measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)\"\\n11729,1,1,\"Objective response rate assessed by Independent Review Committee per Response Evaluation Criteria in Solid Tumors Version 1.1\"\\n11730,1,1,\"Objective response rate assessed by RECIST V1.1\"\\n11731,1,1,\"Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST)\"\\n11732,1,1,\"Objective Response Rate at 12 Months\"\\n11733,1,1,\"Objective Response Rate at 6 Months\"\\n11734,1,1,\"Objective Response Rate at Week 24 (ORR24W)\"\\n11735,1,1,\"Objective Response Rate at Weeks 17 and 25\"\\n11736,1,1,\"Objective response rate based on independent radiology review\"\\n11737,1,1,\"Objective response rate based on RECIST 1.1 for Solid Tumors (Dose Expansion phase)\"\\n11738,1,1,\"Objective response rate based on RECIST Version 1.1 in subjects with selected tumor types in phase 1b\"\\n11739,1,1,\"Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as either a complete or partial response\"\\n11740,1,1,\"Objective response rate based on Response Evaluation Criteria in Solid tumors (RECIST) Version 1.1\"\\n11741,1,1,\"Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in participants with selected tumor types\"\\n11742,1,1,\"Objective response rate based on the Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n11743,1,1,\"Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors\"\\n11744,1,1,\"Objective response rate by Lugano criteria for Lymphoma (Dose Expansion Phase)\"\\n11745,1,1,\"Objective Response Rate by RECIST 1.1\"\\n11746,1,1,\"Objective Response Rate by RECIST Criteria Following\"\\n11747,1,1,\"Objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (Part B)\"\\n11748,1,1,\"Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria\"\\n11749,1,1,\"Objective response rate defined as per RECIST v1.1.\"\\n11750,1,1,\"Objective response rate defined as the number of patients with complete response or partial response\"\\n11751,1,1,\"Objective response rate defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIS)T 1.1\"\\n11752,1,1,\"Objective Response Rate Estimated as the Proportion of Responders\"\\n11753,1,1,\"Objective Response Rate for Neratinib in Patients With Non-small Cell Lung Cancer\"\\n11754,1,1,\"Objective Response Rate for Part 1\"\\n11755,1,1,\"Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3\"\\n11756,1,1,\"Objective Response Rate in MSI Positive Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n11757,1,1,\"Objective Response Rate in Non-Adenocarcinoma Participants: Phase 2\"\\n11758,1,1,\"Objective Response Rate in Participants with Metastatic Melanoma That Are PD-1 Na√Øve (Arm A) or That Have Progressed on PD-1 Directed Therapy (Arm B)\"\\n11759,1,1,\"Objective Response Rate in Patients With Cancers Other Than Melanoma\"\\n11760,1,1,\"Objective response rate in the brain\"\\n11761,1,1,\"Objective response rate in the CNS\"\\n11762,1,1,\"Objective response rate in the dose expansion (Part 2) arms\"\\n11763,1,1,\"Objective response rate measured by RECIST 1.1 criteria to anti-cancer therapy selected by QPOP (prospective analysis).\"\\n11764,1,1,\"Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n11765,1,1,\"Objective response rate measured by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1\"\\n11766,1,1,\"Objective Response Rate of CC-122 in Combination With Nivolumab\"\\n11767,1,1,\"Objective response rate of Metastatic Colorectal Cancer,inculdthe proportion of patients with complete response or partial response\"\\n11768,1,1,\"Objective Response Rate of Oral Testosterone Undecanoate (CT Scan)\"\\n11769,1,1,\"Objective Response Rate of Participants as Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\"\\n11770,1,1,\"Objective Response Rate of Participants Using A Combination of ABT-751 and Carboplatin\"\\n11771,1,1,\"Objective response rate of patients with measurable disease by Response Evaluation Criteria in Solid tumours\"\\n11772,1,1,\"Objective Response Rate of Patients With Metastatic Melanoma\"\\n11773,1,1,\"Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer\"\\n11774,1,1,\"Objective response rate of tumor biological activity.\"\\n11775,1,1,\"Objective response rate of tumor size.\"\\n11776,1,1,\"Objective Response Rate of Two Patients With Metastatic and Refractory Choriocarcinoma by RECIST 1.1 Including Measurement of Serum Œ≤- hCG\"\\n11777,1,1,\"Objective Response Rate Per BIRC Assessment\"\\n11778,1,1,\"Objective Response Rate per Immune Response Evaluation Criteria in Solid Tumors (iRECIST) (iORR) by Independent Central Review\"\\n11779,1,1,\"Objective Response Rate Per Investigator Assessment According to RECIST 1.1 for Alpelisib vs. Placebo - PIK3CA Mutant Cohort\"\\n11780,1,1,\"Objective Response Rate per modified Response Evaluation Criteria in Solid Tumors (iRECIST) (iORR)\"\\n11781,1,1,\"Objective response rate per RECIST v1.1 criteria of ciforadenant as a single agent and in combination with atezolizumab\"\\n11782,1,1,\"Objective Response Rate Per RECIST v1.1 in Phase 2\"\\n11783,1,1,\"Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.\"\\n11784,1,1,\"Objective response rate using RECIST v1.1 to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.\"\\n11785,1,1,\"Objective Response Rate Using Response Evaluation Criteria in Solid Tumors\"\\n11786,1,1,\"Objective Response Rate using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) (Part C)\"\\n11787,1,1,\"Objective Response Rate using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) (Phase2)\"\\n11788,1,1,\"Objective response rate using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11789,1,1,\"Objective Response Rate With MTD\"\\n11790,5,2,\"Objective Response Rate ÔºàORRÔºâ\"\\n11791,35,7,\"Objective Response Rate(ORR)\"\\n11792,22,9,\"Objective response rate(ORR)\"\\n11793,9,1,\"objective response rate(ORR)\"\\n11794,1,1,\"Objective response rate(ORR) of patients with solid tumors treated with HX009 per Investigator Assessment\"\\n11795,1,1,\"Objective Response Rate(ORR)(Phase 2a dose expansion)\"\\n11796,1,1,\"Objective response rate(ORR)evaluated by RECIST 1.1-Phase2\"\\n11797,1,1,\"Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11798,1,1,\"Objective Response Rate, Complete (CR) or Partial (PR) Response\"\\n11799,1,1,\"Objective response rate, defined as confirmed Complete Response (CR) or Partial Response (PR)\"\\n11800,1,1,\"Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1\"\\n11801,7,1,\"Objective response rate, ORR\"\\n11802,1,1,\"Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.\"\\n11803,1,1,\"Objective Response Rate-Percentage of Participants with Objective Response\"\\n11804,1,1,\"Objective Response Rate.\"\\n11805,1,1,\"Objective response rate: partial or complete response during at least 4 weeks from week 22 after the beginning of the first cycle of cytokines.\"\\n11806,1,1,\"Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11807,1,1,\"Objective Response Rate: Phase 2\"\\n11808,5,2,\"Objective Response Rates\"\\n11809,9,1,\"Objective response rates\"\\n11810,1,1,\"Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria\"\\n11811,6,1,\"Objective Response Rates (ORR)\"\\n11812,10,2,\"Objective response rates (ORR)\"\\n11813,3,3,\"Objective Response Rates (ORR) - Part 2 (Phase 2a)\"\\n11814,1,1,\"Objective Response Rates (Partial and Complete Responses)\"\\n11815,1,1,\"Objective response rates (RECIST1.1)\"\\n11816,1,1,\"Objective Response Rates. Assessed With Cranial MRI\"\\n11817,1,1,\"Objective response rateÔºàORR)\"\\n11818,10,2,\"Objective Response RateÔºàORRÔºâ\"\\n11819,9,1,\"objective response rateÔºàORRÔºâ\"\\n11820,1,1,\"Objective response ratio (Complete response (CR) and partial response (PR)) (part 2)\"\\n11821,1,1,\"Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer.\"\\n11822,1,1,\"Objective response using RECIST version 1.1\"\\n11823,1,1,\"Objective response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n11824,1,1,\"Objective Response Within 6 Months of Treatment Onset - Ewing Sarcoma\"\\n11825,1,1,\"Objective Response Within 6 Months of Treatment Onset - Osteosarcoma\"\\n11826,1,1,\"Objective Response, Evaluated Using RECIST\"\\n11827,19,9,\"Objective Tumor Response\"\\n11828,15,5,\"Objective tumor response\"\\n11829,1,1,\"Objective tumor response (complete and partial overall response) as defined by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11830,1,1,\"Objective Tumor Response (Complete and Partial)\"\\n11831,1,1,\"Objective Tumor Response (Complete or Partial Response)\"\\n11832,1,1,\"Objective Tumor Response (Complete or Partial)\"\\n11833,1,1,\"Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and Bevacizumab\"\\n11834,1,1,\"Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.\"\\n11835,1,1,\"Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria)\"\\n11836,1,1,\"Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria)\"\\n11837,1,1,\"Objective Tumor Response (Partial or Complete Response) According to RECIST\"\\n11838,2,2,\"Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review\"\\n11839,1,1,\"Objective Tumor Response According to RECIST\"\\n11840,1,1,\"Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)\"\\n11841,1,1,\"Objective tumor response assessed according to Response Evaluation Criteria in Solid Tumors version 1.1\"\\n11842,1,1,\"Objective Tumor Response Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n11843,1,1,\"Objective Tumor Response Based on the Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST) Criteria\"\\n11844,1,1,\"Objective tumor response by modified Response Evaluation Criteria in Solid Tumor (RECIST)\"\\n11845,11,7,\"Objective Tumor Response Rate\"\\n11846,11,1,\"Objective tumor response rate\"\\n11847,4,1,\"objective tumor response rate\"\\n11848,1,1,\"Objective Tumor Response Rate (Complete or Partial Response)\"\\n11849,1,1,\"Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria\"\\n11850,1,1,\"Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria)\"\\n11851,1,1,\"Objective tumor response rate (ORR) (complete response + partial response)\"\\n11852,1,1,\"Objective tumor response rate (RECIST complete response, or partial response ) confirmed by CT and MRI as the preferred methods for tumor assessments and Chest x-ray is acceptable for pulmonary lesions\"\\n11853,1,1,\"Objective Tumor Response Rate - AXL expression\"\\n11854,1,1,\"Objective tumor response rate 2 (ORR2) after first progression, assessed by RECIST v1.1\"\\n11855,1,1,\"Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee\"\\n11856,2,2,\"Objective Tumor Response Rate Assessed by RECIST\"\\n11857,1,1,\"Objective Tumor Response Rate at 3, 6, and 12 Months\"\\n11858,1,1,\"Objective tumor response rate1 (ORR1) in study patients, assessed by RECIST v1.1\"\\n11859,1,1,\"Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1\"\\n11860,1,1,\"Objective tumour response (CR and PR) at study closure based on the RECIST\"\\n11861,1,1,\"Objective tumour response (CR and PR) at study closure based on the Response Evaluation Criteria in Solid Tumours (RECIST)\"\\n11862,1,1,\"Objective Tumour Response According to RECIST Criteria\"\\n11863,1,1,\"Objective Tumour Response Evaluated According to the Response Evaluation Criteria in Solid Tumours (RECIST 1.0) by Central Review of the Tumour Images\"\\n11864,1,1,\"Objective tumour response or the ratio of time-to-progression over the preceding period\"\\n11865,2,1,\"Objective tumour response rate\"\\n11866,1,1,\"Observation of safety following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.\"\\n11867,1,1,\"Observed Accrual Rate Defined as Rate of Accrual Remaining >= 80% of the Expected\"\\n11868,1,1,\"Observed Accumulation Ratio (Rac) for Palbociclib\"\\n11869,1,1,\"Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)\"\\n11870,1,1,\"Observed Concentration of Relatlimab at End of Infusion (Ceoi)\"\\n11871,1,1,\"Observed Dose Limited Toxicities (DLTs) in safety lead in phase\"\\n11872,1,1,\"Observed maximum concentration of Hemay020\"\\n11873,1,1,\"Observed Maximum Plasma Concentration (Cmax)\"\\n11874,1,1,\"Observed Maximum Plasma Concentration (Cmax) of Niraparib and M1 During PK Phase\"\\n11875,1,1,\"Observed Maximum Serum Concentration (Cmax) of EMD 525797 After First Infusion\"\\n11876,1,1,\"Observed Maximum Serum Concentration (Cmax) of EMD 525797 After Third Infusion\"\\n11877,1,1,\"Observed Overall Response Rate\"\\n11878,1,1,\"Observed serum concentration at the end of a dosing interval (Ctau)\"\\n11879,1,1,\"Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery\"\\n11880,1,1,\"Observed terminal half-life [t1/2] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n11881,1,1,\"Observed trough serum concentration (Cmin)\"\\n11882,1,1,\"Obstructive sleep apnea (OSA) rate before and after chemoradiation therapy (CRT) in stage III-IVb patients undergoing CRT\"\\n11883,1,1,\"Obtain data on the detection and quantification of changes in levels of protein expression and phosphorylation status using human hair samples at baseline and after completion of study\"\\n11884,1,1,\"Obtain preliminary biodistribution data for [I-124]-CPD-1028\"\\n11885,4,3,\"Obtain the maximum tolerated dose of CD70 CAR-T cells[Safety and Tolerability]\"\\n11886,2,2,\"Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability]\"\\n11887,1,1,\"Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability]\"\\n11888,1,1,\"Obtaining samples for research\"\\n11889,1,1,\"Occurence and frequence of AE and SAE (phase 1)\"\\n11890,1,1,\"Occurence of Adverse event rate\"\\n11891,1,1,\"Occurence of adverse events and antibody formation to NESP\"\\n11892,1,1,\"Occurence of AE and SAEÔºàNCI CTCAE 5.0Ôºâ\"\\n11893,1,1,\"Occurence of CTCAE Grade >= 2 Diarrhea\"\\n11894,1,1,\"Occurence of DLT\"\\n11895,1,1,\"Occurence of DLTs\"\\n11896,1,1,\"Occurence of DLTs for both schedules\"\\n11897,1,1,\"Occurence of dose limiting toxicity according to CTCAE\"\\n11898,1,1,\"Occurence of drug related dose limiting toxicities for determination of Maximum Tolerated Dose (MTD) (Part I)\"\\n11899,1,1,\"Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination\"\\n11900,1,1,\"Occurrence and numbers of DLT (phase 1)\"\\n11901,19,2,\"Occurrence of Adverse Events\"\\n11902,38,2,\"Occurrence of adverse events\"\\n11903,9,1,\"Occurrence of adverse events (AEs)\"\\n11904,3,1,\"Occurrence of Adverse Events and Serious Adverse Events\"\\n11905,2,1,\"Occurrence of Adverse Events and Treatment-Related Adverse Events\"\\n11906,1,1,\"Occurrence of adverse events by NCI CTCAE grade and associated dose of GDC-0068\"\\n11907,1,1,\"Occurrence of adverse events by NCI CTCAE grade and associated dose of GDC-0941\"\\n11908,2,1,\"Occurrence of all adverse events\"\\n11909,1,1,\"Occurrence of clinically meaningful chemotherapy induced peripheral neuropathy (CIPN) (binary outcome: yes vs. no)\"\\n11910,1,1,\"Occurrence of death (Dose Escalation Phase)\"\\n11911,1,1,\"Occurrence of Detected Changes in Regions of Interest (ROIs)\"\\n11912,2,2,\"Occurrence of DLTs\"\\n11913,1,1,\"Occurrence of DLTs during the DLT evaluation period - BNT153\"\\n11914,4,1,\"Occurrence of Dose Limiting Toxicities\"\\n11915,5,1,\"Occurrence of dose limiting toxicities\"\\n11916,3,1,\"Occurrence of Dose Limiting Toxicities (DLT)\"\\n11917,1,1,\"Occurrence of Dose Limiting Toxicities (DLTs)\"\\n11918,1,1,\"Occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period - BNT152\"\\n11919,1,1,\"Occurrence of dose limiting toxicities (DLTs) during the maximum tolerated dose (MTD) evaluation period\"\\n11920,1,1,\"Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period in combination therapy\"\\n11921,1,1,\"Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period in monotherapy\"\\n11922,1,1,\"Occurrence of dose limiting toxicities (DLTs) within a patient during the DLT evaluation period in Part 1.\"\\n11923,1,1,\"Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC)\"\\n11924,1,1,\"Occurrence of dose limiting toxicities (Part 2: Subjects with other solid tumors)\"\\n11925,6,2,\"Occurrence of Dose Limiting Toxicity\"\\n11926,3,2,\"Occurrence of Dose Limiting Toxicity (DLT)\"\\n11927,4,1,\"Occurrence of dose limiting toxicity (DLT)\"\\n11928,1,1,\"Occurrence of Dose Limiting Toxicity (DLT) Events\"\\n11929,1,1,\"Occurrence of dose limiting toxicity (DLT) of IPH5301 in monotherapy in the dose escalation and in combination with paclitaxel and trastuzumab in the expansion cohort\"\\n11930,1,1,\"Occurrence of Dose Limiting Toxicity during first treatment cycle\"\\n11931,1,1,\"Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAE\"\\n11932,1,1,\"Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAE.\"\\n11933,1,1,\"Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAEs\"\\n11934,1,1,\"Occurrence of dose reductions and discontinuation of BNT141 due to TEAEs throughout the study and up to 60 days after last subject last treatment\"\\n11935,1,1,\"Occurrence of dose reductions and discontinuation of BNT142 due to TEAEs\"\\n11936,5,4,\"Occurrence of dose-limiting toxicities\"\\n11937,1,1,\"Occurrence of dose-limiting toxicities (DLT)\"\\n11938,2,2,\"Occurrence of Dose-limiting Toxicities (DLTs)\"\\n11939,5,3,\"Occurrence of dose-limiting toxicities (DLTs)\"\\n11940,1,1,\"Occurrence of dose-limiting toxicities (DLTs) by NCI CTCAE grade and associated dose of GDC-0068\"\\n11941,1,1,\"Occurrence of dose-limiting toxicities (DLTs) by NCI CTCAE grade and associated dose of GDC-0941\"\\n11942,1,1,\"Occurrence of dose-limiting toxicities (DLTs) during Cycle 1\"\\n11943,1,1,\"Occurrence of dose-limiting toxicities (DLTs) within a patient during the DLT evaluation period\"\\n11944,2,2,\"Occurrence of dose-limiting toxicities (DLTs).\"\\n11945,1,1,\"Occurrence of Dose-limiting Toxicities and Adverse Events\"\\n11946,1,1,\"Occurrence of Dose-Limiting Toxicities(DLTs)\"\\n11947,1,1,\"Occurrence of dose-limiting toxicity (DLT) within a patient during the DLT evaluation period\"\\n11948,2,2,\"Occurrence of Drug Limited Toxicities (DLTs)\"\\n11949,2,2,\"Occurrence of General Toxicity\"\\n11950,2,2,\"Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980\"\\n11951,1,1,\"Occurrence of Grade 3 or 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0068\"\\n11952,1,1,\"Occurrence of Grade 3 or 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0941\"\\n11953,1,1,\"Occurrence of grade 4 hematologic AEs (Dose Expansion Phase)\"\\n11954,1,1,\"Occurrence of one or more grade 3 or higher adverse event in a given patient (Cohort 1)\"\\n11955,1,1,\"occurrence of osteonecrosis of the jaw\"\\n11956,4,1,\"Occurrence of Serious Adverse Events\"\\n11957,1,1,\"Occurrence of serious adverse events (SAE)\"\\n11958,9,1,\"Occurrence of serious adverse events (SAEs)\"\\n11959,1,1,\"Occurrence of Severe (Grade 4) Neutropenia\"\\n11960,1,1,\"Occurrence of severe or worse non-hematological immune-related adverse event (irAE)\"\\n11961,2,1,\"Occurrence of skin cancer\"\\n11962,2,1,\"Occurrence of Study related adverse events\"\\n11963,26,1,\"Occurrence of study related adverse events\"\\n11964,1,1,\"Occurrence of the progression or death of the patient.\"\\n11965,2,1,\"Occurrence of toxicity\"\\n11966,1,1,\"Occurrence of treatment emergent adverse event (TEAE) within a patient including Grade ‚â•3, serious, fatal TEAE by relationship.\"\\n11967,1,1,\"Occurrence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (Version 4.03)\"\\n11968,1,1,\"Occurrence of treatment emergent adverse events (TEAEs) including Grade ‚â•3, serious, or fatal TEAEs by causal relationship to trial treatment\"\\n11969,1,1,\"Occurrence of treatment emergent AEs\"\\n11970,2,1,\"Occurrence of Treatment Related Adverse Events\"\\n11971,3,2,\"occurrence of treatment related adverse events\"\\n11972,4,3,\"Occurrence of treatment related adverse events as assessed by CTCAE v4.03\"\\n11973,2,2,\"Occurrence of treatment-emergent adverse event (AEs) and serious adverse events (SAEs).\"\\n11974,1,1,\"Occurrence of treatment-emergent adverse events (TEAEs) including Grade ‚â• 3, serious, fatal TEAE by causal relationship to trial treatment\"\\n11975,1,1,\"Occurrence of treatment-emergent adverse events (TEAEs) reported by relationship, seriousness, and grade according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0\"\\n11976,1,1,\"Occurrence of treatment-emergent adverse events (TEAEs) within a patient including Grade ‚â• 3, serious, fatal TEAE by relationship\"\\n11977,1,1,\"Occurrence of treatment-emergent adverse events (TEAEs) within a patient including ‚â• Grade 3, serious, fatal TEAEs by relationship\"\\n11978,1,1,\"Occurrence of Treatment-related Non-serious Treatment-Emergent Adverse Events (TEAEs), All Serious AEs, Immunerelated AEs and Infusion-related Reactions According to Version of National Cancer Institute Common Technology Criteria for Adverse Events\"\\n11979,1,1,\"Occurrence of unanticipated serious adverse events (SAEs)\"\\n11980,1,1,\"Occurrence of: possible catheter infection, suitability of citrate/heparin anticoagulation, adverse events/serious adverse events in general\"\\n11981,1,1,\"Oligo-progression disease rate in NSCLC patients developing acquired resistance to ICI treatment.\"\\n11982,1,1,\"Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast\"\\n11983,1,1,\"one year overall survival (OS)\"\\n11984,1,1,\"one year progression free survival\"\\n11985,1,1,\"One Year Progression Free Survival Rate\"\\n11986,1,1,\"One Year Survival Rate\"\\n11987,1,1,\"One-year Overall Survival Rate\"\\n11988,1,1,\"One-year Overall Survival Rate (OSR) Estimated by Complete Case Method\"\\n11989,1,1,\"One-Year Relapse Free Survival (RFS) Rates With Post-Operative Adjuvant Durvalumab\"\\n11990,1,1,\"Onset time of adverse event associated with bevacizumab\"\\n11991,1,1,\"Operational and logistical feasibility of administering cognitive assessment battery in medical oncology clinic environment during administration of chemotherapy.\"\\n11992,1,1,\"Optimal 89Zr-DFO-REGN3767 dose and PET imaging timepoint\"\\n11993,1,1,\"Optimal Biologic Dose (OBD)\"\\n11994,1,1,\"Optimal biologic dose (OBD)\"\\n11995,1,1,\"Optimal Biologic Dose of Hydroxychloroquine\"\\n11996,2,1,\"Optimal Biological Dose\"\\n11997,2,1,\"Optimal biological dose (OBD)\"\\n11998,1,1,\"Optimal biological dose (OBD) of ES014\"\\n11999,1,1,\"Optimal Biological Dose (OBD) of RO6874281\"\\n12000,1,1,\"Optimal Biologically Effective Dose (OBED) of MEDI-573\"\\n12001,1,1,\"optimal dose and regimen of TrasGEX‚Ñ¢\"\\n12002,1,1,\"Optimal dose of veliparib with gemcitabine hydrochloride and cisplatin (non-randomized part I)\"\\n12003,1,1,\"Optimal Doses of Temozolomide and Bortezomib (Phase I)\"\\n12004,1,1,\"Optimal Dosing for Phase II Studies.\"\\n12005,1,1,\"Optimal Imaging Parameters\"\\n12006,1,1,\"Optimal Timepoint During the Course of Neoadjuvant Therapy [CRT, CT (Chemotherapy) or RT Radiotherapy)] That FLT-PET Imaging Can Predict Response\"\\n12007,1,1,\"Optimal tolerated dose (OTD) of CRAd 3/5\"\\n12008,1,1,\"Optimal TTI-621 delivery regimen\"\\n12009,2,1,\"Optimally Tolerated Dose\"\\n12010,1,1,\"Optimism by Life Orientation Test at baseline\"\\n12011,1,1,\"Optimum length of treatment with letrozole (2.5 mg daily) preoperatively, on tumour measured by clinical examination and breast ultrasound\"\\n12012,1,1,\"Optimum starting dose\"\\n12013,1,1,\"Optimum tolerated regimen (OTR) for each combination regimen in each arm of the study.OTR determined by evaluation of AEs and change in lab values.OTR defined as highest dosing regimen that results in dose limiting toxicity in no more than 1 of 6 subject\"\\n12014,1,1,\"Optimum tolerated regimen (OTR) for each regimen in each arm of the study. OTR determined evaluation of AEs and change in lab values. OTR defined as the highest dosing regimen that results in dose limiting toxicity in no more than 1 of 6 subjects\"\\n12015,1,1,\"Oral Bioavailability of Pimasertib After Single Oral Dose of Unlabeled Pimasertib and Intravenous (IV) Single Tracer Dose of [14C] Pimasertib\"\\n12016,1,1,\"Oral Clearance For Dextromethorphan 3 Days Prior to PF-00299804 Dosing\"\\n12017,1,1,\"Oral Clearance For Dextromethorphan on Cycle 2 Day 7\"\\n12018,1,1,\"oral morphine equivalent doseresponse criteria\"\\n12019,1,1,\"Organ-specific grade 3 toxicity.\"\\n12020,1,1,\"Organ-specific grade 4 toxicity.\"\\n12021,1,1,\"Organ-specific grade 5 toxicity.\"\\n12022,1,1,\"ORGANOTREAT-01: Chemogram\"\\n12023,1,1,\"ORGANOTREAT-02A: GMI\"\\n12024,1,1,\"ORGANOTREAT-02B: PFS\"\\n12025,259,43,\"ORR\"\\n12026,1,1,\"ORR (Cohort 3)\"\\n12027,1,1,\"ORR (Cohort 4)\"\\n12028,2,1,\"ORR (CR + PR)\"\\n12029,1,1,\"ORR (CR + PR) based on RECIST 1.1, and as determined by investigator\"\\n12030,8,1,\"ORR (Objective Response Rate)\"\\n12031,3,1,\"ORR (Objective response rate)\"\\n12032,1,1,\"ORR (PR + CR) Using the Cheson et al Parameters\"\\n12033,3,1,\"ORR 3\"\\n12034,1,1,\"ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F)\"\\n12035,1,1,\"ORR according to RECIST 1.1 by an Independent Central Review (ICR)\"\\n12036,1,1,\"ORR according to RECIST Version 1.1\"\\n12037,1,1,\"ORR as assessed by RECIST 1.1 criteria (efficacy)\"\\n12038,1,1,\"ORR Assessed by BICR in Participants With Squamous NSCLC Who Had Received 1 and 2 or More Prior Lines of Therapy in the Dose-expansion Phase\"\\n12039,1,1,\"ORR Assessed by BICR in Participants With UC Post-platinum (Programmed Cell Death Ligand [PD-L1] Status High) Who Had Received at Least 1 Line of Prior Therapy (2L+) in the Dose-expansion Phase\"\\n12040,1,1,\"ORR at 6 months\"\\n12041,1,1,\"ORR Based on Investigator Assessment\"\\n12042,1,1,\"ORR Based on Response Assessment in Neuro-Oncology (RANO) per IRC\"\\n12043,6,6,\"ORR by Immune-related response criteria (irRC )\"\\n12044,1,1,\"ORR by Immune-related response criteria (irRC)\"\\n12045,1,1,\"ORR by International Working Group (IWG) Response Criteria (Cheson, 2007) per BICR Assessment for rrcHL Cohort\"\\n12046,1,1,\"ORR by RECIST 1.1 per Site Assessment for MSI-H or TMBH Solid Tumors (Each Cohort Evaluated Separately)\"\\n12047,1,1,\"ORR defined by RECIST 1.1 (Eisenhauer, 2009) in combination with cemiplimab or REGN4018 (separately by cohort and combination)\"\\n12048,1,1,\"ORR defined by RECIST 1.1 for REGN4018 with cemiplimab\"\\n12049,1,1,\"ORR in Part B\"\\n12050,1,1,\"ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status\"\\n12051,1,1,\"ORR in Phase 2 Subjects With Recurrent Platinum-refractory Ovarian Cancer (Cohort B)\"\\n12052,3,2,\"ORR in Phase II\"\\n12053,1,1,\"ORR Objective Response Rate\"\\n12054,1,1,\"ORR of HCC patients in dose expansion study\"\\n12055,1,1,\"ORR of HX008 combined with irinotecan and HX008 single drug\"\\n12056,1,1,\"ORR ORR\"\\n12057,1,1,\"ORR Per BIRC Assessment by PD-L1 Expression Level\"\\n12058,1,1,\"ORR per Modified RECIST (mRECIST) 1.1 as Assessed by Investigator\"\\n12059,1,1,\"ORR per mRECIST 1.1 by BICR in IMDC all-risk patients with previously untreated advanced RCC\"\\n12060,1,1,\"ORR per RECIST 1.1 as Assessed by Investigator\"\\n12061,1,1,\"ORR Per RECIST 1.1 by BICR in Subgroup of Cohort A and Cohort B Participants With PD-L1 CPS ‚â•1\"\\n12062,1,1,\"ORR Per RECIST 1.1 by BICR in Subgroup of Cohort A and Cohort B Participants With Programmed Cell Death Ligand -1 (PD-L1) Combined Positive Score (CPS) ‚â•10\"\\n12063,1,1,\"ORR Per RECIST 1.1 by CIV in Subgroup of Cohort A Participants With Programmed Cell Death- Ligand 1 (PD-L1) Positive Tumor Expression\"\\n12064,1,1,\"ORR per RECIST 1.1 or RANO (GBM) by Blinded Independent Central Review (BICR) in Expanded Cohorts (Combined with Initial Cohorts)\"\\n12065,1,1,\"ORR using mRECIST 1.1 by BICR in IMDC intermediate- or poor-risk patients with previously untreated advanced RCC\"\\n12066,6,2,\"ORR(Objective Response Rate)\"\\n12067,4,1,\"ORR(Objective response rate)\"\\n12068,1,1,\"ORR, CR rate and PR rate as assessed by RECIST 1.1 criteria (efficacy)\"\\n12069,1,1,\"ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations\"\\n12070,2,1,\"ORR, Objective Response Rate\"\\n12071,3,1,\"ORR, objective response rate\"\\n12072,1,1,\"ORRÔºàObjective Response Rate)\"\\n12073,104,12,\"OS\"\\n12074,1,1,\"OS - Participants With PD-L1 Positive Tumors\"\\n12075,1,1,\"OS - Participants With Strongly PD-L1 Positive Tumors\"\\n12076,1,1,\"OS and PFS\"\\n12077,1,1,\"OS Assessed From Point of Randomization\"\\n12078,1,1,\"OS for Participants with Left-sided Tumors\"\\n12079,1,1,\"OS in All Participants\"\\n12080,1,1,\"OS in all randomized participants\"\\n12081,1,1,\"OS in IMDC all-risk patients with previously untreated advanced RCC\"\\n12082,1,1,\"OS in Low Risk Subjects\"\\n12083,1,1,\"OS in participants receiving dostarlimab + docetaxel relative to participants receiving docetaxel alone\"\\n12084,1,1,\"OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ‚â•10)\"\\n12085,1,1,\"OS in Participants With CPS ‚â•1\"\\n12086,1,1,\"OS in Participants With Detectable PD-L1\"\\n12087,1,1,\"OS in Participants With ESCC\"\\n12088,1,1,\"OS in Participants With PD-L1 Positive (TPS ‚â•1%) Tumors (All Participants)\"\\n12089,1,1,\"OS in Participants With PD-L1 TPS 1% to 49%\"\\n12090,1,1,\"OS in Participants With PD-L1 TPS ‚â•1%\"\\n12091,1,1,\"OS in PD-L1 biomarker-positive participants\"\\n12092,1,1,\"OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ‚â•1 Population\"\\n12093,1,1,\"OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP\"\\n12094,1,1,\"OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP\"\\n12095,1,1,\"OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP\"\\n12096,1,1,\"OS in the Intent-To-Treat (ITT) Population\"\\n12097,1,1,\"OS in the PD-L1 Expression High (CPS ‚â•20) Population\"\\n12098,1,1,\"OS is defined as the time from randomization to death due to any cause. ÔºàStage IIÔºâ\"\\n12099,1,1,\"OS: SP-ITT\"\\n12100,1,1,\"OS: TC1/2/3 or IC1/2/3 Subgroup of PP\"\\n12101,1,1,\"OS: TC1/2/3 Or IC1/2/3 Subgroup of SP\"\\n12102,1,1,\"OS: TC2/3 or IC2/3 Subgroup of SP\"\\n12103,1,1,\"OS: TC3 or IC3 Subgroup of SP\"\\n12104,1,1,\"OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set\"\\n12105,1,1,\"Osteoporosis after chemotherapy\"\\n12106,1,1,\"other PK parameters\"\\n12107,1,1,\"Ototoxicity Measurement\"\\n12108,1,1,\"Out-of-field ORR improvement\"\\n12109,1,1,\"Outcome Measure: safety and tolerability, based on the rate of dose-limiting toxicities, toxicity grade, and reversibility of toxicity.\"\\n12110,1,1,\"Outcome Measure:pediatric solid tumor survivors are at an increased risk for developing generalized or regional osteoporosis as a result of chemotherapy for pediatric solid tumors.\"\\n12111,2,2,\"Outcome of TEAEs\"\\n12112,1,1,\"Outcomes for Primary Aim 1 - 50 intervention participants with a diagnosis for lung, breast or ovarian cancer measuring the prevalence and severity of 18 different symptoms reported from home over 3 months.\"\\n12113,1,1,\"Outcomes from: PRO-CTCAE, Neuro-QOL, Numeric Rating Scale for Pain, 6-Minute Walking Test, Stroop Test, and Normalized Reaction Time Tests\"\\n12114,1,1,\"Outcomes of patients treated on a trial vs those not treated with the same disease\"\\n12115,6,1,\"Over all survival\"\\n12116,2,1,\"Overall accrual\"\\n12117,1,1,\"Overall and Complete Response Rates\"\\n12118,1,1,\"Overall assessment score: Post\"\\n12119,1,1,\"Overall assessment score: Pre\"\\n12120,1,1,\"Overall Best Confirmed Response\"\\n12121,1,1,\"Overall Best Response\"\\n12122,1,1,\"Overall Clinical Benefit of Tarceva in CRPC.\"\\n12123,2,1,\"Overall Clinical Response Rate\"\\n12124,1,1,\"Overall Confirmed Response Rate\"\\n12125,2,1,\"Overall disease control rate\"\\n12126,1,1,\"Overall Disease Response Rate\"\\n12127,1,1,\"Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus.\"\\n12128,1,1,\"Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities)\"\\n12129,1,1,\"Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b)\"\\n12130,1,1,\"Overall Maximum Tolerated Dose of Intraperitoneal Autologous Monocytes\"\\n12131,1,1,\"Overall Maximum Tolerated Dose of Sylatron (Peginterferon Alpha-2b)\"\\n12132,1,1,\"Overall median survival\"\\n12133,1,1,\"Overall mood\"\\n12134,2,1,\"Overall mortality rate\"\\n12135,1,1,\"Overall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant\"\\n12136,1,1,\"Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant\"\\n12137,1,1,\"Overall Number of Participants Who Achieve a Response Rate (Complete Response, Partial Response, and Stable Disease) at 3 Months\"\\n12138,1,1,\"Overall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab\"\\n12139,1,1,\"Overall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab\"\\n12140,1,1,\"Overall Number of Participants With Non-Serious Adverse Events by Event Outcome\"\\n12141,1,1,\"Overall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03\"\\n12142,1,1,\"Overall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE)\"\\n12143,1,1,\"Overall Number of Participants With Serious Adverse Events by Action Taken With Study Drug\"\\n12144,1,1,\"Overall Number of Participants With Serious Adverse Events by Event Outcome\"\\n12145,1,1,\"Overall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme), According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)\"\\n12146,1,1,\"Overall Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events Following DS-1103a Combination Therapy (Dose Expansion)\"\\n12147,20,9,\"Overall Objective Response\"\\n12148,1,1,\"Overall Objective Response (Complete Response or Partial Response)\"\\n12149,1,1,\"Overall Objective Response of OSI-774\"\\n12150,4,1,\"Overall Objective Response Rate\"\\n12151,4,1,\"Overall objective response rate\"\\n12152,1,1,\"Overall Objective Response Rate (CR + PR)\"\\n12153,3,3,\"Overall Objective Response Rate (ORR)\"\\n12154,1,1,\"Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin\\'s Criteria (RECIST)\"\\n12155,1,1,\"Overall Objective Response Rate According to RECIST (Phase II)\"\\n12156,1,1,\"Overall objective response rate evaluated according to modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1 and immune related [ir]RECIST)\"\\n12157,1,1,\"Overall outcome\"\\n12158,2,1,\"Overall Participant Response\"\\n12159,1,1,\"Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR)\"\\n12160,1,1,\"Overall Progression-Free Survival (PFS).\"\\n12161,1,1,\"Overall Progression-free Survival in Participants After a Dosage of CS-7017 Administered Twice Daily in Combination With Paclitaxel Administered Once Every 3 Weeks to Participants With Advanced Anaplastic Thyroid Cancer (ATC)\"\\n12162,1,1,\"overall quality of bowel preparation using a 0-3 scale for each parameter (Homogeneity of solid-fluid fecal tagging, volume of residual fluid, colon distension).\"\\n12163,6,1,\"Overall Quality of Life\"\\n12164,1,1,\"Overall R0/R1 resection rate\"\\n12165,1,1,\"Overall Radiographic Response Rate (ORR)\"\\n12166,2,2,\"Overall radiological response rate\"\\n12167,1,1,\"Overall Rate of Response\"\\n12168,1,1,\"Overall Rate Response (ORR)\"\\n12169,1,1,\"Overall RECIST 1.1 Response Rate Based on BICR Review for Participants in Cohort B2\"\\n12170,37,6,\"Overall Response\"\\n12171,26,3,\"Overall response\"\\n12172,1,1,\"Overall Response (Applicable for: Dose Escalation Phase and Dose Expansion Phase in Cohorts of Colorectal Cancer, Ovarian Cancer and Cervical Cancer)\"\\n12173,1,1,\"Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants\"\\n12174,10,2,\"Overall Response (OR)\"\\n12175,1,1,\"Overall Response (OR) of the injected tumor\"\\n12176,1,1,\"Overall Response (OR) Within 6 Months\"\\n12177,1,1,\"Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator\"\\n12178,1,1,\"Overall Response (Partial Response + Complete Response) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer (BC)\"\\n12179,1,1,\"Overall Response (Partial Response + Complete Response) for Participants With Triple Negative Breast Cancer (TNBC)\"\\n12180,1,1,\"Overall response (phase II)\"\\n12181,1,1,\"Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)\"\\n12182,1,1,\"Overall Response After 3 Cycles of Botezomib Plus ICE (BICE) Versus Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma\"\\n12183,1,1,\"Overall response at 12 months\"\\n12184,1,1,\"Overall Response Based on RECIST V1.1 Following Oral Doses of Pexidartinib (Efficacy Analysis Set)\"\\n12185,1,1,\"Overall Response by RECIST Criteria\"\\n12186,1,1,\"Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Response Rate Based on Blinded Independent Central Radiology (BICR) Review (Cohorts A, B, C, and D)\"\\n12187,2,1,\"Overall Response in Phase II\"\\n12188,1,1,\"Overall response of AFP464 in the treatment of solid tumors\"\\n12189,280,63,\"Overall Response Rate\"\\n12190,268,34,\"Overall response rate\"\\n12191,84,10,\"overall response rate\"\\n12192,1,1,\"Overall Response Rate (Applicable for: phase II stage) .\"\\n12193,1,1,\"Overall response rate (Arm 2)\"\\n12194,1,1,\"overall response rate (clinical complete response and partial response)\"\\n12195,1,1,\"Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteria\"\\n12196,2,1,\"Overall response rate (complete and partial response)\"\\n12197,1,1,\"Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1\"\\n12198,1,1,\"Overall Response Rate (Complete and Partial Responses) as Assessed by RECIST Criteria\"\\n12199,1,1,\"Overall response rate (complete and partial responses).\"\\n12200,1,1,\"Overall Response Rate (Complete Plus Partial Response) Using RECIST Criteria v1.1\"\\n12201,1,1,\"Overall Response Rate (Complete Plus Partial) (Phase II)\"\\n12202,1,1,\"Overall Response Rate (Complete Response + Partial Response)\"\\n12203,4,1,\"Overall response rate (complete response + partial response)\"\\n12204,1,1,\"Overall Response Rate (Complete Response + Partial Response) to Axitinib as Assessed Using RECIST Version 1.1\"\\n12205,1,1,\"Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%\"\\n12206,1,1,\"Overall Response Rate (Confirmed)\"\\n12207,1,1,\"Overall Response Rate (CR + PR) Determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.\"\\n12208,1,1,\"Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n12209,1,1,\"Overall Response Rate (CR, Marrow CR + PR) of LBH in Patients With Relapsed or Refractory MDS.\"\\n12210,1,1,\"Overall response rate (expansion cohort)\"\\n12211,1,1,\"Overall Response Rate (in Cohorts 1-3)\"\\n12212,1,1,\"Overall Response Rate (OR) Per irRECIST\"\\n12213,321,92,\"Overall Response Rate (ORR)\"\\n12214,1,1,\"Overall Response rate (ORR)\"\\n12215,213,36,\"Overall response rate (ORR)\"\\n12216,1,1,\"Overall response rate (ORR) (Arm 1)\"\\n12217,1,1,\"Overall response rate (ORR) (Cohort II)\"\\n12218,1,1,\"Overall response rate (ORR) (Expansion Cohort)\"\\n12219,1,1,\"Overall response rate (ORR) (expansion cohort)\"\\n12220,1,1,\"Overall Response Rate (ORR) (for Part 1b)\"\\n12221,1,1,\"Overall Response Rate (ORR) (In participants presenting with measurable visceral disease or measurable extrapelvic adenopathy at baseline)\"\\n12222,1,1,\"Overall response rate (ORR) (Part 2)\"\\n12223,1,1,\"Overall response rate (ORR) (Part 3)\"\\n12224,1,1,\"Overall response rate (ORR) (phase 1b expansion)\"\\n12225,1,1,\"Overall Response Rate (ORR) (phase 2 only)\"\\n12226,1,1,\"Overall Response Rate (ORR) (Phase 2)\"\\n12227,11,3,\"Overall response rate (ORR) (Phase II)\"\\n12228,1,1,\"Overall Response Rate (ORR) (Stage 1 and Stage 2)\"\\n12229,1,1,\"Overall Response Rate (ORR) - Independent Central Review (ICR)\"\\n12230,1,1,\"Overall Response Rate (ORR) - MET Exon 14 Cohort\"\\n12231,1,1,\"Overall Response Rate (ORR) - Number of Participants Who Responded to Treatment\"\\n12232,1,1,\"Overall Response Rate (ORR) - Phase ll\"\\n12233,1,1,\"Overall Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per an Independent Endpoint Review Committee (IERC)\"\\n12234,1,1,\"Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D)\"\\n12235,1,1,\"Overall Response Rate (ORR) after 24 weeks of cemiplimab\"\\n12236,1,1,\"Overall Response Rate (ORR) After 4 Cycles of Treatment\"\\n12237,1,1,\"Overall Response Rate (ORR) After Neoadjuvant treatment\"\\n12238,1,1,\"Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)\"\\n12239,1,1,\"Overall Response Rate (ORR) as Assessed by Independent Review Committee (IRC)\"\\n12240,1,1,\"Overall response rate (ORR) as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n12241,1,1,\"Overall Response Rate (ORR) as Assessed by the Investigator\"\\n12242,1,1,\"Overall Response Rate (ORR) as determined by RECIST 1.1\"\\n12243,1,1,\"Overall response rate (ORR) as measured by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) criteria 1.1\"\\n12244,1,1,\"Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Local Radiology Assessment: Phase 2\"\\n12245,1,1,\"Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR)\"\\n12246,1,1,\"Overall response rate (ORR) assessed by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n12247,1,1,\"Overall response rate (ORR) assessed by Independent Review Committee (IRC)\"\\n12248,1,1,\"Overall response rate (ORR) assessed by IRC\"\\n12249,1,1,\"Overall Response Rate (ORR) assessed by the Independent Central Review Committee (ICRC) according to the Study Response Criteria\"\\n12250,1,1,\"Overall response rate (ORR) assessed per immune related Response Evaluation Criteria in Solid Tumors (irRECIST)\"\\n12251,1,1,\"Overall Response Rate (ORR) at any time during the study, in Phase II (Cohort C and D).\"\\n12252,1,1,\"Overall Response Rate (ORR) at Week 16 for Phase 2\"\\n12253,1,1,\"Overall Response Rate (ORR) Based on Central Review by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria (Cohorts 1 to 4 and 6)\"\\n12254,1,1,\"Overall Response Rate (ORR) based on central review of tumor measurement using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n12255,1,1,\"Overall Response Rate (ORR) Based on Independent Radiological Review (IRR)\"\\n12256,1,1,\"Overall Response Rate (ORR) Based on Local Assessment: Group 3 (Phase II Only)\"\\n12257,2,1,\"Overall Response Rate (ORR) based on RECIST 1.1\"\\n12258,2,2,\"Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n12259,1,1,\"Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per Independent Review Committee (IRC)\"\\n12260,1,1,\"Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) (Phase I dose expansion and phase II)\"\\n12261,1,1,\"Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) (Phase II Part)\"\\n12262,1,1,\"Overall response rate (ORR) by blinded independent review committee (BIRC) in cohort A\"\\n12263,1,1,\"Overall Response Rate (ORR) by Measurement of Target Lesions in Phase II\"\\n12264,1,1,\"Overall response rate (ORR) by RECIST - for solid tumor arms\"\\n12265,1,1,\"Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)\"\\n12266,1,1,\"Overall response rate (ORR) by Response Criteria in Solid Tumors (RECIST) v1.1\"\\n12267,1,1,\"Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator\"\\n12268,1,1,\"Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1\"\\n12269,1,1,\"Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1).\"\\n12270,1,1,\"Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Strongly PD-L1 Positive Participants\"\\n12271,1,1,\"Overall response rate (ORR) defined as the percentage of participants with a best overall response of CR or PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by the investigator\"\\n12272,1,1,\"Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1\"\\n12273,1,1,\"Overall Response Rate (ORR) for combination with Binimetinib or in combination with Crizotinib Dose Expansion by Blinded Independent Review Committee\"\\n12274,1,1,\"Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator\"\\n12275,1,1,\"Overall Response Rate (ORR) in Dose Expansion\"\\n12276,1,1,\"Overall response rate (ORR) in each tumour-defined cohort, as defined by RECIST 1.1\"\\n12277,1,1,\"Overall Response Rate (ORR) in Part 2\"\\n12278,1,1,\"Overall Response Rate (ORR) in Patients\"\\n12279,1,1,\"Overall Response Rate (ORR) in Patients With Metastatic HER2 Negative Breast Cancer Treated With Durvalumab in Combination With Tremelimumab\"\\n12280,1,1,\"Overall Response Rate (ORR) in Patients With Triple Negative Breast Cancer (TNBC) Treated With Durvalumab in Combination With Tremelimumab\"\\n12281,1,1,\"Overall Response Rate (ORR) in Phase 2 Subjects With Recurrent Platinum-resistant Ovarian Cancer (Cohort A)\"\\n12282,1,1,\"Overall Response Rate (ORR) in stage 2\"\\n12283,2,2,\"Overall response rate (ORR) in stage ‚Ö°\"\\n12284,1,1,\"Overall response rate (ORR) of ALKS 4230 monotherapy in patients with melanoma or renal cell carcinoma (Part B) and in combination with pembrolizumab in patients with advanced solid tumors (Part C)\"\\n12285,1,1,\"Overall Response Rate (ORR) of Participants\"\\n12286,1,1,\"Overall Response Rate (ORR) of Participants Using RECIST Criteria\"\\n12287,1,1,\"Overall Response Rate (ORR) of Patients Treated at MTD/Phase II Dose Level\"\\n12288,1,1,\"Overall Response Rate (ORR) of treatment with milademetan, as defined as the percentage of patients who have achieved confirmed complete response (CR) or Partial Response (PR) according to RECIST v1.1 criteria\"\\n12289,1,1,\"Overall Response Rate (ORR) of TY-302 combine with Tamoxifen\"\\n12290,1,1,\"Overall Response Rate (ORR) Per Central Radiology Review Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n12291,1,1,\"Overall response rate (ORR) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) version 1.1 (Phase II)\"\\n12292,1,1,\"Overall Response Rate (ORR) Per Investigator Assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n12293,1,1,\"Overall Response Rate (ORR) per investigator assessment using RECIST v1.1\"\\n12294,1,1,\"Overall response rate (ORR) per RECIST v1.1\"\\n12295,1,1,\"Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\"\\n12296,1,1,\"Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohorts 1 and 2)\"\\n12297,1,1,\"Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase 2)\"\\n12298,1,1,\"Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)\"\\n12299,1,1,\"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0\"\\n12300,1,1,\"Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent clinical review (BICR)\"\\n12301,1,1,\"Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 (dose expansion)\"\\n12302,1,1,\"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment\"\\n12303,1,1,\"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n12304,1,1,\"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator\"\\n12305,1,1,\"Overall Response Rate (ORR) Phase 2\"\\n12306,1,1,\"Overall Response Rate (ORR) Phase II Part\"\\n12307,1,1,\"Overall response rate (ORR) using Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 at any time during the study\"\\n12308,1,1,\"Overall Response Rate (ORR) ‚â• 16 Weeks. FAS\"\\n12309,1,1,\"Overall response rate (ORR)(for Part 1 and Part 2 expansion)\"\\n12310,1,1,\"Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922\"\\n12311,1,1,\"Overall response rate (ORR), defined as the proportion of participants whose confirmed best overall response is either a PR or CR after treatment with paclitaxel and a high dose of tremelimumab based upon the RECIST v1.1 guidelines.\"\\n12312,1,1,\"Overall response rate (ORR), defined as the proportion of participants whose confirmed best overall response is either a PR or CR after treatment with paclitaxel, tremelimumab and durvalumab based upon the RECIST v1.1 guidelines.\"\\n12313,8,4,\"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment\"\\n12314,1,1,\"Overall Response Rate (ORR), the Sum of Complete and Partial Responses\"\\n12315,1,1,\"Overall response rate (ORR)-RECIST\"\\n12316,1,1,\"Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)\"\\n12317,1,1,\"Overall Response Rate (Part 2)\"\\n12318,1,1,\"Overall Response Rate (Patients That Achieve a CR or PR)\"\\n12319,1,1,\"Overall Response Rate (Percentage Subjects With Confirmed Complete or Partial Response)\"\\n12320,2,1,\"Overall Response Rate (Phase 2)\"\\n12321,1,1,\"Overall response rate (Phase I dose expansion)\"\\n12322,7,5,\"Overall Response Rate (Phase II)\"\\n12323,2,1,\"Overall Response Rate (PR + CR)\"\\n12324,1,1,\"Overall response rate (PR + CR) after 4 cycles of combination use\"\\n12325,1,1,\"Overall response rate (probability of complete response [CR] or partial response [PR])\"\\n12326,1,1,\"Overall response rate (stabilization and response) (stage I)\"\\n12327,1,1,\"Overall response rate (Stage 2)\"\\n12328,1,1,\"Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)]\"\\n12329,1,1,\"Overall Response Rate [Phase II]\"\\n12330,1,1,\"Overall Response Rate according to RECIST 1.1\"\\n12331,1,1,\"Overall Response Rate Among PD-L1 Positive Participants Treated With MEDI4736\"\\n12332,1,1,\"Overall response rate as defined by the proportion of patients achieving a confirmed partial response (PR) and complete response (CR) (defined by response evaluation criteria in solid tumors (RECIST 1.1) as evaluated by the local treating investigator.\"\\n12333,1,1,\"Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings\"\\n12334,1,1,\"Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (MDVN) Participants\"\\n12335,1,1,\"Overall response rate assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\"\\n12336,1,1,\"Overall response rate associated with RGX-104 treatment as a single agent, and separately, in combination with docetaxel or pembrolizumab plus carboplatin/pemetrexed.\"\\n12337,1,1,\"Overall Response Rate at 4 Months\"\\n12338,1,1,\"Overall response rate based on modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\"\\n12339,1,1,\"Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n12340,1,1,\"Overall response rate by RECIST 1.1\"\\n12341,1,1,\"Overall Response Rate by RECIST v 1.1\"\\n12342,1,1,\"Overall Response Rate by the Lugano Classification Per Independent Review Assessment\"\\n12343,1,1,\"Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria.\"\\n12344,1,1,\"Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors\"\\n12345,1,1,\"Overall Response Rate for Len Refractory Patients\"\\n12346,1,1,\"Overall response rate for unirradiated lesions (ORR)\"\\n12347,1,1,\"Overall response rate in DTC treated advanced ovary cancer\"\\n12348,1,1,\"Overall Response Rate in Part 2\"\\n12349,1,1,\"Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA)\"\\n12350,1,1,\"Overall Response rate in PD-L1+ patients\"\\n12351,1,1,\"Overall Response Rate in Select Tumor Types\"\\n12352,1,1,\"Overall Response Rate of Complete or Partial Response\"\\n12353,1,1,\"Overall Response Rate of DS-9606a as Assessed by the Investigator in Participants Receiving DS-9606a (Dose Expansion)\"\\n12354,1,1,\"Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer\"\\n12355,1,1,\"Overall Response Rate of Intracranial Disease\"\\n12356,1,1,\"Overall response rate of lenvatinib and eribulin\"\\n12357,1,1,\"Overall Response rate of pembrolizumab in combination with paclitaxel in HR+/HER2- non-luminal subtype advanced breast cancer defined by the PAM50 assay\"\\n12358,1,1,\"Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.\"\\n12359,2,1,\"Overall response rate of tumor\"\\n12360,1,1,\"Overall response rate per immune-modified response evaluation criteria in solid tumors\"\\n12361,1,1,\"Overall Response Rate Per RECIST Version 1.1 (Part 2)\"\\n12362,1,1,\"Overall Response Rate Phase (Phase 2)\"\\n12363,1,1,\"Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc\"\\n12364,1,1,\"Overall Response Rate Using RECIST\"\\n12365,1,1,\"Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1\"\\n12366,1,1,\"Overall Response Rate Will Measured Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Tumor Assessment for All Lesions Must be Performed Every Eight Weeks While on Study by CT Scan.\"\\n12367,1,1,\"Overall Response Rate With Everolimus Treatment.\"\\n12368,8,1,\"Overall response rate(ORR)\"\\n12369,1,1,\"Overall Response Rate, Defined as the Percentage of Patients With a Confirmed Clinical Response (CR) or Partial Response (PR)\"\\n12370,1,1,\"Overall Response Rate-Besylate Sub-study\"\\n12371,1,1,\"Overall Response Rate-Part 1 BID\"\\n12372,1,1,\"Overall Response Rate-Part 1 QD\"\\n12373,1,1,\"Overall Response Rate-Part 2\"\\n12374,2,2,\"Overall Response Rate.\"\\n12375,1,1,\"Overall Response Rate/ORR\"\\n12376,1,1,\"Overall response rate: number of participants with response (Part A)\"\\n12377,1,1,\"Overall Response rates (ORR)\"\\n12378,1,1,\"Overall Response rateÔºàORRÔºâ\"\\n12379,1,1,\"Overall Response to CVT Chemotherapy.\"\\n12380,1,1,\"Overall response(CR+PR) and Clinical benefit (CR+PR+SD)\"\\n12381,1,1,\"Overall response, defined as the number of patients who achieve any response according to disease type in the first 6 courses of treatment\"\\n12382,1,1,\"Overall Response.\"\\n12383,1,1,\"Overall Responsive Rate (ORR) as assessed in RECIST 1.1\"\\n12384,1,1,\"Overall Safety and determination of MTD, and recommended Phase 2 dose\"\\n12385,1,1,\"Overall safety and tolerability profile of YH001 (adverse events)\"\\n12386,1,1,\"Overall safety and tolerability profile of YH003 in combination with Toripalimab.\"\\n12387,1,1,\"Overall safety of pacritinib in patients with treatment refractory solid tumors\"\\n12388,2,1,\"Overall Safety Profile\"\\n12389,1,1,\"Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment\"\\n12390,1,1,\"Overall safety profile characterized by type, frequency, severity (as graded using NCI CTC AE v. 3.0), timing, seriousness and relationship to trial treatment of adverse events and laboratory abnormalities.\"\\n12391,1,1,\"Overall safety profile including adverse events\"\\n12392,1,1,\"Overall safety profile including laboratory abnormalities\"\\n12393,1,1,\"Overall safety profile including vital signs\"\\n12394,1,1,\"Overall safety: type, grade and frequency of all adverse events and laboratory abnormalities\"\\n12395,1,1,\"Overall satisfaction with port placement\"\\n12396,6,1,\"Overall success rate\"\\n12397,708,120,\"Overall Survival\"\\n12398,1053,58,\"Overall survival\"\\n12399,334,4,\"overall survival\"\\n12400,1,1,\"Overall Survival (12-month Rate Reported)\"\\n12401,1,1,\"Overall survival (at 1 year)\"\\n12402,1,1,\"Overall survival (expansion cohort)\"\\n12403,1,1,\"Overall survival (High risk)\"\\n12404,1,1,\"Overall survival (months)\"\\n12405,496,212,\"Overall Survival (OS)\"\\n12406,313,53,\"Overall survival (OS)\"\\n12407,40,6,\"overall survival (OS)\"\\n12408,1,1,\"Overall survival (OS) (Cohort II)\"\\n12409,1,1,\"Overall survival (OS) (Cohorts 1 and 2)\"\\n12410,1,1,\"Overall survival (OS) (in stage ‚Ö°)\"\\n12411,1,1,\"Overall survival (OS) (Phase 3 only)\"\\n12412,11,5,\"Overall survival (OS) (Phase III)\"\\n12413,1,1,\"Overall Survival (OS) - All Participants\"\\n12414,1,1,\"Overall Survival (OS) - Days (FAS)\"\\n12415,2,2,\"Overall Survival (OS) - Pembrolizumab+Chemotherapy and Placebo+Chemotherapy Treatment Arms\"\\n12416,1,1,\"Overall Survival (OS) - Percentage of Participants With an Event\"\\n12417,1,1,\"Overall Survival (OS) - Phase 2 (Dose Selection Portion of the Study)\"\\n12418,1,1,\"Overall Survival (OS) - Stratified Analysis, Randomized Portion\"\\n12419,1,1,\"Overall survival (OS) [Part 3]\"\\n12420,1,1,\"Overall survival (OS) according to VEGFR2 levels, evaluating the difference in terms of median OS among patients with high VEGFR2 activity and patients with low VEGFR2 activity\"\\n12421,1,1,\"Overall Survival (OS) After Initiation of Second Line Sunitinib Therapy\"\\n12422,1,1,\"Overall Survival (OS) Among All Randomized Patients\"\\n12423,1,1,\"Overall Survival (OS) as Median Time to Event During the Overall Study\"\\n12424,1,1,\"Overall survival (OS) at 1 year\"\\n12425,1,1,\"Overall survival (OS) at 12 months (OS12).\"\\n12426,1,1,\"Overall survival (OS) at 2 years\"\\n12427,1,1,\"Overall survival (OS) at 3 years\"\\n12428,1,1,\"Overall Survival (OS) at 53 Months\"\\n12429,1,1,\"Overall Survival (OS) Duration\"\\n12430,1,1,\"Overall Survival (OS) During the Study\"\\n12431,1,1,\"Overall Survival (OS) For All Participants\"\\n12432,1,1,\"Overall Survival (OS) for All Participants\"\\n12433,1,1,\"Overall Survival (OS) For Participants With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ‚â•1%\"\\n12434,1,1,\"Overall Survival (OS) for the Full Analysis Population (FAP)\"\\n12435,1,1,\"Overall Survival (OS) from Advanced Diagnosis\"\\n12436,1,1,\"Overall Survival (OS) From Time of Randomization\"\\n12437,4,3,\"Overall Survival (OS) in All Participants\"\\n12438,1,1,\"Overall Survival (OS) in all participants\"\\n12439,2,2,\"Overall Survival (OS) in All Randomized Participants\"\\n12440,1,1,\"Overall survival (OS) in Arm A compared with Arm C (OS A vs. C)\"\\n12441,1,1,\"Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population\"\\n12442,1,1,\"Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population\"\\n12443,1,1,\"Overall survival (OS) in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC\"\\n12444,1,1,\"Overall survival (OS) in cisplatin-ineligible randomized participants\"\\n12445,1,1,\"Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)\"\\n12446,1,1,\"Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)\"\\n12447,1,1,\"Overall survival (OS) in IMDC intermediate- or poor-risk patients with previously untreated advanced RCC\"\\n12448,1,1,\"Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)\"\\n12449,1,1,\"Overall Survival (OS) in ITT Population\"\\n12450,1,1,\"Overall Survival (OS) in mITT Population\"\\n12451,1,1,\"Overall Survival (OS) in Modified Intent-To-Treat (mITT) Popluation\"\\n12452,2,1,\"Overall survival (OS) in overall population\"\\n12453,1,1,\"Overall survival (OS) in participants receiving cobolimab + dostarlimab + docetaxel relative to participants receiving docetaxel alone\"\\n12454,2,2,\"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ‚â•1%\"\\n12455,2,2,\"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ‚â•20%\"\\n12456,2,2,\"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ‚â•50%\"\\n12457,1,1,\"Overall Survival (OS) in Participants With Combined Positive Score (CPS) ‚â•10\"\\n12458,1,1,\"Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ‚â•10)\"\\n12459,1,1,\"Overall Survival (OS) in Participants With PD-L1 CPS‚â•1\"\\n12460,1,1,\"Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Positive (Tumor Proportion Score [TPS] ‚â•50%) Tumors\"\\n12461,1,1,\"Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ‚â•50%\"\\n12462,1,1,\"Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ‚â•20\"\\n12463,2,2,\"Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ‚â•10 (PD-L1 CPS ‚â•10)\"\\n12464,2,2,\"Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus\"\\n12465,1,1,\"Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo\"\\n12466,1,1,\"Overall survival (OS) in PD-L1 positive (>=1%) randomized participants by immunohistochemistry (IHC)\"\\n12467,1,1,\"Overall Survival (OS) in PD-L1 Positive Participants\"\\n12468,1,1,\"Overall Survival (OS) in Phase 2\"\\n12469,1,1,\"Overall Survival (OS) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status\"\\n12470,1,1,\"Overall survival (OS) in randomized participants with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ‚â• 1\"\\n12471,1,1,\"Overall Survival (OS) in the China Population\"\\n12472,1,1,\"Overall Survival (OS) in the Entire Study Population\"\\n12473,1,1,\"Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP\"\\n12474,1,1,\"Overall Survival (OS) in the Global Population\"\\n12475,1,1,\"Overall Survival (OS) in the ITT (Non-squamous) Population\"\\n12476,1,1,\"Overall Survival (OS) in the ITT Population\"\\n12477,1,1,\"Overall Survival (OS) in the ITT-WT Population\"\\n12478,1,1,\"Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup\"\\n12479,1,1,\"Overall survival (OS) in the MET Immunohistochemistry (IHC) 2+/3+ Participant Subgroup\"\\n12480,1,1,\"Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ‚â•1 Population\"\\n12481,1,1,\"Overall Survival (OS) in the Randomized Part of the Study\"\\n12482,1,1,\"Overall Survival (OS) in the TROP2 biomarker positive population\"\\n12483,1,1,\"Overall Survival (OS) investigation [ Time Frame: 2.5 years]\"\\n12484,1,1,\"Overall Survival (OS) Leiomyosarcoma (LMS)\"\\n12485,1,1,\"Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup\"\\n12486,1,1,\"Overall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)\"\\n12487,1,1,\"Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib\"\\n12488,1,1,\"Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participants\"\\n12489,1,1,\"Overall Survival (OS) post-Infusion\"\\n12490,6,2,\"Overall Survival (OS) Rate\"\\n12491,3,2,\"Overall survival (OS) rate\"\\n12492,1,1,\"Overall Survival (OS) Rate at 24 Months\"\\n12493,1,1,\"Overall Survival (OS) Rate at 9 Months\"\\n12494,1,1,\"Overall Survival (OS) Rate at Month 12\"\\n12495,1,1,\"Overall Survival (OS) Rate in All Randomized Participants\"\\n12496,1,1,\"Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)\"\\n12497,10,4,\"Overall Survival (OS) Time\"\\n12498,1,1,\"Overall survival (OS) time following treatment with Sym004 versus TAS-102.\"\\n12499,2,2,\"Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint\"\\n12500,1,1,\"Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS)\"\\n12501,1,1,\"Overall survival (OS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)\"\\n12502,1,1,\"Overall survival (OS) with targeted therapy + atezolizumab in cohorts 1 and 3 with anaplastic thyroid carcinoma (ATC)\"\\n12503,3,2,\"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death\"\\n12504,1,1,\"Overall Survival (OS)- Phase 3\"\\n12505,1,1,\"Overall Survival (OS): Number of Events\"\\n12506,1,1,\"Overall Survival (OS): PP-ITT\"\\n12507,1,1,\"Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ‚â•20 Mutations Per Megabase (Mut/Mb) Analysis Set\"\\n12508,1,1,\"Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy\"\\n12509,2,1,\"Overall Survival (Phase 2)\"\\n12510,1,1,\"Overall survival (Phase I dose expansion)\"\\n12511,3,2,\"Overall Survival (Phase II)\"\\n12512,13,4,\"Overall survival (Phase II)\"\\n12513,6,1,\"Overall survival (Phase III)\"\\n12514,1,1,\"Overall survival - assessed from the start of study drug until death in non-irradiation metastases in the rest of the body by routine imaging.\"\\n12515,1,1,\"Overall Survival - Days (PPS)\"\\n12516,1,1,\"Overall Survival - FAS\"\\n12517,1,1,\"Overall Survival - ITT Population\"\\n12518,1,1,\"Overall Survival - Overall Survival\"\\n12519,1,1,\"Overall Survival - PD-L1-Positive Subpopulation\"\\n12520,1,1,\"Overall Survival - Time to Event\"\\n12521,1,1,\"Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n12522,2,1,\"Overall survival after surgery.\"\\n12523,1,1,\"Overall survival among newly diagnosed DIPG and recurrent HGG patients\"\\n12524,1,1,\"Overall Survival as of 19 October 2015\"\\n12525,2,1,\"Overall Survival at 1 Year\"\\n12526,2,1,\"Overall Survival at 12 Months\"\\n12527,1,1,\"Overall survival at 12 months (OS-12)\"\\n12528,1,1,\"Overall Survival at 18 Months\"\\n12529,5,1,\"Overall Survival at 2 Years\"\\n12530,2,1,\"overall survival at 2-year interval\"\\n12531,2,1,\"overall survival at 5-year interval\"\\n12532,1,1,\"Overall survival based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n12533,1,1,\"Overall survival defined as the delay between randomization and death, all causes.\"\\n12534,1,1,\"Overall Survival Following Treatment With Tivantinib (ARQ 197) Plus Erlotinib Compared to Placebo Plus Erlotinib in Previously Treated Participants With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer\"\\n12535,1,1,\"Overall Survival for Patients in Combination Dose Expansion Cohorts\"\\n12536,1,1,\"Overall Survival for the Per Protocol (PP) Population\"\\n12537,1,1,\"Overall survival from the time of starting first-line therapy\"\\n12538,1,1,\"Overall Survival in All Participants\"\\n12539,1,1,\"Overall Survival in All Randomized Participants\"\\n12540,1,1,\"Overall survival in cachectic and non-cachectic patient\"\\n12541,1,1,\"Overall Survival in part II\"\\n12542,1,1,\"Overall Survival in Participants After a Dosage of CS-7017 Administered Twice Daily in Combination With Paclitaxel Administered Once Every 3 Weeks to Participants With Advanced Anaplastic Thyroid Cancer (ATC)\"\\n12543,1,1,\"Overall Survival in Participants in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)\"\\n12544,1,1,\"Overall Survival in Participants Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab\"\\n12545,1,1,\"Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel\"\\n12546,1,1,\"Overall Survival in Participants With PD-L1 CPS ‚â•1\"\\n12547,1,1,\"Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) ‚â•10\"\\n12548,1,1,\"Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I\"\\n12549,1,1,\"Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II\"\\n12550,1,1,\"Overall Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.\"\\n12551,1,1,\"Overall Survival of Groups by FDG Response at Day 56\"\\n12552,1,1,\"Overall Survival of Groups by FLT Response at Day 56\"\\n12553,1,1,\"Overall Survival of Patients With FDG CR/PR Versus FDG PD in Patients With CT SD at Day 56\"\\n12554,1,1,\"Overall Survival of Patients With FLT CR/PR Versus FLT PD in Patients With CT SD at Day 56\"\\n12555,1,1,\"Overall survival of the participants(OS)\"\\n12556,61,5,\"Overall survival rate\"\\n12557,1,1,\"Overall survival rate (Phase II)\"\\n12558,1,1,\"Overall Survival rate after receiving 4SCART infusion\"\\n12559,1,1,\"Overall survival rate after scheduled TACE-RT for HCC with PVTT\"\\n12560,3,2,\"Overall Survival Rate at 6 Months\"\\n12561,1,1,\"Overall survival rate in DTC treated advanced ovary cancer\"\\n12562,8,4,\"Overall Survival Time\"\\n12563,5,2,\"Overall Survival Time (OS)\"\\n12564,1,1,\"Overall survival time distribution\"\\n12565,22,7,\"Overall Survival(OS)\"\\n12566,20,3,\"Overall survival(OS)\"\\n12567,1,1,\"overall survival(OS) at 3 year\"\\n12568,1,1,\"Overall Survival, Defined as the Time from Randomization to Death from Any Cause\"\\n12569,1,1,\"Overall survival, OS\"\\n12570,1,1,\"Overall Survival-Part 2\"\\n12571,1,1,\"overall survival.\"\\n12572,1,1,\"Overall Survival: Cervical Cancer Population\"\\n12573,1,1,\"Overall Survival: Final Analysis\"\\n12574,1,1,\"Overall Survival: HPV+ Head and Neck Cancer Population\"\\n12575,1,1,\"Overall Survival: Second Interim Analysis (Co-primary Endpoint)\"\\n12576,1,1,\"Overall Survival: the time from randomization to death due to any cause\"\\n12577,1,1,\"Overall Survival: Time From Randomization to Date of Death\"\\n12578,2,1,\"Overall Survival: Time From Randomization to Death From Any Cause\"\\n12579,1,1,\"Overall Survival; Phase II\"\\n12580,1,1,\"Overall SurvivalÔºàOS)\"\\n12581,3,1,\"Overall SurvivalÔºàOSÔºâ\"\\n12582,4,2,\"Overall survivalÔºàOSÔºâ\"\\n12583,1,1,\"Overall suvival (OS)\"\\n12584,2,1,\"Overall tolerability\"\\n12585,1,1,\"Overall toxicity incidence as well as toxicity profiles as measured by dose level, patient, and primary disease site as measured by NCI CTCAE v3.0\"\\n12586,1,1,\"overall toxicity of drug combination\"\\n12587,6,5,\"Overall Tumor Response\"\\n12588,1,1,\"Overall Tumor Response (OR)\"\\n12589,1,1,\"Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]\"\\n12590,1,1,\"Overall tumor response according to radiologic assessments associated with clemizole HCl.\"\\n12591,1,1,\"Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT\"\\n12592,1,1,\"Overall tumor response per RECIST\"\\n12593,2,1,\"Overall Tumor Response Rate\"\\n12594,1,1,\"Overall Tumor Response Rate (ORR)\"\\n12595,1,1,\"Overall Tumor Response Rate as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Sum of Partial Responses (PR) and Complete Responses (CR).\"\\n12596,1,1,\"Overall tumor response rate by Response Evaluation Criteria in Solid Tumor (RECIST)\"\\n12597,1,1,\"Overall tumour Response Rate, according to RECIST v 1.\"\\n12598,2,1,\"Overallsurvival\"\\n12599,2,1,\"Overview of Adverse Events\"\\n12600,1,1,\"Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)\"\\n12601,1,1,\"Overview of Treatment-emergent Adverse Events (TEAEs)\"\\n12602,1,1,\"Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase\"\\n12603,1,1,\"Overview of Treatment-emergent All Causalities AEs in Expansion Phase\"\\n12604,1,1,\"Overview of Treatment-emergent, Treatment-related AEs in Escalation Phase\"\\n12605,1,1,\"Overview of Treatment-emergent, Treatment-related AEs in Expansion Phase\"\\n12606,1,1,\"OX-40 expression\"\\n12607,49,1,\"Oxygen saturation\"\\n12608,1,1,\"P1b: Proportion of subjects with Dose-Limiting Toxicity (DLT)\"\\n12609,1,1,\"P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTC\"\\n12610,1,1,\"Paclitaxel PK parameters\"\\n12611,1,1,\"Pain - EVA Scale. Scale from 1 to 10\"\\n12612,1,1,\"Pain as measured by brief pain inventory (BPI)\"\\n12613,3,1,\"Pain Duration\"\\n12614,1,1,\"Pain incongruence\"\\n12615,113,1,\"Pain Intensity\"\\n12616,256,1,\"Pain intensity\"\\n12617,52,1,\"pain intensity\"\\n12618,1,1,\"Pain intensity during the procedure\"\\n12619,1,1,\"Pain intensity rating (NRS)\"\\n12620,1,1,\"Pain level measured by VAS (self-evaluation) during the first care using standard treatment.\"\\n12621,1,1,\"Pain level measured by VAS (self-evaluation) during the second care using virtual reality\"\\n12622,1,1,\"Pain level measured by VAS (self-evaluation) during the third care using virtual reality or standard treatment\"\\n12623,1,1,\"Pain relief rate\"\\n12624,12,2,\"Pain response\"\\n12625,1,1,\"Pain response (McGill-Melzack Scale)\"\\n12626,1,1,\"Pain Response as Measured by VAS at 3 Months\"\\n12627,75,1,\"Pain Score\"\\n12628,130,1,\"Pain score\"\\n12629,1,1,\"Pain-related Distress\"\\n12630,1,1,\"pancreatic mass anatomopathological characterization\"\\n12631,1,1,\"PAR-4 increase\"\\n12632,1,1,\"Parameters derived from PET scan images to assess uptake in tumour lesions and normal tissues\"\\n12633,1,1,\"Parameters derived from PET scans for organs and tumour lesions\"\\n12634,1,1,\"Parameters of response: tumor measurement: Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n12635,1,1,\"Parent\\'s confidence in being able to talk with her child about the child\\'s cancer-related concerns (CASE Help Child Subscale)\"\\n12636,1,1,\"Parents\\' level of concern regarding the use of opioids for pain in their children.\"\\n12637,1,1,\"Parents\\' skills in helping their child cope and manage the toll of the parents\\' cancer (Connecting and Coping Subscale)\"\\n12638,4,1,\"Part 1\"\\n12639,1,1,\"Part 1 & Part 2: Frequency and severity of AEs\"\\n12640,1,1,\"Part 1 (1A and 1B): Number of treatment-emergent adverse events (TEAEs)\"\\n12641,1,1,\"Part 1 (1A and 1B): Recommended Dose for Expansion (RDE)\"\\n12642,1,1,\"Part 1 (a): Number of participants achieving dose limiting toxicity (DLTs)\"\\n12643,1,1,\"Part 1 (b,c,d): Number of participants achieving dose limiting toxicity (DLTs)\"\\n12644,1,1,\"Part 1 (dose escalation part): DLT occurrence\"\\n12645,1,1,\"Part 1 (Dose Escalation Phase) - Number of participants with abnormal assessments\"\\n12646,1,1,\"Part 1 (Dose Escalation Phase) - Number of participants with dose limiting toxicities\"\\n12647,1,1,\"Part 1 (Dose Escalation Phase) - Numbers of participants with adverse events, dose interruptions and modifications\"\\n12648,1,1,\"Part 1 (Dose Escalation): Number of dose-limiting toxicities (DLTs)\"\\n12649,1,1,\"Part 1 (e) and Part 2: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1\"\\n12650,1,1,\"Part 1 (f,g,h): Number of participants achieving dose limiting toxicity (DLTs)\"\\n12651,1,1,\"Part 1 (FP and TP Safety Run-in): Number of Participants who Discontinued Study Treatment Due to an AE\"\\n12652,1,1,\"Part 1 (FP and TP Safety Run-in): Number of Participants With Adverse Events (AEs)\"\\n12653,1,1,\"Part 1 (FP and TP Safety Run-in): Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n12654,1,1,\"Part 1 (Initial Dose Selection): characterize safety, tolerability, and pharmacokinetics following single dose oral administration of GSK2636771 and to determine the starting dose for Part 2.\"\\n12655,1,1,\"Part 1 (Monotherapy), Dose escalation: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period.\"\\n12656,1,1,\"Part 1 (Monotherapy), Dose expansion: Objective response (OR) defined as best overall response (BOR) of confirmed intratumoral immunotherapy complete response (itCR) or confirmed partial response (itPR)\"\\n12657,1,1,\"PART 1 (PHASE 1): Dose limiting toxicity (DLT) evaluation\"\\n12658,1,1,\"PART 1 (PHASE 1): To evaluate safety and tolerability of PBP1510\"\\n12659,1,1,\"Part 1 (Phase 1A) - Determination of the MTD and the RP2D of GRN-300 single-agent based on evaluation of the DLT in the study population.\"\\n12660,1,1,\"Part 1 (Phase 1A) - Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.\"\\n12661,1,1,\"Part 1 - Adverse Event (AE)\"\\n12662,1,1,\"Part 1 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite\"\\n12663,1,1,\"Part 1 - Incidence of Treatment Emergent Adverse Events (TEAEs)\"\\n12664,2,1,\"Part 1 - Maximum Tolerated Dose\"\\n12665,1,1,\"Part 1 - Maximum tolerated dose (MTD) of BTP-114 determined during the dose escalation phase of study based on number of patients experiencing a dose-limiting toxicity.\"\\n12666,1,1,\"Part 1 - Maximum tolerated dose (MTD) of SM08502 when combined with standard of care agents.\"\\n12667,1,1,\"Part 1 - Number of Participants Who Discontinue Study Treatment Due to an AE\"\\n12668,1,1,\"Part 1 - Number of Participants Who Experience at Least One Adverse Event (AE)\"\\n12669,1,1,\"Part 1 - Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)\"\\n12670,1,1,\"Part 1 - Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.3 during the study.\"\\n12671,1,1,\"Part 1 - Pharmacokinetic profile\"\\n12672,1,1,\"Part 1 - Plasma drug concentration\"\\n12673,1,1,\"Part 1 - Recommended Phase 2 Dose (RP2D) of BTP-114 based on the MTD, review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study.\"\\n12674,1,1,\"Part 1 - RP2D Of Fruquintinib In Combination With Tislelizumab\"\\n12675,1,1,\"Part 1 A and B: Number of Participants with Dose Limiting Toxicities (DLTs)\"\\n12676,1,1,\"Part 1 A and B: Number of Participants with Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs\"\\n12677,1,1,\"Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events\"\\n12678,1,1,\"Part 1 and 2: Number of Participants With Adverse Events (AEs)\"\\n12679,1,1,\"Part 1 and 2: Number of Participants With AEs by Severity\"\\n12680,2,1,\"Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n12681,1,1,\"Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n12682,1,1,\"Part 1 and 2: Pharmacokinetic profile of CriPec¬Æ docetaxel following IV infusion\"\\n12683,1,1,\"Part 1 and Part 2 - Number of dose interruptions, dose modifications, and discontinuations due to AEs\"\\n12684,1,1,\"Part 1 and Part 2 - Number of participants with clinically significant change from baseline in laboratory abnormalities\"\\n12685,1,1,\"Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR)\"\\n12686,1,1,\"Part 1 and Part 2, cohort 1 (expansion cohort - STS): Dose-limiting toxicity (DLT)\"\\n12687,1,1,\"Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs)\"\\n12688,1,1,\"Part 1 and Part 2- Number of participants with treatment-emergent adverse events (AEs)\"\\n12689,1,1,\"Part 1 and Part 2: Change from Baseline in arterial oxygen saturation\"\\n12690,1,1,\"Part 1 and Part 2: Change from Baseline in body weight\"\\n12691,1,1,\"Part 1 and Part 2: Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)\"\\n12692,2,1,\"Part 1 and Part 2: Frequency and severity of AEs\"\\n12693,3,1,\"Part 1 and Part 2: Incidence of Adverse Events (AEs)\"\\n12694,2,1,\"Part 1 and Part 2: Number of Participants with Adverse Events (AEs)\"\\n12695,1,1,\"Part 1 and Part 2: Number of participants with adverse events (AEs)\"\\n12696,7,3,\"Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability\"\\n12697,1,1,\"Part 1 and Part 2: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)\"\\n12698,1,1,\"Part 1 and Part 2: Number of Participants with AE\\'s by Severity\"\\n12699,2,2,\"Part 1 and Part 2: Number of Participants with AEs by Severity\"\\n12700,1,1,\"Part 1 and Part 2: Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value\"\\n12701,1,1,\"Part 1 and Part 2: Number of participants with any clinically significant clinical laboratory test value\"\\n12702,1,1,\"Part 1 and Part 2: Number of participants with any clinically significant vital sign value\"\\n12703,1,1,\"Part 1 and Part 2: Number of Participants with Dose Limiting Toxicity (DLT) of KB-0742\"\\n12704,1,1,\"Part 1 and Part 2: Number of Participants with Dose-limiting Toxicities (DLTs)\"\\n12705,1,1,\"Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events\"\\n12706,1,1,\"Part 1 and Part 3: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Budigalimab\"\\n12707,1,1,\"Part 1 and Part 3: Maximum Observed Serum Concentration (Cmax) of Budigalimab\"\\n12708,1,1,\"Part 1 and Part 3: Terminal Half-life (t1/2) of Budigalimab\"\\n12709,1,1,\"Part 1 and Part 3: Time to Cmax (Tmax) of Budigalimab\"\\n12710,1,1,\"Part 1 Arm 1: Dose-limiting toxicity\"\\n12711,1,1,\"Part 1 Arm 1: Treatment-emergent adverse events (AEs) and serious AEs (SAEs)\"\\n12712,1,1,\"Part 1 Arm 2: Dose-limiting toxicity\"\\n12713,1,1,\"Part 1 Arm 2: Treatment-emergent adverse events (AEs) and serious AEs (SAEs)\"\\n12714,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in 12-lead Electrocardiograms (ECGs)\"\\n12715,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n12716,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Laboratory Values\"\\n12717,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Vital Signs\"\\n12718,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Dose Interruption\"\\n12719,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Dose Limiting Toxicity (DLT)\"\\n12720,1,1,\"Part 1 Combination Therapy: Number of Patients who Experience a Dose Reduction\"\\n12721,1,1,\"Part 1 Combination Therapy: Number of Patients Who Experience a Serious Adverse Event (SAE)\"\\n12722,1,1,\"Part 1 Combination Therapy: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)\"\\n12723,1,1,\"Part 1 Combination Therapy: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above\"\\n12724,1,1,\"Part 1 Combination Therapy: Number of Patients with a Serious Adverse Event (SAE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above\"\\n12725,1,1,\"Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window\"\\n12726,1,1,\"Part 1 Dose Escalation: Incidence of treatment emergent adverse events (TEAEs)\"\\n12727,1,1,\"Part 1 Dose Escalation: Recommended Phase 2 Dose (RP2D) of IMP7068 monotherapy\"\\n12728,1,1,\"Part 1 Dose Escalation: Severity of treatment emergent adverse events (TEAEs), according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0\"\\n12729,1,1,\"Part 1 Dose Escalation: The Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001 for IV infusion in patients with over-expressing Folate Receptor Alpha tumors.\"\\n12730,1,1,\"Part 1 Maximum Tolerated Dose (MTD)\"\\n12731,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Clinically Significant Change from Baseline in 12-lead Electrocardiograms (ECGs)\"\\n12732,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n12733,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Laboratory Values\"\\n12734,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Vital Signs\"\\n12735,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Dose Interruption\"\\n12736,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Dose Limiting Toxicity (DLT)\"\\n12737,1,1,\"Part 1 Monotherapy: Number of Patients who Experience a Dose Reduction\"\\n12738,1,1,\"Part 1 Monotherapy: Number of Patients Who Experience a Serious Adverse Event (SAE)\"\\n12739,1,1,\"Part 1 Monotherapy: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)\"\\n12740,1,1,\"Part 1 Monotherapy: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above\"\\n12741,1,1,\"Part 1 Monotherapy: Number of Patients with a Serious Adverse Event (SAE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above\"\\n12742,1,1,\"Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator\"\\n12743,1,1,\"Part 1 Only: Serum Concentrations of Tarlatamab\"\\n12744,1,1,\"Part 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD)\"\\n12745,1,1,\"Part 1 Safety and tolerability of study treatment\"\\n12746,1,1,\"Part 1(dose-escalation part):Maximum Tolerated Dose (MTD)\"\\n12747,1,1,\"Part 1, 2, 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n12748,1,1,\"Part 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-931 Tablets in Reference to PIC\"\\n12749,1,1,\"Part 1, AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-931 Tablets in Reference to PIC\"\\n12750,1,1,\"Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-931 Tablets in Reference to PIC\"\\n12751,1,1,\"Part 1, Dose Escalation Component: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788\"\\n12752,1,1,\"Part 1, Dose Escalation Phase: Maximum Tolerated Dose (MTD)\"\\n12753,1,1,\"Part 1, Dose Escalation Phase: Recommendation Phase 2 Dose (RP2D)\"\\n12754,1,1,\"Part 1, Part 2, Part 3: Number of Participants with Adverse Events\"\\n12755,1,1,\"Part 1- Incidence of Grade 3 or 4 drug related adverse events\"\\n12756,1,1,\"Part 1-MTD\"\\n12757,1,1,\"Part 1.1 (Dose Escalation): AUC(0-inf) of STX-478\"\\n12758,1,1,\"Part 1.1 (Dose Escalation): AUC(0-t) of STX-478\"\\n12759,1,1,\"Part 1.1 (Dose Escalation): AUC(0-œÑ) of STX-478\"\\n12760,1,1,\"Part 1.1 (Dose Escalation): Change from baseline in ctDNA levels.\"\\n12761,1,1,\"Part 1.1 (Dose Escalation): Changes in circulating markers of glucose metabolism as assessed by changes in circulating glycosylated hemoglobin [HbA1c]\"\\n12762,1,1,\"Part 1.1 (Dose Escalation): Changes in circulating markers of glucose metabolism as assessed by circulating C-peptide.\"\\n12763,1,1,\"Part 1.1 (Dose Escalation): Changes in circulating markers of glucose metabolism as assessed by circulating fasting plasma glucose.\"\\n12764,1,1,\"Part 1.1 (Dose Escalation): Cmax of STX-478\"\\n12765,1,1,\"Part 1.1 (Dose Escalation): Frequency of TEAEs according to CTCAE v5.0 criteria.\"\\n12766,1,1,\"Part 1.1 (Dose Escalation): Incidence of TEAEs/SAEs ‚â• grade 2.\"\\n12767,1,1,\"Part 1.1 (Dose Escalation): Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)\"\\n12768,1,1,\"Part 1.1 (Dose Escalation): Objective response rate (ORR).\"\\n12769,1,1,\"Part 1.1 (Dose Escalation): Proportion of participants who experience at least 1 DLT during the first 28 days of treatment.\"\\n12770,1,1,\"Part 1: Akt inhibition\"\\n12771,1,1,\"Part 1: Area under the concentration-time curve (AUC)\"\\n12772,1,1,\"Part 1: Area under the curve (AUC) of PLX9486\"\\n12773,1,1,\"Part 1: Area under the plasma concentration time curve from time 0 to last time of quantifiable concentration (AUC [0-T]) of GSK525762 and trametinib\"\\n12774,1,1,\"Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.\"\\n12775,1,1,\"Part 1: Change from Baseline circulating protein or ribonucleic acid (RNA) biomarkers\"\\n12776,1,1,\"Part 1: Change from baseline in 12-lead electrocardiograms (ECG) assessment\"\\n12777,1,1,\"Part 1: Change from baseline in chemistry and hematology laboratory values\"\\n12778,1,1,\"Part 1: Change from baseline in echocardiogram (ECHO) or Multi Gated Acquisition (MUGA) scans assessment\"\\n12779,1,1,\"Part 1: Change from baseline in physical examination findings\"\\n12780,1,1,\"Part 1: Change from Baseline in the phosphorylation of extracellular signal-regulated kinase (pERK) levels\"\\n12781,2,1,\"Part 1: Change from baseline in vital signs\"\\n12782,1,1,\"Part 1: Change from Baseline transcriptional levels and mitogen activated protein (MAP) kinase signaling\"\\n12783,1,1,\"Part 1: Change in serum macrophage inhibitory cytokine-1 (MIC-1)\"\\n12784,1,1,\"Part 1: Combination 1: Incidence of Specified Toxicities\"\\n12785,1,1,\"Part 1: Composite of pharmacokinetic (PK) parameters following trametinib and palbociclib administration\"\\n12786,1,1,\"Part 1: Determination of the dose of itacitinib that is safe and tolerable in combination with erlotinib as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.\"\\n12787,1,1,\"Part 1: Determination of the Maximum Tolerated Dose (MTD) for WX-554 by the evaluation of DLTs in 3-6 patients at the end of 1 treatment cycle\"\\n12788,1,1,\"Part 1: Determination of the MTD\"\\n12789,1,1,\"Part 1: Determination of the Optimal Biological Dose (OBD) by the assessment of ERK phosphorylation (pERK) in peripheral blood mononuclear cells (PBMC) and assessment of TNF-alpha in plasma.\"\\n12790,1,1,\"Part 1: Determination of the RP2D\"\\n12791,1,1,\"Part 1: Disease control rate (DCR)\"\\n12792,1,1,\"Part 1: DLT\"\\n12793,1,1,\"Part 1: Dose Escalation Determine the MTD/maximum administered dose (MAD) and RP2D of SAR443216\"\\n12794,1,1,\"Part 1: Dose Escalation: Safety of SAR443216\"\\n12795,1,1,\"Part 1: Dose limiting toxicities (DLTs)\"\\n12796,1,1,\"Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Administered SC and Given in Combination With Pembrolizumab\"\\n12797,1,1,\"Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Given in Combination With Pembrolizumab\"\\n12798,1,1,\"Part 1: Duration of response (DOR)\"\\n12799,1,1,\"Part 1: Emergence of Mutant KRAS\"\\n12800,1,1,\"Part 1: Evaluate Safety [Toxicity, Serious Adverse Events (SAEs) and Reasons for Participant\\'s Discontinuation]\"\\n12801,1,1,\"Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events\"\\n12802,1,1,\"Part 1: Frequency and Severity of Dose-Limiting Toxicity (DLT)\"\\n12803,1,1,\"Part 1: Frequency and type of DLT\"\\n12804,1,1,\"Part 1: Frequency of dose-limiting toxicities (DLTs)\"\\n12805,1,1,\"Part 1: Half life (T1/2) of PLX9486\"\\n12806,1,1,\"Part 1: Incidence of Adverse Events [Safety and Tolerability]\"\\n12807,1,1,\"Part 1: Incidence of clinical laboratory abnormalities as a measure of safety and tolerability.\"\\n12808,1,1,\"Part 1: Incidence of DLTs\"\\n12809,1,1,\"Part 1: Incidence of Dose Limiting Toxicities\"\\n12810,1,1,\"Part 1: Incidence of Dose Limiting Toxicities [Tolerability]\"\\n12811,1,1,\"Part 1: Incidence of electrocardiogram (ECG) abnormalities as a measure of safety and tolerability.\"\\n12812,1,1,\"Part 1: Incidence of grade 3 or 4 adverse events (AEs) as a measure of safety and tolerability.\"\\n12813,1,1,\"Part 1: Incidence of study drug-related dose-limiting toxicity (DLT) at Cycle 1 and Cycle 2\"\\n12814,1,1,\"Part 1: Incidence of TEAEs\"\\n12815,1,1,\"Part 1: Incidence of treatment emergent adverse events\"\\n12816,1,1,\"Part 1: Incidence of treatment-emergent adverse events\"\\n12817,1,1,\"Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)\"\\n12818,1,1,\"Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]\"\\n12819,1,1,\"Part 1: Maximally Tolerated Dose (MTD) of KB-0742\"\\n12820,1,1,\"Part 1: Maximum concentration (Cmax)\"\\n12821,1,1,\"Part 1: Maximum concentration (Cmax) of PLX9486\"\\n12822,1,1,\"Part 1: Maximum observed plasma concentration (Cmax) of GSK525762 and trametinib\"\\n12823,1,1,\"Part 1: Maximum Tolerated Dose (MTD)\"\\n12824,1,1,\"Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib\"\\n12825,1,1,\"Part 1: Maximum Tolerated Dose (MTD) as Determined by Percentage of Participants with Dose Limiting Toxicities (DLTs)\"\\n12826,1,1,\"Part 1: Maximum tolerated dose (MTD) of Budigalimab\"\\n12827,1,1,\"Part 1: Maximum Tolerated Dose (MTD) of Capecitabine\"\\n12828,1,1,\"Part 1: Maximum Tolerated Dose (MTD) of JNJ-42756493\"\\n12829,1,1,\"Part 1: Maximum Tolerated Dose (MTD) of RO6874813\"\\n12830,1,1,\"Part 1: Maximum tolerated dose (MTD) of RX108\"\\n12831,1,1,\"Part 1: Maximum Tolerated Dose (MTD) of TAS-102\"\\n12832,1,1,\"Part 1: Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of RO5509554 as a Single Agent and in Combination With Paclitaxel\"\\n12833,1,1,\"Part 1: MK-2206 levels in tumor tissue\"\\n12834,1,1,\"Part 1: MTD\"\\n12835,1,1,\"Part 1: MTD of Bevacizumab\"\\n12836,1,1,\"Part 1: MTD of Erlotinib\"\\n12837,1,1,\"Part 1: Number of participants assigned to the every 2 weeks regimen with dose-limiting toxicities (DLTs)\"\\n12838,1,1,\"Part 1: Number of participants assigned to the every 3 weeks regimen with DLTs\"\\n12839,1,1,\"Part 1: Number of participants receiving concomitant medications\"\\n12840,1,1,\"Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events\"\\n12841,1,1,\"Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events\"\\n12842,1,1,\"Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events\"\\n12843,1,1,\"Part 1: Number of participants requiring dose modifications\"\\n12844,1,1,\"Part 1: Number of Participants who Discontinued Study Treatment Due to an AE\"\\n12845,1,1,\"Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)\"\\n12846,1,1,\"Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)\"\\n12847,1,1,\"Part 1: Number of Participants Who Experience a Treatment-related Adverse Event\"\\n12848,2,1,\"Part 1: Number of Participants Who Experience at Least One Adverse Event (AE)\"\\n12849,1,1,\"Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)\"\\n12850,1,1,\"Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs)\"\\n12851,1,1,\"Part 1: Number of Participants With a Dose Limiting Toxicity (DLT)\"\\n12852,2,2,\"Part 1: Number of Participants with a Dose-limiting Toxicity\"\\n12853,1,1,\"Part 1: Number of participants with abnormal clinical chemistry parameters\"\\n12854,2,1,\"Part 1: Number of participants with abnormal electrocardiogram (ECG) parameters\"\\n12855,2,2,\"Part 1: Number of Participants With Abnormal Findings for Electrocardiogram (ECG) Parameters\"\\n12856,1,1,\"Part 1: Number of Participants With Abnormal Findings Undergoing Physical Examinations\"\\n12857,1,1,\"Part 1: Number of participants with abnormal hematology parameters\"\\n12858,1,1,\"Part 1: Number of participants with abnormal physical examination.\"\\n12859,1,1,\"Part 1: Number of participants with abnormal thyroid function\"\\n12860,1,1,\"Part 1: Number of participants with abnormal urine parameters\"\\n12861,2,1,\"Part 1: Number of participants with abnormal vital signs\"\\n12862,1,1,\"Part 1: Number of participants with abnormality in clinical chemistry parameters\"\\n12863,1,1,\"Part 1: Number of participants with abnormality in electrocardiogram (ECG) parameters\"\\n12864,1,1,\"Part 1: Number of participants with abnormality in hematology parameters\"\\n12865,3,1,\"Part 1: Number of Participants with Adverse Events (AEs)\"\\n12866,2,1,\"Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n12867,1,1,\"Part 1: Number of participants with adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, treatment emergent adverse events (TEAEs), TEAEs leading to death and immune-related adverse events (irAEs)\"\\n12868,1,1,\"Part 1: Number of Participants With AEs by Severity Grades\"\\n12869,1,1,\"Part 1: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the Study\"\\n12870,1,1,\"Part 1: Number of participants with any adverse events (AEs) and serious adverse events (SAEs)\"\\n12871,1,1,\"Part 1: Number of Participants With Any Decrease From Baseline in Vital Sign According to Markedly Abnormal Criteria\"\\n12872,1,1,\"Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters\"\\n12873,1,1,\"Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters\"\\n12874,1,1,\"Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)\"\\n12875,1,1,\"Part 1: Number of Participants With Any Increase From Baseline in Corrected QT Interval Using Fredericia\\'s Formula (QTcF) According to Markedly Abnormal Criteria\"\\n12876,1,1,\"Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)\"\\n12877,1,1,\"Part 1: Number of Participants With Change From Baseline in Chemistry Parameters With Respect to the Normal Range\"\\n12878,1,1,\"Part 1: Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal Range\"\\n12879,1,1,\"Part 1: Number of Participants With Change in Clinical Chemistry Toxicity Grade From Baseline\"\\n12880,1,1,\"Part 1: Number of Participants With Change in Hematology Toxicity Grade From Baseline\"\\n12881,1,1,\"Part 1: Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG) findings, Eastern Cooperative Oncology Group (ECOG) status, physical examination and use of concomitant medications\"\\n12882,1,1,\"Part 1: Number of participants with clinically significant changes in vital signs, physical examination and laboratory parameters\"\\n12883,1,1,\"Part 1: Number of Participants with Clinically Significant physical examinations, electrocardiograms (ECGs), and laboratory assessments\"\\n12884,1,1,\"Part 1: Number of Participants With Dose Interruptions\"\\n12885,4,2,\"Part 1: Number of Participants With Dose Limiting Toxicities (DLT)\"\\n12886,7,4,\"Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n12887,3,2,\"Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)\"\\n12888,2,1,\"Part 1: Number of participants with dose limiting toxicities (DLTs)\"\\n12889,4,2,\"Part 1: Number of Participants With Dose Limiting Toxicity (DLT)\"\\n12890,1,1,\"Part 1: Number of participants with dose limiting toxicity (DLT)\"\\n12891,1,1,\"Part 1: Number of Participants With Dose Reduction or Delays\"\\n12892,2,1,\"Part 1: Number of Participants With Dose Reductions\"\\n12893,1,1,\"Part 1: Number of Participants With Dose Reductions or Delay\"\\n12894,1,1,\"Part 1: Number of Participants With Dose-limiting Toxicities\"\\n12895,2,1,\"Part 1: Number of participants with dose-limiting toxicities\"\\n12896,1,1,\"Part 1: Number of Participants With Dose-limiting Toxicities (DLT)\"\\n12897,1,1,\"Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)\"\\n12898,1,1,\"Part 1: Number of participants with dose-limiting toxicities (DLTs)\"\\n12899,2,1,\"Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)\"\\n12900,1,1,\"Part 1: Number of Participants With Dose-limiting Toxicity (DLT)\"\\n12901,4,4,\"Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)\"\\n12902,3,2,\"Part 1: Number of Participants with Dose-limiting Toxicity (DLT)\"\\n12903,1,1,\"Part 1: Number of participants with dose-limiting toxicity at each dose level\"\\n12904,1,1,\"Part 1: Number of participants with immune related AEs of interest\"\\n12905,1,1,\"Part 1: Number of Participants With Increase From Baseline in Vital Signs According to Markedly Abnormal Criteria\"\\n12906,1,1,\"Part 1: Number of Participants With Non-Serious Adverse Events (Non-SAEs) and SAEs\"\\n12907,1,1,\"Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT)\"\\n12908,2,2,\"Part 1: Number of Participants with One or More Adverse Events\"\\n12909,1,1,\"Part 1: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs\"\\n12910,1,1,\"Part 1: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)\"\\n12911,1,1,\"Part 1: Number of participants with serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)\"\\n12912,1,1,\"Part 1: Number of Participants With TEAEs Leading to Discontinuation\"\\n12913,1,1,\"Part 1: Number of Participants With TEAEs Leading to Dose Reductions or Dose Delays\"\\n12914,1,1,\"Part 1: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs\"\\n12915,1,1,\"Part 1: Number of participants with treatment emergent AEs (TEAEs)\"\\n12916,1,1,\"Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (STEAEs)\"\\n12917,1,1,\"Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature\"\\n12918,1,1,\"Part 1: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters\"\\n12919,1,1,\"Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)\"\\n12920,1,1,\"Part 1: Number of Participants With Worst Case Change From Baseline in Hematology Parameters\"\\n12921,1,1,\"Part 1: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant Electrocardiogram (ECG) Findings\"\\n12922,1,1,\"Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria\"\\n12923,1,1,\"Part 1: Number of Participants Withdrawn Due to AEs\"\\n12924,1,1,\"Part 1: Number of Participants Withdrawn Due to Toxicities\"\\n12925,1,1,\"Part 1: Number of patients with Dose Limiting Toxicities (DLTs) within the first cycle of treatment\"\\n12926,1,1,\"Part 1: Number of patients with Dose-Limiting Toxicity (DLT) at each dose level studied.\"\\n12927,1,1,\"Part 1: Number of patients with treatment-emergent adverse events as assessed by CTCAE v5.0\"\\n12928,1,1,\"Part 1: Number of subjects with adverse events (AEs)\"\\n12929,1,1,\"Part 1: Number of subjects with adverse events (AEs) and serious adverse events (SAEs)\"\\n12930,1,1,\"Part 1: Number of subjects with anti-cancer activity\"\\n12931,1,1,\"Part 1: Number of subjects with dose limiting toxicities (DLT) as a measure of safety\"\\n12932,2,1,\"Part 1: Number of Subjects with Dose Limiting Toxicities (DLTs)\"\\n12933,1,1,\"Part 1: Number of Treatment Emergent Adverse Events (TEAEs) as assessed by CTAE v.4.0\"\\n12934,1,1,\"Part 1: Number of treatment-emergent adverse events in participants receiving single-agent INCB001158\"\\n12935,1,1,\"Part 1: Number of treatment-emergent adverse events in participants receiving single-agent INCMGA00012\"\\n12936,1,1,\"Part 1: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator\"\\n12937,1,1,\"Part 1: Observation of DLT\"\\n12938,1,1,\"Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration\"\\n12939,1,1,\"Part 1: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period (Cycle 1, i.e., 21 days after the first dose) during the dose escalation\"\\n12940,1,1,\"Part 1: Overall response rate (ORR)\"\\n12941,1,1,\"Part 1: Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n12942,1,1,\"Part 1: Percentage of Participants Reporting One or More Dose-Limiting Toxicities (DLTs) Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n12943,1,1,\"Part 1: Percentage of Participants Who Discontinued Study Drug Due to an AE - All Participants\"\\n12944,1,1,\"Part 1: Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0)\"\\n12945,1,1,\"Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants\"\\n12946,1,1,\"Part 1: Percentage of Participants Whose Best Confirmed Response is Partial Response (PR) or Complete Response (CR)\"\\n12947,1,1,\"Part 1: Percentage of Participants With Adverse Events (AEs)\"\\n12948,1,1,\"Part 1: Percentage of Participants With Dose-Limiting Toxicity (DLT)\"\\n12949,1,1,\"Part 1: PRD of Bevacizumab for Part 2\"\\n12950,1,1,\"Part 1: PRD of Erlotinib for Part 2\"\\n12951,1,1,\"Part 1: Pre-dose (trough) concentration at the end of a dosing interval (Ctau) of GSK525762 and trametinib\"\\n12952,1,1,\"Part 1: Preliminary Recommended Dose (PRD) of Capecitabine for Part 2\"\\n12953,1,1,\"Part 1: Proportion of subjects with Dose-Limiting Toxicity (DLT)\"\\n12954,1,1,\"Part 1: Recommended Dose (RD) of E7090 in Combination With Other Anticancer Agents\"\\n12955,1,1,\"Part 1: Recommended Part 2 Dose of Talazoparib\"\\n12956,1,1,\"Part 1: Recommended Phase 2 Dose (RP2D) as Determined by Percentage of Participants with DLTs and Cumulative Safety\"\\n12957,1,1,\"Part 1: Recommended Phase 2 Dose (RP2D) of KB-0742\"\\n12958,1,1,\"Part 1: Recommended Phase 2 Dose (RP2D) of RO6874813\"\\n12959,1,1,\"Part 1: Recommended Phase 2 Dose (RPTD) for Budigalimab\"\\n12960,1,1,\"Part 1: Recommended phase 2 doses (RP2Ds)\"\\n12961,1,1,\"Part 1: RP2D\"\\n12962,1,1,\"Part 1: Safety and tolerability in continuation as determined by the number of patients with adverse events, serious adverse events, dose reductions or delays, withdrawals due to toxicities and changes in lab values and vital signs from baseline\"\\n12963,1,1,\"Part 1: Safety and tolerability in first 4 weeks as determined by the number of patients with adverse events, serious adverse events, dose reductions or delays, withdrawals due to toxicities and changes in lab values and vital signs from baseline\"\\n12964,1,1,\"Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG)\"\\n12965,1,1,\"Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs)\"\\n12966,1,1,\"Part 1: Safety assessment as assessed by change from baseline in laboratory values\"\\n12967,1,1,\"Part 1: Safety assessment as assessed by echocardiogram\"\\n12968,1,1,\"Part 1: Safety assessment as assessed by eye examination\"\\n12969,1,1,\"Part 1: Safety assessment as assessed by urine protein to creatinine (UPC) ratio\"\\n12970,1,1,\"Part 1: Safety assessment as assessed by vital signs\"\\n12971,1,1,\"Part 1: Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)\"\\n12972,1,1,\"Part 1: The detection of new mutations from circulating tumor DNA (ctDNA) analyses or change in the frequency of mutations found in archival tumor Whole Exome Sequencing (WES) analyses.\"\\n12973,1,1,\"Part 1: The incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs). Part 2: Overall survival (OS)\"\\n12974,1,1,\"Part 1: Time to Cmax (Tmax) of GSK525762 and trametinib\"\\n12975,1,1,\"Part 1: Time to peak concentration (Tmax) of PLX9486\"\\n12976,1,1,\"Part 1: To determine the DLTs and MTD of the combination of ADH300004 and 5 FU administered orally in a weekly regimen, for 3 weeks with 1 week rest per cycle, in subjects with incurable solid tumors\"\\n12977,1,1,\"Part 1: To determine the maximum tolerated dose (MTD) of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin. Measured by incidence of Dose Limiting Toxicity.\"\\n12978,1,1,\"part 1: to determine the maximum tolerated dose (MTD) of single-agent oral CEP-9722 administered daily to patients with advanced or metastatic solid tumors, as defined by first-cycle dose-limiting toxicities (DLTs)\"\\n12979,1,1,\"Part 1: To evaluate the effect of CYP3A4 inhibition by itraconazole on the steady-state pharmacokinetics (PK) of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, AUC0-t, Cmax\"\\n12980,1,1,\"Part 1: To identify the recommended Phase 2 dose (RP2D) of PLX9486 for further evaluation in dose extension\"\\n12981,1,1,\"Part 1:Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)\"\\n12982,1,1,\"Part 1:Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE)\"\\n12983,1,1,\"Part 1:Number of Participants With Abnormal Values for Vital Signs\"\\n12984,1,1,\"Part 1:Number of Participants With Critical Changes in Values of Vital Signs in Response to Drug\"\\n12985,1,1,\"Part 1:Number of subjects with DLT in each dose group within 2 cycles (42 days) after the first trial administration\"\\n12986,1,1,\"Part 1:Recommended Phase 2 Dose (RP2D)\"\\n12987,1,1,\"Part 1A - Maximum Tolerated Dose (MTD)\"\\n12988,1,1,\"Part 1a - pharmacokinetics - AUC\"\\n12989,1,1,\"Part 1a - pharmacokinetics - Cmax\"\\n12990,1,1,\"Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)\"\\n12991,1,1,\"Part 1A and 1B: Number of participants with Adverse Events (AEs)\"\\n12992,1,1,\"Part 1A and 1B: Number of participants with Dose Limiting Toxicities (DLTs)\"\\n12993,1,1,\"Part 1A and 1B: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period (28 Days)\"\\n12994,1,1,\"Part 1A and Part 1B: AUC0-24 of SM08502 and SM08955 following single dose administration of SM08502\"\\n12995,1,1,\"Part 1A and Part 1B: AUC0-24,ss of SM08502 and SM08955 following repeat dose administration of SM08502\"\\n12996,1,1,\"Part 1A and Part 1B: AUClast of SM08502 and SM08955 following single dose administration of SM08502\"\\n12997,1,1,\"Part 1A and Part 1B: Cmax of SM08502 and its metabolite (SM08955) following single dose administration of SM08502\"\\n12998,1,1,\"Part 1A and Part 1B: Cmax,ss of SM08502 and SM08955 following repeat dose administration of SM08502\"\\n12999,1,1,\"Part 1A and Part 1B: Cmin,ss of SM08502 and SM08955 following repeat dose administration of SM08502\"\\n13000,1,1,\"Part 1A and Part 1B: tmax of SM08502 and SM08955 following single dose administration of SM08502\"\\n13001,1,1,\"Part 1A and Part 1B: tmax,ss of SM08502 and SM08955 following repeat dose administration of SM08502\"\\n13002,1,1,\"Part 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute\\'s Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03\"\\n13003,1,1,\"Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters\"\\n13004,1,1,\"Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs\"\\n13005,1,1,\"Part 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities\"\\n13006,1,1,\"Part 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 1\"\\n13007,1,1,\"Part 1A Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Who Experienced a Treatment Related Adverse Events (TRAE) According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03\"\\n13008,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameter: lactic acid dehydrogenase [LDH] (units per liter)\"\\n13009,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: albumin (grams per day)\"\\n13010,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: aspartate aminotransferase [AST], alanine aminotransferase (ALT), alkaline phosphatase [ALP] (international units per liter)\"\\n13011,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: blood urea nitrogen [BUN], creatinine, glucose, potassium, sodium, calcium (micromoles per liter)\"\\n13012,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: chloride, bicarbonate (millimoles per liter)\"\\n13013,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in blood pressure (systolic and diastolic) (millimeters of mercury)\"\\n13014,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in body temperature (degrees celsius)\"\\n13015,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in electrocardiogram (ECG) parameters: PR interval, QRS interval, QT interval, QTcF (milliseconds)\"\\n13016,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in hematology parameter: hematocrit (proportion of red blood cells in blood)\"\\n13017,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in hematology parameter: hemoglobin [Hb] (grams per liter)\"\\n13018,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in hematology parameter: red blood cells [RBC] count (trillion cells per liter)\"\\n13019,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelet count (cells/microliter)\"\\n13020,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in pulse rate (beats per minute)\"\\n13021,1,1,\"Part 1A, Part 1B and Part 2: Change from baseline in respiratory rate (breaths per minute)\"\\n13022,1,1,\"Part 1A, Part 1B and Part 2: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0\"\\n13023,1,1,\"Part 1A, Part 1B: Maximum tolerated dose (MTD) of SM08502 based on the frequency and severity of dose-limiting toxicities (DLTs)\"\\n13024,1,1,\"Part 1a, Part 1c and 2B: Number of participants experiencing DLT\"\\n13025,1,1,\"Part 1A: Change from baseline in partial thromboplastin time [PTT] (seconds)\"\\n13026,1,1,\"Part 1A: Change from baseline in prothrombin time [PT] (seconds)\"\\n13027,1,1,\"Part 1A: Change from baseline in urinalysis parameter: clarity\"\\n13028,1,1,\"Part 1A: Change from baseline in urinalysis parameter: glucose (millimole per liter)\"\\n13029,1,1,\"Part 1A: Change from baseline in urinalysis parameter: ketones (millimoles per liter)\"\\n13030,1,1,\"Part 1A: Change from baseline in urinalysis parameter: leukocytes (counts per high power field)\"\\n13031,1,1,\"Part 1A: Change from baseline in urinalysis parameter: nitrite\"\\n13032,1,1,\"Part 1A: Change from baseline in urinalysis parameter: occult blood (10^9 cells per liter)\"\\n13033,1,1,\"Part 1A: Change from baseline in urinalysis parameter: protein\"\\n13034,1,1,\"Part 1A: Change from baseline in urinalysis parameter: specific gravity (ratio)\"\\n13035,1,1,\"Part 1A: Change from baseline in urinalysis parameter: urine pH\"\\n13036,1,1,\"Part 1A: Number of Participants With Clinical Significant Changes in Vital Signs, Laboratory Parameters, and 12-Lead Electrocardiogram (ECG) Findings\"\\n13037,1,1,\"Part 1A: Number of participants with dose limiting toxicities (DLTs)\"\\n13038,1,1,\"Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)\"\\n13039,1,1,\"Part 1a: Number of subjects with DLT in each dose group within 1 cycles (21 days) after the first drug administration\"\\n13040,1,1,\"Part 1A: Occurrence of Adverse Events (AEs) and Treatment-Related AEs\"\\n13041,1,1,\"Part 1A: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period\"\\n13042,1,1,\"Part 1A: The proportion of patients experiencing dose limiting toxicity (DLT) events\"\\n13043,1,1,\"Part 1A: To determine the safety, tolerability and recommended Phase II dose of GSK1120212 and GSK2141795 administered in combination orally, once daily continuously\"\\n13044,1,1,\"Part 1B - Number of Participants With Response to Treatment as a Measure of Preliminary Efficacy\"\\n13045,1,1,\"Part 1b - pharmacokinetics - AUC\"\\n13046,1,1,\"Part 1b - pharmacokinetics - Cmax\"\\n13047,1,1,\"Part 1b - pharmacokinetics - Tmax\"\\n13048,1,1,\"Part 1B: Number of Participants With Clinical Significant Changes in Vital Signs, Laboratory Parameters, and 12-Lead Electrocardiogram (ECG) Findings\"\\n13049,1,1,\"Part 1B: Number of participants with DLTs\"\\n13050,1,1,\"Part 1B: Occurrence of Adverse Events (AEs) and Treatment-Related AEs\"\\n13051,1,1,\"Part 1b: ORR\"\\n13052,1,1,\"Part 1B:To determine the safety, tolerability and recommended Phase II dose of GSK1120212 and GSK2141795 administered in combination with an alternate schedule (i.e., at least one agent is dosed intermittently)\"\\n13053,1,1,\"Part 1Ôºàdose-escalation partÔºâ: Maximum Tolerated Dose (MTD)\"\\n13054,1,1,\"Part 1ÔºöIncidence of dose limiting toxicities (DLTs)\"\\n13055,1,1,\"Part 1ÔºöMaximum Tolerated Dose (MTD) and/or Biological effective dose (BED) based on safety, tolerability, PK profile and preliminary efficacy data\"\\n13056,1,1,\"Part 1ÔºöNumber, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0\"\\n13057,4,1,\"Part 2\"\\n13058,1,1,\"Part 2 (2A & 2B): Number of treatment-emergent adverse events\"\\n13059,1,1,\"Part 2 (2A & B): RDE in combination with INCMGA00012\"\\n13060,1,1,\"Part 2 (Combination Therapy), Dose escalation: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period.\"\\n13061,1,1,\"Part 2 (Dose Escalation): characterize safety, tolerability, and pharmacokinetics following single- and repeat-dose oral administration of GSK2636771 and to determine the recommended dose and schedule for Part 3.\"\\n13062,1,1,\"Part 2 (Dose Expansion Phase) - Number of participants with overall survival\"\\n13063,1,1,\"Part 2 (Dose Expansion Phase) - Number of participants with partial response data\"\\n13064,1,1,\"Part 2 (Dose Expansion Phase) - Number of participants with progression-free survival\"\\n13065,1,1,\"Part 2 (Dose Expansion): Arm 1 (mCRPC only): Number of patients with change from Baseline in prostate-specific antigen (PSA) at the end of Cycles 3 and 6\"\\n13066,1,1,\"Part 2 (expansion part #1): Objective response rate after 3 months\"\\n13067,1,1,\"Part 2 (expansion part):Overall Response Rate\"\\n13068,1,1,\"Part 2 (Main Study): Overall Survival (OS) in all Participants\"\\n13069,1,1,\"Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants\"\\n13070,1,1,\"Part 2 (Phase 1B) - Determination of the MTD and the RP2D of GRN-300 with paclitaxel based on evaluation of the DLT in the study population\"\\n13071,1,1,\"Part 2 (Phase 1B) - Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.\"\\n13072,1,1,\"PART 2 (PHASE 2a): To assess the efficacy of PBP1510 in combination with gemcitabine\"\\n13073,1,1,\"PART 2 (PHASE 2a): To establish safety of PBP1510 in combination with gemcitabine\"\\n13074,1,1,\"Part 2 - Change in tumour size from baseline using RECIST 1.1 and mRECIST in patients treated with MTL-CEBPA in combination with sorafenib\"\\n13075,1,1,\"Part 2 - Dose Escalation Cohort: Pharmacokinetic testing\"\\n13076,1,1,\"Part 2 - Duration of response (DOR) measured from the date of first CR or PR until the first date of progressive disease or death from any cause.\"\\n13077,1,1,\"Part 2 - Incidence of Safety and tolerability of SM08502\"\\n13078,1,1,\"Part 2 - INRC\"\\n13079,1,1,\"Part 2 - Objective response rate\"\\n13080,1,1,\"Part 2 - Objective Response Rate (ORR)\"\\n13081,1,1,\"Part 2 - Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator\"\\n13082,1,1,\"Part 2 - Progression Free Survival (PFS)\"\\n13083,1,1,\"Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.\"\\n13084,1,1,\"Part 2 - Proportion of patients whose disease is controlled (DCR) using RECIST, Version 1.1 or PCWG2 criteria.\"\\n13085,1,1,\"Part 2 - Proportion of patients with an objective response (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 or the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria.\"\\n13086,1,1,\"Part 2 - RANO\"\\n13087,1,1,\"Part 2 - RECIST\"\\n13088,1,1,\"Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D)\"\\n13089,1,1,\"Part 2 Arm 1: Remission rate\"\\n13090,1,1,\"Part 2 Arm 2: Overall response rate\"\\n13091,1,1,\"Part 2 Cohorts D4 and H: Objective Response Rate (ORR)\"\\n13092,1,1,\"Part 2 Cohorts G+ and G-: Objective Response Rate (ORR)\"\\n13093,1,1,\"Part 2 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in 12-lead Electrocardiograms (ECGs)\"\\n13094,1,1,\"Part 2 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status\"\\n13095,1,1,\"Part 2 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Laboratory Values\"\\n13096,1,1,\"Part 2 Combination Therapy: Number of Patients who Experience a Clinically Significant Change from Baseline in Vital Signs\"\\n13097,1,1,\"Part 2 Combination Therapy: Number of Patients who Experience a Dose Interruption\"\\n13098,1,1,\"Part 2 Combination Therapy: Number of Patients who Experience a Dose Reduction\"\\n13099,1,1,\"Part 2 Combination Therapy: Number of Patients Who Experience a Serious Adverse Event (SAE)\"\\n13100,1,1,\"Part 2 Combination Therapy: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)\"\\n13101,1,1,\"Part 2 Combination Therapy: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above\"\\n13102,1,1,\"Part 2 Combination Therapy: Number of Patients with a Serious Adverse Event (SAE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above\"\\n13103,1,1,\"Part 2 Dose Expansion: Overall Response Rate (ORR)\"\\n13104,1,1,\"Part 2 Dose Expansion: To determine overall response rate (ORR) (complete response [CR] + partial response [PR]) of ELU001 for IV infusion in patients with over-expressing Folate Receptor Alpha tumors, per RECIST v1.1.\"\\n13105,1,1,\"Part 2 Monotherapy: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n13106,1,1,\"Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)\"\\n13107,1,1,\"Part 2 Only: Objective Response Rate (ORR)\"\\n13108,1,1,\"Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS)\"\\n13109,1,1,\"Part 2 Overall Response Rate (ORR)\"\\n13110,1,1,\"Part 2, Cohort 2 (phase IIa - melanoma): Disease control (DC) according to RECIST 1.1\"\\n13111,1,1,\"Part 2, Dose Expansion Phase: Overall Response Rate (ORR)\"\\n13112,1,1,\"Part 2, Expansion Cohort 3: Intracranial ORR (iORR) Assessed by Independent Review Committee (IRC)\"\\n13113,1,1,\"Part 2, Expansion Cohort 6: Confirmed ORR Assessed by IRC\"\\n13114,1,1,\"Part 2, Expansion Cohorts 1, 2, 4, 5 and 7: Confirmed Objective Response Rate (ORR) Assessed by the Investigator\"\\n13115,1,1,\"Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n13116,1,1,\"Part 2-RANO\"\\n13117,1,1,\"Part 2-RECIST\"\\n13118,1,1,\"Part 2: (Combination Cohorts) Determine MTD\"\\n13119,1,1,\"Part 2: (Combination Cohorts) Determine RP2D\"\\n13120,1,1,\"Part 2: (Combination Cohorts) Incidence, type, and severity of AEs and SAEs\"\\n13121,1,1,\"Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.\"\\n13122,1,1,\"Part 2: AUC [0-T] of GSK525762 and trametinib\"\\n13123,1,1,\"Part 2: Change from Baseline circulating protein or RNA biomarkers\"\\n13124,1,1,\"Part 2: Change from Baseline in the pERK levels\"\\n13125,1,1,\"Part 2: Change from baseline in tumor biomarkers\"\\n13126,1,1,\"Part 2: Change from Baseline transcriptional levels and MAP kinase signaling\"\\n13127,1,1,\"Part 2: Clinical response\"\\n13128,1,1,\"Part 2: Cmax of GSK525762 and trametinib\"\\n13129,1,1,\"Part 2: Combination 1: Objective Response Rate (ORR)\"\\n13130,1,1,\"Part 2: Combination 2: Composite Response Rate (RR)\"\\n13131,1,1,\"Part 2: Combinations 1: Incidence of Adverse Events (AEs)\"\\n13132,1,1,\"Part 2: Combinations 1: Severity of Adverse Events\"\\n13133,1,1,\"Part 2: Compare Progression-Free Survival (PFS) Between the 2 Treatment Arms Through the Assessment of Tumor Response\"\\n13134,1,1,\"Part 2: Concordance between WES analyses of serial tumor biopsies.\"\\n13135,1,1,\"Part 2: Confirmation of recommended RP2D and schedule of SB 11285 in combination with atezolizumab\"\\n13136,1,1,\"Part 2: Ctau of GSK525762 and trametinib\"\\n13137,1,1,\"Part 2: DCR\"\\n13138,1,1,\"Part 2: Disease Control Rate (DCR) based on RECIST 1.1/RECIL 2017\"\\n13139,1,1,\"Part 2: Documented, Confirmed Objective Response (OR)\"\\n13140,1,1,\"Part 2: Dose expansion - Objective response rate (ORR) as assessed by Central Imaging Review\"\\n13141,1,1,\"Part 2: Dose Expansion Duration of response (DoR) of SAR443216 in all participants.\"\\n13142,1,1,\"Part 2: Dose Expansion Objective response rate (ORR) of SAR443216 in all participants\"\\n13143,1,1,\"Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested\"\\n13144,1,1,\"Part 2: Duration of Response (DOR)\"\\n13145,1,1,\"Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators\"\\n13146,1,1,\"Part 2: Duration of response (DoR) based on RECIST 1.1/RECIL 2017\"\\n13147,1,1,\"Part 2: Duration of Response (DOR)- Efficacy\"\\n13148,1,1,\"Part 2: GBM cohort: Six-month progression free survival (PFS) rate\"\\n13149,1,1,\"Part 2: Incidence of adverse events (AEs) and serious adverse events (SAEs).\"\\n13150,1,1,\"Part 2: Incidence of adverse events [Safety and Tolerability]\"\\n13151,1,1,\"Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose (MTD) of CriPec¬Æ docetaxel as defined in Part 1\"\\n13152,1,1,\"Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose (MTD) of CriPec¬Æ docetaxel as defined in Part 1\"\\n13153,1,1,\"Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose (MTD) of CriPec¬Æ docetaxel as defined in Part 1.\"\\n13154,1,1,\"Part 2: Incidence of TEAEs\"\\n13155,1,1,\"Part 2: Incidence of treatment emergent adverse events\"\\n13156,1,1,\"Part 2: Length of Time for Progression-free Survival (PFS)\"\\n13157,1,1,\"Part 2: Long term safety assessed as change from baseline in laboratory values\"\\n13158,1,1,\"Part 2: Long term safety assessment as assessed by 12-lead ECG\"\\n13159,1,1,\"Part 2: Long term safety assessment as assessed by AEs and SAEs\"\\n13160,1,1,\"Part 2: Long term safety assessment as assessed by echocardiogram\"\\n13161,1,1,\"Part 2: Long term safety assessment as assessed by eye examination\"\\n13162,1,1,\"Part 2: Long term safety assessment as assessed by UPC ratio\"\\n13163,1,1,\"Part 2: Long term safety assessment as assessed by vital signs\"\\n13164,1,1,\"Part 2: Median Overall Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2\"\\n13165,1,1,\"Part 2: Median Progression-free Survival (PFS) in Weeks Based on Enhanced Response Evaluation Criteria In Solid Tumors Version 1.1 (Enhanced RECIST 1.1) by Independent Radiology Review\"\\n13166,1,1,\"Part 2: MTD of RO6895882\"\\n13167,1,1,\"Part 2: Number of Participants Achieving Disease Control Rate at Week 16\"\\n13168,1,1,\"Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events\"\\n13169,1,1,\"Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events\"\\n13170,1,1,\"Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)\"\\n13171,1,1,\"Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events\"\\n13172,1,1,\"Part 2: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)\"\\n13173,1,1,\"Part 2: Number of Participants Who Experience at Least One Adverse Event (AE)\"\\n13174,1,1,\"Part 2: Number of Participants Who Experienced One or More Adverse Events (AEs)\"\\n13175,1,1,\"Part 2: Number of participants with abscopal response in non-irradiated target lesions\"\\n13176,1,1,\"Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs\"\\n13177,1,1,\"Part 2: Number of Participants With Any QTcF Interval Increases From Baseline According to Markedly Abnormal Criteria\"\\n13178,1,1,\"Part 2: Number of Participants With Change From Baseline in Chemistry Parameters With Respect to the Normal Range\"\\n13179,1,1,\"Part 2: Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal Range\"\\n13180,1,1,\"Part 2: Number of Participants With Each Type of Response Evaluation Criteria in Solid Tumors (RECIST)-Determined Overall Best Response\"\\n13181,1,1,\"Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy\"\\n13182,1,1,\"Part 2: Number of Participants With TEAEs and STEAEs\"\\n13183,1,1,\"Part 2: Number of Participants With TEAEs Leading to Discontinuation\"\\n13184,1,1,\"Part 2: Number of Participants With TEAEs Leading to Dose Reductions or Dose Delays\"\\n13185,1,1,\"Part 2: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs\"\\n13186,1,1,\"Part 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n13187,1,1,\"Part 2: Number of Participants With Vital Signs Any Decreases From Baseline According to Markedly Abnormal Criteria\"\\n13188,1,1,\"Part 2: Number of Participants With Vital Signs Any Increases From Baseline According to Markedly Abnormal Criteria\"\\n13189,2,1,\"Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria\"\\n13190,1,1,\"Part 2: Number of subjects with abnormal body temperature\"\\n13191,1,1,\"Part 2: Number of subjects with abnormal clinical chemistry laboratory tests\"\\n13192,1,1,\"Part 2: Number of subjects with abnormal electrocardiogram (ECG) findings\"\\n13193,1,1,\"Part 2: Number of subjects with abnormal hematology laboratory tests\"\\n13194,1,1,\"Part 2: Number of subjects with abnormal pulse rate\"\\n13195,1,1,\"Part 2: Number of subjects with abnormal respiratory rate\"\\n13196,1,1,\"Part 2: Number of subjects with abnormal routine urinalysis laboratory tests\"\\n13197,1,1,\"Part 2: Number of subjects with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) as a measure of safety\"\\n13198,1,1,\"Part 2: Number of subjects with AEs and SAEs\"\\n13199,1,1,\"Part 2: Number of subjects with cardiotoxicity and gastrointestinal (GI) toxicity\"\\n13200,1,1,\"Part 2: Number of subjects with dose reductions or delays as a measure of safety\"\\n13201,1,1,\"Part 2: Number of subjects withdrawals due to toxicities\"\\n13202,1,1,\"Part 2: Number of treatment-emergent adverse events in participants receiving INCB001158 in combination with INCMGA00012\"\\n13203,1,1,\"Part 2: Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0\"\\n13204,1,1,\"Part 2: Objective response\"\\n13205,1,1,\"Part 2: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators\"\\n13206,1,1,\"Part 2: Objective response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Assessed by Investigator\"\\n13207,1,1,\"Part 2: Objective Response (OR) Rate\"\\n13208,2,1,\"Part 2: Objective response rate\"\\n13209,3,2,\"Part 2: Objective Response Rate (ORR)\"\\n13210,2,2,\"Part 2: Objective response rate (ORR)\"\\n13211,1,1,\"Part 2: Objective response rate (ORR) based on RECIST 1.1/RECIL 2017\"\\n13212,1,1,\"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1\"\\n13213,1,1,\"Part 2: Objective Response Rate (ORR) per RECIST v1.1\"\\n13214,1,1,\"Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator in Participants Without BRAF V600 E or K Mutations\"\\n13215,1,1,\"Part 2: Objective Response Rate- Efficacy\"\\n13216,3,2,\"Part 2: ORR\"\\n13217,1,1,\"Part 2: OS - Participants With PD-L1 CPS ‚â•1 Tumors\"\\n13218,1,1,\"Part 2: OS - Participants With PD-L1 CPS ‚â•10 Tumors\"\\n13219,1,1,\"Part 2: OS in All Participants\"\\n13220,2,1,\"Part 2: Overall Response Rate\"\\n13221,12,3,\"Part 2: Overall Response Rate (ORR)\"\\n13222,2,1,\"Part 2: Overall response rate (ORR)\"\\n13223,1,1,\"Part 2: Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Subjects With Selected Advanced Solid Tumors\"\\n13224,2,1,\"Part 2: Overall survival\"\\n13225,3,3,\"Part 2: Overall Survival (OS)\"\\n13226,1,1,\"Part 2: Overall Survival (OS) - All Participants\"\\n13227,1,1,\"Part 2: Overall Survival (OS) in Participants with Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ‚â•1\"\\n13228,1,1,\"Part 2: Participants with NHL: ORR based on Lugano criteria\"\\n13229,1,1,\"Part 2: Participants with solid tumors (non-GBM): Overall response rate (ORR) based on Evaluation Criteria In Solid Tumors (RECIST) 1.1\"\\n13230,1,1,\"Part 2: Percent change in tumor dimensions of target lesions- Efficacy\"\\n13231,1,1,\"Part 2: Percentage of Participants Achieving Objective Response Rate (ORR)\"\\n13232,1,1,\"Part 2: Percentage of Participants Achieving Overall Response Rate\"\\n13233,1,1,\"Part 2: Percentage of Participants With an Objective Response\"\\n13234,1,1,\"Part 2: Percentage of Participants With Clinical Benefit\"\\n13235,1,1,\"Part 2: Percentage of Participants With Dose-Limiting Toxicity (DLT)\"\\n13236,1,1,\"Part 2: Percentage of Participants With Objective Tumor Response (Response Rate)\"\\n13237,1,1,\"Part 2: Percentage of Participants with Serious Adverse Events (SAEs)\"\\n13238,1,1,\"Part 2: Percentage of Participants with Treatment Discontinuations and Treatment Modifications due to Adverse Events (AEs) and Laboratory Abnormalities\"\\n13239,1,1,\"Part 2: Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) and Laboratory Abnormalities\"\\n13240,1,1,\"Part 2: PFS - Participants With PD-L1 CPS ‚â•10 Tumors\"\\n13241,1,1,\"Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ‚â•1 Tumors\"\\n13242,1,1,\"Part 2: PFS or ORR [Preliminary Efficacy]\"\\n13243,1,1,\"Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants\"\\n13244,1,1,\"Part 2: Preliminary antitumor activity of SB 11285 in combination with atezolizumab\"\\n13245,3,1,\"Part 2: Progression Free Survival (PFS)\"\\n13246,1,1,\"Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)\"\\n13247,2,2,\"Part 2: Progression-Free Survival (PFS)\"\\n13248,2,1,\"Part 2: Progression-free survival (PFS)\"\\n13249,1,1,\"Part 2: Progression-Free Survival (PFS) - All Participants\"\\n13250,2,2,\"Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ\"\\n13251,1,1,\"Part 2: Progression-free Survival (PFS) based on RECIST 1.1/RECIL 2017\"\\n13252,1,1,\"Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants with PD-L1 CPS ‚â•1\"\\n13253,1,1,\"Part 2: Radiologic Progression-free Survival (PFS)\"\\n13254,1,1,\"Part 2: Recommended Phase 2 Dose (RP2D) based on safety, tolerability, PK profile, and preliminary efficacy data\"\\n13255,1,1,\"Part 2: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Rovalpituzumab Tesirine Combination\"\\n13256,1,1,\"Part 2: Relative bioavailability: Area under the concentration-time curves (AUCs)\"\\n13257,1,1,\"Part 2: Response rate\"\\n13258,1,1,\"Part 2: Therapeutic efficacy\"\\n13259,1,1,\"Part 2: Time to Response (TTR)- Efficacy\"\\n13260,1,1,\"Part 2: Tmax of GSK525762 and trametinib\"\\n13261,1,1,\"Part 2: To assess the progression free survival (PFS) of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin. Measured by Tumor assessments.\"\\n13262,1,1,\"Part 2: To determine the DLTs and MTD of the combination of ADH300004 and 5-FU administered orally as a split dose for 3 out of 4 weeks in subjects with HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and breast cancer\"\\n13263,1,1,\"Part 2: To estimate the relative treatment effect of platinum-based chemotherapy and AMG 479, and of platinum-based chemotherapy and AMG 102, compared to platinum-based chemotherapy and placebo as measured by the respective HR for overall survival\"\\n13264,1,1,\"Part 2: To evaluate the effect of CYP3A4 induction by rifampin on the steady-state PK of Tazemetostat when administered as a single and twice daily oral dose in subjects with advanced malignancies, AUC0-t, Cmax.\"\\n13265,1,1,\"part 2: to evaluate the safety and tolerability of the MTD of CEP-9722 identified in part 1, as defined by numbers and severity of adverse events\"\\n13266,1,1,\"Part 2: To further determine the safety and tolerability by evaluating the incidence and severity of adverse events and serious adverse events (as per CTCAE grading), changes in hematology and chemistry values, vital signs, ECGs.\"\\n13267,1,1,\"Part 2: To study the duration of response (DoR) of the combination of surufatinib and gemcitabine in pediatric patients with Ewing sarcoma, RMS, or NRSTS.\"\\n13268,1,1,\"Part 2: To study the progression-free survival (PFS) of the combination of surufatinib and gemcitabine in pediatric patients with Ewing sarcoma, RMS, or NRSTS.\"\\n13269,1,1,\"Part 2: To study the rate of patients who have achieved Complete Response (CR) or Partial Response (PR) in pediatric patients with Ewing sarcoma, Rhabdomyosarcoma (RMS), or Non-RMS (NRSTS) treated with the combination of surufatinib and gemcitabine.\"\\n13270,1,1,\"Part 2: To study the Time to Response (TTR) of the combination of surufatinib and gemcitabine in pediatric patients with Ewing sarcoma, RMS, or NRSTS.\"\\n13271,1,1,\"Part 2: Tumor response as measured by RECIST 1.1 (Response Evaluation Criteria In Solid Tumors) or PCWG3 (Prostate Cancer Working Group 3) criteria where appropriate\"\\n13272,1,1,\"Part 2:ORR\"\\n13273,1,1,\"Part 2A: Number of participants receiving concomitant medications\"\\n13274,1,1,\"Part 2A: Number of participants with abnormal clinical chemistry parameters\"\\n13275,1,1,\"Part 2A: Number of participants with abnormal ECG\"\\n13276,1,1,\"Part 2A: Number of participants with abnormal hematology parameters\"\\n13277,1,1,\"Part 2A: Number of participants with abnormal physical examination\"\\n13278,1,1,\"Part 2A: Number of participants with abnormal thyroid function\"\\n13279,1,1,\"Part 2A: Number of participants with abnormal urine parameters\"\\n13280,1,1,\"Part 2A: Number of participants with abnormal vital signs\"\\n13281,1,1,\"Part 2A: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study\"\\n13282,1,1,\"Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters\"\\n13283,1,1,\"Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters\"\\n13284,1,1,\"Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBP\"\\n13285,1,1,\"Part 2A: Number of Participants With Any SAE and Non-SAE\"\\n13286,1,1,\"Part 2A: Number of Participants With DLTs\"\\n13287,1,1,\"Part 2A: Number of Participants With Dose Reductions or Delay\"\\n13288,1,1,\"Part 2A: Number of participants with immune related AEs of interest\"\\n13289,1,1,\"Part 2A: Number of participants with TEAEs\"\\n13290,1,1,\"Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature\"\\n13291,1,1,\"Part 2A: Number of Participants With Worst Case Change From Baseline in HR\"\\n13292,1,1,\"Part 2A: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings\"\\n13293,1,1,\"Part 2A: Number of patients whose disease responds to study drugs, as determined by Overall Response Rate (ORR)\"\\n13294,2,1,\"Part 2A: Objective Response Rate (ORR)\"\\n13295,1,1,\"Part 2A: Objective response rate (ORR)\"\\n13296,1,1,\"Part 2A: Progression-free survival rate at 6 months (PFS6) in participants with osteosarcoma\"\\n13297,1,1,\"Part 2A:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146 in combination with PD-(L)1 antibody\"\\n13298,1,1,\"Part 2A:Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)\"\\n13299,1,1,\"Part 2A:Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE)\"\\n13300,1,1,\"Part 2B: Cohort A1 Duration of response (DOR)\"\\n13301,1,1,\"Part 2B: Cohort A1 Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\"\\n13302,1,1,\"Part 2B: Cohort A2 Duration of response (DOR)\"\\n13303,1,1,\"Part 2B: Cohort A2 ORR by RECIST version 1.1\"\\n13304,1,1,\"Part 2B: Cohort E ORR by immune related Response Evaluation Criteria in Solid Tumors per irRECIST\"\\n13305,1,1,\"Part 2B: Cohort F Duration of response (DOR)\"\\n13306,1,1,\"Part 2B: Cohort F ORR by RECIST version 1.1\"\\n13307,1,1,\"Part 2B: Cohort G ORR by RECIST version 1.1\"\\n13308,1,1,\"Part 2B: Number of participants receiving concomitant medications\"\\n13309,1,1,\"Part 2B: Number of participants with abnormal clinical chemistry parameters\"\\n13310,1,1,\"Part 2B: Number of participants with abnormal ECG parameters\"\\n13311,1,1,\"Part 2B: Number of participants with abnormal hematology parameters\"\\n13312,1,1,\"Part 2B: Number of participants with abnormal physical examination\"\\n13313,1,1,\"Part 2B: Number of participants with abnormal thyroid function\"\\n13314,1,1,\"Part 2B: Number of participants with abnormal urine parameters\"\\n13315,1,1,\"Part 2B: Number of participants with abnormal vital signs\"\\n13316,1,1,\"Part 2B: Number of participants with abnormality in clinical chemistry parameters\"\\n13317,1,1,\"Part 2B: Number of participants with abnormality in ECG parameters\"\\n13318,1,1,\"Part 2B: Number of participants with abnormality in hematology parameters\"\\n13319,1,1,\"Part 2B: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study\"\\n13320,1,1,\"Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters\"\\n13321,1,1,\"Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters\"\\n13322,1,1,\"Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBP\"\\n13323,1,1,\"Part 2B: Number of Participants With Any SAE and Non-SAE\"\\n13324,1,1,\"Part 2B: Number of Participants With DLTs\"\\n13325,1,1,\"Part 2B: Number of Participants With Dose Reductions or Delay\"\\n13326,1,1,\"Part 2B: Number of participants with immune related AEs of interest\"\\n13327,1,1,\"Part 2B: Number of participants with SAEs, TEAEs and irAEs\"\\n13328,1,1,\"Part 2B: Number of participants with TEAEs\"\\n13329,1,1,\"Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature\"\\n13330,1,1,\"Part 2B: Number of Participants With Worst Case Change From Baseline in HR\"\\n13331,1,1,\"Part 2B: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings\"\\n13332,1,1,\"Part 2B: Number of patients whose disease responds to study drugs, as determined by Overall response rate (ORR)\"\\n13333,1,1,\"Part 2b: Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 (PLX9486 in combination of PLX3397)\"\\n13334,1,1,\"Part 2B: Objective response rate (ORR) in participants with neuroblastoma\"\\n13335,1,1,\"Part 2b: To determine the clinical benefit rate of PLX9486 and PLX3397 treatment at applicable RP2D in Part 2b\"\\n13336,1,1,\"Part 2b: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with PLX3397 for further evaluation\"\\n13337,1,1,\"Part 2e: Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 (PLX9486 in combination with sunitinib)\"\\n13338,1,1,\"Part 2e: To determine the clinical benefit rate of PLX9486 and sunitinib treatment at applicable RP2D in Part 2e\"\\n13339,1,1,\"Part 2e: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with sunitinib for further evaluation\"\\n13340,1,1,\"Part 2Ôºàexpansion partÔºâ: Overall Response Rate\"\\n13341,1,1,\"Part 3 (Expansion cohorts):To further evaluate the clinical activity of oral GSK2636771 in PTEN deficient CRPC, CRC and multiple PTEN deficient tumor types.\"\\n13342,1,1,\"Part 3 (expansion part #2): Objective response rate after 3 months in RH+ patients with endometrial carcinoma\"\\n13343,1,1,\"Part 3 - RECIST\"\\n13344,1,1,\"Part 3 - Safety Expanded Cohort: Laboratory tests\"\\n13345,1,1,\"Part 3 - Safety Expanded Cohort: Number of subjects with adverse events\"\\n13346,1,1,\"Part 3 - Safety Expanded Cohort: Vital signs\"\\n13347,1,1,\"Part 3 Arm B\"\\n13348,1,1,\"Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window\"\\n13349,1,1,\"Part 3, Extension Cohort: Confirmed ORR Assessed by IRC\"\\n13350,1,1,\"Part 3- Overall response\"\\n13351,1,1,\"Part 3: Area Under the Serum Concentration Time Curve from Time 0 to 24 Hours Post-dose (AUC(0-24)) of Venetoclax\"\\n13352,1,1,\"Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.\"\\n13353,1,1,\"Part 3: Duration of Response (DoR) as Determined by the Investigator Using RECIST v1.1\"\\n13354,1,1,\"Part 3: Food effect: Area under the concentration-time curves (AUCs)\"\\n13355,1,1,\"Part 3: Maximum Observed Serum Concentration (Cmax) for Venetoclax\"\\n13356,1,1,\"Part 3: Median Overall Survival (OS)\"\\n13357,1,1,\"Part 3: Median Progression-Free Survival (PFS) as Determined by the Investigator Using RECIST v1.1\"\\n13358,1,1,\"Part 3: Number of Participants With Any TEAE\"\\n13359,1,1,\"Part 3: Objective Response Rate\"\\n13360,1,1,\"Part 3: Objective Response Rate (ORR)\"\\n13361,1,1,\"Part 3: Percentage of Participants Who are Alive at Month 12\"\\n13362,1,1,\"Part 3: Percentage of Participants Who are Progression-Free at Month 6 as Determined by the Investigator Using RECIST v1.1\"\\n13363,1,1,\"Part 3: Percentage of Participants Who are Progression-Free at Months 3 as Determined by the Investigator Using RECIST v1.1\"\\n13364,1,1,\"Part 3: Percentage of Participants With Disease Control as Determined by the Investigator Using RECIST v1.1\"\\n13365,1,1,\"Part 3: Percentage of Participants With Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n13366,1,1,\"Part 3: Progression Free Survival (PFS)\"\\n13367,1,1,\"Part 3: Progression Free Survival (PFS) According to RECIST Version 1.1 Assessed by Investigator\"\\n13368,1,1,\"Part 3: Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator in Participants With BRAF V600 E or K Mutations\"\\n13369,1,1,\"Part 3: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Venetoclax Combination.\"\\n13370,1,1,\"Part 3: Time to Cmax (Tmax) of Venetoclax\"\\n13371,1,1,\"Part 4 Only : Determination of the Efficacy of INCB053914 in Combination With Azacitidine in Subjects With Newly Diagnosed AML Who Are 65 Years or Older and Unfit for Intensive Chemotherapy Based on ORR\"\\n13372,1,1,\"Part 4 Only : Determination of the Efficacy of INCB053914 in Combination With the Intermediate-dose Cytarabine (I DAC) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Based on Objective Remission Rate (ORR)\"\\n13373,1,1,\"Part 4, Cohort 4: Complete Response (CR)\"\\n13374,1,1,\"Part 4: Overall Response Rate (ORR)\"\\n13375,1,1,\"Part 4: Plasma concentrations of SAR442720 in combination with pembrolizumab under impact of food\"\\n13376,1,1,\"Part 5: Average Concentration (Cavg) of JNJ-63723283\"\\n13377,1,1,\"Part 5: ORR Per RECIST 1.1 as Assessed by Investigator in Participants Without BRAF V600 E or K Mutations or With Solid Tumors Irrespective of BRAF Status\"\\n13378,1,1,\"Part 5: Serum Concentration Observed at the Last Timepoint Prior to Dosing at Steady State (Ctrough,ss) of JNJ-63723283\"\\n13379,1,1,\"Part A & B & C: Frequency and severity of AEs as assessed by CTCAE v5.0\"\\n13380,1,1,\"Part A (dose escalation) - incidence of adverse events (AEs)\"\\n13381,1,1,\"Part A (dose escalation) - incidence of dose limiting toxicities (DLTs)\"\\n13382,2,1,\"Part A (dose escalation): Incidence of adverse events\"\\n13383,1,1,\"Part A (dose selection part): Dose Limiting Toxicities (DLTs)\"\\n13384,1,1,\"Part A - Determine the maximum tolerated dose (MTD) or recommended Phase 2 dose(s) (RP2D)\"\\n13385,1,1,\"Part A - Maximum tolerated dose of BI 891065\"\\n13386,1,1,\"Part A - number of patients with Dose-limiting toxicities (DLTs) during the first treatment cycle.\"\\n13387,1,1,\"Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab\"\\n13388,1,1,\"Part A - Overall Survival\"\\n13389,1,1,\"Part A and B: Evaluate the incidents of treatment emergent adverse events and laboratory abnormalities\"\\n13390,1,1,\"Part A and B: Occurrence and Severity of Treatment Emergent Adverse Events (TEAEs) and related TEAEs\"\\n13391,1,1,\"Part A and B: Safety and Tolerability of DKN-01 in G/GEJ patients\"\\n13392,1,1,\"Part A and Part B- Determination of Maximum tolerated dose (MTD)\"\\n13393,1,1,\"Part A and Part B- Determination of the Recommended Phase 2 dose (RP2D)\"\\n13394,1,1,\"Part A AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN4924 and MLN4924 + Fluconazole\"\\n13395,1,1,\"Part A AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN4924 and MLN4924 + Itraconazole\"\\n13396,1,1,\"Part A AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN4924 and MLN4924 + Fluconazole\"\\n13397,1,1,\"Part A AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN4924 and MLN4924 + Itraconazole\"\\n13398,1,1,\"Part A Cmax: Maximum Observed Plasma Concentration for MLN4924 and MLN4924 + Fluconazole\"\\n13399,1,1,\"Part A Cmax: Maximum Observed Plasma Concentration for MLN4924 and MLN4924 + Itraconazole\"\\n13400,1,1,\"Part A, AUClast: Area Under the Plasma Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration for Pevonedistat Following a Single Dose\"\\n13401,1,1,\"Part A, AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam\"\\n13402,1,1,\"Part A, AUC‚àû: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity for Pevonedistat Following a Single Dose\"\\n13403,1,1,\"Part A, Cmax: Maximum Observed Plasma Concentration for Midazolam\"\\n13404,1,1,\"Part A, Cmax: Maximum Observed Plasma Concentration for Pevonedistat Following a Single Dose\"\\n13405,1,1,\"Part A, Part B and Part C- Number of patients with serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)\"\\n13406,1,1,\"Part A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam\"\\n13407,1,1,\"Part A-1 and A-2 (escalations): Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities from BT5528 treatment alone and in combination with nivolumab\"\\n13408,1,1,\"Part A-1 and A-2(escalations): Number of participants receiving BT5528 alone and in combination with nivolumab with treatment-emergent adverse events\"\\n13409,1,1,\"Part A-1: Number of subjects with Dose Limiting Toxicities (DLTs)\"\\n13410,1,1,\"Part A-2: Number of subjects with Dose Limiting Toxicities (DLTs) when prophylactic use of G-CSF is allowed during Cycle 1\"\\n13411,1,1,\"Part A/B/C: Dose Limiting Toxicities (DLT)\"\\n13412,1,1,\"Part A1 and B1: To Determine the Recommended Dose Expansion (RDE) for M1774 in Combination With Niraparib in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors\"\\n13413,1,1,\"Part A1 Dose escalation monotherapy:\"\\n13414,1,1,\"Part A1, A3 and B1: Number of Participants With Abnormalities in Vital Signs\"\\n13415,1,1,\"Part A1, A3 and B1: Number of Participants With Clinical Significant Abnormalities in Electrocardiogram(ECG) Findings\"\\n13416,1,1,\"Part A1, A3 and B1: Number of Participants With Grade 3 or Higher Laboratory Findings According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0\"\\n13417,1,1,\"Part A1, A3 and B1: Occurrence of Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs) and Death According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0\"\\n13418,1,1,\"Part A1: Change from Baseline in Pharmacodynamic (PD) Biomarker\"\\n13419,1,1,\"Part A1: Number of Participants with Adverse Events (AEs) and Treatment-Related AEs\"\\n13420,1,1,\"Part A1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period\"\\n13421,1,1,\"Part A1: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period\"\\n13422,1,1,\"Part A2 Dose Escalation: KIN-2787 + Binimetinib Combination\"\\n13423,1,1,\"Part A2: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours Post Dose (AUC 0-24h) of M1774\"\\n13424,1,1,\"Part A2: Maximum Observed Plasma Concentration (Cmax) of M1774\"\\n13425,1,1,\"Part A2: Maximum Tolerated Dose (MTD) of M4344 Administered With a Dose Dense Schedule\"\\n13426,1,1,\"Part A2: Number of Participants With Clinically Relevant Findings in Vital Signs\"\\n13427,1,1,\"Part A2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)\"\\n13428,1,1,\"Part A2: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0)\"\\n13429,1,1,\"Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n13430,1,1,\"Part A2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve (Frel[AUC]) of M1774 Under Fed Condition as Compared to Fasting Condition\"\\n13431,1,1,\"Part A2: Relative Bioavailability Based on Maximum Observed Plasma Concentration (Frel[Cmax]) of M1774 Under Fed Condition as Compared to Fasting Condition\"\\n13432,1,1,\"Part A3: Objective Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1\"\\n13433,1,1,\"Part A: Adverse Events\"\\n13434,1,1,\"Part A: Aefeces,14C: Cumulative Amount of [14C]-Pevonedistat Excreted in Feces up to the Last Sampling Interval\"\\n13435,1,1,\"Part A: Aetotal,14C: Total Cumulative Excretion of [14C]-Pevonedistat From the Body\"\\n13436,1,1,\"Part A: Aeurine,14C: Cumulative Amount of [14C]-Pevonedistat Excreted in Urine up to the Last Sampling Interval\"\\n13437,1,1,\"Part A: Aeurine: Cumulative Amount of Pevonedistat Dose Excreted in Urine at 144-168 Hours Post-dose\"\\n13438,1,1,\"Part A: Apparent total body clearance of drug from plasma (CL/F)\"\\n13439,1,1,\"Part A: Apparent volume of distribution based on the terminal phase (Vz/F)\"\\n13440,1,1,\"Part A: Area Under Plasma Concentration-time Curve (AUC)\"\\n13441,1,1,\"Part A: Area under the concentration-time curve from time zero to infinity (AUCinf)\"\\n13442,1,1,\"Part A: Area under the curve (AUC)\"\\n13443,1,1,\"Part A: Area under the plasma concentration-time curve from time zero to the time \"\"t\"\" of the last quantifiable concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)\"\\n13444,1,1,\"Part A: Area under the plasma concentration-time curve from zero to infinity for cocktail parent compounds (midazolam, omeprazole and caffeine)\"\\n13445,1,1,\"Part A: AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites\"\\n13446,1,1,\"Part A: AUC from time zero to time of last measurable concentration (AUClast)\"\\n13447,1,1,\"Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib\"\\n13448,1,1,\"Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA\"\\n13449,1,1,\"Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA\"\\n13450,1,1,\"Part A: AUClast: Area Under the Plasma and Whole Blood Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Pevonedistat\"\\n13451,1,1,\"Part A: AUClast: Area Under the Plasma and Whole Blood TRA Concentration Curve From Time 0 to Time of the Last Quantifiable Concentration for [14C]-Pevonedistat Drug-related Material\"\\n13452,1,1,\"Part A: AZD5069 With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansion\"\\n13453,1,1,\"Part A: Change From Time-matched Baseline in QTcF Post-dose Pevonedistat on Day 1\"\\n13454,1,1,\"Part A: Change From Time-matched Baseline in QTcF Post-dose Pevonedistat on Day 8\"\\n13455,1,1,\"Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).\"\\n13456,1,1,\"Part A: Clinically significant changes in neurological examinations\"\\n13457,1,1,\"Part A: Clinically significant changes in physical examinations\"\\n13458,1,1,\"Part A: Clinically significant changes in vital signs and electrocardiogram - including the evaluation of the QT interval\"\\n13459,1,1,\"Part A: Cmax of Tazemetostat During Co-administration With Fluconazole\"\\n13460,1,1,\"Part A: Cmax: Maximum Observed Plasma and Whole Blood Concentration for Pevonedistat\"\\n13461,1,1,\"Part A: Cmax: Maximum Observed Plasma and Whole Blood TRA Concentration for [14C]-Pevonedistat Drug-related Material\"\\n13462,1,1,\"Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib\"\\n13463,1,1,\"Part A: Cmax: Maximum Observed Plasma Concentration of TRA\"\\n13464,1,1,\"Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA\"\\n13465,1,1,\"Part A: Cumulative excretion of radioactivity in feces\"\\n13466,1,1,\"Part A: Cumulative excretion of radioactivity in urine\"\\n13467,1,1,\"Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine\"\\n13468,1,1,\"Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces\"\\n13469,1,1,\"Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine\"\\n13470,1,1,\"Part A: Danvatirsen With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansion\"\\n13471,1,1,\"Part A: Define a maximum single dose at which there are tolerable side effects and/or maximum PK/PcD parameter changes\"\\n13472,1,1,\"Part A: Determine the maximum tolerated dose (MTD) of ASN002\"\\n13473,1,1,\"Part A: Determine the maximum tolerated dose (MTD) of ASN003\"\\n13474,1,1,\"Part A: Determine the maximum tolerated dose (MTD) of ASN007\"\\n13475,1,1,\"Part A: Dose limiting toxicity (DLT)\"\\n13476,1,1,\"Part A: Dose-normalized AUClast (Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)\"\\n13477,1,1,\"Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule Formulations (PIC)\"\\n13478,1,1,\"Part A: Duration of TEAEs and Related TEAEs\"\\n13479,1,1,\"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)\"\\n13480,1,1,\"Part A: Evaluate the occurrence of dose-limiting toxicities (DLTs) during Cycle 1\"\\n13481,1,1,\"Part A: excretion of radioactivity\"\\n13482,1,1,\"Part A: Excretion ratio of radioactivity in feces\"\\n13483,1,1,\"Part A: Excretion ratio of radioactivity in urine\"\\n13484,1,1,\"Part A: Feurine: Cumulative Percentage of Pevonedistat Dose Excreted in Urine at 144-168 Hours Post-dose\"\\n13485,1,1,\"Part A: Frequency and type of DLT s using the CTCAE v5.0\"\\n13486,2,1,\"Part A: Incidence and severity of adverse events (AEs)\"\\n13487,1,1,\"Part A: Incidence and severity of dose-limiting toxicities (DLTs)\"\\n13488,1,1,\"Part A: Incidence and severity of serious adverse events (SAEs)\"\\n13489,1,1,\"Part A: Incidence of dose limiting toxicity\"\\n13490,1,1,\"Part A: Incidence of dose limiting toxicity (DLTs)\"\\n13491,1,1,\"Part A: Incidence of dose-limiting toxicities (DLTs)\"\\n13492,1,1,\"Part A: Incidence of treatment emergent adverse events\"\\n13493,1,1,\"Part A: Incidence of withdrawals due to AEs\"\\n13494,1,1,\"Part A: Incidence, nature and severity of Adverse Events\"\\n13495,1,1,\"Part A: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0\"\\n13496,1,1,\"Part A: Maximum Plasma (Peak) Concentration (Cmax)\"\\n13497,1,1,\"Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib\"\\n13498,1,1,\"Part A: Maximum plasma drug concentration (Cmax)\"\\n13499,1,1,\"Part A: maximum plasma drug concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)\"\\n13500,2,1,\"Part A: Maximum Tolerated Dose (MTD)\"\\n13501,1,1,\"Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from ART0380 monotherapy and in combination with gemcitabine or irinotecan\"\\n13502,1,1,\"Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from MTB-9655 monotherapy\"\\n13503,1,1,\"Part A: Maximum Tolerated Dose (MTD) in subjects receiving AZD9150 plus durvalumab and AZD9150 plus durvalumab plus chemotherapy.\"\\n13504,1,1,\"Part A: Maximum Tolerated Dose (MTD) of M4344 Administered Twice Weekly (BIW)\"\\n13505,1,1,\"Part A: Maximum Tolerated Dose (MTD) of VX-984 in Combination With Pegylated Liposomal Doxorubicin (PLD)\"\\n13506,1,1,\"Part A: Maximum Tolerated Dose and RP2D in solid tumours\"\\n13507,2,1,\"Part A: Number of Adverse Events (AEs)\"\\n13508,1,1,\"Part A: Number Of Participants Experiencing Adverse Events (AEs)\"\\n13509,1,1,\"Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)\"\\n13510,1,1,\"Part A: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)\"\\n13511,1,1,\"Part A: Number of Participants with a Dose-Limiting Toxicity (DLT)\"\\n13512,1,1,\"Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)\"\\n13513,1,1,\"Part A: Number of Participants With Clinical Significant Abnormalities Echocardiograms\"\\n13514,1,1,\"Part A: Number of Participants With Clinical Significant Abnormalities in Electrocardiogram(ECG) Parameters\"\\n13515,1,1,\"Part A: Number of Participants With Clinical Significant Abnormalities in Vital Signs\"\\n13516,1,1,\"Part A: Number of Participants With Clinically Relevant Findings in Vital Signs\"\\n13517,1,1,\"Part A: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)\"\\n13518,1,1,\"Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1\"\\n13519,2,2,\"Part A: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n13520,1,1,\"Part A: Number of participants with dose limiting toxicities (DLTs) from ART4215 monotherapy, in combination with talazoparib or in combination with niraparib\"\\n13521,1,1,\"Part A: Number of participants with dose limiting toxicities (DLTs) from MTB-9655 monotherapy in patients with locally advanced or metastatic solid tumors.\"\\n13522,1,1,\"Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab\"\\n13523,1,1,\"Part A: Number of Participants With Dose-limiting Toxicities\"\\n13524,1,1,\"Part A: Number of participants with dose-limiting toxicities\"\\n13525,1,1,\"Part A: Number of Participants With Dose-limiting Toxicity (DLT)\"\\n13526,1,1,\"Part A: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0)\"\\n13527,1,1,\"Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs)\"\\n13528,1,1,\"Part A: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration\"\\n13529,1,1,\"Part A: Number of Participants With Toxicity Grade 3 or Higher in Laboratory Abnormalities\"\\n13530,1,1,\"Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n13531,2,1,\"Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs\"\\n13532,1,1,\"Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n13533,2,1,\"Part A: Number of Participants with Treatment-emergent Adverse Events (TEAEs)\"\\n13534,1,1,\"Part A: Number of Patients With Dose Limiting Toxicities (DLTs)\"\\n13535,1,1,\"Part A: Number of Subjects With Dose Limiting Toxicities (DLTs)\"\\n13536,1,1,\"Part A: Occurrence of Dose-limiting Toxicities (DLTs)\"\\n13537,1,1,\"Part A: Overall Response Rate (ORR) according to RECIST 1.1\"\\n13538,1,1,\"Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate)\"\\n13539,1,1,\"Part A: Percentage of Participants with Adverse Events\"\\n13540,1,1,\"Part A: Percentage of Participants with Dose-Limiting Toxicities (DLTs)\"\\n13541,1,1,\"Part A: Percentage of Participants With Dose-Limiting Toxicities (DLTs) From Debio 1347\"\\n13542,1,1,\"Part A: Percentage of Patients Experiencing Adverse Events (AEs)\"\\n13543,1,1,\"Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-‚àû)] in Cycle 1\"\\n13544,1,1,\"Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-‚àû)] in Cycle 2\"\\n13545,1,1,\"Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 1\"\\n13546,1,1,\"Part A: Pharmacokinetics - Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Paclitaxel in Cycle 2\"\\n13547,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in plasma: AUCinf\"\\n13548,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in plasma: AUClast\"\\n13549,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in plasma: Cmax\"\\n13550,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in plasma: t1/2\"\\n13551,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in plasma: tmax\"\\n13552,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in urine CLr\"\\n13553,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in urine: % of dose excreted (Aelast%)\"\\n13554,1,1,\"Part A: Pharmacokinetics of ASP8273 and possible metabolites in urine: (Aelast)\"\\n13555,1,1,\"Part A: Radioactivity in emesis (if applicable)\"\\n13556,1,1,\"Part A: Radioactivity in plasma: AUCinf\"\\n13557,1,1,\"Part A: Radioactivity in plasma: AUClast\"\\n13558,1,1,\"Part A: Radioactivity in plasma: Cmax\"\\n13559,1,1,\"Part A: Radioactivity in plasma: t1/2\"\\n13560,1,1,\"Part A: Radioactivity in plasma: tmax\"\\n13561,1,1,\"Part A: Radioactivity in whole blood: AUCinf\"\\n13562,1,1,\"Part A: Radioactivity in whole blood: AUClast\"\\n13563,1,1,\"Part A: Radioactivity in whole blood: Cmax\"\\n13564,1,1,\"Part A: Radioactivity in whole blood: t1/2\"\\n13565,1,1,\"Part A: Radioactivity in whole blood: tmax\"\\n13566,1,1,\"Part A: Radioactivity ratio for whole blood/plasma AUCinf\"\\n13567,1,1,\"Part A: Radioactivity ratio for whole blood/plasma AUClast\"\\n13568,1,1,\"Part A: Radioactivity ratio for whole blood/plasma concentration (per time point.)\"\\n13569,1,1,\"Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC‚àû) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)\"\\n13570,1,1,\"Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)\"\\n13571,1,1,\"Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)\"\\n13572,1,1,\"Part A: Recommend at least two doses of INX-315 to be evaluated in the expansion phase\"\\n13573,1,1,\"Part A: Recommended Phase 2 Dose (RP2D) of Debio1143\"\\n13574,1,1,\"Part A: Renal Clearance (CLR) for Pevonedistat\"\\n13575,1,1,\"Part A: Renal Clearance of Ixazomib\"\\n13576,1,1,\"Part A: Safety and Tolerability in Terms of Adverse Events\"\\n13577,1,1,\"Part A: Terminal elimination half-life (t¬ΩŒªz)\"\\n13578,1,1,\"Part A: Terminal Elimination Phase Half-Life (T1/2) of CC-223\"\\n13579,1,1,\"Part A: The incidence of AEs upon causality to the IMPs.\"\\n13580,1,1,\"Part A: The incidence of dose-limiting toxicities (DLTs)\"\\n13581,1,1,\"Part A: The recommended Phase 2 dose (RP2D) of BGB-10188 monotherapy\"\\n13582,1,1,\"Part A: The severity of AEs per National Cancer Institute\\'s Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) upon causality to the IMPs.\"\\n13583,1,1,\"Part A: Time to maximum observed concentration (Tmax)\"\\n13584,1,1,\"Part A: Time to peak concentration (Tmax)\"\\n13585,1,1,\"Part A: Tmax: Time to Reach the Cmax for TRA\"\\n13586,1,1,\"Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib\"\\n13587,1,1,\"Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA\"\\n13588,1,1,\"Part A: Tmax: Time to Reach the Maximum Plasma and Whole Blood Concentration (Cmax) for Pevonedistat\"\\n13589,1,1,\"Part A: Tmax: Time to Reach the Maximum Plasma and Whole Blood TRA Concentration (Cmax) for [14C]-Pevonedistat Drug-related Material\"\\n13590,1,1,\"Part A: To assess the safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events\"\\n13591,1,1,\"Part A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxel\"\\n13592,1,1,\"Part A: To determine the MTD or the RP2D of MPT-0118\"\\n13593,1,1,\"Part A: To determine the RD(Recommended Dose) of ZB716\"\\n13594,1,1,\"Part A: Total cumulative excretion of radioactivity in urine and feces\"\\n13595,1,1,\"Part A: Total excretion ratio of radioactivity in urine and feces\"\\n13596,1,1,\"Part A: TRX518 peak concentration (Cmax)\"\\n13597,1,1,\"Part A; Number of Participants With Eastern Cooperative Oncology Group [ECOG] Performance Status Score\"\\n13598,1,1,\"Part A;Number of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0\"\\n13599,1,1,\"Part A;Number of Participants With Clinically Significant Change From Screening in Vital Signs\"\\n13600,1,1,\"Part A;Number of Participants With Dose-Limiting Toxicities (DLT):\"\\n13601,1,1,\"Part A;Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0: Biochemistry and Hematology\"\\n13602,1,1,\"Part A;Number of Participants With Laboratory Test Abnormalities: Urinalysis\"\\n13603,1,1,\"Part A;Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs\"\\n13604,1,1,\"Part A;Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n13605,2,1,\"Part B (cohort expansion): Objective response rate\"\\n13606,1,1,\"Part B (dose expansion) - disease control rate (DCR): the proportion of participants who achieve stable disease, PR, or CR\"\\n13607,1,1,\"Part B (dose expansion) - duration of response (DOR): the length of time between initial tumor response to documented tumor progression\"\\n13608,1,1,\"Part B (dose expansion) - objective response rate (ORR): the proportion of participants who have achieved partial response (PR) or complete response (CR) according to RECIST v1.1\"\\n13609,1,1,\"Part B (dose expansion) - progression-free survival (PFS): the length of time until documented tumor progression\"\\n13610,1,1,\"Part B (expansion cohort): The 3-month objective response rate (ORR)\"\\n13611,1,1,\"Part B - Maximum tolerated dose of BI 891065 in combination with BI 754091\"\\n13612,1,1,\"Part B - number of patients with Dose-limiting toxicities (DLTs) during the first treatment cycle.\"\\n13613,1,1,\"Part B - Overall response rate (ORR) assessed by blinded independent central review (BICR)\"\\n13614,1,1,\"Part B - Overall Survival (OS)\"\\n13615,1,1,\"Part B - Patient safety as characterized by frequency and severity of adverse events\"\\n13616,1,1,\"Part B adolescents: Incidence and severity of adverse events (AEs)\"\\n13617,1,1,\"Part B adolescents: Incidence and severity of dose-limiting toxicities (DLTs)\"\\n13618,1,1,\"Part B adolescents: Incidence and severity of serious adverse events (SAEs)\"\\n13619,1,1,\"Part B adolescents: Incidence of withdrawals due to AEs\"\\n13620,1,1,\"Part B1 and B2: Number of participants with adverse events following administration of ART4215\"\\n13621,1,1,\"Part B1: Change from Baseline in Pharmacodynamic (PD) Biomarker\"\\n13622,1,1,\"Part B1: Maximum Tolerated Dose (MTD) of M4344 (Monotherapy) Administered in Combination With Carboplatin\"\\n13623,1,1,\"Part B1: Number of Participants with Adverse Events (AEs) and Treatment-Related AEs\"\\n13624,1,1,\"Part B1: Number of participants with adverse events following administration of ART0380 monotherapy and in combination with gemcitabine or irinotecan monotherapy and in combination with gemcitabine or irinotecan\"\\n13625,1,1,\"Part B1: Number of Participants With Clinically Relevant Findings in Vital Signs\"\\n13626,1,1,\"Part B1: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)\"\\n13627,1,1,\"Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period\"\\n13628,1,1,\"Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0)\"\\n13629,1,1,\"Part B1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n13630,1,1,\"Part B1: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period\"\\n13631,1,1,\"Part B2: Progression free survival by RECIST 1.1 in participants receiving ART0380 in combination with gemcitabine or gemcitabine alone\"\\n13632,1,1,\"Part B3: Progression free survival (PFS) as a measure of efficacy for ART4215 in combination with talazoparib or talazoparib alone\"\\n13633,1,1,\"Part B: antitumour efficacy\"\\n13634,1,1,\"Part B: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food\"\\n13635,1,1,\"Part B: AUCœÑ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration\"\\n13636,1,1,\"Part B: Best Overall Response (BOR) by Investigator Assessment\"\\n13637,1,1,\"Part B: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).\"\\n13638,1,1,\"Part B: Clinical Benefit Rate (CBR)\"\\n13639,1,1,\"Part B: Clinical benefit rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatment\"\\n13640,1,1,\"Part B: Cmax of Omeprazole During Co-administration With Tazemetostat\"\\n13641,1,1,\"Part B: Cmax of Repaglinide During Co-administration With Tazemetostat\"\\n13642,1,1,\"Part B: Cmax of Tazemetostat During Co-administration With Omeprazole\"\\n13643,1,1,\"Part B: Cmax: Maximum Observed Concentration for Alisertib Administered as an Oral Solution With Food Versus Without Food\"\\n13644,1,1,\"Part B: Cmax: Maximum Plasma Concentration for Alisertib Oral Solution Following Multiple-Dose Administration\"\\n13645,1,1,\"Part B: Confirmed Objective Response Rate (ORR)\"\\n13646,1,1,\"Part B: dECG intervals (QTcF) for absolute values and time-matched change from baseline\"\\n13647,1,1,\"Part B: Disease Control Rate (DCR)\"\\n13648,1,1,\"Part B: Disease control rate (DCR)\"\\n13649,1,1,\"Part B: Disease Control Rate (DCR), Defined as ORR + Stable Disease Rate (SDR)\"\\n13650,1,1,\"Part B: Dose Expansion - Incidence and severity of Adverse Events\"\\n13651,1,1,\"Part B: Durable Response Rate (DRR)\"\\n13652,1,1,\"Part B: Duration of remission (DOR)\"\\n13653,1,1,\"Part B: Duration Of Response (DOR)\"\\n13654,1,1,\"Part B: Duration of Response (DOR)\"\\n13655,1,1,\"Part B: Duration of response by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatment\"\\n13656,1,1,\"Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)\"\\n13657,1,1,\"Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN002 for the treatment of lymphoma, MF and CLL.\"\\n13658,1,1,\"Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer.\"\\n13659,1,1,\"Part B: evaluates the preliminary efficacy of ASN003 in subjects with selected BRAF and PI3 kinase mutated cancers\"\\n13660,1,1,\"Part B: Incidence of dose-limiting toxicities (DLTs)\"\\n13661,1,1,\"Part B: Median Radiological Progression-Free Survival (rPFS) Time\"\\n13662,1,1,\"Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)\"\\n13663,1,1,\"Part B: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment\"\\n13664,1,1,\"Part B: Number of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0\"\\n13665,1,1,\"Part B: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)\"\\n13666,1,1,\"Part B: Number of Participants With Clinically Significant Change From Screening in Vital Signs\"\\n13667,1,1,\"Part B: Number of Participants With DLT\"\\n13668,1,1,\"Part B: Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase\"\\n13669,1,1,\"Part B: Number of Participants With Eastern Cooperative Oncology Group [ECOG]\"\\n13670,1,1,\"Part B: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0: Biochemistry and Hematology\"\\n13671,1,1,\"Part B: Number of Participants With Laboratory Test Abnormalities: Urinalysis\"\\n13672,1,1,\"Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13673,1,1,\"Part B: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure\"\\n13674,1,1,\"Part B: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events\"\\n13675,1,1,\"Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events\"\\n13676,1,1,\"Part B: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range\"\\n13677,1,1,\"Part B: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline\"\\n13678,1,1,\"Part B: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range\"\\n13679,1,1,\"Part B: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline\"\\n13680,1,1,\"Part B: Objective response rate\"\\n13681,4,3,\"Part B: Objective Response Rate (ORR)\"\\n13682,2,2,\"Part B: Objective response rate (ORR)\"\\n13683,1,1,\"Part B: Objective response rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 tumor expression receiving BT5528 treatment\"\\n13684,1,1,\"Part B: Objective Response Rate, Assessed According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n13685,1,1,\"Part B: Occurrence of Dose-limiting Toxicities (DLTs)\"\\n13686,1,1,\"Part B: ORR (Objective Response Rate) in Patients With IL/2L RM-SCCHN.\"\\n13687,2,1,\"Part B: Overall Response Rate (ORR)\"\\n13688,1,1,\"Part B: Overall response rate (ORR)\"\\n13689,1,1,\"Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)\"\\n13690,1,1,\"Part B: Overall Survival (OS)\"\\n13691,1,1,\"Part B: Overall survival (OS)\"\\n13692,1,1,\"Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment\"\\n13693,1,1,\"Part B: Percentage of Participants Achieving a Best Response (Clinical Benefit Rate)\"\\n13694,1,1,\"Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]\"\\n13695,1,1,\"Part B: Percentage of participants with adverse events (AEs) and serious AEs (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria\"\\n13696,1,1,\"Part B: Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)\"\\n13697,1,1,\"Part B: Percentage of Patients With Progression Events or Death (rPFS)\"\\n13698,1,1,\"Part B: PFS at 6 months by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatment\"\\n13699,1,1,\"Part B: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Ramucirumab From Time Zero to Infinity [AUC(0-‚àû)] as Monotherapy\"\\n13700,1,1,\"Part B: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Olaratumab\"\\n13701,1,1,\"Part B: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Olaratumab\"\\n13702,1,1,\"Part B: Plasma pazopanib, clearance (CL) and AUC(0-t), AUC(0-8),Cmax and half-life (t1/2) pazopanib and pazopanib metabolites (GSK 1268992, GSK1268997, GSK1071306 and GW700201)\"\\n13703,2,2,\"Part B: Progression Free Survival (PFS)\"\\n13704,1,1,\"Part B: Progression Free Survival (PFS) according to RECIST 1.1\"\\n13705,1,1,\"Part B: Progression Free Survival (PFS) Rate at 6 Months for GBM Participants\"\\n13706,1,1,\"Part B: Progression-free Survival (PFS)\"\\n13707,2,1,\"Part B: Progression-free survival (PFS)\"\\n13708,1,1,\"Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs First\"\\n13709,1,1,\"Part B: Progression-free survival by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment\"\\n13710,1,1,\"Part B: Recommended phase II dose\"\\n13711,1,1,\"Part B: RP2D of BGB-10188 in combination with zanubrutinib\"\\n13712,1,1,\"Part B: Selection of Recommended Phase 2 Dose (RP2D)\"\\n13713,1,1,\"Part B: Severity of Laboratory Abnormalities\"\\n13714,1,1,\"Part B: Severity of Treatment-Emergent AEs\"\\n13715,1,1,\"Part B: The incidence of treatment-emergent adverse events (TEAEs)\"\\n13716,1,1,\"Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-‚àû)\"\\n13717,1,1,\"Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-‚àû)\"\\n13718,1,1,\"Part B: Time to tumor progression by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment\"\\n13719,1,1,\"Part B: Tmax: Time of First Occurrence of Cmax Over the Dosing Interval for Alisertib Oral Solution Following Multiple-Dose Administration\"\\n13720,1,1,\"Part B: To assess antitumor activities at the ZB716 RD in monotherapy\"\\n13721,1,1,\"Part B: To assess safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events\"\\n13722,1,1,\"Part B: To assess the clinical benefit of MRx0518 in combination with pembrolizumab\"\\n13723,1,1,\"Part B: To determine the MTD or the RP2D of MPT-0118 + pembrolizumab\"\\n13724,2,1,\"Part B: Tolerability\"\\n13725,1,1,\"Part C (Crossover): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator\"\\n13726,1,1,\"Part C (Crossover): Progression-free Survival (PFS) as Assessed by the Investigator\"\\n13727,1,1,\"Part C (Randomized): Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR)\"\\n13728,1,1,\"Part C (Randomized): Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)\"\\n13729,1,1,\"Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator\"\\n13730,1,1,\"Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR)\"\\n13731,1,1,\"Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure\"\\n13732,1,1,\"Part C (Randomized): Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range\"\\n13733,1,1,\"Part C (Randomized): Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline\"\\n13734,1,1,\"Part C (Randomized): Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range\"\\n13735,1,1,\"Part C (Randomized): Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline\"\\n13736,1,1,\"Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR)\"\\n13737,1,1,\"Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Investigator\"\\n13738,1,1,\"Part C - Objective response (OR) is defined as best overall response of Complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n13739,1,1,\"Part C and E: Overall response rate (ORR)\"\\n13740,1,1,\"Part C- Objective response rate (ORR)\"\\n13741,1,1,\"Part C: AUClast: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food\"\\n13742,1,1,\"Part C: AUC‚àû: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food\"\\n13743,1,1,\"Part C: Cmax: Maximum Observed Concentration for Alisertib Administered as an Enteric-Coated Capsule (ECT) With Food Versus Without Food\"\\n13744,1,1,\"Part C: Duration of response (DoR) based on RECIST v1.1 and iRECIST\"\\n13745,1,1,\"Part C: Incidence of dose limiting toxicity\"\\n13746,1,1,\"Part C: Number of Participants With Clinically Relevant Findings in Vital Signs\"\\n13747,1,1,\"Part C: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)\"\\n13748,1,1,\"Part C: Number of Participants With DLT\"\\n13749,1,1,\"Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0)\"\\n13750,1,1,\"Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13751,1,1,\"Part C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Related AEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0\"\\n13752,1,1,\"Part C: Number of subjects with TEAEs as assessed by NCI-CTCAE v5.0\"\\n13753,1,1,\"Part C: Objective Response Rate\"\\n13754,1,1,\"Part C: Objective Response Rate (ORR)\"\\n13755,1,1,\"Part C: Objective response rate (ORR) based on RECIST v1.1 and iRECIST\"\\n13756,1,1,\"Part C: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator\"\\n13757,1,1,\"Part C: Progression Free Survival (PFS) in G/GEJ DKK1 high patients treated with DKN-01 in combination with tislelizumab and chemotherapy vs tislelizumab and chemotherapy as a first-line therapy\"\\n13758,1,1,\"Part C: Progression-free survival (PFS) based on RECIST v1.1 and iRECIST\"\\n13759,1,1,\"Part C: Recommended Phase 2 Dose (RP2D) and Tolerability\"\\n13760,1,1,\"Part C: To determine the RD of ZB716 in combination with palbociclib\"\\n13761,1,1,\"Part D (Analyte=GSK2118436): AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib\"\\n13762,1,1,\"Part D (Analyte=GSK2118436): Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib\"\\n13763,1,1,\"Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib\"\\n13764,1,1,\"Part D/E: Adverse Events (AE) and safety laboratory values\"\\n13765,1,1,\"Part D: Area under the plasma concentration versus time curve at steady state [AUC(ss)] of AZD9150 administered once per week in combination with durvalumab.\"\\n13766,1,1,\"Part D: Incidence of dose limiting toxicity\"\\n13767,1,1,\"Part D: Minimum plasma concentration at steady state [Ctrough (ss)] of AZD9150 administered once per week in combination with durvalumab.\"\\n13768,1,1,\"Part D: Number of Participants with Adverse Event as a Measure of Safety and Tolerability\"\\n13769,1,1,\"Part D: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)\"\\n13770,1,1,\"Part D: Number of Participants With DLT\"\\n13771,1,1,\"Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13772,1,1,\"Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure\"\\n13773,1,1,\"Part D: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range\"\\n13774,1,1,\"Part D: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline\"\\n13775,1,1,\"Part D: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range\"\\n13776,1,1,\"Part D: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline\"\\n13777,1,1,\"Part D: Objective Response Rate\"\\n13778,1,1,\"Part D: Plasma Concentration of Lazertinib After Administration of Multiple Dose (MD)\"\\n13779,1,1,\"Part D: Plasma Concentration of Lazertinib After Administration of Single Dose (SD)\"\\n13780,1,1,\"Part D: RP2D of BGB-10188 in combination with tislelizumab\"\\n13781,1,1,\"Part D: To assess antitumor activities in the combination therapy of ZB716 and Palbociclib\"\\n13782,1,1,\"Part E: Incidence of dose limiting toxicity\"\\n13783,1,1,\"Part E: Number of Participants With DLT\"\\n13784,1,1,\"Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13785,1,1,\"Part F: Number of Participants With DLT\"\\n13786,1,1,\"Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13787,1,1,\"Part FE: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M3814\"\\n13788,1,1,\"Part FE: Maximum Observed Drug Concentration (Cmax) of M3814\"\\n13789,1,1,\"Part G: Number of Participants With DLT\"\\n13790,1,1,\"Part G: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13791,1,1,\"Part H: Number of Participants With DLT\"\\n13792,1,1,\"Part H: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13793,1,1,\"Part I - Maximum-tolerated dose (MTD) of the BI 754111 plus BI 754091 combination\"\\n13794,1,1,\"Part I - Number of patients experiencing Dose-limiting toxicity (DLTs) during the combination Maximum-tolerated dose (MTD) evaluation period (first cycle of BI 754111 plus BI 754091 combination therapy) in patients with solid tumours\"\\n13795,1,1,\"Part I and II: Maximum tolerated dose (MTD)\"\\n13796,1,1,\"Part I and II: Number of patients with Dose Limiting Toxicity (DLTs) in the Maximum tolerated dose (MTD) evaluation period\"\\n13797,1,1,\"Part I: Adverse Event profile for each drug dose of RM-1929\"\\n13798,1,1,\"Part I: Maximum tolerated dose (MTD) of BI 754091\"\\n13799,1,1,\"Part I: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) of RM-1929, whichever is lowest\"\\n13800,1,1,\"Part I: MTDÔºàMaximum tolerable doseÔºâor RDÔºàRecommended doseÔºâ\"\\n13801,1,1,\"Part I: Number of Participants With DLT\"\\n13802,1,1,\"Part I: Number of Participants With Non-serious TEAEs, STEAEs and AESIs\"\\n13803,1,1,\"Part I: Number of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period (first cycle of treatment)\"\\n13804,1,1,\"Part I: Occurrence of dose-limiting toxicities\"\\n13805,1,1,\"Part I: Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progrerssive Disease (PD) by Biomarker\"\\n13806,1,1,\"Part I: Photosafety (sunburn) Testing\"\\n13807,1,1,\"Part I: Progression Free Survival (PFS) by Biomarker\"\\n13808,1,1,\"Part I: Recommended Phase 2 Dose (RP2D)\"\\n13809,1,1,\"Part I: Safety and tolerability assessed by vital signs, laboratory measurements, and frequency and severity of treatment-related adverse events\"\\n13810,1,1,\"Part I: Time to Progression (TTP) by Biomarker\"\\n13811,1,1,\"Part I: To evaluate the incidence, severity and relationship of (S)AEs to establish the MTD/MAD of Sym024 monotherapy.\"\\n13812,1,1,\"Part IA and IB: Occurrence of Change From Baseline in Eastern Cooperative Oncology Group Performance Status\"\\n13813,1,1,\"Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Clinical Laboratory Measures\"\\n13814,1,1,\"Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Electrocardiogram Findings\"\\n13815,1,1,\"Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Vital Signs\"\\n13816,1,1,\"Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events (TRAEs) According to the National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 5\"\\n13817,1,1,\"Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) as per Severity and Deaths\"\\n13818,1,1,\"Part IA: Percentage of Participants with Adverse Events and Serious Adverse Events\"\\n13819,1,1,\"Part IB: Maximum Tolerated Dose (MTD) of Selicrelumab\"\\n13820,1,1,\"Part IB: Percentage of Participants with Adverse Events and Serious Adverse Events\"\\n13821,1,1,\"Part IB: Percentage of Participants With Dose-Limiting Toxicities (DLTs)\"\\n13822,1,1,\"Part IB: Recommended Part II Dose of Selicrelumab\"\\n13823,1,1,\"Part II - Objective response (OR) - confirmed complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as assessed by the Investigator during the entire treatment\"\\n13824,1,1,\"Part II: Clinical Activity of SC Selicrelumab in Combination with Bevacizumab as Assessed by Response Evaluation in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n13825,1,1,\"Part II: Duration of Objective Response per RECIST v1.1 Criteria\"\\n13826,1,1,\"Part II: Duration of Objective Response, as Determined by Investigator Using RECIST Version 1.1\"\\n13827,1,1,\"Part II: Duration of Objective Response, as Determined by Investigator Using Unidimensional irRC\"\\n13828,1,1,\"Part II: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) of a fixed drug dose with fixed light dose\"\\n13829,1,1,\"Part II: MTD of the BI 754091 plus BI 754111 combination\"\\n13830,1,1,\"Part II: Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment)\"\\n13831,1,1,\"Part II: Objective Response Rate (ORR)\"\\n13832,1,1,\"Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing)\"\\n13833,1,1,\"Part II: Objective Response Rate of Pertuzumab Therapy\"\\n13834,1,1,\"Part II: Objective Response Rate of Trastuzumab Therapy\"\\n13835,1,1,\"Part II: ORR(Objective Response Rate ) by investigator\"\\n13836,1,1,\"Part II: Overall Survival\"\\n13837,1,1,\"Part II: Percentage of Participants With a Best Overall Response of CR, PR, SD or PD by Biomarker\"\\n13838,1,1,\"Part II: Percentage of Participants with Adverse Events and Serious Adverse Events\"\\n13839,1,1,\"Part II: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria\"\\n13840,1,1,\"Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n13841,1,1,\"Part II: Percentage of Participants With Best Overall Response, as Determined by Investigator Using Unidimensional Immune-Related Response Criteria (irRC)\"\\n13842,1,1,\"Part II: Percentage of Participants With Disease Control per RECIST v1.1 Criteria\"\\n13843,1,1,\"Part II: Percentage of Participants With Disease Control, as Determined by Investigator Using RECIST Version 1.1\"\\n13844,1,1,\"Part II: Percentage of Participants With Disease Control, as Determined by Investigator Using Unidimensional irRC\"\\n13845,1,1,\"Part II: PFS, as Determined by Investigator Using Unidimensional irRC\"\\n13846,1,1,\"Part II: Progression Free Survival (PFS) by Biomarker\"\\n13847,1,1,\"Part II: Progression-free Survival (PFS) per RECIST v1.1 Criteria\"\\n13848,1,1,\"Part II: Progression-Free Survival (PFS), as Determined by Investigator Using RECIST Version 1.1\"\\n13849,1,1,\"Part II: Prostate-specific antigen (PSA) response rate\"\\n13850,1,1,\"Part II: Safety with repeat dosing\"\\n13851,1,1,\"Part II: To evaluate the incidence, severity and relationship of (S)AEs to establish MTD/MAD of Sym024 in combination with Sym021.\"\\n13852,1,1,\"Part II: TTP by Biomarker\"\\n13853,1,1,\"Part III: Objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator\"\\n13854,1,1,\"Part III: To evaluate the incidence, severity and relationship of (S)AEs to further assess safety of Sym024 when administered alone or in combination with Sym021.\"\\n13855,1,1,\"Part Worths\"\\n13856,1,1,\"Part1: Dose-limiting toxicities (DLT) for each dose level of rilotumumab tested\"\\n13857,2,1,\"Part1: Frequency of AE and SAEÔºàNCI CTCAE 5.0Ôºâ\"\\n13858,1,1,\"Part1: MTD / RDL\"\\n13859,1,1,\"Part1: Occurrence of AE and SAEÔºàNCI CTCAE 5.0Ôºâ\"\\n13860,1,1,\"Part1: Occurrence of DLT\"\\n13861,1,1,\"Part1:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146\"\\n13862,1,1,\"Part1:Number of subjects with DLT in each dose group within 1 cycles (21 days) after the first drug administration\"\\n13863,1,1,\"Part1:Recommended Phase 2 dose (RP2D) of HBM4003 combined with toripalimab\"\\n13864,1,1,\"Part1:The maximum tolerated dose (MTD) of HBM4003 combined with toripalimab\"\\n13865,1,1,\"Part2: Frequency of AE and SAEÔºàNCI CTCAE 5.0Ôºâ\"\\n13866,1,1,\"Part2: Occurrence of AE and SAEÔºàNCI CTCAE 5.0Ôºâ\"\\n13867,1,1,\"Part2:ORR, as determined by the Investigator using RECIST 1.1\"\\n13868,2,1,\"Partial remission (PR)\"\\n13869,1,1,\"Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n13870,1,1,\"Partial Response Rate in Both Groups of Patients.\"\\n13871,1,1,\"Partial Response Rate of the Drug Regimen\"\\n13872,1,1,\"Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1\"\\n13873,1,1,\"Participant Clinical Benefit Response Rate\"\\n13874,1,1,\"Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)\"\\n13875,1,1,\"Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)\"\\n13876,1,1,\"Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)\"\\n13877,1,1,\"Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)\"\\n13878,1,1,\"Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)\"\\n13879,1,1,\"Participant Incidence of Adverse Events\"\\n13880,1,1,\"Participant Overall Response (by Tumor Type Subsolid or Solid Tumor) as Measured by RECIST Criteria at 12 Months\"\\n13881,1,1,\"Participant Pain Severity Score Measured Using Brief Pain Inventory\"\\n13882,2,1,\"Participant Response Rate\"\\n13883,1,1,\"Participant response rate\"\\n13884,1,1,\"Participant Response Rate of Irinotecan and Cisplatin\"\\n13885,3,1,\"Participant Responses\"\\n13886,1,1,\"Participant Safety and Tolerability of TST001 in combination with gemcitabine and albumin-bound paclitaxel as characterized by frequency and severity of adverse events\"\\n13887,1,1,\"Participant Safety and Tolerability of TST001 in combination with Nivolumab and mFOLFOX6 as characterized by frequency and severity of adverse events\"\\n13888,1,1,\"Participant Safety and Tolerability of TST001 in combination with Nivolumab as characterized by frequency and severity of adverse events\"\\n13889,1,1,\"Participant Safety as characterized by frequency and severity of adverse events\"\\n13890,1,1,\"Participant Safety as characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0)\"\\n13891,1,1,\"Participant Safety as characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0).\"\\n13892,1,1,\"Participant Tumor Response Assessed by RECIST\"\\n13893,1,1,\"Participant With Weight Loss ‚â• 5% at the 8- Week Assessment When Compared to Baseline\"\\n13894,1,1,\"Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria\"\\n13895,1,1,\"Participants Achieving the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)\"\\n13896,1,1,\"Participants Experiencing a Dose Limiting Toxicity (DLT)\"\\n13897,2,2,\"Participants Experiencing Dose Limiting Toxicity (DLT)\"\\n13898,1,1,\"Participants Who Were Alive at the 90 Day Follow-Up\"\\n13899,4,2,\"Participants with Adverse Events\"\\n13900,2,1,\"Participants With Adverse Events (AEs)\"\\n13901,1,1,\"Participants With At Least One Treatment-Emergent Adverse Event (TEAE)\"\\n13902,1,1,\"Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)\"\\n13903,1,1,\"Participants With Dose Limiting Toxicities\"\\n13904,1,1,\"Participants With Dose Limiting Toxicities (DLT)\"\\n13905,1,1,\"Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period\"\\n13906,1,1,\"Participants With Dose Limiting Toxicities by Preferred Term in Cycle 1 (28 Days) - in Phase I\"\\n13907,1,1,\"Participants With Dose Limiting Toxicities During Dose Escalation\"\\n13908,1,1,\"Participants With Hematological and Biochemical Toxicities\"\\n13909,1,1,\"Participants With Injection Site Reactions to Tbo-Filgrastim Administration\"\\n13910,1,1,\"Participants With Mucositis and Hematological Toxicities With the Addition of Radioprotector Amifostine\"\\n13911,1,1,\"Participants With Negative Shifts From Baseline to End of Study in Physical Exam Findings\"\\n13912,1,1,\"Participants With Negative Shifts From Baseline to End of Study in Spleen Sonography Findings\"\\n13913,1,1,\"Participants With Potentially Clinically Significant Abnormal Electrocardiogram Results\"\\n13914,1,1,\"Participants With Potentially Clinically Significant Abnormal Hematology Results\"\\n13915,1,1,\"Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results\"\\n13916,1,1,\"Participants With Potentially Clinically Significant Abnormal Vital Signs\"\\n13917,1,1,\"Participants with Progression Free Survival at 1-Year\"\\n13918,1,1,\"Participants With Severity of Adverse Effects as Assessed by CTCAE v3.0\"\\n13919,1,1,\"Participants With Treatment -Emergent Adverse Events (TEAEs)\"\\n13920,1,1,\"Participants With Treatment -Emergent Adverse Events (TEAEs) Related to AMG 820 Treatment\"\\n13921,1,1,\"Participants With Treatment -Emergent Adverse Events (TEAEs) Related to Pembrolizumab Treatment\"\\n13922,1,1,\"Participation rate, defined as percentage of recruited patients who completed at least 70% of the scheduled questionnaires for 6 months out of all patients eligible for the study\"\\n13923,1,1,\"Parts 1 & 2: Intratumoral T-cell infiltration of CD8+C45RO+ cells\"\\n13924,1,1,\"Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)\"\\n13925,1,1,\"Parts 1 and 2: Number of participants requiring dose modifications\"\\n13926,1,1,\"Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)\"\\n13927,1,1,\"Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)\"\\n13928,1,1,\"Parts 1 and 2: Number of participants with any months adverse event(s) (AE) and serious adverse event(s) (SAE)\"\\n13929,1,1,\"Parts 1 and 2: Number of participants with clinically significant changes in laboratory parameters and vital signs\"\\n13930,1,1,\"Parts 1 and 2: Number of participants with dose limiting toxicity (DLT)\"\\n13931,1,1,\"Parts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)\"\\n13932,1,1,\"Parts 1 and 2: Percentage of Participants That Discontinued Study Treatment Due to an AE\"\\n13933,1,1,\"Parts 1 and 2: Percentage of Participants That Experienced an Adverse Event (AE)\"\\n13934,1,1,\"Parts 1 and 2: Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event (AE)\"\\n13935,1,1,\"Parts 1 and 2: Percentage of Participants With Adverse Events (AEs)\"\\n13936,1,1,\"Parts 1 and 2: Percentage of Participants With Anti-Drug Antibodies (ADAs)\"\\n13937,1,1,\"Parts 1 and 3: Number of participants with any adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, dose interruptions and reductions\"\\n13938,1,1,\"Parts 1 and 3: Number of participants with clinically significant changes in laboratory parameters, vital signs, physical examination and organ-specific parameters.\"\\n13939,1,1,\"Parts 1, 2 and 3: Number of participants with treatment emergent adverse events (AEs)\"\\n13940,1,1,\"Parts 1, 2, 4, and 5: Number of Participants Who Discontinued Study Treatment Due to an AE\"\\n13941,1,1,\"Parts 1, 2, 4, and 5: Number of Participants Who Experienced an Adverse Event (AE)\"\\n13942,1,1,\"Parts 1, 2, 4, and 5: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs)\"\\n13943,1,1,\"Parts 1, 2, and 3: Number of participants with dose limiting toxicities (DLTs)\"\\n13944,1,1,\"Parts 1, 2, and 3: Number of participants with laboratory abnormalities\"\\n13945,1,1,\"Parts 1.2-DE, 1.3, and 2.2 (Dose Expansion): ORR defined as the percentage of participants with partial response or complete response based on RECIST 1.1.\"\\n13946,1,1,\"Parts 1.2-DS and 2.1 (RP2D Selection): Change in ECOG performance status.\"\\n13947,1,1,\"Parts 1.2-DS and 2.1 (RP2D Selection): Frequency counts and percentages of AEs based on MedDRA and CTCAE v5.0\"\\n13948,1,1,\"Parts 1.2-DS and 2.1 (RP2D Selection): ORR\"\\n13949,1,1,\"Parts 1.2-DS and 2.1 (RP2D Selection): Proportion of participants with DLTs.\"\\n13950,1,1,\"Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03\"\\n13951,1,1,\"Parts 1a and 1b: MTD\"\\n13952,1,1,\"Parts 1a and 1b: RP2D\"\\n13953,1,1,\"Parts 1a and 1b; incidence of AEs, serious adverse events (SAEs), and DLTs\"\\n13954,1,1,\"Parts 1A and 2A: Number of participants achieving dose-limiting toxicity (DLT)\"\\n13955,1,1,\"Parts 1A and 2A: Number of participants with adverse events (AEs) and serious adverse events (SAEs) by severity\"\\n13956,1,1,\"Parts 1A/2A: Incidence and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0\"\\n13957,1,1,\"Parts 2 and 3: Complete Remission Rate Within 2 Cycles of Study Treatment in Participants with TP53 WT Leukemia\"\\n13958,1,1,\"Parts 2 and 3: Percentage of Participants with TP53 Wild-Type (WT) Neuroblastoma Achieving an Objective Response\"\\n13959,1,1,\"Parts 2 and 3: Percentage of Participants with TP53 WT ALL who are Minimal Residual Disease (MRD)-Negative Within 2 Cycles of Study Treatment\"\\n13960,1,1,\"Parts 2A/2B: To evaluate the clinical activity of GSK1120212 and GSK2141795 administered in combination in subjects with solid tumors that are predicted to be sensitive to the inhibition of MEK and/or AKT, including TNBC and BRAF-wild type melanoma\"\\n13961,1,1,\"Parts 3 and 4: Area Under the Serum Concentration Versus Time Curve from Time Zero to Dosing Interval (AUC [0-tau])\"\\n13962,1,1,\"Parts A and B: Anti-tumour activity by measurement of changes in circulating prostate-specific antigen (PSA)\"\\n13963,1,1,\"Parts A and B: Anti-tumour activity by measurement of changes in circulating tumour cells (CTC)\"\\n13964,1,1,\"Parts A and B: Anti-tumour activity by measurement of malignant soft tissue response rate\"\\n13965,1,1,\"Parts A and B: Anti-tumour activity by measurement of metastatic bone disease status\"\\n13966,1,1,\"Parts A, B and D: Number of participants experiencing Adverse Events (AEs) Leading to Discontinuation\"\\n13967,1,1,\"Parts A, B, and D: Number of participants experiencing Severe Adverse Events (SAEs)\"\\n13968,1,1,\"Parts A, B, and D: Number of participants experiencing Treatment Emergent Adverse Events (TEAEs)\"\\n13969,1,1,\"Parts A, B, B2, C1, C2, C3: Safety parameters, including adverse event (AEs), clinical laboratory values (serum chemistry, hematology, and urinalysis), vital signs, and electrocardiogram (ECG) assessments\"\\n13970,1,1,\"Parts A,B,C,D,E & F : Safety and tolerability of AZD5363 in terms of adverse events and serious adverse events\"\\n13971,1,1,\"Parts A,B,C,D,E & F : Safety and tolerability of AZD5363 in terms of death\"\\n13972,1,1,\"Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing changes from baseline in electrocardiogram (ECG) parameters\"\\n13973,1,1,\"Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing changes from baseline of glucose laboratory parameters (Urine, serum and plasma glucose, glycosylated haemoglobin).\"\\n13974,1,1,\"Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing changes from baseline of laboratory data (clinical chemistry, haematology, urinalysis)\"\\n13975,1,1,\"Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing left ventricular ejection fraction (LVEF).\"\\n13976,1,1,\"Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 in terms of changes from baseline in vital signs and in electrocardiogram (ECG) parameters\"\\n13977,1,1,\"Parts B and C: Adverse Events\"\\n13978,1,1,\"Parts B and C: Disease Control Rate\"\\n13979,1,1,\"Parts B and C: Duration of Response\"\\n13980,1,1,\"Parts B and C: Objective Response Rate\"\\n13981,1,1,\"Parts B and C: Overall Survival\"\\n13982,1,1,\"Parts B and C: Progression-free Survival\"\\n13983,1,1,\"Parts B and C: Time to Response\"\\n13984,1,1,\"Parts C1, C2, C3: Overall Response Rate (ORR) for all participants in Part C1 (NSCLC), ORR for participants in Part C2 (TNBC) who are basaloid subtype and BRCA1/BRCA2 germline wild-type, ORR for all participants in Part C3 (SCLC)\"\\n13985,1,1,\"Pathologic Changes From Bronchoscopic Laser Ablation of Peripheral Lung Tumors\"\\n13986,22,1,\"Pathologic Complete Response\"\\n13987,16,2,\"Pathologic complete response\"\\n13988,10,1,\"pathologic complete response\"\\n13989,1,1,\"Pathologic complete response (CR) rate\"\\n13990,1,1,\"Pathologic Complete Response (PCR)\"\\n13991,15,1,\"Pathologic Complete Response (pCR)\"\\n13992,13,2,\"Pathologic complete response (pCR)\"\\n13993,4,2,\"pathologic Complete Response (pCR)\"\\n13994,1,1,\"Pathologic complete response (pCR) (Phase II)\"\\n13995,1,1,\"Pathologic complete response (pCR) by local review\"\\n13996,1,1,\"Pathologic Complete Response (pCR) in the Breast\"\\n13997,1,1,\"Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).\"\\n13998,1,1,\"Pathologic complete response (pCR) or complete clinical response (cCR) at 12 months\"\\n13999,6,1,\"Pathologic Complete Response (pCR) Rate\"\\n14000,13,2,\"Pathologic complete response (pCR) rate\"\\n14001,9,1,\"pathologic complete response (pCR) rate\"\\n14002,1,1,\"Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery\"\\n14003,1,1,\"Pathologic Complete Response (pCR), as Determined by Local Pathologic Review\"\\n14004,21,1,\"Pathologic Complete Response Rate\"\\n14005,14,2,\"Pathologic complete response rate\"\\n14006,1,1,\"Pathologic Complete Response Rate (pCR Rate)\"\\n14007,1,1,\"Pathologic Complete Response Rate (pCRR) After Induction Chemotherapy With Carboplatin, Nab-paclitaxel, and Durvalumab in Previously Untreated Stage III and IV SCCHN Amenable to Surgical Resection\"\\n14008,2,1,\"Pathologic complete response rate (Phase II)\"\\n14009,1,1,\"Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.\"\\n14010,1,1,\"Pathologic Complete Response Rate of Neoadjuvant Gemcitabine and Fractionated Cisplatin for Patients With Muscle Invasive Bladder Cancer Whom Are Not Candidates for High Dose Cisplatin.\"\\n14011,1,1,\"Pathologic complete response rate(pCR)\"\\n14012,1,1,\"pathologic Complete Response, PCR\"\\n14013,3,1,\"pathologic complete responseÔºàpCRÔºâ\"\\n14014,1,1,\"Pathologic Downstaging and Margin Status\"\\n14015,1,1,\"Pathologic No Response (pNR)\"\\n14016,9,1,\"Pathologic response\"\\n14017,1,1,\"Pathologic response in cohort 1\"\\n14018,1,1,\"Pathologic Response Rate (pRR) for Cohort 1 as Determined by Independent Pathologic Review\"\\n14019,1,1,\"pathological assessment of response to treatment\"\\n14020,3,1,\"Pathological complete remission (pCR)\"\\n14021,10,1,\"Pathological Complete Response\"\\n14022,20,1,\"Pathological complete response\"\\n14023,1,1,\"Pathological Complete Response (pathCR) Rate\"\\n14024,2,2,\"Pathological Complete Response (pathCR) Rate - Pembrolizumab+Chemotherapy and Placebo+Chemotherapy Treatment Arms\"\\n14025,14,4,\"Pathological Complete Response (pCR)\"\\n14026,13,2,\"Pathological complete response (pCR)\"\\n14027,11,1,\"pathological complete response (pCR)\"\\n14028,1,1,\"Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort\"\\n14029,1,1,\"Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Wild-type Cohort\"\\n14030,9,2,\"Pathological Complete Response (pCR) Rate\"\\n14031,15,3,\"Pathological complete response (pCR) rate\"\\n14032,1,1,\"Pathological Complete Response (pCR) Rate at the Time of Surgery - All Participants\"\\n14033,1,1,\"Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Mutant (MT)\"\\n14034,1,1,\"Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Wild Type (WT)\"\\n14035,1,1,\"Pathological Complete Response (pCR) rate defined as the complete absence of invasive carcinoma on histological examination of the breast at the time of definitive surgery and confirmed by blinded centralized review\"\\n14036,1,1,\"Pathological complete response (pCR) rate defined as the percentage of participants who have no residual invasive disease in the breast and no residual disease in the lymph node.\"\\n14037,1,1,\"Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only)\"\\n14038,1,1,\"Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery.\"\\n14039,1,1,\"Pathological Complete Response (pCR) RCB-0 or RCB-1\"\\n14040,25,2,\"Pathological complete response rate\"\\n14041,2,2,\"Pathological complete response rate (pCR) (ypT0/is N0)\"\\n14042,1,1,\"Pathological complete response rate (pCR, Becker criteria, TRG 1A)\"\\n14043,1,1,\"Pathological complete response rate (randomized phase)\"\\n14044,1,1,\"Pathological complete response rate based on blinded, independent, central review\"\\n14045,1,1,\"Pathological impact of PD-L1 neutralisation (by atezolizumab) with or without radiotherapy versus radiotherapy alone in operable localised STS\"\\n14046,1,1,\"Pathological objective response (ORR) rate\"\\n14047,6,1,\"Pathological Response\"\\n14048,6,1,\"Pathological response\"\\n14049,1,1,\"Pathological Response for Basal Group 2\"\\n14050,21,1,\"Pathological response rate\"\\n14051,1,1,\"Pathological response rate evaluated after 4 cycles of neoadjuvant Toripalimab in combination with gemcitabine and cisplatin at time of radical cystectomy, each cycle is 21 days\"\\n14052,1,1,\"Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC)\"\\n14053,1,1,\"Pathology tpCR (ypT0/is, ypN0) rate\"\\n14054,1,1,\"Patient accrual per center over a 12-month period\"\\n14055,1,1,\"Patient advocate foundation (PAF) navigators\"\\n14056,1,1,\"Patient Benefit Rate at 12 Weeks\"\\n14057,1,1,\"Patient completion of the Educate, Nurture, Advise, Before Life Ends (ENABLE) program\"\\n14058,2,1,\"Patient Compliance\"\\n14059,9,1,\"Patient compliance\"\\n14060,5,1,\"Patient demographics\"\\n14061,1,1,\"Patient Global Survey/Caregiver Global Survey\"\\n14062,1,1,\"Patient interviews : qualitative comparison versus EORTC PAL 15 questionary\"\\n14063,1,1,\"Patient needs detected\"\\n14064,1,1,\"Patient Pain Visual Analog Scale Score at Visit 1\"\\n14065,6,1,\"Patient quality of life\"\\n14066,1,1,\"Patient Related Outcomes\"\\n14067,5,1,\"Patient Reported Outcomes Measurement Information System (PROMIS)\"\\n14068,1,1,\"Patient reported outcomes.\"\\n14069,3,2,\"Patient Response Rate\"\\n14070,1,1,\"Patient Response Rate (Percentage)\"\\n14071,1,1,\"Patient response rate according to RECIST criteria\"\\n14072,1,1,\"Patient Response to Treatment Measured by RECIST Criteria\"\\n14073,1,1,\"Patient Results of functional tests of postural control (Timed 50 feet walk + Timed Get Up & Go Test)\"\\n14074,1,1,\"Patient Risk Score (PRS) for All Patients\"\\n14075,1,1,\"Patient Risk Score (PRS) for Patients Receiving Chemotherapy With 10-20% FN Risk by Tumor Type\"\\n14076,1,1,\"Patient satisfaction survey with telemedicine in radiation oncology (RO)\"\\n14077,1,1,\"Patient Satisfaction With Anaesthesia Technique\"\\n14078,1,1,\"Patient Satisfaction With Communication About Age-related Concerns: Measured by Health Care Climate Questionnaire (HCCQ). [NCI Specified]\"\\n14079,1,1,\"Patient satisfaction with the PCI\"\\n14080,1,1,\"Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity\"\\n14081,1,1,\"Patient vomiting\"\\n14082,1,1,\"Patient Weight by Tumor Type (Solid Tumor vs. Hematological Tumor)\"\\n14083,1,1,\"Patient\\'s ability to complete the assessment\"\\n14084,1,1,\"Patient\\'s Global Assessment of Disease Activity at Visit 1\"\\n14085,1,1,\"Patient\\'s progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy.\"\\n14086,1,1,\"Patient-Centered Communication in Cancer Care\"\\n14087,1,1,\"Patient-level opportunity costs associated with oncology care\"\\n14088,1,1,\"Patient-reported maximum score\"\\n14089,1,1,\"Patient-reported outcomes (PROs) and physician rated Common Terminology Criteria for Adverse Events (CTCAE) (Arm 2)\"\\n14090,1,1,\"Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-Short Form\"\\n14091,1,1,\"Patient-reported physical function as assessed by the Functional Assessment of Cancer Therapy Physical Well-Being Subscale (FACIT PWB) in cancer survivors.\"\\n14092,1,1,\"Patient-reported severity of anxiety\"\\n14093,1,1,\"Patient-reported severity of depression\"\\n14094,1,1,\"Patient-reported severity of distress\"\\n14095,1,1,\"Patient/Center-level Covariance Parameter Estimates of Absolute Neutrophil Count\"\\n14096,1,1,\"Patients alive with grade 3 or 4 infusional toxicity (Phase II)\"\\n14097,1,1,\"Patients alive without grade 3, 4 infusional toxicity (Phase II)\"\\n14098,1,1,\"Patients Experienced Grade >=3 Toxicity at Dose Level 5 (1,000 mg/m2 IP Pemetrexed)\"\\n14099,1,1,\"Patients Experiencing Dose-limiting Toxicity\"\\n14100,1,1,\"Patients not alive (Phase II)\"\\n14101,1,1,\"Patients That Completed at Least 6 Courses of Therapy of Pemetrexed Along With Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)at the Determined Maximum Tolerated Dose\"\\n14102,1,1,\"Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, \\'DEFINITE\\', \\'POSSIBLE\\',\\'PROBABLE\\'\"\\n14103,1,1,\"Patients Who Have Objective Tumor Response (Complete or Partial Response)\"\\n14104,1,1,\"Patients who suffered bleeding complication\"\\n14105,1,1,\"Patients Who Survive Progression-free for at Least 6 Months\"\\n14106,1,1,\"Patients who wear Philips Actiwatch and have data captured successfully for at least 75% of the time\"\\n14107,1,1,\"Patients with dose limiting toxicities\"\\n14108,1,1,\"Patients With Dose Limiting Toxicities (DLT)\"\\n14109,1,1,\"Patients with Dose Limiting Toxicity\"\\n14110,2,1,\"Patients with Dose Limiting Toxicity (DLT)\"\\n14111,1,1,\"Patients with Dose Limiting Toxicity (DTL)\"\\n14112,1,1,\"Patients With Elevated Par-4 Levels\"\\n14113,1,1,\"Patients with high impairment of EORTC QLQ-C30 scoring\"\\n14114,1,1,\"Patients with high improvement in EORTC QLQ-C3 scoring\"\\n14115,1,1,\"Patients with mild impairment of EORTC QLQ-C30 scoring\"\\n14116,1,1,\"Patients with mild improvement in Quality of life questionnaire - Current standard version 3.0 (EORTC QLQ-C30) scoring\"\\n14117,1,1,\"Patients with mild/moderate/high improvement in EORTC QLQ-C30\"\\n14118,1,1,\"Patients with moderate impairment of EORTC QLQ-C30 scoring\"\\n14119,1,1,\"Patients with moderate improvement in EORTC QLQ-C30 scoring\"\\n14120,1,1,\"Patients With Progression-free Survival\"\\n14121,1,1,\"Patients With Progression-free Survival (PFS) Greater Than or Equal to 12 Weeks (Phase II)\"\\n14122,1,1,\"Patients With PSA <4 ng/mL at the End of the Study\"\\n14123,1,1,\"Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A.\"\\n14124,1,1,\"Patients\\' and caregivers\\' opinions on quality of care\"\\n14125,1,1,\"patients\\' autonomy\"\\n14126,1,1,\"patients\\' expectations for therapeutic benefit\"\\n14127,1,1,\"Patients\\' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14128,1,1,\"Patients\\' perceptions of healthcare provider empathy\"\\n14129,1,1,\"Patients\\' perceptions, motivations, and expectations as assessed by survey prior to and 2 months after enrollment on a phase I clinical trial\"\\n14130,1,1,\"Patients\\' preference\"\\n14131,1,1,\"Patients\\' Reported Satisfaction with Acupuncture Services\"\\n14132,1,1,\"Patients\\' symptom intensity and symptom interference with daily activities\"\\n14133,1,1,\"PBPC mobilization profiles and success rate of achieving planned chemotherapy administration on time.\"\\n14134,4,1,\"PCR\"\\n14135,3,1,\"pCR Rate\"\\n14136,1,1,\"pCR Rate After Treatment.\"\\n14137,1,1,\"pCR(complete pathological response)\"\\n14138,1,1,\"PD-L1 expression\"\\n14139,1,1,\"PD-L1 protein levels in the membrane of circulating tumor cells\"\\n14140,1,1,\"PD1+ cell pharmacodynamic response in blood to tremelimumab/durvalumab treatment\"\\n14141,16,1,\"Peak concentration (Cmax)\"\\n14142,1,1,\"Peak Concentration (Cmax) of RO5185426 on Day 1 - Dose Escalation: Original Formulation\"\\n14143,1,1,\"Peak Concentration (Cmax) of RO5185426 on Day 15 - Dose Escalation: Original Formulation\"\\n14144,1,1,\"Peak concentrations (Cmax) of vorinostat at 400, 1200, and 1600 mg\"\\n14145,98,2,\"Peak Plasma Concentration (Cmax)\"\\n14146,1,1,\"Peak plasma concentration (Cmax) of CM082\"\\n14147,1,1,\"Peak Plasma Concentration (Cmax) of MGCD516\"\\n14148,1,1,\"Peak plasma concentration after drug administration (Cmax) of BAY3375968\"\\n14149,1,1,\"Peak Plasma Concentration of Entinostat: C-Max\"\\n14150,1,1,\"Peak plasma concentration of regorafenib\"\\n14151,1,1,\"Peak plasma concentration(Cmax) of CM082 (test product or reference product) under fasted state or after meal\"\\n14152,1,1,\"Peak plasma drug concentration (Cmax)\"\\n14153,2,1,\"peak time (Tmax)\"\\n14154,3,1,\"Peak time(Tmax)\"\\n14155,1,1,\"Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort\"\\n14156,1,1,\"Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort\"\\n14157,1,1,\"Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort\"\\n14158,1,1,\"Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort\"\\n14159,1,1,\"Peak Transgene Copy Number Per 1000ng PBMC DNA\"\\n14160,1,1,\"Pearson\\'s correlation between the initial Tumour Metabolic Total Volume and the area under the curve of iPD-1 .\"\\n14161,1,1,\"Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)\"\\n14162,1,1,\"Pembro Combo vs Chemo: Overall Survival (OS)\"\\n14163,1,1,\"Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n14164,1,1,\"Pembro Combo vs Control: OS in Participants With PD-L1 CPS ‚â•1\"\\n14165,1,1,\"Pembro Combo vs Control: OS in Participants With PD-L1 CPS ‚â•20\"\\n14166,1,1,\"Pembro Combo vs Control: Overall Survival (OS) in All Participants\"\\n14167,1,1,\"Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ‚â•20\"\\n14168,1,1,\"Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ‚â•1\"\\n14169,1,1,\"Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants\"\\n14170,1,1,\"Pembro Combo vs SOC: OS in Participants With PD-L1 CPS ‚â•10\"\\n14171,1,1,\"Pembro Combo vs SOC: Overall Survival (OS) in Participants With PD-L1 CPS ‚â•1 (All Participants)\"\\n14172,1,1,\"Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ‚â•1 (All Participants)\"\\n14173,1,1,\"Pembro Mono vs Control: OS in All Participants\"\\n14174,1,1,\"Pembro Mono vs Control: OS in Participants With PD-L1 CPS ‚â•1\"\\n14175,1,1,\"Pembro Mono vs Control: OS in Participants With PD-L1 CPS ‚â•20\"\\n14176,1,1,\"Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in All Participants\"\\n14177,1,1,\"Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ‚â•1\"\\n14178,1,1,\"Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ‚â•20\"\\n14179,1,1,\"Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ‚â•1 (All Participants)\"\\n14180,1,1,\"Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ‚â•10\"\\n14181,1,1,\"Pembro vs Chemo: OS\"\\n14182,1,1,\"Pembro vs Chemo: OS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ‚â•10%\"\\n14183,1,1,\"Pembrolizumab Absorption Rate (Ka)\"\\n14184,1,1,\"Pembrolizumab Area Under the Concentration-Time Curve (AUC) - Pembrolizumab Sequence 1-6\"\\n14185,1,1,\"Pembrolizumab Bioavailability (F)\"\\n14186,1,1,\"Pembrolizumab Central Volume of Distribution (Vc)\"\\n14187,1,1,\"Pembrolizumab Clearance (CL)\"\\n14188,1,1,\"Pembrolizumab Maximum Plasma Concentration (Cmax) - Pembrolizumab Sequence 1-6\"\\n14189,1,1,\"Pembrolizumab Time of Maximum Plasma Concentration (Tmax)\"\\n14190,1,1,\"Pep-Pal Self-Report sessions at 12 Weeks\"\\n14191,1,1,\"Perceived availability of social support\"\\n14192,3,1,\"Perceived barriers\"\\n14193,2,1,\"Perceived benefits\"\\n14194,1,1,\"Perceived physical function incongruence\"\\n14195,1,1,\"Perceived usefulness of individual items\"\\n14196,1,1,\"Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)\"\\n14197,1,1,\"Percent Change From Baseline in Activated and Memory T Cells\"\\n14198,1,1,\"Percent Change From Baseline in Chemistry Parameters During Combination Treatment Period: Blood Urea Nitrogen (BUN), Uric Acid\"\\n14199,1,1,\"Percent Change From Baseline in Chemistry Parameters in Combination Treatment Period:ALT, Albumin, ALP, AST, Calcium, CO2, Chloride, Creatinine, Direct Bilirubin, Glucose, Lactate Dehydrogenase, Magnesium, Potassium, Sodium, Total Bilirubin, Total Protein\"\\n14200,1,1,\"Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood\"\\n14201,1,1,\"Percent Change From Baseline in Gene Expression of PDGF A, PDGF B, PDGF C, and PDGF-D Canonical Ligands in Tumor Tissue\"\\n14202,1,1,\"Percent Change From Baseline in Gene Expression of Platelet-Derived Growth Factor Receptor Alpha (PGDFRŒ±) and PGDFR Beta (Œ≤) in Tumor Tissue\"\\n14203,1,1,\"Percent Change From Baseline in Hematology Parameters During Combination Treatment Period: Basophils, Eosinophils, Hematocrit, Hemoglobin, Lymphocytes, MCH, MCV, Monocytes, Total Neutrophils, Platelet Count, WBC Count\"\\n14204,1,1,\"Percent Change From Baseline in Hematology Parameters During Combination Treatment Period: International Normalized Ratio (INR), Prothrombin Time (PT), Partial Thromboplastin Time (PTT)\"\\n14205,1,1,\"Percent Change From Baseline in Urine Concentration of Calcium, Creatinine Concentration, Magnesium, Phosphate, Protein During Combination Treatment Period\"\\n14206,1,1,\"Percent Change From Baseline to 2 Weeks in Ki67 Expression\"\\n14207,1,1,\"Percent Change in Delayed Recall at 4 Months as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)\"\\n14208,1,1,\"Percent Change in Ki-67 by Immunohistochemistry (IHC)\"\\n14209,1,1,\"Percent Change in Peripheral blood CRP level\"\\n14210,1,1,\"Percent change in scores on the ACE over time\"\\n14211,1,1,\"Percent change in scores on the TOVA over time\"\\n14212,1,1,\"Percent decrease of phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 in tumor cells\"\\n14213,1,1,\"Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5)\"\\n14214,1,1,\"Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition\"\\n14215,1,1,\"Percent inhibition of peripheral blood mononuclear cell PARP enzyme activity (Part A, B, and C)\"\\n14216,1,1,\"Percent of good quality tumor samples obtained\"\\n14217,1,1,\"Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)\"\\n14218,1,1,\"Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) Œ≥H2AX at the Day 8 Biopsy\"\\n14219,1,1,\"Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB.\"\\n14220,1,1,\"Percent of Participants With 100-day Survival Without Graft Failure\"\\n14221,1,1,\"Percent of Participants With All Grade Neutrophil Count Decrease\"\\n14222,1,1,\"Percent of Participants With Best Overall Response Rate in Safety Population and in Tumor Evaluable Population\"\\n14223,1,1,\"Percent of Participants With Grade 2 or Higher Toxicities\"\\n14224,1,1,\"Percent of Participants With Grade 2-5 Toxicity Using National Cancer Institute Common Toxicity Criteria Version 4.0\"\\n14225,1,1,\"Percent of Participants With Grade 3 or Higher Non-hematological Toxicities and Symptomatic Congestive Heart Failure\"\\n14226,1,1,\"Percent of Participants With Grade 3 or Higher Toxicities Attributable to Treatment\"\\n14227,1,1,\"Percent of participants with positive ANC engraftment\"\\n14228,1,1,\"Percent of Participants With Progression Free Survival (PFS) After 1 Year Treatment\"\\n14229,1,1,\"Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC)\"\\n14230,1,1,\"Percent of Patients Experiencing an Unacceptable Toxicity\"\\n14231,1,1,\"Percent of patients who achieve \"\"data capture success\"\" defined as having both PRO data and accelerometry data transmitted to the investigators in 80% of the observation days\"\\n14232,1,1,\"Percent of patients who demonstrate simultaneous Rad51 activation\"\\n14233,1,1,\"Percent of Patients Who Progressed After Treatment (Part 2)\"\\n14234,1,1,\"Percent of patients who receive a treatment that targets a genomic variant for which there is sufficient data to support actionability\"\\n14235,1,1,\"Percent of patients who require intubation or meet criteria for intubation\"\\n14236,1,1,\"Percent of Patients Who Survived After Treatment (Part 2)\"\\n14237,1,1,\"Percent of Patients With a Prostate-specific Antigen (PSA) Decline of at Least 50% Below Baseline PSA50 Response Rate\"\\n14238,1,1,\"Percent of patients with acute or chronic grade >= 3 treatment-related toxicity per Common Terminology Criteria for Adverse Events version 4.0\"\\n14239,1,1,\"Percent of patients with an adverse event (AE)\"\\n14240,1,1,\"Percent of Patients With Disease Control\"\\n14241,1,1,\"Percent of Total Radioactivity (TRA) in Urine and Feces\"\\n14242,1,1,\"Percent Probability of Participants With 6-month Progression-free Survival (PFS)\"\\n14243,1,1,\"Percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events\"\\n14244,1,1,\"Percent tapered off of opioid in the telehealth group over time compared to usual care (opioid naive)\"\\n14245,1,1,\"Percent tapered off of opioid in the telehealth group over time compared to usual care (opioid tolerant)\"\\n14246,1,1,\"Percent Tumor Necrosis\"\\n14247,1,1,\"Percentage and severity of Participants With Adverse Events (AEs)\"\\n14248,1,1,\"Percentage cell viability\"\\n14249,1,1,\"Percentage change from baseline in tumour size\"\\n14250,1,1,\"Percentage Change From Baseline in Tumour Size at 12 Weeks\"\\n14251,1,1,\"Percentage change in DCE-MRI and DCE-CT vascular parameters. Comparison between vascular parameters of each imaging modality and between modalities.\"\\n14252,1,1,\"Percentage change in glucocorticoid-induced tumor necrosis factor receptor-Related(GITR)+ Treg density\"\\n14253,1,1,\"Percentage change in reduction of hypoxia by atovaquone\"\\n14254,1,1,\"Percentage change of GLi levels in treated vs untreated tumors\"\\n14255,1,1,\"Percentage change of urinary N-terminal telopeptide of type 1 collagen/creatine (U-NTX/Cr) from baseline to week 13\"\\n14256,1,1,\"Percentage extrapolation calculated as (AUC0-‚àû-AUC0-t)/(AUC0-‚àû)x100\"\\n14257,1,1,\"Percentage of adverse effects after CART/CTL/DCvac cells injection\"\\n14258,2,2,\"percentage of adverse effects after EIE cell injection\"\\n14259,1,1,\"percentage of adverse effects after OC-IgT cells injection\"\\n14260,11,1,\"Percentage of adverse events\"\\n14261,3,1,\"Percentage of Adverse Events (AEs)\"\\n14262,2,2,\"Percentage of adverse events (AEs)\"\\n14263,1,1,\"Percentage of Area Under the Plasma Concentration Curve Extrapolated to Infinity (%AUC(Extra))\"\\n14264,1,1,\"Percentage of Asian Participants With Symptomatic Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Per Response Evaluation Criteria in Solid Tumors Version 1.1 at Week 25\"\\n14265,1,1,\"Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ‚â•16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)\"\\n14266,1,1,\"Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1\"\\n14267,1,1,\"Percentage of Breast Cancer Cohort Participants With Objective Response Assessed Using RECIST v1.1\"\\n14268,1,1,\"Percentage of CD4 and CD8 T cells expressing PD-1\"\\n14269,1,1,\"Percentage of CD8 cells in on-treatment biopsies\"\\n14270,1,1,\"Percentage of cells killed\"\\n14271,1,1,\"percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 2 blood volume processed)\"\\n14272,1,1,\"percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed)\"\\n14273,1,1,\"Percentage of Dose Excreted in Urine for TAK-659\"\\n14274,2,2,\"Percentage of dose limiting toxicities (DLTs)\"\\n14275,1,1,\"Percentage of Dose of Talazoparib Excreted During Each Collection Interval (Aet1-t2%) of Talazoparib\"\\n14276,1,1,\"Percentage of Dose-Limiting Toxicities (DLTs)\"\\n14277,1,1,\"Percentage of enrolled patients by cancer type and treatment regimen overall\"\\n14278,1,1,\"Percentage of Epidermal Growth Factor Receptor (EGFR) Immunohistochemistry (IHC) Positive Participants With PD or Death (Data Cutoff 17 May 2008)\"\\n14279,1,1,\"Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months\"\\n14280,2,2,\"Percentage of events requiring withdrawal\"\\n14281,1,1,\"Percentage of Geriatric Assessments for which all three items (Timed Up and Go Assessment, Blessed Orientation-Memory-Concentration Test, and the healthcare professional-rated Karnofsky performance status) are completed\"\\n14282,1,1,\"Percentage of Group B2 participants with resectable tumors\"\\n14283,1,1,\"Percentage of HER2-positive lesions\"\\n14284,1,1,\"Percentage of immune cells\"\\n14285,1,1,\"Percentage of kidney transplant recipients who do not experience allograft loss\"\\n14286,1,1,\"Percentage of kidney transplant recipients who experience complete response (CR), partial response (PR) or stable disease (SD)\"\\n14287,1,1,\"Percentage of minority and underserved study participants accrued\"\\n14288,1,1,\"Percentage of overall response rate (ORR)\"\\n14289,1,1,\"Percentage of overall response rate (ORR) by immunotherapy RECIST (iRECIST) at the RP2D\"\\n14290,1,1,\"Percentage of overall response rate (ORR) by RECIST 1.1 at the RP2D\"\\n14291,1,1,\"Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)\"\\n14292,1,1,\"Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment\"\\n14293,1,1,\"Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment\"\\n14294,1,1,\"Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment\"\\n14295,1,1,\"Percentage of Participant With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n14296,1,1,\"Percentage of Participant With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n14297,1,1,\"Percentage of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n14298,1,1,\"Percentage of Participant With Different Symptoms Prior to Treatment (MDASI Questionnaire)\"\\n14299,1,1,\"Percentage of Participant With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment\"\\n14300,1,1,\"Percentage of Participant With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment\"\\n14301,1,1,\"Percentage of Participant With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment\"\\n14302,1,1,\"Percentage of Participant with Radiographic Imaging Modality\"\\n14303,1,1,\"Percentage of participant with reported DLT (Phase 1)\"\\n14304,1,1,\"Percentage of Participant With Various Fatigue Severity 10-12 Weeks After Start of Treatment\"\\n14305,1,1,\"Percentage of Participant With Various Fatigue Severity 3-4 Weeks After Start of Treatment\"\\n14306,1,1,\"Percentage of Participant With Various Fatigue Severity 6-8 Weeks After Start of Treatment\"\\n14307,1,1,\"Percentage of Participant With Various Fatigue Severity Prior To Treatment\"\\n14308,1,1,\"Percentage of Participants (Par.) With 5-month Progression-free Survival (PFS)\"\\n14309,1,1,\"Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)\"\\n14310,1,1,\"Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)\"\\n14311,1,1,\"Percentage of Participants Achieving Complete Resection (R0 Resection)\"\\n14312,1,1,\"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])\"\\n14313,1,1,\"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Guidelines\"\\n14314,1,1,\"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria-Part 3\"\\n14315,1,1,\"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)\"\\n14316,1,1,\"Percentage of Participants Achieving Complete Response or Partial Response Based on RECIST 1.1 Criteria-Part 4\"\\n14317,1,1,\"Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population\"\\n14318,1,1,\"Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Pretreated Participants\"\\n14319,1,1,\"Percentage of Participants Achieving Objective Response (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 as Assessed by Independent Review Facility (IRF)\"\\n14320,1,1,\"Percentage of Participants Achieving Objective Response Rate (ORR) (Complete Response + Partial Response)\"\\n14321,1,1,\"Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects\\' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET)\"\\n14322,1,1,\"Percentage of Participants Achieving Overall Disease Control (ODC)\"\\n14323,1,1,\"Percentage of Participants Achieving Overall Survival\"\\n14324,2,2,\"Percentage of Participants Achieving Pathological Complete Response (pCR)\"\\n14325,1,1,\"Percentage of participants achieving Pathological Complete Response (pCR) as Assessed by the Independent Review Committee (IRC)\"\\n14326,1,1,\"Percentage of Participants Achieving pCR by Breast Cancer Type\"\\n14327,1,1,\"Percentage of Participants Achieving pCR by Hormone Receptor Status\"\\n14328,1,1,\"Percentage of Participants Achieving pCR by Lymph Node Status\"\\n14329,1,1,\"Percentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS)\"\\n14330,2,1,\"Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months\"\\n14331,1,1,\"Percentage of Participants Achieving Prostate Specific Antigen (PSA) Response at Week 12\"\\n14332,1,1,\"Percentage of Participants Achieving Prostate-specific Antigen (PSA) Response (PSA Response Rate) by 12 Weeks of Therapy\"\\n14333,1,1,\"Percentage of participants achieving Prostate-Specific Antigen (PSA) response up to 12 weeks\"\\n14334,1,1,\"Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest\"\\n14335,1,1,\"Percentage of Participants Alive and Without Progressive Disease at Month 6\"\\n14336,1,1,\"Percentage of Participants Based on Type of EGFR Mutation\"\\n14337,1,1,\"Percentage of Participants by Best Overall Response\"\\n14338,1,1,\"Percentage of Participants by Level of Importance of Factors Determining the Use of Nivestim\"\\n14339,1,1,\"Percentage of Participants by Number of Treatment Cycles Received\"\\n14340,1,1,\"Percentage of Participants Classified Based on Number of Metastatic Sites at the Time of Local or Metastatic Progression\"\\n14341,1,1,\"Percentage of Participants Developing Diarrhea (Grade 1 to 4)\"\\n14342,2,1,\"Percentage of participants discontinuing from study therapy due to AE\"\\n14343,4,2,\"Percentage of Participants Discontinuing Study Drug Due to AEs\"\\n14344,1,1,\"Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 12\"\\n14345,1,1,\"Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 18\"\\n14346,1,1,\"Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 24\"\\n14347,1,1,\"Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 6\"\\n14348,1,1,\"Percentage of Participants Event Free at 1 Year\"\\n14349,1,1,\"Percentage of Participants Event Free at 2 Years\"\\n14350,1,1,\"Percentage of Participants Event Free at 3 Years\"\\n14351,1,1,\"Percentage of Participants Event-Free (Alive) at 1 Year During the Overall Study\"\\n14352,5,2,\"Percentage of Participants Experiencing Adverse Events (AEs)\"\\n14353,1,1,\"Percentage of Participants Experiencing Adverse Events (AEs) According to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), Version 5.0\"\\n14354,2,2,\"Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\"\\n14355,1,1,\"Percentage of Participants Experiencing Adverse Events According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\"\\n14356,1,1,\"Percentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C)\"\\n14357,1,1,\"Percentage of Participants Experiencing any Adverse Events\"\\n14358,1,1,\"Percentage of Participants Experiencing Any Clinically Significant Laboratory Abnormalities\"\\n14359,1,1,\"Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0\"\\n14360,1,1,\"Percentage of Participants Experiencing any Serious Adverse Events\"\\n14361,3,2,\"Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events\"\\n14362,9,4,\"Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)\"\\n14363,1,1,\"Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Safety Run-in Cohort\"\\n14364,1,1,\"Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)\"\\n14365,1,1,\"Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts\"\\n14366,1,1,\"Percentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C)\"\\n14367,1,1,\"Percentage of Participants Experiencing Lab Abnormalities According to the NCI CTCAE Version 5.0\"\\n14368,6,2,\"Percentage of Participants Experiencing Laboratory Abnormalities\"\\n14369,1,1,\"Percentage of Participants Experiencing Laboratory Abnormalities According to NCI CTCAE, Version 5.0\"\\n14370,1,1,\"Percentage of Participants Experiencing Laboratory Abnormalities According to the NCI CTCAE v5.0\"\\n14371,1,1,\"Percentage of Participants Experiencing Laboratory Abnormalities According to the NCI CTCAE Version 5.0\"\\n14372,1,1,\"Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)\"\\n14373,1,1,\"Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)\"\\n14374,1,1,\"Percentage of Participants Experiencing Neither of the 2 Mineralocorticoid Excess Toxicity During the First 24 Weeks of Treatment\"\\n14375,1,1,\"Percentage of Participants experiencing Treatment Emergent Adverse Events (TEAEs)\"\\n14376,8,2,\"Percentage of Participants Experiencing Treatment-Emergent Adverse Events\"\\n14377,5,1,\"Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)\"\\n14378,1,1,\"Percentage of Participants Free From Disease Progression or Death at 6 Months\"\\n14379,1,1,\"Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator\"\\n14380,1,1,\"Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months\"\\n14381,1,1,\"Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study\"\\n14382,2,2,\"Percentage of participants in whom we successfully apply CURATE.AI profile.\"\\n14383,1,1,\"Percentage of Participants Overall Response Rate (ORR) and Clinical Benefit Rate (CBR) Utilizing RECIST 1.1 at Approximately 16 Weeks\"\\n14384,1,1,\"Percentage of Participants Progression Free at 12 and 24 Months\"\\n14385,1,1,\"Percentage of Participants Progression-free\"\\n14386,1,1,\"Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)\"\\n14387,1,1,\"Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment\"\\n14388,1,1,\"Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ‚â• 1 g/dL\"\\n14389,1,1,\"Percentage of Participants Receiving Lenvatinib Monotherapy who Discontinue Study Treatment Due to an Adverse Event (AE)\"\\n14390,1,1,\"Percentage of Participants Receiving Lenvatinib Monotherapy who Experience an AE\"\\n14391,1,1,\"Percentage of Participants Receiving Pembrolizumab Plus Lenvatinib who Discontinue Study Treatment Due to an AE\"\\n14392,1,1,\"Percentage of Participants Receiving Pembrolizumab Plus Lenvatinib who Experience an Adverse Event (AE)\"\\n14393,1,1,\"Percentage of Participants Receiving Primary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia\"\\n14394,1,1,\"Percentage of Participants Receiving Primary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia\"\\n14395,1,1,\"Percentage of Participants Receiving Primary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia\"\\n14396,1,1,\"Percentage of Participants Receiving Secondary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia\"\\n14397,1,1,\"Percentage of Participants Receiving Secondary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia\"\\n14398,1,1,\"Percentage of Participants Receiving Secondary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia\"\\n14399,1,1,\"Percentage of Participants Receiving Treatment With Any Daily G-CSF Who Experienced Febrile Neutropenia\"\\n14400,1,1,\"Percentage of Participants Receiving Treatment With Any Other G-CSF Who Experienced Febrile Neutropenia\"\\n14401,1,1,\"Percentage of Participants Receiving Treatment With Pegfilgrastim Who Experienced Febrile Neutropenia\"\\n14402,1,1,\"Percentage of Participants Receiving Various Chemotherapy Regimens\"\\n14403,1,1,\"Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator\"\\n14404,1,1,\"Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0\"\\n14405,1,1,\"Percentage of participants showing CR/PR to IHNI-based BNCT\"\\n14406,1,1,\"Percentage of Participants Surviving at 6 Months\"\\n14407,1,1,\"Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response\"\\n14408,1,1,\"Percentage of Participants That Are Able to Meet Feasibility Parameters.\"\\n14409,1,1,\"Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year\"\\n14410,1,1,\"Percentage of Participants to Discontinue Steroid Treatment After Rituximab\"\\n14411,1,1,\"Percentage of Participants to Discontinue Steroid Treatment After Tocilizumab\"\\n14412,1,1,\"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])\"\\n14413,1,1,\"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) in Part A and Part B\"\\n14414,1,1,\"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR)\"\\n14415,1,1,\"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])\"\\n14416,1,1,\"Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)\"\\n14417,1,1,\"Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment\"\\n14418,1,1,\"Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment with Mixed Dosing Regimen\"\\n14419,1,1,\"Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment\"\\n14420,1,1,\"Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment with Mixed Dosing Regimen\"\\n14421,1,1,\"Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment\"\\n14422,1,1,\"Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment with Mixed Dosing Regimen\"\\n14423,1,1,\"Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent Radiology Assessment (IRA)\"\\n14424,1,1,\"Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery\"\\n14425,1,1,\"Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response\"\\n14426,1,1,\"Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment\"\\n14427,1,1,\"Percentage of Participants Who Achieved Either a Confirmed Complete Response or Partial Response Per RECIST Criteria\"\\n14428,1,1,\"Percentage of Participants Who Are Feasibility \"\"Failure\"\"\"\\n14429,1,1,\"Percentage of Participants Who Are Progression-free (PFS) at 6 Months\"\\n14430,1,1,\"Percentage of participants who can enroll in an A2 Biotherapeutics, Inc. CAR T-cell therapy study after undergoing apheresis\"\\n14431,2,1,\"Percentage of participants who completed the study\"\\n14432,1,1,\"Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies\"\\n14433,1,1,\"Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis\"\\n14434,6,1,\"Percentage of Participants Who Died\"\\n14435,1,1,\"Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010)\"\\n14436,1,1,\"Percentage of Participants Who Died - FAS\"\\n14437,1,1,\"Percentage of Participants Who Died Assessed From Point of Randomization\"\\n14438,1,1,\"Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons\"\\n14439,1,1,\"Percentage of Participants Who Died During the Overall Study\"\\n14440,1,1,\"Percentage of Participants Who Died of Any Cause in ITT Population\"\\n14441,1,1,\"Percentage of Participants Who Died: Final Analysis\"\\n14442,1,1,\"Percentage of Participants Who Died: PP-ITT\"\\n14443,1,1,\"Percentage of Participants Who Died: Second Interim Analysis\"\\n14444,1,1,\"Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP\"\\n14445,4,2,\"Percentage of Participants Who Discontinue Study Drug Due to an AE\"\\n14446,2,2,\"Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) - Pembrolizumab+FLOT and Placebo+FLOT Cohorts\"\\n14447,4,4,\"Percentage of participants who discontinue study treatment due to an AE\"\\n14448,1,1,\"Percentage of participants who discontinue study treatment due to an AE: Safety lead-in\"\\n14449,1,1,\"Percentage of Participants Who Discontinued From Leuprorelin Administration of IAD Regimen\"\\n14450,4,1,\"Percentage of Participants Who Discontinued Study Treatment Due to an AE\"\\n14451,1,1,\"Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).\"\\n14452,1,1,\"Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days\"\\n14453,4,2,\"Percentage of participants who experience a Dose Limiting Toxicity\"\\n14454,1,1,\"Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT)\"\\n14455,1,1,\"Percentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-in phase\"\\n14456,1,1,\"Percentage of Participants who Experience a Recurrence\"\\n14457,1,1,\"Percentage of participants who experience adverse events and serious adverse events to determine safety and tolerability of SNX281 given as a single agent and in combination with pembrolizumab\"\\n14458,2,1,\"Percentage of Participants Who Experience an Adverse Event (AE)\"\\n14459,4,4,\"Percentage of participants who experience an adverse event (AE)\"\\n14460,1,1,\"Percentage of participants who experience an adverse event (AE): Safety lead-in\"\\n14461,1,1,\"Percentage of Participants Who Experience an AE of Infusion Site Reaction\"\\n14462,1,1,\"Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)\"\\n14463,2,2,\"Percentage of Participants Who Experience One or More Adverse Events (AEs) - Pembrolizumab+FLOT and Placebo+FLOT Cohorts\"\\n14464,1,1,\"Percentage of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1\"\\n14465,3,1,\"Percentage of Participants Who Experienced an Adverse Event\"\\n14466,1,1,\"Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs)\"\\n14467,1,1,\"Percentage of Participants Who Experienced At Least 2-Fold Increase in Expression of IL-12 Protein in the Tumor Tissue After Intratumoral (IT) pIL-12 Injections and In Vivo Electroporation\"\\n14468,2,1,\"Percentage of Participants Who Experienced At Least One Adverse Event (AE)\"\\n14469,1,1,\"Percentage of Participants Who Experienced Dose Limiting Toxicities (DLTs)\"\\n14470,1,1,\"Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment\"\\n14471,1,1,\"Percentage of Participants Who Experienced One or More Dose-limiting Toxicities (DLTs)\"\\n14472,1,1,\"Percentage of participants who experienced treatment-related adverse events\"\\n14473,1,1,\"Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.\"\\n14474,1,1,\"Percentage of Participants Who Have a Clinical or Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 to 5 Toxicity\"\\n14475,1,1,\"Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression)\"\\n14476,1,1,\"Percentage of Participants Who Have a Drug-related Clinical or Laboratory CTCAE Grade 3 to 5 Toxicity\"\\n14477,1,1,\"Percentage of Participants who Received Allogeneic Stem Cell Transplantation (AlloSCT)\"\\n14478,1,1,\"Percentage of Participants who Received Autologous Stem Cell Transplantation (AutoSCT)\"\\n14479,1,1,\"Percentage of Participants who Received Chemotherapy Regimens as per National Guidelines\"\\n14480,1,1,\"Percentage of Participants Who Received First-Line Endocrine Therapy at the Time of Local or Metastatic Progression\"\\n14481,1,1,\"Percentage of Participants Who Received No Prophylaxis or Treatment With Granulocyte Colony-stimulating Factors (G-CSF) Who Experienced Febrile Neutropenia\"\\n14482,1,1,\"Percentage of Participants who Received Radiotherapy Including Site (Extended/Involved) and Total Dosing\"\\n14483,1,1,\"Percentage of Participants Who Remained Progression-free 12 Weeks After Randomization\"\\n14484,1,1,\"Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters\"\\n14485,1,1,\"Percentage of Participants Who Tested Positive for EGFR Mutations\"\\n14486,1,1,\"Percentage of Participants Who Were Alive 1 Year After Start of Treatment\"\\n14487,1,1,\"Percentage of Participants Who Were Alive and Disease Free at Year 2 (For Participants Treated in the Adjuvant Setting), According to RECIST, or Modified RECIST, or Cheson Criteria (As per Center Practice)\"\\n14488,1,1,\"Percentage of Participants Who Were Alive at Year 1\"\\n14489,2,1,\"Percentage of Participants Who Were Alive at Year 2\"\\n14490,1,1,\"Percentage of Participants Who Were Disease-Free for at Least 12 Months After Initial Diagnosis\"\\n14491,1,1,\"Percentage of Participants Who Were Disease-Free for at Least 24 Months After Initial Diagnosis\"\\n14492,1,1,\"Percentage of Participants who Were Eligible for AutoSCT did not Receive it (Including Reasons)\"\\n14493,1,1,\"Percentage of Participants Who Were Progression Free at 12 and 24 Months\"\\n14494,1,1,\"Percentage of Participants With (Complete Response (CR) + Partial Response (PR)) to 5-Fluro-2\\'-Deoxycytidine (FdCyd)\"\\n14495,1,1,\"Percentage of Participants With 1 Year Progression Free Survival (PFS): Phase 2\"\\n14496,1,1,\"Percentage of Participants With 1-year Overall Survival\"\\n14497,1,1,\"Percentage of Participants With 2-year Progression Free Survival (PFS)\"\\n14498,1,1,\"Percentage of Participants With 3-year Progression Free Survival (PFS)\"\\n14499,1,1,\"Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1\"\\n14500,1,1,\"Percentage of Participants With 6 Month Progression Free Survival (PFS)\"\\n14501,1,1,\"Percentage of Participants With a >= 50% Decline in Prostate-specific Antigen (PSA) Value\"\\n14502,1,1,\"Percentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) and Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria\"\\n14503,1,1,\"Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate)\"\\n14504,1,1,\"Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)\"\\n14505,1,1,\"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]\"\\n14506,1,1,\"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14507,1,1,\"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level\"\\n14508,2,2,\"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)\"\\n14509,1,1,\"Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)\"\\n14510,1,1,\"Percentage of Participants With a Complete Response (CR) or Partial Response (PR)\"\\n14511,1,1,\"Percentage of Participants With a Confirmed and an Unconfirmed Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST Version (v) 1.0 - Extension: BRAFV600E- Positive Melanoma\"\\n14512,1,1,\"Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to RECIST v1.1\"\\n14513,1,1,\"Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n14514,1,1,\"Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According Modified RECIST\"\\n14515,1,1,\"Percentage of Participants With a Confirmed Objective Tumor Response Using RECIST Version 1.0\"\\n14516,1,1,\"Percentage of Participants With a Decrease of ‚â•50% in Prostatic Specific Antigen (PSA)\"\\n14517,1,1,\"Percentage of participants with a dose limiting toxicity (DLT)\"\\n14518,2,1,\"Percentage of Participants With a Partial or Complete Response\"\\n14519,1,1,\"Percentage of Participants With a Pathological Complete Response\"\\n14520,1,1,\"Percentage of Participants With a Repeat Paracentesis Response (RPR)\"\\n14521,4,2,\"Percentage of Participants With a Response\"\\n14522,1,1,\"Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category\"\\n14523,1,1,\"Percentage of Participants With a Response to Treatment During the Proof of Concept Period\"\\n14524,1,1,\"Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)\"\\n14525,62,18,\"Percentage of Participants With Adverse Events\"\\n14526,36,17,\"Percentage of Participants with Adverse Events\"\\n14527,5,2,\"Percentage of participants with Adverse Events\"\\n14528,2,1,\"Percentage of Participants With Adverse Events (AE)\"\\n14529,1,1,\"Percentage of Participants With Adverse Events (AE), Serious Adverse Events (SAE), AEs With Grade >=3, and AEs Related To Treatment\"\\n14530,45,12,\"Percentage of Participants With Adverse Events (AEs)\"\\n14531,40,9,\"Percentage of Participants with Adverse Events (AEs)\"\\n14532,1,1,\"Percentage of Participants with Adverse Events (AEs) (Parts 1 and 2)\"\\n14533,1,1,\"Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters\"\\n14534,19,4,\"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n14535,3,1,\"Percentage of Participants With Adverse Events (AEs) and Serious AEs\"\\n14536,1,1,\"Percentage of Participants with Adverse Events (AEs) and Serious AEs\"\\n14537,2,1,\"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)\"\\n14538,1,1,\"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs)\"\\n14539,1,1,\"Percentage of Participants with Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0\"\\n14540,1,1,\"Percentage of Participants With Adverse Events (AEs) by Severity as Graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)\"\\n14541,1,1,\"Percentage of Participants with Adverse Events (AEs) Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\"\\n14542,2,2,\"Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)\"\\n14543,1,1,\"Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs) - MBC and LABC Population\"\\n14544,1,1,\"Percentage of Participants With Adverse Events (AEs), Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)\"\\n14545,2,2,\"Percentage of participants with adverse events (AEs), serious adverse events and AEs of special interest\"\\n14546,1,1,\"Percentage of Participants with Adverse Events (AEs), treatment-related AE (TRAE), immune-related AEs (irAE) and serious adverse event (SAE) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0\"\\n14547,1,1,\"Percentage of Participants with Adverse Events (AEs), treatment-related AE (TRAE), immune-related AEs (irAE) and serious adverse event (SAE) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 ;\"\\n14548,2,1,\"Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected SAEs/SADRs\"\\n14549,3,1,\"Percentage of Participants With Adverse Events and Serious Adverse Events\"\\n14550,1,1,\"Percentage of participants with Adverse Events grade 3-4\"\\n14551,1,1,\"Percentage of Participants with Adverse Events in Part 1 and Part 2\"\\n14552,1,1,\"Percentage of Participants With Adverse Events Leading to Treatment Discontinuation\"\\n14553,1,1,\"Percentage of Participants With Adverse Events of Clinical Interest\"\\n14554,1,1,\"Percentage of Participants With Adverse Events of Primary Interest (AEPIs)\"\\n14555,3,1,\"Percentage of Participants With Adverse Events of Special Interest\"\\n14556,1,1,\"Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)\"\\n14557,2,1,\"Percentage of Participants with AEs and SAEs\"\\n14558,1,1,\"Percentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades\"\\n14559,1,1,\"Percentage of Participants With AEs Leading to Discontinuation\"\\n14560,1,1,\"Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)\"\\n14561,1,1,\"Percentage of Participants With AEs of Special Interest\"\\n14562,1,1,\"Percentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA)\"\\n14563,1,1,\"Percentage of Participants with AEs, SAEs, and AESIs\"\\n14564,1,1,\"Percentage of Participants With an Immune Response to Prostatic Acid Phosphatase (PAP) and/or PA2024\"\\n14565,1,1,\"Percentage of Participants With an Objective Overall Response\"\\n14566,2,1,\"Percentage of Participants With an Objective Response\"\\n14567,1,1,\"Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants With Solid Tumors\"\\n14568,1,1,\"Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma\"\\n14569,1,1,\"Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Response Assessment in Neuro-Oncology (RANO) Criteria in Participants With Atypical Teratoid Rhabdoid Tumor (ATRT)\"\\n14570,1,1,\"Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin\\'s Lymphoma or Non-Hodgkin\\'s Lymphoma\"\\n14571,1,1,\"Percentage of Participants With an Objective Response (Partial Response (PR) + Complete Response (CR) for Sunitinib in Participants With Relapsed or Refractory Thymoma or Thymic Carcinoma\"\\n14572,1,1,\"Percentage of Participants With an Objective Response as Assessed Through Independent Radiologic Review\"\\n14573,2,1,\"Percentage of Participants With an Overall Response Rate\"\\n14574,1,1,\"Percentage of Participants With Androgen Receptor (AR) Copy Number Alterations and Mutations\"\\n14575,1,1,\"Percentage of Participants with Anti-Atezolizumab Antibodies\"\\n14576,1,1,\"Percentage of Participants with Anti-Cergutuzumab Amunaleukin Antibodies\"\\n14577,1,1,\"Percentage of Participants With Anti-drug Antibodies (ADAs) Against RO6895882\"\\n14578,1,1,\"Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO6958688\"\\n14579,1,1,\"Percentage of Participants With Anti-Human Antibodies (HAHAs) to lumretuzumab [RO5479599]\"\\n14580,1,1,\"Percentage of Participants With Anti-MEHD7945A Antibodies\"\\n14581,1,1,\"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab\"\\n14582,1,1,\"Percentage of Participants With Anti-tumor Activity\"\\n14583,1,1,\"Percentage of Participants With Any Significant Comorbidities\"\\n14584,1,1,\"Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation\"\\n14585,1,1,\"Percentage of Participants With At Least 1 Red Blood Cell (RBC) Transfusion\"\\n14586,1,1,\"Percentage of Participants With At Least 1 Sick Leave\"\\n14587,3,1,\"Percentage of Participants With at Least One Adverse Event\"\\n14588,1,1,\"Percentage of Participants With At Least One Adverse Event (AE)\"\\n14589,9,1,\"Percentage of Participants With at Least One Adverse Event (AE)\"\\n14590,1,1,\"Percentage of Participants With at Least One Adverse Event of Special Interest\"\\n14591,1,1,\"Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay\"\\n14592,1,1,\"Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction\"\\n14593,1,1,\"Percentage of Participants With at Least One Dose Interruptions\"\\n14594,1,1,\"Percentage of Participants With at Least One Dose Reduction\"\\n14595,1,1,\"Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period\"\\n14596,1,1,\"Percentage of Participants With at Least One Left Ventricular Ejection Fraction (LVEF) Significant Decline, Defined as a Drop in LVEF of at Least 10 Percentage Points From Baseline and to Below 50%, During the Neoadjuvant Treatment Period\"\\n14597,1,1,\"Percentage of Participants With at Least One Panitumumab Dose Delay\"\\n14598,1,1,\"Percentage of Participants With at Least One Panitumumab Dose Reduction\"\\n14599,4,1,\"Percentage of Participants With at Least One Serious Adverse Event (SAE)\"\\n14600,1,1,\"Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment\"\\n14601,1,1,\"Percentage of Participants With Best Objective Central Nervous System (CNS) Response, Assessed by Centralized Independent Expert According to Magnetic Resonance Imaging (MRI) - Intent-to-Treat (ITT) Population\"\\n14602,1,1,\"Percentage of Participants With Best Objective CNS Response, Assessed by Centralized Independent Expert According to MRI - Per-Protocol (PP) Population\"\\n14603,3,1,\"Percentage of Participants With Best Objective Response\"\\n14604,1,1,\"Percentage of Participants With Best Overall Response\"\\n14605,1,1,\"Percentage of Participants with Best Overall Response\"\\n14606,1,1,\"Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n14607,1,1,\"Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n14608,1,1,\"Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or Cancer Antigen 125 (CA-125) Changes\"\\n14609,1,1,\"Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR), as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1) Criteria\"\\n14610,1,1,\"Percentage of Participants With Best Response to Treatment of Complete or Partial\"\\n14611,1,1,\"Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study\"\\n14612,1,1,\"Percentage of Participants With Bevacizumab-Related Adverse Events\"\\n14613,1,1,\"Percentage of Participants With Bevacizumab-related Serious Adverse Events\"\\n14614,1,1,\"Percentage of Participants With Bone Metastases at 12 Months\"\\n14615,1,1,\"Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation\"\\n14616,1,1,\"Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: Original Formulation\"\\n14617,1,1,\"Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Extension: BRAFV600E- Positive CRC\"\\n14618,1,1,\"Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type\"\\n14619,1,1,\"Percentage of Participants With Breast Cancer (BRCA) Mutation at the Time of Local or Metastatic Progression\"\\n14620,1,1,\"Percentage of Participants With Breast Cancer Type 1 Associated Protein-1 (BAP1) Somatic Mutations Who Experienced Partial or Complete Response.\"\\n14621,1,1,\"Percentage of participants with change in worst grades for hematological and biochemical toxicities according to CTCAE version 4.03, based on laboratory measurements\"\\n14622,1,1,\"Percentage of Participants With Clinical and Histologic Remission\"\\n14623,2,2,\"Percentage of Participants With Clinical Benefit\"\\n14624,1,1,\"Percentage of Participants with Clinical Benefit\"\\n14625,1,1,\"Percentage of Participants With Clinical Benefit as Determined by the Investigator According to RECIST v1.1 Criteria in Participants With Osteosarcoma\"\\n14626,1,1,\"Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population\"\\n14627,1,1,\"Percentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population\"\\n14628,1,1,\"Percentage of Participants With Clinical Benefit of CR, PR, or Stable Disease (SD)\"\\n14629,1,1,\"Percentage of Participants With Clinical Benefit Response (CBR)\"\\n14630,1,1,\"Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee\"\\n14631,1,1,\"Percentage of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose\"\\n14632,1,1,\"Percentage of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose\"\\n14633,1,1,\"Percentage of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose\"\\n14634,1,1,\"Percentage of Participants With Clinical Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\"\\n14635,1,1,\"Percentage of Participants With Clinically Significant Change from Baseline in Clinical Laboratory Test Results\"\\n14636,1,1,\"Percentage of Participants With Clinically Significant Change From Baseline in RR and QT Intervals as Measured by Electrocardiogram (ECG)\"\\n14637,2,1,\"Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs\"\\n14638,1,1,\"Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts\"\\n14639,1,1,\"Percentage of Participants with Complete Resection After IDS\"\\n14640,1,1,\"Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor\"\\n14641,1,1,\"Percentage of Participants With Complete Response (CR)\"\\n14642,1,1,\"Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)\"\\n14643,3,2,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR)\"\\n14644,1,1,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response )\"\\n14645,2,2,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])\"\\n14646,1,1,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]\"\\n14647,1,1,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]\"\\n14648,1,1,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14649,1,1,\"Percentage of Participants With Complete Response (CR) or Partial Response (PR)ÔºàObjective response rate [ORR]Ôºâ\"\\n14650,1,1,\"Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)]\"\\n14651,1,1,\"Percentage of Participants With Complete Response and Partial Response (Objective Response Rate)\"\\n14652,1,1,\"Percentage of Participants With Complete Response or Partial Response According to RECIST v1.1\"\\n14653,1,1,\"Percentage of Participants With Composite Response\"\\n14654,1,1,\"Percentage of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment\"\\n14655,1,1,\"Percentage of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment\"\\n14656,1,1,\"Percentage of Participants With Concomitant Symptoms of Various Severity 4-6 Weeks After Start of Treatment\"\\n14657,1,1,\"Percentage of Participants With Concomitant Symptoms of Various Severity Prior To Treatment\"\\n14658,1,1,\"Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator\"\\n14659,1,1,\"Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment\"\\n14660,1,1,\"Percentage of Participants With Confirmed Objective Response (OR) by Independent External Review (IER)\"\\n14661,1,1,\"Percentage of Participants With Confirmed Objective Response (OR) by Investigators\\' Assessment\"\\n14662,1,1,\"Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)\"\\n14663,1,1,\"Percentage of Participants With Confirmed Objective Response by Modified RECIST v1.1\"\\n14664,1,1,\"Percentage of Participants With Confirmed Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n14665,1,1,\"Percentage of Participants with Confirmed Overall Response, as Assessed by the Investigator According to RECIST v1.1 or According to RANO Criteria for Primary CNS Tumors\"\\n14666,1,1,\"Percentage of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12\"\\n14667,1,1,\"Percentage of Participants With Confirmed Prostate-specific Antigen (PSA) Response Per Prostate Cancer Working Group 3 (PCWG3) Criteria\"\\n14668,1,1,\"Percentage of Participants With Confirmed Tumor Responses\"\\n14669,1,1,\"Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab\"\\n14670,1,1,\"Percentage of Participants With CR for Group B: Phase 2\"\\n14671,1,1,\"Percentage of Participants With Cross Results for Both ER and PR at the Time of Local or Metastatic Progression\"\\n14672,1,1,\"Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment\"\\n14673,1,1,\"Percentage of Participants with Different CC Scores After IDS\"\\n14674,1,1,\"Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n14675,1,1,\"Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n14676,1,1,\"Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n14677,1,1,\"Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Prior Receiving Treatment at 30000 IU Once Weekly\"\\n14678,1,1,\"Percentage of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment\"\\n14679,1,1,\"Percentage of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment\"\\n14680,1,1,\"Percentage of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment\"\\n14681,1,1,\"Percentage of Participants With Different Symptoms Who Had Clinical Response Prior to Treatment\"\\n14682,1,1,\"Percentage of Participants With Different Types of Haematological Malignancies\"\\n14683,1,1,\"Percentage of Participants With Different Types of Solid Tumour\"\\n14684,2,1,\"Percentage of Participants With Discontinued, Delayed or Interrupted Therapy\"\\n14685,1,1,\"Percentage of Participants With Disease Control as Per irRECIST Criteria (Part A and Part B): Cervical Cancer Population\"\\n14686,1,1,\"Percentage of Participants With Disease Control as Per irRECIST Criteria (Part A): HPV+ Head and Neck Cancer Population\"\\n14687,1,1,\"Percentage of Participants With Disease Control as Per RECIST Criteria (Part A and Part B): Cervical Cancer Population\"\\n14688,1,1,\"Percentage of Participants With Disease Control as Per RECIST Criteria (Part A): HPV+ Head and Neck Cancer Population\"\\n14689,1,1,\"Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n14690,1,1,\"Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n14691,1,1,\"Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population\"\\n14692,8,6,\"Percentage of Participants With Disease Progression or Death\"\\n14693,1,1,\"Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011)\"\\n14694,1,1,\"Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)\"\\n14695,1,1,\"Percentage of Participants With Disease Progression or Death at 12 Months After Baseline\"\\n14696,1,1,\"Percentage of Participants With Disease Progression Per RECIST v1.1 Via IRC Assessment or Death in Immune Cell 1/2/3 (IC1/2/3) Population\"\\n14697,1,1,\"Percentage of Participants With Disease Progression Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Via Independent Review Committee (IRC) Assessment or Death in Intent-to-Treat (ITT) Population\"\\n14698,1,1,\"Percentage of Participants With Disease-free Survival (DFS) at Month 18\"\\n14699,1,1,\"Percentage of Participants with DLT\"\\n14700,1,1,\"Percentage of participants with DLT and Adverse Events\"\\n14701,1,1,\"Percentage of Participants With DLTs\"\\n14702,1,1,\"Percentage of Participants with DLTs Associated with AG-270 Administration During the First Cycle (First 28 Days) of Treatment\"\\n14703,1,1,\"Percentage of Participants with DLTs Associated with the Combination of AG-270 and Docetaxel Administration During the First Cycle (First 28 Days) of Treatment\"\\n14704,1,1,\"Percentage of Participants with DLTs Associated with the Combination of AG-270, nab-paclitaxel, and Gemcitabine Administration During the First Cycle (First 28 Days) of Treatment\"\\n14705,2,2,\"Percentage of Participants With Dose Limiting Toxicities\"\\n14706,1,1,\"Percentage of Participants With Dose Limiting Toxicities (DLT)\"\\n14707,1,1,\"Percentage of Participants With Dose Limiting Toxicities (DLT) in Cycle 1 for the Determination of the Maximum Tolerated Dose (MTD) of Volasertib\"\\n14708,8,6,\"Percentage of Participants With Dose Limiting Toxicities (DLTs)\"\\n14709,1,1,\"Percentage of participants with Dose Limiting Toxicities (DLTs)\"\\n14710,1,1,\"Percentage of Participants with Dose Limiting toxicities (DLTs) in Cycle 1\"\\n14711,1,1,\"Percentage of Participants With Dose Limiting Toxicities (DLTs) in Western Safety Cohort\"\\n14712,1,1,\"Percentage of Participants With Dose Limiting Toxicity\"\\n14713,2,1,\"Percentage of Participants with Dose-Limiting Toxicities\"\\n14714,1,1,\"Percentage of participants with Dose-limiting toxicities (DLT)\"\\n14715,1,1,\"Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1\"\\n14716,15,10,\"Percentage of Participants With Dose-Limiting Toxicities (DLTs)\"\\n14717,1,1,\"Percentage of Participants With Dose-limiting Toxicities (DLTs)\"\\n14718,22,18,\"Percentage of Participants with Dose-Limiting Toxicities (DLTs)\"\\n14719,1,1,\"Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A)\"\\n14720,1,1,\"Percentage of Participants with Dose-Limiting Toxicities (DLTs) (Parts 1 and 2)\"\\n14721,1,1,\"Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]\"\\n14722,1,1,\"Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle (28 Days)\"\\n14723,1,1,\"Percentage of Participants With Dose-Limiting Toxicities (DLTs) in First Cycle of Therapy\"\\n14724,1,1,\"Percentage of Participants With Dose-Limiting Toxicities (DLTs) of MEHD7945A\"\\n14725,1,1,\"Percentage of Participants with Dose-Limiting Toxicities (DLTs) that Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination\"\\n14726,1,1,\"Percentage of Participants With Drug-related AEs\"\\n14727,1,1,\"Percentage of Participants With Drug-related Grade 3 or Above AEs\"\\n14728,1,1,\"Percentage of Participants With Early Treatment Response: Day 21 to 42\"\\n14729,1,1,\"Percentage of Participants With Early Treatment Response: Day 28 to 42\"\\n14730,1,1,\"Percentage of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG PS) at the Time of Local or Metastatic Progression\"\\n14731,1,1,\"Percentage of Participants With EGFR Mutations by Subgroup\"\\n14732,1,1,\"Percentage of Participants With Either Peripheral Neuropathy ‚â• Grade 2 or Myelosuppression Adverse Events (AEs) ‚â• Grade 3 Based on Local Laboratory Values\"\\n14733,1,1,\"Percentage of Participants With Estrogen Receptors (ER) at the Time of Local or Metastatic Progression\"\\n14734,1,1,\"Percentage of Participants With Event (Death)\"\\n14735,1,1,\"Percentage of Participants With Febrile Neutropenia (FN)\"\\n14736,1,1,\"Percentage of Participants with GI Perforation/Fistula Events by Grade According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\"\\n14737,1,1,\"Percentage of Participants with GI-Vaginal Fistula Events by Grade According to NCI-CTCAE Version 4.0\"\\n14738,1,1,\"Percentage of Participants with Grade 2 or higher renal toxicities\"\\n14739,1,1,\"Percentage of Participants with Grade 2 or Higher Treatment-emergent Adverse Events\"\\n14740,1,1,\"Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS)\"\\n14741,1,1,\"Percentage of Participants with Grade 3 or 4 Abnormalities in Safety-Related Laboratory Parameters\"\\n14742,1,1,\"Percentage of Participants With Grade 3 or 4 Neutropenia\"\\n14743,1,1,\"Percentage of Participants With Grade 3 or Above AEs\"\\n14744,1,1,\"Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)\"\\n14745,1,1,\"Percentage of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs) in the First 24 Weeks\"\\n14746,1,1,\"Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy\"\\n14747,1,1,\"Percentage of Participants With Greater Than or Equals to (>=)50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)\"\\n14748,1,1,\"Percentage of Participants with GU Fistula Events by Grade According to NCI-CTCAE Version 4.0\"\\n14749,1,1,\"Percentage of Participants With HR Status at the Time of Local or Metastatic Progression\"\\n14750,1,1,\"Percentage of Participants with Immune-Mediated Adverse Events (imAEs)\"\\n14751,1,1,\"Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months\"\\n14752,1,1,\"Percentage of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment\"\\n14753,1,1,\"Percentage of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment\"\\n14754,1,1,\"Percentage of Participants with Infusion-Related Reactions\"\\n14755,1,1,\"Percentage of Participants with Infusion-related Reactions (IRRs)\"\\n14756,1,1,\"Percentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks\"\\n14757,1,1,\"Percentage of Participants With Ki67 (MiB1) at the Time of Local or Metastatic Progression\"\\n14758,1,1,\"Percentage of Participants With Laboratory Abnormalities\"\\n14759,1,1,\"Percentage of Participants With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks\"\\n14760,1,1,\"Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%\"\\n14761,1,1,\"Percentage of Participants With Major Pathologic Response (MPR)\"\\n14762,1,1,\"Percentage of Participants With Maximum Pain Level Decreased by ‚â• 2 Points at 2 Months After Radiofrequency Ablation (RFA)\"\\n14763,1,1,\"Percentage of Participants With Menopausal Status at the Time of Local or Metastatic Progression\"\\n14764,1,1,\"Percentage of Participants With Messenger Ribonucleic Acid (mRNA) Markers of Pathological Complete Response, as Assessed by Magnetic Resonance Imaging (MRI)\"\\n14765,1,1,\"Percentage of Participants With Metastatic Disease at Identified Metastatic Sites at the Time of Local or Metastatic Progression\"\\n14766,1,1,\"Percentage of Participants With Mitotic Index (MI) at the Time of Local or Metastatic Progression\"\\n14767,1,1,\"Percentage of Participants With Negative HER2 Status at the Time of Local or Metastatic Progression\"\\n14768,1,1,\"Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14769,1,1,\"Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Based on Investigator and Independent Reviewers\"\\n14770,10,4,\"Percentage of Participants With Objective Response\"\\n14771,1,1,\"Percentage of Participants With Objective Response (Cohort 1)\"\\n14772,1,1,\"Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)\"\\n14773,1,1,\"Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1\"\\n14774,1,1,\"Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II)\"\\n14775,1,1,\"Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)\"\\n14776,1,1,\"Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)\"\\n14777,2,1,\"Percentage of Participants With Objective Response (Objective Response Rate)\"\\n14778,14,12,\"Percentage of Participants With Objective Response (OR)\"\\n14779,1,1,\"Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1\"\\n14780,1,1,\"Percentage of Participants With Objective Response (OR) at Week 12: Part 2\"\\n14781,1,1,\"Percentage of Participants With Objective Response (OR) by Centrally Assessed Breast Magnetic Resonance Imaging (MRI) Via Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1\"\\n14782,1,1,\"Percentage of Participants With Objective Response (OR) in Exploration Cohorts C1A and C1B\"\\n14783,1,1,\"Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR)\"\\n14784,1,1,\"Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2\"\\n14785,2,1,\"Percentage of Participants With Objective Response (OR): Phase 2\"\\n14786,1,1,\"Percentage of Participants With Objective Response (OR; Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)\"\\n14787,1,1,\"Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])\"\\n14788,1,1,\"Percentage of Participants With Objective Response (Part 1 and Part 2)\"\\n14789,1,1,\"Percentage of Participants With Objective Response (Part 2)\"\\n14790,1,1,\"Percentage of Participants With Objective Response - Arm B Expansion\"\\n14791,1,1,\"Percentage of Participants With Objective Response - Part 2\"\\n14792,1,1,\"Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14793,1,1,\"Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14794,1,1,\"Percentage of Participants with Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n14795,1,1,\"Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase II\"\\n14796,1,1,\"Percentage of Participants With Objective Response as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n14797,1,1,\"Percentage of participants with Objective Response as determined by Investigator\"\\n14798,1,1,\"Percentage of Participants with Objective Response as Determined By The Independent Review Facility (IRF) According To Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Arm A)\"\\n14799,1,1,\"Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)\"\\n14800,1,1,\"Percentage of Participants With Objective Response as Per irRECIST Criteria (Part A and Part B): Cervical Cancer Population\"\\n14801,1,1,\"Percentage of Participants With Objective Response as Per irRECIST Criteria (Part A): HPV+ Head and Neck Cancer Population\"\\n14802,1,1,\"Percentage of Participants With Objective Response as Per RECIST Criteria (Part A and Part B): Cervical Cancer Population\"\\n14803,1,1,\"Percentage of Participants With Objective Response as Per RECIST Criteria (Part A): HPV+ Head and Neck Cancer Population\"\\n14804,1,1,\"Percentage of Participants With Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Response-evaluable Population\"\\n14805,1,1,\"Percentage of Participants with Objective Response during Stage 1 According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1\"\\n14806,1,1,\"Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors\"\\n14807,1,1,\"Percentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria\"\\n14808,1,1,\"Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n14809,1,1,\"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator\"\\n14810,2,1,\"Percentage of Participants With Objective Response Rate (ORR)\"\\n14811,1,1,\"Percentage of Participants With Objective Response Rate (ORR) (Part 2 & 3)\"\\n14812,1,1,\"Percentage of Participants With Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n14813,1,1,\"Percentage of Participants With Objective Response Rate (ORR) by Treatment\"\\n14814,2,2,\"Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\"\\n14815,1,1,\"Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)\"\\n14816,1,1,\"Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors\"\\n14817,1,1,\"Percentage of Participants With Objective Response: Phase 2\"\\n14818,1,1,\"Percentage of Participants With Ocular Melanoma Treated With Young Tumor Infiltrating Lymphocytes (TIL) With or Without High Dose Aldesleukin With an Objective Response Rate of (Complete Response (CR) + Partial Response (PR))\"\\n14819,2,1,\"Percentage of Participants With One or More Serious Adverse Events\"\\n14820,1,1,\"Percentage of Participants With OR by Centrally Assessed Breast MRI Via mRECIST Version 1.1 in Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha (PIK3CA) Mutant (MT) Participants\"\\n14821,1,1,\"Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)\"\\n14822,1,1,\"Percentage of Participants With Overall Clinical Benefit Response (CBR)\"\\n14823,1,1,\"Percentage of Participants With Overall Confirmed Objective Disease Response\"\\n14824,1,1,\"Percentage of Participants With Overall Objective Response\"\\n14825,1,1,\"Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy\"\\n14826,9,3,\"Percentage of Participants With Overall Response\"\\n14827,1,1,\"Percentage of Participants With Overall Response During First-Line Therapy (ORR1)\"\\n14828,1,1,\"Percentage of Participants With Overall Response Rate\"\\n14829,4,1,\"Percentage of Participants With Overall Response Rate (ORR)\"\\n14830,1,1,\"Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n14831,1,1,\"Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib\"\\n14832,2,1,\"Percentage of Participants With Overall Survival\"\\n14833,1,1,\"Percentage of Participants With Overall Survival (OS) at 12 Months\"\\n14834,1,1,\"Percentage of Participants With Overall Tumor Response (Response Rate)\"\\n14835,1,1,\"Percentage of Participants With Pancreatobiliary Cancer and LMB-100 Plasma Drug Levels Above Threshold 600ng/mL During Cycle 2 Who Received LMB-100 at Maximum Tolerated Dose\"\\n14836,1,1,\"Percentage of Participants With Partial Response (PR)\"\\n14837,1,1,\"Percentage of Participants with Pathologic Complete Response (pCR)\"\\n14838,1,1,\"Percentage of Participants With Pathologic Complete Response (pCR) (For Participants Treated in Neo-Adjuvant Setting), According to Response Evaluation Criteria in Solid Tumor (RECIST), or Modified RECIST, or Cheson Criteria (As per Center Practice)\"\\n14839,1,1,\"Percentage of participants with pathologic complete response rate (pCR)\"\\n14840,9,5,\"Percentage of Participants With Pathological Complete Response (pCR)\"\\n14841,1,1,\"Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants)\"\\n14842,1,1,\"Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes\"\\n14843,1,1,\"Percentage of Participants With Pathological Complete Response as per Chevallier\\'s Classification as Reviewed by an Independent Committee\"\\n14844,1,1,\"Percentage of Participants With Pathological Complete Response Following Principle Investigator Review\"\\n14845,1,1,\"Percentage of Participants With Pathologically Complete Response\"\\n14846,1,1,\"Percentage of Participants With pCR in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in Participants Who Have Phosphatase and Tensin Homolog [PTEN]-Low Tumors)\"\\n14847,1,1,\"Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008)\"\\n14848,1,1,\"Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)\"\\n14849,1,1,\"Percentage of Participants With PFS Event by Investigator Assessment\"\\n14850,1,1,\"Percentage of Participants With Phosphatase and Tensin Homologue Gene (PTEN) Copy Number Alterations and Mutations\"\\n14851,1,1,\"Percentage of Participants With Positive HER2 Test Result\"\\n14852,1,1,\"Percentage of Participants With Previous and Concurrent Disease at the Time of Local or Metastatic Progression\"\\n14853,1,1,\"Percentage of Participants With Professional Activity: Baseline\"\\n14854,1,1,\"Percentage of Participants With Progesterone Receptors (PR) at the Time of Local or Metastatic Progression\"\\n14855,6,2,\"Percentage of Participants With Progression Free Survival\"\\n14856,3,1,\"Percentage of Participants With Progression Free Survival (PFS)\"\\n14857,1,1,\"Percentage of Participants With Progression Free Survival (PFS) as Per Intention-to-treat (ITT) at 6 Months\"\\n14858,1,1,\"Percentage of Participants With Progression Free Survival (PFS) at 2 Months\"\\n14859,1,1,\"Percentage of Participants With Progression Free Survival (PFS) at 6 Months\"\\n14860,1,1,\"Percentage of Participants With Progression Free Survival at 6 Months\"\\n14861,1,1,\"Percentage of Participants With Progression or Death in High Baseline Plasma Vascular Endothelial Growth Factor-A (VEGF-A) ITT Population\"\\n14862,1,1,\"Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population\"\\n14863,3,1,\"Percentage of Participants With Progression-free Survival (PFS)\"\\n14864,1,1,\"Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks\"\\n14865,1,1,\"Percentage of Participants With Progression-free Survival (PFS) at 6 Months\"\\n14866,1,1,\"Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate)\"\\n14867,1,1,\"Percentage of Participants With Progression-free Survival (PFS) at Week 24\"\\n14868,1,1,\"Percentage of Participants With Progression-Free Survival (PFS) Rate at 24 Weeks\"\\n14869,1,1,\"Percentage of Participants With Progression-Free Survival (PFS) Rate at Six Months\"\\n14870,1,1,\"Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer\"\\n14871,1,1,\"Percentage of Participants With Progression-Free Survival at 18 Weeks Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-na√Øve Participants With Metastatic Non-small Cell Lung Cancer\"\\n14872,1,1,\"Percentage of Participants With Progression-free Survival at 6 Months\"\\n14873,3,3,\"Percentage of Participants with Progression-free Survival at 6 Months\"\\n14874,1,1,\"Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6)\"\\n14875,1,1,\"Percentage of Participants With Progression-free Survival at Week 52\"\\n14876,1,1,\"Percentage of Participants With Progression-Free Survival Based on Radiologic and Clinical Assessments and Death After Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-na√Øve Participants With Metastatic Non-small Cell Lung Cancer\"\\n14877,1,1,\"Percentage of Participants With Progression-Free Survival Events\"\\n14878,1,1,\"Percentage of Participants With Progressive Disease\"\\n14879,1,1,\"Percentage of Participants With Progressive Disease (PD) After Initiation of Second Line Sunitinib Therapy\"\\n14880,1,1,\"Percentage of Participants With Progressive Disease at Week 12 in Cohort 1\"\\n14881,3,3,\"Percentage of Participants With Prostate Specific Antigen (PSA) Response\"\\n14882,1,1,\"Percentage of Participants with Prostate-Specific Antigen (PSA) Response\"\\n14883,1,1,\"Percentage of Participants With PSA Response\"\\n14884,1,1,\"Percentage of participants with PSA50 response\"\\n14885,1,1,\"Percentage of Participants With PSA50 Response (Parts 2A, 2B)\"\\n14886,1,1,\"Percentage of Participants With Quality of Life Integral Value (IV) Reduction Prior To Treatment\"\\n14887,1,1,\"Percentage of Participants With Radiographic Progression-free Survival at 6 Months (Phase 1b/2 RP2D)\"\\n14888,1,1,\"Percentage of Participants With Reduction in Grade 3/4 Neutropenia\"\\n14889,1,1,\"Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615) (Clinical Response Rate)\"\\n14890,8,1,\"Percentage of Participants With Response\"\\n14891,1,1,\"Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen\"\\n14892,1,1,\"Percentage of Participants With Response to Study Treatment\"\\n14893,1,1,\"Percentage of Participants With Retinoblastoma Gene (RB1) Copy Number Alterations and Mutations\"\\n14894,1,1,\"Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\"\\n14895,2,1,\"Percentage of Participants With Serious Adverse Events\"\\n14896,12,1,\"Percentage of Participants With Serious Adverse Events (SAEs)\"\\n14897,1,1,\"Percentage of Participants With Serious Adverse Events Considered Related to Onartuzumab\"\\n14898,1,1,\"Percentage of Participants with Seroconversion of Autoantibodies\"\\n14899,1,1,\"Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period\"\\n14900,4,1,\"Percentage of Participants With Stable Disease\"\\n14901,1,1,\"Percentage of Participants With Stable Disease (SD)\"\\n14902,1,1,\"Percentage of Participants With Stable Disease (SD) After Initiation of Second Line Sunitinib Therapy\"\\n14903,1,1,\"Percentage of Participants With Stable Disease (SD) or Objective Response (Complete and Partial Response [CR + PR] According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n14904,1,1,\"Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With That of Placebo Per Response Evaluation Criteria in Solid Tumors Version 1.1 at Week 25\"\\n14905,1,1,\"Percentage of Participants With TEAEs (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Safety Population)\"\\n14906,1,1,\"Percentage of Participants With Total Pathologic Complete Response (Total pCR), Defined as Having pCR in Both Breast and Axilla, Using American Joint Committee on Cancer (AJCC) Staging System\"\\n14907,2,2,\"Percentage of Participants With Total Pathologic Complete Response (tpCR)\"\\n14908,1,1,\"Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)\"\\n14909,1,1,\"Percentage of Participants With Total pCR , Defined as Having pCR in Both Breast and Axilla, Using AJCC Staging System in PIK3CA MT Participants\"\\n14910,1,1,\"Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events(SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug\"\\n14911,1,1,\"Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading to Dose Modifications and TEAEs Leading to Treatment Discontinuation in Western Safety Cohort\"\\n14912,1,1,\"Percentage of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)\"\\n14913,1,1,\"Percentage of Participants With Treatment-emergent Adverse Event (TEAE)\"\\n14914,1,1,\"Percentage of participants with treatment-emergent adverse events\"\\n14915,1,1,\"Percentage of Participants With Treatment-emergent Adverse Events (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Safety Population)\"\\n14916,1,1,\"Percentage of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)\"\\n14917,1,1,\"Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) - Part 1\"\\n14918,16,2,\"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n14919,1,1,\"Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events (AEs)\"\\n14920,3,1,\"Percentage of participants with treatment-related adverse events\"\\n14921,1,1,\"Percentage of Participants With Treatment-Related Grade 3-5 Adverse Events (AEs) During the Induction Period (Period 1 and 2)\"\\n14922,1,1,\"Percentage of Participants With Tumor Metabolic Response (Reduction of ‚â•15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET)\"\\n14923,1,1,\"Percentage of Participants With Tumor Protein 53 Gene (TP53) Copy Number Alterations and Mutations\"\\n14924,1,1,\"Percentage of Participants With Tumor Response\"\\n14925,1,1,\"Percentage of Participants With Tumor Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate) at 12 Weeks\"\\n14926,1,1,\"Percentage of Participants With Unacceptable Toxicity\"\\n14927,1,1,\"Percentage of Participants With Various Fatigue Severity 10-12 Weeks After Start of Treatment\"\\n14928,1,1,\"Percentage of Participants With Various Fatigue Severity 3-4 Weeks After Start of Treatment\"\\n14929,1,1,\"Percentage of Participants With Various Fatigue Severity 6-8 Weeks After Start of Treatment\"\\n14930,1,1,\"Percentage of Participants With Various Responses in the Breast, Evaluated Using Per Protocol Criteria\"\\n14931,1,1,\"Percentage of Participants With Visceral Involvement at the Time of Local or Metastatic Progression\"\\n14932,1,1,\"Percentage of Participants With Vismodegib Treatment Interruption\"\\n14933,3,1,\"Percentage of participants with ‚â•1 adverse event (AE)\"\\n14934,1,1,\"Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months\"\\n14935,1,1,\"Percentage of Participants Without Disease Progression at 12 Months\"\\n14936,1,1,\"Percentage of patient with adverse events / serious adverse events (AEs/SAEs) [Safety and Tolerability]\"\\n14937,2,1,\"Percentage of patients\"\\n14938,1,1,\"Percentage of patients (goal is 50%) who are evaluable for MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival\"\\n14939,1,1,\"Percentage of Patients Achieving Overall Response - (Phase II)\"\\n14940,1,1,\"Percentage of Patients Alive and Free of Progression at 12 Weeks (PFS12)\"\\n14941,1,1,\"Percentage of Patients Alive and Free of Progression at 6 Months\"\\n14942,1,1,\"Percentage of Patients Alive and Progression Free Survival at 12 Weeks\"\\n14943,1,1,\"Percentage of Patients Alive at 1 Year (1-Year Survival Rate)\"\\n14944,1,1,\"Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks of the Expected Start Date, and Received Both Weekly Doses\"\\n14945,1,1,\"Percentage of patients completing 4 weeks of time-restricted eating during RT\"\\n14946,1,1,\"Percentage of Patients Completing at Least 3 Months of Therapy With a PSA Below Baseline.\"\\n14947,2,1,\"Percentage of patients completing the study\"\\n14948,1,1,\"Percentage of patients enrolled in genomics-driven clinical trials and in the PRECISION 2 clinical trial.\"\\n14949,1,1,\"Percentage of patients enrolling in the study\"\\n14950,1,1,\"Percentage of Patients Experiencing a Grade 3 or Higher Adverse Event During Therapy.\"\\n14951,2,1,\"Percentage of patients experiencing adverse events\"\\n14952,1,1,\"Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy\"\\n14953,1,1,\"Percentage of Patients Failure Free at 2 Years Following Study Entry\"\\n14954,1,1,\"Percentage of Patients in Remission at 1 Year\"\\n14955,1,1,\"Percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful\"\\n14956,2,1,\"Percentage of patients in whom the actual dose of sorafenib equaled the planned dose\"\\n14957,1,1,\"Percentage of Patients Needing a Dose Reduction.\"\\n14958,1,1,\"Percentage of Patients Progression Free at 6 Months Following Treatment With Trametinib and I-124 (Cohort A)\"\\n14959,1,1,\"Percentage of Patients Remaining Alive and Progression Free at 3 Months (i.e. Week 12 ¬± 1) as Per RECIST1.1 (PFS3).\"\\n14960,1,1,\"Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate).\"\\n14961,1,1,\"Percentage of Patients Showing a Presence of Methylated Tumor Suppressor Genes in Their Tumor Tissue and/or Serum Achieving Partial or Complete Response to Protocol Therapy.\"\\n14962,1,1,\"Percentage of Patients That Achieved Target Suramin Concentrations in Plasma\"\\n14963,1,1,\"Percentage of patients that are treated based on their molecular tumor profile\"\\n14964,1,1,\"Percentage of patients that receive DST-guided treatmens\"\\n14965,1,1,\"Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity\"\\n14966,1,1,\"Percentage of patients treated according to clinical practice guidelines for head and neck cancer\"\\n14967,1,1,\"Percentage of patients treated according to MTB recommendation\"\\n14968,1,1,\"Percentage of Patients Who Achieve an Overall Response, Defined as Achieving a Complete Response, an Unconfirmed Complete Response (SLL Only), or a Partial Response (Phase II)\"\\n14969,1,1,\"Percentage of Patients Who Are Progression Free at 6 Months or Later.\"\\n14970,1,1,\"Percentage of patients who are progression-free after 24 weeks of treatment with G-202\"\\n14971,1,1,\"Percentage of patients who experience grade 4-5 non-hematologic toxicities assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n14972,1,1,\"Percentage of patients who experience major complications that require escalated care\"\\n14973,1,1,\"Percentage of Patients Who Experienced a 50% or Greater Reduction (Including Discontinuation) of All Antihypertensive Medication(s) Lasting for at Least Six Months.\"\\n14974,1,1,\"Percentage of patients who gain weight over 1 month\"\\n14975,1,1,\"Percentage of Patients Who Have a Partial Response or Complete Response Through Measurement of Tumour Lesion Sizes\"\\n14976,1,1,\"Percentage of patients who identify a scale to be upsetting or difficult to understand\"\\n14977,1,1,\"Percentage of patients who receive all planned radiotherapy.\"\\n14978,1,1,\"Percentage of patients who receive at least one dose of personalized neoantigen vaccine\"\\n14979,1,1,\"Percentage of Patients Who Survive Progression-free\"\\n14980,1,1,\"Percentage of patients whose wearable activity monitor provides movement data\"\\n14981,1,1,\"Percentage of patients with \"\"actionable\"\" driven mutations.\"\\n14982,1,1,\"Percentage of Patients With a 2 Year Disease-Free Survival (DFS) as a Measure of Efficacy\"\\n14983,1,1,\"Percentage of Patients With a 2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET) Response at Day 56 in All Patients and in Epidermal Growth Factor Receptor (EGFR) Mutant and Wild-type Subgroups\"\\n14984,1,1,\"Percentage of patients with a molecular tumor board (MTB) treatment recommendation\"\\n14985,1,1,\"Percentage of patients with a partial or complete response to treatment\"\\n14986,1,1,\"Percentage of patients with access to wearable device\"\\n14987,8,4,\"Percentage of patients with adverse events\"\\n14988,1,1,\"Percentage of patients with Adverse Events (AEs)\"\\n14989,1,1,\"Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.\"\\n14990,1,1,\"Percentage of patients with Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest as assessed by CTCAE v4.03\"\\n14991,1,1,\"Percentage of patients with anti-brontictuzumab antibodies\"\\n14992,1,1,\"Percentage of patients with anti-MEHD7945A antibodies\"\\n14993,1,1,\"Percentage of Patients With Anti-PReferentially Expressed Antigen of MElanoma (Anti-PRAME) Humoral Immune Response (Phase I)\"\\n14994,2,1,\"Percentage of patients with changes in laboratory parameters from baseline\"\\n14995,1,1,\"Percentage of Patients With Chemotherapy-induced Sensory Peripheral Neuropathy ‚â• Grade 2\"\\n14996,1,1,\"Percentage of Patients With Complete Tumor Regression Rate (TRG1)\"\\n14997,1,1,\"Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase\"\\n14998,1,1,\"Percentage of patients with disease progression after 24 months of treatment\"\\n14999,1,1,\"Percentage of patients with dose limiting toxicities\"\\n15000,1,1,\"Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)\"\\n15001,1,1,\"Percentage of patients with dose limiting toxicities (Parts 1A, 1B)\"\\n15002,1,1,\"Percentage of patients with dose limiting toxicity by CTCAE v.5.0 for each dose level\"\\n15003,1,1,\"Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study\"\\n15004,2,2,\"Percentage of patients with dose-limiting toxicities\"\\n15005,1,1,\"Percentage of patients with dose-limiting toxicities (DLTs)\"\\n15006,1,1,\"Percentage of patients with Dose-Limiting toxicities (DLTs) of AVA6000 during the DLT period\"\\n15007,1,1,\"Percentage of Patients With Each Chemotherapy Risk Score (CRS) Result by Tumor Type\"\\n15008,1,1,\"Percentage of Patients With Each EORTC-identified Risk Factors for FN at Baseline\"\\n15009,1,1,\"Percentage of Patients With Each EORTC-identified Risk Factors for FN in Patients With Chemotherapy Risk 10-20% at Baseline\"\\n15010,1,1,\"Percentage of patients with each genetic abnormality among all examination cases\"\\n15011,1,1,\"Percentage of Patients With Each Prophylaxis Decision by Chemotherapy-associated FN Risk\"\\n15012,1,1,\"Percentage of patients with grade 3 or more adverse events\"\\n15013,1,1,\"Percentage of Patients With Grade 4 or Higher Irreversible Adverse Events\"\\n15014,1,1,\"Percentage of Patients With Grade 4 or Higher Renal Adverse Event.\"\\n15015,1,1,\"Percentage of patients with imaging parameter change(s) among the patients with immunological response\"\\n15016,2,2,\"Percentage of patients with objective response\"\\n15017,1,1,\"Percentage of Patients With Objective Response (OR) in Part A According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1\"\\n15018,1,1,\"Percentage of patients with one or more genetic abnormalities among all examination cases\"\\n15019,1,1,\"Percentage of Patients With Overall Objective Response (OR) based on independent central review (ICR)\"\\n15020,1,1,\"Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II\"\\n15021,1,1,\"Percentage of Patients With Overall Survival at 6 Months\"\\n15022,1,1,\"Percentage of Patients With Progression-free Survival > 6 Months\"\\n15023,1,1,\"Percentage of Patients With Progression-free Survival at 16 Weeks.\"\\n15024,1,1,\"Percentage of Patients With PSA Doubling Time >=3 Months.\"\\n15025,1,1,\"Percentage of patients with successful comprehensive panel testing\"\\n15026,1,1,\"Percentage of patients with surgical complications as assessed by the Clavien-Dindo Classification\"\\n15027,1,1,\"Percentage of patients with toxicity by CTCAE v.5.0\"\\n15028,1,1,\"Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment\"\\n15029,1,1,\"Percentage of Patients Without Distant Metastases by Three Years\"\\n15030,1,1,\"Percentage of patients without treatment failure at 24 months\"\\n15031,1,1,\"Percentage of Progression Free Participants After 16 Weeks of Treatment\"\\n15032,1,1,\"Percentage of Progression-free Patients by Month 6\"\\n15033,1,1,\"Percentage of radioactive dose excreted in urine, feces and expired air\"\\n15034,1,1,\"Percentage of Randomly Assigned Subjects Remaining Progression Free at 12 Weeks Following Random Assignment to Tivozanib (AV-951) or Placebo\"\\n15035,1,1,\"Percentage of samples with identifiable Notch, Wnt and Hedghog pathways in the chemo naive esophageal tumor as well as in cancer stem cell populations (CSC).\"\\n15036,1,1,\"Percentage of scheduled treatment fractions delivered successfully using the surface guidance system\"\\n15037,1,1,\"Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing\"\\n15038,1,1,\"Percentage of screened patients allocated to trials based upon outcome of genetic screening effort.\"\\n15039,4,1,\"Percentage of Serious Adverse Events (SAEs)\"\\n15040,2,2,\"Percentage of serious adverse events (SAEs)\"\\n15041,2,2,\"Percentage of subjects reporting adverse events\"\\n15042,2,2,\"Percentage of subjects reporting serious adverse events\"\\n15043,1,1,\"Percentage of subjects that were subject to surgical resection\"\\n15044,1,1,\"Percentage of Subjects Who Experienced DLT\"\\n15045,1,1,\"Percentage of subjects who proceed to radical nephrectomy\"\\n15046,2,1,\"Percentage of Subjects Who Reached Seroprotection by Visit\"\\n15047,1,1,\"Percentage of subjects with 1 or more SAEs\"\\n15048,1,1,\"Percentage of subjects with 1 or more SAEs (Part 1)\"\\n15049,1,1,\"Percentage of subjects with 1 or more SAEs (Part 2)\"\\n15050,1,1,\"Percentage of subjects with 1 or more TEAEs leading to dose modification\"\\n15051,1,1,\"Percentage of subjects with 1 or more TEAEs leading to dose modifications (Part 1)\"\\n15052,1,1,\"Percentage of subjects with 1 or more TEAEs leading to dose modifications (Part 2)\"\\n15053,1,1,\"Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation\"\\n15054,1,1,\"Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 1)\"\\n15055,1,1,\"Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 2)\"\\n15056,1,1,\"Percentage of subjects with Adverse Events (AEs)\"\\n15057,2,1,\"Percentage of subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5\"\\n15058,1,1,\"Percentage of Subjects With Best Overall Confirmed Response Rate (BORR)\"\\n15059,1,1,\"Percentage of subjects with clinical benefit\"\\n15060,1,1,\"Percentage of Subjects With Detectable Circulating T Cells After Treatment\"\\n15061,2,1,\"Percentage of subjects with Dose Limiting Toxicities (DLTs)\"\\n15062,1,1,\"Percentage of Subjects With Dose-Limiting Toxicities (DLT)\"\\n15063,1,1,\"Percentage of Subjects with Dose-Limiting Toxicities (DLTs)\"\\n15064,1,1,\"Percentage of subjects with dose-limiting toxicities (DLTs) as assessed by NCI CTCAE (Version 5)\"\\n15065,1,1,\"Percentage of subjects with grade ‚â• 3 TEAEs\"\\n15066,1,1,\"Percentage of subjects with grade ‚â•3 TEAEs (Part 1)\"\\n15067,1,1,\"Percentage of subjects with grade ‚â•3 TEAEs (Part 2)\"\\n15068,1,1,\"Percentage of Subjects With Neither Germline Deoxyribonuclecic Acid (DNA) Repair Mutations Nor Somatic Breast Cancer Type 1 Associated Protein-1 (BAP1) Mutations Who Experienced Partial or Complete Response.\"\\n15069,1,1,\"Percentage of Subjects With Persistent Partial Response (PR) or Complete Response (CR) at 1 Year Since Nivolumab Discontinuation (Arm A Only)\"\\n15070,1,1,\"Percentage of Subjects With Stable or Progressive Disease (SD/PD) to Nivolumab Induction That Convert to Complete or Partial Response (CR/PR) Upon the Addition of Ipilimumab to Nivolumab (Arm B Only)\"\\n15071,1,1,\"Percentage of Subjects With Time Point Responses According to Response Evaluation Criteria in Solid Tumours (RECIST) Assessments at Weeks 25 and 53\"\\n15072,1,1,\"Percentage of subjects woth Dose-Limitine toxicities(DLTs)\"\\n15073,1,1,\"Percentage of T790M Positive Patients With Confirmed Response Per Investigator\"\\n15074,1,1,\"Percentage of TEAEs ‚â• Grade 3\"\\n15075,1,1,\"Percentage of the children to whom 5.106 cells CD34 + / kg can be collected in 2 masses blood treated (one cytapheresis).\"\\n15076,1,1,\"Percentage of time in assessment periods 1 and 2 (i.e., first 4 weeks) with a Box-Scale (BS)-11 pain score of ‚â§ 4 (i.e., mild pain)\"\\n15077,1,1,\"Percentage of Total Cyclin-dependent Kinase (CDC2)-Positive Cells That Were Phosphorylated (pCDC2) in Skin Cells at Baseline and 8 Hours After MK-1775 Dosing\"\\n15078,1,1,\"Percentage of Total Dose in 14C-labeled RO5185426 and 14C-labeled Metabolite in Pooled Fecal Samples\"\\n15079,1,1,\"Percentage of Total Dose in 14C-labeled RO5185426 and 14C-labeled Metabolite in Pooled Urine Samples\"\\n15080,1,1,\"Percentage of Total Integrated Radioactivity in Feces of 14C-labeled RO5185426 and 14C-labeled Metabolite\"\\n15081,1,1,\"Percentage of Total Integrated Radioactivity in Plasma of 14C-labeled RO5185426 and 14C-labeled Metabolite\"\\n15082,1,1,\"Percentage of Total Integrated Radioactivity in Urine of 14C-labeled RO5185426 and 14C-labeled Metabolite\"\\n15083,1,1,\"Percentage of Total pCDC2 in Skin Cells at Baseline and 24 Hours After MK-1775 Dosing\"\\n15084,1,1,\"Percentage of Total pCDC2 in Skin Cells at Baseline and 48 Hours After MK-1775 Dosing\"\\n15085,1,1,\"Percentage of Total Phase II Participants With Chemotherapy Pre-Treated Triple Negative Metastatic Breast Cancer Who Are Progression Free at 3 Months\"\\n15086,1,1,\"Percentage of Total Radioactivity Excreted in Urine\"\\n15087,1,1,\"Percentage of treatment emergent adverse events (TEAEs)\"\\n15088,1,1,\"Percentage of True Positive Plus True Negative Patients\"\\n15089,1,1,\"Percentage of tumor cells in S and G2 phase of the cell cycle\"\\n15090,1,1,\"Percentage of Tumor Shrinkage as a Continuous Variable\"\\n15091,1,1,\"Percentage of Vaccines Associated With Grade 1 and Grade 2 Adverse Events Related to Vaccine in the Colorectal Cancer and Non-Colorectal Cancer Arm/Group\"\\n15092,1,1,\"Percentage of voxel-based mean apparent diffusion coefficient (ADC) increase per lesion\"\\n15093,1,1,\"Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died\"\\n15094,1,1,\"Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy\"\\n15095,1,1,\"Percentage Recovery of 14^C- Lenvatinib Related Material in the Feces\"\\n15096,1,1,\"Percentage Recovery of 14^C- Lenvatinib Related Material in the Urine\"\\n15097,1,1,\"Percentage reduction of urine NTX and serum CTX\"\\n15098,1,1,\"Percentage weight loss by measuring height and weight at baseline and at 3 months\"\\n15099,1,1,\"Percentage With Objective Response (Complete Response or Partial Response) (Cohort A)\"\\n15100,1,1,\"Percentages of the DLTEs\"\\n15101,1,1,\"Perceptions of cure\"\\n15102,1,1,\"Perform 500 post mortems\"\\n15103,1,1,\"Perform analysis of gene expression profiles. [RNA] ribonucleic acid will be isolated from fresh frozen tumor specimens and hybridized to Affymetrix gene expression arrays.\"\\n15104,1,1,\"Perform initial assessment of the safety profile of SL-901\"\\n15105,1,1,\"performance and quality of life (EQ5D_3L) questionnaire\"\\n15106,1,1,\"Performance for specific cancer types using Harbinger Test\"\\n15107,1,1,\"Performance of fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) response criteria as a binary predictor of progression-free survival (PFS)\"\\n15108,1,1,\"Performance of MD Anderson Symptom Inventory (MDASI) modified for use with adolescents (adolescent version)\"\\n15109,1,1,\"Performance of model\"\\n15110,1,1,\"Performance of selected domains and items for classification and assessment of pain and cachexia\"\\n15111,1,1,\"Performance on experimental working memory measures (computerized self-ordered pointing tasks)\"\\n15112,1,1,\"Performance Related Measures of Functional Independence as Assessed by the Hand Grip Strength Test\"\\n15113,1,1,\"Performance Related Measures of Functional Independence as Assessed by the Time Up and Go (TUG) Walking Test\"\\n15114,1,1,\"Performance status using Karnofsky performance status criteria\"\\n15115,1,1,\"Performing retrospective research\"\\n15116,1,1,\"Perfusion MRI outputs\"\\n15117,1,1,\"Peri-apical radiolucency\"\\n15118,1,1,\"Period 1: Percent Fecal Recovery (fefeces) of Total Radioactivity\"\\n15119,1,1,\"Period 1: Percent Total Recovery in Urine and Feces (fetotal) of Total Radioactivity\"\\n15120,1,1,\"Period 1: Percent Urinary Recovery (feurine) of Total Radioactivity\"\\n15121,1,1,\"Period 1: Pharmacokinetic (PK) Plasma and Urine Concentration of M6620\"\\n15122,2,1,\"Period 1: Pharmacokinetic Plasma and Blood Concentration of Total Radioactivity\"\\n15123,1,1,\"Peripheral immune response\"\\n15124,1,1,\"Peripheral neuropathy as measured by Peripheral Neuropathy Scale every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment\"\\n15125,1,1,\"Peripheral T cell activation and proliferation\"\\n15126,1,1,\"Permanent chemotherapy-induced alopecia\"\\n15127,1,1,\"Permanent discontinuation of SNB-101 and dose reduction due to adverse events(AEs)\"\\n15128,1,1,\"Persistence and frequency of circulating EBV CTL\"\\n15129,1,1,\"Persistence of Transduced T Cells\"\\n15130,1,1,\"Personal ideas about the handbook\"\\n15131,1,1,\"Personalized medicine recommendation\"\\n15132,1,1,\"PET/CT scan images\"\\n15133,1,1,\"PF-03512676 Augments Antibody Mediated Cytoxicity (ADCC)Against Trastuzumab-coated Target Cells in Metastatic HER2 Overexpressing Breast Cancer.\"\\n15134,345,33,\"PFS\"\\n15135,2,1,\"PFS (Phase III)\"\\n15136,7,1,\"PFS (Progression Free Survival)\"\\n15137,1,1,\"PFS (Progression Free Survival) by investigator\"\\n15138,1,1,\"PFS (progression-free survival )\"\\n15139,1,1,\"PFS (The Randomized Double-blinded Part)\"\\n15140,1,1,\"PFS (time to event)\"\\n15141,1,1,\"PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months\"\\n15142,1,1,\"PFS - Percentage of Participants With an Event\"\\n15143,3,1,\"PFS - Progression Free Survival\"\\n15144,1,1,\"PFS - Progression Free Survival (time - months)\"\\n15145,4,3,\"PFS - Time to Event\"\\n15146,1,1,\"PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)\"\\n15147,1,1,\"PFS According to RECIST v1.1 in Participants With Estrogen Receptor (ESR)1 Mutations\"\\n15148,1,1,\"PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels\"\\n15149,1,1,\"PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels\"\\n15150,1,1,\"PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels\"\\n15151,1,1,\"PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels\"\\n15152,1,1,\"PFS and OS\"\\n15153,1,1,\"PFS as Assessed by Investigator Using RECIST v1.1 at Final Analysis\"\\n15154,2,2,\"PFS as Assessed by the Investigator\"\\n15155,1,1,\"PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone\"\\n15156,1,1,\"PFS as Determined by the Investigator Using mINRC in Participants With Neuroblastoma\"\\n15157,1,1,\"PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)\"\\n15158,1,1,\"PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)\"\\n15159,1,1,\"PFS as Determined by the Investigator Using RANO Criteria in Participants With ATRT\"\\n15160,1,1,\"PFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)\"\\n15161,1,1,\"PFS as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin\\'s Lymphoma or Non-Hodgkin\\'s Lymphoma\"\\n15162,1,1,\"PFS assessed by BICR using RECIST v1.1 in PD-L1 positive patients\"\\n15163,1,1,\"PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation\"\\n15164,2,2,\"PFS assessed by IRC\"\\n15165,1,1,\"PFS assessed by IRC per RECIST 1.1.\"\\n15166,1,1,\"PFS at 12 months\"\\n15167,2,1,\"PFS at 6 months\"\\n15168,1,1,\"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).\"\\n15169,1,1,\"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.\"\\n15170,1,1,\"PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n15171,1,1,\"PFS by BICR (with or without Pembrolizumab)\"\\n15172,1,1,\"PFS by Therapeutic Regimens\"\\n15173,1,1,\"PFS for all participants\"\\n15174,1,1,\"PFS for PD-L1 positive participants\"\\n15175,1,1,\"PFS in All Participants (Data Cutoff 17 May 2008)\"\\n15176,1,1,\"PFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008)\"\\n15177,1,1,\"PFS in High Baseline Plasma VEGF-A ITT Population\"\\n15178,1,1,\"PFS in Low-ERCC1 Participants\"\\n15179,1,1,\"PFS in Participants With Hemoglobin A1c (HbA1c) Less Than (<) 5.7% at Baseline\"\\n15180,1,1,\"PFS in Participants With PD-L1 TPS ‚â•50%\"\\n15181,1,1,\"PFS in the MSI\"\\n15182,1,1,\"PFS of Patients With FDG-PET Complete Response (CR)/Partial Response (PR) Versus FDG-PET Progressive Disease (PD) in Patients With Computed Tomography (CT) Stable Disease (SD) at Day 56\"\\n15183,1,1,\"PFS Per RECIST 1.1 - Participants With Programmed Cell Death-Ligand (PD-L1) Positive Tumors\"\\n15184,1,1,\"PFS Per RECIST 1.1 - Participants With Strongly PD-L1 Positive Tumors\"\\n15185,1,1,\"PFS Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 Positive (TPS ‚â•1%) Tumors (All Participants)\"\\n15186,1,1,\"PFS per RECIST 1.1 as Assessed by Investigator at 12 months\"\\n15187,1,1,\"PFS per RECIST 1.1 as Assessed by Investigator at 9 months\"\\n15188,1,1,\"PFS Per RECIST 1.1 As Assessed By Investigator in All Participants\"\\n15189,1,1,\"PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ‚â•10)\"\\n15190,1,1,\"PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants\"\\n15191,1,1,\"PFS Per RECIST v1.1 Via IRC Assessment in IC1/2/3 Population\"\\n15192,1,1,\"PFS per RECIST Version 1.1 in PD-L1 biomarker-positive participants\"\\n15193,1,1,\"PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n15194,2,1,\"PFS Rate\"\\n15195,1,1,\"PFS rate of lurbinectedin with doxorubicin compared to doxorubicin alone in participants with advanced LMS\"\\n15196,1,1,\"PFS ratio\"\\n15197,1,1,\"PFS Status\"\\n15198,1,1,\"PFS Using RECIST 1.1 as Assessed by BICR\"\\n15199,1,1,\"PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (‚â• 75% of Tumor Staining)\"\\n15200,1,1,\"PFS-IRF Per RECIST v1.1 in the China Population\"\\n15201,1,1,\"PFS: defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first.\"\\n15202,1,1,\"PFS: Time to Event\"\\n15203,3,1,\"PFSÔºàProgress free survivalÔºâ\"\\n15204,1,1,\"PFSÔºàprogress free survivalÔºâ\"\\n15205,1,1,\"Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors\"\\n15206,1,1,\"Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Topotecan\"\\n15207,1,1,\"Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of VX-970 (M6620)\"\\n15208,1,1,\"Ph II Determine overall response rate of Durvalumab-O and Durvalumab-C in patients with recurrent ovarian cancer\"\\n15209,1,1,\"Ph II: Number of Participants With a Clinical Response\"\\n15210,1,1,\"Ph. 1: incidence of adverse events of DAB, TRA and HCQ\"\\n15211,1,1,\"Ph. 2 Arm A: objective response rate (ORR) of DAB, TRA and HCQ\"\\n15212,1,1,\"Ph1a: Adverse Events of IGM-8444 as single agent and with FOLFIRI ¬± bevacizumab, IGM-8444 with birinapant, IGM-8444 with venetoclax, IGM-8444 with venetoclax and azacitadine, and IGM-8444 with gemcitabine and docetaxel\"\\n15213,1,1,\"Ph1a: To identify the recommended expansion dose for IGM-8444 as single agent, with FOLFIRI ¬± bevacizumab, IGM-8444 with birinapant, IGM-8444 with venetoclax, IGM-8444 with venetoclax and azacitadine, and IGM-8444 with gemcitabine and docetaxel\"\\n15214,1,1,\"Ph1b: Objective Response Rate (ORR)\"\\n15215,1,1,\"Pharmacodynamic (PD) parameters\"\\n15216,1,1,\"Pharmacodynamic (PD) response rate\"\\n15217,1,1,\"Pharmacodynamic analysis of cellular inhibitor of apoptosis (cIAP) protein\"\\n15218,1,1,\"Pharmacodynamic assessments (e.g., changes in phosphorylation of ERK, Rad51 expression, number of CTCs, and tumor glucose metabolism measured by FDG-PET)\"\\n15219,1,1,\"Pharmacodynamic Biomarker p70S6K\"\\n15220,1,1,\"Pharmacodynamic change on FLT-PET/CT\"\\n15221,1,1,\"Pharmacodynamic effects as measured by changes in biomarkers in pre- and post-dose tumor and blood specimens\"\\n15222,1,1,\"Pharmacodynamic optimal dose of sirolimus by evaluation of p70s6 kinase inhibition in peripheral blood mononuclear cells (PBMC) and normal skin\"\\n15223,1,1,\"Pharmacodynamic parameters (percent inhibition of pERK, pKDR, and pEGFR)\"\\n15224,1,1,\"Pharmacodynamic parameters of prexasertib\"\\n15225,5,1,\"Pharmacodynamics\"\\n15226,1,1,\"Pharmacodynamics ex vivo\"\\n15227,12,1,\"Pharmacokinetic\"\\n15228,1,1,\"Pharmacokinetic (PK) characteristics 1\"\\n15229,1,1,\"Pharmacokinetic (PK) characteristics 2\"\\n15230,1,1,\"Pharmacokinetic (PK) parameter (time to reach the maximum observed plasma concentration Cmax [Tmax]) for binimetinib\"\\n15231,1,1,\"Pharmacokinetic (PK) parameter - Area under the curve (AUC) (Cohorts D and E)\"\\n15232,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - AUC0-12: area under the concentration-time curve from time zero to 12 hr post-dose\"\\n15233,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - AUC0-24: area under the concentration-time curve from time zero to 24 hr post-dose\"\\n15234,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - AUC0-t: area under the concentration-time curve from time zero to the last measurable concentration\"\\n15235,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - AUC0-‚àû: area under the concentration-time curve from time zero extrapolated to infinity\"\\n15236,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - Cmax: Maximum concentration\"\\n15237,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - Ke: apparent first-order terminal elimination rate constant\"\\n15238,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - T1/2: apparent first-order terminal elimination half-life\"\\n15239,1,1,\"Pharmacokinetic (PK) parameter from plasma ABN401 concentration - Tmax: Time to reach maximum concentration\"\\n15240,1,1,\"Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258\"\\n15241,1,1,\"Pharmacokinetic (PK) parameter of AUClast following a single dose of TKI258 and at steady state\"\\n15242,1,1,\"Pharmacokinetic (PK) parameter of Cmax following a single dose of TKI258 and at the steady state\"\\n15243,1,1,\"Pharmacokinetic (PK) parameter of Tmax following a single dose of TKI258 and at the steady state\"\\n15244,1,1,\"Pharmacokinetic (PK) Parameter: Area under the plasma concentration versus time curve (AUC).\"\\n15245,1,1,\"Pharmacokinetic (PK) parameter: drug clearance\"\\n15246,1,1,\"Pharmacokinetic (PK) parameter: half-life\"\\n15247,1,1,\"Pharmacokinetic (PK) Parameter: Peak plasma concentration (Cmax).\"\\n15248,1,1,\"Pharmacokinetic (PK) parameter: systemic exposure\"\\n15249,1,1,\"Pharmacokinetic (PK) Parameter: Terminal phase half-life (t1/2).\"\\n15250,4,3,\"Pharmacokinetic (PK) parameters\"\\n15251,1,1,\"Pharmacokinetic (PK) Parameters After the First Dose: Maximum Observed Plasma Concentration Cmax for T-DM1 Concentrations\"\\n15252,1,1,\"Pharmacokinetic (PK) Parameters of Adavosertib in Terms of Systemic Exposure, AUC\"\\n15253,1,1,\"Pharmacokinetic (PK) Parameters of Adavosertib in Terms of Systemic Exposure, Cmax\"\\n15254,1,1,\"Pharmacokinetic (PK) Parameters of Adavosertib in Terms of Systemic Exposure, HL-Lambda (Half Life)\"\\n15255,1,1,\"Pharmacokinetic (PK) Parameters of Adavosertib in Terms of Systemic Exposure, Tmax\"\\n15256,1,1,\"Pharmacokinetic (PK) parameters of tivantinib\"\\n15257,1,1,\"Pharmacokinetic (PK) parameters of trebananib\"\\n15258,1,1,\"Pharmacokinetic (PK) parameters: Clearance (CL)\"\\n15259,1,1,\"Pharmacokinetic (PK) parameters: Peak concentration\"\\n15260,1,1,\"Pharmacokinetic (PK) parameters: Time-averaged concentration\"\\n15261,1,1,\"Pharmacokinetic (PK) parameters: Trough concentration\"\\n15262,1,1,\"Pharmacokinetic (PK) parameters: Volume of distribution (Vd)\"\\n15263,1,1,\"Pharmacokinetic (PK) profile of PROMITIL\"\\n15264,1,1,\"Pharmacokinetic (PK) profile of PRTH-101 alone and in combination with pembrolizumab\"\\n15265,1,1,\"Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method\"\\n15266,1,1,\"Pharmacokinetic (PK) variables corresponding to the disposition of vorinostat (SAHA) (Group 1)\"\\n15267,1,1,\"Pharmacokinetic (predominantly AUC-dependent specific vascular effects) dependent effects (duration and magnitude of effect on blood flow/volume) in the tumor tissue compared to renal tissue using data from volumetric assessments via DCE-CT\"\\n15268,4,1,\"pharmacokinetic analysis\"\\n15269,1,1,\"Pharmacokinetic analysis of 89Zr-Anti-CLDN18.2 mAbs (NY005).\"\\n15270,1,1,\"Pharmacokinetic Analysis: AUC(0-‚àû)\"\\n15271,1,1,\"Pharmacokinetic and molecular studies\"\\n15272,1,1,\"Pharmacokinetic Assessment of Axitinib Concentrations in Plasma Samples\"\\n15273,1,1,\"Pharmacokinetic Cmax (maximum concentration)\"\\n15274,3,2,\"Pharmacokinetic Evaluation\"\\n15275,1,1,\"Pharmacokinetic evaluation of belinostat\"\\n15276,5,1,\"Pharmacokinetic interaction\"\\n15277,2,2,\"Pharmacokinetic interactions\"\\n15278,1,1,\"Pharmacokinetic modelling comparing pharmacokinetic parameters to investigate the key factors involved in determining individual exposures to parent drugs and metabolites\"\\n15279,1,1,\"Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP341 (Dose Finding Phase)\"\\n15280,1,1,\"Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve of Geometric Means of Serum Free Form of CS-7017 (R-150033) After Administration of CS-7017 and Carboplatin/Paclitaxel in Participants With Stage IIIb/IV Non-small Cell Lung Cancer\"\\n15281,1,1,\"Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve of Serum Free Form of CS-7017 (R-150033) After CS-7017 and Erlotinib in Participants With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer\"\\n15282,1,1,\"Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP341 (Dose Finding Phase)\"\\n15283,1,1,\"Pharmacokinetic Parameter Clearance (CL) of JZP341 (Dose Finding Phase)\"\\n15284,3,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)\"\\n15285,3,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)\"\\n15286,2,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)\"\\n15287,3,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)\"\\n15288,3,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)\"\\n15289,2,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)\"\\n15290,2,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)\"\\n15291,3,1,\"Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)\"\\n15292,1,1,\"Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP341 (Dose Finding Phase)\"\\n15293,1,1,\"Pharmacokinetic Parameter Observed Serum Concentration (Cmax) of Geometric Means of Serum Free Form of CS-7017 (R-150033) Following Administration of CS-7017 and Carboplatin/Paclitaxel in Participants With Stage IIIb/IV Non-small Cell Lung Cancer\"\\n15294,1,1,\"Pharmacokinetic Parameter Observed Serum Concentration (Cmax) of Serum Free Form of CS-7017 (R-150033) After CS-7017 and Erlotinib in Participants With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer\"\\n15295,1,1,\"Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve Following Treatment With DS-8201a and Itraconazole - Cohort 2\"\\n15296,1,1,\"Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve Following Treatment With DS-8201a and Ritonavir - Cohort 1\"\\n15297,1,1,\"Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve of MAAA-1181a Following Treatment With DS-8201a and Itraconazole - Cohort 2\"\\n15298,1,1,\"Pharmacokinetic Parameter of Area Under the Serum Concentration-time Curve of MAAA-1181a Following Treatment With DS-8201a and Ritonavir - Cohort 1\"\\n15299,1,1,\"Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Itraconazole - Cohort 2\"\\n15300,1,1,\"Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Ritonavir - Cohort 1\"\\n15301,1,1,\"Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) For MAAA-1181a Following Treatment With DS-8201a and Ritonavir - Cohort 1\"\\n15302,1,1,\"Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) of MAAA-1181a Following Treatment With DS-8201a and Itraconazole - Cohort 2\"\\n15303,1,1,\"Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Geometric Means of Serum Free Form of CS-7017 (R-150033) Following Administration of CS-7017 and Carboplatin/Paclitaxel in Participants With Stage IIIb/IV Non-small Cell Lung Cancer\"\\n15304,1,1,\"Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Serum Free Form of CS-7017 (R-150033) After CS-7017 and Erlotinib in Participants With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer\"\\n15305,1,1,\"Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP341 (Dose Finding Phase)\"\\n15306,1,1,\"Pharmacokinetic Parameter Volume of Distribution (Vd) of JZP341 (Dose Finding Phase)\"\\n15307,2,2,\"Pharmacokinetic parameter: 5-day AUCtau\"\\n15308,34,4,\"Pharmacokinetic parameters\"\\n15309,1,1,\"Pharmacokinetic Parameters Area Under the Concentration-Time Curve After Cycle 1 and Cycle 3 Treatments With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer\"\\n15310,1,1,\"Pharmacokinetic Parameters Area Under the Concentration-Time Curve of MAAA-1181 After Cycle 1 and Cycle 3 Treatments With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer\"\\n15311,1,1,\"Pharmacokinetic parameters for SN2310 and SN-38\"\\n15312,1,1,\"Pharmacokinetic parameters of copper Cu 64 anti-CEA monoclonal antibody M5A\"\\n15313,1,1,\"Pharmacokinetic parameters of dasatinib\"\\n15314,1,1,\"Pharmacokinetic parameters of GDC-0623 (total exposure, maximum and minimum plasma concentrations, time to maximum plasma concentration, elimination half-life)\"\\n15315,1,1,\"Pharmacokinetic Parameters of Intravenous Topotecan With and Without Erlotinib (Dose-Normalized AUC)\"\\n15316,1,1,\"Pharmacokinetic Parameters of Intravenous Topotecan With and Without Erlotinib (Mean Clearance)\"\\n15317,1,1,\"Pharmacokinetic Parameters of Intravenous Topotecan With and Without Erlotinib (Renal Clearance)\"\\n15318,1,1,\"Pharmacokinetic Parameters of Maximum Serum Concentration (Cmax) After Cycle 1 and Cycle 3 Treatments With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer\"\\n15319,1,1,\"Pharmacokinetic Parameters of Maximum Serum Concentration (Cmax) of MAAA-1181 After Cycle 1 and Cycle 3 Treatments With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer\"\\n15320,1,1,\"Pharmacokinetic parameters will be assessed for T-ChOS\"\\n15321,1,1,\"Pharmacokinetic parameters, and maximum tolerated dose (Part 1)\"\\n15322,1,1,\"Pharmacokinetic parameters, including Cmax, Tmax, AUC, t ¬Ω Œ±, t ¬Ω Œ≤, Vd, and clearance\"\\n15323,1,1,\"Pharmacokinetic parameters,Cmax, AUC(0-t), AUC(0-8)] from free base and bisphosphate salt formulations in Part 1 of the study.\"\\n15324,10,2,\"Pharmacokinetic Profile\"\\n15325,14,2,\"Pharmacokinetic profile\"\\n15326,1,1,\"pharmacokinetic profile\"\\n15327,1,1,\"Pharmacokinetic profile (assay for ABT-806)\"\\n15328,1,1,\"Pharmacokinetic profile (assay for ABT-806) Dose Escalation Cohort\"\\n15329,1,1,\"Pharmacokinetic profile (assay for ABT-806) Expanded Safety Cohort\"\\n15330,1,1,\"Pharmacokinetic profile as measured on days 1, 2, and 4 in course 1\"\\n15331,3,1,\"Pharmacokinetic profile evaluation\"\\n15332,1,1,\"Pharmacokinetic Profile of AMG 386 - blood levels of AMG 386 to be measured throughout the study.\"\\n15333,1,1,\"Pharmacokinetic profile of AT9283\"\\n15334,1,1,\"Pharmacokinetic profile of BBI503\"\\n15335,1,1,\"Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib.\"\\n15336,1,1,\"Pharmacokinetic profile of cabazitaxel in study population\"\\n15337,1,1,\"Pharmacokinetic profile of DS-5573a\"\\n15338,1,1,\"Pharmacokinetic profile of nanosomal docetaxel lipid suspension\"\\n15339,1,1,\"Pharmacokinetic profile of oral cediranib maleate in combination with bevacizumab\"\\n15340,1,1,\"Pharmacokinetic Profile of Pazopanib\"\\n15341,1,1,\"Pharmacokinetic profile of trametinib\"\\n15342,1,1,\"pharmacokinetic profiles\"\\n15343,1,1,\"pharmacokinetic profiles of Chidamide, open-label period\"\\n15344,1,1,\"Pharmacokinetic profiles of eribulin mesylate and gemcitabine hydrochloride\"\\n15345,1,1,\"pharmacokinetic profiles of exemestane, open-label period\"\\n15346,1,1,\"Pharmacokinetic property of GDC-0425: determination of plasma drug concentration\"\\n15347,1,1,\"Pharmacokinetic property of GDC-0425: exposure\"\\n15348,1,1,\"Pharmacokinetic property of GDC-0425: half-life\"\\n15349,1,1,\"Pharmacokinetic Tmax (Time of maximum concentration)\"\\n15350,114,14,\"Pharmacokinetics\"\\n15351,1,1,\"Pharmacokinetics (PK) - Time to maximum concentration (Tmax)\"\\n15352,1,1,\"Pharmacokinetics (PK) observed maximum concentration (Cmax)\"\\n15353,1,1,\"Pharmacokinetics (PK) of 89Zr-DFO-REGN3767\"\\n15354,1,1,\"Pharmacokinetics (PK) of a Single-dose Belinostat (400 mg/m^2)) According to Degree of Liver Dysfunction: Maximum Plasma Concentrations (Cmax)\"\\n15355,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: Area under the concentration-time curve (AUC) from the time of dosing to the last measurable concentration (AUClast)\"\\n15356,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: AUCinf\"\\n15357,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: AUCinf %extrap\"\\n15358,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: AUClast\"\\n15359,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: AUCtau\"\\n15360,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: CL\"\\n15361,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: Cmax\"\\n15362,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: Ctrough\"\\n15363,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: t1/2\"\\n15364,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: tlast\"\\n15365,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: tmax\"\\n15366,1,1,\"Pharmacokinetics (PK) of ASP1948 in serum: V\"\\n15367,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCinf\"\\n15368,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCinf%extrap\"\\n15369,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUClast\"\\n15370,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCtau\"\\n15371,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: CL\"\\n15372,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Cmax\"\\n15373,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Ctrough\"\\n15374,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: t 1/2\"\\n15375,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: tlast\"\\n15376,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: tmax\"\\n15377,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Vss\"\\n15378,1,1,\"Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Vz\"\\n15379,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: AUCinf\"\\n15380,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: AUCinf%extrap\"\\n15381,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: AUClast\"\\n15382,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: AUCtau\"\\n15383,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: CL\"\\n15384,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: Cmax\"\\n15385,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: Ctrough\"\\n15386,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: t 1/2\"\\n15387,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: tlast\"\\n15388,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: tmax\"\\n15389,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: Vss\"\\n15390,1,1,\"Pharmacokinetics (PK) of ASP1951 in serum: Vz\"\\n15391,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: AUCinf (Initial treatment, escalation cohorts in monotherapy only)\"\\n15392,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: AUClast\"\\n15393,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: AUClast (Initial treatment, escalation cohorts in monotherapy only)\"\\n15394,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: AUCtau (Initial treatment, escalation cohorts in monotherapy only)\"\\n15395,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: CL (Initial treatment, escalation cohorts in monotherapy only)\"\\n15396,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: Cmax (Initial treatment, escalation cohorts in monotherapy only)\"\\n15397,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: Ctrough (Initial treatment, escalation and expansion cohorts in both monotherapy and combination therapy)\"\\n15398,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: Ctrough (Re-treatment, escalation and expansion cohorts in both monotherapy and combination therapy)\"\\n15399,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: t1/2 (Initial treatment, escalation cohorts in monotherapy only)\"\\n15400,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: tmax (Initial treatment, escalation cohorts in monotherapy only)\"\\n15401,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: Vss (Initial treatment, escalation cohorts in monotherapy only)\"\\n15402,1,1,\"Pharmacokinetics (PK) of ASP8374 in serum: Vz (Initial treatment, escalation cohorts in monotherapy only)\"\\n15403,1,1,\"Pharmacokinetics (PK) of cabazitaxel (part 3 and 4)\"\\n15404,1,1,\"Pharmacokinetics (PK) of cixutumumab\"\\n15405,1,1,\"Pharmacokinetics (PK) of DRP-104\"\\n15406,1,1,\"Pharmacokinetics (PK) of NKTR-102 and its metabolites\"\\n15407,1,1,\"Pharmacokinetics (PK) of pembrolizumab in serum: Ctrough (Initial treatment, escalation cohorts in combination therapy)\"\\n15408,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf)\"\\n15409,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Area Under the Plasma Concentration Time Curve Extrapolated to Infinity(AUC0-inf) of Belinostat\"\\n15410,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Clearance (CL)\"\\n15411,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Half-Life (t1/2)\"\\n15412,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Metabolic Ratios of Area Under the Plasma Concentration Time Curve Extrapolated to Infinity (AUC0-inf) for the Belinostat Metabolic Pathway\"\\n15413,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Metabolic Ratios of Maximum Plasma Concentrations (Cmax) for the Belinostat Metabolic Pathway\"\\n15414,1,1,\"Pharmacokinetics (PK) of Single-dose Belinostat (400 mg/m^2) According to Degree of Liver Dysfunction: Volume of Distribution at Steady State (Vss)\"\\n15415,1,1,\"Pharmacokinetics (PK) parameter AUClast for S- and R-warfarin\"\\n15416,1,1,\"Pharmacokinetics (PK): Area Under the Concentration -Time Curve Over a Dosing Interval at Steady State (AUCt,ss) of Enzastaurin, It\\'s Metabolites and Total Analytes in Plasma\"\\n15417,1,1,\"Pharmacokinetics (PK): Area Under The Concentration Curve Zero to Infinity (AUC[0-‚àû]) Doxorubicin\"\\n15418,1,1,\"Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Abemaciclib\"\\n15419,1,1,\"Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Ramucirumab\"\\n15420,1,1,\"Pharmacokinetics (PK): AUC0-24h\"\\n15421,1,1,\"Pharmacokinetics (PK): AUC0-t\"\\n15422,1,1,\"Pharmacokinetics (PK): AUClast\"\\n15423,1,1,\"Pharmacokinetics (PK): CL/F\"\\n15424,1,1,\"Pharmacokinetics (PK): Cmax\"\\n15425,1,1,\"Pharmacokinetics (PK): Maximum Concentration (Cmax)\"\\n15426,1,1,\"Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib\"\\n15427,1,1,\"Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab\"\\n15428,1,1,\"Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Necitumumab After a Single Dose\"\\n15429,1,1,\"Pharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib\"\\n15430,1,1,\"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab\"\\n15431,1,1,\"Pharmacokinetics (PK): Predose Concentration (Cmin) of Abemaciclib\"\\n15432,1,1,\"Pharmacokinetics (PK): T1/2\"\\n15433,1,1,\"Pharmacokinetics (PK): Tlast\"\\n15434,1,1,\"Pharmacokinetics (PK): Tmax\"\\n15435,1,1,\"Pharmacokinetics (PK): Vz/F\"\\n15436,1,1,\"Pharmacokinetics (PKs) of dactinomycin\"\\n15437,1,1,\"Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients\\' peripheral blood)\"\\n15438,1,1,\"Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients\\' urine)\"\\n15439,1,1,\"Pharmacokinetics - Area Under the Curve (AUC) of IMC-CS4\"\\n15440,8,1,\"Pharmacokinetics - AUC\"\\n15441,1,1,\"Pharmacokinetics - AUC(0-t)\"\\n15442,2,1,\"Pharmacokinetics - CL\"\\n15443,10,1,\"Pharmacokinetics - CL/F\"\\n15444,27,4,\"Pharmacokinetics - Cmax\"\\n15445,1,1,\"Pharmacokinetics - Maximum concentration (Cmax) of IMC-CS4\"\\n15446,1,1,\"Pharmacokinetics - Minimum concentration (Cmin) of IMC-CS4\"\\n15447,5,1,\"Pharmacokinetics - T1/2\"\\n15448,9,1,\"Pharmacokinetics - t1/2\"\\n15449,15,2,\"Pharmacokinetics - Tmax\"\\n15450,2,1,\"Pharmacokinetics - Tmax (Hours)\"\\n15451,1,1,\"Pharmacokinetics - Volume of distribution at steady state (Vss) of IMC-CS4\"\\n15452,2,1,\"Pharmacokinetics - Vss\"\\n15453,7,1,\"Pharmacokinetics - Vz/F\"\\n15454,2,1,\"Pharmacokinetics -AUC\"\\n15455,1,1,\"Pharmacokinetics -Clearance (Cl) of IMC-CS4\"\\n15456,1,1,\"Pharmacokinetics alone &amp; in combination\"\\n15457,1,1,\"Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)\"\\n15458,1,1,\"Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)\"\\n15459,1,1,\"Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)\"\\n15460,1,1,\"Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)\"\\n15461,1,1,\"Pharmacokinetics as measured by cmax and AUC\"\\n15462,1,1,\"Pharmacokinetics assessments of Alimta, Cisplatin, and regorafenib in Cycle 1 and 2\"\\n15463,1,1,\"Pharmacokinetics AUC (0-t) for Eribulin in Plasma\"\\n15464,1,1,\"Pharmacokinetics AUC (Area Under the Curve)\"\\n15465,1,1,\"Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)\"\\n15466,1,1,\"Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)\"\\n15467,1,1,\"Pharmacokinetics AUC-t - Stage I (Bioequivalence)\"\\n15468,1,1,\"Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)\"\\n15469,1,1,\"Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed)\"\\n15470,1,1,\"Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel\"\\n15471,1,1,\"Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel\"\\n15472,1,1,\"Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed)\"\\n15473,1,1,\"Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed)\"\\n15474,1,1,\"Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed)\"\\n15475,1,1,\"Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel\"\\n15476,1,1,\"Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed)\"\\n15477,1,1,\"Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel\"\\n15478,1,1,\"Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed)\"\\n15479,1,1,\"Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed)\"\\n15480,1,1,\"Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel\"\\n15481,1,1,\"Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed)\"\\n15482,1,1,\"Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed)\"\\n15483,1,1,\"Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel\"\\n15484,1,1,\"Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel\"\\n15485,1,1,\"Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed)\"\\n15486,1,1,\"Pharmacokinetics Cmax - Stage I (Bioequivalence)\"\\n15487,1,1,\"Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)\"\\n15488,1,1,\"Pharmacokinetics in terms of 20S proteasome activity following bortezomib administration\"\\n15489,1,1,\"Pharmacokinetics Measured as Area Under Curve (AUC[0-12h])\"\\n15490,1,1,\"Pharmacokinetics Measured as Concentration (Cmax at Tmax and Cmin at Tmin)\"\\n15491,1,1,\"Pharmacokinetics Measured as Concentration (Cmax Normalized at Tmax and Cmin Normalized at Tmin)\"\\n15492,1,1,\"Pharmacokinetics methoxyamine and temozolomide, when given alone or in combination\"\\n15493,1,1,\"Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Area under the plasma concentration versus time curve (AUC)\"\\n15494,1,1,\"Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): ClearanceÔºàCLÔºâ\"\\n15495,1,1,\"Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Half lifeÔºàt1/2Ôºâ\"\\n15496,1,1,\"Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak Plasma Concentration(Cmax)\"\\n15497,1,1,\"Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak timeÔºàTmaxÔºâ\"\\n15498,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): AUCtau\"\\n15499,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): CL/F\"\\n15500,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): Cmax\"\\n15501,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): t1/2\"\\n15502,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): tmax\"\\n15503,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): AUCtau\"\\n15504,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): CL/F\"\\n15505,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): Cmax\"\\n15506,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): t1/2\"\\n15507,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): tmax\"\\n15508,1,1,\"Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity ratio of whole blood/plasma concentrations): AUC\"\\n15509,1,1,\"Pharmacokinetics of 14C-labeled rucaparib (radioactivity in whole blood and plasma): tmax\"\\n15510,1,1,\"Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): AUC\"\\n15511,1,1,\"Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): CL/F\"\\n15512,1,1,\"Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): Cmax\"\\n15513,1,1,\"Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): t1/2\"\\n15514,1,1,\"Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): V/F\"\\n15515,1,1,\"Pharmacokinetics of AL2846 (in plasma)\"\\n15516,1,1,\"Pharmacokinetics of alvespimycin hydrochloride in blood, urine, and tumor tissue\"\\n15517,2,1,\"Pharmacokinetics of Anlotinib (in whole blood):Area under the plasma concentration versus time curve (AUC)\"\\n15518,1,1,\"Pharmacokinetics of Anlotinib (in whole blood):ClearanceÔºàCLÔºâ\"\\n15519,1,1,\"Pharmacokinetics of Anlotinib (in whole blood):Half lifeÔºàt1/2Ôºâ\"\\n15520,2,1,\"Pharmacokinetics of Anlotinib (in whole blood):Peak Plasma Concentration(Cmax)\"\\n15521,1,1,\"Pharmacokinetics of Anlotinib (in whole blood):Peak timeÔºàTmaxÔºâ\"\\n15522,1,1,\"Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to infinity (AUC)\"\\n15523,1,1,\"Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration (Cmax)\"\\n15524,1,1,\"Pharmacokinetics of benzoylphenylurea\"\\n15525,1,1,\"Pharmacokinetics of CKD-810 and Taxotere inj.\"\\n15526,1,1,\"Pharmacokinetics of continuous intraventricular infusion of methotrexate\"\\n15527,1,1,\"Pharmacokinetics of DMXAA\"\\n15528,1,1,\"Pharmacokinetics of DocetaxelPNP and Taxotere in terms of Area Under the Curve (AUC)\"\\n15529,1,1,\"Pharmacokinetics of EMD 525797 - Trough Values\"\\n15530,1,1,\"Pharmacokinetics of erlotinib hydrochloride\"\\n15531,1,1,\"Pharmacokinetics of ERY974 in combination with atezolizumab and bevacizumab [Dose escalation part]\"\\n15532,1,1,\"Pharmacokinetics of ERY974 in combination with atezolizumab and bevacizumab from initiation [Concomitant use part]\"\\n15533,1,1,\"Pharmacokinetics of fentanyl citrate\"\\n15534,1,1,\"Pharmacokinetics of gefitinib\"\\n15535,1,1,\"Pharmacokinetics of gilteritinib (in plasma): AUCtau\"\\n15536,1,1,\"Pharmacokinetics of gilteritinib (in plasma): CL/F\"\\n15537,1,1,\"Pharmacokinetics of gilteritinib (in plasma): Cmax\"\\n15538,1,1,\"Pharmacokinetics of gilteritinib (in plasma): tmax\"\\n15539,1,1,\"Pharmacokinetics of gilteritinib (in urine): Aetau\"\\n15540,1,1,\"Pharmacokinetics of gilteritinib (in urine): AETAU%\"\\n15541,1,1,\"Pharmacokinetics of gilteritinib (in urine): CLR\"\\n15542,1,1,\"Pharmacokinetics of IMC-A12\"\\n15543,1,1,\"Pharmacokinetics of irinotecan\"\\n15544,1,1,\"Pharmacokinetics of ketoconazole\"\\n15545,1,1,\"Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients\"\\n15546,1,1,\"Pharmacokinetics of LTLD\"\\n15547,1,1,\"Pharmacokinetics of Nimotuzumab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors: Single doseÔºöTmaxÔºåCmaxÔºå AUCÔºåVcÔºåt1/2Œ±Ôºåt1/2Œ≤ÔºåCL. Multiple doseÔºöTmaxÔºåCss-minÔºåCss-maxÔºåCss-aÔºåt1/2Œ≤ÔºåCLÔºåAUCssÔºåDF.\"\\n15548,1,1,\"Pharmacokinetics of Olaparib (AUC)\"\\n15549,1,1,\"Pharmacokinetics of Olaparib (AUC0-t)\"\\n15550,1,1,\"Pharmacokinetics of Olaparib (Cmax and tmax)\"\\n15551,1,1,\"Pharmacokinetics of olaparib :terminal rate constant (Œªz)\"\\n15552,2,2,\"Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to infinity (AUC)\"\\n15553,1,1,\"Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to the last measurable time point, AUC0-t, if AUC is not adequately estimable).\"\\n15554,1,1,\"Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to the last measurable time point, AUC0-t, if AUC is not adequately estimable.\"\\n15555,2,2,\"Pharmacokinetics of olaparib by assessment of maximum plasma olaparib concentration (Cmax)\"\\n15556,1,1,\"Pharmacokinetics of olaparib olaparib apparent clearance (CL/F)\"\\n15557,1,1,\"Pharmacokinetics of Olaparib Pharmacokinetics of Olaparib (CL/F, Vz/F, Œªz and t¬Ω)\"\\n15558,1,1,\"Pharmacokinetics of olaparib time to reach maximum plasma concentration for olaparib (tmax)\"\\n15559,1,1,\"Pharmacokinetics of olaparib: area under the plasma concentration time curve from zero to the last measurable time point, AUC0-t, if AUC is not adequately estimable (AUC0-t)\"\\n15560,1,1,\"Pharmacokinetics of olaparib: area under the plasma-time curve from zero to infinity (AUC)\"\\n15561,1,1,\"Pharmacokinetics of olaparib:apparent volume of distribution (Vz/F)\"\\n15562,1,1,\"Pharmacokinetics of olaparib:maximum olaparib concentration (Cmax)\"\\n15563,1,1,\"Pharmacokinetics of olaparib:terminal half-life (t1/2).\"\\n15564,1,1,\"Pharmacokinetics of pazopanib hydrochloride\"\\n15565,1,1,\"Pharmacokinetics of probe substrates (AUC, Cmax, etc.)\"\\n15566,1,1,\"Pharmacokinetics of rifampin\"\\n15567,1,1,\"Pharmacokinetics of rucaparib (in urine): CLR\"\\n15568,1,1,\"Pharmacokinetics of SAHA\"\\n15569,1,1,\"Pharmacokinetics of selumetinib and N desmethyl selumetinib, by assessment of maximum plasma concentration (Cmax)\"\\n15570,1,1,\"Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC)\"\\n15571,1,1,\"Pharmacokinetics of selumetinib by assessment of area under the plasma concentration-time curve from time zero to infinity (AUC)\"\\n15572,1,1,\"Pharmacokinetics of SN-38\"\\n15573,1,1,\"Pharmacokinetics of SPYK04 [Dose escalation]\"\\n15574,1,1,\"Pharmacokinetics of sunitinib malate using liquid spectrometry/mass spectroscopy methods\"\\n15575,1,1,\"Pharmacokinetics of SYP-0704A and Taxotere in terms of AUC\"\\n15576,1,1,\"Pharmacokinetics of temsirolimus\"\\n15577,1,1,\"Pharmacokinetics of Tolbutamide, Concurrent Dosing, Area Under the Curve (AUC 0-‚àû)\"\\n15578,1,1,\"Pharmacokinetics of total radioactivity in plasma and whole blood\"\\n15579,1,1,\"Pharmacokinetics of TQ-B3101 (in whole blood):Area under the plasma concentration versus time curve (AUC)\"\\n15580,1,1,\"Pharmacokinetics of TQ-B3101 (in whole blood):ClearanceÔºàCLÔºâ\"\\n15581,1,1,\"Pharmacokinetics of TQ-B3101 (in whole blood):Half lifeÔºàt1/2Ôºâ\"\\n15582,1,1,\"Pharmacokinetics of TQ-B3101 (in whole blood):Peak Plasma Concentration(Cmax)\"\\n15583,1,1,\"Pharmacokinetics of TQ-B3101 (in whole blood):Peak timeÔºàTmaxÔºâ\"\\n15584,3,3,\"Pharmacokinetics of trabectedin\"\\n15585,1,1,\"Pharmacokinetics of treatment, including AUC, C-max, half-life, and clearance obtained in patients treated at the MTD\"\\n15586,1,1,\"Pharmacokinetics of XL184 and rosiglitazone\"\\n15587,1,1,\"Pharmacokinetics on day of positron-emission tomography scan\"\\n15588,2,2,\"Pharmacokinetics parameter: AUC of digoxin\"\\n15589,1,1,\"Pharmacokinetics parameter: AUClast of NE and EE alone and in combination with trametinib\"\\n15590,1,1,\"Pharmacokinetics parameter: AUCtau of NE and EE alone and in combination with trametinib\"\\n15591,2,2,\"Pharmacokinetics parameter: Cmax of digoxin\"\\n15592,1,1,\"Pharmacokinetics parameter: Cmax of NE and EE alone and in combination with trametinib\"\\n15593,1,1,\"Pharmacokinetics parameter: Tmax of NE and EE alone and incombination with trametinib\"\\n15594,6,1,\"Pharmacokinetics parameters\"\\n15595,1,1,\"Pharmacokinetics parameters including estimation of Cmax, half-life, and area under the time-concentration curve (AUC)\"\\n15596,1,1,\"Pharmacokinetics profile in excreta: Cumulative Ae (0-t), Ae (0-infinity), percent radioactive dose excreted in urine and feces, AeUF, CLR, CLNR for TH-302 and its active metabolite Br-IPM\"\\n15597,1,1,\"Pharmacokinetics profile in plasma: Cmax, Tmax, AUC (0-t), lambda_z, t1/2, AUC (0-infinity), CL, Vss, Vz, MRT for TH-302 and its active metabolite Br-IPM\"\\n15598,1,1,\"Pharmacokinetics profile of BAY79-4620\"\\n15599,1,1,\"Pharmacokinetics profile of BAY79-4620 and its key metabolites\"\\n15600,1,1,\"Pharmacokinetics Terminal Half-Life (t¬Ω) - Stage I (Bioequivalence)\"\\n15601,1,1,\"Pharmacokinetics Terminal Half-Life (t¬Ω) - Stage II (Food Effect Bioavailability)\"\\n15602,1,1,\"Pharmacokinetics Tmax - Stage I (Bioequivalence)\"\\n15603,1,1,\"Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)\"\\n15604,1,1,\"Pharmacokinetics Œªz (Terminal Rate) - Stage I (Bioequivalence)\"\\n15605,1,1,\"Pharmacokinetics Œªz (Terminal Rate) - Stage II (Food Effect Bioavailability)\"\\n15606,2,1,\"Pharmacokinetics- AUC\"\\n15607,3,1,\"Pharmacokinetics- CL/F\"\\n15608,5,1,\"Pharmacokinetics- Cmax\"\\n15609,3,1,\"Pharmacokinetics- t1/2\"\\n15610,1,1,\"Pharmacokinetics- tmax\"\\n15611,3,1,\"Pharmacokinetics- Vz/F\"\\n15612,1,1,\"Pharmacokinetics-AUC\"\\n15613,1,1,\"Pharmacokinetics: Accumulation Ratio of lumretuzumab [RO5479599]\"\\n15614,1,1,\"Pharmacokinetics: Apparent terminal elimination half-life\"\\n15615,2,1,\"Pharmacokinetics: Area under the concentration-time curve\"\\n15616,1,1,\"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) in single dose\"\\n15617,1,1,\"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of lumretuzumab [RO5479599]\"\\n15618,1,1,\"Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab\"\\n15619,1,1,\"Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity [AUC(0-‚àû)] of S-Warfarin and R-Warfarin\"\\n15620,1,1,\"Pharmacokinetics: Assessment of plasma concentrations of aflibercept, CPT-11 (irinotecan) and Fluorouracil (5-FU)\"\\n15621,1,1,\"Pharmacokinetics: AUC (0-t) for Total Radioactivity in Plasma\"\\n15622,1,1,\"Pharmacokinetics: AUC in multiple dose\"\\n15623,1,1,\"Pharmacokinetics: Clearance (CL) of lumretuzumab [RO5479599]\"\\n15624,1,1,\"Pharmacokinetics: Cmax in multiple dose\"\\n15625,1,1,\"Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Docetaxel From Time Zero to Infinity [AUC(0-‚àû)] Following a Single Dose in Cycle 1\"\\n15626,1,1,\"Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Docetaxel From Time Zero to Infinity [AUC(0-‚àû)] Following a Single Dose in Cycle 2\"\\n15627,1,1,\"Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-‚àû)] in Cycle 1\"\\n15628,1,1,\"Pharmacokinetics: Dose-Normalized AUC(0-‚àû) of Irinotecan and Its Metabolite SN-38 in Cycle 2\"\\n15629,1,1,\"Pharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2\"\\n15630,1,1,\"Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Docetaxel in Cycle 1\"\\n15631,1,1,\"Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Docetaxel in Cycle 2\"\\n15632,1,1,\"Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1\"\\n15633,1,1,\"Pharmacokinetics: Elimination Half-Life (t1/2) of lumretuzumab [RO5479599]\"\\n15634,1,1,\"Pharmacokinetics: Maximum Concentration (Cmax) in single dose\"\\n15635,1,1,\"Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab\"\\n15636,1,1,\"Pharmacokinetics: Maximum Plasma Concentration (Cmax) of S-Warfarin and R-Warfarin\"\\n15637,1,1,\"Pharmacokinetics: Maximum plasma concentrations\"\\n15638,1,1,\"Pharmacokinetics: Maximum Serum Concentration (Cmax) of lumretuzumab [RO5479599]\"\\n15639,1,1,\"Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab\"\\n15640,1,1,\"Pharmacokinetics: Minimum plasma concentrations\"\\n15641,1,1,\"Pharmacokinetics: plasma concentration-time profiles of SarCNU\"\\n15642,1,1,\"Pharmacokinetics: Plasma concentrations of BAY1000394 will be measured. The following parameters will be calculated: Cmax, tmax, AUC(0-tn), AUC, and half-life.\"\\n15643,1,1,\"Pharmacokinetics: Serum Concentration at the Time of DLT of lumretuzumab [RO5479599]\"\\n15644,1,1,\"Pharmacokinetics: Serum Concentration at the Time of Infusion-Related Reactions (IRR) of lumretuzumab [RO5479599]\"\\n15645,1,1,\"Pharmacokinetics: Serum Concentration at the Time of Tumor and Skin Biopsy (Cb) of lumretuzumab [RO5479599]\"\\n15646,1,1,\"Pharmacokinetics: Serum Concentration at the Time of Tumor Progression (Cprog) of lumretuzumab [RO5479599]\"\\n15647,1,1,\"Pharmacokinetics: Serum Concentration at the Time of Tumor Response (Complete response [CR]/Partial Response [PR]) of lumretuzumab [RO5479599]\"\\n15648,1,1,\"Pharmacokinetics: Time of Maximal Plasma Concentration (Tmax) of S-Warfarin and R-Warfarin\"\\n15649,2,1,\"Pharmacokinetics: Time to maximum plasma concentration\"\\n15650,1,1,\"Pharmacokinetics: Time to Reach Maximum Serum Concentration (tmax) of lumretuzumab [RO5479599]\"\\n15651,1,1,\"Pharmacokinetics: Trough Serum Concentration (Ct) of lumretuzumab [RO5479599]\"\\n15652,1,1,\"Pharmacokinetics: Volume of distribution (V) of lumretuzumab [RO5479599]\"\\n15653,1,1,\"Pharmacological profile\"\\n15654,1,1,\"Pharmacology and pharmacokinetics\"\\n15655,1,1,\"Phase 1 (Dose escalation): Safety and Recommended Phase 2 Dose (RPTD)\"\\n15656,1,1,\"Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1\"\\n15657,1,1,\"Phase 1 (Dose expansion): Objective Response Rate (ORR)\"\\n15658,1,1,\"Phase 1 (dose-escalation): Maximum Tolerated Dose (MTD)\"\\n15659,1,1,\"Phase 1 (dose-expansion): Recommended Phase 2 dose (RP2D)\"\\n15660,1,1,\"Phase 1 (LA/mGC): MTD of Capecitabine When Combined With Trastuzumab Emtansine (2.4 mg/kg QW)\"\\n15661,1,1,\"Phase 1 (LA/mGC): Percentage of Participants With DLTs\"\\n15662,1,1,\"Phase 1 (mBC): Maximum Tolerated Dose (MTD) of Capecitabine When Combined With Trastuzumab Emtansine (3.6 mg/kg Every 3 Weeks)\"\\n15663,1,1,\"Phase 1 (mBC): Percentage of Participants With Dose-Limiting Toxicities (DLTs)\"\\n15664,1,1,\"Phase 1 - Maximum Tolerated Dose\"\\n15665,3,1,\"Phase 1 - Maximum Tolerated Dose (MTD)\"\\n15666,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg)\"\\n15667,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin\"\\n15668,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin\"\\n15669,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of Docetaxel and Cisplatin\"\\n15670,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin\"\\n15671,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of Sorafenib Administered With Cetuximab (400 mg/m2 Loading Dose Followed by 250 mg/m2 Weekly)\"\\n15672,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of STI571\"\\n15673,1,1,\"Phase 1 - Maximum Tolerated Dose (MTD) of Vinorelbine in Combination With a Fixed Dose of Trastuzumab Emtansine.\"\\n15674,1,1,\"Phase 1 - Pharmacokinetic profile\"\\n15675,1,1,\"Phase 1 - Rate of Participants Experiencing Adverse Events\"\\n15676,1,1,\"Phase 1 - Safety (Number of subjects with adverse events and/or dose limiting toxicities)\"\\n15677,1,1,\"Phase 1 - To determine recommended Phase 2 dose (RP2D) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.\"\\n15678,1,1,\"Phase 1 - To determine recommended Phase 2 dose (RP2D) of SNK01 in combination with trastuzumab in subjects with advanced HER2 cancers.\"\\n15679,1,1,\"Phase 1 - To determine the maximum tolerated dose (MTD) of SD-101 administered alone via PRVI.\"\\n15680,1,1,\"Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE)\"\\n15681,1,1,\"Phase 1 A: Recommended Phase 2 Dose (RP2D) for BGB-333\"\\n15682,1,1,\"Phase 1 a: To determine the MTD/RP2D of LOXO-260: Dose limiting toxicity (DLT) rate\"\\n15683,1,1,\"Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicities\"\\n15684,1,1,\"Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)\"\\n15685,1,1,\"Phase 1 Adverse events\"\\n15686,1,1,\"Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n15687,1,1,\"Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC\"\\n15688,1,1,\"Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12\"\\n15689,2,2,\"Phase 1 and 2: Safety Profile\"\\n15690,1,1,\"phase 1 and 2a: Number of subjects with dose limiting toxicity (DLT)\"\\n15691,1,1,\"Phase 1 and Phase 2 : Number of Participants With Abnormal Electrocardiograms (ECG)\"\\n15692,1,1,\"Phase 1 and Phase 2 : Number of Participants With Abnormal Lab Assessment Results\"\\n15693,1,1,\"Phase 1 and Phase 2 : Number of Participants With Abnormalities During Physical Examinations - Ophthalmology Findings\"\\n15694,1,1,\"Phase 1 and Phase 2 : Number of Participants With Adverse Events and Serious Adverse Events\"\\n15695,1,1,\"Phase 1 and Phase 2 : ORR Based on RECIST v1.1 and mRECIST\"\\n15696,1,1,\"Phase 1 and Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]\"\\n15697,1,1,\"Phase 1 Arm I Maximum-tolerated Dose (MTD) of RO4929097 in Combination With Whole-brain Radiotherapy (WBRT)\"\\n15698,1,1,\"Phase 1 Arm II MTD of RO4929097 in Combination With Stereotactic Surgery (SRS)\"\\n15699,1,1,\"Phase 1 Co-Primary Objective - Identify Maximum Tolerated Dose (MTD)\"\\n15700,1,1,\"Phase 1 Co-Primary Objective - Safety\"\\n15701,1,1,\"Phase 1 Cohorts\"\\n15702,1,1,\"Phase 1 Component - Maximum Tolerated Dose (MTD) of Vandetanib and Metformin When Used in Combination in Patients With Metastatic Renal Cell Carcinoma (RCC)\"\\n15703,1,1,\"Phase 1 Dose Escalation - Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)\"\\n15704,1,1,\"Phase 1 Dose Escalation - Number of participants experiencing Serious Adverse Events (SAEs)\"\\n15705,1,1,\"Phase 1 Dose Escalation - Recommended Phase Ib dose (RP2D) of ociperlimab in combination with tislelizumab\"\\n15706,1,1,\"Phase 1 Dose Escalation - Regimens A and B: AUC of GB1275\"\\n15707,1,1,\"Phase 1 Dose Escalation - Regimens A and B: CL/F of GB1275\"\\n15708,1,1,\"Phase 1 Dose Escalation - Regimens A and B: Cmax of GB1275\"\\n15709,1,1,\"Phase 1 Dose Escalation - Regimens A and B: Ctrough of GB1275\"\\n15710,1,1,\"Phase 1 Dose Escalation - Regimens A and B: t1/2 of GB1275\"\\n15711,1,1,\"Phase 1 Dose Escalation - Regimens A and B: Tmax of GB1275\"\\n15712,1,1,\"Phase 1 Dose Escalation - Regimens A, B, and C and Phase 1 Expansion - Regimen B: Incidence of adverse events (AEs)\"\\n15713,1,1,\"Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs)\"\\n15714,1,1,\"Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group\"\\n15715,1,1,\"Phase 1 Dose Escalation and Phase 2 Safety lead-in: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n15716,1,1,\"Phase 1 Dose Escalation Only - Number of Participants With DLTs\"\\n15717,1,1,\"Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394\"\\n15718,1,1,\"Phase 1 Dose Escalation: Maximum Tolerated Dose (MTD)\"\\n15719,1,1,\"Phase 1 Dose Escalation: Safety and tolerability of NUV-422 to determine the recommended Phase 2 dose (RP2D)\"\\n15720,1,1,\"Phase 1 Dosing Schedule\"\\n15721,1,1,\"Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2D\"\\n15722,1,1,\"Phase 1 Maximum Tolerated Dose\"\\n15723,1,1,\"Phase 1 Maximum Tolerated dose of RC88\"\\n15724,1,1,\"Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D)\"\\n15725,1,1,\"Phase 1 Only: Safety and Tolerability of INCB001158 in Combination With Epacadostat ¬± Pembrolizumab as Assessed by Number of Participants With a Treatment-emergent Adverse Event (TEAE)\"\\n15726,1,1,\"Phase 1 Part A: To determine the maximum tolerated doses (MTD).\"\\n15727,1,1,\"Phase 1 Part B: To determine the recommended Phase 2 dose (R2PD).\"\\n15728,1,1,\"Phase 1 Part: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788\"\\n15729,1,1,\"Phase 1 Primary Outcome: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy\"\\n15730,1,1,\"Phase 1 Safe and Tolerable Phase 2 Dose.\"\\n15731,1,1,\"Phase 1 Safety: Number of Subjects Reporting Adverse Events\"\\n15732,1,1,\"Phase 1 Stage 1: Percentage of Participants With Dose-Limiting Toxicities\"\\n15733,1,1,\"Phase 1 Surgical Substudy (GB): Pharmacokinetic (PK) profile of NUV-422\"\\n15734,1,1,\"Phase 1 To determine the maximum tolerated dose of E7449 and in combination with carboplatin and paclitaxel\"\\n15735,1,1,\"Phase 1 To determine the maximum tolerated dose of E7449 and in combination with TMZ\"\\n15736,1,1,\"Phase 1 To determine the maximum tolerated dose of E7449 as a single agent\"\\n15737,1,1,\"Phase 1, Part 1 and 2: Safety assessed by the frequency of adverse events, serious adverse events, and deaths\"\\n15738,1,1,\"Phase 1, Part 1: Safety and tolerability of epacadostat and nivolumab assessed by number of subjects with dose limiting toxicities (DLTs)\"\\n15739,1,1,\"Phase 1, Part 2: Safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with DLTs\"\\n15740,1,1,\"Phase 1- Adverse events and clinical laboratory abnormalities\"\\n15741,1,1,\"Phase 1- Number of Participants Experiencing Dose-limiting Toxicities (DLTs)\"\\n15742,1,1,\"Phase 1- Number of Participants Reporting One or More Serious Adverse Events (SAE)\"\\n15743,1,1,\"Phase 1- Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)\"\\n15744,1,1,\"Phase 1- Number of Participants With Clinically Significant Change From Baseline in Vital Signs\"\\n15745,1,1,\"Phase 1- Number of Participants With Markedly Abnormal Laboratory Values\"\\n15746,1,1,\"Phase 1- Part A: Percentage of participants with Dose Limiting Toxicities (DLTs) in Cycle 1\"\\n15747,1,1,\"Phase 1- Recommended Phase 2 Dose (RP2D)\"\\n15748,1,1,\"Phase 1/1B: Number of patients who experience a treatment-related adverse event\"\\n15749,1,1,\"Phase 1/1b: Number of patients who experience a treatment-related adverse event\"\\n15750,1,1,\"Phase 1/Dose Escalation\"\\n15751,2,1,\"Phase 1:\"\\n15752,1,1,\"Phase 1: Adverse Events\"\\n15753,1,1,\"Phase 1: Adverse Events (AEs) by CTCAE Grade 3 or Higher\"\\n15754,1,1,\"Phase 1: Apparent plasma terminal elimination rate constant (Œªz) and associated terminal half life (t¬Ω)\"\\n15755,1,1,\"Phase 1: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-‚àû]) of Etoposide With and Without Veliparib\"\\n15756,1,1,\"Phase 1: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration (AUClast) of Brigatinib\"\\n15757,1,1,\"Phase 1: Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC[0-t]) of Etoposide With and Without Veliparib\"\\n15758,1,1,\"Phase 1: Area under the drug concentration by time curve (AUC)\"\\n15759,1,1,\"Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC[0-12]) of Veliparib\"\\n15760,1,1,\"Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose (AUC[0-8]) of Veliparib\"\\n15761,1,1,\"Phase 1: assess the MTD/RP2D regimen\"\\n15762,2,2,\"Phase 1: changes in electrocardiogram parameters\"\\n15763,2,2,\"Phase 1: changes in laboratory parameters\"\\n15764,2,2,\"Phase 1: changes in vital signs\"\\n15765,1,1,\"Phase 1: Cycle 1- AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for MLN0264\"\\n15766,1,1,\"Phase 1: Cycle 1- AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for MMAE\"\\n15767,1,1,\"Phase 1: Cycle 1- AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for TAb\"\\n15768,1,1,\"Phase 1: Cycle 1- AUCint: Area Under the Serum/Plasma Concentration-time Curve From Time 0 to End of the 21-day Dosing Interval (AUCint) for MLN0264\"\\n15769,1,1,\"Phase 1: Cycle 1- AUCint: Area Under the Serum/Plasma Concentration-time Curve From Time 0 to End of the 21-day Dosing Interval (AUCint) for MMAE\"\\n15770,1,1,\"Phase 1: Cycle 1- AUCint: Area Under the Serum/Plasma Concentration-time Curve From Time 0 to End of the 21-day Dosing Interval (AUCint) for TAb\"\\n15771,1,1,\"Phase 1: Cycle 1- Cmax: Maximum Observed Plasma Concentration for MLN0264\"\\n15772,1,1,\"Phase 1: Cycle 1- Cmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)\"\\n15773,1,1,\"Phase 1: Cycle 1- Cmax: Maximum Observed Serum Concentration for Total Antibody (TAb)\"\\n15774,1,1,\"Phase 1: Cycle 1- Ctrough: Observed Concentration Measured at the End of a Dosing Interval for MLN0264\"\\n15775,1,1,\"Phase 1: Cycle 1- Ctrough: Observed Concentration Measured at the End of a Dosing Interval for MMAE\"\\n15776,1,1,\"Phase 1: Cycle 1- Ctrough: Observed Concentration Measured at the End of a Dosing Interval for TAb\"\\n15777,1,1,\"Phase 1: Cycle 1- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0264\"\\n15778,1,1,\"Phase 1: Cycle 1- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MMAE\"\\n15779,1,1,\"Phase 1: Cycle 1- Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAb\"\\n15780,1,1,\"Phase 1: Cycle 2- AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for MLN0264\"\\n15781,1,1,\"Phase 1: Cycle 2- AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for MMAE\"\\n15782,1,1,\"Phase 1: Cycle 2- AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for TAb\"\\n15783,1,1,\"Phase 1: Cycle 2- AUCint: Area Under the Serum/Plasma Concentration-time Curve From Time 0 to End of the 21-day Dosing Interval (AUCint) for MLN0264\"\\n15784,1,1,\"Phase 1: Cycle 2- AUCint: Area Under the Serum/Plasma Concentration-time Curve From Time 0 to End of the 21-day Dosing Interval (AUCint) for MMAE\"\\n15785,1,1,\"Phase 1: Cycle 2- AUCint: Area Under the Serum/Plasma Concentration-time Curve From Time 0 to End of the 21-day Dosing Interval (AUCint) for TAb\"\\n15786,1,1,\"Phase 1: Cycle 2- Cmax: Maximum Observed Plasma Concentration for MLN0264\"\\n15787,1,1,\"Phase 1: Cycle 2- Cmax: Maximum Observed Plasma Concentration for MMAE\"\\n15788,1,1,\"Phase 1: Cycle 2- Cmax: Maximum Observed Serum Concentration for TAb\"\\n15789,1,1,\"Phase 1: Cycle 2- Ctrough: Observed Concentration Measured at the End of a Dosing Interval for MLN0264\"\\n15790,1,1,\"Phase 1: Cycle 2- Ctrough: Observed Concentration Measured at the End of a Dosing Interval for MMAE\"\\n15791,1,1,\"Phase 1: Cycle 2- Ctrough: Observed Concentration Measured at the End of a Dosing Interval for TAb\"\\n15792,1,1,\"Phase 1: Cycle 2- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0264\"\\n15793,1,1,\"Phase 1: Cycle 2- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MMAE\"\\n15794,1,1,\"Phase 1: Cycle 2- Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAb\"\\n15795,1,1,\"Phase 1: Determination of the Recommended doses and the Dose Limiting Toxicities (DLT)\"\\n15796,1,1,\"Phase 1: Determine the Maximum Tolerated Dose (MTD)\"\\n15797,1,1,\"Phase 1: Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities\"\\n15798,1,1,\"Phase 1: Determine the maximum tolerated dose of poly-ICLC that can be combined with pembrolizumab\"\\n15799,1,1,\"Phase 1: Determine the recommended phase 2 dose (RP2D) of venetoclax with irinotecan in patients with relapsed or refractory SCLC\"\\n15800,1,1,\"Phase 1: Determine the Recommended Phase 2 Dose for LY2603618 When Administered After Gemcitabine\"\\n15801,1,1,\"Phase 1: Dose Expansion Parts: Frequency of adverse events\"\\n15802,1,1,\"Phase 1: Dose Expansion Parts: Percentage of Participants With Complete Response or Partial Response\"\\n15803,2,2,\"Phase 1: dose interruptions, reductions, and discontinuations\"\\n15804,1,1,\"Phase 1: Dose Limiting Toxicities\"\\n15805,1,1,\"Phase 1: Dose-Limiting Toxicities\"\\n15806,1,1,\"Phase 1: Dose-limiting toxicity (DLT)\"\\n15807,1,1,\"Phase 1: Dose-normalized Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-‚àû]) of Etoposide With and Without Veliparib\"\\n15808,1,1,\"Phase 1: Dose-normalized Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC[0-t]) of Etoposide With and Without Veliparib\"\\n15809,1,1,\"Phase 1: Dose-normalized Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose of Veliparib\"\\n15810,1,1,\"Phase 1: Dose-normalized Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose of Veliparib\"\\n15811,1,1,\"Phase 1: Dose-normalized Maximum Observed Plasma Concentration (Cmax) of Etoposide With and Without Veliparib\"\\n15812,1,1,\"Phase 1: Dose-normalized Maximum Observed Plasma Concentration of Veliparib\"\\n15813,1,1,\"Phase 1: Effect of pre-dose administration of vofatamab on the radiation dosimetry of [111In]-FPI-1967 and [225Ac]-FPI-1966.\"\\n15814,1,1,\"Phase 1: Evaluate the safety of ELI-002 7P\"\\n15815,1,1,\"Phase 1: First Cycle Dose-Limiting Toxicities (DLT)\"\\n15816,2,2,\"Phase 1: Frequency of Dose-limiting toxicities (DLTs)\"\\n15817,1,1,\"Phase 1: incidence and severity of adverse events (AE)\"\\n15818,1,1,\"Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE)\"\\n15819,1,1,\"Phase 1: Incidence and severity of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects during Cycle 1\"\\n15820,2,2,\"Phase 1: Incidence of dose limiting toxicities (DLTs) during Cycle 1\"\\n15821,1,1,\"Phase 1: Incidence of dose limiting toxicities using CTCAE, Version 4.03\"\\n15822,1,1,\"Phase 1: Incidence of dose-limiting toxicities (DLT)\"\\n15823,1,1,\"PHASE 1: Incidence of Dose-limiting Toxicities (DLTs) and Treatment Emergent Adverse Events.\"\\n15824,1,1,\"Phase 1: Incidence of dose-limiting toxicity\"\\n15825,1,1,\"Phase 1: Incidence of Dose-limiting toxicity (DLT)s\"\\n15826,1,1,\"Phase 1: Incidence of treatment-emergent adverse events (TEAEs)\"\\n15827,1,1,\"Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate\"\\n15828,1,1,\"Phase 1: Maximum Observed Plasma Concentration (Cmax) of Brigatinib\"\\n15829,1,1,\"Phase 1: Maximum Observed Plasma Concentration (Cmax) of Etoposide With and Without Veliparib\"\\n15830,1,1,\"Phase 1: Maximum Observed Plasma Concentration (Cmax) of Veliparib\"\\n15831,1,1,\"Phase 1: Maximum observed plasma drug concentration (Cmax)\"\\n15832,6,2,\"Phase 1: Maximum Tolerated Dose\"\\n15833,7,2,\"Phase 1: Maximum Tolerated Dose (MTD)\"\\n15834,1,1,\"phase 1: Maximum tolerated dose (MTD)\"\\n15835,1,1,\"Phase 1: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of daily oral BAL101553 based on the number of participants with adverse effects as measure of tolerability at various dose levels\"\\n15836,1,1,\"Phase 1: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)\"\\n15837,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel\"\\n15838,1,1,\"Phase 1: Maximum tolerated dose (MTD) of [225Ac]-FPI-1966\"\\n15839,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate\"\\n15840,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) of DB-1303\"\\n15841,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) of GSK2110183\"\\n15842,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib\"\\n15843,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy\"\\n15844,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) of TU2218 administered alone (Part A) and in combination with anti-PD-1 antibody (Part B)\"\\n15845,1,1,\"Phase 1: Maximum Tolerated Dose (MTD) Regimen of Brigatinib Monotherapy\"\\n15846,1,1,\"Phase 1: Maximum Tolerated Dose of Cabazitaxel\"\\n15847,1,1,\"Phase 1: Maximum tolerated/recommended phase 2 dose\"\\n15848,1,1,\"Phase 1: MTD\"\\n15849,1,1,\"Phase 1: MTD and RP2D for Paclitaxel in Combination With Alisertib\"\\n15850,1,1,\"Phase 1: MTD and RP2D of HEC169096\"\\n15851,1,1,\"Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose\"\\n15852,1,1,\"Phase 1: Number of dose-limiting toxicities\"\\n15853,1,1,\"Phase 1: Number of Participants Based on Severity of TEAEs\"\\n15854,2,1,\"Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)\"\\n15855,1,1,\"Phase 1: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)\"\\n15856,1,1,\"Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)\"\\n15857,1,1,\"Phase 1: Number of participants in an assigned dose cohort with treatment emergent adverse events (TEAEs) by grade assessed by NCI-CTCAE v 4.03 who experience a DLT\"\\n15858,1,1,\"Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)\"\\n15859,1,1,\"Phase 1: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)\"\\n15860,1,1,\"Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)\"\\n15861,1,1,\"Phase 1: Number of Participants With a Grade 3 or Higher TEAE\"\\n15862,1,1,\"Phase 1: Number of Participants With Adverse Event (AEs) and Serious Adverse Events (SAEs) and Adverse Events Leading to Discontinuation\"\\n15863,1,1,\"Phase 1: Number of Participants With Adverse Events\"\\n15864,1,1,\"Phase 1: Number of Participants With Adverse Events (AEs)\"\\n15865,2,2,\"Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n15866,1,1,\"Phase 1: Number of Participants with Adverse events (AEs) by Severity\"\\n15867,2,1,\"Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)\"\\n15868,1,1,\"Phase 1: Number of Participants With Change from Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status\"\\n15869,1,1,\"Phase 1: Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG)\"\\n15870,1,1,\"Phase 1: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters\"\\n15871,1,1,\"Phase 1: Number of Participants With Clinically Significant Abnormalities in Physical Examination\"\\n15872,1,1,\"Phase 1: Number of Participants With Clinically Significant Abnormalities in Vital Signs\"\\n15873,1,1,\"Phase 1: Number of Participants With Clinically Significant Change From Baseline in Body Weight\"\\n15874,1,1,\"Phase 1: Number of Participants With Clinically Significant Change from Baseline in Electrocardiograms (ECG)\"\\n15875,1,1,\"Phase 1: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters\"\\n15876,1,1,\"Phase 1: Number of Participants with Clinically Significant Change From Baseline in Vital Signs\"\\n15877,3,3,\"Phase 1: Number of Participants With Clinically Significant Laboratory Values\"\\n15878,1,1,\"Phase 1: Number of Participants with Clinically Significant Physical Examination Findings\"\\n15879,1,1,\"Phase 1: Number of Participants With Clinically Significant Vital Sign Findings\"\\n15880,4,3,\"Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n15881,1,1,\"Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs)\"\\n15882,1,1,\"Phase 1: Number of Participants With Dose Limiting Toxicity (DLT)\"\\n15883,2,1,\"Phase 1: Number of Participants With Dose-limiting Toxicities\"\\n15884,2,2,\"Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)\"\\n15885,3,1,\"Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)\"\\n15886,1,1,\"Phase 1: Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)\"\\n15887,1,1,\"Phase 1: Number of Participants With Hypersensitivity and Neurotoxicity\"\\n15888,1,1,\"Phase 1: Number of Participants With No Dose Interruptions or Reductions\"\\n15889,1,1,\"Phase 1: Number of Participants With One or More Serious Adverse Events (SAEs)\"\\n15890,1,1,\"Phase 1: Number of Participants with One or More TEAEs Leading to Dose Modifications and Treatment Discontinuation\"\\n15891,1,1,\"Phase 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs)\"\\n15892,1,1,\"Phase 1: Number of participants with TEAEs\"\\n15893,1,1,\"Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)\"\\n15894,2,1,\"Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)\"\\n15895,3,3,\"Phase 1: Number of Patients who Experience Dose-Limiting Toxicity\"\\n15896,1,1,\"Phase 1: Number of patients with AEs\"\\n15897,1,1,\"Phase 1: Number of patients with treatment related AEs according to NCI CTCAE v 5\"\\n15898,1,1,\"Phase 1: Number of Subjects Reporting Hematologic and/or Non-hematologic Dose-limiting Toxicity (DLT)\"\\n15899,1,1,\"Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (‚â•) 3 in Severity\"\\n15900,1,1,\"Phase 1: Number or Participants With Dose Limiting Toxicities (DLTs)\"\\n15901,1,1,\"Phase 1: Occurrence and Severity of Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03)\"\\n15902,1,1,\"Phase 1: Occurrence of Adverse Events\"\\n15903,1,1,\"Phase 1: Occurrence of Dose Limiting Toxicity\"\\n15904,1,1,\"Phase 1: Participants with treatment-emergent adverse events (TEAE)\"\\n15905,1,1,\"Phase 1: Percentage of Participants Experiencing Dose-limiting toxicity (DLTs) per Dose level\"\\n15906,1,1,\"Phase 1: Percentage of Participants Experiencing laboratory abnormalities Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03\"\\n15907,1,1,\"Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03\"\\n15908,1,1,\"Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)\"\\n15909,2,2,\"Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.\"\\n15910,2,2,\"Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.\"\\n15911,2,2,\"Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.\"\\n15912,1,1,\"Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events\"\\n15913,1,1,\"Phase 1: Phase 1: Incidence of AEs to evaluate safety and tolerability of [225Ac]-FPI-1966, [111In]-FPI-1967, and vofatamab.\"\\n15914,1,1,\"Phase 1: Plasma clearance (CL)\"\\n15915,1,1,\"Phase 1: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)\"\\n15916,1,1,\"Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level\"\\n15917,1,1,\"PHASE 1: Recommended dose for phase II study\"\\n15918,1,1,\"Phase 1: Recommended Dose of Aflibercept for Phase 2\"\\n15919,1,1,\"Phase 1: Recommended Phase 1b Dose\"\\n15920,2,1,\"Phase 1: Recommended Phase 2 Dose\"\\n15921,6,2,\"Phase 1: Recommended Phase 2 Dose (RP2D)\"\\n15922,1,1,\"Phase 1: Recommended Phase 2 Dose (RP2D) candidate\"\\n15923,1,1,\"Phase 1: Recommended Phase 2 Dose (RP2D) of Brigatinib Monotherapy\"\\n15924,1,1,\"Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1303\"\\n15925,1,1,\"Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1305\"\\n15926,1,1,\"Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan Hydrochloride\"\\n15927,1,1,\"Phase 1: Recommended Phase 2 Dose for Daily x 3 every 3 weeks schedule of CBX-12\"\\n15928,1,1,\"Phase 1: Recommended Phase 2 Dose for Once Weekly schedule of CBX-12\"\\n15929,1,1,\"Phase 1: Recommended Phase 2 Dose of LY2603618\"\\n15930,1,1,\"Phase 1: RP2D\"\\n15931,2,2,\"Phase 1: Safety Profile\"\\n15932,1,1,\"Phase 1: Safety profile of RXDX-107 as characterized by Adverse Events, ECG and laboratory abnormalities\"\\n15933,1,1,\"Phase 1: Severity of TEAEs\"\\n15934,1,1,\"Phase 1: Terminal Phase Elimination Half-life (t1/2) of Etoposide With and Without Veliparib\"\\n15935,1,1,\"Phase 1: The frequency and severity of adverse events of ES104\"\\n15936,1,1,\"Phase 1: The incidence of DLTs (during DLT observation period)\"\\n15937,1,1,\"Phase 1: Time of First Occurrence of Maximum Observed Plasma Concentration (Tmax) of Brigatinib\"\\n15938,1,1,\"Phase 1: Time to Cmax, by inspection (tmax)\"\\n15939,1,1,\"Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Etoposide With and Without Veliparib\"\\n15940,1,1,\"Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Veliparib\"\\n15941,1,1,\"Phase 1: To assess the safety and determine the recommended phase II dose (RP2D) when given by IT injection and by IV infusion, as monotherapy and in combination with pembrolizumab.\"\\n15942,1,1,\"Phase 1: to characterize the PK of brigatinib\"\\n15943,1,1,\"Phase 1: To Determine the Maximum Tolerable Dose (MTD) or Optimal Dose of SD-101 alone, in Combination with Nivolumab, and in Combination with Both Nivolumab and Ipilimumab\"\\n15944,1,1,\"Phase 1: To determine the Recommended phase 2 dose (RP2D) of niraparib and neratinib in patients with advanced solid tumors\"\\n15945,1,1,\"Phase 1: To Determine the Recommended Phase 2 Dose of the MM-121 + Erlotinib Combination Based Upon Either the Maximum Tolerated Dose (MTD) or the Maximum Feasible Dose of the Combination in Patients With NSCLC.\"\\n15946,1,1,\"Phase 1: To Determine the Safety of SD-101 Alone, in Combination with Nivolumab, and in Combination with Both Nivolumab and Ipilimumab\"\\n15947,1,1,\"Phase 1: To evaluate the safety of TmPSMA-02 in adult patients with mCRPC\"\\n15948,1,1,\"Phase 1: To identify the recommended Phase 2 dose of TmPSMA-02 administered in combination with LD chemotherapy\"\\n15949,1,1,\"Phase 1: Volume of distribution (Vz)\"\\n15950,1,1,\"Phase 1a (general) : Percentage of participants who experience a Dose Limiting Toxicity (DLT)\"\\n15951,1,1,\"Phase 1a - Number of dose interruptions, dose modifications, and discontinuations due to AEs\"\\n15952,1,1,\"Phase 1a - Number of participants with clinically significant change from baseline in laboratory abnormalities\"\\n15953,1,1,\"Phase 1a - Number of participants with dose limiting toxicities (DLTs)\"\\n15954,1,1,\"Phase 1a - Number of participants with treatment emergent adverse events (AEs)\"\\n15955,1,1,\"Phase 1A - Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities\"\\n15956,1,1,\"Phase 1A - Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities (DLTs)\"\\n15957,1,1,\"Phase 1a and 1b : Incidence of Dose-Limiting Toxicities (DLTs)\"\\n15958,1,1,\"Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)\"\\n15959,1,1,\"Phase 1a and Phase 1b: Number of Participants with Dose Limiting Toxicity (DLT)\"\\n15960,1,1,\"Phase 1a and Phase 1b: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)\"\\n15961,1,1,\"Phase 1a Dose Escalation Primary Objective: Incidence and Severity of Treatment-Emergent Adverse Events, Serious Adverse Events, and Dose Limiting Toxicities\"\\n15962,1,1,\"Phase 1a Dose Escalation: Assess safety, tolerability, and recommended phase 2 dose (RP2D) of BBP-398 in combination with nivolumab\"\\n15963,1,1,\"Phase 1a Dose Escalation: Maximum Tolerated Dose (MTD) of TACH101\"\\n15964,1,1,\"Phase 1a Dose Escalation: Recommended Phase 2 Dose (RP2D) of TACH101\"\\n15965,1,1,\"Phase 1a: Determination of any Dose limiting toxicities (DLT)s of SNDX-6352\"\\n15966,1,1,\"Phase 1a: Determination of Maximum tolerable dose (MTD) of SNDX-6352\"\\n15967,1,1,\"Phase 1a: Determination of Recommended Phase 2 dose (RP2D) of SNDX-6352\"\\n15968,1,1,\"Phase 1a: Determine DLTs and RP2Ds in INV-1120\"\\n15969,1,1,\"Phase 1a: Determine safety and tolerability of AVID100\"\\n15970,1,1,\"Phase 1a: Dose Limiting Toxicities (DLT)\"\\n15971,1,1,\"Phase 1a: Incidence Rate of Dose-Limiting Toxicity (DLT)\"\\n15972,1,1,\"Phase 1a: Maximum tolerated dose (MTD)\"\\n15973,1,1,\"Phase 1a: Maximum tolerated dose (MTD) defined as the highest dose with less than 25% risk of the true Dose-limiting toxicity (DLT) rate being equal or above 33% during the MTD evaluation period\"\\n15974,1,1,\"Phase 1a: Maximum Tolerated Dose (MTD) of BGB-3245, and the recommended Phase 2 Dose (RP2D) for BGB-3245\"\\n15975,1,1,\"Phase 1a: Maximum Tolerated Dose (MTD) of BGB-A445\"\\n15976,1,1,\"Phase 1a: Maximum Tolerated Dose (MTD) of BGB-B167\"\\n15977,1,1,\"Phase 1a: Number of Participants and Severity Experiencing Adverse Events (AEs)\"\\n15978,1,1,\"Phase 1a: Number of Participants and Severity Experiencing Serious Adverse Events (SAEs)\"\\n15979,1,1,\"Phase 1A: Number of Participants Experiencing Adverse Events (AEs)\"\\n15980,3,3,\"Phase 1a: Number of Participants Experiencing Adverse Events (AEs)\"\\n15981,1,1,\"Phase 1a: Number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria\"\\n15982,1,1,\"Phase 1a: number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria\"\\n15983,2,2,\"Phase 1a: Number of Participants Experiencing AEs Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria\"\\n15984,1,1,\"Phase 1a: Number of Participants Experiencing Dose Limiting Toxicities\"\\n15985,1,1,\"Phase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings\"\\n15986,3,3,\"Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)\"\\n15987,1,1,\"Phase 1A: Number Of Participants Experiencing Severe AEs\"\\n15988,1,1,\"Phase 1A: Number Of Participants With Abnormal Electrocardiograms\"\\n15989,1,1,\"Phase 1A: Number Of Participants With Abnormal Laboratory Values\"\\n15990,1,1,\"Phase 1A: Number Of Participants With Abnormal Physical Examination Values\"\\n15991,1,1,\"Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n15992,1,1,\"Phase 1a: Number of participants with dose limiting toxicities (DLTs)\"\\n15993,1,1,\"Phase 1a: Number of patients experiencing Dose Limiting Toxicity (DLT) graded according to CTCAE Version 4.03 / 5.0, observed in the first cycle (3 weeks) in order to meet the objective of assessment of the Maximum-tolerated Dose of BI 754091.\"\\n15994,1,1,\"Phase 1a: Number of patients with DLTs in the MTD evaluation period\"\\n15995,2,2,\"Phase 1a: Recommended Phase 2 doses (RP2Ds)\"\\n15996,1,1,\"Phase 1a: Safety and tolerability of ASTX295 including determination of maximum tolerated dose (MTD), and/or recommended dose for expansion (RDE) to Phase 1b\"\\n15997,1,1,\"Phase 1a: Safety assessments in patients receiving the trial drug\"\\n15998,1,1,\"Phase 1a: The incidence, nature, and severity of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 in patients receiving the trial drug\"\\n15999,1,1,\"Phase 1a: The maximum tolerated dose (MTD) of HLX301\"\\n16000,1,1,\"Phase 1a: The proportion of patients experiencing dose limiting toxicity (DLT) events\"\\n16001,1,1,\"Phase 1a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-435: Number of patients with dose-limiting toxicities (DLTs)\"\\n16002,1,1,\"Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy\"\\n16003,1,1,\"Phase 1b (Cohort B-n, D-1 and E-n ) : Objective Response Rate (ORR)\"\\n16004,1,1,\"Phase 1b (PLX2853 + carboplatin combination): establish the MTD/RP2D for the combination of PLX2853 and carboplatin\"\\n16005,2,2,\"Phase 1B - Efficacy: Objective Response Rate (ORR)\"\\n16006,1,1,\"Phase 1b - Overall response\"\\n16007,1,1,\"Phase 1b - Selection of suitable schedule for repeat cycle IV administration\"\\n16008,1,1,\"Phase 1b - To determine the safety of SD-101 administered via PRVI in combination with pembrolizumab and to assess the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 overall response rate (ORR)\"\\n16009,1,1,\"Phase 1b and Phase 2 Safety Lead-in: Number of Participants Reporting one or More Serious Adverse Event (SAEs)\"\\n16010,1,1,\"Phase 1b and Phase 2 Safety Lead-in: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)\"\\n16011,1,1,\"Phase 1b and Phase 2 Safety Lead-in: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n16012,1,1,\"Phase 1b and Phase 2 Safety Lead-in: Number of Participants with Grade 3 or Higher TEAEs\"\\n16013,1,1,\"Phase 1b and Phase 2 Safety Lead-in: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations\"\\n16014,1,1,\"Phase 1b and Phase 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)\"\\n16015,1,1,\"Phase 1b Dose Confirmation - Anti-tumor activity of ociperlimab in combination with tislelizumab in patients with select advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using RECIST v. 1.1.\"\\n16016,1,1,\"Phase 1b Dose Escalation, NUV-868 + Enzalutamide: Pharmacokinetic (PK) profiles of NUV-868 and enzalutamide when administered in combination\"\\n16017,1,1,\"Phase 1b Dose Escalation, NUV-868 + Enzalutamide: Safety and tolerability of NUV-868 in combination with enzalutamide to determine the RP2cD\"\\n16018,1,1,\"Phase 1b Dose Escalation, NUV-868 + Olaparib: Pharmacokinetic (PK) profiles of NUV-868 and olaparib when administered in combination\"\\n16019,1,1,\"Phase 1b Dose Escalation, NUV-868 + Olaparib: Safety and tolerability of NUV-868 in combination with olaparib to determine the recommended Phase 2 combination dose (RP2cD)\"\\n16020,1,1,\"Phase 1b Dose Escalation: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) Through Day 28 at Each Dose Level of GS-5829\"\\n16021,1,1,\"Phase 1b Dose Expansion/Optimization Primary Objective: Incidence and Severity of Treatment-Emergent Adverse Events, and Serious Adverse Events\"\\n16022,1,1,\"Phase 1b Dose Expansion/Optimization Primary Objective: Overall Response Rate (ORR)\"\\n16023,1,1,\"Phase 1b Dose Expansion: Assess antitumor activity of BBP-398 in combination with nivolumab\"\\n16024,1,1,\"Phase 1b Dose Expansion: Objective Response Rate (ORR)\"\\n16025,1,1,\"Phase 1b Dose Limiting Toxicity (DLT) rate\"\\n16026,1,1,\"Phase 1b Lead-in: Number of Participants With Dose-Limiting Toxicities (DLT)\"\\n16027,1,1,\"Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs)\"\\n16028,1,1,\"Phase 1b Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n16029,1,1,\"Phase 1b primary outcome measure: Maximum Tolerated Dose of AZD5363 in combination with fulvestrant\"\\n16030,1,1,\"Phase 1b, Part A: Number of Participants With Dose-Limiting Toxicities (DLT)\"\\n16031,1,1,\"Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6\"\\n16032,1,1,\"Phase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 2\"\\n16033,1,1,\"Phase 1b: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered in Combination With Sorafenib at Day -7\"\\n16034,1,1,\"Phase 1b: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered in Combination With Sorafenib at Day 1 Cycle 1\"\\n16035,1,1,\"Phase 1b: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered in Combination With Sorafenib at Day 28 Cycle 1\"\\n16036,1,1,\"Phase 1b: Change in clinical laboratory abnormalities\"\\n16037,1,1,\"Phase 1b: Change in Eastern Cooperative Oncology Group (ECOG) performance status\"\\n16038,1,1,\"Phase 1b: Cmax: Maximum Observed Plasma Concentration for Golvatinib When Administered in Combination With Sorafenib at Day -7\"\\n16039,1,1,\"Phase 1b: Cmax: Maximum Observed Plasma Concentration for Golvatinib When Administered in Combination With Sorafenib at Day 1 Cycle 1\"\\n16040,1,1,\"Phase 1b: Cmax: Maximum Observed Plasma Concentration for Golvatinib When Administered in Combination With Sorafenib at Day 28 Cycle 1\"\\n16041,1,1,\"Phase 1b: Confirm RP2D\"\\n16042,1,1,\"Phase 1b: Confirmed objective response (OR) as assessed by the investigator\"\\n16043,1,1,\"Phase 1b: Confirmed Objective Response (OR), defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator.\"\\n16044,1,1,\"Phase 1b: Determination of any Dose limiting toxicities (DLT)s of SNDX-6352 when given in combination with a fixed dose of durvalumab\"\\n16045,1,1,\"Phase 1b: Determination of Maximum tolerable dose (MTD) of SNDX-6352 when given in combination with a fixed dose of durvalumab\"\\n16046,1,1,\"Phase 1b: Determination of Recommended Phase 2 dose (RP2D) of SNDX-6352 when given in combination with a fixed dose of durvalumab\"\\n16047,1,1,\"Phase 1b: Determine RP2D and DLTs of the combination of INV-1120 and pembrolizumab\"\\n16048,1,1,\"Phase 1b: Determine the MTD and RP2D of DAY101 in combination with other therapies\"\\n16049,1,1,\"Phase 1b: Determine the safety of DAY101 in combination with other therapies\"\\n16050,1,1,\"Phase 1b: Disease Control Rate (DCR) at 6 Cycles (28-Day Cycles)\"\\n16051,1,1,\"Phase 1b: Evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) of AsiDNA administered in combination with olaparib in participants with advanced and/or metastatic ovarian, breast, or prostate cancer.\"\\n16052,1,1,\"Phase 1b: Frequency and severity of adverse events of ES101\"\\n16053,1,1,\"Phase 1b: Frequency of dose limiting toxicities (DLT) at each dose level associated with administration of copanlisib and nivolumab\"\\n16054,1,1,\"Phase 1b: Identify the recommended Phase 2 dose (RP2D) of CTX in combination with fixed doses of TRX518 ¬± avelumab\"\\n16055,1,1,\"Phase 1b: Incidence and severity of adverse events (AEs)\"\\n16056,1,1,\"Phase 1b: Incidence and severity of dose-limiting toxicities (DLTs)\"\\n16057,1,1,\"Phase 1b: Incidence of dose-limiting toxicities (DLTs)\"\\n16058,1,1,\"Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 (RP2) Dose\"\\n16059,1,1,\"Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Golvatinib in Combination With Lenvatinib\"\\n16060,1,1,\"Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Golvatinib\"\\n16061,1,1,\"Phase 1b: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\"\\n16062,1,1,\"Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab\"\\n16063,1,1,\"Phase 1b: Maximum Tolerated Dose (MTD) or Highest Tolerated Dose (HTD)\"\\n16064,1,1,\"Phase 1b: Number of DLTs\"\\n16065,1,1,\"Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT)\"\\n16066,1,1,\"Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity\"\\n16067,1,1,\"Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events (AEs) Version 4.0\"\\n16068,1,1,\"Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)\"\\n16069,1,1,\"Phase 1b: Number of Participants Who Experience a Serious Adverse Event (SAE)\"\\n16070,1,1,\"Phase 1b: Number of Participants Who Experience an Adverse Event (AE)\"\\n16071,1,1,\"Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)\"\\n16072,1,1,\"Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment\"\\n16073,1,1,\"Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose.\"\\n16074,1,1,\"Phase 1b: Number of Participants with Clinically Significant Changes in ECG Measurements\"\\n16075,1,1,\"Phase 1b: Number of Participants with Clinically Significant Changes in Laboratory Test Values\"\\n16076,1,1,\"Phase 1b: Number of Participants with Clinically Significant Changes in Vital Signs\"\\n16077,2,2,\"Phase 1b: Number of Participants With Dose Limiting Toxicities\"\\n16078,1,1,\"Phase 1b: Number of Participants with Dose Limiting Toxicities (DLT)\"\\n16079,6,2,\"Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n16080,2,2,\"Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)\"\\n16081,1,1,\"Phase 1b: Number of Participants With Dose Limiting Toxicity (DLT)\"\\n16082,1,1,\"Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)\"\\n16083,1,1,\"Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)\"\\n16084,1,1,\"Phase 1b: Number of participants with Dose-Limiting Toxicities (DLT)\"\\n16085,3,2,\"Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)\"\\n16086,1,1,\"Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0)\"\\n16087,1,1,\"Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)\"\\n16088,1,1,\"Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6\"\\n16089,1,1,\"Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT)\"\\n16090,1,1,\"Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0\"\\n16091,1,1,\"Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs)\"\\n16092,1,1,\"Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1\"\\n16093,1,1,\"Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Laboratory (Hematological and Chemistry) Values\"\\n16094,1,1,\"Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Vital Signs\"\\n16095,1,1,\"Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs\"\\n16096,1,1,\"Phase 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs)\"\\n16097,1,1,\"Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs\"\\n16098,1,1,\"Phase 1b: Number of Participants with Treatment-related Adverse Events\"\\n16099,1,1,\"Phase 1b: Number of Patients With Adverse Events as a Measure of Safety and Tolerability\"\\n16100,1,1,\"Phase 1b: Number of Patients With DLT\"\\n16101,1,1,\"Phase 1b: Number of patients with DLTs during the MTD evaluation period assessed in the first 6 patients\"\\n16102,1,1,\"Phase 1b: Number of patients with Dose Limiting Toxicity (DLT) observed during the entire treatment period.\"\\n16103,1,1,\"Phase 1b: Number of subjects with dose limiting toxicities which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)\"\\n16104,1,1,\"Phase 1B: Objective Response Rate (ORR)\"\\n16105,3,2,\"Phase 1b: Objective Response Rate (ORR)\"\\n16106,1,1,\"Phase 1b: Objective Response Rate (ORR) as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n16107,1,1,\"Phase 1b: Objective Response Rate (ORR) confirmed Complete Response and Partial Response\"\\n16108,1,1,\"Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.\"\\n16109,1,1,\"Phase 1b: Occurrence of Adverse Events\"\\n16110,1,1,\"Phase 1b: ORR Solid tumors: objective response rate (ORR) assessed by Investigator per RECIST 1.1 CTCL: ORR assessed by Investigator per global response (Olsen 2011)\"\\n16111,2,2,\"Phase 1b: Overall Response Rate (ORR)\"\\n16112,1,1,\"Phase 1b: Overall Response Rate (ORR) as Assessed by the Investigator\"\\n16113,1,1,\"Phase 1b: Overall Response Rate (ORR) as assessed by the investigator\"\\n16114,1,1,\"Phase 1b: Percentage of participants experiencing Adverse Events\"\\n16115,1,1,\"Phase 1b: Percentage of Participants with Dose-Limiting Toxicity (DLT)\"\\n16116,1,1,\"Phase 1b: Percentage of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)\"\\n16117,1,1,\"Phase 1b: Percentage of Participants With Objective Response\"\\n16118,1,1,\"Phase 1b: Plasma Concentration of Golvatinib When Given in Combination With Cetuximab\"\\n16119,1,1,\"Phase 1b: Recommended Phase 2 Dose\"\\n16120,1,1,\"Phase 1b: Recommended phase 2 dose (RP2D)\"\\n16121,1,1,\"Phase 1b: Recommended Phase 2 dose (RP2D) and regimen of ASTX295 to proceed to Phase 2\"\\n16122,1,1,\"Phase 1b: Recommended Phase 2 Dose (RP2D) of of ES101\"\\n16123,1,1,\"Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD])\"\\n16124,1,1,\"Phase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD)\"\\n16125,1,1,\"Phase 1b: RP2D of BGB-A445 when Administered Alone\"\\n16126,1,1,\"Phase 1b: RP2D of E7389-LF in Combination With Nivolumab\"\\n16127,1,1,\"Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7\"\\n16128,1,1,\"Phase 1b: Safety Profile of sacituzumab plus chemoimmunotherapy\"\\n16129,1,1,\"Phase 1b: t1/2: Terminal Elimination Half-life for Golvatinib When Administered in Combination With Sorafenib at Day -7\"\\n16130,1,1,\"Phase 1b: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered in Combination With Sorafenib at Day -7\"\\n16131,1,1,\"Phase 1b: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered in Combination With Sorafenib at Day 1 Cycle 1\"\\n16132,1,1,\"Phase 1b: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered in Combination With Sorafenib at Day 28 Cycle 1\"\\n16133,1,1,\"Phase 1b: To Assess Overall Response Rate (ORR)\"\\n16134,1,1,\"Phase 1b: To Assess Overall Survival (OS)\"\\n16135,1,1,\"Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents\"\\n16136,1,1,\"Phase 1b: To Determine the Maximum Tolerable Dose (MTD) or Optimal Dose of SD-101 alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and Ipilimumab\"\\n16137,1,1,\"Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-na√Øve participants with advanced NSCLC in combination with pembrolizumab\"\\n16138,1,1,\"Phase 1b: To Determine the Safety of SD-101 Alone, in Combination with Pembrolizumab, and in Combination with Nivolumab and Ipilimumab\"\\n16139,1,1,\"Phase 1b: To evaluate clinical benefit (‚â•4-month progression-free survival [PFS]) of niraparib and neratinib in patients with platinum-resistant ovarian cancer.\"\\n16140,1,1,\"Phase 1b: To evaluate the preliminary antitumor activity of LOXO-435: Overall response rate (ORR)\"\\n16141,1,1,\"Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)\"\\n16142,1,1,\"Phase 2 (mBC): Percentage of Participants With Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n16143,1,1,\"Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator\"\\n16144,1,1,\"Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)\"\\n16145,1,1,\"Phase 2 - Efficacy\"\\n16146,1,1,\"Phase 2 - Number of Participants With Stable Disease In Response to Study Therapy\"\\n16147,1,1,\"Phase 2 - Objective Response Rate (ORR)\"\\n16148,1,1,\"Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)\"\\n16149,1,1,\"Phase 2 - Rate of Progression-Free Survival (PFS)\"\\n16150,1,1,\"Phase 2 - Survival Probability at 2 Years\"\\n16151,1,1,\"Phase 2 Anti-neoplastic Activity\"\\n16152,1,1,\"Phase 2 Cohort 1: PFS as Determined by Investigator Assessment Using RECIST Version 1.1\"\\n16153,1,1,\"Phase 2 Cohorts 1: Progression-free survival (PFS)\"\\n16154,1,1,\"Phase 2 Cohorts 2 and 3: Objective Response Rate (ORR)\"\\n16155,1,1,\"Phase 2 Cohorts: Objective Response Rate (ORR)\"\\n16156,1,1,\"Phase 2 Component - Percentage of Participants With an Overall Response Rate Following Treatment With the Combination of Vandetanib and Metformin\"\\n16157,1,1,\"Phase 2 dose (RP2D) of GT90001 in combination with KN046\"\\n16158,1,1,\"Phase 2 Dose Expansion Cohort 1 (IDH-WT GB): Objective Response\"\\n16159,1,1,\"Phase 2 Dose Expansion Cohort 2 (HR+HER2- mBC): Objective response\"\\n16160,1,1,\"Phase 2 Dose Expansion Cohort 3 (mCRPC): Objective response\"\\n16161,1,1,\"Phase 2 Dose Expansion Cohort 4 (HR+HER2- mBC with brain metastases): Objective response\"\\n16162,2,1,\"Phase 2 Dose Expansion: Objective Response Rate (ORR)\"\\n16163,2,1,\"Phase 2 Dosing\"\\n16164,1,1,\"Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1\"\\n16165,1,1,\"Phase 2 Evaluates preliminary anti-tumor activity of MRT-2359 by overall response rate (ORR) as determined by RECIST 1.1\"\\n16166,1,1,\"Phase 2 Expansion: Overall Response Rate (ORR)\"\\n16167,1,1,\"Phase 2 Monotherapy Expansion: Change from Baseline in Prostate-specific antigen (PSA) measurements\"\\n16168,1,1,\"Phase 2 Monotherapy Expansion: Change from Baseline in Tumor Imaging\"\\n16169,1,1,\"Phase 2 Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)\"\\n16170,1,1,\"Phase 2 Objective Response Rate (Partial Response (PR) + Complete Response (CR)).\"\\n16171,1,1,\"Phase 2 Only: Objective Response Rate (ORR) of INCB001158 in Combination With Epacadostat ¬± Pembrolizumab\"\\n16172,1,1,\"Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1\"\\n16173,1,1,\"Phase 2 open-label, randomized: Event-free survival (EFS) based on Investigator assessment.\"\\n16174,1,1,\"Phase 2 Part: Objective Response Rate (ORR)\"\\n16175,1,1,\"Phase 2 Part: Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC)\"\\n16176,1,1,\"Phase 2 Primary Objective - Progression-free Survival\"\\n16177,1,1,\"Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with Cetuximab\"\\n16178,1,1,\"Phase 2 Primary Outcome: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with Chemotherapy\"\\n16179,1,1,\"Phase 2 primary outcome: Progression free survival (PFS)\"\\n16180,1,1,\"Phase 2 recommended dose for the combined regimens\"\\n16181,1,1,\"Phase 2 recommended doses of tanespimycin\"\\n16182,1,1,\"Phase 2- Overall Response Rate\"\\n16183,1,1,\"Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1)\"\\n16184,2,1,\"Phase 2:\"\\n16185,1,1,\"Phase 2: Adverse Events (AEs)\"\\n16186,1,1,\"Phase 2: AUC 0-tau: Area Under the Plasma Concentration Versus Time Curve Zero to the Time of the End of the Dosing Interval for Orteronel\"\\n16187,1,1,\"Phase 2: AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Docetaxel\"\\n16188,1,1,\"Phase 2: AUCœÑ of PF-06801591 at steady state, at Week 12\"\\n16189,1,1,\"Phase 2: AUC‚àû: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Docetaxel\"\\n16190,1,1,\"Phase 2: Best Overall Response (BOR)\"\\n16191,2,2,\"Phase 2: Best overall response (BOR)\"\\n16192,1,1,\"Phase 2: Best overall response rate (ORR) (complete response (CR) + partial response (PR)) per RECIST v1.1\"\\n16193,1,1,\"Phase 2: Best PSA Response\"\\n16194,1,1,\"Phase 2: Brain metastasis response rate (BMRR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (mRECIST v1.1)\"\\n16195,1,1,\"Phase 2: Clinical Benefit Rate (CBR)\"\\n16196,1,1,\"Phase 2: Clinical Benefit Rate at 16 Weeks (CBR-16)\"\\n16197,1,1,\"Phase 2: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for Orteronel\"\\n16198,1,1,\"Phase 2: Cmax: Maximum Observed Plasma Concentration for Docetaxel\"\\n16199,1,1,\"Phase 2: Cohort A - Overall Response Rate (ORR)\"\\n16200,1,1,\"Phase 2: Cohort B - ORR\"\\n16201,1,1,\"Phase 2: Complete Response Rate (CRR) Based on RECIST v1.1\"\\n16202,1,1,\"Phase 2: Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) and as Adjudicated by the Investigator\"\\n16203,1,1,\"Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\"\\n16204,1,1,\"Phase 2: Confirmed Objective Response Rate (ORR)\"\\n16205,1,1,\"Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1\"\\n16206,1,1,\"Phase 2: Ctrough of PF-06801591 at steady state, at Week 12\"\\n16207,1,1,\"Phase 2: Determine confirmed objective response with CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma\"\\n16208,1,1,\"Phase 2: Determine whether ELI-002 7P improves relapse-free survival (RFS) compared with Observation\"\\n16209,1,1,\"Phase 2: Disease control rate (DCR) defined as achieving the complete response, partial response, or stable disease as determined by the investigator according to RECIST v1.1\"\\n16210,1,1,\"Phase 2: Disease control rate (DCR) in Cohort 1\"\\n16211,1,1,\"Phase 2: Duration of Response (DOR)\"\\n16212,3,3,\"Phase 2: Duration of response (DOR)\"\\n16213,1,1,\"Phase 2: Duration of response (DOR) defined as the time from the first occurrence of a documented ORR to disease progression, as determined by the investigator according to RECIST v1.1\"\\n16214,1,1,\"Phase 2: Efficacy determined by Objective Response Rate (ORR:CR+PR) per RECIST 1.1.\"\\n16215,1,1,\"Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.\"\\n16216,1,1,\"Phase 2: Efficacy of ponatinib assessed by complete response (CR) in participants with leukemias other than BCR-ABL-positive leukemias to determine the efficacy of ponatinib\"\\n16217,1,1,\"Phase 2: Efficacy of ponatinib assessed by CR in participants with lymphoma\"\\n16218,1,1,\"Phase 2: Efficacy of ponatinib assessed by incomplete complete response (iCR) in participants with leukemias other than BCR-ABL-positive leukemias\"\\n16219,1,1,\"Phase 2: Efficacy of ponatinib assessed by major cytogenetic response (MCyR) in participants with chronic-phase chronic myeloid leukemia (CP-CML)\"\\n16220,1,1,\"Phase 2: Efficacy of ponatinib assessed by major hematologic response (MaHR) or major molecular response (MMR) in participants with BCR-ABL-positive leukemias\"\\n16221,1,1,\"Phase 2: Efficacy of ponatinib assessed by overall response rate in participants with solid tumors\"\\n16222,1,1,\"Phase 2: EFS in ALCL\"\\n16223,1,1,\"Phase 2: Evaluate the anti-tumor activity of AsiDNA in combination with olaparib.\"\\n16224,1,1,\"Phase 2: Evaluate the efficacy of DAY101 monotherapy\"\\n16225,1,1,\"Phase 2: Evaluate the efficacy of venetoclax with irinotecan in patients with relapsed or refractory SCLC\"\\n16226,1,1,\"Phase 2: Investigator-Confirmed Objective Response Rate (ORR)\"\\n16227,1,1,\"Phase 2: Molecular response defined as ‚â• 50% decrease from baseline in circulating tumor DNA (ctDNA)\"\\n16228,1,1,\"Phase 2: Number of Participants Who Were Progression-free at 12 Weeks (PFS Status) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n16229,1,1,\"Phase 2: Number of Participants with Adverse Event (AEs)\"\\n16230,1,1,\"Phase 2: Number of Participants With Adverse Events Related to Vital Signs\"\\n16231,1,1,\"Phase 2: Number of Participants With AEs by Severity Grades\"\\n16232,1,1,\"Phase 2: Number of Participants with an Objective Response Rate (ORR)\"\\n16233,1,1,\"Phase 2: Number of Participants With Clinically Significant Change From Baseline in Blood Pressure Including Systolic and Diastolic Blood Pressures\"\\n16234,1,1,\"Phase 2: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values\"\\n16235,1,1,\"Phase 2: Number of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)\"\\n16236,1,1,\"Phase 2: Number of Participants With Markedly Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters\"\\n16237,1,1,\"Phase 2: Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values\"\\n16238,1,1,\"Phase 2: Number of Participants With Markedly Abnormal Physical Examinations Findings\"\\n16239,1,1,\"Phase 2: Number of Participants With Markedly Abnormal Vital Sign Values\"\\n16240,1,1,\"Phase 2: Number of Participants With Objective Response Rate (ORR) Using RECIST v1.1\"\\n16241,3,3,\"Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)\"\\n16242,1,1,\"Phase 2: Number of Participants With Worst Shifts Post Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS)\"\\n16243,1,1,\"PHASE 2: Number of patients with response to treatment\"\\n16244,7,5,\"Phase 2: Objective Response Rate\"\\n16245,4,3,\"Phase 2: Objective response rate\"\\n16246,12,6,\"Phase 2: Objective Response Rate (ORR)\"\\n16247,8,5,\"Phase 2: Objective response rate (ORR)\"\\n16248,1,1,\"Phase 2: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\"\\n16249,1,1,\"Phase 2: Objective Response Rate (ORR) according to RECIST 1.1\"\\n16250,1,1,\"Phase 2: Objective Response Rate (ORR) as Determined by Radiographic Disease Assessments Per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n16251,1,1,\"Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1\"\\n16252,1,1,\"Phase 2: Objective Response Rate (ORR) Based on Investigator Assessment (IA)\"\\n16253,1,1,\"Phase 2: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n16254,1,1,\"Phase 2: Objective Response Rate (ORR) by independent data monitoring committee (IDMC)\"\\n16255,1,1,\"Phase 2: Objective response rate (ORR) defined as achieving a complete response or partial response as determined by the investigator according to RECIST v1.1\"\\n16256,1,1,\"Phase 2: Objective Response Rate (ORR) Determined by Independent Review Committee (IRC)\"\\n16257,1,1,\"Phase 2: Objective Response Rate (ORR) in Hematological Malignancies\"\\n16258,1,1,\"Phase 2: Objective Response Rate (ORR) Per RECIST v1.1\"\\n16259,1,1,\"Phase 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1\"\\n16260,1,1,\"Phase 2: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for subjects with solid tumors and per Cheson criteria for subjects with DLBCL\"\\n16261,1,1,\"Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1\"\\n16262,1,1,\"Phase 2: Objective response rate as a measure of antitumor activity\"\\n16263,1,1,\"Phase 2: ORR\"\\n16264,1,1,\"Phase 2: ORR in IMT\"\\n16265,1,1,\"PHASE 2: ORR in the Two Defined Patient Groups According to Guidelines Set Forth by the 2018 IWCLL\"\\n16266,6,2,\"Phase 2: Overall Response Rate\"\\n16267,9,3,\"Phase 2: Overall Response Rate (ORR)\"\\n16268,4,3,\"Phase 2: Overall response rate (ORR)\"\\n16269,1,1,\"Phase 2: Overall Response Rate (ORR) (Partial Response [PR] or Better) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment\"\\n16270,1,1,\"Phase 2: Overall Response Rate (ORR) as Assessed by the Investigator According to RECIST, Version 1.1\"\\n16271,1,1,\"Phase 2: Overall response rate (ORR) as per RECIST v 1.1 (Response evaluation criteria in solid tumors, v 1.1) (by local investigator\"\\n16272,1,1,\"Phase 2: Overall response rate (ORR) by IRRC\"\\n16273,1,1,\"Phase 2: Overall response rate (ORR) in Cohorts 2, 3, 4, 5, and 6\"\\n16274,1,1,\"Phase 2: Overall Response rate (ORR) of TU2218 administered alone (Part A) and in combination with anti-PD-1 antibody (Part B)\"\\n16275,1,1,\"Phase 2: Overall Response Rate (ORR) Per RECIST 1.1\"\\n16276,1,1,\"Phase 2: Overall Response Rate (ORR), defined by RECIST v1.1.\"\\n16277,1,1,\"Phase 2: Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) in Colorectal Cancer (CRC) Cohorts and Other Tumors Cohort\"\\n16278,3,1,\"Phase 2: Overall Survival\"\\n16279,6,4,\"Phase 2: Overall Survival (OS)\"\\n16280,3,3,\"Phase 2: Overall survival (OS)\"\\n16281,1,1,\"Phase 2: Overall Survival (OS) (Olaratumab-Naive)\"\\n16282,1,1,\"Phase 2: Overall survival (OS) for subjects with Glioblatoma\"\\n16283,1,1,\"Phase 2: Participants With Greater Than or Equal to 50 Percent Decline in Prostate Specific Antigen (PSA)\"\\n16284,1,1,\"Phase 2: Pathologic Complete Response Rate (pCR)\"\\n16285,1,1,\"Phase 2: Patients With Adverse Events as a Measure of Safety and Tolerability\"\\n16286,1,1,\"Phase 2: Percentage of Participants Who Achieved Partial Response (PR) or Complete Response (CR) [Objective Response Rate (ORR)]\"\\n16287,1,1,\"Phase 2: Percentage of Participants Who Experienced TEAEs\"\\n16288,1,1,\"Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles\"\\n16289,1,1,\"Phase 2: Percentage of Participants With Objective Response\"\\n16290,1,1,\"Phase 2: Percentage of Participants With Objective Response (OR)\"\\n16291,2,2,\"Phase 2: Percentage of Participants With Objective Response by investigator assessment\"\\n16292,1,1,\"Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year\"\\n16293,1,1,\"Phase 2: Percentage of Participants With Prostate Specific Antigen (PSA) Response\"\\n16294,1,1,\"Phase 2: Percentage of Participants With Prostate-specific Antigen (PSA) Response of 30 Percent (%), 50%, and 90%\"\\n16295,1,1,\"Phase 2: Preliminary Antitumor Activity\"\\n16296,4,3,\"Phase 2: Progression Free Survival (PFS)\"\\n16297,4,4,\"Phase 2: Progression free survival (PFS)\"\\n16298,1,1,\"Phase 2: Progression Free Survival (PFS) of Patients With RCC\"\\n16299,1,1,\"Phase 2: Progression Free Survival in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib\"\\n16300,1,1,\"Phase 2: Progression-Free Survival\"\\n16301,1,1,\"Phase 2: Progression-free Survival\"\\n16302,2,2,\"Phase 2: Progression-Free Survival (PFS)\"\\n16303,2,1,\"Phase 2: Progression-free Survival (PFS)\"\\n16304,1,1,\"Phase 2: Progression-free Survival (PFS) in Participants Treated With LY2228820 Plus Gemcitabine and Carboplatin Versus Placebo Plus Gemcitabine and Carboplatin\"\\n16305,1,1,\"Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts)\"\\n16306,1,1,\"Phase 2: Progression-Free Survival (PFS) With the Enzastaurin Plus Erlotinib Combination Regimen\"\\n16307,1,1,\"Phase 2: Progression-free Survival of the MM-121 + Erlotinib Combination\"\\n16308,1,1,\"Phase 2: Progression-Free Survival Time\"\\n16309,1,1,\"Phase 2: Terminal Phase Elimination Half-life (T1/2) for Docetaxel\"\\n16310,1,1,\"Phase 2: The anti-tumor activity of ES104\"\\n16311,1,1,\"Phase 2: The Overall Response Rate (ORR) for patients\"\\n16312,1,1,\"Phase 2: The rate of locoregional control at one year\"\\n16313,1,1,\"Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC)\"\\n16314,1,1,\"Phase 2: Time to Progression (TTP) by Independent Review Assessment\"\\n16315,1,1,\"Phase 2: To Assess Overall Response Rate (ORR)\"\\n16316,1,1,\"Phase 2: To assess the safety and preliminary antitumor response T3P when given by IT injection and/or IV infusion, as monotherapy and in combination with pembrolizumab.\"\\n16317,1,1,\"Phase 2: To evaluate the efficacy of MRTX849 monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.\"\\n16318,1,1,\"Phase 2: To evaluate the objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1\"\\n16319,1,1,\"Phase 2: To investigate the antitumor activity of ZN-c3 in combination with niraparib - Objective Response Rate\"\\n16320,1,1,\"Phase 2: To investigate the antitumor activity of ZN-c3 in combination with niraparib - Progression Free Survival at 4 months\"\\n16321,1,1,\"Phase 2: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC) Treated With Daily Oral Vandetanib and Bortezomib\"\\n16322,1,1,\"Phase 2: Tumor Response Rate According to Response Evaluation Criteria In Solid Tumors (RECIST 1.1)\"\\n16323,1,1,\"Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1\"\\n16324,1,1,\"Phase 2a (PLX2853 + carboplatin combination): ORR as measured by RECIST v1.1\"\\n16325,1,1,\"Phase 2a (PLX2853 monotherapy): overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n16326,1,1,\"Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.\"\\n16327,1,1,\"Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with trastuzumab in subjects with advanced HER2 cancers.\"\\n16328,1,1,\"Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohort\"\\n16329,1,1,\"Phase 2a Expansion Groups\"\\n16330,1,1,\"Phase 2a/Expansion\"\\n16331,1,1,\"Phase 2a: Best objective response according to RANO criteria\"\\n16332,1,1,\"Phase 2a: Efficacy in Breast and Ovarian Cancer Groups: objective response rate\"\\n16333,1,1,\"Phase 2a: Efficacy in Prostate Cancer Group: objective response rate\"\\n16334,1,1,\"Phase 2a: Efficacy of PEN-866 in patients with endometrial adenocarcinoma using best overall response rate\"\\n16335,1,1,\"Phase 2a: Efficacy of PEN-866 in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma using best overall response rate\"\\n16336,1,1,\"Phase 2a: Efficacy of PEN-866 in patients with pancreatic adenocarcinoma using Disease Control Rate (DCR)\"\\n16337,1,1,\"Phase 2a: Efficacy of PEN-866 in patients with SCLC using best overall response rate\"\\n16338,1,1,\"Phase 2a: Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia (anus, cervix, vulva, or penis) using best overall response rate\"\\n16339,1,1,\"Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO\"\\n16340,1,1,\"Phase 2a: Evaluation of the preliminary antineoplastic effects of AVID100\"\\n16341,1,1,\"phase 2a: Objective response rate (ORR)\"\\n16342,1,1,\"Phase 2a: Overall Response Rate\"\\n16343,2,2,\"Phase 2a: Overall Response Rate (complete response [CR] + partial response [PR])\"\\n16344,2,2,\"Phase 2a: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.\"\\n16345,2,2,\"Phase 2a: Percentage of Participants with Treatment Emergent adverse events (TEAEs) as assessed by CTCAE v5.0.\"\\n16346,2,2,\"Phase 2a: Percentage participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.\"\\n16347,1,1,\"Phase 2a: Preliminary Assessment of the Objective Response Rate (ORR) of NT-I7 in Combination with Pembrolizumab\"\\n16348,1,1,\"Phase 2b Combination Expansion, NUV-868 + Enzalutamide: Change from Baseline in PSA measurements\"\\n16349,1,1,\"Phase 2b Combination Expansion, NUV-868 + Olaparib: Change from Baseline in PSA measurements\"\\n16350,1,1,\"Phase 2b Combination Expansion, NUV-868 + Olaparib: Change from Baseline in Tumor Imaging\"\\n16351,1,1,\"Phase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy\"\\n16352,1,1,\"Phase 2B: Overall Response Rate (ORR) Determined by Investigators Based on RECIST Version 1.1\"\\n16353,1,1,\"Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n16354,1,1,\"Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1\"\\n16355,1,1,\"Phase 3: Evaluate progression-free survival for subjects receiving CMP-001 in combination with nivolumab versus nivolumab monotherapy for unresectable or metastatic melanoma\"\\n16356,1,1,\"Phase 3: Overall Survival\"\\n16357,1,1,\"Phase 3: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessed Using Modified RECIST 1.1\"\\n16358,1,1,\"Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC)\"\\n16359,1,1,\"Phase 3: To compare efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy\"\\n16360,1,1,\"Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin\"\\n16361,1,1,\"Phase I - Determine the maximum tolerated dose (MTD) of BLU-451\"\\n16362,1,1,\"Phase I - Determine the Recommended Phase 2 Dose (RP2D) of BLU-451\"\\n16363,1,1,\"Phase I - Dose Limiting Toxicities\"\\n16364,1,1,\"Phase I - Dose-Limiting Toxicity\"\\n16365,2,1,\"Phase I - Identification of the dose limiting toxicity (DLT)\"\\n16366,4,1,\"Phase I - Maximum Tolerated Dose (MTD)\"\\n16367,1,1,\"Phase I - Number of Participants Who Experienced Dose Limiting Toxicities and Adverse Reactions\"\\n16368,1,1,\"Phase I - Rate and severity of Adverse Events (AEs) of BLU-451\"\\n16369,1,1,\"Phase I - Recommended Phase II Dose (RP2D)\"\\n16370,1,1,\"Phase I - Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel in Combination With Prednisone. (Azacitidine and Docetaxel)\"\\n16371,1,1,\"Phase I - Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel in Combination With Prednisone. (Prednisone)\"\\n16372,1,1,\"Phase I - Safety and Tolerability of RP-3500 in combination with radiation therapy\"\\n16373,1,1,\"Phase I : Number of patients with drug-related adverse events as assessed by CTCAEv4.0\"\\n16374,1,1,\"PHASE I : Recommended phase II dose (RP2D)\"\\n16375,1,1,\"Phase I and Phase II: safety and tolerability\"\\n16376,1,1,\"Phase I Dose Escalation: Determine Phase II dose based on incidence of dose-limiting toxicities.\"\\n16377,1,1,\"Phase I Maximum Tolerated Dose\"\\n16378,1,1,\"Phase I Maximum Tolerated Dose of Nab-Paclitaxel\"\\n16379,1,1,\"Phase I Number of Participants With Treatment-related Adverse Events\"\\n16380,1,1,\"Phase I part: Incidence of adverse events of special interest (AESIs) after TAE/TACE treatment with T-ACE Oil\"\\n16381,1,1,\"Phase I part: Incidence of all adverse events (AEs) after TAE/TACE treatment with T-ACE Oil\"\\n16382,1,1,\"Phase I part: Incidence of all serious adverse events (SAEs) after TAE/TACE treatment with T-ACE Oil\"\\n16383,1,1,\"Phase I part: incidence of Dose Limiting Toxicities (DLTs)\"\\n16384,1,1,\"Phase I part: Safety variables evaluation - Bilirubin\"\\n16385,1,1,\"Phase I part: Safety variables evaluation - Blood pressures\"\\n16386,1,1,\"Phase I part: Safety variables evaluation - blood urea nitrogen test\"\\n16387,1,1,\"Phase I part: Safety variables evaluation - Body temperature.\"\\n16388,1,1,\"Phase I part: Safety variables evaluation - Body weight.\"\\n16389,1,1,\"Phase I part: Safety variables evaluation - Coagulation function\"\\n16390,1,1,\"Phase I part: Safety variables evaluation - ECG test\"\\n16391,1,1,\"Phase I part: Safety variables evaluation - Hb\"\\n16392,1,1,\"Phase I part: Safety variables evaluation - Liver function\"\\n16393,1,1,\"Phase I part: Safety variables evaluation - Platelet count\"\\n16394,1,1,\"Phase I part: Safety variables evaluation - pulse rate\"\\n16395,1,1,\"Phase I part: Safety variables evaluation - Renal function\"\\n16396,1,1,\"Phase I part: Safety variables evaluation - Respiratory rate\"\\n16397,1,1,\"Phase I part: Safety variables evaluation - Thyroid function (Free T4)\"\\n16398,1,1,\"Phase I part: Safety variables evaluation - Thyroid function (T3)\"\\n16399,1,1,\"Phase I part: Safety variables evaluation - Thyroid function (TSH)\"\\n16400,1,1,\"Phase I part: Safety variables evaluation - WBC\"\\n16401,1,1,\"Phase I Participants Only: Overall Response Rate (ORR)\"\\n16402,1,1,\"Phase I Primary Objective: Maximum Tolerated Dose (MTD) of VS-6766 combined with Cetuximab\"\\n16403,1,1,\"Phase I Stage 1: Maximum Tolerated Dose of GDC-0032\"\\n16404,1,1,\"Phase I Stage I: Percentage of Participants With Adverse Events and Serious Adverse Events\"\\n16405,1,1,\"Phase I Step: Safety of BIBW 2992 Assessed Based on Incidence of Dose Limiting Toxicity (DLT) and Incidence & Intensity of Adverse Events According to CTCAE\"\\n16406,1,1,\"Phase I study:\"\\n16407,1,1,\"Phase I Toxicity Based Upon Adverse Events Clasified by the NCI Common Terminology Ctireria Version 2.0 (Phase I)\"\\n16408,1,1,\"Phase I ÔºöMTD or MAD\"\\n16409,1,1,\"Phase I, Part A: Recommended dose for Part B (RDPB) definition\"\\n16410,1,1,\"Phase I- Maximum Tolerated Dose (MTD)\"\\n16411,1,1,\"Phase I- Part B: Overall response rate (ORR) as assessed by Blinded Independent Review Committee (BIRC)\"\\n16412,1,1,\"Phase I-Dose Escalation to Determine MTD, Safety\"\\n16413,1,1,\"Phase I: Accumulation Ratio (AR) (Area Under the Concentration Time Curve at Steady-State Divided by Area Under the Concentration Time Curve for First Dose) of GDC-0032\"\\n16414,1,1,\"Phase I: Adverse Events\"\\n16415,1,1,\"Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR T cells\"\\n16416,1,1,\"Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells\"\\n16417,1,1,\"Phase I: Apparent Clearance (CL/F) of GDC-0032\"\\n16418,1,1,\"Phase I: Area Under the Concentration-Time Curve (AUC) From Zero to Infinity of GDC-0032\"\\n16419,1,1,\"Phase I: Area under the plasma concentration and time curve(AUC)\"\\n16420,1,1,\"Phase I: AUC From Zero to tau (AUCtau) of GDC-0032\"\\n16421,1,1,\"Phase I: Change From Baseline in Oxygen Saturation (SpO2) Measured Via Pulse Oxymetry at the Indicated Time Points\"\\n16422,1,1,\"Phase I: Change From Baseline in Weight at the Indicated Time Points\"\\n16423,1,1,\"Phase I: Definition of the Maximum Tolerated Dose (MTD) of Pazopanib in combination with Vinflunine.\"\\n16424,1,1,\"Phase I: Demonstrate safety and tolerability of LAE001/prednisone and afuresertib as combination therapy.\"\\n16425,1,1,\"Phase I: Determination of Maximum Tolerated Dose (MTD)/ Recommended phase two dose (RP2D) of [177Lu]-NeoB\"\\n16426,1,1,\"Phase I: Determination of the Maximum Tolerated Dose (MTD) and Recommended Dose (RD)\"\\n16427,1,1,\"Phase I: determine a phase II dose of Turalio\"\\n16428,1,1,\"Phase I: Determine recommended dose for phase II studies of CP-4055 when given five consecutive days twice in a 4 week schedule, D1-5 and D8(+2)-12(+2) q4w\"\\n16429,1,1,\"Phase I: Determine the dose-limiting toxicities (DLT) during the first 28-day cycle of SY-5007 treatment\"\\n16430,1,1,\"Phase I: Determine the maximum tolerated dose (MTD) of Z-208 in patients with advanced hepatocellular carcinoma\"\\n16431,1,1,\"Phase I: Determine the MTD/RP2D of EP0057 plus olaparib in patients with refractory cancers.\"\\n16432,1,1,\"Phase I: Determine the recommended Phase II dose (RP2D)\"\\n16433,1,1,\"Phase I: Dose limiting toxicities (DLT)\"\\n16434,1,1,\"Phase I: Dose Limiting Toxicity (DLT) of the combination treatment.\"\\n16435,3,2,\"Phase I: Dose-limiting toxicity (DLT)\"\\n16436,1,1,\"Phase I: Establish the maximum tolerated dose (MTD) to the oesophagus to use as the recommended Phase II dose.\"\\n16437,1,1,\"Phase I: Frequency and severity of Adverse Events (AEs),including incidence rate of DLTs\"\\n16438,1,1,\"Phase I: Half-life (t1/2) of GDC-0032\"\\n16439,1,1,\"Phase I: Incidence of dose limiting toxicities (DLTs) of [177Lu]-NeoB\"\\n16440,1,1,\"Phase I: Incidence of Dose-Limiting Toxicities (DLT) During Cycle 1\"\\n16441,1,1,\"Phase I: Incidence of dose-limiting toxicities (DLTs)\"\\n16442,1,1,\"Phase I: Laboratory abnormalities will be assessed according to NCI CTCAE v4\"\\n16443,1,1,\"Phase I: Maximum Observed Concentration (Cmax) of GDC-0032\"\\n16444,1,1,\"Phase I: Maximum observed plasma concentration(Cmax)\"\\n16445,1,1,\"Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride\"\\n16446,4,2,\"Phase I: Maximum Tolerated Dose\"\\n16447,12,3,\"Phase I: Maximum Tolerated Dose (MTD)\"\\n16448,1,1,\"Phase I: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs)\"\\n16449,1,1,\"Phase I: Maximum Tolerated Dose (MTD) and/or recommended phase II dose (RP2D)\"\\n16450,1,1,\"Phase I: Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D28) of Trabectedin when administered in association with CP\"\\n16451,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of Daily Oral Bortezomib\"\\n16452,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of Daily Oral Vandetanib\"\\n16453,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of Pazopanib and Liposomal Doxorubicin\"\\n16454,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX\"\\n16455,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of Pemetrexed\"\\n16456,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of Sirolimus\"\\n16457,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks.\"\\n16458,1,1,\"Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC)\"\\n16459,1,1,\"Phase I: Maximum Tolerated Dose of Cobimetinib\"\\n16460,1,1,\"Phase I: Maximum tolerated dose(MTD) (if any) and/or Recommended phases 2 dose (RP2D)\"\\n16461,1,1,\"Phase I: Minimum Observed Concentration (Cmin) of GDC-0032\"\\n16462,3,2,\"Phase I: MTD\"\\n16463,1,1,\"Phase I: Number and serious for Adverse Events (AEs)\"\\n16464,1,1,\"Phase I: Number of Participants Experiencing at Least One Dose-Limiting Toxicity (DLT) Adverse Event (AE) During the First Four Weeks of Dalotuzumab Plus Erlotinib Treatment\"\\n16465,1,1,\"Phase I: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs)\"\\n16466,1,1,\"Phase I: Number of Participants With a Dose-limiting Toxicity (DLT)\"\\n16467,1,1,\"Phase I: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Recommended Phase II Dose\"\\n16468,1,1,\"Phase I: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)\"\\n16469,2,1,\"Phase I: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n16470,1,1,\"Phase I: Number of Participants With Dose Reductions and Dose Interruption/Delays\"\\n16471,1,1,\"Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n16472,1,1,\"Phase I: Number of Participants With the Indicated Electrocardiogram (ECG) Findings at the Indicated Time Points\"\\n16473,1,1,\"Phase I: Number of Participants With the Indicated Urinalysis Parameters\"\\n16474,1,1,\"Phase I: Number of Participants With the Indicated Worst-case Change From Baseline (BL) in the Indicated Clinical Chemistry Parameters (CCPs)\"\\n16475,1,1,\"Phase I: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Hematology Parameters\"\\n16476,1,1,\"Phase I: Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance (Pef) Status\"\\n16477,1,1,\"Phase I: Number of participants with treatment-related adverse events as determined by CTCAE v4.0, dose-limiting toxicities, and laboratory abnormalities.\"\\n16478,1,1,\"Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Heart Rate\"\\n16479,1,1,\"Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Assessed by Echocardiogram (ECHO)\"\\n16480,1,1,\"Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Temperature\"\\n16481,1,1,\"Phase I: Number of Participants With Worst-case On-therapy Increase From Baseline in Systolic and Diastolic Blood Pressure to Grade 2 or Grade 3\"\\n16482,1,1,\"Phase I: Number of patients with adverse events and serious adverse events\"\\n16483,1,1,\"Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)\"\\n16484,1,1,\"Phase I: Objective Response Rate-Investigator Assessment\"\\n16485,1,1,\"Phase I: Percentage of Participants Responding to Treatment\"\\n16486,1,1,\"Phase I: Percentage of Participants With Dose-Limiting Toxicities (DLTs)\"\\n16487,1,1,\"Phase I: Plasma Concentration of GSK525762\"\\n16488,1,1,\"Phase I: Recommend Phase II Dose (RPDII)\"\\n16489,1,1,\"Phase I: Recommended Dose of Single-Agent GDC-0032\"\\n16490,1,1,\"Phase I: Recommended Phase II dose\"\\n16491,2,1,\"Phase I: Recommended Phase II Dose (RP2D)\"\\n16492,1,1,\"Phase I: Recommended Phase II Dose (RPTD) of the Combination of Sorafenib and GEMOX in Patients With Advanced Biliary Tract Cancer (BTC).\"\\n16493,1,1,\"Phase I: Recommended Phase II Dose of Cobimetinib when Combined with Atezolizumab\"\\n16494,1,1,\"Phase I: Safe Dose of Dasatinib When Given With Ganitumab in Participants With Relapsed or Refractory Embryonal or Alveolar Rhabdomyosarcoma (RMS)\"\\n16495,1,1,\"Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)\"\\n16496,1,1,\"Phase I: safety and tolerability (Serious adverse events, adverse events, dose-limiting toxicities, clinical laboratory data, vital signs, ECG, ECOG performance status)\"\\n16497,1,1,\"Phase I: Safety: Dose-limiting toxicity (DLT) incidence rate.\"\\n16498,1,1,\"Phase I: Safety: MTD and RP2D.\"\\n16499,1,1,\"Phase I: The adverse events (AEs)\"\\n16500,1,1,\"Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel\"\\n16501,1,1,\"Phase I: Time to Reach Cmax (tmax) of GDC-0032\"\\n16502,1,1,\"Phase I: To define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of T-Cell Receptor T cells\"\\n16503,1,1,\"Phase I: to determine the safety of 18 F-FLT.\"\\n16504,1,1,\"Phase I: to establish the recommended phase II dose (RP2D) of BCT-100 in children and young adults as assessed by dose limiting toxicity (DLT) and complete arginine depletion\"\\n16505,1,1,\"Phase I: Toxicity as measured by adverse events\"\\n16506,1,1,\"Phase I: Type, frequency, severity, seriousness and relatedness of adverse events\"\\n16507,1,1,\"Phase I:Number of participants with treatment-related adverse events assessed by NCI-CTCAE v4.03 Phase II: Objective response rate\"\\n16508,1,1,\"Phase I:To determine the recommended phase 2 doses (RP2Ds) of Onivyde combined with talazoparib (Arm A) and Onivyde combined with temozolomide (Arm B) administered to children, adolescents and young adults with refractory or recurrent solid malignancies.\"\\n16509,1,1,\"Phase Ia (Arm A): Number of Subjects Experiencing at Least one Dose-limiting Toxicity (DLT)\"\\n16510,1,1,\"Phase Ia (Arm B): Number of Subjects Experiencing at Least one DLT\"\\n16511,1,1,\"Phase Ia - maximum tolerated dose (MTD) of BI 907828 in combination with ezabenlimab based on the number of patients with dose limiting toxicities (DLTs) during the first treatment cycle\"\\n16512,1,1,\"Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B)\"\\n16513,1,1,\"Phase Ia and Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to Tiragolumab\"\\n16514,1,1,\"Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycle\"\\n16515,1,1,\"Phase Ia: Dose Limited Toxicity (DLT)\"\\n16516,9,8,\"Phase Ia: Dose limiting toxicity (DLT)\"\\n16517,1,1,\"Phase Ia: Maximum administered dose (MAD)\"\\n16518,2,2,\"Phase Ia: Maximum Tolerated Dose (MTD)\"\\n16519,9,8,\"Phase Ia: Maximum tolerated dose (MTD)\"\\n16520,1,1,\"Phase Ia: Maximum Tolerated Dose of GDC-0810 When Used as a Single Agent\"\\n16521,1,1,\"Phase Ia: Number of Participants with Dose Limiting Toxicities (DLTs)\"\\n16522,1,1,\"Phase Ia: Number of Participants with Treatment Emergent Adverse Events\"\\n16523,1,1,\"Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation period\"\\n16524,1,1,\"Phase Ia: RP2D of GDC-0810 When Used as a Single Agent\"\\n16525,1,1,\"Phase Ia: Treatment-Emergent Adverse Event (TEAE)\"\\n16526,1,1,\"Phase IaÔºöTo determine the maximum tolerated dose (MTD)\"\\n16527,1,1,\"Phase Ib (Arm A expansion Cohort): Number of subjects experiencing at least one DLT\"\\n16528,1,1,\"Phase Ib (Safety Evaluation): Dose Limiting Toxicity (DLT)\"\\n16529,1,1,\"Phase Ib (Safety Evaluation): Number of participants with adverse events\"\\n16530,1,1,\"Phase Ib - Cohort 3: Objective response according to RECIST 1.1 by investigator assessment\"\\n16531,1,1,\"Phase Ib - Cohorts 1 and 2 : Objective response (OR) as assessed by central independent review\"\\n16532,1,1,\"Phase Ib - Number of patients with DLTs during the first treatment cycle\"\\n16533,1,1,\"Phase Ib - Objective response (OR)\"\\n16534,1,1,\"Phase Ib - Progression free survival\"\\n16535,1,1,\"Phase Ib - Progression-free survival\"\\n16536,1,1,\"Phase Ib - Safety and Tolerability Tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib) by assessing the grade and frequency of adverse events and serious adverse events.\"\\n16537,1,1,\"Phase Ib : Maximum Tolerated Dose evaluated on the first cycle (D1 to D28) of the combination of JX-594 And metronomic cyclophosphamide\"\\n16538,1,1,\"Phase Ib and II: Progression Free Survival (PFS)\"\\n16539,1,1,\"Phase Ib part: incidence of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs) at Recommended Phase 2 Dose (RP2D)\"\\n16540,1,1,\"Phase Ib Portion: Response Rate (RR)\"\\n16541,1,1,\"Phase Ib Study: Number of Participants With Dose-Limiting Toxicities\"\\n16542,1,1,\"Phase Ib/II starting dose for ACE1702\"\\n16543,1,1,\"Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.\"\\n16544,1,1,\"Phase Ib: 2. The number of participants with treatment-related adverse events.\"\\n16545,1,1,\"Phase Ib: 3. The number of participants with treatment-related serious adverse events.\"\\n16546,1,1,\"Phase Ib: Determination of Recommended Phase II dose (RP2D) of Escalating Dose of M3814 in Combination With Cisplatin and Etoposide for the Phase II Part of the Study\"\\n16547,1,1,\"Phase Ib: Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs).\"\\n16548,1,1,\"Phase Ib: Determination of the safety and tolerability of DSP-7888 Dosing Emulsion given intradermally with a checkpoint inhibitor (Nivolumab or Pembrolizumab) in adult patients with advanced solid tumors by assessing dose-limiting toxicities (DLTs).\"\\n16549,1,1,\"Phase Ib: Dose Limiting Toxicities of Dose of Pazopanib and Fosbretabulin\"\\n16550,1,1,\"Phase Ib: Dose Limiting Toxicity and Recommended Phase II Dose\"\\n16551,1,1,\"Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen\"\\n16552,1,1,\"Phase Ib: Estimation of Maximum Tolerated Dose (MTD) by measuring incidence of dose limiting toxicities (DLT)\"\\n16553,1,1,\"Phase Ib: Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) by measuring incidence of dose limiting toxicities\"\\n16554,1,1,\"Phase Ib: Identification of Maximum Tolerated Dose (MTD)\"\\n16555,1,1,\"Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1\"\\n16556,1,1,\"Phase Ib: Incidence of dose-limiting toxicities (DLTs) of drug combination nanoliposomal-Irinotecan, 5-fluorouracil, leucovorin and nivolumab\"\\n16557,1,1,\"Phase Ib: Incidence of Treatment Related adverse events (AEs)\"\\n16558,1,1,\"Phase IB: Number and Severity of Grade 1-2 Adverse Events Possibly, Probably, or Definitely Related to Treatment\"\\n16559,1,1,\"Phase IB: Number and Severity of Grade 3-5 Adverse Events Possibly, Probably, or Definitely Related to Treatment\"\\n16560,1,1,\"Phase Ib: Number of Dose Interruptions Per Participant\"\\n16561,1,1,\"Phase Ib: Number of Participants with DLTs\"\\n16562,1,1,\"Phase Ib: Number of participants with dose limiting toxicities (DLTs)\"\\n16563,1,1,\"Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment\"\\n16564,1,1,\"Phase Ib: Number of Participants With Dose Reductions\"\\n16565,1,1,\"Phase Ib: Number of Participants with Treatment Emergent Adverse Events\"\\n16566,1,1,\"Phase Ib: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period.\"\\n16567,1,1,\"Phase Ib: Number of subjects experiencing treatment emergent adverse events (TEAEs)\"\\n16568,1,1,\"Phase Ib: Number of Subjects With at Least One Dose Interruption\"\\n16569,1,1,\"Phase Ib: Number of Subjects With Clinically Significant Vital signs, Electrocardiogram (ECG) and Laboratory Abnormalities\"\\n16570,1,1,\"Phase Ib: Overall Response (OR)\"\\n16571,1,1,\"Phase Ib: Patients With Event(s) of Dose-limiting Toxicity\"\\n16572,1,1,\"Phase Ib: Percentage of Participants with ADAs to Atezolizumab\"\\n16573,1,1,\"Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety\"\\n16574,1,1,\"Phase Ib: phase II clinical studies (RP2D)\"\\n16575,1,1,\"Phase Ib: Phase II clinical study recommended dose (RP2D)\"\\n16576,1,1,\"Phase Ib: Planned Dose Intensity - MCS110\"\\n16577,1,1,\"Phase Ib: Planned Dose Intensity - PDR001\"\\n16578,1,1,\"Phase Ib: Recommended Dose for Phase II Clinical Studies (RP2D)\"\\n16579,9,6,\"Phase Ib: Recommended Phase II Dose (RP2D)\"\\n16580,1,1,\"Phase Ib: Relative Dose Intensity - MCS110\"\\n16581,1,1,\"Phase Ib: Relative Dose Intensity - PDR001\"\\n16582,1,1,\"Phase Ib: RP2D of GDC-0810 When Used in Combination With Palbociclib and/or LHRH\"\\n16583,1,1,\"Phase Ib: Safety and Tolerance\"\\n16584,1,1,\"Phase Ib: To evaluate the safety and tolerability of the combination of TG4001 plus avelumab in patients with recurrent or metastatic HPV-16 positive advanced malignancies\"\\n16585,1,1,\"Phase IbÔºöIncidence of dose-limiting toxicity (DLT) events\"\\n16586,1,1,\"PHASE II (7cohorts A, C, D, E, F and G) : Assessment of the antitumor activity of regorafenib\"\\n16587,1,1,\"Phase II (cohort A\\'): Assessment of the antitumor activity of regorafenib\"\\n16588,1,1,\"Phase II (cohorts B, H, I, M, N, O and P): Assessment of the antitumor activity of regorafenib\"\\n16589,1,1,\"Phase II (Efficacy Expansion): Objective response rate (ORR)\"\\n16590,1,1,\"Phase II - Antitumor effect\"\\n16591,1,1,\"Phase II - Assess 6 month local control rate of patients with pathogenic ATM who received RP-3500 and palliative RT\"\\n16592,1,1,\"Phase II - Disease Control Rate at 4 Months\"\\n16593,1,1,\"Phase II - Efficacy (Disease Response Rate)\"\\n16594,1,1,\"Phase II - Number of Participants With Overall Response (OR)\"\\n16595,1,1,\"Phase II - Percent of Participants With Desired Response\"\\n16596,1,1,\"Phase II - Radiographic Response\"\\n16597,1,1,\"Phase II - The Overall Response Rate (ORR) rate of BLU-451\"\\n16598,1,1,\"Phase II 2-year Progression-free Survival\"\\n16599,1,1,\"Phase II : Advanced Breast cancer: Assessment of the antitumor activity of avelumab in combination with IT JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment following RECIST v1.1 criteria\"\\n16600,1,1,\"Phase II : Advanced Breast cancer: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment (CR or PR) following RECIST v1.1 criteria\"\\n16601,1,1,\"Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of Avelumab in combination with IT JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria\"\\n16602,1,1,\"Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria\"\\n16603,1,1,\"Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n16604,1,1,\"Phase II : Bayesian Inference of Overall Response Rate (ORR) - Per RECIST v1.1 - Mean\"\\n16605,1,1,\"Phase II : Number of patients that do not progress according to RECIST v1.1\"\\n16606,1,1,\"Phase II : Overall Response Rate (ORR) - Per RECIST v1.1\"\\n16607,1,1,\"Phase II best response\"\\n16608,1,1,\"Phase II best response per Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n16609,1,1,\"Phase II clinical recommended dose (RP2D)\"\\n16610,6,4,\"Phase II dose (RP2D)\"\\n16611,1,1,\"Phase II Dose Expansion: Number of participants with preliminary antitumor activity based on objective response rate and disease control rate.\"\\n16612,1,1,\"Phase II dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when administered in combination with a standard dose of docetaxel (Phase 1)\"\\n16613,1,1,\"Phase II dose of MM-151 alone and in combination with irinotecan based either on the maximum tolerated dose (MTD) or maximum dose of 18 mg/kg in patients with advanced solid malignancies.\"\\n16614,1,1,\"Phase II dose will be defined as the lowest dose at or below the maximum tolerated dose (MTD; based on dose limiting toxicity) consistent with a plateau reduction in DNA methylation in target tumor tissue\"\\n16615,1,1,\"Phase II expansion: Best overall tumour response\"\\n16616,1,1,\"Phase II Group 1, 2 and 3: Overall Response Rate per RECIST 1.1\"\\n16617,1,1,\"Phase II Group 4: Dose intensity\"\\n16618,1,1,\"Phase II Group 4: Number of participants with Adverse Events (AEs) and Serious AEs (SAEs)\"\\n16619,1,1,\"Phase II Group 4: Number of participants with dose modifications\"\\n16620,1,1,\"Phase II Group 5: ORR per RECIST 1.1 based on investigator\\'s assessment of INC280 monotherapy\"\\n16621,1,1,\"Phase II Overall Response\"\\n16622,1,1,\"Phase II part 1: Overall Response Rate (ORR) by RECIST 1.1\"\\n16623,1,1,\"Phase II part 2: Progression Free Survival (PFS) by RECISIT 1.1\"\\n16624,1,1,\"Phase II part: mRECIST overall response at 6 weeks after TAE/TACE treatment.\"\\n16625,1,1,\"Phase II part: T-ACE Oil or Lipiodol deposition type on CT scan after TAE/TACE treatment.\"\\n16626,1,1,\"Phase II part: target lesion response at 6 weeks after TAE/TACE treatment.\"\\n16627,1,1,\"Phase II recommended combination dose per Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.03\"\\n16628,1,1,\"Phase II recommended dose\"\\n16629,1,1,\"phase II recommended dose\"\\n16630,1,1,\"Phase II recommended dose (RP2D).\"\\n16631,1,1,\"Phase II recommended dose(RP2D)\"\\n16632,1,1,\"Phase II Resolution of MPE\"\\n16633,1,1,\"Phase II Step: Objective Tumour Response According to Response Evaluation Criteria in Solid Tumours (RECIST)\"\\n16634,1,1,\"Phase II- ORR as assessed by BIRC\"\\n16635,1,1,\"Phase II- Overall Response Rate (ORR)\"\\n16636,1,1,\"Phase II: Antitumor activity of MEK162 in combination with AMG 479 by evaluating Objective Response Rate (ORR) in colorectal carcinoma and melanoma and by evaluating Disease Control Rate (DCR) at week 10 in pancreatic carcinoma\"\\n16637,1,1,\"Phase II: Assessment of the antitumor activity of the association of Trabectedin and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria\"\\n16638,1,1,\"Phase II: Bayesian Inference of Clinical Benefit Rate - Per RECIST v1.1- Mean\"\\n16639,1,1,\"Phase II: Best response (CR or PR)\"\\n16640,1,1,\"Phase II: Bevacizumab plus dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin as first-line treatment leads to an improved response rate in patients with metastatic colorectal cancer\"\\n16641,1,1,\"Phase II: Clinical benefit rate\"\\n16642,1,1,\"Phase II: Clinical benefit rate (CBR) of treatment combination\"\\n16643,1,1,\"Phase II: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) > 4 Month)) - Per RECIST v1.1\"\\n16644,1,1,\"Phase II: Clinical efficacy\"\\n16645,1,1,\"Phase II: Clinical Response Rate\"\\n16646,1,1,\"Phase II: Determine the antitumour activity of CP-4055\"\\n16647,1,1,\"Phase II: Determine the overall response rate to therapy with ribavirin\"\\n16648,1,1,\"Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.\"\\n16649,1,1,\"Phase II: Disease Assessment for Progression-Free Survival (PFS)\"\\n16650,1,1,\"Phase II: Efficacy - Rate of non progression at the end of treatment (C6D21).\"\\n16651,1,1,\"Phase II: Evaluation of the preliminary antitumor activity of DSP-7888 Dosing Emulsion administered with pembrolizumab in terms of Objective Response Rate (ORR) in patients with platinum-resistant ovarian cancer (PROC).\"\\n16652,1,1,\"Phase II: Incidence of Adverse Events as characterized by type, frequency, severity (NCI CTCAE Version 5.0), timing, seriousness, and relationship to study therapy.\"\\n16653,1,1,\"Phase II: Investigation of the anti-cancer activity of L19TNFŒ± as measured by Objective Response Rate (ORR)\"\\n16654,1,1,\"Phase II: Median Progression Free Survival (PFS) in Participants Receiving Dalotuzumab Plus Erlotinib Treatment\"\\n16655,1,1,\"Phase II: Median Progression-Free Survival (PFS)\"\\n16656,1,1,\"Phase II: Number of Participant With Confirmed Overall Response\"\\n16657,1,1,\"Phase II: Number of Participants That is Without Progression at 4 Months\"\\n16658,1,1,\"Phase II: Number of Participants Who Experience an Objective Clinical Response (CR or PR) When Treated With Ganitumab Plus Dasatinib\"\\n16659,1,1,\"Phase II: Number of Participants With a Best Overall Response (BOR)\"\\n16660,1,1,\"Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n16661,3,1,\"Phase II: Objective Response Rate\"\\n16662,6,3,\"Phase II: Objective Response Rate (ORR)\"\\n16663,1,1,\"Phase II: Objective Response Rate (ORR) Assessed by Investigator Based on RECIST Version 1.1\"\\n16664,1,1,\"Phase II: Objective response rate (ORR) by BIRC assessment\"\\n16665,1,1,\"Phase II: Objective response rate (ORR) evaluated by Investigator assessments using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\"\\n16666,1,1,\"Phase II: Objective response rate (ORR): Defined as the rate of complete responses [CR] or partial responses [PR] per RECIST Version 1.1 as assessed by an independent central review\"\\n16667,1,1,\"Phase II: Objective response rate by RECIST v1.1\"\\n16668,1,1,\"Phase II: Objective response rate(ORR)\"\\n16669,1,1,\"Phase II: Objective tumour response rate (ORR) using RECIST v1.1.\"\\n16670,1,1,\"Phase II: Obtain an Estimate of the 9-month Progression-free Survival Rate in Patients With Advanced BTC Receiving the RPTD of the Combination Sorafenib and GEMOX.\"\\n16671,3,2,\"Phase II: ORR\"\\n16672,1,1,\"Phase II: ORR (Objective Response Rate)\"\\n16673,4,1,\"Phase II: Overall Response Rate\"\\n16674,2,1,\"Phase II: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria\"\\n16675,1,1,\"Phase II: Overall Response Rate (ORR) based on RECIST 1.1\"\\n16676,1,1,\"Phase II: Overall response rate (ORR) per RECIST 1.1\"\\n16677,1,1,\"Phase II: Overall Survival\"\\n16678,1,1,\"Phase II: Percentage of Participants With Clinical Benefit, as Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1\"\\n16679,1,1,\"Phase II: Percentage of Participants With Objective Response Rate (ORR) Measured Using RECIST 1.0 Criteria\"\\n16680,1,1,\"Phase II: Percentage of Participants With Objective Response, as Assessed Using RECIST Version 1.1\"\\n16681,1,1,\"Phase II: PFS (Progression Free survival) rate\"\\n16682,1,1,\"Phase II: preliminary antitumor activity\"\\n16683,1,1,\"Phase II: Preliminary antitumor activity of the combination of varlilumab and nivolumab as measured by objective response rate (ORR) in patients with CRC, ovarian cancer, RCC and SCCHN and Overall Survival-12 months in GBM.\"\\n16684,2,1,\"Phase II: Progression Free Survival\"\\n16685,5,3,\"Phase II: Progression Free Survival (PFS)\"\\n16686,1,1,\"Phase II: Progression Free Survival (PFS) as Assessed by the Investigator according to RECIST v1.1\"\\n16687,1,1,\"Phase II: Progression-free rate (PFR)\"\\n16688,1,1,\"Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician\\'s Choice\"\\n16689,1,1,\"Phase II: Progression-free Survival at 1 Year\"\\n16690,1,1,\"Phase II: Progression-free survival rate\"\\n16691,1,1,\"Phase II: Progression-free-survival (PFS) Were Analyzed in Patients Treated With AZD8931 in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone\"\\n16692,1,1,\"Phase II: Progressive disease\"\\n16693,1,1,\"Phase II: Radiological progression free survival (rPFS) based changes per Prostate Cancer Working Group 3 (PCWG3)\"\\n16694,1,1,\"Phase II: Radiological progression free survival (rPFS) based on change in tumor per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n16695,1,1,\"Phase II: Stratum-specific Objective Response (CR+PR) Rate\"\\n16696,1,1,\"Phase II: the objective response rate (ORR)\"\\n16697,1,1,\"Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC)\"\\n16698,1,1,\"Phase II: Time to progression (TTP2)\"\\n16699,1,1,\"Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores.\"\\n16700,1,1,\"Phase II: to determine the activity of single agent BCT-100 against relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade glioma in children and young adults as measured by disease response after 8 weeks.\"\\n16701,1,1,\"Phase II: Tolerance - Percentage of patients for whom at least one of the 3 defined tolerance criteria (see description) is observed.\"\\n16702,1,1,\"Phase II: Toxicity rate (grade 3 and 4) at three months.\"\\n16703,1,1,\"Phase II:To estimate the progression-free survival (PFS) of Onivyde plus talazoparib and Onivyde plus temozolomide in patients with refractory or recurrent Ewing sarcoma.\"\\n16704,1,1,\"Phase IIa (Cohort D): Absorbed radiation doses of [177Lu]-NeoB in organs and tumor lesions\"\\n16705,1,1,\"Phase IIa (Cohort D): Concentration of [177Lu]-NeoB in blood over time and derived PK parameters\"\\n16706,1,1,\"Phase IIa (Cohorts A, B and C): Disease Control Rate (DCR)\"\\n16707,1,1,\"Phase IIa (except Soft Tissue Sarcoma cohort): Immune Overall Response Rate (iORR) by iRECIST\"\\n16708,1,1,\"Phase IIa (Soft Tissue Sarcoma cohort): Immune Disease Control Rate (iDCR) at 6 months by iRECIST\"\\n16709,1,1,\"Phase IIa study:\"\\n16710,1,1,\"Phase IIa: Percentage of Participants With Clinical Benefit Response of GDC-0810 According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n16711,1,1,\"Phase IIa: Percentage of Participants With Confirmed Objective Tumor Response of GDC-0810 According to RECIST v1.1\"\\n16712,1,1,\"Phase III: 1. Progression Free Survival (PFS).\"\\n16713,1,1,\"Phase III: Overall survival (in months).\"\\n16714,1,1,\"Phase IÔºöIncidence of dose limiting toxicity (DLT) events\"\\n16715,1,1,\"Phase IÔºöIncidence of dose-limiting toxicity (DLT) events\"\\n16716,1,1,\"Phase l: Incidence of Dose Limiting Toxicities (DLTs)\"\\n16717,1,1,\"Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days)\"\\n16718,1,1,\"Phase ll: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\"\\n16719,1,1,\"Phase1 and 2: Evaluation of Safety profile of PEP503\"\\n16720,1,1,\"Phase1/1B: Number of patients who experience a treatment-related adverse event\"\\n16721,1,1,\"Phase1a: Number of Participants With LY3415244 Dose-Limiting Toxicities (DLTs)\"\\n16722,1,1,\"Phase2\"\\n16723,1,1,\"PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1\"\\n16724,1,1,\"Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs\"\\n16725,1,1,\"Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n16726,1,1,\"Phases 1 and 2: Objective Response Rate (ORR)\"\\n16727,1,1,\"Phases Ia and Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]\"\\n16728,1,1,\"Phospho-Cyclin-Dependent Kinase 2 (pCdk2) Levels in Fresh Tumor\"\\n16729,1,1,\"Phospho-Cyclin-Dependent Kinase 2 (pCdk2) Levels in Skin Tissue\"\\n16730,1,1,\"Phosphorylated or total STAT3 expression levels\"\\n16731,1,1,\"Phosphorylation level of ERK protein (pERK) in tumor tissues [Part B]\"\\n16732,133,2,\"Physical activity\"\\n16733,1,1,\"Physical Activity (PA) Assessment\"\\n16734,1,1,\"Physical decline - prehension force\"\\n16735,1,1,\"Physical decline - walking speed\"\\n16736,5,1,\"Physical exam\"\\n16737,1,1,\"Physical Exam (Safety and Tolerability in the Dose Escalation Phase)\"\\n16738,39,1,\"Physical examination\"\\n16739,1,1,\"physical examination abnormalities\"\\n16740,2,1,\"Physical Examinations\"\\n16741,10,1,\"Physical examinations\"\\n16742,1,1,\"physical examinations changes from baseline\"\\n16743,1,1,\"physical function for patients receiving palliative oncologic treatment\"\\n16744,1,1,\"Physical function numerical rating scale (NRS) scores\"\\n16745,1,1,\"Physical health (patient-reported health-related quality of life)\"\\n16746,2,1,\"Physical intimacy\"\\n16747,1,1,\"Physician\\'s Global Assessment of Disease Activity at Visit 1\"\\n16748,1,1,\"Physiologic cost index (PCI)\"\\n16749,1,1,\"Physiological mechanism behind proteinuria and hypertension induced by antiangiogenic therapies\"\\n16750,3,1,\"Physiological parameters\"\\n16751,1,1,\"Physiological parameters (Laboratory evaluations)\"\\n16752,1,1,\"Pilot Phase: Tumour Levels of Irinotecan and SN-38 at Cycle 1 Day 4\"\\n16753,1,1,\"Pivotal Part: Confirmed objective response rate (cORR)\"\\n16754,1,1,\"PJP diagnosis rate\"\\n16755,1,1,\"PK - Area under the concentration-time curve (AUClast)\"\\n16756,1,1,\"PK - Half-life (T1/2)\"\\n16757,1,1,\"PK - Maximum peak plasma concentration (Cmax)\"\\n16758,1,1,\"PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)\"\\n16759,1,1,\"PK characterization - Cmax\"\\n16760,1,1,\"PK characterization - tmax\"\\n16761,1,1,\"PK data, AEs, changes in laboratory values and vital signs, physical exam, clinical testing and PD data\"\\n16762,1,1,\"PK evaluation of area under the plasma concentration versus time curve (AUC) of LP-118\"\\n16763,1,1,\"PK evaluation of peak plasma concentration (Cmax) of LP-118\"\\n16764,1,1,\"PK evaluation of time to maximum concentration (Tmax) of LP-118\"\\n16765,1,1,\"PK for REGN2810 Area under the curve (AUC2w)\"\\n16766,1,1,\"PK for REGN2810 Concentration at end of infusion (Ceoi)\"\\n16767,1,1,\"PK for REGN2810 estimated Observed terminal half-life (t1/2)\"\\n16768,1,1,\"PK measure of sorafenib\"\\n16769,1,1,\"PK measures of Sorafenib\"\\n16770,1,1,\"PK of ASP1948 in serum: AUC from the time of dosing extrapolated to time infinity (AUCinf)\"\\n16771,1,1,\"PK of ASP1948 in serum: AUC from the time of dosing to the start of next dosing interval (AUCtau)\"\\n16772,1,1,\"PK of ASP1948 in serum: concentration immediately prior to dosing at multiple dosing (Ctrough)\"\\n16773,1,1,\"PK of ASP1948 in serum: dosing time of maximum concentration (tmax)\"\\n16774,1,1,\"PK of ASP1948 in serum: maximum concentration (Cmax)\"\\n16775,1,1,\"PK of ASP1948 in serum: Percentage of AUCinf due to extrapolation from the last measurable concentration to time infinity (AUCinf(%extrap))\"\\n16776,1,1,\"PK of ASP1948 in serum: time of last measurable concentration (tlast)\"\\n16777,1,1,\"PK of ASP1948 in serum: total clearance after intravenous dosing (CL)\"\\n16778,1,1,\"PK of ASP1948 in serum: volume of distribution after intravenous dosing (V)\"\\n16779,1,1,\"PK of ASP1948 in serum:dosing: terminal elimination half-life (t1/2)\"\\n16780,1,1,\"PK of ASP8374 in serum: AUCinf\"\\n16781,1,1,\"PK of ASP8374 in serum: AUCinf(%extrap)\"\\n16782,1,1,\"PK of ASP8374 in serum: AUCtau\"\\n16783,1,1,\"PK of ASP8374 in serum: CL\"\\n16784,1,1,\"PK of ASP8374 in serum: Cmax\"\\n16785,1,1,\"PK of ASP8374 in serum: Ctrough\"\\n16786,1,1,\"PK of ASP8374 in serum: t1/2\"\\n16787,1,1,\"PK of ASP8374 in serum: tlast\"\\n16788,1,1,\"PK of ASP8374 in serum: tmax\"\\n16789,1,1,\"PK of ASP8374 in serum: Vss\"\\n16790,1,1,\"PK of ASP8374 in serum: Vz\"\\n16791,2,2,\"PK outcome: Cmax of ONO-4538\"\\n16792,1,1,\"PK outcome: Tmax of ONO-4538\"\\n16793,2,1,\"PK parameter\"\\n16794,1,1,\"PK parameter (area under the plasma concentration-time curve from time zero to Tlast [AUClast]) for binimetinib\"\\n16795,1,1,\"PK parameter (AUClast) for AR00426032\"\\n16796,1,1,\"PK parameter (AUClast) for encorafenib\"\\n16797,1,1,\"PK parameter (AUClast) for LHY746\"\\n16798,1,1,\"PK parameter (Cmax) for AR00426032\"\\n16799,1,1,\"PK parameter (Cmax) for binimetinib\"\\n16800,1,1,\"PK parameter (Cmax) for encorafenib\"\\n16801,1,1,\"PK parameter (Cmax) for LHY746\"\\n16802,1,1,\"PK parameter (Ctrough) for AR00426032\"\\n16803,1,1,\"PK parameter (Ctrough) for encorafenib\"\\n16804,1,1,\"PK parameter (Ctrough) for LHY746\"\\n16805,1,1,\"PK parameter (time of last PK sample [Tlast]) for binimetinib\"\\n16806,1,1,\"PK parameter (Tlast) for AR00426032\"\\n16807,1,1,\"PK parameter (Tlast) for encorafenib\"\\n16808,1,1,\"PK parameter (Tlast) for LHY746\"\\n16809,1,1,\"PK parameter (Tmax) for binimetinib\\'s active metabolite (AR00426032)\"\\n16810,1,1,\"PK parameter (Tmax) for encorafenib\"\\n16811,1,1,\"PK parameter (Tmax) for encorafenib\\'s metabolite (LHY746)\"\\n16812,1,1,\"PK parameter (trough concentration [Ctrough]) for binimetinib\"\\n16813,1,1,\"PK parameter - Maximum concentration (Cmax) (Cohorts D and E)\"\\n16814,1,1,\"PK parameter - Time to maximum concentration (Tmax) (Cohorts D and E)\"\\n16815,1,1,\"PK parameter - Trough concentration (Ctrough) (Cohorts D and E)\"\\n16816,1,1,\"PK parameter AUCinf for bupropion\"\\n16817,1,1,\"PK parameter AUCinf for S- and R-warfarin\"\\n16818,1,1,\"PK parameter AUClast for bupropion\"\\n16819,1,1,\"PK parameter Cmax for S- and R-warfarin\"\\n16820,1,1,\"PK Parameter: AUC_0-168 of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy\"\\n16821,1,1,\"PK Parameter: AUC_last of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy\"\\n16822,1,1,\"PK Parameter: Cmax of Free SN-38, SN-38 Glucuronide, Total SN-38, and Sacituzumab Govitecan-hziy\"\\n16823,13,1,\"PK parameters\"\\n16824,2,2,\"PK parameters after doses of GDC-0980\"\\n16825,1,1,\"PK parameters after single and multiple doses of GDC-0068\"\\n16826,1,1,\"PK parameters after single and multiple doses of GDC-0941\"\\n16827,1,1,\"PK Parameters After the First Dose: Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-‚àû] for T-DM1 Concentrations\"\\n16828,1,1,\"PK Parameters After the First Dose: Terminal Half-life (t¬Ω) for T-DM1 Concentrations\"\\n16829,1,1,\"PK parameters Cmax for bupropion\"\\n16830,1,1,\"PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data\"\\n16831,1,1,\"PK parameters for oral rosuvastatin, ethinylestradiol and levonorgestrel without and with rucaparib treatment.\"\\n16832,1,1,\"PK parameters of CKD-516 and its metabolite, S516, when CKD-516 administered on Days 1 and 8 of a 21-day cycle\"\\n16833,1,1,\"PK parameters of FTD, FTY, and TPI in plasma (Cmax, Tmax, AUC0-last, AUC0-inf, T1/2, CL/F, and Vd/F)\"\\n16834,2,2,\"PK parameters of FTD, FTY, and TPI in plasma after a single dose of TAS-102\"\\n16835,1,1,\"PK parameters of genakumab: accumulation ratio\"\\n16836,1,1,\"PK parameters of genakumab: area under time-concentration curve (AUC)\"\\n16837,1,1,\"PK parameters of genakumab: bioavailability\"\\n16838,1,1,\"PK parameters of genakumab: peak concentration (Cmax)\"\\n16839,1,1,\"PK parameters of genakumab: steady-state peak concentration\"\\n16840,1,1,\"PK parameters of genakumab: steady-state trough concentration\"\\n16841,1,1,\"PK parameters of genakumab: t1/2\"\\n16842,1,1,\"PK parameters of icotinib hydrochloride\"\\n16843,1,1,\"PK parameters of probe drugs; AUC from time zero to infinity (AUC‚àû)\"\\n16844,1,1,\"PK parameters of probe drugs; AUC from time zero to the last data point (AUC-last)\"\\n16845,1,1,\"PK parameters of probe drugs; C-max\"\\n16846,1,1,\"PK parameters of total radioactivity (AUC0-inf, AUC0-last, Cmax, Tmax, and T1/2) in whole blood and plasma after a single dose of TAS-102\"\\n16847,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): AUC (0-24h)\"\\n16848,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): AUC(0-24h)\"\\n16849,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): Cavg.ss\"\\n16850,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): Cmax\"\\n16851,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): Cmax.ss\"\\n16852,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): Cmin.ss\"\\n16853,1,1,\"PK parameters of trametinib following single and repeat dose(2mg QD): Tmax\"\\n16854,1,1,\"PK parameters of veliparib\"\\n16855,1,1,\"PK Phase Primary Outcome: To determine the comparative bioavailability of a new tablet formulation of AZD2281 compared to the existing capsule formulation\"\\n16856,1,1,\"PK Profile of Rucaparib - AUC Last (Part 1)\"\\n16857,1,1,\"PK Profile of Rucaparib - Cmax (Part 1)\"\\n16858,1,1,\"PK Profile of Rucaparib - Tmax (Part 1)\"\\n16859,1,1,\"PK profile: AMG 900 PK parameters including, but not limited to, maximum observed concentration (Cmax), minimum observed concentration, area under the plasma concentration-time curve and, if feasible, half-life\"\\n16860,1,1,\"PK Profile: MLN8237 concentrations in plasma samples\"\\n16861,1,1,\"PK study of AND019\"\\n16862,1,1,\"PK testing levels of gemcitabine, its metabolite difluorodeoxyuridine (dFdU), and gemcitabine necleotides in peripheral blood and DIPG tissue\"\\n16863,1,1,\"PK- Apparent Total Volume of Distribution (Vz/F)\"\\n16864,1,1,\"PK- terminal half-life; t1/2\"\\n16865,2,1,\"PK-Apparent total body clearance (CL/F)\"\\n16866,2,1,\"PK-Area under the plasma concentration time curve (AUC)\"\\n16867,1,1,\"PK-dose Proportionality as Assessed With AUC of GDC-0575\"\\n16868,1,1,\"PK-dose Proportionality as Assessed With Cmax of GDC-0575\"\\n16869,1,1,\"PK-Time to maximal plasma concentration (Tmax)\"\\n16870,1,1,\"PK: Area Under Concentration Versus Time Curve During One Dosing Interval (AUCtau)\"\\n16871,1,1,\"PK: Area Under Concentration-Time Curve From Zero to Time 168 (AUC[-168]) of Necitumumab\"\\n16872,1,1,\"PK: Area Under the Concentration-Time Curve From Time 0 to 336 h Postdose [AUC(0-336)] of Necitumumab After Multiple Doses\"\\n16873,1,1,\"PK: Area Under the Concentration-Time Curve From Time 0 to Infinity [AUC(0-‚àû)] of Necitumumab After a Single Dose\"\\n16874,1,1,\"PK: Area Under the Concentration-Time Curve From Time 0 to Last Time Point [AUC (0-tlast)] of Necitumumab After a Single Dose\"\\n16875,1,1,\"PK: Area Under the Curve From Zero to Infinity AUC(0-‚àû)\"\\n16876,1,1,\"PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, (AUC[0-‚àû]) of Necitumumab\"\\n16877,1,1,\"PK: Average Concentration During a Dosing Interval at Steady State (Cav,ss) of Enzastaurin, It\\'s Metabolites and Total Analytes in Plasma\"\\n16878,1,1,\"PK: CL of Necitumumab After Multiple Doses\"\\n16879,1,1,\"PK: Clearance (CL) of Necitumumab After a Single Dose\"\\n16880,1,1,\"PK: Cmax of Necitumumab After Multiple Doses\"\\n16881,1,1,\"PK: Cmin of Necitumumab After Multiple Doses\"\\n16882,1,1,\"PK: Dose Normalized AUC(0-‚àû) of Gemcitabine\"\\n16883,1,1,\"PK: Dose-Normalized AUC(0-24) of Gemcitabine\"\\n16884,1,1,\"PK: Dose-Normalized AUC(0-5) of Cisplatin\"\\n16885,1,1,\"PK: Dose-Normalized Cmax of Cisplatin\"\\n16886,1,1,\"PK: Dose-Normalized Cmax of Gemcitabine\"\\n16887,1,1,\"PK: Half-Life (t¬Ω) of Necitumumab After a Single Dose\"\\n16888,1,1,\"PK: Maximum Concentration (Cmax) Doxorubicin\"\\n16889,2,1,\"PK: Maximum Concentration (Cmax) of Ramucirumab\"\\n16890,1,1,\"PK: Maximum Observed Drug Concentration at Steady State (Cmax,ss) of Enzastaurin, It\\'s Metabolites and Total Analytes in Plasma\"\\n16891,1,1,\"PK: Mean Steady State Concentrations of Irinotecan\"\\n16892,1,1,\"PK: Mean Steady State Concentrations of Temozolomide\"\\n16893,1,1,\"PK: Minimum Concentration (Cmin) of Necitumumab After a Single Dose\"\\n16894,1,1,\"PK: Serum Trough Concentration (Ctrough) of Ramucirumab\"\\n16895,1,1,\"PK: Steady-State Volume of Distribution (Vss) of Necitumumab After Single Dose\"\\n16896,1,1,\"PK: Terminal Elimination Half-Life of Enzastaurin, It\\'s Metabolites and Total Analytes in Plasma\"\\n16897,1,1,\"PK: Time of Maximal Plasma Concentration at Steady State (Tmax, ss) of Enzastaurin, It\\'s Metabolites and Total Analytes in Plasma\"\\n16898,1,1,\"PK: t¬Ω of Necitumumab After Multiple Doses\"\\n16899,1,1,\"PK: Vss of Necitumumab After Multiple Doses\"\\n16900,1,1,\"Plaque index in percentages\"\\n16901,1,1,\"Plasma 14C-labeled RO5185426 and 14C-labeled Metabolite Levels\"\\n16902,1,1,\"Plasma and urine concentrations of belinostat will be measured\"\\n16903,1,1,\"Plasma Apparent Elimination Rate Constant of Idasanutlin Metabolite\"\\n16904,1,1,\"Plasma Apparent Elimination Rate Constant of Unlabeled Idasanutlin\"\\n16905,1,1,\"Plasma area under the curve (AUC) for F2 formulation alone or in combination with omeprazole\"\\n16906,1,1,\"Plasma area under the curve (AUC) of AFP464\"\\n16907,1,1,\"Plasma AZD9833 concentrations and derived PK parameters.\"\\n16908,1,1,\"Plasma b-FGF Level Response\"\\n16909,1,1,\"Plasma Clearance (CL) of Concentration of Paclitaxel in Cycle 1 (in the Absence of T-DM1) and Cycle 2 (in the Presence of T-DM1)\"\\n16910,3,1,\"Plasma Concentration\"\\n16911,2,2,\"Plasma concentration (Cmax)\"\\n16912,1,1,\"Plasma concentration and pharmacodynamic effects of warfarin\"\\n16913,1,1,\"Plasma Concentration at Steady State (Css) for Total and Unbound GDC-0449\"\\n16914,1,1,\"Plasma Concentration of Abemaciclib at Specified Timepoints\"\\n16915,1,1,\"Plasma Concentration of Alectinib\"\\n16916,1,1,\"Plasma Concentration of Alectinib Metabolite (M4)\"\\n16917,1,1,\"Plasma concentration of BAY1161909 characterized by Cmax\"\\n16918,1,1,\"Plasma concentration of BAY86-9766\"\\n16919,1,1,\"Plasma concentration of D-1553 as a single agent or in combination with other therapies in subjects wiht advanced or metastatic solid tumors with KRas G12C mutation.\"\\n16920,1,1,\"Plasma concentration of dFdU\"\\n16921,1,1,\"Plasma Concentration of GDC-1971\"\\n16922,1,1,\"Plasma concentration of Gemcitabine\"\\n16923,1,1,\"Plasma Concentration of Giredestrant at Specified Timepoints\"\\n16924,1,1,\"Plasma Concentration of Inavolisib at Specified Timepoints\"\\n16925,1,1,\"Plasma Concentration of Ipatasertib at Specified Timepoints\"\\n16926,1,1,\"Plasma concentration of M17 and M11\"\\n16927,1,1,\"Plasma Concentration of MK-1775 at 8 Hours After Administration (C8hr) of Single or Multiple Oral Doses\"\\n16928,1,1,\"Plasma concentration of Paclitaxel characterized by Cmax\"\\n16929,1,1,\"Plasma Concentration of Palbociclib at Specified Timepoints\"\\n16930,1,1,\"Plasma Concentration of Ribociclib at Specified Timepoints\"\\n16931,1,1,\"Plasma Concentration of Samuraciclib at Specified Timepoints\"\\n16932,1,1,\"Plasma concentration-time levels of KRN5500 as determined by reversed-phase high-performance liquid chromatography with electrospray ionization mass spectrometric detection\"\\n16933,1,1,\"Plasma concentration-time profile of BMS-214662 when given as a continuous IV infusion escalating to 24 hr\"\\n16934,1,1,\"Plasma Concentrations of [14C] Pimasertib\"\\n16935,1,1,\"Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib\"\\n16936,1,1,\"Plasma concentrations of LUNA18 [Part A]\"\\n16937,1,1,\"Plasma Concentrations of Pimasertib Metabolites\"\\n16938,1,1,\"Plasma concentrations of suramin of 10-20 uM (Phase I)\"\\n16939,35,1,\"Plasma Decay Half-Life (t1/2)\"\\n16940,1,1,\"Plasma Decay Half-Life (t1/2) For Dextrorphan 3 Days Prior to PF-00299804 Dosing\"\\n16941,1,1,\"Plasma Decay Half-Life (t1/2) For Dextrorphan on Cycle 2 Day 7\"\\n16942,1,1,\"Plasma Decay Half-Life (t1/2) of Carboplatin\"\\n16943,1,1,\"Plasma Decay Half-Life (t1/2) of S,R-TLC388\"\\n16944,1,1,\"Plasma Decay Half-Life (t1/2) of S,S-TLC388\"\\n16945,1,1,\"Plasma Decay Half-Life (t1/2) of TLC-U1\"\\n16946,1,1,\"Plasma Decay Half-Life (t1/2) of TLC-U2\"\\n16947,1,1,\"Plasma Decay Half-Life (t1/2) of Topotecan\"\\n16948,1,1,\"Plasma Elimination Half-Life (t1/2) of Unlabeled Idasanutlin\"\\n16949,1,1,\"Plasma Elimination Half-life (t1/2): Docetaxel PK Parameters\"\\n16950,1,1,\"Plasma levels for GSK461364 will be taken at:Schedule 1:Day 1, 8, 15, & 22 for Cycle 1 and Day 1, 8 & 15 for subsequent cycles.Schedule 2:Day 1, 2, 8, 9, 15, & 16 for all cycles.Schedule 3:Day 1 to 5 for all cycles.\"\\n16951,1,1,\"Plasma levels for SB-715992 and Capecitabine\"\\n16952,1,1,\"Plasma Maximum Observed Concentration (Cmax) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole\"\\n16953,1,1,\"Plasma Pamiparib Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)\"\\n16954,1,1,\"Plasma Pamiparib Pharmacokinetics: Apparent Total Clearance (CL/F)\"\\n16955,1,1,\"Plasma Pamiparib Pharmacokinetics: Apparent Volume of Distribution (Vz/F)\"\\n16956,1,1,\"Plasma Pamiparib Pharmacokinetics: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-‚àû)\"\\n16957,1,1,\"Plasma Pamiparib Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC0-t)\"\\n16958,1,1,\"Plasma Pamiparib Pharmacokinetics: AUC0-‚àû of Plasma Pamiparib Relative to AUC0-‚àû of Plasma Total Radioactivity\"\\n16959,1,1,\"Plasma Pamiparib Pharmacokinetics: Maximum Observed Concentration (Cmax) of Pamiparib\"\\n16960,1,1,\"Plasma Pamiparib Pharmacokinetics: Time of Cmax (Tmax)\"\\n16961,1,1,\"Plasma Pazopanib Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC[0-24]) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole\"\\n16962,1,1,\"Plasma Pharmacokinetic measures (AUC max, AUCmax-ss)\"\\n16963,1,1,\"Plasma Pharmacokinetic measures (Cmax, Cmax-ss)\"\\n16964,5,1,\"Plasma pharmacokinetics\"\\n16965,1,1,\"Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC)\"\\n16966,1,1,\"Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-‚àû)]\"\\n16967,1,1,\"Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of Desipramine [AUC(0-tlast)]\"\\n16968,1,1,\"Plasma Pharmacokinetics of Desipramine: the Maximum Concentration of Desipramine in the Plasma (Cmax)\"\\n16969,1,1,\"Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-‚àû)]\"\\n16970,1,1,\"Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of LY2603618 [AUC(0-tlast)]\"\\n16971,1,1,\"Plasma Pharmacokinetics of LY2603618: the Maximum Concentration of LY2603618 in the Plasma (Cmax)\"\\n16972,1,1,\"Plasma pharmacokinetics of oral administration of XL888 when administered on an intermittent schedule\"\\n16973,1,1,\"Plasma Pharmacokinetics: AUC0-‚àû of Whole Blood Total Radioactivity to AUC0-‚àû of Plasma Total Radioactivity\"\\n16974,1,1,\"Plasma PK of [14C] tazemetostat, tazemetostat, and its metabolite EPZ-6930 after IV administration of approximately 12 ¬µg of [14C] tazemetostat containing approximately 500 nCi of radioactivity and oral BID administration of 800 mg tazemetostat (AUC 0-7)\"\\n16975,1,1,\"Plasma RO5185426 Trough Concentrations on Days 15,16, and 17\"\\n16976,1,1,\"Plasma t1/2 of [13C]-Labeled Idasanutlin\"\\n16977,1,1,\"Plasma t1/2 of Idasanutlin Metabolite\"\\n16978,1,1,\"Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Apparent Terminal Elimination Half-Life (t1/2)\"\\n16979,1,1,\"Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to Infinity (AUC0-‚àû)\"\\n16980,1,1,\"Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: AUC From Time Zero to the Last Quantifiable Concentration (AUC-t)\"\\n16981,1,1,\"Plasma Total Radioactivity and Whole Blood Total Radioactivity Pharmacokinetics: Maximum Observed Concentration (Cmax)\"\\n16982,1,1,\"Plasma Total Radioactivity Whole Blood Total Radioactivity Pharmacokinetics: Time of Cmax (Tmax)\"\\n16983,1,1,\"Plasma Uric Acid Responder\"\\n16984,1,1,\"Plasma VEGF and HIF1-alpha levels\"\\n16985,1,1,\"Platelet detection in excised brain/medurally tumors\"\\n16986,1,1,\"Platelet function, measured using a bleeding time test\"\\n16987,1,1,\"Pneumonitis relapse\"\\n16988,1,1,\"Pneumonitis related deaths\"\\n16989,1,1,\"Pneumonitis response rate\"\\n16990,1,1,\"Point in Time Objective Response Prior to Surgery\"\\n16991,1,1,\"Poly (ADP-ribose) polymerase inhibitor (PARP)-1 activity as assessed by fluorine F 18 fluorthanatrace positron emission tomography/computed tomography\"\\n16992,1,1,\"Polysomnography Evaluation (Sleep Profiler PSG2 or WatchPAT)\"\\n16993,1,1,\"Population Estimates for Daunorubicin Hydrochloride Clearance\"\\n16994,1,1,\"Population Estimates for Daunorubicin Hydrochloride Volume of Distribution\"\\n16995,1,1,\"Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab\"\\n16996,1,1,\"Population PK parameters for dactinomycin and VCR\"\\n16997,1,1,\"Port Failure Within 12 Months of Port Insertion\"\\n16998,1,1,\"Positive correlations between different measures of functional status\"\\n16999,10,1,\"Positive Predictive Value (PPV)\"\\n17000,1,1,\"Positive predictive value (PPV) on a per-region- and per-patient-basis (table 3) of 68Ga-FAPI46 PET for detection of histopathology-FAP-positive tumor lesions, confirmed by histopathology/biopsy (reached for ‚â• 75%).\"\\n17001,1,1,\"Positive response based on plasma uric acid levels.\"\\n17002,1,1,\"Positivity rate with LDCT screening\"\\n17003,1,1,\"Positron emission tomography (PET)\"\\n17004,1,1,\"Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy\"\\n17005,1,1,\"Possible influence of National Cancer Institute Community Oncology Research Program site size (Aim 1a)\"\\n17006,15,1,\"Post-operative complications\"\\n17007,3,1,\"post-operative morbidity\"\\n17008,1,1,\"post-operative mortality\"\\n17009,1,1,\"Post_TACE hepatic cell failure\"\\n17010,7,1,\"Postoperative hospital stay\"\\n17011,63,1,\"Postoperative Pain\"\\n17012,1,1,\"Potential activity of patupilone once every 21 days in patients that completed the core study\"\\n17013,1,1,\"Potential benefit of increasing/maintaining physical functioning in pediatric subjects undergoing chemotherapy and childhood cancer treatment\"\\n17014,1,1,\"PR interval by ECG\"\\n17015,1,1,\"PR interval duration\"\\n17016,1,1,\"Prat 1 :MTD\"\\n17017,1,1,\"Prat 1 :RP2D\"\\n17018,1,1,\"Precision of achieving the targeted carboplatin AUC\"\\n17019,1,1,\"Precision of the formula for eGFR currently in existence in patients with cancer\"\\n17020,1,1,\"Predict hospital length of stay\"\\n17021,1,1,\"Predict Mortality\"\\n17022,1,1,\"Prediction of grade 3-5 chemotherapy toxicity risk in elderly patients (aged ‚â•65 years old) with advanced solid tumors by measurement of CARG risk score (Cancer and Aging Research Group).\"\\n17023,1,1,\"Predictive Biomarkers\"\\n17024,1,1,\"Predictive of tumor response\"\\n17025,1,1,\"Predictive value of reticulocyte increase\"\\n17026,1,1,\"Predictive value of soluble factors in the development of proteinuria or hypertension\"\\n17027,1,1,\"Predictive value of steady state drug concentrations in the development of proteinuria or hypertension\"\\n17028,1,1,\"Predictive value of the screening tool to undergo standard anticancer treatment in terms of toxicity according to the NCI-CTC\"\\n17029,1,1,\"Predictors in pattern recognition analyses\"\\n17030,1,1,\"Predictors of Absolute Neutrophil Count\"\\n17031,2,1,\"Predose plasma concentration\"\\n17032,1,1,\"Preferred decision-making role\"\\n17033,1,1,\"Preliminary anti tumor activity\"\\n17034,1,1,\"Preliminary anti-tumor activitiy of MEDI5752 (versus pembrolizumab, where applicable) using Objective Response based on RECIST v1.1 (Dose-expansion phase)\"\\n17035,1,1,\"Preliminary anti-tumor activity of IO-108 + pembrolizumab\"\\n17036,1,1,\"Preliminary anti-tumor activity of LUNA18 [Part C]\"\\n17037,1,1,\"Preliminary anti-tumor activity of SAIL66 when administered at selected dose(s) in each cohort [Part 2]\"\\n17038,1,1,\"Preliminary anti-tumor activity of SPYK04 [Cohort expansion]\"\\n17039,2,1,\"Preliminary anti-tumour activity\"\\n17040,1,1,\"Preliminary anti-tumour activity evaluation (in Part B)\"\\n17041,1,1,\"Preliminary anti-tumour activity of AZD7789\"\\n17042,1,1,\"Preliminary anti-tumour assessment of triplet combination (RECIST criteria version 1.1) in patients with PIK3CA mutant advanced ER+ve HER2-ve breast cancer.\"\\n17043,1,1,\"preliminary antitumor activity of drug combination\"\\n17044,1,1,\"preliminary antitumor activity of SC-43\"\\n17045,1,1,\"Preliminary determination of the recommended phase II dose (RP2D) of CAL056 mesylate\"\\n17046,1,1,\"Preliminary efficacy determination as evaluated by disease specific response criteria\"\\n17047,1,1,\"Preliminary efficacy/Objective response rate (ORR)\"\\n17048,1,1,\"Preliminary evaluation of AMV564 efficacy in subjects enrolled in the expansion phase\"\\n17049,1,1,\"Preliminary pooled keratinocyte carcinoma event rate\"\\n17050,1,1,\"Preliminary RDE/RP2D\"\\n17051,1,1,\"Preliminary validation of a family quality of life questionnaire\"\\n17052,1,1,\"Premature discontinuation rate, defined as percentage of recruited patients who have not been followed-up until the end of 6-month course of study enrollment (withdrawal, death or less than 70% completed questionnaires)\"\\n17053,1,1,\"Presence of auto-immune side effects\"\\n17054,1,1,\"Presence of dose limiting toxicities in a 56-day treatment period\"\\n17055,1,1,\"Presence of reflexive testing protocols for guideline-recommended biomarkers\"\\n17056,1,1,\"Presence of symptoms at the vulvovaginal level and their intensity\"\\n17057,1,1,\"Presence or absence of atelectasis for each patient\"\\n17058,1,1,\"Presence or absence of atelectasis within each of the 6 bronchial segments\"\\n17059,2,1,\"Presence or absence of circulating tumor cells\"\\n17060,1,1,\"Presence or absence of Dose Limiting Toxicity(DLT) expression\"\\n17061,2,1,\"Presence or absence of new atelectasis for each segment\"\\n17062,1,1,\"Presence/absence of clinical fungal infection\"\\n17063,1,1,\"Presence/absence of documented fungal infection\"\\n17064,1,1,\"Prevalence of adjustment disorder\"\\n17065,1,1,\"Prevalence of affective and anxiety disorders\"\\n17066,1,1,\"Prevalence of bone marrow failure\"\\n17067,1,1,\"Prevalence of HER2 expression change between initial diagnosis versus any of the subsequent BC relapses\"\\n17068,1,1,\"Prevalence of Human Leukocyte Antigen (HLA) genotypes (HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06)\"\\n17069,1,1,\"Prevalence of hypercalcemia (hypercalcemic hyperparathyroidism)\"\\n17070,1,1,\"Prevalence of hyperparathyroidism (HPT)\"\\n17071,1,1,\"Prevalence of INTRAPATIENT INTERMETASTATIC HETEROGENEITY\"\\n17072,1,1,\"Prevalence of lesion detection (sensitivity)\"\\n17073,1,1,\"Prevalence of mental disorders according to the DSM-5 (objective need for psycho-oncological support) in cancer patients and the changes over time\"\\n17074,1,1,\"Prevalence of other endocrine and non-endocrine neoplasia (1)\"\\n17075,1,1,\"Prevalence of other endocrine and non-endocrine neoplasia (2)\"\\n17076,1,1,\"Prevalence of pathogenic germline mutations\"\\n17077,1,1,\"Prevalence of pathogenic germline mutations in enrolled patients within each cancer site\"\\n17078,1,1,\"Prevalence of positive pathogenic germline mutations\"\\n17079,1,1,\"Prevalence of solid tumors in RASopathies\"\\n17080,1,1,\"Prevalence of substance use disorders\"\\n17081,1,1,\"Prevalence of thyroid nodules\"\\n17082,1,1,\"Prevalence of toxicities evaluated according to the classification of the Common for Toxicity Criteria for Adverse Events (CTCAE) V4.03\"\\n17083,1,1,\"Prevalence of variants in ctDNA with clinical significance across different levels of evidence\"\\n17084,1,1,\"Prevention of hearing loss\"\\n17085,1,1,\"Primary - progression-free survival (PFS)\"\\n17086,1,1,\"Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)\"\\n17087,1,1,\"Primary criterion - Hematological reconstitution and chimerism post-transplantation\"\\n17088,26,1,\"Primary Effectiveness Endpoint\"\\n17089,3,1,\"Primary efficacy outcome\"\\n17090,2,1,\"Primary Efficacy Outcome Measure\"\\n17091,1,1,\"Primary Efficacy Outcome: Progression Free Survival (PFS)\"\\n17092,1,1,\"Primary End Point of PFS\"\\n17093,1,1,\"Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin¬Æ Plus Taxane in the ITT1 Population\"\\n17094,1,1,\"Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria.\"\\n17095,1,1,\"Primary endpoint is Objective Response Rate (ORR).\"\\n17096,1,1,\"Primary Endpoint: Efficacy\"\\n17097,3,1,\"Primary Endpoints\"\\n17098,1,1,\"Primary Health Care Providers Beliefs Regarding Current Cervical Cancer Screening Guidelines\"\\n17099,1,1,\"Primary objective 1: Response of treated target lesion(s) assessed by CT or MRI\"\\n17100,1,1,\"Primary objective 2: The number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria of Adverse Events (CTCAE) v.5\"\\n17101,1,1,\"Primary objective : Number of patients with primary immune deficiency diagnosed after an admission in intensive care unit.\"\\n17102,1,1,\"primary objective is to determine the safety and tolerability of multiple oral doses fo AZD2171 when co-administered with fixed daily oral doses of ZD1839\"\\n17103,1,1,\"primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.\"\\n17104,1,1,\"Primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as a dose limiting toxicity in subjects treated with AMG 386 plus paclitaxel and trastuzumab or with AMG 386 plus capecitabine and lapatinib\"\\n17105,44,1,\"Primary Outcome\"\\n17106,3,1,\"Primary outcome 1\"\\n17107,3,1,\"Primary outcome 2\"\\n17108,1,1,\"Primary outcome in PRIS 1: Urinary continence\"\\n17109,1,1,\"Primary outcome in PRIS 2: Irritative urinary symptoms\"\\n17110,30,1,\"Primary Outcome Measure\"\\n17111,1,1,\"Primary Outcome Measure - Dose Limiting Toxicities (DLTs)\"\\n17112,1,1,\"Primary Outcome Measure - Number of participants with adverse events and serious adverse events\"\\n17113,1,1,\"Primary outcome measured will be the identification of intra-abdominal injury\"\\n17114,1,1,\"Primary Outcome Measures: Maximum tolerated dose of LEE011 when administered orally once daily, as assessed by Frequency of DLTs as a function of LEE011 dose\"\\n17115,1,1,\"Primary Outcome: Optimal Biological Dose (OBD)\"\\n17116,1,1,\"Primary Phase 1b - Define Maximum Tolerated Dose of RP-3500-03 (camonsertib) in combination with niraparib or olaparib and Recommended Phase 2 dose and preferred schedule by assessing frequency of Dose limiting Toxicities observed at each dose level\"\\n17117,1,1,\"Primary Phase 2 - Assess preliminary anti-tumor activity of RP-3500 (camonsertib) with niraparib or olaparib in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria (RECIST 1.1)\"\\n17118,1,1,\"Primary PK 1\"\\n17119,1,1,\"Primary PK 2\"\\n17120,1,1,\"Primary PK 3\"\\n17121,1,1,\"Primary prevention of AKs in recently transplanted solid organ recipient\"\\n17122,1,1,\"Primary prevention of NMSC in recently transplanted solid organ recipient\"\\n17123,1,1,\"Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial.\"\\n17124,58,1,\"Primary Safety Endpoint\"\\n17125,1,1,\"Primary safety outcome\"\\n17126,1,1,\"Primary Safety Outcome Measure\"\\n17127,1,1,\"Primary Site Complete Response Rate\"\\n17128,1,1,\"Primary tumor control rate, as measured from the time of treatment completion until the first documented date of local failure\"\\n17129,1,1,\"Primary: Disease control as assessed by RECIST 1.1 criteria\"\\n17130,1,1,\"Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteria\"\\n17131,1,1,\"Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria\"\\n17132,1,1,\"Primary: Number of subjects with adverse events of interest\"\\n17133,1,1,\"Primary: Number of subjects with clinically significant changes in clinical laboratory values\"\\n17134,1,1,\"Primary: Number of subjects with clinically significant changes in physical examination results\"\\n17135,1,1,\"Primary: Number of subjects with clinically significant changes in vital signs\"\\n17136,1,1,\"Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)\"\\n17137,1,1,\"Primary: Number of subjects with dose-limiting toxicities (DLTs)\"\\n17138,1,1,\"Primary: Number of subjects with grade ‚â•3 treatment-emergent adverse events\"\\n17139,1,1,\"Primary: Number of subjects with serious adverse events\"\\n17140,1,1,\"Primary: Number of subjects with treatment-emergent adverse events\"\\n17141,1,1,\"Primary: Number of subjects with treatment-related adverse events\"\\n17142,1,1,\"Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria\"\\n17143,1,1,\"Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST): Primary Efficacy Population\"\\n17144,1,1,\"Primary: Time to response (TTR) as assessed by RECIST 1.1 criteria\"\\n17145,1,1,\"Probability of a Dose Limiting Toxicity (DLT) by the end of the first treatment cycle (DLT)\"\\n17146,1,1,\"Probability of Being Progression Free 12 Months After Baseline\"\\n17147,1,1,\"Probability of dose escalation according to true dose limiting toxicity (DLT) rate, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0\"\\n17148,1,1,\"Probability of Dose-Limiting Toxicity (DLT)\"\\n17149,1,1,\"Probability of Objective Response (OR)\"\\n17150,1,1,\"Probability Rates of Progression-free Survival at 9 Months\"\\n17151,1,1,\"Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive and Progression Free at 6 Months (Data Cutoff 17 May 2008)\"\\n17152,1,1,\"Probable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)\"\\n17153,1,1,\"Probable Percentage of Participants Remaining Alive at 1 Year\"\\n17154,1,1,\"Probe substrate concentration from time zero to the time of last quantifiable concentration (AUClast) in Arms 1 and 2\"\\n17155,1,1,\"Probe substrate peak plasma concentration (Cmax) in Arms 1 and 2\"\\n17156,1,1,\"Probe substrate pharmacokinetics (PK) parameters: Cmax (Maximum (peak) concentration of drug)\"\\n17157,1,1,\"Probe substrate PK parameters: AUCinf\"\\n17158,1,1,\"Probe substrate PK parameters: AUCtlast (Area Under the Curve)\"\\n17159,1,1,\"Probe substrate PK parameters: HL (Half-life time)\"\\n17160,1,1,\"Probe substrate PK parameters:CL/F (Apparent Oral Clearance)\"\\n17161,1,1,\"Probe substrate PK parameters:Tmax (Time to maximum concentration)\"\\n17162,1,1,\"Probe substrate PK parameters:Vz/F (apparent volume of distribution)\"\\n17163,1,1,\"Procure, store and distribute longitudinal biospecimens and associated clinical data\"\\n17164,1,1,\"Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent\"\\n17165,1,1,\"Procurement of the histologic core\"\\n17166,1,1,\"Procurement of tissue and blood specimens for research purposes\"\\n17167,1,1,\"Profile and identification of metabolites of [14C]-AMG 706 in plasma, urine, and faeces\"\\n17168,11,1,\"Progress Free Survival\"\\n17169,12,5,\"Progress free survival\"\\n17170,10,2,\"Progress Free Survival (PFS)\"\\n17171,18,10,\"Progress free survival (PFS)\"\\n17172,1,1,\"Progress free survival (PFS) based on investigator assessment\"\\n17173,1,1,\"Progress free survival (PFS) for phase ‚Ö°\"\\n17174,5,1,\"Progress Free Survival(PFS)\"\\n17175,1,1,\"Progress free survivalÔºàPFS)\"\\n17176,3,1,\"Progress free survivalÔºàPFSÔºâ\"\\n17177,24,4,\"Progress-free survival\"\\n17178,1,1,\"Progress-Free Survival (PFS)\"\\n17179,16,7,\"Progress-free survival (PFS)\"\\n17180,1,1,\"progress-free survival time\"\\n17181,10,3,\"Progress-free survival(PFS)\"\\n17182,13,2,\"Progression\"\\n17183,1,1,\"Progression - Free Survival (PFS)\"\\n17184,1,1,\"Progression as assessed by RECIST criteria\"\\n17185,1,1,\"progression free rate (PFR)\"\\n17186,1,1,\"Progression Free Rate (PFR) at 12 Weeks\"\\n17187,1,1,\"Progression free rate after 3 months of treatment\"\\n17188,1,1,\"Progression Free Rate at 12 weeks (PFR-12W)\"\\n17189,390,91,\"Progression Free Survival\"\\n17190,18,4,\"Progression Free survival\"\\n17191,392,33,\"Progression free survival\"\\n17192,125,8,\"progression free survival\"\\n17193,1,1,\"Progression Free Survival (Cohort A)\"\\n17194,1,1,\"Progression Free Survival (Independent Assessment)\"\\n17195,1,1,\"Progression Free Survival (irPFS)\"\\n17196,1,1,\"Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)\"\\n17197,1,1,\"Progression Free Survival (Part A and Part B): Cervical Cancer Population\"\\n17198,1,1,\"Progression Free Survival (Part A): Human Papillomavirus (HPV)+ Head and Neck Cancer Population\"\\n17199,1,1,\"Progression Free Survival (Part B)\"\\n17200,412,154,\"Progression Free Survival (PFS)\"\\n17201,1,1,\"Progression free Survival (PFS)\"\\n17202,222,44,\"Progression free survival (PFS)\"\\n17203,29,2,\"progression free survival (PFS)\"\\n17204,1,1,\"Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)\"\\n17205,1,1,\"Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST])\"\\n17206,1,1,\"Progression free survival (PFS) (Cohort 1)\"\\n17207,1,1,\"Progression free survival (PFS) (Cohort A)\"\\n17208,1,1,\"Progression free survival (PFS) (Cohort I)\"\\n17209,1,1,\"Progression free survival (PFS) (expansion cohort)\"\\n17210,1,1,\"Progression free survival (PFS) (Part 2)\"\\n17211,9,5,\"Progression free survival (PFS) (Phase II)\"\\n17212,1,1,\"Progression free survival (PFS) (Phase IIb)\"\\n17213,1,1,\"Progression Free Survival (PFS) - Central Review Assessment\"\\n17214,1,1,\"Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone\"\\n17215,1,1,\"Progression Free Survival (PFS) - Part B\"\\n17216,1,1,\"Progression Free Survival (PFS) [Phase 2]\"\\n17217,2,2,\"Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)\"\\n17218,1,1,\"Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator\"\\n17219,1,1,\"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants\"\\n17220,1,1,\"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n17221,1,1,\"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)\"\\n17222,1,1,\"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)\"\\n17223,1,1,\"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intent-to-Treat (ITT) Population\"\\n17224,1,1,\"Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)\"\\n17225,1,1,\"Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer\"\\n17226,1,1,\"Progression Free Survival (PFS) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17227,1,1,\"Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17228,1,1,\"Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 .\"\\n17229,2,1,\"Progression Free Survival (PFS) as Assessed by Central Independent Review\"\\n17230,1,1,\"Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR)\"\\n17231,1,1,\"Progression Free Survival (PFS) as Assessed by Investigators\"\\n17232,1,1,\"Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n17233,1,1,\"Progression Free Survival (PFS) as determined by RECIST 1.1\"\\n17234,1,1,\"Progression Free Survival (PFS) as Determined by the Independent Radiology Committee (IRC)\"\\n17235,1,1,\"Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population\"\\n17236,1,1,\"Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST)\"\\n17237,1,1,\"Progression Free Survival (PFS) as measured using RECIST 1.1\"\\n17238,1,1,\"Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review\"\\n17239,1,1,\"Progression Free Survival (PFS) as Per Intention-to-treat (ITT)\"\\n17240,1,1,\"Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review\"\\n17241,1,1,\"Progression Free Survival (PFS) assessed by BIRC\"\\n17242,1,1,\"Progression Free Survival (PFS) assessed by Independent review committee (IRC)\"\\n17243,1,1,\"Progression Free Survival (PFS) Assessed by Investigator as per RECIST v1.1\"\\n17244,1,1,\"Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST)\"\\n17245,1,1,\"Progression free survival (PFS) assessed by investigators according to modified Response Evalutaion Criteria in Solid Tumors (mRECIST).\"\\n17246,1,1,\"Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).\"\\n17247,1,1,\"Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST)\"\\n17248,3,1,\"Progression Free Survival (PFS) assessed by IRC\"\\n17249,1,1,\"Progression Free Survival (PFS) assessed by RECIST 1.1\"\\n17250,1,1,\"Progression Free Survival (PFS) at 12 months\"\\n17251,1,1,\"Progression free survival (PFS) at 12 months\"\\n17252,1,1,\"Progression Free Survival (PFS) at 12 Weeks\"\\n17253,2,1,\"Progression free survival (PFS) at 12 weeks\"\\n17254,1,1,\"Progression Free Survival (PFS) at 20 Weeks in MSI Positive Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n17255,1,1,\"Progression Free Survival (PFS) at 5 months (= proportion of patients alive and free of progression 5 months after starting therapy in the sunitinib arm (control arm = only for descriptive purpose)\"\\n17256,1,1,\"Progression Free Survival (PFS) at 6 months\"\\n17257,1,1,\"Progression free survival (PFS) at 6 months assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n17258,1,1,\"Progression Free Survival (PFS) at 7 Months\"\\n17259,1,1,\"Progression Free Survival (PFS) at 7 Months From Registration\"\\n17260,1,1,\"Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines\"\\n17261,1,1,\"Progression Free Survival (PFS) Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17262,1,1,\"Progression free survival (PFS) based on central review by RECIST 1.1 criteria (Cohort 5 only)\"\\n17263,1,1,\"Progression Free Survival (PFS) based on central review of tumor measurement using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n17264,1,1,\"Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment\"\\n17265,1,1,\"Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review\"\\n17266,1,1,\"Progression Free Survival (PFS) Based on Independent Radiologist\"\\n17267,1,1,\"Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS)\"\\n17268,1,1,\"Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort\"\\n17269,2,1,\"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)\"\\n17270,1,1,\"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)\"\\n17271,1,1,\"Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)\"\\n17272,1,1,\"Progression Free Survival (PFS) by GCIC Criteria\"\\n17273,1,1,\"Progression Free Survival (PFS) by Independent Central Review (Phase II Treatment Period)\"\\n17274,1,1,\"Progression Free Survival (PFS) by Investigator Assessment\"\\n17275,1,1,\"Progression Free Survival (PFS) by RECIST Criteria\"\\n17276,1,1,\"Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assess-ment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).\"\\n17277,1,1,\"Progression Free Survival (PFS) During the First-line Treatment Phase\"\\n17278,1,1,\"Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods\"\\n17279,1,1,\"Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria\"\\n17280,1,1,\"Progression Free Survival (PFS) for Crossover Medication\"\\n17281,1,1,\"Progression Free Survival (PFS) for First Line Medication\"\\n17282,1,1,\"Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST\"\\n17283,1,1,\"Progression Free Survival (PFS) in Adult Participants With Previously Treated Metastatic Renal Cell Cancer (mRCC) in Part II\"\\n17284,1,1,\"Progression Free Survival (PFS) in ITT Population\"\\n17285,1,1,\"Progression Free Survival (PFS) in Part 2 of Study\"\\n17286,1,1,\"Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer\"\\n17287,1,1,\"Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab\"\\n17288,1,1,\"Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer\"\\n17289,1,1,\"Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)\"\\n17290,1,1,\"Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients]\"\\n17291,1,1,\"Progression Free Survival (PFS) in Phase II\"\\n17292,1,1,\"Progression Free Survival (PFS) in the Expansion Cohort\"\\n17293,1,1,\"Progression Free Survival (PFS) in the Intent-to-Treat Population\"\\n17294,1,1,\"Progression Free Survival (PFS) in the Overall Study Population\"\\n17295,1,1,\"Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone\"\\n17296,1,1,\"Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy\"\\n17297,1,1,\"Progression Free Survival (PFS) of Groups by FDG Response at Day 56\"\\n17298,1,1,\"Progression Free Survival (PFS) of Participants in the HER2-Positive Population as Assessed by the Investigator\"\\n17299,1,1,\"Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1\"\\n17300,1,1,\"Progression Free Survival (PFS) Per Investigator\\'s Assessment\"\\n17301,1,1,\"Progression Free Survival (PFS) per RECIST 1.1 assessed by BICR\"\\n17302,1,1,\"Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive (TPS ‚â•50%) Tumors\"\\n17303,2,2,\"Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR).\"\\n17304,1,1,\"Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment\"\\n17305,1,1,\"Progression Free Survival (PFS) Prostate Cancer Working Group 2 (PCWG2) Criteria or Based on the Onset of a Skeletal Related Event.\"\\n17306,6,3,\"Progression Free Survival (PFS) Rate\"\\n17307,4,1,\"Progression Free Survival (PFS) rate\"\\n17308,6,2,\"Progression free survival (PFS) rate\"\\n17309,1,1,\"Progression Free Survival (PFS) Rate as Measured at Week 8\"\\n17310,2,2,\"Progression Free Survival (PFS) Rate at 12 Months\"\\n17311,1,1,\"Progression free survival (PFS) rate at 12 weeks\"\\n17312,1,1,\"Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma.\"\\n17313,1,1,\"Progression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months)\"\\n17314,2,2,\"Progression Free Survival (PFS) Rate at 6 Months\"\\n17315,2,1,\"Progression Free Survival (PFS) Rate at Month 6\"\\n17316,1,1,\"Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).\"\\n17317,5,5,\"Progression Free Survival (PFS) Time\"\\n17318,1,1,\"Progression Free Survival (PFS) Time From the Date of Randomization to Date of Disease Progression or Death, Whichever Occurred First.\"\\n17319,1,1,\"Progression Free Survival (PFS) to validate biomarkers\"\\n17320,1,1,\"Progression free survival (PFS) using a targeted treatment selected by molecular profiling compared to the PFS for the most recent regimen\"\\n17321,1,1,\"Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)\"\\n17322,1,1,\"Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)\"\\n17323,1,1,\"Progression free survival (PFS) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 definition of progression as determined by the investigator.\"\\n17324,1,1,\"Progression Free Survival (PFS) When Bevacizumab is Administered to Patients With Unresectable and/or Metastatic Papillary Renal Cell Carcinoma.\"\\n17325,1,1,\"Progression Free Survival (PFS) With Carboplatin, Etoposide and MPDL3280A Compared to Chemotherapy Alone According to RECIST v1.1\"\\n17326,1,1,\"Progression Free Survival (PFS), as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\"\\n17327,1,1,\"Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population\"\\n17328,1,1,\"Progression free survival (PFS), as measured by Response Evaluation Criteria in Solid Tumors criteria (modified RECIST) per local review\"\\n17329,1,1,\"Progression Free Survival (PFS), Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1\"\\n17330,1,1,\"Progression free survival (PFS), measured from time of first study treatment until objective tumor progression as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria or death from any cause, whichever occurs earlier.\"\\n17331,3,1,\"Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease\"\\n17332,1,1,\"Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS)\"\\n17333,1,1,\"Progression Free Survival (PFS): First-Line Participants\"\\n17334,1,1,\"Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS)\"\\n17335,1,1,\"Progression Free Survival (PFS): International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Stratification\"\\n17336,1,1,\"Progression Free Survival (PFS): Memorial Sloan-Kettering Cancer Center (MSKCC) Stratification\"\\n17337,1,1,\"Progression Free Survival (PFS): Second-Line Participants\"\\n17338,3,1,\"Progression Free Survival (PFS1)\"\\n17339,1,1,\"Progression Free Survival (PFS; Data Cutoff 14 November 2011)\"\\n17340,1,1,\"Progression Free Survival (Phase 2 only)\"\\n17341,1,1,\"Progression Free Survival (Phase 2)\"\\n17342,1,1,\"Progression free survival (Phase I dose expansion)\"\\n17343,5,3,\"Progression Free Survival (Phase II)\"\\n17344,3,2,\"Progression free survival (Phase II)\"\\n17345,2,1,\"progression free survival (phase II)\"\\n17346,1,1,\"Progression free survival 1\"\\n17347,4,2,\"Progression Free Survival [PFS]\"\\n17348,1,1,\"Progression free survival and/or objective clinical response rate (Phase 2)\"\\n17349,1,1,\"Progression free survival and/or radiographic tumor evaluation\"\\n17350,1,1,\"Progression Free Survival as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1\"\\n17351,1,1,\"Progression Free Survival as Measured by Number of Days Without Disease Progression\"\\n17352,1,1,\"Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic Progression\"\\n17353,1,1,\"Progression Free Survival at 12 Weeks\"\\n17354,1,1,\"Progression Free Survival at 12 Weeks for Patients With Soft Tissue Sarcoma (STS) Treated With Pazopanib and Oral Topotecan\"\\n17355,2,1,\"Progression Free Survival at 6 Months\"\\n17356,3,1,\"Progression Free Survival at 6 months (PFS-6)\"\\n17357,1,1,\"Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment\"\\n17358,1,1,\"Progression Free Survival at 9 months\"\\n17359,1,1,\"Progression Free Survival at One Year.\"\\n17360,1,1,\"Progression Free Survival at Six Months\"\\n17361,1,1,\"Progression Free Survival at Week 12\"\\n17362,1,1,\"Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\"\\n17363,1,1,\"Progression free survival based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n17364,1,1,\"Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in\"\\n17365,1,1,\"Progression Free Survival by independent central reviewer\"\\n17366,1,1,\"Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population\"\\n17367,1,1,\"Progression Free Survival Determined Using Response Evaluation Criteria in Solid Tumors Version 1.1 Criteria\"\\n17368,1,1,\"Progression Free Survival During Maintenance Phase\"\\n17369,1,1,\"Progression Free Survival During Maintenance Treatment Phase\"\\n17370,1,1,\"Progression Free Survival First-Line (PFS 1-L)\"\\n17371,1,1,\"Progression Free Survival for Re-challenge With Sunitinib\"\\n17372,1,1,\"Progression Free Survival for Subjects With Locally Advanced or Metastatic (Stage IIIB or Stage IV) Non-Small Cell Lung Cancer (NSCLC) After Systemic Treatment With Gemcitabine, Docetaxel, and Bevacizumab as First Line Therapy\"\\n17373,1,1,\"Progression Free Survival in part II\"\\n17374,1,1,\"Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine Treatment.\"\\n17375,1,1,\"Progression free survival in week 12\"\\n17376,1,1,\"Progression Free Survival of Groups by FLT Response at Day 56\"\\n17377,1,1,\"Progression Free Survival of Patients With FLT CR/PR Versus FLT PD in Patients With CT SD at Day 56\"\\n17378,1,1,\"Progression Free Survival of Patients With Unresectable Angiosarcoma\"\\n17379,1,1,\"Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma\"\\n17380,7,3,\"Progression Free Survival Rate\"\\n17381,1,1,\"Progression Free Survival Rate (PFSR) at 24 Weeks.\"\\n17382,1,1,\"Progression Free Survival Rate (PFSR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17383,1,1,\"Progression free survival rate and/or overall clinical response rate (Phase 2)\"\\n17384,1,1,\"Progression Free Survival rate at 10 months (PFS@10m)\"\\n17385,1,1,\"Progression free survival rate at 18 weeks\"\\n17386,2,1,\"Progression Free Survival Rate at 24 Weeks\"\\n17387,8,1,\"Progression free survival rate at 6 months\"\\n17388,1,1,\"Progression Free Survival Time\"\\n17389,1,1,\"Progression free survival time (PFS) (dose expansion phase)\"\\n17390,1,1,\"Progression Free Survival Using the RECIST 1.1 Criteria\"\\n17391,1,1,\"Progression free survival using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1\"\\n17392,1,1,\"Progression Free Survival With Sunitinib as First Line of Therapy\"\\n17393,1,1,\"Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0\"\\n17394,17,5,\"Progression Free Survival(PFS)\"\\n17395,12,2,\"Progression free survival(PFS)\"\\n17396,1,1,\"Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)\"\\n17397,1,1,\"Progression free survival(PFS) of the subjects\"\\n17398,1,1,\"Progression free survival(PFS) per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)\"\\n17399,1,1,\"Progression Free Survival, PFS\"\\n17400,4,1,\"Progression free survival, PFS\"\\n17401,4,1,\"Progression Free Survival.\"\\n17402,2,1,\"Progression Free Survival/PFS\"\\n17403,1,1,\"Progression Free Survival/PFS at 1 Year Post UCBT.\"\\n17404,1,1,\"Progression Free Survival: Second Line of Treatment\"\\n17405,1,1,\"Progression Free Survival: Third Line Treatment\"\\n17406,6,2,\"Progression free survivalÔºàPFSÔºâ\"\\n17407,1,1,\"Progression free survivalÔºåPFS\"\\n17408,1,1,\"progression free survivalÔºåPFS\"\\n17409,1,1,\"Progression Free-Survival (PFS)\"\\n17410,1,1,\"Progression Free-Survival in the Ovarian Cancer Cohort\"\\n17411,1,1,\"Progression in 3 mo\"\\n17412,1,1,\"Progression- free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 (Expansion cohort)\"\\n17413,1,1,\"Progression- Free Survival at 6 Months From Initiation of Trial Treatment\"\\n17414,1,1,\"Progression-free (PFS) survival according to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n17415,1,1,\"Progression-free > Survival at 24 Months (Phase 2, Transformed/Composite)\"\\n17416,2,1,\"Progression-Free Rate\"\\n17417,2,1,\"Progression-free rate\"\\n17418,1,1,\"Progression-free Rate at 12 Weeks (PFR12wks)\"\\n17419,1,1,\"Progression-Free Rate at 4 Month\"\\n17420,1,1,\"Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.\"\\n17421,92,25,\"Progression-Free Survival\"\\n17422,208,83,\"Progression-free Survival\"\\n17423,561,52,\"Progression-free survival\"\\n17424,137,12,\"progression-free survival\"\\n17425,1,1,\"Progression-free survival (according to mRECIST)\"\\n17426,1,1,\"Progression-free Survival (Bevacizumab- na√Øve Group)\"\\n17427,1,1,\"Progression-free Survival (Bevacizumab-treated Group)\"\\n17428,1,1,\"Progression-free survival (central imaging assessment)\"\\n17429,1,1,\"Progression-free Survival (Efficacy Evaluable Population) - Dose Extension\"\\n17430,1,1,\"Progression-free Survival (Final Results After Crossover)\"\\n17431,1,1,\"Progression-free survival (Part 2)\"\\n17432,231,124,\"Progression-Free Survival (PFS)\"\\n17433,230,91,\"Progression-free Survival (PFS)\"\\n17434,355,81,\"Progression-free survival (PFS)\"\\n17435,45,8,\"progression-free survival (PFS)\"\\n17436,1,1,\"Progression-free survival (PFS) (assessed by the independent radiology review committee [IRRC] based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)\"\\n17437,1,1,\"Progression-free Survival (PFS) (at between 2-3.9 months)\"\\n17438,1,1,\"Progression-free Survival (PFS) (at between 4-7.9 months)\"\\n17439,1,1,\"Progression-free survival (PFS) (Cohort I)\"\\n17440,1,1,\"Progression-free survival (PFS) (Cohort II)\"\\n17441,1,1,\"Progression-free Survival (PFS) (Evaluable Randomized Patients)\"\\n17442,1,1,\"Progression-free survival (PFS) (in stage ‚Ö°)\"\\n17443,1,1,\"Progression-free Survival (PFS) (Part 2)\"\\n17444,1,1,\"Progression-free survival (PFS) (Part B)\"\\n17445,1,1,\"Progression-free Survival (PFS) (Phase II Analysis Group 2 - Initial Treatment Period)\"\\n17446,19,7,\"Progression-free survival (PFS) (Phase II)\"\\n17447,1,1,\"Progression-free Survival (PFS) (RECIST1.1)\"\\n17448,1,1,\"Progression-free Survival (PFS) - All Participants\"\\n17449,1,1,\"Progression-free Survival (PFS) - Initial Treatment Period\"\\n17450,1,1,\"Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months\"\\n17451,5,4,\"Progression-Free Survival (PFS) - Percentage of Participants With an Event\"\\n17452,1,1,\"Progression-Free Survival (PFS) - Phase 2\"\\n17453,1,1,\"Progression-free Survival (PFS) - Two or More Doses\"\\n17454,1,1,\"Progression-free Survival (PFS) = > 6 Months\"\\n17455,1,1,\"Progression-free survival (PFS) [Part 3]\"\\n17456,1,1,\"Progression-free Survival (PFS) According to Grade of Rash\"\\n17457,1,1,\"Progression-Free Survival (PFS) According to IRF Assessment\"\\n17458,1,1,\"Progression-Free Survival (PFS) According to RECIST v1.1 as Assessed by Blinded Independent Central Review (BICR)\"\\n17459,1,1,\"Progression-Free Survival (PFS) According to RECIST v1.1 by Blinded Independent Central Review (BICR)\"\\n17460,1,1,\"Progression-Free Survival (PFS) According to RECIST v1.1 Guidelines as Assessed by Blinded Independent Central Review (BICR)\"\\n17461,1,1,\"Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD (Homologous Recombination Deficiency) Subgroups (Part 1 of Study)\"\\n17462,1,1,\"Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants\"\\n17463,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)\"\\n17464,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator\"\\n17465,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17466,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17467,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review\"\\n17468,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n17469,1,1,\"Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)\"\\n17470,1,1,\"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by local investigators\"\\n17471,1,1,\"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Investigator\"\\n17472,1,1,\"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants Who Have not Received Prior Systemic Therapy or Have Progressed to Prior First-line Treatment\"\\n17473,1,1,\"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECISTv.1.1) After Randomization\"\\n17474,1,1,\"Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation\"\\n17475,1,1,\"Progression-free survival (PFS) among participants who received the molecularly targeted matched treatment.\"\\n17476,1,1,\"Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy.\"\\n17477,1,1,\"Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.\"\\n17478,1,1,\"Progression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessments\"\\n17479,1,1,\"Progression-free Survival (PFS) as Assessed by an Independent Radiologist: Randomized Phase\"\\n17480,1,1,\"Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)\"\\n17481,1,1,\"Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)\"\\n17482,1,1,\"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)\"\\n17483,3,3,\"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17484,1,1,\"Progression-Free Survival (PFS) as Assessed by Investigator According to RECIST v1.1\"\\n17485,1,1,\"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) at Primary Analysis\"\\n17486,1,1,\"Progression-free Survival (PFS) As Assessed By Investigators\"\\n17487,2,2,\"Progression-free Survival (PFS) as Assessed by Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17488,2,2,\"Progression-free Survival (PFS) as assessed by RECIST 1.1\"\\n17489,3,3,\"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17490,1,1,\"Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)\"\\n17491,2,1,\"Progression-Free Survival (PFS) as Assessed by the Investigator\"\\n17492,1,1,\"Progression-free Survival (PFS) as Assessed by the Investigator\"\\n17493,1,1,\"Progression-Free Survival (PFS) as Assessed by the Investigator (INV)\"\\n17494,1,1,\"Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4\"\\n17495,1,1,\"Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1\"\\n17496,1,1,\"Progression-Free Survival (PFS) as Assessed by the Investigator.\"\\n17497,1,1,\"Progression-Free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0) Criteria\"\\n17498,1,1,\"Progression-free survival (PFS) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\"\\n17499,1,1,\"Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1\"\\n17500,1,1,\"Progression-Free Survival (PFS) as Determined by Investigator\\'s Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\"\\n17501,1,1,\"Progression-Free Survival (PFS) as Determined by Investigator\\'s Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\"\\n17502,1,1,\"Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines\"\\n17503,1,1,\"Progression-Free Survival (PFS) as determined by the Independent Review Facility (IRF) according to RECIST v 1.1 (Arm F)\"\\n17504,1,1,\"Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population\"\\n17505,1,1,\"Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)\"\\n17506,1,1,\"Progression-Free Survival (PFS) as Determined by the Investigator Using RECIST v1.1 in Participants With Solid Tumors\"\\n17507,1,1,\"Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n17508,1,1,\"Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (brand name) or death, whichever occurs first\"\\n17509,1,1,\"Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n17510,1,1,\"Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population\"\\n17511,1,1,\"Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Median PFS\"\\n17512,1,1,\"Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death\"\\n17513,1,1,\"Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment\"\\n17514,1,1,\"Progression-Free Survival (PFS) Assessed as per Modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\"\\n17515,1,1,\"Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17516,1,1,\"Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in overall population\"\\n17517,1,1,\"Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17518,1,1,\"Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intend to Treat patients.\"\\n17519,1,1,\"Progression-Free Survival (PFS) Assessed by Investigator\"\\n17520,1,1,\"Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population\"\\n17521,1,1,\"Progression-Free Survival (PFS) Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Participants Treated with Atezolizumab Combination Therapy Compared With Placebo Arm\"\\n17522,1,1,\"Progression-free survival (PFS) assessed by RECIST criteria\"\\n17523,1,1,\"Progression-free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17524,1,1,\"Progression-free Survival (PFS) Assessed by the Independent Review Panel According to Response Evaluation Criteria for Solid Tumors (RECIST) 1.1\"\\n17525,1,1,\"Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)\"\\n17526,2,2,\"Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1\"\\n17527,1,1,\"Progression-free Survival (PFS) Assessed by the Investigator as per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)\"\\n17528,1,1,\"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population\"\\n17529,1,1,\"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status\"\\n17530,1,1,\"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by Independent Review Committee (IRC)\"\\n17531,1,1,\"Progression-free Survival (PFS) at 2 years\"\\n17532,1,1,\"Progression-Free Survival (PFS) at 4 Months\"\\n17533,4,1,\"Progression-free Survival (PFS) at 6 Months\"\\n17534,2,1,\"Progression-free survival (PFS) at 6 months\"\\n17535,1,1,\"Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months\"\\n17536,1,1,\"Progression-free Survival (PFS) at 6 Months - Expansion Cohort\"\\n17537,1,1,\"Progression-free Survival (PFS) at 6-months\"\\n17538,1,1,\"Progression-Free Survival (PFS) at Any Site\"\\n17539,1,1,\"Progression-Free Survival (PFS) at Month 4 (PFS4m) - Phase 2\"\\n17540,1,1,\"Progression-Free Survival (PFS) at Month 4: Cohort A\"\\n17541,1,1,\"Progression-free Survival (PFS) at One Year\"\\n17542,1,1,\"Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment\"\\n17543,1,1,\"Progression-Free Survival (PFS) at the End of Study\"\\n17544,1,1,\"Progression-free Survival (PFS) at the Maximum Tolerated Dose/Recommended Phase 2 Dose of Cediranib Maleate With Olaparib Compared to That of Olaparib Alone (Phase II)\"\\n17545,1,1,\"Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17546,1,1,\"Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR)\"\\n17547,1,1,\"Progression-free survival (PFS) based on blinded independent central review (BICR)\"\\n17548,1,1,\"Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation\"\\n17549,2,1,\"Progression-free Survival (PFS) Based on Central Independent Review\"\\n17550,1,1,\"Progression-free Survival (PFS) Based on Independent Radiological Review for the First Intervention Period\"\\n17551,1,1,\"Progression-Free Survival (PFS) Based on Independent Radiologist\"\\n17552,1,1,\"Progression-Free Survival (PFS) Based on Investigator\\'s Assessment\"\\n17553,1,1,\"Progression-free survival (PFS) based on local investigator assessment as per RECIST 1.1\"\\n17554,1,1,\"Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for Arm B and C\"\\n17555,1,1,\"Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)\"\\n17556,2,2,\"Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR)\"\\n17557,1,1,\"Progression-free Survival (PFS) Based on the RECIST Criteria\"\\n17558,1,1,\"Progression-free survival (PFS) by blinded independent central review (BICR)\"\\n17559,1,1,\"Progression-free survival (PFS) by blinded independent central review (BICR) (using RECIST 1.1) in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC\"\\n17560,1,1,\"Progression-free survival (PFS) by blinded independent central review (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria\"\\n17561,1,1,\"Progression-free survival (PFS) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in all randomized participants\"\\n17562,1,1,\"Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)\"\\n17563,1,1,\"Progression-Free Survival (PFS) by Central Review Assessment\"\\n17564,1,1,\"Progression-free Survival (PFS) by Independent Imaging Review (IIR)\"\\n17565,1,1,\"Progression-free survival (PFS) by Independent Review Committee\"\\n17566,1,1,\"Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population\"\\n17567,1,1,\"Progression-free survival (PFS) by investigator\"\\n17568,1,1,\"Progression-Free Survival (PFS) by Investigator Assessment\"\\n17569,1,1,\"Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17570,1,1,\"Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17571,1,1,\"Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17572,1,1,\"Progression-free Survival (PFS) by the Investigator Using Modified Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n17573,1,1,\"Progression-Free Survival (PFS) Comparison\"\\n17574,1,1,\"Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)\"\\n17575,1,1,\"Progression-free survival (PFS) during the maintenance treatment phase\"\\n17576,1,1,\"Progression-free survival (PFS) evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17577,1,1,\"Progression-free survival (PFS) evaluated by the Blinded Independent Central Review Committee (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17578,1,1,\"Progression-free survival (PFS) evaluated using Response Evaluation Criteria in Solid Tumors 1.1\"\\n17579,1,1,\"Progression-Free Survival (PFS) Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer With Wild-Type K-ras Oncogene (KRAS) Who Have Received Front-Line Systemic Therapy\"\\n17580,1,1,\"Progression-Free Survival (PFS) For All Participants\"\\n17581,1,1,\"Progression-Free Survival (PFS) for Dose Expansion\"\\n17582,1,1,\"Progression-Free Survival (PFS) For Participants With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ‚â•1%\"\\n17583,1,1,\"Progression-free survival (PFS) for patient population with non-squamous no-small cell lung cancer (NSCLC)\"\\n17584,1,1,\"Progression-Free Survival (PFS) for phase 2\"\\n17585,1,1,\"Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)\"\\n17586,1,1,\"Progression-Free Survival (PFS) From Initiation of Sunitinib Therapy\"\\n17587,1,1,\"Progression-free Survival (PFS) From Local Investigator\\'s Assessment Based on Treatment Crossover Analysis Set\"\\n17588,1,1,\"Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression\"\\n17589,1,1,\"Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17590,1,1,\"Progression-free survival (PFS) in all subjects evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17591,1,1,\"Progression-Free Survival (PFS) in both study arms after randomization\"\\n17592,1,1,\"Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)\"\\n17593,1,1,\"Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)\"\\n17594,1,1,\"Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation\"\\n17595,1,1,\"Progression-Free Survival (PFS) in eligible patients randomized to erlotinib or pemetrexed treatment arms\"\\n17596,1,1,\"Progression-free Survival (PFS) in Final Analysis\"\\n17597,1,1,\"Progression-free Survival (PFS) in High-ERCC1 Patients\"\\n17598,1,1,\"Progression-Free Survival (PFS) in Intent-to-Treat (ITT), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n17599,1,1,\"Progression-free Survival (PFS) in Interim Analysis\"\\n17600,1,1,\"Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)\"\\n17601,1,1,\"Progression-free Survival (PFS) in Participants with BM at Baseline (Cohort 2)\"\\n17602,1,1,\"Progression-free survival (PFS) in participants with central nervous system (CNS) metastases at baseline\"\\n17603,1,1,\"Progression-free Survival (PFS) in Participants With Hormone Refractory Prostate Cancer (HRPC) Administered LY2181308 Sodium Plus Docetaxel Compared to Docetaxel Alone\"\\n17604,1,1,\"Progression-Free Survival (PFS) in Participants With PD-L1 TPS ‚â•1%\"\\n17605,1,1,\"Progression-Free Survival (PFS) in Patients with PIK3CA/AKT1/PTEN Altered Tumors, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n17606,2,1,\"Progression-Free Survival (PFS) in Phase 2\"\\n17607,1,1,\"Progression-free Survival (PFS) in Phase 2 Cohort 2B\"\\n17608,1,1,\"progression-free survival (PFS) in PL-D1 positive patients\"\\n17609,1,1,\"Progression-free survival (PFS) in stage ‚Ö°\"\\n17610,1,1,\"Progression-Free Survival (PFS) in the BRCA-deficient Population\"\\n17611,1,1,\"Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort\"\\n17612,1,1,\"Progression-Free Survival (PFS) in the Intent-to-treat (ITT) Analysis set as assessed by the Independent Review Committee (IRC)\"\\n17613,1,1,\"Progression-Free Survival (PFS) in the Intention-to-treat Population\"\\n17614,1,1,\"Progression-Free Survival (PFS) in the TROP2 biomarker positive population\"\\n17615,1,1,\"Progression-free survival (PFS) of bintrafusp alfa in combination with docetaxel versus (vs) docetaxel alone\"\\n17616,1,1,\"Progression-free Survival (PFS) of EGFR FISH-positive Patients by Institutional Review\"\\n17617,1,1,\"Progression-free survival (PFS) of men with AVPC treated with 6 cycles of cabazitaxel + carboplatin followed by olaparib maintenance versus observation\"\\n17618,1,1,\"Progression-Free Survival (PFS) of MTD/Phase II Patients\"\\n17619,1,1,\"Progression-free Survival (PFS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)\"\\n17620,1,1,\"Progression-free Survival (PFS) of Participants Who Received RAD001 Plus Bevacizumab Versus Participants Who Received IFN Plus Bevacizumab\"\\n17621,1,1,\"Progression-Free Survival (PFS) of patients using RECIST 1.1\"\\n17622,1,1,\"Progression-free Survival (PFS) of the Treated Lesion(s) According to RECIST and EASL Criteria\"\\n17623,1,1,\"Progression-free Survival (PFS) of TY-302 combine with Tamoxifen\"\\n17624,1,1,\"Progression-Free Survival (PFS) per Independent Central Review (ICR)\"\\n17625,1,1,\"Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.\"\\n17626,1,1,\"Progression-Free Survival (PFS) Per Independent Radiologic Review.\"\\n17627,1,1,\"Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)\"\\n17628,1,1,\"Progression-free Survival (PFS) Per Local Radiological Review\"\\n17629,1,1,\"Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as Assessed by Investigator\"\\n17630,1,1,\"Progression-Free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17631,1,1,\"Progression-free Survival (PFS) per RECIST 1.1\"\\n17632,1,1,\"Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR\"\\n17633,1,1,\"Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator, by Positive Versus Negative bTMB Groups\"\\n17634,1,1,\"Progression-Free Survival (PFS) Per RECIST v1.1 Via IRC Assessment in ITT Population\"\\n17635,1,1,\"Progression-free Survival (PFS) Per RECIST Version 1.0\"\\n17636,1,1,\"Progression-free Survival (PFS) per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n17637,1,1,\"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n17638,3,3,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging\"\\n17639,1,1,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)\"\\n17640,1,1,\"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ‚â•1 Population\"\\n17641,1,1,\"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator assessment\"\\n17642,1,1,\"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population\"\\n17643,1,1,\"Progression-free survival (PFS) per Response evaluation criteria in solid tumors (RECIST) version 1.1 according to investigator assessment (Phase 3 only)\"\\n17644,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants\"\\n17645,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ‚â•1\"\\n17646,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ‚â•10\"\\n17647,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Investigator\"\\n17648,1,1,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17649,4,4,\"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17650,4,4,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\"\\n17651,1,1,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All Participants\"\\n17652,1,1,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review\"\\n17653,2,2,\"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n17654,2,2,\"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n17655,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)\"\\n17656,1,1,\"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For All Participants\"\\n17657,1,1,\"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For RAS Wild-type Participants\"\\n17658,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator\"\\n17659,1,1,\"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC\"\\n17660,1,1,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator\"\\n17661,1,1,\"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants with Programmed Death-Ligand 1 (PD-L1)-Positive Tumors (Combined Positive Score [CPS]‚â•10)\"\\n17662,1,1,\"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)\"\\n17663,1,1,\"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC)\"\\n17664,1,1,\"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)\"\\n17665,1,1,\"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST 1.1) as determined by Blinded Independent Central Review (BICR)\"\\n17666,1,1,\"Progression-Free Survival (PFS) Rate\"\\n17667,3,1,\"Progression-free Survival (PFS) Rate\"\\n17668,8,1,\"Progression-free survival (PFS) rate\"\\n17669,1,1,\"Progression-free survival (PFS) rate (Phase II)\"\\n17670,1,1,\"Progression-Free Survival (PFS) rate at 1 year\"\\n17671,2,1,\"Progression-free Survival (PFS) Rate at 3 Months\"\\n17672,1,1,\"Progression-free Survival (PFS) Rate at 4 Months\"\\n17673,1,1,\"Progression-Free Survival (PFS) rate at 6 months\"\\n17674,1,1,\"Progression-free Survival (PFS) Rate at 6 Months\"\\n17675,4,1,\"Progression-free survival (PFS) rate at 6 months\"\\n17676,1,1,\"Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months)\"\\n17677,1,1,\"Progression-Free Survival (PFS) Rate at 6 Months Per RECIST v1.1\"\\n17678,1,1,\"Progression-Free Survival (PFS) Rate at 6-month\"\\n17679,1,1,\"Progression-free survival (PFS) rate for Cohort 2 (Relapsed/Refractory Synovial Sarcoma)\"\\n17680,1,1,\"Progression-free Survival (PFS) Rate: Percentage of Participants With PFS\"\\n17681,3,2,\"Progression-Free Survival (PFS) Time\"\\n17682,5,4,\"Progression-free Survival (PFS) Time\"\\n17683,1,1,\"Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)\"\\n17684,1,1,\"Progression-free Survival (PFS) Time: Independent Read Assessments\"\\n17685,1,1,\"Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments\"\\n17686,1,1,\"Progression-free Survival (PFS) Time: Investigator Read\"\\n17687,1,1,\"Progression-free Survival (PFS) Times\"\\n17688,1,1,\"Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)\"\\n17689,1,1,\"Progression-Free Survival (PFS) Using Computed Best Response Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy\"\\n17690,1,1,\"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator\"\\n17691,1,1,\"Progression-free survival (PFS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)\"\\n17692,1,1,\"Progression-free survival (PFS)(IRC) (phase ‚Ö¢)\"\\n17693,1,1,\"Progression-free Survival (PFS), [95% CI]\"\\n17694,1,1,\"Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study\"\\n17695,1,1,\"Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n17696,1,1,\"Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17697,1,1,\"Progression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\"\\n17698,1,1,\"Progression-Free Survival (PFS), Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n17699,1,1,\"Progression-Free Survival (PFS), Core Radiology Assessment\"\\n17700,1,1,\"progression-free survival (PFS), double-blinded period\"\\n17701,1,1,\"Progression-Free Survival (PFS), Investigator\\'s Assessment\"\\n17702,1,1,\"Progression-free Survival (PFS), Time to Event\"\\n17703,1,1,\"Progression-free survival (PFS). Cohort A\"\\n17704,1,1,\"Progression-free survival (PFS). Cohort B\"\\n17705,1,1,\"Progression-free survival (PFS). Cohort C\"\\n17706,1,1,\"Progression-free survival (PFS). Cohort D\"\\n17707,1,1,\"Progression-free survival (PFS). Cohort E\"\\n17708,1,1,\"Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment\"\\n17709,1,1,\"Progression-Free Survival (PFS): Independent Radiologist Review\"\\n17710,1,1,\"Progression-Free Survival (PFS): Independent-Assessment\"\\n17711,1,1,\"Progression-Free Survival (PFS): Investigator Assessment\"\\n17712,1,1,\"Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death\"\\n17713,2,2,\"Progression-Free Survival (PFS): Time to Event\"\\n17714,1,1,\"Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy\"\\n17715,1,1,\"Progression-free Survival (PFS)Assessed by Local Investigator\\'s Assessment (Phase ll)\"\\n17716,1,1,\"Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatment.\"\\n17717,1,1,\"Progression-free survival (PFSÔºâ\"\\n17718,2,1,\"Progression-Free Survival (Phase 2)\"\\n17719,1,1,\"Progression-free Survival (Phase II Futility Analysis)\"\\n17720,6,4,\"Progression-free Survival (Phase II)\"\\n17721,7,2,\"Progression-free survival (Phase II)\"\\n17722,1,1,\"Progression-Free Survival (Site Read, Investigator Assessment)\"\\n17723,3,3,\"Progression-Free Survival - Time to Event\"\\n17724,1,1,\"Progression-Free Survival 1\"\\n17725,1,1,\"Progression-free survival 6 (PFS6; Part 2)\"\\n17726,3,2,\"Progression-free Survival > 6 Months\"\\n17727,1,1,\"Progression-free survival [PFS]\"\\n17728,1,1,\"Progression-free survival according appropriate criteria (RANO, RAPNO, WHO, INRC, RECIST v1.1).\"\\n17729,1,1,\"Progression-free Survival According to RECIST\"\\n17730,1,1,\"Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n17731,1,1,\"Progression-free Survival According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n17732,1,1,\"Progression-free Survival According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n17733,1,1,\"Progression-free survival among newly diagnosed HGG patients\"\\n17734,1,1,\"Progression-free Survival as Assessed by BICR\"\\n17735,1,1,\"Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1)\"\\n17736,1,1,\"Progression-free Survival Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) (Phase II)\"\\n17737,1,1,\"Progression-free survival associated with RGX-104 treatment as a single agent, and separately, in combination with docetaxel or pembrolizumab plus carboplatin/pemetrexed.\"\\n17738,1,1,\"Progression-free Survival at 12 Weeks\"\\n17739,1,1,\"Progression-free Survival at 16 Weeks (Phase II)\"\\n17740,3,1,\"Progression-free Survival at 2 Years\"\\n17741,1,1,\"Progression-free Survival at 24 Weeks\"\\n17742,1,1,\"Progression-free Survival at 3 Months\"\\n17743,2,1,\"Progression-Free Survival at 6 months\"\\n17744,14,6,\"Progression-free Survival at 6 Months\"\\n17745,14,1,\"Progression-free survival at 6 months\"\\n17746,1,1,\"Progression-free Survival at 6 Months (PFS6) (Phase II)\"\\n17747,1,1,\"Progression-free Survival at 6 Months (Stratum 1)\"\\n17748,1,1,\"Progression-free Survival at 6 Months and 12 Months (Phase II)\"\\n17749,1,1,\"Progression-free Survival Based on Blinded Independent Central Review in Participants Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab\"\\n17750,1,1,\"Progression-free Survival Based on Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)\"\\n17751,1,1,\"Progression-free survival based on investigator assessment using RECIST and clinical findings\"\\n17752,1,1,\"Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator\"\\n17753,1,1,\"Progression-free survival based on tumor imaging according to RECIST 1.1 criteria.\"\\n17754,1,1,\"Progression-free Survival by CYP2D6 Status in 2 Categories\"\\n17755,1,1,\"Progression-free survival defined as a binary outcome (progression-free or not)\"\\n17756,1,1,\"Progression-Free Survival During First-Line Therapy (PFS1)\"\\n17757,1,1,\"Progression-free survival during the first phase of the study\"\\n17758,1,1,\"Progression-free survival during the second phase of the study\"\\n17759,1,1,\"Progression-Free Survival Following U3-1287 (AMG 888) in Combination With Erlotinib\"\\n17760,1,1,\"Progression-free Survival for Patients in Expansion Cohorts\"\\n17761,3,2,\"Progression-free Survival Greater Than 6 Months\"\\n17762,1,1,\"Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review\"\\n17763,1,1,\"Progression-free survival in DTC treated advanced ovary cancer\"\\n17764,1,1,\"Progression-Free Survival in Participants With High Heregulin-Expressing Tumors Following U3-1287 (AMG 888) in Combination With Erlotinib\"\\n17765,1,1,\"Progression-Free Survival in Participants With Low Heregulin-Expressing Tumors Following U3-1287 (AMG 888) in Combination With Erlotinib\"\\n17766,1,1,\"Progression-Free Survival in Participants With PD-L1 Expression >= 5%\"\\n17767,1,1,\"Progression-free Survival in Patients With Met Diagnostic-Positive Tumors\"\\n17768,1,1,\"Progression-free survival in Randomized part\"\\n17769,1,1,\"Progression-free Survival in the Subgroup of Participants With Œ≤III-tubulin Positive Tumors\"\\n17770,1,1,\"Progression-free survival of OSI-906 in combination with Erlotinib or Erlotinib plus placebo\"\\n17771,1,1,\"Progression-Free Survival of Participant Until Disease Progression or Death\"\\n17772,1,1,\"Progression-free Survival of Patients Treated With Chemoradiotherapy Plus Veliparib (Phase II)\"\\n17773,1,1,\"Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy.\"\\n17774,1,1,\"Progression-free survival per RECIST 1.1\"\\n17775,1,1,\"Progression-free Survival Per RECIST, v. 1.1 (PFS1)\"\\n17776,1,1,\"Progression-free survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohorts 1 and 2)\"\\n17777,1,1,\"Progression-free Survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Assessed by an Independent Central Imaging Laboratory\"\\n17778,1,1,\"Progression-free Survival Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); the time from randomization to progression or death due to any cause, whichever occurs first\"\\n17779,1,1,\"Progression-free Survival Per Stratum (BICR)\"\\n17780,1,1,\"Progression-free Survival Per Stratum (Sensitivity Analysis)\"\\n17781,1,1,\"Progression-Free survival PFS6 (Efficacy)\"\\n17782,1,1,\"Progression-free survival probability (PFSP) at 6 months (Phase II)\"\\n17783,6,2,\"Progression-free Survival Rate\"\\n17784,27,5,\"Progression-free survival rate\"\\n17785,5,1,\"progression-free survival rate\"\\n17786,1,1,\"Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization\"\\n17787,1,1,\"Progression-free Survival Rate (PFSR)\"\\n17788,1,1,\"Progression-free survival rate (PFSR)\"\\n17789,1,1,\"Progression-Free Survival Rate (PFSR) - Phase 2\"\\n17790,1,1,\"Progression-free survival rate (PFSR) at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator\"\\n17791,3,2,\"Progression-free survival rate (Phase II)\"\\n17792,2,2,\"Progression-free Survival Rate at 12 Weeks\"\\n17793,1,1,\"Progression-free survival rate at 12 weeks after starting treatment, defined according to the Response Evaluation Criteria In Solid Tumours(RECIST criteria)\"\\n17794,1,1,\"Progression-free Survival Rate at 18 Weeks\"\\n17795,1,1,\"Progression-free Survival Rate at 24 Weeks\"\\n17796,1,1,\"Progression-free survival rate at 35 months\"\\n17797,1,1,\"Progression-free survival rate at 4 months\"\\n17798,1,1,\"Progression-free Survival Rate at 6 Months (PFS-6) by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Estimated Using the Kaplan-Meier Method\"\\n17799,1,1,\"Progression-free Survival Rate at 6 Weeks\"\\n17800,1,1,\"Progression-free Survival Rate at Four Months (PFS4)\"\\n17801,1,1,\"Progression-free Survival Rate at Three Months\"\\n17802,1,1,\"Progression-free Survival Rate at Weeks 17 and 25\"\\n17803,3,2,\"Progression-free Survival Time\"\\n17804,3,1,\"Progression-free survival time (PFS)\"\\n17805,1,1,\"Progression-Free Survival Time by Response Evaluation Criteria in Solid Tumor (RECIST) Criteria in the Intent-to-treat Population\"\\n17806,1,1,\"Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate\"\\n17807,6,4,\"Progression-Free Survival(PFS)\"\\n17808,8,3,\"Progression-free Survival(PFS)\"\\n17809,22,2,\"Progression-free survival(PFS)\"\\n17810,13,1,\"progression-free survival(PFS)\"\\n17811,1,1,\"Progression-free Survival(PFS) Rate\"\\n17812,1,1,\"Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population\"\\n17813,1,1,\"Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\"\\n17814,1,1,\"Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1\"\\n17815,1,1,\"Progression-free survival, defined as the time to neurological progression or death\"\\n17816,1,1,\"Progression-Free Survival, PFS\"\\n17817,3,1,\"Progression-free Survival, PFS\"\\n17818,7,1,\"Progression-free survival, PFS\"\\n17819,3,1,\"progression-free survival, PFS\"\\n17820,1,1,\"Progression-Free Survival,PFS\"\\n17821,1,1,\"Progression-free Survival.\"\\n17822,1,1,\"Progression-free survive, calculated from registration until progression or death\"\\n17823,8,1,\"Progression-Free-Survival\"\\n17824,7,1,\"Progression-free-survival\"\\n17825,6,1,\"Progression-Free-Survival (PFS)\"\\n17826,1,1,\"Progression-Free-SurvivalÔºàPFSÔºâ\"\\n17827,1,1,\"Progressive disease (PD)\"\\n17828,2,1,\"Progressive disease rate\"\\n17829,1,1,\"Progressive Disease Response\"\\n17830,1,1,\"Progressive Disease(PD)\"\\n17831,1,1,\"Progressive-free Survival (PFS)\"\\n17832,1,1,\"Progressive-free Survival (PFS) Per Investigator Assessment\"\\n17833,1,1,\"Proliferation of Circulating T-cells as Measured by Mean Fold-change Between Baseline and Day 1 in Ki67 Levels.\"\\n17834,1,1,\"Proliferative index diagnosis\"\\n17835,1,1,\"Proliferative index prognosis\"\\n17836,1,1,\"Prolonged Stable Disease According to RECIST\"\\n17837,1,1,\"Prolonged Stable Disease Rate (Defined as Stable Disease for ‚â• 16 Weeks)\"\\n17838,1,1,\"Proportion by pathogen type of infectious pathogens\"\\n17839,1,1,\"Proportion of Confirmed Response, Defined as a Partial Response (PR) or Better (Phase II)\"\\n17840,1,1,\"Proportion of confirmed responses, evaluated using the RECIST v1.1\"\\n17841,1,1,\"Proportion of Confirmed Tumor Responses (Complete or Partial Response)\"\\n17842,1,1,\"Proportion of confirmed tumor responses assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort II)\"\\n17843,1,1,\"Proportion of Deaths\"\\n17844,1,1,\"Proportion of dose limiting toxicities at each dose level assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n17845,1,1,\"Proportion of eligible patients for PSMA-RLT or OCTREOTATE-RLT\"\\n17846,1,1,\"Proportion of enrolled patients for whom a personalized vaccine is developed and ready to administer (cohorts A and B)\"\\n17847,1,1,\"Proportion of enrolled patients who complete CPET and 6MWD test without significant testing-related adverse events\"\\n17848,1,1,\"Proportion of enrolled patients who receive at least 1 dose of vaccine at any time post-enrollment (cohorts A and B)\"\\n17849,1,1,\"Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)\"\\n17850,1,1,\"Proportion of HCA-cancer surveillance (SM)\"\\n17851,1,1,\"Proportion of HCA-cardiometabolic surveillance (CM)\"\\n17852,1,1,\"Proportion of home tested blood count results transferred to the hospital team on the day of the venous blood test performed prior to the subsequent SACT cycle\"\\n17853,1,1,\"Proportion of neuroendocrine lesion\"\\n17854,1,1,\"Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI\"\\n17855,1,1,\"Proportion of Participants alive at 6 months\"\\n17856,1,1,\"Proportion of participants completing each of the 3 program components\"\\n17857,1,1,\"Proportion of Participants Completing Paclitaxel Infusions\"\\n17858,1,1,\"Proportion of participants completing the entire program and 6 month follow up\"\\n17859,1,1,\"Proportion of participants eligible for a linked Roche clinical trial\"\\n17860,2,1,\"Proportion of participants enrolled\"\\n17861,1,1,\"Proportion of participants that achieve clinical benefit (CR, PR or SD) per RECIST 1.1\"\\n17862,1,1,\"Proportion of participants with >= 2-fold increase in the number of tumor-infiltrating immune cells (TIICs)\"\\n17863,1,1,\"Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])\"\\n17864,1,1,\"Proportion of Participants With a Complete Response\"\\n17865,1,1,\"Proportion of Participants With a Pathologic Complete Response Rate\"\\n17866,1,1,\"Proportion of participants with Adverse Events (AEs)\"\\n17867,1,1,\"Proportion of participants with AEs leading to discontinuation of treatment\"\\n17868,1,1,\"Proportion of Participants With an Objective Response (Partial Response + Complete Response)\"\\n17869,1,1,\"Proportion of Participants With an Objective Response Rate (ORR)\"\\n17870,1,1,\"Proportion of participants with any AEs of severity grade 3 or higher\"\\n17871,1,1,\"Proportion of participants with DLTs (Part A)\"\\n17872,1,1,\"Proportion of participants with evaluable biomarker results\"\\n17873,1,1,\"Proportion of Participants With Grade 2-4 Toxicities\"\\n17874,1,1,\"Proportion of Participants With Highest Grade, Treatment-related, Immune Response Adverse Events (IRAEs)\"\\n17875,1,1,\"Proportion of participants with immunogenicity following full vaccination (6 months after last dose).\"\\n17876,1,1,\"Proportion of participants with laboratory abnormalities in blood\"\\n17877,1,1,\"Proportion of participants with laboratory abnormalities in blood serum\"\\n17878,1,1,\"Proportion of participants with laboratory abnormalities in urine\"\\n17879,1,1,\"Proportion of Participants With Objective Response\"\\n17880,1,1,\"Proportion of Participants with Progression-Free Survival\"\\n17881,2,1,\"Proportion of participants with R0 resection\"\\n17882,1,1,\"Proportion of participants with reported dose-limiting toxicities (DLTs)\"\\n17883,1,1,\"Proportion of participants with Serious Adverse Events (SAEs)\"\\n17884,1,1,\"Proportion of participants with the c-KIT mutation who remain progression free at 6 months.\"\\n17885,1,1,\"Proportion of participants with treatment related adverse events (TRAEs) leading to study discontinuation\"\\n17886,1,1,\"Proportion of participants with treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and serious adverse events (SAEs)\"\\n17887,1,1,\"Proportion of participating oncology practitioners prescribing XGEVA¬Æ who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round)\"\\n17888,1,1,\"Proportion of pathologic and human papillomavirus cell-free tumor deoxyribonucleic acid (ctHPVDNA) response\"\\n17889,1,1,\"Proportion of patients achieving at least a doubling of peripheral blood CD34+ count during Stage 2\"\\n17890,1,1,\"Proportion of patients alive and progression free at 4 months\"\\n17891,3,1,\"Proportion of patients alive and progression-free\"\\n17892,1,1,\"Proportion of Patients Alive and Progression-free at 6 Months\"\\n17893,1,1,\"Proportion of Patients Alive and Progression-free at 8 Weeks\"\\n17894,1,1,\"Proportion of Patients Alive and Without Progression of Disease at 1 Year From Start of Protocol-based Therapy.\"\\n17895,1,1,\"Proportion of Patients Alive at 8 Months\"\\n17896,1,1,\"Proportion of Patients Alive Who Continue Study Drug and Complete the Health-related Quality of Life and Other Forms\"\\n17897,2,2,\"Proportion of patients being approached that agree to participate in the study\"\\n17898,1,1,\"Proportion of patients compliant with treatment plan\"\\n17899,1,1,\"Proportion of patients continuing TKI at 1st progression and proportion of patients discontinuing EGFR TKI at 1st progression. Analysis of the therapeutic management in the 2 groups. This outcome consists in multiple measures.\"\\n17900,1,1,\"Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status\"\\n17901,1,1,\"Proportion of patients Eligible for CTE versus Actual CTE\"\\n17902,1,1,\"Proportion of Patients Enrolled - Those Electronically Referred\"\\n17903,1,1,\"Proportion of patients for whom all data is successfully recorded within database\"\\n17904,1,1,\"Proportion of patients for whom all data is successfully recorded within the database\"\\n17905,1,1,\"Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery.\"\\n17906,1,1,\"Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3\"\\n17907,1,1,\"Proportion of patients on cancer therapy having humoral immune vaccine response of SARS-CoV-2-specific antibodies\"\\n17908,1,1,\"Proportion of patients presenting at least one genomic alteration\"\\n17909,1,1,\"proportion of patients presenting at least one targetable genomic alteration\"\\n17910,1,1,\"Proportion of patients receiving therapy based on genomic analyses among all eligible patients\"\\n17911,1,1,\"Proportion of Patients Receiving Vascular Endothelial Growth Factor (VEGF) Trap With 6-month Progression-free Survival\"\\n17912,1,1,\"Proportion of Patients Requiring Rescue Medication for Breakthrough Nausea or Emesis During Inpatient Chemotherapy\"\\n17913,1,1,\"Proportion of Patients Requiring Temporary (>1 Day) or Permanent Withdrawal of AZD2171 Prior to Progression and Within 12 Weeks of First Dose of AZD2171\"\\n17914,1,1,\"Proportion of patients successfully completing the entire treatment plan\"\\n17915,1,1,\"Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels\"\\n17916,1,1,\"Proportion of Patients Who Achieve a Confirmed Response\"\\n17917,1,1,\"Proportion of patients who achieve complete response and partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n17918,1,1,\"Proportion of Patients Who Are Alive and Progression-free for at Least 12 Months After Study Entry in Patients With Newly Diagnosed Stage III or IV Clear Cell Ovarian Cancer in the Following Populations: Patients in the U.S./Worldwide and Japan\"\\n17919,2,2,\"Proportion of patients who are progression-free\"\\n17920,1,1,\"Proportion of patients who are progression-free as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v2.0 at 6 months\"\\n17921,1,1,\"Proportion of patients who complete both baseline and follow up CPET tests without significant testing-related adverse events\"\\n17922,1,1,\"Proportion of patients who enroll and complete the serial measures\"\\n17923,1,1,\"Proportion of Patients Who Experience a PSA (Prostate-Specific Antigen) Decline of at Least 30%\"\\n17924,1,1,\"Proportion of patients who experience at least one bleeding event\"\\n17925,1,1,\"Proportion of patients who experience decrease of IL-6 or hsCRP by >20%\"\\n17926,2,2,\"Proportion of patients who experience DLTs\"\\n17927,1,1,\"Proportion of patients who experience DLTs (Dose Limiting Toxicity) 28 days following the first dose of HuMax-IL8, as well as all DLTs occurring during the study thereafter.\"\\n17928,2,1,\"Proportion of patients who experience grade 3-5 toxicity within 3 months of initiation, graded according to the National Cancer Institute (NCI) CTCAE version (v)4.0\"\\n17929,5,1,\"Proportion of patients who gave their consent to participate in the study\"\\n17930,1,1,\"Proportion of Patients Who Have Any Response to Treatment (Complete Response or Partial Response), Determined According to Response Evaluation Criteria in Solid Tumors (Phase II)\"\\n17931,1,1,\"Proportion of patients who have multiple options recommended\"\\n17932,1,1,\"Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab\"\\n17933,1,1,\"Proportion of patients who have one recommended therapy\"\\n17934,1,1,\"Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin)\"\\n17935,1,1,\"Proportion of Patients Who Have Their Surgery Delayed by More Than 4 Days or Surgery Never Occurs as a Direct or Indirect Result of Ipilimumab and Nivolumab Treatment.\"\\n17936,1,1,\"Proportion of patients who meet exercise recommendations.\"\\n17937,1,1,\"Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief\"\\n17938,1,1,\"Proportion of patients who report that the health provider discussed complimentary and alternative medicine (CAM) use\"\\n17939,1,1,\"Proportion of patients who undergo assessments using ultrahigh frequency (UHF) and evoked otoacoustic emission (OAE) testing\"\\n17940,1,1,\"Proportion of patients who undergo TURBT or cystectomy as scheduled\"\\n17941,1,1,\"Proportion of patients who wear HealthPatch and have data captured successfully for at least 75% of the time\"\\n17942,1,1,\"Proportion of patients who will select \"\"Complete Agree/Partially Agree\"\" in Question 1 \"\"I found the audio recording useful after the visit\"\"\"\\n17943,1,1,\"Proportion of patients who will select \"\"Complete Agree/Partially Agree\"\" in Question 2 \"\"I was able to effectively discuss my medical condition with my family member(s) and/or caregiver(s) who were not present at the clinical visit\"\\n17944,1,1,\"Proportion of patients with a >= 2-fold increase in the number of tumor-infiltrating immune cells (TIICs) in post- versus (vs.) pre-pembrolizumab treatment tumor specimens\"\\n17945,1,1,\"Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.\"\\n17946,1,1,\"Proportion of Patients With a Complete or Partial Response (Overall Response Rate [ORR])\"\\n17947,1,1,\"Proportion of patients with a complete response (CR) (Phase II)\"\\n17948,1,1,\"Proportion of patients with a complete response (CR) or partial response (PR)\"\\n17949,1,1,\"Proportion of patients with a confirmed tumor response at any time during the study.\"\\n17950,1,1,\"Proportion of patients with a confirmed tumor response, defined as complete response or partial response estimated using Response Evaluation Criteria in Solid Tumors 1.1 criteria\"\\n17951,1,1,\"Proportion of patients with a neutralizing antibody titer greater than 1/10 towards the wild strain and the English VOC 202012/01, South African 501Y.V2 variants and any other variants that may emerge\"\\n17952,1,1,\"Proportion of patients with a PFS2 to PFS1 ratio superior to 1.5.\"\\n17953,1,1,\"Proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account\"\\n17954,6,1,\"Proportion of patients with adverse events\"\\n17955,1,1,\"Proportion of Patients With Adverse Events as Assessed by CTCAE v4.0\"\\n17956,1,1,\"Proportion of patients with Adverse Events grade ‚â•3 related to LON002 and Serious Adverse Events related to LON002 as a measure of safety and tolerability.\"\\n17957,1,1,\"Proportion of patients with cancer admitted in ICU who will be eligible for optimal anti-cancer treatment after discharge from ICU\"\\n17958,1,1,\"Proportion of Patients With Complete and Partial Tumor Response\"\\n17959,1,1,\"Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1\"\\n17960,1,1,\"Proportion of patients with complete standard audiometry data (excluding UHF and OAE evaluations)\"\\n17961,1,1,\"Proportion of Patients With Confirmed Responses\"\\n17962,1,1,\"Proportion of Patients With Confirmed Tumor Response\"\\n17963,1,1,\"Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1\"\\n17964,1,1,\"proportion of patients with ctDNA clearance\"\\n17965,1,1,\"Proportion of patients with diminished respiratory failure and death\"\\n17966,1,1,\"Proportion of patients with DLT (dose limiting toxicity) during the first cycle (first 28 days of the combination of both study compounds), per dose level explored\"\\n17967,1,1,\"Proportion of patients with dose limiting toxicities\"\\n17968,1,1,\"Proportion of patients with dose-limiting toxicity (DLT) following treatment with pembrolizumab and 225Ac-J591\"\\n17969,1,1,\"Proportion of patients with grade 3 or higher toxicities and recommended phase II dose of sunitinib in the presence of bevacizumab or sunitinib alone graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n17970,1,1,\"Proportion of patients with lack of progressive disease for the index site at 1 year\"\\n17971,1,1,\"Proportion of Patients With no Nausea\"\\n17972,1,1,\"Proportion of patients with objective evidence of improvement to complete response among those patients who had disease progression at baseline on prior anti-PD-(L)1 therapy\"\\n17973,1,1,\"Proportion of patients with objective evidence of improvement to complete response among those patients who had stable disease or partial response at baseline on prior anti-PD-(L)1 therapy\"\\n17974,1,1,\"Proportion of patients with objective evidence of improvement to partial response among those patients who had disease progression at baseline on prior anti-PD-(L)1 therapy\"\\n17975,1,1,\"Proportion of patients with objective evidence of improvement to partial response among those patients who had stable disease at baseline on prior anti-PD-(L)1 therapy\"\\n17976,1,1,\"Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST)\"\\n17977,1,1,\"Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria)\"\\n17978,1,1,\"Proportion of Patients With Objective Tumor Response\"\\n17979,1,1,\"Proportion of patients with ototoxic hearing loss\"\\n17980,2,2,\"Proportion of Patients With PSA Response\"\\n17981,1,1,\"Proportion of patients with radiological response (ORR)\"\\n17982,1,1,\"Proportion of Patients With Response to Depsipeptide\"\\n17983,1,1,\"Proportion of patients with severe toxicity within 6 months from randomization.\"\\n17984,1,1,\"Proportion of patients with successful normalization of beta hCG\"\\n17985,1,1,\"Proportion of Patients With Target Adverse Events for the Step 2 Treatment\"\\n17986,1,1,\"Proportion of patients with treatment-related dose limiting toxicities (DLT) using the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n17987,1,1,\"Proportion of patients with treatment-related serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0\"\\n17988,1,1,\"Proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs\"\\n17989,1,1,\"Proportion of Planned Dose Received During First 12 Weeks of Therapy With AZD2171\"\\n17990,1,1,\"Proportion of planned patients receiving treatment in the MRgRT facility\"\\n17991,1,1,\"Proportion of positive lesions on FAP-2286 PET (Cohort 3 only)\"\\n17992,1,1,\"Proportion of progression-free participants\"\\n17993,1,1,\"Proportion of Progression-free Patients at 6 Months (Phase II)\"\\n17994,1,1,\"Proportion of progression-free survivors assessed by Response Evaluation Criteria for Solid Tumors (RECIST)\"\\n17995,1,1,\"Proportion of PSMA+ subjects (by imaging criteria) with PSA decline following treatment with the combination of 225Ac-J591 and 177Lu-PSMA I&T.\"\\n17996,1,1,\"Proportion of radiation-absorbed doses of radiolabeled FAP-2286 (Cohorts 1a/1b only)\"\\n17997,1,1,\"Proportion of recruited patients who wear Fitbit for at least 8 hours per day\"\\n17998,1,1,\"Proportion of resectable patients\"\\n17999,1,1,\"proportion of screened patients in whom a molecular abnormality for which a targeted therapy exists\"\\n18000,1,1,\"Proportion of sessions attended\"\\n18001,1,1,\"Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment\"\\n18002,1,1,\"Proportion of Subjects Experiencing Diarrhoea of Grade 2 and Above (up to 24 Weeks)\"\\n18003,1,1,\"Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of BPX-603\"\\n18004,1,1,\"Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)\"\\n18005,1,1,\"Proportion of Subjects Surviving at One Year\"\\n18006,1,1,\"Proportion of subjects who achieve an intracranial complete response or partial response (Phase II)\"\\n18007,1,1,\"Proportion of Subjects Who Experienced a Partial or Complete Response\"\\n18008,1,1,\"Proportion of subjects who participate or show high adherence to the intervention\"\\n18009,1,1,\"Proportion of subjects with an abscopal response\"\\n18010,1,1,\"Proportion of subjects with dose limiting toxicity (DLT) of 225Ac-J591 and 177Lu-PSMA-I&T during dose-escalation phase.\"\\n18011,1,1,\"Proportion of subjects with dose-limiting toxicity (DLT)\"\\n18012,1,1,\"Proportion of subjects with treatment-emergent AEs (TEAEs) and serious AEs (SAEs)\"\\n18013,1,1,\"Proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol\"\\n18014,1,1,\"Proportion of survived patients at 16 weeks\"\\n18015,1,1,\"Proportion of targeted therapy guided by tumor molecular characteristics\"\\n18016,1,1,\"Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.\"\\n18017,1,1,\"Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm (Taxotere)\"\\n18018,1,1,\"Proportion of time using application\"\\n18019,1,1,\"proportion of treated patients by 4 cycles of chimiotherapy that will prefere at least 1 modified version of meal.\"\\n18020,1,1,\"Proportion of treatment \"\"responders\"\" who do not require modification of chemotherapy regimen because of thrombocytopenia (PC <100√ó109/L) during two planned consecutive chemotherapy cycles without the use of rescue treatment.\"\\n18021,1,1,\"Proportion of tumor responses, defined as complete response or partial response as assessed using Response Evaluation Criteria In Solid Tumors\"\\n18022,1,1,\"Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)\"\\n18023,1,1,\"Proportions of Participants With Treatment-related Adverse Events\"\\n18024,1,1,\"Proportions of VS and meningiomas after exposure to RAD001\"\\n18025,1,1,\"Prorated AUC of Total Fatigue as Measured by the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4\"\\n18026,1,1,\"Prospective Power/Time Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics in Hepato-Pancreato-Biliary Sold Tumors Utilizing a Single Generator at a Single Surgical Center\"\\n18027,1,1,\"prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response.\"\\n18028,1,1,\"Prostate specific antigen (PSA) nadir < 0.2\"\\n18029,1,1,\"Prostate Specific Antigen (PSA) Response (>50% Reduction From Baseline)\"\\n18030,1,1,\"Prostate Specific Antigen (PSA) Response According to Consensus Criteria\"\\n18031,3,2,\"Prostate Specific Antigen (PSA) Response Rate\"\\n18032,1,1,\"Prostate-specific antigen (PSA) response (for prostate cancer participants only) based on Prostate Cancer Working Group 2 (PCWG2) criteria\"\\n18033,1,1,\"Prostate-specific antigen (PSA) response rate as determined by investigator according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Cohort 7 only)\"\\n18034,1,1,\"Prostatic Specific Antigen (PSA) Response Rate\"\\n18035,1,1,\"Prostatic Specific Antigen response\"\\n18036,1,1,\"Protein concentration measured using ELISA\"\\n18037,1,1,\"Protein-specific Antigen (PSA) Response Rate\"\\n18038,1,1,\"Proteomic changes in both biopsies and resected tumors\"\\n18039,1,1,\"Proteomics of blood samples\"\\n18040,1,1,\"Proteomics of exhaled air condensate samples\"\\n18041,1,1,\"Proteomics of tissue samples\"\\n18042,1,1,\"Proteomics of urine samples\"\\n18043,1,1,\"Prothrombin time in whole blood sample\"\\n18044,1,1,\"Protocol-defined maximum tolerated dose (MTD) or maximum administered dose (MAAD)\"\\n18045,1,1,\"Provide information access that is vital to research collaborators\"\\n18046,1,1,\"Provider satisfaction survey with telemedicine in radiation oncology (RO)\"\\n18047,1,1,\"Provision of blinded reference set of cancer versus non-cancer blood samples\"\\n18048,1,1,\"PSA Doubling Time (PSADT) at the Detection of Castration Resistance in Participants with mCRPC\"\\n18049,1,1,\"PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC\"\\n18050,3,1,\"PSA Progression\"\\n18051,15,1,\"PSA response\"\\n18052,1,1,\"PSA Response as Defined by the Recommendations of the Prostate-Specific Antigen Working Group\"\\n18053,15,5,\"PSA Response Rate\"\\n18054,8,2,\"PSA response rate\"\\n18055,1,1,\"PSA Response Rate, Defined as >= 50% Decline in PSA From Baseline Maintained for at Least 3 Weeks and Measured by the Same Laboratory, and Without Evidence of Other Disease Progression Documented at Time of Confirmatory Values\"\\n18056,1,1,\"PSA Response, Defined as Occurrence of PSA Decline to Greater Than or Equal to 50% From Baseline\"\\n18057,1,1,\"PSA-Progression free survival (PSA-PFS)\"\\n18058,1,1,\"PSA-RR\"\\n18059,1,1,\"Psychiatric disorders of the chronically-ill children/adolescents (SDQ)\"\\n18060,2,1,\"Psychological trauma\"\\n18061,1,1,\"Psychometric properties and dimensionality of the measure (step 3)\"\\n18062,1,1,\"Psychosocial Functioning as assessed by the global severity index (GSI) of the symptom checklist 90.\"\\n18063,1,1,\"Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90.\"\\n18064,1,1,\"Psychosocial Outcomes of Employed Males with Cancer using PROMIS domains\"\\n18065,1,1,\"Psychosocial Outcomes of Employed Males with Cancer using the validated Stress Thermometer.\"\\n18066,1,1,\"PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib\"\\n18067,1,1,\"PTV isodose coverage\"\\n18068,1,1,\"Pulmonary complication following hematopoietic stem cell transplant (HCT)\"\\n18069,19,1,\"Pulse rate\"\\n18070,1,1,\"Pulse Rate (beats/min)\"\\n18071,1,1,\"QASICC questionnaire\\'s 27 items tested on 990 patients to confirm the internal structure\"\\n18072,1,1,\"QoL (EQ-5D) at nivolumab initiation\"\\n18073,1,1,\"QOL and Symptoms by Functional Assessment of Cancer Therapy-General (FACT-G) at baseline, 3 months, and 1 year\"\\n18074,1,1,\"QoL Measurements Using FACT-HEP Questionnaire Before and After Treatment\"\\n18075,1,1,\"QPOP applicability: percentage of participants with successful application of QPOP drug selection.\"\\n18076,1,1,\"QRS by ECG\"\\n18077,1,1,\"QRS interval determined from 12-lead Electrocardiogram\"\\n18078,1,1,\"QRS interval duration\"\\n18079,1,1,\"QT by ECG\"\\n18080,3,1,\"QT interval duration\"\\n18081,1,1,\"QT time, assessed by QTcF / QTcB (QT interval corrected for heart rate according to Fridericia / Bazett)\"\\n18082,1,1,\"QTc by ECG\"\\n18083,1,1,\"QTc Friderica (QTcF) parameter\"\\n18084,10,1,\"QTc interval\"\\n18085,1,1,\"QTc interval determined from 12-lead Electrocardiogram\"\\n18086,1,1,\"QTc Sub-study: Evaluation of the concentration response analysis of XMT-1536 versus the change in QTcF values\"\\n18087,3,1,\"QTcF\"\\n18088,1,1,\"QTcF (QT interval, corrected for heart rate according to Fridericia\\'s formula) interval duration\"\\n18089,1,1,\"QTcF interval values\"\\n18090,1,1,\"QTcP (QT interval, corrected for heart rate using a population-specific correction) interval duration\"\\n18091,1,1,\"Qualitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients\"\\n18092,1,1,\"Qualitative and quantitative evaluation of palliative care services provided\"\\n18093,1,1,\"Qualitative and Quantitative Toxicities in Regard to Organ Specificity\"\\n18094,1,1,\"Qualitative assessment of 89Zr-girentuximab uptake within individual tumor deposits\"\\n18095,1,1,\"Qualitative assessment of holographic image quality\"\\n18096,6,1,\"Qualitative data\"\\n18097,6,1,\"Qualitative interview\"\\n18098,1,1,\"Quality and quantity of adverse events due to administration of erlotinib + 5-azacytidine, as therapy for the treatment of advanced or metastatic cancer.\"\\n18099,1,1,\"Quality of end of life care\"\\n18100,154,2,\"Quality of Life\"\\n18101,261,4,\"Quality of life\"\\n18102,20,1,\"Quality of Life (QoL)\"\\n18103,7,1,\"Quality of life (QOL)\"\\n18104,7,1,\"Quality of life (QoL)\"\\n18105,1,1,\"Quality of life (QOL) assessed using Functional Assessment of Cancer Therapy-Ovarian questionnaire\"\\n18106,1,1,\"Quality of Life (QOL) by SF-12 at baseline\"\\n18107,1,1,\"Quality of Life (QOL) Outcomes\"\\n18108,1,1,\"Quality of Life (QOL) Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Vanderbilt Cystectomy Index (FACT-VCI) Questionnaire\"\\n18109,1,1,\"Quality of Life (QOL) Outcomes as Assessed by the Short Form 8 (SF-8) Questionnaire\"\\n18110,1,1,\"Quality of life - SF 36\"\\n18111,1,1,\"Quality of life - SF36\"\\n18112,1,1,\"Quality of life as measured by Functional Assessment of Cancer Therapy\"\\n18113,1,1,\"Quality of Life at baseline\"\\n18114,1,1,\"Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 10-12 Weeks After Start of Treatment\"\\n18115,1,1,\"Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 3-4 Weeks After Start of Treatment\"\\n18116,1,1,\"Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 6-8 Weeks After Start of Treatment\"\\n18117,1,1,\"Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) Prior to Treatment\"\\n18118,1,1,\"Quality of Life of Anemic Participants Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment\"\\n18119,1,1,\"Quality of Life of Anemic Participants Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment\"\\n18120,1,1,\"Quality of Life of Anemic Participants Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment\"\\n18121,1,1,\"Quality of Life of Anemic Participants Using Short Form 36 (SF-36) Questionnaire Prior To Treatment\"\\n18122,1,1,\"Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment\"\\n18123,1,1,\"Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment\"\\n18124,1,1,\"Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment\"\\n18125,1,1,\"Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire Prior To Treatment\"\\n18126,1,1,\"Quality of Life of the parents (EQ-5D)\"\\n18127,1,1,\"quality of life questionary 36-item short form survey instrument (36-SF)\"\\n18128,16,1,\"Quality of life questionnaire\"\\n18129,1,1,\"Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) score\"\\n18130,1,1,\"Quality of life using patient questionnaire Karnofsky performance status\"\\n18131,1,1,\"Quality of life using World Health Organization Quality of Life questionnaire (WHOQoL-BREF)\"\\n18132,1,1,\"Quality Of Life: Functional assessment of chronic illness therapy-prostate questionnaire will be used\"\\n18133,1,1,\"Quality of Parent-ChildRelationship: Conflict, Closeness, Dependence Subscales\"\\n18134,1,1,\"Quality of the sample in relation to the technique\"\\n18135,1,1,\"Quantification and characterization of CD8 staining pattern\"\\n18136,2,2,\"Quantification of Cell Death and Immune Cell Biomarkers by IHC and In-Situ Hybridization\"\\n18137,2,2,\"Quantification of Cell Death and Immune Cell Biomarkers by Immunohistochemistry (IHC) and In-Situ Hybridization (ISH) in Resected Tissue\"\\n18138,1,1,\"Quantification of cellular glycogen\"\\n18139,1,1,\"Quantification of CIC structure in tumor tissue\"\\n18140,1,1,\"Quantification of false alerts and downstream clinical actions (Arm 2)\"\\n18141,1,1,\"Quantification of fraction of cells positive for apoptosis and drug target engagement biomarkers around injected drugs\"\\n18142,1,1,\"Quantification of LTh17 by flow cytometry\"\\n18143,2,2,\"Quantification of obstructive severity\"\\n18144,1,1,\"Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum\"\\n18145,1,1,\"Quantification of the Change in Regulatory T Cells (Tregs) During the Study Treatment.\"\\n18146,1,1,\"Quantification of tissue quality\"\\n18147,1,1,\"Quantification of trametinib in resected brain metastatic lesions utilizing high performance liquid chromatography/tandem mass spectrometry (Cohort B)\"\\n18148,1,1,\"Quantitation of pimonidazole staining (a.u./cm2) in radical prostatectomy specimens as determinant of biochemical failure\"\\n18149,1,1,\"Quantitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients\"\\n18150,1,1,\"Quantitative assessment of 89Zr-girentuximab uptake within individual tumor deposits\"\\n18151,1,1,\"Quantitative change in the sum of Response Evaluation Criteria in Solid Tumors (RECIST) - measurable index lesions on paired, pre-and post-treatment computed tomography scans (delta change in T)\"\\n18152,2,1,\"Quantitative frequency of TCR\"\\n18153,1,1,\"Quantitive analysis of the concentrations of Fluzoparib in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.\"\\n18154,1,1,\"Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor to obtain the mass balance data and the main excretion pathway in human body.\"\\n18155,1,1,\"Quantity of cfDNA in blood\"\\n18156,1,1,\"Quantity of cfDNA in bone marrow\"\\n18157,1,1,\"Quantity of cfDNA in urine\"\\n18158,1,1,\"Quantity of CTCs isolated during liver and/or lung metastasectomy\"\\n18159,1,1,\"Questionnaire G8 oncodage\"\\n18160,1,1,\"QuIC-A score (Quality of Informed Consent questionnaire - Part A, Objective)\"\\n18161,1,1,\"R0 recession rate\"\\n18162,5,2,\"R0 Resection Rate\"\\n18163,54,7,\"R0 resection rate\"\\n18164,1,1,\"R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment\"\\n18165,1,1,\"R0 resection rates in each cohort as measured by macroscopically complete tumor removal with negative microscopic surgical margins\"\\n18166,1,1,\"Rac: Accumulation Ratio for Alisertib\"\\n18167,1,1,\"RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort\"\\n18168,1,1,\"RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort\"\\n18169,1,1,\"Radiation Absorbed Doses by Organ for 177-Lu-cG250\"\\n18170,6,1,\"Radiation dose\"\\n18171,1,1,\"Radiation dose of [111In]-FPI-2058 and [225Ac]-FPI-2059 to whole body, organs, and selected regions of interest\"\\n18172,1,1,\"Radiation dose to 70% of the tumor volume, evaluated using PET-CT\"\\n18173,1,1,\"Radiation-induced Esophageal Toxicity\"\\n18174,1,1,\"Radical surgical resection rate\"\\n18175,3,1,\"Radioactivity concentration of each feces sample\"\\n18176,3,1,\"Radioactivity concentration of each plasma sample\"\\n18177,4,1,\"Radioactivity concentration of each urine samples\"\\n18178,1,1,\"Radioactivity in whole blood and plasma\"\\n18179,1,1,\"radioactivity measured to determine pharmacokinetics of 124I-hu3F8\"\\n18180,1,1,\"Radioactivity ratio in blood/plasma\"\\n18181,1,1,\"Radiographic imaging\"\\n18182,1,1,\"Radiographic PFS (rPFS) by Prostate Cancer Working Group 3 (PCWG3) (Cohort 2)\"\\n18183,1,1,\"Radiographic progression free survival\"\\n18184,2,1,\"Radiographic progression free survival (PFS)\"\\n18185,7,5,\"Radiographic Progression Free Survival (rPFS)\"\\n18186,6,1,\"Radiographic progression free survival (rPFS)\"\\n18187,1,1,\"Radiographic progression free survival (rPFS) between patients receiving apalutamide and apalutamide + carotuximab\"\\n18188,1,1,\"Radiographic progression free survival assessed by assessment using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) criteria\"\\n18189,1,1,\"Radiographic Progression-Free Survival\"\\n18190,1,1,\"Radiographic Progression-Free Survival (PFS)\"\\n18191,4,3,\"Radiographic Progression-Free Survival (rPFS)\"\\n18192,11,6,\"Radiographic Progression-free Survival (rPFS)\"\\n18193,2,1,\"Radiographic progression-free survival (rPFS)\"\\n18194,1,1,\"Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria\"\\n18195,5,5,\"Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review\"\\n18196,1,1,\"Radiographic Progression-Free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator\"\\n18197,1,1,\"Radiographic recurrence-free survival\"\\n18198,5,1,\"Radiographic Response\"\\n18199,1,1,\"Radiographic Response (RR)\"\\n18200,1,1,\"Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment\"\\n18201,3,2,\"Radiographic Response Rate\"\\n18202,3,1,\"Radiographic response rate\"\\n18203,1,1,\"Radiographic Response Rate (RRR) in the CNS in Patients With HER2-positive Breast Cancer Who Have Brain Metastasis Treated With Palbociclib\"\\n18204,1,1,\"Radiographic Response Rate of Aflibercept in Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy\"\\n18205,1,1,\"Radiographic Response Rates\"\\n18206,1,1,\"Radiographic Treatment Response\"\\n18207,1,1,\"Radiographic tumor assessment per RECIST v1.1 criteria\"\\n18208,1,1,\"Radiographically (X-OPT) calculated bone loss in millimeters\"\\n18209,1,1,\"Radiologic Response\"\\n18210,4,1,\"Radiological assessment\"\\n18211,1,1,\"Radiological evaluation of response to neoadjuvant chemotheraphy for breast cancer\"\\n18212,4,4,\"Radiological progression free survival (rPFS)\"\\n18213,1,1,\"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only\"\\n18214,1,1,\"Radiological Progression-Free Survival (rPFS)\"\\n18215,1,1,\"Radiological regression of pneumonitis\"\\n18216,1,1,\"Radiological Response Defined as Complete or Partial Response and Assessed Using RECIST Criteria\"\\n18217,1,1,\"Radiological volumetric response to treatment\"\\n18218,1,1,\"Radix relicta\"\\n18219,1,1,\"RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment\"\\n18220,1,1,\"Randomised phase II: Best overall tumour response\"\\n18221,1,1,\"Randomised tablet formulation continued supply expansion phase (Group 8): To determine the safety and tolerability profile of selected tablet dose schedules of the melt-extrusion (tablet) formulation.\"\\n18222,1,1,\"Randomized Cohort: Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n18223,1,1,\"Randomized cohorts: Objective response rate (ORR) (co-primary)\"\\n18224,1,1,\"Randomized cohorts: Progression-free survival (PFS) (co-primary)\"\\n18225,1,1,\"Randomized Part: Overall Survival (OS)\"\\n18226,1,1,\"Randomized Part: Progression Free Survival (PFS)\"\\n18227,1,1,\"Randomized part: Progression free survival (PFS)\"\\n18228,1,1,\"Randomized Part: Progression Free Survival (PFS) Time - Independent Read\"\\n18229,1,1,\"Randomized Phase 2 Dose Expansion: Progression-Free Survival\"\\n18230,1,1,\"Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR)\"\\n18231,1,1,\"Randomized Treatment Phase: Overall Survival (OS)\"\\n18232,1,1,\"Range of physiologic variables associated with receipt of radiation and chemotherapy (Arm 2)\"\\n18233,1,1,\"Rash severity\"\\n18234,1,1,\"Rate and Extent of Excretion Mass Balance Based on the Total Radioactivity in Urine and Faeces: Cumulative Fraction of Excretion 504 Hours After Start of Drug Infusion.\"\\n18235,1,1,\"Rate and Severity of Adverse Reactions\"\\n18236,1,1,\"Rate and Severity of Dose-limiting toxicity ÔºàDLTÔºâ\"\\n18237,1,1,\"Rate of 6 Month Progression-Free Survival\"\\n18238,9,1,\"Rate of adherence\"\\n18239,11,1,\"Rate of Adverse Events\"\\n18240,26,1,\"Rate of adverse events\"\\n18241,1,1,\"Rate of adverse events (AEs), including serious adverse events (SAEs) and AEs leading to treatment discontinuation\"\\n18242,1,1,\"Rate of adverse events (Dose Escalation Phase)\"\\n18243,2,2,\"Rate of adverse events as assessed by CTCAE v5.0\"\\n18244,1,1,\"Rate of Adverse Events including SAEs (Safety/tolerability) of VB10.NEO and the combination of VB10.NEO and bempegaldesleukin (NKTR-214)\"\\n18245,1,1,\"Rate of adverse events including SAEs and AEs leading to changes in ECOG status\"\\n18246,1,1,\"Rate of adverse events including SAEs and AEs leading to changes in safety laboratory evaluations\"\\n18247,1,1,\"Rate of adverse events including SAEs and AEs leading to physical examination findings\"\\n18248,1,1,\"Rate of adverse events including SAEs and AEs leading to treatment discontinuation\"\\n18249,1,1,\"Rate of adverse events including SAEs and AEs leading to vital signs findings\"\\n18250,1,1,\"Rate of at least one grade improvement using the NCI CTCAE v5.0\"\\n18251,1,1,\"Rate of AZD2936 discontinuation due to toxicity\"\\n18252,1,1,\"Rate of chemotherapy-related toxicity\"\\n18253,1,1,\"Rate of Common Terminology Criteria (CTC) (version [v]5.0) grade 3 or greater immune-related adverse events\"\\n18254,1,1,\"Rate of Complete Response\"\\n18255,1,1,\"Rate of Complete Response as Determined by the IMWG Criteria\"\\n18256,1,1,\"Rate of complete tumor necrosis\"\\n18257,1,1,\"Rate of completion of all adjuvant immunotherapy\"\\n18258,1,1,\"Rate of completion of all preoperative and operative therapy\"\\n18259,2,1,\"Rate of consent\"\\n18260,1,1,\"Rate of core tissue acquisition adequate for histologic analysis.\"\\n18261,1,1,\"Rate of CR + CRi (which includes CRc and CRd) will be determined by assessing the proportion of patients who achieved CR or CRi among all evaluable patients.\"\\n18262,1,1,\"Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n18263,1,1,\"Rate of deaths\"\\n18264,1,1,\"Rate of diarrhea and skin rash across the short, medium, and long genotype frequencies of the CA polymorphism\"\\n18265,1,1,\"Rate of Disease Control (Freedom From Disease Progression)\"\\n18266,1,1,\"Rate of Disease Progression at 2 Years\"\\n18267,2,1,\"Rate of Dose Limiting Toxicities (DLT)\"\\n18268,1,1,\"Rate of dose limiting toxicities (DLTs) during cycle 1 of therapy with MR-HIFU hyperthermia directed liposomal doxorubicin\"\\n18269,1,1,\"rate of dose limiting toxicities (DLTs) during defined DLT period\"\\n18270,1,1,\"Rate of dose limiting toxicities (DLTs) during the dose escalation phase\"\\n18271,1,1,\"Rate of dose limiting toxicities (Dose Escalation Phase)\"\\n18272,2,2,\"Rate of dose limiting toxicities of each subject\"\\n18273,5,2,\"Rate of Dose Limiting Toxicity (DLT)\"\\n18274,1,1,\"Rate of Dose-Limiting Toxicities (DLTs)- Cohorts A, B, C, and D\"\\n18275,6,1,\"Rate of event free survival\"\\n18276,1,1,\"Rate of Foxp3-positive patients in tumor by immunohistochemical analysis\"\\n18277,1,1,\"Rate of functional uterus defined as successful fertility sparing surgery (FSS) with no adjuvant therapy\"\\n18278,2,1,\"Rate of grade 3-5 adverse events\"\\n18279,1,1,\"Rate of grade 3-5 toxicity during chemotherapy\"\\n18280,2,1,\"Rate of grade III or higher organ toxicity attributable to conditioning\"\\n18281,1,1,\"Rate of HRQOL questionnaire completion\"\\n18282,1,1,\"Rate of immune-related adverse events (irAEs)\"\\n18283,1,1,\"rate of intolerable refractory immune mediated adverse events assessed during the defined DLT evaluation period\"\\n18284,1,1,\"Rate of Laboratory Abnormalities\"\\n18285,1,1,\"Rate of LMD (leptomeningeal disease) occurrence\"\\n18286,1,1,\"Rate of Local Control Over time (RECIST Criteria)\"\\n18287,1,1,\"Rate of Locoregional Failure/Progression (LRF/LRP) in Study Participants Receiving Protocol Therapy.\"\\n18288,2,1,\"Rate of malnutrition\"\\n18289,1,1,\"Rate of Margin Negative Surgical Resection (R0 Resection Rate)\"\\n18290,1,1,\"Rate of Meeting Feasibility Requirements\"\\n18291,1,1,\"Rate of mutation detection\"\\n18292,1,1,\"Rate of mutation detection via genetic testing to clinical practice guidelines of traditional family history criteria\"\\n18293,1,1,\"rate of new primary nonmelanoma skin cancers\"\\n18294,1,1,\"Rate of non-engraftment and secondary graft failure\"\\n18295,1,1,\"Rate of objective disease control\"\\n18296,1,1,\"Rate of objective response (complete and partial)\"\\n18297,1,1,\"Rate of objective response (complete or partial response)\"\\n18298,1,1,\"Rate of occurrence of dose-limiting toxicities (DLT) within cycle 1 (21 days) after initiation of the study treatment for both parts.\"\\n18299,1,1,\"Rate of Overall Response\"\\n18300,1,1,\"Rate of Overall Survival\"\\n18301,3,1,\"Rate of Participant Retention\"\\n18302,1,1,\"Rate of Participants Achieving 3-Month Progression-Free Survival (PFS)\"\\n18303,1,1,\"Rate of Participants Achieving Complete Response or Partial Response to Therapy.\"\\n18304,1,1,\"Rate of Participants Requiring Dose Holds\"\\n18305,1,1,\"Rate of Participants With a Dose Reduction\"\\n18306,1,1,\"Rate of Pathogenic Germline Variants (PGV)\"\\n18307,1,1,\"Rate of Pathologic Complete Response\"\\n18308,7,1,\"Rate of pathologic complete response\"\\n18309,4,2,\"Rate of Pathologic Complete Response (pCR)\"\\n18310,1,1,\"Rate of pathologic complete response (pCR) based on Response Evaluation Criteria in Solid Tumors criteria\"\\n18311,1,1,\"Rate of Pathologic Complete Response (pCR) by HER2 Amplification Status Non-Heterogeneous\"\\n18312,1,1,\"Rate of Pathologic Complete Responses (pCR) at the Time of Definitive Surgical Resection of Non-small Cell Lung Cancer\"\\n18313,1,1,\"Rate of pathological complete responses\"\\n18314,1,1,\"Rate of Patients Alive and Progression-free 6 Months After Inclusion.\"\\n18315,1,1,\"Rate of patients who report optimal compliance to surveillance\"\\n18316,1,1,\"Rate of patients with at least a 10-point decrease in anxiety score (evolution between the baseline and the 6th and last radiotherapy session)\"\\n18317,1,1,\"Rate of patients with sarcopenia diagnosed with metastatic cancer.\"\\n18318,1,1,\"Rate of PCR Negativity\"\\n18319,1,1,\"Rate of Percent Change (Relative to Baseline per 4 Week Interval) in Forced Vital Capacity (FVC) Through Week 52\"\\n18320,1,1,\"Rate of poor risk patients as defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria who are free of disease progression at 6 months after start of first line treatment with pazopanib.\"\\n18321,1,1,\"Rate of Positive Results of T-SPOT.TB (%)\"\\n18322,1,1,\"Rate of posttraumatic growth\"\\n18323,1,1,\"Rate of pPDX engraftment\"\\n18324,1,1,\"Rate of Progression Free Survival\"\\n18325,1,1,\"Rate of Progression Free Survival (PFS)\"\\n18326,1,1,\"Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy\"\\n18327,1,1,\"Rate of Progression-Free Survival\"\\n18328,1,1,\"Rate of R0 Resection\"\\n18329,1,1,\"Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria\"\\n18330,1,1,\"Rate of relapse (Phase II)\"\\n18331,1,1,\"Rate of Relapse-free Survival at 18 Months\"\\n18332,1,1,\"Rate of remission (CR, PR) according to RECIST Criteria\"\\n18333,3,1,\"Rate of Response\"\\n18334,1,1,\"Rate of response (Complete Response [CR] or Partial Response [PR]) in DNA repair proficient (DRPro) patients\"\\n18335,1,1,\"Rate of results reporting\"\\n18336,1,1,\"Rate of serious adverse events (Dose Escalation Phase)\"\\n18337,1,1,\"Rate of serious adverse events (SAEs)\"\\n18338,1,1,\"Rate of Seroconversion After 1 Dose of Vaccine\"\\n18339,1,1,\"Rate of Seroprotection After 1 Dose of Vaccine\"\\n18340,1,1,\"Rate of Severe Treatment-Induced Toxicity\"\\n18341,3,1,\"Rate of side effects\"\\n18342,1,1,\"Rate of Smoking Cessation at 6 months\"\\n18343,1,1,\"Rate of Successful Administration\"\\n18344,1,1,\"Rate of surgical delay (Bladder cohort)\"\\n18345,1,1,\"Rate of T and B cell activity\"\\n18346,1,1,\"Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)\"\\n18347,1,1,\"Rate of Toxicity\"\\n18348,1,1,\"Rate of treatment completion\"\\n18349,1,1,\"Rate of treatment delay (greater than 4 weeks) during preoperative therapy\"\\n18350,2,1,\"Rate of treatment emergent adverse events (TEAEs)\"\\n18351,1,1,\"Rate of treatment related adverse events (TRAE) according to CTCAE v5.0\"\\n18352,1,1,\"Rate of treatment related Grade III/IV adverse events (CTCAE V4.03)\"\\n18353,1,1,\"Rate of treatment-related toxicity during preoperative therapy assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4\"\\n18354,1,1,\"Rate of Treatment-related Toxicity in Study Participants\"\\n18355,1,1,\"Rate of Treg decrease in PBMC compared to baseline\"\\n18356,1,1,\"Rate of Tumor Response as Evaluated by Response Evaluation Criteria in Solid Tumors Version 1.1\"\\n18357,2,1,\"Rate of utilization of nutritional interventions\"\\n18358,1,1,\"Rates and routes of excretion of LBH589 and its metabolites in urine and feces following administration of a single oral dose of [14C] LBH589\"\\n18359,1,1,\"Rates of those with and without antibodies to SARS-CoV-2 after 3rd or 4th vaccine\"\\n18360,1,1,\"Ratio of Alisertib Plasma AUClast to Drug-Related Material TRA Plasma AUClast\"\\n18361,1,1,\"Ratio of Alisertib Plasma AUC‚àû to Drug-Related Material TRA Plasma AUC‚àû\"\\n18362,1,1,\"Ratio of Alisertib Plasma Cmax to Drug-Related Material TRA Plasma Cmax\"\\n18363,1,1,\"Ratio of Apparent Clearance Following Oral Administration (CL/F)\"\\n18364,1,1,\"Ratio of Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC) - Mild vs Normal and Moderate vs Normal\"\\n18365,1,1,\"Ratio of Area Under the Plasma Concentration Time Curve From Zero to the Last Measureable Time Point(AUC 0-t)\"\\n18366,1,1,\"Ratio of AUCinf of plasma adavosertib relative to AUCinf of plasma total radioactivity [AUCinf Plasma:Total Plasma Ratio]\"\\n18367,1,1,\"Ratio of AUCinf of whole blood total radioactivity to AUCinf of plasma total radioactivity [AUCinf Blood:Plasma Ratio]\"\\n18368,1,1,\"Ratio of AUCss for Day 4 to Day 11\"\\n18369,1,1,\"Ratio of AZD2014 Concentration to Total Radioactivity Concentration in Saliva\"\\n18370,1,1,\"Ratio of Css,Max for Day 4 to Day 11\"\\n18371,1,1,\"Ratio of Dendritic Cells (DC) to Circulating Immature Cells (ImC) Before and After Treatment\"\\n18372,1,1,\"Ratio of Maximum Plasma Concentration (Cmax) - Mild vs Normal and Moderate vs Normal\"\\n18373,1,1,\"Ratio of pCDC2 Response in Skin Following Administration of Cytotoxic Therapy\"\\n18374,1,1,\"Ratio of the AUC0-‚àû of the two formulations of CO-1.01 given as a 30 min i.v. infusion at 1250 mg/m2\"\\n18375,1,1,\"Ratio of Total and Unbound Trough GDC-0449 Concentration Between Day 57 to Day 15\"\\n18376,1,1,\"Ratio of Whole Blood Total Radioactivity (TRA) Cmax to Plasma TRA Cmax\"\\n18377,1,1,\"Ratio of Whole Blood Total Radioactivity to Plasma Total Radioactivity\"\\n18378,1,1,\"Ratio of Whole Blood TRA AUClast to Plasma TRA AUClast\"\\n18379,1,1,\"Ratio of Whole Blood TRA AUC‚àû to Plasma TRA AUC‚àû\"\\n18380,1,1,\"Ratios of geometric means of AUCinf (Area under plasma concentration-time curve from time zero to infinity) when administered in combination with itraconazole/rifampicin/omeprazole relative to adavosertib alone\"\\n18381,1,1,\"Ratios of geometric means of AUClast (Area under the plasma concentration-time curve from zero to time of last quantifiable concentration) when administered in combination with itraconazole/rifampicin/omeprazole relative to adavosertib alone\"\\n18382,1,1,\"Ratios of geometric means of Cmax (maximum observed plasma concentration) when administered in combination with itraconazole/rifampicin/omeprazole relative to adavosertib alone\"\\n18383,3,2,\"RD\"\\n18384,1,1,\"RD, defined as the highest dose level at which less than 33% of at least six patients experience DLT\"\\n18385,1,1,\"RDE (Part 1 and Part 2)\"\\n18386,1,1,\"RDFE of BGB-15025 in combination with tislelizumab\"\\n18387,1,1,\"RDL Determination\"\\n18388,1,1,\"Real-World Progression Free Survival (rwPFS)\"\\n18389,1,1,\"Reason for going off-study\"\\n18390,1,1,\"Reason for not enrolling on a clinical trial\"\\n18391,1,1,\"Reasons for Discontinuation of Next LoT\"\\n18392,1,1,\"Reasons for Discontinuation of Panitumumab\"\\n18393,1,1,\"Recall rates of personal genomic results\"\\n18394,1,1,\"Recidive free survival (RFS)\"\\n18395,2,1,\"RECIST\"\\n18396,1,1,\"RECIST and PERCIST Tumor Response\"\\n18397,2,1,\"RECIST criteria\"\\n18398,2,1,\"RECIST Response\"\\n18399,1,1,\"RECIST the Response criteria for solid tumors will be used to identify clinical benefit rate (CBR) including complete Response (CR), partial Response (PR) and stable disease (SD)\"\\n18400,1,1,\"RECIST v 1.1 response rate or specific criteria for prostate cancer\"\\n18401,1,1,\"RECIST(Response Evaluation Criteria in Solid Tumors)\"\\n18402,1,1,\"recommedded phase 2 dose\"\\n18403,1,1,\"Recommend a phase II dose and dosing schedule for VS-6766, as a single agent and also in combination with everolimus.\"\\n18404,1,1,\"Recommend dose of TJ004309\"\\n18405,1,1,\"recommend phase 2 dose\"\\n18406,1,1,\"Recommend Phase 2 Dose(RP2D) of single dose of FS-1502\"\\n18407,1,1,\"Recommended combination dose of ziv-aflibercept and pembrolizumab\"\\n18408,1,1,\"Recommended Dosage of the Durvalumab and Trabectedin Combination\"\\n18409,7,3,\"Recommended dose\"\\n18410,3,1,\"recommended dose\"\\n18411,9,4,\"Recommended Dose (RD)\"\\n18412,6,4,\"Recommended dose (RD)\"\\n18413,1,1,\"Recommended Dose (RD) of Cabiralizumab in Combination With Nivolumab (Phase 1a)\"\\n18414,1,1,\"Recommended Dose (RD) of ETC-1922159 when administered with pembrolizumab (Part B Dose Escalation)\"\\n18415,1,1,\"Recommended dose (RD) of rSIFN-co\"\\n18416,1,1,\"Recommended dose (RD) of the combination PM01183 and cisplatin\"\\n18417,1,1,\"Recommended Dose and Regimen (mono and combination therapy)\"\\n18418,1,1,\"Recommended dose and schedule\"\\n18419,1,1,\"Recommended Dose and Schedule for Phase 2 Studies\"\\n18420,1,1,\"Recommended dose determined by incidence of dose limiting toxicity.\"\\n18421,1,1,\"Recommended Dose Expansion (RDE) of M9140\"\\n18422,2,2,\"Recommended dose for dose expansion\"\\n18423,3,2,\"Recommended dose for expansion (RDE)\"\\n18424,1,1,\"Recommended Dose for Expansion (RDE) of BC006\"\\n18425,1,1,\"Recommended Dose for Extension (RDE) of RO7284755 in Parts 1 and 2\"\\n18426,1,1,\"Recommended Dose for Further Development of RO6874281\"\\n18427,4,3,\"Recommended Dose for Phase 2 Studies\"\\n18428,1,1,\"Recommended dose for Phase 2 Studies\"\\n18429,1,1,\"Recommended Dose for Phase 2 Studies : Maximum Tolerated Dose (MTD)\"\\n18430,1,1,\"Recommended Dose for Phase 2 Studies of LY573636-Sodium Combined With Sunitinib in Participants With Metastatic Renal Cell Carcinoma\"\\n18431,1,1,\"Recommended Dose for Phase 2 Studies/Maximum Tolerated Dose (MTD)\"\\n18432,1,1,\"Recommended dose for Phase II\"\\n18433,3,2,\"Recommended dose for phase II (RP2D)\"\\n18434,1,1,\"Recommended Dose Level for Phase II Testing (RPTD) (Phase I)\"\\n18435,1,1,\"Recommended Dose Level of Flavopiridol\"\\n18436,1,1,\"Recommended dose level of the combination\"\\n18437,1,1,\"Recommended dose of GZ17-6.02 for future phase II clinical studies\"\\n18438,1,1,\"Recommended dose of intratumoral urelumab\"\\n18439,1,1,\"Recommended Dose of IPN60090 in Part A\"\\n18440,1,1,\"Recommended Dose of PDX Given in Combination With a Fixed Dose of 5-FU Administered as a 48-hour Infusion Given Every Other Week\"\\n18441,1,1,\"Recommended Dose of RO6874281\"\\n18442,1,1,\"Recommended dose of SBRT given in combination with immunotherapy\"\\n18443,1,1,\"Recommended dose of the combination based on Dose Limiting Toxicities observed\"\\n18444,1,1,\"Recommended dose of TL-895\"\\n18445,1,1,\"Recommended dose schedule for NL-201 (Parts 1 and 2)\"\\n18446,1,1,\"Recommended dose schedule for NL-201 in combination with Pembrolizumab (Parts 3 and 4)\"\\n18447,1,1,\"Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapy\"\\n18448,1,1,\"Recommended dosing for the combination of dalteparin and sunitinib malate\"\\n18449,1,1,\"Recommended expansion dose (RED)\"\\n18450,1,1,\"Recommended Expansion Dose and/or Maximum Tolerated Dose of ABBV-CLS-579\"\\n18451,1,1,\"Recommended Expansion Dose and/or Maximum Tolerated Dose of ABBV-CLS-579 and a PD-1 Inhibitor\"\\n18452,1,1,\"Recommended Extended Dose\"\\n18453,1,1,\"Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])\"\\n18454,1,1,\"Recommended maximum tolerated dose (MTD)\"\\n18455,1,1,\"Recommended optimal dose of intravenous IPP-204106N administered for at least 5 consecutive days.\"\\n18456,1,1,\"Recommended Part II Dose of DMUC4064A\"\\n18457,1,1,\"Recommended phase 2 (RP2D) dose o TBI-1301 when administered following cyclophosphamide and fludarabine pre-treatment\"\\n18458,1,1,\"Recommended phase 2 dosage\"\\n18459,13,9,\"Recommended Phase 2 Dose\"\\n18460,11,2,\"Recommended Phase 2 dose\"\\n18461,12,6,\"Recommended phase 2 dose\"\\n18462,1,1,\"recommended phase 2 Dose\"\\n18463,1,1,\"Recommended phase 2 dose (Dose escalation phase)\"\\n18464,1,1,\"Recommended Phase 2 Dose (Part 1 Only)\"\\n18465,2,2,\"Recommended phase 2 dose (Part A)\"\\n18466,2,1,\"Recommended Phase 2 Dose (Phase 1)\"\\n18467,1,1,\"Recommended phase 2 dose (Phase I)\"\\n18468,1,1,\"recommended phase 2 dose (Phase Ib)\"\\n18469,1,1,\"Recommended phase 2 dose (R2PD)\"\\n18470,1,1,\"Recommended phase 2 dose (R2PD) (Phase I)\"\\n18471,72,52,\"Recommended Phase 2 Dose (RP2D)\"\\n18472,17,7,\"Recommended Phase 2 dose (RP2D)\"\\n18473,19,8,\"Recommended phase 2 dose (RP2D)\"\\n18474,1,1,\"Recommended Phase 2 Dose (RP2D) (Dose Escalation Phase)\"\\n18475,1,1,\"Recommended phase 2 dose (RP2D) (if has) (Part 1a)\"\\n18476,3,2,\"Recommended Phase 2 Dose (RP2D) (Phase 1)\"\\n18477,3,1,\"Recommended phase 2 dose (RP2D) (Phase I)\"\\n18478,1,1,\"Recommended Phase 2 dose (RP2D) (Phase Ib)\"\\n18479,5,5,\"Recommended phase 2 dose (RP2D) (Phase Ib)\"\\n18480,2,2,\"Recommended Phase 2 Dose (RP2D) - Part 1 (Phase 1b)\"\\n18481,2,1,\"Recommended Phase 2 Dose (RP2D) - Phase 1\"\\n18482,1,1,\"Recommended phase 2 dose (RP2D) and schedule of PRT1419\"\\n18483,1,1,\"Recommended phase 2 dose (RP2D) and schedule of PRT2527\"\\n18484,1,1,\"Recommended Phase 2 Dose (RP2D) and/or maximum tolerated dose (MTD)\"\\n18485,1,1,\"Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib\"\\n18486,1,1,\"Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin\"\\n18487,1,1,\"Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study\"\\n18488,1,1,\"Recommended Phase 2 Dose (RP2D) by determination of highest feasible dose (MFD) and any Dose Limiting Toxicities\"\\n18489,1,1,\"Recommended phase 2 dose (RP2D) determined after maximally tolerated dose is set and four dose expansion cohorts have evaluable data\"\\n18490,1,1,\"Recommended Phase 2 Dose (RP2D) Determined in the Dose Escalation Phase (Phase 1)\"\\n18491,1,1,\"Recommended Phase 2 dose (RP2D) dose (RP2D)\"\\n18492,1,1,\"Recommended Phase 2 Dose (RP2D) for MDNA11\"\\n18493,1,1,\"Recommended phase 2 dose (RP2D) for NL-201 (Parts 1 and 2)\"\\n18494,1,1,\"Recommended phase 2 dose (RP2D) for NL-201 in combination with Pembrolizumab (Parts 3 and 4)\"\\n18495,1,1,\"Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapy\"\\n18496,1,1,\"Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01\"\\n18497,1,1,\"Recommended Phase 2 Dose (RP2D) in Part 1\"\\n18498,1,1,\"Recommended phase 2 dose (RP2D) in Stage I\"\\n18499,1,1,\"Recommended Phase 2 Dose (RP2D) of ABBV-184 (Dose-Escalation Phase)\"\\n18500,1,1,\"Recommended Phase 2 Dose (RP2D) of ABBV-706\"\\n18501,1,1,\"Recommended Phase 2 dose (RP2D) of ADG206\"\\n18502,1,1,\"Recommended Phase 2 Dose (RP2D) of Alectinib\"\\n18503,1,1,\"Recommended Phase 2 Dose (RP2D) of AMG 256\"\\n18504,1,1,\"Recommended Phase 2 Dose (RP2D) of ASP1650\"\\n18505,2,1,\"Recommended Phase 2 Dose (RP2D) of Atezolizumab\"\\n18506,1,1,\"Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride\"\\n18507,1,1,\"Recommended phase 2 dose (RP2D) of BAY 1895344\"\\n18508,1,1,\"Recommended Phase 2 dose (RP2D) of BAY2965501\"\\n18509,1,1,\"Recommended phase 2 dose (RP2D) of BOS172738\"\\n18510,1,1,\"Recommended Phase 2 Dose (RP2D) of Brigatinib\"\\n18511,1,1,\"Recommended Phase 2 Dose (RP2D) of CA-170\"\\n18512,1,1,\"Recommended Phase 2 dose (RP2D) of CBP-1018 in Part A\"\\n18513,1,1,\"Recommended Phase 2 Dose (RP2D) of CF33-hNIS as a monotherapy or in combination with pembrolizumab\"\\n18514,1,1,\"Recommended phase 2 dose (RP2D) of copanlisib and nivolumab combination\"\\n18515,1,1,\"Recommended Phase 2 Dose (RP2D) of Debio 0123 When Administered in Combination with Carboplatin\"\\n18516,1,1,\"Recommended Phase 2 Dose (RP2D) of Decoy20\"\\n18517,1,1,\"Recommended phase 2 dose (RP2D) of derazantinib-paclitaxel-ramucirumab in combination (Substudy 2)\"\\n18518,1,1,\"Recommended Phase 2 Dose (RP2D) of DHES0815A\"\\n18519,1,1,\"Recommended Phase 2 Dose (RP2D) of DMOT4039A\"\\n18520,1,1,\"Recommended Phase 2 Dose (RP2D) of E7046\"\\n18521,1,1,\"Recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced solid tumors\"\\n18522,1,1,\"Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)\"\\n18523,1,1,\"Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules\"\\n18524,1,1,\"Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules\"\\n18525,1,1,\"Recommended Phase 2 Dose (RP2D) of IMX-110 in patients with advanced solid tumors\"\\n18526,1,1,\"Recommended Phase 2 dose (RP2D) of KM602\"\\n18527,1,1,\"Recommended phase 2 dose (RP2D) of LDM Topotecan\"\\n18528,1,1,\"Recommended Phase 2 Dose (RP2D) of Lenvatinib\"\\n18529,1,1,\"Recommended Phase 2 dose (RP2D) of lenvatinib in combination with everolimus: Phase 1\"\\n18530,1,1,\"Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel\"\\n18531,1,1,\"Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules\"\\n18532,1,1,\"Recommended Phase 2 Dose (RP2D) of MLN2480\"\\n18533,1,1,\"Recommended Phase 2 dose (RP2D) of MTB-9655 monotherapy in patients with locally advanced or metastatic solid tumors.\"\\n18534,1,1,\"Recommended Phase 2 Dose (RP2D) of NHS-IL12 (M9241) Given With Bintrafusp Alfa (M7824) in Combination With Stereotactic Body Radiation Therapy (SBRT) as Neoadjuvant / Perioperative Treatment in Participants With Pancreas Cancer\"\\n18535,1,1,\"Recommended Phase 2 Dose (RP2D) of ONCR-177\"\\n18536,1,1,\"Recommended Phase 2 Dose (RP2D) of PMD-026\"\\n18537,1,1,\"Recommended Phase 2 Dose (RP2D) of PRL3-zumab defined as the most appropriate dose to maximize a favorable risk/benefit reward for the participant population\"\\n18538,1,1,\"Recommended Phase 2 dose (RP2D) of RP2\"\\n18539,1,1,\"Recommended phase 2 dose (RP2D) of RP3\"\\n18540,1,1,\"Recommended Phase 2 Dose (RP2D) of TAK-164\"\\n18541,1,1,\"Recommended Phase 2 Dose (RP2D) of TAK-280\"\\n18542,1,1,\"Recommended Phase 2 Dose (RP2D) of TAS-117 in Part A\"\\n18543,1,1,\"Recommended phase 2 dose (RP2D) of tazemetostat in combination with pembrolizumab\"\\n18544,1,1,\"Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction\"\\n18545,1,1,\"Recommended Phase 2 Dose (RP2D) of TH1902.\"\\n18546,1,1,\"Recommended Phase 2 Dose (RP2D) of Trabectedin in Combination with Doxorubucin and Olaratumab\"\\n18547,1,1,\"Recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152)\"\\n18548,1,1,\"Recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) in combination with Keytruda¬Æ (pembrolizumab)\"\\n18549,1,1,\"Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)\"\\n18550,1,1,\"Recommended Phase 2 Dose (RP2D)- Cohorts A, B, C, and D\"\\n18551,1,1,\"Recommended Phase 2 Dose (RP2D): Part 1\"\\n18552,1,1,\"Recommended Phase 2 Dose (RP2D): Phase 1b\"\\n18553,1,1,\"Recommended phase 2 dose (RP2DÔºâ(for Part 1a)\"\\n18554,1,1,\"Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181\"\\n18555,1,1,\"Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or Nivolumab\"\\n18556,1,1,\"Recommended Phase 2 Dose (RPTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab\"\\n18557,1,1,\"Recommended Phase 2 dose (RPTD) of veliparib (ABT-888) in combination with nivolumab and platinum doublet chemotherapy in participants with metastatic or advanced Non-Small Cell Lung Cancer (NSCLC).\"\\n18558,1,1,\"Recommended phase 2 dose (Stage 1)\"\\n18559,1,1,\"Recommended Phase 2 Dose [RP2D]\"\\n18560,1,1,\"Recommended Phase 2 dose and schedule\"\\n18561,1,1,\"Recommended phase 2 dose and schedule\"\\n18562,1,1,\"Recommended phase 2 dose and schedule of ACY 241 in combination with paclitaxel on a weekly schedule.\"\\n18563,1,1,\"Recommended phase 2 dose as determined by number of participants at each dose level with dose limiting toxicities\"\\n18564,1,1,\"Recommended Phase 2 Dose by Identification of Any Dose Limiting Toxicities\"\\n18565,1,1,\"Recommended Phase 2 Dose for Enzastaurin Plus Erlotinib Combination Therapy (Assess the Tolerated Dose of the Combination Erlotinib and Enzastaurin)\"\\n18566,1,1,\"Recommended phase 2 dose for gefitnib and BKM120 combination therapy\"\\n18567,1,1,\"Recommended phase 2 dose for the combination of glembatumumab vedotin and nivolumab (Phase Ib)\"\\n18568,1,1,\"Recommended Phase 2 dose of ABBV-221\"\\n18569,1,1,\"Recommended phase 2 dose of alpelisib in combination with cisplatin, based upon evaluation of dose-limiting toxicities\"\\n18570,1,1,\"Recommended phase 2 dose of anetumab ravtansine with combination of pembrolizumab\"\\n18571,1,1,\"Recommended Phase 2 Dose of AZD5312 in patients with advanced solid tumours where androgen receptor pathway is a potential factor.\"\\n18572,1,1,\"Recommended phase 2 dose of botensilimab, balstilimab, and regorafenib (Phase I)\"\\n18573,1,1,\"Recommended phase 2 dose of cabozantinib S-malate (cabozantinib) (Phase I)\"\\n18574,1,1,\"Recommended Phase 2 Dose of Dasatinib Administered With Docetaxel, 75 mg/m^2\"\\n18575,1,1,\"Recommended phase 2 dose of HLX23\"\\n18576,1,1,\"Recommended Phase 2 Dose of INT-1B3\"\\n18577,1,1,\"Recommended phase 2 dose of irinotecan hydrochloride (Dose escalation)\"\\n18578,1,1,\"Recommended phase 2 dose of magrolimab (dose finding cohort)\"\\n18579,1,1,\"Recommended Phase 2 Dose of MK-2206 in Combination With Trastuzumab (Part 1) and With Trastuzumab/Lapatinib (Part 2)\"\\n18580,1,1,\"Recommended Phase 2 Dose of Pevonedistat When Combined With Pembrolizumab (Phase I)\"\\n18581,1,1,\"Recommended phase 2 dose of seviteronel plus dexamethasone and docetaxel\"\\n18582,1,1,\"Recommended phase 2 dose of SJG-136\"\\n18583,1,1,\"Recommended Phase 2 Dose of SRA737\"\\n18584,1,1,\"Recommended Phase 2 dose of SRA737 in combination with gemcitabine.\"\\n18585,1,1,\"Recommended Phase 2 Dose of TAK-117 in Phase 1b\"\\n18586,1,1,\"Recommended phase 2 dose of talazoparib, graded according to NCI CTCAE version 4.0\"\\n18587,1,1,\"Recommended Phase 2 Dose of Telaglenastat in Combination with Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Incidence and Nature of Protocol Defined Dose-Limiting Toxicities (DLTs) During the Safety Run-in Period\"\\n18588,1,1,\"Recommended phase 2 dose of veliparib/dinaciclib\"\\n18589,1,1,\"Recommended Phase 2 Dose of WGI-0301\"\\n18590,1,1,\"Recommended Phase 2 dose(RP2D) (Applicable for: phase I stage in various solid tumor types).\"\\n18591,1,1,\"Recommended phase 2 dose(RP2D) of apatinib\"\\n18592,1,1,\"Recommended Phase 2 Dose(RP2D) of CS5001 (for dose escalation part)\"\\n18593,1,1,\"Recommended phase 2 dose(RP2D) of SC-43\"\\n18594,1,1,\"Recommended Phase 2 Dose: Maximum Tolerated Dose\"\\n18595,1,1,\"Recommended phase 2 doses for the combination of pemetrexed disodium with sorafenib tosylate\"\\n18596,1,1,\"recommended phase II clinical study dose (RP2D)\"\\n18597,1,1,\"Recommended phase II clinical study dose (RP2D) of oral HMPL-295S1.\"\\n18598,1,1,\"recommended phase II does of Prexasertib\"\\n18599,11,6,\"Recommended Phase II Dose\"\\n18600,21,10,\"Recommended phase II dose\"\\n18601,1,1,\"recommended phase II dose\"\\n18602,1,1,\"Recommended Phase II dose (Part A)\"\\n18603,2,2,\"Recommended Phase II Dose (Phase I)\"\\n18604,5,3,\"Recommended phase II dose (Phase I)\"\\n18605,1,1,\"Recommended phase II dose (Phase Ib)\"\\n18606,30,15,\"Recommended Phase II Dose (RP2D)\"\\n18607,6,1,\"Recommended Phase II dose (RP2D)\"\\n18608,24,11,\"Recommended phase II dose (RP2D)\"\\n18609,1,1,\"recommended phase II dose (RP2D)\"\\n18610,1,1,\"Recommended phase II dose (RP2D) (Part 1)\"\\n18611,1,1,\"recommended phase II dose (RP2D) (phase I)\"\\n18612,1,1,\"Recommended Phase II dose (RP2D) and schedule of CX-4945 in combination with gemcitabine plus cisplatin (Phase I)\"\\n18613,1,1,\"Recommended Phase II Dose (RP2D) based on safety, tumor pharmacodynamics, and pharmacokinetics\"\\n18614,1,1,\"Recommended phase II dose (RP2D) for each stratum\"\\n18615,1,1,\"Recommended phase II dose (RP2D) of alvespimycin hydrochloride for future studies determined by toxicity assessments\"\\n18616,1,1,\"Recommended Phase II Dose (RP2D) of Atezolizumab and Erlotinib\"\\n18617,1,1,\"Recommended Phase II Dose (RP2D) of Atezolizumab When Given in Combination With Ipilimumab and Interferon Alfa-2b\"\\n18618,1,1,\"Recommended Phase II Dose (RP2D) of BAY1436032\"\\n18619,1,1,\"Recommended phase II dose (RP2D) of BAY1895344\"\\n18620,1,1,\"Recommended Phase II dose (RP2D) of BAY2416964\"\\n18621,1,1,\"Recommended Phase II Dose (RP2D) of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I).\"\\n18622,1,1,\"Recommended Phase II dose (RP2D) of elimusertib\"\\n18623,1,1,\"Recommended phase II dose (RP2D) of everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)\"\\n18624,1,1,\"Recommended Phase II Dose (RP2D) of Gemcitabine in Combination With Pembrolizumab\"\\n18625,1,1,\"Recommended Phase II Dose (RP2D) of HRS-1167\"\\n18626,1,1,\"Recommended Phase II Dose (RP2D) of Ipatasertib\"\\n18627,1,1,\"recommended Phase II dose (RP2D) of LAE005 and afuresertib and nab-paclitaxel as a combination treatment in patients with advanced solid tumours (including mTNBC)\"\\n18628,1,1,\"Recommended Phase II Dose (RP2D) of LDE225 (Sonidegib) in Combination With Docetaxel\"\\n18629,1,1,\"Recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer\"\\n18630,1,1,\"Recommended phase II dose (RP2D) of minnelide and osimertinib\"\\n18631,1,1,\"Recommended Phase II Dose (RP2D) of Pictilisib\"\\n18632,1,1,\"Recommended Phase II Dose (RP2D) of RO6958688\"\\n18633,1,1,\"Recommended Phase II Dose (RP2D) of Rucaparib for the Combination [Part 1]\"\\n18634,1,1,\"Recommended phase II dose (RP2D) of study drugs\"\\n18635,1,1,\"Recommended phase II dose (RP2D) of vorolanib plus nivolumab\"\\n18636,1,1,\"Recommended phase II dose (RP2D) of vorolanib plus pembrolizumab\"\\n18637,1,1,\"Recommended phase II dose (RP2D).\"\\n18638,1,1,\"Recommended Phase II Dose (RP2D): Phase I\"\\n18639,1,1,\"Recommended Phase II dose (RPIID) of HM95573 and cobimetinib, or HM95573 and cetuximab\"\\n18640,1,1,\"Recommended Phase II Dose (RPTD) for the Capecitabine and Aflibercept Doublet Combination\"\\n18641,1,1,\"Recommended phase II dose (RPTD) of mirvetuximab soravtansine and rucaparib camsylate in combination\"\\n18642,1,1,\"Recommended phase II dose and maximum tolerated dose of sorafenib tosylate when administered in combination with cisplatin and etoposide or carboplatin and pemetrexed disodium\"\\n18643,1,1,\"Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)\"\\n18644,1,1,\"Recommended phase II dose as assessed by NCI toxicity scale during 3-4 weeks of treatment\"\\n18645,1,1,\"Recommended phase II dose assessed by Common Terminology Criteria for Adverse Events version 4\"\\n18646,1,1,\"Recommended phase II dose defined as the dose level at which less than or equal to 1 of 6 patients experienced DLT assessed using NCI CTCAE version 4.0\"\\n18647,1,1,\"Recommended phase II dose of 17-allylamino-17-demethoxygeldanamycin (17-AAG) at 4 weeks\"\\n18648,1,1,\"Recommended phase II dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) at 28 days after treatment\"\\n18649,1,1,\"Recommended phase II dose of AT9283\"\\n18650,1,1,\"Recommended phase II dose of capecitabine\"\\n18651,1,1,\"Recommended Phase II Dose of Cergutuzumab Amunaleukin\"\\n18652,1,1,\"Recommended phase II dose of combination regimen\"\\n18653,1,1,\"Recommended phase II dose of eribulin mesylate in combination with gemcitabine hydrochloride\"\\n18654,1,1,\"Recommended phase II dose of everolimus\"\\n18655,1,1,\"Recommended phase II dose of flavopiridol defined as the highest dose for which no more than one patient develop a >= grade 3 toxicity\"\\n18656,1,1,\"Recommended phase II dose of gamma-secretase inhibitor RO4929097 defined as the dose level at which < 1/6 patients experience dose-limiting toxicity as graded by the National Cancer Institute (NCI) CTCAE version 4.0\"\\n18657,1,1,\"Recommended Phase II Dose of GDC-0575\"\\n18658,1,1,\"Recommended phase II dose of human anti-CD19 CAR-T cells\"\\n18659,1,1,\"Recommended Phase II Dose of Inavolisib\"\\n18660,1,1,\"Recommended Phase II dose of Ixabepilone when administered with Sunitinib\"\\n18661,1,1,\"Recommended Phase II Dose of lumretuzumab [RO5479599]\"\\n18662,1,1,\"Recommended phase II dose of niraparib and temozolomide combination (Phase Ib)\"\\n18663,1,1,\"Recommended phase II dose of NK012 in patients with UGT1A1*28 (wt/wt and wt/*28) genotype\"\\n18664,1,1,\"Recommended phase II dose of OGX-011\"\\n18665,1,1,\"Recommended Phase II dose of OPB-51602\"\\n18666,1,1,\"Recommended Phase II dose of ribociclib and gemcitabine hydrochloride, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0)\"\\n18667,1,1,\"Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0\"\\n18668,1,1,\"Recommended Phase II Dose of Selicrelumab in Combination With Vanucizumab\"\\n18669,1,1,\"Recommended phase II dose of temsirolimus, carboplatin, and paclitaxel\"\\n18670,1,1,\"Recommended phase II dose of the combination of dabrafenib, trametinib, and navitoclax (Phase I)\"\\n18671,1,1,\"Recommended phase II dose of the combination of XL888 and pembrolizumab as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n18672,1,1,\"Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)\"\\n18673,2,1,\"Recommended Phase II Dose(RP2D)\"\\n18674,1,1,\"Recommended phase II doses of enzastaurin hydrochloride and bevacizumab\"\\n18675,5,5,\"Recommended Phase-2 Dose (RP2D)\"\\n18676,1,1,\"Recommended phase-2 dose (RP2D) of JS014\"\\n18677,1,1,\"recommended phase-2 dose (RP2D).\"\\n18678,1,1,\"Recommended phaseII dose\"\\n18679,1,1,\"Recommended RP2D of Atezolizumab and Alectinib\"\\n18680,1,1,\"Recommended stereotactic body radiotherapy (SBRT) dose in combination with pembrolizumab.\"\\n18681,1,1,\"Recovery Rate (Phase II)\"\\n18682,80,1,\"Recruitment Rate\"\\n18683,1,1,\"Recruitment rate, defined as percentage of patients eligible for the study from all patients who were screened for the study.\"\\n18684,36,1,\"recurrence\"\\n18685,1,1,\"Recurrence after primary tumor resection\"\\n18686,1,1,\"Recurrence Free Survival (RFS) by Independent Assessment\"\\n18687,1,1,\"Recurrence of fluoropyrimidine related cardiac toxicity after switch to S-1 based treatment\"\\n18688,59,1,\"Recurrence rate\"\\n18689,1,1,\"Recurrence Rate at the Surgical Site as Measured by MRI\"\\n18690,1,1,\"Recurrence rate of lower grade sarcoma\"\\n18691,8,1,\"Recurrence-free Survival\"\\n18692,49,1,\"Recurrence-free survival\"\\n18693,1,1,\"Recurrence-free survival (Low risk)\"\\n18694,6,1,\"Recurrence-free Survival (RFS)\"\\n18695,1,1,\"Recurrence-free survival (RFS) for Arm A vs Arm C\"\\n18696,1,1,\"recurrence-free survival rate\"\\n18697,1,1,\"Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee\"\\n18698,1,1,\"Red blood cell count in whole blood sample\"\\n18699,1,1,\"Red Blood Cell Mass\"\\n18700,1,1,\"Reduce 8-week depressive symptoms among African American adolescents on the Child Depression Inventory (CDI-2)\"\\n18701,2,1,\"reduction in pain\"\\n18702,1,1,\"Reduction in the dimensions of measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n18703,1,1,\"Reduction of bowel activity\"\\n18704,1,1,\"reduction of chemotherapy related nausea\"\\n18705,1,1,\"Reduction of diarrhea as measured by NCI CTC version 2.0 weekly during pelvic radiotherapy\"\\n18706,1,1,\"Reduction of the item pool based on content validity assessment (step 2)\"\\n18707,1,1,\"Referral efficiency\"\\n18708,1,1,\"Referral patterns\"\\n18709,1,1,\"Referrals to Supportive Care Services\"\\n18710,2,1,\"Regimen Limiting Toxicity\"\\n18711,1,1,\"Regional failure\"\\n18712,1,1,\"REGN4659 and cemiplimab concentrations in serum over time\"\\n18713,1,1,\"REGN5093 concentrations in serum over time\"\\n18714,1,1,\"Regression of indeterminate pulmonary nodules (IPNs)\"\\n18715,12,1,\"relapse\"\\n18716,14,2,\"Relapse Free Survival\"\\n18717,1,1,\"Relapse Rate (local and/or distant)\"\\n18718,34,1,\"Relapse-free survival\"\\n18719,1,1,\"Relation of gene expression and polymorphisms to the intracellular content of pemetrexed disodium\"\\n18720,1,1,\"Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response\"\\n18721,1,1,\"relationship between BMI and EORTC-QLQC30 according to tumor stage\"\\n18722,1,1,\"Relationship between CYP3A5 genotype and ifosfamide nephrotoxicity\"\\n18723,1,1,\"Relationship between patient\\'s sense of being a burden on primary caregiver & increase in patient desire for hastened death (DHD) by Caregiver Demands Scale (CDS) at baseline & Schedule of Attitudes toward Hastened Death (SAHD) at 2 & 4 mo.\"\\n18724,1,1,\"Relationship between the pharmacokinetics and measures of renal dysfunction categorized by creatinine clearance as estimated by the Cockcroft and Gault formula (Part 1)\"\\n18725,1,1,\"Relationship between the status, numerical changes of ctDNA during HIPEC combined with PD1/PDL1 inhibitor conversion therapy and postoperative R0 resection rate.\"\\n18726,1,1,\"Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response\"\\n18727,1,1,\"Relationship of AEs\"\\n18728,1,1,\"Relative abundance and composition of immunotherapy response-associated bacterial species in patients with advanced/unresectable or metastatic solid tumors\"\\n18729,1,1,\"Relative abundance and composition of immunotherapy toxicity-associated bacterial species in patients with advanced/unresectable or metastatic solid tumors\"\\n18730,1,1,\"Relative bioavailability: Area under the concentration-time curve (AUC)\"\\n18731,1,1,\"Relative cerebral blood flow by MRI\"\\n18732,1,1,\"Relative change from baseline in response markers related to bone metabolism (B-ALP and S P1NP).\"\\n18733,1,1,\"Relative change of imaging parameters (tumor volume, standardized uptake value [SUV], tumor to muscle ratio [TMR], hypoxic tumor volume [HTV1, HTV2], and total lesion hypoxia [TLH1, TLH2])\"\\n18734,3,1,\"Relative dose intensity\"\\n18735,1,1,\"Relative Dose Intensity (RDI) of Treatment Administered to Subjects in Each Treatment Arm\"\\n18736,1,1,\"Relative Dose Intensity - End of Treatment\"\\n18737,1,1,\"Relative Dose Intensity - Mid Treatment\"\\n18738,1,1,\"Relative Dose Intensity as Measured by Mean Percent of Intended Cycles Completed\"\\n18739,2,2,\"Relative dose-intensity (RDI) of the myelosupressive therapy course\"\\n18740,1,1,\"Relative incidence of fungemia\"\\n18741,1,1,\"Relative Percent Change in Ki67 Scores From Baseline to Week 2\"\\n18742,4,1,\"Relative Prolongation Ability Score for Gadolinium subdermally injected.\"\\n18743,1,1,\"Relative satisfaction rate\"\\n18744,1,1,\"Relative solid stress by MRI\"\\n18745,7,7,\"Relief degree\"\\n18746,1,1,\"Relief degree evaluated by RECIST\"\\n18747,2,2,\"Relief degree evaluated by the RECIST\"\\n18748,26,25,\"Relief degree of tumors\"\\n18749,1,1,\"Renal and blood pressure changes\"\\n18750,1,1,\"Renal Clearance (CL[R]) of AZD2014 From Plasma.\"\\n18751,1,1,\"Renal Clearance (CLR) of Alisertib\"\\n18752,1,1,\"Renal Clearance (CLR) of TAK-659\"\\n18753,1,1,\"Renal Clearance (CLr) of Talazoparib\"\\n18754,1,1,\"Renal Clearance (CLr) of Unlabeled Idasanutlin\"\\n18755,1,1,\"Renal clearance of adavosertib from plasma (CLR)\"\\n18756,1,1,\"Renal Clearance of Lenvatinib (CLr)\"\\n18757,1,1,\"Renal Clearance of Pamiparib (CLR)\"\\n18758,1,1,\"Renal clearance of radioactivity (CLR)\"\\n18759,1,1,\"Renal function and nephrotoxicity\"\\n18760,1,1,\"Repeatability of diffusion-weighted imaging on PET/MR as measured by difference in mean ADC\"\\n18761,1,1,\"Repeatability of diffusion-weighted imaging on PET/MR as measured by differences in minimum ADC\"\\n18762,1,1,\"Repeatability of lesional PET/CT characteristics\"\\n18763,1,1,\"Reponse Rate of the Combination Sorafenib and Temsirolimus in I-131 Refractory Thyroid Cancer.\"\\n18764,1,1,\"Report Dose limiting toxicity (DLT)\"\\n18765,1,1,\"Reported Adverse Events.\"\\n18766,1,1,\"Repository of malignant, borderline malignant neoplasms, and related biological specimens\"\\n18767,1,1,\"Research Data: Health Related Quality of Life instrument\"\\n18768,1,1,\"Researchers use artificial intelligence (AI) support system to assist in diagnosis of pancreatic solid space-occupying lesions\"\\n18769,1,1,\"Residual Cancer Burden (RCB) by Symmans Criteria.\"\\n18770,1,1,\"Resiliency Administered Assessments - Change of Blessed Orientation Memory and Concentration Test (BOMC)\"\\n18771,1,1,\"Resiliency Administered Assessments - Change of Grip Strength\"\\n18772,1,1,\"Resiliency Administered Assessments - Change of Short Physical Performance Battery (SPPB)\"\\n18773,1,1,\"Resiliency factors\"\\n18774,1,1,\"Respiration rate in mg Œºl/h¬∑g of ECG\"\\n18775,1,1,\"Respiration rate of Vital Signs by stethoscope\"\\n18776,48,2,\"Respiratory rate\"\\n18777,1,1,\"Respiratory rate (bpm)\"\\n18778,1,1,\"Respond Evaluation Criteria in Solid Tumors\"\\n18779,6,1,\"Responders\"\\n18780,1,1,\"Responders\\' global perceptions of usefulness and adherence to the handbook during COVID-19\"\\n18781,1,1,\"Responders\\' profession\"\\n18782,1,1,\"Responders\\' self-reported professional satisfaction\"\\n18783,98,10,\"Response\"\\n18784,16,3,\"response\"\\n18785,1,1,\"Response (Complete Response (CR) + Partial Response (PR)) to Therapy\"\\n18786,1,1,\"Response (Complete Response [CR] + Partial Response [PR])\"\\n18787,1,1,\"Response (Complete Response or Partial Response) (Part B)\"\\n18788,1,1,\"Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates\"\\n18789,1,1,\"Response and progression using RECIST criteria\"\\n18790,1,1,\"Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18791,1,1,\"Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in Only the Largest Diameter of the Tumor Lesions Are Used.\"\\n18792,1,1,\"Response and Progression-free survival\"\\n18793,2,2,\"Response as assessed by RECIST criteria\"\\n18794,1,1,\"Response as measured by International Antimicrobial Therapy Group (IATG) specific criteria at the completion of allocated treatment\"\\n18795,1,1,\"Response as measured by RECIST criteria every 9 weeks\"\\n18796,1,1,\"Response assessed using RECIST criteria\"\\n18797,1,1,\"Response Assessment\"\\n18798,1,1,\"Response Assessment by Study Stratum - Per Investigator Assessment\"\\n18799,1,1,\"Response Assessment in Neuro-Oncology (RANO) to validate biomarkers\"\\n18800,1,1,\"Response associated with increased dose of SRS as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)\"\\n18801,1,1,\"Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria\"\\n18802,1,1,\"Response by Investigator Assessment\"\\n18803,1,1,\"Response confirmed by non-investigational CT or MRI, or confirmed by biopsy\"\\n18804,1,1,\"Response defined by a complete response (CR) or partial response (PR) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n18805,9,1,\"Response duration\"\\n18806,1,1,\"Response duration measured from the time complete response or partial response (whichever is first recorded) is documented until the first date that recurrent or progressive disease is objectively documented\"\\n18807,1,1,\"Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Category\"\\n18808,1,1,\"Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\"\\n18809,1,1,\"Response Evaluation Criteria In Solid Tumors (RECIST) (Phase 2)\"\\n18810,1,1,\"Response Evaluation Criteria in Solid Tumors (RECIST) criteria to validate biomarkers\"\\n18811,1,1,\"Response Evaluation Criteria in Solid Tumors (RECIST) Response\"\\n18812,1,1,\"Response Evaluation Criteria in Solid Tumors (RECIST) Response (Complete Response [CR] or Partial Response [PR] vs Not CR or PR) (Cohort I)\"\\n18813,1,1,\"Response Evaluation Criteria in Solid Tumors (RESIST) [Phase I and II]\"\\n18814,1,1,\"Response Evaluation Criteria in Solid Tumors Criteria (RECIST) 1.0 Best Response\"\\n18815,4,4,\"Response Evaluation Criteria in Solid Tumors(RECIST) 1.1\"\\n18816,1,1,\"Response of active tumor volume to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans\"\\n18817,1,1,\"Response of BAY 1895344 (elimusertib)\"\\n18818,1,1,\"Response of Hemangioma (IH) to Treatment\"\\n18819,1,1,\"Response of Intracranial Metastases (Complete and Partial Response)\"\\n18820,1,1,\"Response of Liver Metastases\"\\n18821,1,1,\"Response of SUVmax to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans\"\\n18822,1,1,\"Response of total lesion activation to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans\"\\n18823,1,1,\"Response Per RECIST Criteria\"\\n18824,2,2,\"Response profile\"\\n18825,1,1,\"Response profile, assessed using modified Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18826,219,46,\"Response Rate\"\\n18827,370,35,\"Response rate\"\\n18828,111,5,\"response rate\"\\n18829,1,1,\"Response rate (Arm B)\"\\n18830,1,1,\"Response rate (Cohorts 1 and 2)\"\\n18831,6,2,\"Response Rate (Complete and Partial Response)\"\\n18832,1,1,\"Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts Who Have Received Prior Bevacizumab.\"\\n18833,1,1,\"Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma\"\\n18834,1,1,\"Response Rate (Complete or Partial Response)\"\\n18835,1,1,\"Response Rate (Complete Response (CR) +Partial Response (PR)\"\\n18836,1,1,\"Response Rate (Complete Response (CR) or Partial Response (PR))\"\\n18837,2,1,\"Response rate (complete response + partial response)\"\\n18838,1,1,\"Response rate (complete response [CR] + partial response [PR]) of CRAd 3/5-delta in combination with standard M-ILI (Phase II)\"\\n18839,1,1,\"Response rate (complete response [CR] and partial response [PR]) according to Response Evaluation Criteria in Solid Tumor (RECIST) and World Health Organization (WHO) criteria\"\\n18840,1,1,\"Response Rate (Complete Response or Partial Response)\"\\n18841,1,1,\"Response rate (complete response or partial response)\"\\n18842,1,1,\"Response Rate (Complete Response(CR) / Partial Response (PR))\"\\n18843,1,1,\"Response Rate (Complete, Partial Response and Stable Disease) as Assessed by RECIST\"\\n18844,1,1,\"Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants\"\\n18845,1,1,\"Response Rate (Confirmed Complete Response or Partial Response), Determined According to Response Evaluation Criteria in Solid Tumors\"\\n18846,1,1,\"Response rate (CR + PR)\"\\n18847,1,1,\"Response rate (CR/PR/SD) according to RECIST criteria 1.1 (Part II).\"\\n18848,1,1,\"Response rate (dose-expansion)\"\\n18849,1,1,\"Response Rate (ie, the Percentage of Subjects With a Confirmed Complete or Partial Response)\"\\n18850,1,1,\"Response Rate (Measured as the Percentage of Participants With Response [Complete Response or Partial Response])\"\\n18851,1,1,\"response rate (ORR)\"\\n18852,1,1,\"Response Rate (ORR) (Phase II)\"\\n18853,1,1,\"Response Rate (Partial and Complete Response) in Patients With or Without ASS Expression Present in Tumor.\"\\n18854,1,1,\"Response rate (partial response [PR] + complete response [CR]) (Phase II)\"\\n18855,1,1,\"Response Rate (Per RECIST 1.1)\"\\n18856,2,2,\"Response Rate (Percentage of Participants With Partial or Complete Response)\"\\n18857,4,1,\"Response Rate (Phase II)\"\\n18858,6,1,\"Response rate (Phase II)\"\\n18859,1,1,\"Response rate (Response Evaluation Criteria in Solid Tumors (RECIST) criteria with pelvic MRI and PET-CT)\"\\n18860,1,1,\"Response rate (Response Evaluation Criteria In Solid Tumors (RECIST))\"\\n18861,1,1,\"response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria)\"\\n18862,20,8,\"Response Rate (RR)\"\\n18863,13,1,\"Response rate (RR)\"\\n18864,1,1,\"Response Rate (RR) (complete + partial responses)\"\\n18865,1,1,\"Response Rate (RR) (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1\"\\n18866,1,1,\"Response rate (RR) according to RECIST1.1\"\\n18867,1,1,\"Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n18868,1,1,\"Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1)\"\\n18869,1,1,\"Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC)\"\\n18870,1,1,\"Response Rate (RR):\"\\n18871,1,1,\"Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on \"\"Response Evaluation Criteria in Solid Tumors (RECIST)\"\" in patients with no prior chemotherapy\"\\n18872,1,1,\"Response rate according to hemoglobin level\"\\n18873,1,1,\"Response Rate According to RECIST Criteria\"\\n18874,1,1,\"Response rate according to reduction in BPI most acute pain score from Baseline\"\\n18875,1,1,\"Response Rate According to Response Evaluation Criteria in Solid Tumors\"\\n18876,2,2,\"Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18877,1,1,\"Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST), Including Confirmed and Unconfirmed Complete and Partial Responses (Phase II)\"\\n18878,1,1,\"Response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18879,1,1,\"Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment\"\\n18880,1,1,\"Response Rate After Relapse\"\\n18881,1,1,\"Response rate as assessed by the Independent Review Facility (IRF) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n18882,1,1,\"Response Rate as Determined by RECIST.\"\\n18883,1,1,\"Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria\"\\n18884,1,1,\"Response rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks during treatment\"\\n18885,1,1,\"Response rate as measured by Wechsler Intelligence Scale for Children-III (WISC III) subtest: Coding, Symbol Search and Digit Span at baseline, and 3 weeks after the start of study treatment\"\\n18886,1,1,\"Response rate assessed according to immune-related RECIST 1.1 criteria\"\\n18887,1,1,\"Response rate assessment to evaluate the clinical activity / efficacy of PC14586 (Phase 2)\"\\n18888,1,1,\"Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18889,1,1,\"response rate by RECIST criteria\"\\n18890,1,1,\"Response Rate by RECIST Criteria of Oral Dichloroacetate in Patients With Recurrent and/or Metastatic and Pretreated Breast and Non-small Cell Lung Cancer.\"\\n18891,1,1,\"Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18892,1,1,\"Response Rate by Solid Tumor Response Criteria (RECIST)\"\\n18893,1,1,\"Response Rate Categorized by p63/p73 Ratio\"\\n18894,1,1,\"Response Rate Defined as CR\"\\n18895,1,1,\"Response Rate Defined as Partial Response (PR)\"\\n18896,1,1,\"Response rate defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase 2)\"\\n18897,1,1,\"Response rate defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n18898,1,1,\"Response rate evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18899,1,1,\"Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy.\"\\n18900,1,1,\"Response rate for Group F patients\"\\n18901,1,1,\"Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA)\"\\n18902,1,1,\"Response rate in each taxane-resistant tumor type assessed per RECIST guidelines (part 2 - dose expansion only)\"\\n18903,1,1,\"Response Rate in MEDI4736-treated Participants\"\\n18904,1,1,\"Response Rate in Patients Treated With Pentamidine\"\\n18905,1,1,\"Response Rate in Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (Phase II)\"\\n18906,1,1,\"Response rate in patients with epithelial CNS metastases as assessed by RECIST criteria\"\\n18907,1,1,\"Response rate in patients with recurrent glial tumors as assessed by RECIST criteria\"\\n18908,1,1,\"Response Rate of at Least 30%\"\\n18909,1,1,\"Response Rate of Ilorasertib (ABT-348) in Participants with Cancers Harboring CDKN2A Deletion or Mutation as Tumor Response\"\\n18910,1,1,\"Response Rate of Patients With Lung or Head and Neck SCC Treated With Ponatinib\"\\n18911,1,1,\"Response rate of pembrolizuab\"\\n18912,1,1,\"Response rate of primary tumor based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria\"\\n18913,1,1,\"Response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to SAHA using RECIST criteria.\"\\n18914,1,1,\"Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.\"\\n18915,1,1,\"Response rate of single-agent AGEN2034 and combination AGEN2034 + AGEN1884\"\\n18916,1,1,\"Response rate of single-agent veliparib (Part II)\"\\n18917,1,1,\"Response rate of sonidegib in combination with pembrolizumab (Part B)\"\\n18918,1,1,\"Response rate of the combination of Velcade and Doxil in patients with metastatic breast cancer\"\\n18919,1,1,\"Response rate of treated participants\"\\n18920,1,1,\"Response rate of VEGFR inhibitor-associated hand-foot skin reaction\"\\n18921,1,1,\"Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy\"\\n18922,1,1,\"Response Rate on Step 1\"\\n18923,1,1,\"Response Rate R-HCVAD vs. R-CHOP\"\\n18924,1,1,\"Response Rate to Bevacizumab in This Population.\"\\n18925,1,1,\"Response rate to combination therapy with bevacizumab and vinorelbine, defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n18926,1,1,\"Response rate to gemcitabine hydrochloride and cisplatin with versus without veliparib (randomized Part I)\"\\n18927,1,1,\"Response Rate to Induction Chemotherapy Prior to Definitive Therapy (Surgery or Radiation)\"\\n18928,1,1,\"Response rate to New York esophageal squamous cell carcinoma (NYESO) T cells\"\\n18929,1,1,\"Response rate to NYESO T cells\"\\n18930,1,1,\"Response rate to panitumumab as measured by evaluation of the Criteria in Solid Tumors (RECIST) 1.1.\"\\n18931,1,1,\"Response rate to talimogene laherparepvec alone (Part I)\"\\n18932,1,1,\"Response rate using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18933,1,1,\"Response rate using the international criteria RECIST\"\\n18934,1,1,\"Response rate was assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline\"\\n18935,1,1,\"Response rate, CR + PR of GSK1120212 and everolimus in KRAS-mutant NSCLC.\"\\n18936,1,1,\"Response Rate, Defined as Complete Response (CR) + Partial Response (PR), Using the Response Evaluation Criteria in Solid Tumors\"\\n18937,1,1,\"Response rate, defined as the proportion of patients whose tumor responds to treatment (Cohort II)\"\\n18938,1,1,\"Response rate, determined using the RECIST criteria\"\\n18939,1,1,\"Response rate: Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18940,1,1,\"Response Rate: The Total Number of Participants With Progression of Disease\"\\n18941,6,1,\"Response Rates\"\\n18942,1,1,\"Response Rates (RR) in Metastatic Gastric/GE Junction Tumors\"\\n18943,1,1,\"Response rates and distribution of the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (Erk)-phosphorylated expression groups based on the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18944,1,1,\"Response Rates Confirmed With CT or MRI\"\\n18945,1,1,\"Response Rates of Radiographically Measurable Disease\"\\n18946,1,1,\"Response rates, as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n18947,1,1,\"Response to angiogenic treatment following morphological RECIST criteria\"\\n18948,3,1,\"Response to chemotherapy\"\\n18949,2,1,\"response to chemotherapy\"\\n18950,1,1,\"Response to KRN5500 by fluorothymidine-positron emission tomography (FLT-PET) scanning at the MTD in patients with measurable disease\"\\n18951,1,1,\"Response to radioiodine therapy after redifferentiation\"\\n18952,1,1,\"Response to sorafenib therapy shown in PET Scans\"\\n18953,1,1,\"Response to the Appetite and Symptom Questionnaire at baseline\"\\n18954,1,1,\"Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1.\"\\n18955,10,1,\"Response to Treatment\"\\n18956,35,3,\"Response to treatment\"\\n18957,8,2,\"response to treatment\"\\n18958,2,1,\"Response to treatment according to RECIST criteria\"\\n18959,1,1,\"Response to treatment as assessed by mobility via the Tomita mobility scale\"\\n18960,1,1,\"Response to Treatment Based on RECIST Criteria (Intent-to-Treat [ITT] Population)\"\\n18961,1,1,\"Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population)\"\\n18962,1,1,\"Response to treatment of advanced NSCLC with high or low TAM.\"\\n18963,1,1,\"Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease\"\\n18964,1,1,\"Response: Response will be evaluated after three and six cycles of chemotherapy using modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with appropriate clinical assessment and radiological investigations.\"\\n18965,1,1,\"Responses in patients treated with this regimen\"\\n18966,1,1,\"Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration\"\\n18967,1,1,\"Results of HLA typing in combination with tumor genetic testing of subjects to identify a TCR match for treatment on the TCR001-201 study.\"\\n18968,1,1,\"Retention in clinical research protocols\"\\n18969,1,1,\"Retention on the Phase I trial\"\\n18970,90,1,\"Retention rate\"\\n18971,27,1,\"Retention rates\"\\n18972,1,1,\"RFS assessment per RECIST 1.1.\"\\n18973,1,1,\"Ridaforolimus geometric mean area under the concentration curve from Hour 0 to Hour 24 (AUC [0-24]) in combination therapy\"\\n18974,1,1,\"Risk of Cancer with Specific Mutations\"\\n18975,2,1,\"Ro resection rate\"\\n18976,1,1,\"ROC curve AUC regarding diagnostic accuracy of progastrin levels at baseline in cancer patients compared to non-cancer controls\"\\n18977,55,28,\"RP2D\"\\n18978,1,1,\"RP2D (phase 1)\"\\n18979,1,1,\"RP2D and/or MTD of IK-930\"\\n18980,1,1,\"RP2D Dose\"\\n18981,2,1,\"RP2D in Phase I\"\\n18982,1,1,\"RP2D of BAY2666605\"\\n18983,1,1,\"RP2D Of Botensilimab\"\\n18984,1,1,\"RP2D of Docetaxel (Phase 1b)\"\\n18985,1,1,\"RP2D of Phase 2 Dose of ET0038\"\\n18986,1,1,\"RP2D of PT199 as a single agent and/or in combination with a PD-1 inhibitor.\"\\n18987,1,1,\"RP2D of the combination of tivantinib and bevacizumab, defined as the dose level at which the dose-limiting toxicity (DLT) rate is closest to 1/6 graded according to the National Cancer Institute (NCI) CTCAE v4.0\"\\n18988,1,1,\"RP2D of trebananib and temsirolimus defined as the dose level at which =< 1/6 patients experienced dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) CTCAE version 4.0\"\\n18989,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): AUC(0-inf) of STX-478\"\\n18990,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): AUC(0-t) of STX-478\"\\n18991,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): AUC(0-œÑ) of STX-478\"\\n18992,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): Change from baseline in ctDNA levels.\"\\n18993,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): Changes in circulating markers of glucose metabolism as assessed by changes in circulating glycosylated hemoglobin [HbA1c]\"\\n18994,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): Changes in circulating markers of glucose metabolism as assessed by circulating C-peptide\"\\n18995,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): Changes in circulating markers of glucose metabolism as assessed by circulating fasting plasma glucose.\"\\n18996,1,1,\"RP2D Selection (Parts 1.2-DS and 2.1): Cmax of STX-478\"\\n18997,1,1,\"RP2D(Phase Ib)\"\\n18998,1,1,\"RP2D: Incidence and severity of AEs, AESI, and SAEs, including but not limited to laboratory values, PK and biomarkers.\"\\n18999,1,1,\"RP3D\"\\n19000,2,1,\"rPFS\"\\n19001,1,1,\"rPFS Based on ICR of Bone Scan According to Protocol Assessment Criteria\"\\n19002,1,1,\"rPFS by blinded independent central review (BICR) using RESIST1.1 and PCWG3\"\\n19003,1,1,\"RPII dose of NC-6300\"\\n19004,9,1,\"RR\"\\n19005,1,1,\"Run-In Food Effect Period: Area under the concentration time curve (AUC) based on pelabresib concentrations in plasma measured using validated plasma assay\"\\n19006,1,1,\"Run-In Food Effect Period: maximal plasma concentration (Cmax) based on pelabresib concentrations in plasma measured using validated plasma assay\"\\n19007,1,1,\"Run-In Food Effect Period: Time to maximal plasma concentration (Tmax) based on pelabresib concentrations in plasma measured using validated plasma assay\"\\n19008,1,1,\"Run-in part: Incidence of dose limiting toxicities (DLTs)\"\\n19009,1,1,\"Run-in Part: Percentage of Participants With Adverse Events (AEs)\"\\n19010,1,1,\"Run-in Part: Percentage of Participants With at Least One Dose Interruption\"\\n19011,1,1,\"Run-in Part: Percentage of Participants With at Least One Dose Reduction.\"\\n19012,1,1,\"Run-in Part: Percentage of Participants With Dose Limiting Toxicities (DLTs)\"\\n19013,1,1,\"Run-in Part: Relative Dose Intensity Received by Participants\"\\n19014,1,1,\"Run-in Portion: Number of Participants With Adverse Events (AEs)\"\\n19015,1,1,\"Run-in Portion: Number of Participants With AEs Leading to Dose Reduction or Interruption of Any Study Medication\"\\n19016,1,1,\"Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) and Vital Signs\"\\n19017,1,1,\"Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Hematology and Blood Chemistry)\"\\n19018,1,1,\"Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I]\"\\n19019,1,1,\"RXC004 + nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1\"\\n19020,1,1,\"RXC004 Monotherapy: Disease control rate (DCR) using each patients Best Overall Response (BOR) according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1)\"\\n19021,1,1,\"S-1 Extension Phase: Efficacy (antitumor response)\"\\n19022,1,1,\"S-1 Extension Phase: Pharmacokinetic profiles of the components of S-1 and their metabolites, and duration of DPD inhibition after administration of multiple doses (end of Cycle 1)\"\\n19023,1,1,\"S-1 Extension Phase: Safety (Adverse events, lab assessments)\"\\n19024,11,1,\"SAE\"\\n19025,1,1,\"SAE(Serious Adverse Events)\"\\n19026,8,2,\"SAEs\"\\n19027,1,1,\"Safe and effective dose defined as the dose at which less than 2 of 6 patients have dose-limiting acute or late toxicity and the mean value of signal-to-noise ratio is greater than or equal to 75\"\\n19028,560,38,\"Safety\"\\n19029,55,2,\"safety\"\\n19030,1,1,\"Safety & tolerability as determined by dose limiting toxicities and maximum tolerated or assessed dose of MEDI9197 administered by IT injection in combo with durvalumab and durvalumab plus palliative radiation to subjects with solid tumor cancers.\"\\n19031,1,1,\"Safety & Tolerability: Dose-limiting Toxicities (DLT)\"\\n19032,1,1,\"Safety & Tolerability: Incidence, type, and severity of Adverse Events (AE)\"\\n19033,1,1,\"Safety (AE)\"\\n19034,1,1,\"Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)\"\\n19035,1,1,\"Safety (composite outcome measure): Incidence of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, pregnancies, adverse drug reactions (ADRs); unexpected ADRs; expected ADRs\"\\n19036,1,1,\"Safety (DILI)\"\\n19037,1,1,\"Safety (dose limiting toxicities) as well as the recommended doses & dosing schedules for phase 2 trials in adult patients with advanced solid tumors.\"\\n19038,1,1,\"Safety (Dose limiting toxicities, maximum tolerated dose)\"\\n19039,1,1,\"Safety (Frequency and severity of adverse events (CTCAE classification))\"\\n19040,1,1,\"Safety (Number of cases of early termination of participation in the study due to the development of Serious Adverse Events and Other Adverse Events associated with the study therapy)\"\\n19041,1,1,\"Safety (Number of subjects with adverse events and/or dose-limiting toxicities)\"\\n19042,1,1,\"Safety (Number of subjects with adverse events)\"\\n19043,1,1,\"Safety (Phase 1) - Dose-limiting toxicities including incidence of Treatment-Emergent Adverse Events\"\\n19044,1,1,\"Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results\"\\n19045,1,1,\"Safety (Presence/absence of dose-limiting toxicities (DLTs))\"\\n19046,1,1,\"Safety (Rate of grade 3 and higher grade treatment-related adverse events)\"\\n19047,2,1,\"Safety (SAE)\"\\n19048,1,1,\"Safety (serious adverse events, adverse events, blood pressure and laboratory tests)\"\\n19049,1,1,\"Safety - Adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V4.03\"\\n19050,1,1,\"Safety - Number of CTCAE v3.0 Events 1 Month Post DEB-TACE\"\\n19051,1,1,\"Safety - Toxicities will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3\"\\n19052,1,1,\"Safety :the incidence of all adverse events by type and grade, abnormal laboratory changes\"\\n19053,1,1,\"Safety and Dose Limiting Toxicity (DLT) measured by number of subjects with adverse events (AEs)\"\\n19054,7,2,\"safety and efficacy\"\\n19055,1,1,\"Safety and efficacy assessment including vitals signs, physical assessments, and blood tests\"\\n19056,1,1,\"Safety and efficacy of the combination of Tarceva and Erbitux\"\\n19057,1,1,\"Safety and feasibility (Phase I)\"\\n19058,1,1,\"Safety and feasibility of combining RAD001 with carboplatin and etoposide in advanced solid tumors, with emphasis on SCLC.\"\\n19059,1,1,\"Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03\"\\n19060,1,1,\"Safety and feasibility of oral panobinostat in combination with cisplatin and pemetrexed\"\\n19061,1,1,\"Safety and identification of dose-limiting toxicities\"\\n19062,1,1,\"Safety and Maximum Tolerated Dose\"\\n19063,4,1,\"Safety and MTD\"\\n19064,1,1,\"Safety and MTD/recommended phase 2 dose (RP2D) determination (Number of Participants with Adverse Events)\"\\n19065,1,1,\"Safety and Optimal Dose of Regimen\"\\n19066,1,1,\"Safety and Pharmacokinetics\"\\n19067,1,1,\"Safety and pharmacokinetics of the three agents: sorafenib administered daily, without a break in dosing, in combination with carboplatin and paclitaxel, administered every 3 weeks\"\\n19068,1,1,\"Safety and reactogenicity of MRNA-1273 of a booster vaccination\"\\n19069,1,1,\"Safety and reactogenicity of MRNA-1273 vaccine\"\\n19070,124,14,\"Safety and Tolerability\"\\n19071,186,31,\"Safety and tolerability\"\\n19072,29,3,\"safety and tolerability\"\\n19073,2,1,\"Safety and tolerability (Adverse Event reported per CTCAE v5)\"\\n19074,1,1,\"Safety and tolerability (CTCAE version 4.0).\"\\n19075,1,1,\"Safety and Tolerability - Evaluation of AEs and DLT\"\\n19076,1,1,\"Safety and tolerability - Number of patients experiencing adverse events\"\\n19077,1,1,\"Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.\"\\n19078,1,1,\"Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms\"\\n19079,1,1,\"Safety and tolerability as assessed by Adverse events, vital signs, ECGs, Pulmonary Function Tests (DLco, FEV, FVC, Oxygen saturation) and laboratory data (chemistry, hematology and Urinalysis)\"\\n19080,1,1,\"Safety and tolerability as assessed by CTCAE v3.0\"\\n19081,1,1,\"Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity.\"\\n19082,4,1,\"Safety and tolerability as assessed by NCI CTCAE v3.0\"\\n19083,2,2,\"Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs)\"\\n19084,1,1,\"Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral injection to subjects with CTCL\"\\n19085,1,1,\"Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral injection to subjects with solid tumor cancers\"\\n19086,1,1,\"Safety and tolerability as determined by frequency and severity of adverse events\"\\n19087,1,1,\"Safety and tolerability as measured by adverse events and dose limiting toxicities\"\\n19088,2,1,\"Safety and tolerability as measured by incidence of adverse events\"\\n19089,1,1,\"Safety and tolerability as measured by incidence of AEs (Adverse Events)\"\\n19090,1,1,\"Safety and tolerability assessed by 12- lead electrocardiogram (ECG)\"\\n19091,4,2,\"Safety and tolerability assessed by 12-lead electrocardiogram (ECG)\"\\n19092,1,1,\"Safety and tolerability assessed by Adverse Events\"\\n19093,1,1,\"Safety and Tolerability assessed by Adverse Events (AEs)\"\\n19094,2,2,\"Safety and tolerability assessed by Adverse Events (AEs)\"\\n19095,3,3,\"Safety and tolerability assessed by adverse events (AEs)\"\\n19096,1,1,\"Safety and tolerability assessed by Adverse Events (AEs) (Initial Treatment)\"\\n19097,1,1,\"Safety and tolerability assessed by Adverse Events (AEs) (Retreatment)\"\\n19098,1,1,\"Safety and tolerability assessed by Adverse Events Characterization of the pharmacokinetic profile of gimatecan Anti-tumor activity assessed by Response Evaluation Criteria in Solid Tumors RECIST)\"\\n19099,1,1,\"Safety and tolerability assessed by dose limiting toxicities (DLTs)\"\\n19100,3,3,\"Safety and tolerability assessed by Dose Limiting Toxicity (DLT)\"\\n19101,1,1,\"Safety and tolerability assessed by eastern cooperative oncology group (ECOG) performance status\"\\n19102,2,2,\"Safety and tolerability assessed by ECOG performance status\"\\n19103,1,1,\"Safety and tolerability assessed by immune-related Adverse Events (irAEs) (Initial Treatment)\"\\n19104,1,1,\"Safety and tolerability assessed by immune-related Adverse Events (irAEs) (Retreatment)\"\\n19105,3,3,\"Safety and tolerability assessed by immune-related AEs (irAEs)\"\\n19106,1,1,\"Safety and tolerability assessed by incidence of adverse events (AEs) in Safety Part\"\\n19107,1,1,\"Safety and tolerability assessed by infusion-related reaction (IRRs) (Initial Treatment)\"\\n19108,1,1,\"Safety and tolerability assessed by infusion-related reaction (IRRs) (Retreatment)\"\\n19109,1,1,\"Safety and tolerability assessed by infusion-related reactions (IRRs)\"\\n19110,2,2,\"Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs)\"\\n19111,3,3,\"Safety and tolerability assessed by serious adverse events (SAEs)\"\\n19112,1,1,\"Safety and tolerability assessed by Serious Adverse Events (SAEs) (Initial Treatment)\"\\n19113,1,1,\"Safety and tolerability assessed by Serious Adverse Events (SAEs) (Retreatment)\"\\n19114,1,1,\"Safety and tolerability assessed by toxicity evaluation and prothrombin time assessments\"\\n19115,1,1,\"Safety and tolerability assessed primarily by adverse events including abnormal values of clinical laboratory test, ECG and vital sign\"\\n19116,1,1,\"Safety and tolerability assessments of Oraxol compared with IV paclitaxel, as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information\"\\n19117,1,1,\"Safety and tolerability at the MTD in patients with metastatic renal cell carcinoma (RCC)\"\\n19118,1,1,\"Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events\"\\n19119,1,1,\"Safety and tolerability by Common Terminology Criteria for Adverse Events (CTCAE) v4.03\"\\n19120,2,1,\"Safety and Tolerability by means of Adverse Events (AEs) and laboratory data\"\\n19121,1,1,\"Safety and tolerability endpoints will consist of the valuation of adverse events (AEs),vital signs and laboratory values. A dose regimen where 1 of 6 (or 17%) subjects experience a dose-limiting toxicity.\"\\n19122,1,1,\"Safety and tolerability endpoints will consist of the valuation of adverse events (AEs),vital signs and laboratory values. A dose regimen where = 1 of 6 (or =17%) subjects experience a dose-limiting toxicity.\"\\n19123,1,1,\"Safety and tolerability in patients with hepatic impairment will be assessed by adverse events (AEs), serious adverse events (SAEs) and out of range lab values\"\\n19124,1,1,\"Safety and tolerability in patients with metastatic HR+/HER2- breast cancer\"\\n19125,4,3,\"Safety and tolerability in terms of adverse events\"\\n19126,1,1,\"Safety and tolerability indexes\"\\n19127,3,1,\"Safety and tolerability measure through Adverse Events/Serious Adverse Events\"\\n19128,1,1,\"Safety and Tolerability measured\"\\n19129,1,1,\"Safety and tolerability measured by adverse events\"\\n19130,1,1,\"Safety and Tolerability measured by assessing serious adverse events (SAEs)and adverse events (AEs)\"\\n19131,1,1,\"Safety and Tolerability measured by Eastern Cooperative Oncology Group(ECOG) performance status\"\\n19132,1,1,\"Safety and Tolerability of 1RG-CART Therapy\"\\n19133,1,1,\"Safety and tolerability of 64Cu-DOTA-U3-1287 (all cohorts)\"\\n19134,1,1,\"Safety and tolerability of 7HP349 in healthy male subjects as assessed by incidence of treatment-emergent adverse events according to CTCAE v5.0 criteria\"\\n19135,1,1,\"Safety and tolerability of AC220 given once daily without food continuously for 28 days (1 cycle) to patients with advanced solid tumors.\"\\n19136,1,1,\"Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values\"\\n19137,1,1,\"Safety and tolerability of AGI-134 injected intra-tumourally (IT) by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)\"\\n19138,1,1,\"Safety and tolerability of AMC303\"\\n19139,1,1,\"Safety and tolerability of an anti-PlGF antibody\"\\n19140,1,1,\"Safety and Tolerability of ASALN001\"\\n19141,2,2,\"Safety and tolerability of ASP3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and clinical observations\"\\n19142,1,1,\"safety and tolerability of AZD4205\"\\n19143,1,1,\"Safety and tolerability of AZD5312 in patients assessed in terms of AEs, labs, vitals, ECGs and conc. med use.\"\\n19144,1,1,\"Safety and tolerability of AZD8055\"\\n19145,1,1,\"Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations.\"\\n19146,1,1,\"Safety and tolerability of BIIB021\"\\n19147,1,1,\"Safety and Tolerability of BIIB028\"\\n19148,1,1,\"Safety and tolerability of BTX-A51\"\\n19149,1,1,\"Safety and tolerability of C. novyi-NT spore administration in patients with advanced solid tumor malignancies will be measured over a 7-day inpatient admission with routine labs and continuous adverse event assessments.\"\\n19150,3,1,\"Safety and tolerability of CB-839: Incidence of adverse events\"\\n19151,1,1,\"Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0\"\\n19152,1,1,\"Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0\"\\n19153,1,1,\"Safety and tolerability of combination cedazuridine with decitabine as assessed by number of participants who experience adverse events\"\\n19154,1,1,\"Safety and tolerability of combination therapy study treatment itacitinib (INCB039110) plus nab-paclitaxel and gemcitabine as measured by the number of participants with adverse events\"\\n19155,1,1,\"Safety and Tolerability of CR6086 combined with AGEN2034\"\\n19156,1,1,\"Safety and tolerability of CT-322\"\\n19157,1,1,\"Safety and tolerability of derazantinib 200 mg twice a day as monotherapy\"\\n19158,1,1,\"Safety and tolerability of derazantinib 200 mg twice a day with atezolizumab 1200 mg every three weeks\"\\n19159,1,1,\"Safety and tolerability of E7090 as a measure of Adverse Events/ Serious Adverse Events\"\\n19160,1,1,\"Safety and tolerability of enoblituzumab.\"\\n19161,1,1,\"Safety and tolerability of EO4010 in combination with nivolumab\"\\n19162,1,1,\"Safety and tolerability of ERY974 in combination with atezolizumab and bevacizumab (Adverse Events) [Expansion part]\"\\n19163,1,1,\"Safety and tolerability of ERY974 in combination with atezolizumab and bevacizumab (Dose limiting toxicities) [Dose escalation part]\"\\n19164,1,1,\"Safety and tolerability of ERY974 in combination with atezolizumab and bevacizumab (Electrocardiograms in triplicate) [Dose escalation part]\"\\n19165,1,1,\"Safety and tolerability of ERY974 in combination with atezolizumab and bevacizumab from initiation (Dose limiting toxicities) [Concomitant use part]\"\\n19166,1,1,\"Safety and tolerability of escalating doses of PF-01367338 in combination with chemotherapy (as defined by first-cycle DLTs)\"\\n19167,1,1,\"Safety and tolerability of escalating doses T3011\"\\n19168,1,1,\"Safety and tolerability of Foxy-5\"\\n19169,1,1,\"Safety and Tolerability of Gentulizumab as Measured by the Number of Participants Experiencing Dose-limiting Toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs).\"\\n19170,1,1,\"Safety and tolerability of GLS-010 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)\"\\n19171,1,1,\"Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.\"\\n19172,1,1,\"Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.\"\\n19173,1,1,\"Safety and Tolerability of Hu5F9-G4\"\\n19174,1,1,\"Safety and tolerability of IK-175 as a single agent and in combination with nivolumab including acute and chronic toxicities, in determining a recommended phase 2 dose (RP2D) of IK- 175.\"\\n19175,1,1,\"Safety and tolerability of IK-930\"\\n19176,1,1,\"Safety and tolerability of INCB047986 monotherapy and in combination with gemcitabine and nab-paclitaxel as assessed by summary of clinical laboratory assessments, Electrocardiogram (ECG), and Adverse Events (AEs).\"\\n19177,1,1,\"Safety and tolerability of INCB059872 in monotherapy and in combination with other therapies as measured by the frequency, duration, and severity of adverse events (AEs) in participants, and determine recommended dose(s) for further study\"\\n19178,1,1,\"Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)\"\\n19179,1,1,\"Safety and tolerability of increasing doses of ADC-1013, assessed by medical review of AE reports and vital signs measurements (blood pressure, pulse rate, body temperature), physical examinations, ECGs and clinical laboratory tests.\"\\n19180,1,1,\"Safety and Tolerability of intravenous ALN-VSP02\"\\n19181,1,1,\"Safety and tolerability of Karonudib (TH1579) will be evaluated.\"\\n19182,1,1,\"Safety and Tolerability of LAM561\"\\n19183,1,1,\"Safety and Tolerability of LPM3480226 assessed by adverse events\"\\n19184,1,1,\"Safety and tolerability of LUNA18 (Adverse Events) [Part A, B and C]\"\\n19185,1,1,\"Safety and tolerability of LUNA18 (Dose-limiting toxicities) [Part A]\"\\n19186,1,1,\"Safety and tolerability of MBG453 alone and in combination with PDR001 or in combination with decitabine as assessed by incidence and severity of adverse events\"\\n19187,1,1,\"Safety and tolerability of MEDI-547 will be assessed based on the incidence of AEs, SAEs, laboratory abnormalities, physical examination changes, toxicities leading to permanent discontinuation of MEDI-547 and MEDI-547-related deaths.\"\\n19188,1,1,\"Safety and tolerability of MetMAb alone or in combination with bevacizumab will be assessed (frequency and nature of dose-limiting toxicities; nature, severity, and relatedness of adverse events; changes in vital signs and clinical laboratory parameters)\"\\n19189,1,1,\"Safety and tolerability of metoprolol in patients treated by CAR T infusions.\"\\n19190,1,1,\"Safety and tolerability of MK-8033 based on drug-related dose limiting toxicity.\"\\n19191,1,1,\"Safety and tolerability of MK-8033 F2 formulation alone or in combination with omeprazole based on incidence of adverse experiences\"\\n19192,1,1,\"Safety and tolerability of MK0731 administered as a 24-hour CIV Infusion. Dose limiting toxicities. Maximum tolerated dose and recommended Phase II dose of L-001154704 administered as a 24 hour CIV infusion.\"\\n19193,1,1,\"Safety and tolerability of MK6592 alone and in combination with docetaxel\"\\n19194,1,1,\"Safety and tolerability of MRx0518 as determined by clinically significant changes in electrocardiogram (ECG) results.\"\\n19195,1,1,\"Safety and tolerability of MRx0518 as determined by clinically significant changes upon physical examination.\"\\n19196,1,1,\"Safety and tolerability of MRx0518 as determined through the collection of the number and severity of adverse vents (AEs) and serious adverse events (SAEs).\"\\n19197,1,1,\"Safety and tolerability of MRx0518 determined by clinically significant changes in biochemistry, haematology and urinalysis laboratory results.\"\\n19198,1,1,\"Safety and tolerability of MRx0518 determined by clinically significant changes in vital signs.\"\\n19199,1,1,\"Safety and tolerability of MSB0254\"\\n19200,2,2,\"Safety and tolerability of MSB2311\"\\n19201,1,1,\"Safety and tolerability of multiple daily doses of BMS-986115\"\\n19202,1,1,\"Safety and tolerability of nab-paclitaxel in combination with pembrolizumab as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities.\"\\n19203,1,1,\"Safety and tolerability of ONO-7746 across ascending multiple doses using vital signs, physical examinations, ECGs, ECOG performance status, CT/MRI, laboratory tests\"\\n19204,1,1,\"Safety and tolerability of OPB-111077\"\\n19205,1,1,\"Safety and tolerability of oral dosing with XL147 capsules in subjects with lymphoma, and of XL147 capsules and tablets in subjects with solid tumors\"\\n19206,1,1,\"Safety and tolerability of oral HMPL-295S1 monotherapy for patients with advanced solid tumors;\"\\n19207,1,1,\"Safety and tolerability of Oraxol (Incidence of Treatment-Emergent Adverse Events)\"\\n19208,1,1,\"Safety and tolerability of Paclitaxel Micelles for Injection in dose ascending and dose extension as measured by assessment of maximum tolerated dose (MTD) and dose limiting toxicity (DLT).\"\\n19209,1,1,\"Safety and tolerability of patients to multiple doses of CAVATAK\"\\n19210,1,1,\"Safety and tolerability of PRT3645: AEs, CTCAE Assessments\"\\n19211,1,1,\"Safety and tolerability of PRT3789: AEs, CTCAE Assessments\"\\n19212,1,1,\"Safety and tolerability of radio-labeled FF21101\"\\n19213,1,1,\"Safety and tolerability of repeated ascending oral doses of 4SC-205. Determination of the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT).\"\\n19214,1,1,\"Safety and tolerability of RMT\"\\n19215,1,1,\"Safety and Tolerability of RP-6306 in combination with RP-3500 in patients with advanced solid tumors as assessed by NCI CTCAE v5.0\"\\n19216,1,1,\"Safety and Tolerability of RP-6306 in patients with advanced solid tumors as assessed by NCI CTCAE v5.0\"\\n19217,1,1,\"Safety and tolerability of SB17170\"\\n19218,1,1,\"Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity\"\\n19219,1,1,\"Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity.\"\\n19220,1,1,\"Safety and tolerability of SCIB1 in participants receiving either nivolumab with ipilimumab or pembrolizumab assessed by the evaluation of adverse events (AEs) and the use of concomitant medications (Run-In Sub-Cohorts)\"\\n19221,1,1,\"Safety and tolerability of SCIB1 in participants receiving either nivolumab with ipilimumab or pembrolizumab assessed by the evaluation of vital signs, physical examination, 12-lead ECG, laboratory assessments and performance status (Run-In Sub-Cohorts)\"\\n19222,1,1,\"Safety and tolerability of SCIB1 in participants receiving either nivolumab with ipilimumab or pembrolizumab assessed by the injection site reaction (Run-In Sub-Cohorts)\"\\n19223,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events\"\\n19224,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of blood pressure (BP)\"\\n19225,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of body temperature\"\\n19226,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Echocardiogram (ECHO)\"\\n19227,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Electrocardiogram (ECG)\"\\n19228,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Multigated Acquisition (MUGA)\"\\n19229,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (best corrected visual acuity)\"\\n19230,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (Intraocular pressure)\"\\n19231,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)\"\\n19232,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of physical examinations\"\\n19233,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of pulse\"\\n19234,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of respiratory rate\"\\n19235,1,1,\"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of safety laboratory tests\"\\n19236,1,1,\"Safety and tolerability of SG001 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)\"\\n19237,1,1,\"Safety and tolerability of single agent SRK-181\"\\n19238,1,1,\"Safety and tolerability of SP-2577\"\\n19239,1,1,\"Safety and tolerability of SPYK04 (Adverse Events) [Dose escalation]\"\\n19240,1,1,\"Safety and tolerability of SPYK04 (Dose limiting toxicities) [Dose escalation]\"\\n19241,1,1,\"Safety and tolerability of SPYK04 (Electrocardiograms in triplicate) [Dose escalation]\"\\n19242,1,1,\"Safety and tolerability of SRK-181 in combination with anti-PD-(L)1 antibody therapy\"\\n19243,1,1,\"Safety and tolerability of sunitinib malate as measured by the incidence, severity, seriousness and relatedness to treatment adverse events (AEs), laboratory abnormalities, vital signs (blood pressure) and the use of concomitant medications.\"\\n19244,1,1,\"Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohorts\"\\n19245,1,1,\"Safety and tolerability of TAS-116 with palbociclib.\"\\n19246,1,1,\"Safety and tolerability of TAS-119 in combination with paclitaxel\"\\n19247,1,1,\"Safety and Tolerability of TAVO412 according to Adverse Events and Number of Participants With Dose Limiting Toxicity (DLT) using National Cancer Institute CTCAE v5.0\"\\n19248,1,1,\"Safety and tolerability of tazemetostat 1600 mg once daily for Cohort 8 (Epithelioid Sarcoma)\"\\n19249,1,1,\"Safety and Tolerability of Telaglenastat Plus Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Type, Incidence, Severity, Seriousness, and Study Drug Relatedness of Adverse Events per CTCAE v5.0\"\\n19250,1,1,\"Safety and Tolerability of telaglenestat (CB-839) in combination with palbociclib: (CR) number of participants with treatment related adverse events\"\\n19251,1,1,\"Safety and tolerability of temozolomide in combination with VPA and Whole-Brain Radiation\"\\n19252,1,1,\"safety and tolerability of the association between Gefitinib (fixed dose) and Tremelimumab (dose escalation)\"\\n19253,1,1,\"Safety and tolerability of the combination of ABT-888 with topotecan hydrochloride in patients with refractory solid tumors and lymphomas; Establish the maximum tolerated dose of ABT-888 with topotecan hydrochloride.\"\\n19254,1,1,\"Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)\"\\n19255,1,1,\"Safety and tolerability of the combination regimen assessed by adverse events (AEs)\"\\n19256,1,1,\"Safety and tolerability of the combination therapy\"\\n19257,1,1,\"safety and tolerability of the combination therapy assessed by analysis of adverse events\"\\n19258,1,1,\"safety and tolerability of the combination therapy assessed by analysis of laboratory tests\"\\n19259,1,1,\"safety and tolerability of the combination therapy assessed by analysis of other assessments within the protocol\"\\n19260,1,1,\"Safety and tolerability of the combination using the NCI Common Toxicity Criteria v4.0 grading system for adverse events\"\\n19261,1,1,\"Safety and tolerability of the OXIRI regimen as measured by the frequency of significant adverse events incurred by the participants, using CTCAE ver. 4 grading system\"\\n19262,1,1,\"Safety and Tolerability of Tranexamic Acid in Participants as the Number of Patients With Any Adverse Events and Serious Adverse Events (SAE) as Assessed by CTCAE v4.03\"\\n19263,1,1,\"Safety and Tolerability of TRE-515 as assessed by the Number of Participants with Adverse Events (AEs) as assessed by NCI-CTCAE v5.0Safety and tolerability of oral TRE-515\"\\n19264,1,1,\"Safety and tolerability of treatment with TKM-080301\"\\n19265,1,1,\"safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with Bevacizumab to patients with advanced solid tumours by assessment of adverse events, vital signs, ECG, clinical chem, haematology, urinalysis and phys exam\"\\n19266,1,1,\"Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.\"\\n19267,1,1,\"Safety and tolerability of vantictumab in combination with docetaxel in patients with recurrent or advanced NSCLC. The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with weekly paclitaxel.\"\\n19268,1,1,\"Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation\"\\n19269,1,1,\"Safety and tolerability of XL844 as a single agent and in combination with gemcitabine when administered orally to subjects with advanced malignancies\"\\n19270,1,1,\"Safety and tolerability of XNW7201 tablets in subjects with advanced solid tumor;\"\\n19271,1,1,\"Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events\"\\n19272,1,1,\"Safety and tolerability of ZSP1241 in single dose ascending (SAD) and multiple dose ascending (MAD) as measured by assessment of maximum tolerated dose (MTD), dose limiting toxicity (DLT) and treatment emergent adverse events (TEAEs)\"\\n19273,1,1,\"Safety and tolerability of ZX-4081\"\\n19274,1,1,\"Safety and tolerability of ‚Å∏‚ÅπZr-Df-IAB22M2C assessed by local and systemic signs and symptoms of infusion reactions,incidence of adverse events,changes in laboratory test results,dose limiting toxicities,vital signs and 12-lead electrocardiogram findings\"\\n19275,1,1,\"Safety and tolerability profile of efti in combination with weekly paclitaxel both given the same day\"\\n19276,1,1,\"Safety and tolerability profile of SHR-1701\"\\n19277,1,1,\"Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.\"\\n19278,2,1,\"Safety and tolerability taking into account treatment-limiting toxicities (TLTs)\"\\n19279,1,1,\"Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms\"\\n19280,1,1,\"Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.\"\\n19281,1,1,\"Safety and Tolerability will be evaluated\"\\n19282,1,1,\"Safety and tolerability will be evaluated\"\\n19283,1,1,\"Safety and tolerability will be the primary endpoint and will be assessed by monitoring the frequency, duration, and severity of AEs\"\\n19284,1,1,\"Safety and tolerability will include evaluation of adverse events (AE) and changes from baseline in vital signs and clinical laboratory parameters. PK endpoints will include Cl, Vd, AUC, Cmax, and t¬Ω.\"\\n19285,1,1,\"Safety and tolerability(Incidence and severity of adverse events (AEs))\"\\n19286,3,1,\"Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through 12-lead ECG\"\\n19287,3,1,\"Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Physical exam\"\\n19288,2,1,\"Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign- blood pressure\"\\n19289,2,1,\"Safety and tolerability(Incidence of Treatment-Emergent Adverse Events) measure through Vital Sign-heart rate\"\\n19290,1,1,\"Safety and Tolerability, in Phase I, Cohort A and B.\"\\n19291,2,1,\"Safety and tolerability: 12-lead electrocardiogram (ECG)\"\\n19292,1,1,\"Safety and tolerability: Adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 5.0\"\\n19293,1,1,\"Safety and tolerability: Adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0\"\\n19294,1,1,\"Safety and tolerability: Clinical laboratory tests\"\\n19295,1,1,\"Safety and tolerability: Dose-limiting toxicities (DLTs)\"\\n19296,3,3,\"Safety and Tolerability: incidence of adverse events and any dose limiting toxicity\"\\n19297,1,1,\"safety and tolerability: percentage of patients experiencing treatment-related and treatment-emergent adverse events\"\\n19298,1,1,\"Safety and tolerability: Physical examination\"\\n19299,2,1,\"Safety and tolerability: Vital signs\"\\n19300,1,1,\"Safety and Tolerability; define Maximum Tolerated dose\"\\n19301,1,1,\"Safety and tolerability; MTD will be established\"\\n19302,1,1,\"Safety and tolerabilty\"\\n19303,7,2,\"Safety and tolerance\"\\n19304,1,1,\"Safety and toxicities as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0\"\\n19305,5,2,\"Safety and Toxicity\"\\n19306,6,1,\"Safety and toxicity\"\\n19307,1,1,\"Safety and toxicity assessed weekly during treatment\"\\n19308,1,1,\"Safety and toxicity evaluated according to the NCI CTCAE version 3.0\"\\n19309,1,1,\"Safety and toxicity of combination therapy with sunitinib and bortezomib\"\\n19310,1,1,\"Safety and Toxicity of Erlotinib Hydrochloride and Docetaxel as Measured by NCI CTC v3.0 on Day 8 of Course 1 and on Day 1 of Every Subsequent Course (Phase I [Completed as of 12/01/2004])\"\\n19311,1,1,\"Safety and Toxicity of H-D IL-2 Followed by Low Dose Temozolomide\"\\n19312,1,1,\"Safety and Toxicity Profile (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)\"\\n19313,1,1,\"Safety and Toxicity Profile 9adverse event to ONX-0801 and grading severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0)\"\\n19314,1,1,\"Safety and toxicity profile as assessed by NCI CTCAE version 3.0\"\\n19315,1,1,\"Safety and toxicity profile of combination bevacizumab and cediranib maleate\"\\n19316,1,1,\"Safety and Toxicity Profile of Combining Both Bevacizumab and Erlotinib Hydrochloride With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy\"\\n19317,1,1,\"Safety and Validity profiles\"\\n19318,9,1,\"Safety as assessed by adverse events\"\\n19319,3,1,\"Safety as assessed by clinical laboratory tests\"\\n19320,1,1,\"Safety as assessed by electrocardiograms (ECG)\"\\n19321,1,1,\"Safety as Assessed by Grade 1, 2, 3, 4, Fatal Toxicity, Need for Dose Reduction, Treatment Interruption, or Treatment Discontinuation\"\\n19322,1,1,\"Safety as assessed by NCI CTCAE v3.0\"\\n19323,5,3,\"Safety as assessed by number of participants experiencing adverse events\"\\n19324,1,1,\"Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0\"\\n19325,1,1,\"Safety as assessed by the NCI CTCAE version 4.0\"\\n19326,5,1,\"Safety as assessed by vital signs\"\\n19327,1,1,\"Safety as defined by the presence of adverse events (AE), serious adverse events (SAE), and dose limiting toxicities (DLT).\"\\n19328,1,1,\"Safety as determined by assessment of dose limiting toxicities per protocol of CAN 1012 with cancers.\"\\n19329,1,1,\"Safety as measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity\"\\n19330,7,1,\"Safety as measured by adverse events\"\\n19331,1,1,\"Safety as measured by AE information. Tolerability as measured by DLT observation.\"\\n19332,1,1,\"Safety as measured by NCI Common Toxicity Criteria and a recommended Phase II dose (RPTD)\"\\n19333,1,1,\"Safety as measured by number of participants with Grade 3 and 4 adverse events\"\\n19334,1,1,\"Safety as measured by physical examinations, electrocardiograms, laboratory assessments, vital signs, adverse events and serious adverse events\"\\n19335,1,1,\"Safety as measured by rate of adverse events during study drug treatment\"\\n19336,2,1,\"Safety as measured by serious adverse events\"\\n19337,1,1,\"Safety as Measured by the Number of Patients With Dose Limiting Toxicities (DLT)\"\\n19338,1,1,\"Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.\"\\n19339,2,1,\"Safety as measured by the rate of adverse events\"\\n19340,1,1,\"Safety as measured by the rate of adverse events, and serious adverse events\"\\n19341,1,1,\"safety as occurence of adverse events ‚â• Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent\"\\n19342,1,1,\"Safety assessed by 12- lead electrocardiogram (ECG) (Initial Treatment)\"\\n19343,1,1,\"Safety assessed by 12- lead electrocardiogram (ECG) (Retreatment)\"\\n19344,1,1,\"Safety assessed by 12- lead electrocardiograms (ECGs) adverse events\"\\n19345,3,1,\"Safety assessed by Adverse Events (AEs)\"\\n19346,1,1,\"Safety assessed by CTCAE\"\\n19347,1,1,\"Safety assessed by Eastern Cooperative Oncology Group (ECOG) performance status in Safety Part\"\\n19348,1,1,\"Safety assessed by Eastern Cooperative Oncology Group Performance Status (ECOG PS) (Initial Treatment)\"\\n19349,1,1,\"Safety assessed by Eastern Cooperative Oncology Group Performance Status (ECOG PS) (Retreatment)\"\\n19350,1,1,\"Safety assessed by incidence of serious adverse events (SAE)\"\\n19351,1,1,\"Safety assessed by incidence of treatment emergent adverse events (TEAE)\"\\n19352,2,2,\"Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)\"\\n19353,1,1,\"Safety assessed by overall incidence of adverse events (AEs) and serious adverse events (SAEs)\"\\n19354,1,1,\"Safety assessed by recording of adverse events, clinical laboratory evaluation, electrocardiograms (ECGs) physical examinations, and vital signs\"\\n19355,1,1,\"Safety assessed by severity of adverse events (AEs) and serious adverse events (SAEs)\"\\n19356,1,1,\"Safety assessed by the vital signs, incidence of adverse events, labo-tests and 12-lead EGC\"\\n19357,1,1,\"Safety assessed using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0.\"\\n19358,23,2,\"Safety Assessment\"\\n19359,16,2,\"Safety assessment\"\\n19360,1,1,\"Safety assessment based on reports of adverse events and clinical laboratory tests as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)\"\\n19361,1,1,\"Safety Assessment by rate of Adverse Events (AEs)\"\\n19362,1,1,\"Safety assessment in dose-escalation phase\"\\n19363,1,1,\"Safety assessment: Adverse event\"\\n19364,1,1,\"Safety Assessment: Measured by incidence of Treatment Emergent Adverse Events (TEAEs)\"\\n19365,1,1,\"Safety assessments (laboratory tests)\"\\n19366,1,1,\"Safety assessments of adverse events per CTCAE\"\\n19367,1,1,\"Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests\"\\n19368,1,1,\"Safety Assessments: progression free survival\"\\n19369,1,1,\"Safety attributable to 111In-Pertuzumab injections\"\\n19370,2,2,\"Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0\"\\n19371,2,2,\"Safety by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.\"\\n19372,1,1,\"Safety cohort: 14 participants with treatment related serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V5.0.\"\\n19373,1,1,\"safety endpoint\"\\n19374,3,1,\"Safety endpoints\"\\n19375,1,1,\"Safety endpoints including assessment of both serious and non-serious AEs\"\\n19376,1,1,\"Safety endpoints: adverse events(AEs), serious adverse eventsÔºàSAEsÔºâ.\"\\n19377,2,1,\"safety evaluation\"\\n19378,1,1,\"Safety evaluation by the incidence of adverse events (AEs) and serious adverse events (SAEs)\"\\n19379,1,1,\"Safety evaluation due to results of physical examinations, vital signs, AEs, abnormal laboratory tests and 12-lead ECG, cardiac function test and ophthalmological examination.\"\\n19380,3,1,\"Safety evaluation indicators\"\\n19381,1,1,\"Safety evaluation of OMTX705\"\\n19382,1,1,\"Safety Evaluation: frequency and severity of AEs\"\\n19383,1,1,\"Safety follow-up\"\\n19384,2,2,\"Safety in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19385,2,2,\"Safety in the first 28-Days of Therapy\"\\n19386,1,1,\"Safety in the treatment of ipilimumab followed by SHR1210\"\\n19387,1,1,\"Safety Incidence of DLT severity of adverse events (AEs) and serious adverse events (SAEs)and tolerability\"\\n19388,1,1,\"Safety including adverse events, clinically significant changes in laboratory results, ECG, and vital signs, to be measured throughout the study. Pharmacokinetic Profile of AMG 386 - blood levels of AMG 386 to be measured throughout the study.\"\\n19389,1,1,\"Safety laboratory parameters (biochemistry)\"\\n19390,1,1,\"Safety laboratory parameters (coagulation)\"\\n19391,1,1,\"Safety laboratory parameters (endocrines)\"\\n19392,1,1,\"Safety laboratory parameters (hematology)\"\\n19393,1,1,\"Safety laboratory parameters (hematology, biochemistry, coagulation, endocrines)\"\\n19394,1,1,\"Safety Lead-In (SLI) Part: Incidence of Dose-limiting toxicities (DLTs)\"\\n19395,1,1,\"Safety Lead-in Phase: Incidence of Dose Limiting Toxicities (DLTs) during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI)\"\\n19396,2,2,\"Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE\"\\n19397,2,2,\"Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)\"\\n19398,2,2,\"Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)\"\\n19399,1,1,\"Safety Lead-in: Incidence and severity of adverse events (AEs)\"\\n19400,1,1,\"Safety Lead-in: Incidence of dose modifications due to AEs\"\\n19401,1,1,\"Safety Lead-in: Incidence of dose-limiting toxicities (DLTs)\"\\n19402,1,1,\"Safety Lead-in: Incidence of treatment discontinuations due to AEs\"\\n19403,1,1,\"Safety measured by adverse events To assess the toxicity of LNA-i-miR-221\"\\n19404,1,1,\"Safety Measurement - Percentage of Patients Experiencing Serious Adverse Events (SAEs) in the First 4 Months of Treatment.\"\\n19405,2,1,\"Safety Measurements\"\\n19406,3,1,\"Safety measurements\"\\n19407,11,1,\"Safety Measures\"\\n19408,3,3,\"Safety monitoring including adverse events, vital signs, and laboratory assessments\"\\n19409,1,1,\"Safety objectives\"\\n19410,1,1,\"Safety of 3 drugs combination treatment\"\\n19411,1,1,\"Safety of [F-18]MeFAMP\"\\n19412,1,1,\"Safety of a multiple dose regimen of AdAPT-001\"\\n19413,1,1,\"Safety of Allocetra-OTS\"\\n19414,1,1,\"Safety of AMG 232\"\\n19415,1,1,\"Safety of AO-176 and paclitaxel assessed by adverse events and laboratory abnormalities\"\\n19416,1,1,\"Safety of AO-176 and pembrolizumab assessed by adverse events and laboratory abnormalities\"\\n19417,1,1,\"Safety of AO-176 assessed by adverse events and laboratory abnormalities\"\\n19418,1,1,\"Safety of B7-H3-CAR T cells\"\\n19419,1,1,\"Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs\"\\n19420,1,1,\"Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events\"\\n19421,2,2,\"Safety of CART cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19422,1,1,\"Safety of CART cells infusion\"\\n19423,1,1,\"Safety of CC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19424,1,1,\"Safety of CCT301-59 CAR T cell therapy\"\\n19425,1,1,\"Safety of CGTC-102 in patients with solid tumors\"\\n19426,1,1,\"Safety of combination retifanlimab and radiation with and without temozolomide as assessed by number of participants who experience adverse events\"\\n19427,1,1,\"Safety of combined administration of 131I-L19SIP and whole brain radiation therapy (WBRT)\"\\n19428,1,1,\"Safety of combined therapy of XRT plus RAI measured by NCI-CTCAE toxicity\"\\n19429,1,1,\"Safety of concurrent sildenafil with doxorubicin-based chemotherapy\"\\n19430,1,1,\"Safety of DKC as assessed by adverse event (AE)\"\\n19431,1,1,\"Safety of DKC as assessed by combining with concomitant anticancer treatment\"\\n19432,1,1,\"Safety of DKC as assessed by dose-limiting toxicity (DLT)\"\\n19433,1,1,\"Safety of DKC as assessed by laboratory examinations\"\\n19434,1,1,\"Safety of DKC as assessed by serious adverse event (SAE)\"\\n19435,1,1,\"Safety of DKY709 single agent treatment or DKY709 in combination with PDR001.\"\\n19436,1,1,\"Safety of Drosophila Generated PBL Administered in Combination With a Lymphodepleting Preparative Regimen and Supportive Systemic Aldesleukin\"\\n19437,1,1,\"Safety of engineered T cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19438,1,1,\"Safety of entolimod\"\\n19439,1,1,\"safety of escalating NK cell doses of adoptively infused ex vivo expanded autologous NK cells in subjects with treatment refractory metastatic tumors or hematological malignancies that are sensitized to NK cell toxicity with bortezomib.\"\\n19440,1,1,\"Safety of fhB7H3.CAR-T cells\"\\n19441,1,1,\"Safety of fourth generation anti-CD19 and anti-CD20/CD22/CD70/PSMA/CD13/CD79b/GD2 CAR-T cells infusion\"\\n19442,1,1,\"Safety of FPAC\"\\n19443,5,3,\"Safety of infusion\"\\n19444,1,1,\"safety of infusion of autologous anti-mesothelin CAR T cells as assessed by the incidents of treatment related adverse events per NCI CTCAE V4.0\"\\n19445,1,1,\"Safety of infusion of autologous CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells\"\\n19446,1,1,\"Safety of infusion of autologous IgT cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.\"\\n19447,1,1,\"Safety of infusion of autologous immunomodulatory DC Vaccine is assessed by the NCI CTCAE V4.0 criteria.\"\\n19448,1,1,\"Safety of infusion of autologous mesothelin specific CAR T cells\"\\n19449,1,1,\"Safety of LC-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19450,1,1,\"Safety of MRx0518 and Avelumab combination treatment\"\\n19451,1,1,\"Safety of Nivestim¬Æ to reduce or prevent febrile neutropenia in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.\"\\n19452,1,1,\"Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs)\"\\n19453,1,1,\"Safety of OC-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19454,1,1,\"Safety of OC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events\"\\n19455,1,1,\"Safety of OPB-111077\"\\n19456,1,1,\"Safety of PLX51107 as measured by adverse events and serious adverse events.\"\\n19457,1,1,\"Safety of PLX73086, as measured by adverse events and serious adverse events [Part 1 and Part 2 of research study]\"\\n19458,1,1,\"Safety of PLX7486 as single agent as measured by adverse events and serious adverse events.\"\\n19459,1,1,\"Safety of PRECIOUS-01\"\\n19460,1,1,\"Safety of PTK787/ZK 222584 in combination with paclitaxel\"\\n19461,1,1,\"Safety of RAPA-201 Cell Therapy\"\\n19462,1,1,\"Safety of SBRT in OP malignancies\"\\n19463,1,1,\"Safety of SG001 in patients with advanced tumors.\"\\n19464,1,1,\"Safety of Shortened duration of tacrolimus as assessed by number of participants with NRM and Grade III-IV acute GVHD at Day 120\"\\n19465,1,1,\"Safety of STA-9090 (ganetespib) and docetaxel combination\"\\n19466,1,1,\"Safety of STI-6643\"\\n19467,1,1,\"Safety of Sunitinib Administration in Participants With Von Hippel-Lindau Syndrome (VHL)\"\\n19468,1,1,\"Safety of TCD-717 given by 4-hour intravenous infusion\"\\n19469,1,1,\"Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)\"\\n19470,1,1,\"Safety of the combined regimen of SHR2150, chemotherapy, PD-1 or CD47 antibody\"\\n19471,1,1,\"safety of the cyclophosphamide combined tumor specific epitope peptide cocktail\"\\n19472,1,1,\"Safety of the DC bead TACE\"\\n19473,1,1,\"Safety of the pancreatic radiofrequency ablation under EUS guidance\"\\n19474,1,1,\"Safety of the scalp cooling device as descripted by CTCAE\"\\n19475,1,1,\"Safety of the T cell therapy, with and without dendritic cell vaccine, as evaluated according to the NCI CTCAE scale version 4.0\"\\n19476,1,1,\"Safety of the treatment as assessed by 30-day postoperative mortality\"\\n19477,1,1,\"Safety of TILs/CAR-TILs treatment in advanced solid cancers\"\\n19478,2,1,\"Safety of Treatment\"\\n19479,1,1,\"Safety of tumor resection\"\\n19480,1,1,\"Safety of YS-ON-001 by monitoring any adverse events (AE) and serious adverse events (SAE)\"\\n19481,1,1,\"Safety of ZGGS18\"\\n19482,1,1,\"Safety outcome evaluation - Dose Limited Toxicity (DLT), Maximum Tolerated Dose (MTD).\"\\n19483,1,1,\"Safety outcome evaluation - incidence, severity and outcomes of AEs (Adverse Event)\"\\n19484,1,1,\"Safety outcome: The number of deaths\"\\n19485,1,1,\"Safety outcome: The number of subjects with overall adverse events\"\\n19486,1,1,\"Safety parameters (adverse events, laboratory data, vital signs, electrocardiogram data, Eastern Cooperative Oncology Group [ECOG] scores, and physical and neurological exams).\"\\n19487,1,1,\"Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity)\"\\n19488,7,2,\"Safety Profile\"\\n19489,12,3,\"Safety profile\"\\n19490,1,1,\"Safety profile (adverse events including dose limiting toxicities, clinical safety assessments such as human antihumanized antibody (HAHA) and neutr. HAHA), tolerability (maximum tolerated dose or maximum feasible dose), and pharmacokinetic profile.\"\\n19491,1,1,\"Safety profile (i.e. adverse events, presence/absence of RCR, analysis of clonality and PK of TBI-1301) assessed by CTCAE v.4.0 and laboratory testings.\"\\n19492,1,1,\"Safety Profile (Number and severity of treatment related AEs); Phase Ib and II\"\\n19493,1,1,\"Safety profile and effectiveness of escalating doses of ALT-803\"\\n19494,1,1,\"Safety profile and tolerability of Doxil in combination with PSC 833\"\\n19495,1,1,\"Safety Profile as Assessed by Incidence of Adverse Events (AEs), Treatment-Related AEs and Dose-Limiting Toxicities (DLTs)\"\\n19496,1,1,\"Safety profile assessed using NCI CTCAE version 4.0\"\\n19497,5,5,\"Safety Profile Measured by Grade ‚â•3 TEAEs\"\\n19498,1,1,\"Safety profile of Acelarin in combination with Cisplatin, assessed by total incidence and rate of grade 3 and 4 adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)\"\\n19499,1,1,\"Safety profile of ASTX727 in combination with paclitaxel and pembrolizumab (MK-3475) (Dose Finding Phase)\"\\n19500,1,1,\"safety profile of combination of Talazoparib and Selinexor in advanced/ metastatic solid tumors using NCI CTCAE toxicity grading version 5.0.\"\\n19501,1,1,\"Safety profile of OMP-52M51 in subjects with relapsed or refractory solid tumors\"\\n19502,1,1,\"Safety profile of six different administration schedules of RO4929097\"\\n19503,1,1,\"Safety profile of SL-172154\"\\n19504,1,1,\"Safety profile of SL-279252 - Incidence of all treatment emergent adverse events\"\\n19505,1,1,\"Safety profile of trebananib and temsirolimus as assessed by NCI CTCAE version 4.0\"\\n19506,1,1,\"Safety profile, including dose-limiting toxicities, maximum tolerated dose, recommended Phase II dose; and the pharmacokinetic profile.\"\\n19507,1,1,\"Safety profile, maximum tolerated dose (MTD) or maximum feasible dose (MFD) of TAK-441 administered as an oral formulation in patients wtih advanced nonhematologic malignancies\"\\n19508,1,1,\"Safety related biomarkers\"\\n19509,1,1,\"Safety Run In-Recommended Phase 2 dose (RP2D)\"\\n19510,1,1,\"Safety run-in arm: Number of participants with treatment related adverse events (NCI CTCAE; Version 4.03)\"\\n19511,1,1,\"Safety Run-in Cohort: Percentage of Participants Experiencing Adverse Events (AEs) According to the NCI-CTCAE Version 5.0\"\\n19512,1,1,\"Safety Run-in Cohort: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\"\\n19513,1,1,\"Safety Run-in Cohort: Percentage of Participants Experiencing Laboratory Abnormalities According to NCI-CTCAE Version 5.0\"\\n19514,1,1,\"Safety Run-in Cohorts: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\"\\n19515,1,1,\"Safety Run-in Cohorts: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs), Adverse Events (AEs), and Laboratory Abnormalities According to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), Version 5.0\"\\n19516,2,1,\"Safety run-in part: Incidence of dose limiting toxicities (DLTs)\"\\n19517,1,1,\"Safety Run-in Part: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)\"\\n19518,1,1,\"Safety Run-in Part: Number of Participants with Clinically Significant Changes From Baseline in Vital Signs, 12-Lead Electrocardiogram (ECG) Findings and Laboratory Parameters\"\\n19519,1,1,\"Safety Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n19520,1,1,\"Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n19521,1,1,\"Safety Run-in Part: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs\"\\n19522,1,1,\"Safety run-in: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0)\"\\n19523,1,1,\"Safety tolerability assessment\"\\n19524,1,1,\"Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.\"\\n19525,1,1,\"Safety variables (Incidence of Adverse Events [Safety and Tolerability])\"\\n19526,1,1,\"Safety will be assessed according to common terminology criteria for adverse events version 4.0 (CTC AE 4.0)\"\\n19527,1,1,\"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination\"\\n19528,1,1,\"Safety will be assessed by analysis of adverse experiences, clinical laboratory tests, and physical examinations.\"\\n19529,1,1,\"Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.\"\\n19530,1,1,\"Safety will be determined by clinical adverse events, laboratory abnormalities, withdrawals due to adverse events, and drug-related neurotoxicities.\"\\n19531,1,1,\"Safety&Tolerability\"\\n19532,1,1,\"Safety, as assessed by incidence of adverse events graded according to the NCI-CTCAE, version 4.0\"\\n19533,1,1,\"Safety, as determined by frequency, nature, and severity of adverse events; and the profile of dose-limiting toxicities\"\\n19534,1,1,\"Safety, as measured by the rate of adverse events and serious adverse events\"\\n19535,1,1,\"Safety, defined as onset of grade 3 or 4 (G3/4) treatment-related adverse events (TRAEs), assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 5.\"\\n19536,1,1,\"Safety, DLT, and MTD\"\\n19537,1,1,\"Safety, in terms of absences of severe adverse events (SAE) and unacceptable toxicity\"\\n19538,1,1,\"Safety, in terms of adverse events and dose-limiting toxicity, as measured by NCI CTC v2.0 at up to 4 weeks after the start of treatment\"\\n19539,1,1,\"Safety, in terms of dose-limiting toxicity of adding oral soy isoflavone supplementation to concurrent chemotherapy and radiotherapy, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4\"\\n19540,1,1,\"Safety, maximum tolerated dose (MTD) and dose-limiting toxicity(DLT)of MDX-1105\"\\n19541,2,1,\"Safety, tolerability\"\\n19542,2,1,\"safety, tolerability\"\\n19543,1,1,\"Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort\"\\n19544,1,1,\"Safety, tolerability, and efficacy of atezolizumab, bevacizumab, and cobimetinib (Arm II)\"\\n19545,1,1,\"Safety, tolerability, and feasibility\"\\n19546,1,1,\"Safety, tolerability, and maximum tolerated dose (MTD) of daily oral administration of XL765 in two treatment schedules\"\\n19547,1,1,\"Safety, tolerability, and maximum tolerated dose (MTD) of once daily or twice daily oral administration of XL281\"\\n19548,1,1,\"Safety, tolerability, and maximum tolerated dose (MTD) of XL647 administered in combination with XL147 orally daily\"\\n19549,1,1,\"Safety, tolerability, and maximum tolerated dose of oral administration of two formulations of XL147 in two treatment schedules\"\\n19550,1,1,\"Safety, tolerability, and maximum tolerated dose of oral administration of XL888 when administered on an intermittent schedule to adults with solid tumors\"\\n19551,1,1,\"Safety, tolerability, and maximum tolerated dose of XL147 administered in combination with erlotinib\"\\n19552,1,1,\"Safety, tolerability, and maximum tolerated dose of XL418 with daily oral administration\"\\n19553,1,1,\"Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with erlotinib\"\\n19554,1,1,\"Safety, tolerability, maximum tolerated dose\"\\n19555,1,1,\"Safety, tolerability, maximum tolerated dose (MTD), and dose-limiting toxicity of oral administration of XL184\"\\n19556,1,1,\"Safety, tolerability, toxicity profile, and dose-limiting toxicities as assessed by NCI CTCAE v.30\"\\n19557,1,1,\"Safety, tolerability, toxicity profile, and dose-limiting toxicity of AT9283\"\\n19558,1,1,\"Safety, tolerability, toxicity profile, and dose-limiting toxicity of eribulin mesylate\"\\n19559,1,1,\"Safety, toxicity profile, dose-limiting toxicity (DLT), and maximum tolerated doses (MTD)\"\\n19560,7,1,\"Safety/Tolerability\"\\n19561,1,1,\"Safety/tolerability as measured by number of patients with adverse events\"\\n19562,1,1,\"Safety/tolerability of ECO-4601\"\\n19563,1,1,\"Safety/tolerability of NB1011 infusions\"\\n19564,1,1,\"Safety/tolerability of olaparib in combination with AZD5363\"\\n19565,1,1,\"Safety/tolerability of oral DCC-2618: incidence of adverse events\"\\n19566,1,1,\"Safety/tolerability: incidence of adverse events\"\\n19567,1,1,\"Safety/Tolerability; incidence of adverse events\"\\n19568,1,1,\"Safety/Toxicity: Incidence of treatment-related adverse events; treatment-related serious adverse events; treatment-related Grade 3/4 toxicities; and clinically-significant, treatment-related changes from baseline in routine laboratory parameters\"\\n19569,2,1,\"Safety: adverse event profile\"\\n19570,2,1,\"Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety.\"\\n19571,2,1,\"Safety: adverse events as assessed by CTCAE v5.0\"\\n19572,1,1,\"Safety: Clinical and laboratory criteria\"\\n19573,2,1,\"Safety: Clinical Lab Tests will be performed for each participant as a safety measure.\"\\n19574,1,1,\"Safety: Dose Intensity\"\\n19575,1,1,\"Safety: Frequency of adverse events\"\\n19576,1,1,\"Safety: Incidence and Severity of adverse events (AEs) and IRRs\"\\n19577,1,1,\"Safety: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Phase 1)\"\\n19578,1,1,\"Safety: incidence and severity of adverse events and serious adverse events\"\\n19579,3,1,\"Safety: incidence and severity of adverse events, laboratory test abnormalities\"\\n19580,55,3,\"Safety: Incidence of adverse events\"\\n19581,1,1,\"Safety: Incidence of adverse events (AE)\"\\n19582,1,1,\"Safety: Incidence of anti-therapeutic antibodies against onartuzumab.\"\\n19583,1,1,\"Safety: Incidence of Dose Modifications\"\\n19584,1,1,\"Safety: Incidence of dose-limiting toxicities (DLTs) of vermurafenib and/or cobimetinib used in combination with onartuzumab.\"\\n19585,1,1,\"Safety: incidence of dose-limiting toxicities, adverse events, laboratory abnormalities; incidence of anti-drug antibodies, abnormal findings on physical examination, infusion-related reactions (composite outcome measure)\"\\n19586,1,1,\"Safety: Incidence of Post Chemotherapy Surgical Debulking\"\\n19587,1,1,\"Safety: Incidence of Treatment Emergent Adverse Events\"\\n19588,1,1,\"Safety: Laboratory Tests Summaries of Abnormal Findings for Each Subject\"\\n19589,1,1,\"Safety: Maximum Tolerated Dose\"\\n19590,1,1,\"Safety: Multiple Gated Acquisition (MUGA) will be assessed at specified time points as a measure of safety.\"\\n19591,1,1,\"Safety: Number of Participants With Adverse Events and Serious Adverse Events (Phase 1a and 1b)\"\\n19592,1,1,\"Safety: Number of Participants With at Least One Adverse Event\"\\n19593,1,1,\"Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity\"\\n19594,1,1,\"Safety: Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT) (Phase 1a)\"\\n19595,1,1,\"Safety: Number of Participants With Serious and Specific Adverse Events\"\\n19596,1,1,\"Safety: Number of Participants With Treatment Discontinuations, Modifications, or Interruptions Due to Adverse Events (Phase 1b)\"\\n19597,1,1,\"Safety: Number of participants with treatment-related adverse events as assessed by CTCAE V4.03\"\\n19598,1,1,\"Safety: Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities\"\\n19599,1,1,\"Safety: Percentage of Participants With Adverse Events (AEs)\"\\n19600,1,1,\"Safety: Percentage of Participants With Adverse Events Leading to Dose Reduction\"\\n19601,1,1,\"Safety: Percentage of Participants With Adverse Events Leading to Treatment Interruption\"\\n19602,1,1,\"Safety: Percentage of Participants With Grade 3 and 4 AEs\"\\n19603,1,1,\"Safety: Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Decline During Pre-operative (Neoadjuvant) Period\"\\n19604,1,1,\"Safety: Percentage of Participants With Significant Decline in Left Ventricular Ejection Fraction (LVEF)\"\\n19605,1,1,\"Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator\"\\n19606,2,1,\"Safety: Physical Examination and Vital Signs - Physical examination will be performed and vital signs will be assessed for participants as a measure of safety.\"\\n19607,1,1,\"Safety: Physical Examination Summaries of Non-normal Findings for Each Subject\"\\n19608,1,1,\"Safety: Recommended Phase II Dose\"\\n19609,1,1,\"Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject\"\\n19610,1,1,\"Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests\"\\n19611,1,1,\"Safety: The incidence and severity of adverse experiences and laboratory abnormalities will be tabulated and presented overall and by dose.\"\\n19612,1,1,\"Safety: Toxicities will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3\"\\n19613,1,1,\"Safety: Vital Sign Summary of Abnormal Findings for Each Subject\"\\n19614,1,1,\"Safety[DLTs„ÄÅAEs„ÄÅECG]\"\\n19615,1,1,\"sample adequacy\"\\n19616,1,1,\"Sampling Adequacy\"\\n19617,1,1,\"SAR405838 (pimasertib) RP2D assessed by dose-limiting toxicities and pharmacological activities\"\\n19618,1,1,\"SARS COVID N Ab trends among different subgroups (anti-cancer therapies)\"\\n19619,1,1,\"SARS COVID S Ab trends among different subgroups (anti-cancer therapies)\"\\n19620,12,1,\"SARS-CoV-2 infection\"\\n19621,1,1,\"SARS-CoV-2 infection rate in patients with solid tumors.\"\\n19622,1,1,\"SARS-CoV-2 vaccine immunization\"\\n19623,1,1,\"SARS-CoV-2 vaccine response at 12 months\"\\n19624,28,1,\"Satisfaction\"\\n19625,1,1,\"Satisfaction with care by FACIT-TS-PS at 3 months and 1 year\"\\n19626,1,1,\"Satisfaction with communication, measured by the Family Satisfaction with Advanced Cancer Care (FAMCARE)\"\\n19627,1,1,\"Satisfaction with patient-physician communication by Medical Interview Satisfaction Survey and Face Valid Survey given immediately after the first consultation\"\\n19628,1,1,\"Savolitinib area under plasma concentration-time curve from time zero to infinity (AUC) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)\"\\n19629,1,1,\"Savolitinib maximum observed plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)\"\\n19630,1,1,\"Savolitinib: Maximum plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)\"\\n19631,1,1,\"Scan coverage\"\\n19632,1,1,\"Scores of children\\'s quality of life\"\\n19633,1,1,\"scores of digestive physiological and social psychological functions\"\\n19634,2,1,\"Screening coverage\"\\n19635,1,1,\"Screening for cognitive impairment - Pfeiffer Test\"\\n19636,2,1,\"Screening intentions\"\\n19637,1,1,\"Search for secondary cause of hyperparathyroidism (1): vit D deficiency\"\\n19638,1,1,\"Search for secondary cause of hyperparathyroidism (2): renal failure\"\\n19639,1,1,\"Second co-primary outcome measure is quality of life\"\\n19640,1,1,\"Second-line Dose Expansion: Objective Response Rate (ORR)\"\\n19641,1,1,\"Second-Line PFS\"\\n19642,1,1,\"Secondary resection rate\"\\n19643,1,1,\"Security (Incidence and severity of adverse events)\"\\n19644,13,1,\"Sedentary time\"\\n19645,1,1,\"See result section upon availability\"\\n19646,1,1,\"Segment 1: Determine whether the steady state pharmacokinetics of 20 mg of dasatinib are affected by co-administration with ketoconazole in patients with advanced solid tumors\"\\n19647,1,1,\"Segment 2: Assess the pharmacodynamic activity of dasatinib\"\\n19648,1,1,\"Seizure control (lack of seizure activity)\"\\n19649,1,1,\"Selection of a dose schedule of the combination of mitomycin C and veliparib for phase II trials\"\\n19650,1,1,\"Selection of a dose schedule of veliparib monotherapy for phase II trials\"\\n19651,1,1,\"Selection of One of Two Treatment Regimens (Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel) for Further Study in a Phase III Trial, Based on Median Progression-free Survival for ‚â• 3 Months\"\\n19652,1,1,\"Self-assessment of motor activity\"\\n19653,43,1,\"Self-efficacy\"\\n19654,1,1,\"Self-Perception Profile for Adolescents/Emerging Adults (SPPA/EA).\"\\n19655,1,1,\"Self-Reported Questionnaire: Change From Baseline on the Impact of Health on Regular Activities at Week 12 to 16\"\\n19656,1,1,\"Self-Reported Questionnaire: Change From Baseline on the Impact of Health on Regular Activities at Week 24 to 28\"\\n19657,1,1,\"Self-Reported Questionnaire: Change From Baseline on the Impact of Health on Regular Activities at Week 4 to 6\"\\n19658,1,1,\"Self-Reported Questionnaire: Percentage of Participants With Current Employment at Baseline\"\\n19659,1,1,\"Self-Reported Questionnaire: Percentage of Participants With Current Employment at Week 12 to 16\"\\n19660,1,1,\"Self-Reported Questionnaire: Percentage of Participants With Current Employment at Week 24 to 28\"\\n19661,1,1,\"Self-Reported Questionnaire: Percentage of Participants With Current Employment at Week 4 to 6\"\\n19662,1,1,\"SENP1 expression\"\\n19663,120,2,\"Sensitivity\"\\n19664,18,1,\"Sensitivity and Specificity\"\\n19665,2,1,\"Sensitivity and Specificity of Cybrid Score for Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors\"\\n19666,1,1,\"sensitivity and specificity of the FISH technique for the detection of the ALK rearrangement in CTCs Change from Baseline to 6 and 12 months\"\\n19667,1,1,\"Sensitivity and specificity rates of the ICG guided neoplastic disease identification\"\\n19668,1,1,\"Sensitivity of 11C-YJH08 PET in metastatic lesion detection (Cohort A only)\"\\n19669,1,1,\"sensitivity of circulating tumor cells for the diagnostic of pancreatic adenocarcinoma\"\\n19670,2,1,\"Sensitivity of confocal imaging (solid pattern) for the diagnostic of the pulmonary nodule\"\\n19671,1,1,\"Sensitivity of mTORC1 and mTORC2\"\\n19672,1,1,\"Sensitivity of PET/CT and PET/MRI (Cohort III)\"\\n19673,1,1,\"Sensitivity of pMRI\"\\n19674,1,1,\"Sensitivity of postoperative ctDNA in monitoring recurrence and metastasis\"\\n19675,1,1,\"Sensitivity of the digital application\"\\n19676,1,1,\"Sensitivity, specificity, and predictive value (positive and negative) of different markers\"\\n19677,1,1,\"Sensitivity, specificity, positive predictive value and negative predictive value of novel digital neurotoxicity tests (BF-Neuro) (Arm 1)\"\\n19678,1,1,\"Sensitivity, specificity, positive predictive value and negative predictive value of remote monitoring-based CRS detection/ prediction (Arm 1)\"\\n19679,15,1,\"Sepsis\"\\n19680,1,1,\"Sequence-dependent toxicity\"\\n19681,1,1,\"Sequencing of treatment initiation, termination, and duration\"\\n19682,9,1,\"Serious Adverse Event\"\\n19683,1,1,\"Serious adverse event (SAE)\"\\n19684,1,1,\"Serious Adverse Event(SAE)\"\\n19685,64,1,\"Serious Adverse Events\"\\n19686,38,3,\"Serious adverse events\"\\n19687,14,2,\"Serious Adverse Events (SAEs)\"\\n19688,1,1,\"Serious Adverse events (SAEs)\"\\n19689,18,1,\"Serious adverse events (SAEs)\"\\n19690,2,2,\"serious adverse events (SAEs)\"\\n19691,1,1,\"Serious Adverse Events (SAEs) and non-serious adverse events (AEs) considered to be at least possibly related to MOv18 IgE\"\\n19692,1,1,\"Serious adverse eventÔºàSAE)\"\\n19693,1,1,\"Serious adverse eventÔºàSAEÔºâ\"\\n19694,2,2,\"Seriousness of TEAEs\"\\n19695,1,1,\"Serological outcome post vaccination, immune response to vaccination against COVID-19 (measured as antibody titre 1 month after completion of vaccination\"\\n19696,1,1,\"Serological outcome post vaccination, immune response to vaccination against COVID-19 (measured as antibody titre 3 months after completion of vaccination\"\\n19697,5,2,\"Seroprotection rate\"\\n19698,1,1,\"Serum Clearance (CL) of Panitumumab\"\\n19699,1,1,\"Serum concentration\"\\n19700,1,1,\"Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Avelumab\"\\n19701,1,1,\"Serum Concentration of Atezolizumab at Specified Timepoints\"\\n19702,1,1,\"Serum Concentration of Pertuzumab in PH FDC SC Treatment Arms at Specified Timepoints\"\\n19703,1,1,\"Serum Concentration of Trastuzumab in PH FDC SC Treatment Arms at Specified Timepoints\"\\n19704,14,1,\"Serum Creatinine\"\\n19705,1,1,\"Serum creatinine concentration.\"\\n19706,1,1,\"Serum Decay Half-Life (t1/2) of Avelumab\"\\n19707,1,1,\"Serum drug exposure level equivalent to exposure in adults at adult recommended dose.\"\\n19708,1,1,\"serum pharmacokinetics of DS-8895a\"\\n19709,1,1,\"Serum PK AUC for CUE-102\"\\n19710,1,1,\"Serum PK Cmax for CUE-102\"\\n19711,1,1,\"Serum PK parameters of 89Zr-S095012 at baseline (Part B)\"\\n19712,1,1,\"Serum PK parameters of 89Zr-S095012 during the range finding period (Part A)\"\\n19713,1,1,\"Serum PK parameters of 89Zr-S095012 on treatment (Part C- schedule 1)\"\\n19714,1,1,\"Serum PK T1/2 for CUE-102\"\\n19715,2,1,\"Serum protein markers\"\\n19716,1,1,\"Serum-Ascites Albumin Gradient Prevalence\"\\n19717,7,2,\"Severe adverse events\"\\n19718,2,1,\"Severe drug-related adverse events\"\\n19719,1,1,\"Severe Toxicities (ST) in Run-In Phase Part\"\\n19720,1,1,\"Severe Treatment-related Toxicity\"\\n19721,1,1,\"Severities of AEs\"\\n19722,1,1,\"Severity Adverse Event (SAE)\"\\n19723,1,1,\"Severity and frequency of adverse events to determine safety of Pexa-Vec administered by IV infusions or IT injections in combination with IV Cemiplimab\"\\n19724,1,1,\"Severity and number of adverse events related to escalating doses of MM-141\"\\n19725,1,1,\"Severity Grade Of AEs By Dose Of iNKT Cell Therapy\"\\n19726,6,1,\"Severity of Adverse Events\"\\n19727,16,5,\"Severity of adverse events\"\\n19728,1,1,\"Severity of adverse events (AEs) (Phase 1b)\"\\n19729,1,1,\"Severity of Adverse Events as Assessed by NCI CTCAE v3.0\"\\n19730,1,1,\"Severity of adverse events in HX009 treatment of patients with relapsed/refractory lymphoma\"\\n19731,1,1,\"Severity of adverse events of ES101\"\\n19732,1,1,\"Severity of adverse events of INBRX-105\"\\n19733,1,1,\"Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab\"\\n19734,7,2,\"Severity of AEs\"\\n19735,1,1,\"Severity of AEs in patients with solid tumors enrolled in the study.\"\\n19736,1,1,\"Severity of all adverse events graded according to NCI CTCAE, v4.0\"\\n19737,1,1,\"Severity of all adverse events, graded according to NCI CTCAE v4.0\"\\n19738,1,1,\"Severity of depression (PHQ-9)\"\\n19739,1,1,\"Severity of generalized anxiety disorder\"\\n19740,1,1,\"Severity of hepatic disease as assessed by the Child-Pugh criteria\"\\n19741,1,1,\"severity of immune-related adverse events (irAE)\"\\n19742,1,1,\"Severity of insomnia as assessed by the insomnia severity index and daily sleeep diaries.\"\\n19743,1,1,\"Severity of ITCH\"\\n19744,2,1,\"Severity of liver disease\"\\n19745,1,1,\"Severity of neuropathy\"\\n19746,1,1,\"Severity of protocol-defined adverse events (AEs)\"\\n19747,2,1,\"Severity of serious adverse events (SAEs)\"\\n19748,3,1,\"Severity of symptoms\"\\n19749,12,3,\"Severity of TEAEs\"\\n19750,1,1,\"Severity of TESAEs\"\\n19751,3,2,\"Severity of treatment emergent adverse events (TEAEs)\"\\n19752,1,1,\"Severity of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)\"\\n19753,1,1,\"Severity of treatment emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) and dose-limiting toxicities (DLTs)\"\\n19754,1,1,\"Severity of treatment emergent serious adverse events (TESAEs)\"\\n19755,7,2,\"Severity of treatment-emergent adverse events\"\\n19756,5,2,\"Severity of treatment-emergent adverse events (TEAEs)\"\\n19757,1,1,\"Severity of Treatment-Emergent Adverse Events(TEAEs)\"\\n19758,1,1,\"Severity of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs)\"\\n19759,1,1,\"Severity of Weight Loss\"\\n19760,1,1,\"Severity Score of Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n19761,1,1,\"Severity Score of Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n19762,1,1,\"Severity Score of Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)\"\\n19763,1,1,\"Severity Score of Different Symptoms in Anemic Participants With Clinical Response 10-12 Weeks After Start of Treatment\"\\n19764,1,1,\"Severity Score of Different Symptoms in Anemic Participants With Clinical Response 3-4 Weeks After Start of Treatment\"\\n19765,1,1,\"Severity Score of Different Symptoms in Anemic Participants With Clinical Response 6-8 Weeks After Start of Treatment\"\\n19766,1,1,\"Severity Score of Different Symptoms in Anemic Participants With Clinical Response Prior To Treatment\"\\n19767,1,1,\"Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n19768,1,1,\"Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n19769,1,1,\"Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly\"\\n19770,1,1,\"Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors Prior to Treatment at 30000 IU Once Weekly\"\\n19771,1,1,\"Severity Score of Different Symptoms Prior toTreatment (MDASI Questionnaire)\"\\n19772,9,1,\"Sexual Function\"\\n19773,1,1,\"Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale\"\\n19774,1,1,\"Short and long term event free and overall survival\"\\n19775,1,1,\"short-term effectsÔºàThe response rateÔºåRRÔºâ\"\\n19776,1,1,\"Short-term efficacy (lung-metastases free survival) and acute tolerance of whole lung IMRT\"\\n19777,1,1,\"Show that the NETs rate is higher at diagnosis in solid cancer patients with ETV within 4 months of diagnosis compared to patients without ETV\"\\n19778,1,1,\"SIAEs and SAEs\"\\n19779,1,1,\"Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II)\"\\n19780,1,1,\"Side effects as assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 2.0\"\\n19781,1,1,\"Side effects of pulsed low dose rate radiation therapy\"\\n19782,2,1,\"Signal detection\"\\n19783,1,1,\"Signal-to-noise Ratio (Part A)\"\\n19784,1,1,\"Signal-to-noise ratio (Part A)\"\\n19785,1,1,\"Significant Toxicity\"\\n19786,1,1,\"Signs and symptoms of infusion reactions\"\\n19787,1,1,\"Single agent and combination dose exploration studyÔºösafety\"\\n19788,2,1,\"Single Cell Sequencing\"\\n19789,1,1,\"single diagnostic yield of the histologic core\"\\n19790,1,1,\"Single dose AUCtau\"\\n19791,1,1,\"Single dose AXL1717 serum pharmacokinetic profile under fasting versus fed condition in each patient\"\\n19792,1,1,\"Single dose Cmax (Maximum plasma concentration)\"\\n19793,1,1,\"Single Dose PK Parameter--AUC\"\\n19794,1,1,\"Single Dose PK Parameter--CL/F\"\\n19795,1,1,\"Single Dose PK Parameter--Cmax\"\\n19796,1,1,\"Single Dose PK Parameter--t1/2, Œªz\"\\n19797,1,1,\"Single Dose PK Parameter--tmax\"\\n19798,1,1,\"Single Dose PK Parameter--Vz/F\"\\n19799,1,1,\"Single Dose: Maximum Observed Plasma Concentration (Cmax)\"\\n19800,1,1,\"Single Dose: Plasma Decay Half-Life (t1/2)\"\\n19801,1,1,\"Single Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)\"\\n19802,1,1,\"Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs).\"\\n19803,1,1,\"Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib\"\\n19804,1,1,\"Single-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib\"\\n19805,1,1,\"Single-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib\"\\n19806,1,1,\"Single-dose PK: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC(0-‚àû))\"\\n19807,1,1,\"Single-dose PK: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC(0-t)) for Platinum\"\\n19808,1,1,\"Single-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib\"\\n19809,1,1,\"Single-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib\"\\n19810,1,1,\"Single-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib\"\\n19811,1,1,\"Single-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib\"\\n19812,1,1,\"Single-dose PK: Maximum Observed Serum Concentration (Cmax) for Platinum\"\\n19813,1,1,\"Single-dose PK: Mean Residence Time (MRT) for Palbociclib\"\\n19814,1,1,\"Single-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib\"\\n19815,1,1,\"Single-dose PK: Serum Decay Half-Life (T1/2) for Platinum\"\\n19816,1,1,\"Single-dose PK: Terminal Half-Life (t1/2) for Palbociclib\"\\n19817,1,1,\"Single-dose PK: Time to Reach Maximum Observed Serum Concentration (Tmax) for Platinum\"\\n19818,1,1,\"Single-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib\"\\n19819,1,1,\"Single-Photon Emission Computerized Tomography (SPECT)\"\\n19820,1,1,\"Six Month Progression Free Survival (PFS)\"\\n19821,1,1,\"Six Month Progression-Free Survival (PFS6)\"\\n19822,1,1,\"Six Month Survival\"\\n19823,1,1,\"Six Month Survival Rate\"\\n19824,1,1,\"Six-month Progression Free Survival\"\\n19825,1,1,\"Six-month Progression-free Survival\"\\n19826,1,1,\"Six-Month Progression-Free Survival (PFS) as Assessed by BICR per RECIST 1.1\"\\n19827,1,1,\"Six-month Progression-free Survival (PFS) Rate at 6 Months\"\\n19828,1,1,\"Six-month progression-free survival rate\"\\n19829,1,1,\"Size of CT- Detected Lung Nodules by Participant\"\\n19830,1,1,\"size of tumor\"\\n19831,4,1,\"Skin\"\\n19832,3,1,\"Skin elasticity\"\\n19833,1,1,\"Skin pigmentation\"\\n19834,1,1,\"Sleep as measured by Pittsburgh Sleep Quality Index (PSQI)\"\\n19835,1,1,\"Sleep disturbance, pain, anxiety, depression, fatigue (SPADE) symptom scores\"\\n19836,2,1,\"Sleep disturbances\"\\n19837,1,1,\"Smoking abstinence as measured by 7-day point prevalence abstinence at 12 months following treatment\"\\n19838,1,1,\"Smoking-habit for Smokers or Ex-smokers (Packs in Years)\"\\n19839,1,1,\"Smoking-habit or Smokers or Ex-smokers (Smoking/Quit Smoking )\"\\n19840,1,1,\"Social functioning as assessed by parent-completed measures and child-completed measures\"\\n19841,1,1,\"Social situation analysis - Abbreviated Gij√≥n Scale\"\\n19842,1,1,\"Social Support by Shortened Social Support Scale at baseline, 3 months, and 1 year\"\\n19843,1,1,\"Solid tumor biological insights\"\\n19844,1,1,\"Solid Tumor Growth After Completion of Interventional Bronchoscopies\"\\n19845,1,1,\"Solid tumor size\"\\n19846,1,1,\"Sorafenib Activity\"\\n19847,1,1,\"Spatial coordination as measured by EF5 binding at completion of accrual\"\\n19848,1,1,\"Spatial Resolution\"\\n19849,87,1,\"Specificity\"\\n19850,1,1,\"Specificity for Lung Cancer\"\\n19851,1,1,\"Specificity of pMRI\"\\n19852,1,1,\"Specificity of postoperative ctDNA in monitoring recurrence and metastasis\"\\n19853,1,1,\"SPECT CT\"\\n19854,1,1,\"SPECT-based [99mTc]Tc(CO)3-(HE)3-Ec1 uptake value (counts)\"\\n19855,1,1,\"SPECT-based [99mTc]Tc(CO)3-(HE)3-Ec1 value in tumor lesions (counts)\"\\n19856,1,1,\"sPFS\"\\n19857,2,2,\"Spiritual Well-Being measured with the FACIT Spiritual Well-Being Scale\"\\n19858,1,1,\"Spirituality by Functional Assessment of Chronic Illness Therapy (FACIT)-Sp at baseline, 3 months, and 1 year\"\\n19859,1,1,\"Splenic function\"\\n19860,1,1,\"SR/SH pancreas EUS-elastography\"\\n19861,3,1,\"Stable disease\"\\n19862,2,1,\"Stable disease (SD)\"\\n19863,1,1,\"Stable disease (SD) rate and progression-free survival (PFS) times\"\\n19864,1,1,\"Stable Disease at 12 Weeks - Interim Analysis of First 60 Participants\"\\n19865,1,1,\"Stable disease duration measured from the time of start of therapy until the criteria for progression are met\"\\n19866,1,1,\"Stable Disease Response\"\\n19867,1,1,\"Stable Disease(SD)\"\\n19868,1,1,\"Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review\"\\n19869,1,1,\"Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs)\"\\n19870,1,1,\"Stage 1(Pick the Winner Study): Complete Response\"\\n19871,1,1,\"Stage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 1\"\\n19872,1,1,\"Stage 1: Cohort 1: Objective Response Rate (ORR)\"\\n19873,1,1,\"Stage 1: Cohort 2: Objective Response Rate\"\\n19874,1,1,\"Stage 1: Cohort 3: Objective Response Rate\"\\n19875,1,1,\"Stage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 1\"\\n19876,1,1,\"Stage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule\"\\n19877,1,1,\"Stage 1: Number of participants with treatment-related adverse events as assessed by CTC AE 4.03, 1 year in average\"\\n19878,1,1,\"Stage 1: Percentage of Participants With Dose Limiting Toxicities\"\\n19879,1,1,\"Stage 1: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period\"\\n19880,1,1,\"Stage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 1\"\\n19881,1,1,\"Stage 1A: MTD of Cobimetinib in 14/14 Schedule\"\\n19882,1,1,\"Stage 2 (Cohort Expansion Study): Failure-free survival (FFS)\"\\n19883,1,1,\"Stage 2: Cohort 1A and Cohort 2A: Objective Response Rate\"\\n19884,1,1,\"Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period\"\\n19885,1,1,\"Stage 2: To determine the objective response rate (ORR) as assessed by RECIST, Version 1.1\"\\n19886,1,1,\"Stage 2ÔºöIncidence of adverse events AE of single and multiple dose for AB011 combinate with XELOX or Gem/nab-P (according to NCI CTCAE 5.0)\"\\n19887,1,1,\"Stage 2ÔºöIncidence of adverse events SAE of single and multiple dose for AB011 combinate with XELOX or Gem/nab-P (according to NCI CTCAE 5.0)\"\\n19888,1,1,\"Stage 3: Area under the plasma concentration-time curve from time 0 to infinity time (AUC)\"\\n19889,1,1,\"Stage 3: Detect CL/F for Pop-PK analysis\"\\n19890,1,1,\"Stage 3: Detect Ka for Pop-PK analysis\"\\n19891,1,1,\"Stage 3: Detect Vc/F for Pop-PK analysis\"\\n19892,1,1,\"Stage 3: Maximum plasma concentration (Cmax)\"\\n19893,1,1,\"Stage 3: Terminal elimination half-life (t1/2)\"\\n19894,1,1,\"STAGE A1 - Determine the best tolerated M6620 treatment schedule (or phase II recommended dose), administered concomitantly with radiotherapy only in the palliative treatment of oesophageal cancer\"\\n19895,1,1,\"STAGE A2 - Determine the best tolerated M6620 treatment schedule (or phase II recommended dose) administered concomitantly with chemotherapy (Cisplatin and Capecitabine) only in the palliative treatment of solid cancer\"\\n19896,1,1,\"STAGE B - Determine the best tolerated M6620 treatment schedule (or phase II recommended dose) administered concomitantly with radiotherapy (dCRT) in combination with Cisplatin and Capecitabine in the radical treatment of oesophageal cancer\"\\n19897,1,1,\"Stage1ÔºöIncidence of adverse events AE of single and multiple dose (according to NCI CTCAE 5.0)\"\\n19898,1,1,\"Stage1ÔºöIncidence of adverse events SAE of single and multiple dose (according to NCI CTCAE 5.0)\"\\n19899,1,1,\"Standard differential blood count\"\\n19900,1,1,\"Standard of Care Data (routinely collected in clinic)\"\\n19901,1,1,\"Standard System Usability Score on a Likert Scale\"\\n19902,1,1,\"Standard technics of disease assessment\"\\n19903,1,1,\"Standard Therapeutic Response\"\\n19904,6,1,\"Standard uptake value (SUV)\"\\n19905,1,1,\"Standard Uptake Value (SUV) mean and max in lesions detected by PET scans\"\\n19906,1,1,\"Standard uptake value as measured by 3\\'-deoxy-3\\'-[18F] fluorothymidine (FLT)-PET/CT scans\"\\n19907,1,1,\"Standardised Mean Change From Baseline in Age-adjusted IGF-1 Levels at the EOST/EW Visit\"\\n19908,1,1,\"Standardized phase angle measure\"\\n19909,10,3,\"Standardized uptake value (SUV)\"\\n19910,1,1,\"Standardized Uptake Value (SUV) of 89ZrRO5479599 Determined by Positron Emission Tomography (PET) Scan Over Regions of Interest (ROI)\"\\n19911,1,1,\"Standardized Uptake Value (SUV) on PET/CT Compared to PET/MRI\"\\n19912,1,1,\"Standardized Uptake Value (SUV).\"\\n19913,3,1,\"standardized uptake value ratio (SUVR)\"\\n19914,1,1,\"Standardized Uptake Values (SUVs) (Cohort 2 only)\"\\n19915,4,2,\"Standardized uptake valueÔºàSUVÔºâ\"\\n19916,1,1,\"stathmin levels\"\\n19917,1,1,\"Status nodule\"\\n19918,1,1,\"Steady State Accumulation Ratio (Rss) for Palbociclib\"\\n19919,1,1,\"Steady state area under the concentration-time curve from 0-24 hours (AUC0-24,ss) after multiple doses\"\\n19920,1,1,\"Steady State AUC of Crizotinib\"\\n19921,1,1,\"Steady State C Average of Crizotinib\"\\n19922,1,1,\"Steady State C Max of Crizotinib\"\\n19923,1,1,\"Steady State Clearance of Crizotinib\"\\n19924,1,1,\"Steady state maximum concentration (Cmax,ss) after multiple doses\"\\n19925,1,1,\"Steady State PK Parameter--AUCss at Day 8\"\\n19926,1,1,\"Steady State PK Parameter--AUCss at Day 9\"\\n19927,1,1,\"Steady State PK Parameter--CLss/F at Day 8\"\\n19928,1,1,\"Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 8\"\\n19929,1,1,\"Steady State PK Parameter--Cmax, ss and Cmin, ss at Day 9\"\\n19930,1,1,\"Steady State PK Parameter--RAC and TCP at Day 8\"\\n19931,1,1,\"Steady State PK Parameter--tmax, ss at Day 8\"\\n19932,1,1,\"Steady State PK Parameter--tmax, ss at Day 9\"\\n19933,1,1,\"Steady state trough concentration (Ctrough,ss) after multiple doses\"\\n19934,1,1,\"Steady-state Serum Concentration of Dalotuzumab at 336 Hours (C336) After the First Maintenance Dose\"\\n19935,1,1,\"Step 1 (dose escalation Parts A and B): Maximum Tolerated Dose (MTD) determination\"\\n19936,1,1,\"Step 1 (dose escalation Parts A and B): Number of patients with Dose-Limiting Toxicities (DLTs) during the first treatment cycle\"\\n19937,1,1,\"Step 1: MTD of oral CP-4126 in patients with advanced solid tumours, followed by establishing the recommended dose\"\\n19938,1,1,\"Step 2 (expansion combination Part C): Number of patients with DLT-like events during the whole treatment\"\\n19939,1,1,\"Step 2: Pharmacokinetic parameters comparison of oral CP-4126 with IV gemcitabine\"\\n19940,15,1,\"Step length\"\\n19941,1,1,\"Stereotactic body radiation therapy (SBRT) into a treatment plan\"\\n19942,3,1,\"stool consistency\"\\n19943,2,1,\"Stool routine\"\\n19944,1,1,\"Stool-based test for colorectal cancer\"\\n19945,1,1,\"Strain ratio for all lesions measured by comparing the lesion to the adjacent normal tissue\"\\n19946,1,1,\"Structured Interviews and Focus Groups\"\\n19947,1,1,\"Study acceptability\"\\n19948,1,1,\"Study accrual and retention\"\\n19949,1,1,\"Study completion (defined as completing the final assessment)\"\\n19950,3,2,\"Study completion rate\"\\n19951,1,1,\"Study discontinuations due to adverse events (AEs)\"\\n19952,1,1,\"Study Endpoints (cohort 1 and cohort 2, part A subjects): Safety of apheresis collection\"\\n19953,1,1,\"Study Endpoints (for cohort 2, part B subjects only): Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs)\"\\n19954,1,1,\"Study of related adverse events\"\\n19955,1,1,\"study of related adverse events\"\\n19956,1,1,\"Study the feasibility, toxicity, and response rate of allogeneic cell therapy induced by selective intra-lesional and systemic administration of mismatched alloreactive lymphocytes in patients with metastatic cancer\"\\n19957,1,1,\"Study the pharmacokinetic interaction between ABT-263 and gemcitabine.\"\\n19958,1,1,\"Study the pharmacokinetic interaction of navitoclax (ABT-263) and docetaxel\"\\n19959,1,1,\"Study the pharmacokinetic of ABT-348\"\\n19960,1,1,\"Study tissue samples by molecular methods, including gene microarrays\"\\n19961,1,1,\"SU-011248 Clearance on Cycle 1 Day 28\"\\n19962,1,1,\"Subgroup Analysis by Age (‚â§65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ‚â•3 TEAEs, Any-Grade and Grade ‚â•3 TEAEs Related to Pertuzumab, and TEAEs to Monitor\"\\n19963,1,1,\"Subgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ‚â•3 TEAEs, and Grade ‚â•3 TEAEs Related to Pertuzumab\"\\n19964,1,1,\"Subgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ‚â•3 TEAEs, and Grade ‚â•3 TEAEs Related to Pertuzumab\"\\n19965,1,1,\"Subgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ‚â•3 TEAEs, and Grade ‚â•3 TEAEs Related to Pertuzumab\"\\n19966,1,1,\"Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ‚â•3 TEAEs, and Grade ‚â•3 TEAEs Related to Pertuzumab\"\\n19967,1,1,\"Subgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ‚â•3 TEAEs, and Grade ‚â•3 TEAEs Related to Pertuzumab\"\\n19968,1,1,\"Subgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ‚â•3 TEAEs, Any-Grade and Grade ‚â•3 TEAEs Related to Pertuzumab, and TEAEs to Monitor\"\\n19969,1,1,\"Subgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ‚â•3 TEAEs, and Grade ‚â•3 TEAEs Related to Pertuzumab\"\\n19970,2,1,\"Subject incidence of changes in vital signs\"\\n19971,1,1,\"Subject incidence of clinical laboratory tests\"\\n19972,1,1,\"Subject incidence of clinically significant changes in clinical laboratory tests\"\\n19973,1,1,\"Subject incidence of clinically significant changes in ECGs\"\\n19974,1,1,\"Subject incidence of clinically significant changes in vital signs and physical assessments\"\\n19975,1,1,\"Subject incidence of dose limiting toxicities (DLT)\"\\n19976,1,1,\"Subject incidence of Dose limiting toxicities (DLTs)\"\\n19977,4,4,\"Subject incidence of Dose-limiting toxicities (DLT)\"\\n19978,2,1,\"Subject incidence of treatment emergent adverse events\"\\n19979,2,1,\"Subject incidence of treatment related adverse events\"\\n19980,7,1,\"Subject incidence of treatment-emergent adverse events\"\\n19981,1,1,\"Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate\"\\n19982,1,1,\"Subject incidence of treatment-related adverse events\"\\n19983,2,1,\"Subject retention\"\\n19984,1,1,\"Subjective parameters including ECOG performance status, specific symptoms, and side effects are graded according to standard Common Terminology Criteria for Adverse Events (CTCAE) v.30 criteria.\"\\n19985,4,1,\"Subjects With Treatment Emergent Adverse Events\"\\n19986,1,1,\"Subsequent recommended doses of Hemay181\"\\n19987,1,1,\"Substudy 1, 2 and 3: Frequency of dose limiting toxicities (DLTs)\"\\n19988,1,1,\"Substudy 1, 2 and 3:Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity\"\\n19989,1,1,\"Substudy 1: Anti-cancer activity of derazantinib by Objective Response Rate (ORR)\"\\n19990,1,1,\"Substudy 1: Overall response rate (ORR)\"\\n19991,1,1,\"Substudy 2: Anti-tumor activity of derazantinib by Progression Fress Survival at 3 months (PFS 3)\"\\n19992,1,1,\"Substudy 2: Overall response rate (ORR) as assessed by central independent review\"\\n19993,1,1,\"Success rate for each strategy\"\\n19994,1,1,\"Success rate of conversion to resection\"\\n19995,1,1,\"Success rate of methionine (MET) for visualizing tumors\"\\n19996,1,1,\"Success, defined as R1 and R2 without treatment failure\"\\n19997,1,1,\"Successful administration of enteral feedings via a nasogastric tube for 50% or more of the total nutritional-support days\"\\n19998,1,1,\"Successful expansion of NK cells in patient\\'s circulatory system\"\\n19999,1,1,\"Successful Induction of Mixed Hematopoietic Chimerism as Assessed by the Percentage of Peripheral Blood T Cells That Are of Donor Origin\"\\n20000,1,1,\"Sum Common Toxicity Criteria score (Sum CTC score)\"\\n20001,1,1,\"Sum CTC score\"\\n20002,1,1,\"sum of ROM(range of motion)\"\\n20003,1,1,\"Summarized change of FACT-G score (scale = 0 to 4)\"\\n20004,1,1,\"Summarized patient characteristics\"\\n20005,1,1,\"Summary Listing of Percentage of Participants Reporting Treatment-Emergent Adverse Events\"\\n20006,1,1,\"Summary of 111-In-CMD-193 Biodistribution Based on Gamma Camera Images\"\\n20007,1,1,\"Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy\"\\n20008,1,1,\"Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Escalation (Efficacy Evaluable Population)\"\\n20009,1,1,\"Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Extension (Efficacy Evaluable Population)\"\\n20010,1,1,\"Summary of Disease Progression in Study Participants, Intent-to-treat Population\"\\n20011,1,1,\"Summary of Independent Reviewer-Assessed Objective Response Rate (ORR) by RECIST v1.1\"\\n20012,1,1,\"Summary of Left Ventricular Ejection Fraction Values\"\\n20013,1,1,\"Summary of Objective Response Rate Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors\"\\n20014,1,1,\"Summary of Overall Response (ORR) and Clinical Benefit (CBR)\"\\n20015,1,1,\"Summary of Overall Survival\"\\n20016,1,1,\"Summary of Participants Reporting Adverse Events\"\\n20017,1,1,\"Summary of Patients With Adverse Events (AE)\"\\n20018,1,1,\"Summary of the adverse events (type, severity, and incidence) related to CC-\"\\n20019,1,1,\"Summary of Total Adverse Events (AE)\"\\n20020,1,1,\"Summary of Treatment Emergent Adverse Events (AEs) by Preferred Term Occurring In >20% Patients (All causality)\"\\n20021,1,1,\"Summary of Treatment Emergent Serious Adverse Events (SAEs) by Preferred Term (All causality)\"\\n20022,1,1,\"Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups\"\\n20023,1,1,\"Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Area Under the Curve (AUC0-24), Study Day Cycle 1 Day 15, Stratified by Cohort - Dose Escalation\"\\n20024,1,1,\"Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Cmax, Study Day Cycle 1 Day 15, Stratified by Cohort - Dose Escalation\"\\n20025,1,1,\"Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Tmax, Study Day Cycle 1 Day 15, Stratified by Cohort - Dose Escalation\"\\n20026,1,1,\"Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)\"\\n20027,1,1,\"Supportive services provided to patients\"\\n20028,1,1,\"Surgery Rate\"\\n20029,1,1,\"Surgical resection rate\"\\n20030,3,1,\"Survey completion rate\"\\n20031,1,1,\"Survey data analysis\"\\n20032,397,10,\"Survival\"\\n20033,55,2,\"survival\"\\n20034,1,1,\"Survival and time to failure as measured by Kaplan-Meier\"\\n20035,1,1,\"Survival at 24 Weeks\"\\n20036,1,1,\"Survival in patients with fungemia\"\\n20037,1,1,\"Survival is the observed length of life from the initiation of treatment to death or the date of last contact\"\\n20038,1,1,\"Survival proportion\"\\n20039,1,1,\"Survival Status of Participants Treated With Nanaliposomal Irinotecan With Continuous Low-dose Temozolomide in Patients With Recurrent Glioblastoma.\"\\n20040,1,1,\"Survival with a WHO performance status 0-2 as measured by Logrank at 8 weeks after completion of study treatment, and then every 3 months until death\"\\n20041,1,1,\"Survival Without Grade 3 or 4 Toxicity\"\\n20042,1,1,\"Survival without tumor progression\"\\n20043,2,1,\"Sustained pain response\"\\n20044,8,4,\"SUV\"\\n20045,2,1,\"SUV (Standardized Uptake Value)\"\\n20046,14,2,\"SUVmax\"\\n20047,1,1,\"Swallowing Function Mean\"\\n20048,1,1,\"Swallowing Function T-Test\"\\n20049,1,1,\"SWE/SWD pancreas EUS shear wave\"\\n20050,1,1,\"SX-682 Maximum Tolerated Dose (MTD) during Monotherapy Stage\"\\n20051,1,1,\"SX-682 Maximum Tolerated Dose during Combination Therapy Stage\"\\n20052,1,1,\"Symptomatic skeletal event (SSE)-free survival (FS)\"\\n20053,1,1,\"Symptomatic Skeletal Event Free Survival - Three Dose Groups As Randomized\"\\n20054,1,1,\"Symptomatic Skeletal Event-Free Survival - Extended Dose vs. Standard Dose\"\\n20055,1,1,\"Symptomatic Skeletal Event-Free Survival - High Dose vs. Standard Dose\"\\n20056,26,1,\"Symptoms\"\\n20057,1,1,\"Symptoms, other than pain, considered important to the pediatric population\"\\n20058,46,1,\"System Usability Scale\"\\n20059,4,1,\"Systemic Clearance (CL)\"\\n20060,1,1,\"Systemic Clearance (CL) of Atezolizumab (PK phase only)\"\\n20061,1,1,\"Systemic Clearance (CL) of RO6874281\"\\n20062,1,1,\"Systemic Clearance (PK)\"\\n20063,1,1,\"Systemic Clearance at Steady State (CLss) for AMG 386\"\\n20064,1,1,\"Systemic Cytokine Concentrations\"\\n20065,1,1,\"Systemic Tumor Response Rates (Complete Response+Partial Response)\"\\n20066,1,1,\"T cell count after in vitro expansion\"\\n20067,1,1,\"T cell marker\"\\n20068,1,1,\"T Max of Pevonedistat in Combination With Irinotecan and Temozolomide\"\\n20069,1,1,\"T Max of Talazoparib\"\\n20070,1,1,\"T Max of Talazoparib in Combination With Temozolomide\"\\n20071,1,1,\"T Max of Temozolomide in Combination With Talazoparib\"\\n20072,1,1,\"T ¬ΩÔºàTerminal elimination half-lifeÔºâ\"\\n20073,1,1,\"T(Last) for [14C] Radioactivity in Whole Blood and Saliva\"\\n20074,1,1,\"T-cell activation in blood samples\"\\n20075,1,1,\"T-cell receptor (TCR) clonality\"\\n20076,1,1,\"T-cell receptor (TCR) diversity\"\\n20077,1,1,\"T-cell receptor (TCR) profiles\"\\n20078,1,1,\"T-cell responses to GEN-009 adjuvanted vaccine\"\\n20079,36,1,\"T1/2\"\\n20080,51,3,\"t1/2\"\\n20081,1,1,\"T1/2 at Single Dose\"\\n20082,1,1,\"t1/2 beta (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n20083,1,1,\"t1/2 for ABBV-321\"\\n20084,1,1,\"T1/2 of digoxin and rosuvastatin\"\\n20085,1,1,\"T1/2 of midazolam and caffeine\"\\n20086,1,1,\"t1/2 of Olaparib\"\\n20087,1,1,\"t1/2 of Probe Parent Drugs and Their Metabolites on Day 20\"\\n20088,1,1,\"T1/2: Terminal Half Life for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution\"\\n20089,1,1,\"T1/2: Terminal Half-Life for Alisertib\"\\n20090,1,1,\"T1/2: Terminal Half-life for Eribulin Mesylate\"\\n20091,1,1,\"T1/2zÔºöapparent terminal half-life\"\\n20092,1,1,\"Target lesion size will be assessed clinically or radiologically in two directions . RECIST (Response Evaluation Criteria In Solid Tumors) will be implemented to determine response\"\\n20093,1,1,\"TBRÔºàTumor-to-Backgroud RatioÔºâ\"\\n20094,9,2,\"TEAE\"\\n20095,14,6,\"TEAEs\"\\n20096,36,1,\"Temperature\"\\n20097,1,1,\"Temperature (¬∞F or ¬∞C)\"\\n20098,1,1,\"Temporal variations in the frequency and morphology of SSNs according to the COVID-19 epidemic\"\\n20099,1,1,\"Terminal elimination half life\"\\n20100,1,1,\"Terminal elimination half life (PK)\"\\n20101,3,1,\"Terminal elimination half life (t1/2)\"\\n20102,1,1,\"Terminal elimination half life of ABBV-085.\"\\n20103,4,1,\"Terminal elimination half-life (T1/2)\"\\n20104,1,1,\"Terminal elimination half-life (T1/2) for niraparib-Stages 1, 2 and 3 PK Phase\"\\n20105,1,1,\"Terminal Elimination Half-Life (t1/2) in the Fasted and Fed States\"\\n20106,1,1,\"Terminal Elimination Half-Life (t1/2) of 14C- Radioactivity in Plasma\"\\n20107,1,1,\"Terminal Elimination Half-Life (t1/2) of ABBV-514\"\\n20108,1,1,\"Terminal Elimination Half-Life (t1/2) of GDC-0941\"\\n20109,1,1,\"Terminal Elimination Half-Life (t1/2) of Talazoparib\"\\n20110,1,1,\"Terminal Elimination Half-Life (t1/2) of Vemurafenib on Day 15\"\\n20111,3,1,\"Terminal elimination half-life (t¬Ω)\"\\n20112,2,1,\"Terminal elimination rate constant (Kel)\"\\n20113,1,1,\"Terminal Elimination Rate Constant (Kel) of RO5185426 on Day 21\"\\n20114,1,1,\"Terminal Elimination Rate Constant (lambda_z) for AZD2014 in Plasma\"\\n20115,6,2,\"Terminal elimination rate constant (Œªz)\"\\n20116,1,1,\"Terminal Elimination Rate Constant (Œªz) of Avelumab\"\\n20117,1,1,\"Terminal Exponential Half-life (t1/2) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib in Plasma\"\\n20118,16,1,\"Terminal half-life (t1/2)\"\\n20119,1,1,\"Terminal half-life (t1/2) of ABBV-181\"\\n20120,1,1,\"Terminal Half-Life (t1/2) of ABBV-181 (Arm 3 Only)\"\\n20121,1,1,\"Terminal Half-Life (t1/2) of ABBV-368\"\\n20122,1,1,\"Terminal half-life (t1/2) of ABBV-368\"\\n20123,1,1,\"Terminal half-life (t1/2) of ABBV-428\"\\n20124,1,1,\"Terminal half-life (t1/2) of ABBV-927\"\\n20125,1,1,\"Terminal Half-Life (t1/2) of Atezolizumab (PK phase only)\"\\n20126,1,1,\"terminal half-life (t1/2) of Capivasertib\"\\n20127,1,1,\"Terminal half-life (t1/2) of Ipatasertib and GO37220\"\\n20128,1,1,\"Terminal Half-Life (t1/2) of Tilsotolimod\"\\n20129,1,1,\"Terminal Half-life (t¬Ω)\"\\n20130,1,1,\"Terminal Half-life (t¬Ω) of Niraparib and M1 During PK Phase\"\\n20131,1,1,\"Terminal Half-Life for CC-115\"\\n20132,1,1,\"Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort\"\\n20133,1,1,\"Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort\"\\n20134,1,1,\"Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole\"\\n20135,1,1,\"Terminal Phase Elimination Half-life (T1/2) for AMG 386\"\\n20136,1,1,\"Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort\"\\n20137,1,1,\"Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort\"\\n20138,1,1,\"Terminal Phase Elimination Half-life (t1/2) of ABBV-621 in Plasma\"\\n20139,1,1,\"Terminal Phase Elimination Half-Life (t1/2) of ABBV-706\"\\n20140,1,1,\"Terminal Phase Elimination Half-Life (t1/2) Of ABBV-CLS-579\"\\n20141,1,1,\"Terminal Phase Elimination Half-Life (t1/2) Of Metabolite M4\"\\n20142,1,1,\"Terminal Phase Elimination Half-Life (t1/2) Of PD-1 Inhibitor\"\\n20143,1,1,\"Terminal Phase Elimination Half-Life (t1/2) Of VEGFR TKI\"\\n20144,1,1,\"Terminal Phase Elimination Half-life (t1/2) of Venetoclax in Plasma\"\\n20145,1,1,\"Terminal phase elimination rate constant (Œ≤) for ABBV-321\"\\n20146,1,1,\"Terminal phase elimination rate constant (Œ≤) for ABBV-621\"\\n20147,1,1,\"Terminal phase elimination rate constant (Œ≤) for Venetoclax\"\\n20148,1,1,\"Terminal phase elimination rate constant (Œ≤) of ABBV-368\"\\n20149,1,1,\"Terminal Phase Elimination Rate Constant (Œ≤) Of ABBV-CLS-579\"\\n20150,1,1,\"Terminal Phase Elimination Rate Constant (Œ≤) Of Metabolite M4\"\\n20151,1,1,\"Terminal Phase Elimination Rate Constant (Œ≤) Of PD-1 Inhibitor\"\\n20152,1,1,\"Terminal Phase Elimination Rate Constant (Œ≤) Of VEGFR TKI\"\\n20153,1,1,\"Terminal Phase Half-life of Azacitidine (t¬Ω)\"\\n20154,1,1,\"Terminal Phase Half-life of Azacitidine (t¬Ω) After Single and Multiple Doses of Azacitidine\"\\n20155,1,1,\"Terminal Phase Rate Constant (Œªz) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib in Plasma\"\\n20156,1,1,\"Terminal rate constant (Œªz) and associated half-life (t¬Ω)\"\\n20157,1,1,\"Terminal-Phase Elimination Rate Constant (Œ≤) of ABBV-181\"\\n20158,1,1,\"Terminal-Phase Elimination Rate Constant (Œ≤) of ABBV-181 (Arm 3 Only)\"\\n20159,1,1,\"Terminal-Phase Elimination Rate Constant (Œ≤) of ABBV-368\"\\n20160,1,1,\"Terminal-Phase Elimination Rate Constant (Œ≤) of ABBV-927\"\\n20161,1,1,\"Terminal-Phase Elimination Rate Constant (Œ≤) of Tilsotolimod\"\\n20162,1,1,\"Test Image and Retest Image Reproducibility of Fluciclatide Injection ([18F]AH111585) Uptake by Solid Tumors Following Intravenous Administration of AH111585 (18F) Injection Via PET Imaging.\"\\n20163,1,1,\"test performance\"\\n20164,1,1,\"Testosterone Concentration in Prostate Tissue\"\\n20165,1,1,\"TGFalpha\"\\n20166,1,1,\"ThatPET/CT will be superior (15% improvement) to conventional methods of follow-up in terms of 5 year survival, cost and time to identification of new disease\"\\n20167,1,1,\"The Ability of a Combination of Aldesleukin (IL-2) and Zanolimumab (Anti-CD4 mAb) Administration to Mediate Tumor Regression in Patients With Metastatic Melanoma and Metastatic Kidney Cancer.\"\\n20168,1,1,\"The ability of the imaging system to detect the expression of the ICG in the nodule/mass (i.e tumor) and discern the uptake of the dye by the tumor.\"\\n20169,1,1,\"The ablation success\"\\n20170,1,1,\"The absorption of oral docetaxel\"\\n20171,1,1,\"The acquisition rate of the core tissue sample\"\\n20172,3,3,\"The adverse events (AEs)\"\\n20173,2,2,\"The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.\"\\n20174,2,2,\"The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.\"\\n20175,1,1,\"The amount of GSK2141795 in the blood (ng/ml) from baseline\"\\n20176,1,1,\"The amount of sample size\"\\n20177,1,1,\"The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008\"\\n20178,1,1,\"The Anti-tumor Activity of the Combination of Low Dose Cyclophosphamide and CTLA-4 Blockade Using Objective Response Rate (ORR)\"\\n20179,1,1,\"The antitumor effect of denosumab alone as represented by the change in density of tumor-infiltrating cluster of differentiation (CD8+) cells (TILs) in tumor tissue.\"\\n20180,1,1,\"The antitumor effect of denosumab alone as represented by the change in recent thymic emigrant cells in peripheral blood\"\\n20181,1,1,\"The antitumor effect of denosumab combined with anti-PD-1 inhibitor as represented by the change in density of tumor-infiltrating cluster of differentiation (CD8+) cells (TILs) in tumor tissue.\"\\n20182,1,1,\"The antitumor effect of denosumab combined with anti-PD-1 inhibitor as represented by the change in recent thymic emigrant cells in peripheral blood\"\\n20183,1,1,\"The Area under the curve of COM701 in subjects receiving the 3-drug combination.\"\\n20184,1,1,\"The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib\"\\n20185,1,1,\"The assessment of Treatment-related Adverse Events of SHR-A1403 in subjects with advanced solid tumors\"\\n20186,1,1,\"The association of disease recurrence with plasma levels of exosome and its subgroups.\"\\n20187,2,2,\"The AUC of docetaxel (area under the curve)\"\\n20188,1,1,\"the Best Overall Clinical Response\"\\n20189,1,1,\"The best overall response rate (BORR) of brain metastases to nivolumab will be assessed on Magnetic Resonance Imaging (MRI) using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.\"\\n20190,1,1,\"The Best Overall Response Rate (ORR)\"\\n20191,1,1,\"The biodistribution and biologic effect of OH2 injection\"\\n20192,1,1,\"The change between 2 groups in overall response rate and disease control rate\"\\n20193,1,1,\"The change from baseline in time-matched difference in QTc interval to post-baseline time points after a single 900 mg dose and multiple 600 mg BID doses of tipifarnib in subjects with Advanced Solid Malignancies\"\\n20194,1,1,\"The change in the the ratio (BV5/TBV) of blood volume in small < 5mm2 blood vessels (BV5) to the total pulmonary blood volume (TBV).\"\\n20195,1,1,\"The change in Tumor pressure\"\\n20196,1,1,\"The change in Tumor stiffness\"\\n20197,1,1,\"the change of lymphocyte surface markers percentage at 2 month after 6th cycle of chemotherapy, from day 22 of 6th cycle of chemotherapy\"\\n20198,1,1,\"the change of lymphocyte surface markers percentage at day 14 of 2nd chemotherapy, from day 7 of 2nd chemotherapy\"\\n20199,1,1,\"the change of lymphocyte surface markers percentage at day 22 of 6th cycle of chemotherapy, from day 7 of 4th cycle of chemotherapy\"\\n20200,1,1,\"the change of lymphocyte surface markers percentage at day 7 of 2nd chemotherapy, from baseline.\"\\n20201,1,1,\"the change of lymphocyte surface markers percentage at day 7 of 4th cycle of chemotherapy, from day 14 of 2nd chemotherapy\"\\n20202,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at 2nd month after chemotherapy, from day 22 of 6th cycle of chemotherapy\"\\n20203,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 1 of 3rd cycle, from day 14 of 2nd cycle of chemotherapy\"\\n20204,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 1 of 5th cycle, from day 7 of 4th cycle of chemotherapy\"\\n20205,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 1 of 6th cycle, from day 7 of 5th cycle of chemotherapy\"\\n20206,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 14 of 2nd cycle, from day 7 of 2nd cycle of chemotherapy\"\\n20207,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 22 of 6th cycle, from day 7 of 6th cycle of chemotherapy\"\\n20208,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 3rd cycle, from day 1 of 3rd cycle of chemotherapy\"\\n20209,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 4th cycle, from day 7 of 3rd cycle of chemotherapy\"\\n20210,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 5th cycle, from day 1 of 5th cycle of chemotherapy\"\\n20211,1,1,\"the change of total white blood cells, neutrophils, and lymphocytes at day 7 of 6th cycle, from day 1 of 6th cycle of chemotherapy\"\\n20212,2,2,\"The changes from baseline of lymphocyte counts\"\\n20213,1,1,\"The changes in genomic landscape related to progression from Stage 0 to Stage I lung cancer that could be utilized for early lung cancer diagnosis and intervention.\"\\n20214,1,1,\"The changes of blood flow perfusion in secondary malignant neoplasm of liver\"\\n20215,1,1,\"The changes of the immunoreactivity during treatment.\"\\n20216,1,1,\"The clinical benefit rate (CBR) of this therapy selection approach.\"\\n20217,1,1,\"The clinical practice for patients under anticoagulation regime\"\\n20218,1,1,\"The cMax (peak concentration) of docetaxel\"\\n20219,2,1,\"The Cmax of Viral RNA\"\\n20220,2,2,\"The Cmax of Viral RNA in blood\"\\n20221,1,1,\"The combination of lurbinectedin chemotherapy with maintenance avelumab immunotherapy in patients with advanced cancer of the urinary tract\"\\n20222,1,1,\"The Completion Rate of Chemotherapy in Combination With Chemoradiation\"\\n20223,1,1,\"The concentration of antiviral antibody\"\\n20224,1,1,\"The concentration of antiviral antibody.\"\\n20225,1,1,\"the concordance bettwen CINs and treatment outcomes The concordance between CINs and treatment outcomes\"\\n20226,1,1,\"The concordance between 68Ga-DOTA-hLAG-3 PET/CT and histopathological result in LAG-3 expression\"\\n20227,1,1,\"The cycle of neoadjuvant chemotherapy\"\\n20228,1,1,\"The degree to which participants exercise compassion towards themselves under difficult circumstances and how this impacts their emotions\"\\n20229,1,1,\"The diagnostic yields\"\\n20230,1,1,\"the diameter of the measurable lesion\"\\n20231,1,1,\"The difference in left ventricular ejection fraction (LVEF) between arms\"\\n20232,1,1,\"The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.\"\\n20233,1,1,\"The Difference in the Change From Baseline (Predose on Day 1) in QTc Intervals Trabectedin Relative to Placebo at 24 Hour Post Dose by Bazett\\'s Correction\"\\n20234,1,1,\"The Difference in the Change From Baseline (Predose on Day 1) in QTc Intervals Trabectedin Relative to Placebo at 24 Hour Post Dose by Fridericia Correction\"\\n20235,1,1,\"The distribution of Fluzoparib in the whole blood and plasma and whole.radioactive pharmacokinetics following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.\"\\n20236,1,1,\"The documentation of the Maximum Tolerated Dose (MID)\"\\n20237,1,1,\"The dose limiting toxicity ( DLT)\"\\n20238,1,1,\"The dose limiting toxicity of combination of RG7388 and Pegasys\"\\n20239,1,1,\"The dose limiting toxicity of RG7388\"\\n20240,1,1,\"The dose of atovaquone associated with no more than 48% dose limiting toxicity (DLT) rate (target toxicity level)\"\\n20241,1,1,\"the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of daily oral MPT0E028 in subjects with advanced solid malignancies\"\\n20242,1,1,\"The Dose-Limiting Toxicities (DLTs) associated with LeY CAR T-cell infusion\"\\n20243,1,1,\"The dose-limiting toxicities (DLTs) of OH2 injection as single agent and in combination with HX008 in patients with solid tumors\"\\n20244,1,1,\"The dose-limiting toxicities (DLTs) of SynOV1.1 in patients with HCC\"\\n20245,1,1,\"The Dose-Limiting Toxicity (DLT) of HLX26 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid Tumors or Lymphomas\"\\n20246,1,1,\"The dose-limiting toxicity (DLT) of OH2 injection and Keytruda in patients with solid tumors\"\\n20247,1,1,\"The dose-limiting toxicity (DLT) of XNW7201\"\\n20248,1,1,\"The dose-limiting toxicity (DLT) rate\"\\n20249,1,1,\"The dose-limiting toxicity of Radiation Therapy With Temozolomide and Pembrolizumab will be evaluated\"\\n20250,1,1,\"The duration of grade 4 neutropenia\"\\n20251,1,1,\"The Duration of Local Control\"\\n20252,1,1,\"The Effect of Rucaparib on the Immune Microenvironment\"\\n20253,1,1,\"The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.\"\\n20254,2,1,\"The effectiveness of CAR-T cell immunotherapy\"\\n20255,1,1,\"The effectiveness of sirolimus followed by durvalumab will be assessed by complete pathologic response rate in the efficacy population\"\\n20256,1,1,\"The effects of iniparib on changes in the ECG with special focus on the QTcF interval duration\"\\n20257,1,1,\"The efficacy of crizotinib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the crizotinib target genes, per cohort, per pathology, and per target.\"\\n20258,1,1,\"The evaluation of PCA home feasibility\"\\n20259,1,1,\"The evaluation of the threshold value\"\\n20260,1,1,\"The excretion balance and systemic exposure of radioactivity after intravenous (IV) administration of [14C]-iniparib\"\\n20261,1,1,\"The extent to which COVID-19 experiences are associated with COVID-19 specific psychological distress, health, financial and social disruptions, perceived benefits and social support, and health-related quality of life (HRQoL)\"\\n20262,1,1,\"The feasibility of implementing Eischens yoga interventions for solid tumor cancer patients undergoing radiation therapy. This will be measured by the success rate of recruitment and retention for 10 subjects.\"\\n20263,1,1,\"The fraction (in %) of patients having a tumor molecular profiling done, for whom a molecularly \"\"druggable\"\" variant can be identified\"\\n20264,1,1,\"The Fraction of Participants for Whom E7 T-Cell Receptor (TCR) Induction Therapy is Feasible in Participants With Cervical Cancer\"\\n20265,1,1,\"The frequency and severity of adverse events of ES002023\"\\n20266,2,2,\"The frequency and severity of adverse events of ES014\"\\n20267,1,1,\"The Frequency of \"\"Actionable\"\" Oncogenic Mutations\"\\n20268,1,1,\"The frequency of pain relief for the proposed regimen, using a scale that takes into account the subjective feeling and the use of analgesics\"\\n20269,1,1,\"The frequency of paroxysmal pain\"\\n20270,2,2,\"The hematological and non-hematological toxicity profile of oral docetaxel in combination with ritonavir\"\\n20271,1,1,\"The highest dose level at which less than 33% of the patients experienced a dose-limiting toxicity (DLT) during Cycle 1.\"\\n20272,1,1,\"The highest dose level of CUDC-101 at which <33% of at least 6 or more subjects experiences a dose limiting toxicity.\"\\n20273,1,1,\"The identification of the dose limiting toxicity (DLT)\"\\n20274,1,1,\"The identification of the maximum tolerated dose for twice or once weekly dosing, on three weeks out of four\"\\n20275,1,1,\"The IFN-Œ≥ T cells responses induced by neoantigen\"\\n20276,1,1,\"The impact of diet on adiponectin\"\\n20277,1,1,\"The impact of diet on HOMA-IR\"\\n20278,1,1,\"The impact of diet on hsCRP\"\\n20279,1,1,\"The impact of diet on IGF-1\"\\n20280,1,1,\"The impact of diet on IGFBP-3\"\\n20281,1,1,\"The impact of diet on IL-6\"\\n20282,1,1,\"The impact of diet on the Glasgow Prognostic Score for cancer outcomes\"\\n20283,3,3,\"The incidence and case number of DLT (Dose Limiting Toxicity) during observation period\"\\n20284,1,1,\"The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 once every 3 weeks in 21 days cycles during observation period\"\\n20285,1,1,\"The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 Q2W in 28 days cycles during observation period\"\\n20286,1,1,\"The incidence and characteristics of adverse events, associated with ascending doses of NAP in combination with a set dose of durvalumab\"\\n20287,1,1,\"The incidence and characteristics of adverse events, associated with ascending doses of NAP in combination with a set dose of durvalumab and following pretreatment with obinutuzumab.\"\\n20288,1,1,\"The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.\"\\n20289,1,1,\"The incidence and frequency of FNA passes\"\\n20290,1,1,\"The incidence and safety profile of participants with adverse events (AEs), serious adverse events(SAE), and immune-related adverse event(irAE)\"\\n20291,1,1,\"The incidence and severity of adverse event (AE) of ICP-033 assessed by NCI-CTCAE V5.0.\"\\n20292,1,1,\"The incidence and severity of adverse event (AE) of ICP-189 assessed by NCI-CTCAE V5.0\"\\n20293,3,2,\"The incidence and severity of adverse events (AE)\"\\n20294,1,1,\"The incidence and severity of adverse events (AEs) and serious adverse events\"\\n20295,1,1,\"The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)\"\\n20296,1,1,\"The Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and any Clinically meaningful trends in safety parameters\"\\n20297,1,1,\"The incidence and severity of adverse events including dose limiting toxicities\"\\n20298,1,1,\"The incidence of a three-fold increase of high-sensitivity troponin I (hs-TnI)/T (hs-TnT) within the first three months of treatment compared to baseline levels.\"\\n20299,1,1,\"The incidence of abnormal laboratory results\"\\n20300,1,1,\"The incidence of Adverse event and SAE\"\\n20301,12,3,\"The incidence of adverse events\"\\n20302,5,3,\"The incidence of adverse events (AE) and serious adverse events (SAE) were assessed\"\\n20303,1,1,\"The incidence of adverse events (including adverse events detected via laboratory assessment, vital signs and ECG)\"\\n20304,1,1,\"The incidence of adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0\"\\n20305,1,1,\"The incidence of adverse events following infusion of cord blood-derived cytokine-induced killer cells.\"\\n20306,1,1,\"The incidence of adverse events following infusion of NKT cells\"\\n20307,1,1,\"The Incidence of Adverse Events.\"\\n20308,1,1,\"The Incidence of Death.\"\\n20309,1,1,\"The incidence of DLT events and treatment-emergent AEs (TEAEs)\"\\n20310,1,1,\"The incidence of DLT in each cohort\"\\n20311,1,1,\"The Incidence of DLTs\"\\n20312,1,1,\"The incidence of DLTs at each dose level in the Dose Escalation part of the study\"\\n20313,3,3,\"The incidence of DLTs during the first cycle of treatment.\"\\n20314,1,1,\"The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation\"\\n20315,2,2,\"The incidence of Dose Limiting Toxicities (DLTs)\"\\n20316,1,1,\"The incidence of dose-limiting toxicites (DLTs)\"\\n20317,1,1,\"The incidence of dose-limiting toxicities (DLTs) as a measure of safety and tolerability\"\\n20318,1,1,\"The incidence of dose-limiting toxicities (DLTs) associated with AZD1775 monotherapy administered once daily (QD) in 14 day cycles (5 days on, followed by 9 days rest) in patients with locally advanced or metastatic solid tumours.\"\\n20319,1,1,\"The incidence of dose-limiting toxicities (DLTs) associated with AZD1775 monotherapy administered once daily (QD) in 21-day cycles (5 days on, followed by 2 days rest) in patients with locally advanced or metastatic solid tumours.\"\\n20320,1,1,\"The incidence of dose-limiting toxicities (DLTs) associated with AZD1775 monotherapy administered twice daily (BID) in 14-day cycles (5 days on, followed by 9 days rest) in patients with locally advanced or metastatic solid tumours.\"\\n20321,1,1,\"The incidence of dose-limiting toxicities (DLTs) during the DLT period\"\\n20322,1,1,\"The incidence of Dose-Limiting Toxicities (DLTs) in patients receiving AZD4635 in combination with durvalumab.\"\\n20323,1,1,\"The incidence of Dose-Limiting Toxicities (DLTs) in patients receiving AZD4635 in combination with either abiraterone acetate or enzalutamide.\"\\n20324,1,1,\"The incidence of Dose-Limiting Toxicities (DLTs) in patients receiving AZD4635 monotherapy orally.\"\\n20325,1,1,\"The incidence of dose-limiting toxicity (DLT)\"\\n20326,1,1,\"The incidence of Dose-limiting toxicity (DLTs)\"\\n20327,1,1,\"The incidence of grade 3 and above adverse events associated with Disitamab Vedotin treatment during the study period.\"\\n20328,1,1,\"The incidence of Grade 3 or 4 or greater adverse events (AEs) according to CTCAE v4.03 criteria and clinical laboratory abnormalities defined as dose-limiting toxicities (DLTs).\"\\n20329,1,1,\"The incidence of grade II and less oral mucositis at the end of treatment\"\\n20330,1,1,\"The incidence of MIL97 treatment-emergent adverse events in patients with advanced or metastatic solid tumor\"\\n20331,1,1,\"The incidence of participants having at least one RT-qPCR proven infection in the 6-month follow-up period after 3rd or 4th vaccine\"\\n20332,1,1,\"The incidence of participants hospitalised due to COVID-19 and deaths due to COVID-19 by 6 months.\"\\n20333,1,1,\"The incidence of serious and nonserious treatment-emergent adverse events (TEAEs)\"\\n20334,1,1,\"The Incidence of Seriuos Adverse Events.\"\\n20335,2,1,\"The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.\"\\n20336,1,1,\"The incidence of suspected unexpected serious adverse reactions(SUSAR)\"\\n20337,2,1,\"The incidence of symptomatic or asymptomatic VTE\"\\n20338,1,1,\"The incidence of TEAEs including TESAEs\"\\n20339,1,1,\"the incidence of the pancreatic fistula\"\\n20340,1,1,\"The incidence of treatment emergent adverse events (TEAEs) including treatment-emergent serious adverse events (TESAEs) and dose-limiting toxicities (DLTs)\"\\n20341,1,1,\"The Incidence of Treatment-Emergent Adverse Events of ZN-A-1041 as a monotherapy in Phase 1a\"\\n20342,1,1,\"The Incidence of Treatment-Emergent Adverse Events of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta\"\\n20343,1,1,\"The Incidence of Treatment-Related Adverse Events\"\\n20344,1,1,\"The incidence of treatment-related adverse events AE(s)\"\\n20345,1,1,\"The investigator will determine the patient\\'s response to VELCADE treatment following completion of Cycle 2 (Day 21).\"\\n20346,1,1,\"The Laboratory abnormalities\"\\n20347,1,1,\"The level of serum antibody increased after vaccination\"\\n20348,1,1,\"the level of tumor markers in serum.\"\\n20349,1,1,\"The lowest effective dose of theophylline that will prevent or maximally ameliorate erlotinib\\'s diarrhea at the standard dose of erlotinib at 150 mg/day taken daily for 28 days every 28 days\"\\n20350,1,1,\"The main primary endpoint will be reached, if the xenograft rate using patients\\' samples is ‚â• 50% with the INOVOTION automated process.\"\\n20351,1,1,\"The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.\"\\n20352,1,1,\"The mass balance of [14C]-AMG 706 (as the percentage of the dose administered) in urine and faeces\"\\n20353,1,1,\"The Maximal Tolerated dose (MTD)\"\\n20354,1,1,\"The maximum (or peak) serum ,Cmax\"\\n20355,1,1,\"The maximum observed concentrations (Cmax)(ng/mL)\"\\n20356,2,1,\"The maximum tolerate dosage\"\\n20357,11,8,\"The maximum tolerated dose (MTD)\"\\n20358,2,1,\"the maximum tolerated dose (MTD)\"\\n20359,1,1,\"The maximum tolerated dose (MTD) (if available) and recommended phase 2 dose (RP2D) in stage I\"\\n20360,1,1,\"The maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D)\"\\n20361,1,1,\"The maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D) of BAY1895344\"\\n20362,1,1,\"The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297\"\\n20363,1,1,\"The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297.\"\\n20364,1,1,\"The maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)\"\\n20365,1,1,\"The maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) or NKTR-255 in combination with cetuximab in R/R HNSCC or CRC for Phase 1b Dose Escalation\"\\n20366,1,1,\"The Maximum Tolerated Dose (MTD) for Each Treatment Arm\"\\n20367,1,1,\"The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)\"\\n20368,1,1,\"The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by the CTCAE v4.03\"\\n20369,1,1,\"The maximum tolerated dose (MTD) in the pediatric cohort\"\\n20370,1,1,\"The maximum tolerated dose (MTD) of AL2846\"\\n20371,1,1,\"The maximum tolerated dose (MTD) of BGB-15025\"\\n20372,1,1,\"The Maximum Tolerated Dose (MTD) of Cediranib in Combination With Olaparib in the Treatment of Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Metastatic Triple-negative Breast Cancer (Phase I)\"\\n20373,1,1,\"The Maximum Tolerated Dose (MTD) of Cediranib in Combination With Olaparib Tablet Formulation in the Treatment of Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer (Phase I-T).\"\\n20374,1,1,\"The maximum tolerated dose (MTD) of Docetaxel-PNP\"\\n20375,1,1,\"the Maximum Tolerated Dose (MTD) of HB002.1T\"\\n20376,1,1,\"The Maximum Tolerated Dose (MTD) of HLX26 within 3 weeks after the first Administration in patients with Advanced/Metastatic Solid\"\\n20377,1,1,\"The Maximum Tolerated Dose (MTD) of LeY CAR T-cell infusion\"\\n20378,1,1,\"The maximum tolerated dose (MTD) of LNA-i-miR-221\"\\n20379,1,1,\"The maximum tolerated dose (MTD) of lurbinectedin with doxorubicin in participants with advanced soft-tissue sarcoma\"\\n20380,1,1,\"The maximum tolerated dose (MTD) of Oradoxel based on dose-limiting toxicity (DLT) in subjects with advanced malignancies\"\\n20381,1,1,\"The maximum tolerated dose (MTD) of SAIT301 and the dose level of SAIT301 where dose limiting toxicity (DLT) is observed in subjects with advanced solid tumors\"\\n20382,1,1,\"The maximum tolerated dose (MTD) of TQ-B3101\"\\n20383,1,1,\"The Maximum Tolerated Dose (MTD) or Highest Protocol-Defined Dose\"\\n20384,1,1,\"The maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in patients treated with OMP-336B11\"\\n20385,1,1,\"The maximum tolerated dose (MTD), and/or recommended Phase 2 dose (RP2D) together with the biologically effective dose (BED) of PT01.\"\\n20386,1,1,\"The Maximum Tolerated Dose (MTD), Optimal Biological Dose (OBD) and/or the Recommended Phase 2 Dose (RP2D) of ES002023\"\\n20387,1,1,\"The maximum tolerated dose (MTD)/optimal biological dose (OBD) of BI 905681\"\\n20388,1,1,\"The maximum tolerated dose (MTD)/recommended phase II dose (RP2D) is the dose at which less than or equal to 1 of 6 patients experience a dose limiting toxicity (DLT) with the next higher dose having at least 2 of 3 or 2 of 6 patients experiencing a DLT.\"\\n20389,1,1,\"The maximum tolerated dose of ARQ761 in combination with Olaparib.\"\\n20390,1,1,\"The maximum tolerated dose of HLX07 combined with different chemotherapy regimen\"\\n20391,1,1,\"The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer.\"\\n20392,1,1,\"The maximum tolerated dose of sorafenib given twice each day when given in combination with cyclophosphamide/topotecan for 5 days\"\\n20393,1,1,\"The maximum-tolerated dose (MTD) of DTP348 as single agent\"\\n20394,1,1,\"The maximum-tolerated dose (MTD) of nab-rapamycin in combination with pazopanib (Phase I)\"\\n20395,1,1,\"The maximum-tolerated dose (MTD) of OH2 injection in combination with Keytruda in patients with solid tumors\"\\n20396,1,1,\"The maximum-tolerated dose (MTD) of SynOV1.1 in patients with HCC\"\\n20397,1,1,\"The maximum-tolerated dose (MTD) regimen of DTP348 as single agent in combination with radiotherapy\"\\n20398,1,1,\"The maximum-tolerated dose (MTD) regimen of henatinib will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle.\"\\n20399,1,1,\"The maximum-tolerated dose (MTD) regimen of the combination will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle.\"\\n20400,3,1,\"The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing one treatment cycle.\"\\n20401,1,1,\"The maximum-tolerated doses (MTDs) of OH2 injection as single agent and in combination with HX008 in patients with solid tumors\"\\n20402,1,1,\"The Maximun Tolerated Dose (MTD) of PBF-999\"\\n20403,2,1,\"The Measure CTCAE of Safety\"\\n20404,1,1,\"The Median Survival in the Study Population\"\\n20405,1,1,\"The Median Survival Time Will be Determined.\"\\n20406,1,1,\"The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy\"\\n20407,1,1,\"The metabolic pathways of iniparib and identify the chemical structures of the main metabolites.\"\\n20408,1,1,\"The model\\'s ability to differentiate pancreatic cancer from other pancreatic solid lesion\"\\n20409,1,1,\"The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics\"\\n20410,2,2,\"The MTD\"\\n20411,1,1,\"The MTD of TAS-114/ capecitabine (defined as the highest dose level at which less than 33% of the patients experience a Dose Limiting Toxicity (DLT) during the first cycle of treatment); DLTs defined by protocol\"\\n20412,1,1,\"The nature, frequency and severity of adverse events\"\\n20413,1,1,\"The negative predictive value (NPV) determined from shear wave elastography\"\\n20414,1,1,\"the non progression rate after 12 weeks (3 months) of treatment, based on the response evaluated by CT scan or MRI according to RECIST criteria (RECIST version 1.1) and validated by a central review committee.\"\\n20415,1,1,\"The number and types of mutated genes.\"\\n20416,1,1,\"The number and types of toxicities of sorafenib when administered in combination with cyclophosphamide and topotecan.\"\\n20417,1,1,\"The number of additional technologies and new treatment strategies that are introduced in the care for advanced pediatric cancers through this research program.\"\\n20418,1,1,\"The number of days from the date of the stem cell infusion to engraftment of absolute neutrophils (ANC) and platelets (PLT) will be determined based on daily CBC and differential counts.\"\\n20419,1,1,\"The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ‚â•10 Weeks From the First Infusion (6 Weeks After the Second Infusion) According to the RECIST Criteria\"\\n20420,1,1,\"The Number of Men With Advanced Prostate Cancer Treated With Sunitinib Who Have a Prostate Specific Antigen (PSA) Response\"\\n20421,1,1,\"The number of objective responses (partial and complete responses) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 integrated with response of serum tumor markers.\"\\n20422,1,1,\"The number of of drug related adverse events meeting the defined dose limiting toxicity at Cycle 1\"\\n20423,1,1,\"The Number of Participant Deaths\"\\n20424,1,1,\"The Number of Participant Deaths in the Study - Parts 1, 2 and 5\"\\n20425,1,1,\"The Number of Participants Experience Adverse Events (AE) Leading to Discontinuation\"\\n20426,1,1,\"The Number of Participants Experiencing Abnormal Hepatic Laboratory Test Results\"\\n20427,1,1,\"The Number of Participants Experiencing Adverse Events (AE)\"\\n20428,2,2,\"The Number of Participants Experiencing Adverse Events (AEs)\"\\n20429,1,1,\"The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation\"\\n20430,1,1,\"The Number of Participants Experiencing Adverse Events (AEs) Meeting Dose Limiting Toxicity (DLT) Criteria\"\\n20431,1,1,\"The Number of Participants Experiencing Adverse Events Leading to Discontinuation\"\\n20432,1,1,\"The Number of Participants Experiencing Adverse Events Resulting in Death\"\\n20433,1,1,\"The Number of Participants Experiencing Clinical Laboratory Abnormalities\"\\n20434,1,1,\"The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)\"\\n20435,1,1,\"The Number of Participants Experiencing Drug-Related Grade 3-4 Adverse Events (AEs)\"\\n20436,1,1,\"The Number of Participants Experiencing Drug-Related Grade 3-4 Serious Adverse Events (SAEs)\"\\n20437,1,1,\"The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests\"\\n20438,1,1,\"The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests\"\\n20439,1,1,\"The Number of Participants Experiencing Serious Adverse Events (SAE)\"\\n20440,2,2,\"The Number of Participants Experiencing Serious Adverse Events (SAEs)\"\\n20441,1,1,\"The Number of Participants Experiencing Toxicity Grade 3-4 Laboratory Test Results\"\\n20442,1,1,\"The number of participants that respond to a combination of HIGRT and MPDL3280A (PD-L1)\"\\n20443,1,1,\"The Number of Participants Who Experienced at Least One Grade 3 Adverse Event\"\\n20444,1,1,\"The Number of Participants With a Dose Interruption of ABI-007\"\\n20445,3,2,\"The Number of Participants With Adverse Events\"\\n20446,1,1,\"The number of participants with adverse events that are related to treatment\"\\n20447,1,1,\"The number of participants with adverse events/serious adverse events\"\\n20448,1,1,\"The Number of Participants With at Least One Dose Delay for ABI-007\"\\n20449,1,1,\"The Number of Participants With at Least One Dose Reduction for ABI-007\"\\n20450,1,1,\"The Number of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n20451,1,1,\"The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology)\"\\n20452,1,1,\"The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION)\"\\n20453,1,1,\"The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING )\"\\n20454,1,1,\"The Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose of Temozolomide and Talazoparib Combination Therapy\"\\n20455,1,1,\"The number of participants with grade 4 toxicities\"\\n20456,1,1,\"The number of participants with laboratory abnormalities that are related to treatment\"\\n20457,1,1,\"The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy na√Øve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.\"\\n20458,1,1,\"The number of participants with severe, life-threatening or fatal adverse events\"\\n20459,1,1,\"The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety\"\\n20460,1,1,\"The number of participants with treatment-related Adverse Events as Assessed by Cancer Therapy Evaluation Program Common Toxicity Criteria (CTCAE) Version 5.0 for toxicity and Adverse Event reporting\"\\n20461,1,1,\"The number of patients in Phase 1b part of the study with any adverse events (AE).\"\\n20462,1,1,\"The number of patients reported adverse events\"\\n20463,1,1,\"The number of patients reporting adverse events as a measure of safety\"\\n20464,1,1,\"The Number of Patients That Respond to Treatment\"\\n20465,1,1,\"the number of patients who have experienced Dose Limiting Toxicity\"\\n20466,1,1,\"The number of patients with a dose limiting toxicity (DLT) in the first treatment cycle\"\\n20467,1,1,\"The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle\"\\n20468,1,1,\"The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS).\"\\n20469,2,1,\"The number of patients with adverse events\"\\n20470,2,1,\"The number of patients with adverse events.\"\\n20471,1,1,\"The number of patients with antibodies to the study drug\"\\n20472,1,1,\"The number of patients with changes from baseline laboratory findings, ECGs and vital signs\"\\n20473,1,1,\"The number of patients with dose limiting toxicity (DLT) observed between Days 1 and 21 after start of treatment (after first 3 weekly administrations of SH U04722 plus 7 days)\"\\n20474,1,1,\"The Number of Patients With Dose-Limiting Toxicities (DLTs) in the First Course of Each Treatment Arm\"\\n20475,1,1,\"The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.\"\\n20476,1,1,\"The Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest\"\\n20477,1,1,\"The number of patients with homologous recombination repair deficiencies compared to the number of patients that do not have homologous recombination repair deficiencies.\"\\n20478,1,1,\"The number of patients with serious adverse events\"\\n20479,1,1,\"The number of patients with somatic BRCA mutations compared to number of patients without somatic BRCA mutations\"\\n20480,1,1,\"The Number of Patients With Tumor Size Reduction (Objective Response Rate)\"\\n20481,1,1,\"The number of subjects experiencing a dose limiting toxicity at various dose levels when given CX-2009 as a monotherapy\"\\n20482,1,1,\"The number of subjects experiencing a dose limiting toxicity at various dose levels when given multiple doses of CX-072 as a monotherapy or in combination with ipilimumab or vemurafenib\"\\n20483,1,1,\"The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-188 as a monotherapy\"\\n20484,1,1,\"The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy\"\\n20485,1,1,\"The number of subjects experiencing abnormal electrocardiograms (ECG) reported as Adverse Events\"\\n20486,1,1,\"The number of subjects experiencing abnormal electrocardiograms (ECG) reported as Adverse Events (Dose-escalation phase)\"\\n20487,1,1,\"The number of subjects experiencing abnormal laboratory evaluations\"\\n20488,1,1,\"The number of subjects experiencing abnormal laboratory evaluations (Dose-escalation phase)\"\\n20489,2,1,\"The number of subjects experiencing adverse events (AEs) (Phase Ib)\"\\n20490,1,1,\"The number of subjects experiencing changes from baseline in vital signs reported as adverse events\"\\n20491,1,1,\"The number of subjects experiencing changes from baseline in vital signs reported as adverse events (Dose-escalation phase)\"\\n20492,1,1,\"The number of subjects experiencing dose-limiting toxicities (DLTs)\"\\n20493,1,1,\"The number of subjects experiencing dose-limiting toxicities (DLTs) (Dose-escalation phase)\"\\n20494,1,1,\"The number of subjects experiencing dose-limiting toxicities (DLTs) (Phase Ib)\"\\n20495,1,1,\"The number of subjects experiencing treatment related adverse events (AEs)\"\\n20496,1,1,\"The number of subjects experiencing treatment related adverse events (AEs) (Dose-escalation phase)\"\\n20497,1,1,\"The number of subjects experiencing treatment related serious adverse events (SAEs)\"\\n20498,1,1,\"The number of subjects experiencing treatment related serious adverse events (SAEs) (Dose-escalation phase)\"\\n20499,1,1,\"The number of subjects with adverse events based on the Common Terminology Criteria for Adverse Evens (CTCAE) v5.0 following treatment with DT2216.\"\\n20500,1,1,\"The number of subjects with adverse events of different grades based on the CTCAE v5.0\"\\n20501,3,3,\"The number of subjects with adverse events/serious adverse events\"\\n20502,1,1,\"The number of subjects with dose limiting toxicity (DLT) of DT2216.\"\\n20503,1,1,\"The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.\"\\n20504,5,5,\"The number of subjects with dose-limiting toxicity, as defined in the protocol.\"\\n20505,1,1,\"The number of subjects with no progression.\"\\n20506,1,1,\"The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.\"\\n20507,2,2,\"The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.\"\\n20508,1,1,\"The number of successfully manufactured EGFR806 and EGFR806xCD19 CAR T cell products will be assessed\"\\n20509,1,1,\"The numbers and proportions of T lymphocyte subpopulations in peripheral blood\"\\n20510,1,1,\"The numbers of participants with treatment-related adverse events assessed by CTCAE 5.0\"\\n20511,1,1,\"The objective of protocol PCYC-1145-LT is to provide long-term access to ibrutinib for subjects who meet the selection criteria.\"\\n20512,1,1,\"The objective response (investigator-assessed) to CMP-001 in combination with pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC).\"\\n20513,1,1,\"The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1\"\\n20514,1,1,\"The objective response rate (ORR) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n20515,1,1,\"The objective response rate (ORR) based on RECIST 1.1\"\\n20516,1,1,\"The objective response rate (ORR) will be defined as the proportion of patients with a complete response (CR) or a partial response (PR) as best overall response during the study\"\\n20517,1,1,\"The objective response rate to DaRT treatment\"\\n20518,1,1,\"The Objective Response Rate(ORR)\"\\n20519,1,1,\"The observed tumor response duration\"\\n20520,1,1,\"The observed tumor response rate\"\\n20521,1,1,\"The occurrence and frequency of adverse events and serious adverse events\"\\n20522,1,1,\"The occurrence of adverse events (AEs) reported in all subjects who received study drug\"\\n20523,1,1,\"The occurrence of AEs and SAEs during the study treatment\"\\n20524,1,1,\"The occurrence of any adverse event\"\\n20525,1,1,\"The occurrence of dose limiting toxicity\"\\n20526,1,1,\"The occurrence of treatment-emergent adverse events (TEAs)\"\\n20527,1,1,\"The occurrence of treatment-related adverse events meeting the criteria for dose limiting toxicities (DLTs)\"\\n20528,1,1,\"The occurrence rate of adverse event during at least three consecutive cycles chemotherapy\"\\n20529,1,1,\"The occurrence rate of all adverse events (AEs)\"\\n20530,1,1,\"The Optimal Tolerated Regimen of Pazopanib and Ixabepilone When Used in Combination\"\\n20531,1,1,\"The outcome of clinical diagnosis of suspected patients with colorectal cancer or lesion (Benign/Malignant).\"\\n20532,1,1,\"The outcome of clinical diagnosis of suspected patients with COVID-19 (Positive/Negative).\"\\n20533,1,1,\"The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule)\"\\n20534,1,1,\"The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule).\"\\n20535,1,1,\"The outcome of clinical diagnosis of suspected patients with pulmonary tuberculosis (Positive/Negative).\"\\n20536,1,1,\"The outcome of clinical diagnosis of suspected patients with stomach cancer or lesion (Benign/Malignant).\"\\n20537,1,1,\"The overall diagnostic performance of a new computer aided prediction (CAP) model for malignancy in small pulmonary nodules (% diagnostic accuracy).\"\\n20538,5,3,\"The overall response rate (ORR)\"\\n20539,1,1,\"The Overall response rate (ORR)- Response Evaluation Criteria In Solid Tumors Criteria (RECIST)\"\\n20540,1,1,\"The overall response rate using RECIST 1.1\"\\n20541,4,1,\"The pathological complete response rate(pCR)\"\\n20542,1,1,\"The patient 6-minute walk test (6-MWT) over the 6-month follow up (6-MFU)\"\\n20543,1,1,\"The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period\"\\n20544,1,1,\"The percent of absolute bioavailability (F) of GSK2118436 following single-dose oral HPMC capsule and a concomitant IV microdose\"\\n20545,1,1,\"The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction (EOI).\"\\n20546,1,1,\"The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)\"\\n20547,1,1,\"The Percentage of Participants Who Exhibit a Hematopoietic Response\"\\n20548,1,1,\"The Percentage of Participants With No Vomiting - Overall Stage\"\\n20549,1,1,\"The percentage of patients alive and without progression at 6 months\"\\n20550,1,1,\"The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment\"\\n20551,1,1,\"The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy\"\\n20552,1,1,\"The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).\"\\n20553,2,1,\"The Percentage of Patients Who Survive Progression Free for at Least 6 Months\"\\n20554,1,1,\"The percentage of patients whose cancer shrinks or disappears after treatment. Treatment response expressed as a complete response; partial response; stable disease; progression based on clinical judgment on imaging.\"\\n20555,1,1,\"The Percentage of Patients With a ‚â• 50% Prostate-specific Antigen (PSA) Decline Post-therapy\"\\n20556,1,1,\"The percentage of patients with Local Regional Recurrence (LRR) of disease\"\\n20557,1,1,\"The Percentage of Patients With Objective Response Either Partial Response (PR) or Complete Response(CR).\"\\n20558,1,1,\"The percentage of patients with recurrent or refractory pediatric solid tumor or leukemia that could be attributed to treatment with matched targeted agents\"\\n20559,1,1,\"The percentage of uptake of cascade testing among patients\\' first-degree at-risk relatives\"\\n20560,1,1,\"The PFR, Defined as the Proportion of Patients With Refractory Germ Cell Tumors Free of Objective Disease Progression After 4 Cycles (16 Weeks) of Therapy With Erlotinib and Sirolimus\"\\n20561,1,1,\"the pharmacodynamic (PD) effects of MPT0E028 in subjects with advanced solid malignancies through the measurement of the biomarker peripheral blood mononuclear cell (PBMC) histone acetylation\"\\n20562,1,1,\"The pharmacodynamics (serum concentrations of corticosterone, testosterone, DHEA-S, 11-deoxycorticosterone)\"\\n20563,1,1,\"the pharmacokinetic (PK) profile of MPT0E028 in subjects with advanced solid malignancies\"\\n20564,1,1,\"The pharmacokinetic parameters (free docetaxel and total docetaxel) : AUC0-t„ÄÅAUC0-‚àû\"\\n20565,1,1,\"The pharmacokinetic parameters (free docetaxel and total docetaxel) : Cmax\"\\n20566,1,1,\"The pharmacokinetics of iniparib, iodo-amino-benzamide (IABM) and iodo-amino-benzoic acid (IABA) and their contribution to overall exposure of radioactivity\"\\n20567,1,1,\"the phase II studyÔºöObjective response rate (ORR)\"\\n20568,1,1,\"The PK exposure parameters of digoxin\"\\n20569,1,1,\"The plasma concentration time curve of KZR-261 (Part 1)\"\\n20570,1,1,\"The predictive biomarkers of PLD induced hypersensitivity\"\\n20571,1,1,\"The predictive value of 18F-FDG-PET for the absence of response compared to the lack of clinical benefit at convential CT at 2 months\"\\n20572,1,1,\"The Prevalence of Genomic, Transcriptomic, and Proteomic Abnormalities in Human Cancer\"\\n20573,1,1,\"The primary efficacy endpoint is objective response rate (ORR)\"\\n20574,1,1,\"The primary efficacy variable is response to therapy. Response will be evaluated using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.\"\\n20575,1,1,\"The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).\"\\n20576,1,1,\"The primary endpoint (safety and tolerability) for this study is the occurrence and intensity of adverse events.\"\\n20577,1,1,\"The primary endpoint for efficacy is the percentage of patients achieving complete or partial response according to WHO guidelines, after having received 4 cycles of gemcitabine-oxaliplatin (8 weeks).\"\\n20578,1,1,\"The primary endpoint is evaluation of safety and tolerability during all the study of therapy following the initiation of multiple dosing of Volitinib (HMPL-504).\"\\n20579,3,3,\"The primary endpoint is pathological complete remission (pCR)\"\\n20580,1,1,\"The primary endpoint is the change in SUV between baseline 89Zr-bevacizumab PET scan and the scan performed after 2 and 6 weeks of treatment with sunitinib or bevacizumab plus interferon in patients with RCC.\"\\n20581,1,1,\"The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.\"\\n20582,1,1,\"The primary endpoint is the incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\"\\n20583,1,1,\"The primary endpoint is the Objective Response Rate (ORR) at 6 weeks.\"\\n20584,1,1,\"The Primary Endpoint is the Occurrence of Dose Limiting Toxicity (DLT).\"\\n20585,1,1,\"The primary endpoint is the rate of patients with tumors harboring a low level of genomic alteration (mutation, amplification or deletion) in genes (i.e. mutation, amplification, deletion) identified as causally implicated in cancer\"\\n20586,1,1,\"The primary endpoint is to determine the maximum tolerated dose (MTD) based on the number of patients presenting dose limiting toxicity (DLT) using CTCAE V4.03, during the first course and judged to be related to the study medication\"\\n20587,1,1,\"The primary endpoint of the study will be overall survival (OS).\"\\n20588,1,1,\"The Primary Endpoint of the Study Will be to Determine the Feasibility of Combining External Beam Radiotherapy (EBRT) and Bexxar by Assessing the Toxicities Associated With the Treatment.\"\\n20589,1,1,\"The primary endpoint of the trial is clinical progression free survival.\"\\n20590,1,1,\"The primary endpoint of the trial is objective response (OR), defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator\"\\n20591,1,1,\"The primary endpoint of this trial is the safety of the combination of BIBW 2992/BIBF 1120 when administered concomitantly, and this is assessed by the dose limiting toxicity\"\\n20592,1,1,\"The primary endpoint to assess the maximum tolerated dose (MTD) is based on the number of patients presenting dose-limiting toxicities (DLTs) using CTCAE v4.03, judged to be related to the study medication evaluated over the first cycle of treatment.\"\\n20593,1,1,\"The primary objective is to determine the rates & routes of excretion of 14C radiolabelled AZD2171 in patients by assessment of concentrations of total 14C radioactivity and AZD2171 in plasma & concentrations of total radioactivity in urine&faeces\"\\n20594,1,1,\"The primary objective is to estimate the pathological complete response rate of neoadjuvant therapy in operable newly diagnosed ER+ breast cancer patients using the combination of Avastin and Letrozole.\"\\n20595,1,1,\"The primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan\"\\n20596,1,1,\"The primary objective of Part 2 is: To further assess the safety and tolerability of ARX517 including multi cycle safety\"\\n20597,1,1,\"The primary objective of the dose finding component is to determine the maximum tolerated dose (MTD) of HCW9218\"\\n20598,1,1,\"The primary objective of the study is to assess the pharmacokinetics of BIIB021 taken under fed conditions compared to BIIB021 taken under fasting conditions in subjects with advanced solid tumors.\"\\n20599,1,1,\"The primary objective of the study is to determine the safety and tolerability of CVA21 given by intravenous infusion in multiple escalating doses.\"\\n20600,1,1,\"The primary objective of the study is to evaluate the safety of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.\"\\n20601,1,1,\"The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12.\"\\n20602,1,1,\"The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and Biliary Cancers.\"\\n20603,1,1,\"The primary objective of this study is to assess the feasibility of the combined treatment with dinutuximab beta, zoledronic acid and low-dose interleukin 2.\"\\n20604,1,1,\"The primary objective of this study is to assess the safety and tolerability of AZD7762 alone and in combination with Irinotecan\"\\n20605,1,1,\"The primary objective of this study is to determine the effect of BMS-582664 on subjects with varying levels of hepatic impairment and guide prescribers with regards to dosing in specialized populations\"\\n20606,1,1,\"The primary objective of this study is to determine the maximum tolerated dose of XMT-1107 when given via IV once every three weeks.\"\\n20607,1,1,\"The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with invasive solid tumors\"\\n20608,1,1,\"The primary objective of this study is to determine the safety and objective response rate (ORR).\"\\n20609,1,1,\"The primary objective of this study is to determine the safety and tolerability of AZD2281.\"\\n20610,1,1,\"The primary objective of this study is to evaluate the safety and tolerability of AZD0530 in Japanese patients with advanced solid malignancies by assessment of AEs, vital signs, ECG, laboratory findings, thoracic imaging and pulmonary function test.\"\\n20611,1,1,\"The primary objective of this study is to investigate leukemia risk as a function of radiation ionizing radiation from occupational exposure (Chernobyl nuclear power plant)\"\\n20612,1,1,\"The primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality.\"\\n20613,1,1,\"The primary objectives of Part 1:\"\\n20614,1,1,\"The primary objectives of Part 1: Safety and tolerability of ARX517\"\\n20615,1,1,\"The primary objectives of this Phase 1 study of pegaspargase in combination with gemcitabine are to determine the maximum tolerated dose of IV pegaspargase when administered with gemcitabine\"\\n20616,1,1,\"The primary objectives of this study are to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-010 given weekly for 3 weeks followed by 1 week of rest (Cycle 1); to determine MTD and DLTs of ABI-010 given in combination\"\\n20617,1,1,\"The primary outcome is to determine the safety and toxicity of ixabepilone and dasatinib in combination in patients with metastatic or locally advanced/unresectable solid tumors that have progressed through standard therapy.\"\\n20618,1,1,\"The primary outcome measure will be the assessment of response-rate (RR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\"\\n20619,1,1,\"The primary outcomes of this study are self-reported fatigue, depression, and quality of life scores of patients before, at midpoint, and at completion of each cycle of their cancer treatment.\"\\n20620,1,1,\"The primary safety endpoint will be the Adverse Events (AE) reported during the combined treatment of Nerofe and low Dose doxorubicin , using the CTCAE score.\"\\n20621,1,1,\"The prognostic value of MRD\"\\n20622,1,1,\"The Progression Free Survival (PFS)\"\\n20623,1,1,\"The Progression Free Survival-6m rate defined as the proportion of subjects that are alive and progression-free at 6-months from the date of first dosing based on RECIST 1.1.\"\\n20624,1,1,\"The progression-free survival (PFS) rates at 6 months\"\\n20625,1,1,\"The proportion of 3/4 degree diarrhea in group A From the first day of treatment to the 22nd day of treatment\"\\n20626,1,1,\"The proportion of clinical practice guidelines (CPG)-consistent care of fever and neutropenia (FN) episodes\"\\n20627,1,1,\"The proportion of CPG-consistent care of chemotherapy induced nausea and vomiting (CINV) episodes\"\\n20628,1,1,\"The proportion of CPG-consistent care of fertility preservation (FP) episodes\"\\n20629,1,1,\"The proportion of ctDNA content decreased in patients with good therapeutic effect\"\\n20630,1,1,\"The proportion of enrolled patients for whom Nelfinavir dose can be successfully administered in combination with Cisplatin and Pelvic Radiation Therapy.\"\\n20631,1,1,\"The proportion of grade 4 neutropenia\"\\n20632,1,1,\"The proportion of participants with and without antibodies to SARS-CoV-2\"\\n20633,1,1,\"The proportion of PAT acquisitions in which the target lymph node is visible, as judged by the mean of both readers\\' qualitative scores\"\\n20634,1,1,\"The proportion of patients experiencing dose limiting toxicities\"\\n20635,3,3,\"The proportion of patients experiencing dose limiting toxicity (DLT) events\"\\n20636,1,1,\"The Proportion of Patients Experiencing no Vomiting and no Nausea, Without Use of Any Rescue Antiemetic Medication(s), From Days 2-10 Following the Radiation Therapy (Delayed RINV).\"\\n20637,1,1,\"The Proportion of Patients in Each Arm Who Develop Grade-2 or Higher HFSR Within The First 8 Weeks of Protocol Therapy\"\\n20638,1,1,\"The Proportion of Patients in Each Intervention Arm Who Develop HFSR of Any Grade\"\\n20639,1,1,\"The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria\"\\n20640,1,1,\"The Proportion of Patients Who Achieve Gut Microbiome Diversity at One Month Following the Final Post-HCT FMT\"\\n20641,4,1,\"The proportion of patients with an abscopal response assessed at 7-8 weeks after the initiation of treatment.\"\\n20642,1,1,\"The proportion of patients with CDK12 loss of function metastatic CRPC that respond to treatment.\"\\n20643,1,1,\"The Proportion of Patients With Objective Response (Complete Response or Partial Response)\"\\n20644,1,1,\"The proportion of subjects experiencing dose limiting toxicities\"\\n20645,1,1,\"The proportion of subjects who achieve a complete response (defined as no vomiting/retching and no rescue therapy).\"\\n20646,1,1,\"The proportion of subjects with adverse events in the 1st cycle during dose escalation within the DLT window (28 days).\"\\n20647,1,1,\"The proportion of subjects with adverse events on the study.\"\\n20648,1,1,\"The proportion of successful CTC culture growths.\"\\n20649,1,1,\"The proportion of treatment responders.\"\\n20650,1,1,\"The proportion of viable melanoma tissue, compared to baseline, in dissected lymph node and / or in-transit tumour tissue after 12 weeks of neoadjuvant treatment.\"\\n20651,1,1,\"The purpose will be to evaluate safety using donor lymphocytes labelled in-vitro with bispecific antibodies for metastatic cancer patients.\"\\n20652,1,1,\"The radiologic response rate\"\\n20653,1,1,\"The rate of Accurate diagnosis of pancreatic lesions\"\\n20654,1,1,\"The rate of Adverse events\"\\n20655,2,1,\"the rate of adverse events\"\\n20656,2,2,\"The rate of adverse events and severe adverse events leading to treatment discontinuation\"\\n20657,1,1,\"The rate of pathological complete response\"\\n20658,1,1,\"The rate of patients alive and without progression at 10 months after inclusion\"\\n20659,2,1,\"the rate of patients converted to resection for liver metastases\"\\n20660,1,1,\"The rate of progression free patients at six months\"\\n20661,1,1,\"the rate of reverse events\"\\n20662,1,1,\"The rate of SAR-COV2 infection development in association with tumor characteristics.\"\\n20663,1,1,\"The rate of Senior Adverse Events\"\\n20664,1,1,\"The rate of subjects with viral shedding of Revottack\"\\n20665,1,1,\"The rate of subjects with viral shedding of RT-01\"\\n20666,1,1,\"The Rate of Suppression of Serum Testosterone to Castrate Level\"\\n20667,1,1,\"The rate of toxicities after TAA-T infusion\"\\n20668,1,1,\"The Rate of Toxicities from Protocol Therapy\"\\n20669,1,1,\"The rate of willingness and completeness of LDCT screening after the detailed questionnaire survey for the eligible participants.\"\\n20670,1,1,\"The ratio (BV5/TBV) of blood volume in small < 5mm2 blood vessels (BV5) to the total pulmonary blood volume (TBV).\"\\n20671,2,1,\"The recommended dose\"\\n20672,1,1,\"The recommended dose for expansion (RDFE) of the combination.\"\\n20673,4,3,\"The recommended dose for future clinical study\"\\n20674,2,2,\"The recommended dose for the phase II study\"\\n20675,1,1,\"The recommended dose of everolimus in combination with eribulin in metastatic triple negative breast cancer\"\\n20676,1,1,\"The recommended dose of phase II\"\\n20677,1,1,\"The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.\"\\n20678,1,1,\"The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.\"\\n20679,1,1,\"The recommended phase 2 dose (RP2D) regimen of ET140202 T-cell therapy\"\\n20680,1,1,\"the recommended Phase 2 dose(RP2D) or the maximum tolerated dose(MTD) of NOV1601\"\\n20681,1,1,\"The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination.\"\\n20682,1,1,\"The recommended phase II dose for FCN-011\"\\n20683,1,1,\"The recommended phase II dose of Docetaxel-PNP\"\\n20684,1,1,\"The recommended Phase II dose of eribulin when used in combination with oral irinotecan\"\\n20685,1,1,\"The recommended phase II dose of LNA-i-miR-221 (RP2D)\"\\n20686,1,1,\"The recommended Phase II dose will be based on acceptable dose-limiting toxicity\"\\n20687,1,1,\"The Recovery of 14C-Radioactivity as a Percentage of the Administered Dose\"\\n20688,1,1,\"The relationship between [18F]FPIA uptake and percent positive tumour cells reported as counts defined per area from whole section immunohistochemistry for PHH3.\"\\n20689,1,1,\"The relationship of the dose of GBR 1302 with the incidence, nature, and intensity of AEs according to CTCAEv4.03\"\\n20690,1,1,\"The repeatability of NaF PET/CT imaging for evaluating bone metastases in patients with metastatic castrate-resistant prostate cancer.\"\\n20691,1,1,\"The Residual Cancer Burden Grade III (RCB-III).\"\\n20692,1,1,\"The response (ORR, CBR and irORR) to the treatment.\"\\n20693,1,1,\"The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume).\"\\n20694,2,1,\"The response rate\"\\n20695,1,1,\"The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]\"\\n20696,1,1,\"The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\"\\n20697,1,1,\"The response rate of patients with HCC receiving SynOV1.1\"\\n20698,1,1,\"The RP2D either with or without obinutuzumab pretreatment\"\\n20699,1,1,\"The safe dose of AUY922 when administered once a week\"\\n20700,1,1,\"the safety & feasibility of PET imaging with radiolabeled 68Ga-F(ab\\')2-trastuzumab fragments in pts w invasive solid tumors; by using the organ/tissue & body rt dosimetry inform following i.v. injection of 68Ga-F(ab\\')2-trastuzumab fragments (HERScan)\"\\n20701,2,2,\"The safety and tolerability\"\\n20702,1,1,\"The safety and tolerability of ADG116 in combination with pembrolizumab\"\\n20703,1,1,\"the safety and tolerability of ADG126 in combination with pembrolizumab\"\\n20704,1,1,\"The safety and tolerability of cetuximab and neratinib during the Phase I portion of the study.\"\\n20705,1,1,\"The safety and tolerability of MEDI4736 in combination with olaparib (¬±bevacizumab) by assessment of blood samples\"\\n20706,1,1,\"The safety and tolerability of MEDI4736 in combination with olaparib (¬±bevacizumab) by assessment of the number and grade of adverse events\"\\n20707,1,1,\"The safety and tolerability of MEDI4736 in combination with olaparib (¬±bevacizumab) by assessment of the number and grade of immune-related adverse events\"\\n20708,1,1,\"The safety and tolerability of MEDI4736 in combination with olaparib (¬±bevacizumab) by assessment of treatment modifications.\"\\n20709,1,1,\"The safety and tolerability of MEDI4736 in combination with olaparib (¬±bevacizumab) by assessment of vital signs\"\\n20710,1,1,\"The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0\"\\n20711,1,1,\"The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0.\"\\n20712,1,1,\"The safety and tolerability of single and multiple doses of HMPL-504 administered to patients.\"\\n20713,1,1,\"The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities\"\\n20714,1,1,\"The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities and evaluation of Adverse Events in relation to Study Drug.\"\\n20715,1,1,\"The Safety and Toxicity of the Combination Therapy of Lapatinib and Everolimus Will be Monitored Using the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v. 3.0. The Incidence of Any Grade 3 or 4 Toxicities Will be Analyzed.\"\\n20716,1,1,\"the safety of 177Lu-LNC1004 Injection\"\\n20717,1,1,\"The safety of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths\"\\n20718,1,1,\"The safety of MLN8054 will be based on the continuous monitoring and observation of patients and the collection and evaluation of adverse events and serious adverse events and the assessment of their potential relationship to the study medication.\"\\n20719,1,1,\"The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions\"\\n20720,1,1,\"The safety of ScTIL210\"\\n20721,1,1,\"The safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1c\"\\n20722,1,1,\"The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1a\"\\n20723,1,1,\"The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1b\"\\n20724,1,1,\"The sensitivity and specificity of DRS and OCT in the detection of renal malignancy\"\\n20725,1,1,\"The sensitivity of standard Beacon FNA needle compared with the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.\"\\n20726,1,1,\"The Serum Proteome\"\\n20727,1,1,\"The severity of adverse event during at least three consecutive cycles chemotherapy\"\\n20728,1,1,\"The severity of adverse events (AEs) determined as per NCI CTCAE V4.03.\"\\n20729,1,1,\"The severity of all adverse events (AEs)\"\\n20730,1,1,\"The severity of TEAEs including TESAEs\"\\n20731,1,1,\"The Simon optimal two-stage design (Richard Simon, Controlled Clinical Trials 1989)\"\\n20732,1,1,\"The success rate of patient derived tumor cell model establishment\"\\n20733,1,1,\"The terminal elimination half life of ABT-165\"\\n20734,1,1,\"The threshold value of sound velocity for benign and malignant pancreatic lesions\"\\n20735,1,1,\"The time to disease progression\"\\n20736,1,1,\"The time to first flatus\"\\n20737,1,1,\"The time to progression after start of treatment combination treatment of sirolimus and cyclophosphamide\"\\n20738,1,1,\"The time-matched difference in the QTcF interval at each timepoint after both single and multiple doses of tivantinib compared with placebo\"\\n20739,1,1,\"The TITE-CRM dose escalation scheme will be used in this study to determine the maximum tolerated dose (MTD) of the combination therapy.\"\\n20740,2,1,\"The Tmax of Viral RNA\"\\n20741,2,2,\"The Tmax of Viral RNA in blood\"\\n20742,1,1,\"The tolerability of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths\"\\n20743,1,1,\"The total area of procured tissue between the FNA and FNB needles\"\\n20744,1,1,\"The Total Cost (RMB)\"\\n20745,1,1,\"The Toxicities of the Combination of Sirolimus and Erlotinib Administered on This Schedule.\"\\n20746,1,1,\"The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0.\"\\n20747,1,1,\"The toxicity of MLN9708 when combined with nelfinavir based on CTCAE grading criteria v. 4.0\"\\n20748,1,1,\"The treatment duration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor re-administration\"\\n20749,1,1,\"The trial will observe the subject\\'s cancer status for 3 months after the granulocyte infusions are completed. Response at 90 days will be based on comparison of tumor measurements at baseline.\"\\n20750,1,1,\"The type of dose-limiting toxicity(ies) (DLT[s]) of AL2846\"\\n20751,1,1,\"The type of dose-limiting toxicity(ies) (DLT[s]) of TQ-B3101\"\\n20752,1,1,\"The types of additional technologies and new treatment strategies that are introduced in the care for advanced pediatric cancers through this research program.\"\\n20753,1,1,\"The value of NLR and PLR ratio\"\\n20754,1,1,\"Therapeutic antitumor activity of everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)\"\\n20755,1,1,\"Therapeutic competence\"\\n20756,1,1,\"Therapeutic efficacy will be evaluated according to RECIST1.1.\"\\n20757,1,1,\"Therapeutic toxicity\"\\n20758,4,1,\"Therapy Completion Rate\"\\n20759,1,1,\"These tissues will be utilised to perform pharmacodynamic (PD) assays to demonstrate the evidence of target modulation. Together with pharmacokinetic data, scientific information from these assays will help researchers optimise drug dosing and schedule\"\\n20760,1,1,\"Thickness of the vaginal epithelium\"\\n20761,1,1,\"This is a safety and tolerability-based study in which the MTD may be determined\"\\n20762,1,1,\"Three-month Progression-free Survival\"\\n20763,1,1,\"Three-year disease free survival (DFS)\"\\n20764,1,1,\"Threshold at which oxaliplatin-DNA adducts predict response to therapy\"\\n20765,1,1,\"Throat\"\\n20766,1,1,\"Thromboembolic complications:\"\\n20767,1,1,\"Thrombokinetic changes\"\\n20768,1,1,\"Thyroglobulin\"\\n20769,1,1,\"Thyrotropin (Safety and Tolerability in the Dose Escalation Phase)\"\\n20770,1,1,\"Thyroxine Free (Safety and Tolerability in the Dose Escalation Phase)\"\\n20771,1,1,\"Time at maximum concentration (Tmax) after multiple doses\"\\n20772,1,1,\"Time at maximum concentration (Tmax) after single dose\"\\n20773,1,1,\"Time at which the highest drug concentration occurs (tmax)\"\\n20774,1,1,\"Time at which the highest drug concentration occurs at steady-state (tss,max)\"\\n20775,1,1,\"Time Course by Which Vemurafenib and Cobimetinib Increases T Cell Infiltration\"\\n20776,1,1,\"Time Dependency of Cblood Cells/Cplasma Ratio and Cblood/Cplasma Ratio of 14C-radioactivity\"\\n20777,1,1,\"Time from administration of the dose to the first quantifiable concentration (Tlag) for niraparib-Stage 3 PK Phase\"\\n20778,1,1,\"Time from ADT Initiation to nmCRPC\"\\n20779,1,1,\"Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC\"\\n20780,1,1,\"Time from first dosing date of olaparib to date of disease progression or death from any cause (if this occurs before disease progression)\"\\n20781,1,1,\"Time From First Line Immune-Oncologic Therapy Discontinuation to Initiation of Second Line Sunitinib Therapy\"\\n20782,1,1,\"Time from MTB recommendation to treatment initiation\"\\n20783,1,1,\"Time from nmCRPC to High-Risk (HR) nmCRPC\"\\n20784,1,1,\"Time From Patient Recruitment to Final Results ‚â§ 21 Days in ‚â• 90% of Patients\"\\n20785,1,1,\"time from the first day of treatment until diarrhea returns to level 0 or baseline during the first day of treatment to the 22nd day of treatment\"\\n20786,1,1,\"Time it took to screen\"\\n20787,1,1,\"Time of getting out of bed after operation\"\\n20788,3,1,\"time of hematopoietic recovery\"\\n20789,12,1,\"Time of maximum concentration (Tmax)\"\\n20790,1,1,\"Time of maximum concentration (Tmax) of CM082 (test product or reference product) under fasted state or after meal\"\\n20791,1,1,\"Time of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3\"\\n20792,1,1,\"Time of maximum concentration of Hemay020\"\\n20793,1,1,\"Time of maximum concentrationÔºàTmaxÔºâof CM082\"\\n20794,7,1,\"Time of maximum observed concentration (Tmax)\"\\n20795,1,1,\"Time of Maximum Observed Concentration (Tmax) of GDC-0941\"\\n20796,1,1,\"Time of maximum observed plasma concentration (Tmax) for eribulin mesylate\"\\n20797,2,2,\"Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab\"\\n20798,2,1,\"Time of maximum observed serum concentration (Tmax)\"\\n20799,1,1,\"Time of Maximum Plasma Concentration (tmax)\"\\n20800,1,1,\"time of maximum plasma concentration (tmax) of midazolam\"\\n20801,1,1,\"Time of Maximum Plasma Concentration (Tmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib\"\\n20802,1,1,\"Time of Maximum Plasma Concentration (Tmax) of RO5185426 on Day 1\"\\n20803,1,1,\"Time of myelosuppression\"\\n20804,1,1,\"Time of Occurrence of Cmax (Tmax) of Pazopanib Alone and of Pazopanib in Combination With Ketoconazole and Esomeprazole\"\\n20805,1,1,\"Time of the last positive (quantifiable) concentration [tlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n20806,1,1,\"Time of tumor progression radiologically (CTScan) measured by mRECIST (Modified Response Evaluation Criteria In Solid Tumor).\"\\n20807,1,1,\"Time Since First Rheumatologist Visit\"\\n20808,1,1,\"Time Since Recalled Symptom Onset\"\\n20809,1,1,\"Time Taken for Plasma Concentration to Reduce by 50 Percent or Apparent Terminal Plasma Elimination Half-life (T Half)\"\\n20810,1,1,\"Time Taken to Reach Maximum Plasma Concentration (Tmax) of Cobimetinib on Day 1, Cycle 1\"\\n20811,2,1,\"Time to accrual\"\\n20812,2,2,\"Time to achieve Cmax (Tmax)\"\\n20813,1,1,\"time to achieve Cmax (tmax) of AMG 510\"\\n20814,1,1,\"Time to Achieve Maximum Observed Plasma Concentration (Tmax) After a Single Dose of GDC-0449\"\\n20815,1,1,\"Time to Appearance of New Lesions (TTNL)\"\\n20816,1,1,\"Time to Attain Maximum Observed Plasma Concentration (Tmax) of 14C- Radioactivity\"\\n20817,1,1,\"Time to Attain Maximum Observed Plasma Concentration (Tmax) of Talazoparib\"\\n20818,1,1,\"Time to Attain Maximum Observed Whole Blood Concentration (Tmax) of 14C- Radioactivity\"\\n20819,1,1,\"Time to castration resistant\"\\n20820,1,1,\"Time to Clinical Response as Assessed by Investigator According to RECIST v1.1\"\\n20821,1,1,\"Time to Cmax (peak time, Tmax) for ABBV-075\"\\n20822,20,4,\"Time to Cmax (Tmax)\"\\n20823,1,1,\"Time to Cmax (Tmax) of ABBV-181\"\\n20824,1,1,\"Time to Cmax (Tmax) of ABBV-368\"\\n20825,1,1,\"Time to Cmax (Tmax) of ABBV-428\"\\n20826,1,1,\"Time to Cmax (Tmax) of ABBV-621\"\\n20827,1,1,\"Time to Cmax (Tmax) of ABBV-706\"\\n20828,1,1,\"Time to Cmax (Tmax) of ABBV-927\"\\n20829,1,1,\"Time To Cmax (Tmax) Of ABBV-CLS-579\"\\n20830,1,1,\"Time to Cmax (tmax) of BAY1082439 after a single dose\"\\n20831,1,1,\"Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose\"\\n20832,1,1,\"Time To Cmax (Tmax) Of Metabolite M4\"\\n20833,1,1,\"Time To Cmax (Tmax) Of PD-1 Inhibitor\"\\n20834,1,1,\"Time To Cmax (Tmax) Of VEGFR TKI\"\\n20835,1,1,\"Time to Cmax (Tmax) of Venetoclax\"\\n20836,1,1,\"Time to Cmax [tmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n20837,1,1,\"Time to Complete Remission of Lesions\"\\n20838,8,1,\"Time to Death\"\\n20839,1,1,\"Time to development of a catheter-related bloodstream infections during the period of lock therapy administration\"\\n20840,1,1,\"Time to development of new distant metastases\"\\n20841,2,1,\"Time to discontinuation (TTD)\"\\n20842,26,5,\"Time to Disease Progression\"\\n20843,28,4,\"Time to disease progression\"\\n20844,1,1,\"Time to Disease Progression (Initial Treatment)\"\\n20845,3,1,\"Time to Disease Progression (TDP)\"\\n20846,1,1,\"Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n20847,1,1,\"Time to Disease Progression - Median Time to Progression and Log-Rank Test\"\\n20848,1,1,\"Time to disease progression in third line therapy\"\\n20849,1,1,\"Time to Disease Progression or Death\"\\n20850,1,1,\"Time to Disease Progression or Death by Line of Treatment\"\\n20851,1,1,\"Time to disease progression using RECIST criteria\"\\n20852,1,1,\"Time to Disease Worsening\"\\n20853,1,1,\"Time to Dose Modification\"\\n20854,1,1,\"Time to early discontinuation of the study drug (doxorubicin)\"\\n20855,1,1,\"Time to early withdrawal\"\\n20856,1,1,\"Time to elimination half-life (T1/2) for SHR116637 after Single dose\"\\n20857,4,3,\"Time to failure\"\\n20858,1,1,\"Time to Failure (TTF)\"\\n20859,1,1,\"Time To First Disease Progression\"\\n20860,1,1,\"Time to First Incidence of Adverse Events of Special Interest\"\\n20861,1,1,\"Time to First Occurrence of Cmax (Tmax) on Cycle 1 Day 1\"\\n20862,1,1,\"Time to First Occurrence of Cmax (Tmax) on Cycle 1 Day 28\"\\n20863,1,1,\"Time to First RBC Transfusions\"\\n20864,1,1,\"Time to First-Line Sunitinib Treatment Discontinuation\"\\n20865,1,1,\"Time to Improvement in the 7-point ordinal scale\"\\n20866,1,1,\"Time to Initiation of Subsequent Prostate Cancer Treatment\"\\n20867,1,1,\"Time to intracranial progression (Phase II)\"\\n20868,1,1,\"Time to Intrahepatic Progression\"\\n20869,1,1,\"Time to Last Measurable Concentration (t[Last]) for AZD2014 in Plasma and Saliva\"\\n20870,1,1,\"Time to Local Failure Relative to Multi-Fraction Radiosurgery in Patients with Previously Irradiated Spinal Metastases\"\\n20871,1,1,\"Time to local progression - TTLP\"\\n20872,4,1,\"Time to Local Recurrence\"\\n20873,1,1,\"Time to local recurrence per treated nodule\"\\n20874,1,1,\"Time to Maximum Concentration (T Max)\"\\n20875,7,1,\"Time to maximum concentration (tmax)\"\\n20876,1,1,\"Time to Maximum Concentration (Tmax) for Rociletinib and Rociletinib Metabolites\"\\n20877,1,1,\"Time to Maximum Concentration (Tmax) of CC-223\"\\n20878,1,1,\"Time to Maximum Concentration (Tmax) of Golvatinib\"\\n20879,1,1,\"Time to Maximum Concentration (Tmax) of MK-2206 in Participants Receiving Multiple QOD Dosing\"\\n20880,1,1,\"Time to Maximum Concentration (Tmax) of Niraparib and M1 During PK Phase\"\\n20881,1,1,\"Time to Maximum Concentration of CC-115\"\\n20882,1,1,\"Time to maximum concentration of SIM1803-1A in plasma (Tmax)\"\\n20883,1,1,\"Time to maximum drug concentration in plasma (tmax)\"\\n20884,4,1,\"Time to maximum observed concentration (Tmax)\"\\n20885,1,1,\"Time to Maximum Observed Concentration (Tmax) for AZD2014 in Plasma and Saliva\"\\n20886,1,1,\"Time to maximum observed concentration of DCC-3014\"\\n20887,1,1,\"Time to maximum observed plasma concentration (Tmax) for Famitinib after Single dose\"\\n20888,1,1,\"Time to maximum observed plasma concentration (Tmax) for SHR116637 after Single dose\"\\n20889,1,1,\"Time to Maximum Observed Serum Concentration (Tmax) of ABBV-514\"\\n20890,1,1,\"Time to Maximum Plasma Concentration (Tmax) After a Single Dose of GDC-0449\"\\n20891,1,1,\"Time to maximum plasma concentration (tmax) of Ipatasertib\"\\n20892,1,1,\"Time to maximum plasma concentration (Tmax) of Pemigatinib as monotherapy\"\\n20893,1,1,\"Time to Maximum Plasma Concentration (Tmax) of Tilsotolimod\"\\n20894,1,1,\"Time to Maximum Plasma Concentration of Azacitidine (Tmax)\"\\n20895,1,1,\"Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine\"\\n20896,1,1,\"Time to Maximum Plasma Concentration of MK-2206 (Tmax)\"\\n20897,1,1,\"Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1\"\\n20898,1,1,\"Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2\"\\n20899,1,1,\"Time to Maximum Serum Concentration (Tmax) of ABBV-181 (Arm 3 Only)\"\\n20900,1,1,\"Time to Maximum Serum Concentration (Tmax) of ABBV-368\"\\n20901,1,1,\"time to morphologic progression in the brain as evidenced on MRI (RECIST criteria)\"\\n20902,3,1,\"Time to Neurocognitive Failure\"\\n20903,1,1,\"Time to neutrophil count recovery following myelosuppressive chemotherapy\"\\n20904,1,1,\"Time to Next Therapy\"\\n20905,2,1,\"Time to next treatment\"\\n20906,1,1,\"Time to occurrence of AKs in recently transplanted solid organ recipient\"\\n20907,1,1,\"Time to occurrence of NMSC in recently transplanted solid organ recipient\"\\n20908,1,1,\"Time to Onset of the First Episode of Congestive Heart Failure\"\\n20909,1,1,\"Time to peak concentration (Tmax)\"\\n20910,1,1,\"Time to peak concentration (Tmax) of FORE8394\"\\n20911,1,1,\"Time to peak concentration (Tmax) of PLX2853.\"\\n20912,1,1,\"Time to peak concentration (Tmax) of PLX51107.\"\\n20913,1,1,\"Time to peak concentration (Tmax) of PLX73086 [Part 1 of research study]\"\\n20914,1,1,\"Time to Peak Concentration (Tmax) of RO5185426 on Day 1 - Dose Escalation: Original Formulation\"\\n20915,1,1,\"Time to Peak Concentration (Tmax) of RO5185426 on Day 15 - Dose Escalation: Original Formulation\"\\n20916,1,1,\"Time to peak plasma drug concentration (Tmax)\"\\n20917,58,17,\"Time to Progression\"\\n20918,103,13,\"Time to progression\"\\n20919,1,1,\"Time to Progression (Progression-free Survival [PFS]), Defined From the Date of Randomization to the Date of Documented Progression or Death Per RECIST\"\\n20920,25,11,\"Time to Progression (TTP)\"\\n20921,21,2,\"Time to progression (TTP)\"\\n20922,1,1,\"Time to Progression (TTP) - Expert Evaluation Committee Assessment\"\\n20923,1,1,\"Time to Progression (TTP) - Independent Radiological Review (Primary Analysis)\"\\n20924,1,1,\"Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer\"\\n20925,2,2,\"Time to Progression (TTP) in Phase II\"\\n20926,1,1,\"Time to Progression (TTP) in Women With Hormone Responsive Advanced Breast Cancer Treated With Combination of Exemestane and Fulvestrant.\"\\n20927,1,1,\"Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria\"\\n20928,1,1,\"Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease\"\\n20929,3,2,\"Time to Progression (TTP).\"\\n20930,1,1,\"Time to Progression (TTP): Group 1 & Group 2 (Phase II Only)\"\\n20931,1,1,\"Time to progression according to RECIST version 1.1\"\\n20932,1,1,\"Time to progression and time to treatment failure\"\\n20933,1,1,\"Time to Progression as Evaluated by the Independent Review Committee (IRC)\"\\n20934,1,1,\"Time to Progression as Evaluated by the Investigator\"\\n20935,1,1,\"Time to progression based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n20936,1,1,\"Time to Progression from mCSPC to mCRPC in Participants with mCSPC\"\\n20937,1,1,\"Time to Progression of Brain Metastases\"\\n20938,1,1,\"Time to Progression of Disease or Death\"\\n20939,2,2,\"Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1\"\\n20940,1,1,\"Time To Progression(TTP)\"\\n20941,1,1,\"Time to Progression- Independent Review\"\\n20942,1,1,\"Time to Progression-Blinded Independent Central Review (BICR) Assessment\"\\n20943,1,1,\"Time to Progression-Free Survival (PFS)\"\\n20944,1,1,\"Time to Progression-free Survival (PFS)\"\\n20945,1,1,\"Time to progression: Prostate-specific antigen (PSA) evolution (Prostate-Specific Antigen Working Group Recommendations [PSAWGR criteria]).\"\\n20946,1,1,\"Time to progression: RECIST (Response Evaluation Criteria in Solid Tumors) criteria\"\\n20947,1,1,\"Time to Progressive Disease (TTPD) by Treatment Drug\"\\n20948,1,1,\"Time to Progressive Disease (TTPD) by Treatment Schedule\"\\n20949,1,1,\"Time to Prostate Specific Antigen (PSA) Progression\"\\n20950,1,1,\"Time to prostate specific antigen (PSA) progression\"\\n20951,1,1,\"Time to prostate specific antigen (PSA) progression (TTPP)\"\\n20952,3,1,\"Time to Prostate-specific Antigen (PSA) Progression\"\\n20953,1,1,\"Time to prostate-specific antigen (PSA) progression\"\\n20954,5,1,\"Time to PSA Progression\"\\n20955,1,1,\"Time to Radiographic Evidence of Disease Progression\"\\n20956,1,1,\"Time to radiological progression free survival (PFS) rate\"\\n20957,1,1,\"Time to Radiological Progression Free Survival [PFS]\"\\n20958,1,1,\"Time to Radiological Progression-Free Survival (PFS)\"\\n20959,1,1,\"Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study\"\\n20960,1,1,\"Time to reach Cmax (Tmax)(h)\"\\n20961,1,1,\"Time to Reach Cmax in Both Blood and Plasma\"\\n20962,1,1,\"Time to Reach Maximal Plasma Concentration (Tmax) in the Fasted and Fed States\"\\n20963,1,1,\"Time to reach maximum drug concentration (tmax)\"\\n20964,1,1,\"Time to Reach Maximum Observed Concentration (T Max)\"\\n20965,62,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax)\"\\n20966,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady-State for Both Total and Unbound GDC-0449\"\\n20967,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) For Dextromethorphan and Dextrorphan 3 Days Prior to PF-00299804 Dosing\"\\n20968,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) For Dextromethorphan and Dextrorphan on Cycle 2 Day 7\"\\n20969,1,1,\"Time to reach maximum observed plasma concentration (Tmax) for niraparib-Stages 1, 2 and 3 PK Phase\"\\n20970,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) for Sunitinib and Its Metabolite\"\\n20971,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Docetaxel in Cycle 1\"\\n20972,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Docetaxel in Cycle 4\"\\n20973,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of GDC-0575\"\\n20974,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of S,R-TLC388\"\\n20975,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of S,S-TLC388\"\\n20976,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of TLC-U1\"\\n20977,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of TLC-U2\"\\n20978,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Topotecan\"\\n20979,1,1,\"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Unlabeled Idasanutlin\"\\n20980,1,1,\"Time to Reach Maximum Observed Plasma Drug Concentration (Tmax)\"\\n20981,1,1,\"Time to Reach Maximum Observed Serum Concentration (Tmax) for Avelumab\"\\n20982,5,1,\"Time to Reach Maximum Plasma Concentration (Tmax)\"\\n20983,1,1,\"Time to Reach Maximum Plasma Concentration (Tmax) of Probe Parent Drugs and Their Metabolites on Day 1\"\\n20984,1,1,\"Time to Reach Maximum Plasma Concentration (Tmax) of Vemurafenib on Day 1\"\\n20985,1,1,\"Time to Reach Maximum Plasma Concentration (Tmax) of Vemurafenib on Day 15\"\\n20986,1,1,\"Time to Reach Maximum Plasma Concentration (Tmax) of Vemurafenib on Day 9\"\\n20987,1,1,\"Time to Reach Maximum Plasma Concentration (Tmax): Docetaxel PK Parameters\"\\n20988,1,1,\"Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters\"\\n20989,1,1,\"Time to Reach Maximum Plasma Concentration of Entinostat: T-Max\"\\n20990,1,1,\"Time to Reach Maximum Plasma Concentration of RO5212054\"\\n20991,1,1,\"Time to reach maximum plasma drug concentration (Tmax) of LUNA18 [Part A]\"\\n20992,1,1,\"Time to reach peak or maximum observed concentration following drug administration (tmax)\"\\n20993,1,1,\"Time to reach the maximum observed plasma concentration (Tmax) of encapsulated doxorubicin\"\\n20994,1,1,\"Time to Recovery From Grade 2 or 3 irAE (Phase II)\"\\n20995,1,1,\"Time to Resolution of Febrile Neutropenia\"\\n20996,1,1,\"Time to resolution of hypotension\"\\n20997,3,1,\"Time to Response\"\\n20998,5,1,\"Time to response\"\\n20999,3,2,\"Time To Response (TTR)\"\\n21000,3,1,\"Time to Response (TTR)\"\\n21001,1,1,\"Time to response (TTR) (Phase I dose expansion)\"\\n21002,1,1,\"Time to second outpatient or inpatient diagnosis of any cancer (excluding NMSC and any carcinoma in situ diagnosis)\"\\n21003,1,1,\"Time to Skeletal-Related Events\"\\n21004,1,1,\"Time to start of systemic therapy (TTST)\"\\n21005,1,1,\"Time to the First On-Study Skeletal-Related Event (Non-Inferiority)\"\\n21006,1,1,\"time to the first passage of flatus after surgery\"\\n21007,1,1,\"Time to Therapeutic Goal\"\\n21008,1,1,\"Time to Treatment Discontinuation (TTD) of First Line Immune-Oncologic Therapy\"\\n21009,1,1,\"Time to Treatment Discontinuation (TTD) of Second Line Sunitinib Therapy\"\\n21010,11,2,\"Time to Treatment Failure\"\\n21011,41,8,\"Time to treatment failure\"\\n21012,8,1,\"time to treatment failure\"\\n21013,1,1,\"Time to Treatment Failure (Defined as Progression of Disease [According to the Response Evaluation Criteria in Solid Tumors (RECIST) or World Health Organization (WHO) Criteria] or Unacceptable Toxicity Leading to Discontinuation of Treatment or Death).\"\\n21014,2,1,\"Time to Treatment Failure (TTF)\"\\n21015,13,1,\"Time to treatment failure (TTF)\"\\n21016,1,1,\"Time to Treatment Failure (TTF) (Main Overall Survival Analysis Cut-off Date, 08 April 2016)\"\\n21017,1,1,\"Time to Treatment Failure (TTF) After Initiation of Tyrosine Kinase Inhibitor Therapy\"\\n21018,1,1,\"Time to treatment failure (TTF) for fulvestrant plus abemaciclib with or without a 1-month run-in of fulvestrant\"\\n21019,1,1,\"Time to treatment failure (TTF) for the conventional oxaliplatin (CO) schedule in comparison with the intermittent oxaliplatin (IO) schedule\"\\n21020,1,1,\"Time to Treatment Failure (TTF), by Gene Signature\"\\n21021,1,1,\"Time to treatment failure in the brain (TTF) as determined by the radiological response rate\"\\n21022,1,1,\"Time to Treatment Initiation\"\\n21023,1,1,\"Time to Treatment Progression\"\\n21024,7,3,\"Time to Tumor Progression\"\\n21025,4,2,\"Time to Tumor Progression (TTP)\"\\n21026,1,1,\"Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase\"\\n21027,1,1,\"Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study\"\\n21028,1,1,\"Time to Tumor Progression (TTP) Assessed Using Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Factors Model\"\\n21029,1,1,\"Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).\"\\n21030,1,1,\"Time to Tumor Progression (TTP) of Targeted Lesions\"\\n21031,1,1,\"Time to tumor recurrence (relapse)\"\\n21032,2,1,\"Time to tumour progression\"\\n21033,1,1,\"Time until adverse liver outcome, assessed by incidence of adverse liver outcome\"\\n21034,1,1,\"Time until any treatment related toxicity\"\\n21035,1,1,\"Time until any treatment-related toxicity\"\\n21036,1,1,\"Time until any treatment-related toxicity, as assessed by the NCI CTCAE version 4.0\"\\n21037,1,1,\"Time until any treatment-related toxicity, time until treatment-related grade 3+ toxicity, and time until hematologic nadirs (WBC, ANC, platelets)\"\\n21038,1,1,\"Time until decrease in quality of life by 5-points between groups\"\\n21039,1,1,\"Time until hematologic nadir for ANC\"\\n21040,1,1,\"Time until hematologic nadir for platelets\"\\n21041,1,1,\"Time until hematologic nadir for WBC\"\\n21042,1,1,\"Time until hematologic nadirs\"\\n21043,1,1,\"Time until hematologic nadirs (ANC, platelets, hemoglobin) , as assessed by the NCI CTCAE version 4.0\"\\n21044,1,1,\"Time until hematologic nadirs (WBC, ANC, platelets)\"\\n21045,1,1,\"Time until treatment related grade 3+ toxicity\"\\n21046,1,1,\"Time until treatment-related grade 3+ toxicity\"\\n21047,1,1,\"Time until treatment-related grade 3+ toxicity, as assessed by the NCI CTCAE version 4.0\"\\n21048,1,1,\"Time-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)\"\\n21049,1,1,\"Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia\\'s Correction Fomulation (QTcF)\"\\n21050,1,1,\"Time-to progression-free survival (PFS)\"\\n21051,1,1,\"Time-to-Event Outcome Measure\"\\n21052,2,1,\"Time-to-Progression (TTP)\"\\n21053,3,1,\"Time-to-progression (TTP)\"\\n21054,1,1,\"Time-to-progression ratio (TTP)\"\\n21055,1,1,\"Time-to-treatment discontinuation (TTD) from treatment initiation until discontinuation of capmatinib line of therapy or death, whichever was earlier\"\\n21056,1,1,\"Time-to-Treatment Failure (Intent-To-Treat Analysis)\"\\n21057,1,1,\"Timing and intensity of oral pain\"\\n21058,1,1,\"Tissue Acquisition\"\\n21059,1,1,\"Tissue acquisition rate of EUS FNA\"\\n21060,1,1,\"Tissue adequacy rate will be measured by assessing for the presence of histological core tissue representative of the lesion in the samples obtained using the two needles\"\\n21061,1,1,\"tissue analysis\"\\n21062,1,1,\"Tissue and cell repository for Wake Forest University Comprehensive Cancer Center investigators\"\\n21063,1,1,\"Tissue Biopsy Specimen vs Tumor Explant Model Prediction\"\\n21064,1,1,\"Tissue to Background Ratio\"\\n21065,1,1,\"tissue yield\"\\n21066,1,1,\"Titer of neutralization antibody\"\\n21067,1,1,\"Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)\"\\n21068,1,1,\"TKI258 pharmacokinetics (PK) parameters: AUC 0-24 hr (Area Under the Curve)\"\\n21069,1,1,\"TKI258 pharmacokinetics (PK) parameters: AUC 0-72 hr\"\\n21070,1,1,\"TKI258 pharmacokinetics (PK) parameters: CL/F (Apparent Oral Clearance)\"\\n21071,1,1,\"TKI258 pharmacokinetics (PK) parameters: Cmax (Maximum (peak) concentration of drug)\"\\n21072,1,1,\"TKI258 pharmacokinetics (PK) parameters: T1/2 (Half-life time)\"\\n21073,1,1,\"TKI258 pharmacokinetics (PK) parameters: Tmax (Time to maximum concentration)\"\\n21074,1,1,\"TKI258 pharmacokinetics (PK) parameters: Vz/F (apparent volume of distribution)\"\\n21075,1,1,\"Tlag Following Single Dose of Drug\"\\n21076,176,7,\"Tmax\"\\n21077,25,1,\"tmax\"\\n21078,1,1,\"Tmax (PK)\"\\n21079,1,1,\"Tmax (time to maximum plasma concentration)\"\\n21080,1,1,\"Tmax (time to reach maximum drug concentration in blood) of FTD and TPI\"\\n21081,1,1,\"tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me\"\\n21082,1,1,\"Tmax After Multiple Doses of GDC-0449\"\\n21083,1,1,\"Tmax Following Steady State Exposure for 14 Days\"\\n21084,1,1,\"Tmax for [14C] Radioactivity in Whole Blood and Saliva\"\\n21085,1,1,\"Tmax of [13C]-Labeled Idasanutlin\"\\n21086,1,1,\"Tmax of ABBV-321\"\\n21087,1,1,\"Tmax of Cobimetinib on Day 14 (Steady State), Cycle 1\"\\n21088,1,1,\"Tmax of digoxin and rosuvastatin\"\\n21089,1,1,\"Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose\"\\n21090,1,1,\"Tmax of Idasanutlin Metabolite\"\\n21091,1,1,\"Tmax of midazolam and caffeine\"\\n21092,1,1,\"Tmax of MK-2206 in Participants Receiving Multiple QW Dosing\"\\n21093,1,1,\"Tmax of N-desmethyl Selumetinib After Single Dose\"\\n21094,1,1,\"Tmax of N-desmethyl Selumetinib During Oral Twice Daily Dose of Selumetinib\"\\n21095,1,1,\"Tmax of Olaparib\"\\n21096,1,1,\"Tmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3\"\\n21097,1,1,\"Tmax of Probe Parent Drugs and Their Metabolites on Day 20\"\\n21098,1,1,\"Tmax of RO5185426 Following Day 21 Dose\"\\n21099,1,1,\"Tmax of RO5185426 on Day 1 - Dose Escalation: MBP Formulation\"\\n21100,1,1,\"Tmax of RO5185426 on Day 1 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- CRC\"\\n21101,1,1,\"Tmax of RO5185426 on Day 15 - Dose Escalation: MBP Formulation\"\\n21102,1,1,\"Tmax of RO5185426 on Day 15 - Extension: BRAFV600E- Positive Melanoma and BRAFV600E- CRC\"\\n21103,1,1,\"Tmax of Selumetinib After Single Dose\"\\n21104,1,1,\"Tmax of Selumetinib During Oral Twice Daily Dose of Selumetinib\"\\n21105,1,1,\"Tmax of Vemurafenib\"\\n21106,1,1,\"Tmax of Vemurafenib on Day -1, Cycle 1 in Participants Previously Treated With Vemurafenib Prior to Enrollment Into This Study\"\\n21107,1,1,\"Tmax of Vemurafenib on Day 1, Cycle 1 in BRAFi-na√Øve Participants\"\\n21108,1,1,\"Tmax of Vemurafenib on Day 14, Cycle 1\"\\n21109,1,1,\"Tmax\\'Following Single Dose of Drug\"\\n21110,1,1,\"Tmax(Peak Time)\"\\n21111,1,1,\"Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib\"\\n21112,1,1,\"Tmax: the time of Cmax;\"\\n21113,1,1,\"Tmax: Time of First Occurrence of Cmax for Alisertib and Drug-Related Material in Plasma Following a Single Dose of [^14C]-Alisertib Oral Solution\"\\n21114,1,1,\"Tmax: Time to First Occurrence of Cmax for Alisertib\"\\n21115,1,1,\"Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort\"\\n21116,1,1,\"Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort\"\\n21117,1,1,\"Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort\"\\n21118,1,1,\"Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-659\"\\n21119,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort\"\\n21120,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole\"\\n21121,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin\"\\n21122,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Eribulin Mesylate\"\\n21123,3,2,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib\"\\n21124,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 1\"\\n21125,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 15\"\\n21126,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659\"\\n21127,1,1,\"Tmax: Time to Reach the Maximum Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted Conditions Approximately 24 Hours After Paclitaxel Infusion\"\\n21128,1,1,\"Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for AMG 386 After Week 1 Dose\"\\n21129,1,1,\"Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for AMG 386 After Week 4 Dose\"\\n21130,1,1,\"TmaxÔºöobserved time to reach Cmax\"\\n21131,1,1,\"TNS - Total Neuropathy Score\"\\n21132,1,1,\"To adaptively adjust the estimate of the MTD of TAK-901 from the escalation phase in an expansion cohort of subjects.\"\\n21133,1,1,\"To analyzed the pain relief in visual analogue scalewith the scale endpoints from 0 to 10 of two different radiotherapeutic regimens.\"\\n21134,1,1,\"To assess cumulative toxicity signals and safety profile (Number and severity of adverse events) following repeated dosing and determine the recommended phase 2 dose (RP2D)\"\\n21135,1,1,\"To assess for evidence of anti-tumor activity with this combination, per tumor measurements\"\\n21136,2,1,\"To assess number of participants with adverse events as a measure of safety and tolerability during dose escalating\"\\n21137,1,1,\"To assess Objective Response Rate in subjects treated with GTx024\"\\n21138,1,1,\"To assess progression-free survival (PFS at 12 months, RECIST v. 1.1) with Durvalumab+ Cisplatin/Carboplatin+Etoposide in patients with advanced treatment-naive LCNEC\"\\n21139,1,1,\"To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.\"\\n21140,1,1,\"To assess progression-free survival under treatment with imatinib mesylate in patients with relapsing/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT.\"\\n21141,1,1,\"To assess safety and tolerability and to identify a dose for BMS-690514 in combination with paclitaxel/carboplatin for Phase II evaluation\"\\n21142,1,1,\"To assess safety and tolerability during and for 1 hour following a 15 mg/kg dose of CP 675,206 administered as a one hour infusion.\"\\n21143,1,1,\"To assess safety and tolerability of oral DCA\"\\n21144,1,1,\"To assess safety and tolerability of SUPLEXA in subjects with malignant solid tumour and haematologic malignancies.\"\\n21145,1,1,\"To assess safety of the CA4P-paclitaxel-carboplatin combination in advanced imageable malignancies\"\\n21146,1,1,\"To assess the accuracy (bias) of the Affinity prototype device against laboratory testing (capillary vs. venous sample)\"\\n21147,1,1,\"To assess the anti-tumor activity of GEN-001, when administered as combined with avelumab\"\\n21148,1,1,\"To assess the change in tumor blood flow by use of MRI in advanced imageable malignancies\"\\n21149,1,1,\"To assess the detection rate of patients with an EGFR actionable alteration when using the combination of two diagnostic procedures which include liquid biopsy analysis (by droplet digital PCR or allele specific PCR) and tissue analysis\"\\n21150,1,1,\"To assess the dose limiting toxicities (DLTs) of BIND-014 when on day 1 of a 21-day cycle or when given on day 1, 8 and 15 of a 28-day cycle.\"\\n21151,1,1,\"To assess the dose limiting toxicities (DLTs) of SF1126 and the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose.\"\\n21152,1,1,\"To assess the effect of hepatic impairment on the pharmacokinetics of patupilone and its metabolite\"\\n21153,1,1,\"To assess the effect of SAR566658 at the recommended dose on CYP3A enzyme activity using midazolam as probe\"\\n21154,1,1,\"To assess the effect of various degrees of impairment in hepatic function as measured by the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) criteria, on the pharmacokinetics of panobinostat.\"\\n21155,1,1,\"To assess the effect of varying degrees of renal function as defined by creatinine clearance), on the pharmacokinetics of panobinostat.\"\\n21156,1,1,\"To assess the efficacy of olaparib single agent in non-BRCA MBC patients whose tumours exhibit an homologous recombination deficiency (HRD) signature, as determined by Clinical Benefit Rate (CBR) using RECIST 1.1 criteria\"\\n21157,1,1,\"To assess the efficacy of SBRT in inducing a regressive genetic trajectory of KRAS gene (evaluated by NGS technique) after SBRT treatment.\"\\n21158,1,1,\"To assess the efficacy of the treatment in terms of the Progression Free Survival (PFS) at 12 months\"\\n21159,1,1,\"To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC by observing the Disease Control Rate (DCR) in telomerase-positive subjects.\"\\n21160,1,1,\"To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC by observing the Overall Response Rate (ORR) in telomerase-positive subjucts.\"\\n21161,1,1,\"To assess the feasibility in improving tumor oxygenation\"\\n21162,1,1,\"To assess the feasibility of performing PET-CT for the evaluation of pulmonary nodules in children with solid malignancies and to obtain preliminary data for sample size determination for a larger, multi-institutional prospective study.\"\\n21163,1,1,\"To assess the feasibility of Revlimid as salvage treatment in PTCL\"\\n21164,1,1,\"To assess the immune response to neoantigen synthetic long peptide vaccines as measured by percent of patients with ELISPOT positive response\"\\n21165,1,1,\"To assess the improvement of disease-free survival rate by adjuvant therapy with pembrolizumab for solid or micropapillary adenocarcinoma with pathologic stage I and tumor size no more than 4 cm.\"\\n21166,1,1,\"To assess the incidence of adverse events of CFI-402257 as a single agent and at the recommended phase 2 dose (RP2D)\"\\n21167,1,1,\"To assess the incidence of adverse events of CFI-402257 in combination with fulvestrant and at the recommended phase 2 dose (RP2D)\"\\n21168,1,1,\"To assess the incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D).\"\\n21169,1,1,\"To assess the incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D.\"\\n21170,1,1,\"To assess the incidence of thrombosis.\"\\n21171,1,1,\"To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells\"\\n21172,1,1,\"To assess the maximum tolerated dose of weekly taxotere, cisplatin and CPT-11 in patients with incurable solid tumor malignancies.\"\\n21173,1,1,\"To Assess the Number of Patients Who Experienced Adverse Events for Phase IB.\"\\n21174,1,1,\"To assess the pharmacokinetic/pharmacodynamic/preliminary clinical activity relationship following XL281 administration in different tumor types from subjects treated at the MTD\"\\n21175,1,1,\"To assess the pharmacokinetics of PU-H71 in patients with advanced malignancies.\"\\n21176,1,1,\"To assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies\"\\n21177,1,1,\"To assess the pharmacokinetics of single dose of cediranib 20mg or 30 mg by assessment of area under the curve over the time (AUC) and maximum concentration in Chinese patients with advanced solid malignant tumours\"\\n21178,1,1,\"To assess the pharmacokinetics of the solid dose form of AZD6244\"\\n21179,1,1,\"To assess the plasma pharmacokinetics (PK) of MGCD0103 (and/or its metabolites) and IV docetaxel administered in combination.\"\\n21180,1,1,\"To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.\"\\n21181,1,1,\"To assess the prognostic impact of ctDNA (mortality) in digestive and gynecological / breast cancers.\"\\n21182,1,1,\"To assess the rate of response/control of cerebral metastases from solid tumors to extended low dose, continuous oral temozolomide\"\\n21183,1,1,\"To assess the relationship between changes in 18FML10 uptake in the target lesions (PET/CT) obtained before and after radiotherapy (SRS), and changes of the lesions size (MRI, ~8w after SRS) in response to treatment, according to the WHO criteria\"\\n21184,1,1,\"To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n21185,1,1,\"To assess the role of serum biomarkers in patients with LM.\"\\n21186,1,1,\"To assess the safety and dose-limiting toxicity of HGS1029 administered weekly X 3, repeated every 4 weeks\"\\n21187,1,1,\"To assess the safety and tolerability of AMG 780 in subjects with advanced solid malignancies (including adverse event rate, incidence of dose-limiting toxicities, and determination of maximum tolerated dose)\"\\n21188,1,1,\"To assess the safety and tolerability of AZD7762 alone and in combination with Gemcitabine\"\\n21189,1,1,\"To assess the safety and tolerability of CAN04 in combination with selected standard hemotherapy regimens and to establish MTD and/or RP2D.\"\\n21190,1,1,\"To assess the safety and tolerability of daily oral RAD001, administered in combination with CP-751,871 given as an intravenous infusion in patients with advanced sarcomas and other advanced solid tumors that are incurable with any current modality.\"\\n21191,1,1,\"To assess the safety and tolerability of FB849 and to identify maximum tolerated dose (MTD)/ recommended Phase II dose (RP2D) and dosing schedule of FB849 in subjects with advanced solid tumors\"\\n21192,1,1,\"To assess the safety and tolerability of intravenously (IV) administered 2B3-101 in combination with trastuzumab, in patients with HER2+ breast cancer with brain metastases\"\\n21193,1,1,\"To assess the safety and tolerability of intravenously infused CCI-001 in patients with recurrent and/or metastatic solid tumours by determining the dose-limiting toxicity (DLT) of the compound.\"\\n21194,1,1,\"To assess the safety and tolerability of multiple ascending doses of BMS-663513 when given in combination with paclitaxel and carboplatin to subjects with advanced malignancies\"\\n21195,1,1,\"To assess the safety and tolerability of multiple doses of TAB006 in combination with toripalimab.\"\\n21196,1,1,\"To assess the safety and tolerability of SB939, administered orally every other day 3 times a week for 3 consecutive weeks, repeated every 4 weeks, either alone (Arms A and B), or in combination with azacitidine therapy in (Arm C).\"\\n21197,1,1,\"To assess the safety and tolerability of SNS-314\"\\n21198,1,1,\"To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD).\"\\n21199,1,1,\"To assess the safety and tolerability of XL228 administered as a once-weekly or twice-weekly 1-hour intravenous (IV) infusion in subjects with advanced malignancies.\"\\n21200,1,1,\"To assess the safety and toxicity of FUSA administered alone or in combination with PD-1 antibody blockade.\"\\n21201,1,1,\"To assess the safety of Panzem NCD administered orally in combination with intravenous infusion of bevacizumab by evaluation of the frequency and severity of treatment emergent adverse events\"\\n21202,1,1,\"To assess the safety of PU-H71 in patients with advanced malignancies.\"\\n21203,1,1,\"To assess the safety of rhEndostatin protein in pediatric patients with recurrent or progressive cancer that is measurable and that is refractory to standard therapies.\"\\n21204,1,1,\"To assess the safety profile\"\\n21205,1,1,\"To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib or gemcitabine in subjects with advanced solid tumors\"\\n21206,1,1,\"To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).\"\\n21207,1,1,\"To assess the steady-state PK parameters of cediranib in the presence and absence of ketoconazole.\"\\n21208,1,1,\"To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin\"\\n21209,1,1,\"To assess the tolerability of PU-H71 in patients with advanced malignancies.\"\\n21210,1,1,\"To assess the utility of baseline advanced MRI & changes between baseline & follow up advanced MRI in predicting high risk areas that are likely to develop progressive glioma despite chemoradiotherapy.\"\\n21211,1,1,\"To assess the value of the initial measurement of reticulocyte haemoglobin content (RET-He) in predicting response to martial therapy\"\\n21212,1,1,\"To assess the Vulnerable Elders Survey score (VES-13)\"\\n21213,1,1,\"To assess whether food influences the rate and extent of AZD6244 absorption\"\\n21214,1,1,\"To assess whether the safety of a 23-week treatment with MaaT013, combined with ipilimumab+nivolumab, is different from that of ipilimumab+nivolumab+placebo in patients with melanoma na√Øve to Ipilimumab and anti-PD1\"\\n21215,1,1,\"To Characterize Dose-limiting Toxicities (DLTs) Associated With the Combination of MM-121 With Anticancer Therapies\"\\n21216,1,1,\"To characterize patient mobility over time.\"\\n21217,1,1,\"To characterize pharmacokinetic (PK) profile\"\\n21218,1,1,\"To characterize PKs.\"\\n21219,1,1,\"To characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours, assessed by blood, urine and faecal sampling\"\\n21220,1,1,\"To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies\"\\n21221,1,1,\"To characterize the pharmacokinetic profile of patupilone including any potential metabolite(s) in blood/plasma as well as the total radioactivity in blood and plasma.\"\\n21222,1,1,\"To characterize the pharmacokinetics of amrubicin and amrubicinol (metabolite) in plasma, whole blood, and urine in patients given amrubicin as 5 minute IV infusions at 40 mg/m2 for 3 consecutive days; data will be obtained from blood & urine samples\"\\n21223,1,1,\"To characterize the pharmacokinetics of Bardoxolone methyl in this patient population.\"\\n21224,1,1,\"To characterize the safety and tolerability of elesclomol sodium administered once weekly to subjects with solid tumors\"\\n21225,1,1,\"To characterize the safety and tolerability of intravenously administered 2B3-101 in patients with advanced solid tumors and metastatic brain cancer or recurrent malignant glioma.\"\\n21226,1,1,\"To characterize the safety and tolerability of intravenously administered ANG1005 in patients with advanced solid tumors and metastatic brain cancer.\"\\n21227,1,1,\"To characterize the safety and tolerability of LB1908 and determine the optimal dose or recommended dose for expansion (RDE)\"\\n21228,1,1,\"To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE)\"\\n21229,1,1,\"To characterize the safety and tolerability of LBH589, including acute and chronic toxicities in Japanese patients with advanced solid tumors.\"\\n21230,1,1,\"To characterize the safety of GSK2126458 and GSK1120212 dosed orally in combination through adverse event assessment and changes in safety assessments including laboratory parameters, vital signs, and ECG parameters.\"\\n21231,1,1,\"To characterize the safety, tolerability, and pharmacokinetics (PK) of AB0024 after multiple intravenous (IV) administrations in patients with advanced solid tumors.\"\\n21232,1,1,\"To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors and hematologic malignancies\"\\n21233,1,1,\"To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors.\"\\n21234,1,1,\"To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer\"\\n21235,1,1,\"To Collect Information on Hepatic Function and Hepatitis Viral Activity in Cirrhosis and Upon Potential Alterations in the Setting of VEGF-inhibition\"\\n21236,1,1,\"To collect physician reported outcomes after the first chemotherapy utilized following the receipt of a final report from ChemoFx¬Æ in solid tumor malignancies for the generation of hypotheses for further sub-study.\"\\n21237,1,1,\"To collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients with HCC.\"\\n21238,1,1,\"To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide¬Æ ISA 51 VG with regard to immunological efficacy\"\\n21239,1,1,\"To compare in a randomized fashion the effect of zoledronate and pamidronate 90 mg on pain relief as assessed by pain score after 1-dose treatment in patients with bone pain induced by any solid tumors with bone metastases or Multiple Myeloma\"\\n21240,1,1,\"To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC\"\\n21241,1,1,\"To compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on.\"\\n21242,1,1,\"To compare the effectiveness of KRN321(darbepoetin alfa) on the proportion of subjects achieving hemoglobin response\"\\n21243,1,1,\"To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms.\"\\n21244,1,1,\"To Compare the proportion of patients without evidence of disease progression at 30 weeks following randomization between IT-101 at 12 mg/m2/dose or 15 mg/m2/dose to a placebo infusion treatment administered every other week.\"\\n21245,1,1,\"To compare volumetric response achieved using semi-automated computer techniques with the uni-dimensional (RECIST) and bi-dimensional (WHO) criteria as part of clinical trials running at MSKCC, testing new agents for different types of solid tumors.\"\\n21246,1,1,\"To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)\"\\n21247,1,1,\"To confirm if ketoconazole inhibition of CYP3A activity affects fractional excretion of docetaxel in the urine.\"\\n21248,1,1,\"To confirm the maximum tolerated dose (MTD) for APR-246 in combination with pembrolizumab\"\\n21249,1,1,\"To correlate drug sensitivity profiles of the expanded circulating tumor cells with the clinical treatment response.\"\\n21250,1,1,\"to correlate patient\\'s symptoms with outcome\"\\n21251,1,1,\"To correlate patients\\' immune profile to disease severity and patient\\'s outcome\"\\n21252,1,1,\"To create an immune profile for each COVID19-positive patient during their ICU stay\"\\n21253,1,1,\"To define a feasible treatment schedule for the combination therapy with sorafenib and everolimus\"\\n21254,1,1,\"To define a recommended phase II dose for the combination of CNTO 95 plus bevacizumab in subjects with advanced solid tumors.\"\\n21255,1,1,\"To define a tolerable dose of oral CLA, given on a daily schedule, that maximally inhibits S14 expression in adipocytes of patients with advanced solid tumors.\"\\n21256,1,1,\"To define and confirm recommended Phase 2 dose\"\\n21257,1,1,\"To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various non-prostate malignancies\"\\n21258,1,1,\"To define specific patterns of metabolises using long-echo time multislice proton nuclear magnetic resonance spectroscopic imaging in pediatric patients with brain tumors.\"\\n21259,1,1,\"To define the dose limiting and other toxicities of the combination therapy\"\\n21260,1,1,\"To define the maximal tolerated dose (if any) and the recommended phase II dose for the triplet combination of everolimus plus LBH589 plus bevacizumab in subjects with advanced solid tumors\"\\n21261,1,1,\"To define the maximal tolerated dose (MTD) and/or recommended phase II dose (RPTD) for the doublet AMG 479 in combination with everolimus in subjects with advanced solid tumors.\"\\n21262,1,1,\"To define the maximal tolerated dose (MTD) and/or recommended phase II dose (RPTD) for the triplet AMG 479 in combination with everolimus and panitumumab in subjects with advanced solid tumors.\"\\n21263,2,2,\"To define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.\"\\n21264,1,1,\"To define the maximum tolerated dose (MTD) of KRN-951 when administered orally for 21 days followed by a 7-day rest period.\"\\n21265,1,1,\"To define the Maximum Tolerated Dose (MTD) which will then be used to inform and determine the Recommended Phase 2 Dose (RP2D) and schedule alone or in combination with talazoparib or gemcitabine\"\\n21266,1,1,\"To define the maximum tolerated dose and dose-limiting toxicities of temsirolimus in combination with erlotinib in patients with resistant solid malignancies.\"\\n21267,1,1,\"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.\"\\n21268,1,1,\"To define the maximum tolerated doses (MTD) of TAK-659 and paclitaxel\"\\n21269,1,1,\"to define the MTD of OVV-01\"\\n21270,1,1,\"To define the MTD of RP-6306 in combination with RP-3500, and determine a recommended Phase 2 dose (RP2D) and preferred schedule\"\\n21271,1,1,\"To define the MTD of RP-6306 monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule\"\\n21272,1,1,\"To define the recommended phase II dose and regimen\"\\n21273,1,1,\"To define the toxicities of oral pazopanib tablet or suspension.\"\\n21274,1,1,\"To define toxicities and characterize pharmacokinetics.\"\\n21275,1,1,\"To demonstrate that WBRT concomitant to DepoCyte is as safe as WBRT & sequential DepoCyte in treating solid tumour neoplastic meningitis with/without brain metastasis.\"\\n21276,1,1,\"To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma\"\\n21277,1,1,\"To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.\"\\n21278,1,1,\"To describe dose limiting toxicities (DLT) of PRT543\"\\n21279,1,1,\"To describe dose limiting toxicities (DLT) of PRT811\"\\n21280,1,1,\"To describe the dose limiting toxicities as a measure of the adverse event profile\"\\n21281,1,1,\"To describe the dose limiting toxicities, adverse event profile, and Phase II recommended dose of Camptothecin-20-O-Propionate hydrate (CZ48).\"\\n21282,1,1,\"To detect circulating tumor DNA (ctDNA) in serial blood samples from patients with pediatric non-CNS solid tumors using low pass whole genome sequencing.\"\\n21283,1,1,\"To determination the maximal tolerance dose and dose-limiting toxicity of Mitoxantrone Hydrochloride Liposome\"\\n21284,1,1,\"To Determind the Maximum Tolerable Dose for Antroquinonol\"\\n21285,1,1,\"To determine a dose regimen and schedule of CTM-N2D at which no more than one patient out of up to six patients at the same dose level experience a CTM-N2D-related DLT\"\\n21286,1,1,\"To determine a maximally tolerated (or optimal) dose of vorinostat\"\\n21287,2,2,\"To determine a Recommended Phase 2 Dose (RP2D) during Dose Expansion\"\\n21288,1,1,\"To determine a safe dose of oral Satraplatin to be administered for 5 consecutive days every week in combination with a 30 minute infusion of Abraxane administered weekly for 3 weeks out of 4 weeks.\"\\n21289,1,1,\"To determine a safe dose recommended (SDR) for the routine application of oral vorinostat (involving dose escalation) in children and adolescents (3-18 years) with relapsed/refractory solid tumor, lymphoma or leukemia.\"\\n21290,1,1,\"To determine activity of PAC-1 and nivolumab\"\\n21291,1,1,\"To Determine and Compare the Frequency and Severity of Adverse Events as Assessed by CTCAE Version 3.0 for the Regimens Administered on This Study.\"\\n21292,1,1,\"To determine and establish the safety profile of everolimus and dovitinib and define the dose limiting toxicity (DLT)\"\\n21293,1,1,\"To determine DLT (Dose Limiting Toxicity) in subjects with advanced solid tumor\"\\n21294,1,1,\"To determine dose limited toxicity (DLT) of JK-1201I in patients with SCLC.\"\\n21295,1,1,\"To determine dose limiting toxicity, maximum tolerated dose and recommended Phase II dose of both capecitabine and 5-fluorouracil in this patient population.\"\\n21296,1,1,\"To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended Phase II dose (RP2D) of CN1 administered to patients with advanced solid tumor or B-cell lymphoma.\"\\n21297,1,1,\"To Determine Efficacy as Measured by Progression Free Survival (PFS) in Non-small Cell Lung Cancer Patients\"\\n21298,1,1,\"To determine efficacy in terms of response rate according to RECIST criteria\"\\n21299,1,1,\"To determine if 5000 IU of Fragmin administered daily when compared to placebo will reduce the incidence of clinically relevant CRCs in cancer patients receiving chemotherapy by CVC\"\\n21300,1,1,\"To determine if AMG 479 in combination with gemcitabine improves overall survival as compared with placebo in combination with gemcitabine in subjects with metastatic adenocarcinoma of the pancreas\"\\n21301,1,1,\"To determine if DFMO at 500 mg daily will be well tolerated and not affect organ transplant viability\"\\n21302,1,1,\"To determine if measuring plasma EBV DNA (half-life) early during chemotherapy can predict survival\"\\n21303,1,1,\"To determine if measuring tumor metabolic response during chemotherapy can predict survival\"\\n21304,1,1,\"To determine if ODSH is safe in pediatric patients\"\\n21305,1,1,\"To determine if the MTD is among the explored dose levels and identify the expansion phase dose\"\\n21306,1,1,\"To determine if there is clinical benefit to any of a set of 3 possible treatments for patients with mCRPC\"\\n21307,1,1,\"To determine maximally tolerated dose of SU011248 (dosed continuously or on a 2/1 Schedule) when given in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin.\"\\n21308,1,1,\"To determine maximum tolerable activity of 177Lu-DOTA\"\\n21309,1,1,\"To determine Maximum Tolerated Dose (MTD)and dose limiting toxicities (DLTs) of Terameprocol (EM-1421) administered as a weekly continuous infusion over 24 hours.\"\\n21310,1,1,\"To determine maximum tolerated dose and optimal immunological dose\"\\n21311,1,1,\"To determine MTD and DLT of Gemcitabine Oral formulation\"\\n21312,1,1,\"To determine MTD of E7107. Safety and tolerability.\"\\n21313,1,1,\"To determine MTD* or RP2D*\"\\n21314,1,1,\"To determine of the maximum tolerated dose (MTD), based upon first cycle APO010-related DLT in patients with solid tumors.\"\\n21315,1,1,\"To determine physicians\\' rate of compliance with ChemoFx assay results in the treatment of subjects with solid tumors.\"\\n21316,1,1,\"To Determine Recommended Phase II Regimen by Assessing the Number of DLTs at Each Dose Level\"\\n21317,1,1,\"To determine safety and the maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors\"\\n21318,1,1,\"To determine safety and tolerability of CVX-045 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors\"\\n21319,1,1,\"To determine safety following the administration of bi-shRNAfurin and GMCSF autologous tumor cell (Vigil‚Ñ¢) vaccine in advanced solid tumor patients who have no acceptable form of standard therapy with curative intent.\"\\n21320,1,1,\"To determine safety following the administration of TAG vaccine in advanced solid tumor patients who have no acceptable form of standard therapy.\"\\n21321,1,1,\"To determine safety, tolerability, and maximum tolerated dose of AP23573 when administered once daily for 5 days on a every 2 week schedule\"\\n21322,1,1,\"To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.\"\\n21323,1,1,\"To determine safety, toxicity and maxinum tolerable Dosage of M2ES injection in Safety and tolerability\"\\n21324,1,1,\"To determine serum predictors of response to immune checkpoint inhibitors 4-weeks after initiation of treatment\"\\n21325,1,1,\"To determine serum predictors of response to immune checkpoint inhibitors anytime between 6-12 weeks after initiating treatment.\"\\n21326,1,1,\"To determine serum predictors of response to immune checkpoint inhibitors at study entry, prior to checkpoint inhibitor therapy\"\\n21327,1,1,\"To determine the (MTD) and (DLTs) of ATI-1123 administered every 3 weeks, over a range of doses in patients with advanced solid tumors.\"\\n21328,1,1,\"To determine the anti-tumor activity (Best Overall Response) of NM21-1480 according to RECIST 1.1\"\\n21329,1,1,\"To determine the anti-tumor activity (Overall Response Rate) of NM21-1480 according to RECIST 1.1\"\\n21330,1,1,\"To determine the bioavailability of XL281 under fed and fasted conditions, and with or without the concomitant use of a single dose of famotidine in subjects with solid tumors\"\\n21331,1,1,\"To Determine the Biochemical Response of This Regimen in Patients With HRPC\"\\n21332,1,1,\"To determine the bioequivalence of new formulation (test) of oral topotecan relative to the current Phase III formulation (reference) of oral topotecan by comparing AUC in patients with advanced solid tumors.\"\\n21333,1,1,\"To determine the distribution and dosimetry of intravenously administered 131-I-TM-601\"\\n21334,1,1,\"To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors\"\\n21335,1,1,\"To determine the dose limiting toxicities (DLTs) of Tivantinib\"\\n21336,1,1,\"To determine the dose limiting toxicities (DLTs)and the maximum tolerated dose (MTD) of the combination of Lapatinib and Sorafenib.\"\\n21337,1,1,\"To determine the dose limiting toxicities and the maximum tolerated dose of AZD6244 in combination with cetuximab in advanced, refractory solid tumors.\"\\n21338,1,1,\"To determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose of CDDO when administered in adult patients with solid tumors and lymphomas.\"\\n21339,1,1,\"To determine the dose limiting toxicity (DLT)\"\\n21340,1,1,\"To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.\"\\n21341,1,1,\"To determine the dose limiting toxicity (DLT), safety\"\\n21342,1,1,\"To determine the dose limiting toxicity and safety of bi-weekly courses of rBBX-01 in patients with resistant solid tumor malignancies.\"\\n21343,1,1,\"To determine the dose recommended for future Phase 2 studies (RP2D) that maximally suppresses Th17 cell activities\"\\n21344,1,1,\"To determine the dose recommended for future Phase 2 studies (RP2D) with an absence of dose limiting toxicity (DLT) and without exceeding the maximum tolerable dose (MTD).\"\\n21345,1,1,\"To determine the dose(s) of T3011 to be examined in Phase 2a\"\\n21346,1,1,\"To determine the dose-limiting toxicity (DLT) and phase II dose\"\\n21347,1,1,\"To determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Bardoxolone methyl Capsules\"\\n21348,1,1,\"To determine the dosing that should be used in future safety and efficacy (Phase II) trials\"\\n21349,1,1,\"To determine the effect of ketoconazole on the pharmacokinetics of ABT- 263.\"\\n21350,1,1,\"To determine the effect of rifampin on the pharmacokinetics of navitoclax.\"\\n21351,1,1,\"To determine the effect on pharmacokinetics of BMS-540215, the active metabolite of brivanib alaninate, when administered following a high fat meal versus administration in a fasted state\"\\n21352,1,1,\"To Determine the Efficacy (Best Response) of BAY 43-9006 (Objective Response Rate and Stable Disease) in Patients With Metastatic Thyroid Carcinoma.\"\\n21353,1,1,\"To determine the efficacy of the RP2D identified in Part A\"\\n21354,1,1,\"To determine the feasibility and safety of administering DCVax-L intradermally combined with intravenous bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian or primary peritoneal cancer.\"\\n21355,1,1,\"To determine the feasibility and toxicity of tandem high dose chemotherapy and peripheral blood stem cells rescue in patients with high-risk or recurrent solid tumors.\"\\n21356,1,1,\"To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP\"\\n21357,1,1,\"To determine the incidence and nature of dose-limiting toxicities (DLTs) of TVB-2640.\"\\n21358,1,1,\"To determine the incidence and severity of other toxicities of temsirolimus in combination with erlotinib in patients with resistant solid malignancies.\"\\n21359,2,2,\"To determine the incidence and severity of other toxicities of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.\"\\n21360,1,1,\"To determine the incidence of dose limiting toxicities (DLTs) [Safety and Tolerability] of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC\"\\n21361,1,1,\"To determine the incidence of serious adverse events (SAEs) [Safety and Tolerability] of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC\"\\n21362,1,1,\"To determine the incidence of treatment emergent Adverse Events (Safety and Tolerability) of various doses of IOS-1002 administered alone and/or in combination with a PD-1 mAb in subjects with advanced solid tumors\"\\n21363,1,1,\"To determine the incidence of treatment-emergent adverse events (TEAEs) [Safety and Tolerability] of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC\"\\n21364,1,1,\"To determine the incidence of treatment-related toxicity and acute and chronic graft versus host disease.\"\\n21365,1,1,\"To determine the maximal tolerated dose (MTD) of capecitabine twice a day for two weeks followed by one week rest period (intermittent schedule) in patients with the advanced/ and or metastatic cancer based on TYMS genotype.\"\\n21366,1,1,\"To determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors.\"\\n21367,2,2,\"To determine the maximally tolerated dose (MTD)\"\\n21368,1,1,\"To determine the Maximally Tolerated Dose and/or Recommended Phase II Dose (RP2D) of nivolumab in combination with dabrafenib and/or trametinib in patients with BRAF- or NRAS-mutated metastatic melanoma\"\\n21369,1,1,\"To determine the maximally tolerated dose of SU011248 (dosed continuously or on a 4/2 or 2/1 Schedule) when given in combination with capecitabine.\"\\n21370,1,1,\"To determine the maximally tolerated dose of SU011248 (dosed on Schedule 4/2 or 2/1) when given in combination with gemcitabine\"\\n21371,1,1,\"To determine the maximum plasma level (Cmax) of PCLX-001\"\\n21372,1,1,\"To determine the Maximum Tolerable Dose\"\\n21373,1,1,\"To determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 injected within unresectable solid tumor(s) within the liver\"\\n21374,1,1,\"To determine the maximum tolerance dose level of JK-1201I in patients with SCLC.\"\\n21375,1,1,\"To determine the maximum tolerated (MTD) and recommended Phase II doses for AMG479 and RAD001 in patients with refractory solid tumors\"\\n21376,1,1,\"To Determine the Maximum Tolerated Dose\"\\n21377,11,8,\"To determine the maximum tolerated dose (MTD)\"\\n21378,1,1,\"To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of P1446A-05 in subjects with advanced refractory malignancies\"\\n21379,1,1,\"To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.\"\\n21380,1,1,\"To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of AS1411\"\\n21381,1,1,\"To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of TH-302 administered weekly x 3, repeated every 4 weeks in patients with advanced solid tumors\"\\n21382,1,1,\"To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of XL228 administered as a once- or twice-weekly 1-hour IV infusion in subjects with advanced malignancies.\"\\n21383,1,1,\"To determine the maximum tolerated dose (MTD) and recommended dose (RD) of the human L19IL2 fusion-cytokine.\"\\n21384,1,1,\"To determine the maximum tolerated dose (MTD) and recommended Phase 2 (monotherapy) dose of oral CUDC-427 administered on a 14 days on/7 days off dosing schedule in subjects with advanced and refractory solid tumors or lymphoma\"\\n21385,1,1,\"To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)\"\\n21386,1,1,\"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of a 3-hour intravenous (IV) infusion of RH-1 administered once every 21 days.\"\\n21387,1,1,\"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of B4T2-001 CAR T cells\"\\n21388,1,1,\"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.\"\\n21389,1,1,\"To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of EP-100\"\\n21390,1,1,\"To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine\"\\n21391,1,1,\"To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.\"\\n21392,1,1,\"To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of GSK1363089 administered orally (up to twelve different doses) to subjects with solid tumors\"\\n21393,1,1,\"To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of XL999 administered as a single 4-hour intravenous (IV) infusion in subjects with solid tumors\"\\n21394,1,1,\"To determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of daily oral administration of GSK1363089 in subjects with solid tumors\"\\n21395,1,1,\"To determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of daily oral dosing of DFP-11207 in patients with solid tumors\"\\n21396,1,1,\"To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for advanced/metastatic disease.\"\\n21397,1,1,\"To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of CS1001\"\\n21398,1,1,\"To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of BJ-005 following IV infusion in patients with advanced solid tumor or lymphoma.\"\\n21399,3,3,\"To determine the maximum tolerated dose (MTD) based on toxicity analysis.\"\\n21400,1,1,\"To determine the maximum tolerated dose (MTD) levels and recommended Phase 2 dose levels of Karenitecin when administered intravenously for 5 consecutive days with a fixed dose of Cytoxan¬Æ\"\\n21401,1,1,\"To determine the maximum tolerated dose (MTD) of ABTL0812, administered orally on a daily continuous schedule in adult patients with advanced solid tumours\"\\n21402,1,1,\"To determine the maximum tolerated dose (MTD) of AMG 208, if possible\"\\n21403,1,1,\"To determine the maximum tolerated dose (MTD) of E7080 for two different schedules incorporating dose interruptions.\"\\n21404,1,1,\"To determine the maximum tolerated dose (MTD) of EMD 1204831 in subjects with advanced solid tumors\"\\n21405,1,1,\"To determine the maximum tolerated dose (MTD) of everolimus and dovitinib given orally in patients with VEGF resistant renal cancer\"\\n21406,1,1,\"To determine the maximum tolerated dose (MTD) of i. v. pancalcitol given weekly, in combination with fixed dose rate infusion of i. v.gemcitabine given weekly in patients with advanced malignancies.\"\\n21407,1,1,\"To Determine the Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With a Fixed Dose of Pembrolizumab in Subjects With Relapsed and/or Refractory Solid Tumors.\"\\n21408,1,1,\"To determine the maximum tolerated dose (MTD) of liposomal doxorubicin (Doxil) administered every 4 weeks or every 2 weeks in combination with docetaxel (Taxotere) administered on a weekly schedule\"\\n21409,1,1,\"To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Cabazitaxel\"\\n21410,1,1,\"To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Carboplatin\"\\n21411,1,1,\"To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Gemcitabine\"\\n21412,1,1,\"To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: MM-121 Doses\"\\n21413,1,1,\"To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Pemetrexed\"\\n21414,1,1,\"To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous cyclophosphamide by assessing the occurrence of dose limiting toxicities\"\\n21415,1,1,\"To determine the maximum tolerated dose (MTD) of Oraxol in subjects with advanced malignancies\"\\n21416,1,1,\"To determine the maximum tolerated dose (MTD) of RAD001 given in combination with erlotinib (Phase I)\"\\n21417,1,1,\"To determine the maximum tolerated dose (MTD) of RAD001 in combination with BIBF 1120 (150mg bid or 200mg bid) (endpoint: dose-limiting toxicities)\"\\n21418,1,1,\"To determine the maximum tolerated dose (MTD) of vorinostat administered in combination with standard doses of vinorelbine.\"\\n21419,1,1,\"To determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.\"\\n21420,1,1,\"To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and select the recommended Phase 2 dose (RP2D).\"\\n21421,1,1,\"To determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD), and to characterize the dose-limiting toxicities (DLTs) of IK-175 as a single agent and in combination with nivolumab.\"\\n21422,1,1,\"To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), and safety profile of escalating doses of orally administered MGCD0103 in combination with two fixed doses (60 mg/m2 and 75 mg/m2) of IV docetaxel.\"\\n21423,2,2,\"To determine the maximum tolerated dose (MTD)-Part Ia\"\\n21424,1,1,\"To determine the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) and dose limiting toxicity (DLT) of oral clofarabine when administered once daily for 5 days every 28 days to adult patients with locally advanced or metastatic solid tumors\"\\n21425,1,1,\"To determine the Maximum tolerated dose (MTD)/Recommended Phase II dose (RP2D) of KD6001 in subjects with solid tumors\"\\n21426,1,1,\"To determine the maximum tolerated dose (MTD)in subjects with advanced solid tumor\"\\n21427,1,1,\"To determine the maximum tolerated dose and characterize dose limiting toxicities of BAL101553\"\\n21428,1,1,\"To determine the maximum tolerated dose and characterize the dose limiting toxicities of LEQ506\"\\n21429,1,1,\"To determine the maximum tolerated dose and Phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors.\"\\n21430,1,1,\"To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept\"\\n21431,1,1,\"To determine the maximum tolerated dose in Single dose\"\\n21432,1,1,\"To determine the maximum tolerated dose of AZD 2461 by collection of adverse events, hematology, clinical chemistry data and vital signs.\"\\n21433,1,1,\"To determine the Maximum Tolerated Dose of BMS-754807 based on the Dose Limited Toxicity which observed during the first 28 days\"\\n21434,1,1,\"To determine the maximum tolerated dose of CI-8993\"\\n21435,1,1,\"To determine the maximum tolerated dose of CXD101 administered twice daily for 5 consecutive days every 21 days\"\\n21436,1,1,\"To determine the maximum tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.\"\\n21437,1,1,\"To determine the maximum tolerated dose of expanded NK cells in research participants with relapsed or refractory hematologic malignancies and sarcomas.\"\\n21438,1,1,\"To determine the maximum tolerated dose of GSK690693 given weekly or twice weekly over 1 - 4 hours.\"\\n21439,1,1,\"To determine the maximum tolerated dose of KML001 in combination with cisplatin\"\\n21440,1,1,\"To determine the maximum tolerated dose of patupilone in patients with hepatic impairment\"\\n21441,1,1,\"to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU\"\\n21442,1,1,\"To determine the maximum tolerated dose of sirolimus when combined with a standard dose and schedule of Sutent(R)\"\\n21443,1,1,\"To determine the maximum tolerated dose of Temsirolimus and Vinorelbine\"\\n21444,1,1,\"To determine the maximum tolerated dose of VB6-845 and to evaluate the safety and tolerability of VB6-845 when administered as a monotherapy IV infusion\"\\n21445,1,1,\"To determine the maximum tolerated dose(MTD)\"\\n21446,1,1,\"To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.\"\\n21447,1,1,\"To determine the maximum tolerated dose, and dose limiting toxicity of capecitabine when given daily for 14 days with docetaxel given on day 8 of a 21 day cycle\"\\n21448,2,2,\"To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity and the recommended dose of Epofolate (BMS-753493)\"\\n21449,1,1,\"To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity of BMS-690514\"\\n21450,1,1,\"To determine the maximum tolerated doses and dose limiting toxicities of LBH589 in combination with gemcitabine when administered to patients with advanced incurable malignant solid tumors.\"\\n21451,1,1,\"To determine the maximum tolerated plasma AUC0-12h of high-dose, pulsatile sorafenib\"\\n21452,1,1,\"To determine the maximum-tolerated dose (MTD)\"\\n21453,1,1,\"To determine the maximum-tolerated dose of LBH589\"\\n21454,1,1,\"To determine the MTD and DLT(s) of TH-302 when used in combination with A) Gemcitabine or B) Docetaxel or C) Pemetrexed in patients with advanced solid tumors\"\\n21455,1,1,\"To determine the MTD and recommended Phase II dose of IMC-A12 (anti-IGFR monoclonal antibody) IV once weekly in combination with temsirolimus IV weekly to children with refractory solid tumors.\"\\n21456,1,1,\"To determine the MTD of ABT-888 with carboplatin and paclitaxel in these patients.\"\\n21457,1,1,\"To determine the MTD of allogenetic NK cells\"\\n21458,1,1,\"To determine the MTD of PX-478 administered orally on days one to five of a 21 day cycle\"\\n21459,1,1,\"To determine the MTD of SX-682 followed by M7824 and CV301 vaccines in participants with advanced or metastatic solid tumors.\"\\n21460,1,1,\"To determine the MTD/RD of single agent CTO in patients with advanced or metastatic solid tumors; or CTO in combination with Temodar¬Æ in patients with glioblastoma or other recurrent malignant gliomas\"\\n21461,1,1,\"To determine the MTD/Recommended Phase II Dose (RPTD) of gemcitabine plus dasatinib once daily and twice daily dosing in patients with advanced solid tumors\"\\n21462,1,1,\"To determine the MTD/recommended phase II regimen and evaluate safety of panitumumab added to RAD001 plus bevacizumab in adult patients with advanced solid tumors.\"\\n21463,1,1,\"To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors.\"\\n21464,1,1,\"To determine the number and type of treatment-related adverse events of the two drug combination as assessed by CTCAE v4.0\"\\n21465,1,1,\"To determine the number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumour\"\\n21466,1,1,\"To determine the Objective Response Rate (ORR) according to Evaluation Criteria (RECIST 1.1) in patients treated with metarrestin at the MTD\"\\n21467,1,1,\"To determine the objective response rate (ORR) to ABN401 according to RECIST 1.1\"\\n21468,1,1,\"To determine the objective tumor response rate in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer treated with irofulven/capecitabine combination therapy\"\\n21469,2,1,\"To determine the occurrence of treatment-emergent adverse events (TEAs)\"\\n21470,3,2,\"To determine the occurrence of treatment-related adverse events meeting the criteria for dose limiting toxicities (DLTs)\"\\n21471,1,1,\"To determine the optimal, safe GD2-SADA protein dose and dosing interval between GD2-SADA and 177Lu-DOTA administrations\"\\n21472,1,1,\"To determine the overall best response to CNA3103.\"\\n21473,1,1,\"To determine the overall response rate of FORE8394 treatment at the applicable RP2D in a) Group A, Cohort 1, and b) Group A, Cohort 2.\"\\n21474,1,1,\"To determine the overall survival of patients with locally advanced or metastatic carcinoid tumors administered oral Panzem NCD in combination with intravenous infusion of bevacizumab\"\\n21475,1,1,\"To determine the overall tumor response of orally administered MGCD0103 in combination with IV docetaxel according to Response Evaluation Criteria in Solid Tumors (RECIST) methodology.\"\\n21476,1,1,\"To determine the percent 100-day survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic stem cell transplantation (SCT).\"\\n21477,1,1,\"To determine the pharmacokinetic profile of linifanib in subjects with advanced or metastatic solid tumors.\"\\n21478,1,1,\"To determine the pharmacokinetics (PK) of erlotinib when administered in combination with sorafenib on a continuous schedule in Refractory Solid Tumors in patients who are smokers and in patients who are nonsmokers.\"\\n21479,1,1,\"To determine the pharmacokinetics and pharmacodynamics of ABT-888 in patients with varying degrees of renal or hepatic dysfunction.\"\\n21480,1,1,\"To determine the pharmacokinetics and pharmacodynamics of ABT-888 in patients with varying degrees of renal or hepatic dysfunction. To determine the MTD of ABT-888 with carboplatin and paclitaxel in these patients.\"\\n21481,1,1,\"To determine the pharmacokinetics and safety of cyclophosphamide when co-administered with 400 mg BID sorafenib and doxorubicin administered\"\\n21482,1,1,\"To Determine the Pharmacokinetics of AZD1775 in Patients With Refractory Solid Tumors.\"\\n21483,1,1,\"To determine the pharmacokinetics of elesclomol in this population when administered once weekly as a 1-hour intravenous infusion\"\\n21484,1,1,\"To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated With Everolimus as Second or Third Line Therapy.\"\\n21485,1,1,\"To determine the recommended dose of phase II\"\\n21486,1,1,\"To determine the recommended dose of the phase ‚Ö° trial of this cell therapy (RP2D)\"\\n21487,1,1,\"To determine the recommended infusion schedule for the investigational new drug administered as a continuous infusion, and to define the safety tolerance and dose limiting toxicities.\"\\n21488,1,1,\"To determine the recommended Phase 2 dose\"\\n21489,1,1,\"To determine the recommended phase 2 dose (RP2D) and schedule of PRT543\"\\n21490,1,1,\"To determine the recommended phase 2 dose (RP2D) and schedule of PRT811\"\\n21491,1,1,\"To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration\"\\n21492,1,1,\"To determine the recommended Phase 2 dose (RP2D) of BTX-1188 in subjects with advanced malignancies\"\\n21493,1,1,\"To determine the recommended phase 2 dose (RP2D) of PEGPH20. To evaluate the safety and tolerability of PEGPH20 in advanced cancer patients over a range of doses.\"\\n21494,1,1,\"To determine the recommended phase 2 dose (RP2D) of the combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.\"\\n21495,1,1,\"To determine the recommended Phase 2 dose and overall safety and tolerability of TRC102 when given alone and when combined with pemetrexed for the treatment of patients with advanced solid or metastatic cancer for whom curative therapy is unavailable.\"\\n21496,1,1,\"To determine the recommended Phase 2 dose for ABT-700\"\\n21497,1,1,\"To determine the recommended Phase II dose and schedule of GSK214179 using the following information: safety and tolerability, pharmacokinetic (single and repeat dose administration) and pharmacodynamic data\"\\n21498,1,1,\"To determine the recommended Phase II dose for the combination of ABT-510 plus bevacizumab\"\\n21499,1,1,\"To determine the recommended radiation dose and preliminarily evaluate the anti-tumor efficacy of CS1001 in combination with low-dose radiotherapy in subjects with limited or extensive stage SCLC who failed the firstline treatment\"\\n21500,1,1,\"To determine the RP2D of NUC-1031 administered as either an I.V. weekly or twice-weekly schedule in patients with advanced solid tumours.\"\\n21501,1,1,\"To determine the RP2D of SX-682 with M7824 and CV301 vaccines in participants with advanced or metastatic solid tumors.\"\\n21502,1,1,\"To determine the RPTD of rosuvastatin given orally daily x 3 weeks then 1 week off (28-day cycle) in combination with erlotinib given orally daily in patients with advanced solid tumors, especially squamous cell carcinomas and NSCLC.\"\\n21503,1,1,\"To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks.\"\\n21504,1,1,\"To determine the safety and the maximum tolerated dose (MTD) of IPI-926\"\\n21505,1,1,\"To determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib\"\\n21506,1,1,\"To determine the safety and tolerability of 40 mg/m2 amrubicin given as 5 minute IV infusions for 3 consecutive days; information will be collected by adverse event monitoring and laboratory safety tests.\"\\n21507,1,1,\"To determine the safety and tolerability of ascending doses of CDK-002\"\\n21508,1,1,\"To determine the safety and tolerability of AZD2281 in combination with Cisplatin (eg Adverse Events, Pharmacokinetic for AZD2281, overall response rate) to patients with advanced solid tumours.\"\\n21509,1,1,\"To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.\"\\n21510,1,1,\"To determine the safety and tolerability of IV administered 131-I-TM-601.\"\\n21511,1,1,\"To determine the safety and tolerability of OPB-51602\"\\n21512,1,1,\"To determine the safety and tolerability of oral CUDC-907 in subjects with advanced/relapsed solid tumors\"\\n21513,1,1,\"To determine the safety and tolerability of SPX-101 in patients with solid tumors\"\\n21514,1,1,\"To determine the safety and toxicity of nelfinavir in human subjects with solid tumors and to determine the maximum tolerated dose in this group of patients.\"\\n21515,1,1,\"To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer\"\\n21516,1,1,\"To determine the safety of intratumoral administration of pbi-shRNA‚Ñ¢ STMN1 LP\"\\n21517,1,1,\"To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors: NCI CTCAEv5 Common Toxicity Criteria\"\\n21518,1,1,\"To determine the safety of multiple intravenous infusions of MORAb-004\"\\n21519,1,1,\"To determine the safety of neoantigen synthetic peptide vaccines by rate of serious safety events by CTCAE v5.\"\\n21520,1,1,\"To determine the safety of OMP-18R5 in subjects with previously treated solid tumors\"\\n21521,1,1,\"To determine the safety of OMP-21M18 in subjects with previously treated solid tumors\"\\n21522,1,1,\"To determine the safety of OMP-59R5 in subjects with previously treated solid tumors\"\\n21523,1,1,\"To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Advanced Solid Tumors: Dose Limiting Toxicities (DLTs)\"\\n21524,1,1,\"To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Primary CNS Tumors: DLTs\"\\n21525,1,1,\"To determine the safety of Pemetrexed in patients with LM.\"\\n21526,1,1,\"To determine the safety of PNT2258 in patients with advanced solid tumors\"\\n21527,1,1,\"To determine the safety of RFA in patients with childhood acquired tumors\"\\n21528,1,1,\"To determine the safety of the proposed treatment in this patient population.\"\\n21529,1,1,\"To determine the safety of the treatment plan using Busulfan and Melphalan followed by infusion of CD133+ selected hematopoietic cells in patients with high-risk malignancies.\"\\n21530,1,1,\"To determine the safety of treatment with CNA3103.\"\\n21531,1,1,\"To determine the safety profile\"\\n21532,1,1,\"To determine the safety profile, dose limiting toxicities (DLT), and maximum tolerated dose (MTD) of C. novyi-NT in humans with treatment-refractory solid tumor malignancies when given as a single intravenous injection\"\\n21533,1,1,\"To determine the safety, dose-limiting toxicities, and maximum tolerated dose of weekly oral Rapamycin in combination with weekly intravenous Abraxane for three out of four consecutive weeks in patients with advanced solid cancers.\"\\n21534,1,1,\"To determine the safety, dose-limiting toxicities,and maximum tolerated dose of daily oral RAD001 in combination with oral topotecan given on days 1-5 q 21 days in patients with advanced or recurrent endometrial cancers\"\\n21535,1,1,\"To determine the safety, maximum tolerated dose and dose-limiting toxicities of oral sorafenib\"\\n21536,1,1,\"To determine the safety, maximum tolerated dose(MTD)of IPI-504 in combination with docetaxel in patients with advanced solid tumors and recommend the Phase II dose of the combination of drugs.\"\\n21537,1,1,\"To determine the safety, tolerability and maximum tolerated dose (MTD) of ARQ 171\"\\n21538,1,1,\"To determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of ARQ 197 when administered in combination with gemcitabine.\"\\n21539,1,1,\"To determine the safety, tolerability and maximum tolerated dosing for the combination of bevacizumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma\"\\n21540,1,1,\"To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 621 administered intravenously.\"\\n21541,1,1,\"To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors\"\\n21542,1,1,\"To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda¬Æ) to subjects with advanced solid tumors\"\\n21543,1,1,\"To determine the safety, tolerability, and MTD of oral aza-TdCyd administered daily for 5 days a week for 2 weeks, with one week off, in 21-day cycles\"\\n21544,1,1,\"To determine the safety, tolerability, and MTD of oral TdCyd administered daily for 5 days a week for 2 weeks, with one week off, q 21-day cycles\"\\n21545,1,1,\"To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination\"\\n21546,1,1,\"To determine the safety, tolerability, dose limiting toxicities (DLT) and recommended dose (RD) of PM02734\"\\n21547,1,1,\"To determine the safety, tolerability, dose-limiting toxicities (DLT), maximum acceptable dose (MAD) and maximum tolerated dose (MTD) of CHR-3996 when administered orally to patients with advanced or treatment refractory solid tumours\"\\n21548,1,1,\"To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered in combination with paclitaxel.\"\\n21549,1,1,\"To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid tumours.\"\\n21550,1,1,\"To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436\"\\n21551,1,1,\"To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436 in combination with dacarbazine.\"\\n21552,1,1,\"To determine the safety, toxicity and maximum tolerated dose of CRLX101 when administered intravenously to subjects with advanced solid tumors.\"\\n21553,1,1,\"To determine the safety/feasibility of Capecitabine with the combination of Cisplatin and Irinotecan. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the combination of Cisplatin and Irinotecan.\"\\n21554,1,1,\"To determine the time to maximum plasma level (Tmax) of PCLX-001\"\\n21555,1,1,\"To determine the tolerability, safety profile and maximum tolerated dose (MTD) of intravenous CALAA-01.\"\\n21556,1,1,\"To determine the tolerance and toxicity profile\"\\n21557,1,1,\"To determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors\"\\n21558,1,1,\"To determine the tumor response rate (according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria) as the proportion of eligible patients with stage IV cutaneous melanoma or stage III not amenable to surgery.\"\\n21559,1,1,\"To determine tumor uptake and retention of [18F]fluciclatide before and after 1 cycle of treatment with targeted anti-angiogenic therapy.\"\\n21560,1,1,\"To determine whether chronic oral administration of topotecan inhibits HIF-1alpha expression.\"\\n21561,1,1,\"To determine whether intratumoral injection or intravenous infusions of HSV1716 is safe in adolescents and young adults with non-CNS solid tumors.\"\\n21562,1,1,\"to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors\"\\n21563,1,1,\"To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma\"\\n21564,1,1,\"To determine whether the presence of a low - intermediate 1 risk MDS, IDUS or ICUS can predict for (myelo)toxicity in older patients with advanced malignancies receiving palliative chemotherapy\"\\n21565,1,1,\"To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia\"\\n21566,1,1,\"To determine whether there is any anti-tumor activity against LM with Pemetrexed.\"\\n21567,1,1,\"To determine, during the dose escalation phase, the recommended dose of intravenously infused CCI-001 for the dose expansion phase of the trial.\"\\n21568,1,1,\"To determine, during the dose escalation phase, the recommended dose of PCLX-001 for the dose expansion phase of the trial.\"\\n21569,1,1,\"To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples\"\\n21570,1,1,\"To establish a dose for Phase II evaluation from the maximum tolerated dose of the combination of VS-6766 and Defactinib.\"\\n21571,1,1,\"To establish a multicomponent intervention that assesses the perspective of cancer survivors\"\\n21572,1,1,\"To establish a multicomponent intervention that assesses the perspective of health care provider\"\\n21573,1,1,\"To establish a safe dose of PLD when delivered in combination with pembrolizumab\"\\n21574,1,1,\"To establish a standardized methods to report key data in electronic health records to better manage cancer patients at time of diagnosis, treatment, follow up, and into survivor-ship.\"\\n21575,1,1,\"To establish Maximum tolerate dose (MTD)\"\\n21576,1,1,\"To establish the DLT and the MTD of ridaforolimus administered daily x 5 every 14 days in pediatric patients with recurrent/refractory solid tumors, including lymphoma and tumors of the central nervous system.\"\\n21577,1,1,\"To Establish the Dose Limiting Toxicity (DLT)\"\\n21578,1,1,\"To establish the dose of EP-100 recommended for future phase II protocols\"\\n21579,1,1,\"To establish the dose recommended for future phase II studies with ATI-1123.\"\\n21580,1,1,\"To establish the dose-limiting toxicity (DLT)\"\\n21581,1,1,\"To Establish the Efficacy (CR (Complete Response) + PR (Partial Response) Rate)\"\\n21582,1,1,\"To establish the intracranial ORR of the pembrolizumab and lenvatinib combination in patients with TNBC or NSCLC and brain metastases, as assessed according to the modified RECIST\"\\n21583,1,1,\"To Establish the Maximum Tolerated Dose (MTD)\"\\n21584,1,1,\"To establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of TAB006 when administered in combination toripalimab 240 mg Q3W.\"\\n21585,1,1,\"To establish the maximum tolerated dose (MTD) and the recommended dose (RD) of F16IL2 when administered in combination with paclitaxel (Phase I).\"\\n21586,1,1,\"To establish the Maximum Tolerated Dose (MTD) and toxicities of vandetanib (Zactima; ZD6474) in combination with fixed dose of GEMOX (gemcitabine/oxaliplatin) and to establish the recommended phase II dose of the GEMOX and vandetanib regimen\"\\n21587,1,1,\"To establish the maximum tolerated dose (MTD) of irinotecan when administered by an intra-peritoneal route every three weeks.\"\\n21588,1,1,\"To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with Paclitaxel/Carboplatin\"\\n21589,1,1,\"To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with topotecan\"\\n21590,1,1,\"To establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly intravenous infusions.\"\\n21591,1,1,\"To establish the maximum tolerated dose (MTD) of SON-1010\"\\n21592,1,1,\"To establish the maximum tolerated dose (MTD) of SON-1010 in combination with Atezolizumab\"\\n21593,1,1,\"To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine\"\\n21594,1,1,\"To establish the maximum tolerated dose (MTD), and a recommended Phase II dose of Ixabepilone when administered every three weeks by assessing status of treatment, dose intensity, and dose-limiting toxicities (DLT)\"\\n21595,1,1,\"To establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 .\"\\n21596,1,1,\"To establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) ZN-c3 and bevacizumab.\"\\n21597,1,1,\"To establish the maximum tolerated dose (MTD)/recommended.\"\\n21598,1,1,\"To establish the MTD and DLT of pazopanib in groups of patients with varying degrees of hepatic dysfunction (mild, moderate, and severe) to provide appropriate dosing recommendations for panzopanib in such patients.\"\\n21599,1,1,\"To establish the MTD and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors\"\\n21600,1,1,\"To establish the MTD of BMS-817378 when administered orally on a daily schedule in subjects with advanced cancers\"\\n21601,1,1,\"To establish the phase II recommended dose of daily oral BKM120\"\\n21602,1,1,\"To establish the recommended MTD dose and Phase 2 dose (RP2D) of FCN-338 for future clinical trials in patients with advanced CLL/SLL\"\\n21603,1,1,\"To establish the recommended Phase 2 Dose (RP2D) of NUC-3373 that will optimise the risk/benefit reward for the participants, administered weekly (Part 1) and when administered fortnightly (Part 2), as a single I.V. infusion.\"\\n21604,1,1,\"To establish the recommended Phase 2 dose (RP2D) of SON-1010\"\\n21605,1,1,\"To establish the recommended Phase 2 dose (RP2D) of YBL-006 in patients with advanced solid tumors\"\\n21606,1,1,\"To establish the Recommended Phase II Dose (RP3D) for the combination of CA4P-paclitaxel-carboplatin in advanced imageable malignancies\"\\n21607,1,1,\"To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors\"\\n21608,1,1,\"To establish the safety and tolerability of weekly (days 1, 8, 15 q28-day cycle) LMP400 in patients with refractory solid tumors and lymphomas\"\\n21609,1,1,\"To establish the safety, tolerability and the maximum tolerated dose (MTD) of LMP744 (NSC 706744)\"\\n21610,1,1,\"To establish the safety, tolerability, and maximum tolerated dose (MTD) of nilotinib plus paclitaxel combination in patients with refractory solid tumors\"\\n21611,1,1,\"To establish the safety, tolerability, and maximum tolerated dose (MTD) of oral TRC102 in combination with oral TMZ in patients with refractory solid tumors.\"\\n21612,1,1,\"To establish the safety, tolerability, and recommended Phase 2 dose of KW 2450 administered orally in subjects with advanced solid tumor who have not responded to standard therapy or for whom no standard therapy is available\"\\n21613,1,1,\"To establish the toxicity profile of this combination\"\\n21614,1,1,\"To establish the use of copanlisib in combination with fulvestrant administered to subjects with selected estrogen receptor-positive (ER+).\"\\n21615,1,1,\"To estimate MTD and Phase II dose of oral pazopanib.\"\\n21616,1,1,\"To estimate the intensity and distribution in critical and non-critical organs.\"\\n21617,1,1,\"To estimate the maximum tolerated dose (MTD) of the intravenous formulation of irinotecan given orally in combination with a fixed dose of oral gefitinib.\"\\n21618,1,1,\"To estimate the mean and standard deviation of the decrease in interstitial fluid pressure in tumors within 72 hours after GRID treatment.\"\\n21619,1,1,\"To estimate the MTD and describe the DLT of the combination of bevacizumab, administered every 2 weeks IV and everolimus administered orally daily to children with recurrent or refractory solid tumors including CNS malignancies\"\\n21620,1,1,\"To estimate the non-comparative efficacy of this treatment combination in patients with malignant melanoma. Response will be assessed using the RECIST Criteria\"\\n21621,1,1,\"To estimate the proportion of patients with increased CD8+ T cell infiltration of spot FUSA-treated metastasis.\"\\n21622,1,1,\"To estimate the rate of immune response of this immunotherapy treatment\"\\n21623,1,1,\"To evaluate acute and chronic changes in INR when Warfarin is co-administered with PTK787/ZK 222584\"\\n21624,1,1,\"To evaluate AE,SAE and DLT of SYHA1801.\"\\n21625,1,1,\"To evaluate clinical activity/efficacy of HS-10375 by assessment of objective response rate-Part Ib/II\"\\n21626,1,1,\"To evaluate clinical activity/efficacy of HS-10376 by assessment of objective response rate-Phase Ib/II\"\\n21627,1,1,\"To evaluate dose limiting as well as non-dose limiting toxicities of this combination.\"\\n21628,1,1,\"To evaluate efficacy of CANSSUFIVE¬Æ Nuvastatic (C5OSEW5050ESA) in Improving Fatigue in Patients with Solid Stage I - IV Tumors.\"\\n21629,1,1,\"To evaluate efficacy of PDR001 by Objective Response rate by RECIST(Response Evaluation Criteria In Solid Tumors)\"\\n21630,1,1,\"To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria\"\\n21631,1,1,\"To evaluate maximum tolerated dose (MTD) of U3-1287(AMG888) when administered intravenously to patients with advanced solid tumors\"\\n21632,1,1,\"To evaluate objective response of axitinib in patients with advanced solid malignancies.\"\\n21633,1,1,\"To evaluate pancreatic tumor ablation effect\"\\n21634,1,1,\"To evaluate potential pharmacodynamic (PD) effects of orally administered MGCD0103 in combination with IV docetaxel.\"\\n21635,1,1,\"To evaluate preliminary efficacy based on objective response rate (ORR), in each disease cohort separately.\"\\n21636,1,1,\"To evaluate safety\"\\n21637,1,1,\"To evaluate safety and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)\"\\n21638,1,1,\"To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases\"\\n21639,1,1,\"To evaluate the ability of bevacizumab and docetaxel to reduce microvessel density and induce apoptosis of endothelial and tumor cells.\"\\n21640,1,1,\"To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients\"\\n21641,1,1,\"To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients\"\\n21642,1,1,\"To evaluate the absolute lymphocyte counts in lung and esophageal cancer patients who had undergone chemoradiation. (CRT)\"\\n21643,1,1,\"To evaluate the activity of R-B combination in terms of complete response rate (CRR).\"\\n21644,1,1,\"To evaluate the AEs leading to dose interruption, dose delays, and permanent treatment stop of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023 +irinotecan)\"\\n21645,1,1,\"To evaluate the anti-tumor activity of CN202 in selected solid tumors or hematologic malignancies as determined by Objective Response Rate (ORR)\"\\n21646,1,1,\"To evaluate the antitumor activity\"\\n21647,1,1,\"To evaluate the antitumor activity of Toripalimab injection (JS001) combined with Axitinib\"\\n21648,1,1,\"To evaluate the antitumor efficacy of immunotherapy in partcipants with unresectable or metastatic melanoma that progressed while on prior treatment(s) that included an anti-PD-1/L1 agent. (Expansion Part)\"\\n21649,1,1,\"To evaluate the association between HR QoL, patient reported symptoms and DLT.\"\\n21650,1,1,\"To Evaluate the Best Overall Response Rate (ORR)\"\\n21651,1,1,\"To evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.\"\\n21652,1,1,\"To evaluate the diagnostic efficacy and the safety of the combined approach with Œ≤-probe and 68Ga-DOTA-TOC PET/CT in the correct identification of primary tumor and lymph node metastases, in patients with GEP-NETs candidates to surgery\"\\n21653,1,1,\"To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children\"\\n21654,1,1,\"To evaluate the dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of CN202 when administered as a single-agent to subjects\"\\n21655,1,1,\"To evaluate the Dose-Limiting Toxicity (DLT) for dose escalation phase\"\\n21656,1,1,\"To evaluate the effect of AV-299 (formerly SCH 900105) on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases\"\\n21657,1,1,\"To evaluate the effect of oral daily cabozantinib, administered for up to 12 months, on the one-year progression-free survival of patients with \"\"ultra-high-risk\"\" pediatric solid tumors.\"\\n21658,1,1,\"To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia\\'s formula (QTcF)\"\\n21659,1,1,\"To evaluate the effectiveness of molecular profiling guided therapies in terms of clinical benefit rate (CR/PR/SD beyond 16 +/- 2 weeks) in Tier 1* population\"\\n21660,1,1,\"To evaluate the effectiveness of two schedules of intravenous rhTPO versus placebo as secondary prophylaxis in reducing the proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia.\"\\n21661,1,1,\"To evaluate the effects of patupilone on the pharmacokinetics of midazolam in patients with advanced malignancies.\"\\n21662,1,1,\"To evaluate the effects of patupilone on the pharmacokinetics of omeprazole in patients with advanced malignancies\"\\n21663,1,1,\"To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.\"\\n21664,1,1,\"To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology\"\\n21665,1,1,\"To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary.\"\\n21666,1,1,\"To evaluate the efficacy of the HIFU treatment in achieving cancer ablation\"\\n21667,1,1,\"To evaluate the efficacy of the treatment\"\\n21668,1,1,\"To evaluate the efficacy of volociximab in combination with liposomal doxorubicin in advanced epithelial ovarian cancer or primary peritoneal cancer. To evaluate the safety and tolerability of volociximab in combination with liposomal doxorubicin.\"\\n21669,1,1,\"To evaluate the efficacy of XL184 in subjects with advanced solid tumors\"\\n21670,1,1,\"To Evaluate the Feasibility of 1RG-CART Therapy in Patients With Relapsed or Refractory Neuroblastoma\"\\n21671,1,1,\"To evaluate the feasibility of [18F]-FBA-A20FMDV2-PET imaging in patients with solid tumours.\"\\n21672,1,1,\"To evaluate the feasibility of molecular profiling guided therapies (MGT) based on genomic alterations in patients with advanced solid tumors in terms of the proportion of receipt of the treatment\"\\n21673,1,1,\"To evaluate the feasibility of obtaining two serial tumor biopsies and plasma pharmacokinetics for the determination of AR-67 half life in tumor and plasma during day 1 of AR-67 treatment given on days 1, 4, 8, 12 and 15 of an every 21-day cycle.\"\\n21674,1,1,\"To evaluate the feasibility of treatment sequence (R-TT or TT-R)\"\\n21675,1,1,\"To evaluate the grade and severity of adverse events as a measure of safety and toxicity\"\\n21676,2,1,\"To evaluate the immunogenicity of RT-01\"\\n21677,1,1,\"To evaluate the impact of custirsen on paclitaxel pharmacokinetics\"\\n21678,1,1,\"To evaluate the imputability of immunotherapy in the ICU admission reason for lung cancer patients treated by immunotherapy.\"\\n21679,1,1,\"To evaluate the incidence and frequency of adverse events following intravenous (IV) infusion of BJ-005 in patients with advanced solid tumor or lymphoma. The assessment will be conducted per CTCAE 5.0 throughout the conduct of the study.\"\\n21680,1,1,\"To evaluate the Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] with BTX-1188 in subjects with advanced malignancies\"\\n21681,1,1,\"To evaluate the incidence, severity, and relationship of (S)AEs collected from administration of the first dose of study drug until 30 days after the last dose of the 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irrinotecan)\"\\n21682,1,1,\"To evaluate the levels of anxiety, depression, post-traumatic stress and well-being amongst patients with cancer during the COVID-19 pandemic using GAD-7\"\\n21683,1,1,\"To evaluate the levels of anxiety, depression, post-traumatic stress and well-being amongst patients with cancer during the COVID-19 pandemic using PC-PTSD-5\"\\n21684,1,1,\"To evaluate the levels of anxiety, depression, post-traumatic stress and well-being amongst patients with cancer during the COVID-19 pandemic using PHQ-9\"\\n21685,1,1,\"To evaluate the levels of anxiety, depression, post-traumatic stress and well-being amongst patients with cancer during the COVID-19 pandemic using Well-being thermometer\"\\n21686,1,1,\"To evaluate the levels of anxiety, depression, post-traumatic stress and well-being amongst patients with cancer during the COVID-19 pandemic using WHO-5\"\\n21687,1,1,\"To evaluate the long-term safety of repeat daily doses of pazopanib in cancer subjects with solid tumors\"\\n21688,1,1,\"To evaluate the Maximum tolerated dose, identify the recommended Phase 2 dose(s), dose limiting toxicities, safety and tolerability of GSK2256098 given orally on consecutive days.\"\\n21689,1,1,\"To evaluate the MTD of SYHA1801\"\\n21690,1,1,\"To evaluate the objective response rate to Nivolumab in bMMRD positive pediatric patients with recurrent hypermutated malignancies.\"\\n21691,1,1,\"To evaluate the objective response rate to Nivolumab in bMMRD positive pediatric patients with refractory hypermutated malignancies\"\\n21692,1,1,\"To evaluate the objective tumor response rate by radiographic means using Response Evaluation Criteria in Solid Tumors\"\\n21693,1,1,\"To evaluate the ORR of MCLA-129 alone or in combination with Osimertinib in molecularly defined populations of advanced/metastatic solid tumors.\"\\n21694,1,1,\"To evaluate the pharmacodynamics of a panel of biomarkers following administration of ARQ 501\"\\n21695,1,1,\"To evaluate the pharmacokinetic (PK) parameters of AMG 780 including, but not limited to Cmax, AUC, and accumulation ratio\"\\n21696,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-8: area under the plasma concentration-time curve from time 0 to 8 hours post dose\"\\n21697,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration\"\\n21698,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-‚àû: area under the plasma concentration-time curve from time 0 extrapolated to infinity\"\\n21699,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Cmax: observed maximum plasma concentration\"\\n21700,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasma\"\\n21701,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, t1/2: terminal elimination half-life\"\\n21702,1,1,\"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Tmax: observed time at Cmax\"\\n21703,1,1,\"To Evaluate the pharmacokinetics of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib\"\\n21704,1,1,\"To evaluate the potential effects on the QT/QTc interval in cancer patients when treated with 5 minute IV infusions of amrubicin 40 mg/m2 daily for 3 consecutive days; data will be obtained by ECG extraction from continuous 12-lead Holter monitoring\"\\n21705,1,1,\"To evaluate the potential for QT/QTc prolongation by 32 mg lenvatinib using a placebo control and moxifloxacin as the positive control.\"\\n21706,1,1,\"To evaluate the preliminary anti-tumor activity which will be assessed by radiological scans every 6 weeks\"\\n21707,1,1,\"To evaluate the preliminary antitumor activity of DSP-0509 in combination with pembrolizumab in patients with HNSCC who have shown primary or acquired resistance to ICIs - Combination arm - Part C (Dose Expansion)\"\\n21708,1,1,\"To evaluate the preliminary efficacy of the combinations Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan in patients with BTC or ESCC by assessing overall response rates (ORRs) per Investigator assessment using RECISTv.1.1\"\\n21709,1,1,\"To evaluate the prevalence of the CPK increase\"\\n21710,1,1,\"To evaluate the progression-free survival (PFS) at 8 months and the disease control rate (DCR) in patients with non-resectable locally-advanced or metastatic or recurrent intrahepatic or extrahepatic CCA following BMS-936558/SBRT treatment\"\\n21711,1,1,\"To evaluate the pulmonary medicine programs adapted that their procedural practices in response to the coronavirus-2019 (COVID-19) epidemic.\"\\n21712,1,1,\"To evaluate the pulmonary medicine programs that adapted their ambulatory operations in response to the coronavirus-2019 (COVID-19) epidemic.\"\\n21713,1,1,\"To evaluate the pulmonary medicine programs that adapted their provider staffing in response to the coronavirus-2019 (COVID-19) epidemic.\"\\n21714,1,1,\"To evaluate the pulmonary medicine programs that adapted their techniques in response to the coronavirus-2019 (COVID-19) epidemic.\"\\n21715,1,1,\"To evaluate the response rate to PROMITIL in combination with external beam radiotherapy (EBR)\"\\n21716,1,1,\"To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)\"\\n21717,1,1,\"To evaluate the safety and PK of 2 dose schedules of panitumumab in subjects with advanced solid tumors, refractory to or with no available standard therapy.\"\\n21718,4,1,\"To evaluate the safety and tolerability\"\\n21719,1,1,\"To evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.\"\\n21720,1,1,\"To evaluate the safety and tolerability of ABN401.\"\\n21721,1,1,\"To evaluate the safety and tolerability of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib\"\\n21722,1,1,\"To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma by monitoring adverse events, clinical laboratory tests, vital signs, physical examinations, and anti-drug antibody tests.\"\\n21723,1,1,\"To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies\"\\n21724,1,1,\"To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ‚â• Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.\"\\n21725,1,1,\"To evaluate the safety and tolerability of APR-246 in combination with pembrolizumab in subjects with solid tumors.\"\\n21726,1,1,\"To evaluate the safety and tolerability of AZD0530 in combination with carboplatin and/or paclitaxel regimens with solid tumours by assessment of AEs, physical examination, BP, pulse, ECG, laboratory findings, PFTs and thoracic CT scans.\"\\n21727,1,1,\"To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies\"\\n21728,1,1,\"To evaluate the safety and tolerability of BIIB022\"\\n21729,1,1,\"To evaluate the safety and tolerability of CANSSUFIVE¬Æ Nuvastatic (C5OSEW5050ESA) in Patients with Solid Stage I - IV Tumors.\"\\n21730,1,1,\"To evaluate the safety and tolerability of CN202 administered to subjects with locally advanced or metastatic solid tumor or hematologic malignancies through adverse events as assessed by NCI-CTCAE v5.0\"\\n21731,1,1,\"To evaluate the safety and tolerability of CS1001\"\\n21732,1,1,\"To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with Abraxane given intravenously at 100 mg/m2 once weekly for 3 weeks in the dose escalation and expansion stages of the study\"\\n21733,1,1,\"To evaluate the safety and tolerability of escalating doses of paclitaxel in combination with PTK787\"\\n21734,1,1,\"To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Anticancer Therapies\"\\n21735,1,1,\"To evaluate the safety and tolerability of escalating doses of twice weekly EMD 121974 in patients with cancer.\"\\n21736,1,1,\"To evaluate the safety and tolerability of hCBE-11 in advanced solid tumors\"\\n21737,1,1,\"To evaluate the safety and tolerability of HF1K16 by AE\"\\n21738,1,1,\"To evaluate the safety and tolerability of HF1K16 by blood pressure of vital signs\"\\n21739,1,1,\"To evaluate the safety and tolerability of HF1K16 by body temperature of vital signs\"\\n21740,1,1,\"To evaluate the safety and tolerability of HF1K16 by ECG from QRS Duration\"\\n21741,1,1,\"To evaluate the safety and tolerability of HF1K16 by ECG from QT Interval\"\\n21742,1,1,\"To evaluate the safety and tolerability of HF1K16 by ECG from QTc Interval\"\\n21743,1,1,\"To evaluate the safety and tolerability of HF1K16 by ECG from ventricular rate\"\\n21744,1,1,\"To evaluate the safety and tolerability of HF1K16 by heart rate of vital signs\"\\n21745,1,1,\"To evaluate the safety and tolerability of HF1K16 by Hemoglobin concentration in whole blood\"\\n21746,1,1,\"To evaluate the safety and tolerability of HF1K16 by International standardized ratio\"\\n21747,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Activated partial thromboplastin time\"\\n21748,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from ALT concentration\"\\n21749,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from AST concentration\"\\n21750,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Changes from White blood cell count in whole blood\"\\n21751,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Creatinine concentration\"\\n21752,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from HDL-C\"\\n21753,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from International sensitivity index\"\\n21754,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from LDL-C\"\\n21755,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Neutrophil count in whole blood\"\\n21756,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Red blood cell count\"\\n21757,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Red blood cell count in whole blood\"\\n21758,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Total bilirubin concentration\"\\n21759,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Total cholesterol concentration\"\\n21760,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Total protein concentration\"\\n21761,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Triglycerides concentration\"\\n21762,1,1,\"To evaluate the safety and tolerability of HF1K16 by Laboratory Examination from Urea concentration\"\\n21763,1,1,\"To evaluate the safety and tolerability of HF1K16 by Prothrombin time\"\\n21764,1,1,\"To evaluate the safety and tolerability of HF1K16 by respiration rate of vital signs\"\\n21765,1,1,\"To evaluate the safety and tolerability of IAE0972 in Phase I\"\\n21766,1,1,\"To evaluate the safety and tolerability of IGM-7354 in participants with cancer including estimation of the MTD or MAD\"\\n21767,1,1,\"To evaluate the safety and tolerability of IMM40H in patients with advanced malignancies.\"\\n21768,1,1,\"To evaluate the safety and tolerability of JS004 injection alone and in combination with Toripalimab in patients with advanced solid tumors.\"\\n21769,1,1,\"To evaluate the safety and tolerability of MK2461 by assessing incidence of toxicities. Pharmacokinetic and pharmacodynamic parameter will be evaluated.\"\\n21770,1,1,\"To evaluate the safety and tolerability of R-B combination in terms of rate of adverse events occurrence.\"\\n21771,1,1,\"To evaluate the safety and tolerability of single agent SX-682.\"\\n21772,1,1,\"To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study: NCI CTCAEv5 Common Toxicity Criteria\"\\n21773,1,1,\"To evaluate the safety and tolerability of SON-1010\"\\n21774,1,1,\"To evaluate the safety and tolerability of SON-1010 in combination with Atezolizumab\"\\n21775,1,1,\"To evaluate the safety and tolerability of the combination of toripalimab and chidamide (Phase Ib)\"\\n21776,1,1,\"To evaluate the safety and tolerability of U3-1287 (AMG888) in patients with advanced solid tumors\"\\n21777,1,1,\"To evaluate the safety and tolerability of veliparib/TMZ combination in subjects with solid tumors\"\\n21778,1,1,\"To evaluate the safety and tolerability of XL647 administered orally as a single dose and as repeat doses\"\\n21779,1,1,\"To evaluate the safety and tolerability profile of RAD001 (10mg daily dose) in Chinese patients who are intolerant of or have progressed on or after VEGF-targeted therapy.\"\\n21780,1,1,\"To evaluate the safety and toxicity profile of sunitinib when used with concurrent radiation therapy\"\\n21781,1,1,\"To evaluate the safety of 89Zr-KN035 in PD-L1 positive solid tumor patients\"\\n21782,1,1,\"To evaluate the safety of CAR-T cell preparations in the treatment of CEA-positive advanced malignancies [Safety and Tolerability]\"\\n21783,1,1,\"To evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma.\"\\n21784,1,1,\"To evaluate the safety profile and the tolerability of KRN951 throughout the study period by assessing adverse events and laboratory values recorded during treatment.\"\\n21785,1,1,\"To evaluate the safety, tolerability and MTD (maximum tolerated dose) of MST-997.\"\\n21786,1,1,\"To evaluate the safety, tolerability and MTD of IV MST-997 throughout patients participation on trial.\"\\n21787,1,1,\"To evaluate the safety, tolerability and potential activity of patupilone once every 21 days in patients that completed the core study\"\\n21788,1,1,\"To evaluate the safety, tolerability, and dose-limiting toxicities (DLT), and determine the maximum tolerated dose (MTD) of AV-412 when administered once daily by the oral route for 4 weeks (4 weeks equals one dosing cycle)\"\\n21789,1,1,\"To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 175 mg/m2) and carboplatin in subjects with advanced solid tumors\"\\n21790,1,1,\"To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 225 mg/m2) and carboplatin in subjects with NSCLC\"\\n21791,1,1,\"To evaluate the safety, tolerability, and preliminary efficacy of novel immunotherapy IPs in participants with unresectable or metastatic melanoma that progressed while on prior treatment that included an anti-PD-1/L1 agent. (Selection Part)\"\\n21792,1,1,\"To evaluate the safety, tolerability, maximum tolerated dose (MTD), and efficacy pharmacokinetics of CPI-613 given twice weekly for three consecutive weeks in cancer patients\"\\n21793,1,1,\"To evaluate the safety.\"\\n21794,1,1,\"To evaluate the SBRT effect on adverse events\"\\n21795,1,1,\"To evaluate the SBRT effect on local progression free survival rate\"\\n21796,1,1,\"To evaluate the time-course changes in GEH200521 (18F) Injection uptake after immune-checkpoint inhibitor (ICI) treatment cycles compared to baseline.\"\\n21797,1,1,\"To evaluate the tolerability and safety\"\\n21798,1,1,\"To evaluate the tolerability of BIBF1120 and RAD001 in combination (endpoints: assessment of adverse events (AEs) according to CTC-AE V4.0)\"\\n21799,1,1,\"To evaluate the tolerability.\"\\n21800,1,1,\"To evaluate the toxicity and tolerability of and the maximum tolerated dose for QBI-139 in patients with advanced refractory solid tumors.\"\\n21801,1,1,\"To evaluate the Tumor Response Rate according to Response Evaluation Criteria in Solid Tumors (RECIST) after 9 weeks (3 cycles) of treatment in patients with measurable disease.\"\\n21802,2,1,\"To evaluate the viral shedding of RT-01\"\\n21803,1,1,\"To evaluate tolerability and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)\"\\n21804,1,1,\"To evaluate tumor response\"\\n21805,1,1,\"To evaluate whether intravenous (IV) 131-I-TM-601 provides tumor-specific localization in patients with recurrent or refractory metastatic (including brain metastases) solid tumors\"\\n21806,1,1,\"To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.\"\\n21807,1,1,\"To examine best overall response rate in subjects treated at multiple dose levels of CFI-402411.\"\\n21808,1,1,\"To examine progression free survival in subjects treated at multiple dose levels of CFI-402411.\"\\n21809,1,1,\"To Examine the Adverse Event Profile\"\\n21810,1,1,\"To examine the association of indoleamine 2,3-dioxygenase (IDO) genetic polymorphisms with clinical outcomes of ovarian cancer.\"\\n21811,2,1,\"To examine the incidence of clinical and laboratory adverse events after multiple doses of ZX-101A\"\\n21812,1,1,\"To explore the response rate of this combination in patients with colon cancer, NSCLC, and granulosa cell ovarian cancer\"\\n21813,1,1,\"To find the highest dose of oral panobinostat that can be given to patients with relapsed AML, HD or NHL without causing severe side effects.\"\\n21814,1,1,\"To find the highest dose of RAD001 that can be given to children with refractory or relapsing solid tumors, leukemias, or brain tumors without causing severe side effects\"\\n21815,1,1,\"To find the highest safe dose of the drug azacitidine that can be given in combination with valproic acid in the treatment of solid tumors.\"\\n21816,1,1,\"to find which symptom or symptoms have a higher relative risk (RR) for NEC diagnosis\"\\n21817,1,1,\"To further characterize the safety and tolerability of LB1908 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D)\"\\n21818,1,1,\"To further characterize the safety and tolerability of LB2102 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D)\"\\n21819,1,1,\"To further evaluate the safety profile of NUC-1031 in an expanded cohort at RP2D\"\\n21820,1,1,\"To identify a maximum tolerated dose (MTD) through evaluation of dose-limiting toxicities (DLTs) at or below a frequency of 25%.\"\\n21821,1,1,\"To identify a maximum tolerated dose in Phase I\"\\n21822,1,1,\"To identify a maximum-tolerated dose of AZD4877 by assessment of the incidence of dose-limiting toxicities as measured by the Common Terminology Criteria for Adverse Events (CTCAE) grade and type of AEs experienced in the first cycle of treatment.\"\\n21823,1,1,\"To identify a recommended Phase II dose (RP2D) of CN202\"\\n21824,1,1,\"To identify and characterize CVX-045-related adverse events (AEs)\"\\n21825,1,1,\"To identify maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of ARQ 197 when administered in combination with sorafenib.\"\\n21826,1,1,\"To identify novel immunotherapy IPs to progress into the expansion part (Selection Part)\"\\n21827,1,1,\"To identify subjects with RNA signatures who may be eligible for clinical trial enrollment\"\\n21828,1,1,\"To identify the dose limiting toxicities (DLTs), determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered every three weeks intravenously (i.v.) over one hour to patients with advanced solid tumors.\"\\n21829,1,1,\"To identify the dose-limiting toxicities (DLTs)\"\\n21830,1,1,\"To identify the maximum tolerated dose\"\\n21831,1,1,\"To identify the maximum tolerated dose (MTD) of ANG1005 in patients with advanced solid tumors and metastatic brain cancer.\"\\n21832,1,1,\"To identify the maximum tolerated dose (MTD) of metarrestin in subjects with metastatic solid tumors\"\\n21833,1,1,\"To identify the maximum tolerated dose (MTD) of of intravenously administered 2B3-101 in combination with trastuzumab in patients with HER2+ breast cancer with brain metastases\"\\n21834,1,1,\"To identify the maximum tolerated dose (MTD) of of intravenously administered 2B3-101 in patients with advanced solid tumors and metastatic brain cancer or recurrent malignant glioma.\"\\n21835,1,1,\"To identify the Maximum Tolerated Dose (MTD) of PQR309 administered in different (continuous and intermittent) dosing schedules. To evaluate efficacy of PQR309 in selected patient population: ‚Ä¢ Solid tumors with PI3K/mTOR activation ‚Ä¢ Human Papilloma\"\\n21836,1,1,\"To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine\"\\n21837,1,1,\"To identify the maximum tolerated doses (MTD) of the combination of patupilone and RAD001\"\\n21838,1,1,\"To identify the MTD and safety of CDC-501 when given in a 6-wk cycle of daily administration of CDC-501 for 4 wks followed by a 2-wk rest in doses of 5 mg/day up to 25 mg/day in pts with solid tumors that are refractory after standard treatment.\"\\n21839,1,1,\"To identify the MTD of TAK-901 administered as either a 3-hour or 1-hour infusion.\"\\n21840,1,1,\"To identify the recommended Phase 2 dose (RP2D) of FORE8394 in Group A (adult patients) for further evaluation in Dose Extension.\"\\n21841,1,1,\"To identify the Recommended Phase 2 Dose (RP2D) of LAM561 in pediatric patients\"\\n21842,1,1,\"To identifymaximum tolerated dose (MTD)\"\\n21843,2,2,\"To investigate dose-limiting toxicity and estimate maximum tolerated dose.\"\\n21844,1,1,\"To investigate overall lung cancer detection rate of high lung cancer risk individuals\"\\n21845,1,1,\"To investigate the antitumor activity of ZN-c3 based on the objective response rate (ORR).\"\\n21846,1,1,\"To investigate the association between the results of Precision\\'s ChemoFx assay results and overall survival in subjects with solid tumors.\"\\n21847,1,1,\"To investigate the effect of ketoconazole on the pharmacokinetics of ABT-869 in subjects with advanced or metastatic solid tumors.\"\\n21848,1,1,\"To investigate the effect of rifampin on the pharmacokinetic of linifanib in subjects with advanced or metastatic solid tumors.\"\\n21849,1,1,\"To investigate the efficacy of F16IL2, in terms of objective response rate in combination with paclitaxel in metastatic melanoma, breast cancer and NSCLC patients amenable to taxane therapy (Phase II)\"\\n21850,1,1,\"To investigate the incidence of prostate cancer in patients who underwent to renal transplantation from July 1991 to September 2016\"\\n21851,1,1,\"To investigate the maximum tolerated dose (MTD) of OPB-111077\"\\n21852,1,1,\"To investigate the potential of GW786034 to inhibit or induce various CYP450 enzymes.\"\\n21853,1,1,\"To investigate the response rate High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation\"\\n21854,1,1,\"To investigate the safety and tolerability IV MG1102\"\\n21855,1,1,\"To investigate the safety and tolerability of AZD1480\"\\n21856,1,1,\"To investigate the safety and tolerability of AZD5363 to define a Recommended Dose (RD) when given orally\"\\n21857,1,1,\"To investigate the safety and tolerability of ZN-c3 in combination with PLD, carboplatin, paclitaxel, or gemcitabine\"\\n21858,1,1,\"To investigate the variability of hypoxia in HCC at baseline as quantified by BOLD MRI\"\\n21859,1,1,\"To investigate the variability of hypoxia in HCC at baseline as quantified by immunohistochemistry\"\\n21860,1,1,\"To learn if using Optison‚Ñ¢ during ultrasound can show the size and location of a tumor, how the tumor is responding to chemotherapy, and whether it has moved into surrounding tissue.\"\\n21861,1,1,\"To learn the best dose of Optison‚Ñ¢ ultrasound contrast agent that can be safely given to children with abdominal or pelvic tumors.\"\\n21862,1,1,\"To learn the effects (good and bad) of using Optison during ultrasound.\"\\n21863,1,1,\"To learn what kind of side effects panobinostat can cause when taken by children with relapsed ALL, AML, HD or NHL.\"\\n21864,1,1,\"To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent\"\\n21865,1,1,\"To measure side effects and adverse event of EUS-guided RFA\"\\n21866,1,1,\"To measure the anti-tumor acitivity of regorafenib treatment in patients with advanced pretreated melanoma.\"\\n21867,1,1,\"To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer\"\\n21868,1,1,\"To measure the technical success of EUS-guided RFA\"\\n21869,2,1,\"To observe the efficacy of local tumor ablation\"\\n21870,1,1,\"To obtain best disease control rate (DCR) data(Phase II)\"\\n21871,1,1,\"To obtain blood samples, ascites and pleural effusion samples from patients with solid tumor malignancies, with the intent of performing translational studies related to cancer.\"\\n21872,1,1,\"To obtain determine the safety and feasibility of an opioid titration order sheet in the hospice setting.\"\\n21873,1,1,\"To obtain PK sample\"\\n21874,1,1,\"To provide a mechanism for the evaluation, follow-up, and standard hematological care of patients by the Hematology Branch\"\\n21875,1,1,\"To provide continued, extended panitumumab treatment to subjects who appeared to have benefited from and tolerated previous panitumumab treatment in Studies 20020374 Part 2 or 20030138 and its extension study, 20040116\"\\n21876,1,1,\"To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501\"\\n21877,1,1,\"To provide specific dosing recommendations for S-1 in patients with hepatic impairment based on the PK of S-1 and its components after single dose and during steady state condition\"\\n21878,1,1,\"To provide specific dosing recommendations for S-1 in patients with renal impairment based on the PK of S-1 and its components after single dose and steady state conditions.\"\\n21879,2,1,\"To quantify the occurrence of adverse events (AEs) reported in all subjects who received study drug\"\\n21880,1,1,\"To set a recommended phase II dose (RP2D)\"\\n21881,1,1,\"To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...\"\\n21882,1,1,\"To study the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin¬Æ (bevacizumab) for patients with advanced cancer that has spread to the liver.\"\\n21883,1,1,\"To study the highest tolerable dose of RTA 744 that can be given to patients with cancer that has spread to the meninges of the brain or the spine.\"\\n21884,1,1,\"To study the influence of moderate and severe renal impairment on the Composite of Pharmacokinetics of HALAVEN following a single intravenous administration to subjects with cancer.\"\\n21885,1,1,\"To study the pharmacokinetics\"\\n21886,1,1,\"To tabulate the Best Overall Response according to unconfirmed RECIST, modified for cutaneous lesions\"\\n21887,1,1,\"To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.\"\\n21888,1,1,\"to verify if bowel wall thickening (BWT) is pathognomonic of neutropenic enterocolitis\"\\n21889,1,1,\"To verify safety of escalating doses of NGR-hTNF\"\\n21890,1,1,\"to verify the hypothesis that US could detect early signs of NEC, guide a prompt treatment eventually reducing mortality\"\\n21891,1,1,\"To verify the safety of escalating doses of NGRhTNF (from 0.2 to 1.6 ¬µg/m^2) in combination with cisplatin (80 mg/m^2) every 3 weeks\"\\n21892,1,1,\"Tobacco use intentions and behavior\"\\n21893,64,5,\"Tolerability\"\\n21894,14,1,\"tolerability\"\\n21895,1,1,\"Tolerability and pharmacokinetic profile of capsule contents sprinkled over applesauce or yogurt\"\\n21896,4,2,\"Tolerability and Safety\"\\n21897,1,1,\"Tolerability and safety assessed according to NCI CTCAE v5.0 grading.\"\\n21898,1,1,\"Tolerability and safety of 68GaNOTA-Anti-MMR-VHH2: reported as type, frequency and severity (graded according to the CTCAEv5) (Part I).\"\\n21899,1,1,\"Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse events\"\\n21900,1,1,\"Tolerability as assessed by numbers of dose changes or interruptions\"\\n21901,1,1,\"Tolerability as determined by assessment of the maximum tolerated dose or maximal assessed dose per protocol of CAN 1012 with cancers.\"\\n21902,1,1,\"Tolerability Evaluation: frequency and severity of AEs\"\\n21903,1,1,\"Tolerability measured by monitoring of fatigue and gastrointestinal-related side effects and when applicable, immune-related side effects in patients (Part B Dose Expansion)\"\\n21904,1,1,\"Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs\"\\n21905,1,1,\"Tolerability of combined modified vaccinia virus Ankara vaccine expressing p53 and pembrolizumab, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.3\"\\n21906,1,1,\"Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.\"\\n21907,1,1,\"Tolerability of MBG453 alone and in combination with PDR001 or in combination with decitabine, as assessed by number of dose changes\"\\n21908,1,1,\"Tolerability of MBG453 alone and in combination with PDR001 or in combination with decitabine, as assessed by number of dose interruptions\"\\n21909,1,1,\"Tolerability of NKTR-214 as Evaluated by Incidence of Dose Limiting Toxicities (DLTs)\"\\n21910,1,1,\"Tolerability of Nozin\"\\n21911,1,1,\"Tolerability of onalespib and CDKI AT7519\"\\n21912,1,1,\"Tolerability of talazoparib in patients with varying degrees of hepatic and renal dysfunction\"\\n21913,2,1,\"Tolerability of the treatment\"\\n21914,1,1,\"Tolerability of the treatment as assessed by 30-day postoperative mortality\"\\n21915,1,1,\"Tolerability of YS-ON-001 by recording AE /SAE, clinically significant changes in lab parameters and performance status (ECOG)\"\\n21916,1,1,\"Tolerability of ZGGS18\"\\n21917,1,1,\"Tolerability: Number of dose interruptions, reductions and dose intensity (Phase 1)\"\\n21918,1,1,\"Tolerability: Ratio of Dose reductions or interruptions\"\\n21919,1,1,\"Tolerance and safety as measured by any ‚â• Grade IV granulocyte toxicity or any Grade III toxicity thought to be drug related at 1 week after each course\"\\n21920,1,1,\"Tolerance and toxicity profile\"\\n21921,1,1,\"Tolerance of immunotherapy following anti-COVID-19 vaccination\"\\n21922,1,1,\"Tolerance, safety, and maximum tolerated dose at 1 week after each course\"\\n21923,2,2,\"Tolerated Dose\"\\n21924,1,1,\"Total [14C]-radioactivity in whole blood, plasma, urine, and feces (and vomit, if applicable)\"\\n21925,1,1,\"Total [14C]-radioactivity whole blood to plasma ratios\"\\n21926,1,1,\"Total area of procured tissue between the two FNB needles\"\\n21927,1,1,\"Total Area Under the Plasma Concentration Curve of Entinostat: AUC\"\\n21928,1,1,\"Total bilirubin concentration in whole blood sample\"\\n21929,6,1,\"Total body clearance (CL)\"\\n21930,1,1,\"Total Body Clearance (CL) of EMD 525797: After Single Dose\"\\n21931,3,1,\"Total Body Clearance (CLT)\"\\n21932,1,1,\"Total Body Clearance (CLT) of Relatlimab\"\\n21933,1,1,\"Total Body Clearance at Steady State (CLss) of EMD 525797\"\\n21934,1,1,\"Total Body Clearance of Drug From Serum (CL) After First Infusion\"\\n21935,1,1,\"Total Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-‚àû])\"\\n21936,1,1,\"Total Carboplatin PK: Maximum Observed Plasma Concentration (Cmax)\"\\n21937,1,1,\"Total Carboplatin PK: Time of Maximum Observed Plasma Concentration (Tmax)\"\\n21938,1,1,\"Total cholesterol concentration in whole blood sample\"\\n21939,1,1,\"Total Cisplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-‚àû])\"\\n21940,1,1,\"Total Cisplatin Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)\"\\n21941,1,1,\"Total Cisplatin Pharmacokinetics: Measurement of the Time After Administration When the Maximum Plasma Concentration is Reached (Tmax)\"\\n21942,1,1,\"Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 1)\"\\n21943,1,1,\"Total Dose Administered to Subjects in Each Treatment Arm (mg)\"\\n21944,1,1,\"Total duration (in hours, minutes and seconds) for investigational product preparation and administration\"\\n21945,1,1,\"Total duration of antibiotic treatment\"\\n21946,1,1,\"Total duration of high fever\"\\n21947,1,1,\"Total excretion of radioactivity\"\\n21948,1,1,\"Total exposure of MetMAb, as measured by area under the concentration-time curve (AUC)\"\\n21949,1,1,\"Total febrile or antibiotic days\"\\n21950,1,1,\"Total number of days of hospitalization (including unplanned readmission) (randomized patients)\"\\n21951,1,1,\"Total number of hospice referrals\"\\n21952,1,1,\"Total Number of Panitumumab Infusions\"\\n21953,1,1,\"Total Number of Participants Requiring Intra-operative Fluid Requirement\"\\n21954,1,1,\"Total number of platelet transfusions during the studied portions of the EFT or D9803 cycles\"\\n21955,1,1,\"Total number of unscheduled outpatient encounters and inpatient admissions\"\\n21956,1,1,\"Total Number of Venous Thromboembolic Events (VTE) in Standard Dose Enoxaparin Arm at 17 Days\"\\n21957,1,1,\"Total numbers of supportive care referrals (social work, dietitian, chaplaincy, psychologist/psychiatrist)\"\\n21958,5,1,\"Total Opioid Consumption\"\\n21959,1,1,\"Total pathologic complete response (tpCR) assessed by Independent Review CommitteeÔºàIRCÔºâ\"\\n21960,1,1,\"Total pathologic complete response (tpCR) rate\"\\n21961,1,1,\"Total plasma dose-normalized AUC0-48h\"\\n21962,1,1,\"Total plasma dose-normalized AUC0-‚àû\"\\n21963,1,1,\"Total plasma dose-normalized Cmax\"\\n21964,1,1,\"Total Postoperative Analgesic Requirements\"\\n21965,1,1,\"Total protein concentration in whole blood sample\"\\n21966,1,1,\"Total radiation dosage per patient (curative and palliative endpoints)\"\\n21967,4,1,\"Total radioactivity\"\\n21968,1,1,\"Total Radioactivity Concentrations in Blood Following Administration of [14C]-AZD2014\"\\n21969,1,1,\"Total Radioactivity Concentrations in Saliva Following Administration of [14C]-AZD2014\"\\n21970,1,1,\"Total Radioactivity in Plasma Following Administration of [14C]-AZD2014\"\\n21971,1,1,\"Total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14C] tazemetostat containing approximately 400 ¬µCi (14.8 MBq) of radioactivity\"\\n21972,4,1,\"Total recovery of radioactivity in urine and feces\"\\n21973,1,1,\"Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral Neuropathy [CIPN20]\"\\n21974,1,1,\"Total tissue area\"\\n21975,1,1,\"Total volume of distribution (VT) of the tracer in the tumour\"\\n21976,1,1,\"Toxic effects of cilengitide described as an adverse event that has an attribution of possibly, probably or definitely related to investigational treatment\"\\n21977,16,4,\"Toxicities\"\\n21978,10,6,\"toxicities\"\\n21979,1,1,\"Toxicities and Adverse Events\"\\n21980,1,1,\"Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0\"\\n21981,1,1,\"Toxicities as assessed by CTCAE version 4\"\\n21982,1,1,\"Toxicities as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n21983,1,1,\"Toxicities as assessed by the NCI CTCAE version 4.0\"\\n21984,1,1,\"Toxicities associated with irinotecan hydrochloride in combination with 7-hydroxystaurosporine in patients with resistant solid tumor malignancies (Part I)\"\\n21985,1,1,\"Toxicities Counts\"\\n21986,1,1,\"Toxicities observed at each dose level utilizing the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0\"\\n21987,1,1,\"Toxicities of adding bevacizumab to the established VOIT regimen using cefixime to reduce irinotecan-associated diarrhea.\"\\n21988,1,1,\"Toxicities of Aerosol Gemcitabine (GCB)\"\\n21989,1,1,\"Toxicities of imetelstat sodium\"\\n21990,1,1,\"Toxicities of ipilimumab, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0\"\\n21991,1,1,\"Toxicities of TAK-593 Pharmacokinetic parameters of TAK-593\"\\n21992,180,29,\"Toxicity\"\\n21993,1,1,\"Toxicity (CTCAE 4.0)\"\\n21994,1,1,\"Toxicity (DLT assessment), in Phase I, Cohort A\"\\n21995,1,1,\"Toxicity and tolerability as assessed by NCI CTC version 2.0\"\\n21996,1,1,\"Toxicity and tolerability of R-(-)-gossypol acetic acid in combination with cisplatin and etoposide in terms of types and severities by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n21997,1,1,\"toxicity and tolerable dosage on the basis of NCI-CTCAE 3.0\"\\n21998,1,1,\"Toxicity as assessed by CTC version 3.0 at the beginning of each treatment course\"\\n21999,2,1,\"Toxicity as assessed by CTCAE v3.0\"\\n22000,8,2,\"Toxicity as assessed by NCI CTCAE v3.0\"\\n22001,1,1,\"Toxicity as Assessed by NCI CTCAE v3.0 (Phase I)\"\\n22002,1,1,\"Toxicity as assessed by physical exam and laboratory data.\"\\n22003,1,1,\"Toxicity as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V3.0\"\\n22004,3,1,\"Toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0\"\\n22005,1,1,\"Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Associated With Gefitinib Therapy: Expected Toxicities (Grade 1 - 3)\"\\n22006,1,1,\"Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Associated With Gefitinib Therapy: UnExpected Toxicities (Grade 1 - 3)\"\\n22007,1,1,\"Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3\"\\n22008,1,1,\"Toxicity as measured by the Southwest Oncology Group Performance Status and Toxicity Criteria on day 1 and in weeks 4, 12, and 20\"\\n22009,1,1,\"Toxicity as measured by type (organ affected or laboratory determination such as absolute neutrophil count), severity (NCI CTCAE v3.0), time of onset (course number), duration, and reversibility or outcome\"\\n22010,1,1,\"Toxicity assessed using Common Toxicity Criteria (CTC) version 2.0\"\\n22011,1,1,\"Toxicity associated with everolimus and vatalanib (Cohort I) (Closed to enrollment as of 12/6/06)\"\\n22012,1,1,\"Toxicity at 3 months\"\\n22013,1,1,\"Toxicity at 6 weeks post infusion\"\\n22014,1,1,\"Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1)\"\\n22015,1,1,\"Toxicity evaluated according to the common toxicity criteria for adverse events (AEs) (CTCAEv4.0)\"\\n22016,2,2,\"Toxicity evaluation (safety evaluation): Toxicity will be evaluated by medical history, vital signs, physical examination and laboratory tests performed during the screening period (D-28 to D0) and treatment period based on NCI-CTCAE (version 3.0).\"\\n22017,1,1,\"Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug\"\\n22018,1,1,\"Toxicity Evaluation: From Time of First Treatment With CT-011 (Pidilizumab, MDV9300)\"\\n22019,1,1,\"Toxicity events\"\\n22020,1,1,\"Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\"\\n22021,2,1,\"Toxicity graded using the NCI CTCAE version 3.0\"\\n22022,1,1,\"Toxicity grading using CTCAE scale\"\\n22023,1,1,\"Toxicity in DTC treated advanced ovary cancer\"\\n22024,1,1,\"Toxicity observed at each dose level, graded using the NCI CTCAE\"\\n22025,1,1,\"Toxicity of DMXAA\"\\n22026,1,1,\"toxicity of escalating doses of decitabine administered by HAI\"\\n22027,1,1,\"Toxicity of nab-paclitaxel\"\\n22028,1,1,\"Toxicity of NeoTIL-ACT in combination with LDI\"\\n22029,1,1,\"Toxicity of single fraction SBRT on spine metastases using CTCAE v.4\"\\n22030,1,1,\"Toxicity of tanespimycin in combination with bortezomib in the treatment of solid tumors\"\\n22031,1,1,\"Toxicity of this combined treatment for recurrent NPC patients\"\\n22032,1,1,\"Toxicity of TIL-ACT and LDI\"\\n22033,1,1,\"Toxicity of Weekly LOC-Paclitaxel\"\\n22034,6,3,\"Toxicity Profile\"\\n22035,7,1,\"Toxicity profile\"\\n22036,1,1,\"Toxicity profile as assessed by NCI CTC v2.0\"\\n22037,1,1,\"Toxicity profile of ephrin type-A receptor 2-targeting 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine-encapsulated short-interfering ribonucleic acid\"\\n22038,1,1,\"Toxicity profile of LTLD\"\\n22039,1,1,\"Toxicity profile of onalespib in combination with paclitaxel\"\\n22040,1,1,\"Toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0\"\\n22041,1,1,\"Toxicity profile per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0\"\\n22042,1,1,\"Toxicity profile per NCI CTCAE v3.0\"\\n22043,1,1,\"Toxicity profile, as assessed by the NCI CTCAE version 4.0\"\\n22044,1,1,\"Toxicity Profile-Hematological\"\\n22045,1,1,\"Toxicity Profile-Non Hematological\"\\n22046,1,1,\"Toxicity reported using the CTC version 2.0\"\\n22047,1,1,\"Toxicity spectrum\"\\n22048,1,1,\"Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)\"\\n22049,1,1,\"Toxicity Summary\"\\n22050,1,1,\"Toxicity will be evaluated with Common Terminology Criteria for Adverse Events (CTCAE 4,0).\"\\n22051,1,1,\"Toxicity will be measured by standard grading methods.\"\\n22052,1,1,\"Toxicity: Number of subjects experiencing high-grade toxicity\"\\n22053,1,1,\"Tracer update of 68GaNOTA-Anti-HER2 VHH1 in different cancer types\"\\n22054,4,2,\"TRAEs\"\\n22055,1,1,\"Transcriptome sequencing of blood samples\"\\n22056,1,1,\"Transcriptome sequencing of exhaled air condensate samples\"\\n22057,1,1,\"Transcriptome sequencing of tissue samples\"\\n22058,1,1,\"Transcriptome sequencing of urine samples\"\\n22059,1,1,\"Transcriptomic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumors\"\\n22060,1,1,\"Transfusion requirement rate\"\\n22061,1,1,\"Transgene Levels of LCAR-C182A CAR-T Cells\"\\n22062,1,1,\"Translation/transcreation of the CONVO intervention\"\\n22063,4,1,\"Transplant-related mortality (TRM)\"\\n22064,1,1,\"Transplantation-related mortality and overall survival of TBI, Fludarabine, Cyclophosphamide and anti-thymocyte globulin for engraftment of CD3 depleted haploidentical peripheral blood stem cells.\"\\n22065,1,1,\"Transrectal Ultrasound-guided prostate biopsy\"\\n22066,26,1,\"Treatment adherence\"\\n22067,1,1,\"Treatment and Progression-free Survival at 6 Months\"\\n22068,6,1,\"Treatment compliance\"\\n22069,1,1,\"Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo and Lapatinib 2000mg\"\\n22070,1,1,\"Treatment Duration With GSK3052230\"\\n22071,1,1,\"Treatment effect (Measurement of tumor burden by irRC criteria)\"\\n22072,2,2,\"Treatment effect by radiology\"\\n22073,9,1,\"Treatment efficacy\"\\n22074,3,3,\"Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.\"\\n22075,1,1,\"Treatment efficacy assessed by parents\\' anxiety [Spielberger State-Trait Anxiety (STAI, state scale)]\"\\n22076,1,1,\"Treatment efficacy assessed by parents\\' mood (CES-D)\"\\n22077,1,1,\"Treatment emergent adverse event\"\\n22078,2,1,\"Treatment Emergent Adverse Event (TEAE)\"\\n22079,14,1,\"Treatment emergent adverse events\"\\n22080,1,1,\"Treatment emergent adverse events (AEs) and serious AEs (SAEs)\"\\n22081,1,1,\"Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs by Severity\"\\n22082,1,1,\"Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics\"\\n22083,1,1,\"Treatment failure (changes in hemoglobin levels)\"\\n22084,1,1,\"Treatment Failure-free Rate\"\\n22085,4,1,\"Treatment feasibility\"\\n22086,1,1,\"Treatment feasibility in terms of investigational agent-related adverse events of a novel treatment combination followed by peripheral blood stem cell rescue\"\\n22087,1,1,\"Treatment Phase Part A: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for E7820\"\\n22088,1,1,\"Treatment Phase Part A: AUC(0-t): Area Under the Plasma Concentration- Time Curve From Time 0 to t for E7820\"\\n22089,1,1,\"Treatment Phase Part A: Cmax: Maximum Observed Plasma Concentration for E7820\"\\n22090,1,1,\"Treatment Phase Part B: Maximum Tolerated Dose (MTD) of E7820 BID Dosing Schedule\"\\n22091,1,1,\"Treatment reality after NGS analysis\"\\n22092,19,1,\"Treatment related adverse events\"\\n22093,1,1,\"Treatment related adverse events rate\"\\n22094,1,1,\"treatment related serious adverse events\"\\n22095,1,1,\"Treatment Related Severe Adverse Effects\"\\n22096,1,1,\"Treatment related toxicities during and after treatment\"\\n22097,16,2,\"Treatment Response\"\\n22098,26,1,\"Treatment response\"\\n22099,1,1,\"Treatment response of anti-cancer therapy at first evaluation in patients with lung cancer/pulmonary nodules (CR, PR, PD, SD).\"\\n22100,1,1,\"Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).\"\\n22101,1,1,\"Treatment response of anti-inflammation and antiviral therapy at first evaluation in patients with COVID-19 (effective/ineffective treatment).\"\\n22102,1,1,\"Treatment response of antituberculous bacilli and anti-inflammation therapy at first evaluation in patients with pulmonary tuberculosis.\"\\n22103,1,1,\"Treatment response to yttrium Y-90 radioembolization\"\\n22104,1,1,\"Treatment response using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria\"\\n22105,2,1,\"treatment safety\"\\n22106,2,1,\"Treatment toxicities\"\\n22107,1,1,\"Treatment-emergent adenopathy, tenderness, or inflammation (inguinal and axillary) assessed before and after each dose\"\\n22108,4,2,\"Treatment-Emergent Adverse Event (TEAE)\"\\n22109,1,1,\"Treatment-Emergent Adverse Event (TEAE) in Part 1 and 2\"\\n22110,15,4,\"Treatment-Emergent Adverse Events\"\\n22111,20,3,\"Treatment-emergent adverse events\"\\n22112,16,1,\"Treatment-emergent adverse events (TEAEs)\"\\n22113,1,1,\"Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With Pembrolizumab\"\\n22114,2,1,\"Treatment-emergent adverse events (TEAEs) including determination of DLTs and serious AEs (SAEs)\"\\n22115,1,1,\"Treatment-emergent adverse events (TEAEs) up to Day 21\"\\n22116,1,1,\"Treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), Dose Limiting Toxicities (DLTs)\"\\n22117,1,1,\"Treatment-emergent adverse events (TEAEs):\"\\n22118,1,1,\"Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)\"\\n22119,1,1,\"Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan)\"\\n22120,1,1,\"Treatment-Emergent Adverse Events Occurring in Participants in Any Treatment Group During Cycle 1 Following Administration of CS-7017 and Carboplatin/Paclitaxel in Participants With Stage IIIb/IV Non-small Cell Lung Cancer\"\\n22121,1,1,\"Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0\"\\n22122,1,1,\"Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations\"\\n22123,1,1,\"Treatment-emergent Adverse Events Related to Laboratory Parameters\"\\n22124,1,1,\"Treatment-emergent Adverse Events Related to Vital Sign Parameters\"\\n22125,1,1,\"Treatment-emergent adverse events requiring withdrawal from IP and incidence of organ allograft rejection\"\\n22126,2,2,\"treatment-emergent adverse events(TEAEs)\"\\n22127,1,1,\"Treatment-emergent changes in autoimmunity evaluations as measured by clinical signs and symptoms and laboratory assessments at periodic intervals during the Treatment Period.\"\\n22128,1,1,\"Treatment-emergent changes in localized injection site reactions following each dose\"\\n22129,1,1,\"Treatment-emergent changes in vital signs (blood pressure, heart rate, respiratory rate, and body temperature) from baseline values obtained prior to each investigative treatment\"\\n22130,2,2,\"Treatment-limiting Toxicity (TLT)\"\\n22131,12,2,\"Treatment-related adverse events\"\\n22132,4,1,\"Treatment-related adverse events (AEs)\"\\n22133,1,1,\"Treatment-related Adverse Events (TRAEs)\"\\n22134,1,1,\"Treatment-related adverse events (TRAEs) leading to discontinuation within 12 weeks after the first dose\"\\n22135,1,1,\"Treatment-related adverse events as assessed by CTCAE v4.03\"\\n22136,1,1,\"treatment-related adverse events as assessed by CTCAE v4.03\"\\n22137,1,1,\"Treatment-related grade‚â•3 and serious adverse events\"\\n22138,1,1,\"Treatment-related moderate-severe adverse events as assessed by Common Terminology Criteria for Adverse Events [CTCAE v5.0]\"\\n22139,2,1,\"TRG0/1\"\\n22140,1,1,\"Triglycerides concentration in whole blood sample\"\\n22141,1,1,\"Trough Concentration (Ctrough) of Pembrolizumab Measured at Steady State\"\\n22142,1,1,\"Trough observed concentration of DCC-3014\"\\n22143,1,1,\"Trough Observed Plasma Concentration (Ctrough) of Relatlimab\"\\n22144,1,1,\"Trough observed serum nivolumab concentration (Ctrough)\"\\n22145,1,1,\"Trough Plasma Concentration (Cmin) of Vemurafenib\"\\n22146,1,1,\"Trough Plasma Concentration (Ctrough) at Time Zero (0): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters\"\\n22147,1,1,\"Trough Plasma Concentration (Ctrough) of RO5185426 on Day 15\"\\n22148,1,1,\"Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1\"\\n22149,1,1,\"Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2\"\\n22150,1,1,\"Trough Plasma Concentrations of Hemay020\"\\n22151,1,1,\"Trough Serum Concentration (Ctrough) of Amivantamab\"\\n22152,1,1,\"Trough Serum Concentration (Ctrough) Of EMD 525797 at Week 1\"\\n22153,1,1,\"Trough Serum Concentration (Ctrough) Of EMD 525797 at Week 3\"\\n22154,1,1,\"Trough Serum Concentration (Ctrough) Of EMD 525797 at Week 5\"\\n22155,1,1,\"Trough-observed serum concentration (Ctrough) of Relatlimab\"\\n22156,1,1,\"True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22157,8,4,\"TTP\"\\n22158,2,1,\"TTR\"\\n22159,1,1,\"Tumor aggressiveness\"\\n22160,1,1,\"Tumor apoptosis as measured by annexin\"\\n22161,2,1,\"Tumor Assessment\"\\n22162,3,1,\"Tumor assessment\"\\n22163,3,2,\"tumor assessment\"\\n22164,1,1,\"Tumor assessment based on RECIST 1.1 (for cohort 6 only)\"\\n22165,1,1,\"Tumor assessments\"\\n22166,2,2,\"Tumor assessments (Part 2)\"\\n22167,1,1,\"Tumor Assessments by RESIST\"\\n22168,1,1,\"Tumor assessments should be performed at screening and then every 2 cycles. A best response according to RECIST (Response Evaluation Criteria in Solid Tumors) will be documented by the investigator for each patient.\"\\n22169,1,1,\"Tumor BCRP expression in patients treated at the MTD\"\\n22170,1,1,\"Tumor Best Response Rate\"\\n22171,1,1,\"Tumor Blood Flow.\"\\n22172,1,1,\"Tumor Burden Reduction\"\\n22173,1,1,\"Tumor complete response (CR) and partial response (PR)\"\\n22174,1,1,\"Tumor concentration of Metformin\"\\n22175,1,1,\"tumor concentrations of a microdose radiolabeled kinase inhibitor\"\\n22176,1,1,\"tumor concentrations of therapeutic kinase inhibitor\"\\n22177,1,1,\"tumor control (time up to progression)\"\\n22178,2,2,\"Tumor Control Rate\"\\n22179,1,1,\"Tumor demethylation response, measured by percent change in DNA methylation using the ALU assay\"\\n22180,1,1,\"Tumor DNA detectability and cytological confirmation of leptomeningeal metastasis.\"\\n22181,1,1,\"Tumor growth control rate (CR, PR, SD) (Part 2)\"\\n22182,1,1,\"Tumor histopathology\"\\n22183,1,1,\"Tumor immune microenvironment response\"\\n22184,1,1,\"Tumor Immune-Related Response to Vigil and Vigil + Pembrolizumab\"\\n22185,1,1,\"Tumor long-term response to therapeutics\"\\n22186,1,1,\"Tumor makers\"\\n22187,1,1,\"Tumor Marker Cancer Antigen-125 (CA-125) (Phase 2)\"\\n22188,1,1,\"Tumor metabolism as assessed by PET scan before and after treatment\"\\n22189,1,1,\"Tumor Mutation Burden (TMB) in Cell-free Circulating Tumor Deoxyribonucleic Acid (ctDNA)\"\\n22190,1,1,\"Tumor necrosis\"\\n22191,1,1,\"Tumor necrosis rate\"\\n22192,2,2,\"Tumor objective response rate (ORR)\"\\n22193,1,1,\"Tumor ORR in patients with PIK3CA hotspot mutations.\"\\n22194,1,1,\"Tumor Overall Response Rates (ORRs) in Phase II Portion\"\\n22195,1,1,\"Tumor PD: phospho-Akt (Protein Kinase B) Levels (Parts A & B)\"\\n22196,1,1,\"Tumor PD: phospho-MAPK (mitogen-activated protein kinase) Levels (Parts A & B)\"\\n22197,1,1,\"Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses\"\\n22198,1,1,\"Tumor Pharmacodynamics (PD): phospho-c-Met (MET or MNNG HOS Transforming gene) Levels (Parts A & B)\"\\n22199,1,1,\"Tumor progression-free survival\"\\n22200,3,1,\"Tumor regression\"\\n22201,3,1,\"Tumor regression grade (TRG)\"\\n22202,1,1,\"Tumor regression grade (TRGÔºâ\"\\n22203,56,33,\"Tumor Response\"\\n22204,60,12,\"Tumor response\"\\n22205,15,1,\"tumor response\"\\n22206,1,1,\"Tumor response (complete response (CR), partial response (PR), stable disease (SD))\"\\n22207,1,1,\"Tumor response (complete response [CR], partial response [PR], progressive disease [PD], and stable disease [SD]) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\"\\n22208,1,1,\"Tumor response (dose expansion)\"\\n22209,1,1,\"Tumor Response (Overall Response Rate) Per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Part I & Part II)\"\\n22210,1,1,\"Tumor response (Phase II)\"\\n22211,1,1,\"Tumor Response - ITT (Intent to Treat) Population\"\\n22212,1,1,\"tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.\"\\n22213,1,1,\"Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1\"\\n22214,1,1,\"Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).\"\\n22215,1,1,\"Tumor response and resistance\"\\n22216,7,7,\"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22217,1,1,\"Tumor response as determined by response criteria\"\\n22218,1,1,\"Tumor Response as Measured by RECIST Criteria\"\\n22219,1,1,\"Tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22220,1,1,\"tumor response assessments\"\\n22221,1,1,\"Tumor Response at End of Treatment\"\\n22222,1,1,\"Tumor response based on RECIST\"\\n22223,1,1,\"Tumor Response by RECIST Criteria\"\\n22224,1,1,\"Tumor Response by RECIST v1.1 Criteria\"\\n22225,1,1,\"Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n22226,1,1,\"Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22227,1,1,\"Tumor response by Response Evaluation Criteria In Solid Tumors (RECIST)\"\\n22228,1,1,\"Tumor response defined by RECIST criteria\"\\n22229,1,1,\"Tumor Response Duration\"\\n22230,1,1,\"Tumor Response During Phase 2 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n22231,1,1,\"Tumor response for non-irradiated brain lesions at 8 weeks according to RECIST1.1\"\\n22232,1,1,\"Tumor Response in Patients With Inoperable HCC Using Belinostat (Phase II)\"\\n22233,1,1,\"Tumor Response in the Ovarian Cancer Cohort\"\\n22234,1,1,\"Tumor Response in the Targeted Population Through the End of Treatment\"\\n22235,1,1,\"Tumor response is assessmented with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1\"\\n22236,16,6,\"Tumor Response Rate\"\\n22237,1,1,\"Tumor Response rate\"\\n22238,23,5,\"Tumor response rate\"\\n22239,1,1,\"Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22240,1,1,\"Tumor Response Rate (Complete Response (CR) or Partial Response (PR)) Based on MRI- or Mammography and/or Sonography According to Modified RECIST Criteria at Month 6\"\\n22241,2,1,\"Tumor Response Rate (RR)\"\\n22242,1,1,\"Tumor Response Rate (TRR) (Complete Response [CR] or Partial Response [PR]) by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)\"\\n22243,1,1,\"Tumor Response Rate - Change at evaluations\"\\n22244,1,1,\"Tumor response rate - Phase II study\"\\n22245,1,1,\"Tumor response rate after Nimotuzumab concurrent with radiotherapy for recurrent NPC patients\"\\n22246,1,1,\"Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD)\"\\n22247,1,1,\"Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)\"\\n22248,1,1,\"Tumor response rate defined as percentage of patients whose objective disease status meets the criteria for Response Evaluation Criteria in Solid Tumors (RECIST) criteria for partial or complete response on two consecutive disease evaluations\"\\n22249,1,1,\"Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan\"\\n22250,1,1,\"Tumor Response Rate Following Zoledronic Acid (Zometa)\"\\n22251,2,2,\"Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22252,1,1,\"Tumor Response Rate of Patients With Gastrointestinal Neuroendocrine Tumors Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.\"\\n22253,1,1,\"Tumor Response Rate to LBH589.\"\\n22254,1,1,\"Tumor Response Rate, as Measured by RECIST Criteria\"\\n22255,5,5,\"Tumor response to DaRT\"\\n22256,1,1,\"Tumor response to HB-001\"\\n22257,3,1,\"Tumor response to utidelone treatment\"\\n22258,1,1,\"Tumor Response using mREcist if applicable\"\\n22259,1,1,\"Tumor response using RECIST version 1.1 throughout study\"\\n22260,1,1,\"Tumor Response using Response Evaluation Criteria in Solid Tumors (RECIST)\"\\n22261,1,1,\"Tumor response, as evaluated by the RECIST\"\\n22262,1,1,\"Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population\"\\n22263,1,1,\"Tumor Response, Evaluated Using the New International Criteria Proposed by the Revised Response Evaluation Criteria in Solid Tumors Guideline (Version 1.1)\"\\n22264,1,1,\"Tumor Responses (Complete and Partial Response)\"\\n22265,1,1,\"Tumor short-term response to therapeutics\"\\n22266,2,1,\"Tumor shrinkage\"\\n22267,18,1,\"Tumor size\"\\n22268,1,1,\"tumor size in injected lesions and non-injected lesions\"\\n22269,2,2,\"Tumor size measurement for evaluating tumor progression\"\\n22270,1,1,\"Tumor stabilization rate\"\\n22271,1,1,\"Tumor targeting potential using PET/CT and correlation to immunohistological MMR staining after resection: assessed using correlation coefficient (Part II).\"\\n22272,1,1,\"Tumor to Background Ratio (TBR) of lesions detected by PET scans\"\\n22273,1,1,\"Tumor to Normal Liver Activity Ratio (TNR)\"\\n22274,1,1,\"Tumor to normal ratio Tumor to Normal ratio prior to greatment\"\\n22275,4,1,\"Tumor volume\"\\n22276,1,1,\"Tumor-free survival\"\\n22277,1,1,\"Tumor-to-background (TBR) Ratio (Cohort 2 only)\"\\n22278,9,1,\"Tumor-to-background ratio (SPECT)\"\\n22279,1,1,\"Tumour Ablation\"\\n22280,3,3,\"Tumour Response\"\\n22281,1,1,\"Tumour response according to response evaluation criteria in solid tumours (RECIST)\"\\n22282,1,1,\"Tumour response measured by RECIST criteria\"\\n22283,1,1,\"Tumour Response Rate\"\\n22284,1,1,\"Tumour response rate, defined as complete response (CR) or partial response (PR) (i.e. at least partial response) measured using the RECIST (Response Evaluation Criteria in Solid Tumours) criteria.\"\\n22285,1,1,\"Tumour Responses\"\\n22286,1,1,\"Tumour Stabilisation Rate\"\\n22287,1,1,\"Tumour type and anatomic location\"\\n22288,1,1,\"Turn around time genomic profiling\"\\n22289,1,1,\"Turnaround time from collection of liquid biopsy to MTB recommendation\"\\n22290,1,1,\"Twelve Month Disease-free Survival Rate\"\\n22291,1,1,\"Twelve-month Progression-free Survival (PFS) Rate in Participants\"\\n22292,2,1,\"Two Year Progression Free Survival Rate\"\\n22293,1,1,\"Two-point pain improvement from baseline (0-10 numeric pain rating scale)\"\\n22294,1,1,\"two-year overall survival\"\\n22295,1,1,\"Two-year progression-free survival in patients with high-risk solid tumors\"\\n22296,1,1,\"Two-years disease free survival rates for patients with longitudinal undetectable MRD\"\\n22297,1,1,\"Two-years Progression-free survival\"\\n22298,1,1,\"Type and duration of immune response measured over time to repeat vaccine administration\"\\n22299,4,1,\"Type and incidence of adverse events (AEs) and serious adverse events (SAEs) by dose group\"\\n22300,1,1,\"Type and incidence of dose-limiting toxicity (DLT) by dose group\"\\n22301,1,1,\"Type and number of adverse events (AEs)\"\\n22302,1,1,\"Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Current NOAC Dose According to Sex\"\\n22303,1,1,\"Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to a Prior Diagnosis of Heart Failure\"\\n22304,1,1,\"Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Age (Categorical)\"\\n22305,1,1,\"Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Chronic Kidney Disease\"\\n22306,1,1,\"Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Coronary Artery Disease\"\\n22307,1,1,\"Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Diabetes\"\\n22308,1,1,\"Type of dose limiting adverse event\"\\n22309,1,1,\"Type of EP 2006 Prophylaxis by Age Group\"\\n22310,1,1,\"Type of EP 2006 Prophylaxis by Tumor Type\"\\n22311,1,1,\"Type of EP2006 Prophylaxis\"\\n22312,1,1,\"Type of EP2006 Prophylaxis by Gender\"\\n22313,1,1,\"Type, incidence and severity of Adverse Events\"\\n22314,1,1,\"Type, incidence and severity of AEs and serious adverse events (SAEs)\"\\n22315,1,1,\"Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only)\"\\n22316,1,1,\"Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only)\"\\n22317,1,1,\"Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities\"\\n22318,1,1,\"Types and grades of toxicity\"\\n22319,1,1,\"Types of Genomic or Genetic Testing\"\\n22320,4,1,\"T¬Ω\"\\n22321,1,1,\"t¬Ω (Elimination half-life)\"\\n22322,1,1,\"T¬Ω (half-life) of FTD and TPI\"\\n22323,1,1,\"t¬Ω of MK-2206 in Participants Receiving Multiple QW Dosing\"\\n22324,1,1,\"UCLA Loneliness Scale.\"\\n22325,1,1,\"Unacceptable Toxicity\"\\n22326,1,1,\"Unacceptable Toxicity Status at the End of 8-week Safety Observation Period\"\\n22327,1,1,\"Unbound Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24u) of Talazoparib on Day 22\"\\n22328,1,1,\"Unbound AUC(0-last): Unbound Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib\"\\n22329,1,1,\"Unbound AUC0-‚àû: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib\"\\n22330,1,1,\"Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib\"\\n22331,1,1,\"Unbound AUClast: Unbound Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib\"\\n22332,1,1,\"Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib\"\\n22333,2,2,\"Unbound Cmax: Unbound Maximum Observed Plasma Concentration for Ixazomib\"\\n22334,1,1,\"Unbound Maximum Observed Plasma Concentration (Cmaxu) of Talazoparib on Day 22\"\\n22335,1,1,\"Univariate analysis to identify risk factors related to cognitive disorders.\"\\n22336,1,1,\"unplanned hospital admissions for patients receiving adjuvant oncologic treatment\"\\n22337,1,1,\"uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13\"\\n22338,1,1,\"uNTX Response Rate at 43 Days\"\\n22339,2,2,\"uNTx/uCr\"\\n22340,1,1,\"Updated Final OS for All Participants\"\\n22341,1,1,\"UPLIFT: Investigator-assessed objective response rate (ORR) of XMT-1536 (upifitamab rilsodotin) in the ITT-Higher NaPi2b population\"\\n22342,1,1,\"Upstream dilation of the main pancreatic duct\"\\n22343,2,1,\"Uptake of 131I-L19SIP or 124I-L19SIP\"\\n22344,1,1,\"Uptake of 64Cu-plerixafor in the target lesion(s) of subjects expressing CXCR4 versus the uptake of 64Cu-plerixafor in the surrounding non-tumor tissues.\"\\n22345,1,1,\"Uptake of FPAC in tumors\"\\n22346,4,1,\"Uptake of genetic testing\"\\n22347,1,1,\"uptake rate constant (Ki) changes\"\\n22348,1,1,\"Urea concentration in whole blood sample\"\\n22349,1,1,\"Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered\"\\n22350,1,1,\"Urinary excretion of AFP464\"\\n22351,1,1,\"Urinary Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered\"\\n22352,1,1,\"Urinary Metabolic Ratio (UMR) of Dextromethorphan to Dextrorphan 3 Days Prior to PF-00299804 Dosing\"\\n22353,1,1,\"Urinary Metabolic Ratio (UMR) of Dextromethorphan to Dextrorphan on Cycle 2 Day 7\"\\n22354,1,1,\"Urinary, fecal, and respiratory excretion of 14C from FTD and urinary and fecal excretion of 14C from TPI\"\\n22355,1,1,\"Urine 6B-Hydroxycortisol to Cortisol Ratio on Day -1\"\\n22356,1,1,\"Urine 6B-Hydroxycortisol to Cortisol Ratio on Day 22\"\\n22357,1,1,\"urine and fecal samples for quantification analysis\"\\n22358,1,1,\"Urine concentration of NGAL\"\\n22359,4,1,\"Urine routine\"\\n22360,1,1,\"Urine values\"\\n22361,38,1,\"Usability\"\\n22362,1,1,\"Usability of the PACT application: System Usability Scale (SUS) [Caregivers]\"\\n22363,1,1,\"Usability of the PACT application: System Usability Scale (SUS) [Patients]\"\\n22364,1,1,\"Use National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) to establish the maximum tolerated dose, a recommended Phase 2 dose range and schedule, and safety profile of BMS-833923\"\\n22365,1,1,\"Use NCI CTCAE to establish the MTD, DLT(s) and safety profile of BMS-833923 administered alone and in combination with carboplatin and etoposide\"\\n22366,1,1,\"Use of Cardiac Biomarkers, B-type Natriuretic Peptide (BNP) and Troponin I (TnI), for Detecting Cardiotoxicity in Patients Undergoing Anthracycline-based Chemotherapy\"\\n22367,1,1,\"Use of depression patient-reported outcomes for measurement-based care\"\\n22368,1,1,\"Use of mechanical ventilator during COVID-19 related hospitalization (Yes/No)\"\\n22369,1,1,\"Use of psycho-oncological support services by patients and relatives and the changes over time\"\\n22370,1,1,\"Use of real time biopsy to establish an individual molecular profile by using next generation sequencing\"\\n22371,1,1,\"User engagement as measured by number of views [Caregivers]\"\\n22372,1,1,\"User engagement as measured by number of views [Patients]\"\\n22373,1,1,\"User engagement as measured by time spent on app [Caregivers]\"\\n22374,1,1,\"User engagement as measured by time spent on app [Patients]\"\\n22375,1,1,\"User satisfaction [Caregivers]\"\\n22376,1,1,\"User satisfaction [Patients]\"\\n22377,1,1,\"Using CTCAE 4 standard to evaluate the level of adverse events after receiving 4SCART infusion\"\\n22378,1,1,\"Using NCI standard measurement to measure primary target lesion size of various types of cancer pstients\"\\n22379,1,1,\"Using three cohorts of patients with fixed dosing of capecitabine in combination with increasing doses of RAD001, the maximum tolerated doses and toxicities will be determined.\"\\n22380,1,1,\"Usual intake of percentage energy from fat\"\\n22381,1,1,\"Utilisation of routine surveillance imaging across European Centers\"\\n22382,1,1,\"Utility of recommended personalized therapy for HR childhood cancer patients.\"\\n22383,1,1,\"Utility of recommended personalized therapy for non-HR childhood cancer patients.\"\\n22384,1,1,\"Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions\"\\n22385,1,1,\"Utilization rates of province-wide genomically-characterized and clinically-annotated patient base in enrollment into specific research initiatives\"\\n22386,1,1,\"V02 peak before and after chemotherapy\"\\n22387,9,1,\"Vaginal pH\"\\n22388,1,1,\"validate HP MRI at MSKCC (are the scans able to be reproduced)\"\\n22389,1,1,\"Validate the 9 dimensions of the CANUT-QVA questionnaire identified during the general population analysis.\"\\n22390,3,1,\"Validation of FAZA PET/MRI as a biomarker of hypoxia\"\\n22391,1,1,\"Validation of germline EPHA5 polymorphism (rs7349683)\"\\n22392,1,1,\"Validation of the moroccan arabic version of the LARS score\"\\n22393,1,1,\"Validation of the moroccan arabic version of the Wexner score\"\\n22394,1,1,\"Validity of domains and items for depression\"\\n22395,1,1,\"Validity profiles\"\\n22396,1,1,\"valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS)\"\\n22397,1,1,\"variability of measurements of liver metastases from neuroendocrine tumors (NET) on different magnetic resonance imaging (MRI) sequences.\"\\n22398,1,1,\"Variability of repeated quantitative measures of FDG uptake as measured by SUVmax\"\\n22399,1,1,\"Variability of repeated quantitative measures of FDG uptake as measured by SUVpeak\"\\n22400,1,1,\"Variations in disease activity as evaluated by FDG-PET imaging\"\\n22401,1,1,\"Variations of patient quality of life\"\\n22402,1,1,\"Vascular pattern (iso or hypervascular)\"\\n22403,1,1,\"Vd/F (apparent volume of distribution) of FTD and TPI\"\\n22404,1,1,\"Vd: Volume of Distribution for Eribulin Mesylate\"\\n22405,1,1,\"Vector Integration Site(s) for Replication-competent Retrovirus/Replication-competent Lentivirus (RCR/RCL) or Insertional Mutagenesis for Confirmed Events Related to the Cell Therapy Product\"\\n22406,1,1,\"Venous Thromboembolism event\"\\n22407,1,1,\"Ventricular rate of ECG\"\\n22408,1,1,\"Vertebral compression fracture rate\"\\n22409,1,1,\"Vibration as measured by tuning fork\"\\n22410,1,1,\"Vibratory sensation as measured by tuning fork at baseline, and then weeks 4, 8, and 12 during study treatment\"\\n22411,1,1,\"Visual Analogue Scale (VAS) score for pain\"\\n22412,4,1,\"Vital sign measurements\"\\n22413,1,1,\"Vital sign values\"\\n22414,79,7,\"Vital signs\"\\n22415,18,1,\"vital signs\"\\n22416,1,1,\"Vital signs abnormality\"\\n22417,1,1,\"vital signs changes from baseline\"\\n22418,1,1,\"Volume fraction of voxels showing treatment-related VB-DTI changes for each lesion\"\\n22419,1,1,\"Volume of distribution (apparent) at steady state following extravascular administration (Vss/F)\"\\n22420,7,1,\"Volume of Distribution (Vd)\"\\n22421,1,1,\"Volume of distribution (VZ)\"\\n22422,2,1,\"Volume of distribution (Vz)\"\\n22423,1,1,\"Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 1)\"\\n22424,8,1,\"Volume of distribution (Vz/F)\"\\n22425,1,1,\"Volume of distribution at steady state (Vdss)(L/kg)\"\\n22426,1,1,\"Volume of distribution at steady state (Vss) for eribulin mesylate\"\\n22427,1,1,\"Volume of Distribution at Steady State (Vss) of Atezolizumab (PK phase only)\"\\n22428,1,1,\"Volume of Distribution at Steady State (Vss) of RO6874281\"\\n22429,1,1,\"Volume of Distribution at Steady State (Vss) of RO6895882\"\\n22430,1,1,\"Volume of Distribution at Steady State (Vss) of RO6958688\"\\n22431,1,1,\"Volume of Distribution at Steady State (Vss) of Sorafenib\"\\n22432,1,1,\"Volume of distribution at steady state [Vss] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n22433,1,1,\"Volume of distribution at steady-state (PK)\"\\n22434,1,1,\"Volume of Distribution at Steady-state (Vss)\"\\n22435,1,1,\"Volume of distribution of the terminal phase [Vz] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)\"\\n22436,1,1,\"Volume of region of interest.\"\\n22437,1,1,\"Volume Transfer Coefficient of Contrast Agent Across the Capillary Walls\"\\n22438,1,1,\"Volume transfer constant (Ktrans), as measured by DCE-MRI\"\\n22439,1,1,\"Volumes for liver to be treated\"\\n22440,1,1,\"Volumetric radiographic response for each lesion\"\\n22441,4,1,\"Vss\"\\n22442,1,1,\"Vss: Volume of Distribution at Steady State for AMG 386\"\\n22443,1,1,\"Vz\"\\n22444,1,1,\"Vz (apparent volume of distribution)\"\\n22445,1,1,\"Vz/F (apparent volume of distribution )\"\\n22446,1,1,\"Vz/F of [13C]-Labeled Idasanutlin\"\\n22447,1,1,\"Vz/F of digoxin and rosuvastatin\"\\n22448,1,1,\"Vz/F of Idasanutlin Metabolite\"\\n22449,1,1,\"Vz/F of midazolam and caffeine\"\\n22450,1,1,\"Vz/F of Olaparib\"\\n22451,1,1,\"Was a multimodal signature developed to risk-stratify participants with locally advanced radically treated head and neck cancer?\"\\n22452,1,1,\"We Conducted the Present Phase II Study to Investigate the Efficacy and Safety of a Biweekly Schedule of Docetaxel and Cisplatin in Patients With Unresectable NSCLC.\"\\n22453,1,1,\"Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 1\"\\n22454,1,1,\"Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 15\"\\n22455,252,1,\"Weight\"\\n22456,1,1,\"Weight (lbs/kg)\"\\n22457,1,1,\"Weight of Pediatric and Adolescent Participants\"\\n22458,2,1,\"Weight stability\"\\n22459,1,1,\"Whether new ctDNA assay can detect genomic alterations in peripheral blood that are consistent with those detected by FoundationOne in matched solid tumor samples\"\\n22460,1,1,\"White blood cell count in whole blood sample\"\\n22461,1,1,\"Whole Blood and Plasma Apparent Elimination Rate Constant of [14C]-Labeled Idasanutlin\"\\n22462,1,1,\"Whole Blood and Plasma AUC(0-inf) of [14C]-Labeled Idasanutlin\"\\n22463,1,1,\"Whole Blood and Plasma AUC(0-last) of [14C]-Labeled Idasanutlin\"\\n22464,1,1,\"Whole Blood and Plasma Cmax of [14C]-Labeled Idasanutlin\"\\n22465,1,1,\"Whole Blood and Plasma Tmax of [14C]-Labeled Idasanutlin\"\\n22466,1,1,\"Whole body planar imaging\"\\n22467,1,1,\"Whole genome sequencing of blood samples\"\\n22468,1,1,\"Whole genome sequencing of exhaled air condensate samples\"\\n22469,1,1,\"Whole genome sequencing of urine samples\"\\n22470,1,1,\"Whole Tumor Volume and Enhancing Tumor Volume\"\\n22471,1,1,\"Whole-body gamma image time activity curve (TAC) versus patient-led external dose rate (SELFIE) TAC.\"\\n22472,1,1,\"Whole-genome sequencing of tissue samples\"\\n22473,1,1,\"with multiple myeloma and other MUC-1 antigen-expressing metastatic carcinomas\"\\n22474,1,1,\"Withdrawals due to adverse events\"\\n22475,1,1,\"Withdrawals from the study due to treatment-related adverse events will be documented\"\\n22476,1,1,\"Worker Well-being\"\\n22477,1,1,\"Worst Pain\"\\n22478,1,1,\"Y-90 distribution and concentration as determined by post embolization PET-CT\"\\n22479,1,1,\"YKL-40 measurements\"\\n22480,1,1,\"Zeaxanthin monotherapy\"\\n22481,1,1,\"Zeaxanthin monotherapy (continued)\"\\n22482,1,1,\"Zeaxanthin plus Pembrolizumab\"\\n22483,1,1,\"Zeaxanthin plus Pembrolizumab (continued)\"\\n22484,1,1,\"ZZ06 AEs\"\\n22485,23,1,\"Œªz\"\\n22486,1,1,\"‚Ä¢ Cmax\"\\n22487,1,1,\"‚Ä¢ Excretion of radioactivity in feces following oral administration of [14C]GSK2118436\"\\n22488,1,1,\"‚Ä¢ Excretion of radioactivity in urine following oral administration of [14C]GSK2118436\"\\n22489,1,1,\"‚Ä¢ Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor\"\\n22490,1,1,\"‚Ä¢ Percentage of patients enrolled in clinical intervention trials based on the mutational profile of their cancer genome\"\\n22491,1,1,\"‚Ä¢ The primary objective of this study is to determine the recommended phase 2 dose of IMO 2055 when combined with FOLFIRI and cetuximab in patients with histologically proven advanced or metastatic colorectal cancer (CRC).\"\\n22492,1,1,\"‚Ä¢ the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).\"\\n22493,1,1,\"‚Ä¢ Tmax\"\\n22494,1,1,\"‚Ä¢ To determine the safety of OMP-54F28 in subjects with previously treated solid tumors\"\\n22495,1,1,\"‚Ö†a (Dose-Escalation Stage): Maximum tolerated dose (MTD) for HS-20093\"\\n22496,1,1,\"‚Ö†b (Dose-Expansion Stage): Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"\\n22497,1,1,\"ÔºåDose-limiting toxicity incidence (participants who experience DLT)\"\\n'"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from requests import get\n",
    "import pandas\n",
    "\n",
    "r = get('https://clinicaltrials.gov/api/query/field_values?expr=solid+tumor&field=PrimaryOutcomeMeasure&fmt=csv')\n",
    "\n",
    "r.text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "import csv\n",
    "with open(\"output.csv\", \"w\") as f:\n",
    "    writer = csv.writer(f)\n",
    "    for line in r.iter_lines():\n",
    "        writer.writerow(line.decode('utf-8').split(','))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "ename": "ParserError",
     "evalue": "Error tokenizing data. C error: Expected 1 fields in line 15, saw 4\n",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mParserError\u001b[0m                               Traceback (most recent call last)",
      "\u001b[0;32m/var/folders/f1/87whmjt97m90gfstrm2p61d80000gn/T/ipykernel_71817/1561355009.py\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mdf\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpandas\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread_csv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"output.csv\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/util/_decorators.py\u001b[0m in \u001b[0;36mwrapper\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    309\u001b[0m                     \u001b[0mstacklevel\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mstacklevel\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    310\u001b[0m                 )\n\u001b[0;32m--> 311\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mfunc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    312\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    313\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mwrapper\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/io/parsers/readers.py\u001b[0m in \u001b[0;36mread_csv\u001b[0;34m(filepath_or_buffer, sep, delimiter, header, names, index_col, usecols, squeeze, prefix, mangle_dupe_cols, dtype, engine, converters, true_values, false_values, skipinitialspace, skiprows, skipfooter, nrows, na_values, keep_default_na, na_filter, verbose, skip_blank_lines, parse_dates, infer_datetime_format, keep_date_col, date_parser, dayfirst, cache_dates, iterator, chunksize, compression, thousands, decimal, lineterminator, quotechar, quoting, doublequote, escapechar, comment, encoding, encoding_errors, dialect, error_bad_lines, warn_bad_lines, on_bad_lines, delim_whitespace, low_memory, memory_map, float_precision, storage_options)\u001b[0m\n\u001b[1;32m    676\u001b[0m     \u001b[0mkwds\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mupdate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkwds_defaults\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    677\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 678\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0m_read\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfilepath_or_buffer\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkwds\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    679\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    680\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/io/parsers/readers.py\u001b[0m in \u001b[0;36m_read\u001b[0;34m(filepath_or_buffer, kwds)\u001b[0m\n\u001b[1;32m    579\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    580\u001b[0m     \u001b[0;32mwith\u001b[0m \u001b[0mparser\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 581\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mparser\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnrows\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    582\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    583\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/io/parsers/readers.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, nrows)\u001b[0m\n\u001b[1;32m   1251\u001b[0m             \u001b[0mnrows\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mvalidate_integer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"nrows\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnrows\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1252\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1253\u001b[0;31m                 \u001b[0mindex\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcolumns\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcol_dict\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnrows\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1254\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mException\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1255\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mclose\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/io/parsers/c_parser_wrapper.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, nrows)\u001b[0m\n\u001b[1;32m    223\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    224\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlow_memory\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 225\u001b[0;31m                 \u001b[0mchunks\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_reader\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread_low_memory\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnrows\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    226\u001b[0m                 \u001b[0;31m# destructive to chunks\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    227\u001b[0m                 \u001b[0mdata\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0m_concatenate_chunks\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mchunks\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/_libs/parsers.pyx\u001b[0m in \u001b[0;36mpandas._libs.parsers.TextReader.read_low_memory\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/_libs/parsers.pyx\u001b[0m in \u001b[0;36mpandas._libs.parsers.TextReader._read_rows\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/_libs/parsers.pyx\u001b[0m in \u001b[0;36mpandas._libs.parsers.TextReader._tokenize_rows\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m/opt/anaconda3/lib/python3.9/site-packages/pandas/_libs/parsers.pyx\u001b[0m in \u001b[0;36mpandas._libs.parsers.raise_parser_error\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mParserError\u001b[0m: Error tokenizing data. C error: Expected 1 fields in line 15, saw 4\n"
     ]
    }
   ],
   "source": [
    "df = pandas.read_csv(\"output.csv\")\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
